[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "DUX4, a homeobox-containing gene present in a tandem array, is implicated in facioscapulohumeral muscular dystrophy (FSHD), a dominant autosomal disease. New findings about DUX4 have raised as many fundamental questions about the molecular pathology of this unique disease as they have answered. This review discusses recent studies addressing the question of whether there is extensive FSHD-related transcription dysregulation in adult-derived myoblasts and myotubes, the precursors for muscle repair. Two models for the role of DUX4 in FSHD are presented. One involves transient pathogenic expression of DUX4 in many cells in the muscle lineage before the myoblast stage resulting in a persistent, disease-related transcription profile ('Majority Rules'), which might be enhanced by subsequent oscillatory expression of DUX4. The other model emphasizes the toxic effects of inappropriate expression of DUX4 in only an extremely small percentage of FSHD myoblasts or myotube nuclei ('Minority Rules'). The currently favored Minority Rules model is not supported by recent studies of transcription dysregulation in FSHD myoblasts and myotubes. It also presents other difficulties, for example, explaining the expression of full-length DUX4 transcripts in FSHD fibroblasts. The Majority Rules model is the simpler explanation of findings about FSHD-associated gene expression and the DUX4-encoded homeodomain-type protein.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "6a92b3312fe9468e9d709a8e59c9fadc", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[64, 64], [160, 160], [91, 91], [188, 188], [20, 20], [212, 212], [226, 226]], "char_spans": [[387, 390], [950, 953], [538, 541], [1115, 1118], [117, 120], [1255, 1258], [1343, 1346]]}]}], "context_tokens": [["DUX4", 0], [",", 4], ["a", 6], ["homeobox", 8], ["-", 16], ["containing", 17], ["gene", 28], ["present", 33], ["in", 41], ["a", 44], ["tandem", 46], ["array", 53], [",", 58], ["is", 60], ["implicated", 63], ["in", 74], ["facioscapulohumeral", 77], ["muscular", 97], ["dystrophy", 106], ["(", 116], ["FSHD", 117], [")", 121], [",", 122], ["a", 124], ["dominant", 126], ["autosomal", 135], ["disease", 145], [".", 152], ["New", 154], ["findings", 158], ["about", 167], ["DUX4", 173], ["have", 178], ["raised", 183], ["as", 190], ["many", 193], ["fundamental", 198], ["questions", 210], ["about", 220], ["the", 226], ["molecular", 230], ["pathology", 240], ["of", 250], ["this", 253], ["unique", 258], ["disease", 265], ["as", 273], ["they", 276], ["have", 281], ["answered", 286], [".", 294], ["This", 296], ["review", 301], ["discusses", 308], ["recent", 318], ["studies", 325], ["addressing", 333], ["the", 344], ["question", 348], ["of", 357], ["whether", 360], ["there", 368], ["is", 374], ["extensive", 377], ["FSHD", 387], ["-", 391], ["related", 392], ["transcription", 400], ["dysregulation", 414], ["in", 428], ["adult", 431], ["-", 436], ["derived", 437], ["myoblasts", 445], ["and", 455], ["myotubes", 459], [",", 467], ["the", 469], ["precursors", 473], ["for", 484], ["muscle", 488], ["repair", 495], [".", 501], ["Two", 503], ["models", 507], ["for", 514], ["the", 518], ["role", 522], ["of", 527], ["DUX4", 530], ["in", 535], ["FSHD", 538], ["are", 543], ["presented", 547], [".", 556], ["One", 558], ["involves", 562], ["transient", 571], ["pathogenic", 581], ["expression", 592], ["of", 603], ["DUX4", 606], ["in", 611], ["many", 614], ["cells", 619], ["in", 625], ["the", 628], ["muscle", 632], ["lineage", 639], ["before", 647], ["the", 654], ["myoblast", 658], ["stage", 667], ["resulting", 673], ["in", 683], ["a", 686], ["persistent", 688], [",", 698], ["disease", 700], ["-", 707], ["related", 708], ["transcription", 716], ["profile", 730], ["(", 738], ["'", 739], ["Majority", 740], ["Rules", 749], ["'", 754], [")", 755], [",", 756], ["which", 758], ["might", 764], ["be", 770], ["enhanced", 773], ["by", 782], ["subsequent", 785], ["oscillatory", 796], ["expression", 808], ["of", 819], ["DUX4", 822], [".", 826], ["The", 828], ["other", 832], ["model", 838], ["emphasizes", 844], ["the", 855], ["toxic", 859], ["effects", 865], ["of", 873], ["inappropriate", 876], ["expression", 890], ["of", 901], ["DUX4", 904], ["in", 909], ["only", 912], ["an", 917], ["extremely", 920], ["small", 930], ["percentage", 936], ["of", 947], ["FSHD", 950], ["myoblasts", 955], ["or", 965], ["myotube", 968], ["nuclei", 976], ["(", 983], ["'", 984], ["Minority", 985], ["Rules", 994], ["'", 999], [")", 1000], [".", 1001], ["The", 1003], ["currently", 1007], ["favored", 1017], ["Minority", 1025], ["Rules", 1034], ["model", 1040], ["is", 1046], ["not", 1049], ["supported", 1053], ["by", 1063], ["recent", 1066], ["studies", 1073], ["of", 1081], ["transcription", 1084], ["dysregulation", 1098], ["in", 1112], ["FSHD", 1115], ["myoblasts", 1120], ["and", 1130], ["myotubes", 1134], [".", 1142], ["It", 1144], ["also", 1147], ["presents", 1152], ["other", 1161], ["difficulties", 1167], [",", 1179], ["for", 1181], ["example", 1185], [",", 1192], ["explaining", 1194], ["the", 1205], ["expression", 1209], ["of", 1220], ["full", 1223], ["-", 1227], ["length", 1228], ["DUX4", 1235], ["transcripts", 1240], ["in", 1252], ["FSHD", 1255], ["fibroblasts", 1260], [".", 1271], ["The", 1273], ["Majority", 1277], ["Rules", 1286], ["model", 1292], ["is", 1298], ["the", 1301], ["simpler", 1305], ["explanation", 1313], ["of", 1325], ["findings", 1328], ["about", 1337], ["FSHD", 1343], ["-", 1347], ["associated", 1348], ["gene", 1359], ["expression", 1364], ["and", 1375], ["the", 1379], ["DUX4-encoded", 1383], ["homeodomain", 1396], ["-", 1407], ["type", 1408], ["protein", 1413], [".", 1420]]}
{"context": "Iron deficiency anemia is common in people with chronic kidney disease (CKD) and its importance in supporting erythropoiesis is unquestioned especially in those patients treated with erythropoietin. Clinical symptomatology such as fatigability, cold intolerance, failure to concentrate and poor effort intolerance is often attributed to anemia or uremia. That iron deficiency, per se, can cause these symptoms is poorly recognized. Clinical and animal studies that support the benefits of iron supplementation, independent of increasing hemoglobin, such as those on immune function, physical performance, thermoregulation, cognition, and restless leg syndrome and aluminum absorption is the subject of this narrative review.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "9a096b481413444ea01bcdaa55383924", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[0, 0], [55, 55], [78, 78]], "char_spans": [[0, 3], [360, 363], [489, 492]]}]}], "context_tokens": [["Iron", 0], ["deficiency", 5], ["anemia", 16], ["is", 23], ["common", 26], ["in", 33], ["people", 36], ["with", 43], ["chronic", 48], ["kidney", 56], ["disease", 63], ["(", 71], ["CKD", 72], [")", 75], ["and", 77], ["its", 81], ["importance", 85], ["in", 96], ["supporting", 99], ["erythropoiesis", 110], ["is", 125], ["unquestioned", 128], ["especially", 141], ["in", 152], ["those", 155], ["patients", 161], ["treated", 170], ["with", 178], ["erythropoietin", 183], [".", 197], ["Clinical", 199], ["symptomatology", 208], ["such", 223], ["as", 228], ["fatigability", 231], [",", 243], ["cold", 245], ["intolerance", 250], [",", 261], ["failure", 263], ["to", 271], ["concentrate", 274], ["and", 286], ["poor", 290], ["effort", 295], ["intolerance", 302], ["is", 314], ["often", 317], ["attributed", 323], ["to", 334], ["anemia", 337], ["or", 344], ["uremia", 347], [".", 353], ["That", 355], ["iron", 360], ["deficiency", 365], [",", 375], ["per", 377], ["se", 381], [",", 383], ["can", 385], ["cause", 389], ["these", 395], ["symptoms", 401], ["is", 410], ["poorly", 413], ["recognized", 420], [".", 430], ["Clinical", 432], ["and", 441], ["animal", 445], ["studies", 452], ["that", 460], ["support", 465], ["the", 473], ["benefits", 477], ["of", 486], ["iron", 489], ["supplementation", 494], [",", 509], ["independent", 511], ["of", 523], ["increasing", 526], ["hemoglobin", 537], [",", 547], ["such", 549], ["as", 554], ["those", 557], ["on", 563], ["immune", 566], ["function", 573], [",", 581], ["physical", 583], ["performance", 592], [",", 603], ["thermoregulation", 605], [",", 621], ["cognition", 623], [",", 632], ["and", 634], ["restless", 638], ["leg", 647], ["syndrome", 651], ["and", 660], ["aluminum", 664], ["absorption", 673], ["is", 684], ["the", 687], ["subject", 691], ["of", 699], ["this", 702], ["narrative", 707], ["review", 717], [".", 723]]}
{"context": "The nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 (Dapivirine) effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission. Both drugs had a favorable therapeutic index. A 24-h treatment with 1,000 nM UC-781 or 100 nM TMC120-R147681 prevented cell-free HIV infection, whereas 10-fold-higher concentrations blocked cell-associated HIV.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "c3236d984bae4fe9a702753a63371250", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[74, 74], [17, 17], [62, 62]], "char_spans": [[479, 481], [142, 144], [402, 404]]}]}], "context_tokens": [["The", 0], ["nonnucleoside", 4], ["reverse", 18], ["transcriptase", 26], ["inhibitors", 40], ["UC-781", 51], ["and", 58], ["TMC120-R147681", 62], ["(", 77], ["Dapivirine", 78], [")", 88], ["effectively", 90], ["prevented", 102], ["human", 112], ["immunodeficiency", 118], ["virus", 135], ["(", 141], ["HIV", 142], [")", 145], ["infection", 147], ["in", 157], ["cocultures", 160], ["of", 171], ["monocyte", 174], ["-", 182], ["derived", 183], ["dendritic", 191], ["cells", 201], ["and", 207], ["T", 211], ["cells", 213], [",", 218], ["representing", 220], ["primary", 233], ["targets", 241], ["in", 249], ["sexual", 252], ["transmission", 259], [".", 271], ["Both", 273], ["drugs", 278], ["had", 284], ["a", 288], ["favorable", 290], ["therapeutic", 300], ["index", 312], [".", 317], ["A", 319], ["24-h", 321], ["treatment", 326], ["with", 336], ["1,000", 341], ["nM", 347], ["UC-781", 350], ["or", 357], ["100", 360], ["nM", 364], ["TMC120-R147681", 367], ["prevented", 382], ["cell", 392], ["-", 396], ["free", 397], ["HIV", 402], ["infection", 406], [",", 415], ["whereas", 417], ["10-fold", 425], ["-", 432], ["higher", 433], ["concentrations", 440], ["blocked", 455], ["cell", 463], ["-", 467], ["associated", 468], ["HIV", 479], [".", 482]]}
{"context": "The purpose of this paper is to assess the reliability and validity of the Spanish version of the Davidson trauma scale (DTS-S) and to determine the prevalence and correlates of post-traumatic stress disorder (PTSD) symptoms in a non-clinical random sample of prison inmates. Probabilistic samples of 1,179 inmates from 26 penal institutions in Puerto Rico were selected using a multistage sampling design. Population estimates and correlations were obtained for PTSD, generalized anxiety and depression. The reliability, factor structure, and convergent validity of the DTS-S were assessed. Cross-validation was employed to confirm the results of the factor analyses. Using the cut-offs adopted by the scale's author, 136 (13.4 percent) of the inmates are likely to have current PTSD and 117 (11.6 percent) reach the cut-off for sub-threshold PTSD. Confirmatory factor analysis generated two factors explaining 53 percent of the variance. High reliabilities were obtained for the total scale (\u03b1=0.95) and for the frequency and severity scales (\u03b1=0.90 and 0.91). Significantly higher DTS-S scores were found for females (t=2.26, p<0.025), for inmates diagnosed with depression or anxiety (t=2.02, p<0.05), and those reporting suicide attempts (t=4.47, p<0.0001). Findings support that the DTS-S is a reliable and valid measure to assess PTSD symptoms in Latino inmate populations and to identify individuals at risk for the disorder that require confirmatory diagnosis and clinical interventions.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b6a2b5c8312645a99ca848d823503319", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[34, 38]], "char_spans": [[178, 207]]}, {"text": "PTSD", "token_spans": [[160, 160], [144, 144], [40, 40], [254, 254], [81, 81]], "char_spans": [[844, 847], [780, 783], [210, 213], [1337, 1340], [463, 466]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["paper", 20], ["is", 26], ["to", 29], ["assess", 32], ["the", 39], ["reliability", 43], ["and", 55], ["validity", 59], ["of", 68], ["the", 71], ["Spanish", 75], ["version", 83], ["of", 91], ["the", 94], ["Davidson", 98], ["trauma", 107], ["scale", 114], ["(", 120], ["DTS", 121], ["-", 124], ["S", 125], [")", 126], ["and", 128], ["to", 132], ["determine", 135], ["the", 145], ["prevalence", 149], ["and", 160], ["correlates", 164], ["of", 175], ["post", 178], ["-", 182], ["traumatic", 183], ["stress", 193], ["disorder", 200], ["(", 209], ["PTSD", 210], [")", 214], ["symptoms", 216], ["in", 225], ["a", 228], ["non", 230], ["-", 233], ["clinical", 234], ["random", 243], ["sample", 250], ["of", 257], ["prison", 260], ["inmates", 267], [".", 274], ["Probabilistic", 276], ["samples", 290], ["of", 298], ["1,179", 301], ["inmates", 307], ["from", 315], ["26", 320], ["penal", 323], ["institutions", 329], ["in", 342], ["Puerto", 345], ["Rico", 352], ["were", 357], ["selected", 362], ["using", 371], ["a", 377], ["multistage", 379], ["sampling", 390], ["design", 399], [".", 405], ["Population", 407], ["estimates", 418], ["and", 428], ["correlations", 432], ["were", 445], ["obtained", 450], ["for", 459], ["PTSD", 463], [",", 467], ["generalized", 469], ["anxiety", 481], ["and", 489], ["depression", 493], [".", 503], ["The", 505], ["reliability", 509], [",", 520], ["factor", 522], ["structure", 529], [",", 538], ["and", 540], ["convergent", 544], ["validity", 555], ["of", 564], ["the", 567], ["DTS", 571], ["-", 574], ["S", 575], ["were", 577], ["assessed", 582], [".", 590], ["Cross", 592], ["-", 597], ["validation", 598], ["was", 609], ["employed", 613], ["to", 622], ["confirm", 625], ["the", 633], ["results", 637], ["of", 645], ["the", 648], ["factor", 652], ["analyses", 659], [".", 667], ["Using", 669], ["the", 675], ["cut", 679], ["-", 682], ["offs", 683], ["adopted", 688], ["by", 696], ["the", 699], ["scale", 703], ["'s", 708], ["author", 711], [",", 717], ["136", 719], ["(", 723], ["13.4", 724], ["percent", 729], [")", 736], ["of", 738], ["the", 741], ["inmates", 745], ["are", 753], ["likely", 757], ["to", 764], ["have", 767], ["current", 772], ["PTSD", 780], ["and", 785], ["117", 789], ["(", 793], ["11.6", 794], ["percent", 799], [")", 806], ["reach", 808], ["the", 814], ["cut", 818], ["-", 821], ["off", 822], ["for", 826], ["sub", 830], ["-", 833], ["threshold", 834], ["PTSD", 844], [".", 848], ["Confirmatory", 850], ["factor", 863], ["analysis", 870], ["generated", 879], ["two", 889], ["factors", 893], ["explaining", 901], ["53", 912], ["percent", 915], ["of", 923], ["the", 926], ["variance", 930], [".", 938], ["High", 940], ["reliabilities", 945], ["were", 959], ["obtained", 964], ["for", 973], ["the", 977], ["total", 981], ["scale", 987], ["(", 993], ["\u03b1=0.95", 994], [")", 1000], ["and", 1002], ["for", 1006], ["the", 1010], ["frequency", 1014], ["and", 1024], ["severity", 1028], ["scales", 1037], ["(", 1044], ["\u03b1=0.90", 1045], ["and", 1052], ["0.91", 1056], [")", 1060], [".", 1061], ["Significantly", 1063], ["higher", 1077], ["DTS", 1084], ["-", 1087], ["S", 1088], ["scores", 1090], ["were", 1097], ["found", 1102], ["for", 1108], ["females", 1112], ["(", 1120], ["t=2.26", 1121], [",", 1127], ["p<0.025", 1129], [")", 1136], [",", 1137], ["for", 1139], ["inmates", 1143], ["diagnosed", 1151], ["with", 1161], ["depression", 1166], ["or", 1177], ["anxiety", 1180], ["(", 1188], ["t=2.02", 1189], [",", 1195], ["p<0.05", 1197], [")", 1203], [",", 1204], ["and", 1206], ["those", 1210], ["reporting", 1216], ["suicide", 1226], ["attempts", 1234], ["(", 1243], ["t=4.47", 1244], [",", 1250], ["p<0.0001", 1252], [")", 1260], [".", 1261], ["Findings", 1263], ["support", 1272], ["that", 1280], ["the", 1285], ["DTS", 1289], ["-", 1292], ["S", 1293], ["is", 1295], ["a", 1298], ["reliable", 1300], ["and", 1309], ["valid", 1313], ["measure", 1319], ["to", 1327], ["assess", 1330], ["PTSD", 1337], ["symptoms", 1342], ["in", 1351], ["Latino", 1354], ["inmate", 1361], ["populations", 1368], ["and", 1380], ["to", 1384], ["identify", 1387], ["individuals", 1396], ["at", 1408], ["risk", 1411], ["for", 1416], ["the", 1420], ["disorder", 1424], ["that", 1433], ["require", 1438], ["confirmatory", 1446], ["diagnosis", 1459], ["and", 1469], ["clinical", 1473], ["interventions", 1482], [".", 1495]]}
{"context": "To assess the potential of polymeric nanoparticles (NPs) to affect the genital distribution and local and systemic pharmacokinetics (PK) of the anti-HIV microbicide drug candidate dapivirine after vaginal delivery. Dapivirine-loaded, poly(ethylene oxide)-coated poly(epsilon-caprolactone) (PEO-PCL) NPs were prepared by a nanoprecipitation method. Genital distribution of NPs and their ability to modify the PK of dapivirine up to 24 h was assessed after vaginal instillation in a female mouse model. Also, the safety of NPs upon daily administration for 14 days was assessed by histological analysis and chemokine/cytokine content in vaginal lavages. PEO-PCL NPs (180-200 nm) were rapidly eliminated after administration but able to distribute throughout the vagina and lower uterus, and capable of tackling mucus and penetrate the epithelial lining. Nanocarriers modified the PK of dapivirine, with higher drug levels being recovered from vaginal lavages and vaginal/lower uterine tissues as compared to a drug suspension. Systemic drug exposure was reduced when NPs were used. Also, NPs were shown safe upon administration for 14 days. Dapivirine-loaded PEO-PCL NPs were able to provide likely favorable genital drug levels, thus attesting the potential value of using this vaginal drug delivery nanosystem in the context of HIV prophylaxis.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "1e55c4f1758248f58dd8977c35ab8ead", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[27, 27], [234, 234]], "char_spans": [[149, 151], [1328, 1330]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["potential", 14], ["of", 24], ["polymeric", 27], ["nanoparticles", 37], ["(", 51], ["NPs", 52], [")", 55], ["to", 57], ["affect", 60], ["the", 67], ["genital", 71], ["distribution", 79], ["and", 92], ["local", 96], ["and", 102], ["systemic", 106], ["pharmacokinetics", 115], ["(", 132], ["PK", 133], [")", 135], ["of", 137], ["the", 140], ["anti", 144], ["-", 148], ["HIV", 149], ["microbicide", 153], ["drug", 165], ["candidate", 170], ["dapivirine", 180], ["after", 191], ["vaginal", 197], ["delivery", 205], [".", 213], ["Dapivirine", 215], ["-", 225], ["loaded", 226], [",", 232], ["poly(ethylene", 234], ["oxide)-coated", 248], ["poly(epsilon", 262], ["-", 274], ["caprolactone", 275], [")", 287], ["(", 289], ["PEO", 290], ["-", 293], ["PCL", 294], [")", 297], ["NPs", 299], ["were", 303], ["prepared", 308], ["by", 317], ["a", 320], ["nanoprecipitation", 322], ["method", 340], [".", 346], ["Genital", 348], ["distribution", 356], ["of", 369], ["NPs", 372], ["and", 376], ["their", 380], ["ability", 386], ["to", 394], ["modify", 397], ["the", 404], ["PK", 408], ["of", 411], ["dapivirine", 414], ["up", 425], ["to", 428], ["24", 431], ["h", 434], ["was", 436], ["assessed", 440], ["after", 449], ["vaginal", 455], ["instillation", 463], ["in", 476], ["a", 479], ["female", 481], ["mouse", 488], ["model", 494], [".", 499], ["Also", 501], [",", 505], ["the", 507], ["safety", 511], ["of", 518], ["NPs", 521], ["upon", 525], ["daily", 530], ["administration", 536], ["for", 551], ["14", 555], ["days", 558], ["was", 563], ["assessed", 567], ["by", 576], ["histological", 579], ["analysis", 592], ["and", 601], ["chemokine", 605], ["/", 614], ["cytokine", 615], ["content", 624], ["in", 632], ["vaginal", 635], ["lavages", 643], [".", 650], ["PEO", 652], ["-", 655], ["PCL", 656], ["NPs", 660], ["(", 664], ["180", 665], ["-", 668], ["200", 669], ["nm", 673], [")", 675], ["were", 677], ["rapidly", 682], ["eliminated", 690], ["after", 701], ["administration", 707], ["but", 722], ["able", 726], ["to", 731], ["distribute", 734], ["throughout", 745], ["the", 756], ["vagina", 760], ["and", 767], ["lower", 771], ["uterus", 777], [",", 783], ["and", 785], ["capable", 789], ["of", 797], ["tackling", 800], ["mucus", 809], ["and", 815], ["penetrate", 819], ["the", 829], ["epithelial", 833], ["lining", 844], [".", 850], ["Nanocarriers", 852], ["modified", 865], ["the", 874], ["PK", 878], ["of", 881], ["dapivirine", 884], [",", 894], ["with", 896], ["higher", 901], ["drug", 908], ["levels", 913], ["being", 920], ["recovered", 926], ["from", 936], ["vaginal", 941], ["lavages", 949], ["and", 957], ["vaginal", 961], ["/", 968], ["lower", 969], ["uterine", 975], ["tissues", 983], ["as", 991], ["compared", 994], ["to", 1003], ["a", 1006], ["drug", 1008], ["suspension", 1013], [".", 1023], ["Systemic", 1025], ["drug", 1034], ["exposure", 1039], ["was", 1048], ["reduced", 1052], ["when", 1060], ["NPs", 1065], ["were", 1069], ["used", 1074], [".", 1078], ["Also", 1080], [",", 1084], ["NPs", 1086], ["were", 1090], ["shown", 1095], ["safe", 1101], ["upon", 1106], ["administration", 1111], ["for", 1126], ["14", 1130], ["days", 1133], [".", 1137], ["Dapivirine", 1139], ["-", 1149], ["loaded", 1150], ["PEO", 1157], ["-", 1160], ["PCL", 1161], ["NPs", 1165], ["were", 1169], ["able", 1174], ["to", 1179], ["provide", 1182], ["likely", 1190], ["favorable", 1197], ["genital", 1207], ["drug", 1215], ["levels", 1220], [",", 1226], ["thus", 1228], ["attesting", 1233], ["the", 1243], ["potential", 1247], ["value", 1257], ["of", 1263], ["using", 1266], ["this", 1272], ["vaginal", 1277], ["drug", 1285], ["delivery", 1290], ["nanosystem", 1299], ["in", 1310], ["the", 1313], ["context", 1317], ["of", 1325], ["HIV", 1328], ["prophylaxis", 1332], [".", 1343]]}
{"context": "By using monoclonal antibodies raised against isolated clam centrosomes, we have identified a novel 135-kD centrosomal protein (Cep135), present in a wide range of organisms. Cep135 is located at the centrosome throughout the cell cycle, and localization is independent of the microtubule network. It distributes throughout the centrosomal area in association with the electron-dense material surrounding centrioles. Sequence analysis of cDNA isolated from CHO cells predicted a protein of 1,145-amino acid residues with extensive alpha-helical domains. Expression of a series of deletion constructs revealed the presence of three independent centrosome-targeting domains. Overexpression of Cep135 resulted in the accumulation of unique whorl-like particles in both the centrosome and the cytoplasm. Although their size, shape, and number varied according to the level of protein expression, these whorls were composed of parallel dense lines arranged in a 6-nm space. Altered levels of Cep135 by protein overexpression and/or suppression of endogenous Cep135 by RNA interference caused disorganization of interphase and mitotic spindle microtubules. Thus, Cep135 may play an important role in the centrosomal function of organizing microtubules in mammalian cells.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "531659cef16e4f2d9ad354129f13c0c8", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[123, 123], [35, 35], [102, 102]], "char_spans": [[770, 779], [200, 209], [643, 652]]}]}], "context_tokens": [["By", 0], ["using", 3], ["monoclonal", 9], ["antibodies", 20], ["raised", 31], ["against", 38], ["isolated", 46], ["clam", 55], ["centrosomes", 60], [",", 71], ["we", 73], ["have", 76], ["identified", 81], ["a", 92], ["novel", 94], ["135-kD", 100], ["centrosomal", 107], ["protein", 119], ["(", 127], ["Cep135", 128], [")", 134], [",", 135], ["present", 137], ["in", 145], ["a", 148], ["wide", 150], ["range", 155], ["of", 161], ["organisms", 164], [".", 173], ["Cep135", 175], ["is", 182], ["located", 185], ["at", 193], ["the", 196], ["centrosome", 200], ["throughout", 211], ["the", 222], ["cell", 226], ["cycle", 231], [",", 236], ["and", 238], ["localization", 242], ["is", 255], ["independent", 258], ["of", 270], ["the", 273], ["microtubule", 277], ["network", 289], [".", 296], ["It", 298], ["distributes", 301], ["throughout", 313], ["the", 324], ["centrosomal", 328], ["area", 340], ["in", 345], ["association", 348], ["with", 360], ["the", 365], ["electron", 369], ["-", 377], ["dense", 378], ["material", 384], ["surrounding", 393], ["centrioles", 405], [".", 415], ["Sequence", 417], ["analysis", 426], ["of", 435], ["cDNA", 438], ["isolated", 443], ["from", 452], ["CHO", 457], ["cells", 461], ["predicted", 467], ["a", 477], ["protein", 479], ["of", 487], ["1,145-amino", 490], ["acid", 502], ["residues", 507], ["with", 516], ["extensive", 521], ["alpha", 531], ["-", 536], ["helical", 537], ["domains", 545], [".", 552], ["Expression", 554], ["of", 565], ["a", 568], ["series", 570], ["of", 577], ["deletion", 580], ["constructs", 589], ["revealed", 600], ["the", 609], ["presence", 613], ["of", 622], ["three", 625], ["independent", 631], ["centrosome", 643], ["-", 653], ["targeting", 654], ["domains", 664], [".", 671], ["Overexpression", 673], ["of", 688], ["Cep135", 691], ["resulted", 698], ["in", 707], ["the", 710], ["accumulation", 714], ["of", 727], ["unique", 730], ["whorl", 737], ["-", 742], ["like", 743], ["particles", 748], ["in", 758], ["both", 761], ["the", 766], ["centrosome", 770], ["and", 781], ["the", 785], ["cytoplasm", 789], [".", 798], ["Although", 800], ["their", 809], ["size", 815], [",", 819], ["shape", 821], [",", 826], ["and", 828], ["number", 832], ["varied", 839], ["according", 846], ["to", 856], ["the", 859], ["level", 863], ["of", 869], ["protein", 872], ["expression", 880], [",", 890], ["these", 892], ["whorls", 898], ["were", 905], ["composed", 910], ["of", 919], ["parallel", 922], ["dense", 931], ["lines", 937], ["arranged", 943], ["in", 952], ["a", 955], ["6-nm", 957], ["space", 962], [".", 967], ["Altered", 969], ["levels", 977], ["of", 984], ["Cep135", 987], ["by", 994], ["protein", 997], ["overexpression", 1005], ["and/or", 1020], ["suppression", 1027], ["of", 1039], ["endogenous", 1042], ["Cep135", 1053], ["by", 1060], ["RNA", 1063], ["interference", 1067], ["caused", 1080], ["disorganization", 1087], ["of", 1103], ["interphase", 1106], ["and", 1117], ["mitotic", 1121], ["spindle", 1129], ["microtubules", 1137], [".", 1149], ["Thus", 1151], [",", 1155], ["Cep135", 1157], ["may", 1164], ["play", 1168], ["an", 1173], ["important", 1176], ["role", 1186], ["in", 1191], ["the", 1194], ["centrosomal", 1198], ["function", 1210], ["of", 1219], ["organizing", 1222], ["microtubules", 1233], ["in", 1246], ["mammalian", 1249], ["cells", 1259], [".", 1264]]}
{"context": "Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor. In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21). We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004). Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clinically relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003). Because most mutation-positive tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime (\"never smokers\"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers. Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001). Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concentrations of drug. Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "29f2855a4f1e49cabf0d468c74465cb7", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[12, 19]], "char_spans": [[60, 103]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["the", 21], ["tyrosine", 25], ["kinase", 34], ["(", 41], ["TK", 42], [")", 44], ["domain", 46], ["of", 53], ["the", 56], ["epidermal", 60], ["growth", 70], ["factor", 77], ["receptor", 84], ["(", 93], ["EGFR", 94], [")", 98], ["gene", 100], ["are", 105], ["reportedly", 109], ["associated", 120], ["with", 131], ["sensitivity", 136], ["of", 148], ["lung", 151], ["cancers", 156], ["to", 164], ["gefitinib", 167], ["(", 177], ["Iressa", 178], [")", 184], [",", 185], ["kinase", 187], ["inhibitor", 194], [".", 203], ["In", 205], ["-", 207], ["frame", 208], ["deletions", 214], ["occur", 224], ["in", 230], ["exon", 233], ["19", 238], [",", 240], ["whereas", 242], ["point", 250], ["mutations", 256], ["occur", 266], ["frequently", 272], ["in", 283], ["codon", 286], ["858", 292], ["(", 296], ["exon", 297], ["21", 302], [")", 304], [".", 305], ["We", 307], ["found", 310], ["from", 316], ["sequencing", 321], ["the", 332], ["EGFR", 336], ["TK", 341], ["domain", 344], ["that", 351], ["7", 356], ["of", 358], ["10", 361], ["gefitinib", 364], ["-", 373], ["sensitive", 374], ["tumors", 384], ["had", 391], ["similar", 395], ["types", 403], ["of", 409], ["alterations", 412], [";", 423], ["no", 425], ["mutations", 428], ["were", 438], ["found", 443], ["in", 449], ["eight", 452], ["gefitinib", 458], ["-", 467], ["refractory", 468], ["tumors", 479], ["(", 486], ["P", 487], ["=", 489], ["0.004", 491], [")", 496], [".", 497], ["Five", 499], ["of", 504], ["seven", 507], ["tumors", 513], ["sensitive", 520], ["to", 530], ["erlotinib", 533], ["(", 543], ["Tarceva", 544], [")", 551], [",", 552], ["a", 554], ["related", 556], ["kinase", 564], ["inhibitor", 571], ["for", 581], ["which", 585], ["the", 591], ["clinically", 595], ["relevant", 606], ["target", 615], ["is", 622], ["undocumented", 625], [",", 637], ["had", 639], ["analogous", 643], ["somatic", 653], ["mutations", 661], [",", 670], ["as", 672], ["opposed", 675], ["to", 683], ["none", 686], ["of", 691], ["10", 694], ["erlotinib", 697], ["-", 706], ["refractory", 707], ["tumors", 718], ["(", 725], ["P", 726], ["=", 728], ["0.003", 730], [")", 735], [".", 736], ["Because", 738], ["most", 746], ["mutation", 751], ["-", 759], ["positive", 760], ["tumors", 769], ["were", 776], ["adenocarcinomas", 781], ["from", 797], ["patients", 802], ["who", 811], ["smoked", 815], ["<", 822], ["100", 823], ["cigarettes", 827], ["in", 838], ["a", 841], ["lifetime", 843], ["(", 852], ["\"", 853], ["never", 854], ["smokers", 860], ["\"", 867], [")", 868], [",", 869], ["we", 871], ["screened", 874], ["EGFR", 883], ["exons", 888], ["2", 894], ["-", 895], ["28", 896], ["in", 899], ["15", 902], ["adenocarcinomas", 905], ["resected", 921], ["from", 930], ["untreated", 935], ["never", 945], ["smokers", 951], [".", 958], ["Seven", 960], ["tumors", 966], ["had", 973], ["TK", 977], ["domain", 980], ["mutations", 987], [",", 996], ["in", 998], ["contrast", 1001], ["to", 1010], ["4", 1013], ["of", 1015], ["81", 1018], ["non", 1021], ["-", 1024], ["small", 1025], ["cell", 1031], ["lung", 1036], ["cancers", 1041], ["resected", 1049], ["from", 1058], ["untreated", 1063], ["former", 1073], ["or", 1080], ["current", 1083], ["smokers", 1091], ["(", 1099], ["P", 1100], ["=", 1102], ["0.0001", 1104], [")", 1110], [".", 1111], ["Immunoblotting", 1113], ["of", 1128], ["lysates", 1131], ["from", 1139], ["cells", 1144], ["transiently", 1150], ["transfected", 1162], ["with", 1174], ["various", 1179], ["EGFR", 1187], ["constructs", 1192], ["demonstrated", 1203], ["that", 1216], [",", 1220], ["compared", 1222], ["to", 1231], ["wild", 1234], ["-", 1238], ["type", 1239], ["protein", 1244], [",", 1251], ["an", 1253], ["exon", 1256], ["19", 1261], ["deletion", 1264], ["mutant", 1273], ["induced", 1280], ["diminished", 1288], ["levels", 1299], ["of", 1306], ["phosphotyrosine", 1309], [",", 1324], ["whereas", 1326], ["the", 1334], ["phosphorylation", 1338], ["at", 1354], ["tyrosine", 1357], ["1092", 1366], ["of", 1371], ["an", 1374], ["exon", 1377], ["21", 1382], ["point", 1385], ["mutant", 1391], ["was", 1398], ["inhibited", 1402], ["at", 1412], ["10-fold", 1415], ["lower", 1423], ["concentrations", 1429], ["of", 1444], ["drug", 1447], [".", 1451], ["Collectively", 1453], [",", 1465], ["these", 1467], ["data", 1473], ["show", 1478], ["that", 1483], ["adenocarcinomas", 1488], ["from", 1504], ["never", 1509], ["smokers", 1515], ["comprise", 1523], ["a", 1532], ["distinct", 1534], ["subset", 1543], ["of", 1550], ["lung", 1553], ["cancers", 1558], [",", 1565], ["frequently", 1567], ["containing", 1578], ["mutations", 1589], ["within", 1599], ["the", 1606], ["TK", 1610], ["domain", 1613], ["of", 1620], ["EGFR", 1623], ["that", 1628], ["are", 1633], ["associated", 1637], ["with", 1648], ["gefitinib", 1653], ["and", 1663], ["erlotinib", 1667], ["sensitivity", 1677], [".", 1688]]}
{"context": "LHCII, the most abundant membrane protein on earth, is the major light-harvesting complex of plants. It is generally accepted that LHCII is associated with Photosystem II and only as a short-term response to overexcitation of PSII a subset moves to Photosystem I, triggered by its phosphorylation (state1 to state2 transition). However, here we show that in most natural light conditions LHCII serves as an antenna of both Photosystem I and Photosystem II and it is quantitatively demonstrated that this is required to achieve excitation balance between the two photosystems. This allows for acclimation to different light intensities simply by regulating the expression of LHCII genes only. It is demonstrated that indeed the amount of LHCII that is bound to both photosystems decreases when growth light intensity increases and vice versa. Finally, time-resolved fluorescence measurements on the photosynthetic thylakoid membranes show that LHCII is even a more efficient light harvester when associated with Photosystem I than with Photosystem II.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "60b7c837674146058fe26d85952d6ef1", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[0, 0], [128, 128], [116, 116], [25, 25], [72, 72], [159, 159]], "char_spans": [[0, 4], [737, 741], [674, 678], [131, 135], [388, 392], [943, 947]]}]}], "context_tokens": [["LHCII", 0], [",", 5], ["the", 7], ["most", 11], ["abundant", 16], ["membrane", 25], ["protein", 34], ["on", 42], ["earth", 45], [",", 50], ["is", 52], ["the", 55], ["major", 59], ["light", 65], ["-", 70], ["harvesting", 71], ["complex", 82], ["of", 90], ["plants", 93], [".", 99], ["It", 101], ["is", 104], ["generally", 107], ["accepted", 117], ["that", 126], ["LHCII", 131], ["is", 137], ["associated", 140], ["with", 151], ["Photosystem", 156], ["II", 168], ["and", 171], ["only", 175], ["as", 180], ["a", 183], ["short", 185], ["-", 190], ["term", 191], ["response", 196], ["to", 205], ["overexcitation", 208], ["of", 223], ["PSII", 226], ["a", 231], ["subset", 233], ["moves", 240], ["to", 246], ["Photosystem", 249], ["I", 261], [",", 262], ["triggered", 264], ["by", 274], ["its", 277], ["phosphorylation", 281], ["(", 297], ["state1", 298], ["to", 305], ["state2", 308], ["transition", 315], [")", 325], [".", 326], ["However", 328], [",", 335], ["here", 337], ["we", 342], ["show", 345], ["that", 350], ["in", 355], ["most", 358], ["natural", 363], ["light", 371], ["conditions", 377], ["LHCII", 388], ["serves", 394], ["as", 401], ["an", 404], ["antenna", 407], ["of", 415], ["both", 418], ["Photosystem", 423], ["I", 435], ["and", 437], ["Photosystem", 441], ["II", 453], ["and", 456], ["it", 460], ["is", 463], ["quantitatively", 466], ["demonstrated", 481], ["that", 494], ["this", 499], ["is", 504], ["required", 507], ["to", 516], ["achieve", 519], ["excitation", 527], ["balance", 538], ["between", 546], ["the", 554], ["two", 558], ["photosystems", 562], [".", 574], ["This", 576], ["allows", 581], ["for", 588], ["acclimation", 592], ["to", 604], ["different", 607], ["light", 617], ["intensities", 623], ["simply", 635], ["by", 642], ["regulating", 645], ["the", 656], ["expression", 660], ["of", 671], ["LHCII", 674], ["genes", 680], ["only", 686], [".", 690], ["It", 692], ["is", 695], ["demonstrated", 698], ["that", 711], ["indeed", 716], ["the", 723], ["amount", 727], ["of", 734], ["LHCII", 737], ["that", 743], ["is", 748], ["bound", 751], ["to", 757], ["both", 760], ["photosystems", 765], ["decreases", 778], ["when", 788], ["growth", 793], ["light", 800], ["intensity", 806], ["increases", 816], ["and", 826], ["vice", 830], ["versa", 835], [".", 840], ["Finally", 842], [",", 849], ["time", 851], ["-", 855], ["resolved", 856], ["fluorescence", 865], ["measurements", 878], ["on", 891], ["the", 894], ["photosynthetic", 898], ["thylakoid", 913], ["membranes", 923], ["show", 933], ["that", 938], ["LHCII", 943], ["is", 949], ["even", 952], ["a", 957], ["more", 959], ["efficient", 964], ["light", 974], ["harvester", 980], ["when", 990], ["associated", 995], ["with", 1006], ["Photosystem", 1011], ["I", 1023], ["than", 1025], ["with", 1030], ["Photosystem", 1035], ["II", 1047], [".", 1049]]}
{"context": "Diamond-Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by hypoproliferative anemia, associated physical malformations and a predisposition to cancer. DBA has been associated with mutations and deletions in the large and small ribosomal protein genes, and genetic aberrations have been detected in \u223c50-60% of patients. In this study, nine Korean DBA patients were screened for mutations in eight known DBA genes (RPS19, RPS24, RPS17, RPS10, RPS26, RPL35A, RPL5 and RPL11) using the direct sequencing method. Mutations in RPS19, RPS26 and RPS17 were detected in four, two and one patient, respectively. Among the mutations detected in RPS19, two mutations were novel (c.26T>A, c.357-2A>G). For the mutation-negative cases, array-CGH analysis was performed to identify copy-number variations, and no deletions involving the known DBA gene regions were identified. The relative mRNA expression of RPS19 estimated using real-time quantitative PCR analysis revealed two- to fourfold reductions in RPS19 mRNA expression in three patients with RPS19 mutations, and p53 protein expression analysis by immunohistochemistry showed variable but significant nuclear staining in the DBA patients. In conclusion, heterozygous mutations in the known DBA genes RPS19, RPS26 and RPS17 were detected in seven out of nine Korean DBA patients. Among these patients, RPS19 was the most frequently mutated gene. In addition, decreased RPS19 mRNA expression and p53 overexpression were observed in the Korean DBA patients, which supports the hypothesis that haploinsufficiency and p53 hyperactivation represent a central pathway underlying the pathogenesis of DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "7b98e597897f4b24bd7030143bae73d8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[5, 5], [229, 229], [74, 74], [218, 218], [294, 294], [28, 28], [244, 244], [167, 167], [274, 274], [65, 65]], "char_spans": [[25, 27], [1268, 1270], [435, 437], [1203, 1205], [1670, 1672], [184, 186], [1343, 1345], [861, 863], [1519, 1521], [379, 381]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["congenital", 35], ["bone", 46], ["marrow", 51], ["failure", 58], ["syndrome", 66], ["characterized", 75], ["by", 89], ["hypoproliferative", 92], ["anemia", 110], [",", 116], ["associated", 118], ["physical", 129], ["malformations", 138], ["and", 152], ["a", 156], ["predisposition", 158], ["to", 173], ["cancer", 176], [".", 182], ["DBA", 184], ["has", 188], ["been", 192], ["associated", 197], ["with", 208], ["mutations", 213], ["and", 223], ["deletions", 227], ["in", 237], ["the", 240], ["large", 244], ["and", 250], ["small", 254], ["ribosomal", 260], ["protein", 270], ["genes", 278], [",", 283], ["and", 285], ["genetic", 289], ["aberrations", 297], ["have", 309], ["been", 314], ["detected", 319], ["in", 328], ["\u223c50", 331], ["-", 334], ["60", 335], ["%", 337], ["of", 339], ["patients", 342], [".", 350], ["In", 352], ["this", 355], ["study", 360], [",", 365], ["nine", 367], ["Korean", 372], ["DBA", 379], ["patients", 383], ["were", 392], ["screened", 397], ["for", 406], ["mutations", 410], ["in", 420], ["eight", 423], ["known", 429], ["DBA", 435], ["genes", 439], ["(", 445], ["RPS19", 446], [",", 451], ["RPS24", 453], [",", 458], ["RPS17", 460], [",", 465], ["RPS10", 467], [",", 472], ["RPS26", 474], [",", 479], ["RPL35A", 481], [",", 487], ["RPL5", 489], ["and", 494], ["RPL11", 498], [")", 503], ["using", 505], ["the", 511], ["direct", 515], ["sequencing", 522], ["method", 533], [".", 539], ["Mutations", 541], ["in", 551], ["RPS19", 554], [",", 559], ["RPS26", 561], ["and", 567], ["RPS17", 571], ["were", 577], ["detected", 582], ["in", 591], ["four", 594], [",", 598], ["two", 600], ["and", 604], ["one", 608], ["patient", 612], [",", 619], ["respectively", 621], [".", 633], ["Among", 635], ["the", 641], ["mutations", 645], ["detected", 655], ["in", 664], ["RPS19", 667], [",", 672], ["two", 674], ["mutations", 678], ["were", 688], ["novel", 693], ["(", 699], ["c.26T", 700], [">", 705], ["A", 706], [",", 707], ["c.357", 709], ["-", 714], ["2A", 715], [">", 717], ["G", 718], [")", 719], [".", 720], ["For", 722], ["the", 726], ["mutation", 730], ["-", 738], ["negative", 739], ["cases", 748], [",", 753], ["array", 755], ["-", 760], ["CGH", 761], ["analysis", 765], ["was", 774], ["performed", 778], ["to", 788], ["identify", 791], ["copy", 800], ["-", 804], ["number", 805], ["variations", 812], [",", 822], ["and", 824], ["no", 828], ["deletions", 831], ["involving", 841], ["the", 851], ["known", 855], ["DBA", 861], ["gene", 865], ["regions", 870], ["were", 878], ["identified", 883], [".", 893], ["The", 895], ["relative", 899], ["mRNA", 908], ["expression", 913], ["of", 924], ["RPS19", 927], ["estimated", 933], ["using", 943], ["real", 949], ["-", 953], ["time", 954], ["quantitative", 959], ["PCR", 972], ["analysis", 976], ["revealed", 985], ["two-", 994], ["to", 999], ["fourfold", 1002], ["reductions", 1011], ["in", 1022], ["RPS19", 1025], ["mRNA", 1031], ["expression", 1036], ["in", 1047], ["three", 1050], ["patients", 1056], ["with", 1065], ["RPS19", 1070], ["mutations", 1076], [",", 1085], ["and", 1087], ["p53", 1091], ["protein", 1095], ["expression", 1103], ["analysis", 1114], ["by", 1123], ["immunohistochemistry", 1126], ["showed", 1147], ["variable", 1154], ["but", 1163], ["significant", 1167], ["nuclear", 1179], ["staining", 1187], ["in", 1196], ["the", 1199], ["DBA", 1203], ["patients", 1207], [".", 1215], ["In", 1217], ["conclusion", 1220], [",", 1230], ["heterozygous", 1232], ["mutations", 1245], ["in", 1255], ["the", 1258], ["known", 1262], ["DBA", 1268], ["genes", 1272], ["RPS19", 1278], [",", 1283], ["RPS26", 1285], ["and", 1291], ["RPS17", 1295], ["were", 1301], ["detected", 1306], ["in", 1315], ["seven", 1318], ["out", 1324], ["of", 1328], ["nine", 1331], ["Korean", 1336], ["DBA", 1343], ["patients", 1347], [".", 1355], ["Among", 1357], ["these", 1363], ["patients", 1369], [",", 1377], ["RPS19", 1379], ["was", 1385], ["the", 1389], ["most", 1393], ["frequently", 1398], ["mutated", 1409], ["gene", 1417], [".", 1421], ["In", 1423], ["addition", 1426], [",", 1434], ["decreased", 1436], ["RPS19", 1446], ["mRNA", 1452], ["expression", 1457], ["and", 1468], ["p53", 1472], ["overexpression", 1476], ["were", 1491], ["observed", 1496], ["in", 1505], ["the", 1508], ["Korean", 1512], ["DBA", 1519], ["patients", 1523], [",", 1531], ["which", 1533], ["supports", 1539], ["the", 1548], ["hypothesis", 1552], ["that", 1563], ["haploinsufficiency", 1568], ["and", 1587], ["p53", 1591], ["hyperactivation", 1595], ["represent", 1611], ["a", 1621], ["central", 1623], ["pathway", 1631], ["underlying", 1639], ["the", 1650], ["pathogenesis", 1654], ["of", 1667], ["DBA", 1670], [".", 1673]]}
{"context": "Disease patterns in RA vary between the sexes; the condition is more commonly seen in women, who exhibit a more aggressive disease and a poorer long-term outcome. Men, however, are more likely than women to die from extra-articular complications of rheumatoid disease. This chapter discusses the outcome and mortality studies that substantiate these conclusions and then examines the possible mechanisms that may account for them, including the HLA system, seropositivity, compliance, response to therapy and pain threshold. In particular, sex and sex hormones emerge as independent risk factors in rheumatoid disease. The epidemiological evidence points towards a peak age of onset of RA at the time of the menopause in women and towards later in life in men. Premenopausal women may fare better than postmenopausal women with RA. The possible protective effects of the oral contraceptive pill and the dramatic amelioration with pregnancy are well documented. In vivo and in vitro studies have demonstrated that sex hormones interfere with a number of the putative processes involved in the pathogenesis of RA, including immunoregulation, interaction with inflammatory mediators and the cytokine system, and direct effects on cartilage itself. All these observations point towards the importance of gonadal hormones. However, trials on the potential therapeutic use of sex hormones in RA are limited and, as yet, disappointing. Further work is necessary to determine whether the roles of sex hormones are as central protagonists or just supporting cast in the complex arena of rheumatoid disease.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "dd55ff8b09a7433aa467295dae5b0c62", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[16, 16], [127, 127], [137, 137], [40, 40], [143, 143]], "char_spans": [[86, 90], [721, 725], [775, 779], [198, 202], [817, 821]]}]}], "context_tokens": [["Disease", 0], ["patterns", 8], ["in", 17], ["RA", 20], ["vary", 23], ["between", 28], ["the", 36], ["sexes", 40], [";", 45], ["the", 47], ["condition", 51], ["is", 61], ["more", 64], ["commonly", 69], ["seen", 78], ["in", 83], ["women", 86], [",", 91], ["who", 93], ["exhibit", 97], ["a", 105], ["more", 107], ["aggressive", 112], ["disease", 123], ["and", 131], ["a", 135], ["poorer", 137], ["long", 144], ["-", 148], ["term", 149], ["outcome", 154], [".", 161], ["Men", 163], [",", 166], ["however", 168], [",", 175], ["are", 177], ["more", 181], ["likely", 186], ["than", 193], ["women", 198], ["to", 204], ["die", 207], ["from", 211], ["extra", 216], ["-", 221], ["articular", 222], ["complications", 232], ["of", 246], ["rheumatoid", 249], ["disease", 260], [".", 267], ["This", 269], ["chapter", 274], ["discusses", 282], ["the", 292], ["outcome", 296], ["and", 304], ["mortality", 308], ["studies", 318], ["that", 326], ["substantiate", 331], ["these", 344], ["conclusions", 350], ["and", 362], ["then", 366], ["examines", 371], ["the", 380], ["possible", 384], ["mechanisms", 393], ["that", 404], ["may", 409], ["account", 413], ["for", 421], ["them", 425], [",", 429], ["including", 431], ["the", 441], ["HLA", 445], ["system", 449], [",", 455], ["seropositivity", 457], [",", 471], ["compliance", 473], [",", 483], ["response", 485], ["to", 494], ["therapy", 497], ["and", 505], ["pain", 509], ["threshold", 514], [".", 523], ["In", 525], ["particular", 528], [",", 538], ["sex", 540], ["and", 544], ["sex", 548], ["hormones", 552], ["emerge", 561], ["as", 568], ["independent", 571], ["risk", 583], ["factors", 588], ["in", 596], ["rheumatoid", 599], ["disease", 610], [".", 617], ["The", 619], ["epidemiological", 623], ["evidence", 639], ["points", 648], ["towards", 655], ["a", 663], ["peak", 665], ["age", 670], ["of", 674], ["onset", 677], ["of", 683], ["RA", 686], ["at", 689], ["the", 692], ["time", 696], ["of", 701], ["the", 704], ["menopause", 708], ["in", 718], ["women", 721], ["and", 727], ["towards", 731], ["later", 739], ["in", 745], ["life", 748], ["in", 753], ["men", 756], [".", 759], ["Premenopausal", 761], ["women", 775], ["may", 781], ["fare", 785], ["better", 790], ["than", 797], ["postmenopausal", 802], ["women", 817], ["with", 823], ["RA", 828], [".", 830], ["The", 832], ["possible", 836], ["protective", 845], ["effects", 856], ["of", 864], ["the", 867], ["oral", 871], ["contraceptive", 876], ["pill", 890], ["and", 895], ["the", 899], ["dramatic", 903], ["amelioration", 912], ["with", 925], ["pregnancy", 930], ["are", 940], ["well", 944], ["documented", 949], [".", 959], ["In", 961], ["vivo", 964], ["and", 969], ["in", 973], ["vitro", 976], ["studies", 982], ["have", 990], ["demonstrated", 995], ["that", 1008], ["sex", 1013], ["hormones", 1017], ["interfere", 1026], ["with", 1036], ["a", 1041], ["number", 1043], ["of", 1050], ["the", 1053], ["putative", 1057], ["processes", 1066], ["involved", 1076], ["in", 1085], ["the", 1088], ["pathogenesis", 1092], ["of", 1105], ["RA", 1108], [",", 1110], ["including", 1112], ["immunoregulation", 1122], [",", 1138], ["interaction", 1140], ["with", 1152], ["inflammatory", 1157], ["mediators", 1170], ["and", 1180], ["the", 1184], ["cytokine", 1188], ["system", 1197], [",", 1203], ["and", 1205], ["direct", 1209], ["effects", 1216], ["on", 1224], ["cartilage", 1227], ["itself", 1237], [".", 1243], ["All", 1245], ["these", 1249], ["observations", 1255], ["point", 1268], ["towards", 1274], ["the", 1282], ["importance", 1286], ["of", 1297], ["gonadal", 1300], ["hormones", 1308], [".", 1316], ["However", 1318], [",", 1325], ["trials", 1327], ["on", 1334], ["the", 1337], ["potential", 1341], ["therapeutic", 1351], ["use", 1363], ["of", 1367], ["sex", 1370], ["hormones", 1374], ["in", 1383], ["RA", 1386], ["are", 1389], ["limited", 1393], ["and", 1401], [",", 1404], ["as", 1406], ["yet", 1409], [",", 1412], ["disappointing", 1414], [".", 1427], ["Further", 1429], ["work", 1437], ["is", 1442], ["necessary", 1445], ["to", 1455], ["determine", 1458], ["whether", 1468], ["the", 1476], ["roles", 1480], ["of", 1486], ["sex", 1489], ["hormones", 1493], ["are", 1502], ["as", 1506], ["central", 1509], ["protagonists", 1517], ["or", 1530], ["just", 1533], ["supporting", 1538], ["cast", 1549], ["in", 1554], ["the", 1557], ["complex", 1561], ["arena", 1569], ["of", 1575], ["rheumatoid", 1578], ["disease", 1589], [".", 1596]]}
{"context": "There has been much debate about the appropriate statistical methodology for the evaluation of malaria field studies and the challenges in interpreting data arising from these trials. The present paper describes, for a pivotal phase III efficacy of the RTS, S/AS01 malaria vaccine, the methods of the statistical analysis and the rationale for their selection. The methods used to estimate efficacy of the primary course of vaccination, and of a booster dose, in preventing clinical episodes of uncomplicated and severe malaria, and to determine the duration of protection, are described. The interpretation of various measures of efficacy in terms of the potential public health impact of the vaccine is discussed. The methodology selected to analyse the clinical trial must be scientifically sound, acceptable to regulatory authorities and meaningful to those responsible for malaria control and public health policy.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "565e79886a2d468ab49544a0c8e4d2c9", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[146, 146], [89, 89], [46, 46], [14, 14]], "char_spans": [[878, 884], [520, 526], [265, 271], [95, 101]]}]}], "context_tokens": [["There", 0], ["has", 6], ["been", 10], ["much", 15], ["debate", 20], ["about", 27], ["the", 33], ["appropriate", 37], ["statistical", 49], ["methodology", 61], ["for", 73], ["the", 77], ["evaluation", 81], ["of", 92], ["malaria", 95], ["field", 103], ["studies", 109], ["and", 117], ["the", 121], ["challenges", 125], ["in", 136], ["interpreting", 139], ["data", 152], ["arising", 157], ["from", 165], ["these", 170], ["trials", 176], [".", 182], ["The", 184], ["present", 188], ["paper", 196], ["describes", 202], [",", 211], ["for", 213], ["a", 217], ["pivotal", 219], ["phase", 227], ["III", 233], ["efficacy", 237], ["of", 246], ["the", 249], ["RTS", 253], [",", 256], ["S", 258], ["/", 259], ["AS01", 260], ["malaria", 265], ["vaccine", 273], [",", 280], ["the", 282], ["methods", 286], ["of", 294], ["the", 297], ["statistical", 301], ["analysis", 313], ["and", 322], ["the", 326], ["rationale", 330], ["for", 340], ["their", 344], ["selection", 350], [".", 359], ["The", 361], ["methods", 365], ["used", 373], ["to", 378], ["estimate", 381], ["efficacy", 390], ["of", 399], ["the", 402], ["primary", 406], ["course", 414], ["of", 421], ["vaccination", 424], [",", 435], ["and", 437], ["of", 441], ["a", 444], ["booster", 446], ["dose", 454], [",", 458], ["in", 460], ["preventing", 463], ["clinical", 474], ["episodes", 483], ["of", 492], ["uncomplicated", 495], ["and", 509], ["severe", 513], ["malaria", 520], [",", 527], ["and", 529], ["to", 533], ["determine", 536], ["the", 546], ["duration", 550], ["of", 559], ["protection", 562], [",", 572], ["are", 574], ["described", 578], [".", 587], ["The", 589], ["interpretation", 593], ["of", 608], ["various", 611], ["measures", 619], ["of", 628], ["efficacy", 631], ["in", 640], ["terms", 643], ["of", 649], ["the", 652], ["potential", 656], ["public", 666], ["health", 673], ["impact", 680], ["of", 687], ["the", 690], ["vaccine", 694], ["is", 702], ["discussed", 705], [".", 714], ["The", 716], ["methodology", 720], ["selected", 732], ["to", 741], ["analyse", 744], ["the", 752], ["clinical", 756], ["trial", 765], ["must", 771], ["be", 776], ["scientifically", 779], ["sound", 794], [",", 799], ["acceptable", 801], ["to", 812], ["regulatory", 815], ["authorities", 826], ["and", 838], ["meaningful", 842], ["to", 853], ["those", 856], ["responsible", 862], ["for", 874], ["malaria", 878], ["control", 886], ["and", 894], ["public", 898], ["health", 905], ["policy", 912], [".", 918]]}
{"context": "Stroke recognition tools have been shown to improve diagnostic accuracy in adults. Development of a similar tool in children is needed to reduce lag time to diagnosis. A critical first step is to determine whether adult stoke scales can be applied in childhood stroke.Our objective was to assess the applicability of adult stroke scales in childhood arterial ischemic stroke (AIS) METHODS: Children aged 1 month to < 18 years with radiologically confirmed acute AIS who presented to a tertiary emergency department (ED) (2003 to 2008) were identified retrospectively. Signs, symptoms, risk factors and initial management were extracted. Two adult stroke recognition tools; ROSIER (Recognition of Stroke in the Emergency Room) and FAST (Face Arm Speech Test) scales were applied retrospectively to all patients to determine test sensitivity. 47 children with AIS were identified. 34 had anterior, 12 had posterior and 1 child had anterior and posterior circulation infarcts. Median age was 9 years and 51% were male. Median time from symptom onset to ED presentation was 21 hours but one third of children presented within 6 hours. The most common presenting stroke symptoms were arm (63%), face (62%), leg weakness (57%), speech disturbance (46%) and headache (46%). The most common signs were arm (61%), face (70%) or leg weakness (57%) and dysarthria (34%). 36 (78%) of children had at least one positive variable on FAST and 38 (81%) had a positive score of \u22651 on the ROSIER scale. Positive scores were less likely in children with posterior circulation stroke. The presenting features of pediatric stroke appear similar to adult strokes. Two adult stroke recognition tools have fair to good sensitivity in radiologically confirmed childhood AIS but require further development and modification. Specificity of the tools also needs to be determined in a prospective cohort of children with stroke and non-stroke brain attacks.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "1c541feb2e3d42fa943dbf7eb67303a8", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[0, 0], [208, 208], [45, 45], [315, 315], [122, 122], [331, 331], [371, 371], [62, 62], [56, 56], [322, 322], [114, 114], [367, 367]], "char_spans": [[0, 5], [1158, 1163], [261, 266], [1557, 1562], [696, 701], [1652, 1657], [1908, 1913], [368, 373], [323, 328], [1602, 1607], [647, 652], [1893, 1898]]}]}], "context_tokens": [["Stroke", 0], ["recognition", 7], ["tools", 19], ["have", 25], ["been", 30], ["shown", 35], ["to", 41], ["improve", 44], ["diagnostic", 52], ["accuracy", 63], ["in", 72], ["adults", 75], [".", 81], ["Development", 83], ["of", 95], ["a", 98], ["similar", 100], ["tool", 108], ["in", 113], ["children", 116], ["is", 125], ["needed", 128], ["to", 135], ["reduce", 138], ["lag", 145], ["time", 149], ["to", 154], ["diagnosis", 157], [".", 166], ["A", 168], ["critical", 170], ["first", 179], ["step", 185], ["is", 190], ["to", 193], ["determine", 196], ["whether", 206], ["adult", 214], ["stoke", 220], ["scales", 226], ["can", 233], ["be", 237], ["applied", 240], ["in", 248], ["childhood", 251], ["stroke", 261], [".", 267], ["Our", 268], ["objective", 272], ["was", 282], ["to", 286], ["assess", 289], ["the", 296], ["applicability", 300], ["of", 314], ["adult", 317], ["stroke", 323], ["scales", 330], ["in", 337], ["childhood", 340], ["arterial", 350], ["ischemic", 359], ["stroke", 368], ["(", 375], ["AIS", 376], [")", 379], ["METHODS", 381], [":", 388], ["Children", 390], ["aged", 399], ["1", 404], ["month", 406], ["to", 412], ["<", 415], ["18", 417], ["years", 420], ["with", 426], ["radiologically", 431], ["confirmed", 446], ["acute", 456], ["AIS", 462], ["who", 466], ["presented", 470], ["to", 480], ["a", 483], ["tertiary", 485], ["emergency", 494], ["department", 504], ["(", 515], ["ED", 516], [")", 518], ["(", 520], ["2003", 521], ["to", 526], ["2008", 529], [")", 533], ["were", 535], ["identified", 540], ["retrospectively", 551], [".", 566], ["Signs", 568], [",", 573], ["symptoms", 575], [",", 583], ["risk", 585], ["factors", 590], ["and", 598], ["initial", 602], ["management", 610], ["were", 621], ["extracted", 626], [".", 635], ["Two", 637], ["adult", 641], ["stroke", 647], ["recognition", 654], ["tools", 666], [";", 671], ["ROSIER", 673], ["(", 680], ["Recognition", 681], ["of", 693], ["Stroke", 696], ["in", 703], ["the", 706], ["Emergency", 710], ["Room", 720], [")", 724], ["and", 726], ["FAST", 730], ["(", 735], ["Face", 736], ["Arm", 741], ["Speech", 745], ["Test", 752], [")", 756], ["scales", 758], ["were", 765], ["applied", 770], ["retrospectively", 778], ["to", 794], ["all", 797], ["patients", 801], ["to", 810], ["determine", 813], ["test", 823], ["sensitivity", 828], [".", 839], ["47", 841], ["children", 844], ["with", 853], ["AIS", 858], ["were", 862], ["identified", 867], [".", 877], ["34", 879], ["had", 882], ["anterior", 886], [",", 894], ["12", 896], ["had", 899], ["posterior", 903], ["and", 913], ["1", 917], ["child", 919], ["had", 925], ["anterior", 929], ["and", 938], ["posterior", 942], ["circulation", 952], ["infarcts", 964], [".", 972], ["Median", 974], ["age", 981], ["was", 985], ["9", 989], ["years", 991], ["and", 997], ["51", 1001], ["%", 1003], ["were", 1005], ["male", 1010], [".", 1014], ["Median", 1016], ["time", 1023], ["from", 1028], ["symptom", 1033], ["onset", 1041], ["to", 1047], ["ED", 1050], ["presentation", 1053], ["was", 1066], ["21", 1070], ["hours", 1073], ["but", 1079], ["one", 1083], ["third", 1087], ["of", 1093], ["children", 1096], ["presented", 1105], ["within", 1115], ["6", 1122], ["hours", 1124], [".", 1129], ["The", 1131], ["most", 1135], ["common", 1140], ["presenting", 1147], ["stroke", 1158], ["symptoms", 1165], ["were", 1174], ["arm", 1179], ["(", 1183], ["63", 1184], ["%", 1186], [")", 1187], [",", 1188], ["face", 1190], ["(", 1195], ["62", 1196], ["%", 1198], [")", 1199], [",", 1200], ["leg", 1202], ["weakness", 1206], ["(", 1215], ["57", 1216], ["%", 1218], [")", 1219], [",", 1220], ["speech", 1222], ["disturbance", 1229], ["(", 1241], ["46", 1242], ["%", 1244], [")", 1245], ["and", 1247], ["headache", 1251], ["(", 1260], ["46", 1261], ["%", 1263], [")", 1264], [".", 1265], ["The", 1267], ["most", 1271], ["common", 1276], ["signs", 1283], ["were", 1289], ["arm", 1294], ["(", 1298], ["61", 1299], ["%", 1301], [")", 1302], [",", 1303], ["face", 1305], ["(", 1310], ["70", 1311], ["%", 1313], [")", 1314], ["or", 1316], ["leg", 1319], ["weakness", 1323], ["(", 1332], ["57", 1333], ["%", 1335], [")", 1336], ["and", 1338], ["dysarthria", 1342], ["(", 1353], ["34", 1354], ["%", 1356], [")", 1357], [".", 1358], ["36", 1360], ["(", 1363], ["78", 1364], ["%", 1366], [")", 1367], ["of", 1369], ["children", 1372], ["had", 1381], ["at", 1385], ["least", 1388], ["one", 1394], ["positive", 1398], ["variable", 1407], ["on", 1416], ["FAST", 1419], ["and", 1424], ["38", 1428], ["(", 1431], ["81", 1432], ["%", 1434], [")", 1435], ["had", 1437], ["a", 1441], ["positive", 1443], ["score", 1452], ["of", 1458], ["\u22651", 1461], ["on", 1464], ["the", 1467], ["ROSIER", 1471], ["scale", 1478], [".", 1483], ["Positive", 1485], ["scores", 1494], ["were", 1501], ["less", 1506], ["likely", 1511], ["in", 1518], ["children", 1521], ["with", 1530], ["posterior", 1535], ["circulation", 1545], ["stroke", 1557], [".", 1563], ["The", 1565], ["presenting", 1569], ["features", 1580], ["of", 1589], ["pediatric", 1592], ["stroke", 1602], ["appear", 1609], ["similar", 1616], ["to", 1624], ["adult", 1627], ["strokes", 1633], [".", 1640], ["Two", 1642], ["adult", 1646], ["stroke", 1652], ["recognition", 1659], ["tools", 1671], ["have", 1677], ["fair", 1682], ["to", 1687], ["good", 1690], ["sensitivity", 1695], ["in", 1707], ["radiologically", 1710], ["confirmed", 1725], ["childhood", 1735], ["AIS", 1745], ["but", 1749], ["require", 1753], ["further", 1761], ["development", 1769], ["and", 1781], ["modification", 1785], [".", 1797], ["Specificity", 1799], ["of", 1811], ["the", 1814], ["tools", 1818], ["also", 1824], ["needs", 1829], ["to", 1835], ["be", 1838], ["determined", 1841], ["in", 1852], ["a", 1855], ["prospective", 1857], ["cohort", 1869], ["of", 1876], ["children", 1879], ["with", 1888], ["stroke", 1893], ["and", 1900], ["non", 1904], ["-", 1907], ["stroke", 1908], ["brain", 1915], ["attacks", 1921], [".", 1928]]}
{"context": "The major protein constituent of Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein, but other proteins, in particular the microtubule-associated protein tau, have been implicated in the pathogenesis of LBs. Tau is the major structural component of neurofibrillary tangles (NFTs). Both direct immunochemical studies of partially purified LBs and indirect immunohistochemical studies have suggested that LBs may contain tau, but most of these studies were based upon a single tau antibody, and immunologic cross-reactivity was not completely excluded. To gain insight into the relation between tau and alpha-synuclein in LBs, double immunostaining was performed in Lewy body cases with a rabbit polyclonal antibody to alpha-synuclein and a panel of monoclonal antibodies to phospho- and nonphospho-tau epitopes (Alz50, CP9, CP13, PG5, TG3, PHFI) that spanned the length of the tau molecule. Tau-immunoreactive LBs were present in the medulla in 80% of the cases, irrespective of Braak stage. All tau antibodies recognized at least some LBs, arguing against nonspecific antibody cross-reactivity. In most lesions the tau immunostaining was present at the periphery of the LB. The phospho-tau antibody, TG3, detected more LBs than any of the other tau antibodies. The proportion of LBs with tau immunoreactivity was greatest in neurons vulnerable to NETs, such as those in the locus ceruleus and basal nucleus of Meynert, and least in neurons resistant to NFTs, such as the dorsal motor nucleus of the vagus in the medulla. The present results suggest that tau may coaggregate with alpha-synuclein in LBs, especially in neuronal populations vulnerable to both NFTs and LBs.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "dd51992abbdc4acdbe0da902d5a6786a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[306, 308], [138, 140], [118, 120], [27, 29]], "char_spans": [[1661, 1675], [799, 813], [683, 697], [150, 164]]}]}], "context_tokens": [["The", 0], ["major", 4], ["protein", 10], ["constituent", 18], ["of", 30], ["Lewy", 33], ["bodies", 38], ["(", 45], ["LBs", 46], [")", 49], [",", 50], ["the", 52], ["pathological", 56], ["hallmark", 69], ["of", 78], ["Parkinson", 81], ["disease", 91], ["and", 99], ["dementia", 103], ["with", 112], ["Lewy", 117], ["bodies", 122], [",", 128], ["is", 130], ["considered", 133], ["to", 144], ["be", 147], ["alpha", 150], ["-", 155], ["synuclein", 156], [",", 165], ["but", 167], ["other", 171], ["proteins", 177], [",", 185], ["in", 187], ["particular", 190], ["the", 201], ["microtubule", 205], ["-", 216], ["associated", 217], ["protein", 228], ["tau", 236], [",", 239], ["have", 241], ["been", 246], ["implicated", 251], ["in", 262], ["the", 265], ["pathogenesis", 269], ["of", 282], ["LBs", 285], [".", 288], ["Tau", 290], ["is", 294], ["the", 297], ["major", 301], ["structural", 307], ["component", 318], ["of", 328], ["neurofibrillary", 331], ["tangles", 347], ["(", 355], ["NFTs", 356], [")", 360], [".", 361], ["Both", 363], ["direct", 368], ["immunochemical", 375], ["studies", 390], ["of", 398], ["partially", 401], ["purified", 411], ["LBs", 420], ["and", 424], ["indirect", 428], ["immunohistochemical", 437], ["studies", 457], ["have", 465], ["suggested", 470], ["that", 480], ["LBs", 485], ["may", 489], ["contain", 493], ["tau", 501], [",", 504], ["but", 506], ["most", 510], ["of", 515], ["these", 518], ["studies", 524], ["were", 532], ["based", 537], ["upon", 543], ["a", 548], ["single", 550], ["tau", 557], ["antibody", 561], [",", 569], ["and", 571], ["immunologic", 575], ["cross", 587], ["-", 592], ["reactivity", 593], ["was", 604], ["not", 608], ["completely", 612], ["excluded", 623], [".", 631], ["To", 633], ["gain", 636], ["insight", 641], ["into", 649], ["the", 654], ["relation", 658], ["between", 667], ["tau", 675], ["and", 679], ["alpha", 683], ["-", 688], ["synuclein", 689], ["in", 699], ["LBs", 702], [",", 705], ["double", 707], ["immunostaining", 714], ["was", 729], ["performed", 733], ["in", 743], ["Lewy", 746], ["body", 751], ["cases", 756], ["with", 762], ["a", 767], ["rabbit", 769], ["polyclonal", 776], ["antibody", 787], ["to", 796], ["alpha", 799], ["-", 804], ["synuclein", 805], ["and", 815], ["a", 819], ["panel", 821], ["of", 827], ["monoclonal", 830], ["antibodies", 841], ["to", 852], ["phospho-", 855], ["and", 864], ["nonphospho", 868], ["-", 878], ["tau", 879], ["epitopes", 883], ["(", 892], ["Alz50", 893], [",", 898], ["CP9", 900], [",", 903], ["CP13", 905], [",", 909], ["PG5", 911], [",", 914], ["TG3", 916], [",", 919], ["PHFI", 921], [")", 925], ["that", 927], ["spanned", 932], ["the", 940], ["length", 944], ["of", 951], ["the", 954], ["tau", 958], ["molecule", 962], [".", 970], ["Tau", 972], ["-", 975], ["immunoreactive", 976], ["LBs", 991], ["were", 995], ["present", 1000], ["in", 1008], ["the", 1011], ["medulla", 1015], ["in", 1023], ["80", 1026], ["%", 1028], ["of", 1030], ["the", 1033], ["cases", 1037], [",", 1042], ["irrespective", 1044], ["of", 1057], ["Braak", 1060], ["stage", 1066], [".", 1071], ["All", 1073], ["tau", 1077], ["antibodies", 1081], ["recognized", 1092], ["at", 1103], ["least", 1106], ["some", 1112], ["LBs", 1117], [",", 1120], ["arguing", 1122], ["against", 1130], ["nonspecific", 1138], ["antibody", 1150], ["cross", 1159], ["-", 1164], ["reactivity", 1165], [".", 1175], ["In", 1177], ["most", 1180], ["lesions", 1185], ["the", 1193], ["tau", 1197], ["immunostaining", 1201], ["was", 1216], ["present", 1220], ["at", 1228], ["the", 1231], ["periphery", 1235], ["of", 1245], ["the", 1248], ["LB", 1252], [".", 1254], ["The", 1256], ["phospho", 1260], ["-", 1267], ["tau", 1268], ["antibody", 1272], [",", 1280], ["TG3", 1282], [",", 1285], ["detected", 1287], ["more", 1296], ["LBs", 1301], ["than", 1305], ["any", 1310], ["of", 1314], ["the", 1317], ["other", 1321], ["tau", 1327], ["antibodies", 1331], [".", 1341], ["The", 1343], ["proportion", 1347], ["of", 1358], ["LBs", 1361], ["with", 1365], ["tau", 1370], ["immunoreactivity", 1374], ["was", 1391], ["greatest", 1395], ["in", 1404], ["neurons", 1407], ["vulnerable", 1415], ["to", 1426], ["NETs", 1429], [",", 1433], ["such", 1435], ["as", 1440], ["those", 1443], ["in", 1449], ["the", 1452], ["locus", 1456], ["ceruleus", 1462], ["and", 1471], ["basal", 1475], ["nucleus", 1481], ["of", 1489], ["Meynert", 1492], [",", 1499], ["and", 1501], ["least", 1505], ["in", 1511], ["neurons", 1514], ["resistant", 1522], ["to", 1532], ["NFTs", 1535], [",", 1539], ["such", 1541], ["as", 1546], ["the", 1549], ["dorsal", 1553], ["motor", 1560], ["nucleus", 1566], ["of", 1574], ["the", 1577], ["vagus", 1581], ["in", 1587], ["the", 1590], ["medulla", 1594], [".", 1601], ["The", 1603], ["present", 1607], ["results", 1615], ["suggest", 1623], ["that", 1631], ["tau", 1636], ["may", 1640], ["coaggregate", 1644], ["with", 1656], ["alpha", 1661], ["-", 1666], ["synuclein", 1667], ["in", 1677], ["LBs", 1680], [",", 1683], ["especially", 1685], ["in", 1696], ["neuronal", 1699], ["populations", 1708], ["vulnerable", 1720], ["to", 1731], ["both", 1734], ["NFTs", 1739], ["and", 1744], ["LBs", 1748], [".", 1751]]}
{"context": "We review the current evidence for medical and surgical treatments of spontaneous intracerebral hemorrhage (ICH). Therapy with hemostatic agents (e.g. factor VIIa and tranexamic acid) if started early after bleeding onset may reduce hematoma expansion, but their clinical effectiveness has not been shown. Rapid anticoagulation reversal with prothrombin concentrates (PCC) plus vitamin K is the first choice in vitamin K antagonist-related ICH. In ICH related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab. PCC are recommended for ICH related to FXa inhibitors, whereas specific reversal agents are not yet approved. While awaiting ongoing trials studying minimally invasive approaches or hemicraniectomy, the role of surgery in ICH remains to be defined. Therapies targeting downstream molecular cascades in order to prevent secondary neuronal damage are promising, but the complexity and multi-phased nature of ICH pathophysiology is challenging. Finally, in addition to blood pressure control, antithrombotic prevention after ICH has to consider the risk of recurrent bleeding as well as the risk of ischemic events. Treatment of acute ICH remains challenging, and many promising interventions for acute ICH await further evidence from trials.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "d40ca4a4e2a1425fbe7308353258a879", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[78, 78]], "char_spans": [[463, 472]]}]}], "context_tokens": [["We", 0], ["review", 3], ["the", 10], ["current", 14], ["evidence", 22], ["for", 31], ["medical", 35], ["and", 43], ["surgical", 47], ["treatments", 56], ["of", 67], ["spontaneous", 70], ["intracerebral", 82], ["hemorrhage", 96], ["(", 107], ["ICH", 108], [")", 111], [".", 112], ["Therapy", 114], ["with", 122], ["hemostatic", 127], ["agents", 138], ["(", 145], ["e.g.", 146], ["factor", 151], ["VIIa", 158], ["and", 163], ["tranexamic", 167], ["acid", 178], [")", 182], ["if", 184], ["started", 187], ["early", 195], ["after", 201], ["bleeding", 207], ["onset", 216], ["may", 222], ["reduce", 226], ["hematoma", 233], ["expansion", 242], [",", 251], ["but", 253], ["their", 257], ["clinical", 263], ["effectiveness", 272], ["has", 286], ["not", 290], ["been", 294], ["shown", 299], [".", 304], ["Rapid", 306], ["anticoagulation", 312], ["reversal", 328], ["with", 337], ["prothrombin", 342], ["concentrates", 354], ["(", 367], ["PCC", 368], [")", 371], ["plus", 373], ["vitamin", 378], ["K", 386], ["is", 388], ["the", 391], ["first", 395], ["choice", 401], ["in", 408], ["vitamin", 411], ["K", 419], ["antagonist", 421], ["-", 431], ["related", 432], ["ICH", 440], [".", 443], ["In", 445], ["ICH", 448], ["related", 452], ["to", 460], ["dabigatran", 463], [",", 473], ["anticoagulation", 475], ["can", 491], ["be", 495], ["rapidly", 498], ["reversed", 506], ["with", 515], ["idarucizumab", 520], [".", 532], ["PCC", 534], ["are", 538], ["recommended", 542], ["for", 554], ["ICH", 558], ["related", 562], ["to", 570], ["FXa", 573], ["inhibitors", 577], [",", 587], ["whereas", 589], ["specific", 597], ["reversal", 606], ["agents", 615], ["are", 622], ["not", 626], ["yet", 630], ["approved", 634], [".", 642], ["While", 644], ["awaiting", 650], ["ongoing", 659], ["trials", 667], ["studying", 674], ["minimally", 683], ["invasive", 693], ["approaches", 702], ["or", 713], ["hemicraniectomy", 716], [",", 731], ["the", 733], ["role", 737], ["of", 742], ["surgery", 745], ["in", 753], ["ICH", 756], ["remains", 760], ["to", 768], ["be", 771], ["defined", 774], [".", 781], ["Therapies", 783], ["targeting", 793], ["downstream", 803], ["molecular", 814], ["cascades", 824], ["in", 833], ["order", 836], ["to", 842], ["prevent", 845], ["secondary", 853], ["neuronal", 863], ["damage", 872], ["are", 879], ["promising", 883], [",", 892], ["but", 894], ["the", 898], ["complexity", 902], ["and", 913], ["multi", 917], ["-", 922], ["phased", 923], ["nature", 930], ["of", 937], ["ICH", 940], ["pathophysiology", 944], ["is", 960], ["challenging", 963], [".", 974], ["Finally", 976], [",", 983], ["in", 985], ["addition", 988], ["to", 997], ["blood", 1000], ["pressure", 1006], ["control", 1015], [",", 1022], ["antithrombotic", 1024], ["prevention", 1039], ["after", 1050], ["ICH", 1056], ["has", 1060], ["to", 1064], ["consider", 1067], ["the", 1076], ["risk", 1080], ["of", 1085], ["recurrent", 1088], ["bleeding", 1098], ["as", 1107], ["well", 1110], ["as", 1115], ["the", 1118], ["risk", 1122], ["of", 1127], ["ischemic", 1130], ["events", 1139], [".", 1145], ["Treatment", 1147], ["of", 1157], ["acute", 1160], ["ICH", 1166], ["remains", 1170], ["challenging", 1178], [",", 1189], ["and", 1191], ["many", 1195], ["promising", 1200], ["interventions", 1210], ["for", 1224], ["acute", 1228], ["ICH", 1234], ["await", 1238], ["further", 1244], ["evidence", 1252], ["from", 1261], ["trials", 1266], [".", 1272]]}
{"context": "H2A.Z is a highly conserved variant of histone H2A with well-characterized roles in transcriptional regulation. We previously reported that H2A.Z and Mcd1, a subunit of the cohesin complex, regulate the establishment of transcriptional silencing at telomeres in Saccharomyces cerevisiae and that H2A.Z broadly dissociated from chromatin during the anaphase-to-telophase transition, coincident with the dissociation of Mcd1 from chromosomes and dissolution of cohesion. In this study, we show that depletion of H2A.Z causes precocious loss of sister chromatid cohesion in yeast without loss of Mcd1 from chromosomes. H2A.Z is deposited into chromatin by the SWR1 complex and is subject to acetylation of its four N-terminal tail lysine residues by the NuA4 and SAGA histone acetyltransferase complexes. We found that cells compromised for function of the SWR1 complex were defective in cohesion, as were cells expressing a form of H2A.Z not subject to acetylation. Finally, inactivation of H2A.Z in metaphase-blocked cells led immediately to cohesion defects, suggesting a direct role for H2A.Z in the maintenance of sister chromatid cohesion.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "4ef05543761e4948b74e9fa078a5e4bc", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[140, 140], [106, 106]], "char_spans": [[854, 857], [657, 660]]}]}], "context_tokens": [["H2A.Z", 0], ["is", 6], ["a", 9], ["highly", 11], ["conserved", 18], ["variant", 28], ["of", 36], ["histone", 39], ["H2A", 47], ["with", 51], ["well", 56], ["-", 60], ["characterized", 61], ["roles", 75], ["in", 81], ["transcriptional", 84], ["regulation", 100], [".", 110], ["We", 112], ["previously", 115], ["reported", 126], ["that", 135], ["H2A.Z", 140], ["and", 146], ["Mcd1", 150], [",", 154], ["a", 156], ["subunit", 158], ["of", 166], ["the", 169], ["cohesin", 173], ["complex", 181], [",", 188], ["regulate", 190], ["the", 199], ["establishment", 203], ["of", 217], ["transcriptional", 220], ["silencing", 236], ["at", 246], ["telomeres", 249], ["in", 259], ["Saccharomyces", 262], ["cerevisiae", 276], ["and", 287], ["that", 291], ["H2A.Z", 296], ["broadly", 302], ["dissociated", 310], ["from", 322], ["chromatin", 327], ["during", 337], ["the", 344], ["anaphase", 348], ["-", 356], ["to", 357], ["-", 359], ["telophase", 360], ["transition", 370], [",", 380], ["coincident", 382], ["with", 393], ["the", 398], ["dissociation", 402], ["of", 415], ["Mcd1", 418], ["from", 423], ["chromosomes", 428], ["and", 440], ["dissolution", 444], ["of", 456], ["cohesion", 459], [".", 467], ["In", 469], ["this", 472], ["study", 477], [",", 482], ["we", 484], ["show", 487], ["that", 492], ["depletion", 497], ["of", 507], ["H2A.Z", 510], ["causes", 516], ["precocious", 523], ["loss", 534], ["of", 539], ["sister", 542], ["chromatid", 549], ["cohesion", 559], ["in", 568], ["yeast", 571], ["without", 577], ["loss", 585], ["of", 590], ["Mcd1", 593], ["from", 598], ["chromosomes", 603], [".", 614], ["H2A.Z", 616], ["is", 622], ["deposited", 625], ["into", 635], ["chromatin", 640], ["by", 650], ["the", 653], ["SWR1", 657], ["complex", 662], ["and", 670], ["is", 674], ["subject", 677], ["to", 685], ["acetylation", 688], ["of", 700], ["its", 703], ["four", 707], ["N", 712], ["-", 713], ["terminal", 714], ["tail", 723], ["lysine", 728], ["residues", 735], ["by", 744], ["the", 747], ["NuA4", 751], ["and", 756], ["SAGA", 760], ["histone", 765], ["acetyltransferase", 773], ["complexes", 791], [".", 800], ["We", 802], ["found", 805], ["that", 811], ["cells", 816], ["compromised", 822], ["for", 834], ["function", 838], ["of", 847], ["the", 850], ["SWR1", 854], ["complex", 859], ["were", 867], ["defective", 872], ["in", 882], ["cohesion", 885], [",", 893], ["as", 895], ["were", 898], ["cells", 903], ["expressing", 909], ["a", 920], ["form", 922], ["of", 927], ["H2A.Z", 930], ["not", 936], ["subject", 940], ["to", 948], ["acetylation", 951], [".", 962], ["Finally", 964], [",", 971], ["inactivation", 973], ["of", 986], ["H2A.Z", 989], ["in", 995], ["metaphase", 998], ["-", 1007], ["blocked", 1008], ["cells", 1016], ["led", 1022], ["immediately", 1026], ["to", 1038], ["cohesion", 1041], ["defects", 1050], [",", 1057], ["suggesting", 1059], ["a", 1070], ["direct", 1072], ["role", 1079], ["for", 1084], ["H2A.Z", 1088], ["in", 1094], ["the", 1097], ["maintenance", 1101], ["of", 1113], ["sister", 1116], ["chromatid", 1123], ["cohesion", 1133], [".", 1141]]}
{"context": "It is increasingly clear that the normal protein alpha-synuclein is in some manner closely associated with presynaptic components of select neuronal types within the adult human central nervous system (CNS) and, in addition, that in its pathologically altered state alpha-synuclein aggregates selectively in the form of filamentous inclusion bodies during certain progressive neurodegenerative disorders, such as familial and sporadic Parkinson's disease. By having the antibody AFshp raised specifically to alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein, an initial attempt is made to map the overall distribution pattern and describe the staining behavior of the immunoreactive punctae in select regions of the prosencephalon. Neocortical immunolabeling is most prominent in the prodigious, but incompletely myelinated, association fields and faintest in the heavily myelinated primary motor and primary sensory fields, with the premotor and first order sensory association areas occupying an intermediate position. Of the thalamic grays evaluated, those containing powerfully myelinated fiber tracts (e.g. centrum medianum, habenular complex) show the weakest immunolabeling, whereas, less sturdily myelinated structures are highly immunoreactive. The fact that the immunostaining spectrum for normal alpha-synuclein is so broad, together with the fact that some thalamic sites actually are immunonegative leads to the following conclusions (1) alpha-synuclein, although present in the synaptic boutons of many nerve cells in the adult human CNS, is by no means ubiquitous there, and (2) neuronal types lacking the normal protein cannot generate the Parkinson's disease-specific filamentous pathology.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "2c9a3ae9437648e1834a87d46d29cd29", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[80, 82], [45, 47], [8, 10], [216, 218], [242, 244]], "char_spans": [[508, 522], [266, 280], [49, 63], [1400, 1414], [1544, 1558]]}]}], "context_tokens": [["It", 0], ["is", 3], ["increasingly", 6], ["clear", 19], ["that", 25], ["the", 30], ["normal", 34], ["protein", 41], ["alpha", 49], ["-", 54], ["synuclein", 55], ["is", 65], ["in", 68], ["some", 71], ["manner", 76], ["closely", 83], ["associated", 91], ["with", 102], ["presynaptic", 107], ["components", 119], ["of", 130], ["select", 133], ["neuronal", 140], ["types", 149], ["within", 155], ["the", 162], ["adult", 166], ["human", 172], ["central", 178], ["nervous", 186], ["system", 194], ["(", 201], ["CNS", 202], [")", 205], ["and", 207], [",", 210], ["in", 212], ["addition", 215], [",", 223], ["that", 225], ["in", 230], ["its", 233], ["pathologically", 237], ["altered", 252], ["state", 260], ["alpha", 266], ["-", 271], ["synuclein", 272], ["aggregates", 282], ["selectively", 293], ["in", 305], ["the", 308], ["form", 312], ["of", 317], ["filamentous", 320], ["inclusion", 332], ["bodies", 342], ["during", 349], ["certain", 356], ["progressive", 364], ["neurodegenerative", 376], ["disorders", 394], [",", 403], ["such", 405], ["as", 410], ["familial", 413], ["and", 422], ["sporadic", 426], ["Parkinson", 435], ["'s", 444], ["disease", 447], [".", 454], ["By", 456], ["having", 459], ["the", 466], ["antibody", 470], ["AFshp", 479], ["raised", 485], ["specifically", 492], ["to", 505], ["alpha", 508], ["-", 513], ["synuclein", 514], ["to", 524], ["label", 527], ["Parkinson", 533], ["disease", 543], ["-", 550], ["specific", 551], ["Lewy", 560], ["bodies", 565], ["and", 572], ["Lewy", 576], ["neurites", 581], ["as", 590], ["well", 593], ["as", 598], ["synaptic", 601], ["boutons", 610], ["containing", 618], ["the", 629], ["unaltered", 633], ["protein", 643], [",", 650], ["an", 652], ["initial", 655], ["attempt", 663], ["is", 671], ["made", 674], ["to", 679], ["map", 682], ["the", 686], ["overall", 690], ["distribution", 698], ["pattern", 711], ["and", 719], ["describe", 723], ["the", 732], ["staining", 736], ["behavior", 745], ["of", 754], ["the", 757], ["immunoreactive", 761], ["punctae", 776], ["in", 784], ["select", 787], ["regions", 794], ["of", 802], ["the", 805], ["prosencephalon", 809], [".", 823], ["Neocortical", 825], ["immunolabeling", 837], ["is", 852], ["most", 855], ["prominent", 860], ["in", 870], ["the", 873], ["prodigious", 877], [",", 887], ["but", 889], ["incompletely", 893], ["myelinated", 906], [",", 916], ["association", 918], ["fields", 930], ["and", 937], ["faintest", 941], ["in", 950], ["the", 953], ["heavily", 957], ["myelinated", 965], ["primary", 976], ["motor", 984], ["and", 990], ["primary", 994], ["sensory", 1002], ["fields", 1010], [",", 1016], ["with", 1018], ["the", 1023], ["premotor", 1027], ["and", 1036], ["first", 1040], ["order", 1046], ["sensory", 1052], ["association", 1060], ["areas", 1072], ["occupying", 1078], ["an", 1088], ["intermediate", 1091], ["position", 1104], [".", 1112], ["Of", 1114], ["the", 1117], ["thalamic", 1121], ["grays", 1130], ["evaluated", 1136], [",", 1145], ["those", 1147], ["containing", 1153], ["powerfully", 1164], ["myelinated", 1175], ["fiber", 1186], ["tracts", 1192], ["(", 1199], ["e.g.", 1200], ["centrum", 1205], ["medianum", 1213], [",", 1221], ["habenular", 1223], ["complex", 1233], [")", 1240], ["show", 1242], ["the", 1247], ["weakest", 1251], ["immunolabeling", 1259], [",", 1273], ["whereas", 1275], [",", 1282], ["less", 1284], ["sturdily", 1289], ["myelinated", 1298], ["structures", 1309], ["are", 1320], ["highly", 1324], ["immunoreactive", 1331], [".", 1345], ["The", 1347], ["fact", 1351], ["that", 1356], ["the", 1361], ["immunostaining", 1365], ["spectrum", 1380], ["for", 1389], ["normal", 1393], ["alpha", 1400], ["-", 1405], ["synuclein", 1406], ["is", 1416], ["so", 1419], ["broad", 1422], [",", 1427], ["together", 1429], ["with", 1438], ["the", 1443], ["fact", 1447], ["that", 1452], ["some", 1457], ["thalamic", 1462], ["sites", 1471], ["actually", 1477], ["are", 1486], ["immunonegative", 1490], ["leads", 1505], ["to", 1511], ["the", 1514], ["following", 1518], ["conclusions", 1528], ["(", 1540], ["1", 1541], [")", 1542], ["alpha", 1544], ["-", 1549], ["synuclein", 1550], [",", 1559], ["although", 1561], ["present", 1570], ["in", 1578], ["the", 1581], ["synaptic", 1585], ["boutons", 1594], ["of", 1602], ["many", 1605], ["nerve", 1610], ["cells", 1616], ["in", 1622], ["the", 1625], ["adult", 1629], ["human", 1635], ["CNS", 1641], [",", 1644], ["is", 1646], ["by", 1649], ["no", 1652], ["means", 1655], ["ubiquitous", 1661], ["there", 1672], [",", 1677], ["and", 1679], ["(", 1683], ["2", 1684], [")", 1685], ["neuronal", 1687], ["types", 1696], ["lacking", 1702], ["the", 1710], ["normal", 1714], ["protein", 1721], ["can", 1729], ["not", 1732], ["generate", 1736], ["the", 1745], ["Parkinson", 1749], ["'s", 1758], ["disease", 1761], ["-", 1768], ["specific", 1769], ["filamentous", 1778], ["pathology", 1790], [".", 1799]]}
{"context": "Mammalian selenium-containing proteins identified thus far contain selenium in the form of a selenocysteine residue encoded by UGA. These proteins lack common amino acid sequence motifs, but 3'-untranslated regions of selenoprotein genes contain a common stem-loop structure, selenocysteine insertion sequence (SECIS) element, that is necessary for decoding UGA as selenocysteine rather than a stop signal. We describe here a computer program, SECISearch, that identifies mammalian selenoprotein genes by recognizing SECIS elements on the basis of their primary and secondary structures and free energy requirements. When SECISearch was applied to search human dbEST, two new mammalian selenoproteins, designated SelT and SelR, were identified. We determined their cDNA sequences and expressed them in a monkey cell line as fusion proteins with a green fluorescent protein. Incorporation of selenium into new proteins was confirmed by metabolic labeling with (75)Se, and expression of SelT was additionally documented in immunoblot assays. SelT and SelR did not have homology to previously characterized proteins, but their putative homologs were detected in various organisms. SelR homologs were present in every organism characterized by complete genome sequencing. The data suggest applicability of SECISearch for identification of new selenoprotein genes in nucleotide data bases.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0d1597667c614526ba0ceede9a3ecc54", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[48, 48], [82, 82]], "char_spans": [[311, 315], [517, 521]]}]}], "context_tokens": [["Mammalian", 0], ["selenium", 10], ["-", 18], ["containing", 19], ["proteins", 30], ["identified", 39], ["thus", 50], ["far", 55], ["contain", 59], ["selenium", 67], ["in", 76], ["the", 79], ["form", 83], ["of", 88], ["a", 91], ["selenocysteine", 93], ["residue", 108], ["encoded", 116], ["by", 124], ["UGA", 127], [".", 130], ["These", 132], ["proteins", 138], ["lack", 147], ["common", 152], ["amino", 159], ["acid", 165], ["sequence", 170], ["motifs", 179], [",", 185], ["but", 187], ["3'-untranslated", 191], ["regions", 207], ["of", 215], ["selenoprotein", 218], ["genes", 232], ["contain", 238], ["a", 246], ["common", 248], ["stem", 255], ["-", 259], ["loop", 260], ["structure", 265], [",", 274], ["selenocysteine", 276], ["insertion", 291], ["sequence", 301], ["(", 310], ["SECIS", 311], [")", 316], ["element", 318], [",", 325], ["that", 327], ["is", 332], ["necessary", 335], ["for", 345], ["decoding", 349], ["UGA", 358], ["as", 362], ["selenocysteine", 365], ["rather", 380], ["than", 387], ["a", 392], ["stop", 394], ["signal", 399], [".", 405], ["We", 407], ["describe", 410], ["here", 419], ["a", 424], ["computer", 426], ["program", 435], [",", 442], ["SECISearch", 444], [",", 454], ["that", 456], ["identifies", 461], ["mammalian", 472], ["selenoprotein", 482], ["genes", 496], ["by", 502], ["recognizing", 505], ["SECIS", 517], ["elements", 523], ["on", 532], ["the", 535], ["basis", 539], ["of", 545], ["their", 548], ["primary", 554], ["and", 562], ["secondary", 566], ["structures", 576], ["and", 587], ["free", 591], ["energy", 596], ["requirements", 603], [".", 615], ["When", 617], ["SECISearch", 622], ["was", 633], ["applied", 637], ["to", 645], ["search", 648], ["human", 655], ["dbEST", 661], [",", 666], ["two", 668], ["new", 672], ["mammalian", 676], ["selenoproteins", 686], [",", 700], ["designated", 702], ["SelT", 713], ["and", 718], ["SelR", 722], [",", 726], ["were", 728], ["identified", 733], [".", 743], ["We", 745], ["determined", 748], ["their", 759], ["cDNA", 765], ["sequences", 770], ["and", 780], ["expressed", 784], ["them", 794], ["in", 799], ["a", 802], ["monkey", 804], ["cell", 811], ["line", 816], ["as", 821], ["fusion", 824], ["proteins", 831], ["with", 840], ["a", 845], ["green", 847], ["fluorescent", 853], ["protein", 865], [".", 872], ["Incorporation", 874], ["of", 888], ["selenium", 891], ["into", 900], ["new", 905], ["proteins", 909], ["was", 918], ["confirmed", 922], ["by", 932], ["metabolic", 935], ["labeling", 945], ["with", 954], ["(", 959], ["75)Se", 960], [",", 965], ["and", 967], ["expression", 971], ["of", 982], ["SelT", 985], ["was", 990], ["additionally", 994], ["documented", 1007], ["in", 1018], ["immunoblot", 1021], ["assays", 1032], [".", 1038], ["SelT", 1040], ["and", 1045], ["SelR", 1049], ["did", 1054], ["not", 1058], ["have", 1062], ["homology", 1067], ["to", 1076], ["previously", 1079], ["characterized", 1090], ["proteins", 1104], [",", 1112], ["but", 1114], ["their", 1118], ["putative", 1124], ["homologs", 1133], ["were", 1142], ["detected", 1147], ["in", 1156], ["various", 1159], ["organisms", 1167], [".", 1176], ["SelR", 1178], ["homologs", 1183], ["were", 1192], ["present", 1197], ["in", 1205], ["every", 1208], ["organism", 1214], ["characterized", 1223], ["by", 1237], ["complete", 1240], ["genome", 1249], ["sequencing", 1256], [".", 1266], ["The", 1268], ["data", 1272], ["suggest", 1277], ["applicability", 1285], ["of", 1299], ["SECISearch", 1302], ["for", 1313], ["identification", 1317], ["of", 1332], ["new", 1335], ["selenoprotein", 1339], ["genes", 1353], ["in", 1359], ["nucleotide", 1362], ["data", 1373], ["bases", 1378], [".", 1383]]}
{"context": "Chronic inflammation contributes to a wide variety of human disorders. In the stomach, longstanding gastritis often results in structural alterations in the gastric mucosa, including metaplastic changes and gastric cancers. Therefore, it is important to elucidate factors that are involved in gastric inflammation. Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins. Here, we have demonstrated that Nrdc crucially regulates gastric inflammation caused by Helicobacter felis infection or forced expression of prostaglandin E", "qas": [{"question": "Which is the enzymatic activity of nardilysin?", "answers": ["Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins."], "qid": "133771e8d5b9448681074f5d120771a8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["enzymatic", 13], ["activity", 23], ["of", 32], ["nardilysin", 35], ["?", 45]], "detected_answers": [{"text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins.", "token_spans": [[49, 93]], "char_spans": [[315, 595]]}]}], "context_tokens": [["Chronic", 0], ["inflammation", 8], ["contributes", 21], ["to", 33], ["a", 36], ["wide", 38], ["variety", 43], ["of", 51], ["human", 54], ["disorders", 60], [".", 69], ["In", 71], ["the", 74], ["stomach", 78], [",", 85], ["longstanding", 87], ["gastritis", 100], ["often", 110], ["results", 116], ["in", 124], ["structural", 127], ["alterations", 138], ["in", 150], ["the", 153], ["gastric", 157], ["mucosa", 165], [",", 171], ["including", 173], ["metaplastic", 183], ["changes", 195], ["and", 203], ["gastric", 207], ["cancers", 215], [".", 222], ["Therefore", 224], [",", 233], ["it", 235], ["is", 238], ["important", 241], ["to", 251], ["elucidate", 254], ["factors", 264], ["that", 272], ["are", 277], ["involved", 281], ["in", 290], ["gastric", 293], ["inflammation", 301], [".", 313], ["Nardilysin", 315], ["(", 326], ["N", 327], ["-", 328], ["arginine", 329], ["dibasic", 338], ["convertase", 346], [";", 356], ["Nrdc", 358], [")", 362], ["is", 364], ["a", 367], ["metalloendopeptidase", 369], ["of", 390], ["the", 393], ["M16", 397], ["family", 401], ["that", 408], ["promotes", 413], ["ectodomain", 422], ["shedding", 433], ["of", 442], ["the", 445], ["precursor", 449], ["forms", 459], ["of", 465], ["various", 468], ["growth", 476], ["factors", 483], ["and", 491], ["cytokines", 495], ["by", 505], ["enhancing", 508], ["the", 518], ["protease", 522], ["activities", 531], ["of", 542], ["a", 545], ["disintegrin", 547], ["and", 559], ["metalloproteinase", 563], ["(", 581], ["ADAM", 582], [")", 586], ["proteins", 588], [".", 596], ["Here", 598], [",", 602], ["we", 604], ["have", 607], ["demonstrated", 612], ["that", 625], ["Nrdc", 630], ["crucially", 635], ["regulates", 645], ["gastric", 655], ["inflammation", 663], ["caused", 676], ["by", 683], ["Helicobacter", 686], ["felis", 699], ["infection", 705], ["or", 715], ["forced", 718], ["expression", 725], ["of", 736], ["prostaglandin", 739], ["E", 753]]}
{"context": "The Romano-Ward long-QT Syndrome (LQTS) is an autosomal dominant inherited trait characterized by prolonged QT interval on ECG, life-threatening arrhythmias, syncope, and sudden death in affected individuals. A gene responsible for this disorder has been shown to be linked to the Harvey ras-1 locus (H-ras-1) DNA marker on the short arm of chromosome 11 (11p) in 7 families. The purpose of this study was to determine, by analyzing 23 families with LQTS for linkage to chromosome 11p, whether evidence exists for more than one gene causing LQTS (ie, locus heterogeneity). Twenty-three families (262 family members) were clinically evaluated using medical histories, ECGs, and Holter recordings. Each corrected QT interval (QTc) were determined using Bazett's formula. Blood for DNA extraction and cell line immortalization was obtained after informed consent. Southern blotting and polymerase chain reaction were performed, and linkage analysis carried out using the LINKAGE computer program (v 5.03). Genetic heterogeneity was determined using the HOMOG 2 (v 2.51) computer program. Twenty-three families were studied for evidence of linkage to chromosome 11p using the H-ras-1 locus probe pTBB-2 and multiple flanking markers, including tyrosine hydroxylase (TH). Two-point linkage analysis using pTBB-2 and TH markers was consistent with linkage in 15 of 23 families, with the maximum single-family LOD score of +3.038 occurring at theta = 0. However, 8 of 23 families had negative LOD scores, with the values in 4 families being less than -2 at theta = 0, consistent with exclusion of linkage. Analysis with the HOMOG program was consistent with genetic heterogeneity (P < .0001). Multipoint linkage data using pTBB-2 and TH were also examined for evidence of heterogeneity. HOMOG analysis of multipoint LOD scores from 100 cM surrounding the H-ras-1 locus also supported heterogeneity (P < .001). In the 23 families with LQTS analyzed for linkage to the H-ras-1 locus on chromosome 11p15.5, 15 of 23 families had LOD scores consistent with linkage. The remaining 8 of 23 families had negative LOD scores, 4 of which were definitively excluded from linkage. Thus, genetic heterogeneity is definitively (P < .001) demonstrated for this disorder.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "16cda57d6f444810a77096b293729095", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[13, 14]], "char_spans": [[46, 63]]}]}], "context_tokens": [["The", 0], ["Romano", 4], ["-", 10], ["Ward", 11], ["long", 16], ["-", 20], ["QT", 21], ["Syndrome", 24], ["(", 33], ["LQTS", 34], [")", 38], ["is", 40], ["an", 43], ["autosomal", 46], ["dominant", 56], ["inherited", 65], ["trait", 75], ["characterized", 81], ["by", 95], ["prolonged", 98], ["QT", 108], ["interval", 111], ["on", 120], ["ECG", 123], [",", 126], ["life", 128], ["-", 132], ["threatening", 133], ["arrhythmias", 145], [",", 156], ["syncope", 158], [",", 165], ["and", 167], ["sudden", 171], ["death", 178], ["in", 184], ["affected", 187], ["individuals", 196], [".", 207], ["A", 209], ["gene", 211], ["responsible", 216], ["for", 228], ["this", 232], ["disorder", 237], ["has", 246], ["been", 250], ["shown", 255], ["to", 261], ["be", 264], ["linked", 267], ["to", 274], ["the", 277], ["Harvey", 281], ["ras-1", 288], ["locus", 294], ["(", 300], ["H", 301], ["-", 302], ["ras-1", 303], [")", 308], ["DNA", 310], ["marker", 314], ["on", 321], ["the", 324], ["short", 328], ["arm", 334], ["of", 338], ["chromosome", 341], ["11", 352], ["(", 355], ["11p", 356], [")", 359], ["in", 361], ["7", 364], ["families", 366], [".", 374], ["The", 376], ["purpose", 380], ["of", 388], ["this", 391], ["study", 396], ["was", 402], ["to", 406], ["determine", 409], [",", 418], ["by", 420], ["analyzing", 423], ["23", 433], ["families", 436], ["with", 445], ["LQTS", 450], ["for", 455], ["linkage", 459], ["to", 467], ["chromosome", 470], ["11p", 481], [",", 484], ["whether", 486], ["evidence", 494], ["exists", 503], ["for", 510], ["more", 514], ["than", 519], ["one", 524], ["gene", 528], ["causing", 533], ["LQTS", 541], ["(", 546], ["ie", 547], [",", 549], ["locus", 551], ["heterogeneity", 557], [")", 570], [".", 571], ["Twenty", 573], ["-", 579], ["three", 580], ["families", 586], ["(", 595], ["262", 596], ["family", 600], ["members", 607], [")", 614], ["were", 616], ["clinically", 621], ["evaluated", 632], ["using", 642], ["medical", 648], ["histories", 656], [",", 665], ["ECGs", 667], [",", 671], ["and", 673], ["Holter", 677], ["recordings", 684], [".", 694], ["Each", 696], ["corrected", 701], ["QT", 711], ["interval", 714], ["(", 723], ["QTc", 724], [")", 727], ["were", 729], ["determined", 734], ["using", 745], ["Bazett", 751], ["'s", 757], ["formula", 760], [".", 767], ["Blood", 769], ["for", 775], ["DNA", 779], ["extraction", 783], ["and", 794], ["cell", 798], ["line", 803], ["immortalization", 808], ["was", 824], ["obtained", 828], ["after", 837], ["informed", 843], ["consent", 852], [".", 859], ["Southern", 861], ["blotting", 870], ["and", 879], ["polymerase", 883], ["chain", 894], ["reaction", 900], ["were", 909], ["performed", 914], [",", 923], ["and", 925], ["linkage", 929], ["analysis", 937], ["carried", 946], ["out", 954], ["using", 958], ["the", 964], ["LINKAGE", 968], ["computer", 976], ["program", 985], ["(", 993], ["v", 994], ["5.03", 996], [")", 1000], [".", 1001], ["Genetic", 1003], ["heterogeneity", 1011], ["was", 1025], ["determined", 1029], ["using", 1040], ["the", 1046], ["HOMOG", 1050], ["2", 1056], ["(", 1058], ["v", 1059], ["2.51", 1061], [")", 1065], ["computer", 1067], ["program", 1076], [".", 1083], ["Twenty", 1085], ["-", 1091], ["three", 1092], ["families", 1098], ["were", 1107], ["studied", 1112], ["for", 1120], ["evidence", 1124], ["of", 1133], ["linkage", 1136], ["to", 1144], ["chromosome", 1147], ["11p", 1158], ["using", 1162], ["the", 1168], ["H", 1172], ["-", 1173], ["ras-1", 1174], ["locus", 1180], ["probe", 1186], ["pTBB-2", 1192], ["and", 1199], ["multiple", 1203], ["flanking", 1212], ["markers", 1221], [",", 1228], ["including", 1230], ["tyrosine", 1240], ["hydroxylase", 1249], ["(", 1261], ["TH", 1262], [")", 1264], [".", 1265], ["Two", 1267], ["-", 1270], ["point", 1271], ["linkage", 1277], ["analysis", 1285], ["using", 1294], ["pTBB-2", 1300], ["and", 1307], ["TH", 1311], ["markers", 1314], ["was", 1322], ["consistent", 1326], ["with", 1337], ["linkage", 1342], ["in", 1350], ["15", 1353], ["of", 1356], ["23", 1359], ["families", 1362], [",", 1370], ["with", 1372], ["the", 1377], ["maximum", 1381], ["single", 1389], ["-", 1395], ["family", 1396], ["LOD", 1403], ["score", 1407], ["of", 1413], ["+3.038", 1416], ["occurring", 1423], ["at", 1433], ["theta", 1436], ["=", 1442], ["0", 1444], [".", 1445], ["However", 1447], [",", 1454], ["8", 1456], ["of", 1458], ["23", 1461], ["families", 1464], ["had", 1473], ["negative", 1477], ["LOD", 1486], ["scores", 1490], [",", 1496], ["with", 1498], ["the", 1503], ["values", 1507], ["in", 1514], ["4", 1517], ["families", 1519], ["being", 1528], ["less", 1534], ["than", 1539], ["-2", 1544], ["at", 1547], ["theta", 1550], ["=", 1556], ["0", 1558], [",", 1559], ["consistent", 1561], ["with", 1572], ["exclusion", 1577], ["of", 1587], ["linkage", 1590], [".", 1597], ["Analysis", 1599], ["with", 1608], ["the", 1613], ["HOMOG", 1617], ["program", 1623], ["was", 1631], ["consistent", 1635], ["with", 1646], ["genetic", 1651], ["heterogeneity", 1659], ["(", 1673], ["P", 1674], ["<", 1676], [".0001", 1678], [")", 1683], [".", 1684], ["Multipoint", 1686], ["linkage", 1697], ["data", 1705], ["using", 1710], ["pTBB-2", 1716], ["and", 1723], ["TH", 1727], ["were", 1730], ["also", 1735], ["examined", 1740], ["for", 1749], ["evidence", 1753], ["of", 1762], ["heterogeneity", 1765], [".", 1778], ["HOMOG", 1780], ["analysis", 1786], ["of", 1795], ["multipoint", 1798], ["LOD", 1809], ["scores", 1813], ["from", 1820], ["100", 1825], ["cM", 1829], ["surrounding", 1832], ["the", 1844], ["H", 1848], ["-", 1849], ["ras-1", 1850], ["locus", 1856], ["also", 1862], ["supported", 1867], ["heterogeneity", 1877], ["(", 1891], ["P", 1892], ["<", 1894], [".001", 1896], [")", 1900], [".", 1901], ["In", 1903], ["the", 1906], ["23", 1910], ["families", 1913], ["with", 1922], ["LQTS", 1927], ["analyzed", 1932], ["for", 1941], ["linkage", 1945], ["to", 1953], ["the", 1956], ["H", 1960], ["-", 1961], ["ras-1", 1962], ["locus", 1968], ["on", 1974], ["chromosome", 1977], ["11p15.5", 1988], [",", 1995], ["15", 1997], ["of", 2000], ["23", 2003], ["families", 2006], ["had", 2015], ["LOD", 2019], ["scores", 2023], ["consistent", 2030], ["with", 2041], ["linkage", 2046], [".", 2053], ["The", 2055], ["remaining", 2059], ["8", 2069], ["of", 2071], ["23", 2074], ["families", 2077], ["had", 2086], ["negative", 2090], ["LOD", 2099], ["scores", 2103], [",", 2109], ["4", 2111], ["of", 2113], ["which", 2116], ["were", 2122], ["definitively", 2127], ["excluded", 2140], ["from", 2149], ["linkage", 2154], [".", 2161], ["Thus", 2163], [",", 2167], ["genetic", 2169], ["heterogeneity", 2177], ["is", 2191], ["definitively", 2194], ["(", 2207], ["P", 2208], ["<", 2210], [".001", 2212], [")", 2216], ["demonstrated", 2218], ["for", 2231], ["this", 2235], ["disorder", 2240], [".", 2248]]}
{"context": "X monosomic mice (39,XO) have a remarkably mild phenotype when compared to women with Turner syndrome (45,XO). The generally accepted hypothesis to explain this discrepancy is that the number of genes on the mouse X chromosome which escape X inactivation, and thus are expressed at higher levels in females, is very small. However this hypothesis has never been tested and only a small number of genes have been assayed for their X-inactivation status in the mouse. We performed a global expression analysis in four somatic tissues (brain, liver, kidney and muscle) of adult 40,XX and 39,XO mice using the Illumina Mouse WG-6 v1_1 Expression BeadChip and an extensive validation by quantitative real time PCR, in order to identify which genes are expressed from both X chromosomes. We identified several genes on the X chromosome which are overexpressed in XX females, including those previously reported as escaping X inactivation, as well as new candidates. However, the results obtained by microarray and qPCR were not fully concordant, illustrating the difficulty in ascertaining modest fold changes, such as those expected for genes escaping X inactivation. Remarkably, considerable variation was observed between tissues, suggesting that inactivation patterns may be tissue-dependent. Our analysis also exposed several autosomal genes involved in mitochondrial metabolism and in protein translation which are differentially expressed between XX and XO mice, revealing secondary transcriptional changes to the alteration in X chromosome dosage. Our results support the prediction that the mouse inactive X chromosome is largely silent, while providing a list of the genes potentially escaping X inactivation in rodents. Although the lower expression of X-linked genes in XO mice may not be relevant in the particular tissues/systems which are affected in human X chromosome monosomy, genes deregulated in XO mice are good candidates for further study in an involvement in Turner Syndrome phenotype.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "f60eb4dfa5774b8c8a56567d0989deff", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[0, 0], [43, 43], [149, 149], [203, 203], [286, 286], [140, 140], [164, 164], [39, 39], [296, 296], [318, 318], [258, 258], [79, 79], [271, 271]], "char_spans": [[0, 0], [240, 240], [817, 817], [1147, 1147], [1698, 1698], [767, 767], [917, 917], [214, 214], [1758, 1758], [1866, 1866], [1529, 1529], [430, 430], [1609, 1609]]}]}], "context_tokens": [["X", 0], ["monosomic", 2], ["mice", 12], ["(", 17], ["39,XO", 18], [")", 23], ["have", 25], ["a", 30], ["remarkably", 32], ["mild", 43], ["phenotype", 48], ["when", 58], ["compared", 63], ["to", 72], ["women", 75], ["with", 81], ["Turner", 86], ["syndrome", 93], ["(", 102], ["45,XO", 103], [")", 108], [".", 109], ["The", 111], ["generally", 115], ["accepted", 125], ["hypothesis", 134], ["to", 145], ["explain", 148], ["this", 156], ["discrepancy", 161], ["is", 173], ["that", 176], ["the", 181], ["number", 185], ["of", 192], ["genes", 195], ["on", 201], ["the", 204], ["mouse", 208], ["X", 214], ["chromosome", 216], ["which", 227], ["escape", 233], ["X", 240], ["inactivation", 242], [",", 254], ["and", 256], ["thus", 260], ["are", 265], ["expressed", 269], ["at", 279], ["higher", 282], ["levels", 289], ["in", 296], ["females", 299], [",", 306], ["is", 308], ["very", 311], ["small", 316], [".", 321], ["However", 323], ["this", 331], ["hypothesis", 336], ["has", 347], ["never", 351], ["been", 357], ["tested", 362], ["and", 369], ["only", 373], ["a", 378], ["small", 380], ["number", 386], ["of", 393], ["genes", 396], ["have", 402], ["been", 407], ["assayed", 412], ["for", 420], ["their", 424], ["X", 430], ["-", 431], ["inactivation", 432], ["status", 445], ["in", 452], ["the", 455], ["mouse", 459], [".", 464], ["We", 466], ["performed", 469], ["a", 479], ["global", 481], ["expression", 488], ["analysis", 499], ["in", 508], ["four", 511], ["somatic", 516], ["tissues", 524], ["(", 532], ["brain", 533], [",", 538], ["liver", 540], [",", 545], ["kidney", 547], ["and", 554], ["muscle", 558], [")", 564], ["of", 566], ["adult", 569], ["40,XX", 575], ["and", 581], ["39,XO", 585], ["mice", 591], ["using", 596], ["the", 602], ["Illumina", 606], ["Mouse", 615], ["WG-6", 621], ["v1_1", 626], ["Expression", 631], ["BeadChip", 642], ["and", 651], ["an", 655], ["extensive", 658], ["validation", 668], ["by", 679], ["quantitative", 682], ["real", 695], ["time", 700], ["PCR", 705], [",", 708], ["in", 710], ["order", 713], ["to", 719], ["identify", 722], ["which", 731], ["genes", 737], ["are", 743], ["expressed", 747], ["from", 757], ["both", 762], ["X", 767], ["chromosomes", 769], [".", 780], ["We", 782], ["identified", 785], ["several", 796], ["genes", 804], ["on", 810], ["the", 813], ["X", 817], ["chromosome", 819], ["which", 830], ["are", 836], ["overexpressed", 840], ["in", 854], ["XX", 857], ["females", 860], [",", 867], ["including", 869], ["those", 879], ["previously", 885], ["reported", 896], ["as", 905], ["escaping", 908], ["X", 917], ["inactivation", 919], [",", 931], ["as", 933], ["well", 936], ["as", 941], ["new", 944], ["candidates", 948], [".", 958], ["However", 960], [",", 967], ["the", 969], ["results", 973], ["obtained", 981], ["by", 990], ["microarray", 993], ["and", 1004], ["qPCR", 1008], ["were", 1013], ["not", 1018], ["fully", 1022], ["concordant", 1028], [",", 1038], ["illustrating", 1040], ["the", 1053], ["difficulty", 1057], ["in", 1068], ["ascertaining", 1071], ["modest", 1084], ["fold", 1091], ["changes", 1096], [",", 1103], ["such", 1105], ["as", 1110], ["those", 1113], ["expected", 1119], ["for", 1128], ["genes", 1132], ["escaping", 1138], ["X", 1147], ["inactivation", 1149], [".", 1161], ["Remarkably", 1163], [",", 1173], ["considerable", 1175], ["variation", 1188], ["was", 1198], ["observed", 1202], ["between", 1211], ["tissues", 1219], [",", 1226], ["suggesting", 1228], ["that", 1239], ["inactivation", 1244], ["patterns", 1257], ["may", 1266], ["be", 1270], ["tissue", 1273], ["-", 1279], ["dependent", 1280], [".", 1289], ["Our", 1291], ["analysis", 1295], ["also", 1304], ["exposed", 1309], ["several", 1317], ["autosomal", 1325], ["genes", 1335], ["involved", 1341], ["in", 1350], ["mitochondrial", 1353], ["metabolism", 1367], ["and", 1378], ["in", 1382], ["protein", 1385], ["translation", 1393], ["which", 1405], ["are", 1411], ["differentially", 1415], ["expressed", 1430], ["between", 1440], ["XX", 1448], ["and", 1451], ["XO", 1455], ["mice", 1458], [",", 1462], ["revealing", 1464], ["secondary", 1474], ["transcriptional", 1484], ["changes", 1500], ["to", 1508], ["the", 1511], ["alteration", 1515], ["in", 1526], ["X", 1529], ["chromosome", 1531], ["dosage", 1542], [".", 1548], ["Our", 1550], ["results", 1554], ["support", 1562], ["the", 1570], ["prediction", 1574], ["that", 1585], ["the", 1590], ["mouse", 1594], ["inactive", 1600], ["X", 1609], ["chromosome", 1611], ["is", 1622], ["largely", 1625], ["silent", 1633], [",", 1639], ["while", 1641], ["providing", 1647], ["a", 1657], ["list", 1659], ["of", 1664], ["the", 1667], ["genes", 1671], ["potentially", 1677], ["escaping", 1689], ["X", 1698], ["inactivation", 1700], ["in", 1713], ["rodents", 1716], [".", 1723], ["Although", 1725], ["the", 1734], ["lower", 1738], ["expression", 1744], ["of", 1755], ["X", 1758], ["-", 1759], ["linked", 1760], ["genes", 1767], ["in", 1773], ["XO", 1776], ["mice", 1779], ["may", 1784], ["not", 1788], ["be", 1792], ["relevant", 1795], ["in", 1804], ["the", 1807], ["particular", 1811], ["tissues", 1822], ["/", 1829], ["systems", 1830], ["which", 1838], ["are", 1844], ["affected", 1848], ["in", 1857], ["human", 1860], ["X", 1866], ["chromosome", 1868], ["monosomy", 1879], [",", 1887], ["genes", 1889], ["deregulated", 1895], ["in", 1907], ["XO", 1910], ["mice", 1913], ["are", 1918], ["good", 1922], ["candidates", 1927], ["for", 1938], ["further", 1942], ["study", 1950], ["in", 1956], ["an", 1959], ["involvement", 1962], ["in", 1974], ["Turner", 1977], ["Syndrome", 1984], ["phenotype", 1993], [".", 2002]]}
{"context": "We report a novel mutation in the XK gene (XK) in a Japanese patient with McLeod syndrome. A 50-year-old man showed progressive muscular atrophy, choreic movement, elevated level of serum creatinine kinase, and acanthocytosis. The expression level of all the Kell antigens in erythrocyte was decreased and molecular analysis revealed a single-base (T) deletion at the nucleotide position 1095 in XK. This deletion caused a frameshift in translation, leading to a premature stop codon at the amino acid position 408. We conclude this single-base deletion causes defective Kx protein, which is responsible for the McLeod phenotype in this patient.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "682f059c5e1247ec92d678ce3cc5a4cc", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[7, 7], [73, 73], [10, 10]], "char_spans": [[34, 35], [396, 397], [43, 44]]}]}], "context_tokens": [["We", 0], ["report", 3], ["a", 10], ["novel", 12], ["mutation", 18], ["in", 27], ["the", 30], ["XK", 34], ["gene", 37], ["(", 42], ["XK", 43], [")", 45], ["in", 47], ["a", 50], ["Japanese", 52], ["patient", 61], ["with", 69], ["McLeod", 74], ["syndrome", 81], [".", 89], ["A", 91], ["50-year", 93], ["-", 100], ["old", 101], ["man", 105], ["showed", 109], ["progressive", 116], ["muscular", 128], ["atrophy", 137], [",", 144], ["choreic", 146], ["movement", 154], [",", 162], ["elevated", 164], ["level", 173], ["of", 179], ["serum", 182], ["creatinine", 188], ["kinase", 199], [",", 205], ["and", 207], ["acanthocytosis", 211], [".", 225], ["The", 227], ["expression", 231], ["level", 242], ["of", 248], ["all", 251], ["the", 255], ["Kell", 259], ["antigens", 264], ["in", 273], ["erythrocyte", 276], ["was", 288], ["decreased", 292], ["and", 302], ["molecular", 306], ["analysis", 316], ["revealed", 325], ["a", 334], ["single", 336], ["-", 342], ["base", 343], ["(", 348], ["T", 349], [")", 350], ["deletion", 352], ["at", 361], ["the", 364], ["nucleotide", 368], ["position", 379], ["1095", 388], ["in", 393], ["XK", 396], [".", 398], ["This", 400], ["deletion", 405], ["caused", 414], ["a", 421], ["frameshift", 423], ["in", 434], ["translation", 437], [",", 448], ["leading", 450], ["to", 458], ["a", 461], ["premature", 463], ["stop", 473], ["codon", 478], ["at", 484], ["the", 487], ["amino", 491], ["acid", 497], ["position", 502], ["408", 511], [".", 514], ["We", 516], ["conclude", 519], ["this", 528], ["single", 533], ["-", 539], ["base", 540], ["deletion", 545], ["causes", 554], ["defective", 561], ["Kx", 571], ["protein", 574], [",", 581], ["which", 583], ["is", 589], ["responsible", 592], ["for", 604], ["the", 608], ["McLeod", 612], ["phenotype", 619], ["in", 629], ["this", 632], ["patient", 637], [".", 644]]}
{"context": "Insulin is the cornerstone of type 1 diabetes mellitus (T1DM) therapy. However, it cannot achieve a delay in the onset or evolution of this condition, while cardiovascular morbidity remains an unquestionable threat. In this review, the authors discuss gevokizumab (XOMA 052), a recombinant monoclonal antibody that can neutralize human IL-1\u03b2 by binding to it. This is relevant, because this IL has been associated with \u03b2-cell toxicity in both diabetes types. Moreover, gevokizumab presents two major advantages: it spares IL-1\u03b1 and it exhibits favorable pharmacokinetic properties. Gevokizumab has already proven its safety and efficacy in improving glycemic control, \u03b2 cell function and inflammation markers in clinical trials in diabetic patients. Despite the very promising characteristics of gevokizumab, important questions remain to be answered. One important question is what to expect from a combination of this agent with insulin and if there is a subset of patients that might respond more favorably to treatment. We also need to know at what stage in the natural history of T1DM could gevokizumab be most efficacious, as well as its potential effects on cardiovascular outcomes.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "c44c66126f324ce3acbc22cbc8a73352", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[60, 60]], "char_spans": [[336, 340]]}]}], "context_tokens": [["Insulin", 0], ["is", 8], ["the", 11], ["cornerstone", 15], ["of", 27], ["type", 30], ["1", 35], ["diabetes", 37], ["mellitus", 46], ["(", 55], ["T1DM", 56], [")", 60], ["therapy", 62], [".", 69], ["However", 71], [",", 78], ["it", 80], ["can", 83], ["not", 86], ["achieve", 90], ["a", 98], ["delay", 100], ["in", 106], ["the", 109], ["onset", 113], ["or", 119], ["evolution", 122], ["of", 132], ["this", 135], ["condition", 140], [",", 149], ["while", 151], ["cardiovascular", 157], ["morbidity", 172], ["remains", 182], ["an", 190], ["unquestionable", 193], ["threat", 208], [".", 214], ["In", 216], ["this", 219], ["review", 224], [",", 230], ["the", 232], ["authors", 236], ["discuss", 244], ["gevokizumab", 252], ["(", 264], ["XOMA", 265], ["052", 270], [")", 273], [",", 274], ["a", 276], ["recombinant", 278], ["monoclonal", 290], ["antibody", 301], ["that", 310], ["can", 315], ["neutralize", 319], ["human", 330], ["IL-1\u03b2", 336], ["by", 342], ["binding", 345], ["to", 353], ["it", 356], [".", 358], ["This", 360], ["is", 365], ["relevant", 368], [",", 376], ["because", 378], ["this", 386], ["IL", 391], ["has", 394], ["been", 398], ["associated", 403], ["with", 414], ["\u03b2", 419], ["-", 420], ["cell", 421], ["toxicity", 426], ["in", 435], ["both", 438], ["diabetes", 443], ["types", 452], [".", 457], ["Moreover", 459], [",", 467], ["gevokizumab", 469], ["presents", 481], ["two", 490], ["major", 494], ["advantages", 500], [":", 510], ["it", 512], ["spares", 515], ["IL-1\u03b1", 522], ["and", 528], ["it", 532], ["exhibits", 535], ["favorable", 544], ["pharmacokinetic", 554], ["properties", 570], [".", 580], ["Gevokizumab", 582], ["has", 594], ["already", 598], ["proven", 606], ["its", 613], ["safety", 617], ["and", 624], ["efficacy", 628], ["in", 637], ["improving", 640], ["glycemic", 650], ["control", 659], [",", 666], ["\u03b2", 668], ["cell", 670], ["function", 675], ["and", 684], ["inflammation", 688], ["markers", 701], ["in", 709], ["clinical", 712], ["trials", 721], ["in", 728], ["diabetic", 731], ["patients", 740], [".", 748], ["Despite", 750], ["the", 758], ["very", 762], ["promising", 767], ["characteristics", 777], ["of", 793], ["gevokizumab", 796], [",", 807], ["important", 809], ["questions", 819], ["remain", 829], ["to", 836], ["be", 839], ["answered", 842], [".", 850], ["One", 852], ["important", 856], ["question", 866], ["is", 875], ["what", 878], ["to", 883], ["expect", 886], ["from", 893], ["a", 898], ["combination", 900], ["of", 912], ["this", 915], ["agent", 920], ["with", 926], ["insulin", 931], ["and", 939], ["if", 943], ["there", 946], ["is", 952], ["a", 955], ["subset", 957], ["of", 964], ["patients", 967], ["that", 976], ["might", 981], ["respond", 987], ["more", 995], ["favorably", 1000], ["to", 1010], ["treatment", 1013], [".", 1022], ["We", 1024], ["also", 1027], ["need", 1032], ["to", 1037], ["know", 1040], ["at", 1045], ["what", 1048], ["stage", 1053], ["in", 1059], ["the", 1062], ["natural", 1066], ["history", 1074], ["of", 1082], ["T1DM", 1085], ["could", 1090], ["gevokizumab", 1096], ["be", 1108], ["most", 1111], ["efficacious", 1116], [",", 1127], ["as", 1129], ["well", 1132], ["as", 1137], ["its", 1140], ["potential", 1144], ["effects", 1154], ["on", 1162], ["cardiovascular", 1165], ["outcomes", 1180], [".", 1188]]}
{"context": "Mutations and deletions of the NSD1 gene, located on chromosome 5q35, are responsible for over 90% of cases of Sotos syndrome. Fluorescent in situ hybridization analysis (FISH), MLPA or multiplex quantitative PCR allow detection of total/partial NSD1 deletions and direct sequencing allows detection of NSD1 mutations. We describe two boys with Sotos syndrome in whom PCR amplification and direct sequencing of the NSD1 gene identified two novel mutations not previously described: c.4736dupG in exon 12 and c.3938_3939insT in exon 7. In addition to the cardinal and major features of the syndrome (abnormal facial appearance, overgrowth, cardiac anomalies, renal anomalies, hypotonia, neonatal jaundice, seizures and brain MRI abnormalities) in both patients, one boy also had cryptorchidism and vertebral anomalies, features considered not common. Despite the wide range of possible combinations of phenotypic features, molecular analysis can correctly identify Sotos syndrome.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "da2112b55fe74ffe80afbc48f42143f7", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[5, 6], [72, 73]], "char_spans": [[31, 39], [415, 423]]}]}], "context_tokens": [["Mutations", 0], ["and", 10], ["deletions", 14], ["of", 24], ["the", 27], ["NSD1", 31], ["gene", 36], [",", 40], ["located", 42], ["on", 50], ["chromosome", 53], ["5q35", 64], [",", 68], ["are", 70], ["responsible", 74], ["for", 86], ["over", 90], ["90", 95], ["%", 97], ["of", 99], ["cases", 102], ["of", 108], ["Sotos", 111], ["syndrome", 117], [".", 125], ["Fluorescent", 127], ["in", 139], ["situ", 142], ["hybridization", 147], ["analysis", 161], ["(", 170], ["FISH", 171], [")", 175], [",", 176], ["MLPA", 178], ["or", 183], ["multiplex", 186], ["quantitative", 196], ["PCR", 209], ["allow", 213], ["detection", 219], ["of", 229], ["total", 232], ["/", 237], ["partial", 238], ["NSD1", 246], ["deletions", 251], ["and", 261], ["direct", 265], ["sequencing", 272], ["allows", 283], ["detection", 290], ["of", 300], ["NSD1", 303], ["mutations", 308], [".", 317], ["We", 319], ["describe", 322], ["two", 331], ["boys", 335], ["with", 340], ["Sotos", 345], ["syndrome", 351], ["in", 360], ["whom", 363], ["PCR", 368], ["amplification", 372], ["and", 386], ["direct", 390], ["sequencing", 397], ["of", 408], ["the", 411], ["NSD1", 415], ["gene", 420], ["identified", 425], ["two", 436], ["novel", 440], ["mutations", 446], ["not", 456], ["previously", 460], ["described", 471], [":", 480], ["c.4736dupG", 482], ["in", 493], ["exon", 496], ["12", 501], ["and", 504], ["c.3938_3939insT", 508], ["in", 524], ["exon", 527], ["7", 532], [".", 533], ["In", 535], ["addition", 538], ["to", 547], ["the", 550], ["cardinal", 554], ["and", 563], ["major", 567], ["features", 573], ["of", 582], ["the", 585], ["syndrome", 589], ["(", 598], ["abnormal", 599], ["facial", 608], ["appearance", 615], [",", 625], ["overgrowth", 627], [",", 637], ["cardiac", 639], ["anomalies", 647], [",", 656], ["renal", 658], ["anomalies", 664], [",", 673], ["hypotonia", 675], [",", 684], ["neonatal", 686], ["jaundice", 695], [",", 703], ["seizures", 705], ["and", 714], ["brain", 718], ["MRI", 724], ["abnormalities", 728], [")", 741], ["in", 743], ["both", 746], ["patients", 751], [",", 759], ["one", 761], ["boy", 765], ["also", 769], ["had", 774], ["cryptorchidism", 778], ["and", 793], ["vertebral", 797], ["anomalies", 807], [",", 816], ["features", 818], ["considered", 827], ["not", 838], ["common", 842], [".", 848], ["Despite", 850], ["the", 858], ["wide", 862], ["range", 867], ["of", 873], ["possible", 876], ["combinations", 885], ["of", 898], ["phenotypic", 901], ["features", 912], [",", 920], ["molecular", 922], ["analysis", 932], ["can", 941], ["correctly", 945], ["identify", 955], ["Sotos", 964], ["syndrome", 970], [".", 978]]}
{"context": "The expression of selenoproteins requires the translational recoding of the UGA stop codon to selenocysteine. In eukaryotes, this requires an RNA stem loop structure in the 3'-untranslated region, termed a selenocysteine insertion sequence (SECIS), and SECIS-binding protein 2 (SBP2). This study implicates SBP2 in dictating the hierarchy of selenoprotein expression, because it is the first to show that SBP2 distinguishes between SECIS elements in vitro. Using RNA electrophoretic mobility shift assays, we demonstrate that a naturally occurring mutation in SBP2, which correlates with abnormal thyroid hormone function in humans, lies within a novel, bipartite RNA-binding domain. This mutation alters the RNA binding affinity of SBP2 such that it no longer stably interacts with a subset of SECIS elements. Assays performed under competitive conditions to mimic intracellular conditions suggest that the differential affinity of SBP2 for various SECIS elements will determine the expression pattern of the selenoproteome. We hypothesize that the selective loss of a subset of selenoproteins, including some involved in thyroid hormone homeostasis, is responsible for the abnormal thyroid hormone metabolism previously observed in the affected individuals.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "4a2ea59ce04b469fb5deddf4edb5b587", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[157, 157], [37, 37], [41, 41], [73, 73], [136, 136]], "char_spans": [[950, 954], [241, 245], [253, 257], [432, 436], [795, 799]]}]}], "context_tokens": [["The", 0], ["expression", 4], ["of", 15], ["selenoproteins", 18], ["requires", 33], ["the", 42], ["translational", 46], ["recoding", 60], ["of", 69], ["the", 72], ["UGA", 76], ["stop", 80], ["codon", 85], ["to", 91], ["selenocysteine", 94], [".", 108], ["In", 110], ["eukaryotes", 113], [",", 123], ["this", 125], ["requires", 130], ["an", 139], ["RNA", 142], ["stem", 146], ["loop", 151], ["structure", 156], ["in", 166], ["the", 169], ["3'-untranslated", 173], ["region", 189], [",", 195], ["termed", 197], ["a", 204], ["selenocysteine", 206], ["insertion", 221], ["sequence", 231], ["(", 240], ["SECIS", 241], [")", 246], [",", 247], ["and", 249], ["SECIS", 253], ["-", 258], ["binding", 259], ["protein", 267], ["2", 275], ["(", 277], ["SBP2", 278], [")", 282], [".", 283], ["This", 285], ["study", 290], ["implicates", 296], ["SBP2", 307], ["in", 312], ["dictating", 315], ["the", 325], ["hierarchy", 329], ["of", 339], ["selenoprotein", 342], ["expression", 356], [",", 366], ["because", 368], ["it", 376], ["is", 379], ["the", 382], ["first", 386], ["to", 392], ["show", 395], ["that", 400], ["SBP2", 405], ["distinguishes", 410], ["between", 424], ["SECIS", 432], ["elements", 438], ["in", 447], ["vitro", 450], [".", 455], ["Using", 457], ["RNA", 463], ["electrophoretic", 467], ["mobility", 483], ["shift", 492], ["assays", 498], [",", 504], ["we", 506], ["demonstrate", 509], ["that", 521], ["a", 526], ["naturally", 528], ["occurring", 538], ["mutation", 548], ["in", 557], ["SBP2", 560], [",", 564], ["which", 566], ["correlates", 572], ["with", 583], ["abnormal", 588], ["thyroid", 597], ["hormone", 605], ["function", 613], ["in", 622], ["humans", 625], [",", 631], ["lies", 633], ["within", 638], ["a", 645], ["novel", 647], [",", 652], ["bipartite", 654], ["RNA", 664], ["-", 667], ["binding", 668], ["domain", 676], [".", 682], ["This", 684], ["mutation", 689], ["alters", 698], ["the", 705], ["RNA", 709], ["binding", 713], ["affinity", 721], ["of", 730], ["SBP2", 733], ["such", 738], ["that", 743], ["it", 748], ["no", 751], ["longer", 754], ["stably", 761], ["interacts", 768], ["with", 778], ["a", 783], ["subset", 785], ["of", 792], ["SECIS", 795], ["elements", 801], [".", 809], ["Assays", 811], ["performed", 818], ["under", 828], ["competitive", 834], ["conditions", 846], ["to", 857], ["mimic", 860], ["intracellular", 866], ["conditions", 880], ["suggest", 891], ["that", 899], ["the", 904], ["differential", 908], ["affinity", 921], ["of", 930], ["SBP2", 933], ["for", 938], ["various", 942], ["SECIS", 950], ["elements", 956], ["will", 965], ["determine", 970], ["the", 980], ["expression", 984], ["pattern", 995], ["of", 1003], ["the", 1006], ["selenoproteome", 1010], [".", 1024], ["We", 1026], ["hypothesize", 1029], ["that", 1041], ["the", 1046], ["selective", 1050], ["loss", 1060], ["of", 1065], ["a", 1068], ["subset", 1070], ["of", 1077], ["selenoproteins", 1080], [",", 1094], ["including", 1096], ["some", 1106], ["involved", 1111], ["in", 1120], ["thyroid", 1123], ["hormone", 1131], ["homeostasis", 1139], [",", 1150], ["is", 1152], ["responsible", 1155], ["for", 1167], ["the", 1171], ["abnormal", 1175], ["thyroid", 1184], ["hormone", 1192], ["metabolism", 1200], ["previously", 1211], ["observed", 1222], ["in", 1231], ["the", 1234], ["affected", 1238], ["individuals", 1247], [".", 1258]]}
{"context": "Centrosomes are composed of a centriole pair surrounded by an intricate proteinaceous matrix referred to as pericentriolar material. Although the mechanisms underpinning the control of centriole duplication are now well understood, we know relatively little about the control of centrosome size and shape. Here we used interaction proteomics to identify the E3 ligase HERC2 and the neuralized homologue NEURL4 as novel interaction partners of the centrosomal protein CP110. Using high resolution imaging, we find that HERC2 and NEURL4 localize to the centrosome and that interfering with their function alters centrosome morphology through the appearance of aberrant filamentous structures that stain for a subset of pericentriolar material proteins including pericentrin and CEP135. Using an RNA interference-resistant transgene approach in combination with structure-function analyses, we show that the association between CP110 and HERC2 depends on nonoverlapping regions of NEURL4. Whereas CP110 binding to NEURL4 is dispensable for the regulation of pericentriolar material architecture, its association with HERC2 is required to maintain normal centrosome integrity. NEURL4 is a substrate of HERC2, and together these results indicate that the NEURL4-HERC2 complex participates in the ubiquitin-dependent regulation of centrosome architecture.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "edb15e5cd3594668933fa0a9f6c83206", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[173, 173], [86, 86], [41, 41], [200, 200], [94, 94]], "char_spans": [[1151, 1160], [551, 560], [279, 288], [1325, 1334], [610, 619]]}]}], "context_tokens": [["Centrosomes", 0], ["are", 12], ["composed", 16], ["of", 25], ["a", 28], ["centriole", 30], ["pair", 40], ["surrounded", 45], ["by", 56], ["an", 59], ["intricate", 62], ["proteinaceous", 72], ["matrix", 86], ["referred", 93], ["to", 102], ["as", 105], ["pericentriolar", 108], ["material", 123], [".", 131], ["Although", 133], ["the", 142], ["mechanisms", 146], ["underpinning", 157], ["the", 170], ["control", 174], ["of", 182], ["centriole", 185], ["duplication", 195], ["are", 207], ["now", 211], ["well", 215], ["understood", 220], [",", 230], ["we", 232], ["know", 235], ["relatively", 240], ["little", 251], ["about", 258], ["the", 264], ["control", 268], ["of", 276], ["centrosome", 279], ["size", 290], ["and", 295], ["shape", 299], [".", 304], ["Here", 306], ["we", 311], ["used", 314], ["interaction", 319], ["proteomics", 331], ["to", 342], ["identify", 345], ["the", 354], ["E3", 358], ["ligase", 361], ["HERC2", 368], ["and", 374], ["the", 378], ["neuralized", 382], ["homologue", 393], ["NEURL4", 403], ["as", 410], ["novel", 413], ["interaction", 419], ["partners", 431], ["of", 440], ["the", 443], ["centrosomal", 447], ["protein", 459], ["CP110", 467], [".", 472], ["Using", 474], ["high", 480], ["resolution", 485], ["imaging", 496], [",", 503], ["we", 505], ["find", 508], ["that", 513], ["HERC2", 518], ["and", 524], ["NEURL4", 528], ["localize", 535], ["to", 544], ["the", 547], ["centrosome", 551], ["and", 562], ["that", 566], ["interfering", 571], ["with", 583], ["their", 588], ["function", 594], ["alters", 603], ["centrosome", 610], ["morphology", 621], ["through", 632], ["the", 640], ["appearance", 644], ["of", 655], ["aberrant", 658], ["filamentous", 667], ["structures", 679], ["that", 690], ["stain", 695], ["for", 701], ["a", 705], ["subset", 707], ["of", 714], ["pericentriolar", 717], ["material", 732], ["proteins", 741], ["including", 750], ["pericentrin", 760], ["and", 772], ["CEP135", 776], [".", 782], ["Using", 784], ["an", 790], ["RNA", 793], ["interference", 797], ["-", 809], ["resistant", 810], ["transgene", 820], ["approach", 830], ["in", 839], ["combination", 842], ["with", 854], ["structure", 859], ["-", 868], ["function", 869], ["analyses", 878], [",", 886], ["we", 888], ["show", 891], ["that", 896], ["the", 901], ["association", 905], ["between", 917], ["CP110", 925], ["and", 931], ["HERC2", 935], ["depends", 941], ["on", 949], ["nonoverlapping", 952], ["regions", 967], ["of", 975], ["NEURL4", 978], [".", 984], ["Whereas", 986], ["CP110", 994], ["binding", 1000], ["to", 1008], ["NEURL4", 1011], ["is", 1018], ["dispensable", 1021], ["for", 1033], ["the", 1037], ["regulation", 1041], ["of", 1052], ["pericentriolar", 1055], ["material", 1070], ["architecture", 1079], [",", 1091], ["its", 1093], ["association", 1097], ["with", 1109], ["HERC2", 1114], ["is", 1120], ["required", 1123], ["to", 1132], ["maintain", 1135], ["normal", 1144], ["centrosome", 1151], ["integrity", 1162], [".", 1171], ["NEURL4", 1173], ["is", 1180], ["a", 1183], ["substrate", 1185], ["of", 1195], ["HERC2", 1198], [",", 1203], ["and", 1205], ["together", 1209], ["these", 1218], ["results", 1224], ["indicate", 1232], ["that", 1241], ["the", 1246], ["NEURL4-HERC2", 1250], ["complex", 1263], ["participates", 1271], ["in", 1284], ["the", 1287], ["ubiquitin", 1291], ["-", 1300], ["dependent", 1301], ["regulation", 1311], ["of", 1322], ["centrosome", 1325], ["architecture", 1336], [".", 1348]]}
{"context": "The BCR-ABL fusion gene represents the hallmark of chronic myelogenous leukemia (CML) and is derived from a translocation between chromosome 9 and 22. The majority of CML patients have a breakpoint in the major BCR region of the BCR gene giving rise to e13a2 or e14a2 BCR-ABL transcripts. Occasionally, other BCR breakpoints occur. The current report describes two e6a2 CML patients with imatinib treatment failure and unusual disease progression. One patient was Philadelphia chromosome positive and one was Philadelphia chromosome negative with an atypical BCR-ABL rearrangement, ins (22;9).", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "da064d93bc6d4d6fa5b680d9a08d7890", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[95, 97], [1, 3], [51, 53]], "char_spans": [[559, 565], [4, 10], [268, 274]]}]}], "context_tokens": [["The", 0], ["BCR", 4], ["-", 7], ["ABL", 8], ["fusion", 12], ["gene", 19], ["represents", 24], ["the", 35], ["hallmark", 39], ["of", 48], ["chronic", 51], ["myelogenous", 59], ["leukemia", 71], ["(", 80], ["CML", 81], [")", 84], ["and", 86], ["is", 90], ["derived", 93], ["from", 101], ["a", 106], ["translocation", 108], ["between", 122], ["chromosome", 130], ["9", 141], ["and", 143], ["22", 147], [".", 149], ["The", 151], ["majority", 155], ["of", 164], ["CML", 167], ["patients", 171], ["have", 180], ["a", 185], ["breakpoint", 187], ["in", 198], ["the", 201], ["major", 205], ["BCR", 211], ["region", 215], ["of", 222], ["the", 225], ["BCR", 229], ["gene", 233], ["giving", 238], ["rise", 245], ["to", 250], ["e13a2", 253], ["or", 259], ["e14a2", 262], ["BCR", 268], ["-", 271], ["ABL", 272], ["transcripts", 276], [".", 287], ["Occasionally", 289], [",", 301], ["other", 303], ["BCR", 309], ["breakpoints", 313], ["occur", 325], [".", 330], ["The", 332], ["current", 336], ["report", 344], ["describes", 351], ["two", 361], ["e6a2", 365], ["CML", 370], ["patients", 374], ["with", 383], ["imatinib", 388], ["treatment", 397], ["failure", 407], ["and", 415], ["unusual", 419], ["disease", 427], ["progression", 435], [".", 446], ["One", 448], ["patient", 452], ["was", 460], ["Philadelphia", 464], ["chromosome", 477], ["positive", 488], ["and", 497], ["one", 501], ["was", 505], ["Philadelphia", 509], ["chromosome", 522], ["negative", 533], ["with", 542], ["an", 547], ["atypical", 550], ["BCR", 559], ["-", 562], ["ABL", 563], ["rearrangement", 567], [",", 580], ["ins", 582], ["(", 586], ["22;9", 587], [")", 591], [".", 592]]}
{"context": "Parkinson's disease (PD) is a neurodegnerative disorder that is pathologically characterized by the presence of Lewy bodies in the brain. We show that Lewy bodies in PD are strongly immunoreactive for torsinA, the protein product of the DYT1 gene, which is associated with primary generalized dystonia. In the substantia nigra, torsinA immunoreactivity is localized to the periphery of Lewy bodies, whereas, in cortical Lewy bodies it is uniformly distributed. The significance of this finding is unknown, but may implicate torsinA in neuronal dysfunction that occurs in PD as well as in primary dystonia.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "630e6932bb704bc7a85107087e4dd2ea", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegnerative", 30], ["disorder", 47], ["that", 56], ["is", 61], ["pathologically", 64], ["characterized", 79], ["by", 93], ["the", 96], ["presence", 100], ["of", 109], ["Lewy", 112], ["bodies", 117], ["in", 124], ["the", 127], ["brain", 131], [".", 136], ["We", 138], ["show", 141], ["that", 146], ["Lewy", 151], ["bodies", 156], ["in", 163], ["PD", 166], ["are", 169], ["strongly", 173], ["immunoreactive", 182], ["for", 197], ["torsinA", 201], [",", 208], ["the", 210], ["protein", 214], ["product", 222], ["of", 230], ["the", 233], ["DYT1", 237], ["gene", 242], [",", 246], ["which", 248], ["is", 254], ["associated", 257], ["with", 268], ["primary", 273], ["generalized", 281], ["dystonia", 293], [".", 301], ["In", 303], ["the", 306], ["substantia", 310], ["nigra", 321], [",", 326], ["torsinA", 328], ["immunoreactivity", 336], ["is", 353], ["localized", 356], ["to", 366], ["the", 369], ["periphery", 373], ["of", 383], ["Lewy", 386], ["bodies", 391], [",", 397], ["whereas", 399], [",", 406], ["in", 408], ["cortical", 411], ["Lewy", 420], ["bodies", 425], ["it", 432], ["is", 435], ["uniformly", 438], ["distributed", 448], [".", 459], ["The", 461], ["significance", 465], ["of", 478], ["this", 481], ["finding", 486], ["is", 494], ["unknown", 497], [",", 504], ["but", 506], ["may", 510], ["implicate", 514], ["torsinA", 524], ["in", 532], ["neuronal", 535], ["dysfunction", 544], ["that", 556], ["occurs", 561], ["in", 568], ["PD", 571], ["as", 574], ["well", 577], ["as", 582], ["in", 585], ["primary", 588], ["dystonia", 596], [".", 604]]}
{"context": "To study the clinical and molecular characteristics of methicillin-resistant Staphylococcus aureus (MRSA) infection in children. A total of 37 MRSA strains were isolated from hospitalized patients in Children's Hospital of Fudan University from March 2009 to November 2011. The clinical characteristics were investigated by a cohort study. Furthermore, the mecA, Panton-Valentine leucocidin (PVL) genes were detected by polymerase chain reaction (PCR), and the genotypes of SCCmec were determined by multiplex PCR. (1) Among the 37 MRSA isolates, infections with 21 were acquired from hospital (HA-MRSA), and 16 isolates were acquired from community (CA-MRSA). (2) In the study, MRSA frequently caused respiratory tract infection, and most of the strains were isolated from intensive care unit (ICU). (3) CA-MRSA was most frequently associated with skin and soft tissue infections (SSTI), suppurative tonsillitis, even pneumonia and septicemia. HA-MRSA infection was more aggressive, most frequently associated with pneumonia, septicemia, and central nervous system (CNS) infections, such as meningitis. In children with fever caused by HA-MRSA or CA-MRSA infection, HA-MRSA showed a longer duration of fever, for 10.5 days. C-reactive protein (CRP) level caused by HA-MRSA (63.00 mg/L) was higher than CA-MRSA (9.50 mg/L) , and there were statistically significant differences between the groups (t = 2.5670, P < 0.05). However, there were no statistically significant differences between the groups in white blood cell count (WBC) or procalcitonin (PCT) level. (4) Among 37 MRSA isolates, the whole isolates were mecA gene positive (100%). SCCmec genotyping results showed that the most frequent SCCmec types were type III, 17 isolates, the others including type IV 8 isolates, type II1 isolates, nontypable 11 isolates, type I and type V were not found in this group. Therein, among 21 HA-MRSA isolates, SCCmec III was the most common, 15 isolates, type IV 1 isolates, nontypable 5 isolates; among 16 CA-MRSA isolates, SCCmec type IV was the most common, 7 isolates, type III 2 isolates, type II 1 isolate, nontypable 6 isolates. (5) Among the 37 MRSA isolates, 28 were PVL gene positive; and among 21 HA-MRSA isolates, 17 were PVL gene positive; Among 16 CA-MRSA isolates, 11 were PVL gene positive; There were no statistically significant differences between the groups (\u03c7(2) = 0.735, P > 0.05) . Compared with CA-MRSA, HA-MRSA infection was more aggressive, and induced higher C reactive protein; the dominant epidemic strains of CA-MRSA was SCCmec type IV, and HA-MRSA was SCCmec type III; the positive rate of PVL gene was high.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "b4d2ae32fe78473ead5fbb79a9000745", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[461, 461], [531, 531], [108, 108], [121, 121], [263, 263], [131, 131], [251, 251], [387, 387], [507, 507], [222, 222], [14, 14], [447, 447], [321, 321], [511, 511], [218, 218], [474, 474], [24, 24], [227, 227], [413, 413], [540, 540], [183, 183], [158, 158], [95, 95]], "char_spans": [[2208, 2211], [2539, 2542], [598, 601], [654, 657], [1306, 1309], [679, 682], [1269, 1272], [1892, 1895], [2419, 2422], [1151, 1154], [100, 103], [2150, 2153], [1576, 1579], [2428, 2431], [1140, 1143], [2262, 2265], [143, 146], [1170, 1173], [2007, 2010], [2571, 2574], [948, 951], [808, 811], [532, 535]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["clinical", 13], ["and", 22], ["molecular", 26], ["characteristics", 36], ["of", 52], ["methicillin", 55], ["-", 66], ["resistant", 67], ["Staphylococcus", 77], ["aureus", 92], ["(", 99], ["MRSA", 100], [")", 104], ["infection", 106], ["in", 116], ["children", 119], [".", 127], ["A", 129], ["total", 131], ["of", 137], ["37", 140], ["MRSA", 143], ["strains", 148], ["were", 156], ["isolated", 161], ["from", 170], ["hospitalized", 175], ["patients", 188], ["in", 197], ["Children", 200], ["'s", 208], ["Hospital", 211], ["of", 220], ["Fudan", 223], ["University", 229], ["from", 240], ["March", 245], ["2009", 251], ["to", 256], ["November", 259], ["2011", 268], [".", 272], ["The", 274], ["clinical", 278], ["characteristics", 287], ["were", 303], ["investigated", 308], ["by", 321], ["a", 324], ["cohort", 326], ["study", 333], [".", 338], ["Furthermore", 340], [",", 351], ["the", 353], ["mecA", 357], [",", 361], ["Panton", 363], ["-", 369], ["Valentine", 370], ["leucocidin", 380], ["(", 391], ["PVL", 392], [")", 395], ["genes", 397], ["were", 403], ["detected", 408], ["by", 417], ["polymerase", 420], ["chain", 431], ["reaction", 437], ["(", 446], ["PCR", 447], [")", 450], [",", 451], ["and", 453], ["the", 457], ["genotypes", 461], ["of", 471], ["SCCmec", 474], ["were", 481], ["determined", 486], ["by", 497], ["multiplex", 500], ["PCR", 510], [".", 513], ["(", 515], ["1", 516], [")", 517], ["Among", 519], ["the", 525], ["37", 529], ["MRSA", 532], ["isolates", 537], [",", 545], ["infections", 547], ["with", 558], ["21", 563], ["were", 566], ["acquired", 571], ["from", 580], ["hospital", 585], ["(", 594], ["HA", 595], ["-", 597], ["MRSA", 598], [")", 602], [",", 603], ["and", 605], ["16", 609], ["isolates", 612], ["were", 621], ["acquired", 626], ["from", 635], ["community", 640], ["(", 650], ["CA", 651], ["-", 653], ["MRSA", 654], [")", 658], [".", 659], ["(", 661], ["2", 662], [")", 663], ["In", 665], ["the", 668], ["study", 672], [",", 677], ["MRSA", 679], ["frequently", 684], ["caused", 695], ["respiratory", 702], ["tract", 714], ["infection", 720], [",", 729], ["and", 731], ["most", 735], ["of", 740], ["the", 743], ["strains", 747], ["were", 755], ["isolated", 760], ["from", 769], ["intensive", 774], ["care", 784], ["unit", 789], ["(", 794], ["ICU", 795], [")", 798], [".", 799], ["(", 801], ["3", 802], [")", 803], ["CA", 805], ["-", 807], ["MRSA", 808], ["was", 813], ["most", 817], ["frequently", 822], ["associated", 833], ["with", 844], ["skin", 849], ["and", 854], ["soft", 858], ["tissue", 863], ["infections", 870], ["(", 881], ["SSTI", 882], [")", 886], [",", 887], ["suppurative", 889], ["tonsillitis", 901], [",", 912], ["even", 914], ["pneumonia", 919], ["and", 929], ["septicemia", 933], [".", 943], ["HA", 945], ["-", 947], ["MRSA", 948], ["infection", 953], ["was", 963], ["more", 967], ["aggressive", 972], [",", 982], ["most", 984], ["frequently", 989], ["associated", 1000], ["with", 1011], ["pneumonia", 1016], [",", 1025], ["septicemia", 1027], [",", 1037], ["and", 1039], ["central", 1043], ["nervous", 1051], ["system", 1059], ["(", 1066], ["CNS", 1067], [")", 1070], ["infections", 1072], [",", 1082], ["such", 1084], ["as", 1089], ["meningitis", 1092], [".", 1102], ["In", 1104], ["children", 1107], ["with", 1116], ["fever", 1121], ["caused", 1127], ["by", 1134], ["HA", 1137], ["-", 1139], ["MRSA", 1140], ["or", 1145], ["CA", 1148], ["-", 1150], ["MRSA", 1151], ["infection", 1156], [",", 1165], ["HA", 1167], ["-", 1169], ["MRSA", 1170], ["showed", 1175], ["a", 1182], ["longer", 1184], ["duration", 1191], ["of", 1200], ["fever", 1203], [",", 1208], ["for", 1210], ["10.5", 1214], ["days", 1219], [".", 1223], ["C", 1225], ["-", 1226], ["reactive", 1227], ["protein", 1236], ["(", 1244], ["CRP", 1245], [")", 1248], ["level", 1250], ["caused", 1256], ["by", 1263], ["HA", 1266], ["-", 1268], ["MRSA", 1269], ["(", 1274], ["63.00", 1275], ["mg", 1281], ["/", 1283], ["L", 1284], [")", 1285], ["was", 1287], ["higher", 1291], ["than", 1298], ["CA", 1303], ["-", 1305], ["MRSA", 1306], ["(", 1311], ["9.50", 1312], ["mg", 1317], ["/", 1319], ["L", 1320], [")", 1321], [",", 1323], ["and", 1325], ["there", 1329], ["were", 1335], ["statistically", 1340], ["significant", 1354], ["differences", 1366], ["between", 1378], ["the", 1386], ["groups", 1390], ["(", 1397], ["t", 1398], ["=", 1400], ["2.5670", 1402], [",", 1408], ["P", 1410], ["<", 1412], ["0.05", 1414], [")", 1418], [".", 1419], ["However", 1421], [",", 1428], ["there", 1430], ["were", 1436], ["no", 1441], ["statistically", 1444], ["significant", 1458], ["differences", 1470], ["between", 1482], ["the", 1490], ["groups", 1494], ["in", 1501], ["white", 1504], ["blood", 1510], ["cell", 1516], ["count", 1521], ["(", 1527], ["WBC", 1528], [")", 1531], ["or", 1533], ["procalcitonin", 1536], ["(", 1550], ["PCT", 1551], [")", 1554], ["level", 1556], [".", 1561], ["(", 1563], ["4", 1564], [")", 1565], ["Among", 1567], ["37", 1573], ["MRSA", 1576], ["isolates", 1581], [",", 1589], ["the", 1591], ["whole", 1595], ["isolates", 1601], ["were", 1610], ["mecA", 1615], ["gene", 1620], ["positive", 1625], ["(", 1634], ["100", 1635], ["%", 1638], [")", 1639], [".", 1640], ["SCCmec", 1642], ["genotyping", 1649], ["results", 1660], ["showed", 1668], ["that", 1675], ["the", 1680], ["most", 1684], ["frequent", 1689], ["SCCmec", 1698], ["types", 1705], ["were", 1711], ["type", 1716], ["III", 1721], [",", 1724], ["17", 1726], ["isolates", 1729], [",", 1737], ["the", 1739], ["others", 1743], ["including", 1750], ["type", 1760], ["IV", 1765], ["8", 1768], ["isolates", 1770], [",", 1778], ["type", 1780], ["II1", 1785], ["isolates", 1789], [",", 1797], ["nontypable", 1799], ["11", 1810], ["isolates", 1813], [",", 1821], ["type", 1823], ["I", 1828], ["and", 1830], ["type", 1834], ["V", 1839], ["were", 1841], ["not", 1846], ["found", 1850], ["in", 1856], ["this", 1859], ["group", 1864], [".", 1869], ["Therein", 1871], [",", 1878], ["among", 1880], ["21", 1886], ["HA", 1889], ["-", 1891], ["MRSA", 1892], ["isolates", 1897], [",", 1905], ["SCCmec", 1907], ["III", 1914], ["was", 1918], ["the", 1922], ["most", 1926], ["common", 1931], [",", 1937], ["15", 1939], ["isolates", 1942], [",", 1950], ["type", 1952], ["IV", 1957], ["1", 1960], ["isolates", 1962], [",", 1970], ["nontypable", 1972], ["5", 1983], ["isolates", 1985], [";", 1993], ["among", 1995], ["16", 2001], ["CA", 2004], ["-", 2006], ["MRSA", 2007], ["isolates", 2012], [",", 2020], ["SCCmec", 2022], ["type", 2029], ["IV", 2034], ["was", 2037], ["the", 2041], ["most", 2045], ["common", 2050], [",", 2056], ["7", 2058], ["isolates", 2060], [",", 2068], ["type", 2070], ["III", 2075], ["2", 2079], ["isolates", 2081], [",", 2089], ["type", 2091], ["II", 2096], ["1", 2099], ["isolate", 2101], [",", 2108], ["nontypable", 2110], ["6", 2121], ["isolates", 2123], [".", 2131], ["(", 2133], ["5", 2134], [")", 2135], ["Among", 2137], ["the", 2143], ["37", 2147], ["MRSA", 2150], ["isolates", 2155], [",", 2163], ["28", 2165], ["were", 2168], ["PVL", 2173], ["gene", 2177], ["positive", 2182], [";", 2190], ["and", 2192], ["among", 2196], ["21", 2202], ["HA", 2205], ["-", 2207], ["MRSA", 2208], ["isolates", 2213], [",", 2221], ["17", 2223], ["were", 2226], ["PVL", 2231], ["gene", 2235], ["positive", 2240], [";", 2248], ["Among", 2250], ["16", 2256], ["CA", 2259], ["-", 2261], ["MRSA", 2262], ["isolates", 2267], [",", 2275], ["11", 2277], ["were", 2280], ["PVL", 2285], ["gene", 2289], ["positive", 2294], [";", 2302], ["There", 2304], ["were", 2310], ["no", 2315], ["statistically", 2318], ["significant", 2332], ["differences", 2344], ["between", 2356], ["the", 2364], ["groups", 2368], ["(", 2375], ["\u03c7(2", 2376], [")", 2379], ["=", 2381], ["0.735", 2383], [",", 2388], ["P", 2390], [">", 2392], ["0.05", 2394], [")", 2398], [".", 2400], ["Compared", 2402], ["with", 2411], ["CA", 2416], ["-", 2418], ["MRSA", 2419], [",", 2423], ["HA", 2425], ["-", 2427], ["MRSA", 2428], ["infection", 2433], ["was", 2443], ["more", 2447], ["aggressive", 2452], [",", 2462], ["and", 2464], ["induced", 2468], ["higher", 2476], ["C", 2483], ["reactive", 2485], ["protein", 2494], [";", 2501], ["the", 2503], ["dominant", 2507], ["epidemic", 2516], ["strains", 2525], ["of", 2533], ["CA", 2536], ["-", 2538], ["MRSA", 2539], ["was", 2544], ["SCCmec", 2548], ["type", 2555], ["IV", 2560], [",", 2562], ["and", 2564], ["HA", 2568], ["-", 2570], ["MRSA", 2571], ["was", 2576], ["SCCmec", 2580], ["type", 2587], ["III", 2592], [";", 2595], ["the", 2597], ["positive", 2601], ["rate", 2610], ["of", 2615], ["PVL", 2618], ["gene", 2622], ["was", 2627], ["high", 2631], [".", 2635]]}
{"context": "Infectious mononucleosis is a common, usually self-limited disease. However, infectious mononucleosis may present with severe manifestations. Complications may also occur. Consequently, diagnostic and treatment issues regarding infectious mononucleosis are of major importance. In this review, we focus on the evaluation of articles providing diagnosis and treatment data for infectious mononucleosis, published during the past 2 years. Twelve studies, deriving from extended search in PubMed, were included. Nine studies provided diagnosis data. The evaluated diagnostic methods were real-time PCR (RT-PCR), IgM/IgG antibodies measured with different assays [measurement of Epstein-Barr virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts, C-reactive protein values, and monospot test]. The sensitivities reported for RT-PCR were high. The available treatment data were scarce (three studies). Two of them suggested that antivirals (mainly acyclovir and valacyclovir) may have a role in the treatment of infectious mononucleosis with complications, whereas the remaining study presented novel potential therapeutic patents including 5-substituted uracyle, azacytosine derivatives, and peptides inhibiting EBV-mediated membrane fusion. RT-PCR and measurement of EBV-VL may provide useful tools for the early diagnosis of infectious mononucleosis in cases with inconclusive serological results. Antiviral agents may provide a useful treatment option in patients with severe infectious mononucleosis.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "fba1c150697a4864bbf8aedacd2d8a94", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[113, 116]], "char_spans": [[675, 692]]}]}], "context_tokens": [["Infectious", 0], ["mononucleosis", 11], ["is", 25], ["a", 28], ["common", 30], [",", 36], ["usually", 38], ["self", 46], ["-", 50], ["limited", 51], ["disease", 59], [".", 66], ["However", 68], [",", 75], ["infectious", 77], ["mononucleosis", 88], ["may", 102], ["present", 106], ["with", 114], ["severe", 119], ["manifestations", 126], [".", 140], ["Complications", 142], ["may", 156], ["also", 160], ["occur", 165], [".", 170], ["Consequently", 172], [",", 184], ["diagnostic", 186], ["and", 197], ["treatment", 201], ["issues", 211], ["regarding", 218], ["infectious", 228], ["mononucleosis", 239], ["are", 253], ["of", 257], ["major", 260], ["importance", 266], [".", 276], ["In", 278], ["this", 281], ["review", 286], [",", 292], ["we", 294], ["focus", 297], ["on", 303], ["the", 306], ["evaluation", 310], ["of", 321], ["articles", 324], ["providing", 333], ["diagnosis", 343], ["and", 353], ["treatment", 357], ["data", 367], ["for", 372], ["infectious", 376], ["mononucleosis", 387], [",", 400], ["published", 402], ["during", 412], ["the", 419], ["past", 423], ["2", 428], ["years", 430], [".", 435], ["Twelve", 437], ["studies", 444], [",", 451], ["deriving", 453], ["from", 462], ["extended", 467], ["search", 476], ["in", 483], ["PubMed", 486], [",", 492], ["were", 494], ["included", 499], [".", 507], ["Nine", 509], ["studies", 514], ["provided", 522], ["diagnosis", 531], ["data", 541], [".", 545], ["The", 547], ["evaluated", 551], ["diagnostic", 561], ["methods", 572], ["were", 580], ["real", 585], ["-", 589], ["time", 590], ["PCR", 595], ["(", 599], ["RT", 600], ["-", 602], ["PCR", 603], [")", 606], [",", 607], ["IgM", 609], ["/", 612], ["IgG", 613], ["antibodies", 617], ["measured", 628], ["with", 637], ["different", 642], ["assays", 652], ["[", 659], ["measurement", 660], ["of", 672], ["Epstein", 675], ["-", 682], ["Barr", 683], ["virus", 688], ["viral", 694], ["load", 700], ["(", 705], ["EBV", 706], ["-", 709], ["VL", 710], [")", 712], ["in", 714], ["peripheral", 717], ["blood", 728], [",", 733], ["neutrophil", 735], ["/", 745], ["lymphocyte", 746], ["/", 756], ["monocyte", 757], ["counts", 766], [",", 772], ["C", 774], ["-", 775], ["reactive", 776], ["protein", 785], ["values", 793], [",", 799], ["and", 801], ["monospot", 805], ["test].", 814], ["The", 821], ["sensitivities", 825], ["reported", 839], ["for", 848], ["RT", 852], ["-", 854], ["PCR", 855], ["were", 859], ["high", 864], [".", 868], ["The", 870], ["available", 874], ["treatment", 884], ["data", 894], ["were", 899], ["scarce", 904], ["(", 911], ["three", 912], ["studies", 918], [")", 925], [".", 926], ["Two", 928], ["of", 932], ["them", 935], ["suggested", 940], ["that", 950], ["antivirals", 955], ["(", 966], ["mainly", 967], ["acyclovir", 974], ["and", 984], ["valacyclovir", 988], [")", 1000], ["may", 1002], ["have", 1006], ["a", 1011], ["role", 1013], ["in", 1018], ["the", 1021], ["treatment", 1025], ["of", 1035], ["infectious", 1038], ["mononucleosis", 1049], ["with", 1063], ["complications", 1068], [",", 1081], ["whereas", 1083], ["the", 1091], ["remaining", 1095], ["study", 1105], ["presented", 1111], ["novel", 1121], ["potential", 1127], ["therapeutic", 1137], ["patents", 1149], ["including", 1157], ["5-substituted", 1167], ["uracyle", 1181], [",", 1188], ["azacytosine", 1190], ["derivatives", 1202], [",", 1213], ["and", 1215], ["peptides", 1219], ["inhibiting", 1228], ["EBV", 1239], ["-", 1242], ["mediated", 1243], ["membrane", 1252], ["fusion", 1261], [".", 1267], ["RT", 1269], ["-", 1271], ["PCR", 1272], ["and", 1276], ["measurement", 1280], ["of", 1292], ["EBV", 1295], ["-", 1298], ["VL", 1299], ["may", 1302], ["provide", 1306], ["useful", 1314], ["tools", 1321], ["for", 1327], ["the", 1331], ["early", 1335], ["diagnosis", 1341], ["of", 1351], ["infectious", 1354], ["mononucleosis", 1365], ["in", 1379], ["cases", 1382], ["with", 1388], ["inconclusive", 1393], ["serological", 1406], ["results", 1418], [".", 1425], ["Antiviral", 1427], ["agents", 1437], ["may", 1444], ["provide", 1448], ["a", 1456], ["useful", 1458], ["treatment", 1465], ["option", 1475], ["in", 1482], ["patients", 1485], ["with", 1494], ["severe", 1499], ["infectious", 1506], ["mononucleosis", 1517], [".", 1530]]}
{"context": "Deubiquitinating enzymes (DUbs) play important roles in many ubiquitin-dependent pathways, yet how DUbs themselves are regulated is not well understood. Here, we provide insight into the mechanism by which ubiquitination directly enhances the activity of ataxin-3, a DUb implicated in protein quality control and the disease protein in the polyglutamine neurodegenerative disorder, Spinocerebellar Ataxia Type 3. We identify Lys-117, which resides near the catalytic triad, as the primary site of ubiquitination in wild type and pathogenic ataxin-3. Further studies indicate that ubiquitin-dependent activation of ataxin-3 at Lys-117 is important for its ability to reduce high molecular weight ubiquitinated species in cells. Ubiquitination at Lys-117 also facilitates the ability of ataxin-3 to induce aggresome formation in cells. Finally, structure-function studies support a model of activation whereby ubiquitination at Lys-117 enhances ataxin-3 activity independent of the known ubiquitin-binding sites in ataxin-3, most likely through a direct conformational change in or near the catalytic domain.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "76df6ea078eb43ef838474f8a30b5d15", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[160, 160], [149, 149], [99, 99], [125, 125], [42, 42], [88, 88]], "char_spans": [[1013, 1020], [943, 950], [614, 621], [785, 792], [255, 262], [540, 547]]}]}], "context_tokens": [["Deubiquitinating", 0], ["enzymes", 17], ["(", 25], ["DUbs", 26], [")", 30], ["play", 32], ["important", 37], ["roles", 47], ["in", 53], ["many", 56], ["ubiquitin", 61], ["-", 70], ["dependent", 71], ["pathways", 81], [",", 89], ["yet", 91], ["how", 95], ["DUbs", 99], ["themselves", 104], ["are", 115], ["regulated", 119], ["is", 129], ["not", 132], ["well", 136], ["understood", 141], [".", 151], ["Here", 153], [",", 157], ["we", 159], ["provide", 162], ["insight", 170], ["into", 178], ["the", 183], ["mechanism", 187], ["by", 197], ["which", 200], ["ubiquitination", 206], ["directly", 221], ["enhances", 230], ["the", 239], ["activity", 243], ["of", 252], ["ataxin-3", 255], [",", 263], ["a", 265], ["DUb", 267], ["implicated", 271], ["in", 282], ["protein", 285], ["quality", 293], ["control", 301], ["and", 309], ["the", 313], ["disease", 317], ["protein", 325], ["in", 333], ["the", 336], ["polyglutamine", 340], ["neurodegenerative", 354], ["disorder", 372], [",", 380], ["Spinocerebellar", 382], ["Ataxia", 398], ["Type", 405], ["3", 410], [".", 411], ["We", 413], ["identify", 416], ["Lys-117", 425], [",", 432], ["which", 434], ["resides", 440], ["near", 448], ["the", 453], ["catalytic", 457], ["triad", 467], [",", 472], ["as", 474], ["the", 477], ["primary", 481], ["site", 489], ["of", 494], ["ubiquitination", 497], ["in", 512], ["wild", 515], ["type", 520], ["and", 525], ["pathogenic", 529], ["ataxin-3", 540], [".", 548], ["Further", 550], ["studies", 558], ["indicate", 566], ["that", 575], ["ubiquitin", 580], ["-", 589], ["dependent", 590], ["activation", 600], ["of", 611], ["ataxin-3", 614], ["at", 623], ["Lys-117", 626], ["is", 634], ["important", 637], ["for", 647], ["its", 651], ["ability", 655], ["to", 663], ["reduce", 666], ["high", 673], ["molecular", 678], ["weight", 688], ["ubiquitinated", 695], ["species", 709], ["in", 717], ["cells", 720], [".", 725], ["Ubiquitination", 727], ["at", 742], ["Lys-117", 745], ["also", 753], ["facilitates", 758], ["the", 770], ["ability", 774], ["of", 782], ["ataxin-3", 785], ["to", 794], ["induce", 797], ["aggresome", 804], ["formation", 814], ["in", 824], ["cells", 827], [".", 832], ["Finally", 834], [",", 841], ["structure", 843], ["-", 852], ["function", 853], ["studies", 862], ["support", 870], ["a", 878], ["model", 880], ["of", 886], ["activation", 889], ["whereby", 900], ["ubiquitination", 908], ["at", 923], ["Lys-117", 926], ["enhances", 934], ["ataxin-3", 943], ["activity", 952], ["independent", 961], ["of", 973], ["the", 976], ["known", 980], ["ubiquitin", 986], ["-", 995], ["binding", 996], ["sites", 1004], ["in", 1010], ["ataxin-3", 1013], [",", 1021], ["most", 1023], ["likely", 1028], ["through", 1035], ["a", 1043], ["direct", 1045], ["conformational", 1052], ["change", 1067], ["in", 1074], ["or", 1077], ["near", 1080], ["the", 1085], ["catalytic", 1089], ["domain", 1099], [".", 1105]]}
{"context": "Allelic polymorphism of the apolipoprotein E (ApoE) gene (ApoE \u03b52, ApoE \u03b53 and ApoE \u03b54 alleles) gives rise to three protein isoforms (ApoE2, ApoE3 and ApoE4) that differ by 1 or 2 amino acids. Inheritance of the ApoE \u03b54 allele is a risk factor for developing Alzheimer's disease (AD). The potential diagnostic value of ApoE protein levels in biological fluids (i.e. cerebrospinal fluid, plasma and serum) for distinguishing between AD patients and healthy elderly subjects is subject to great controversy. Although a recent study reported subnormal total ApoE and ApoE4 levels in the plasma of AD patients, other studies have found normal or even elevated protein levels (versus controls). Because all previously reported assays were based on immunoenzymatic techniques, we decided to develop an orthogonal assay based on targeted mass spectrometry by tracking (i) a proteotypic peptide common to all ApoE isoforms and (ii) a peptide that is specific for the \u03b54 allele. After trypsin digestion, the ApoE4-specific peptide contains an oxidation-prone methionine residue. The endogenous methionine oxidation level was evaluated in a small cohort (n=68) of heterozygous \u03b53\u03b54 carriers containing both healthy controls and AD patients. As expected, the proportion of oxidized residues varied from 0 to 10%, with an average of 5%. We therefore developed a standardized strategy for the unbiased, absolute quantification of ApoE4, based on performic acid oxidization of methionine. Once the sample workflow had been thoroughly validated, it was applied to the concomitant quantification of total ApoE and ApoE4 isoform in a large case-control study (n=669). The final measurements were consistent with most previously reported ApoE concentration values and confirm the influence of the different alleles on the protein expression level. Our results illustrate (i) the reliability of selected reaction monitoring-based assays and (ii) the value of the oxidization step for unbiased monitoring of methionine-containing proteotypic peptides. Furthermore, a statistical analysis indicated that neither total ApoE and ApoE4 levels nor the ApoE/ApoE4 ratio correlated with the diagnosis of AD. These findings reinforce the conclusions of previous studies in which plasma ApoE levels had no obvious clinical significance.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "2594b3b5c34d4b7f830baf5eb3094b4c", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[286, 287]], "char_spans": [[1598, 1610]]}]}], "context_tokens": [["Allelic", 0], ["polymorphism", 8], ["of", 21], ["the", 24], ["apolipoprotein", 28], ["E", 43], ["(", 45], ["ApoE", 46], [")", 50], ["gene", 52], ["(", 57], ["ApoE", 58], ["\u03b52", 63], [",", 65], ["ApoE", 67], ["\u03b53", 72], ["and", 75], ["ApoE", 79], ["\u03b54", 84], ["alleles", 87], [")", 94], ["gives", 96], ["rise", 102], ["to", 107], ["three", 110], ["protein", 116], ["isoforms", 124], ["(", 133], ["ApoE2", 134], [",", 139], ["ApoE3", 141], ["and", 147], ["ApoE4", 151], [")", 156], ["that", 158], ["differ", 163], ["by", 170], ["1", 173], ["or", 175], ["2", 178], ["amino", 180], ["acids", 186], [".", 191], ["Inheritance", 193], ["of", 205], ["the", 208], ["ApoE", 212], ["\u03b54", 217], ["allele", 220], ["is", 227], ["a", 230], ["risk", 232], ["factor", 237], ["for", 244], ["developing", 248], ["Alzheimer", 259], ["'s", 268], ["disease", 271], ["(", 279], ["AD", 280], [")", 282], [".", 283], ["The", 285], ["potential", 289], ["diagnostic", 299], ["value", 310], ["of", 316], ["ApoE", 319], ["protein", 324], ["levels", 332], ["in", 339], ["biological", 342], ["fluids", 353], ["(", 360], ["i.e.", 361], ["cerebrospinal", 366], ["fluid", 380], [",", 385], ["plasma", 387], ["and", 394], ["serum", 398], [")", 403], ["for", 405], ["distinguishing", 409], ["between", 424], ["AD", 432], ["patients", 435], ["and", 444], ["healthy", 448], ["elderly", 456], ["subjects", 464], ["is", 473], ["subject", 476], ["to", 484], ["great", 487], ["controversy", 493], [".", 504], ["Although", 506], ["a", 515], ["recent", 517], ["study", 524], ["reported", 530], ["subnormal", 539], ["total", 549], ["ApoE", 555], ["and", 560], ["ApoE4", 564], ["levels", 570], ["in", 577], ["the", 580], ["plasma", 584], ["of", 591], ["AD", 594], ["patients", 597], [",", 605], ["other", 607], ["studies", 613], ["have", 621], ["found", 626], ["normal", 632], ["or", 639], ["even", 642], ["elevated", 647], ["protein", 656], ["levels", 664], ["(", 671], ["versus", 672], ["controls", 679], [")", 687], [".", 688], ["Because", 690], ["all", 698], ["previously", 702], ["reported", 713], ["assays", 722], ["were", 729], ["based", 734], ["on", 740], ["immunoenzymatic", 743], ["techniques", 759], [",", 769], ["we", 771], ["decided", 774], ["to", 782], ["develop", 785], ["an", 793], ["orthogonal", 796], ["assay", 807], ["based", 813], ["on", 819], ["targeted", 822], ["mass", 831], ["spectrometry", 836], ["by", 849], ["tracking", 852], ["(", 861], ["i", 862], [")", 863], ["a", 865], ["proteotypic", 867], ["peptide", 879], ["common", 887], ["to", 894], ["all", 897], ["ApoE", 901], ["isoforms", 906], ["and", 915], ["(", 919], ["ii", 920], [")", 922], ["a", 924], ["peptide", 926], ["that", 934], ["is", 939], ["specific", 942], ["for", 951], ["the", 955], ["\u03b54", 959], ["allele", 962], [".", 968], ["After", 970], ["trypsin", 976], ["digestion", 984], [",", 993], ["the", 995], ["ApoE4-specific", 999], ["peptide", 1014], ["contains", 1022], ["an", 1031], ["oxidation", 1034], ["-", 1043], ["prone", 1044], ["methionine", 1050], ["residue", 1061], [".", 1068], ["The", 1070], ["endogenous", 1074], ["methionine", 1085], ["oxidation", 1096], ["level", 1106], ["was", 1112], ["evaluated", 1116], ["in", 1126], ["a", 1129], ["small", 1131], ["cohort", 1137], ["(", 1144], ["n=68", 1145], [")", 1149], ["of", 1151], ["heterozygous", 1154], ["\u03b53\u03b54", 1167], ["carriers", 1172], ["containing", 1181], ["both", 1192], ["healthy", 1197], ["controls", 1205], ["and", 1214], ["AD", 1218], ["patients", 1221], [".", 1229], ["As", 1231], ["expected", 1234], [",", 1242], ["the", 1244], ["proportion", 1248], ["of", 1259], ["oxidized", 1262], ["residues", 1271], ["varied", 1280], ["from", 1287], ["0", 1292], ["to", 1294], ["10", 1297], ["%", 1299], [",", 1300], ["with", 1302], ["an", 1307], ["average", 1310], ["of", 1318], ["5", 1321], ["%", 1322], [".", 1323], ["We", 1325], ["therefore", 1328], ["developed", 1338], ["a", 1348], ["standardized", 1350], ["strategy", 1363], ["for", 1372], ["the", 1376], ["unbiased", 1380], [",", 1388], ["absolute", 1390], ["quantification", 1399], ["of", 1414], ["ApoE4", 1417], [",", 1422], ["based", 1424], ["on", 1430], ["performic", 1433], ["acid", 1443], ["oxidization", 1448], ["of", 1460], ["methionine", 1463], [".", 1473], ["Once", 1475], ["the", 1480], ["sample", 1484], ["workflow", 1491], ["had", 1500], ["been", 1504], ["thoroughly", 1509], ["validated", 1520], [",", 1529], ["it", 1531], ["was", 1534], ["applied", 1538], ["to", 1546], ["the", 1549], ["concomitant", 1553], ["quantification", 1565], ["of", 1580], ["total", 1583], ["ApoE", 1589], ["and", 1594], ["ApoE4", 1598], ["isoform", 1604], ["in", 1612], ["a", 1615], ["large", 1617], ["case", 1623], ["-", 1627], ["control", 1628], ["study", 1636], ["(", 1642], ["n=669", 1643], [")", 1648], [".", 1649], ["The", 1651], ["final", 1655], ["measurements", 1661], ["were", 1674], ["consistent", 1679], ["with", 1690], ["most", 1695], ["previously", 1700], ["reported", 1711], ["ApoE", 1720], ["concentration", 1725], ["values", 1739], ["and", 1746], ["confirm", 1750], ["the", 1758], ["influence", 1762], ["of", 1772], ["the", 1775], ["different", 1779], ["alleles", 1789], ["on", 1797], ["the", 1800], ["protein", 1804], ["expression", 1812], ["level", 1823], [".", 1828], ["Our", 1830], ["results", 1834], ["illustrate", 1842], ["(", 1853], ["i", 1854], [")", 1855], ["the", 1857], ["reliability", 1861], ["of", 1873], ["selected", 1876], ["reaction", 1885], ["monitoring", 1894], ["-", 1904], ["based", 1905], ["assays", 1911], ["and", 1918], ["(", 1922], ["ii", 1923], [")", 1925], ["the", 1927], ["value", 1931], ["of", 1937], ["the", 1940], ["oxidization", 1944], ["step", 1956], ["for", 1961], ["unbiased", 1965], ["monitoring", 1974], ["of", 1985], ["methionine", 1988], ["-", 1998], ["containing", 1999], ["proteotypic", 2010], ["peptides", 2022], [".", 2030], ["Furthermore", 2032], [",", 2043], ["a", 2045], ["statistical", 2047], ["analysis", 2059], ["indicated", 2068], ["that", 2078], ["neither", 2083], ["total", 2091], ["ApoE", 2097], ["and", 2102], ["ApoE4", 2106], ["levels", 2112], ["nor", 2119], ["the", 2123], ["ApoE", 2127], ["/", 2131], ["ApoE4", 2132], ["ratio", 2138], ["correlated", 2144], ["with", 2155], ["the", 2160], ["diagnosis", 2164], ["of", 2174], ["AD", 2177], [".", 2179], ["These", 2181], ["findings", 2187], ["reinforce", 2196], ["the", 2206], ["conclusions", 2210], ["of", 2222], ["previous", 2225], ["studies", 2234], ["in", 2242], ["which", 2245], ["plasma", 2251], ["ApoE", 2258], ["levels", 2263], ["had", 2270], ["no", 2274], ["obvious", 2277], ["clinical", 2285], ["significance", 2294], [".", 2306]]}
{"context": "A 75-year-old woman presented with altered mental status, septic picture, and influenza-like symptoms. Initial investigations revealed atypical lymphocytosis, thrombocytopenia, elevated liver enzymes, and a positive monospot test result. Further investigation showed the Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome was due to acute CMV infection. Herein, we report the first case of a heterophile-positive mononucleosis syndrome caused by acute CMV infection in an elderly immunocompetent woman. This case conveys that monospot test can yield false-positive result in the setting of acute CMV infection.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "0460fc84d839453e88d73ec2691da940", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[54, 57], [43, 46]], "char_spans": [[324, 341], [271, 288]]}]}], "context_tokens": [["A", 0], ["75-year", 2], ["-", 9], ["old", 10], ["woman", 14], ["presented", 20], ["with", 30], ["altered", 35], ["mental", 43], ["status", 50], [",", 56], ["septic", 58], ["picture", 65], [",", 72], ["and", 74], ["influenza", 78], ["-", 87], ["like", 88], ["symptoms", 93], [".", 101], ["Initial", 103], ["investigations", 111], ["revealed", 126], ["atypical", 135], ["lymphocytosis", 144], [",", 157], ["thrombocytopenia", 159], [",", 175], ["elevated", 177], ["liver", 186], ["enzymes", 192], [",", 199], ["and", 201], ["a", 205], ["positive", 207], ["monospot", 216], ["test", 225], ["result", 230], [".", 236], ["Further", 238], ["investigation", 246], ["showed", 260], ["the", 267], ["Epstein", 271], ["-", 278], ["Barr", 279], ["virus", 284], ["viral", 290], ["capsid", 296], ["antibody", 303], ["IgM", 312], ["/", 315], ["IgG", 316], ["and", 320], ["Epstein", 324], ["-", 331], ["Barr", 332], ["virus", 337], ["DNA", 343], ["by", 347], ["polymerase", 350], ["chain", 361], ["reaction", 367], ["to", 376], ["be", 379], ["negative", 382], [";", 390], ["however", 392], [",", 399], ["interestingly", 401], ["her", 415], ["cytomegalovirus", 419], ["(", 435], ["CMV", 436], [")", 439], ["IgM", 441], ["and", 445], ["IgG", 449], ["were", 453], ["positive", 458], [",", 466], ["suggesting", 468], ["that", 479], ["her", 484], ["mononucleosis", 488], ["-", 501], ["like", 502], ["syndrome", 507], ["was", 516], ["due", 520], ["to", 524], ["acute", 527], ["CMV", 533], ["infection", 537], [".", 546], ["Herein", 548], [",", 554], ["we", 556], ["report", 559], ["the", 566], ["first", 570], ["case", 576], ["of", 581], ["a", 584], ["heterophile", 586], ["-", 597], ["positive", 598], ["mononucleosis", 607], ["syndrome", 621], ["caused", 630], ["by", 637], ["acute", 640], ["CMV", 646], ["infection", 650], ["in", 660], ["an", 663], ["elderly", 666], ["immunocompetent", 674], ["woman", 690], [".", 695], ["This", 697], ["case", 702], ["conveys", 707], ["that", 715], ["monospot", 720], ["test", 729], ["can", 734], ["yield", 738], ["false", 744], ["-", 749], ["positive", 750], ["result", 759], ["in", 766], ["the", 769], ["setting", 773], ["of", 781], ["acute", 784], ["CMV", 790], ["infection", 794], [".", 803]]}
{"context": "To investigate whether gender is an independent factor associated with disease expression in early rheumatoid arthritis (RA) patients. 438 patients with early RA (disease duration less than one year) were studied. They all were patients with early RA who presented at the Rheumatology Clinic of the University Hospital of Ioannina during the period 1991-2000. All patients fulfilled the American College of Rheumatology criteria for RA. The demographic, clinical, laboratory, radiological and therapeutic characteristics of the disease at diagnosis, and at the last follow-up were analyzed according to gender. We studied 312 women and 126 men with early RA. The female to male ratio was 2.5:1 and the mean age at diagnosis was 49.4 +/- 14.9 years for women and 55.3 +/-15.6 years for men (P < 0.0003). Women had a longer duration of follow-up (P < 0.0003). There were no differences between genders in the general symptoms or the simmetricity of joint involvement at at disease onset. However at disease onset women had a higher erythrocyte sedimentation rate (ESR) (> 30 mm/1st hour), although there were no significant differences between the two groups concerninig the rest of the clinical, laboratory and radiological findings. At the last follow-up women still had a higher ESR (>30 min/1st hour), but no significant differences were found between the two groups concerning the rest of the parameters investigated independently of the follow-up duration. Finally, women and men showed the same degree of radiological changes and functional ability and were treated similarly except for the more frequent use of hydroxychloroquine in women. It seems that gender does not signficantly influence the expression of RA.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "b3aff0ff72834de8bbd3a3ca13a60532", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[235, 235], [275, 275], [150, 150], [301, 301], [108, 108], [136, 136], [190, 190]], "char_spans": [[1255, 1259], [1470, 1474], [803, 807], [1639, 1643], [626, 630], [752, 756], [1011, 1015]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["gender", 23], ["is", 30], ["an", 33], ["independent", 36], ["factor", 48], ["associated", 55], ["with", 66], ["disease", 71], ["expression", 79], ["in", 90], ["early", 93], ["rheumatoid", 99], ["arthritis", 110], ["(", 120], ["RA", 121], [")", 123], ["patients", 125], [".", 133], ["438", 135], ["patients", 139], ["with", 148], ["early", 153], ["RA", 159], ["(", 162], ["disease", 163], ["duration", 171], ["less", 180], ["than", 185], ["one", 190], ["year", 194], [")", 198], ["were", 200], ["studied", 205], [".", 212], ["They", 214], ["all", 219], ["were", 223], ["patients", 228], ["with", 237], ["early", 242], ["RA", 248], ["who", 251], ["presented", 255], ["at", 265], ["the", 268], ["Rheumatology", 272], ["Clinic", 285], ["of", 292], ["the", 295], ["University", 299], ["Hospital", 310], ["of", 319], ["Ioannina", 322], ["during", 331], ["the", 338], ["period", 342], ["1991", 349], ["-", 353], ["2000", 354], [".", 358], ["All", 360], ["patients", 364], ["fulfilled", 373], ["the", 383], ["American", 387], ["College", 396], ["of", 404], ["Rheumatology", 407], ["criteria", 420], ["for", 429], ["RA", 433], [".", 435], ["The", 437], ["demographic", 441], [",", 452], ["clinical", 454], [",", 462], ["laboratory", 464], [",", 474], ["radiological", 476], ["and", 489], ["therapeutic", 493], ["characteristics", 505], ["of", 521], ["the", 524], ["disease", 528], ["at", 536], ["diagnosis", 539], [",", 548], ["and", 550], ["at", 554], ["the", 557], ["last", 561], ["follow", 566], ["-", 572], ["up", 573], ["were", 576], ["analyzed", 581], ["according", 590], ["to", 600], ["gender", 603], [".", 609], ["We", 611], ["studied", 614], ["312", 622], ["women", 626], ["and", 632], ["126", 636], ["men", 640], ["with", 644], ["early", 649], ["RA", 655], [".", 657], ["The", 659], ["female", 663], ["to", 670], ["male", 673], ["ratio", 678], ["was", 684], ["2.5:1", 688], ["and", 694], ["the", 698], ["mean", 702], ["age", 707], ["at", 711], ["diagnosis", 714], ["was", 724], ["49.4", 728], ["+", 733], ["/-", 734], ["14.9", 737], ["years", 742], ["for", 748], ["women", 752], ["and", 758], ["55.3", 762], ["+", 767], ["/-15.6", 768], ["years", 775], ["for", 781], ["men", 785], ["(", 789], ["P", 790], ["<", 792], ["0.0003", 794], [")", 800], [".", 801], ["Women", 803], ["had", 809], ["a", 813], ["longer", 815], ["duration", 822], ["of", 831], ["follow", 834], ["-", 840], ["up", 841], ["(", 844], ["P", 845], ["<", 847], ["0.0003", 849], [")", 855], [".", 856], ["There", 858], ["were", 864], ["no", 869], ["differences", 872], ["between", 884], ["genders", 892], ["in", 900], ["the", 903], ["general", 907], ["symptoms", 915], ["or", 924], ["the", 927], ["simmetricity", 931], ["of", 944], ["joint", 947], ["involvement", 953], ["at", 965], ["at", 968], ["disease", 971], ["onset", 979], [".", 984], ["However", 986], ["at", 994], ["disease", 997], ["onset", 1005], ["women", 1011], ["had", 1017], ["a", 1021], ["higher", 1023], ["erythrocyte", 1030], ["sedimentation", 1042], ["rate", 1056], ["(", 1061], ["ESR", 1062], [")", 1065], ["(", 1067], [">", 1068], ["30", 1070], ["mm/1st", 1073], ["hour", 1080], [")", 1084], [",", 1085], ["although", 1087], ["there", 1096], ["were", 1102], ["no", 1107], ["significant", 1110], ["differences", 1122], ["between", 1134], ["the", 1142], ["two", 1146], ["groups", 1150], ["concerninig", 1157], ["the", 1169], ["rest", 1173], ["of", 1178], ["the", 1181], ["clinical", 1185], [",", 1193], ["laboratory", 1195], ["and", 1206], ["radiological", 1210], ["findings", 1223], [".", 1231], ["At", 1233], ["the", 1236], ["last", 1240], ["follow", 1245], ["-", 1251], ["up", 1252], ["women", 1255], ["still", 1261], ["had", 1267], ["a", 1271], ["higher", 1273], ["ESR", 1280], ["(", 1284], [">", 1285], ["30", 1286], ["min/1st", 1289], ["hour", 1297], [")", 1301], [",", 1302], ["but", 1304], ["no", 1308], ["significant", 1311], ["differences", 1323], ["were", 1335], ["found", 1340], ["between", 1346], ["the", 1354], ["two", 1358], ["groups", 1362], ["concerning", 1369], ["the", 1380], ["rest", 1384], ["of", 1389], ["the", 1392], ["parameters", 1396], ["investigated", 1407], ["independently", 1420], ["of", 1434], ["the", 1437], ["follow", 1441], ["-", 1447], ["up", 1448], ["duration", 1451], [".", 1459], ["Finally", 1461], [",", 1468], ["women", 1470], ["and", 1476], ["men", 1480], ["showed", 1484], ["the", 1491], ["same", 1495], ["degree", 1500], ["of", 1507], ["radiological", 1510], ["changes", 1523], ["and", 1531], ["functional", 1535], ["ability", 1546], ["and", 1554], ["were", 1558], ["treated", 1563], ["similarly", 1571], ["except", 1581], ["for", 1588], ["the", 1592], ["more", 1596], ["frequent", 1601], ["use", 1610], ["of", 1614], ["hydroxychloroquine", 1617], ["in", 1636], ["women", 1639], [".", 1644], ["It", 1646], ["seems", 1649], ["that", 1655], ["gender", 1660], ["does", 1667], ["not", 1672], ["signficantly", 1676], ["influence", 1689], ["the", 1699], ["expression", 1703], ["of", 1714], ["RA", 1717], [".", 1719]]}
{"context": "Chronic myelogenous leukemia (CML) is characterized by a molecular aberration, a fusion BCR-ABL gene encoding for aberrant tyrosine kinase activity, which is crucial in the pathogenesis of CML. In vitro, inhibition of BCR-ABL protein tyrosine kinase activity by a tyrosine kinase inhibitor, Imatinib mesylate (STI571; formerly CGP57148B), successfully suppressed proliferation/survival of the BCR-ABL positive clones. In clinical studies, hematologic and cytogenetic remissions have been achieved in most patients with chronic phase CML; in accelerated and blastic phases of CML, STI571 appeared less effective. In the current study, the authors tested combinations of STI571 and cytarabine and homoharringtonine (HHT), drugs with documented activity in CML. The single agents and their combinations were studied for in vitro effect on proliferation of BCR-ABL positive cell lines KBM5 and KBM7 by 3(4,5-dimethylthiazol-2yl)-2,5 diphenyl-tetrazolium bromide assay and on primary patient-derived BCR-ABL cells by clonogenic assays. The in vitro additive, synergistic, or antagonistic effects of cytarabine and HHT with STI571 were then investigated by computer-assisted analysis using the CalcuSyn software. STI571 consistently suppressed BCR-ABL positive cell proliferation with a dose-effect correlation. In the model system used, STI571/cytarabine and STI571/HHT combinations were more effective in inhibiting KBM5 and KBM7 cell growth than each drug as single agent. These results were also verified in primary CML-derived clonogenic cells in semisolid cultures. In this experimental system, our studies documented additive or synergistic effects with STI571 plus cytarabine or HHT, supporting the future use of STI571 combinations in clinical trials in patients with Philadelphia chromosome-positive leukemias.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee0fc9bc759e4496ab701a203ebb0a81", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[148, 150], [69, 71], [170, 172], [40, 42], [210, 212], [15, 17]], "char_spans": [[853, 859], [393, 399], [995, 1001], [218, 224], [1238, 1244], [88, 94]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["a", 55], ["molecular", 57], ["aberration", 67], [",", 77], ["a", 79], ["fusion", 81], ["BCR", 88], ["-", 91], ["ABL", 92], ["gene", 96], ["encoding", 101], ["for", 110], ["aberrant", 114], ["tyrosine", 123], ["kinase", 132], ["activity", 139], [",", 147], ["which", 149], ["is", 155], ["crucial", 158], ["in", 166], ["the", 169], ["pathogenesis", 173], ["of", 186], ["CML", 189], [".", 192], ["In", 194], ["vitro", 197], [",", 202], ["inhibition", 204], ["of", 215], ["BCR", 218], ["-", 221], ["ABL", 222], ["protein", 226], ["tyrosine", 234], ["kinase", 243], ["activity", 250], ["by", 259], ["a", 262], ["tyrosine", 264], ["kinase", 273], ["inhibitor", 280], [",", 289], ["Imatinib", 291], ["mesylate", 300], ["(", 309], ["STI571", 310], [";", 316], ["formerly", 318], ["CGP57148B", 327], [")", 336], [",", 337], ["successfully", 339], ["suppressed", 352], ["proliferation", 363], ["/", 376], ["survival", 377], ["of", 386], ["the", 389], ["BCR", 393], ["-", 396], ["ABL", 397], ["positive", 401], ["clones", 410], [".", 416], ["In", 418], ["clinical", 421], ["studies", 430], [",", 437], ["hematologic", 439], ["and", 451], ["cytogenetic", 455], ["remissions", 467], ["have", 478], ["been", 483], ["achieved", 488], ["in", 497], ["most", 500], ["patients", 505], ["with", 514], ["chronic", 519], ["phase", 527], ["CML", 533], [";", 536], ["in", 538], ["accelerated", 541], ["and", 553], ["blastic", 557], ["phases", 565], ["of", 572], ["CML", 575], [",", 578], ["STI571", 580], ["appeared", 587], ["less", 596], ["effective", 601], [".", 610], ["In", 612], ["the", 615], ["current", 619], ["study", 627], [",", 632], ["the", 634], ["authors", 638], ["tested", 646], ["combinations", 653], ["of", 666], ["STI571", 669], ["and", 676], ["cytarabine", 680], ["and", 691], ["homoharringtonine", 695], ["(", 713], ["HHT", 714], [")", 717], [",", 718], ["drugs", 720], ["with", 726], ["documented", 731], ["activity", 742], ["in", 751], ["CML", 754], [".", 757], ["The", 759], ["single", 763], ["agents", 770], ["and", 777], ["their", 781], ["combinations", 787], ["were", 800], ["studied", 805], ["for", 813], ["in", 817], ["vitro", 820], ["effect", 826], ["on", 833], ["proliferation", 836], ["of", 850], ["BCR", 853], ["-", 856], ["ABL", 857], ["positive", 861], ["cell", 870], ["lines", 875], ["KBM5", 881], ["and", 886], ["KBM7", 890], ["by", 895], ["3(4,5-dimethylthiazol-2yl)-2,5", 898], ["diphenyl", 929], ["-", 937], ["tetrazolium", 938], ["bromide", 950], ["assay", 958], ["and", 964], ["on", 968], ["primary", 971], ["patient", 979], ["-", 986], ["derived", 987], ["BCR", 995], ["-", 998], ["ABL", 999], ["cells", 1003], ["by", 1009], ["clonogenic", 1012], ["assays", 1023], [".", 1029], ["The", 1031], ["in", 1035], ["vitro", 1038], ["additive", 1044], [",", 1052], ["synergistic", 1054], [",", 1065], ["or", 1067], ["antagonistic", 1070], ["effects", 1083], ["of", 1091], ["cytarabine", 1094], ["and", 1105], ["HHT", 1109], ["with", 1113], ["STI571", 1118], ["were", 1125], ["then", 1130], ["investigated", 1135], ["by", 1148], ["computer", 1151], ["-", 1159], ["assisted", 1160], ["analysis", 1169], ["using", 1178], ["the", 1184], ["CalcuSyn", 1188], ["software", 1197], [".", 1205], ["STI571", 1207], ["consistently", 1214], ["suppressed", 1227], ["BCR", 1238], ["-", 1241], ["ABL", 1242], ["positive", 1246], ["cell", 1255], ["proliferation", 1260], ["with", 1274], ["a", 1279], ["dose", 1281], ["-", 1285], ["effect", 1286], ["correlation", 1293], [".", 1304], ["In", 1306], ["the", 1309], ["model", 1313], ["system", 1319], ["used", 1326], [",", 1330], ["STI571/cytarabine", 1332], ["and", 1350], ["STI571/HHT", 1354], ["combinations", 1365], ["were", 1378], ["more", 1383], ["effective", 1388], ["in", 1398], ["inhibiting", 1401], ["KBM5", 1412], ["and", 1417], ["KBM7", 1421], ["cell", 1426], ["growth", 1431], ["than", 1438], ["each", 1443], ["drug", 1448], ["as", 1453], ["single", 1456], ["agent", 1463], [".", 1468], ["These", 1470], ["results", 1476], ["were", 1484], ["also", 1489], ["verified", 1494], ["in", 1503], ["primary", 1506], ["CML", 1514], ["-", 1517], ["derived", 1518], ["clonogenic", 1526], ["cells", 1537], ["in", 1543], ["semisolid", 1546], ["cultures", 1556], [".", 1564], ["In", 1566], ["this", 1569], ["experimental", 1574], ["system", 1587], [",", 1593], ["our", 1595], ["studies", 1599], ["documented", 1607], ["additive", 1618], ["or", 1627], ["synergistic", 1630], ["effects", 1642], ["with", 1650], ["STI571", 1655], ["plus", 1662], ["cytarabine", 1667], ["or", 1678], ["HHT", 1681], [",", 1684], ["supporting", 1686], ["the", 1697], ["future", 1701], ["use", 1708], ["of", 1712], ["STI571", 1715], ["combinations", 1722], ["in", 1735], ["clinical", 1738], ["trials", 1747], ["in", 1754], ["patients", 1757], ["with", 1766], ["Philadelphia", 1771], ["chromosome", 1784], ["-", 1794], ["positive", 1795], ["leukemias", 1804], [".", 1813]]}
{"context": "Chronic myeloid leukaemia (CML) is characterized cytogenetically by a t(9;22)(q34;ql1) reciprocal translocation which gives origin to a hybrid BCR-ABL gene, encoding a p2lO(BCR-ABL) fusion protein with elevated tyrosine kinase activity and transforming abilities. The t(9;22) was suggested to be associated with genomic imprinting of centromeric regions of chromosomes 9 and 22, but the genes directly affected by the translocation, ABL and BCR, were shown not to be imprinted. For most diagnostic and research purposes the BCR-ABL gene can be efficiently identified by reverse-transcription and polymerase chain reaction (RT/PCR) amplification of its fusion transcripts, which can be quantified by competitive PCR and similar assays for assessment of residual disease in the follow-up of therapy. In the great majority of CML patients the BCR-ABL transcripts exhibit a b2a2 and/or a b3a2 junction; in rare cases, the only detectable BCR-ABL transcripts have unusual junctions, such as b2a3, b3a3, e1a2 or e6a2. There is a recent suggestion that the BCR-ABL gene may not be always 'functional', since extremely low levels of BCR-ABL transcripts can be found in leucocytes from normal individuals and, conversely, it appears that no BCR-ABL transcription can be detected in a proportion of Ph-positive haematopoietic progenitors from some CML patients. The role, if any, of the reciprocal ABL-BCR hybrid gene in CML is unknown. Although its mRNA message is in frame, no ABL-BCR fusion protein has yet been identified in CML patients. The blast crisis of CML has been variably associated with abnormalities of proto-oncogenes, such as RAS and MYC, or of tumour suppressor genes, in particular RB, p53 and p16, or with the generation of chimeric transcription factors, as in the AML1-EVI1 gene fusion. It is likely, therefore, that multiple and alternative molecular defects, as opposed to a single universal mechanism, underlie the acute transformation of the disease.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "bab3517808284dd78fb78dee6116e087", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "ABL/BCR fusion", "token_spans": [[278, 281]], "char_spans": [[1469, 1482]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukaemia", 16], ["(", 26], ["CML", 27], [")", 30], ["is", 32], ["characterized", 35], ["cytogenetically", 49], ["by", 65], ["a", 68], ["t(9;22)(q34;ql1", 70], [")", 85], ["reciprocal", 87], ["translocation", 98], ["which", 112], ["gives", 118], ["origin", 124], ["to", 131], ["a", 134], ["hybrid", 136], ["BCR", 143], ["-", 146], ["ABL", 147], ["gene", 151], [",", 155], ["encoding", 157], ["a", 166], ["p2lO(BCR", 168], ["-", 176], ["ABL", 177], [")", 180], ["fusion", 182], ["protein", 189], ["with", 197], ["elevated", 202], ["tyrosine", 211], ["kinase", 220], ["activity", 227], ["and", 236], ["transforming", 240], ["abilities", 253], [".", 262], ["The", 264], ["t(9;22", 268], [")", 274], ["was", 276], ["suggested", 280], ["to", 290], ["be", 293], ["associated", 296], ["with", 307], ["genomic", 312], ["imprinting", 320], ["of", 331], ["centromeric", 334], ["regions", 346], ["of", 354], ["chromosomes", 357], ["9", 369], ["and", 371], ["22", 375], [",", 377], ["but", 379], ["the", 383], ["genes", 387], ["directly", 393], ["affected", 402], ["by", 411], ["the", 414], ["translocation", 418], [",", 431], ["ABL", 433], ["and", 437], ["BCR", 441], [",", 444], ["were", 446], ["shown", 451], ["not", 457], ["to", 461], ["be", 464], ["imprinted", 467], [".", 476], ["For", 478], ["most", 482], ["diagnostic", 487], ["and", 498], ["research", 502], ["purposes", 511], ["the", 520], ["BCR", 524], ["-", 527], ["ABL", 528], ["gene", 532], ["can", 537], ["be", 541], ["efficiently", 544], ["identified", 556], ["by", 567], ["reverse", 570], ["-", 577], ["transcription", 578], ["and", 592], ["polymerase", 596], ["chain", 607], ["reaction", 613], ["(", 622], ["RT", 623], ["/", 625], ["PCR", 626], [")", 629], ["amplification", 631], ["of", 645], ["its", 648], ["fusion", 652], ["transcripts", 659], [",", 670], ["which", 672], ["can", 678], ["be", 682], ["quantified", 685], ["by", 696], ["competitive", 699], ["PCR", 711], ["and", 715], ["similar", 719], ["assays", 727], ["for", 734], ["assessment", 738], ["of", 749], ["residual", 752], ["disease", 761], ["in", 769], ["the", 772], ["follow", 776], ["-", 782], ["up", 783], ["of", 786], ["therapy", 789], [".", 796], ["In", 798], ["the", 801], ["great", 805], ["majority", 811], ["of", 820], ["CML", 823], ["patients", 827], ["the", 836], ["BCR", 840], ["-", 843], ["ABL", 844], ["transcripts", 848], ["exhibit", 860], ["a", 868], ["b2a2", 870], ["and/or", 875], ["a", 882], ["b3a2", 884], ["junction", 889], [";", 897], ["in", 899], ["rare", 902], ["cases", 907], [",", 912], ["the", 914], ["only", 918], ["detectable", 923], ["BCR", 934], ["-", 937], ["ABL", 938], ["transcripts", 942], ["have", 954], ["unusual", 959], ["junctions", 967], [",", 976], ["such", 978], ["as", 983], ["b2a3", 986], [",", 990], ["b3a3", 992], [",", 996], ["e1a2", 998], ["or", 1003], ["e6a2", 1006], [".", 1010], ["There", 1012], ["is", 1018], ["a", 1021], ["recent", 1023], ["suggestion", 1030], ["that", 1041], ["the", 1046], ["BCR", 1050], ["-", 1053], ["ABL", 1054], ["gene", 1058], ["may", 1063], ["not", 1067], ["be", 1071], ["always", 1074], ["'", 1081], ["functional", 1082], ["'", 1092], [",", 1093], ["since", 1095], ["extremely", 1101], ["low", 1111], ["levels", 1115], ["of", 1122], ["BCR", 1125], ["-", 1128], ["ABL", 1129], ["transcripts", 1133], ["can", 1145], ["be", 1149], ["found", 1152], ["in", 1158], ["leucocytes", 1161], ["from", 1172], ["normal", 1177], ["individuals", 1184], ["and", 1196], [",", 1199], ["conversely", 1201], [",", 1211], ["it", 1213], ["appears", 1216], ["that", 1224], ["no", 1229], ["BCR", 1232], ["-", 1235], ["ABL", 1236], ["transcription", 1240], ["can", 1254], ["be", 1258], ["detected", 1261], ["in", 1270], ["a", 1273], ["proportion", 1275], ["of", 1286], ["Ph", 1289], ["-", 1291], ["positive", 1292], ["haematopoietic", 1301], ["progenitors", 1316], ["from", 1328], ["some", 1333], ["CML", 1338], ["patients", 1342], [".", 1350], ["The", 1352], ["role", 1356], [",", 1360], ["if", 1362], ["any", 1365], [",", 1368], ["of", 1370], ["the", 1373], ["reciprocal", 1377], ["ABL", 1388], ["-", 1391], ["BCR", 1392], ["hybrid", 1396], ["gene", 1403], ["in", 1408], ["CML", 1411], ["is", 1415], ["unknown", 1418], [".", 1425], ["Although", 1427], ["its", 1436], ["mRNA", 1440], ["message", 1445], ["is", 1453], ["in", 1456], ["frame", 1459], [",", 1464], ["no", 1466], ["ABL", 1469], ["-", 1472], ["BCR", 1473], ["fusion", 1477], ["protein", 1484], ["has", 1492], ["yet", 1496], ["been", 1500], ["identified", 1505], ["in", 1516], ["CML", 1519], ["patients", 1523], [".", 1531], ["The", 1533], ["blast", 1537], ["crisis", 1543], ["of", 1550], ["CML", 1553], ["has", 1557], ["been", 1561], ["variably", 1566], ["associated", 1575], ["with", 1586], ["abnormalities", 1591], ["of", 1605], ["proto", 1608], ["-", 1613], ["oncogenes", 1614], [",", 1623], ["such", 1625], ["as", 1630], ["RAS", 1633], ["and", 1637], ["MYC", 1641], [",", 1644], ["or", 1646], ["of", 1649], ["tumour", 1652], ["suppressor", 1659], ["genes", 1670], [",", 1675], ["in", 1677], ["particular", 1680], ["RB", 1691], [",", 1693], ["p53", 1695], ["and", 1699], ["p16", 1703], [",", 1706], ["or", 1708], ["with", 1711], ["the", 1716], ["generation", 1720], ["of", 1731], ["chimeric", 1734], ["transcription", 1743], ["factors", 1757], [",", 1764], ["as", 1766], ["in", 1769], ["the", 1772], ["AML1-EVI1", 1776], ["gene", 1786], ["fusion", 1791], [".", 1797], ["It", 1799], ["is", 1802], ["likely", 1805], [",", 1811], ["therefore", 1813], [",", 1822], ["that", 1824], ["multiple", 1829], ["and", 1838], ["alternative", 1842], ["molecular", 1854], ["defects", 1864], [",", 1871], ["as", 1873], ["opposed", 1876], ["to", 1884], ["a", 1887], ["single", 1889], ["universal", 1896], ["mechanism", 1906], [",", 1915], ["underlie", 1917], ["the", 1926], ["acute", 1930], ["transformation", 1936], ["of", 1951], ["the", 1954], ["disease", 1958], [".", 1965]]}
{"context": "A mutation in the alpha-synuclein gene has recently been linked to some cases of familial Parkinson's disease (PD). We characterized the expression of this presynaptic protein in the midbrain, striatum, and temporal cortex of control, PD, and dementia with Lewy bodies (DLB) brain. Control brain showed punctate pericellular immunostaining. PD brain demonstrated alpha-synuclein immunoreactivity in nigral Lewy bodies, pale bodies and abnormal neurites. Rare neuronal soma in PD brain were immunoreactive for alpha-synuclein. DLB cases demonstrated these findings as well as alpha-synuclein immunoreactivity in cortical Lewy bodies and CA2-3 neurites. These results suggest that, even in sporadic cases, there is an early and direct role for alpha-synuclein in the pathogenesis of PD and the neuropathologically related disorder DLB.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "65a878a609f441afbfab92ba3203df80", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[134, 136], [102, 104], [4, 6], [90, 92], [66, 68]], "char_spans": [[742, 756], [575, 589], [18, 32], [509, 523], [363, 377]]}]}], "context_tokens": [["A", 0], ["mutation", 2], ["in", 11], ["the", 14], ["alpha", 18], ["-", 23], ["synuclein", 24], ["gene", 34], ["has", 39], ["recently", 43], ["been", 52], ["linked", 57], ["to", 64], ["some", 67], ["cases", 72], ["of", 78], ["familial", 81], ["Parkinson", 90], ["'s", 99], ["disease", 102], ["(", 110], ["PD", 111], [")", 113], [".", 114], ["We", 116], ["characterized", 119], ["the", 133], ["expression", 137], ["of", 148], ["this", 151], ["presynaptic", 156], ["protein", 168], ["in", 176], ["the", 179], ["midbrain", 183], [",", 191], ["striatum", 193], [",", 201], ["and", 203], ["temporal", 207], ["cortex", 216], ["of", 223], ["control", 226], [",", 233], ["PD", 235], [",", 237], ["and", 239], ["dementia", 243], ["with", 252], ["Lewy", 257], ["bodies", 262], ["(", 269], ["DLB", 270], [")", 273], ["brain", 275], [".", 280], ["Control", 282], ["brain", 290], ["showed", 296], ["punctate", 303], ["pericellular", 312], ["immunostaining", 325], [".", 339], ["PD", 341], ["brain", 344], ["demonstrated", 350], ["alpha", 363], ["-", 368], ["synuclein", 369], ["immunoreactivity", 379], ["in", 396], ["nigral", 399], ["Lewy", 406], ["bodies", 411], [",", 417], ["pale", 419], ["bodies", 424], ["and", 431], ["abnormal", 435], ["neurites", 444], [".", 452], ["Rare", 454], ["neuronal", 459], ["soma", 468], ["in", 473], ["PD", 476], ["brain", 479], ["were", 485], ["immunoreactive", 490], ["for", 505], ["alpha", 509], ["-", 514], ["synuclein", 515], [".", 524], ["DLB", 526], ["cases", 530], ["demonstrated", 536], ["these", 549], ["findings", 555], ["as", 564], ["well", 567], ["as", 572], ["alpha", 575], ["-", 580], ["synuclein", 581], ["immunoreactivity", 591], ["in", 608], ["cortical", 611], ["Lewy", 620], ["bodies", 625], ["and", 632], ["CA2", 636], ["-", 639], ["3", 640], ["neurites", 642], [".", 650], ["These", 652], ["results", 658], ["suggest", 666], ["that", 674], [",", 678], ["even", 680], ["in", 685], ["sporadic", 688], ["cases", 697], [",", 702], ["there", 704], ["is", 710], ["an", 713], ["early", 716], ["and", 722], ["direct", 726], ["role", 733], ["for", 738], ["alpha", 742], ["-", 747], ["synuclein", 748], ["in", 758], ["the", 761], ["pathogenesis", 765], ["of", 778], ["PD", 781], ["and", 784], ["the", 788], ["neuropathologically", 792], ["related", 812], ["disorder", 820], ["DLB", 829], [".", 832]]}
{"context": "RNA editing usually affects only a fraction of expressed transcripts and there is a vast amount of variation in editing levels of ADAR (adenosine deaminase, RNA-specific) targets. Here we explore natural genetic variation affecting editing levels of particular sites in 81 natural strains of Drosophila melanogaster. The analysis of associations between editing levels and single-nucleotide polymorphisms allows us to map putative cis-regulatory regions affecting editing of 16 A-to-I editing sites (cis-RNA editing quantitative trait loci or cis-edQTLs, P\u00a0<\u00a010(-8)). The observed changes in editing levels are validated by independent molecular technique. All identified regulatory variants are located in close proximity of modulated editing sites. Moreover, colocalized editing sites are often regulated by same loci. Similar to expression and splicing QTL studies, the characterization of edQTLs will greatly expand our understanding of cis-regulatory evolution of gene expression.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "d56d38b84b684192b16ecad81b0152c7", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[22, 22]], "char_spans": [[130, 133]]}, {"text": "adenosine deaminase, RNA-specific", "token_spans": [[24, 29]], "char_spans": [[136, 168]]}]}], "context_tokens": [["RNA", 0], ["editing", 4], ["usually", 12], ["affects", 20], ["only", 28], ["a", 33], ["fraction", 35], ["of", 44], ["expressed", 47], ["transcripts", 57], ["and", 69], ["there", 73], ["is", 79], ["a", 82], ["vast", 84], ["amount", 89], ["of", 96], ["variation", 99], ["in", 109], ["editing", 112], ["levels", 120], ["of", 127], ["ADAR", 130], ["(", 135], ["adenosine", 136], ["deaminase", 146], [",", 155], ["RNA", 157], ["-", 160], ["specific", 161], [")", 169], ["targets", 171], [".", 178], ["Here", 180], ["we", 185], ["explore", 188], ["natural", 196], ["genetic", 204], ["variation", 212], ["affecting", 222], ["editing", 232], ["levels", 240], ["of", 247], ["particular", 250], ["sites", 261], ["in", 267], ["81", 270], ["natural", 273], ["strains", 281], ["of", 289], ["Drosophila", 292], ["melanogaster", 303], [".", 315], ["The", 317], ["analysis", 321], ["of", 330], ["associations", 333], ["between", 346], ["editing", 354], ["levels", 362], ["and", 369], ["single", 373], ["-", 379], ["nucleotide", 380], ["polymorphisms", 391], ["allows", 405], ["us", 412], ["to", 415], ["map", 418], ["putative", 422], ["cis", 431], ["-", 434], ["regulatory", 435], ["regions", 446], ["affecting", 454], ["editing", 464], ["of", 472], ["16", 475], ["A", 478], ["-", 479], ["to", 480], ["-", 482], ["I", 483], ["editing", 485], ["sites", 493], ["(", 499], ["cis", 500], ["-", 503], ["RNA", 504], ["editing", 508], ["quantitative", 516], ["trait", 529], ["loci", 535], ["or", 540], ["cis", 543], ["-", 546], ["edQTLs", 547], [",", 553], ["P", 555], ["<", 557], ["10(-8", 559], [")", 564], [")", 565], [".", 566], ["The", 568], ["observed", 572], ["changes", 581], ["in", 589], ["editing", 592], ["levels", 600], ["are", 607], ["validated", 611], ["by", 621], ["independent", 624], ["molecular", 636], ["technique", 646], [".", 655], ["All", 657], ["identified", 661], ["regulatory", 672], ["variants", 683], ["are", 692], ["located", 696], ["in", 704], ["close", 707], ["proximity", 713], ["of", 723], ["modulated", 726], ["editing", 736], ["sites", 744], [".", 749], ["Moreover", 751], [",", 759], ["colocalized", 761], ["editing", 773], ["sites", 781], ["are", 787], ["often", 791], ["regulated", 797], ["by", 807], ["same", 810], ["loci", 815], [".", 819], ["Similar", 821], ["to", 829], ["expression", 832], ["and", 843], ["splicing", 847], ["QTL", 856], ["studies", 860], [",", 867], ["the", 869], ["characterization", 873], ["of", 890], ["edQTLs", 893], ["will", 900], ["greatly", 905], ["expand", 913], ["our", 920], ["understanding", 924], ["of", 938], ["cis", 941], ["-", 944], ["regulatory", 945], ["evolution", 956], ["of", 966], ["gene", 969], ["expression", 974], [".", 984]]}
{"context": "Prader-Willi syndrome (PWS) results from a deletion of the paternal genes in the region of chromosome 15q11-q13. PWS develops hyperphagia, which when left unmanaged, leads to an excessive ingestion of food. To date there is inadequate pharmacological treatment or supplementation for modification of the PWS hyperphagia and/or the associated behaviors. Therefore, the best practice is familial supervision and restriction of diet and environment. We aimed to determine if the natural supplement of Caralluma fimbriata extract (CFE) could attenuate hyperphagia or the associated appetite behaviors in children and adolescents with PWS over the 4-week pilot trial period. We conducted a placebo-controlled, double-blind, randomized crossover trial over a 10-week period to investigate the effects of CFE on hunger control, in a cohort of children and adolescents with confirmed PWS (n =15, mean age 9.27 \u00b1 3.16 years, body weight 43.98 \u00b1 23.99 kg). Participants from Australia and New Zealand ingested CFE or a placebo of maltodextrin/cabbage leaf over a 4-week period, with a 2-week washout before the crossover to the other treatment. Weekly comparisons in appetite behavior, severity, and drive were recorded by parents, as scaled time-point measures on a hyperphagia questionnaire validated for PWS. CFE administration was found to induce a significant accumulative easing of hyperphagia (P = 0.05), with decreases evident in one-third of the participants. Furthermore due to CFE supplementation, a significant decrease (P \u2264 0.05) was recorded in the category of behavior and a decrease in hyperphagia (n = 8, P = 0.009) was observed at the highest dose 1,000 mg/day (recommended adult dose). There were no reported adverse effects at any dose. We demonstrate that an extract of the Indian cactus succulent Caralluma fimbriata eases hyperphagic appetite behavior within a cohort of children and adolescents (n = 15) with PWS without notable adverse effects. The outcomes of this study will have a potential positive impact on PWS management.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "8b979d0ca3aa47dbbd35ea426dc78be3", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 20]]}]}], "context_tokens": [["Prader", 0], ["-", 6], ["Willi", 7], ["syndrome", 13], ["(", 22], ["PWS", 23], [")", 26], ["results", 28], ["from", 36], ["a", 41], ["deletion", 43], ["of", 52], ["the", 55], ["paternal", 59], ["genes", 68], ["in", 74], ["the", 77], ["region", 81], ["of", 88], ["chromosome", 91], ["15q11-q13", 102], [".", 111], ["PWS", 113], ["develops", 117], ["hyperphagia", 126], [",", 137], ["which", 139], ["when", 145], ["left", 150], ["unmanaged", 155], [",", 164], ["leads", 166], ["to", 172], ["an", 175], ["excessive", 178], ["ingestion", 188], ["of", 198], ["food", 201], [".", 205], ["To", 207], ["date", 210], ["there", 215], ["is", 221], ["inadequate", 224], ["pharmacological", 235], ["treatment", 251], ["or", 261], ["supplementation", 264], ["for", 280], ["modification", 284], ["of", 297], ["the", 300], ["PWS", 304], ["hyperphagia", 308], ["and/or", 320], ["the", 327], ["associated", 331], ["behaviors", 342], [".", 351], ["Therefore", 353], [",", 362], ["the", 364], ["best", 368], ["practice", 373], ["is", 382], ["familial", 385], ["supervision", 394], ["and", 406], ["restriction", 410], ["of", 422], ["diet", 425], ["and", 430], ["environment", 434], [".", 445], ["We", 447], ["aimed", 450], ["to", 456], ["determine", 459], ["if", 469], ["the", 472], ["natural", 476], ["supplement", 484], ["of", 495], ["Caralluma", 498], ["fimbriata", 508], ["extract", 518], ["(", 526], ["CFE", 527], [")", 530], ["could", 532], ["attenuate", 538], ["hyperphagia", 548], ["or", 560], ["the", 563], ["associated", 567], ["appetite", 578], ["behaviors", 587], ["in", 597], ["children", 600], ["and", 609], ["adolescents", 613], ["with", 625], ["PWS", 630], ["over", 634], ["the", 639], ["4-week", 643], ["pilot", 650], ["trial", 656], ["period", 662], [".", 668], ["We", 670], ["conducted", 673], ["a", 683], ["placebo", 685], ["-", 692], ["controlled", 693], [",", 703], ["double", 705], ["-", 711], ["blind", 712], [",", 717], ["randomized", 719], ["crossover", 730], ["trial", 740], ["over", 746], ["a", 751], ["10-week", 753], ["period", 761], ["to", 768], ["investigate", 771], ["the", 783], ["effects", 787], ["of", 795], ["CFE", 798], ["on", 802], ["hunger", 805], ["control", 812], [",", 819], ["in", 821], ["a", 824], ["cohort", 826], ["of", 833], ["children", 836], ["and", 845], ["adolescents", 849], ["with", 861], ["confirmed", 866], ["PWS", 876], ["(", 880], ["n", 881], ["=", 883], ["15", 884], [",", 886], ["mean", 888], ["age", 893], ["9.27", 897], ["\u00b1", 902], ["3.16", 904], ["years", 909], [",", 914], ["body", 916], ["weight", 921], ["43.98", 928], ["\u00b1", 934], ["23.99", 936], ["kg", 942], [")", 944], [".", 945], ["Participants", 947], ["from", 960], ["Australia", 965], ["and", 975], ["New", 979], ["Zealand", 983], ["ingested", 991], ["CFE", 1000], ["or", 1004], ["a", 1007], ["placebo", 1009], ["of", 1017], ["maltodextrin", 1020], ["/", 1032], ["cabbage", 1033], ["leaf", 1041], ["over", 1046], ["a", 1051], ["4-week", 1053], ["period", 1060], [",", 1066], ["with", 1068], ["a", 1073], ["2-week", 1075], ["washout", 1082], ["before", 1090], ["the", 1097], ["crossover", 1101], ["to", 1111], ["the", 1114], ["other", 1118], ["treatment", 1124], [".", 1133], ["Weekly", 1135], ["comparisons", 1142], ["in", 1154], ["appetite", 1157], ["behavior", 1166], [",", 1174], ["severity", 1176], [",", 1184], ["and", 1186], ["drive", 1190], ["were", 1196], ["recorded", 1201], ["by", 1210], ["parents", 1213], [",", 1220], ["as", 1222], ["scaled", 1225], ["time", 1232], ["-", 1236], ["point", 1237], ["measures", 1243], ["on", 1252], ["a", 1255], ["hyperphagia", 1257], ["questionnaire", 1269], ["validated", 1283], ["for", 1293], ["PWS", 1297], [".", 1300], ["CFE", 1302], ["administration", 1306], ["was", 1321], ["found", 1325], ["to", 1331], ["induce", 1334], ["a", 1341], ["significant", 1343], ["accumulative", 1355], ["easing", 1368], ["of", 1375], ["hyperphagia", 1378], ["(", 1390], ["P", 1391], ["=", 1393], ["0.05", 1395], [")", 1399], [",", 1400], ["with", 1402], ["decreases", 1407], ["evident", 1417], ["in", 1425], ["one", 1428], ["-", 1431], ["third", 1432], ["of", 1438], ["the", 1441], ["participants", 1445], [".", 1457], ["Furthermore", 1459], ["due", 1471], ["to", 1475], ["CFE", 1478], ["supplementation", 1482], [",", 1497], ["a", 1499], ["significant", 1501], ["decrease", 1513], ["(", 1522], ["P", 1523], ["\u2264", 1525], ["0.05", 1527], [")", 1531], ["was", 1533], ["recorded", 1537], ["in", 1546], ["the", 1549], ["category", 1553], ["of", 1562], ["behavior", 1565], ["and", 1574], ["a", 1578], ["decrease", 1580], ["in", 1589], ["hyperphagia", 1592], ["(", 1604], ["n", 1605], ["=", 1607], ["8", 1609], [",", 1610], ["P", 1612], ["=", 1614], ["0.009", 1616], [")", 1621], ["was", 1623], ["observed", 1627], ["at", 1636], ["the", 1639], ["highest", 1643], ["dose", 1651], ["1,000", 1656], ["mg", 1662], ["/", 1664], ["day", 1665], ["(", 1669], ["recommended", 1670], ["adult", 1682], ["dose", 1688], [")", 1692], [".", 1693], ["There", 1695], ["were", 1701], ["no", 1706], ["reported", 1709], ["adverse", 1718], ["effects", 1726], ["at", 1734], ["any", 1737], ["dose", 1741], [".", 1745], ["We", 1747], ["demonstrate", 1750], ["that", 1762], ["an", 1767], ["extract", 1770], ["of", 1778], ["the", 1781], ["Indian", 1785], ["cactus", 1792], ["succulent", 1799], ["Caralluma", 1809], ["fimbriata", 1819], ["eases", 1829], ["hyperphagic", 1835], ["appetite", 1847], ["behavior", 1856], ["within", 1865], ["a", 1872], ["cohort", 1874], ["of", 1881], ["children", 1884], ["and", 1893], ["adolescents", 1897], ["(", 1909], ["n", 1910], ["=", 1912], ["15", 1914], [")", 1916], ["with", 1918], ["PWS", 1923], ["without", 1927], ["notable", 1935], ["adverse", 1943], ["effects", 1951], [".", 1958], ["The", 1960], ["outcomes", 1964], ["of", 1973], ["this", 1976], ["study", 1981], ["will", 1987], ["have", 1992], ["a", 1997], ["potential", 1999], ["positive", 2009], ["impact", 2018], ["on", 2025], ["PWS", 2028], ["management", 2032], [".", 2042]]}
{"context": "The translocation (9;22) gives rise to the p190(Bcr-Abl) and p210(Bcr-Abl) tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph(+)) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We conducted a clinical trial in 56 patients with relapsed or refractory Ph(+) acute lymphoblastic leukemia (ALL; 48 patients) or chronic myelogenous leukemia in lymphoid blast crisis (LyBC; 8 patients). Imatinib was given once daily at 400 mg or 600 mg. Imatinib induced complete hematologic responses (CHRs) and complete marrow responses (marrow-CRs) in 29% of ALL patients (CHR, 19%; marrow-CR, 10%), which were sustained for at least 4 weeks in 6% of patients. Median estimated time to progression and overall survival for ALL patients were 2.2 and 4.9 months, respectively. CHRs were reported for 3 (38%) of the patients with LyBC (one sustained CHR). Grade 3 or 4 treatment-related nonhematologic toxicity was reported for 9% of patients; none of the patients discontinued therapy because of nonhematologic adverse reactions. Grade 4 neutropenia and thrombocytopenia occurred in 54% and 27% of patients, respectively. Imatinib therapy resulted in a clinically relevant hematologic response rate in relapsed or refractory Ph(+) acute lymphoid leukemia patients, but development of resistance and subsequent disease progression were rapid. Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "51a1889816af46d0bc6c17f5001e75f4", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[65, 67]], "char_spans": [[374, 380]]}]}], "context_tokens": [["The", 0], ["translocation", 4], ["(", 18], ["9;22", 19], [")", 23], ["gives", 25], ["rise", 31], ["to", 36], ["the", 39], ["p190(Bcr", 43], ["-", 51], ["Abl", 52], [")", 55], ["and", 57], ["p210(Bcr", 61], ["-", 69], ["Abl", 70], [")", 73], ["tyrosine", 75], ["kinase", 84], ["proteins", 91], [",", 99], ["considered", 101], ["sufficient", 112], ["for", 123], ["leukemic", 127], ["transformation", 136], [".", 150], ["Philadelphia", 152], ["-", 164], ["positive", 165], ["(", 174], ["Ph(+", 175], [")", 179], [")", 180], ["acute", 182], ["leukemia", 188], ["patients", 197], ["failing", 206], ["to", 214], ["respond", 217], ["to", 225], ["initial", 228], ["induction", 236], ["therapy", 246], ["have", 254], ["a", 259], ["poor", 261], ["prognosis", 266], ["with", 276], ["few", 281], ["effective", 285], ["treatment", 295], ["options", 305], [".", 312], ["Imatinib", 314], ["is", 323], ["an", 326], ["orally", 329], ["administered", 336], [",", 348], ["potent", 350], ["inhibitor", 357], ["of", 367], ["the", 370], ["Bcr", 374], ["-", 377], ["Abl", 378], ["tyrosine", 382], ["kinase", 391], [".", 397], ["We", 399], ["conducted", 402], ["a", 412], ["clinical", 414], ["trial", 423], ["in", 429], ["56", 432], ["patients", 435], ["with", 444], ["relapsed", 449], ["or", 458], ["refractory", 461], ["Ph(+", 472], [")", 476], ["acute", 478], ["lymphoblastic", 484], ["leukemia", 498], ["(", 507], ["ALL", 508], [";", 511], ["48", 513], ["patients", 516], [")", 524], ["or", 526], ["chronic", 529], ["myelogenous", 537], ["leukemia", 549], ["in", 558], ["lymphoid", 561], ["blast", 570], ["crisis", 576], ["(", 583], ["LyBC", 584], [";", 588], ["8", 590], ["patients", 592], [")", 600], [".", 601], ["Imatinib", 603], ["was", 612], ["given", 616], ["once", 622], ["daily", 627], ["at", 633], ["400", 636], ["mg", 640], ["or", 643], ["600", 646], ["mg", 650], [".", 652], ["Imatinib", 654], ["induced", 663], ["complete", 671], ["hematologic", 680], ["responses", 692], ["(", 702], ["CHRs", 703], [")", 707], ["and", 709], ["complete", 713], ["marrow", 722], ["responses", 729], ["(", 739], ["marrow", 740], ["-", 746], ["CRs", 747], [")", 750], ["in", 752], ["29", 755], ["%", 757], ["of", 759], ["ALL", 762], ["patients", 766], ["(", 775], ["CHR", 776], [",", 779], ["19", 781], ["%", 783], [";", 784], ["marrow", 786], ["-", 792], ["CR", 793], [",", 795], ["10", 797], ["%", 799], [")", 800], [",", 801], ["which", 803], ["were", 809], ["sustained", 814], ["for", 824], ["at", 828], ["least", 831], ["4", 837], ["weeks", 839], ["in", 845], ["6", 848], ["%", 849], ["of", 851], ["patients", 854], [".", 862], ["Median", 864], ["estimated", 871], ["time", 881], ["to", 886], ["progression", 889], ["and", 901], ["overall", 905], ["survival", 913], ["for", 922], ["ALL", 926], ["patients", 930], ["were", 939], ["2.2", 944], ["and", 948], ["4.9", 952], ["months", 956], [",", 962], ["respectively", 964], [".", 976], ["CHRs", 978], ["were", 983], ["reported", 988], ["for", 997], ["3", 1001], ["(", 1003], ["38", 1004], ["%", 1006], [")", 1007], ["of", 1009], ["the", 1012], ["patients", 1016], ["with", 1025], ["LyBC", 1030], ["(", 1035], ["one", 1036], ["sustained", 1040], ["CHR", 1050], [")", 1053], [".", 1054], ["Grade", 1056], ["3", 1062], ["or", 1064], ["4", 1067], ["treatment", 1069], ["-", 1078], ["related", 1079], ["nonhematologic", 1087], ["toxicity", 1102], ["was", 1111], ["reported", 1115], ["for", 1124], ["9", 1128], ["%", 1129], ["of", 1131], ["patients", 1134], [";", 1142], ["none", 1144], ["of", 1149], ["the", 1152], ["patients", 1156], ["discontinued", 1165], ["therapy", 1178], ["because", 1186], ["of", 1194], ["nonhematologic", 1197], ["adverse", 1212], ["reactions", 1220], [".", 1229], ["Grade", 1231], ["4", 1237], ["neutropenia", 1239], ["and", 1251], ["thrombocytopenia", 1255], ["occurred", 1272], ["in", 1281], ["54", 1284], ["%", 1286], ["and", 1288], ["27", 1292], ["%", 1294], ["of", 1296], ["patients", 1299], [",", 1307], ["respectively", 1309], [".", 1321], ["Imatinib", 1323], ["therapy", 1332], ["resulted", 1340], ["in", 1349], ["a", 1352], ["clinically", 1354], ["relevant", 1365], ["hematologic", 1374], ["response", 1386], ["rate", 1395], ["in", 1400], ["relapsed", 1403], ["or", 1412], ["refractory", 1415], ["Ph(+", 1426], [")", 1430], ["acute", 1432], ["lymphoid", 1438], ["leukemia", 1447], ["patients", 1456], [",", 1464], ["but", 1466], ["development", 1470], ["of", 1482], ["resistance", 1485], ["and", 1496], ["subsequent", 1500], ["disease", 1511], ["progression", 1519], ["were", 1531], ["rapid", 1536], [".", 1541], ["Further", 1543], ["studies", 1551], ["are", 1559], ["warranted", 1563], ["to", 1573], ["test", 1576], ["the", 1581], ["effects", 1585], ["of", 1593], ["imatinib", 1596], ["in", 1605], ["combination", 1608], ["with", 1620], ["other", 1625], ["agents", 1631], ["and", 1638], ["to", 1642], ["define", 1645], ["the", 1652], ["mechanisms", 1656], ["of", 1667], ["resistance", 1670], ["to", 1681], ["imatinib", 1684], [".", 1692]]}
{"context": "AtxA, a unique regulatory protein of unknown molecular function, positively controls expression of the major virulence genes of Bacillus anthracis. The 475 amino acid sequence of AtxA reveals DNA binding motifs and regions similar to proteins associated with the phosphoenolpyruvate: carbohydrate phosphotransferase system (PTS). We used strains producing native and functional epitope-tagged AtxA proteins to examine protein-protein interactions in cell lysates and in solutions of purified protein. Co-affinity purification, non-denaturing polyacrylamide gel electrophoresis and bis(maleimido)hexane (BMH) cross-linking experiments revealed AtxA homo-multimers. Dimers were the most abundant species. BMH cross-links available cysteines within 13 \u00c5. To localize interaction sites, six AtxA mutants containing distinct Cys\u2192Ser substitutions were tested for multimerization and cross-linking. All mutants multimerized, but one mutation, C402S, prevented cross-linking. Thus, BMH uses C402 to make the inter-molecular bond between AtxA proteins, but C402 is not required for protein-protein interaction. C402 is in a region bearing amino acid similarity to Enzyme IIB proteins of the PTS. The AtxA EIIB motif may function in protein oligomerization. Finally, cultures grown with elevated CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by shifting the dimer/monomer equilibrium towards the dimeric state.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "47491f59f6b14de09b72e1a703284430", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "bicarbonate", "token_spans": [[240, 240], [219, 219]], "char_spans": [[1428, 1439], [1293, 1304]]}]}], "context_tokens": [["AtxA", 0], [",", 4], ["a", 6], ["unique", 8], ["regulatory", 15], ["protein", 26], ["of", 34], ["unknown", 37], ["molecular", 45], ["function", 55], [",", 63], ["positively", 65], ["controls", 76], ["expression", 85], ["of", 96], ["the", 99], ["major", 103], ["virulence", 109], ["genes", 119], ["of", 125], ["Bacillus", 128], ["anthracis", 137], [".", 146], ["The", 148], ["475", 152], ["amino", 156], ["acid", 162], ["sequence", 167], ["of", 176], ["AtxA", 179], ["reveals", 184], ["DNA", 192], ["binding", 196], ["motifs", 204], ["and", 211], ["regions", 215], ["similar", 223], ["to", 231], ["proteins", 234], ["associated", 243], ["with", 254], ["the", 259], ["phosphoenolpyruvate", 263], [":", 282], ["carbohydrate", 284], ["phosphotransferase", 297], ["system", 316], ["(", 323], ["PTS", 324], [")", 327], [".", 328], ["We", 330], ["used", 333], ["strains", 338], ["producing", 346], ["native", 356], ["and", 363], ["functional", 367], ["epitope", 378], ["-", 385], ["tagged", 386], ["AtxA", 393], ["proteins", 398], ["to", 407], ["examine", 410], ["protein", 418], ["-", 425], ["protein", 426], ["interactions", 434], ["in", 447], ["cell", 450], ["lysates", 455], ["and", 463], ["in", 467], ["solutions", 470], ["of", 480], ["purified", 483], ["protein", 492], [".", 499], ["Co", 501], ["-", 503], ["affinity", 504], ["purification", 513], [",", 525], ["non", 527], ["-", 530], ["denaturing", 531], ["polyacrylamide", 542], ["gel", 557], ["electrophoresis", 561], ["and", 577], ["bis(maleimido)hexane", 581], ["(", 602], ["BMH", 603], [")", 606], ["cross", 608], ["-", 613], ["linking", 614], ["experiments", 622], ["revealed", 634], ["AtxA", 643], ["homo", 648], ["-", 652], ["multimers", 653], [".", 662], ["Dimers", 664], ["were", 671], ["the", 676], ["most", 680], ["abundant", 685], ["species", 694], [".", 701], ["BMH", 703], ["cross", 707], ["-", 712], ["links", 713], ["available", 719], ["cysteines", 729], ["within", 739], ["13", 746], ["\u00c5.", 749], ["To", 752], ["localize", 755], ["interaction", 764], ["sites", 776], [",", 781], ["six", 783], ["AtxA", 787], ["mutants", 792], ["containing", 800], ["distinct", 811], ["Cys\u2192Ser", 820], ["substitutions", 828], ["were", 842], ["tested", 847], ["for", 854], ["multimerization", 858], ["and", 874], ["cross", 878], ["-", 883], ["linking", 884], [".", 891], ["All", 893], ["mutants", 897], ["multimerized", 905], [",", 917], ["but", 919], ["one", 923], ["mutation", 927], [",", 935], ["C402S", 937], [",", 942], ["prevented", 944], ["cross", 954], ["-", 959], ["linking", 960], [".", 967], ["Thus", 969], [",", 973], ["BMH", 975], ["uses", 979], ["C402", 984], ["to", 989], ["make", 992], ["the", 997], ["inter", 1001], ["-", 1006], ["molecular", 1007], ["bond", 1017], ["between", 1022], ["AtxA", 1030], ["proteins", 1035], [",", 1043], ["but", 1045], ["C402", 1049], ["is", 1054], ["not", 1057], ["required", 1061], ["for", 1070], ["protein", 1074], ["-", 1081], ["protein", 1082], ["interaction", 1090], [".", 1101], ["C402", 1103], ["is", 1108], ["in", 1111], ["a", 1114], ["region", 1116], ["bearing", 1123], ["amino", 1131], ["acid", 1137], ["similarity", 1142], ["to", 1153], ["Enzyme", 1156], ["IIB", 1163], ["proteins", 1167], ["of", 1176], ["the", 1179], ["PTS", 1183], [".", 1186], ["The", 1188], ["AtxA", 1192], ["EIIB", 1197], ["motif", 1202], ["may", 1208], ["function", 1212], ["in", 1221], ["protein", 1224], ["oligomerization", 1232], [".", 1247], ["Finally", 1249], [",", 1256], ["cultures", 1258], ["grown", 1267], ["with", 1273], ["elevated", 1278], ["CO(2", 1287], [")", 1291], ["/bicarbonate", 1293], ["exhibited", 1306], ["increased", 1316], ["AtxA", 1326], ["dimer", 1331], ["/", 1336], ["monomer", 1337], ["ratios", 1345], ["and", 1352], ["increased", 1356], ["AtxA", 1366], ["activity", 1371], [",", 1379], ["relative", 1381], ["to", 1390], ["cultures", 1393], ["grown", 1402], ["without", 1408], ["added", 1416], ["CO(2", 1422], [")", 1426], ["/bicarbonate", 1428], [",", 1440], ["suggesting", 1442], ["that", 1453], ["this", 1458], ["host", 1463], ["-", 1467], ["associated", 1468], ["signal", 1479], ["enhances", 1486], ["AtxA", 1495], ["function", 1500], ["by", 1509], ["shifting", 1512], ["the", 1521], ["dimer", 1525], ["/", 1530], ["monomer", 1531], ["equilibrium", 1539], ["towards", 1551], ["the", 1559], ["dimeric", 1563], ["state", 1571], [".", 1576]]}
{"context": "An overdose of oral anticoagulants represents a challenging scenario for emergency physicians. Dabigatran, an oral direct thrombin inhibitor, is increasingly used in place of warfarin. The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis. Idarucizumab is an antibody fragment that binds dabigatran with high affinity. It reverses the anticoagulant effect of dabigatran within minutes and is approved for the reversal of dabigatran during emergency situations. We describe the use of idarucizumab in the management of a 68-year-old woman who was taking dabigatran 150\u2009mg twice daily and ingested 125 capsules. Despite gastric lavage and administration of activated charcoal within two hours of drug intake, the activated partial thromboplastin time (aPTT) and prothrombin time (PT) remained prolonged. The administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26\u2009s, PT from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s). The initially planned emergency hemodialysis was canceled. This case highlights the potential use of idarucizumab for the management of massive dabigatran overdoses.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2b3f550f6fc74ff89e6391af6883b958", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[13, 13], [61, 61], [42, 42], [163, 163], [219, 219], [105, 105], [72, 72], [82, 82]], "char_spans": [[95, 104], [368, 377], [250, 259], [999, 1008], [1298, 1307], [633, 642], [439, 448], [501, 510]]}]}], "context_tokens": [["An", 0], ["overdose", 3], ["of", 12], ["oral", 15], ["anticoagulants", 20], ["represents", 35], ["a", 46], ["challenging", 48], ["scenario", 60], ["for", 69], ["emergency", 73], ["physicians", 83], [".", 93], ["Dabigatran", 95], [",", 105], ["an", 107], ["oral", 110], ["direct", 115], ["thrombin", 122], ["inhibitor", 131], [",", 140], ["is", 142], ["increasingly", 145], ["used", 158], ["in", 163], ["place", 166], ["of", 172], ["warfarin", 175], [".", 183], ["The", 185], ["lack", 189], ["of", 194], ["an", 197], ["antidote", 200], ["is", 209], ["a", 212], ["concern", 214], ["in", 222], ["patients", 225], ["who", 234], ["overdose", 238], ["on", 247], ["dabigatran", 250], [",", 260], ["even", 262], ["though", 267], ["the", 274], ["drug", 278], ["can", 283], ["be", 287], ["eliminated", 290], ["with", 301], ["hemodialysis", 306], [".", 318], ["Idarucizumab", 320], ["is", 333], ["an", 336], ["antibody", 339], ["fragment", 348], ["that", 357], ["binds", 362], ["dabigatran", 368], ["with", 379], ["high", 384], ["affinity", 389], [".", 397], ["It", 399], ["reverses", 402], ["the", 411], ["anticoagulant", 415], ["effect", 429], ["of", 436], ["dabigatran", 439], ["within", 450], ["minutes", 457], ["and", 465], ["is", 469], ["approved", 472], ["for", 481], ["the", 485], ["reversal", 489], ["of", 498], ["dabigatran", 501], ["during", 512], ["emergency", 519], ["situations", 529], [".", 539], ["We", 541], ["describe", 544], ["the", 553], ["use", 557], ["of", 561], ["idarucizumab", 564], ["in", 577], ["the", 580], ["management", 584], ["of", 595], ["a", 598], ["68-year", 600], ["-", 607], ["old", 608], ["woman", 612], ["who", 618], ["was", 622], ["taking", 626], ["dabigatran", 633], ["150", 644], ["mg", 648], ["twice", 651], ["daily", 657], ["and", 663], ["ingested", 667], ["125", 676], ["capsules", 680], [".", 688], ["Despite", 690], ["gastric", 698], ["lavage", 706], ["and", 713], ["administration", 717], ["of", 732], ["activated", 735], ["charcoal", 745], ["within", 754], ["two", 761], ["hours", 765], ["of", 771], ["drug", 774], ["intake", 779], [",", 785], ["the", 787], ["activated", 791], ["partial", 801], ["thromboplastin", 809], ["time", 824], ["(", 829], ["aPTT", 830], [")", 834], ["and", 836], ["prothrombin", 840], ["time", 852], ["(", 857], ["PT", 858], [")", 860], ["remained", 862], ["prolonged", 871], [".", 880], ["The", 882], ["administration", 886], ["of", 901], ["5", 904], ["g", 906], ["of", 908], ["intravenous", 911], ["idarucizumab", 923], ["promptly", 936], ["and", 945], ["completely", 949], ["reversed", 960], ["the", 969], ["anticoagulant", 973], ["activity", 987], ["of", 996], ["dabigatran", 999], ["as", 1010], ["assessed", 1013], ["by", 1022], ["routine", 1025], ["and", 1033], ["specific", 1037], ["coagulation", 1046], ["assays", 1058], ["(", 1065], ["aPTT", 1066], ["from", 1071], ["to", 1076], ["75", 1079], ["to", 1082], ["26", 1085], ["s", 1088], [",", 1089], ["PT", 1091], ["from", 1094], ["26", 1099], ["to", 1102], ["11", 1105], ["s", 1108], ["and", 1110], ["diluted", 1114], ["thrombin", 1122], ["time", 1131], ["from", 1136], ["92", 1141], ["to", 1144], ["27", 1147], ["s", 1150], [")", 1151], [".", 1152], ["The", 1154], ["initially", 1158], ["planned", 1168], ["emergency", 1176], ["hemodialysis", 1186], ["was", 1199], ["canceled", 1203], [".", 1211], ["This", 1213], ["case", 1218], ["highlights", 1223], ["the", 1234], ["potential", 1238], ["use", 1248], ["of", 1252], ["idarucizumab", 1255], ["for", 1268], ["the", 1272], ["management", 1276], ["of", 1287], ["massive", 1290], ["dabigatran", 1298], ["overdoses", 1309], [".", 1318]]}
{"context": "The apolipoprotein E (ApoE) \u03b54 allele is the strongest risk factor of sporadic Alzheimer's disease (AD), however, the fluid concentrations of ApoE and its different isoforms (ApoE2, ApoE3 and ApoE4) in AD patients and among APOE genotypes (APOE \u03b52, \u03b53, \u03b54) remain controversial. Using a novel mass spectrometry-based method, we quantified total ApoE and specific ApoE isoform concentrations and potential associations with age, cognitive status, cholesterol levels and established AD biomarkers in cerebrospinal fluid (CSF) from AD patients versus non-AD individuals with different APOE genotypes. We also investigated plasma total ApoE and ApoE isoform composition in a subset of these individuals. In total n = 43 AD and n = 43 non-AD subjects were included. We found that CSF and plasma total ApoE levels did not correlate with age or cognitive status and did not differ between AD and non-AD subjects deeming ApoE as an unfit diagnostic marker for AD. Also, whereas CSF ApoE levels did not vary between APOE genotypes APOE \u03b54 carriers exhibited significantly decreased plasma ApoE levels attributed to a specific decrease in the ApoE4 isoform concentrations. CSF total ApoE concentrations were positively associated with CSF, total tau, tau phosphorylated at Thr181 and A\u03b21-42 of which the latter association was weaker and only present in APOE \u03b54 carriers indicating a differential involvement of ApoE in tau versus A\u03b2-linked neuropathological processes. Future studies need to elucidate whether the observed plasma ApoE4 deficiency is a life-long condition in APOE \u025b4 carriers and whether this decrease in plasma ApoE predisposes APOE \u025b4 carriers to AD.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "19f812e350824082b6b21522a0ba9fa9", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[210, 211]], "char_spans": [[1133, 1145]]}]}], "context_tokens": [["The", 0], ["apolipoprotein", 4], ["E", 19], ["(", 21], ["ApoE", 22], [")", 26], ["\u03b54", 28], ["allele", 31], ["is", 38], ["the", 41], ["strongest", 45], ["risk", 55], ["factor", 60], ["of", 67], ["sporadic", 70], ["Alzheimer", 79], ["'s", 88], ["disease", 91], ["(", 99], ["AD", 100], [")", 102], [",", 103], ["however", 105], [",", 112], ["the", 114], ["fluid", 118], ["concentrations", 124], ["of", 139], ["ApoE", 142], ["and", 147], ["its", 151], ["different", 155], ["isoforms", 165], ["(", 174], ["ApoE2", 175], [",", 180], ["ApoE3", 182], ["and", 188], ["ApoE4", 192], [")", 197], ["in", 199], ["AD", 202], ["patients", 205], ["and", 214], ["among", 218], ["APOE", 224], ["genotypes", 229], ["(", 239], ["APOE", 240], ["\u03b52", 245], [",", 247], ["\u03b53", 249], [",", 251], ["\u03b54", 253], [")", 255], ["remain", 257], ["controversial", 264], [".", 277], ["Using", 279], ["a", 285], ["novel", 287], ["mass", 293], ["spectrometry", 298], ["-", 310], ["based", 311], ["method", 317], [",", 323], ["we", 325], ["quantified", 328], ["total", 339], ["ApoE", 345], ["and", 350], ["specific", 354], ["ApoE", 363], ["isoform", 368], ["concentrations", 376], ["and", 391], ["potential", 395], ["associations", 405], ["with", 418], ["age", 423], [",", 426], ["cognitive", 428], ["status", 438], [",", 444], ["cholesterol", 446], ["levels", 458], ["and", 465], ["established", 469], ["AD", 481], ["biomarkers", 484], ["in", 495], ["cerebrospinal", 498], ["fluid", 512], ["(", 518], ["CSF", 519], [")", 522], ["from", 524], ["AD", 529], ["patients", 532], ["versus", 541], ["non", 548], ["-", 551], ["AD", 552], ["individuals", 555], ["with", 567], ["different", 572], ["APOE", 582], ["genotypes", 587], [".", 596], ["We", 598], ["also", 601], ["investigated", 606], ["plasma", 619], ["total", 626], ["ApoE", 632], ["and", 637], ["ApoE", 641], ["isoform", 646], ["composition", 654], ["in", 666], ["a", 669], ["subset", 671], ["of", 678], ["these", 681], ["individuals", 687], [".", 698], ["In", 700], ["total", 703], ["n", 709], ["=", 711], ["43", 713], ["AD", 716], ["and", 719], ["n", 723], ["=", 725], ["43", 727], ["non", 730], ["-", 733], ["AD", 734], ["subjects", 737], ["were", 746], ["included", 751], [".", 759], ["We", 761], ["found", 764], ["that", 770], ["CSF", 775], ["and", 779], ["plasma", 783], ["total", 790], ["ApoE", 796], ["levels", 801], ["did", 808], ["not", 812], ["correlate", 816], ["with", 826], ["age", 831], ["or", 835], ["cognitive", 838], ["status", 848], ["and", 855], ["did", 859], ["not", 863], ["differ", 867], ["between", 874], ["AD", 882], ["and", 885], ["non", 889], ["-", 892], ["AD", 893], ["subjects", 896], ["deeming", 905], ["ApoE", 913], ["as", 918], ["an", 921], ["unfit", 924], ["diagnostic", 930], ["marker", 941], ["for", 948], ["AD", 952], [".", 954], ["Also", 956], [",", 960], ["whereas", 962], ["CSF", 970], ["ApoE", 974], ["levels", 979], ["did", 986], ["not", 990], ["vary", 994], ["between", 999], ["APOE", 1007], ["genotypes", 1012], ["APOE", 1022], ["\u03b54", 1027], ["carriers", 1030], ["exhibited", 1039], ["significantly", 1049], ["decreased", 1063], ["plasma", 1073], ["ApoE", 1080], ["levels", 1085], ["attributed", 1092], ["to", 1103], ["a", 1106], ["specific", 1108], ["decrease", 1117], ["in", 1126], ["the", 1129], ["ApoE4", 1133], ["isoform", 1139], ["concentrations", 1147], [".", 1161], ["CSF", 1163], ["total", 1167], ["ApoE", 1173], ["concentrations", 1178], ["were", 1193], ["positively", 1198], ["associated", 1209], ["with", 1220], ["CSF", 1225], [",", 1228], ["total", 1230], ["tau", 1236], [",", 1239], ["tau", 1241], ["phosphorylated", 1245], ["at", 1260], ["Thr181", 1263], ["and", 1270], ["A\u03b21", 1274], ["-", 1277], ["42", 1278], ["of", 1281], ["which", 1284], ["the", 1290], ["latter", 1294], ["association", 1301], ["was", 1313], ["weaker", 1317], ["and", 1324], ["only", 1328], ["present", 1333], ["in", 1341], ["APOE", 1344], ["\u03b54", 1349], ["carriers", 1352], ["indicating", 1361], ["a", 1372], ["differential", 1374], ["involvement", 1387], ["of", 1399], ["ApoE", 1402], ["in", 1407], ["tau", 1410], ["versus", 1414], ["A\u03b2", 1421], ["-", 1423], ["linked", 1424], ["neuropathological", 1431], ["processes", 1449], [".", 1458], ["Future", 1460], ["studies", 1467], ["need", 1475], ["to", 1480], ["elucidate", 1483], ["whether", 1493], ["the", 1501], ["observed", 1505], ["plasma", 1514], ["ApoE4", 1521], ["deficiency", 1527], ["is", 1538], ["a", 1541], ["life", 1543], ["-", 1547], ["long", 1548], ["condition", 1553], ["in", 1563], ["APOE", 1566], ["\u025b4", 1571], ["carriers", 1574], ["and", 1583], ["whether", 1587], ["this", 1595], ["decrease", 1600], ["in", 1609], ["plasma", 1612], ["ApoE", 1619], ["predisposes", 1624], ["APOE", 1636], ["\u025b4", 1641], ["carriers", 1644], ["to", 1653], ["AD", 1656], [".", 1658]]}
{"context": "Siltuximab, a chimeric monoclonal antibody with high affinity and specificity for interleukin-6, has been shown to enhance anti-multiple myeloma activity of bortezomib and corticosteroid in vitro. We evaluated the safety, pharmacokinetics, immunogenicity, and antitumor effect of siltuximab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. This open-label, phase 1, dose-escalating study used two doses of siltuximab: 5.5 and 11.0 mg/kg (administered on day 1 of each 21-day cycle). In total, nine patients were treated. The most common grade 3/4 adverse events, lymphopenia (89 %) and thrombocytopenia (44 %), occurred in patients receiving both doses of siltuximab; however, no dose-limiting toxicities (DLTs) were observed. Following intravenous administration of siltuximab at 5.5 and 11.0 mg/kg, the maximum serum concentration and the area under the curve from 0 to 21 days and from 0 to infinity increased in an approximately dose-proportional manner. Mean half-life, total systemic clearance, and volume of distribution were similar at doses of 5.5 and 11.0 mg/kg. Across both doses, six of the nine patients had complete or partial response (22 and 44 %, respectively). In conclusion, as no DLT was observed, the recommended dose for this combination is 11.0 mg/kg once every 3 weeks. The study is registered at http://www.clinicaltrials.gov as NCT01309412.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "5cd7ff3ebd7f4aeea91e08b630ebba14", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[12, 12]], "char_spans": [[82, 94]]}]}], "context_tokens": [["Siltuximab", 0], [",", 10], ["a", 12], ["chimeric", 14], ["monoclonal", 23], ["antibody", 34], ["with", 43], ["high", 48], ["affinity", 53], ["and", 62], ["specificity", 66], ["for", 78], ["interleukin-6", 82], [",", 95], ["has", 97], ["been", 101], ["shown", 106], ["to", 112], ["enhance", 115], ["anti", 123], ["-", 127], ["multiple", 128], ["myeloma", 137], ["activity", 145], ["of", 154], ["bortezomib", 157], ["and", 168], ["corticosteroid", 172], ["in", 187], ["vitro", 190], [".", 195], ["We", 197], ["evaluated", 200], ["the", 210], ["safety", 214], [",", 220], ["pharmacokinetics", 222], [",", 238], ["immunogenicity", 240], [",", 254], ["and", 256], ["antitumor", 260], ["effect", 270], ["of", 277], ["siltuximab", 280], ["in", 291], ["combination", 294], ["with", 306], ["bortezomib", 311], ["and", 322], ["dexamethasone", 326], ["in", 340], ["Japanese", 343], ["patients", 352], ["with", 361], ["relapsed", 366], ["or", 375], ["refractory", 378], ["multiple", 389], ["myeloma", 398], [".", 405], ["This", 407], ["open", 412], ["-", 416], ["label", 417], [",", 422], ["phase", 424], ["1", 430], [",", 431], ["dose", 433], ["-", 437], ["escalating", 438], ["study", 449], ["used", 455], ["two", 460], ["doses", 464], ["of", 470], ["siltuximab", 473], [":", 483], ["5.5", 485], ["and", 489], ["11.0", 493], ["mg", 498], ["/", 500], ["kg", 501], ["(", 504], ["administered", 505], ["on", 518], ["day", 521], ["1", 525], ["of", 527], ["each", 530], ["21-day", 535], ["cycle", 542], [")", 547], [".", 548], ["In", 550], ["total", 553], [",", 558], ["nine", 560], ["patients", 565], ["were", 574], ["treated", 579], [".", 586], ["The", 588], ["most", 592], ["common", 597], ["grade", 604], ["3/4", 610], ["adverse", 614], ["events", 622], [",", 628], ["lymphopenia", 630], ["(", 642], ["89", 643], ["%", 646], [")", 647], ["and", 649], ["thrombocytopenia", 653], ["(", 670], ["44", 671], ["%", 674], [")", 675], [",", 676], ["occurred", 678], ["in", 687], ["patients", 690], ["receiving", 699], ["both", 709], ["doses", 714], ["of", 720], ["siltuximab", 723], [";", 733], ["however", 735], [",", 742], ["no", 744], ["dose", 747], ["-", 751], ["limiting", 752], ["toxicities", 761], ["(", 772], ["DLTs", 773], [")", 777], ["were", 779], ["observed", 784], [".", 792], ["Following", 794], ["intravenous", 804], ["administration", 816], ["of", 831], ["siltuximab", 834], ["at", 845], ["5.5", 848], ["and", 852], ["11.0", 856], ["mg", 861], ["/", 863], ["kg", 864], [",", 866], ["the", 868], ["maximum", 872], ["serum", 880], ["concentration", 886], ["and", 900], ["the", 904], ["area", 908], ["under", 913], ["the", 919], ["curve", 923], ["from", 929], ["0", 934], ["to", 936], ["21", 939], ["days", 942], ["and", 947], ["from", 951], ["0", 956], ["to", 958], ["infinity", 961], ["increased", 970], ["in", 980], ["an", 983], ["approximately", 986], ["dose", 1000], ["-", 1004], ["proportional", 1005], ["manner", 1018], [".", 1024], ["Mean", 1026], ["half", 1031], ["-", 1035], ["life", 1036], [",", 1040], ["total", 1042], ["systemic", 1048], ["clearance", 1057], [",", 1066], ["and", 1068], ["volume", 1072], ["of", 1079], ["distribution", 1082], ["were", 1095], ["similar", 1100], ["at", 1108], ["doses", 1111], ["of", 1117], ["5.5", 1120], ["and", 1124], ["11.0", 1128], ["mg", 1133], ["/", 1135], ["kg", 1136], [".", 1138], ["Across", 1140], ["both", 1147], ["doses", 1152], [",", 1157], ["six", 1159], ["of", 1163], ["the", 1166], ["nine", 1170], ["patients", 1175], ["had", 1184], ["complete", 1188], ["or", 1197], ["partial", 1200], ["response", 1208], ["(", 1217], ["22", 1218], ["and", 1221], ["44", 1225], ["%", 1228], [",", 1229], ["respectively", 1231], [")", 1243], [".", 1244], ["In", 1246], ["conclusion", 1249], [",", 1259], ["as", 1261], ["no", 1264], ["DLT", 1267], ["was", 1271], ["observed", 1275], [",", 1283], ["the", 1285], ["recommended", 1289], ["dose", 1301], ["for", 1306], ["this", 1310], ["combination", 1315], ["is", 1327], ["11.0", 1330], ["mg", 1335], ["/", 1337], ["kg", 1338], ["once", 1341], ["every", 1346], ["3", 1352], ["weeks", 1354], [".", 1359], ["The", 1361], ["study", 1365], ["is", 1371], ["registered", 1374], ["at", 1385], ["http://www.clinicaltrials.gov", 1388], ["as", 1418], ["NCT01309412", 1421], [".", 1432]]}
{"context": "In mammals, most of the selenium contained in the body is present as an unusual amino acid, selenocysteine (Sec), whose codon is UGA. Because the UGA codon is typically recognized as a translation stop signal, it is intriguing how a cell recognizes and distinguishes a UGA Sec codon from a UGA stop codon. For eukaryotic selenoprotein mRNAs, it has been proposed that a conserved stem-loop structure designated the Sec insertion sequence (SECIS) in the 3'-untranslated (3'-UTR) region is required for recognition of UGA as a Sec codon. Some proteins which bind to SECIS (SBP) have been reported. However, it is not clear how the SECIS element in the 3'-UTR can mediate Sec insertion far at the in-frame UGA Sec codons. The idea that there must be a signal near the UGA Sec codon is still considered. Therefore, we searched for a protein which binds to an RNA sequence surrounding the UGA Sec codon on human glutathione peroxidase (GPx) mRNA. We found a protein which strongly bound to the RNA fragment upstream of the UGA Sec codon. However, this protein did not bind to the RNA sequence downstream of the UGA codon. This protein also bound to the SECIS sequence in the 3'-UTR of human GPx, and this binding to SECIS was competed with the RNA fragment upstream of the UGA Sec codon. Comparison of the RNA fragment with the SECIS fragment identified the conserved regions, which appeared in the region upstream of the in-frame UGA Sec codon of Se-protein mRNAs. Thus, this study proposes a novel model to understand the mechanisms of Sec incorporation at the UGA Sec codon, especially the regions upstream of the UGA codon of mRNAs of mammalian selenoproteins. This model explains that the stem-loop structure covering the UGA codon is recognized by SBP and how the UGA Sec codon escapes from attack by eRF of the peptide releasing factor.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0d37ab3d489b4d7da2bc133cfa75a2d3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[83, 83], [262, 262], [124, 124], [108, 108], [228, 228], [241, 241]], "char_spans": [[439, 443], [1323, 1327], [629, 633], [564, 568], [1148, 1152], [1211, 1215]]}]}], "context_tokens": [["In", 0], ["mammals", 3], [",", 10], ["most", 12], ["of", 17], ["the", 20], ["selenium", 24], ["contained", 33], ["in", 43], ["the", 46], ["body", 50], ["is", 55], ["present", 58], ["as", 66], ["an", 69], ["unusual", 72], ["amino", 80], ["acid", 86], [",", 90], ["selenocysteine", 92], ["(", 107], ["Sec", 108], [")", 111], [",", 112], ["whose", 114], ["codon", 120], ["is", 126], ["UGA", 129], [".", 132], ["Because", 134], ["the", 142], ["UGA", 146], ["codon", 150], ["is", 156], ["typically", 159], ["recognized", 169], ["as", 180], ["a", 183], ["translation", 185], ["stop", 197], ["signal", 202], [",", 208], ["it", 210], ["is", 213], ["intriguing", 216], ["how", 227], ["a", 231], ["cell", 233], ["recognizes", 238], ["and", 249], ["distinguishes", 253], ["a", 267], ["UGA", 269], ["Sec", 273], ["codon", 277], ["from", 283], ["a", 288], ["UGA", 290], ["stop", 294], ["codon", 299], [".", 304], ["For", 306], ["eukaryotic", 310], ["selenoprotein", 321], ["mRNAs", 335], [",", 340], ["it", 342], ["has", 345], ["been", 349], ["proposed", 354], ["that", 363], ["a", 368], ["conserved", 370], ["stem", 380], ["-", 384], ["loop", 385], ["structure", 390], ["designated", 400], ["the", 411], ["Sec", 415], ["insertion", 419], ["sequence", 429], ["(", 438], ["SECIS", 439], [")", 444], ["in", 446], ["the", 449], ["3'-untranslated", 453], ["(", 469], ["3'-UTR", 470], [")", 476], ["region", 478], ["is", 485], ["required", 488], ["for", 497], ["recognition", 501], ["of", 513], ["UGA", 516], ["as", 520], ["a", 523], ["Sec", 525], ["codon", 529], [".", 534], ["Some", 536], ["proteins", 541], ["which", 550], ["bind", 556], ["to", 561], ["SECIS", 564], ["(", 570], ["SBP", 571], [")", 574], ["have", 576], ["been", 581], ["reported", 586], [".", 594], ["However", 596], [",", 603], ["it", 605], ["is", 608], ["not", 611], ["clear", 615], ["how", 621], ["the", 625], ["SECIS", 629], ["element", 635], ["in", 643], ["the", 646], ["3'-UTR", 650], ["can", 657], ["mediate", 661], ["Sec", 669], ["insertion", 673], ["far", 683], ["at", 687], ["the", 690], ["in", 694], ["-", 696], ["frame", 697], ["UGA", 703], ["Sec", 707], ["codons", 711], [".", 717], ["The", 719], ["idea", 723], ["that", 728], ["there", 733], ["must", 739], ["be", 744], ["a", 747], ["signal", 749], ["near", 756], ["the", 761], ["UGA", 765], ["Sec", 769], ["codon", 773], ["is", 779], ["still", 782], ["considered", 788], [".", 798], ["Therefore", 800], [",", 809], ["we", 811], ["searched", 814], ["for", 823], ["a", 827], ["protein", 829], ["which", 837], ["binds", 843], ["to", 849], ["an", 852], ["RNA", 855], ["sequence", 859], ["surrounding", 868], ["the", 880], ["UGA", 884], ["Sec", 888], ["codon", 892], ["on", 898], ["human", 901], ["glutathione", 907], ["peroxidase", 919], ["(", 930], ["GPx", 931], [")", 934], ["mRNA", 936], [".", 940], ["We", 942], ["found", 945], ["a", 951], ["protein", 953], ["which", 961], ["strongly", 967], ["bound", 976], ["to", 982], ["the", 985], ["RNA", 989], ["fragment", 993], ["upstream", 1002], ["of", 1011], ["the", 1014], ["UGA", 1018], ["Sec", 1022], ["codon", 1026], [".", 1031], ["However", 1033], [",", 1040], ["this", 1042], ["protein", 1047], ["did", 1055], ["not", 1059], ["bind", 1063], ["to", 1068], ["the", 1071], ["RNA", 1075], ["sequence", 1079], ["downstream", 1088], ["of", 1099], ["the", 1102], ["UGA", 1106], ["codon", 1110], [".", 1115], ["This", 1117], ["protein", 1122], ["also", 1130], ["bound", 1135], ["to", 1141], ["the", 1144], ["SECIS", 1148], ["sequence", 1154], ["in", 1163], ["the", 1166], ["3'-UTR", 1170], ["of", 1177], ["human", 1180], ["GPx", 1186], [",", 1189], ["and", 1191], ["this", 1195], ["binding", 1200], ["to", 1208], ["SECIS", 1211], ["was", 1217], ["competed", 1221], ["with", 1230], ["the", 1235], ["RNA", 1239], ["fragment", 1243], ["upstream", 1252], ["of", 1261], ["the", 1264], ["UGA", 1268], ["Sec", 1272], ["codon", 1276], [".", 1281], ["Comparison", 1283], ["of", 1294], ["the", 1297], ["RNA", 1301], ["fragment", 1305], ["with", 1314], ["the", 1319], ["SECIS", 1323], ["fragment", 1329], ["identified", 1338], ["the", 1349], ["conserved", 1353], ["regions", 1363], [",", 1370], ["which", 1372], ["appeared", 1378], ["in", 1387], ["the", 1390], ["region", 1394], ["upstream", 1401], ["of", 1410], ["the", 1413], ["in", 1417], ["-", 1419], ["frame", 1420], ["UGA", 1426], ["Sec", 1430], ["codon", 1434], ["of", 1440], ["Se", 1443], ["-", 1445], ["protein", 1446], ["mRNAs", 1454], [".", 1459], ["Thus", 1461], [",", 1465], ["this", 1467], ["study", 1472], ["proposes", 1478], ["a", 1487], ["novel", 1489], ["model", 1495], ["to", 1501], ["understand", 1504], ["the", 1515], ["mechanisms", 1519], ["of", 1530], ["Sec", 1533], ["incorporation", 1537], ["at", 1551], ["the", 1554], ["UGA", 1558], ["Sec", 1562], ["codon", 1566], [",", 1571], ["especially", 1573], ["the", 1584], ["regions", 1588], ["upstream", 1596], ["of", 1605], ["the", 1608], ["UGA", 1612], ["codon", 1616], ["of", 1622], ["mRNAs", 1625], ["of", 1631], ["mammalian", 1634], ["selenoproteins", 1644], [".", 1658], ["This", 1660], ["model", 1665], ["explains", 1671], ["that", 1680], ["the", 1685], ["stem", 1689], ["-", 1693], ["loop", 1694], ["structure", 1699], ["covering", 1709], ["the", 1718], ["UGA", 1722], ["codon", 1726], ["is", 1732], ["recognized", 1735], ["by", 1746], ["SBP", 1749], ["and", 1753], ["how", 1757], ["the", 1761], ["UGA", 1765], ["Sec", 1769], ["codon", 1773], ["escapes", 1779], ["from", 1787], ["attack", 1792], ["by", 1799], ["eRF", 1802], ["of", 1806], ["the", 1809], ["peptide", 1813], ["releasing", 1821], ["factor", 1831], [".", 1837]]}
{"context": "Growth differentiation factor 15 (GDF15), a distant member of the transforming growth factor (TGF)-\u03b2 family, is a secreted protein that circulates as a 25-kDa dimer. In humans, elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity reduces body weight, at least in part, by decreasing food intake. The mechanisms through which GDF15 reduces body weight remain poorly understood, because the cognate receptor for GDF15 is unknown. Here we show that recombinant GDF15 induces weight loss in mice fed a high-fat diet and in nonhuman primates with spontaneous obesity. Furthermore, we find that GDF15 binds with high affinity to GDNF family receptor \u03b1-like (GFRAL), a distant relative of receptors for a distinct class of the TGF-\u03b2 superfamily ligands. Gfral is expressed in neurons of the area postrema and nucleus of the solitary tract in mice and humans, and genetic deletion of the receptor abrogates the ability of GDF15 to decrease food intake and body weight in mice. In addition, diet-induced obesity and insulin resistance are exacerbated in GFRAL-deficient mice, suggesting a homeostatic role for this receptor in metabolism. Finally, we demonstrate that GDF15-induced cell signaling requires the interaction of GFRAL with the coreceptor RET. Our data identify GFRAL as a new regulator of body weight and as the bona fide receptor mediating the metabolic effects of GDF15, enabling a more comprehensive assessment of GDF15 as a potential pharmacotherapy for the treatment of obesity.", "qas": [{"question": "How does increased GDF15 affect body weight?", "answers": ["Reduces body weight"], "qid": "de1a17e690e849e3a857822511b54678", "question_tokens": [["How", 0], ["does", 4], ["increased", 9], ["GDF15", 19], ["affect", 25], ["body", 32], ["weight", 37], ["?", 43]], "detected_answers": [{"text": "Reduces body weight", "token_spans": [[69, 71], [50, 52]], "char_spans": [[375, 393], [274, 292]]}]}], "context_tokens": [["Growth", 0], ["differentiation", 7], ["factor", 23], ["15", 30], ["(", 33], ["GDF15", 34], [")", 39], [",", 40], ["a", 42], ["distant", 44], ["member", 52], ["of", 59], ["the", 62], ["transforming", 66], ["growth", 79], ["factor", 86], ["(", 93], ["TGF)-\u03b2", 94], ["family", 101], [",", 107], ["is", 109], ["a", 112], ["secreted", 114], ["protein", 123], ["that", 131], ["circulates", 136], ["as", 147], ["a", 150], ["25-kDa", 152], ["dimer", 159], [".", 164], ["In", 166], ["humans", 169], [",", 175], ["elevated", 177], ["GDF15", 186], ["correlates", 192], ["with", 203], ["weight", 208], ["loss", 215], [",", 219], ["and", 221], ["the", 225], ["administration", 229], ["of", 244], ["GDF15", 247], ["to", 253], ["mice", 256], ["with", 261], ["obesity", 266], ["reduces", 274], ["body", 282], ["weight", 287], [",", 293], ["at", 295], ["least", 298], ["in", 304], ["part", 307], [",", 311], ["by", 313], ["decreasing", 316], ["food", 327], ["intake", 332], [".", 338], ["The", 340], ["mechanisms", 344], ["through", 355], ["which", 363], ["GDF15", 369], ["reduces", 375], ["body", 383], ["weight", 388], ["remain", 395], ["poorly", 402], ["understood", 409], [",", 419], ["because", 421], ["the", 429], ["cognate", 433], ["receptor", 441], ["for", 450], ["GDF15", 454], ["is", 460], ["unknown", 463], [".", 470], ["Here", 472], ["we", 477], ["show", 480], ["that", 485], ["recombinant", 490], ["GDF15", 502], ["induces", 508], ["weight", 516], ["loss", 523], ["in", 528], ["mice", 531], ["fed", 536], ["a", 540], ["high", 542], ["-", 546], ["fat", 547], ["diet", 551], ["and", 556], ["in", 560], ["nonhuman", 563], ["primates", 572], ["with", 581], ["spontaneous", 586], ["obesity", 598], [".", 605], ["Furthermore", 607], [",", 618], ["we", 620], ["find", 623], ["that", 628], ["GDF15", 633], ["binds", 639], ["with", 645], ["high", 650], ["affinity", 655], ["to", 664], ["GDNF", 667], ["family", 672], ["receptor", 679], ["\u03b1", 688], ["-", 689], ["like", 690], ["(", 695], ["GFRAL", 696], [")", 701], [",", 702], ["a", 704], ["distant", 706], ["relative", 714], ["of", 723], ["receptors", 726], ["for", 736], ["a", 740], ["distinct", 742], ["class", 751], ["of", 757], ["the", 760], ["TGF", 764], ["-", 767], ["\u03b2", 768], ["superfamily", 770], ["ligands", 782], [".", 789], ["Gfral", 791], ["is", 797], ["expressed", 800], ["in", 810], ["neurons", 813], ["of", 821], ["the", 824], ["area", 828], ["postrema", 833], ["and", 842], ["nucleus", 846], ["of", 854], ["the", 857], ["solitary", 861], ["tract", 870], ["in", 876], ["mice", 879], ["and", 884], ["humans", 888], [",", 894], ["and", 896], ["genetic", 900], ["deletion", 908], ["of", 917], ["the", 920], ["receptor", 924], ["abrogates", 933], ["the", 943], ["ability", 947], ["of", 955], ["GDF15", 958], ["to", 964], ["decrease", 967], ["food", 976], ["intake", 981], ["and", 988], ["body", 992], ["weight", 997], ["in", 1004], ["mice", 1007], [".", 1011], ["In", 1013], ["addition", 1016], [",", 1024], ["diet", 1026], ["-", 1030], ["induced", 1031], ["obesity", 1039], ["and", 1047], ["insulin", 1051], ["resistance", 1059], ["are", 1070], ["exacerbated", 1074], ["in", 1086], ["GFRAL", 1089], ["-", 1094], ["deficient", 1095], ["mice", 1105], [",", 1109], ["suggesting", 1111], ["a", 1122], ["homeostatic", 1124], ["role", 1136], ["for", 1141], ["this", 1145], ["receptor", 1150], ["in", 1159], ["metabolism", 1162], [".", 1172], ["Finally", 1174], [",", 1181], ["we", 1183], ["demonstrate", 1186], ["that", 1198], ["GDF15-induced", 1203], ["cell", 1217], ["signaling", 1222], ["requires", 1232], ["the", 1241], ["interaction", 1245], ["of", 1257], ["GFRAL", 1260], ["with", 1266], ["the", 1271], ["coreceptor", 1275], ["RET", 1286], [".", 1289], ["Our", 1291], ["data", 1295], ["identify", 1300], ["GFRAL", 1309], ["as", 1315], ["a", 1318], ["new", 1320], ["regulator", 1324], ["of", 1334], ["body", 1337], ["weight", 1342], ["and", 1349], ["as", 1353], ["the", 1356], ["bona", 1360], ["fide", 1365], ["receptor", 1370], ["mediating", 1379], ["the", 1389], ["metabolic", 1393], ["effects", 1403], ["of", 1411], ["GDF15", 1414], [",", 1419], ["enabling", 1421], ["a", 1430], ["more", 1432], ["comprehensive", 1437], ["assessment", 1451], ["of", 1462], ["GDF15", 1465], ["as", 1471], ["a", 1474], ["potential", 1476], ["pharmacotherapy", 1486], ["for", 1502], ["the", 1506], ["treatment", 1510], ["of", 1520], ["obesity", 1523], [".", 1530]]}
{"context": "The discovery of the Hippo pathway can be traced back to two areas of research. Genetic screens in fruit flies led to the identification of the Hippo pathway kinases and scaffolding proteins that function together to suppress cell proliferation and tumor growth. Independent research, often in the context of muscle biology, described Tead (TEA domain) transcription factors, which bind CATTCC DNA motifs to regulate gene expression. These two research areas were joined by the finding that the Hippo pathway regulates the activity of Tead transcription factors mainly through phosphorylation of the transcriptional coactivators Yap and Taz, which bind to and activate Teads. Additionally, many other signal transduction proteins crosstalk to members of the Hippo pathway forming a Hippo signal transduction network. We discuss evidence that the Hippo signal transduction network plays important roles in myogenesis, regeneration, muscular dystrophy, and rhabdomyosarcoma in skeletal muscle, as well as in myogenesis, organ size control, and regeneration of the heart. Understanding the role of Hippo kinases in skeletal and heart muscle physiology could have important implications for translational research.", "qas": [{"question": "Which are the coactivators of the Yes-associated protein (yap)?", "answers": ["Tead (TEA domain) transcription factors."], "qid": "42652e9339554e27af6c273cfd698386", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["coactivators", 14], ["of", 27], ["the", 30], ["Yes", 34], ["-", 37], ["associated", 38], ["protein", 49], ["(", 57], ["yap", 58], [")", 61], ["?", 62]], "detected_answers": [{"text": "Tead (TEA domain) transcription factors.", "token_spans": [[56, 62]], "char_spans": [[335, 373]]}]}], "context_tokens": [["The", 0], ["discovery", 4], ["of", 14], ["the", 17], ["Hippo", 21], ["pathway", 27], ["can", 35], ["be", 39], ["traced", 42], ["back", 49], ["to", 54], ["two", 57], ["areas", 61], ["of", 67], ["research", 70], [".", 78], ["Genetic", 80], ["screens", 88], ["in", 96], ["fruit", 99], ["flies", 105], ["led", 111], ["to", 115], ["the", 118], ["identification", 122], ["of", 137], ["the", 140], ["Hippo", 144], ["pathway", 150], ["kinases", 158], ["and", 166], ["scaffolding", 170], ["proteins", 182], ["that", 191], ["function", 196], ["together", 205], ["to", 214], ["suppress", 217], ["cell", 226], ["proliferation", 231], ["and", 245], ["tumor", 249], ["growth", 255], [".", 261], ["Independent", 263], ["research", 275], [",", 283], ["often", 285], ["in", 291], ["the", 294], ["context", 298], ["of", 306], ["muscle", 309], ["biology", 316], [",", 323], ["described", 325], ["Tead", 335], ["(", 340], ["TEA", 341], ["domain", 345], [")", 351], ["transcription", 353], ["factors", 367], [",", 374], ["which", 376], ["bind", 382], ["CATTCC", 387], ["DNA", 394], ["motifs", 398], ["to", 405], ["regulate", 408], ["gene", 417], ["expression", 422], [".", 432], ["These", 434], ["two", 440], ["research", 444], ["areas", 453], ["were", 459], ["joined", 464], ["by", 471], ["the", 474], ["finding", 478], ["that", 486], ["the", 491], ["Hippo", 495], ["pathway", 501], ["regulates", 509], ["the", 519], ["activity", 523], ["of", 532], ["Tead", 535], ["transcription", 540], ["factors", 554], ["mainly", 562], ["through", 569], ["phosphorylation", 577], ["of", 593], ["the", 596], ["transcriptional", 600], ["coactivators", 616], ["Yap", 629], ["and", 633], ["Taz", 637], [",", 640], ["which", 642], ["bind", 648], ["to", 653], ["and", 656], ["activate", 660], ["Teads", 669], [".", 674], ["Additionally", 676], [",", 688], ["many", 690], ["other", 695], ["signal", 701], ["transduction", 708], ["proteins", 721], ["crosstalk", 730], ["to", 740], ["members", 743], ["of", 751], ["the", 754], ["Hippo", 758], ["pathway", 764], ["forming", 772], ["a", 780], ["Hippo", 782], ["signal", 788], ["transduction", 795], ["network", 808], [".", 815], ["We", 817], ["discuss", 820], ["evidence", 828], ["that", 837], ["the", 842], ["Hippo", 846], ["signal", 852], ["transduction", 859], ["network", 872], ["plays", 880], ["important", 886], ["roles", 896], ["in", 902], ["myogenesis", 905], [",", 915], ["regeneration", 917], [",", 929], ["muscular", 931], ["dystrophy", 940], [",", 949], ["and", 951], ["rhabdomyosarcoma", 955], ["in", 972], ["skeletal", 975], ["muscle", 984], [",", 990], ["as", 992], ["well", 995], ["as", 1000], ["in", 1003], ["myogenesis", 1006], [",", 1016], ["organ", 1018], ["size", 1024], ["control", 1029], [",", 1036], ["and", 1038], ["regeneration", 1042], ["of", 1055], ["the", 1058], ["heart", 1062], [".", 1067], ["Understanding", 1069], ["the", 1083], ["role", 1087], ["of", 1092], ["Hippo", 1095], ["kinases", 1101], ["in", 1109], ["skeletal", 1112], ["and", 1121], ["heart", 1125], ["muscle", 1131], ["physiology", 1138], ["could", 1149], ["have", 1155], ["important", 1160], ["implications", 1170], ["for", 1183], ["translational", 1187], ["research", 1201], [".", 1209]]}
{"context": "The organic cation transporter 3 (OCT3) is a widely expressed transporter for endogenous and exogenous organic cations. Of particular interest is OCT3 expression and function in the brain, where it plays a role in serotonin clearance and influences mood and behavior. Protein kinase signaling mediates rapid modulation of cerebral processes, but little is known about acute regulation of OCT3 by protein kinases. Therefore, we cloned mouse OCT3 (mOCT3) and generated a human embryonic kidney cell line stably expressing the transporter to study transport characteristics, acute regulation by protein kinases, and interaction with psychotropic drugs. Uptake measurement was performed using the fluorescent cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP(+), 1\u00a0\u03bcM) as a substrate. The translational value of these findings was determined by comparing results obtained with cloned mouse and human OCT3. mOCT3-mediated transport is membrane potential dependent and pH independent. ASP(+) uptake by mOCT3 and human OCT3 (hOCT3) was efficiently inhibited by 1-methyl-4-phenylpyridinium, tetrapentylammonium (TPA(+)), corticosterone, serotonin, and histamine and by the drugs ketamine, fluoxetine, and diazepam. The half maximal inhibitory concentrations of mOCT3 and hOCT3 for TPA(+), serotonin, diazepam, and ketamine are significantly different. Diazepam is a non-transported inhibitor. Furthermore, the activities of mOCT3 and hOCT3 are acutely regulated by the p56 (lck) tyrosine kinase by decreasing their V max. Studies with freshly isolated renal proximal tubules from mOCT1/2(-/-) mice, in which mOCT3 is the only OCT present, confirmed this regulation pathway. Only the activity of hOCT3 is regulated by calmodulin. These findings suggest that even though many transport properties of mOCT3 and hOCT3 are similar, there are also species-specific aspects of OCT3 function.", "qas": [{"question": "How is OCT3 associated with serotonin?", "answers": ["serotonin clearance"], "qid": "bf90e54a60234266b05dd70fed882e86", "question_tokens": [["How", 0], ["is", 4], ["OCT3", 7], ["associated", 12], ["with", 23], ["serotonin", 28], ["?", 37]], "detected_answers": [{"text": "serotonin clearance", "token_spans": [[38, 39]], "char_spans": [[214, 232]]}]}], "context_tokens": [["The", 0], ["organic", 4], ["cation", 12], ["transporter", 19], ["3", 31], ["(", 33], ["OCT3", 34], [")", 38], ["is", 40], ["a", 43], ["widely", 45], ["expressed", 52], ["transporter", 62], ["for", 74], ["endogenous", 78], ["and", 89], ["exogenous", 93], ["organic", 103], ["cations", 111], [".", 118], ["Of", 120], ["particular", 123], ["interest", 134], ["is", 143], ["OCT3", 146], ["expression", 151], ["and", 162], ["function", 166], ["in", 175], ["the", 178], ["brain", 182], [",", 187], ["where", 189], ["it", 195], ["plays", 198], ["a", 204], ["role", 206], ["in", 211], ["serotonin", 214], ["clearance", 224], ["and", 234], ["influences", 238], ["mood", 249], ["and", 254], ["behavior", 258], [".", 266], ["Protein", 268], ["kinase", 276], ["signaling", 283], ["mediates", 293], ["rapid", 302], ["modulation", 308], ["of", 319], ["cerebral", 322], ["processes", 331], [",", 340], ["but", 342], ["little", 346], ["is", 353], ["known", 356], ["about", 362], ["acute", 368], ["regulation", 374], ["of", 385], ["OCT3", 388], ["by", 393], ["protein", 396], ["kinases", 404], [".", 411], ["Therefore", 413], [",", 422], ["we", 424], ["cloned", 427], ["mouse", 434], ["OCT3", 440], ["(", 445], ["mOCT3", 446], [")", 451], ["and", 453], ["generated", 457], ["a", 467], ["human", 469], ["embryonic", 475], ["kidney", 485], ["cell", 492], ["line", 497], ["stably", 502], ["expressing", 509], ["the", 520], ["transporter", 524], ["to", 536], ["study", 539], ["transport", 545], ["characteristics", 555], [",", 570], ["acute", 572], ["regulation", 578], ["by", 589], ["protein", 592], ["kinases", 600], [",", 607], ["and", 609], ["interaction", 613], ["with", 625], ["psychotropic", 630], ["drugs", 643], [".", 648], ["Uptake", 650], ["measurement", 657], ["was", 669], ["performed", 673], ["using", 683], ["the", 689], ["fluorescent", 693], ["cation", 705], ["4-(4-(dimethylamino)styryl)-N", 712], ["-", 741], ["methylpyridinium", 742], ["iodide", 759], ["(", 766], ["ASP(+", 767], [")", 772], [",", 773], ["1", 775], ["\u03bcM", 777], [")", 779], ["as", 781], ["a", 784], ["substrate", 786], [".", 795], ["The", 797], ["translational", 801], ["value", 815], ["of", 821], ["these", 824], ["findings", 830], ["was", 839], ["determined", 843], ["by", 854], ["comparing", 857], ["results", 867], ["obtained", 875], ["with", 884], ["cloned", 889], ["mouse", 896], ["and", 902], ["human", 906], ["OCT3", 912], [".", 916], ["mOCT3-mediated", 918], ["transport", 933], ["is", 943], ["membrane", 946], ["potential", 955], ["dependent", 965], ["and", 975], ["pH", 979], ["independent", 982], [".", 993], ["ASP(+", 995], [")", 1000], ["uptake", 1002], ["by", 1009], ["mOCT3", 1012], ["and", 1018], ["human", 1022], ["OCT3", 1028], ["(", 1033], ["hOCT3", 1034], [")", 1039], ["was", 1041], ["efficiently", 1045], ["inhibited", 1057], ["by", 1067], ["1-methyl-4-phenylpyridinium", 1070], [",", 1097], ["tetrapentylammonium", 1099], ["(", 1119], ["TPA(+", 1120], [")", 1125], [")", 1126], [",", 1127], ["corticosterone", 1129], [",", 1143], ["serotonin", 1145], [",", 1154], ["and", 1156], ["histamine", 1160], ["and", 1170], ["by", 1174], ["the", 1177], ["drugs", 1181], ["ketamine", 1187], [",", 1195], ["fluoxetine", 1197], [",", 1207], ["and", 1209], ["diazepam", 1213], [".", 1221], ["The", 1223], ["half", 1227], ["maximal", 1232], ["inhibitory", 1240], ["concentrations", 1251], ["of", 1266], ["mOCT3", 1269], ["and", 1275], ["hOCT3", 1279], ["for", 1285], ["TPA(+", 1289], [")", 1294], [",", 1295], ["serotonin", 1297], [",", 1306], ["diazepam", 1308], [",", 1316], ["and", 1318], ["ketamine", 1322], ["are", 1331], ["significantly", 1335], ["different", 1349], [".", 1358], ["Diazepam", 1360], ["is", 1369], ["a", 1372], ["non", 1374], ["-", 1377], ["transported", 1378], ["inhibitor", 1390], [".", 1399], ["Furthermore", 1401], [",", 1412], ["the", 1414], ["activities", 1418], ["of", 1429], ["mOCT3", 1432], ["and", 1438], ["hOCT3", 1442], ["are", 1448], ["acutely", 1452], ["regulated", 1460], ["by", 1470], ["the", 1473], ["p56", 1477], ["(", 1481], ["lck", 1482], [")", 1485], ["tyrosine", 1487], ["kinase", 1496], ["by", 1503], ["decreasing", 1506], ["their", 1517], ["V", 1523], ["max", 1525], [".", 1528], ["Studies", 1530], ["with", 1538], ["freshly", 1543], ["isolated", 1551], ["renal", 1560], ["proximal", 1566], ["tubules", 1575], ["from", 1583], ["mOCT1/2(-/-", 1588], [")", 1599], ["mice", 1601], [",", 1605], ["in", 1607], ["which", 1610], ["mOCT3", 1616], ["is", 1622], ["the", 1625], ["only", 1629], ["OCT", 1634], ["present", 1638], [",", 1645], ["confirmed", 1647], ["this", 1657], ["regulation", 1662], ["pathway", 1673], [".", 1680], ["Only", 1682], ["the", 1687], ["activity", 1691], ["of", 1700], ["hOCT3", 1703], ["is", 1709], ["regulated", 1712], ["by", 1722], ["calmodulin", 1725], [".", 1735], ["These", 1737], ["findings", 1743], ["suggest", 1752], ["that", 1760], ["even", 1765], ["though", 1770], ["many", 1777], ["transport", 1782], ["properties", 1792], ["of", 1803], ["mOCT3", 1806], ["and", 1812], ["hOCT3", 1816], ["are", 1822], ["similar", 1826], [",", 1833], ["there", 1835], ["are", 1841], ["also", 1845], ["species", 1850], ["-", 1857], ["specific", 1858], ["aspects", 1867], ["of", 1875], ["OCT3", 1878], ["function", 1883], [".", 1891]]}
{"context": "Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affinity in a 1:1 molar ratio. We investigated the safety, tolerability, and efficacy of increasing doses of idarucizumab for the reversal of anticoagulant effects of dabigatran in a two-part phase 1 study (rising-dose assessment and dose-finding, proof-of-concept investigation). Here we present the results of the proof-of-concept part of the study. In this randomised, placebo-controlled, double-blind, proof-of-concept phase 1 study, we enrolled healthy volunteers (aged 18-45 years) with a body-mass index of 18\u00b75-29\u00b79 kg/m(2) into one of four dose groups at SGS Life Sciences Clinical Research Services, Belgium. Participants were randomly assigned within groups in a 3:1 ratio to idarucizumab or placebo using a pseudorandom number generator and a supplied seed number. Participants and care providers were masked to treatment assignment. All participants received oral dabigatran etexilate 220 mg twice daily for 3 days and a final dose on day 4. Idarucizumab (1 g, 2 g, or 4 g 5-min infusion, or 5 g plus 2\u00b75 g in two 5-min infusions given 1 h apart) was administered about 2 h after the final dabigatran etexilate dose. The primary endpoint was incidence of drug-related adverse events, analysed in all randomly assigned participants who received at least one dose of dabigatran etexilate. Reversal of diluted thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (TT) were secondary endpoints assessed by measuring the area under the effect curve from 2 h to 12 h (AUEC2-12) after dabigatran etexilate ingestion on days 3 and 4. This trial is registered with ClinicalTrials.gov, number NCT01688830. Between Feb 23, and Nov 29, 2013, 47 men completed this part of the study. 12 were enrolled into each of the 1 g, 2 g, or 5 g plus 2\u00b75 g idarucizumab groups (nine to idarucizumab and three to placebo in each group), and 11 were enrolled into the 4 g idarucizumab group (eight to idarucizumab and three to placebo). Drug-related adverse events were all of mild intensity and reported in seven participants: one in the 1 g idarucizumab group (infusion site erythema and hot flushes), one in the 5 g plus 2\u00b75 g idarucizumab group (epistaxis); one receiving placebo (infusion site haematoma), and four during dabigatran etexilate pretreatment (three haematuria and one epistaxis). Idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 AUEC2-12 to day 3 AUEC2-12 for dTT was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction). No serious or severe adverse events were reported, no adverse event led to discontinuation of treatment, and no clinically relevant difference in incidence of adverse events was noted between treatment groups. These phase 1 results show that idarucizumab was associated with immediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy men, and was well tolerated with no unexpected or clinically relevant safety concerns, supporting further testing. Further clinical studies are in progress. Boehringer Ingelheim Pharma GmbH & Co KG.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2997ce0116fe4da1afc9fa4cdf7e48d6", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[267, 267], [474, 474], [490, 490], [324, 324], [39, 39], [184, 184], [8, 8], [238, 238], [623, 623]], "char_spans": [[1357, 1366], [2353, 2362], [2474, 2483], [1630, 1639], [246, 255], [956, 965], [58, 67], [1182, 1191], [3132, 3141]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["monoclonal", 18], ["antibody", 29], ["fragment", 38], ["that", 47], ["binds", 52], ["dabigatran", 58], ["with", 69], ["high", 74], ["affinity", 79], ["in", 88], ["a", 91], ["1:1", 93], ["molar", 97], ["ratio", 103], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["safety", 130], [",", 136], ["tolerability", 138], [",", 150], ["and", 152], ["efficacy", 156], ["of", 165], ["increasing", 168], ["doses", 179], ["of", 185], ["idarucizumab", 188], ["for", 201], ["the", 205], ["reversal", 209], ["of", 218], ["anticoagulant", 221], ["effects", 235], ["of", 243], ["dabigatran", 246], ["in", 257], ["a", 260], ["two", 262], ["-", 265], ["part", 266], ["phase", 271], ["1", 277], ["study", 279], ["(", 285], ["rising", 286], ["-", 292], ["dose", 293], ["assessment", 298], ["and", 309], ["dose", 313], ["-", 317], ["finding", 318], [",", 325], ["proof", 327], ["-", 332], ["of", 333], ["-", 335], ["concept", 336], ["investigation", 344], [")", 357], [".", 358], ["Here", 360], ["we", 365], ["present", 368], ["the", 376], ["results", 380], ["of", 388], ["the", 391], ["proof", 395], ["-", 400], ["of", 401], ["-", 403], ["concept", 404], ["part", 412], ["of", 417], ["the", 420], ["study", 424], [".", 429], ["In", 431], ["this", 434], ["randomised", 439], [",", 449], ["placebo", 451], ["-", 458], ["controlled", 459], [",", 469], ["double", 471], ["-", 477], ["blind", 478], [",", 483], ["proof", 485], ["-", 490], ["of", 491], ["-", 493], ["concept", 494], ["phase", 502], ["1", 508], ["study", 510], [",", 515], ["we", 517], ["enrolled", 520], ["healthy", 529], ["volunteers", 537], ["(", 548], ["aged", 549], ["18", 554], ["-", 556], ["45", 557], ["years", 560], [")", 565], ["with", 567], ["a", 572], ["body", 574], ["-", 578], ["mass", 579], ["index", 584], ["of", 590], ["18\u00b75", 593], ["-", 597], ["29\u00b79", 598], ["kg", 603], ["/", 605], ["m(2", 606], [")", 609], ["into", 611], ["one", 616], ["of", 620], ["four", 623], ["dose", 628], ["groups", 633], ["at", 640], ["SGS", 643], ["Life", 647], ["Sciences", 652], ["Clinical", 661], ["Research", 670], ["Services", 679], [",", 687], ["Belgium", 689], [".", 696], ["Participants", 698], ["were", 711], ["randomly", 716], ["assigned", 725], ["within", 734], ["groups", 741], ["in", 748], ["a", 751], ["3:1", 753], ["ratio", 757], ["to", 763], ["idarucizumab", 766], ["or", 779], ["placebo", 782], ["using", 790], ["a", 796], ["pseudorandom", 798], ["number", 811], ["generator", 818], ["and", 828], ["a", 832], ["supplied", 834], ["seed", 843], ["number", 848], [".", 854], ["Participants", 856], ["and", 869], ["care", 873], ["providers", 878], ["were", 888], ["masked", 893], ["to", 900], ["treatment", 903], ["assignment", 913], [".", 923], ["All", 925], ["participants", 929], ["received", 942], ["oral", 951], ["dabigatran", 956], ["etexilate", 967], ["220", 977], ["mg", 981], ["twice", 984], ["daily", 990], ["for", 996], ["3", 1000], ["days", 1002], ["and", 1007], ["a", 1011], ["final", 1013], ["dose", 1019], ["on", 1024], ["day", 1027], ["4", 1031], [".", 1032], ["Idarucizumab", 1034], ["(", 1047], ["1", 1048], ["g", 1050], [",", 1051], ["2", 1053], ["g", 1055], [",", 1056], ["or", 1058], ["4", 1061], ["g", 1063], ["5-min", 1065], ["infusion", 1071], [",", 1079], ["or", 1081], ["5", 1084], ["g", 1086], ["plus", 1088], ["2\u00b75", 1093], ["g", 1097], ["in", 1099], ["two", 1102], ["5-min", 1106], ["infusions", 1112], ["given", 1122], ["1", 1128], ["h", 1130], ["apart", 1132], [")", 1137], ["was", 1139], ["administered", 1143], ["about", 1156], ["2", 1162], ["h", 1164], ["after", 1166], ["the", 1172], ["final", 1176], ["dabigatran", 1182], ["etexilate", 1193], ["dose", 1203], [".", 1207], ["The", 1209], ["primary", 1213], ["endpoint", 1221], ["was", 1230], ["incidence", 1234], ["of", 1244], ["drug", 1247], ["-", 1251], ["related", 1252], ["adverse", 1260], ["events", 1268], [",", 1274], ["analysed", 1276], ["in", 1285], ["all", 1288], ["randomly", 1292], ["assigned", 1301], ["participants", 1310], ["who", 1323], ["received", 1327], ["at", 1336], ["least", 1339], ["one", 1345], ["dose", 1349], ["of", 1354], ["dabigatran", 1357], ["etexilate", 1368], [".", 1377], ["Reversal", 1379], ["of", 1388], ["diluted", 1391], ["thrombin", 1399], ["time", 1408], ["(", 1413], ["dTT", 1414], [")", 1417], [",", 1418], ["ecarin", 1420], ["clotting", 1427], ["time", 1436], ["(", 1441], ["ECT", 1442], [")", 1445], [",", 1446], ["activated", 1448], ["partial", 1458], ["thromboplastin", 1466], ["time", 1481], ["(", 1486], ["aPTT", 1487], [")", 1491], [",", 1492], ["and", 1494], ["thrombin", 1498], ["time", 1507], ["(", 1512], ["TT", 1513], [")", 1515], ["were", 1517], ["secondary", 1522], ["endpoints", 1532], ["assessed", 1542], ["by", 1551], ["measuring", 1554], ["the", 1564], ["area", 1568], ["under", 1573], ["the", 1579], ["effect", 1583], ["curve", 1590], ["from", 1596], ["2", 1601], ["h", 1603], ["to", 1605], ["12", 1608], ["h", 1611], ["(", 1613], ["AUEC2", 1614], ["-", 1619], ["12", 1620], [")", 1622], ["after", 1624], ["dabigatran", 1630], ["etexilate", 1641], ["ingestion", 1651], ["on", 1661], ["days", 1664], ["3", 1669], ["and", 1671], ["4", 1675], [".", 1676], ["This", 1678], ["trial", 1683], ["is", 1689], ["registered", 1692], ["with", 1703], ["ClinicalTrials.gov", 1708], [",", 1726], ["number", 1728], ["NCT01688830", 1735], [".", 1746], ["Between", 1748], ["Feb", 1756], ["23", 1760], [",", 1762], ["and", 1764], ["Nov", 1768], ["29", 1772], [",", 1774], ["2013", 1776], [",", 1780], ["47", 1782], ["men", 1785], ["completed", 1789], ["this", 1799], ["part", 1804], ["of", 1809], ["the", 1812], ["study", 1816], [".", 1821], ["12", 1823], ["were", 1826], ["enrolled", 1831], ["into", 1840], ["each", 1845], ["of", 1850], ["the", 1853], ["1", 1857], ["g", 1859], [",", 1860], ["2", 1862], ["g", 1864], [",", 1865], ["or", 1867], ["5", 1870], ["g", 1872], ["plus", 1874], ["2\u00b75", 1879], ["g", 1883], ["idarucizumab", 1885], ["groups", 1898], ["(", 1905], ["nine", 1906], ["to", 1911], ["idarucizumab", 1914], ["and", 1927], ["three", 1931], ["to", 1937], ["placebo", 1940], ["in", 1948], ["each", 1951], ["group", 1956], [")", 1961], [",", 1962], ["and", 1964], ["11", 1968], ["were", 1971], ["enrolled", 1976], ["into", 1985], ["the", 1990], ["4", 1994], ["g", 1996], ["idarucizumab", 1998], ["group", 2011], ["(", 2017], ["eight", 2018], ["to", 2024], ["idarucizumab", 2027], ["and", 2040], ["three", 2044], ["to", 2050], ["placebo", 2053], [")", 2060], [".", 2061], ["Drug", 2063], ["-", 2067], ["related", 2068], ["adverse", 2076], ["events", 2084], ["were", 2091], ["all", 2096], ["of", 2100], ["mild", 2103], ["intensity", 2108], ["and", 2118], ["reported", 2122], ["in", 2131], ["seven", 2134], ["participants", 2140], [":", 2152], ["one", 2154], ["in", 2158], ["the", 2161], ["1", 2165], ["g", 2167], ["idarucizumab", 2169], ["group", 2182], ["(", 2188], ["infusion", 2189], ["site", 2198], ["erythema", 2203], ["and", 2212], ["hot", 2216], ["flushes", 2220], [")", 2227], [",", 2228], ["one", 2230], ["in", 2234], ["the", 2237], ["5", 2241], ["g", 2243], ["plus", 2245], ["2\u00b75", 2250], ["g", 2254], ["idarucizumab", 2256], ["group", 2269], ["(", 2275], ["epistaxis", 2276], [")", 2285], [";", 2286], ["one", 2288], ["receiving", 2292], ["placebo", 2302], ["(", 2310], ["infusion", 2311], ["site", 2320], ["haematoma", 2325], [")", 2334], [",", 2335], ["and", 2337], ["four", 2341], ["during", 2346], ["dabigatran", 2353], ["etexilate", 2364], ["pretreatment", 2374], ["(", 2387], ["three", 2388], ["haematuria", 2394], ["and", 2405], ["one", 2409], ["epistaxis", 2413], [")", 2422], [".", 2423], ["Idarucizumab", 2425], ["immediately", 2438], ["and", 2450], ["completely", 2454], ["reversed", 2465], ["dabigatran", 2474], ["-", 2484], ["induced", 2485], ["anticoagulation", 2493], ["in", 2509], ["a", 2512], ["dose", 2514], ["-", 2518], ["dependent", 2519], ["manner", 2529], [";", 2535], ["the", 2537], ["mean", 2541], ["ratio", 2546], ["of", 2552], ["day", 2555], ["4", 2559], ["AUEC2", 2561], ["-", 2566], ["12", 2567], ["to", 2570], ["day", 2573], ["3", 2577], ["AUEC2", 2579], ["-", 2584], ["12", 2585], ["for", 2588], ["dTT", 2592], ["was", 2596], ["1\u00b701", 2600], ["with", 2605], ["placebo", 2610], [",", 2617], ["0\u00b726", 2619], ["with", 2624], ["1", 2629], ["g", 2631], ["idarucizumab", 2633], ["(", 2646], ["74", 2647], ["%", 2649], ["reduction", 2651], [")", 2660], [",", 2661], ["0\u00b706", 2663], ["with", 2668], ["2", 2673], ["g", 2675], ["idarucizumab", 2677], ["(", 2690], ["94", 2691], ["%", 2693], ["reduction", 2695], [")", 2704], [",", 2705], ["0\u00b702", 2707], ["with", 2712], ["4", 2717], ["g", 2719], ["idarucizumab", 2721], ["(", 2734], ["98", 2735], ["%", 2737], ["reduction", 2739], [")", 2748], [",", 2749], ["and", 2751], ["0\u00b701", 2755], ["with", 2760], ["5", 2765], ["g", 2767], ["plus", 2769], ["2\u00b75", 2774], ["g", 2778], ["idarucizumab", 2780], ["(", 2793], ["99", 2794], ["%", 2796], ["reduction", 2798], [")", 2807], [".", 2808], ["No", 2810], ["serious", 2813], ["or", 2821], ["severe", 2824], ["adverse", 2831], ["events", 2839], ["were", 2846], ["reported", 2851], [",", 2859], ["no", 2861], ["adverse", 2864], ["event", 2872], ["led", 2878], ["to", 2882], ["discontinuation", 2885], ["of", 2901], ["treatment", 2904], [",", 2913], ["and", 2915], ["no", 2919], ["clinically", 2922], ["relevant", 2933], ["difference", 2942], ["in", 2953], ["incidence", 2956], ["of", 2966], ["adverse", 2969], ["events", 2977], ["was", 2984], ["noted", 2988], ["between", 2994], ["treatment", 3002], ["groups", 3012], [".", 3018], ["These", 3020], ["phase", 3026], ["1", 3032], ["results", 3034], ["show", 3042], ["that", 3047], ["idarucizumab", 3052], ["was", 3065], ["associated", 3069], ["with", 3080], ["immediate", 3085], [",", 3094], ["complete", 3096], [",", 3104], ["and", 3106], ["sustained", 3110], ["reversal", 3120], ["of", 3129], ["dabigatran", 3132], ["-", 3142], ["induced", 3143], ["anticoagulation", 3151], ["in", 3167], ["healthy", 3170], ["men", 3178], [",", 3181], ["and", 3183], ["was", 3187], ["well", 3191], ["tolerated", 3196], ["with", 3206], ["no", 3211], ["unexpected", 3214], ["or", 3225], ["clinically", 3228], ["relevant", 3239], ["safety", 3248], ["concerns", 3255], [",", 3263], ["supporting", 3265], ["further", 3276], ["testing", 3284], [".", 3291], ["Further", 3293], ["clinical", 3301], ["studies", 3310], ["are", 3318], ["in", 3322], ["progress", 3325], [".", 3333], ["Boehringer", 3335], ["Ingelheim", 3346], ["Pharma", 3356], ["GmbH", 3363], ["&", 3368], ["Co", 3370], ["KG", 3373], [".", 3375]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a small vessel disease of the brain caused by mutations in the NOTCH3 gene. CADASIL progresses, in some cases, to subcortical dementia with a particular cognitive impairment. Different diseases in the dementia spectrum share a central cholinergic and sensorimotor plasticity alteration. We aimed to study different intracortical circuits and sensorimotor plasticity in CADASIL patients using transcranial magnetic stimulation protocols, and to determine whether these characteristics correlated with the results of clinical neuropsychological evaluation. Ten CADASIL patients and 10 healthy subjects were included in the study. All subjects underwent a transcranial magnetic stimulation study examining different intracortical circuits. Sensorimotor plasticity was also assessed using a paired associative stimulation and extensive neuropsychological tests. CADASIL patients showed a lack of intracortical facilitation, short latency afferent inhibition and sensorimotor plasticity when compared with control subjects. CADASIL patients also showed an altered neuropsychological profile. Correlation between sensorimotor plasticity and neuropsychological alterations was observed in CADASIL patients. These results suggest that acetylcholine and glutamate could be involved in the dementia process in CADASIL and that abnormal sensorimotor plasticity correlates with the neuropsychological profile in CADASIL patients.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "27c99f3d44a94401b785406bd2f20967", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[25, 26]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["a", 104], ["small", 106], ["vessel", 112], ["disease", 119], ["of", 127], ["the", 130], ["brain", 134], ["caused", 140], ["by", 147], ["mutations", 150], ["in", 160], ["the", 163], ["NOTCH3", 167], ["gene", 174], [".", 178], ["CADASIL", 180], ["progresses", 188], [",", 198], ["in", 200], ["some", 203], ["cases", 208], [",", 213], ["to", 215], ["subcortical", 218], ["dementia", 230], ["with", 239], ["a", 244], ["particular", 246], ["cognitive", 257], ["impairment", 267], [".", 277], ["Different", 279], ["diseases", 289], ["in", 298], ["the", 301], ["dementia", 305], ["spectrum", 314], ["share", 323], ["a", 329], ["central", 331], ["cholinergic", 339], ["and", 351], ["sensorimotor", 355], ["plasticity", 368], ["alteration", 379], [".", 389], ["We", 391], ["aimed", 394], ["to", 400], ["study", 403], ["different", 409], ["intracortical", 419], ["circuits", 433], ["and", 442], ["sensorimotor", 446], ["plasticity", 459], ["in", 470], ["CADASIL", 473], ["patients", 481], ["using", 490], ["transcranial", 496], ["magnetic", 509], ["stimulation", 518], ["protocols", 530], [",", 539], ["and", 541], ["to", 545], ["determine", 548], ["whether", 558], ["these", 566], ["characteristics", 572], ["correlated", 588], ["with", 599], ["the", 604], ["results", 608], ["of", 616], ["clinical", 619], ["neuropsychological", 628], ["evaluation", 647], [".", 657], ["Ten", 659], ["CADASIL", 663], ["patients", 671], ["and", 680], ["10", 684], ["healthy", 687], ["subjects", 695], ["were", 704], ["included", 709], ["in", 718], ["the", 721], ["study", 725], [".", 730], ["All", 732], ["subjects", 736], ["underwent", 745], ["a", 755], ["transcranial", 757], ["magnetic", 770], ["stimulation", 779], ["study", 791], ["examining", 797], ["different", 807], ["intracortical", 817], ["circuits", 831], [".", 839], ["Sensorimotor", 841], ["plasticity", 854], ["was", 865], ["also", 869], ["assessed", 874], ["using", 883], ["a", 889], ["paired", 891], ["associative", 898], ["stimulation", 910], ["and", 922], ["extensive", 926], ["neuropsychological", 936], ["tests", 955], [".", 960], ["CADASIL", 962], ["patients", 970], ["showed", 979], ["a", 986], ["lack", 988], ["of", 993], ["intracortical", 996], ["facilitation", 1010], [",", 1022], ["short", 1024], ["latency", 1030], ["afferent", 1038], ["inhibition", 1047], ["and", 1058], ["sensorimotor", 1062], ["plasticity", 1075], ["when", 1086], ["compared", 1091], ["with", 1100], ["control", 1105], ["subjects", 1113], [".", 1121], ["CADASIL", 1123], ["patients", 1131], ["also", 1140], ["showed", 1145], ["an", 1152], ["altered", 1155], ["neuropsychological", 1163], ["profile", 1182], [".", 1189], ["Correlation", 1191], ["between", 1203], ["sensorimotor", 1211], ["plasticity", 1224], ["and", 1235], ["neuropsychological", 1239], ["alterations", 1258], ["was", 1270], ["observed", 1274], ["in", 1283], ["CADASIL", 1286], ["patients", 1294], [".", 1302], ["These", 1304], ["results", 1310], ["suggest", 1318], ["that", 1326], ["acetylcholine", 1331], ["and", 1345], ["glutamate", 1349], ["could", 1359], ["be", 1365], ["involved", 1368], ["in", 1377], ["the", 1380], ["dementia", 1384], ["process", 1393], ["in", 1401], ["CADASIL", 1404], ["and", 1412], ["that", 1416], ["abnormal", 1421], ["sensorimotor", 1430], ["plasticity", 1443], ["correlates", 1454], ["with", 1465], ["the", 1470], ["neuropsychological", 1474], ["profile", 1493], ["in", 1501], ["CADASIL", 1504], ["patients", 1512], [".", 1520]]}
{"context": "Given the potential clinical benefit of inhibiting Na+/Ca2+ exchanger (NCX) activity during myocardial ischemia reperfusion (I/R), pharmacological approaches have been pursued to both inhibit and clarify the importance of this exchanger. SEA0400 was reported to have a potent NCX selectivity. Thus, we examined the effect of SEA0400 on NCX currents and I/R induced intracellular Ca2+ overload in mouse ventricular myocytes using patch clamp techniques and fluorescence measurements. Ischemia significantly inhibited inward and outward NCX current (from -0.04+/-0.01 nA to 0 nA at -100 mV; from 0.23+/-0.08 nA to 0.11+/-0.03 nA at +50 mV, n=7), Subsequent reperfusion not only restored the current rapidly but enhanced the current amplitude obviously, especially the outward currents (from 0.23+/-0.08 nA to 0.49+/-0.12 nA at +50 mV, n=7). [Ca2+]i, expressed as the ratio of Fura-2 fluorescence intensity, increased to 138+/-7% (P<0.01) during ischemia and to 210+/-11% (P<0.01) after reperfusion. The change of NCX current and the increase of [Ca2+]i during I/R can be blocked by SEA0400 in a dose-dependent manner with an EC50 value of 31 nM and 28 nM for the inward and outward NCX current, respectively. The results suggested that SEA0400 is a potent NCX inhibitor, which can protect mouse cardiac myocytes from Ca2+ overload during I/R injuries.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "adf00e4aac1141ad956eda51c049bd02", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[59, 59], [11, 11], [181, 181], [219, 219], [88, 88], [232, 232], [47, 47]], "char_spans": [[336, 338], [71, 73], [1011, 1013], [1180, 1182], [535, 537], [1254, 1256], [276, 278]]}]}], "context_tokens": [["Given", 0], ["the", 6], ["potential", 10], ["clinical", 20], ["benefit", 29], ["of", 37], ["inhibiting", 40], ["Na+/Ca2", 51], ["+", 58], ["exchanger", 60], ["(", 70], ["NCX", 71], [")", 74], ["activity", 76], ["during", 85], ["myocardial", 92], ["ischemia", 103], ["reperfusion", 112], ["(", 124], ["I", 125], ["/", 126], ["R", 127], [")", 128], [",", 129], ["pharmacological", 131], ["approaches", 147], ["have", 158], ["been", 163], ["pursued", 168], ["to", 176], ["both", 179], ["inhibit", 184], ["and", 192], ["clarify", 196], ["the", 204], ["importance", 208], ["of", 219], ["this", 222], ["exchanger", 227], [".", 236], ["SEA0400", 238], ["was", 246], ["reported", 250], ["to", 259], ["have", 262], ["a", 267], ["potent", 269], ["NCX", 276], ["selectivity", 280], [".", 291], ["Thus", 293], [",", 297], ["we", 299], ["examined", 302], ["the", 311], ["effect", 315], ["of", 322], ["SEA0400", 325], ["on", 333], ["NCX", 336], ["currents", 340], ["and", 349], ["I", 353], ["/", 354], ["R", 355], ["induced", 357], ["intracellular", 365], ["Ca2", 379], ["+", 382], ["overload", 384], ["in", 393], ["mouse", 396], ["ventricular", 402], ["myocytes", 414], ["using", 423], ["patch", 429], ["clamp", 435], ["techniques", 441], ["and", 452], ["fluorescence", 456], ["measurements", 469], [".", 481], ["Ischemia", 483], ["significantly", 492], ["inhibited", 506], ["inward", 516], ["and", 523], ["outward", 527], ["NCX", 535], ["current", 539], ["(", 547], ["from", 548], ["-0.04+/-0.01", 553], ["nA", 566], ["to", 569], ["0", 572], ["nA", 574], ["at", 577], ["-100", 580], ["mV", 585], [";", 587], ["from", 589], ["0.23+/-0.08", 594], ["nA", 606], ["to", 609], ["0.11+/-0.03", 612], ["nA", 624], ["at", 627], ["+50", 630], ["mV", 634], [",", 636], ["n=7", 638], [")", 641], [",", 642], ["Subsequent", 644], ["reperfusion", 655], ["not", 667], ["only", 671], ["restored", 676], ["the", 685], ["current", 689], ["rapidly", 697], ["but", 705], ["enhanced", 709], ["the", 718], ["current", 722], ["amplitude", 730], ["obviously", 740], [",", 749], ["especially", 751], ["the", 762], ["outward", 766], ["currents", 774], ["(", 783], ["from", 784], ["0.23+/-0.08", 789], ["nA", 801], ["to", 804], ["0.49+/-0.12", 807], ["nA", 819], ["at", 822], ["+50", 825], ["mV", 829], [",", 831], ["n=7", 833], [")", 836], [".", 837], ["[", 839], ["Ca2+]i", 840], [",", 846], ["expressed", 848], ["as", 858], ["the", 861], ["ratio", 865], ["of", 871], ["Fura-2", 874], ["fluorescence", 881], ["intensity", 894], [",", 903], ["increased", 905], ["to", 915], ["138+/-7", 918], ["%", 925], ["(", 927], ["P<0.01", 928], [")", 934], ["during", 936], ["ischemia", 943], ["and", 952], ["to", 956], ["210+/-11", 959], ["%", 967], ["(", 969], ["P<0.01", 970], [")", 976], ["after", 978], ["reperfusion", 984], [".", 995], ["The", 997], ["change", 1001], ["of", 1008], ["NCX", 1011], ["current", 1015], ["and", 1023], ["the", 1027], ["increase", 1031], ["of", 1040], ["[", 1043], ["Ca2+]i", 1044], ["during", 1051], ["I", 1058], ["/", 1059], ["R", 1060], ["can", 1062], ["be", 1066], ["blocked", 1069], ["by", 1077], ["SEA0400", 1080], ["in", 1088], ["a", 1091], ["dose", 1093], ["-", 1097], ["dependent", 1098], ["manner", 1108], ["with", 1115], ["an", 1120], ["EC50", 1123], ["value", 1128], ["of", 1134], ["31", 1137], ["nM", 1140], ["and", 1143], ["28", 1147], ["nM", 1150], ["for", 1153], ["the", 1157], ["inward", 1161], ["and", 1168], ["outward", 1172], ["NCX", 1180], ["current", 1184], [",", 1191], ["respectively", 1193], [".", 1205], ["The", 1207], ["results", 1211], ["suggested", 1219], ["that", 1229], ["SEA0400", 1234], ["is", 1242], ["a", 1245], ["potent", 1247], ["NCX", 1254], ["inhibitor", 1258], [",", 1267], ["which", 1269], ["can", 1275], ["protect", 1279], ["mouse", 1287], ["cardiac", 1293], ["myocytes", 1301], ["from", 1310], ["Ca2", 1315], ["+", 1318], ["overload", 1320], ["during", 1329], ["I", 1336], ["/", 1337], ["R", 1338], ["injuries", 1340], [".", 1348]]}
{"context": "Recombinant tissue plasminogen activator (rT-PA) is an effective treatment for acute ischaemic stroke when given within 3h of symptom onset but can be delayed as patients wait for a diagnosis. The ROSIER assessment tool (Fig. 1) has been found to be effective in diagnosing stroke but to date has only been tested when used by doctors. To compare registered nurses' ability to diagnose stroke using the ROSIER assessment tool with doctors' ability to diagnose stroke using traditional neurological assessment. A prospective audit of all suspected stroke patients (n=106) admitted to the stroke unit of a district general hospital over an eight month period, assessed by registered nurses trained to use the ROSIER assessment tool to identify stroke. Time from admission to the stroke unit until initial assessment by doctors and registered nurses. Comparison of initial diagnosis by doctors and registered nurses with final diagnosis by a consultant for stroke. Of 106 suspected stroke patients, 78 (73.5%) had a final diagnosis of stroke or transient ischaemic attack (TIA) and 28 (26.4%) had an alternative diagnosis. Six patients with TIA were subsequently excluded as they were asymptomatic at the time of assessment, leaving 100 participants in the validation phase of the study. Using the ROSIER tool registered nurses achieved a diagnostic sensitivity for stroke of 98% (95% confidence interval 88-99), positive predictive value (PPV) 83% (95% confidence interval 73-90). Doctors using standard neurological assessment had a similar diagnostic sensitivity of 94% (95% confidence interval 86-98), PPV 80% (95% confidence interval 70-88). The mean time from initial assessment by registered nurses using the ROSIER tool, until assessment by doctor on the stroke unit was 75 min (SD=65.8 min). Registered nurses working on a stroke unit using the ROSIER assessment tool are able to diagnose stroke with a degree of accuracy comparable to doctors using clinical neurological assessment. Prompt assessment of suspected stroke patients by registered nurses using the ROSIER tool could reduce delays in eligible stroke patients being assessed for rT-PA treatment.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "6f0bc4db6f3244efa75413fbbed77285", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[16, 16], [85, 85], [131, 131], [138, 138], [165, 165], [170, 170], [355, 355], [52, 52], [373, 373], [73, 73], [105, 105], [183, 183], [329, 329], [387, 387], [344, 344], [97, 97], [241, 241]], "char_spans": [[95, 100], [460, 465], [742, 747], [777, 782], [954, 959], [979, 984], [1895, 1900], [274, 279], [2021, 2026], [386, 391], [587, 592], [1032, 1037], [1760, 1765], [2112, 2117], [1829, 1834], [547, 552], [1363, 1368]]}]}], "context_tokens": [["Recombinant", 0], ["tissue", 12], ["plasminogen", 19], ["activator", 31], ["(", 41], ["rT", 42], ["-", 44], ["PA", 45], [")", 47], ["is", 49], ["an", 52], ["effective", 55], ["treatment", 65], ["for", 75], ["acute", 79], ["ischaemic", 85], ["stroke", 95], ["when", 102], ["given", 107], ["within", 113], ["3h", 120], ["of", 123], ["symptom", 126], ["onset", 134], ["but", 140], ["can", 144], ["be", 148], ["delayed", 151], ["as", 159], ["patients", 162], ["wait", 171], ["for", 176], ["a", 180], ["diagnosis", 182], [".", 191], ["The", 193], ["ROSIER", 197], ["assessment", 204], ["tool", 215], ["(", 220], ["Fig", 221], [".", 224], ["1", 226], [")", 227], ["has", 229], ["been", 233], ["found", 238], ["to", 244], ["be", 247], ["effective", 250], ["in", 260], ["diagnosing", 263], ["stroke", 274], ["but", 281], ["to", 285], ["date", 288], ["has", 293], ["only", 297], ["been", 302], ["tested", 307], ["when", 314], ["used", 319], ["by", 324], ["doctors", 327], [".", 334], ["To", 336], ["compare", 339], ["registered", 347], ["nurses", 358], ["'", 364], ["ability", 366], ["to", 374], ["diagnose", 377], ["stroke", 386], ["using", 393], ["the", 399], ["ROSIER", 403], ["assessment", 410], ["tool", 421], ["with", 426], ["doctors", 431], ["'", 438], ["ability", 440], ["to", 448], ["diagnose", 451], ["stroke", 460], ["using", 467], ["traditional", 473], ["neurological", 485], ["assessment", 498], [".", 508], ["A", 510], ["prospective", 512], ["audit", 524], ["of", 530], ["all", 533], ["suspected", 537], ["stroke", 547], ["patients", 554], ["(", 563], ["n=106", 564], [")", 569], ["admitted", 571], ["to", 580], ["the", 583], ["stroke", 587], ["unit", 594], ["of", 599], ["a", 602], ["district", 604], ["general", 613], ["hospital", 621], ["over", 630], ["an", 635], ["eight", 638], ["month", 644], ["period", 650], [",", 656], ["assessed", 658], ["by", 667], ["registered", 670], ["nurses", 681], ["trained", 688], ["to", 696], ["use", 699], ["the", 703], ["ROSIER", 707], ["assessment", 714], ["tool", 725], ["to", 730], ["identify", 733], ["stroke", 742], [".", 748], ["Time", 750], ["from", 755], ["admission", 760], ["to", 770], ["the", 773], ["stroke", 777], ["unit", 784], ["until", 789], ["initial", 795], ["assessment", 803], ["by", 814], ["doctors", 817], ["and", 825], ["registered", 829], ["nurses", 840], [".", 846], ["Comparison", 848], ["of", 859], ["initial", 862], ["diagnosis", 870], ["by", 880], ["doctors", 883], ["and", 891], ["registered", 895], ["nurses", 906], ["with", 913], ["final", 918], ["diagnosis", 924], ["by", 934], ["a", 937], ["consultant", 939], ["for", 950], ["stroke", 954], [".", 960], ["Of", 962], ["106", 965], ["suspected", 969], ["stroke", 979], ["patients", 986], [",", 994], ["78", 996], ["(", 999], ["73.5", 1000], ["%", 1004], [")", 1005], ["had", 1007], ["a", 1011], ["final", 1013], ["diagnosis", 1019], ["of", 1029], ["stroke", 1032], ["or", 1039], ["transient", 1042], ["ischaemic", 1052], ["attack", 1062], ["(", 1069], ["TIA", 1070], [")", 1073], ["and", 1075], ["28", 1079], ["(", 1082], ["26.4", 1083], ["%", 1087], [")", 1088], ["had", 1090], ["an", 1094], ["alternative", 1097], ["diagnosis", 1109], [".", 1118], ["Six", 1120], ["patients", 1124], ["with", 1133], ["TIA", 1138], ["were", 1142], ["subsequently", 1147], ["excluded", 1160], ["as", 1169], ["they", 1172], ["were", 1177], ["asymptomatic", 1182], ["at", 1195], ["the", 1198], ["time", 1202], ["of", 1207], ["assessment", 1210], [",", 1220], ["leaving", 1222], ["100", 1230], ["participants", 1234], ["in", 1247], ["the", 1250], ["validation", 1254], ["phase", 1265], ["of", 1271], ["the", 1274], ["study", 1278], [".", 1283], ["Using", 1285], ["the", 1291], ["ROSIER", 1295], ["tool", 1302], ["registered", 1307], ["nurses", 1318], ["achieved", 1325], ["a", 1334], ["diagnostic", 1336], ["sensitivity", 1347], ["for", 1359], ["stroke", 1363], ["of", 1370], ["98", 1373], ["%", 1375], ["(", 1377], ["95", 1378], ["%", 1380], ["confidence", 1382], ["interval", 1393], ["88", 1402], ["-", 1404], ["99", 1405], [")", 1407], [",", 1408], ["positive", 1410], ["predictive", 1419], ["value", 1430], ["(", 1436], ["PPV", 1437], [")", 1440], ["83", 1442], ["%", 1444], ["(", 1446], ["95", 1447], ["%", 1449], ["confidence", 1451], ["interval", 1462], ["73", 1471], ["-", 1473], ["90", 1474], [")", 1476], [".", 1477], ["Doctors", 1479], ["using", 1487], ["standard", 1493], ["neurological", 1502], ["assessment", 1515], ["had", 1526], ["a", 1530], ["similar", 1532], ["diagnostic", 1540], ["sensitivity", 1551], ["of", 1563], ["94", 1566], ["%", 1568], ["(", 1570], ["95", 1571], ["%", 1573], ["confidence", 1575], ["interval", 1586], ["86", 1595], ["-", 1597], ["98", 1598], [")", 1600], [",", 1601], ["PPV", 1603], ["80", 1607], ["%", 1609], ["(", 1611], ["95", 1612], ["%", 1614], ["confidence", 1616], ["interval", 1627], ["70", 1636], ["-", 1638], ["88", 1639], [")", 1641], [".", 1642], ["The", 1644], ["mean", 1648], ["time", 1653], ["from", 1658], ["initial", 1663], ["assessment", 1671], ["by", 1682], ["registered", 1685], ["nurses", 1696], ["using", 1703], ["the", 1709], ["ROSIER", 1713], ["tool", 1720], [",", 1724], ["until", 1726], ["assessment", 1732], ["by", 1743], ["doctor", 1746], ["on", 1753], ["the", 1756], ["stroke", 1760], ["unit", 1767], ["was", 1772], ["75", 1776], ["min", 1779], ["(", 1783], ["SD=65.8", 1784], ["min", 1792], [")", 1795], [".", 1796], ["Registered", 1798], ["nurses", 1809], ["working", 1816], ["on", 1824], ["a", 1827], ["stroke", 1829], ["unit", 1836], ["using", 1841], ["the", 1847], ["ROSIER", 1851], ["assessment", 1858], ["tool", 1869], ["are", 1874], ["able", 1878], ["to", 1883], ["diagnose", 1886], ["stroke", 1895], ["with", 1902], ["a", 1907], ["degree", 1909], ["of", 1916], ["accuracy", 1919], ["comparable", 1928], ["to", 1939], ["doctors", 1942], ["using", 1950], ["clinical", 1956], ["neurological", 1965], ["assessment", 1978], [".", 1988], ["Prompt", 1990], ["assessment", 1997], ["of", 2008], ["suspected", 2011], ["stroke", 2021], ["patients", 2028], ["by", 2037], ["registered", 2040], ["nurses", 2051], ["using", 2058], ["the", 2064], ["ROSIER", 2068], ["tool", 2075], ["could", 2080], ["reduce", 2086], ["delays", 2093], ["in", 2100], ["eligible", 2103], ["stroke", 2112], ["patients", 2119], ["being", 2128], ["assessed", 2134], ["for", 2143], ["rT", 2147], ["-", 2149], ["PA", 2150], ["treatment", 2153], [".", 2162]]}
{"context": "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. A special feature of the Sry gene is its ability to generate linear and circular transcripts, both transcribed in the sense orientation. Here we remark that both sense (e.g. Sry RNA) and antisense (e.g. CDR1as) transcripts could circularize and behave as miRNAs sponges, and importantly, that also protein-coding segments of mRNAs could also assume this role. Thus, it is reasonable to think that the linear Sry sense transcript could additionally act as a miRNA sponge, or as an endogenous competing RNA for miR-138.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "71b0e329f10047c39ece3b5149f7ae9c", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[52, 52], [153, 153]], "char_spans": [[284, 290], [826, 832]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["the", 10], ["sex", 14], ["determining", 18], ["region", 30], ["Y", 37], ["(", 39], ["Sry", 41], [")", 44], ["and", 46], ["the", 50], ["cerebellar", 54], ["degeneration", 65], ["-", 77], ["related", 78], ["protein", 86], ["1", 94], ["(", 96], ["CDR1as", 98], [")", 104], ["RNA", 106], ["transcripts", 110], ["have", 122], ["been", 127], ["described", 132], ["to", 142], ["function", 145], ["as", 154], ["a", 157], ["new", 159], ["class", 163], ["of", 169], ["post", 172], ["-", 176], ["transcriptional", 177], ["regulatory", 193], ["RNAs", 204], ["that", 209], ["behave", 214], ["as", 221], ["circular", 224], ["endogenous", 233], ["RNA", 244], ["sponges", 248], ["for", 256], ["the", 260], ["micro", 264], ["RNAs", 270], ["(", 275], ["miRNAs", 276], [")", 282], ["miR-138", 284], ["and", 292], ["miR-7", 296], [",", 301], ["respectively", 303], [".", 315], ["A", 317], ["special", 319], ["feature", 327], ["of", 335], ["the", 338], ["Sry", 342], ["gene", 346], ["is", 351], ["its", 354], ["ability", 358], ["to", 366], ["generate", 369], ["linear", 378], ["and", 385], ["circular", 389], ["transcripts", 398], [",", 409], ["both", 411], ["transcribed", 416], ["in", 428], ["the", 431], ["sense", 435], ["orientation", 441], [".", 452], ["Here", 454], ["we", 459], ["remark", 462], ["that", 469], ["both", 474], ["sense", 479], ["(", 485], ["e.g.", 486], ["Sry", 491], ["RNA", 495], [")", 498], ["and", 500], ["antisense", 504], ["(", 514], ["e.g.", 515], ["CDR1as", 520], [")", 526], ["transcripts", 528], ["could", 540], ["circularize", 546], ["and", 558], ["behave", 562], ["as", 569], ["miRNAs", 572], ["sponges", 579], [",", 586], ["and", 588], ["importantly", 592], [",", 603], ["that", 605], ["also", 610], ["protein", 615], ["-", 622], ["coding", 623], ["segments", 630], ["of", 639], ["mRNAs", 642], ["could", 648], ["also", 654], ["assume", 659], ["this", 666], ["role", 671], [".", 675], ["Thus", 677], [",", 681], ["it", 683], ["is", 686], ["reasonable", 689], ["to", 700], ["think", 703], ["that", 709], ["the", 714], ["linear", 718], ["Sry", 725], ["sense", 729], ["transcript", 735], ["could", 746], ["additionally", 752], ["act", 765], ["as", 769], ["a", 772], ["miRNA", 774], ["sponge", 780], [",", 786], ["or", 788], ["as", 791], ["an", 794], ["endogenous", 797], ["competing", 808], ["RNA", 818], ["for", 822], ["miR-138", 826], [".", 833]]}
{"context": "This article explains what methicillin-resistant Staphylococcus aureus (MRSA) is, how it is spread and what the real challenges are in healthcare settings in the UK. It explores the different strains of MRSA and points out the main ways to control their spread. It is intended to be a reference source for all nurses.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "2227001cc02f46f4b3d6c776d15071cd", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[37, 37], [10, 10]], "char_spans": [[203, 206], [72, 75]]}]}], "context_tokens": [["This", 0], ["article", 5], ["explains", 13], ["what", 22], ["methicillin", 27], ["-", 38], ["resistant", 39], ["Staphylococcus", 49], ["aureus", 64], ["(", 71], ["MRSA", 72], [")", 76], ["is", 78], [",", 80], ["how", 82], ["it", 86], ["is", 89], ["spread", 92], ["and", 99], ["what", 103], ["the", 108], ["real", 112], ["challenges", 117], ["are", 128], ["in", 132], ["healthcare", 135], ["settings", 146], ["in", 155], ["the", 158], ["UK", 162], [".", 164], ["It", 166], ["explores", 169], ["the", 178], ["different", 182], ["strains", 192], ["of", 200], ["MRSA", 203], ["and", 208], ["points", 212], ["out", 219], ["the", 223], ["main", 227], ["ways", 232], ["to", 237], ["control", 240], ["their", 248], ["spread", 254], [".", 260], ["It", 262], ["is", 265], ["intended", 268], ["to", 277], ["be", 280], ["a", 283], ["reference", 285], ["source", 295], ["for", 302], ["all", 306], ["nurses", 310], [".", 316]]}
{"context": "Interleukin-6 (IL-6) has emerged as a key factor in the pathogenesis of the atypical lymphoproliferative disorder Castleman's disease (CD). Siltuximab is a new anti-IL-6, chimeric monoclonal antibody with potential therapeutic benefit in patients with CD. We report interim results from an open-label, dose-finding, seven-cohort, phase I study in which patients with symptomatic, multicentric or unresectable, unicentric CD received siltuximab at 1-, 2-, or 3-week intervals. The main efficacy end point of clinical benefit response (CBR) was defined as a composite of clinical and laboratory measures relevant to the management of CD. In addition, radiologic response was independently assessed by using modified Cheson criteria. Eighteen (78%) of 23 patients (95% CI, 56% to 93%) achieved CBR, and 12 patients (52%) demonstrated objective tumor response. All 11 patients (95% CI, 72% to 100%) treated with the highest dose of 12 mg/kg achieved CBR, and eight patients (73%) achieved objective tumor response. Overall objective-response duration ranged from 44 to > or = 889 days, and one patient had complete response for > or = 318 days. Hemoglobin increased markedly in 19 patients (median increase, 2.1 g/dL; range, 0.2 to 4.7 g/dL) in the absence of transfusion or erythropoiesis-stimulating agents. No dose-limiting toxicity was reported, and only three patients had grade 3 or higher adverse events after a median exposure of 331 days (range, 1 to 1,148 days). These interim results strongly suggest that siltuximab is an effective treatment with favorable safety for the management of CD. An additional study is planned to fully evaluate safety and efficacy at the recommended dose of 12 mg/kg every 3 weeks.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "d7e76d475083479aa3e0f9111bc68897", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[0, 0]], "char_spans": [[0, 12]]}]}], "context_tokens": [["Interleukin-6", 0], ["(", 14], ["IL-6", 15], [")", 19], ["has", 21], ["emerged", 25], ["as", 33], ["a", 36], ["key", 38], ["factor", 42], ["in", 49], ["the", 52], ["pathogenesis", 56], ["of", 69], ["the", 72], ["atypical", 76], ["lymphoproliferative", 85], ["disorder", 105], ["Castleman", 114], ["'s", 123], ["disease", 126], ["(", 134], ["CD", 135], [")", 137], [".", 138], ["Siltuximab", 140], ["is", 151], ["a", 154], ["new", 156], ["anti", 160], ["-", 164], ["IL-6", 165], [",", 169], ["chimeric", 171], ["monoclonal", 180], ["antibody", 191], ["with", 200], ["potential", 205], ["therapeutic", 215], ["benefit", 227], ["in", 235], ["patients", 238], ["with", 247], ["CD", 252], [".", 254], ["We", 256], ["report", 259], ["interim", 266], ["results", 274], ["from", 282], ["an", 287], ["open", 290], ["-", 294], ["label", 295], [",", 300], ["dose", 302], ["-", 306], ["finding", 307], [",", 314], ["seven", 316], ["-", 321], ["cohort", 322], [",", 328], ["phase", 330], ["I", 336], ["study", 338], ["in", 344], ["which", 347], ["patients", 353], ["with", 362], ["symptomatic", 367], [",", 378], ["multicentric", 380], ["or", 393], ["unresectable", 396], [",", 408], ["unicentric", 410], ["CD", 421], ["received", 424], ["siltuximab", 433], ["at", 444], ["1-", 447], [",", 449], ["2-", 451], [",", 453], ["or", 455], ["3-week", 458], ["intervals", 465], [".", 474], ["The", 476], ["main", 480], ["efficacy", 485], ["end", 494], ["point", 498], ["of", 504], ["clinical", 507], ["benefit", 516], ["response", 524], ["(", 533], ["CBR", 534], [")", 537], ["was", 539], ["defined", 543], ["as", 551], ["a", 554], ["composite", 556], ["of", 566], ["clinical", 569], ["and", 578], ["laboratory", 582], ["measures", 593], ["relevant", 602], ["to", 611], ["the", 614], ["management", 618], ["of", 629], ["CD", 632], [".", 634], ["In", 636], ["addition", 639], [",", 647], ["radiologic", 649], ["response", 660], ["was", 669], ["independently", 673], ["assessed", 687], ["by", 696], ["using", 699], ["modified", 705], ["Cheson", 714], ["criteria", 721], [".", 729], ["Eighteen", 731], ["(", 740], ["78", 741], ["%", 743], [")", 744], ["of", 746], ["23", 749], ["patients", 752], ["(", 761], ["95", 762], ["%", 764], ["CI", 766], [",", 768], ["56", 770], ["%", 772], ["to", 774], ["93", 777], ["%", 779], [")", 780], ["achieved", 782], ["CBR", 791], [",", 794], ["and", 796], ["12", 800], ["patients", 803], ["(", 812], ["52", 813], ["%", 815], [")", 816], ["demonstrated", 818], ["objective", 831], ["tumor", 841], ["response", 847], [".", 855], ["All", 857], ["11", 861], ["patients", 864], ["(", 873], ["95", 874], ["%", 876], ["CI", 878], [",", 880], ["72", 882], ["%", 884], ["to", 886], ["100", 889], ["%", 892], [")", 893], ["treated", 895], ["with", 903], ["the", 908], ["highest", 912], ["dose", 920], ["of", 925], ["12", 928], ["mg", 931], ["/", 933], ["kg", 934], ["achieved", 937], ["CBR", 946], [",", 949], ["and", 951], ["eight", 955], ["patients", 961], ["(", 970], ["73", 971], ["%", 973], [")", 974], ["achieved", 976], ["objective", 985], ["tumor", 995], ["response", 1001], [".", 1009], ["Overall", 1011], ["objective", 1019], ["-", 1028], ["response", 1029], ["duration", 1038], ["ranged", 1047], ["from", 1054], ["44", 1059], ["to", 1062], [">", 1065], ["or", 1067], ["=", 1070], ["889", 1072], ["days", 1076], [",", 1080], ["and", 1082], ["one", 1086], ["patient", 1090], ["had", 1098], ["complete", 1102], ["response", 1111], ["for", 1120], [">", 1124], ["or", 1126], ["=", 1129], ["318", 1131], ["days", 1135], [".", 1139], ["Hemoglobin", 1141], ["increased", 1152], ["markedly", 1162], ["in", 1171], ["19", 1174], ["patients", 1177], ["(", 1186], ["median", 1187], ["increase", 1194], [",", 1202], ["2.1", 1204], ["g", 1208], ["/", 1209], ["dL", 1210], [";", 1212], ["range", 1214], [",", 1219], ["0.2", 1221], ["to", 1225], ["4.7", 1228], ["g", 1232], ["/", 1233], ["dL", 1234], [")", 1236], ["in", 1238], ["the", 1241], ["absence", 1245], ["of", 1253], ["transfusion", 1256], ["or", 1268], ["erythropoiesis", 1271], ["-", 1285], ["stimulating", 1286], ["agents", 1298], [".", 1304], ["No", 1306], ["dose", 1309], ["-", 1313], ["limiting", 1314], ["toxicity", 1323], ["was", 1332], ["reported", 1336], [",", 1344], ["and", 1346], ["only", 1350], ["three", 1355], ["patients", 1361], ["had", 1370], ["grade", 1374], ["3", 1380], ["or", 1382], ["higher", 1385], ["adverse", 1392], ["events", 1400], ["after", 1407], ["a", 1413], ["median", 1415], ["exposure", 1422], ["of", 1431], ["331", 1434], ["days", 1438], ["(", 1443], ["range", 1444], [",", 1449], ["1", 1451], ["to", 1453], ["1,148", 1456], ["days", 1462], [")", 1466], [".", 1467], ["These", 1469], ["interim", 1475], ["results", 1483], ["strongly", 1491], ["suggest", 1500], ["that", 1508], ["siltuximab", 1513], ["is", 1524], ["an", 1527], ["effective", 1530], ["treatment", 1540], ["with", 1550], ["favorable", 1555], ["safety", 1565], ["for", 1572], ["the", 1576], ["management", 1580], ["of", 1591], ["CD", 1594], [".", 1596], ["An", 1598], ["additional", 1601], ["study", 1612], ["is", 1618], ["planned", 1621], ["to", 1629], ["fully", 1632], ["evaluate", 1638], ["safety", 1647], ["and", 1654], ["efficacy", 1658], ["at", 1667], ["the", 1670], ["recommended", 1674], ["dose", 1686], ["of", 1691], ["12", 1694], ["mg", 1697], ["/", 1699], ["kg", 1700], ["every", 1703], ["3", 1709], ["weeks", 1711], [".", 1716]]}
{"context": "Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML). Because of the excellent hematologic and cytogenetic responses, imatinib has moved toward first-line treatment for newly diagnosed CML. However, the emergence of resistance to imatinib remains a major problem in the treatment of Ph-positive leukemia. Several mechanisms of imatinib resistance have been identified, including BCR-ABL gene amplification that leads to overexpression of the BCR-ABL protein, point mutations in the BCR-ABL kinase domain that interfere with imatinib binding, and point mutations outside of the kinase domain that allosterically inhibit imatinib binding to BCR-ABL. The need for alternative or additional treatment for imatinib-resistant BCR-ABL-positive leukemia has guided the way to the design of a second generation of targeted therapies, which has resulted mainly in the development of novel small-molecule inhibitors such as AMN107, dasatinib, NS-187, and ON012380. The major goal of these efforts is to create new compounds that are more potent than imatinib and/or more effective against imatinib-resistant BCR-ABL clones. In this review, we discuss the next generation of BCR-ABL kinase inhibitors for overcoming imatinib resistance.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "f60b00cd2c9944dc95889093639a4381", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[102, 104], [142, 144], [211, 213], [93, 95], [13, 15], [226, 228], [82, 84], [127, 129]], "char_spans": [[609, 615], [847, 853], [1224, 1230], [569, 575], [93, 99], [1290, 1296], [506, 512], [766, 772]]}]}], "context_tokens": [["Imatinib", 0], ["was", 9], ["developed", 13], ["as", 23], ["the", 26], ["first", 30], ["molecularly", 36], ["targeted", 48], ["therapy", 57], ["to", 65], ["specifically", 68], ["inhibit", 81], ["the", 89], ["BCR", 93], ["-", 96], ["ABL", 97], ["kinase", 101], ["in", 108], ["Philadelphia", 111], ["chromosome", 124], ["(", 135], ["Ph)-positive", 136], ["chronic", 149], ["myeloid", 157], ["leukemia", 165], ["(", 174], ["CML", 175], [")", 178], [".", 179], ["Because", 181], ["of", 189], ["the", 192], ["excellent", 196], ["hematologic", 206], ["and", 218], ["cytogenetic", 222], ["responses", 234], [",", 243], ["imatinib", 245], ["has", 254], ["moved", 258], ["toward", 264], ["first", 271], ["-", 276], ["line", 277], ["treatment", 282], ["for", 292], ["newly", 296], ["diagnosed", 302], ["CML", 312], [".", 315], ["However", 317], [",", 324], ["the", 326], ["emergence", 330], ["of", 340], ["resistance", 343], ["to", 354], ["imatinib", 357], ["remains", 366], ["a", 374], ["major", 376], ["problem", 382], ["in", 390], ["the", 393], ["treatment", 397], ["of", 407], ["Ph", 410], ["-", 412], ["positive", 413], ["leukemia", 422], [".", 430], ["Several", 432], ["mechanisms", 440], ["of", 451], ["imatinib", 454], ["resistance", 463], ["have", 474], ["been", 479], ["identified", 484], [",", 494], ["including", 496], ["BCR", 506], ["-", 509], ["ABL", 510], ["gene", 514], ["amplification", 519], ["that", 533], ["leads", 538], ["to", 544], ["overexpression", 547], ["of", 562], ["the", 565], ["BCR", 569], ["-", 572], ["ABL", 573], ["protein", 577], [",", 584], ["point", 586], ["mutations", 592], ["in", 602], ["the", 605], ["BCR", 609], ["-", 612], ["ABL", 613], ["kinase", 617], ["domain", 624], ["that", 631], ["interfere", 636], ["with", 646], ["imatinib", 651], ["binding", 660], [",", 667], ["and", 669], ["point", 673], ["mutations", 679], ["outside", 689], ["of", 697], ["the", 700], ["kinase", 704], ["domain", 711], ["that", 718], ["allosterically", 723], ["inhibit", 738], ["imatinib", 746], ["binding", 755], ["to", 763], ["BCR", 766], ["-", 769], ["ABL", 770], [".", 773], ["The", 775], ["need", 779], ["for", 784], ["alternative", 788], ["or", 800], ["additional", 803], ["treatment", 814], ["for", 824], ["imatinib", 828], ["-", 836], ["resistant", 837], ["BCR", 847], ["-", 850], ["ABL", 851], ["-", 854], ["positive", 855], ["leukemia", 864], ["has", 873], ["guided", 877], ["the", 884], ["way", 888], ["to", 892], ["the", 895], ["design", 899], ["of", 906], ["a", 909], ["second", 911], ["generation", 918], ["of", 929], ["targeted", 932], ["therapies", 941], [",", 950], ["which", 952], ["has", 958], ["resulted", 962], ["mainly", 971], ["in", 978], ["the", 981], ["development", 985], ["of", 997], ["novel", 1000], ["small", 1006], ["-", 1011], ["molecule", 1012], ["inhibitors", 1021], ["such", 1032], ["as", 1037], ["AMN107", 1040], [",", 1046], ["dasatinib", 1048], [",", 1057], ["NS-187", 1059], [",", 1065], ["and", 1067], ["ON012380", 1071], [".", 1079], ["The", 1081], ["major", 1085], ["goal", 1091], ["of", 1096], ["these", 1099], ["efforts", 1105], ["is", 1113], ["to", 1116], ["create", 1119], ["new", 1126], ["compounds", 1130], ["that", 1140], ["are", 1145], ["more", 1149], ["potent", 1154], ["than", 1161], ["imatinib", 1166], ["and/or", 1175], ["more", 1182], ["effective", 1187], ["against", 1197], ["imatinib", 1205], ["-", 1213], ["resistant", 1214], ["BCR", 1224], ["-", 1227], ["ABL", 1228], ["clones", 1232], [".", 1238], ["In", 1240], ["this", 1243], ["review", 1248], [",", 1254], ["we", 1256], ["discuss", 1259], ["the", 1267], ["next", 1271], ["generation", 1276], ["of", 1287], ["BCR", 1290], ["-", 1293], ["ABL", 1294], ["kinase", 1298], ["inhibitors", 1305], ["for", 1316], ["overcoming", 1320], ["imatinib", 1331], ["resistance", 1340], [".", 1350]]}
{"context": "Since the discovery of non-coding, small, highly structured, satellite RNAs (satRNAs) and viroids as subviral pathogens of plants , have been of great interest to molecular biologists as possible living fossils of pre-cellular evolution in an RNA world. Despite extensive studies performed in the last four decades, there is still mystery surrounding the origin and evolutionary relationship between these subviral pathogens. Recent technical advances revealed some commonly shared replication features between these two subviral pathogens. In this review, we discuss our current perception of replication and evolutionary origin of these petite RNA pathogens.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "0133a9c3b1f74db79d96f61d59105870", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[19, 19]], "char_spans": [[90, 96]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["discovery", 10], ["of", 20], ["non", 23], ["-", 26], ["coding", 27], [",", 33], ["small", 35], [",", 40], ["highly", 42], ["structured", 49], [",", 59], ["satellite", 61], ["RNAs", 71], ["(", 76], ["satRNAs", 77], [")", 84], ["and", 86], ["viroids", 90], ["as", 98], ["subviral", 101], ["pathogens", 110], ["of", 120], ["plants", 123], [",", 130], ["have", 132], ["been", 137], ["of", 142], ["great", 145], ["interest", 151], ["to", 160], ["molecular", 163], ["biologists", 173], ["as", 184], ["possible", 187], ["living", 196], ["fossils", 203], ["of", 211], ["pre", 214], ["-", 217], ["cellular", 218], ["evolution", 227], ["in", 237], ["an", 240], ["RNA", 243], ["world", 247], [".", 252], ["Despite", 254], ["extensive", 262], ["studies", 272], ["performed", 280], ["in", 290], ["the", 293], ["last", 297], ["four", 302], ["decades", 307], [",", 314], ["there", 316], ["is", 322], ["still", 325], ["mystery", 331], ["surrounding", 339], ["the", 351], ["origin", 355], ["and", 362], ["evolutionary", 366], ["relationship", 379], ["between", 392], ["these", 400], ["subviral", 406], ["pathogens", 415], [".", 424], ["Recent", 426], ["technical", 433], ["advances", 443], ["revealed", 452], ["some", 461], ["commonly", 466], ["shared", 475], ["replication", 482], ["features", 494], ["between", 503], ["these", 511], ["two", 517], ["subviral", 521], ["pathogens", 530], [".", 539], ["In", 541], ["this", 544], ["review", 549], [",", 555], ["we", 557], ["discuss", 560], ["our", 568], ["current", 572], ["perception", 580], ["of", 591], ["replication", 594], ["and", 606], ["evolutionary", 610], ["origin", 623], ["of", 630], ["these", 633], ["petite", 639], ["RNA", 646], ["pathogens", 650], [".", 659]]}
{"context": "Transcription-coupled repair (TCR) is the major pathway involved in the removal of UV-induced photolesions from the transcribed strand of active genes. Two Cockayne syndrome (CS) complementation group proteins, CSA and CSB, are important for TCR repair. The molecular mechanisms by which CS proteins regulate TCR remain elusive. Here, we report the characterization of KIAA1530, an evolutionarily conserved protein that participates in this pathway through its interaction with CSA and the TFIIH complex. We found that UV irradiation led to the recruitment of KIAA1530 onto chromatin in a CSA-dependent manner. Cells lacking KIAA1530 were highly sensitive to UV irradiation and displayed deficiency in TCR. In addition, KIAA1530 depletion abrogated stability of the CSB protein following UV irradiation. More excitingly, we found that a unique CSA mutant (W361C), which was previously identified in a patient with UV(s)S syndrome, showed defective KIAA1530 binding and resulted in a failure of recruiting KIAA1530 and stabilizing CSB after UV treatment. Together, our data not only reveal that KIAA1530 is an important player in TCR but also lead to a better understanding of the molecular mechanism underlying UV(s)S syndrome.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "0ee48960a85e4cb08d71437204c23131", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[22, 23]], "char_spans": [[116, 133]]}]}], "context_tokens": [["Transcription", 0], ["-", 13], ["coupled", 14], ["repair", 22], ["(", 29], ["TCR", 30], [")", 33], ["is", 35], ["the", 38], ["major", 42], ["pathway", 48], ["involved", 56], ["in", 65], ["the", 68], ["removal", 72], ["of", 80], ["UV", 83], ["-", 85], ["induced", 86], ["photolesions", 94], ["from", 107], ["the", 112], ["transcribed", 116], ["strand", 128], ["of", 135], ["active", 138], ["genes", 145], [".", 150], ["Two", 152], ["Cockayne", 156], ["syndrome", 165], ["(", 174], ["CS", 175], [")", 177], ["complementation", 179], ["group", 195], ["proteins", 201], [",", 209], ["CSA", 211], ["and", 215], ["CSB", 219], [",", 222], ["are", 224], ["important", 228], ["for", 238], ["TCR", 242], ["repair", 246], [".", 252], ["The", 254], ["molecular", 258], ["mechanisms", 268], ["by", 279], ["which", 282], ["CS", 288], ["proteins", 291], ["regulate", 300], ["TCR", 309], ["remain", 313], ["elusive", 320], [".", 327], ["Here", 329], [",", 333], ["we", 335], ["report", 338], ["the", 345], ["characterization", 349], ["of", 366], ["KIAA1530", 369], [",", 377], ["an", 379], ["evolutionarily", 382], ["conserved", 397], ["protein", 407], ["that", 415], ["participates", 420], ["in", 433], ["this", 436], ["pathway", 441], ["through", 449], ["its", 457], ["interaction", 461], ["with", 473], ["CSA", 478], ["and", 482], ["the", 486], ["TFIIH", 490], ["complex", 496], [".", 503], ["We", 505], ["found", 508], ["that", 514], ["UV", 519], ["irradiation", 522], ["led", 534], ["to", 538], ["the", 541], ["recruitment", 545], ["of", 557], ["KIAA1530", 560], ["onto", 569], ["chromatin", 574], ["in", 584], ["a", 587], ["CSA", 589], ["-", 592], ["dependent", 593], ["manner", 603], [".", 609], ["Cells", 611], ["lacking", 617], ["KIAA1530", 625], ["were", 634], ["highly", 639], ["sensitive", 646], ["to", 656], ["UV", 659], ["irradiation", 662], ["and", 674], ["displayed", 678], ["deficiency", 688], ["in", 699], ["TCR", 702], [".", 705], ["In", 707], ["addition", 710], [",", 718], ["KIAA1530", 720], ["depletion", 729], ["abrogated", 739], ["stability", 749], ["of", 759], ["the", 762], ["CSB", 766], ["protein", 770], ["following", 778], ["UV", 788], ["irradiation", 791], [".", 802], ["More", 804], ["excitingly", 809], [",", 819], ["we", 821], ["found", 824], ["that", 830], ["a", 835], ["unique", 837], ["CSA", 844], ["mutant", 848], ["(", 855], ["W361C", 856], [")", 861], [",", 862], ["which", 864], ["was", 870], ["previously", 874], ["identified", 885], ["in", 896], ["a", 899], ["patient", 901], ["with", 909], ["UV(s)S", 914], ["syndrome", 921], [",", 929], ["showed", 931], ["defective", 938], ["KIAA1530", 948], ["binding", 957], ["and", 965], ["resulted", 969], ["in", 978], ["a", 981], ["failure", 983], ["of", 991], ["recruiting", 994], ["KIAA1530", 1005], ["and", 1014], ["stabilizing", 1018], ["CSB", 1030], ["after", 1034], ["UV", 1040], ["treatment", 1043], [".", 1052], ["Together", 1054], [",", 1062], ["our", 1064], ["data", 1068], ["not", 1073], ["only", 1077], ["reveal", 1082], ["that", 1089], ["KIAA1530", 1094], ["is", 1103], ["an", 1106], ["important", 1109], ["player", 1119], ["in", 1126], ["TCR", 1129], ["but", 1133], ["also", 1137], ["lead", 1142], ["to", 1147], ["a", 1150], ["better", 1152], ["understanding", 1159], ["of", 1173], ["the", 1176], ["molecular", 1180], ["mechanism", 1190], ["underlying", 1200], ["UV(s)S", 1211], ["syndrome", 1218], [".", 1226]]}
{"context": "We have used a non-replicating recombinant adenovirus, Ad5MCMVlacZ, which expresses the beta-galactosidase reporter gene, to examine both constitutive and inducible repair of UV-damaged DNA in repair proficient CHO-AA8 Chinese hamster ovary cells and in mutant CHO-UV61 cells which are deficient in the transcription-coupled repair (TCR) pathway of nucleotide excision repair. Host cell reactivation (HCR) of beta-galactosidase activity for UV-irradiated Ad5MCMVlacZ was significantly reduced in non-irradiated CHO-UV61 cells compared to that in non-irradiated CHO-AA8 cells suggesting that repair in the transcribed strand of the UV-damaged reporter gene in untreated cells utilizes TCR. Prior UV-irradiation of cells with low UV fluences resulted in a transient enhancement of HCR for expression of the UV-damaged reporter gene in CHO-AA8 cells but not in TCR deficient CHO-UV61 cells. These results suggest the presence of an inducible DNA pathway in CHO cells that results from an enhancement of TCR or a mechanism that involves the TCR pathway.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "eda2a1c711434788b5b1baf539f5db9a", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[111, 112]], "char_spans": [[605, 622]]}]}], "context_tokens": [["We", 0], ["have", 3], ["used", 8], ["a", 13], ["non", 15], ["-", 18], ["replicating", 19], ["recombinant", 31], ["adenovirus", 43], [",", 53], ["Ad5MCMVlacZ", 55], [",", 66], ["which", 68], ["expresses", 74], ["the", 84], ["beta", 88], ["-", 92], ["galactosidase", 93], ["reporter", 107], ["gene", 116], [",", 120], ["to", 122], ["examine", 125], ["both", 133], ["constitutive", 138], ["and", 151], ["inducible", 155], ["repair", 165], ["of", 172], ["UV", 175], ["-", 177], ["damaged", 178], ["DNA", 186], ["in", 190], ["repair", 193], ["proficient", 200], ["CHO", 211], ["-", 214], ["AA8", 215], ["Chinese", 219], ["hamster", 227], ["ovary", 235], ["cells", 241], ["and", 247], ["in", 251], ["mutant", 254], ["CHO", 261], ["-", 264], ["UV61", 265], ["cells", 270], ["which", 276], ["are", 282], ["deficient", 286], ["in", 296], ["the", 299], ["transcription", 303], ["-", 316], ["coupled", 317], ["repair", 325], ["(", 332], ["TCR", 333], [")", 336], ["pathway", 338], ["of", 346], ["nucleotide", 349], ["excision", 360], ["repair", 369], [".", 375], ["Host", 377], ["cell", 382], ["reactivation", 387], ["(", 400], ["HCR", 401], [")", 404], ["of", 406], ["beta", 409], ["-", 413], ["galactosidase", 414], ["activity", 428], ["for", 437], ["UV", 441], ["-", 443], ["irradiated", 444], ["Ad5MCMVlacZ", 455], ["was", 467], ["significantly", 471], ["reduced", 485], ["in", 493], ["non", 496], ["-", 499], ["irradiated", 500], ["CHO", 511], ["-", 514], ["UV61", 515], ["cells", 520], ["compared", 526], ["to", 535], ["that", 538], ["in", 543], ["non", 546], ["-", 549], ["irradiated", 550], ["CHO", 561], ["-", 564], ["AA8", 565], ["cells", 569], ["suggesting", 575], ["that", 586], ["repair", 591], ["in", 598], ["the", 601], ["transcribed", 605], ["strand", 617], ["of", 624], ["the", 627], ["UV", 631], ["-", 633], ["damaged", 634], ["reporter", 642], ["gene", 651], ["in", 656], ["untreated", 659], ["cells", 669], ["utilizes", 675], ["TCR", 684], [".", 687], ["Prior", 689], ["UV", 695], ["-", 697], ["irradiation", 698], ["of", 710], ["cells", 713], ["with", 719], ["low", 724], ["UV", 728], ["fluences", 731], ["resulted", 740], ["in", 749], ["a", 752], ["transient", 754], ["enhancement", 764], ["of", 776], ["HCR", 779], ["for", 783], ["expression", 787], ["of", 798], ["the", 801], ["UV", 805], ["-", 807], ["damaged", 808], ["reporter", 816], ["gene", 825], ["in", 830], ["CHO", 833], ["-", 836], ["AA8", 837], ["cells", 841], ["but", 847], ["not", 851], ["in", 855], ["TCR", 858], ["deficient", 862], ["CHO", 872], ["-", 875], ["UV61", 876], ["cells", 881], [".", 886], ["These", 888], ["results", 894], ["suggest", 902], ["the", 910], ["presence", 914], ["of", 923], ["an", 926], ["inducible", 929], ["DNA", 939], ["pathway", 943], ["in", 951], ["CHO", 954], ["cells", 958], ["that", 964], ["results", 969], ["from", 977], ["an", 982], ["enhancement", 985], ["of", 997], ["TCR", 1000], ["or", 1004], ["a", 1007], ["mechanism", 1009], ["that", 1019], ["involves", 1024], ["the", 1033], ["TCR", 1037], ["pathway", 1041], [".", 1048]]}
{"context": "Previous X-ray crystal structures have shown that linkers of five amino acid residues connecting pairs of chicken brain alpha-spectrin and human erythroid beta-spectrin repeats can undergo bending without losing their alpha-helical structure. To test whether bending at one linker can influence bending at an adjacent linker, the structures of two and three repeat fragments of chicken brain alpha-spectrin have been determined by X-ray crystallography. The structure of the three-repeat fragment clearly shows that bending at one linker can occur independently of bending at an adjacent linker. This observation increases the possible trajectories of modeled chains of spectrin repeats. Furthermore, the three-repeat molecule crystallized as an antiparallel dimer with a significantly smaller buried interfacial area than that of alpha-actinin, a spectrin-related molecule, but large enough and of a type indicating biological specificity. Comparison of the structures of the spectrin and alpha-actinin dimers supports weak association of the former, which could not be detected by analytical ultracentrifugation, versus strong association of the latter, which has been observed by others. To correlate features of the structure with solution properties and to test a previous model of stable spectrin and dystrophin repeats, the number of inter-helical interactions in each repeat of several spectrin structures were counted and compared to their thermal stabilities. Inter-helical interactions, but not all interactions, increased in parallel with measured thermal stabilities of each repeat and in agreement with the thermal stabilities of two and three repeats and also partial repeats of spectrin.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "159e2ef1d3ca4a3b889fd3fd5ef2acb9", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[127, 127]], "char_spans": [[746, 757]]}]}], "context_tokens": [["Previous", 0], ["X", 9], ["-", 10], ["ray", 11], ["crystal", 15], ["structures", 23], ["have", 34], ["shown", 39], ["that", 45], ["linkers", 50], ["of", 58], ["five", 61], ["amino", 66], ["acid", 72], ["residues", 77], ["connecting", 86], ["pairs", 97], ["of", 103], ["chicken", 106], ["brain", 114], ["alpha", 120], ["-", 125], ["spectrin", 126], ["and", 135], ["human", 139], ["erythroid", 145], ["beta", 155], ["-", 159], ["spectrin", 160], ["repeats", 169], ["can", 177], ["undergo", 181], ["bending", 189], ["without", 197], ["losing", 205], ["their", 212], ["alpha", 218], ["-", 223], ["helical", 224], ["structure", 232], [".", 241], ["To", 243], ["test", 246], ["whether", 251], ["bending", 259], ["at", 267], ["one", 270], ["linker", 274], ["can", 281], ["influence", 285], ["bending", 295], ["at", 303], ["an", 306], ["adjacent", 309], ["linker", 318], [",", 324], ["the", 326], ["structures", 330], ["of", 341], ["two", 344], ["and", 348], ["three", 352], ["repeat", 358], ["fragments", 365], ["of", 375], ["chicken", 378], ["brain", 386], ["alpha", 392], ["-", 397], ["spectrin", 398], ["have", 407], ["been", 412], ["determined", 417], ["by", 428], ["X", 431], ["-", 432], ["ray", 433], ["crystallography", 437], [".", 452], ["The", 454], ["structure", 458], ["of", 468], ["the", 471], ["three", 475], ["-", 480], ["repeat", 481], ["fragment", 488], ["clearly", 497], ["shows", 505], ["that", 511], ["bending", 516], ["at", 524], ["one", 527], ["linker", 531], ["can", 538], ["occur", 542], ["independently", 548], ["of", 562], ["bending", 565], ["at", 573], ["an", 576], ["adjacent", 579], ["linker", 588], [".", 594], ["This", 596], ["observation", 601], ["increases", 613], ["the", 623], ["possible", 627], ["trajectories", 636], ["of", 649], ["modeled", 652], ["chains", 660], ["of", 667], ["spectrin", 670], ["repeats", 679], [".", 686], ["Furthermore", 688], [",", 699], ["the", 701], ["three", 705], ["-", 710], ["repeat", 711], ["molecule", 718], ["crystallized", 727], ["as", 740], ["an", 743], ["antiparallel", 746], ["dimer", 759], ["with", 765], ["a", 770], ["significantly", 772], ["smaller", 786], ["buried", 794], ["interfacial", 801], ["area", 813], ["than", 818], ["that", 823], ["of", 828], ["alpha", 831], ["-", 836], ["actinin", 837], [",", 844], ["a", 846], ["spectrin", 848], ["-", 856], ["related", 857], ["molecule", 865], [",", 873], ["but", 875], ["large", 879], ["enough", 885], ["and", 892], ["of", 896], ["a", 899], ["type", 901], ["indicating", 906], ["biological", 917], ["specificity", 928], [".", 939], ["Comparison", 941], ["of", 952], ["the", 955], ["structures", 959], ["of", 970], ["the", 973], ["spectrin", 977], ["and", 986], ["alpha", 990], ["-", 995], ["actinin", 996], ["dimers", 1004], ["supports", 1011], ["weak", 1020], ["association", 1025], ["of", 1037], ["the", 1040], ["former", 1044], [",", 1050], ["which", 1052], ["could", 1058], ["not", 1064], ["be", 1068], ["detected", 1071], ["by", 1080], ["analytical", 1083], ["ultracentrifugation", 1094], [",", 1113], ["versus", 1115], ["strong", 1122], ["association", 1129], ["of", 1141], ["the", 1144], ["latter", 1148], [",", 1154], ["which", 1156], ["has", 1162], ["been", 1166], ["observed", 1171], ["by", 1180], ["others", 1183], [".", 1189], ["To", 1191], ["correlate", 1194], ["features", 1204], ["of", 1213], ["the", 1216], ["structure", 1220], ["with", 1230], ["solution", 1235], ["properties", 1244], ["and", 1255], ["to", 1259], ["test", 1262], ["a", 1267], ["previous", 1269], ["model", 1278], ["of", 1284], ["stable", 1287], ["spectrin", 1294], ["and", 1303], ["dystrophin", 1307], ["repeats", 1318], [",", 1325], ["the", 1327], ["number", 1331], ["of", 1338], ["inter", 1341], ["-", 1346], ["helical", 1347], ["interactions", 1355], ["in", 1368], ["each", 1371], ["repeat", 1376], ["of", 1383], ["several", 1386], ["spectrin", 1394], ["structures", 1403], ["were", 1414], ["counted", 1419], ["and", 1427], ["compared", 1431], ["to", 1440], ["their", 1443], ["thermal", 1449], ["stabilities", 1457], [".", 1468], ["Inter", 1470], ["-", 1475], ["helical", 1476], ["interactions", 1484], [",", 1496], ["but", 1498], ["not", 1502], ["all", 1506], ["interactions", 1510], [",", 1522], ["increased", 1524], ["in", 1534], ["parallel", 1537], ["with", 1546], ["measured", 1551], ["thermal", 1560], ["stabilities", 1568], ["of", 1580], ["each", 1583], ["repeat", 1588], ["and", 1595], ["in", 1599], ["agreement", 1602], ["with", 1612], ["the", 1617], ["thermal", 1621], ["stabilities", 1629], ["of", 1641], ["two", 1644], ["and", 1648], ["three", 1652], ["repeats", 1658], ["and", 1666], ["also", 1670], ["partial", 1675], ["repeats", 1683], ["of", 1691], ["spectrin", 1694], [".", 1702]]}
{"context": "Christianson syndrome is an X-linked mental retardation syndrome characterized by microcephaly, impaired ocular movement, severe global developmental delay, hypotonia which progresses to spasticity, and early onset seizures of variable types. Gilfillan et al.2008] reported mutations in SLC9A6, the gene encoding the sodium/hydrogen exchanger NHE6, in the family first reported and in three others. They also noted the clinical similarities to Angelman syndrome and found cerebellar atrophy on MRI and elevated glutamate/glutamine in the basal ganglia on MRS. Here we report on nonsense mutations in two additional families. The natural history is detailed in childhood and adult life, the similarities to Angelman syndrome confirmed, and the MRI/MRS findings documented in three affected boys.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "75877e12360244ecaad667bb28813b4c", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[44, 44]], "char_spans": [[287, 292]]}]}], "context_tokens": [["Christianson", 0], ["syndrome", 13], ["is", 22], ["an", 25], ["X", 28], ["-", 29], ["linked", 30], ["mental", 37], ["retardation", 44], ["syndrome", 56], ["characterized", 65], ["by", 79], ["microcephaly", 82], [",", 94], ["impaired", 96], ["ocular", 105], ["movement", 112], [",", 120], ["severe", 122], ["global", 129], ["developmental", 136], ["delay", 150], [",", 155], ["hypotonia", 157], ["which", 167], ["progresses", 173], ["to", 184], ["spasticity", 187], [",", 197], ["and", 199], ["early", 203], ["onset", 209], ["seizures", 215], ["of", 224], ["variable", 227], ["types", 236], [".", 241], ["Gilfillan", 243], ["et", 253], ["al.2008", 256], ["]", 263], ["reported", 265], ["mutations", 274], ["in", 284], ["SLC9A6", 287], [",", 293], ["the", 295], ["gene", 299], ["encoding", 304], ["the", 313], ["sodium", 317], ["/", 323], ["hydrogen", 324], ["exchanger", 333], ["NHE6", 343], [",", 347], ["in", 349], ["the", 352], ["family", 356], ["first", 363], ["reported", 369], ["and", 378], ["in", 382], ["three", 385], ["others", 391], [".", 397], ["They", 399], ["also", 404], ["noted", 409], ["the", 415], ["clinical", 419], ["similarities", 428], ["to", 441], ["Angelman", 444], ["syndrome", 453], ["and", 462], ["found", 466], ["cerebellar", 472], ["atrophy", 483], ["on", 491], ["MRI", 494], ["and", 498], ["elevated", 502], ["glutamate", 511], ["/", 520], ["glutamine", 521], ["in", 531], ["the", 534], ["basal", 538], ["ganglia", 544], ["on", 552], ["MRS", 555], [".", 558], ["Here", 560], ["we", 565], ["report", 568], ["on", 575], ["nonsense", 578], ["mutations", 587], ["in", 597], ["two", 600], ["additional", 604], ["families", 615], [".", 623], ["The", 625], ["natural", 629], ["history", 637], ["is", 645], ["detailed", 648], ["in", 657], ["childhood", 660], ["and", 670], ["adult", 674], ["life", 680], [",", 684], ["the", 686], ["similarities", 690], ["to", 703], ["Angelman", 706], ["syndrome", 715], ["confirmed", 724], [",", 733], ["and", 735], ["the", 739], ["MRI", 743], ["/", 746], ["MRS", 747], ["findings", 751], ["documented", 760], ["in", 771], ["three", 774], ["affected", 780], ["boys", 789], [".", 793]]}
{"context": "Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome. This arises from a balanced translocation between chromosomes 9 and 22, creating the bcr-abl fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation, which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy. After imatinib treatment, > 90% of patients had a complete hematologic response, and 70%-80% had a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging and exhibit a major change in the natural history of the disease. The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance. The outlook today for patients with CML is much brighter than that of a few years ago.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "daeaeaba2d634317b4b23a5d6051f0e1", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[37, 39], [71, 73]], "char_spans": [[238, 244], [418, 424]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["a", 38], ["progressive", 40], ["and", 52], ["often", 56], ["fatal", 62], ["hematopoietic", 68], ["neoplasm", 82], ["characterized", 91], ["by", 105], ["the", 108], ["presence", 112], ["of", 121], ["the", 124], ["Philadelphia", 128], ["chromosome", 141], [".", 151], ["This", 153], ["arises", 158], ["from", 165], ["a", 170], ["balanced", 172], ["translocation", 181], ["between", 195], ["chromosomes", 203], ["9", 215], ["and", 217], ["22", 221], [",", 223], ["creating", 225], ["the", 234], ["bcr", 238], ["-", 241], ["abl", 242], ["fusion", 246], ["gene", 253], [".", 257], ["It", 259], ["is", 262], ["often", 265], ["stated", 271], ["that", 278], ["the", 283], ["only", 287], ["proven", 292], ["curative", 299], ["option", 308], ["is", 315], ["allogeneic", 318], ["stem", 329], ["cell", 334], ["transplantation", 339], [",", 354], ["which", 356], ["is", 362], ["indicated", 365], ["for", 375], ["only", 379], ["a", 384], ["limited", 386], ["subset", 394], ["of", 401], ["patients", 404], [".", 412], ["The", 414], ["Bcr", 418], ["-", 421], ["Abl", 422], ["tyrosine", 426], ["kinase", 435], ["inhibitor", 442], ["imatinib", 452], ["represented", 461], ["a", 473], ["major", 475], ["advance", 481], ["over", 489], ["conventional", 494], ["CML", 507], ["therapy", 511], [".", 518], ["After", 520], ["imatinib", 526], ["treatment", 535], [",", 544], [">", 546], ["90", 548], ["%", 550], ["of", 552], ["patients", 555], ["had", 564], ["a", 568], ["complete", 570], ["hematologic", 579], ["response", 591], [",", 599], ["and", 601], ["70%-80", 605], ["%", 611], ["had", 613], ["a", 617], ["complete", 619], ["cytogenetic", 628], ["response", 640], [".", 648], ["With", 650], ["5", 655], ["years", 657], ["of", 663], ["follow", 666], ["-", 672], ["up", 673], [",", 675], ["the", 677], ["data", 681], ["are", 686], ["very", 690], ["encouraging", 695], ["and", 707], ["exhibit", 711], ["a", 719], ["major", 721], ["change", 727], ["in", 734], ["the", 737], ["natural", 741], ["history", 749], ["of", 757], ["the", 760], ["disease", 764], [".", 771], ["The", 773], ["understanding", 777], ["of", 791], ["some", 794], ["of", 799], ["the", 802], ["mechanisms", 806], ["of", 817], ["resistance", 820], ["to", 831], ["imatinib", 834], ["has", 843], ["led", 847], ["to", 851], ["a", 854], ["rapid", 856], ["development", 862], ["of", 874], ["new", 877], ["agents", 881], ["that", 888], ["might", 893], ["overcome", 899], ["this", 908], ["resistance", 913], [".", 923], ["The", 925], ["outlook", 929], ["today", 937], ["for", 943], ["patients", 947], ["with", 956], ["CML", 961], ["is", 965], ["much", 968], ["brighter", 973], ["than", 982], ["that", 987], ["of", 992], ["a", 995], ["few", 997], ["years", 1001], ["ago", 1007], [".", 1010]]}
{"context": "Atg8-family proteins are the best-studied proteins of the core autophagic machinery. They are essential for the elongation and closure of the phagophore into a proper autophagosome. Moreover, Atg8-family proteins are associated with the phagophore from the initiation of the autophagic process to, or just prior to, the fusion between autophagosomes with lysosomes. In addition to their implication in autophagosome biogenesis, they are crucial for selective autophagy through their ability to interact with selective autophagy receptor proteins necessary for the specific targeting of substrates for autophagic degradation. In the past few years it has been revealed that Atg8-interacting proteins include not only receptors but also components of the core autophagic machinery, proteins associated with vesicles and their transport, and specific proteins that are selectively degraded by autophagy. Atg8-interacting proteins contain a short linear LC3-interacting region/LC3 recognition sequence/Atg8-interacting motif (LIR/LRS/AIM) motif which is responsible for their interaction with Atg8-family proteins. These proteins are referred to as LIR-containing proteins (LIRCPs). So far, many experimental efforts have been carried out to identify new LIRCPs, leading to the characterization of some of them in the past 10\u00a0years. Given the need for the identification of LIRCPs in various organisms, we developed the iLIR database ( https://ilir.warwick.ac.uk ) as a freely available web resource, listing all the putative canonical LIRCPs identified in silico in the proteomes of 8 model organisms using the iLIR server, combined with a Gene Ontology (GO) term analysis. Additionally, a curated text-mining analysis of the literature permitted us to identify novel putative LICRPs in mammals that have not previously been associated with autophagy.", "qas": [{"question": "Which web resource for LIR motif-containing proteins in eukaryotes has been developed?", "answers": ["The iLIR database"], "qid": "16c89e69edec4f89b7e12d57432d4b48", "question_tokens": [["Which", 0], ["web", 6], ["resource", 10], ["for", 19], ["LIR", 23], ["motif", 27], ["-", 32], ["containing", 33], ["proteins", 44], ["in", 53], ["eukaryotes", 56], ["has", 67], ["been", 71], ["developed", 76], ["?", 85]], "detected_answers": [{"text": "The iLIR database", "token_spans": [[230, 231]], "char_spans": [[1416, 1428]]}]}], "context_tokens": [["Atg8-family", 0], ["proteins", 12], ["are", 21], ["the", 25], ["best", 29], ["-", 33], ["studied", 34], ["proteins", 42], ["of", 51], ["the", 54], ["core", 58], ["autophagic", 63], ["machinery", 74], [".", 83], ["They", 85], ["are", 90], ["essential", 94], ["for", 104], ["the", 108], ["elongation", 112], ["and", 123], ["closure", 127], ["of", 135], ["the", 138], ["phagophore", 142], ["into", 153], ["a", 158], ["proper", 160], ["autophagosome", 167], [".", 180], ["Moreover", 182], [",", 190], ["Atg8-family", 192], ["proteins", 204], ["are", 213], ["associated", 217], ["with", 228], ["the", 233], ["phagophore", 237], ["from", 248], ["the", 253], ["initiation", 257], ["of", 268], ["the", 271], ["autophagic", 275], ["process", 286], ["to", 294], [",", 296], ["or", 298], ["just", 301], ["prior", 306], ["to", 312], [",", 314], ["the", 316], ["fusion", 320], ["between", 327], ["autophagosomes", 335], ["with", 350], ["lysosomes", 355], [".", 364], ["In", 366], ["addition", 369], ["to", 378], ["their", 381], ["implication", 387], ["in", 399], ["autophagosome", 402], ["biogenesis", 416], [",", 426], ["they", 428], ["are", 433], ["crucial", 437], ["for", 445], ["selective", 449], ["autophagy", 459], ["through", 469], ["their", 477], ["ability", 483], ["to", 491], ["interact", 494], ["with", 503], ["selective", 508], ["autophagy", 518], ["receptor", 528], ["proteins", 537], ["necessary", 546], ["for", 556], ["the", 560], ["specific", 564], ["targeting", 573], ["of", 583], ["substrates", 586], ["for", 597], ["autophagic", 601], ["degradation", 612], [".", 623], ["In", 625], ["the", 628], ["past", 632], ["few", 637], ["years", 641], ["it", 647], ["has", 650], ["been", 654], ["revealed", 659], ["that", 668], ["Atg8-interacting", 673], ["proteins", 690], ["include", 699], ["not", 707], ["only", 711], ["receptors", 716], ["but", 726], ["also", 730], ["components", 735], ["of", 746], ["the", 749], ["core", 753], ["autophagic", 758], ["machinery", 769], [",", 778], ["proteins", 780], ["associated", 789], ["with", 800], ["vesicles", 805], ["and", 814], ["their", 818], ["transport", 824], [",", 833], ["and", 835], ["specific", 839], ["proteins", 848], ["that", 857], ["are", 862], ["selectively", 866], ["degraded", 878], ["by", 887], ["autophagy", 890], [".", 899], ["Atg8-interacting", 901], ["proteins", 918], ["contain", 927], ["a", 935], ["short", 937], ["linear", 943], ["LC3-interacting", 950], ["region", 966], ["/", 972], ["LC3", 973], ["recognition", 977], ["sequence", 989], ["/", 997], ["Atg8-interacting", 998], ["motif", 1015], ["(", 1021], ["LIR", 1022], ["/", 1025], ["LRS", 1026], ["/", 1029], ["AIM", 1030], [")", 1033], ["motif", 1035], ["which", 1041], ["is", 1047], ["responsible", 1050], ["for", 1062], ["their", 1066], ["interaction", 1072], ["with", 1084], ["Atg8-family", 1089], ["proteins", 1101], [".", 1109], ["These", 1111], ["proteins", 1117], ["are", 1126], ["referred", 1130], ["to", 1139], ["as", 1142], ["LIR", 1145], ["-", 1148], ["containing", 1149], ["proteins", 1160], ["(", 1169], ["LIRCPs", 1170], [")", 1176], [".", 1177], ["So", 1179], ["far", 1182], [",", 1185], ["many", 1187], ["experimental", 1192], ["efforts", 1205], ["have", 1213], ["been", 1218], ["carried", 1223], ["out", 1231], ["to", 1235], ["identify", 1238], ["new", 1247], ["LIRCPs", 1251], [",", 1257], ["leading", 1259], ["to", 1267], ["the", 1270], ["characterization", 1274], ["of", 1291], ["some", 1294], ["of", 1299], ["them", 1302], ["in", 1307], ["the", 1310], ["past", 1314], ["10", 1319], ["years", 1322], [".", 1327], ["Given", 1329], ["the", 1335], ["need", 1339], ["for", 1344], ["the", 1348], ["identification", 1352], ["of", 1367], ["LIRCPs", 1370], ["in", 1377], ["various", 1380], ["organisms", 1388], [",", 1397], ["we", 1399], ["developed", 1402], ["the", 1412], ["iLIR", 1416], ["database", 1421], ["(", 1430], ["https://ilir.warwick.ac.uk", 1432], [")", 1459], ["as", 1461], ["a", 1464], ["freely", 1466], ["available", 1473], ["web", 1483], ["resource", 1487], [",", 1495], ["listing", 1497], ["all", 1505], ["the", 1509], ["putative", 1513], ["canonical", 1522], ["LIRCPs", 1532], ["identified", 1539], ["in", 1550], ["silico", 1553], ["in", 1560], ["the", 1563], ["proteomes", 1567], ["of", 1577], ["8", 1580], ["model", 1582], ["organisms", 1588], ["using", 1598], ["the", 1604], ["iLIR", 1608], ["server", 1613], [",", 1619], ["combined", 1621], ["with", 1630], ["a", 1635], ["Gene", 1637], ["Ontology", 1642], ["(", 1651], ["GO", 1652], [")", 1654], ["term", 1656], ["analysis", 1661], [".", 1669], ["Additionally", 1671], [",", 1683], ["a", 1685], ["curated", 1687], ["text", 1695], ["-", 1699], ["mining", 1700], ["analysis", 1707], ["of", 1716], ["the", 1719], ["literature", 1723], ["permitted", 1734], ["us", 1744], ["to", 1747], ["identify", 1750], ["novel", 1759], ["putative", 1765], ["LICRPs", 1774], ["in", 1781], ["mammals", 1784], ["that", 1792], ["have", 1797], ["not", 1802], ["previously", 1806], ["been", 1817], ["associated", 1822], ["with", 1833], ["autophagy", 1838], [".", 1847]]}
{"context": "The mixed-lineage leukemia protein MLL1 is a transcriptional regulator with an essential role in early development and hematopoiesis. The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain. We have determined the crystal structure of the MLL1 SET domain in complex with cofactor product AdoHcy and a histone H3 peptide. This structure indicates that, in order to form a well-ordered active site, a highly variable but essential component of the SET domain must be repositioned. To test this idea, we compared the effect of the addition of MLL complex members on methyltransferase activity and show that both RbBP5 and Ash2L but not Wdr5 stimulate activity. Additionally, we have determined the effect of posttranslational modifications on histone H3 residues downstream and upstream from the target lysine and provide a structural explanation for why H3T3 phosphorylation and H3K9 acetylation regulate activity.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "76dece4105a44e9e9041be62fc48fbed", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[31, 31]], "char_spans": [[193, 196]]}]}], "context_tokens": [["The", 0], ["mixed", 4], ["-", 9], ["lineage", 10], ["leukemia", 18], ["protein", 27], ["MLL1", 35], ["is", 40], ["a", 43], ["transcriptional", 45], ["regulator", 61], ["with", 71], ["an", 76], ["essential", 79], ["role", 89], ["in", 94], ["early", 97], ["development", 103], ["and", 115], ["hematopoiesis", 119], [".", 132], ["The", 134], ["biological", 138], ["function", 149], ["of", 158], ["MLL1", 161], ["is", 166], ["mediated", 169], ["by", 178], ["the", 181], ["histone", 185], ["H3K4", 193], ["methyltransferase", 198], ["activity", 216], ["of", 225], ["the", 228], ["carboxyl", 232], ["-", 240], ["terminal", 241], ["SET", 250], ["domain", 254], [".", 260], ["We", 262], ["have", 265], ["determined", 270], ["the", 281], ["crystal", 285], ["structure", 293], ["of", 303], ["the", 306], ["MLL1", 310], ["SET", 315], ["domain", 319], ["in", 326], ["complex", 329], ["with", 337], ["cofactor", 342], ["product", 351], ["AdoHcy", 359], ["and", 366], ["a", 370], ["histone", 372], ["H3", 380], ["peptide", 383], [".", 390], ["This", 392], ["structure", 397], ["indicates", 407], ["that", 417], [",", 421], ["in", 423], ["order", 426], ["to", 432], ["form", 435], ["a", 440], ["well", 442], ["-", 446], ["ordered", 447], ["active", 455], ["site", 462], [",", 466], ["a", 468], ["highly", 470], ["variable", 477], ["but", 486], ["essential", 490], ["component", 500], ["of", 510], ["the", 513], ["SET", 517], ["domain", 521], ["must", 528], ["be", 533], ["repositioned", 536], [".", 548], ["To", 550], ["test", 553], ["this", 558], ["idea", 563], [",", 567], ["we", 569], ["compared", 572], ["the", 581], ["effect", 585], ["of", 592], ["the", 595], ["addition", 599], ["of", 608], ["MLL", 611], ["complex", 615], ["members", 623], ["on", 631], ["methyltransferase", 634], ["activity", 652], ["and", 661], ["show", 665], ["that", 670], ["both", 675], ["RbBP5", 680], ["and", 686], ["Ash2L", 690], ["but", 696], ["not", 700], ["Wdr5", 704], ["stimulate", 709], ["activity", 719], [".", 727], ["Additionally", 729], [",", 741], ["we", 743], ["have", 746], ["determined", 751], ["the", 762], ["effect", 766], ["of", 773], ["posttranslational", 776], ["modifications", 794], ["on", 808], ["histone", 811], ["H3", 819], ["residues", 822], ["downstream", 831], ["and", 842], ["upstream", 846], ["from", 855], ["the", 860], ["target", 864], ["lysine", 871], ["and", 878], ["provide", 882], ["a", 890], ["structural", 892], ["explanation", 903], ["for", 915], ["why", 919], ["H3T3", 923], ["phosphorylation", 928], ["and", 944], ["H3K9", 948], ["acetylation", 953], ["regulate", 965], ["activity", 974], [".", 982]]}
{"context": "The proliferation and migration of vascular smooth muscle cells (VSMCs) in the intima of an artery, known as intimal hyperplasia, is an important component of cardiovascular diseases. This is seen most clearly in the case of in-stent restenosis, where drug eluting stents are used to deliver agents that prevent VSMC proliferation and migration. One class of agents that are highly effective in the prevention of in-stent restenosis is the mammalian Target of Rapamycin (mTOR) inhibitors. Inhibition of mTOR blocks protein synthesis, cell cycle progression, and cell migration. Key to the effects on cell cycle progression and cell migration is the inhibition of mTOR-mediated degradation of p27Kip1 protein. p27Kip1 is a cyclin dependent kinase inhibitor that is elevated in quiescent VSMCs and inhibits the G1 to S phase transition and cell migration. Under normal conditions, vascular injury promotes degradation of p27Kip1 protein in an mTOR dependent manner. Recent reports from our lab suggest that in the presence of diabetes mellitus, elevation of extracellular signal response kinase activity may promote decreased p27Kip1 mRNA and produce a relative resistance to mTOR inhibition. Here we review these findings and their relevance to designing treatments for cardiovascular disease in the presence of diabetes mellitus.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "4512014da03b487ba5925f69cc357394", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[80, 83]], "char_spans": [[440, 468]]}]}], "context_tokens": [["The", 0], ["proliferation", 4], ["and", 18], ["migration", 22], ["of", 32], ["vascular", 35], ["smooth", 44], ["muscle", 51], ["cells", 58], ["(", 64], ["VSMCs", 65], [")", 70], ["in", 72], ["the", 75], ["intima", 79], ["of", 86], ["an", 89], ["artery", 92], [",", 98], ["known", 100], ["as", 106], ["intimal", 109], ["hyperplasia", 117], [",", 128], ["is", 130], ["an", 133], ["important", 136], ["component", 146], ["of", 156], ["cardiovascular", 159], ["diseases", 174], [".", 182], ["This", 184], ["is", 189], ["seen", 192], ["most", 197], ["clearly", 202], ["in", 210], ["the", 213], ["case", 217], ["of", 222], ["in", 225], ["-", 227], ["stent", 228], ["restenosis", 234], [",", 244], ["where", 246], ["drug", 252], ["eluting", 257], ["stents", 265], ["are", 272], ["used", 276], ["to", 281], ["deliver", 284], ["agents", 292], ["that", 299], ["prevent", 304], ["VSMC", 312], ["proliferation", 317], ["and", 331], ["migration", 335], [".", 344], ["One", 346], ["class", 350], ["of", 356], ["agents", 359], ["that", 366], ["are", 371], ["highly", 375], ["effective", 382], ["in", 392], ["the", 395], ["prevention", 399], ["of", 410], ["in", 413], ["-", 415], ["stent", 416], ["restenosis", 422], ["is", 433], ["the", 436], ["mammalian", 440], ["Target", 450], ["of", 457], ["Rapamycin", 460], ["(", 470], ["mTOR", 471], [")", 475], ["inhibitors", 477], [".", 487], ["Inhibition", 489], ["of", 500], ["mTOR", 503], ["blocks", 508], ["protein", 515], ["synthesis", 523], [",", 532], ["cell", 534], ["cycle", 539], ["progression", 545], [",", 556], ["and", 558], ["cell", 562], ["migration", 567], [".", 576], ["Key", 578], ["to", 582], ["the", 585], ["effects", 589], ["on", 597], ["cell", 600], ["cycle", 605], ["progression", 611], ["and", 623], ["cell", 627], ["migration", 632], ["is", 642], ["the", 645], ["inhibition", 649], ["of", 660], ["mTOR", 663], ["-", 667], ["mediated", 668], ["degradation", 677], ["of", 689], ["p27Kip1", 692], ["protein", 700], [".", 707], ["p27Kip1", 709], ["is", 717], ["a", 720], ["cyclin", 722], ["dependent", 729], ["kinase", 739], ["inhibitor", 746], ["that", 756], ["is", 761], ["elevated", 764], ["in", 773], ["quiescent", 776], ["VSMCs", 786], ["and", 792], ["inhibits", 796], ["the", 805], ["G1", 809], ["to", 812], ["S", 815], ["phase", 817], ["transition", 823], ["and", 834], ["cell", 838], ["migration", 843], [".", 852], ["Under", 854], ["normal", 860], ["conditions", 867], [",", 877], ["vascular", 879], ["injury", 888], ["promotes", 895], ["degradation", 904], ["of", 916], ["p27Kip1", 919], ["protein", 927], ["in", 935], ["an", 938], ["mTOR", 941], ["dependent", 946], ["manner", 956], [".", 962], ["Recent", 964], ["reports", 971], ["from", 979], ["our", 984], ["lab", 988], ["suggest", 992], ["that", 1000], ["in", 1005], ["the", 1008], ["presence", 1012], ["of", 1021], ["diabetes", 1024], ["mellitus", 1033], [",", 1041], ["elevation", 1043], ["of", 1053], ["extracellular", 1056], ["signal", 1070], ["response", 1077], ["kinase", 1086], ["activity", 1093], ["may", 1102], ["promote", 1106], ["decreased", 1114], ["p27Kip1", 1124], ["mRNA", 1132], ["and", 1137], ["produce", 1141], ["a", 1149], ["relative", 1151], ["resistance", 1160], ["to", 1171], ["mTOR", 1174], ["inhibition", 1179], [".", 1189], ["Here", 1191], ["we", 1196], ["review", 1199], ["these", 1206], ["findings", 1212], ["and", 1221], ["their", 1225], ["relevance", 1231], ["to", 1241], ["designing", 1244], ["treatments", 1254], ["for", 1265], ["cardiovascular", 1269], ["disease", 1284], ["in", 1292], ["the", 1295], ["presence", 1299], ["of", 1308], ["diabetes", 1311], ["mellitus", 1320], [".", 1328]]}
{"context": "The manifestation of Lewy bodies (LB) in the brain is a hallmark of Parkinson's disease. Here, we present a comprehensive analysis of protein elements in Lewy bodies by comparative mass spectrometry. Cortical LB inclusions were enriched by sucrose gradient centrifugation from postmortem brains, and a negative control sample was prepared from specimen without LB pathology. Whereas approximately 550 proteins were identified in the LB-enriched sample by mass spectrometry, quantitative comparison with the control sample revealed that approximately 40 proteins were co-enriched with alpha-synuclein, the major component in Lewy bodies. As expected, the list of proteins included previously reported constituents, such as those involved in protein folding, membrane trafficking and oxidative stress. More interestingly, we discovered in the LB-enriched sample several kinases (MAPKK1/MEK1, protein kinase C, and doublecortin-like kinase), a novel deubiquitinating enzyme (otubain 1), and numerous ubiquitin ligases (KPC and SCF). The proteomic studies provide enzyme candidates to investigate the regulation of alpha-synuclein and/or other LB proteins, which may contribute to the formation of Lewy bodies and the toxicity of alpha-synuclein in the related neurodegenerative disorders.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "c30df28116514592a00694925f3d7a42", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[189, 191], [210, 212], [95, 97]], "char_spans": [[1111, 1125], [1226, 1240], [584, 598]]}]}], "context_tokens": [["The", 0], ["manifestation", 4], ["of", 18], ["Lewy", 21], ["bodies", 26], ["(", 33], ["LB", 34], [")", 36], ["in", 38], ["the", 41], ["brain", 45], ["is", 51], ["a", 54], ["hallmark", 56], ["of", 65], ["Parkinson", 68], ["'s", 77], ["disease", 80], [".", 87], ["Here", 89], [",", 93], ["we", 95], ["present", 98], ["a", 106], ["comprehensive", 108], ["analysis", 122], ["of", 131], ["protein", 134], ["elements", 142], ["in", 151], ["Lewy", 154], ["bodies", 159], ["by", 166], ["comparative", 169], ["mass", 181], ["spectrometry", 186], [".", 198], ["Cortical", 200], ["LB", 209], ["inclusions", 212], ["were", 223], ["enriched", 228], ["by", 237], ["sucrose", 240], ["gradient", 248], ["centrifugation", 257], ["from", 272], ["postmortem", 277], ["brains", 288], [",", 294], ["and", 296], ["a", 300], ["negative", 302], ["control", 311], ["sample", 319], ["was", 326], ["prepared", 330], ["from", 339], ["specimen", 344], ["without", 353], ["LB", 361], ["pathology", 364], [".", 373], ["Whereas", 375], ["approximately", 383], ["550", 397], ["proteins", 401], ["were", 410], ["identified", 415], ["in", 426], ["the", 429], ["LB", 433], ["-", 435], ["enriched", 436], ["sample", 445], ["by", 452], ["mass", 455], ["spectrometry", 460], [",", 472], ["quantitative", 474], ["comparison", 487], ["with", 498], ["the", 503], ["control", 507], ["sample", 515], ["revealed", 522], ["that", 531], ["approximately", 536], ["40", 550], ["proteins", 553], ["were", 562], ["co", 567], ["-", 569], ["enriched", 570], ["with", 579], ["alpha", 584], ["-", 589], ["synuclein", 590], [",", 599], ["the", 601], ["major", 605], ["component", 611], ["in", 621], ["Lewy", 624], ["bodies", 629], [".", 635], ["As", 637], ["expected", 640], [",", 648], ["the", 650], ["list", 654], ["of", 659], ["proteins", 662], ["included", 671], ["previously", 680], ["reported", 691], ["constituents", 700], [",", 712], ["such", 714], ["as", 719], ["those", 722], ["involved", 728], ["in", 737], ["protein", 740], ["folding", 748], [",", 755], ["membrane", 757], ["trafficking", 766], ["and", 778], ["oxidative", 782], ["stress", 792], [".", 798], ["More", 800], ["interestingly", 805], [",", 818], ["we", 820], ["discovered", 823], ["in", 834], ["the", 837], ["LB", 841], ["-", 843], ["enriched", 844], ["sample", 853], ["several", 860], ["kinases", 868], ["(", 876], ["MAPKK1/MEK1", 877], [",", 888], ["protein", 890], ["kinase", 898], ["C", 905], [",", 906], ["and", 908], ["doublecortin", 912], ["-", 924], ["like", 925], ["kinase", 930], [")", 936], [",", 937], ["a", 939], ["novel", 941], ["deubiquitinating", 947], ["enzyme", 964], ["(", 971], ["otubain", 972], ["1", 980], [")", 981], [",", 982], ["and", 984], ["numerous", 988], ["ubiquitin", 997], ["ligases", 1007], ["(", 1015], ["KPC", 1016], ["and", 1020], ["SCF", 1024], [")", 1027], [".", 1028], ["The", 1030], ["proteomic", 1034], ["studies", 1044], ["provide", 1052], ["enzyme", 1060], ["candidates", 1067], ["to", 1078], ["investigate", 1081], ["the", 1093], ["regulation", 1097], ["of", 1108], ["alpha", 1111], ["-", 1116], ["synuclein", 1117], ["and/or", 1127], ["other", 1134], ["LB", 1140], ["proteins", 1143], [",", 1151], ["which", 1153], ["may", 1159], ["contribute", 1163], ["to", 1174], ["the", 1177], ["formation", 1181], ["of", 1191], ["Lewy", 1194], ["bodies", 1199], ["and", 1206], ["the", 1210], ["toxicity", 1214], ["of", 1223], ["alpha", 1226], ["-", 1231], ["synuclein", 1232], ["in", 1242], ["the", 1245], ["related", 1249], ["neurodegenerative", 1257], ["disorders", 1275], [".", 1284]]}
{"context": "To determine long-term efficacy and safety of epilepsy surgery in children and adolescents with malformations of cortical development (MCD) and to identify differences in seizure outcome of the various MCD subgroups. Special focus was set on the newly introduced International League Against Epilepsy (ILAE) classification of focal cortical dysplasia (FCD). This is a single center retrospective cross-sectional analysis of prospectively collected data. age at surgery <18 years, pre-surgical evaluation and epilepsy surgery performed at the Vienna pediatric epilepsy center, histologically proven MCD, complete follow-up data for at least 12 months. Clinical variables evaluated: type and localization of MCD, type of surgery and a variety of clinical characteristics reported to be associated with (un-)favorable outcomes. MCD were classified following the existing classification schemes (Barkovich et al., 2012. Brain. 135, 1348-1369; Palmini et al., 2004. Neurology. 62, S2-S8) and the ILAE classification for FCD recently proposed by Bl\u00fcmcke in 2011. Seizure outcome was classified using the ILAE classification proposed by Wieser in 2001. 60 Patients (51.7% male) were included. Follow up was up to 14 (mean 4.4 \u00b1 3.2) years. Mean age at surgery was 8.0 \u00b1 6.0 (median 6.0) years; mean age at epilepsy onset was 2.9 \u00b1 3.2 (median 2.0) years; duration of epilepsy before surgery was 4.8 \u00b1 4.4 (median 3.0) years. 80% of the patients were seizure free at last follow-up. AEDs were successfully withdrawn in 56.7% of all patients. Extended surgery, lesion localization in the temporal lobes and absence of inter-ictal spikes in postsurgical EEG recordings were predictive of favorable seizure outcomes after surgery. However, no association was found between outcome and MCD sub-types. Epilepsy surgery is highly effective in carefully selected drug-resistant children with MCD. Surrogate markers for complete resection of the epileptogenic zone remain the only significant predictors for seizure freedom after surgery.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "1ca976e520c446edbad5c210775e0dc5", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[53, 55]], "char_spans": [[326, 349]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["long", 13], ["-", 17], ["term", 18], ["efficacy", 23], ["and", 32], ["safety", 36], ["of", 43], ["epilepsy", 46], ["surgery", 55], ["in", 63], ["children", 66], ["and", 75], ["adolescents", 79], ["with", 91], ["malformations", 96], ["of", 110], ["cortical", 113], ["development", 122], ["(", 134], ["MCD", 135], [")", 138], ["and", 140], ["to", 144], ["identify", 147], ["differences", 156], ["in", 168], ["seizure", 171], ["outcome", 179], ["of", 187], ["the", 190], ["various", 194], ["MCD", 202], ["subgroups", 206], [".", 215], ["Special", 217], ["focus", 225], ["was", 231], ["set", 235], ["on", 239], ["the", 242], ["newly", 246], ["introduced", 252], ["International", 263], ["League", 277], ["Against", 284], ["Epilepsy", 292], ["(", 301], ["ILAE", 302], [")", 306], ["classification", 308], ["of", 323], ["focal", 326], ["cortical", 332], ["dysplasia", 341], ["(", 351], ["FCD", 352], [")", 355], [".", 356], ["This", 358], ["is", 363], ["a", 366], ["single", 368], ["center", 375], ["retrospective", 382], ["cross", 396], ["-", 401], ["sectional", 402], ["analysis", 412], ["of", 421], ["prospectively", 424], ["collected", 438], ["data", 448], [".", 452], ["age", 454], ["at", 458], ["surgery", 461], ["<", 469], ["18", 470], ["years", 473], [",", 478], ["pre", 480], ["-", 483], ["surgical", 484], ["evaluation", 493], ["and", 504], ["epilepsy", 508], ["surgery", 517], ["performed", 525], ["at", 535], ["the", 538], ["Vienna", 542], ["pediatric", 549], ["epilepsy", 559], ["center", 568], [",", 574], ["histologically", 576], ["proven", 591], ["MCD", 598], [",", 601], ["complete", 603], ["follow", 612], ["-", 618], ["up", 619], ["data", 622], ["for", 627], ["at", 631], ["least", 634], ["12", 640], ["months", 643], [".", 649], ["Clinical", 651], ["variables", 660], ["evaluated", 670], [":", 679], ["type", 681], ["and", 686], ["localization", 690], ["of", 703], ["MCD", 706], [",", 709], ["type", 711], ["of", 716], ["surgery", 719], ["and", 727], ["a", 731], ["variety", 733], ["of", 741], ["clinical", 744], ["characteristics", 753], ["reported", 769], ["to", 778], ["be", 781], ["associated", 784], ["with", 795], ["(", 800], ["un-)favorable", 801], ["outcomes", 815], [".", 823], ["MCD", 825], ["were", 829], ["classified", 834], ["following", 845], ["the", 855], ["existing", 859], ["classification", 868], ["schemes", 883], ["(", 891], ["Barkovich", 892], ["et", 902], ["al", 905], [".", 907], [",", 908], ["2012", 910], [".", 914], ["Brain", 916], [".", 921], ["135", 923], [",", 926], ["1348", 928], ["-", 932], ["1369", 933], [";", 937], ["Palmini", 939], ["et", 947], ["al", 950], [".", 952], [",", 953], ["2004", 955], [".", 959], ["Neurology", 961], [".", 970], ["62", 972], [",", 974], ["S2-S8", 976], [")", 981], ["and", 983], ["the", 987], ["ILAE", 991], ["classification", 996], ["for", 1011], ["FCD", 1015], ["recently", 1019], ["proposed", 1028], ["by", 1037], ["Bl\u00fcmcke", 1040], ["in", 1048], ["2011", 1051], [".", 1055], ["Seizure", 1057], ["outcome", 1065], ["was", 1073], ["classified", 1077], ["using", 1088], ["the", 1094], ["ILAE", 1098], ["classification", 1103], ["proposed", 1118], ["by", 1127], ["Wieser", 1130], ["in", 1137], ["2001", 1140], [".", 1144], ["60", 1146], ["Patients", 1149], ["(", 1158], ["51.7", 1159], ["%", 1163], ["male", 1165], [")", 1169], ["were", 1171], ["included", 1176], [".", 1184], ["Follow", 1186], ["up", 1193], ["was", 1196], ["up", 1200], ["to", 1203], ["14", 1206], ["(", 1209], ["mean", 1210], ["4.4", 1215], ["\u00b1", 1219], ["3.2", 1221], [")", 1224], ["years", 1226], [".", 1231], ["Mean", 1233], ["age", 1238], ["at", 1242], ["surgery", 1245], ["was", 1253], ["8.0", 1257], ["\u00b1", 1261], ["6.0", 1263], ["(", 1267], ["median", 1268], ["6.0", 1275], [")", 1278], ["years", 1280], [";", 1285], ["mean", 1287], ["age", 1292], ["at", 1296], ["epilepsy", 1299], ["onset", 1308], ["was", 1314], ["2.9", 1318], ["\u00b1", 1322], ["3.2", 1324], ["(", 1328], ["median", 1329], ["2.0", 1336], [")", 1339], ["years", 1341], [";", 1346], ["duration", 1348], ["of", 1357], ["epilepsy", 1360], ["before", 1369], ["surgery", 1376], ["was", 1384], ["4.8", 1388], ["\u00b1", 1392], ["4.4", 1394], ["(", 1398], ["median", 1399], ["3.0", 1406], [")", 1409], ["years", 1411], [".", 1416], ["80", 1418], ["%", 1420], ["of", 1422], ["the", 1425], ["patients", 1429], ["were", 1438], ["seizure", 1443], ["free", 1451], ["at", 1456], ["last", 1459], ["follow", 1464], ["-", 1470], ["up", 1471], [".", 1473], ["AEDs", 1475], ["were", 1480], ["successfully", 1485], ["withdrawn", 1498], ["in", 1508], ["56.7", 1511], ["%", 1515], ["of", 1517], ["all", 1520], ["patients", 1524], [".", 1532], ["Extended", 1534], ["surgery", 1543], [",", 1550], ["lesion", 1552], ["localization", 1559], ["in", 1572], ["the", 1575], ["temporal", 1579], ["lobes", 1588], ["and", 1594], ["absence", 1598], ["of", 1606], ["inter", 1609], ["-", 1614], ["ictal", 1615], ["spikes", 1621], ["in", 1628], ["postsurgical", 1631], ["EEG", 1644], ["recordings", 1648], ["were", 1659], ["predictive", 1664], ["of", 1675], ["favorable", 1678], ["seizure", 1688], ["outcomes", 1696], ["after", 1705], ["surgery", 1711], [".", 1718], ["However", 1720], [",", 1727], ["no", 1729], ["association", 1732], ["was", 1744], ["found", 1748], ["between", 1754], ["outcome", 1762], ["and", 1770], ["MCD", 1774], ["sub", 1778], ["-", 1781], ["types", 1782], [".", 1787], ["Epilepsy", 1789], ["surgery", 1798], ["is", 1806], ["highly", 1809], ["effective", 1816], ["in", 1826], ["carefully", 1829], ["selected", 1839], ["drug", 1848], ["-", 1852], ["resistant", 1853], ["children", 1863], ["with", 1872], ["MCD", 1877], [".", 1880], ["Surrogate", 1882], ["markers", 1892], ["for", 1900], ["complete", 1904], ["resection", 1913], ["of", 1923], ["the", 1926], ["epileptogenic", 1930], ["zone", 1944], ["remain", 1949], ["the", 1956], ["only", 1960], ["significant", 1965], ["predictors", 1977], ["for", 1988], ["seizure", 1992], ["freedom", 2000], ["after", 2008], ["surgery", 2014], [".", 2021]]}
{"context": "Selective degradation of proteins by the ubiquitin-proteasome pathway is a critical determinant for maintaining cellular homeostasis. Most intracellular proteins are degraded by the proteasome, a multicatalytic enzyme complex containing a 20S catalytic core and two 19S regulatory complexes. Many proteasome target proteins are involved in the regulation of important processes of carcinogenesis and cancer cell survival, such as cell cycle progression, cell proliferation, differentiation and apoptosis. Indeed, the ubiquitin-proteasome-dependent degradation pathway plays an essential role in both the up-regulation of cell proliferation and down-regulation of cell death in human cancer cells. Both in vitro and in vivo experimental and clinical results have demonstrated the potential use of proteasome inhibitors as novel anticancer drugs. Proteasome inhibition in cancer cells leads to accumulation of pro-apoptotic target proteins followed by induction of cell death. The clinical efficacy of the proteasome inhibitor bortezomib toward multiple myeloma and other hematologic malignancies provides the \"proof of concept\" that targeting the proteasome is a promising strategy for cancer treatment. Several other proteasome inhibitors have also been identified from natural resources, such as marine microbial metabolites, green tea polyphenols, flavonoids, and medicinal compounds. Additionally, the use of metal complexes as proteasome inhibitors has also been investigated as a potential anticancer strategy. The clinical significance of targeting the tumor survival-associated proteasome pathway for cancer treatment, intervention and prevention will be discussed.", "qas": [{"question": "Which is the target of bortezomib used in cancer therapy?", "answers": ["The ubiquitin/proteasome pathway"], "qid": "db311c7e2115419da83e01e6c5610862", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["bortezomib", 23], ["used", 34], ["in", 39], ["cancer", 42], ["therapy", 49], ["?", 56]], "detected_answers": [{"text": "The ubiquitin/proteasome pathway", "token_spans": [[6, 9]], "char_spans": [[41, 68]]}]}], "context_tokens": [["Selective", 0], ["degradation", 10], ["of", 22], ["proteins", 25], ["by", 34], ["the", 37], ["ubiquitin", 41], ["-", 50], ["proteasome", 51], ["pathway", 62], ["is", 70], ["a", 73], ["critical", 75], ["determinant", 84], ["for", 96], ["maintaining", 100], ["cellular", 112], ["homeostasis", 121], [".", 132], ["Most", 134], ["intracellular", 139], ["proteins", 153], ["are", 162], ["degraded", 166], ["by", 175], ["the", 178], ["proteasome", 182], [",", 192], ["a", 194], ["multicatalytic", 196], ["enzyme", 211], ["complex", 218], ["containing", 226], ["a", 237], ["20S", 239], ["catalytic", 243], ["core", 253], ["and", 258], ["two", 262], ["19S", 266], ["regulatory", 270], ["complexes", 281], [".", 290], ["Many", 292], ["proteasome", 297], ["target", 308], ["proteins", 315], ["are", 324], ["involved", 328], ["in", 337], ["the", 340], ["regulation", 344], ["of", 355], ["important", 358], ["processes", 368], ["of", 378], ["carcinogenesis", 381], ["and", 396], ["cancer", 400], ["cell", 407], ["survival", 412], [",", 420], ["such", 422], ["as", 427], ["cell", 430], ["cycle", 435], ["progression", 441], [",", 452], ["cell", 454], ["proliferation", 459], [",", 472], ["differentiation", 474], ["and", 490], ["apoptosis", 494], [".", 503], ["Indeed", 505], [",", 511], ["the", 513], ["ubiquitin", 517], ["-", 526], ["proteasome", 527], ["-", 537], ["dependent", 538], ["degradation", 548], ["pathway", 560], ["plays", 568], ["an", 574], ["essential", 577], ["role", 587], ["in", 592], ["both", 595], ["the", 600], ["up", 604], ["-", 606], ["regulation", 607], ["of", 618], ["cell", 621], ["proliferation", 626], ["and", 640], ["down", 644], ["-", 648], ["regulation", 649], ["of", 660], ["cell", 663], ["death", 668], ["in", 674], ["human", 677], ["cancer", 683], ["cells", 690], [".", 695], ["Both", 697], ["in", 702], ["vitro", 705], ["and", 711], ["in", 715], ["vivo", 718], ["experimental", 723], ["and", 736], ["clinical", 740], ["results", 749], ["have", 757], ["demonstrated", 762], ["the", 775], ["potential", 779], ["use", 789], ["of", 793], ["proteasome", 796], ["inhibitors", 807], ["as", 818], ["novel", 821], ["anticancer", 827], ["drugs", 838], [".", 843], ["Proteasome", 845], ["inhibition", 856], ["in", 867], ["cancer", 870], ["cells", 877], ["leads", 883], ["to", 889], ["accumulation", 892], ["of", 905], ["pro", 908], ["-", 911], ["apoptotic", 912], ["target", 922], ["proteins", 929], ["followed", 938], ["by", 947], ["induction", 950], ["of", 960], ["cell", 963], ["death", 968], [".", 973], ["The", 975], ["clinical", 979], ["efficacy", 988], ["of", 997], ["the", 1000], ["proteasome", 1004], ["inhibitor", 1015], ["bortezomib", 1025], ["toward", 1036], ["multiple", 1043], ["myeloma", 1052], ["and", 1060], ["other", 1064], ["hematologic", 1070], ["malignancies", 1082], ["provides", 1095], ["the", 1104], ["\"", 1108], ["proof", 1109], ["of", 1115], ["concept", 1118], ["\"", 1125], ["that", 1127], ["targeting", 1132], ["the", 1142], ["proteasome", 1146], ["is", 1157], ["a", 1160], ["promising", 1162], ["strategy", 1172], ["for", 1181], ["cancer", 1185], ["treatment", 1192], [".", 1201], ["Several", 1203], ["other", 1211], ["proteasome", 1217], ["inhibitors", 1228], ["have", 1239], ["also", 1244], ["been", 1249], ["identified", 1254], ["from", 1265], ["natural", 1270], ["resources", 1278], [",", 1287], ["such", 1289], ["as", 1294], ["marine", 1297], ["microbial", 1304], ["metabolites", 1314], [",", 1325], ["green", 1327], ["tea", 1333], ["polyphenols", 1337], [",", 1348], ["flavonoids", 1350], [",", 1360], ["and", 1362], ["medicinal", 1366], ["compounds", 1376], [".", 1385], ["Additionally", 1387], [",", 1399], ["the", 1401], ["use", 1405], ["of", 1409], ["metal", 1412], ["complexes", 1418], ["as", 1428], ["proteasome", 1431], ["inhibitors", 1442], ["has", 1453], ["also", 1457], ["been", 1462], ["investigated", 1467], ["as", 1480], ["a", 1483], ["potential", 1485], ["anticancer", 1495], ["strategy", 1506], [".", 1514], ["The", 1516], ["clinical", 1520], ["significance", 1529], ["of", 1542], ["targeting", 1545], ["the", 1555], ["tumor", 1559], ["survival", 1565], ["-", 1573], ["associated", 1574], ["proteasome", 1585], ["pathway", 1596], ["for", 1604], ["cancer", 1608], ["treatment", 1615], [",", 1624], ["intervention", 1626], ["and", 1639], ["prevention", 1643], ["will", 1654], ["be", 1659], ["discussed", 1662], [".", 1671]]}
{"context": "Lysosomal storage diseases arise from a genetic loss-of-function defect in enzymes mediating key catabolic steps resulting in accumulation of substrate within the lysosome. Treatment of several of these disorders has been achieved by enzyme replacement therapy (ERT), in which a recombinant version of the defective enzyme is expressed in vitro and administered by infusion. However, in many cases the biodistribution of the administered protein does not match that of the accumulated substrate due to the glycosylation-mediated clearance of the enzymes from circulation, resulting in poor or absent substrate clearance from some tissues. To overcome this limitation, we have evaluated several peptide-based targeting motifs to redirect recombinant human alpha-galactosidase (rhalphaGal) to specific receptors. A reversible thiol-based PEGylation chemistry was developed to achieve multivalent peptide display with lysosomal release. In vitro, cell uptake was peptide dependent and independent of the normal mannose-6-phosphate receptor mediated pathway. Surprisingly, despite increased plasma half-life and decreased liver uptake, none of the peptide conjugates showed significantly altered biodistribution in alphaGal-knockout mice. This suggests that these peptide-based targeting motifs are unlikely to provide substantial therapeutic benefit likely due to the complexity of factors affecting PK and biodistribution.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "17805ad0408c48df91cdeb947ccf3371", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[124, 126]], "char_spans": [[755, 773]]}]}], "context_tokens": [["Lysosomal", 0], ["storage", 10], ["diseases", 18], ["arise", 27], ["from", 33], ["a", 38], ["genetic", 40], ["loss", 48], ["-", 52], ["of", 53], ["-", 55], ["function", 56], ["defect", 65], ["in", 72], ["enzymes", 75], ["mediating", 83], ["key", 93], ["catabolic", 97], ["steps", 107], ["resulting", 113], ["in", 123], ["accumulation", 126], ["of", 139], ["substrate", 142], ["within", 152], ["the", 159], ["lysosome", 163], [".", 171], ["Treatment", 173], ["of", 183], ["several", 186], ["of", 194], ["these", 197], ["disorders", 203], ["has", 213], ["been", 217], ["achieved", 222], ["by", 231], ["enzyme", 234], ["replacement", 241], ["therapy", 253], ["(", 261], ["ERT", 262], [")", 265], [",", 266], ["in", 268], ["which", 271], ["a", 277], ["recombinant", 279], ["version", 291], ["of", 299], ["the", 302], ["defective", 306], ["enzyme", 316], ["is", 323], ["expressed", 326], ["in", 336], ["vitro", 339], ["and", 345], ["administered", 349], ["by", 362], ["infusion", 365], [".", 373], ["However", 375], [",", 382], ["in", 384], ["many", 387], ["cases", 392], ["the", 398], ["biodistribution", 402], ["of", 418], ["the", 421], ["administered", 425], ["protein", 438], ["does", 446], ["not", 451], ["match", 455], ["that", 461], ["of", 466], ["the", 469], ["accumulated", 473], ["substrate", 485], ["due", 495], ["to", 499], ["the", 502], ["glycosylation", 506], ["-", 519], ["mediated", 520], ["clearance", 529], ["of", 539], ["the", 542], ["enzymes", 546], ["from", 554], ["circulation", 559], [",", 570], ["resulting", 572], ["in", 582], ["poor", 585], ["or", 590], ["absent", 593], ["substrate", 600], ["clearance", 610], ["from", 620], ["some", 625], ["tissues", 630], [".", 637], ["To", 639], ["overcome", 642], ["this", 651], ["limitation", 656], [",", 666], ["we", 668], ["have", 671], ["evaluated", 676], ["several", 686], ["peptide", 694], ["-", 701], ["based", 702], ["targeting", 708], ["motifs", 718], ["to", 725], ["redirect", 728], ["recombinant", 737], ["human", 749], ["alpha", 755], ["-", 760], ["galactosidase", 761], ["(", 775], ["rhalphaGal", 776], [")", 786], ["to", 788], ["specific", 791], ["receptors", 800], [".", 809], ["A", 811], ["reversible", 813], ["thiol", 824], ["-", 829], ["based", 830], ["PEGylation", 836], ["chemistry", 847], ["was", 857], ["developed", 861], ["to", 871], ["achieve", 874], ["multivalent", 882], ["peptide", 894], ["display", 902], ["with", 910], ["lysosomal", 915], ["release", 925], [".", 932], ["In", 934], ["vitro", 937], [",", 942], ["cell", 944], ["uptake", 949], ["was", 956], ["peptide", 960], ["dependent", 968], ["and", 978], ["independent", 982], ["of", 994], ["the", 997], ["normal", 1001], ["mannose-6-phosphate", 1008], ["receptor", 1028], ["mediated", 1037], ["pathway", 1046], [".", 1053], ["Surprisingly", 1055], [",", 1067], ["despite", 1069], ["increased", 1077], ["plasma", 1087], ["half", 1094], ["-", 1098], ["life", 1099], ["and", 1104], ["decreased", 1108], ["liver", 1118], ["uptake", 1124], [",", 1130], ["none", 1132], ["of", 1137], ["the", 1140], ["peptide", 1144], ["conjugates", 1152], ["showed", 1163], ["significantly", 1170], ["altered", 1184], ["biodistribution", 1192], ["in", 1208], ["alphaGal", 1211], ["-", 1219], ["knockout", 1220], ["mice", 1229], [".", 1233], ["This", 1235], ["suggests", 1240], ["that", 1249], ["these", 1254], ["peptide", 1260], ["-", 1267], ["based", 1268], ["targeting", 1274], ["motifs", 1284], ["are", 1291], ["unlikely", 1295], ["to", 1304], ["provide", 1307], ["substantial", 1315], ["therapeutic", 1327], ["benefit", 1339], ["likely", 1347], ["due", 1354], ["to", 1358], ["the", 1361], ["complexity", 1365], ["of", 1376], ["factors", 1379], ["affecting", 1387], ["PK", 1397], ["and", 1400], ["biodistribution", 1404], [".", 1419]]}
{"context": "The relevance of the Simpson grading system as a predictor of meningioma progression or recurrence in modern neurosurgical practice has recently been called into question. The aim of our study was to compare the risk of progression/recurrence of tumours that had been treated with different Simpson grade resections in a contemporary population of benign (WHO grade I) meningioma patients. One hundred eighty-three patients with histologically confirmed WHO grade I meningioma were retrospectively analysed. All patients underwent first-time craniotomy as their initial therapy between 2004 and 2012. Univariate analysis was performed using log-rank testing and Kaplan-Meier analysis for progression/recurrence-free survival. Multivariate analysis was performed using Cox proportional hazards regression modelling. The three-year progression/recurrence-free survival rates for patients receiving Simpson grade 1, 2 or 4 resections were 95 %, 87 % and 67 %, respectively. Simpson grade 4 resections progressed/recurred at a significantly greater rate than Simpson grade 1 resections (hazard ratio [HR]\u2009=\u20093.26, P\u2009=\u20090.04), whereas Simpson grade 2 resections did not progress/recur at a significantly greater rate than Simpson grade 1 resections (HR\u2009=\u20091.78, P\u2009=\u20090.29). Subtotal resections progressed/recurred at a significantly greater rate than gross-total resections (HR\u2009=\u20092.47, P\u2009=\u20090.03). Tumours that undergo subtotal resection are at a significantly greater risk of progression/recurrence than tumours that undergo gross-total resection. Gross-total resection should therefore be the aim of surgery. However, given modern access to follow-up imaging and stereotactic radiosurgery, these results should not be used to justify overly 'heroic' tumour resection.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "44e178e35d844cdd95994960d939d4dd", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[11, 11], [77, 77], [62, 62]], "char_spans": [[62, 71], [466, 475], [369, 378]]}]}], "context_tokens": [["The", 0], ["relevance", 4], ["of", 14], ["the", 17], ["Simpson", 21], ["grading", 29], ["system", 37], ["as", 44], ["a", 47], ["predictor", 49], ["of", 59], ["meningioma", 62], ["progression", 73], ["or", 85], ["recurrence", 88], ["in", 99], ["modern", 102], ["neurosurgical", 109], ["practice", 123], ["has", 132], ["recently", 136], ["been", 145], ["called", 150], ["into", 157], ["question", 162], [".", 170], ["The", 172], ["aim", 176], ["of", 180], ["our", 183], ["study", 187], ["was", 193], ["to", 197], ["compare", 200], ["the", 208], ["risk", 212], ["of", 217], ["progression", 220], ["/", 231], ["recurrence", 232], ["of", 243], ["tumours", 246], ["that", 254], ["had", 259], ["been", 263], ["treated", 268], ["with", 276], ["different", 281], ["Simpson", 291], ["grade", 299], ["resections", 305], ["in", 316], ["a", 319], ["contemporary", 321], ["population", 334], ["of", 345], ["benign", 348], ["(", 355], ["WHO", 356], ["grade", 360], ["I", 366], [")", 367], ["meningioma", 369], ["patients", 380], [".", 388], ["One", 390], ["hundred", 394], ["eighty", 402], ["-", 408], ["three", 409], ["patients", 415], ["with", 424], ["histologically", 429], ["confirmed", 444], ["WHO", 454], ["grade", 458], ["I", 464], ["meningioma", 466], ["were", 477], ["retrospectively", 482], ["analysed", 498], [".", 506], ["All", 508], ["patients", 512], ["underwent", 521], ["first", 531], ["-", 536], ["time", 537], ["craniotomy", 542], ["as", 553], ["their", 556], ["initial", 562], ["therapy", 570], ["between", 578], ["2004", 586], ["and", 591], ["2012", 595], [".", 599], ["Univariate", 601], ["analysis", 612], ["was", 621], ["performed", 625], ["using", 635], ["log", 641], ["-", 644], ["rank", 645], ["testing", 650], ["and", 658], ["Kaplan", 662], ["-", 668], ["Meier", 669], ["analysis", 675], ["for", 684], ["progression", 688], ["/", 699], ["recurrence", 700], ["-", 710], ["free", 711], ["survival", 716], [".", 724], ["Multivariate", 726], ["analysis", 739], ["was", 748], ["performed", 752], ["using", 762], ["Cox", 768], ["proportional", 772], ["hazards", 785], ["regression", 793], ["modelling", 804], [".", 813], ["The", 815], ["three", 819], ["-", 824], ["year", 825], ["progression", 830], ["/", 841], ["recurrence", 842], ["-", 852], ["free", 853], ["survival", 858], ["rates", 867], ["for", 873], ["patients", 877], ["receiving", 886], ["Simpson", 896], ["grade", 904], ["1", 910], [",", 911], ["2", 913], ["or", 915], ["4", 918], ["resections", 920], ["were", 931], ["95", 936], ["%", 939], [",", 940], ["87", 942], ["%", 945], ["and", 947], ["67", 951], ["%", 954], [",", 955], ["respectively", 957], [".", 969], ["Simpson", 971], ["grade", 979], ["4", 985], ["resections", 987], ["progressed", 998], ["/", 1008], ["recurred", 1009], ["at", 1018], ["a", 1021], ["significantly", 1023], ["greater", 1037], ["rate", 1045], ["than", 1050], ["Simpson", 1055], ["grade", 1063], ["1", 1069], ["resections", 1071], ["(", 1082], ["hazard", 1083], ["ratio", 1090], ["[", 1096], ["HR", 1097], ["]", 1099], ["=", 1101], ["3.26", 1103], [",", 1107], ["P", 1109], ["=", 1111], ["0.04", 1113], [")", 1117], [",", 1118], ["whereas", 1120], ["Simpson", 1128], ["grade", 1136], ["2", 1142], ["resections", 1144], ["did", 1155], ["not", 1159], ["progress", 1163], ["/", 1171], ["recur", 1172], ["at", 1178], ["a", 1181], ["significantly", 1183], ["greater", 1197], ["rate", 1205], ["than", 1210], ["Simpson", 1215], ["grade", 1223], ["1", 1229], ["resections", 1231], ["(", 1242], ["HR", 1243], ["=", 1246], ["1.78", 1248], [",", 1252], ["P", 1254], ["=", 1256], ["0.29", 1258], [")", 1262], [".", 1263], ["Subtotal", 1265], ["resections", 1274], ["progressed", 1285], ["/", 1295], ["recurred", 1296], ["at", 1305], ["a", 1308], ["significantly", 1310], ["greater", 1324], ["rate", 1332], ["than", 1337], ["gross", 1342], ["-", 1347], ["total", 1348], ["resections", 1354], ["(", 1365], ["HR", 1366], ["=", 1369], ["2.47", 1371], [",", 1375], ["P", 1377], ["=", 1379], ["0.03", 1381], [")", 1385], [".", 1386], ["Tumours", 1388], ["that", 1396], ["undergo", 1401], ["subtotal", 1409], ["resection", 1418], ["are", 1428], ["at", 1432], ["a", 1435], ["significantly", 1437], ["greater", 1451], ["risk", 1459], ["of", 1464], ["progression", 1467], ["/", 1478], ["recurrence", 1479], ["than", 1490], ["tumours", 1495], ["that", 1503], ["undergo", 1508], ["gross", 1516], ["-", 1521], ["total", 1522], ["resection", 1528], [".", 1537], ["Gross", 1539], ["-", 1544], ["total", 1545], ["resection", 1551], ["should", 1561], ["therefore", 1568], ["be", 1578], ["the", 1581], ["aim", 1585], ["of", 1589], ["surgery", 1592], [".", 1599], ["However", 1601], [",", 1608], ["given", 1610], ["modern", 1616], ["access", 1623], ["to", 1630], ["follow", 1633], ["-", 1639], ["up", 1640], ["imaging", 1643], ["and", 1651], ["stereotactic", 1655], ["radiosurgery", 1668], [",", 1680], ["these", 1682], ["results", 1688], ["should", 1696], ["not", 1703], ["be", 1707], ["used", 1710], ["to", 1715], ["justify", 1718], ["overly", 1726], ["'", 1733], ["heroic", 1734], ["'", 1740], ["tumour", 1742], ["resection", 1749], [".", 1758]]}
{"context": "TGF-\u03b21 regulates bone metabolism and mediates bone turnover during postmenopause. Sclerostin negatively regulates Wnt signaling pathway and also has an important role in postmenopausal bone loss. Little is known about the relationship between serum TGF-\u03b21 and sclerostin during menopause. We compared serum levels of TGF-\u03b21 and sclerostin in pre- and postmenopausal women and assessed the potential correlations of these levels with each other and with serum levels of bone turnover markers and bone mineral density. A total of 176 women (58 premenopausal, 62 early postmenopausal, and 56 late postmenopausal) were included in this study. Serum TGF-\u03b21 level was significantly higher in early postmenopausal women compared with premenopausal (32.0\u00b17.19 vs. 26.55\u00b16.67 ng/ml, p=0.01) and late postmenopausal (32.0\u00b17.19 vs. 28.65\u00b17.70 pg/ml, p=0.031) women, and no significant differences in serum sclerostin levels were observed among the 3 groups. There was a significant negative correlation between TGF-\u03b21 and sclerostin in early postmenopausal women, but not in other groups of women. Based on multiple regression analysis, only TGF-\u03b21 (\u03b2=-0.362; p=0.007) was an independent predictor of sclerostin during early postmenopause. Our findings suggest that serum TGF-\u03b21 level increases during postmenopause and declines in old age. Sclerostin production is inhibited by TGF-\u03b21 during early postmenopause.", "qas": [{"question": "Sclerostin regulates what process?", "answers": ["bone metabolism"], "qid": "ba738d6a94a647e9b9d8ac77b74a34a3", "question_tokens": [["Sclerostin", 0], ["regulates", 11], ["what", 21], ["process", 26], ["?", 33]], "detected_answers": [{"text": "bone metabolism", "token_spans": [[4, 5]], "char_spans": [[17, 31]]}]}], "context_tokens": [["TGF", 0], ["-", 3], ["\u03b21", 4], ["regulates", 7], ["bone", 17], ["metabolism", 22], ["and", 33], ["mediates", 37], ["bone", 46], ["turnover", 51], ["during", 60], ["postmenopause", 67], [".", 80], ["Sclerostin", 82], ["negatively", 93], ["regulates", 104], ["Wnt", 114], ["signaling", 118], ["pathway", 128], ["and", 136], ["also", 140], ["has", 145], ["an", 149], ["important", 152], ["role", 162], ["in", 167], ["postmenopausal", 170], ["bone", 185], ["loss", 190], [".", 194], ["Little", 196], ["is", 203], ["known", 206], ["about", 212], ["the", 218], ["relationship", 222], ["between", 235], ["serum", 243], ["TGF", 249], ["-", 252], ["\u03b21", 253], ["and", 256], ["sclerostin", 260], ["during", 271], ["menopause", 278], [".", 287], ["We", 289], ["compared", 292], ["serum", 301], ["levels", 307], ["of", 314], ["TGF", 317], ["-", 320], ["\u03b21", 321], ["and", 324], ["sclerostin", 328], ["in", 339], ["pre-", 342], ["and", 347], ["postmenopausal", 351], ["women", 366], ["and", 372], ["assessed", 376], ["the", 385], ["potential", 389], ["correlations", 399], ["of", 412], ["these", 415], ["levels", 421], ["with", 428], ["each", 433], ["other", 438], ["and", 444], ["with", 448], ["serum", 453], ["levels", 459], ["of", 466], ["bone", 469], ["turnover", 474], ["markers", 483], ["and", 491], ["bone", 495], ["mineral", 500], ["density", 508], [".", 515], ["A", 517], ["total", 519], ["of", 525], ["176", 528], ["women", 532], ["(", 538], ["58", 539], ["premenopausal", 542], [",", 555], ["62", 557], ["early", 560], ["postmenopausal", 566], [",", 580], ["and", 582], ["56", 586], ["late", 589], ["postmenopausal", 594], [")", 608], ["were", 610], ["included", 615], ["in", 624], ["this", 627], ["study", 632], [".", 637], ["Serum", 639], ["TGF", 645], ["-", 648], ["\u03b21", 649], ["level", 652], ["was", 658], ["significantly", 662], ["higher", 676], ["in", 683], ["early", 686], ["postmenopausal", 692], ["women", 707], ["compared", 713], ["with", 722], ["premenopausal", 727], ["(", 741], ["32.0\u00b17.19", 742], ["vs.", 752], ["26.55\u00b16.67", 756], ["ng", 767], ["/", 769], ["ml", 770], [",", 772], ["p=0.01", 774], [")", 780], ["and", 782], ["late", 786], ["postmenopausal", 791], ["(", 806], ["32.0\u00b17.19", 807], ["vs.", 817], ["28.65\u00b17.70", 821], ["pg", 832], ["/", 834], ["ml", 835], [",", 837], ["p=0.031", 839], [")", 846], ["women", 848], [",", 853], ["and", 855], ["no", 859], ["significant", 862], ["differences", 874], ["in", 886], ["serum", 889], ["sclerostin", 895], ["levels", 906], ["were", 913], ["observed", 918], ["among", 927], ["the", 933], ["3", 937], ["groups", 939], [".", 945], ["There", 947], ["was", 953], ["a", 957], ["significant", 959], ["negative", 971], ["correlation", 980], ["between", 992], ["TGF", 1000], ["-", 1003], ["\u03b21", 1004], ["and", 1007], ["sclerostin", 1011], ["in", 1022], ["early", 1025], ["postmenopausal", 1031], ["women", 1046], [",", 1051], ["but", 1053], ["not", 1057], ["in", 1061], ["other", 1064], ["groups", 1070], ["of", 1077], ["women", 1080], [".", 1085], ["Based", 1087], ["on", 1093], ["multiple", 1096], ["regression", 1105], ["analysis", 1116], [",", 1124], ["only", 1126], ["TGF", 1131], ["-", 1134], ["\u03b21", 1135], ["(", 1138], ["\u03b2=-0.362", 1139], [";", 1147], ["p=0.007", 1149], [")", 1156], ["was", 1158], ["an", 1162], ["independent", 1165], ["predictor", 1177], ["of", 1187], ["sclerostin", 1190], ["during", 1201], ["early", 1208], ["postmenopause", 1214], [".", 1227], ["Our", 1229], ["findings", 1233], ["suggest", 1242], ["that", 1250], ["serum", 1255], ["TGF", 1261], ["-", 1264], ["\u03b21", 1265], ["level", 1268], ["increases", 1274], ["during", 1284], ["postmenopause", 1291], ["and", 1305], ["declines", 1309], ["in", 1318], ["old", 1321], ["age", 1325], [".", 1328], ["Sclerostin", 1330], ["production", 1341], ["is", 1352], ["inhibited", 1355], ["by", 1365], ["TGF", 1368], ["-", 1371], ["\u03b21", 1372], ["during", 1375], ["early", 1382], ["postmenopause", 1388], [".", 1401]]}
{"context": "More than 500 unrelated patients with neurofibromatosis type 1 (NF1) were screened for mutations in the NF1 gene. For each patient, the whole coding sequence and all splice sites were studied for aberrations, either by the protein truncation test (PTT), temperature-gradient gel electrophoresis (TGGE) of genomic PCR products, or, most often, by direct genomic sequencing (DGS) of all individual exons. A total of 301 sequence variants, including 278 bona fide pathogenic mutations, were identified. As many as 216 or 183 of the genuine mutations, comprising 179 or 161 different ones, can be considered novel when compared to the recent findings of Upadhyaya and Cooper, or to the NNFF mutation database. Mutation-detection efficiencies of the various screening methods were similar: 47.1% for PTT, 53.7% for TGGE, and 54.9% for DGS. Some 224 mutations (80.2%) yielded directly or indirectly premature termination codons. These mutations showed even distribution over the whole gene from exon 1 to exon 47. Of all sequence variants determined in our study, <20% represent C-->T or G-->A transitions within a CpG dinucleotide, and only six different mutations also occur in NF1 pseudogenes, with five being typical C-->T transitions in a CpG. Thus, neither frequent deamination of 5-methylcytosines nor interchromosomal gene conversion may account for the high mutation rate of the NF1 gene. As opposed to the truncating mutations, the 28 (10.1%) missense or single-amino-acid-deletion mutations identified clustered in two distinct regions, the GAP-related domain (GRD) and an upstream gene segment comprising exons 11-17. The latter forms a so-called cysteine/serine-rich domain with three cysteine pairs suggestive of ATP binding, as well as three potential cAMP-dependent protein kinase (PKA) recognition sites obviously phosphorylated by PKA. Coincidence of mutated amino acids and those conserved between human and Drosophila strongly suggest significant functional relevance of this region, with major roles played by exons 12a and 15 and part of exon 16.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "beeb58f583fa4c9192e2fdb72f727d1a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[224, 224], [18, 18], [256, 256], [10, 10]], "char_spans": [[1174, 1176], [104, 106], [1382, 1384], [64, 66]]}]}], "context_tokens": [["More", 0], ["than", 5], ["500", 10], ["unrelated", 14], ["patients", 24], ["with", 33], ["neurofibromatosis", 38], ["type", 56], ["1", 61], ["(", 63], ["NF1", 64], [")", 67], ["were", 69], ["screened", 74], ["for", 83], ["mutations", 87], ["in", 97], ["the", 100], ["NF1", 104], ["gene", 108], [".", 112], ["For", 114], ["each", 118], ["patient", 123], [",", 130], ["the", 132], ["whole", 136], ["coding", 142], ["sequence", 149], ["and", 158], ["all", 162], ["splice", 166], ["sites", 173], ["were", 179], ["studied", 184], ["for", 192], ["aberrations", 196], [",", 207], ["either", 209], ["by", 216], ["the", 219], ["protein", 223], ["truncation", 231], ["test", 242], ["(", 247], ["PTT", 248], [")", 251], [",", 252], ["temperature", 254], ["-", 265], ["gradient", 266], ["gel", 275], ["electrophoresis", 279], ["(", 295], ["TGGE", 296], [")", 300], ["of", 302], ["genomic", 305], ["PCR", 313], ["products", 317], [",", 325], ["or", 327], [",", 329], ["most", 331], ["often", 336], [",", 341], ["by", 343], ["direct", 346], ["genomic", 353], ["sequencing", 361], ["(", 372], ["DGS", 373], [")", 376], ["of", 378], ["all", 381], ["individual", 385], ["exons", 396], [".", 401], ["A", 403], ["total", 405], ["of", 411], ["301", 414], ["sequence", 418], ["variants", 427], [",", 435], ["including", 437], ["278", 447], ["bona", 451], ["fide", 456], ["pathogenic", 461], ["mutations", 472], [",", 481], ["were", 483], ["identified", 488], [".", 498], ["As", 500], ["many", 503], ["as", 508], ["216", 511], ["or", 515], ["183", 518], ["of", 522], ["the", 525], ["genuine", 529], ["mutations", 537], [",", 546], ["comprising", 548], ["179", 559], ["or", 563], ["161", 566], ["different", 570], ["ones", 580], [",", 584], ["can", 586], ["be", 590], ["considered", 593], ["novel", 604], ["when", 610], ["compared", 615], ["to", 624], ["the", 627], ["recent", 631], ["findings", 638], ["of", 647], ["Upadhyaya", 650], ["and", 660], ["Cooper", 664], [",", 670], ["or", 672], ["to", 675], ["the", 678], ["NNFF", 682], ["mutation", 687], ["database", 696], [".", 704], ["Mutation", 706], ["-", 714], ["detection", 715], ["efficiencies", 725], ["of", 738], ["the", 741], ["various", 745], ["screening", 753], ["methods", 763], ["were", 771], ["similar", 776], [":", 783], ["47.1", 785], ["%", 789], ["for", 791], ["PTT", 795], [",", 798], ["53.7", 800], ["%", 804], ["for", 806], ["TGGE", 810], [",", 814], ["and", 816], ["54.9", 820], ["%", 824], ["for", 826], ["DGS", 830], [".", 833], ["Some", 835], ["224", 840], ["mutations", 844], ["(", 854], ["80.2", 855], ["%", 859], [")", 860], ["yielded", 862], ["directly", 870], ["or", 879], ["indirectly", 882], ["premature", 893], ["termination", 903], ["codons", 915], [".", 921], ["These", 923], ["mutations", 929], ["showed", 939], ["even", 946], ["distribution", 951], ["over", 964], ["the", 969], ["whole", 973], ["gene", 979], ["from", 984], ["exon", 989], ["1", 994], ["to", 996], ["exon", 999], ["47", 1004], [".", 1006], ["Of", 1008], ["all", 1011], ["sequence", 1015], ["variants", 1024], ["determined", 1033], ["in", 1044], ["our", 1047], ["study", 1051], [",", 1056], ["<", 1058], ["20", 1059], ["%", 1061], ["represent", 1063], ["C-->T", 1073], ["or", 1079], ["G-->A", 1082], ["transitions", 1088], ["within", 1100], ["a", 1107], ["CpG", 1109], ["dinucleotide", 1113], [",", 1125], ["and", 1127], ["only", 1131], ["six", 1136], ["different", 1140], ["mutations", 1150], ["also", 1160], ["occur", 1165], ["in", 1171], ["NF1", 1174], ["pseudogenes", 1178], [",", 1189], ["with", 1191], ["five", 1196], ["being", 1201], ["typical", 1207], ["C-->T", 1215], ["transitions", 1221], ["in", 1233], ["a", 1236], ["CpG.", 1238], ["Thus", 1243], [",", 1247], ["neither", 1249], ["frequent", 1257], ["deamination", 1266], ["of", 1278], ["5-methylcytosines", 1281], ["nor", 1299], ["interchromosomal", 1303], ["gene", 1320], ["conversion", 1325], ["may", 1336], ["account", 1340], ["for", 1348], ["the", 1352], ["high", 1356], ["mutation", 1361], ["rate", 1370], ["of", 1375], ["the", 1378], ["NF1", 1382], ["gene", 1386], [".", 1390], ["As", 1392], ["opposed", 1395], ["to", 1403], ["the", 1406], ["truncating", 1410], ["mutations", 1421], [",", 1430], ["the", 1432], ["28", 1436], ["(", 1439], ["10.1", 1440], ["%", 1444], [")", 1445], ["missense", 1447], ["or", 1456], ["single", 1459], ["-", 1465], ["amino", 1466], ["-", 1471], ["acid", 1472], ["-", 1476], ["deletion", 1477], ["mutations", 1486], ["identified", 1496], ["clustered", 1507], ["in", 1517], ["two", 1520], ["distinct", 1524], ["regions", 1533], [",", 1540], ["the", 1542], ["GAP", 1546], ["-", 1549], ["related", 1550], ["domain", 1558], ["(", 1565], ["GRD", 1566], [")", 1569], ["and", 1571], ["an", 1575], ["upstream", 1578], ["gene", 1587], ["segment", 1592], ["comprising", 1600], ["exons", 1611], ["11", 1617], ["-", 1619], ["17", 1620], [".", 1622], ["The", 1624], ["latter", 1628], ["forms", 1635], ["a", 1641], ["so", 1643], ["-", 1645], ["called", 1646], ["cysteine", 1653], ["/", 1661], ["serine", 1662], ["-", 1668], ["rich", 1669], ["domain", 1674], ["with", 1681], ["three", 1686], ["cysteine", 1692], ["pairs", 1701], ["suggestive", 1707], ["of", 1718], ["ATP", 1721], ["binding", 1725], [",", 1732], ["as", 1734], ["well", 1737], ["as", 1742], ["three", 1745], ["potential", 1751], ["cAMP", 1761], ["-", 1765], ["dependent", 1766], ["protein", 1776], ["kinase", 1784], ["(", 1791], ["PKA", 1792], [")", 1795], ["recognition", 1797], ["sites", 1809], ["obviously", 1815], ["phosphorylated", 1825], ["by", 1840], ["PKA", 1843], [".", 1846], ["Coincidence", 1848], ["of", 1860], ["mutated", 1863], ["amino", 1871], ["acids", 1877], ["and", 1883], ["those", 1887], ["conserved", 1893], ["between", 1903], ["human", 1911], ["and", 1917], ["Drosophila", 1921], ["strongly", 1932], ["suggest", 1941], ["significant", 1949], ["functional", 1961], ["relevance", 1972], ["of", 1982], ["this", 1985], ["region", 1990], [",", 1996], ["with", 1998], ["major", 2003], ["roles", 2009], ["played", 2015], ["by", 2022], ["exons", 2025], ["12a", 2031], ["and", 2035], ["15", 2039], ["and", 2042], ["part", 2046], ["of", 2051], ["exon", 2054], ["16", 2059], [".", 2061]]}
{"context": "The rarity and the inconsistent criteria for defining atypical meningioma prior to the WHO 2007 classification made its management and prognostic factors poorly understood. Only few articles have addressed the survival rates of WHO-classified atypical meningiomas. The small number or the disproportionate representation of irradiated patients was a weakness for these articles. This study evaluated whether the extent of surgery and receiving adjuvant radiotherapy after an initial operation along with other patient characteristics influenced the recurrence and survival rates of atypical meningiomas. The clinical and surgical notes of the 79 patients with grade II atypical meningioma treated at our center over 13 years were retrospectively evaluated. The histology grading was consistent with WHO 2007 classification. The Simpson grading system was used to assess the extent of surgical resection. Kaplan Meier analysis, Cox multivariate regression analysis, and the Log-rank test were conducted using STATA\u00ae statistical package. The average age at the time of initial operation was 58 years, and 54 % were males. The mean follow-up period was 50 months. In Cox multivariate analysis, only Simpson grading was predictive of recurrence (hazard ratio = 2.22 / 1 increase in Simpson grade. p\u2009=\u20090.003). Simpson grade I patients had a relapse-free survival rate of 97 and 74 % at one and five years, respectively, compared with 88 and 32 % in the subtotal resection group (Simpson grades II to IV). There was no statistically significant correlation between recurrence and subjecting patients to postoperative radiotherapy. Apart from Simpson grade I patients, there was a general trend for worse outcome in irradiated patients. The most important prognostic factor in determining recurrence was Simpson grading. There was no statistically significant impact of adjuvant radiotherapy on the recurrence of atypical meningiomas. Meta-analysis for the existing literature is needed.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "8a4e9bb9b22a4d77b479e8ccadb64015", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[9, 9], [101, 101]], "char_spans": [[63, 72], [678, 687]]}]}], "context_tokens": [["The", 0], ["rarity", 4], ["and", 11], ["the", 15], ["inconsistent", 19], ["criteria", 32], ["for", 41], ["defining", 45], ["atypical", 54], ["meningioma", 63], ["prior", 74], ["to", 80], ["the", 83], ["WHO", 87], ["2007", 91], ["classification", 96], ["made", 111], ["its", 116], ["management", 120], ["and", 131], ["prognostic", 135], ["factors", 146], ["poorly", 154], ["understood", 161], [".", 171], ["Only", 173], ["few", 178], ["articles", 182], ["have", 191], ["addressed", 196], ["the", 206], ["survival", 210], ["rates", 219], ["of", 225], ["WHO", 228], ["-", 231], ["classified", 232], ["atypical", 243], ["meningiomas", 252], [".", 263], ["The", 265], ["small", 269], ["number", 275], ["or", 282], ["the", 285], ["disproportionate", 289], ["representation", 306], ["of", 321], ["irradiated", 324], ["patients", 335], ["was", 344], ["a", 348], ["weakness", 350], ["for", 359], ["these", 363], ["articles", 369], [".", 377], ["This", 379], ["study", 384], ["evaluated", 390], ["whether", 400], ["the", 408], ["extent", 412], ["of", 419], ["surgery", 422], ["and", 430], ["receiving", 434], ["adjuvant", 444], ["radiotherapy", 453], ["after", 466], ["an", 472], ["initial", 475], ["operation", 483], ["along", 493], ["with", 499], ["other", 504], ["patient", 510], ["characteristics", 518], ["influenced", 534], ["the", 545], ["recurrence", 549], ["and", 560], ["survival", 564], ["rates", 573], ["of", 579], ["atypical", 582], ["meningiomas", 591], [".", 602], ["The", 604], ["clinical", 608], ["and", 617], ["surgical", 621], ["notes", 630], ["of", 636], ["the", 639], ["79", 643], ["patients", 646], ["with", 655], ["grade", 660], ["II", 666], ["atypical", 669], ["meningioma", 678], ["treated", 689], ["at", 697], ["our", 700], ["center", 704], ["over", 711], ["13", 716], ["years", 719], ["were", 725], ["retrospectively", 730], ["evaluated", 746], [".", 755], ["The", 757], ["histology", 761], ["grading", 771], ["was", 779], ["consistent", 783], ["with", 794], ["WHO", 799], ["2007", 803], ["classification", 808], [".", 822], ["The", 824], ["Simpson", 828], ["grading", 836], ["system", 844], ["was", 851], ["used", 855], ["to", 860], ["assess", 863], ["the", 870], ["extent", 874], ["of", 881], ["surgical", 884], ["resection", 893], [".", 902], ["Kaplan", 904], ["Meier", 911], ["analysis", 917], [",", 925], ["Cox", 927], ["multivariate", 931], ["regression", 944], ["analysis", 955], [",", 963], ["and", 965], ["the", 969], ["Log", 973], ["-", 976], ["rank", 977], ["test", 982], ["were", 987], ["conducted", 992], ["using", 1002], ["STATA", 1008], ["\u00ae", 1013], ["statistical", 1015], ["package", 1027], [".", 1034], ["The", 1036], ["average", 1040], ["age", 1048], ["at", 1052], ["the", 1055], ["time", 1059], ["of", 1064], ["initial", 1067], ["operation", 1075], ["was", 1085], ["58", 1089], ["years", 1092], [",", 1097], ["and", 1099], ["54", 1103], ["%", 1106], ["were", 1108], ["males", 1113], [".", 1118], ["The", 1120], ["mean", 1124], ["follow", 1129], ["-", 1135], ["up", 1136], ["period", 1139], ["was", 1146], ["50", 1150], ["months", 1153], [".", 1159], ["In", 1161], ["Cox", 1164], ["multivariate", 1168], ["analysis", 1181], [",", 1189], ["only", 1191], ["Simpson", 1196], ["grading", 1204], ["was", 1212], ["predictive", 1216], ["of", 1227], ["recurrence", 1230], ["(", 1241], ["hazard", 1242], ["ratio", 1249], ["=", 1255], ["2.22", 1257], ["/", 1262], ["1", 1264], ["increase", 1266], ["in", 1275], ["Simpson", 1278], ["grade", 1286], [".", 1291], ["p", 1293], ["=", 1295], ["0.003", 1297], [")", 1302], [".", 1303], ["Simpson", 1305], ["grade", 1313], ["I", 1319], ["patients", 1321], ["had", 1330], ["a", 1334], ["relapse", 1336], ["-", 1343], ["free", 1344], ["survival", 1349], ["rate", 1358], ["of", 1363], ["97", 1366], ["and", 1369], ["74", 1373], ["%", 1376], ["at", 1378], ["one", 1381], ["and", 1385], ["five", 1389], ["years", 1394], [",", 1399], ["respectively", 1401], [",", 1413], ["compared", 1415], ["with", 1424], ["88", 1429], ["and", 1432], ["32", 1436], ["%", 1439], ["in", 1441], ["the", 1444], ["subtotal", 1448], ["resection", 1457], ["group", 1467], ["(", 1473], ["Simpson", 1474], ["grades", 1482], ["II", 1489], ["to", 1492], ["IV", 1495], [")", 1497], [".", 1498], ["There", 1500], ["was", 1506], ["no", 1510], ["statistically", 1513], ["significant", 1527], ["correlation", 1539], ["between", 1551], ["recurrence", 1559], ["and", 1570], ["subjecting", 1574], ["patients", 1585], ["to", 1594], ["postoperative", 1597], ["radiotherapy", 1611], [".", 1623], ["Apart", 1625], ["from", 1631], ["Simpson", 1636], ["grade", 1644], ["I", 1650], ["patients", 1652], [",", 1660], ["there", 1662], ["was", 1668], ["a", 1672], ["general", 1674], ["trend", 1682], ["for", 1688], ["worse", 1692], ["outcome", 1698], ["in", 1706], ["irradiated", 1709], ["patients", 1720], [".", 1728], ["The", 1730], ["most", 1734], ["important", 1739], ["prognostic", 1749], ["factor", 1760], ["in", 1767], ["determining", 1770], ["recurrence", 1782], ["was", 1793], ["Simpson", 1797], ["grading", 1805], [".", 1812], ["There", 1814], ["was", 1820], ["no", 1824], ["statistically", 1827], ["significant", 1841], ["impact", 1853], ["of", 1860], ["adjuvant", 1863], ["radiotherapy", 1872], ["on", 1885], ["the", 1888], ["recurrence", 1892], ["of", 1903], ["atypical", 1906], ["meningiomas", 1915], [".", 1926], ["Meta", 1928], ["-", 1932], ["analysis", 1933], ["for", 1942], ["the", 1946], ["existing", 1950], ["literature", 1959], ["is", 1970], ["needed", 1973], [".", 1979]]}
{"context": "Disruption of FOXP2, a gene encoding a forkhead-domain transcription factor, causes a severe developmental disorder of verbal communication, involving profound articulation deficits, accompanied by linguistic and grammatical impairments. Investigation of the neural basis of this disorder has been limited previously to neuroimaging of affected children and adults. The discovery of the gene responsible, FOXP2, offers a unique opportunity to explore the relevant neural mechanisms from a molecular perspective. In the present study, we have determined the detailed spatial and temporal expression pattern of FOXP2 mRNA in the developing brain of mouse and human. We find expression in several structures including the cortical plate, basal ganglia, thalamus, inferior olives and cerebellum. These data support a role for FOXP2 in the development of corticostriatal and olivocerebellar circuits involved in motor control. We find intriguing concordance between regions of early expression and later sites of pathology suggested by neuroimaging. Moreover, the homologous pattern of FOXP2/Foxp2 expression in human and mouse argues for a role for this gene in development of motor-related circuits throughout mammalian species. Overall, this study provides support for the hypothesis that impairments in sequencing of movement and procedural learning might be central to the FOXP2-related speech and language disorder.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "2c0e0f4aa55c4021a72dbdfb12a37f40", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[95, 95], [133, 133], [62, 62], [2, 2]], "char_spans": [[609, 613], [822, 826], [405, 409], [14, 18]]}]}], "context_tokens": [["Disruption", 0], ["of", 11], ["FOXP2", 14], [",", 19], ["a", 21], ["gene", 23], ["encoding", 28], ["a", 37], ["forkhead", 39], ["-", 47], ["domain", 48], ["transcription", 55], ["factor", 69], [",", 75], ["causes", 77], ["a", 84], ["severe", 86], ["developmental", 93], ["disorder", 107], ["of", 116], ["verbal", 119], ["communication", 126], [",", 139], ["involving", 141], ["profound", 151], ["articulation", 160], ["deficits", 173], [",", 181], ["accompanied", 183], ["by", 195], ["linguistic", 198], ["and", 209], ["grammatical", 213], ["impairments", 225], [".", 236], ["Investigation", 238], ["of", 252], ["the", 255], ["neural", 259], ["basis", 266], ["of", 272], ["this", 275], ["disorder", 280], ["has", 289], ["been", 293], ["limited", 298], ["previously", 306], ["to", 317], ["neuroimaging", 320], ["of", 333], ["affected", 336], ["children", 345], ["and", 354], ["adults", 358], [".", 364], ["The", 366], ["discovery", 370], ["of", 380], ["the", 383], ["gene", 387], ["responsible", 392], [",", 403], ["FOXP2", 405], [",", 410], ["offers", 412], ["a", 419], ["unique", 421], ["opportunity", 428], ["to", 440], ["explore", 443], ["the", 451], ["relevant", 455], ["neural", 464], ["mechanisms", 471], ["from", 482], ["a", 487], ["molecular", 489], ["perspective", 499], [".", 510], ["In", 512], ["the", 515], ["present", 519], ["study", 527], [",", 532], ["we", 534], ["have", 537], ["determined", 542], ["the", 553], ["detailed", 557], ["spatial", 566], ["and", 574], ["temporal", 578], ["expression", 587], ["pattern", 598], ["of", 606], ["FOXP2", 609], ["mRNA", 615], ["in", 620], ["the", 623], ["developing", 627], ["brain", 638], ["of", 644], ["mouse", 647], ["and", 653], ["human", 657], [".", 662], ["We", 664], ["find", 667], ["expression", 672], ["in", 683], ["several", 686], ["structures", 694], ["including", 705], ["the", 715], ["cortical", 719], ["plate", 728], [",", 733], ["basal", 735], ["ganglia", 741], [",", 748], ["thalamus", 750], [",", 758], ["inferior", 760], ["olives", 769], ["and", 776], ["cerebellum", 780], [".", 790], ["These", 792], ["data", 798], ["support", 803], ["a", 811], ["role", 813], ["for", 818], ["FOXP2", 822], ["in", 828], ["the", 831], ["development", 835], ["of", 847], ["corticostriatal", 850], ["and", 866], ["olivocerebellar", 870], ["circuits", 886], ["involved", 895], ["in", 904], ["motor", 907], ["control", 913], [".", 920], ["We", 922], ["find", 925], ["intriguing", 930], ["concordance", 941], ["between", 953], ["regions", 961], ["of", 969], ["early", 972], ["expression", 978], ["and", 989], ["later", 993], ["sites", 999], ["of", 1005], ["pathology", 1008], ["suggested", 1018], ["by", 1028], ["neuroimaging", 1031], [".", 1043], ["Moreover", 1045], [",", 1053], ["the", 1055], ["homologous", 1059], ["pattern", 1070], ["of", 1078], ["FOXP2/Foxp2", 1081], ["expression", 1093], ["in", 1104], ["human", 1107], ["and", 1113], ["mouse", 1117], ["argues", 1123], ["for", 1130], ["a", 1134], ["role", 1136], ["for", 1141], ["this", 1145], ["gene", 1150], ["in", 1155], ["development", 1158], ["of", 1170], ["motor", 1173], ["-", 1178], ["related", 1179], ["circuits", 1187], ["throughout", 1196], ["mammalian", 1207], ["species", 1217], [".", 1224], ["Overall", 1226], [",", 1233], ["this", 1235], ["study", 1240], ["provides", 1246], ["support", 1255], ["for", 1263], ["the", 1267], ["hypothesis", 1271], ["that", 1282], ["impairments", 1287], ["in", 1299], ["sequencing", 1302], ["of", 1313], ["movement", 1316], ["and", 1325], ["procedural", 1329], ["learning", 1340], ["might", 1349], ["be", 1355], ["central", 1358], ["to", 1366], ["the", 1369], ["FOXP2-related", 1373], ["speech", 1387], ["and", 1394], ["language", 1398], ["disorder", 1407], [".", 1415]]}
{"context": "Mowat-Wilson syndrome is a recently delineated autosomal dominant developmental anomaly, whereby heterozygous mutations in the ZFHX1B gene cause mental retardation, delayed motor development, epilepsy and a wide spectrum of clinically heterogeneous features, suggestive of neurocristopathies at the cephalic, cardiac and vagal levels. However, our understanding of the etiology of this condition at the cellular level remains vague. This study presents the Zfhx1b protein expression domain in mouse embryos and correlates this with a novel mouse model involving a conditional mutation in the Zfhx1b gene in neural crest precursor cells. These mutant mice display craniofacial and gastrointestinal malformations that show resemblance to those found in human patients with Mowat-Wilson syndrome. In addition to these clinically recognized alterations, we document developmental defects in the heart, melanoblasts and sympathetic and parasympathetic anlagen. The latter observations in our mouse model for Mowat-Wilson suggest a hitherto unknown role for Zfhx1b in the development of these particular neural crest derivatives, which is a set of observations that should be acknowledged in the clinical management of this genetic disorder.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "9095328339f447188880bc5412e035d4", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[163, 163], [92, 92], [71, 71], [18, 18]], "char_spans": [[1052, 1057], [592, 597], [457, 462], [127, 132]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["recently", 27], ["delineated", 36], ["autosomal", 47], ["dominant", 57], ["developmental", 66], ["anomaly", 80], [",", 87], ["whereby", 89], ["heterozygous", 97], ["mutations", 110], ["in", 120], ["the", 123], ["ZFHX1B", 127], ["gene", 134], ["cause", 139], ["mental", 145], ["retardation", 152], [",", 163], ["delayed", 165], ["motor", 173], ["development", 179], [",", 190], ["epilepsy", 192], ["and", 201], ["a", 205], ["wide", 207], ["spectrum", 212], ["of", 221], ["clinically", 224], ["heterogeneous", 235], ["features", 249], [",", 257], ["suggestive", 259], ["of", 270], ["neurocristopathies", 273], ["at", 292], ["the", 295], ["cephalic", 299], [",", 307], ["cardiac", 309], ["and", 317], ["vagal", 321], ["levels", 327], [".", 333], ["However", 335], [",", 342], ["our", 344], ["understanding", 348], ["of", 362], ["the", 365], ["etiology", 369], ["of", 378], ["this", 381], ["condition", 386], ["at", 396], ["the", 399], ["cellular", 403], ["level", 412], ["remains", 418], ["vague", 426], [".", 431], ["This", 433], ["study", 438], ["presents", 444], ["the", 453], ["Zfhx1b", 457], ["protein", 464], ["expression", 472], ["domain", 483], ["in", 490], ["mouse", 493], ["embryos", 499], ["and", 507], ["correlates", 511], ["this", 522], ["with", 527], ["a", 532], ["novel", 534], ["mouse", 540], ["model", 546], ["involving", 552], ["a", 562], ["conditional", 564], ["mutation", 576], ["in", 585], ["the", 588], ["Zfhx1b", 592], ["gene", 599], ["in", 604], ["neural", 607], ["crest", 614], ["precursor", 620], ["cells", 630], [".", 635], ["These", 637], ["mutant", 643], ["mice", 650], ["display", 655], ["craniofacial", 663], ["and", 676], ["gastrointestinal", 680], ["malformations", 697], ["that", 711], ["show", 716], ["resemblance", 721], ["to", 733], ["those", 736], ["found", 742], ["in", 748], ["human", 751], ["patients", 757], ["with", 766], ["Mowat", 771], ["-", 776], ["Wilson", 777], ["syndrome", 784], [".", 792], ["In", 794], ["addition", 797], ["to", 806], ["these", 809], ["clinically", 815], ["recognized", 826], ["alterations", 837], [",", 848], ["we", 850], ["document", 853], ["developmental", 862], ["defects", 876], ["in", 884], ["the", 887], ["heart", 891], [",", 896], ["melanoblasts", 898], ["and", 911], ["sympathetic", 915], ["and", 927], ["parasympathetic", 931], ["anlagen", 947], [".", 954], ["The", 956], ["latter", 960], ["observations", 967], ["in", 980], ["our", 983], ["mouse", 987], ["model", 993], ["for", 999], ["Mowat", 1003], ["-", 1008], ["Wilson", 1009], ["suggest", 1016], ["a", 1024], ["hitherto", 1026], ["unknown", 1035], ["role", 1043], ["for", 1048], ["Zfhx1b", 1052], ["in", 1059], ["the", 1062], ["development", 1066], ["of", 1078], ["these", 1081], ["particular", 1087], ["neural", 1098], ["crest", 1105], ["derivatives", 1111], [",", 1122], ["which", 1124], ["is", 1130], ["a", 1133], ["set", 1135], ["of", 1139], ["observations", 1142], ["that", 1155], ["should", 1160], ["be", 1167], ["acknowledged", 1170], ["in", 1183], ["the", 1186], ["clinical", 1190], ["management", 1199], ["of", 1210], ["this", 1213], ["genetic", 1218], ["disorder", 1226], [".", 1234]]}
{"context": "Tuberculosis is responsible for more then 2 million deaths worldwide each year and vies with HIV as the world's most fatal infectious disease. In many developing countries, attempts to control the spread of infection rely solely on identification and treatment of those with active disease, ignoring subclinical infection. However, in developed countries, large efforts are also expended to identify and give prophylactic drugs to people with latent tuberculosis infection. Until recently, the 100-year-old tuberculin skin test (Mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations. Advances in scientific knowledge have led to the development of tests for tuberculosis that measure the production of interferon-gamma by T-cells stimulated in vitro with Mycobacterium tuberculosis-specific antigens. These interferon-gamma tests are highly specific and unaffected by prior Bacille Calmette-Gu\u00e9rin vaccination or immune reactivity to most atypical mycobacteria. They are more sensitive than the tuberculin skin test in detecting people with active tuberculosis, and their results correlate more closely with M. tuberculosis exposure risk factors than the tuberculin skin test in people likely to have latent tuberculosis infection. Science has caught up with one of the oldest diagnostic tests still in use worldwide, and the adoption of new, tuberculosis-specific interferon-gamma-based tests should move us one step closer to better control of this insidious pathogen.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "fc2548420f034a03b63b99f76249f358", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[0, 0], [99, 99], [122, 122], [74, 74], [234, 234], [140, 140], [184, 184], [194, 194], [209, 209]], "char_spans": [[0, 11], [593, 604], [732, 743], [450, 461], [1417, 1428], [843, 854], [1122, 1133], [1185, 1196], [1282, 1293]]}]}], "context_tokens": [["Tuberculosis", 0], ["is", 13], ["responsible", 16], ["for", 28], ["more", 32], ["then", 37], ["2", 42], ["million", 44], ["deaths", 52], ["worldwide", 59], ["each", 69], ["year", 74], ["and", 79], ["vies", 83], ["with", 88], ["HIV", 93], ["as", 97], ["the", 100], ["world", 104], ["'s", 109], ["most", 112], ["fatal", 117], ["infectious", 123], ["disease", 134], [".", 141], ["In", 143], ["many", 146], ["developing", 151], ["countries", 162], [",", 171], ["attempts", 173], ["to", 182], ["control", 185], ["the", 193], ["spread", 197], ["of", 204], ["infection", 207], ["rely", 217], ["solely", 222], ["on", 229], ["identification", 232], ["and", 247], ["treatment", 251], ["of", 261], ["those", 264], ["with", 270], ["active", 275], ["disease", 282], [",", 289], ["ignoring", 291], ["subclinical", 300], ["infection", 312], [".", 321], ["However", 323], [",", 330], ["in", 332], ["developed", 335], ["countries", 345], [",", 354], ["large", 356], ["efforts", 362], ["are", 370], ["also", 374], ["expended", 379], ["to", 388], ["identify", 391], ["and", 400], ["give", 404], ["prophylactic", 409], ["drugs", 422], ["to", 428], ["people", 431], ["with", 438], ["latent", 443], ["tuberculosis", 450], ["infection", 463], [".", 472], ["Until", 474], ["recently", 480], [",", 488], ["the", 490], ["100-year", 494], ["-", 502], ["old", 503], ["tuberculin", 507], ["skin", 518], ["test", 523], ["(", 528], ["Mantoux", 529], [")", 536], ["has", 538], ["been", 542], ["the", 547], ["only", 551], ["available", 556], ["diagnostic", 566], ["test", 577], ["for", 582], ["latent", 586], ["tuberculosis", 593], ["infection", 606], [",", 615], ["despite", 617], ["its", 625], ["many", 629], ["well", 634], ["-", 638], ["known", 639], ["limitations", 645], [".", 656], ["Advances", 658], ["in", 667], ["scientific", 670], ["knowledge", 681], ["have", 691], ["led", 696], ["to", 700], ["the", 703], ["development", 707], ["of", 719], ["tests", 722], ["for", 728], ["tuberculosis", 732], ["that", 745], ["measure", 750], ["the", 758], ["production", 762], ["of", 773], ["interferon", 776], ["-", 786], ["gamma", 787], ["by", 793], ["T", 796], ["-", 797], ["cells", 798], ["stimulated", 804], ["in", 815], ["vitro", 818], ["with", 824], ["Mycobacterium", 829], ["tuberculosis", 843], ["-", 855], ["specific", 856], ["antigens", 865], [".", 873], ["These", 875], ["interferon", 881], ["-", 891], ["gamma", 892], ["tests", 898], ["are", 904], ["highly", 908], ["specific", 915], ["and", 924], ["unaffected", 928], ["by", 939], ["prior", 942], ["Bacille", 948], ["Calmette", 956], ["-", 964], ["Gu\u00e9rin", 965], ["vaccination", 972], ["or", 984], ["immune", 987], ["reactivity", 994], ["to", 1005], ["most", 1008], ["atypical", 1013], ["mycobacteria", 1022], [".", 1034], ["They", 1036], ["are", 1041], ["more", 1045], ["sensitive", 1050], ["than", 1060], ["the", 1065], ["tuberculin", 1069], ["skin", 1080], ["test", 1085], ["in", 1090], ["detecting", 1093], ["people", 1103], ["with", 1110], ["active", 1115], ["tuberculosis", 1122], [",", 1134], ["and", 1136], ["their", 1140], ["results", 1146], ["correlate", 1154], ["more", 1164], ["closely", 1169], ["with", 1177], ["M.", 1182], ["tuberculosis", 1185], ["exposure", 1198], ["risk", 1207], ["factors", 1212], ["than", 1220], ["the", 1225], ["tuberculin", 1229], ["skin", 1240], ["test", 1245], ["in", 1250], ["people", 1253], ["likely", 1260], ["to", 1267], ["have", 1270], ["latent", 1275], ["tuberculosis", 1282], ["infection", 1295], [".", 1304], ["Science", 1306], ["has", 1314], ["caught", 1318], ["up", 1325], ["with", 1328], ["one", 1333], ["of", 1337], ["the", 1340], ["oldest", 1344], ["diagnostic", 1351], ["tests", 1362], ["still", 1368], ["in", 1374], ["use", 1377], ["worldwide", 1381], [",", 1390], ["and", 1392], ["the", 1396], ["adoption", 1400], ["of", 1409], ["new", 1412], [",", 1415], ["tuberculosis", 1417], ["-", 1429], ["specific", 1430], ["interferon", 1439], ["-", 1449], ["gamma", 1450], ["-", 1455], ["based", 1456], ["tests", 1462], ["should", 1468], ["move", 1475], ["us", 1480], ["one", 1483], ["step", 1487], ["closer", 1492], ["to", 1499], ["better", 1502], ["control", 1509], ["of", 1517], ["this", 1520], ["insidious", 1525], ["pathogen", 1535], [".", 1543]]}
{"context": "Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs. In 2008, the next-generation NNRTI etravirine was approved for the treatment of HIV-infected antiretroviral therapy-experienced individuals, including those with prior NNRTI exposure. NNRTIs are also increasingly being included in strategies to prevent HIV-1 infection. For example: (1) nevirapine is used to prevent mother-to-child transmission; (2) the ASPIRE (MTN 020) study will test whether a vaginal ring containing dapivirine can prevent HIV-1 infection in women; (3) a microbicide gel formulation containing the urea-PETT derivative MIV-150 is in a phase I study to evaluate safety, pharmacokinetics, pharmacodynamics and acceptability; and (4) a long acting rilpivirine formulation is under-development for pre-exposure prophylaxis. Given their widespread use, particularly in resource-limited settings, as well as their low genetic barriers to resistance, there are concerns about overlapping resistance between the different NNRTIs. Consequently, a better understanding of the resistance and cross-resistance profiles among the NNRTI class is important for predicting response to treatment, and surveillance of transmitted drug-resistance.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "f8585ae680a84b258cfa4b315d1378ba", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[48, 48]], "char_spans": [[309, 311]]}]}], "context_tokens": [["Nonnucleoside", 0], ["reverse", 14], ["transcriptase", 22], ["inhibitors", 36], ["(", 47], ["NNRTIs", 48], [")", 54], ["are", 56], ["widely", 60], ["used", 67], ["to", 72], ["treat", 75], ["HIV-1-infected", 81], ["individuals", 96], [";", 107], ["indeed", 109], ["most", 116], ["first", 121], ["-", 126], ["line", 127], ["antiretroviral", 132], ["therapies", 147], ["typically", 157], ["include", 167], ["one", 175], ["NNRTI", 179], ["in", 185], ["combination", 188], ["with", 200], ["two", 205], ["nucleoside", 209], ["analogs", 220], [".", 227], ["In", 229], ["2008", 232], [",", 236], ["the", 238], ["next", 242], ["-", 246], ["generation", 247], ["NNRTI", 258], ["etravirine", 264], ["was", 275], ["approved", 279], ["for", 288], ["the", 292], ["treatment", 296], ["of", 306], ["HIV", 309], ["-", 312], ["infected", 313], ["antiretroviral", 322], ["therapy", 337], ["-", 344], ["experienced", 345], ["individuals", 357], [",", 368], ["including", 370], ["those", 380], ["with", 386], ["prior", 391], ["NNRTI", 397], ["exposure", 403], [".", 411], ["NNRTIs", 413], ["are", 420], ["also", 424], ["increasingly", 429], ["being", 442], ["included", 448], ["in", 457], ["strategies", 460], ["to", 471], ["prevent", 474], ["HIV-1", 482], ["infection", 488], [".", 497], ["For", 499], ["example", 503], [":", 510], ["(", 512], ["1", 513], [")", 514], ["nevirapine", 516], ["is", 527], ["used", 530], ["to", 535], ["prevent", 538], ["mother", 546], ["-", 552], ["to", 553], ["-", 555], ["child", 556], ["transmission", 562], [";", 574], ["(", 576], ["2", 577], [")", 578], ["the", 580], ["ASPIRE", 584], ["(", 591], ["MTN", 592], ["020", 596], [")", 599], ["study", 601], ["will", 607], ["test", 612], ["whether", 617], ["a", 625], ["vaginal", 627], ["ring", 635], ["containing", 640], ["dapivirine", 651], ["can", 662], ["prevent", 666], ["HIV-1", 674], ["infection", 680], ["in", 690], ["women", 693], [";", 698], ["(", 700], ["3", 701], [")", 702], ["a", 704], ["microbicide", 706], ["gel", 718], ["formulation", 722], ["containing", 734], ["the", 745], ["urea", 749], ["-", 753], ["PETT", 754], ["derivative", 759], ["MIV-150", 770], ["is", 778], ["in", 781], ["a", 784], ["phase", 786], ["I", 792], ["study", 794], ["to", 800], ["evaluate", 803], ["safety", 812], [",", 818], ["pharmacokinetics", 820], [",", 836], ["pharmacodynamics", 838], ["and", 855], ["acceptability", 859], [";", 872], ["and", 874], ["(", 878], ["4", 879], [")", 880], ["a", 882], ["long", 884], ["acting", 889], ["rilpivirine", 896], ["formulation", 908], ["is", 920], ["under", 923], ["-", 928], ["development", 929], ["for", 941], ["pre", 945], ["-", 948], ["exposure", 949], ["prophylaxis", 958], [".", 969], ["Given", 971], ["their", 977], ["widespread", 983], ["use", 994], [",", 997], ["particularly", 999], ["in", 1012], ["resource", 1015], ["-", 1023], ["limited", 1024], ["settings", 1032], [",", 1040], ["as", 1042], ["well", 1045], ["as", 1050], ["their", 1053], ["low", 1059], ["genetic", 1063], ["barriers", 1071], ["to", 1080], ["resistance", 1083], [",", 1093], ["there", 1095], ["are", 1101], ["concerns", 1105], ["about", 1114], ["overlapping", 1120], ["resistance", 1132], ["between", 1143], ["the", 1151], ["different", 1155], ["NNRTIs", 1165], [".", 1171], ["Consequently", 1173], [",", 1185], ["a", 1187], ["better", 1189], ["understanding", 1196], ["of", 1210], ["the", 1213], ["resistance", 1217], ["and", 1228], ["cross", 1232], ["-", 1237], ["resistance", 1238], ["profiles", 1249], ["among", 1258], ["the", 1264], ["NNRTI", 1268], ["class", 1274], ["is", 1280], ["important", 1283], ["for", 1293], ["predicting", 1297], ["response", 1308], ["to", 1317], ["treatment", 1320], [",", 1329], ["and", 1331], ["surveillance", 1335], ["of", 1348], ["transmitted", 1351], ["drug", 1363], ["-", 1367], ["resistance", 1368], [".", 1378]]}
{"context": "Secretory phospholipase A2 (sPLA2), which links surfactant catabolism and lung inflammation, is associated with lung stiffness, surfactant dysfunction, and degree of respiratory support in acute respiratory distress syndrome and in some forms of neonatal lung injury. Varespladib potently inhibits sPLA2 in animal models. The authors investigate varespladib ex vivo efficacy in different forms of neonatal lung injury. Bronchoalveolar lavage fluid was obtained from 40 neonates affected by hyaline membrane disease, infections, or meconium aspiration and divided in 4 aliquots added with increasing varespladib or saline. sPLA2 activity, proteins, and albumin were measured. Dilution was corrected with the urea ratio. Varespladib was also tested in vitro against pancreatic sPLA2 mixed with different albumin concentration. Varespladib was able to inhibit sPLA2 in the types of neonatal lung injury investigated. sPLA2 activity was reduced in hyaline membrane disease (P < .0001), infections (P = .003), and meconium aspiration (P = .04) using 40 \u00b5M varespladib; 10 \u00b5M was able to lower enzyme activity (P = .001), with an IC(50) of 87 \u00b5M. An inverse relationship existed between protein level and activity reduction (r = 0.5; P = .029). The activity reduction/protein ratio tended to be higher in hyaline membrane disease. Varespladib efficacy was higher in vitro than in lavage fluids obtained from neonates (P < .001).", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "1aedf35d15b449439a4efb13c4c5ebd0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[0, 2]], "char_spans": [[0, 25]]}]}], "context_tokens": [["Secretory", 0], ["phospholipase", 10], ["A2", 24], ["(", 27], ["sPLA2", 28], [")", 33], [",", 34], ["which", 36], ["links", 42], ["surfactant", 48], ["catabolism", 59], ["and", 70], ["lung", 74], ["inflammation", 79], [",", 91], ["is", 93], ["associated", 96], ["with", 107], ["lung", 112], ["stiffness", 117], [",", 126], ["surfactant", 128], ["dysfunction", 139], [",", 150], ["and", 152], ["degree", 156], ["of", 163], ["respiratory", 166], ["support", 178], ["in", 186], ["acute", 189], ["respiratory", 195], ["distress", 207], ["syndrome", 216], ["and", 225], ["in", 229], ["some", 232], ["forms", 237], ["of", 243], ["neonatal", 246], ["lung", 255], ["injury", 260], [".", 266], ["Varespladib", 268], ["potently", 280], ["inhibits", 289], ["sPLA2", 298], ["in", 304], ["animal", 307], ["models", 314], [".", 320], ["The", 322], ["authors", 326], ["investigate", 334], ["varespladib", 346], ["ex", 358], ["vivo", 361], ["efficacy", 366], ["in", 375], ["different", 378], ["forms", 388], ["of", 394], ["neonatal", 397], ["lung", 406], ["injury", 411], [".", 417], ["Bronchoalveolar", 419], ["lavage", 435], ["fluid", 442], ["was", 448], ["obtained", 452], ["from", 461], ["40", 466], ["neonates", 469], ["affected", 478], ["by", 487], ["hyaline", 490], ["membrane", 498], ["disease", 507], [",", 514], ["infections", 516], [",", 526], ["or", 528], ["meconium", 531], ["aspiration", 540], ["and", 551], ["divided", 555], ["in", 563], ["4", 566], ["aliquots", 568], ["added", 577], ["with", 583], ["increasing", 588], ["varespladib", 599], ["or", 611], ["saline", 614], [".", 620], ["sPLA2", 622], ["activity", 628], [",", 636], ["proteins", 638], [",", 646], ["and", 648], ["albumin", 652], ["were", 660], ["measured", 665], [".", 673], ["Dilution", 675], ["was", 684], ["corrected", 688], ["with", 698], ["the", 703], ["urea", 707], ["ratio", 712], [".", 717], ["Varespladib", 719], ["was", 731], ["also", 735], ["tested", 740], ["in", 747], ["vitro", 750], ["against", 756], ["pancreatic", 764], ["sPLA2", 775], ["mixed", 781], ["with", 787], ["different", 792], ["albumin", 802], ["concentration", 810], [".", 823], ["Varespladib", 825], ["was", 837], ["able", 841], ["to", 846], ["inhibit", 849], ["sPLA2", 857], ["in", 863], ["the", 866], ["types", 870], ["of", 876], ["neonatal", 879], ["lung", 888], ["injury", 893], ["investigated", 900], [".", 912], ["sPLA2", 914], ["activity", 920], ["was", 929], ["reduced", 933], ["in", 941], ["hyaline", 944], ["membrane", 952], ["disease", 961], ["(", 969], ["P", 970], ["<", 972], [".0001", 974], [")", 979], [",", 980], ["infections", 982], ["(", 993], ["P", 994], ["=", 996], [".003", 998], [")", 1002], [",", 1003], ["and", 1005], ["meconium", 1009], ["aspiration", 1018], ["(", 1029], ["P", 1030], ["=", 1032], [".04", 1034], [")", 1037], ["using", 1039], ["40", 1045], ["\u00b5M", 1048], ["varespladib", 1051], [";", 1062], ["10", 1064], ["\u00b5M", 1067], ["was", 1070], ["able", 1074], ["to", 1079], ["lower", 1082], ["enzyme", 1088], ["activity", 1095], ["(", 1104], ["P", 1105], ["=", 1107], [".001", 1109], [")", 1113], [",", 1114], ["with", 1116], ["an", 1121], ["IC(50", 1124], [")", 1129], ["of", 1131], ["87", 1134], ["\u00b5M.", 1137], ["An", 1141], ["inverse", 1144], ["relationship", 1152], ["existed", 1165], ["between", 1173], ["protein", 1181], ["level", 1189], ["and", 1195], ["activity", 1199], ["reduction", 1208], ["(", 1218], ["r", 1219], ["=", 1221], ["0.5", 1223], [";", 1226], ["P", 1228], ["=", 1230], [".029", 1232], [")", 1236], [".", 1237], ["The", 1239], ["activity", 1243], ["reduction", 1252], ["/", 1261], ["protein", 1262], ["ratio", 1270], ["tended", 1276], ["to", 1283], ["be", 1286], ["higher", 1289], ["in", 1296], ["hyaline", 1299], ["membrane", 1307], ["disease", 1316], [".", 1323], ["Varespladib", 1325], ["efficacy", 1337], ["was", 1346], ["higher", 1350], ["in", 1357], ["vitro", 1360], ["than", 1366], ["in", 1371], ["lavage", 1374], ["fluids", 1381], ["obtained", 1388], ["from", 1397], ["neonates", 1402], ["(", 1411], ["P", 1412], ["<", 1414], [".001", 1416], [")", 1420], [".", 1421]]}
{"context": "Identifying and tackling the social determinants of infectious diseases has become a public health priority following the recognition that individuals with lower socioeconomic status are disproportionately affected by infectious diseases. In many parts of the world, epidemiologically and genotypically defined community-associated (CA) methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged to become frequent causes of hospital infection. The aim of this study was to use spatial models with adjustment for area-level hospital attendance to determine the transmission niche of genotypically defined CA- and health-care-associated (HA)-MRSA strains across a diverse region of South East London and to explore a potential link between MRSA carriage and markers of social and material deprivation. This study involved spatial analysis of cross-sectional data linked with all MRSA isolates identified by three National Health Service (NHS) microbiology laboratories between 1 November 2011 and 29 February 2012. The cohort of hospital-based NHS microbiology diagnostic services serves 867,254 usual residents in the Lambeth, Southwark, and Lewisham boroughs in South East London, United Kingdom (UK). Isolates were classified as HA- or CA-MRSA based on whole genome sequencing. All MRSA cases identified over 4 mo within the three-borough catchment area (n = 471) were mapped to small geographies and linked to area-level aggregated socioeconomic and demographic data. Disease mapping and ecological regression models were used to infer the most likely transmission niches for each MRSA genetic classification and to describe the spatial epidemiology of MRSA in relation to social determinants. Specifically, we aimed to identify demographic and socioeconomic population traits that explain cross-area extra variation in HA- and CA-MRSA relative risks following adjustment for hospital attendance data. We explored the potential for associations with the English Indices of Deprivation 2010 (including the Index of Multiple Deprivation and several deprivation domains and subdomains) and the 2011 England and Wales census demographic and socioeconomic indicators (including numbers of households by deprivation dimension) and indicators of population health. Both CA-and HA-MRSA were associated with household deprivation (CA-MRSA relative risk [RR]: 1.72 [1.03-2.94]; HA-MRSA RR: 1.57 [1.06-2.33]), which was correlated with hospital attendance (Pearson correlation coefficient [PCC] = 0.76). HA-MRSA was also associated with poor health (RR: 1.10 [1.01-1.19]) and residence in communal care homes (RR: 1.24 [1.12-1.37]), whereas CA-MRSA was linked with household overcrowding (RR: 1.58 [1.04-2.41]) and wider barriers, which represent a combined score for household overcrowding, low income, and homelessness (RR: 1.76 [1.16-2.70]). CA-MRSA was also associated with recent immigration to the UK (RR: 1.77 [1.19-2.66]). For the area-level variation in RR for CA-MRSA, 28.67% was attributable to the spatial arrangement of target geographies, compared with only 0.09% for HA-MRSA. An advantage to our study is that it provided a representative sample of usual residents receiving care in the catchment areas. A limitation is that relationships apparent in aggregated data analyses cannot be assumed to operate at the individual level. There was no evidence of community transmission of HA-MRSA strains, implying that HA-MRSA cases identified in the community originate from the hospital reservoir and are maintained by frequent attendance at health care facilities. In contrast, there was a high risk of CA-MRSA in deprived areas linked with overcrowding, homelessness, low income, and recent immigration to the UK, which was not explainable by health care exposure. Furthermore, areas adjacent to these deprived areas were themselves at greater risk of CA-MRSA, indicating community transmission of CA-MRSA. This ongoing community transmission could lead to CA-MRSA becoming the dominant strain types carried by patients admitted to hospital, particularly if successful hospital-based MRSA infection control programmes are maintained. These results suggest that community infection control programmes targeting transmission of CA-MRSA will be required to control MRSA in both the community and hospital. These epidemiological changes will also have implications for effectiveness of risk-factor-based hospital admission MRSA screening programmes.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "c8be4f51b2ab4a5381c642b0ef7213c6", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[213, 213], [141, 141], [205, 205], [275, 275], [429, 429], [629, 629], [715, 715], [622, 622], [707, 707], [765, 765], [771, 771], [383, 383], [513, 513], [399, 399], [305, 305], [118, 118], [54, 54], [374, 374], [662, 662], [726, 726], [796, 796], [265, 265], [567, 567], [745, 745], [466, 466], [545, 545]], "char_spans": [[1297, 1300], [891, 894], [1254, 1257], [1669, 1672], [2512, 2515], [3435, 3438], [3918, 3921], [3404, 3407], [3872, 3875], [4246, 4249], [4279, 4282], [2341, 2344], [2853, 2856], [2387, 2390], [1847, 1850], [752, 755], [382, 385], [2289, 2292], [3622, 3625], [3977, 3980], [4436, 4439], [1597, 1600], [3090, 3093], [4101, 4104], [2649, 2652], [2978, 2981]]}]}], "context_tokens": [["Identifying", 0], ["and", 12], ["tackling", 16], ["the", 25], ["social", 29], ["determinants", 36], ["of", 49], ["infectious", 52], ["diseases", 63], ["has", 72], ["become", 76], ["a", 83], ["public", 85], ["health", 92], ["priority", 99], ["following", 108], ["the", 118], ["recognition", 122], ["that", 134], ["individuals", 139], ["with", 151], ["lower", 156], ["socioeconomic", 162], ["status", 176], ["are", 183], ["disproportionately", 187], ["affected", 206], ["by", 215], ["infectious", 218], ["diseases", 229], [".", 237], ["In", 239], ["many", 242], ["parts", 247], ["of", 253], ["the", 256], ["world", 260], [",", 265], ["epidemiologically", 267], ["and", 285], ["genotypically", 289], ["defined", 303], ["community", 311], ["-", 320], ["associated", 321], ["(", 332], ["CA", 333], [")", 335], ["methicillin", 337], ["-", 348], ["resistant", 349], ["Staphylococcus", 359], ["aureus", 374], ["(", 381], ["MRSA", 382], [")", 386], ["strains", 388], ["have", 396], ["emerged", 401], ["to", 409], ["become", 412], ["frequent", 419], ["causes", 428], ["of", 435], ["hospital", 438], ["infection", 447], [".", 456], ["The", 458], ["aim", 462], ["of", 466], ["this", 469], ["study", 474], ["was", 480], ["to", 484], ["use", 487], ["spatial", 491], ["models", 499], ["with", 506], ["adjustment", 511], ["for", 522], ["area", 526], ["-", 530], ["level", 531], ["hospital", 537], ["attendance", 546], ["to", 557], ["determine", 560], ["the", 570], ["transmission", 574], ["niche", 587], ["of", 593], ["genotypically", 596], ["defined", 610], ["CA-", 618], ["and", 622], ["health", 626], ["-", 632], ["care", 633], ["-", 637], ["associated", 638], ["(", 649], ["HA)-MRSA", 650], ["strains", 659], ["across", 667], ["a", 674], ["diverse", 676], ["region", 684], ["of", 691], ["South", 694], ["East", 700], ["London", 705], ["and", 712], ["to", 716], ["explore", 719], ["a", 727], ["potential", 729], ["link", 739], ["between", 744], ["MRSA", 752], ["carriage", 757], ["and", 766], ["markers", 770], ["of", 778], ["social", 781], ["and", 788], ["material", 792], ["deprivation", 801], [".", 812], ["This", 814], ["study", 819], ["involved", 825], ["spatial", 834], ["analysis", 842], ["of", 851], ["cross", 854], ["-", 859], ["sectional", 860], ["data", 870], ["linked", 875], ["with", 882], ["all", 887], ["MRSA", 891], ["isolates", 896], ["identified", 905], ["by", 916], ["three", 919], ["National", 925], ["Health", 934], ["Service", 941], ["(", 949], ["NHS", 950], [")", 953], ["microbiology", 955], ["laboratories", 968], ["between", 981], ["1", 989], ["November", 991], ["2011", 1000], ["and", 1005], ["29", 1009], ["February", 1012], ["2012", 1021], [".", 1025], ["The", 1027], ["cohort", 1031], ["of", 1038], ["hospital", 1041], ["-", 1049], ["based", 1050], ["NHS", 1056], ["microbiology", 1060], ["diagnostic", 1073], ["services", 1084], ["serves", 1093], ["867,254", 1100], ["usual", 1108], ["residents", 1114], ["in", 1124], ["the", 1127], ["Lambeth", 1131], [",", 1138], ["Southwark", 1140], [",", 1149], ["and", 1151], ["Lewisham", 1155], ["boroughs", 1164], ["in", 1173], ["South", 1176], ["East", 1182], ["London", 1187], [",", 1193], ["United", 1195], ["Kingdom", 1202], ["(", 1210], ["UK", 1211], [")", 1213], [".", 1214], ["Isolates", 1216], ["were", 1225], ["classified", 1230], ["as", 1241], ["HA-", 1244], ["or", 1248], ["CA", 1251], ["-", 1253], ["MRSA", 1254], ["based", 1259], ["on", 1265], ["whole", 1268], ["genome", 1274], ["sequencing", 1281], [".", 1291], ["All", 1293], ["MRSA", 1297], ["cases", 1302], ["identified", 1308], ["over", 1319], ["4", 1324], ["mo", 1326], ["within", 1329], ["the", 1336], ["three", 1340], ["-", 1345], ["borough", 1346], ["catchment", 1354], ["area", 1364], ["(", 1369], ["n", 1370], ["=", 1372], ["471", 1374], [")", 1377], ["were", 1379], ["mapped", 1384], ["to", 1391], ["small", 1394], ["geographies", 1400], ["and", 1412], ["linked", 1416], ["to", 1423], ["area", 1426], ["-", 1430], ["level", 1431], ["aggregated", 1437], ["socioeconomic", 1448], ["and", 1462], ["demographic", 1466], ["data", 1478], [".", 1482], ["Disease", 1484], ["mapping", 1492], ["and", 1500], ["ecological", 1504], ["regression", 1515], ["models", 1526], ["were", 1533], ["used", 1538], ["to", 1543], ["infer", 1546], ["the", 1552], ["most", 1556], ["likely", 1561], ["transmission", 1568], ["niches", 1581], ["for", 1588], ["each", 1592], ["MRSA", 1597], ["genetic", 1602], ["classification", 1610], ["and", 1625], ["to", 1629], ["describe", 1632], ["the", 1641], ["spatial", 1645], ["epidemiology", 1653], ["of", 1666], ["MRSA", 1669], ["in", 1674], ["relation", 1677], ["to", 1686], ["social", 1689], ["determinants", 1696], [".", 1708], ["Specifically", 1710], [",", 1722], ["we", 1724], ["aimed", 1727], ["to", 1733], ["identify", 1736], ["demographic", 1745], ["and", 1757], ["socioeconomic", 1761], ["population", 1775], ["traits", 1786], ["that", 1793], ["explain", 1798], ["cross", 1806], ["-", 1811], ["area", 1812], ["extra", 1817], ["variation", 1823], ["in", 1833], ["HA-", 1836], ["and", 1840], ["CA", 1844], ["-", 1846], ["MRSA", 1847], ["relative", 1852], ["risks", 1861], ["following", 1867], ["adjustment", 1877], ["for", 1888], ["hospital", 1892], ["attendance", 1901], ["data", 1912], [".", 1916], ["We", 1918], ["explored", 1921], ["the", 1930], ["potential", 1934], ["for", 1944], ["associations", 1948], ["with", 1961], ["the", 1966], ["English", 1970], ["Indices", 1978], ["of", 1986], ["Deprivation", 1989], ["2010", 2001], ["(", 2006], ["including", 2007], ["the", 2017], ["Index", 2021], ["of", 2027], ["Multiple", 2030], ["Deprivation", 2039], ["and", 2051], ["several", 2055], ["deprivation", 2063], ["domains", 2075], ["and", 2083], ["subdomains", 2087], [")", 2097], ["and", 2099], ["the", 2103], ["2011", 2107], ["England", 2112], ["and", 2120], ["Wales", 2124], ["census", 2130], ["demographic", 2137], ["and", 2149], ["socioeconomic", 2153], ["indicators", 2167], ["(", 2178], ["including", 2179], ["numbers", 2189], ["of", 2197], ["households", 2200], ["by", 2211], ["deprivation", 2214], ["dimension", 2226], [")", 2235], ["and", 2237], ["indicators", 2241], ["of", 2252], ["population", 2255], ["health", 2266], [".", 2272], ["Both", 2274], ["CA", 2279], ["-", 2281], ["and", 2282], ["HA", 2286], ["-", 2288], ["MRSA", 2289], ["were", 2294], ["associated", 2299], ["with", 2310], ["household", 2315], ["deprivation", 2325], ["(", 2337], ["CA", 2338], ["-", 2340], ["MRSA", 2341], ["relative", 2346], ["risk", 2355], ["[", 2360], ["RR", 2361], ["]", 2363], [":", 2364], ["1.72", 2366], ["[", 2371], ["1.03", 2372], ["-", 2376], ["2.94", 2377], ["]", 2381], [";", 2382], ["HA", 2384], ["-", 2386], ["MRSA", 2387], ["RR", 2392], [":", 2394], ["1.57", 2396], ["[", 2401], ["1.06", 2402], ["-", 2406], ["2.33", 2407], ["]", 2411], [")", 2412], [",", 2413], ["which", 2415], ["was", 2421], ["correlated", 2425], ["with", 2436], ["hospital", 2441], ["attendance", 2450], ["(", 2461], ["Pearson", 2462], ["correlation", 2470], ["coefficient", 2482], ["[", 2494], ["PCC", 2495], ["]", 2498], ["=", 2500], ["0.76", 2502], [")", 2506], [".", 2507], ["HA", 2509], ["-", 2511], ["MRSA", 2512], ["was", 2517], ["also", 2521], ["associated", 2526], ["with", 2537], ["poor", 2542], ["health", 2547], ["(", 2554], ["RR", 2555], [":", 2557], ["1.10", 2559], ["[", 2564], ["1.01", 2565], ["-", 2569], ["1.19", 2570], ["]", 2574], [")", 2575], ["and", 2577], ["residence", 2581], ["in", 2591], ["communal", 2594], ["care", 2603], ["homes", 2608], ["(", 2614], ["RR", 2615], [":", 2617], ["1.24", 2619], ["[", 2624], ["1.12", 2625], ["-", 2629], ["1.37", 2630], ["]", 2634], [")", 2635], [",", 2636], ["whereas", 2638], ["CA", 2646], ["-", 2648], ["MRSA", 2649], ["was", 2654], ["linked", 2658], ["with", 2665], ["household", 2670], ["overcrowding", 2680], ["(", 2693], ["RR", 2694], [":", 2696], ["1.58", 2698], ["[", 2703], ["1.04", 2704], ["-", 2708], ["2.41", 2709], ["]", 2713], [")", 2714], ["and", 2716], ["wider", 2720], ["barriers", 2726], [",", 2734], ["which", 2736], ["represent", 2742], ["a", 2752], ["combined", 2754], ["score", 2763], ["for", 2769], ["household", 2773], ["overcrowding", 2783], [",", 2795], ["low", 2797], ["income", 2801], [",", 2807], ["and", 2809], ["homelessness", 2813], ["(", 2826], ["RR", 2827], [":", 2829], ["1.76", 2831], ["[", 2836], ["1.16", 2837], ["-", 2841], ["2.70", 2842], ["]", 2846], [")", 2847], [".", 2848], ["CA", 2850], ["-", 2852], ["MRSA", 2853], ["was", 2858], ["also", 2862], ["associated", 2867], ["with", 2878], ["recent", 2883], ["immigration", 2890], ["to", 2902], ["the", 2905], ["UK", 2909], ["(", 2912], ["RR", 2913], [":", 2915], ["1.77", 2917], ["[", 2922], ["1.19", 2923], ["-", 2927], ["2.66", 2928], ["]", 2932], [")", 2933], [".", 2934], ["For", 2936], ["the", 2940], ["area", 2944], ["-", 2948], ["level", 2949], ["variation", 2955], ["in", 2965], ["RR", 2968], ["for", 2971], ["CA", 2975], ["-", 2977], ["MRSA", 2978], [",", 2982], ["28.67", 2984], ["%", 2989], ["was", 2991], ["attributable", 2995], ["to", 3008], ["the", 3011], ["spatial", 3015], ["arrangement", 3023], ["of", 3035], ["target", 3038], ["geographies", 3045], [",", 3056], ["compared", 3058], ["with", 3067], ["only", 3072], ["0.09", 3077], ["%", 3081], ["for", 3083], ["HA", 3087], ["-", 3089], ["MRSA", 3090], [".", 3094], ["An", 3096], ["advantage", 3099], ["to", 3109], ["our", 3112], ["study", 3116], ["is", 3122], ["that", 3125], ["it", 3130], ["provided", 3133], ["a", 3142], ["representative", 3144], ["sample", 3159], ["of", 3166], ["usual", 3169], ["residents", 3175], ["receiving", 3185], ["care", 3195], ["in", 3200], ["the", 3203], ["catchment", 3207], ["areas", 3217], [".", 3222], ["A", 3224], ["limitation", 3226], ["is", 3237], ["that", 3240], ["relationships", 3245], ["apparent", 3259], ["in", 3268], ["aggregated", 3271], ["data", 3282], ["analyses", 3287], ["can", 3296], ["not", 3299], ["be", 3303], ["assumed", 3306], ["to", 3314], ["operate", 3317], ["at", 3325], ["the", 3328], ["individual", 3332], ["level", 3343], [".", 3348], ["There", 3350], ["was", 3356], ["no", 3360], ["evidence", 3363], ["of", 3372], ["community", 3375], ["transmission", 3385], ["of", 3398], ["HA", 3401], ["-", 3403], ["MRSA", 3404], ["strains", 3409], [",", 3416], ["implying", 3418], ["that", 3427], ["HA", 3432], ["-", 3434], ["MRSA", 3435], ["cases", 3440], ["identified", 3446], ["in", 3457], ["the", 3460], ["community", 3464], ["originate", 3474], ["from", 3484], ["the", 3489], ["hospital", 3493], ["reservoir", 3502], ["and", 3512], ["are", 3516], ["maintained", 3520], ["by", 3531], ["frequent", 3534], ["attendance", 3543], ["at", 3554], ["health", 3557], ["care", 3564], ["facilities", 3569], [".", 3579], ["In", 3581], ["contrast", 3584], [",", 3592], ["there", 3594], ["was", 3600], ["a", 3604], ["high", 3606], ["risk", 3611], ["of", 3616], ["CA", 3619], ["-", 3621], ["MRSA", 3622], ["in", 3627], ["deprived", 3630], ["areas", 3639], ["linked", 3645], ["with", 3652], ["overcrowding", 3657], [",", 3669], ["homelessness", 3671], [",", 3683], ["low", 3685], ["income", 3689], [",", 3695], ["and", 3697], ["recent", 3701], ["immigration", 3708], ["to", 3720], ["the", 3723], ["UK", 3727], [",", 3729], ["which", 3731], ["was", 3737], ["not", 3741], ["explainable", 3745], ["by", 3757], ["health", 3760], ["care", 3767], ["exposure", 3772], [".", 3780], ["Furthermore", 3782], [",", 3793], ["areas", 3795], ["adjacent", 3801], ["to", 3810], ["these", 3813], ["deprived", 3819], ["areas", 3828], ["were", 3834], ["themselves", 3839], ["at", 3850], ["greater", 3853], ["risk", 3861], ["of", 3866], ["CA", 3869], ["-", 3871], ["MRSA", 3872], [",", 3876], ["indicating", 3878], ["community", 3889], ["transmission", 3899], ["of", 3912], ["CA", 3915], ["-", 3917], ["MRSA", 3918], [".", 3922], ["This", 3924], ["ongoing", 3929], ["community", 3937], ["transmission", 3947], ["could", 3960], ["lead", 3966], ["to", 3971], ["CA", 3974], ["-", 3976], ["MRSA", 3977], ["becoming", 3982], ["the", 3991], ["dominant", 3995], ["strain", 4004], ["types", 4011], ["carried", 4017], ["by", 4025], ["patients", 4028], ["admitted", 4037], ["to", 4046], ["hospital", 4049], [",", 4057], ["particularly", 4059], ["if", 4072], ["successful", 4075], ["hospital", 4086], ["-", 4094], ["based", 4095], ["MRSA", 4101], ["infection", 4106], ["control", 4116], ["programmes", 4124], ["are", 4135], ["maintained", 4139], [".", 4149], ["These", 4151], ["results", 4157], ["suggest", 4165], ["that", 4173], ["community", 4178], ["infection", 4188], ["control", 4198], ["programmes", 4206], ["targeting", 4217], ["transmission", 4227], ["of", 4240], ["CA", 4243], ["-", 4245], ["MRSA", 4246], ["will", 4251], ["be", 4256], ["required", 4259], ["to", 4268], ["control", 4271], ["MRSA", 4279], ["in", 4284], ["both", 4287], ["the", 4292], ["community", 4296], ["and", 4306], ["hospital", 4310], [".", 4318], ["These", 4320], ["epidemiological", 4326], ["changes", 4342], ["will", 4350], ["also", 4355], ["have", 4360], ["implications", 4365], ["for", 4378], ["effectiveness", 4382], ["of", 4396], ["risk", 4399], ["-", 4403], ["factor", 4404], ["-", 4410], ["based", 4411], ["hospital", 4417], ["admission", 4426], ["MRSA", 4436], ["screening", 4441], ["programmes", 4451], [".", 4461]]}
{"context": "In order to determine the prevalence of latent infection due to Mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the Monotest and, for reference purposes, to the Mantoux test. The overall prevalence of subjects with a tuberculin skin reaction size > or = 5 mm in the Mantoux test was 25.7%; utilizing a cut-off of > or = 10 mm, the prevalence was 11.4%. Irrespective of cut-off, the Monotest showed a sensitivity of > 90% and a specificity of > 80%. At a prevalence of 25.7%, and with cut-offs of > or = 5 or > or = 10 mm, the positive predictive value was 83% or 62.2%, respectively. Irrespective of cut-off, the negative predictive value was > 97%. In conclusion, the Monotest proved satisfactory as a tool for epidemiological screening in a population with a high prevalence for latent tuberculosis, namely drug users.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "36caa3ccb74340beb0182b812e4fbc13", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[12, 12], [189, 189], [28, 28]], "char_spans": [[78, 89], [902, 913], [169, 180]]}]}], "context_tokens": [["In", 0], ["order", 3], ["to", 9], ["determine", 12], ["the", 22], ["prevalence", 26], ["of", 37], ["latent", 40], ["infection", 47], ["due", 57], ["to", 61], ["Mycobacterium", 64], ["tuberculosis", 78], ["in", 91], ["drug", 94], ["users", 99], ["and", 105], ["to", 109], ["provide", 112], ["centres", 120], ["for", 128], ["drug", 132], ["users", 137], ["with", 143], ["a", 148], ["practical", 150], ["tool", 160], ["for", 165], ["tuberculosis", 169], ["screening", 182], [",", 191], ["237", 193], ["drug", 197], ["users", 202], ["were", 208], ["subjected", 213], ["to", 223], ["the", 226], ["Monotest", 230], ["and", 239], [",", 242], ["for", 244], ["reference", 248], ["purposes", 258], [",", 266], ["to", 268], ["the", 271], ["Mantoux", 275], ["test", 283], [".", 287], ["The", 289], ["overall", 293], ["prevalence", 301], ["of", 312], ["subjects", 315], ["with", 324], ["a", 329], ["tuberculin", 331], ["skin", 342], ["reaction", 347], ["size", 356], [">", 361], ["or", 363], ["=", 366], ["5", 368], ["mm", 370], ["in", 373], ["the", 376], ["Mantoux", 380], ["test", 388], ["was", 393], ["25.7", 397], ["%", 401], [";", 402], ["utilizing", 404], ["a", 414], ["cut", 416], ["-", 419], ["off", 420], ["of", 424], [">", 427], ["or", 429], ["=", 432], ["10", 434], ["mm", 437], [",", 439], ["the", 441], ["prevalence", 445], ["was", 456], ["11.4", 460], ["%", 464], [".", 465], ["Irrespective", 467], ["of", 480], ["cut", 483], ["-", 486], ["off", 487], [",", 490], ["the", 492], ["Monotest", 496], ["showed", 505], ["a", 512], ["sensitivity", 514], ["of", 526], [">", 529], ["90", 531], ["%", 533], ["and", 535], ["a", 539], ["specificity", 541], ["of", 553], [">", 556], ["80", 558], ["%", 560], [".", 561], ["At", 563], ["a", 566], ["prevalence", 568], ["of", 579], ["25.7", 582], ["%", 586], [",", 587], ["and", 589], ["with", 593], ["cut", 598], ["-", 601], ["offs", 602], ["of", 607], [">", 610], ["or", 612], ["=", 615], ["5", 617], ["or", 619], [">", 622], ["or", 624], ["=", 627], ["10", 629], ["mm", 632], [",", 634], ["the", 636], ["positive", 640], ["predictive", 649], ["value", 660], ["was", 666], ["83", 670], ["%", 672], ["or", 674], ["62.2", 677], ["%", 681], [",", 682], ["respectively", 684], [".", 696], ["Irrespective", 698], ["of", 711], ["cut", 714], ["-", 717], ["off", 718], [",", 721], ["the", 723], ["negative", 727], ["predictive", 736], ["value", 747], ["was", 753], [">", 757], ["97", 759], ["%", 761], [".", 762], ["In", 764], ["conclusion", 767], [",", 777], ["the", 779], ["Monotest", 783], ["proved", 792], ["satisfactory", 799], ["as", 812], ["a", 815], ["tool", 817], ["for", 822], ["epidemiological", 826], ["screening", 842], ["in", 852], ["a", 855], ["population", 857], ["with", 868], ["a", 873], ["high", 875], ["prevalence", 880], ["for", 891], ["latent", 895], ["tuberculosis", 902], [",", 914], ["namely", 916], ["drug", 923], ["users", 928], [".", 933]]}
{"context": "Embryonic neuroepithelia and adult subventricular zone (SVZ) stem and progenitor cells express nestin. We characterized a transgenic line that expresses enhanced green fluorescent protein (eGFP) specified to neural tissue by the second intronic enhancer of the nestin promoter that had several novel features. During embryogenesis, the dorsal telencephalon contained many and the ventral telencephalon few eGFP+ cells. eGFP+ cells were found in postnatal and adult neurogenic regions. eGFP+ cells in the SVZ expressed multiple phenotype markers, glial fibrillary acidic protein, Dlx, and neuroblast-specific molecules suggesting the transgene is expressed through the lineage. eGFP+ cell numbers increased in the SVZ after cortical injury, suggesting this line will be useful in probing postinjury neurogenesis. In non-neurogenic regions, eGFP was strongly expressed in oligodendrocyte progenitors, but not in astrocytes, even when they were reactive. This eGFP+ mouse will facilitate studies of proliferative neuroepithelia and adult neurogenesis, as well as of parenchymal oligodendrocytes.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "1f13212b55544ebc9031055963334233", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[41, 41], [14, 14]], "char_spans": [[261, 266], [95, 100]]}]}], "context_tokens": [["Embryonic", 0], ["neuroepithelia", 10], ["and", 25], ["adult", 29], ["subventricular", 35], ["zone", 50], ["(", 55], ["SVZ", 56], [")", 59], ["stem", 61], ["and", 66], ["progenitor", 70], ["cells", 81], ["express", 87], ["nestin", 95], [".", 101], ["We", 103], ["characterized", 106], ["a", 120], ["transgenic", 122], ["line", 133], ["that", 138], ["expresses", 143], ["enhanced", 153], ["green", 162], ["fluorescent", 168], ["protein", 180], ["(", 188], ["eGFP", 189], [")", 193], ["specified", 195], ["to", 205], ["neural", 208], ["tissue", 215], ["by", 222], ["the", 225], ["second", 229], ["intronic", 236], ["enhancer", 245], ["of", 254], ["the", 257], ["nestin", 261], ["promoter", 268], ["that", 277], ["had", 282], ["several", 286], ["novel", 294], ["features", 300], [".", 308], ["During", 310], ["embryogenesis", 317], [",", 330], ["the", 332], ["dorsal", 336], ["telencephalon", 343], ["contained", 357], ["many", 367], ["and", 372], ["the", 376], ["ventral", 380], ["telencephalon", 388], ["few", 402], ["eGFP+", 406], ["cells", 412], [".", 417], ["eGFP+", 419], ["cells", 425], ["were", 431], ["found", 436], ["in", 442], ["postnatal", 445], ["and", 455], ["adult", 459], ["neurogenic", 465], ["regions", 476], [".", 483], ["eGFP+", 485], ["cells", 491], ["in", 497], ["the", 500], ["SVZ", 504], ["expressed", 508], ["multiple", 518], ["phenotype", 527], ["markers", 537], [",", 544], ["glial", 546], ["fibrillary", 552], ["acidic", 563], ["protein", 570], [",", 577], ["Dlx", 579], [",", 582], ["and", 584], ["neuroblast", 588], ["-", 598], ["specific", 599], ["molecules", 608], ["suggesting", 618], ["the", 629], ["transgene", 633], ["is", 643], ["expressed", 646], ["through", 656], ["the", 664], ["lineage", 668], [".", 675], ["eGFP+", 677], ["cell", 683], ["numbers", 688], ["increased", 696], ["in", 706], ["the", 709], ["SVZ", 713], ["after", 717], ["cortical", 723], ["injury", 732], [",", 738], ["suggesting", 740], ["this", 751], ["line", 756], ["will", 761], ["be", 766], ["useful", 769], ["in", 776], ["probing", 779], ["postinjury", 787], ["neurogenesis", 798], [".", 810], ["In", 812], ["non", 815], ["-", 818], ["neurogenic", 819], ["regions", 830], [",", 837], ["eGFP", 839], ["was", 844], ["strongly", 848], ["expressed", 857], ["in", 867], ["oligodendrocyte", 870], ["progenitors", 886], [",", 897], ["but", 899], ["not", 903], ["in", 907], ["astrocytes", 910], [",", 920], ["even", 922], ["when", 927], ["they", 932], ["were", 937], ["reactive", 942], [".", 950], ["This", 952], ["eGFP+", 957], ["mouse", 963], ["will", 969], ["facilitate", 974], ["studies", 985], ["of", 993], ["proliferative", 996], ["neuroepithelia", 1010], ["and", 1025], ["adult", 1029], ["neurogenesis", 1035], [",", 1047], ["as", 1049], ["well", 1052], ["as", 1057], ["of", 1060], ["parenchymal", 1063], ["oligodendrocytes", 1075], [".", 1091]]}
{"context": "Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for posttraumatic stress disorder (PTSD). Serotonergic (5HT) attenuation of stress sensitivity is postulated from SSRIs' effects in other anxiety disorders, and we studied this in PTSD. Ten patients with PTSD fully recovered on SSRIs (Clinical Global Impression Scale-I 1 and 2) were enrolled in the study. Patients were tested on two occasions 1 week apart; in each session, they received a drink containing large neutral amino acids (LNAAs) either with (sham tryptophan depletion [STD], control) or without (acute tryptophan depletion [ATD]) tryptophan. At 5.5 hours after the drink, subjects were exposed to a trauma-related exposure challenge. Self-reports of PTSD (visual analogue scales [VAS] and the Davidson Trauma Scale [DTS]), anxiety (Spielberger State Inventory [STAI] Form Y-1), and mood (Profile of Mood States [POMS]) were obtained. Heart rate (HR), systolic (SBP) and diastolic (DBP) blood pressure were also measured. The trauma-related exposure challenge induced anxiety on both days, with more marked responses on the ATD day according to VAS, DTS, POMS, and DBP (p < .05). A trend of significance (.1 > p > .05) was observed for STAI Form Y-1, HR, and SBP. These data demonstrate that ATD accentuates responses to trauma-related stimuli in SSRI-recovered PTSD. They also suggest that SSRI-induced increases in serotonin function restrain PTSD symptoms, especially under provocation, supporting a role for serotonin in mediating stress resilience.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "a197452996814e96bc9331b41b870709", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[283, 283], [44, 44], [297, 297], [17, 17], [143, 143], [49, 49]], "char_spans": [[1349, 1352], [254, 257], [1432, 1435], [109, 112], [738, 741], [278, 281]]}]}], "context_tokens": [["Selective", 0], ["serotonin", 10], ["reuptake", 20], ["inhibitors", 29], ["(", 40], ["SSRIs", 41], [")", 46], ["are", 48], ["first", 52], ["-", 57], ["line", 58], ["treatments", 63], ["for", 74], ["posttraumatic", 78], ["stress", 92], ["disorder", 99], ["(", 108], ["PTSD", 109], [")", 113], [".", 114], ["Serotonergic", 116], ["(", 129], ["5HT", 130], [")", 133], ["attenuation", 135], ["of", 147], ["stress", 150], ["sensitivity", 157], ["is", 169], ["postulated", 172], ["from", 183], ["SSRIs", 188], ["'", 193], ["effects", 195], ["in", 203], ["other", 206], ["anxiety", 212], ["disorders", 220], [",", 229], ["and", 231], ["we", 235], ["studied", 238], ["this", 246], ["in", 251], ["PTSD", 254], [".", 258], ["Ten", 260], ["patients", 264], ["with", 273], ["PTSD", 278], ["fully", 283], ["recovered", 289], ["on", 299], ["SSRIs", 302], ["(", 308], ["Clinical", 309], ["Global", 318], ["Impression", 325], ["Scale", 336], ["-", 341], ["I", 342], ["1", 344], ["and", 346], ["2", 350], [")", 351], ["were", 353], ["enrolled", 358], ["in", 367], ["the", 370], ["study", 374], [".", 379], ["Patients", 381], ["were", 390], ["tested", 395], ["on", 402], ["two", 405], ["occasions", 409], ["1", 419], ["week", 421], ["apart", 426], [";", 431], ["in", 433], ["each", 436], ["session", 441], [",", 448], ["they", 450], ["received", 455], ["a", 464], ["drink", 466], ["containing", 472], ["large", 483], ["neutral", 489], ["amino", 497], ["acids", 503], ["(", 509], ["LNAAs", 510], [")", 515], ["either", 517], ["with", 524], ["(", 529], ["sham", 530], ["tryptophan", 535], ["depletion", 546], ["[", 556], ["STD", 557], ["]", 560], [",", 561], ["control", 563], [")", 570], ["or", 572], ["without", 575], ["(", 583], ["acute", 584], ["tryptophan", 590], ["depletion", 601], ["[", 611], ["ATD", 612], ["]", 615], [")", 616], ["tryptophan", 618], [".", 628], ["At", 630], ["5.5", 633], ["hours", 637], ["after", 643], ["the", 649], ["drink", 653], [",", 658], ["subjects", 660], ["were", 669], ["exposed", 674], ["to", 682], ["a", 685], ["trauma", 687], ["-", 693], ["related", 694], ["exposure", 702], ["challenge", 711], [".", 720], ["Self", 722], ["-", 726], ["reports", 727], ["of", 735], ["PTSD", 738], ["(", 743], ["visual", 744], ["analogue", 751], ["scales", 760], ["[", 767], ["VAS", 768], ["]", 771], ["and", 773], ["the", 777], ["Davidson", 781], ["Trauma", 790], ["Scale", 797], ["[", 803], ["DTS", 804], ["]", 807], [")", 808], [",", 809], ["anxiety", 811], ["(", 819], ["Spielberger", 820], ["State", 832], ["Inventory", 838], ["[", 848], ["STAI", 849], ["]", 853], ["Form", 855], ["Y-1", 860], [")", 863], [",", 864], ["and", 866], ["mood", 870], ["(", 875], ["Profile", 876], ["of", 884], ["Mood", 887], ["States", 892], ["[", 899], ["POMS", 900], ["]", 904], [")", 905], ["were", 907], ["obtained", 912], [".", 920], ["Heart", 922], ["rate", 928], ["(", 933], ["HR", 934], [")", 936], [",", 937], ["systolic", 939], ["(", 948], ["SBP", 949], [")", 952], ["and", 954], ["diastolic", 958], ["(", 968], ["DBP", 969], [")", 972], ["blood", 974], ["pressure", 980], ["were", 989], ["also", 994], ["measured", 999], [".", 1007], ["The", 1009], ["trauma", 1013], ["-", 1019], ["related", 1020], ["exposure", 1028], ["challenge", 1037], ["induced", 1047], ["anxiety", 1055], ["on", 1063], ["both", 1066], ["days", 1071], [",", 1075], ["with", 1077], ["more", 1082], ["marked", 1087], ["responses", 1094], ["on", 1104], ["the", 1107], ["ATD", 1111], ["day", 1115], ["according", 1119], ["to", 1129], ["VAS", 1132], [",", 1135], ["DTS", 1137], [",", 1140], ["POMS", 1142], [",", 1146], ["and", 1148], ["DBP", 1152], ["(", 1156], ["p", 1157], ["<", 1159], [".05", 1161], [")", 1164], [".", 1165], ["A", 1167], ["trend", 1169], ["of", 1175], ["significance", 1178], ["(", 1191], [".1", 1192], [">", 1195], ["p", 1197], [">", 1199], [".05", 1201], [")", 1204], ["was", 1206], ["observed", 1210], ["for", 1219], ["STAI", 1223], ["Form", 1228], ["Y-1", 1233], [",", 1236], ["HR", 1238], [",", 1240], ["and", 1242], ["SBP", 1246], [".", 1249], ["These", 1251], ["data", 1257], ["demonstrate", 1262], ["that", 1274], ["ATD", 1279], ["accentuates", 1283], ["responses", 1295], ["to", 1305], ["trauma", 1308], ["-", 1314], ["related", 1315], ["stimuli", 1323], ["in", 1331], ["SSRI", 1334], ["-", 1338], ["recovered", 1339], ["PTSD", 1349], [".", 1353], ["They", 1355], ["also", 1360], ["suggest", 1365], ["that", 1373], ["SSRI", 1378], ["-", 1382], ["induced", 1383], ["increases", 1391], ["in", 1401], ["serotonin", 1404], ["function", 1414], ["restrain", 1423], ["PTSD", 1432], ["symptoms", 1437], [",", 1445], ["especially", 1447], ["under", 1458], ["provocation", 1464], [",", 1475], ["supporting", 1477], ["a", 1488], ["role", 1490], ["for", 1495], ["serotonin", 1499], ["in", 1509], ["mediating", 1512], ["stress", 1522], ["resilience", 1529], [".", 1539]]}
{"context": "The actions of benzodiazepines are due to the potentiation of the neural inhibition that is mediated by gamma-aminobutyric acid (GABA). Practically all effects of the benzodiazepines result from their actions on the ionotropic GABA(A) receptors in the central nervous system. Benzodiazepines do not activate GABA(A) receptors directly but they require GABA. The main effects of benzodiazepines are sedation, hypnosis, decreased anxiety, anterograde amnesia, centrally mediated muscle relaxation and anti-convulsant activity. In addition to their action on the central nervous system, benzodiazepines have a dose-dependent ventilatory depressant effect and they also cause a modest reduction in arterial blood pressure and an increase in heart rate as a result of a decrease of systemic vascular resistance. The four benzodiazepines, widely used in clinical anaesthesia, are the agonists midazolam, diazepam and lorazepam and the antagonist flumazenil. Midazolam, diazepam and flumazenil are metabolized by cytochrome P450 (CYP) enzymes and by glucuronide conjugation whereas lorazepam directly undergoes glucuronide conjugation. CYP3A4 is important in the biotransformation of both midazolam and diazepam. CYP2C19 is important in the biotransformation of diazepam. Liver and renal dysfunction have only a minor effect on the pharmacokinetics of lorazepam but they slow down the elimination of the other benzodiazepines used in clinical anaesthesia. The duration of action of all benzodiazepines is strongly dependent on the duration of their administration. Based on clinical studies and computer simulations, midazolam has the shortest recovery profile followed by lorazepam and diazepam. Being metabolized by CYP enzymes, midazolam and diazepam have many clinically significant interactions with inhibitors and inducers of CYP3A4 and 2C19. In addition to pharmacokinetic interactions, benzodiazepines have synergistic interactions with other hypnotics and opioids. Midazolam, diazepam and lorazepam are widely used for sedation and to some extent also for induction and maintenance of anaesthesia. Flumazenil is very useful in reversing benzodiazepine-induced sedation as well as to diagnose or treat benzodiazepine overdose.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "0652e34262bc426d97340af838f8da7e", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[161, 161], [155, 155], [330, 330]], "char_spans": [[976, 985], [940, 949], [2100, 2109]]}]}], "context_tokens": [["The", 0], ["actions", 4], ["of", 12], ["benzodiazepines", 15], ["are", 31], ["due", 35], ["to", 39], ["the", 42], ["potentiation", 46], ["of", 59], ["the", 62], ["neural", 66], ["inhibition", 73], ["that", 84], ["is", 89], ["mediated", 92], ["by", 101], ["gamma", 104], ["-", 109], ["aminobutyric", 110], ["acid", 123], ["(", 128], ["GABA", 129], [")", 133], [".", 134], ["Practically", 136], ["all", 148], ["effects", 152], ["of", 160], ["the", 163], ["benzodiazepines", 167], ["result", 183], ["from", 190], ["their", 195], ["actions", 201], ["on", 209], ["the", 212], ["ionotropic", 216], ["GABA(A", 227], [")", 233], ["receptors", 235], ["in", 245], ["the", 248], ["central", 252], ["nervous", 260], ["system", 268], [".", 274], ["Benzodiazepines", 276], ["do", 292], ["not", 295], ["activate", 299], ["GABA(A", 308], [")", 314], ["receptors", 316], ["directly", 326], ["but", 335], ["they", 339], ["require", 344], ["GABA", 352], [".", 356], ["The", 358], ["main", 362], ["effects", 367], ["of", 375], ["benzodiazepines", 378], ["are", 394], ["sedation", 398], [",", 406], ["hypnosis", 408], [",", 416], ["decreased", 418], ["anxiety", 428], [",", 435], ["anterograde", 437], ["amnesia", 449], [",", 456], ["centrally", 458], ["mediated", 468], ["muscle", 477], ["relaxation", 484], ["and", 495], ["anti", 499], ["-", 503], ["convulsant", 504], ["activity", 515], [".", 523], ["In", 525], ["addition", 528], ["to", 537], ["their", 540], ["action", 546], ["on", 553], ["the", 556], ["central", 560], ["nervous", 568], ["system", 576], [",", 582], ["benzodiazepines", 584], ["have", 600], ["a", 605], ["dose", 607], ["-", 611], ["dependent", 612], ["ventilatory", 622], ["depressant", 634], ["effect", 645], ["and", 652], ["they", 656], ["also", 661], ["cause", 666], ["a", 672], ["modest", 674], ["reduction", 681], ["in", 691], ["arterial", 694], ["blood", 703], ["pressure", 709], ["and", 718], ["an", 722], ["increase", 725], ["in", 734], ["heart", 737], ["rate", 743], ["as", 748], ["a", 751], ["result", 753], ["of", 760], ["a", 763], ["decrease", 765], ["of", 774], ["systemic", 777], ["vascular", 786], ["resistance", 795], [".", 805], ["The", 807], ["four", 811], ["benzodiazepines", 816], [",", 831], ["widely", 833], ["used", 840], ["in", 845], ["clinical", 848], ["anaesthesia", 857], [",", 868], ["are", 870], ["the", 874], ["agonists", 878], ["midazolam", 887], [",", 896], ["diazepam", 898], ["and", 907], ["lorazepam", 911], ["and", 921], ["the", 925], ["antagonist", 929], ["flumazenil", 940], [".", 950], ["Midazolam", 952], [",", 961], ["diazepam", 963], ["and", 972], ["flumazenil", 976], ["are", 987], ["metabolized", 991], ["by", 1003], ["cytochrome", 1006], ["P450", 1017], ["(", 1022], ["CYP", 1023], [")", 1026], ["enzymes", 1028], ["and", 1036], ["by", 1040], ["glucuronide", 1043], ["conjugation", 1055], ["whereas", 1067], ["lorazepam", 1075], ["directly", 1085], ["undergoes", 1094], ["glucuronide", 1104], ["conjugation", 1116], [".", 1127], ["CYP3A4", 1129], ["is", 1136], ["important", 1139], ["in", 1149], ["the", 1152], ["biotransformation", 1156], ["of", 1174], ["both", 1177], ["midazolam", 1182], ["and", 1192], ["diazepam", 1196], [".", 1204], ["CYP2C19", 1206], ["is", 1214], ["important", 1217], ["in", 1227], ["the", 1230], ["biotransformation", 1234], ["of", 1252], ["diazepam", 1255], [".", 1263], ["Liver", 1265], ["and", 1271], ["renal", 1275], ["dysfunction", 1281], ["have", 1293], ["only", 1298], ["a", 1303], ["minor", 1305], ["effect", 1311], ["on", 1318], ["the", 1321], ["pharmacokinetics", 1325], ["of", 1342], ["lorazepam", 1345], ["but", 1355], ["they", 1359], ["slow", 1364], ["down", 1369], ["the", 1374], ["elimination", 1378], ["of", 1390], ["the", 1393], ["other", 1397], ["benzodiazepines", 1403], ["used", 1419], ["in", 1424], ["clinical", 1427], ["anaesthesia", 1436], [".", 1447], ["The", 1449], ["duration", 1453], ["of", 1462], ["action", 1465], ["of", 1472], ["all", 1475], ["benzodiazepines", 1479], ["is", 1495], ["strongly", 1498], ["dependent", 1507], ["on", 1517], ["the", 1520], ["duration", 1524], ["of", 1533], ["their", 1536], ["administration", 1542], [".", 1556], ["Based", 1558], ["on", 1564], ["clinical", 1567], ["studies", 1576], ["and", 1584], ["computer", 1588], ["simulations", 1597], [",", 1608], ["midazolam", 1610], ["has", 1620], ["the", 1624], ["shortest", 1628], ["recovery", 1637], ["profile", 1646], ["followed", 1654], ["by", 1663], ["lorazepam", 1666], ["and", 1676], ["diazepam", 1680], [".", 1688], ["Being", 1690], ["metabolized", 1696], ["by", 1708], ["CYP", 1711], ["enzymes", 1715], [",", 1722], ["midazolam", 1724], ["and", 1734], ["diazepam", 1738], ["have", 1747], ["many", 1752], ["clinically", 1757], ["significant", 1768], ["interactions", 1780], ["with", 1793], ["inhibitors", 1798], ["and", 1809], ["inducers", 1813], ["of", 1822], ["CYP3A4", 1825], ["and", 1832], ["2C19", 1836], [".", 1840], ["In", 1842], ["addition", 1845], ["to", 1854], ["pharmacokinetic", 1857], ["interactions", 1873], [",", 1885], ["benzodiazepines", 1887], ["have", 1903], ["synergistic", 1908], ["interactions", 1920], ["with", 1933], ["other", 1938], ["hypnotics", 1944], ["and", 1954], ["opioids", 1958], [".", 1965], ["Midazolam", 1967], [",", 1976], ["diazepam", 1978], ["and", 1987], ["lorazepam", 1991], ["are", 2001], ["widely", 2005], ["used", 2012], ["for", 2017], ["sedation", 2021], ["and", 2030], ["to", 2034], ["some", 2037], ["extent", 2042], ["also", 2049], ["for", 2054], ["induction", 2058], ["and", 2068], ["maintenance", 2072], ["of", 2084], ["anaesthesia", 2087], [".", 2098], ["Flumazenil", 2100], ["is", 2111], ["very", 2114], ["useful", 2119], ["in", 2126], ["reversing", 2129], ["benzodiazepine", 2139], ["-", 2153], ["induced", 2154], ["sedation", 2162], ["as", 2171], ["well", 2174], ["as", 2179], ["to", 2182], ["diagnose", 2185], ["or", 2194], ["treat", 2197], ["benzodiazepine", 2203], ["overdose", 2218], [".", 2226]]}
{"context": "Chronic myeloid leukemia (CML) is arguably the best understood of all human malignancies. Its origins in the hematopoietic stem cell can be traced to a reciprocal translocation involving chromosomes 9 and 22, dubbed the Philadelphia chromosome, which is observed in essentially all patients. The resulting fusion gene, BCR/ABL, encodes an activated tyrosine kinase that can act alone to induce a CML-like syndrome in mouse models. These animal models have validated BCR/ABL as a target for the development of specific pharmaceutical inhibitors. The kinase inhibitor imatinib mesylate (Gleevec) is highly specific, effective, and minimally toxic, but may not effect cures as a single agent, particularly in patients with accelerated and blast-phase disease. Resistance to imatinib can confound therapy. Surprisingly, a high percentage of resistant cases manifest intact or augmented BCR/ABL signaling, suggesting that this oncoprotein, or signaling pathways emanating from it, remain viable targets. Combination chemotherapy is under active investigation, and among the most compelling strategies is dual treatment with agents that both target BCR/ABL signal transduction. BCR/ABL activates Ras, and compounds designed to antagonize Ras function called farnesyl transferase inhibitors (FTIs) have shown potent activity in vitro and in animal models of BCR/ABL-induced leukemia. Initial clinical trials in patients with refractory acute myeloid leukemia and CML in blast crisis have shown significant activity, suggesting that trials combining imatinib and FTIs are warranted.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7ab997001a3a4c77a2cb4d78612ac48f", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[54, 56], [197, 199], [234, 236], [203, 205], [83, 85], [155, 157]], "char_spans": [[319, 325], [1143, 1149], [1351, 1357], [1172, 1178], [466, 472], [882, 888]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["arguably", 34], ["the", 43], ["best", 47], ["understood", 52], ["of", 63], ["all", 66], ["human", 70], ["malignancies", 76], [".", 88], ["Its", 90], ["origins", 94], ["in", 102], ["the", 105], ["hematopoietic", 109], ["stem", 123], ["cell", 128], ["can", 133], ["be", 137], ["traced", 140], ["to", 147], ["a", 150], ["reciprocal", 152], ["translocation", 163], ["involving", 177], ["chromosomes", 187], ["9", 199], ["and", 201], ["22", 205], [",", 207], ["dubbed", 209], ["the", 216], ["Philadelphia", 220], ["chromosome", 233], [",", 243], ["which", 245], ["is", 251], ["observed", 254], ["in", 263], ["essentially", 266], ["all", 278], ["patients", 282], [".", 290], ["The", 292], ["resulting", 296], ["fusion", 306], ["gene", 313], [",", 317], ["BCR", 319], ["/", 322], ["ABL", 323], [",", 326], ["encodes", 328], ["an", 336], ["activated", 339], ["tyrosine", 349], ["kinase", 358], ["that", 365], ["can", 370], ["act", 374], ["alone", 378], ["to", 384], ["induce", 387], ["a", 394], ["CML", 396], ["-", 399], ["like", 400], ["syndrome", 405], ["in", 414], ["mouse", 417], ["models", 423], [".", 429], ["These", 431], ["animal", 437], ["models", 444], ["have", 451], ["validated", 456], ["BCR", 466], ["/", 469], ["ABL", 470], ["as", 474], ["a", 477], ["target", 479], ["for", 486], ["the", 490], ["development", 494], ["of", 506], ["specific", 509], ["pharmaceutical", 518], ["inhibitors", 533], [".", 543], ["The", 545], ["kinase", 549], ["inhibitor", 556], ["imatinib", 566], ["mesylate", 575], ["(", 584], ["Gleevec", 585], [")", 592], ["is", 594], ["highly", 597], ["specific", 604], [",", 612], ["effective", 614], [",", 623], ["and", 625], ["minimally", 629], ["toxic", 639], [",", 644], ["but", 646], ["may", 650], ["not", 654], ["effect", 658], ["cures", 665], ["as", 671], ["a", 674], ["single", 676], ["agent", 683], [",", 688], ["particularly", 690], ["in", 703], ["patients", 706], ["with", 715], ["accelerated", 720], ["and", 732], ["blast", 736], ["-", 741], ["phase", 742], ["disease", 748], [".", 755], ["Resistance", 757], ["to", 768], ["imatinib", 771], ["can", 780], ["confound", 784], ["therapy", 793], [".", 800], ["Surprisingly", 802], [",", 814], ["a", 816], ["high", 818], ["percentage", 823], ["of", 834], ["resistant", 837], ["cases", 847], ["manifest", 853], ["intact", 862], ["or", 869], ["augmented", 872], ["BCR", 882], ["/", 885], ["ABL", 886], ["signaling", 890], [",", 899], ["suggesting", 901], ["that", 912], ["this", 917], ["oncoprotein", 922], [",", 933], ["or", 935], ["signaling", 938], ["pathways", 948], ["emanating", 957], ["from", 967], ["it", 972], [",", 974], ["remain", 976], ["viable", 983], ["targets", 990], [".", 997], ["Combination", 999], ["chemotherapy", 1011], ["is", 1024], ["under", 1027], ["active", 1033], ["investigation", 1040], [",", 1053], ["and", 1055], ["among", 1059], ["the", 1065], ["most", 1069], ["compelling", 1074], ["strategies", 1085], ["is", 1096], ["dual", 1099], ["treatment", 1104], ["with", 1114], ["agents", 1119], ["that", 1126], ["both", 1131], ["target", 1136], ["BCR", 1143], ["/", 1146], ["ABL", 1147], ["signal", 1151], ["transduction", 1158], [".", 1170], ["BCR", 1172], ["/", 1175], ["ABL", 1176], ["activates", 1180], ["Ras", 1190], [",", 1193], ["and", 1195], ["compounds", 1199], ["designed", 1209], ["to", 1218], ["antagonize", 1221], ["Ras", 1232], ["function", 1236], ["called", 1245], ["farnesyl", 1252], ["transferase", 1261], ["inhibitors", 1273], ["(", 1284], ["FTIs", 1285], [")", 1289], ["have", 1291], ["shown", 1296], ["potent", 1302], ["activity", 1309], ["in", 1318], ["vitro", 1321], ["and", 1327], ["in", 1331], ["animal", 1334], ["models", 1341], ["of", 1348], ["BCR", 1351], ["/", 1354], ["ABL", 1355], ["-", 1358], ["induced", 1359], ["leukemia", 1367], [".", 1375], ["Initial", 1377], ["clinical", 1385], ["trials", 1394], ["in", 1401], ["patients", 1404], ["with", 1413], ["refractory", 1418], ["acute", 1429], ["myeloid", 1435], ["leukemia", 1443], ["and", 1452], ["CML", 1456], ["in", 1460], ["blast", 1463], ["crisis", 1469], ["have", 1476], ["shown", 1481], ["significant", 1487], ["activity", 1499], [",", 1507], ["suggesting", 1509], ["that", 1520], ["trials", 1525], ["combining", 1532], ["imatinib", 1542], ["and", 1551], ["FTIs", 1555], ["are", 1560], ["warranted", 1564], [".", 1573]]}
{"context": "Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the lysosomal exoglycosidase responsible for the hydrolysis of terminal alpha-galactosyl residues from glycoconjugates and is the defective enzyme causing Fabry disease (McKusick 301500). An unusally elevated level of plasma alpha-Gal A activity (> 2.5 times the normal mean) was detected in two unrelated normal males and the elevated activities were inherited as X-linked traits in their families. Sequencing of the alpha-Gal A coding region, intron/exon boundaries and 5'-flanking region from the proband identified a single mutation, a G-->A transition 30 nt upstream from the initiation of translation codon in exon 1. The -30G-->A mutation occurred in a putative NF kappa B/Ets consensus binding site that was recently shown to inhibit protein binding to the 5'-untranslated region of the gene, providing a possible explanation for its high activity. To further characterize the mutation, the mRNA and protein expressed by this variant allele were studied. Purified plasma and lymphoblast alpha-Gal A activity from individuals with the -30G-->A mutation had normal physical and kinetic properties. In vitro translation of mRNAs from the cloned normal and high plasma activity alleles resulted in similar levels of alpha-Gal A protein, indicating that this mutation did not enhance translation. These findings suggest that the -30G-->A mutation in the 5'-untranslated region of the alpha-Gal A gene enhances transcription, presumably by interfering with the binding of negatively-acting transcription factors which normally decrease alpha-Gal A expression in various cells. Preliminary studies of the frequency of the -30G-->A mutation in 395 unrelated normal males of mixed ancestry revealed two additional unrelated individuals who had high plasma enzymatic activity and the mutation, confirming the effect of this mutation on enzyme expression and suggesting that about 0.5% of normal individuals have high plasma alpha-Gal A activity due to this variant allele.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "cd3dcbcaf34943d0be36358f319a997a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[1, 3]], "char_spans": [[6, 24]]}]}], "context_tokens": [["Human", 0], ["alpha", 6], ["-", 11], ["galactosidase", 12], ["A", 26], ["(", 28], ["EC", 29], ["3.2.1.22", 32], [";", 40], ["alpha", 42], ["-", 47], ["Gal", 48], ["A", 52], [")", 53], ["is", 55], ["the", 58], ["lysosomal", 62], ["exoglycosidase", 72], ["responsible", 87], ["for", 99], ["the", 103], ["hydrolysis", 107], ["of", 118], ["terminal", 121], ["alpha", 130], ["-", 135], ["galactosyl", 136], ["residues", 147], ["from", 156], ["glycoconjugates", 161], ["and", 177], ["is", 181], ["the", 184], ["defective", 188], ["enzyme", 198], ["causing", 205], ["Fabry", 213], ["disease", 219], ["(", 227], ["McKusick", 228], ["301500", 237], [")", 243], [".", 244], ["An", 246], ["unusally", 249], ["elevated", 258], ["level", 267], ["of", 273], ["plasma", 276], ["alpha", 283], ["-", 288], ["Gal", 289], ["A", 293], ["activity", 295], ["(", 304], [">", 305], ["2.5", 307], ["times", 311], ["the", 317], ["normal", 321], ["mean", 328], [")", 332], ["was", 334], ["detected", 338], ["in", 347], ["two", 350], ["unrelated", 354], ["normal", 364], ["males", 371], ["and", 377], ["the", 381], ["elevated", 385], ["activities", 394], ["were", 405], ["inherited", 410], ["as", 420], ["X", 423], ["-", 424], ["linked", 425], ["traits", 432], ["in", 439], ["their", 442], ["families", 448], [".", 456], ["Sequencing", 458], ["of", 469], ["the", 472], ["alpha", 476], ["-", 481], ["Gal", 482], ["A", 486], ["coding", 488], ["region", 495], [",", 501], ["intron", 503], ["/", 509], ["exon", 510], ["boundaries", 515], ["and", 526], ["5'-flanking", 530], ["region", 542], ["from", 549], ["the", 554], ["proband", 558], ["identified", 566], ["a", 577], ["single", 579], ["mutation", 586], [",", 594], ["a", 596], ["G-->A", 598], ["transition", 604], ["30", 615], ["nt", 618], ["upstream", 621], ["from", 630], ["the", 635], ["initiation", 639], ["of", 650], ["translation", 653], ["codon", 665], ["in", 671], ["exon", 674], ["1", 679], [".", 680], ["The", 682], ["-30G-->A", 686], ["mutation", 695], ["occurred", 704], ["in", 713], ["a", 716], ["putative", 718], ["NF", 727], ["kappa", 730], ["B", 736], ["/", 737], ["Ets", 738], ["consensus", 742], ["binding", 752], ["site", 760], ["that", 765], ["was", 770], ["recently", 774], ["shown", 783], ["to", 789], ["inhibit", 792], ["protein", 800], ["binding", 808], ["to", 816], ["the", 819], ["5'-untranslated", 823], ["region", 839], ["of", 846], ["the", 849], ["gene", 853], [",", 857], ["providing", 859], ["a", 869], ["possible", 871], ["explanation", 880], ["for", 892], ["its", 896], ["high", 900], ["activity", 905], [".", 913], ["To", 915], ["further", 918], ["characterize", 926], ["the", 939], ["mutation", 943], [",", 951], ["the", 953], ["mRNA", 957], ["and", 962], ["protein", 966], ["expressed", 974], ["by", 984], ["this", 987], ["variant", 992], ["allele", 1000], ["were", 1007], ["studied", 1012], [".", 1019], ["Purified", 1021], ["plasma", 1030], ["and", 1037], ["lymphoblast", 1041], ["alpha", 1053], ["-", 1058], ["Gal", 1059], ["A", 1063], ["activity", 1065], ["from", 1074], ["individuals", 1079], ["with", 1091], ["the", 1096], ["-30G-->A", 1100], ["mutation", 1109], ["had", 1118], ["normal", 1122], ["physical", 1129], ["and", 1138], ["kinetic", 1142], ["properties", 1150], [".", 1160], ["In", 1162], ["vitro", 1165], ["translation", 1171], ["of", 1183], ["mRNAs", 1186], ["from", 1192], ["the", 1197], ["cloned", 1201], ["normal", 1208], ["and", 1215], ["high", 1219], ["plasma", 1224], ["activity", 1231], ["alleles", 1240], ["resulted", 1248], ["in", 1257], ["similar", 1260], ["levels", 1268], ["of", 1275], ["alpha", 1278], ["-", 1283], ["Gal", 1284], ["A", 1288], ["protein", 1290], [",", 1297], ["indicating", 1299], ["that", 1310], ["this", 1315], ["mutation", 1320], ["did", 1329], ["not", 1333], ["enhance", 1337], ["translation", 1345], [".", 1356], ["These", 1358], ["findings", 1364], ["suggest", 1373], ["that", 1381], ["the", 1386], ["-30G-->A", 1390], ["mutation", 1399], ["in", 1408], ["the", 1411], ["5'-untranslated", 1415], ["region", 1431], ["of", 1438], ["the", 1441], ["alpha", 1445], ["-", 1450], ["Gal", 1451], ["A", 1455], ["gene", 1457], ["enhances", 1462], ["transcription", 1471], [",", 1484], ["presumably", 1486], ["by", 1497], ["interfering", 1500], ["with", 1512], ["the", 1517], ["binding", 1521], ["of", 1529], ["negatively", 1532], ["-", 1542], ["acting", 1543], ["transcription", 1550], ["factors", 1564], ["which", 1572], ["normally", 1578], ["decrease", 1587], ["alpha", 1596], ["-", 1601], ["Gal", 1602], ["A", 1606], ["expression", 1608], ["in", 1619], ["various", 1622], ["cells", 1630], [".", 1635], ["Preliminary", 1637], ["studies", 1649], ["of", 1657], ["the", 1660], ["frequency", 1664], ["of", 1674], ["the", 1677], ["-30G-->A", 1681], ["mutation", 1690], ["in", 1699], ["395", 1702], ["unrelated", 1706], ["normal", 1716], ["males", 1723], ["of", 1729], ["mixed", 1732], ["ancestry", 1738], ["revealed", 1747], ["two", 1756], ["additional", 1760], ["unrelated", 1771], ["individuals", 1781], ["who", 1793], ["had", 1797], ["high", 1801], ["plasma", 1806], ["enzymatic", 1813], ["activity", 1823], ["and", 1832], ["the", 1836], ["mutation", 1840], [",", 1848], ["confirming", 1850], ["the", 1861], ["effect", 1865], ["of", 1872], ["this", 1875], ["mutation", 1880], ["on", 1889], ["enzyme", 1892], ["expression", 1899], ["and", 1910], ["suggesting", 1914], ["that", 1925], ["about", 1930], ["0.5", 1936], ["%", 1939], ["of", 1941], ["normal", 1944], ["individuals", 1951], ["have", 1963], ["high", 1968], ["plasma", 1973], ["alpha", 1980], ["-", 1985], ["Gal", 1986], ["A", 1990], ["activity", 1992], ["due", 2001], ["to", 2005], ["this", 2008], ["variant", 2013], ["allele", 2021], [".", 2027]]}
{"context": "GATA-1 and the ets factor PU.1 have been reported to functionally antagonize one another in the regulation of erythroid versus myeloid gene transcription and development. The CCAAT enhancer binding protein epsilon (C/EBPepsilon) is expressed as multiple isoforms and has been shown to be essential to myeloid (granulocyte) terminal differentiation. We have defined a novel synergistic, as opposed to antagonistic, combinatorial interaction between GATA-1 and PU.1, and a unique repressor role for certain C/EBPepsilon isoforms in the transcriptional regulation of a model eosinophil granulocyte gene, the major basic protein (MBP). The eosinophil-specific P2 promoter of the MBP gene contains GATA-1, C/EBP, and PU.1 consensus sites that bind these factors in nuclear extracts of the eosinophil myelocyte cell line, AML14.3D10. The promoter is transactivated by GATA-1 alone but is synergistically transactivated by low levels of PU.1 in the context of optimal levels of GATA-1. The C/EBPepsilon(27) isoform strongly represses GATA-1 activity and completely blocks GATA-1/PU.1 synergy. In vitro mutational analyses of the MBP-P2 promoter showed that both the GATA-1/PU.1 synergy, and repressor activity of C/EBPepsilon(27) are mediated via protein-protein interactions through the C/EBP and/or GATA-binding sites but not the PU.1 sites. Co-immunoprecipitations using lysates of AML14.3D10 eosinophils show that both C/EBPepsilon(32/30) and epsilon(27) physically interact in vivo with PU.1 and GATA-1, demonstrating functional interactions among these factors in eosinophil progenitors. Our findings identify novel combinatorial protein-protein interactions for GATA-1, PU.1, and C/EBPepsilon isoforms in eosinophil gene transcription that include GATA-1/PU.1 synergy and repressor activity for C/EBPepsilon(27).", "qas": [{"question": "Which gene controls the expression of GATA-1 isoforms?", "answers": ["PU.1"], "qid": "301b11ff9a5742d3b24508da29ebffcd", "question_tokens": [["Which", 0], ["gene", 6], ["controls", 11], ["the", 20], ["expression", 24], ["of", 35], ["GATA-1", 38], ["isoforms", 45], ["?", 53]], "detected_answers": [{"text": "PU.1", "token_spans": [[229, 229], [5, 5], [74, 74], [124, 124], [281, 281], [158, 158], [255, 255]], "char_spans": [[1325, 1328], [26, 29], [459, 462], [712, 715], [1670, 1673], [930, 933], [1485, 1488]]}]}], "context_tokens": [["GATA-1", 0], ["and", 7], ["the", 11], ["ets", 15], ["factor", 19], ["PU.1", 26], ["have", 31], ["been", 36], ["reported", 41], ["to", 50], ["functionally", 53], ["antagonize", 66], ["one", 77], ["another", 81], ["in", 89], ["the", 92], ["regulation", 96], ["of", 107], ["erythroid", 110], ["versus", 120], ["myeloid", 127], ["gene", 135], ["transcription", 140], ["and", 154], ["development", 158], [".", 169], ["The", 171], ["CCAAT", 175], ["enhancer", 181], ["binding", 190], ["protein", 198], ["epsilon", 206], ["(", 214], ["C", 215], ["/", 216], ["EBPepsilon", 217], [")", 227], ["is", 229], ["expressed", 232], ["as", 242], ["multiple", 245], ["isoforms", 254], ["and", 263], ["has", 267], ["been", 271], ["shown", 276], ["to", 282], ["be", 285], ["essential", 288], ["to", 298], ["myeloid", 301], ["(", 309], ["granulocyte", 310], [")", 321], ["terminal", 323], ["differentiation", 332], [".", 347], ["We", 349], ["have", 352], ["defined", 357], ["a", 365], ["novel", 367], ["synergistic", 373], [",", 384], ["as", 386], ["opposed", 389], ["to", 397], ["antagonistic", 400], [",", 412], ["combinatorial", 414], ["interaction", 428], ["between", 440], ["GATA-1", 448], ["and", 455], ["PU.1", 459], [",", 463], ["and", 465], ["a", 469], ["unique", 471], ["repressor", 478], ["role", 488], ["for", 493], ["certain", 497], ["C", 505], ["/", 506], ["EBPepsilon", 507], ["isoforms", 518], ["in", 527], ["the", 530], ["transcriptional", 534], ["regulation", 550], ["of", 561], ["a", 564], ["model", 566], ["eosinophil", 572], ["granulocyte", 583], ["gene", 595], [",", 599], ["the", 601], ["major", 605], ["basic", 611], ["protein", 617], ["(", 625], ["MBP", 626], [")", 629], [".", 630], ["The", 632], ["eosinophil", 636], ["-", 646], ["specific", 647], ["P2", 656], ["promoter", 659], ["of", 668], ["the", 671], ["MBP", 675], ["gene", 679], ["contains", 684], ["GATA-1", 693], [",", 699], ["C", 701], ["/", 702], ["EBP", 703], [",", 706], ["and", 708], ["PU.1", 712], ["consensus", 717], ["sites", 727], ["that", 733], ["bind", 738], ["these", 743], ["factors", 749], ["in", 757], ["nuclear", 760], ["extracts", 768], ["of", 777], ["the", 780], ["eosinophil", 784], ["myelocyte", 795], ["cell", 805], ["line", 810], [",", 814], ["AML14.3D10", 816], [".", 826], ["The", 828], ["promoter", 832], ["is", 841], ["transactivated", 844], ["by", 859], ["GATA-1", 862], ["alone", 869], ["but", 875], ["is", 879], ["synergistically", 882], ["transactivated", 898], ["by", 913], ["low", 916], ["levels", 920], ["of", 927], ["PU.1", 930], ["in", 935], ["the", 938], ["context", 942], ["of", 950], ["optimal", 953], ["levels", 961], ["of", 968], ["GATA-1", 971], [".", 977], ["The", 979], ["C", 983], ["/", 984], ["EBPepsilon(27", 985], [")", 998], ["isoform", 1000], ["strongly", 1008], ["represses", 1017], ["GATA-1", 1027], ["activity", 1034], ["and", 1043], ["completely", 1047], ["blocks", 1058], ["GATA-1/PU.1", 1065], ["synergy", 1077], [".", 1084], ["In", 1086], ["vitro", 1089], ["mutational", 1095], ["analyses", 1106], ["of", 1115], ["the", 1118], ["MBP", 1122], ["-", 1125], ["P2", 1126], ["promoter", 1129], ["showed", 1138], ["that", 1145], ["both", 1150], ["the", 1155], ["GATA-1/PU.1", 1159], ["synergy", 1171], [",", 1178], ["and", 1180], ["repressor", 1184], ["activity", 1194], ["of", 1203], ["C", 1206], ["/", 1207], ["EBPepsilon(27", 1208], [")", 1221], ["are", 1223], ["mediated", 1227], ["via", 1236], ["protein", 1240], ["-", 1247], ["protein", 1248], ["interactions", 1256], ["through", 1269], ["the", 1277], ["C", 1281], ["/", 1282], ["EBP", 1283], ["and/or", 1287], ["GATA", 1294], ["-", 1298], ["binding", 1299], ["sites", 1307], ["but", 1313], ["not", 1317], ["the", 1321], ["PU.1", 1325], ["sites", 1330], [".", 1335], ["Co", 1337], ["-", 1339], ["immunoprecipitations", 1340], ["using", 1361], ["lysates", 1367], ["of", 1375], ["AML14.3D10", 1378], ["eosinophils", 1389], ["show", 1401], ["that", 1406], ["both", 1411], ["C", 1416], ["/", 1417], ["EBPepsilon(32/30", 1418], [")", 1434], ["and", 1436], ["epsilon(27", 1440], [")", 1450], ["physically", 1452], ["interact", 1463], ["in", 1472], ["vivo", 1475], ["with", 1480], ["PU.1", 1485], ["and", 1490], ["GATA-1", 1494], [",", 1500], ["demonstrating", 1502], ["functional", 1516], ["interactions", 1527], ["among", 1540], ["these", 1546], ["factors", 1552], ["in", 1560], ["eosinophil", 1563], ["progenitors", 1574], [".", 1585], ["Our", 1587], ["findings", 1591], ["identify", 1600], ["novel", 1609], ["combinatorial", 1615], ["protein", 1629], ["-", 1636], ["protein", 1637], ["interactions", 1645], ["for", 1658], ["GATA-1", 1662], [",", 1668], ["PU.1", 1670], [",", 1674], ["and", 1676], ["C", 1680], ["/", 1681], ["EBPepsilon", 1682], ["isoforms", 1693], ["in", 1702], ["eosinophil", 1705], ["gene", 1716], ["transcription", 1721], ["that", 1735], ["include", 1740], ["GATA-1/PU.1", 1748], ["synergy", 1760], ["and", 1768], ["repressor", 1772], ["activity", 1782], ["for", 1791], ["C", 1795], ["/", 1796], ["EBPepsilon(27", 1797], [")", 1810], [".", 1811]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by the Philadelphia translocation that fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9. The chimerical Bcr-Abl protein expressed by CML cells has constitutive tyrosine kinase activity, which is essential for the pathogenesis of the disease. Imatinib, an ATP-competitive selective inhibitor of Bcr-Abl, has unprecedented efficacy for the treatment of CML. Most patients with early stage disease achieve durable complete hematological and complete cytogenetic remissions, with minimal toxicity. In contrast, responses are less stable in patients with advanced CML. This review highlights the pathogenesis of CML, its clinical features, and the development of imatinib as a specific molecularly targeted therapy. Aspects of disease monitoring and side effects are covered as well as resistance to imatinib and strategies to overcome resistance, such as alternative signal transduction inhibitors and drug combinations. Perspectives for further development are also discussed.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "d31cc811c4ed4d9a840643c3c97ec8b6", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[30, 32], [63, 65]], "char_spans": [[183, 189], [373, 379]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["the", 51], ["Philadelphia", 55], ["translocation", 68], ["that", 82], ["fuses", 87], ["BCR", 93], ["sequences", 97], ["from", 107], ["chromosome", 112], ["22", 123], ["upstream", 126], ["of", 135], ["the", 138], ["ABL", 142], ["gene", 146], ["on", 151], ["chromosome", 154], ["9", 165], [".", 166], ["The", 168], ["chimerical", 172], ["Bcr", 183], ["-", 186], ["Abl", 187], ["protein", 191], ["expressed", 199], ["by", 209], ["CML", 212], ["cells", 216], ["has", 222], ["constitutive", 226], ["tyrosine", 239], ["kinase", 248], ["activity", 255], [",", 263], ["which", 265], ["is", 271], ["essential", 274], ["for", 284], ["the", 288], ["pathogenesis", 292], ["of", 305], ["the", 308], ["disease", 312], [".", 319], ["Imatinib", 321], [",", 329], ["an", 331], ["ATP", 334], ["-", 337], ["competitive", 338], ["selective", 350], ["inhibitor", 360], ["of", 370], ["Bcr", 373], ["-", 376], ["Abl", 377], [",", 380], ["has", 382], ["unprecedented", 386], ["efficacy", 400], ["for", 409], ["the", 413], ["treatment", 417], ["of", 427], ["CML", 430], [".", 433], ["Most", 435], ["patients", 440], ["with", 449], ["early", 454], ["stage", 460], ["disease", 466], ["achieve", 474], ["durable", 482], ["complete", 490], ["hematological", 499], ["and", 513], ["complete", 517], ["cytogenetic", 526], ["remissions", 538], [",", 548], ["with", 550], ["minimal", 555], ["toxicity", 563], [".", 571], ["In", 573], ["contrast", 576], [",", 584], ["responses", 586], ["are", 596], ["less", 600], ["stable", 605], ["in", 612], ["patients", 615], ["with", 624], ["advanced", 629], ["CML", 638], [".", 641], ["This", 643], ["review", 648], ["highlights", 655], ["the", 666], ["pathogenesis", 670], ["of", 683], ["CML", 686], [",", 689], ["its", 691], ["clinical", 695], ["features", 704], [",", 712], ["and", 714], ["the", 718], ["development", 722], ["of", 734], ["imatinib", 737], ["as", 746], ["a", 749], ["specific", 751], ["molecularly", 760], ["targeted", 772], ["therapy", 781], [".", 788], ["Aspects", 790], ["of", 798], ["disease", 801], ["monitoring", 809], ["and", 820], ["side", 824], ["effects", 829], ["are", 837], ["covered", 841], ["as", 849], ["well", 852], ["as", 857], ["resistance", 860], ["to", 871], ["imatinib", 874], ["and", 883], ["strategies", 887], ["to", 898], ["overcome", 901], ["resistance", 910], [",", 920], ["such", 922], ["as", 927], ["alternative", 930], ["signal", 942], ["transduction", 949], ["inhibitors", 962], ["and", 973], ["drug", 977], ["combinations", 982], [".", 994], ["Perspectives", 996], ["for", 1009], ["further", 1013], ["development", 1021], ["are", 1033], ["also", 1037], ["discussed", 1042], [".", 1051]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disorder linked to contractions of the D4Z4 repeat array in the subtelomeric region of chromosome 4q. By comparing genome-wide gene expression data from muscle biopsies of patients with FSHD to those of 11 other neuromuscular disorders, paired-like homeodomain transcription factor 1 (PITX1) was found specifically up-regulated in patients with FSHD. In addition, we showed that the double homeobox 4 gene (DUX4) that maps within the D4Z4 repeat unit was up-regulated in patient myoblasts at both mRNA and protein level. We further showed that the DUX4 protein could activate transient expression of a luciferase reporter gene fused to the Pitx1 promoter as well as the endogenous Pitx1 gene in transfected C2C12 cells. In EMSAs, DUX4 specifically interacted with a 30-bp sequence 5'-CGGATGCTGTCTTCTAATTAGTTTGGACCC-3' in the Pitx1 promoter. Mutations of the TAAT core affected Pitx1-LUC activation in C2C12 cells and DUX4 binding in vitro. Our results suggest that up-regulation of both DUX4 and PITX1 in FSHD muscles may play critical roles in the molecular mechanisms of the disease.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "5d0d556d41284947986e2a22525e867b", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[4, 4], [69, 69], [41, 41], [186, 186]], "char_spans": [[40, 43], [416, 419], [257, 260], [1076, 1079]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["an", 49], ["autosomal", 52], ["dominant", 62], ["disorder", 71], ["linked", 80], ["to", 87], ["contractions", 90], ["of", 103], ["the", 106], ["D4Z4", 110], ["repeat", 115], ["array", 122], ["in", 128], ["the", 131], ["subtelomeric", 135], ["region", 148], ["of", 155], ["chromosome", 158], ["4q", 169], [".", 171], ["By", 173], ["comparing", 176], ["genome", 186], ["-", 192], ["wide", 193], ["gene", 198], ["expression", 203], ["data", 214], ["from", 219], ["muscle", 224], ["biopsies", 231], ["of", 240], ["patients", 243], ["with", 252], ["FSHD", 257], ["to", 262], ["those", 265], ["of", 271], ["11", 274], ["other", 277], ["neuromuscular", 283], ["disorders", 297], [",", 306], ["paired", 308], ["-", 314], ["like", 315], ["homeodomain", 320], ["transcription", 332], ["factor", 346], ["1", 353], ["(", 355], ["PITX1", 356], [")", 361], ["was", 363], ["found", 367], ["specifically", 373], ["up", 386], ["-", 388], ["regulated", 389], ["in", 399], ["patients", 402], ["with", 411], ["FSHD", 416], [".", 420], ["In", 422], ["addition", 425], [",", 433], ["we", 435], ["showed", 438], ["that", 445], ["the", 450], ["double", 454], ["homeobox", 461], ["4", 470], ["gene", 472], ["(", 477], ["DUX4", 478], [")", 482], ["that", 484], ["maps", 489], ["within", 494], ["the", 501], ["D4Z4", 505], ["repeat", 510], ["unit", 517], ["was", 522], ["up", 526], ["-", 528], ["regulated", 529], ["in", 539], ["patient", 542], ["myoblasts", 550], ["at", 560], ["both", 563], ["mRNA", 568], ["and", 573], ["protein", 577], ["level", 585], [".", 590], ["We", 592], ["further", 595], ["showed", 603], ["that", 610], ["the", 615], ["DUX4", 619], ["protein", 624], ["could", 632], ["activate", 638], ["transient", 647], ["expression", 657], ["of", 668], ["a", 671], ["luciferase", 673], ["reporter", 684], ["gene", 693], ["fused", 698], ["to", 704], ["the", 707], ["Pitx1", 711], ["promoter", 717], ["as", 726], ["well", 729], ["as", 734], ["the", 737], ["endogenous", 741], ["Pitx1", 752], ["gene", 758], ["in", 763], ["transfected", 766], ["C2C12", 778], ["cells", 784], [".", 789], ["In", 791], ["EMSAs", 794], [",", 799], ["DUX4", 801], ["specifically", 806], ["interacted", 819], ["with", 830], ["a", 835], ["30-bp", 837], ["sequence", 843], ["5'-CGGATGCTGTCTTCTAATTAGTTTGGACCC-3", 852], ["'", 887], ["in", 889], ["the", 892], ["Pitx1", 896], ["promoter", 902], [".", 910], ["Mutations", 912], ["of", 922], ["the", 925], ["TAAT", 929], ["core", 934], ["affected", 939], ["Pitx1-LUC", 948], ["activation", 958], ["in", 969], ["C2C12", 972], ["cells", 978], ["and", 984], ["DUX4", 988], ["binding", 993], ["in", 1001], ["vitro", 1004], [".", 1009], ["Our", 1011], ["results", 1015], ["suggest", 1023], ["that", 1031], ["up", 1036], ["-", 1038], ["regulation", 1039], ["of", 1050], ["both", 1053], ["DUX4", 1058], ["and", 1063], ["PITX1", 1067], ["in", 1073], ["FSHD", 1076], ["muscles", 1081], ["may", 1089], ["play", 1093], ["critical", 1098], ["roles", 1107], ["in", 1113], ["the", 1116], ["molecular", 1120], ["mechanisms", 1130], ["of", 1141], ["the", 1144], ["disease", 1148], [".", 1155]]}
{"context": "Facio-scapulo-humeral dystrophy (FSHD) results from deletions in the subtelomeric macrosatellite D4Z4 array on the 4q35 region. Upregulation of the DUX4 retrogene from the last D4Z4 repeated unit is thought to underlie FSHD pathophysiology. However, no one knows what triggers muscle defect and when alteration arises. To gain further insights into the molecular mechanisms of the disease, we evaluated at the molecular level, the perturbation linked to the FSHD genotype with no a priori on disease onset, severity or penetrance and prior to any infiltration by fibrotic or adipose tissue in biopsies from fetuses carrying a short pathogenic D4Z4 array (n = 6) compared with fetuses with a non-pathogenic D4Z4 array (n = 21). By measuring expression of several muscle-specific markers and 4q35 genes including the DUX4 retrogene by an RT-PCR and western blotting, we observed a global dysregulation of genes involved in myogenesis including MYOD1 in samples with <11 D4Z4. The DUX4-fl pathogenic transcript was detected in FSHD biopsies but also in controls. Importantly, in FSHD fetuses, we mainly detected the non-spliced DUX4-fl isoform. In addition, several other genes clustered at the 4q35 locus are upregulated in FSHD fetuses. Our study is the first to examine fetuses carrying an FSHD-linked genotype and reveals an extensive dysregulation of several muscle-specific and 4q35 genes at early development stage at a distance from any muscle defect. Overall, our work suggests that even if FSHD is an adult-onset muscular dystrophy, the disease might also involve early molecular defects arising during myogenesis or early differentiation.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "4fc29c2642a542c698f2e6a566dc9c37", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[221, 221], [38, 38], [234, 234], [7, 7], [184, 184], [194, 194], [79, 79], [271, 271]], "char_spans": [[1222, 1225], [219, 222], [1290, 1293], [33, 36], [1024, 1027], [1076, 1079], [458, 461], [1497, 1500]]}]}], "context_tokens": [["Facio", 0], ["-", 5], ["scapulo", 6], ["-", 13], ["humeral", 14], ["dystrophy", 22], ["(", 32], ["FSHD", 33], [")", 37], ["results", 39], ["from", 47], ["deletions", 52], ["in", 62], ["the", 65], ["subtelomeric", 69], ["macrosatellite", 82], ["D4Z4", 97], ["array", 102], ["on", 108], ["the", 111], ["4q35", 115], ["region", 120], [".", 126], ["Upregulation", 128], ["of", 141], ["the", 144], ["DUX4", 148], ["retrogene", 153], ["from", 163], ["the", 168], ["last", 172], ["D4Z4", 177], ["repeated", 182], ["unit", 191], ["is", 196], ["thought", 199], ["to", 207], ["underlie", 210], ["FSHD", 219], ["pathophysiology", 224], [".", 239], ["However", 241], [",", 248], ["no", 250], ["one", 253], ["knows", 257], ["what", 263], ["triggers", 268], ["muscle", 277], ["defect", 284], ["and", 291], ["when", 295], ["alteration", 300], ["arises", 311], [".", 317], ["To", 319], ["gain", 322], ["further", 327], ["insights", 335], ["into", 344], ["the", 349], ["molecular", 353], ["mechanisms", 363], ["of", 374], ["the", 377], ["disease", 381], [",", 388], ["we", 390], ["evaluated", 393], ["at", 403], ["the", 406], ["molecular", 410], ["level", 420], [",", 425], ["the", 427], ["perturbation", 431], ["linked", 444], ["to", 451], ["the", 454], ["FSHD", 458], ["genotype", 463], ["with", 472], ["no", 477], ["a", 480], ["priori", 482], ["on", 489], ["disease", 492], ["onset", 500], [",", 505], ["severity", 507], ["or", 516], ["penetrance", 519], ["and", 530], ["prior", 534], ["to", 540], ["any", 543], ["infiltration", 547], ["by", 560], ["fibrotic", 563], ["or", 572], ["adipose", 575], ["tissue", 583], ["in", 590], ["biopsies", 593], ["from", 602], ["fetuses", 607], ["carrying", 615], ["a", 624], ["short", 626], ["pathogenic", 632], ["D4Z4", 643], ["array", 648], ["(", 654], ["n", 655], ["=", 657], ["6", 659], [")", 660], ["compared", 662], ["with", 671], ["fetuses", 676], ["with", 684], ["a", 689], ["non", 691], ["-", 694], ["pathogenic", 695], ["D4Z4", 706], ["array", 711], ["(", 717], ["n", 718], ["=", 720], ["21", 722], [")", 724], [".", 725], ["By", 727], ["measuring", 730], ["expression", 740], ["of", 751], ["several", 754], ["muscle", 762], ["-", 768], ["specific", 769], ["markers", 778], ["and", 786], ["4q35", 790], ["genes", 795], ["including", 801], ["the", 811], ["DUX4", 815], ["retrogene", 820], ["by", 830], ["an", 833], ["RT", 836], ["-", 838], ["PCR", 839], ["and", 843], ["western", 847], ["blotting", 855], [",", 863], ["we", 865], ["observed", 868], ["a", 877], ["global", 879], ["dysregulation", 886], ["of", 900], ["genes", 903], ["involved", 909], ["in", 918], ["myogenesis", 921], ["including", 932], ["MYOD1", 942], ["in", 948], ["samples", 951], ["with", 959], ["<", 964], ["11", 965], ["D4Z4", 968], [".", 972], ["The", 974], ["DUX4-fl", 978], ["pathogenic", 986], ["transcript", 997], ["was", 1008], ["detected", 1012], ["in", 1021], ["FSHD", 1024], ["biopsies", 1029], ["but", 1038], ["also", 1042], ["in", 1047], ["controls", 1050], [".", 1058], ["Importantly", 1060], [",", 1071], ["in", 1073], ["FSHD", 1076], ["fetuses", 1081], [",", 1088], ["we", 1090], ["mainly", 1093], ["detected", 1100], ["the", 1109], ["non", 1113], ["-", 1116], ["spliced", 1117], ["DUX4-fl", 1125], ["isoform", 1133], [".", 1140], ["In", 1142], ["addition", 1145], [",", 1153], ["several", 1155], ["other", 1163], ["genes", 1169], ["clustered", 1175], ["at", 1185], ["the", 1188], ["4q35", 1192], ["locus", 1197], ["are", 1203], ["upregulated", 1207], ["in", 1219], ["FSHD", 1222], ["fetuses", 1227], [".", 1234], ["Our", 1236], ["study", 1240], ["is", 1246], ["the", 1249], ["first", 1253], ["to", 1259], ["examine", 1262], ["fetuses", 1270], ["carrying", 1278], ["an", 1287], ["FSHD", 1290], ["-", 1294], ["linked", 1295], ["genotype", 1302], ["and", 1311], ["reveals", 1315], ["an", 1323], ["extensive", 1326], ["dysregulation", 1336], ["of", 1350], ["several", 1353], ["muscle", 1361], ["-", 1367], ["specific", 1368], ["and", 1377], ["4q35", 1381], ["genes", 1386], ["at", 1392], ["early", 1395], ["development", 1401], ["stage", 1413], ["at", 1419], ["a", 1422], ["distance", 1424], ["from", 1433], ["any", 1438], ["muscle", 1442], ["defect", 1449], [".", 1455], ["Overall", 1457], [",", 1464], ["our", 1466], ["work", 1470], ["suggests", 1475], ["that", 1484], ["even", 1489], ["if", 1494], ["FSHD", 1497], ["is", 1502], ["an", 1505], ["adult", 1508], ["-", 1513], ["onset", 1514], ["muscular", 1520], ["dystrophy", 1529], [",", 1538], ["the", 1540], ["disease", 1544], ["might", 1552], ["also", 1558], ["involve", 1563], ["early", 1571], ["molecular", 1577], ["defects", 1587], ["arising", 1595], ["during", 1603], ["myogenesis", 1610], ["or", 1621], ["early", 1624], ["differentiation", 1630], [".", 1645]]}
{"context": "Nivolumab was developed as a monoclonal antibody against programmed death receptor-1, an immune checkpoint inhibitor which negatively regulates T-cell proliferation and activation. Intravenous administration of nivolumab was approved for the treatment of unresectable malignant melanoma in 2014 in Japan. When advanced melanoma patients were treated with nivolumab, median overall survival became longer. Overall survival rate was significantly better in nivolumab-treated melanoma patients than dacarbazine-treated melanoma patients. Nivolumab had an acceptable long-term tolerability profile, with 22% of patients experiencing grade 3 or 4 adverse events related to the drug. Therefore, nivolumab can become an alternative therapy for advanced malignant melanoma.", "qas": [{"question": "Which is the target protein of the drug nivolumab?", "answers": ["programmed death receptor-1"], "qid": "2b04e73544f7459d9232316ec0e13a4a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["protein", 20], ["of", 28], ["the", 31], ["drug", 35], ["nivolumab", 40], ["?", 49]], "detected_answers": [{"text": "programmed death receptor-1", "token_spans": [[8, 10]], "char_spans": [[57, 83]]}]}], "context_tokens": [["Nivolumab", 0], ["was", 10], ["developed", 14], ["as", 24], ["a", 27], ["monoclonal", 29], ["antibody", 40], ["against", 49], ["programmed", 57], ["death", 68], ["receptor-1", 74], [",", 84], ["an", 86], ["immune", 89], ["checkpoint", 96], ["inhibitor", 107], ["which", 117], ["negatively", 123], ["regulates", 134], ["T", 144], ["-", 145], ["cell", 146], ["proliferation", 151], ["and", 165], ["activation", 169], [".", 179], ["Intravenous", 181], ["administration", 193], ["of", 208], ["nivolumab", 211], ["was", 221], ["approved", 225], ["for", 234], ["the", 238], ["treatment", 242], ["of", 252], ["unresectable", 255], ["malignant", 268], ["melanoma", 278], ["in", 287], ["2014", 290], ["in", 295], ["Japan", 298], [".", 303], ["When", 305], ["advanced", 310], ["melanoma", 319], ["patients", 328], ["were", 337], ["treated", 342], ["with", 350], ["nivolumab", 355], [",", 364], ["median", 366], ["overall", 373], ["survival", 381], ["became", 390], ["longer", 397], [".", 403], ["Overall", 405], ["survival", 413], ["rate", 422], ["was", 427], ["significantly", 431], ["better", 445], ["in", 452], ["nivolumab", 455], ["-", 464], ["treated", 465], ["melanoma", 473], ["patients", 482], ["than", 491], ["dacarbazine", 496], ["-", 507], ["treated", 508], ["melanoma", 516], ["patients", 525], [".", 533], ["Nivolumab", 535], ["had", 545], ["an", 549], ["acceptable", 552], ["long", 563], ["-", 567], ["term", 568], ["tolerability", 573], ["profile", 586], [",", 593], ["with", 595], ["22", 600], ["%", 602], ["of", 604], ["patients", 607], ["experiencing", 616], ["grade", 629], ["3", 635], ["or", 637], ["4", 640], ["adverse", 642], ["events", 650], ["related", 657], ["to", 665], ["the", 668], ["drug", 672], [".", 676], ["Therefore", 678], [",", 687], ["nivolumab", 689], ["can", 699], ["become", 703], ["an", 710], ["alternative", 713], ["therapy", 725], ["for", 733], ["advanced", 737], ["malignant", 746], ["melanoma", 756], [".", 764]]}
{"context": "A 60-year-old man diagnosed clinically with Becker's muscular dystrophy 20 years ago by another physician presented with gradually progressive proximal muscle weakness since teenage years. Family history revealed a strong paternal familial inheritance pattern of similar distribution of weakness-face, forearm flexion, knee extension and foot dorsiflexion. Work-ups revealed B12 deficiency and allele 1 deletion in fascioscapulohumeral muscular dystrophy (FSHD) DNA testing. FSHD is the third most common muscular dystrophy. Clinical diagnosis is made from the distinctive pattern of weakness, autosomal-dominant inheritance, and confirmed by genetic testing. This case strongly demonstrates the importance of a thorough and careful clinical evaluation even in a case with a long standing diagnosis.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "ff8ede38609d4622af0f985023a70e89", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[95, 97]], "char_spans": [[594, 611]]}]}], "context_tokens": [["A", 0], ["60-year", 2], ["-", 9], ["old", 10], ["man", 14], ["diagnosed", 18], ["clinically", 28], ["with", 39], ["Becker", 44], ["'s", 50], ["muscular", 53], ["dystrophy", 62], ["20", 72], ["years", 75], ["ago", 81], ["by", 85], ["another", 88], ["physician", 96], ["presented", 106], ["with", 116], ["gradually", 121], ["progressive", 131], ["proximal", 143], ["muscle", 152], ["weakness", 159], ["since", 168], ["teenage", 174], ["years", 182], [".", 187], ["Family", 189], ["history", 196], ["revealed", 204], ["a", 213], ["strong", 215], ["paternal", 222], ["familial", 231], ["inheritance", 240], ["pattern", 252], ["of", 260], ["similar", 263], ["distribution", 271], ["of", 284], ["weakness", 287], ["-", 295], ["face", 296], [",", 300], ["forearm", 302], ["flexion", 310], [",", 317], ["knee", 319], ["extension", 324], ["and", 334], ["foot", 338], ["dorsiflexion", 343], [".", 355], ["Work", 357], ["-", 361], ["ups", 362], ["revealed", 366], ["B12", 375], ["deficiency", 379], ["and", 390], ["allele", 394], ["1", 401], ["deletion", 403], ["in", 412], ["fascioscapulohumeral", 415], ["muscular", 436], ["dystrophy", 445], ["(", 455], ["FSHD", 456], [")", 460], ["DNA", 462], ["testing", 466], [".", 473], ["FSHD", 475], ["is", 480], ["the", 483], ["third", 487], ["most", 493], ["common", 498], ["muscular", 505], ["dystrophy", 514], [".", 523], ["Clinical", 525], ["diagnosis", 534], ["is", 544], ["made", 547], ["from", 552], ["the", 557], ["distinctive", 561], ["pattern", 573], ["of", 581], ["weakness", 584], [",", 592], ["autosomal", 594], ["-", 603], ["dominant", 604], ["inheritance", 613], [",", 624], ["and", 626], ["confirmed", 630], ["by", 640], ["genetic", 643], ["testing", 651], [".", 658], ["This", 660], ["case", 665], ["strongly", 670], ["demonstrates", 679], ["the", 692], ["importance", 696], ["of", 707], ["a", 710], ["thorough", 712], ["and", 721], ["careful", 725], ["clinical", 733], ["evaluation", 742], ["even", 753], ["in", 758], ["a", 761], ["case", 763], ["with", 768], ["a", 773], ["long", 775], ["standing", 780], ["diagnosis", 789], [".", 798]]}
{"context": "Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone. A randomized, double-blind, gender-balanced, parallel-group study was performed in 4 groups of 20 healthy subjects each. Four subjects in each group received placebo during the entire study. Sixteen subjects in one group received placebo once daily for 11 days and on day 12, 200 mg entacapone concomitantly with each levodopa/carbidopa dose (three times separated by a 5-h interval). Sixteen subjects in each of the remaining three groups received respectively 25, 50, and 75 mg opicapone once daily for 11 days and on day 12, placebo concomitantly with each levodopa/carbidopa dose. Levodopa minimum plasma concentration (Cmin) for each levodopa/carbidopa dose and for the mean of all levodopa/carbidopa doses increased substantially with all active treatments (entacapone and opicapone) when compared to the control group (placebo), with values ranging from 1.7-fold (200 mg entacapone) to 3.3-fold (75 mg opicapone). No statistical difference was found for levodopa peak of systemic exposure (as assessed by maximum observed plasma concentration (Cmax)) between all active treatments and placebo. A significant increase in the levodopa extent of systemic exposure (as assessed by concentration-time curve (AUC)) occurred with all opicapone treatments in relation to placebo. No statistical difference was found for levodopa AUC when entacapone was compared to placebo. When compared to entacapone, both 50 and 75 mg opicapone presented a significant increase for the levodopa AUC. All active treatments significantly inhibited both peak (as assessed by Emax) and extent (as assessed by effect-time curve (AUEC)) of the COMT activity in relation to placebo. When compared to entacapone, all opicapone treatments significantly decreased the extent (AUEC) of the COMT activity due to a long-lasting and sustained effect. The tolerability profile was favorable for all active treatments. Opicapone, a novel third generation COMT inhibitor, when compared to entacapone, provides a superior response upon the bioavailability of levodopa associated to more pronounced, long-lasting, and sustained COMT inhibition. The tolerability profile was favorable. On the basis of the results presented in this study and along with the earlier pharmacology studies, it is anticipated that opicapone adjunct therapy at the dosages of 25 and 50 mg will provide an enhancement in levodopa availability that will translate into clinical benefit for Parkinson's disease patients.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "0e5ff4402f1e44c1a1d80868713f9b9f", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[6, 10]], "char_spans": [[38, 65]]}]}], "context_tokens": [["Opicapone", 0], ["is", 10], ["a", 13], ["novel", 15], ["third", 21], ["generation", 27], ["catechol", 38], ["-", 46], ["O", 47], ["-", 48], ["methyltransferase", 49], ["(", 67], ["COMT", 68], [")", 72], ["inhibitor", 74], [".", 83], ["The", 85], ["purpose", 89], ["of", 97], ["this", 100], ["study", 105], ["was", 111], ["to", 115], ["compare", 118], ["the", 126], ["levodopa", 130], ["pharmacokinetic", 139], ["profile", 155], ["throughout", 163], ["a", 174], ["day", 176], ["driven", 180], ["by", 187], ["the", 190], ["COMT", 194], ["inhibition", 199], ["either", 210], ["following", 217], ["repeated", 227], ["doses", 236], ["of", 242], ["opicapone", 245], ["or", 255], ["concomitant", 258], ["administration", 270], ["with", 285], ["entacapone", 290], [".", 300], ["A", 302], ["randomized", 304], [",", 314], ["double", 316], ["-", 322], ["blind", 323], [",", 328], ["gender", 330], ["-", 336], ["balanced", 337], [",", 345], ["parallel", 347], ["-", 355], ["group", 356], ["study", 362], ["was", 368], ["performed", 372], ["in", 382], ["4", 385], ["groups", 387], ["of", 394], ["20", 397], ["healthy", 400], ["subjects", 408], ["each", 417], [".", 421], ["Four", 423], ["subjects", 428], ["in", 437], ["each", 440], ["group", 445], ["received", 451], ["placebo", 460], ["during", 468], ["the", 475], ["entire", 479], ["study", 486], [".", 491], ["Sixteen", 493], ["subjects", 501], ["in", 510], ["one", 513], ["group", 517], ["received", 523], ["placebo", 532], ["once", 540], ["daily", 545], ["for", 551], ["11", 555], ["days", 558], ["and", 563], ["on", 567], ["day", 570], ["12", 574], [",", 576], ["200", 578], ["mg", 582], ["entacapone", 585], ["concomitantly", 596], ["with", 610], ["each", 615], ["levodopa", 620], ["/", 628], ["carbidopa", 629], ["dose", 639], ["(", 644], ["three", 645], ["times", 651], ["separated", 657], ["by", 667], ["a", 670], ["5-h", 672], ["interval", 676], [")", 684], [".", 685], ["Sixteen", 687], ["subjects", 695], ["in", 704], ["each", 707], ["of", 712], ["the", 715], ["remaining", 719], ["three", 729], ["groups", 735], ["received", 742], ["respectively", 751], ["25", 764], [",", 766], ["50", 768], [",", 770], ["and", 772], ["75", 776], ["mg", 779], ["opicapone", 782], ["once", 792], ["daily", 797], ["for", 803], ["11", 807], ["days", 810], ["and", 815], ["on", 819], ["day", 822], ["12", 826], [",", 828], ["placebo", 830], ["concomitantly", 838], ["with", 852], ["each", 857], ["levodopa", 862], ["/", 870], ["carbidopa", 871], ["dose", 881], [".", 885], ["Levodopa", 887], ["minimum", 896], ["plasma", 904], ["concentration", 911], ["(", 925], ["Cmin", 926], [")", 930], ["for", 932], ["each", 936], ["levodopa", 941], ["/", 949], ["carbidopa", 950], ["dose", 960], ["and", 965], ["for", 969], ["the", 973], ["mean", 977], ["of", 982], ["all", 985], ["levodopa", 989], ["/", 997], ["carbidopa", 998], ["doses", 1008], ["increased", 1014], ["substantially", 1024], ["with", 1038], ["all", 1043], ["active", 1047], ["treatments", 1054], ["(", 1065], ["entacapone", 1066], ["and", 1077], ["opicapone", 1081], [")", 1090], ["when", 1092], ["compared", 1097], ["to", 1106], ["the", 1109], ["control", 1113], ["group", 1121], ["(", 1127], ["placebo", 1128], [")", 1135], [",", 1136], ["with", 1138], ["values", 1143], ["ranging", 1150], ["from", 1158], ["1.7-fold", 1163], ["(", 1172], ["200", 1173], ["mg", 1177], ["entacapone", 1180], [")", 1190], ["to", 1192], ["3.3-fold", 1195], ["(", 1204], ["75", 1205], ["mg", 1208], ["opicapone", 1211], [")", 1220], [".", 1221], ["No", 1223], ["statistical", 1226], ["difference", 1238], ["was", 1249], ["found", 1253], ["for", 1259], ["levodopa", 1263], ["peak", 1272], ["of", 1277], ["systemic", 1280], ["exposure", 1289], ["(", 1298], ["as", 1299], ["assessed", 1302], ["by", 1311], ["maximum", 1314], ["observed", 1322], ["plasma", 1331], ["concentration", 1338], ["(", 1352], ["Cmax", 1353], [")", 1357], [")", 1358], ["between", 1360], ["all", 1368], ["active", 1372], ["treatments", 1379], ["and", 1390], ["placebo", 1394], [".", 1401], ["A", 1403], ["significant", 1405], ["increase", 1417], ["in", 1426], ["the", 1429], ["levodopa", 1433], ["extent", 1442], ["of", 1449], ["systemic", 1452], ["exposure", 1461], ["(", 1470], ["as", 1471], ["assessed", 1474], ["by", 1483], ["concentration", 1486], ["-", 1499], ["time", 1500], ["curve", 1505], ["(", 1511], ["AUC", 1512], [")", 1515], [")", 1516], ["occurred", 1518], ["with", 1527], ["all", 1532], ["opicapone", 1536], ["treatments", 1546], ["in", 1557], ["relation", 1560], ["to", 1569], ["placebo", 1572], [".", 1579], ["No", 1581], ["statistical", 1584], ["difference", 1596], ["was", 1607], ["found", 1611], ["for", 1617], ["levodopa", 1621], ["AUC", 1630], ["when", 1634], ["entacapone", 1639], ["was", 1650], ["compared", 1654], ["to", 1663], ["placebo", 1666], [".", 1673], ["When", 1675], ["compared", 1680], ["to", 1689], ["entacapone", 1692], [",", 1702], ["both", 1704], ["50", 1709], ["and", 1712], ["75", 1716], ["mg", 1719], ["opicapone", 1722], ["presented", 1732], ["a", 1742], ["significant", 1744], ["increase", 1756], ["for", 1765], ["the", 1769], ["levodopa", 1773], ["AUC", 1782], [".", 1785], ["All", 1787], ["active", 1791], ["treatments", 1798], ["significantly", 1809], ["inhibited", 1823], ["both", 1833], ["peak", 1838], ["(", 1843], ["as", 1844], ["assessed", 1847], ["by", 1856], ["Emax", 1859], [")", 1863], ["and", 1865], ["extent", 1869], ["(", 1876], ["as", 1877], ["assessed", 1880], ["by", 1889], ["effect", 1892], ["-", 1898], ["time", 1899], ["curve", 1904], ["(", 1910], ["AUEC", 1911], [")", 1915], [")", 1916], ["of", 1918], ["the", 1921], ["COMT", 1925], ["activity", 1930], ["in", 1939], ["relation", 1942], ["to", 1951], ["placebo", 1954], [".", 1961], ["When", 1963], ["compared", 1968], ["to", 1977], ["entacapone", 1980], [",", 1990], ["all", 1992], ["opicapone", 1996], ["treatments", 2006], ["significantly", 2017], ["decreased", 2031], ["the", 2041], ["extent", 2045], ["(", 2052], ["AUEC", 2053], [")", 2057], ["of", 2059], ["the", 2062], ["COMT", 2066], ["activity", 2071], ["due", 2080], ["to", 2084], ["a", 2087], ["long", 2089], ["-", 2093], ["lasting", 2094], ["and", 2102], ["sustained", 2106], ["effect", 2116], [".", 2122], ["The", 2124], ["tolerability", 2128], ["profile", 2141], ["was", 2149], ["favorable", 2153], ["for", 2163], ["all", 2167], ["active", 2171], ["treatments", 2178], [".", 2188], ["Opicapone", 2190], [",", 2199], ["a", 2201], ["novel", 2203], ["third", 2209], ["generation", 2215], ["COMT", 2226], ["inhibitor", 2231], [",", 2240], ["when", 2242], ["compared", 2247], ["to", 2256], ["entacapone", 2259], [",", 2269], ["provides", 2271], ["a", 2280], ["superior", 2282], ["response", 2291], ["upon", 2300], ["the", 2305], ["bioavailability", 2309], ["of", 2325], ["levodopa", 2328], ["associated", 2337], ["to", 2348], ["more", 2351], ["pronounced", 2356], [",", 2366], ["long", 2368], ["-", 2372], ["lasting", 2373], [",", 2380], ["and", 2382], ["sustained", 2386], ["COMT", 2396], ["inhibition", 2401], [".", 2411], ["The", 2413], ["tolerability", 2417], ["profile", 2430], ["was", 2438], ["favorable", 2442], [".", 2451], ["On", 2453], ["the", 2456], ["basis", 2460], ["of", 2466], ["the", 2469], ["results", 2473], ["presented", 2481], ["in", 2491], ["this", 2494], ["study", 2499], ["and", 2505], ["along", 2509], ["with", 2515], ["the", 2520], ["earlier", 2524], ["pharmacology", 2532], ["studies", 2545], [",", 2552], ["it", 2554], ["is", 2557], ["anticipated", 2560], ["that", 2572], ["opicapone", 2577], ["adjunct", 2587], ["therapy", 2595], ["at", 2603], ["the", 2606], ["dosages", 2610], ["of", 2618], ["25", 2621], ["and", 2624], ["50", 2628], ["mg", 2631], ["will", 2634], ["provide", 2639], ["an", 2647], ["enhancement", 2650], ["in", 2662], ["levodopa", 2665], ["availability", 2674], ["that", 2687], ["will", 2692], ["translate", 2697], ["into", 2707], ["clinical", 2712], ["benefit", 2721], ["for", 2729], ["Parkinson", 2733], ["'s", 2742], ["disease", 2745], ["patients", 2753], [".", 2761]]}
{"context": "The FOXP2 gene is important for the development of proper speech motor control in humans. However, the role of the gene in general vocal behavior in other mammals, including mice, is unclear. Here, we track the vocal development of Foxp2 heterozygous knockout (Foxp2+/-) mice and their wildtype (WT) littermates from juvenile to adult ages, and observe severe abnormalities in the courtship song of Foxp2+/- mice. In comparison to their WT littermates, Foxp2+/- mice vocalized less, produced shorter syllable sequences, and possessed an abnormal syllable inventory. In addition, Foxp2+/- song also exhibited irregular rhythmic structure, and its development did not follow the consistent trajectories observed in WT vocalizations. These results demonstrate that the Foxp2 gene is critical for normal vocal behavior in juvenile and adult mice, and that Foxp2 mutant mice may provide a tractable model system for the study of the gene's role in general vocal motor control.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "9d3f3ba44ee44d29bc6fd1b262200ffb", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[45, 45], [131, 131], [74, 74], [147, 147], [84, 84], [104, 104], [1, 1], [49, 49]], "char_spans": [[232, 236], [766, 770], [399, 406], [852, 856], [453, 460], [579, 586], [4, 8], [261, 268]]}]}], "context_tokens": [["The", 0], ["FOXP2", 4], ["gene", 10], ["is", 15], ["important", 18], ["for", 28], ["the", 32], ["development", 36], ["of", 48], ["proper", 51], ["speech", 58], ["motor", 65], ["control", 71], ["in", 79], ["humans", 82], [".", 88], ["However", 90], [",", 97], ["the", 99], ["role", 103], ["of", 108], ["the", 111], ["gene", 115], ["in", 120], ["general", 123], ["vocal", 131], ["behavior", 137], ["in", 146], ["other", 149], ["mammals", 155], [",", 162], ["including", 164], ["mice", 174], [",", 178], ["is", 180], ["unclear", 183], [".", 190], ["Here", 192], [",", 196], ["we", 198], ["track", 201], ["the", 207], ["vocal", 211], ["development", 217], ["of", 229], ["Foxp2", 232], ["heterozygous", 238], ["knockout", 251], ["(", 260], ["Foxp2+/-", 261], [")", 269], ["mice", 271], ["and", 276], ["their", 280], ["wildtype", 286], ["(", 295], ["WT", 296], [")", 298], ["littermates", 300], ["from", 312], ["juvenile", 317], ["to", 326], ["adult", 329], ["ages", 335], [",", 339], ["and", 341], ["observe", 345], ["severe", 353], ["abnormalities", 360], ["in", 374], ["the", 377], ["courtship", 381], ["song", 391], ["of", 396], ["Foxp2+/-", 399], ["mice", 408], [".", 412], ["In", 414], ["comparison", 417], ["to", 428], ["their", 431], ["WT", 437], ["littermates", 440], [",", 451], ["Foxp2+/-", 453], ["mice", 462], ["vocalized", 467], ["less", 477], [",", 481], ["produced", 483], ["shorter", 492], ["syllable", 500], ["sequences", 509], [",", 518], ["and", 520], ["possessed", 524], ["an", 534], ["abnormal", 537], ["syllable", 546], ["inventory", 555], [".", 564], ["In", 566], ["addition", 569], [",", 577], ["Foxp2+/-", 579], ["song", 588], ["also", 593], ["exhibited", 598], ["irregular", 608], ["rhythmic", 618], ["structure", 627], [",", 636], ["and", 638], ["its", 642], ["development", 646], ["did", 658], ["not", 662], ["follow", 666], ["the", 673], ["consistent", 677], ["trajectories", 688], ["observed", 701], ["in", 710], ["WT", 713], ["vocalizations", 716], [".", 729], ["These", 731], ["results", 737], ["demonstrate", 745], ["that", 757], ["the", 762], ["Foxp2", 766], ["gene", 772], ["is", 777], ["critical", 780], ["for", 789], ["normal", 793], ["vocal", 800], ["behavior", 806], ["in", 815], ["juvenile", 818], ["and", 827], ["adult", 831], ["mice", 837], [",", 841], ["and", 843], ["that", 847], ["Foxp2", 852], ["mutant", 858], ["mice", 865], ["may", 870], ["provide", 874], ["a", 882], ["tractable", 884], ["model", 894], ["system", 900], ["for", 907], ["the", 911], ["study", 915], ["of", 921], ["the", 924], ["gene", 928], ["'s", 932], ["role", 935], ["in", 940], ["general", 943], ["vocal", 951], ["motor", 957], ["control", 963], [".", 970]]}
{"context": "A novel approach to design selective spleen tyrosine kinase (Syk) inhibitors is described. Inhibition of spleen tyrosine kinase has attracted much attention as a mechanism for the treatment of autoimmune diseases such as asthma, rheumatoid arthritis, and SLE. Fostamatinib, a Syk inhibitor that successfully completed phase II clinical trials, also exhibits some undesirable side effects. More selective Syk inhibitors could offer safer, alternative treatments. Through a systematic evaluation of the kinome, we identified Pro455 and Asn457 in the Syk ATP binding site as a rare combination among sequence aligned kinases and hypothesized that optimizing the interaction between them and a Syk inhibitor molecule would impart high selectivity for Syk over other kinases. We report the structure-guided identification of three series of selective spleen tyrosine kinase inhibitors that support our hypothesis and offer useful guidance to other researchers in the field.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "a684e2797a984c48b274c3513981d491", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[137, 139], [18, 20], [6, 8]], "char_spans": [[846, 867], [105, 126], [37, 58]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["approach", 8], ["to", 17], ["design", 20], ["selective", 27], ["spleen", 37], ["tyrosine", 44], ["kinase", 53], ["(", 60], ["Syk", 61], [")", 64], ["inhibitors", 66], ["is", 77], ["described", 80], [".", 89], ["Inhibition", 91], ["of", 102], ["spleen", 105], ["tyrosine", 112], ["kinase", 121], ["has", 128], ["attracted", 132], ["much", 142], ["attention", 147], ["as", 157], ["a", 160], ["mechanism", 162], ["for", 172], ["the", 176], ["treatment", 180], ["of", 190], ["autoimmune", 193], ["diseases", 204], ["such", 213], ["as", 218], ["asthma", 221], [",", 227], ["rheumatoid", 229], ["arthritis", 240], [",", 249], ["and", 251], ["SLE", 255], [".", 258], ["Fostamatinib", 260], [",", 272], ["a", 274], ["Syk", 276], ["inhibitor", 280], ["that", 290], ["successfully", 295], ["completed", 308], ["phase", 318], ["II", 324], ["clinical", 327], ["trials", 336], [",", 342], ["also", 344], ["exhibits", 349], ["some", 358], ["undesirable", 363], ["side", 375], ["effects", 380], [".", 387], ["More", 389], ["selective", 394], ["Syk", 404], ["inhibitors", 408], ["could", 419], ["offer", 425], ["safer", 431], [",", 436], ["alternative", 438], ["treatments", 450], [".", 460], ["Through", 462], ["a", 470], ["systematic", 472], ["evaluation", 483], ["of", 494], ["the", 497], ["kinome", 501], [",", 507], ["we", 509], ["identified", 512], ["Pro455", 523], ["and", 530], ["Asn457", 534], ["in", 541], ["the", 544], ["Syk", 548], ["ATP", 552], ["binding", 556], ["site", 564], ["as", 569], ["a", 572], ["rare", 574], ["combination", 579], ["among", 591], ["sequence", 597], ["aligned", 606], ["kinases", 614], ["and", 622], ["hypothesized", 626], ["that", 639], ["optimizing", 644], ["the", 655], ["interaction", 659], ["between", 671], ["them", 679], ["and", 684], ["a", 688], ["Syk", 690], ["inhibitor", 694], ["molecule", 704], ["would", 713], ["impart", 719], ["high", 726], ["selectivity", 731], ["for", 743], ["Syk", 747], ["over", 751], ["other", 756], ["kinases", 762], [".", 769], ["We", 771], ["report", 774], ["the", 781], ["structure", 785], ["-", 794], ["guided", 795], ["identification", 802], ["of", 817], ["three", 820], ["series", 826], ["of", 833], ["selective", 836], ["spleen", 846], ["tyrosine", 853], ["kinase", 862], ["inhibitors", 869], ["that", 880], ["support", 885], ["our", 893], ["hypothesis", 897], ["and", 908], ["offer", 912], ["useful", 918], ["guidance", 925], ["to", 934], ["other", 937], ["researchers", 943], ["in", 955], ["the", 958], ["field", 962], [".", 967]]}
{"context": "The identification of the alpha-synuclein gene on chromosome 4q as a locus for familial Lewy-body parkinsonism and of alpha-synuclein as a component of Lewy bodies has heralded a new era in the study of Parkinson's disease. We have identified a large family with Lewy body parkinsonism linked to a novel locus on chromosome 4p15 that does not have a mutation in the alpha-synuclein gene. Here we report the clinical and neuropathological findings in an individual from this family and describe unusual high molecular weight alpha-synuclein-immunoreactive proteins in brain homogenates from brain regions with the most marked neuropathology. Distinctive histopathology was revealed with alpha-synuclein immunostaining, including pleomorphic Lewy bodies, synuclein-positive glial inclusions and widespread, severe neuritic dystrophy. We also discuss the relationship of this familial disorder to a Lewy body disease clinical spectrum, ranging from Parkinson's disease to dementia with psychosis.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "89d94b385eb34bc8ba92ccfb2605442f", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[22, 24], [70, 72], [118, 120], [4, 6], [95, 97]], "char_spans": [[118, 132], [366, 380], [686, 700], [26, 40], [524, 538]]}]}], "context_tokens": [["The", 0], ["identification", 4], ["of", 19], ["the", 22], ["alpha", 26], ["-", 31], ["synuclein", 32], ["gene", 42], ["on", 47], ["chromosome", 50], ["4q", 61], ["as", 64], ["a", 67], ["locus", 69], ["for", 75], ["familial", 79], ["Lewy", 88], ["-", 92], ["body", 93], ["parkinsonism", 98], ["and", 111], ["of", 115], ["alpha", 118], ["-", 123], ["synuclein", 124], ["as", 134], ["a", 137], ["component", 139], ["of", 149], ["Lewy", 152], ["bodies", 157], ["has", 164], ["heralded", 168], ["a", 177], ["new", 179], ["era", 183], ["in", 187], ["the", 190], ["study", 194], ["of", 200], ["Parkinson", 203], ["'s", 212], ["disease", 215], [".", 222], ["We", 224], ["have", 227], ["identified", 232], ["a", 243], ["large", 245], ["family", 251], ["with", 258], ["Lewy", 263], ["body", 268], ["parkinsonism", 273], ["linked", 286], ["to", 293], ["a", 296], ["novel", 298], ["locus", 304], ["on", 310], ["chromosome", 313], ["4p15", 324], ["that", 329], ["does", 334], ["not", 339], ["have", 343], ["a", 348], ["mutation", 350], ["in", 359], ["the", 362], ["alpha", 366], ["-", 371], ["synuclein", 372], ["gene", 382], [".", 386], ["Here", 388], ["we", 393], ["report", 396], ["the", 403], ["clinical", 407], ["and", 416], ["neuropathological", 420], ["findings", 438], ["in", 447], ["an", 450], ["individual", 453], ["from", 464], ["this", 469], ["family", 474], ["and", 481], ["describe", 485], ["unusual", 494], ["high", 502], ["molecular", 507], ["weight", 517], ["alpha", 524], ["-", 529], ["synuclein", 530], ["-", 539], ["immunoreactive", 540], ["proteins", 555], ["in", 564], ["brain", 567], ["homogenates", 573], ["from", 585], ["brain", 590], ["regions", 596], ["with", 604], ["the", 609], ["most", 613], ["marked", 618], ["neuropathology", 625], [".", 639], ["Distinctive", 641], ["histopathology", 653], ["was", 668], ["revealed", 672], ["with", 681], ["alpha", 686], ["-", 691], ["synuclein", 692], ["immunostaining", 702], [",", 716], ["including", 718], ["pleomorphic", 728], ["Lewy", 740], ["bodies", 745], [",", 751], ["synuclein", 753], ["-", 762], ["positive", 763], ["glial", 772], ["inclusions", 778], ["and", 789], ["widespread", 793], [",", 803], ["severe", 805], ["neuritic", 812], ["dystrophy", 821], [".", 830], ["We", 832], ["also", 835], ["discuss", 840], ["the", 848], ["relationship", 852], ["of", 865], ["this", 868], ["familial", 873], ["disorder", 882], ["to", 891], ["a", 894], ["Lewy", 896], ["body", 901], ["disease", 906], ["clinical", 914], ["spectrum", 923], [",", 931], ["ranging", 933], ["from", 941], ["Parkinson", 946], ["'s", 955], ["disease", 958], ["to", 966], ["dementia", 969], ["with", 978], ["psychosis", 983], [".", 992]]}
{"context": "Type 2 diabetes mellitus (T2DM) is increasing worldwide. Treatment of T2DM continues to present challenges, with a significant proportion of patients failing to achieve and maintain glycemic targets. Despite the availability of many oral antidiabetic agents, therapeutic efficacy is also offset by side effects such as weight gain and hypoglycemia. Therefore, the search for novel therapeutic agents with an improved benefit-risk profile continues. In the following review we focus on a novel class of oral antidiabetic drugs, the sodium glucose transporter protein 2 (SGLT2) inhibitors, which have unique characteristics. SGLT2 inhibitors focus on the kidney as a therapeutic target, where they inhibit the reabsorption of glucose in the proximal tubule, causing an increase in urinary glucose excretion. Doing this, they reduce plasma glucose independently of the \u03b2-cell function of the pancreas. SGLT2 inhibitors are effective at lowering hemoglobin A1c, but also induce weight loss and reduce blood pressure, with a low risk of hypoglycemia. In general, the SGLT2 inhibitors are well tolerated, with the most frequent adverse events being mild urinal and genital infections. Since their primary site of effect is the kidney, these drugs are less effective in patients with impaired kidney function but evidence is emerging that these drugs may also have a protective effect against diabetic nephropathy. This review focuses on the most extensively studied SGLT2 inhibitors dapagliflozin, canagliflozin and empagliflozin. Dapagliflozin and canagliflozin have already been approved for marketing by the US Food and Drug Administration. The European Medicines Agency has accepted all three drugs for marketing.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "4978663209ad4e3098899ad04290262e", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[96, 96], [154, 154], [105, 105], [249, 249], [184, 184]], "char_spans": [[569, 573], [899, 903], [623, 627], [1460, 1464], [1062, 1066]]}]}], "context_tokens": [["Type", 0], ["2", 5], ["diabetes", 7], ["mellitus", 16], ["(", 25], ["T2DM", 26], [")", 30], ["is", 32], ["increasing", 35], ["worldwide", 46], [".", 55], ["Treatment", 57], ["of", 67], ["T2DM", 70], ["continues", 75], ["to", 85], ["present", 88], ["challenges", 96], [",", 106], ["with", 108], ["a", 113], ["significant", 115], ["proportion", 127], ["of", 138], ["patients", 141], ["failing", 150], ["to", 158], ["achieve", 161], ["and", 169], ["maintain", 173], ["glycemic", 182], ["targets", 191], [".", 198], ["Despite", 200], ["the", 208], ["availability", 212], ["of", 225], ["many", 228], ["oral", 233], ["antidiabetic", 238], ["agents", 251], [",", 257], ["therapeutic", 259], ["efficacy", 271], ["is", 280], ["also", 283], ["offset", 288], ["by", 295], ["side", 298], ["effects", 303], ["such", 311], ["as", 316], ["weight", 319], ["gain", 326], ["and", 331], ["hypoglycemia", 335], [".", 347], ["Therefore", 349], [",", 358], ["the", 360], ["search", 364], ["for", 371], ["novel", 375], ["therapeutic", 381], ["agents", 393], ["with", 400], ["an", 405], ["improved", 408], ["benefit", 417], ["-", 424], ["risk", 425], ["profile", 430], ["continues", 438], [".", 447], ["In", 449], ["the", 452], ["following", 456], ["review", 466], ["we", 473], ["focus", 476], ["on", 482], ["a", 485], ["novel", 487], ["class", 493], ["of", 499], ["oral", 502], ["antidiabetic", 507], ["drugs", 520], [",", 525], ["the", 527], ["sodium", 531], ["glucose", 538], ["transporter", 546], ["protein", 558], ["2", 566], ["(", 568], ["SGLT2", 569], [")", 574], ["inhibitors", 576], [",", 586], ["which", 588], ["have", 594], ["unique", 599], ["characteristics", 606], [".", 621], ["SGLT2", 623], ["inhibitors", 629], ["focus", 640], ["on", 646], ["the", 649], ["kidney", 653], ["as", 660], ["a", 663], ["therapeutic", 665], ["target", 677], [",", 683], ["where", 685], ["they", 691], ["inhibit", 696], ["the", 704], ["reabsorption", 708], ["of", 721], ["glucose", 724], ["in", 732], ["the", 735], ["proximal", 739], ["tubule", 748], [",", 754], ["causing", 756], ["an", 764], ["increase", 767], ["in", 776], ["urinary", 779], ["glucose", 787], ["excretion", 795], [".", 804], ["Doing", 806], ["this", 812], [",", 816], ["they", 818], ["reduce", 823], ["plasma", 830], ["glucose", 837], ["independently", 845], ["of", 859], ["the", 862], ["\u03b2", 866], ["-", 867], ["cell", 868], ["function", 873], ["of", 882], ["the", 885], ["pancreas", 889], [".", 897], ["SGLT2", 899], ["inhibitors", 905], ["are", 916], ["effective", 920], ["at", 930], ["lowering", 933], ["hemoglobin", 942], ["A1c", 953], [",", 956], ["but", 958], ["also", 962], ["induce", 967], ["weight", 974], ["loss", 981], ["and", 986], ["reduce", 990], ["blood", 997], ["pressure", 1003], [",", 1011], ["with", 1013], ["a", 1018], ["low", 1020], ["risk", 1024], ["of", 1029], ["hypoglycemia", 1032], [".", 1044], ["In", 1046], ["general", 1049], [",", 1056], ["the", 1058], ["SGLT2", 1062], ["inhibitors", 1068], ["are", 1079], ["well", 1083], ["tolerated", 1088], [",", 1097], ["with", 1099], ["the", 1104], ["most", 1108], ["frequent", 1113], ["adverse", 1122], ["events", 1130], ["being", 1137], ["mild", 1143], ["urinal", 1148], ["and", 1155], ["genital", 1159], ["infections", 1167], [".", 1177], ["Since", 1179], ["their", 1185], ["primary", 1191], ["site", 1199], ["of", 1204], ["effect", 1207], ["is", 1214], ["the", 1217], ["kidney", 1221], [",", 1227], ["these", 1229], ["drugs", 1235], ["are", 1241], ["less", 1245], ["effective", 1250], ["in", 1260], ["patients", 1263], ["with", 1272], ["impaired", 1277], ["kidney", 1286], ["function", 1293], ["but", 1302], ["evidence", 1306], ["is", 1315], ["emerging", 1318], ["that", 1327], ["these", 1332], ["drugs", 1338], ["may", 1344], ["also", 1348], ["have", 1353], ["a", 1358], ["protective", 1360], ["effect", 1371], ["against", 1378], ["diabetic", 1386], ["nephropathy", 1395], [".", 1406], ["This", 1408], ["review", 1413], ["focuses", 1420], ["on", 1428], ["the", 1431], ["most", 1435], ["extensively", 1440], ["studied", 1452], ["SGLT2", 1460], ["inhibitors", 1466], ["dapagliflozin", 1477], [",", 1490], ["canagliflozin", 1492], ["and", 1506], ["empagliflozin", 1510], [".", 1523], ["Dapagliflozin", 1525], ["and", 1539], ["canagliflozin", 1543], ["have", 1557], ["already", 1562], ["been", 1570], ["approved", 1575], ["for", 1584], ["marketing", 1588], ["by", 1598], ["the", 1601], ["US", 1605], ["Food", 1608], ["and", 1613], ["Drug", 1617], ["Administration", 1622], [".", 1636], ["The", 1638], ["European", 1642], ["Medicines", 1651], ["Agency", 1661], ["has", 1668], ["accepted", 1672], ["all", 1681], ["three", 1685], ["drugs", 1691], ["for", 1697], ["marketing", 1701], [".", 1710]]}
{"context": "Diabetic nephropathy is the leading cause of end-stage renal disease in humans in the Western world. The recent development of Na+-glucose cotransporter 2 (SGLT2) inhibitors offers a new antidiabetic therapy via enhanced glucose excretion. Whether this strategy exerts beneficial effects on the development of type 2 diabetic nephropathy is still largely unclear. We investigated the effects of the specific SGLT2 inhibitor empagliflozin in BTBR.Cg-Lep<ob>/WiscJ (BTBR ob/ob) mice, which spontaneously develop type 2 diabetic nephropathy. In the first experiment, BTBR ob/ob mice received either a diet containing 300 ppm empagliflozin or equicaloric placebo chow for 12 wk. In the second experiment, BTBR ob/ob mice received 1 \u03bcg\u00b7kg body wt(-1)\u00b7day(-1) ANG II to induce arterial hypertension and were separated into the same two diet groups for 6 wk. In both experiments, empagliflozin treatment enhanced glucosuria, thereby lowering blood glucose. Independently of hypertension, empagliflozin reduced albuminuria in diabetic mice. However, empagliflozin treatment affected diabetes-related glomerular hypertrophy, markers of renal inflammation, and mesangial matrix expansion only in BTBR ob/ob mice without hypertension. In summary, empagliflozin demonstrated significant antihyperglycemic effects, differentially ameliorating early features of diabetic nephropathy in BTBR ob/ob mice with and without hypertension.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "eee52f339cdf4af89a3273019a0da1ab", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[27, 27], [66, 66]], "char_spans": [[156, 160], [408, 412]]}]}], "context_tokens": [["Diabetic", 0], ["nephropathy", 9], ["is", 21], ["the", 24], ["leading", 28], ["cause", 36], ["of", 42], ["end", 45], ["-", 48], ["stage", 49], ["renal", 55], ["disease", 61], ["in", 69], ["humans", 72], ["in", 79], ["the", 82], ["Western", 86], ["world", 94], [".", 99], ["The", 101], ["recent", 105], ["development", 112], ["of", 124], ["Na+-glucose", 127], ["cotransporter", 139], ["2", 153], ["(", 155], ["SGLT2", 156], [")", 161], ["inhibitors", 163], ["offers", 174], ["a", 181], ["new", 183], ["antidiabetic", 187], ["therapy", 200], ["via", 208], ["enhanced", 212], ["glucose", 221], ["excretion", 229], [".", 238], ["Whether", 240], ["this", 248], ["strategy", 253], ["exerts", 262], ["beneficial", 269], ["effects", 280], ["on", 288], ["the", 291], ["development", 295], ["of", 307], ["type", 310], ["2", 315], ["diabetic", 317], ["nephropathy", 326], ["is", 338], ["still", 341], ["largely", 347], ["unclear", 355], [".", 362], ["We", 364], ["investigated", 367], ["the", 380], ["effects", 384], ["of", 392], ["the", 395], ["specific", 399], ["SGLT2", 408], ["inhibitor", 414], ["empagliflozin", 424], ["in", 438], ["BTBR.Cg", 441], ["-", 448], ["Lep", 449], ["<", 452], ["ob>/WiscJ", 453], ["(", 463], ["BTBR", 464], ["ob", 469], ["/", 471], ["ob", 472], [")", 474], ["mice", 476], [",", 480], ["which", 482], ["spontaneously", 488], ["develop", 502], ["type", 510], ["2", 515], ["diabetic", 517], ["nephropathy", 526], [".", 537], ["In", 539], ["the", 542], ["first", 546], ["experiment", 552], [",", 562], ["BTBR", 564], ["ob", 569], ["/", 571], ["ob", 572], ["mice", 575], ["received", 580], ["either", 589], ["a", 596], ["diet", 598], ["containing", 603], ["300", 614], ["ppm", 618], ["empagliflozin", 622], ["or", 636], ["equicaloric", 639], ["placebo", 651], ["chow", 659], ["for", 664], ["12", 668], ["wk", 671], [".", 673], ["In", 675], ["the", 678], ["second", 682], ["experiment", 689], [",", 699], ["BTBR", 701], ["ob", 706], ["/", 708], ["ob", 709], ["mice", 712], ["received", 717], ["1", 726], ["\u03bcg\u00b7kg", 728], ["body", 734], ["wt(-1)\u00b7day(-1", 739], [")", 752], ["ANG", 754], ["II", 758], ["to", 761], ["induce", 764], ["arterial", 771], ["hypertension", 780], ["and", 793], ["were", 797], ["separated", 802], ["into", 812], ["the", 817], ["same", 821], ["two", 826], ["diet", 830], ["groups", 835], ["for", 842], ["6", 846], ["wk", 848], [".", 850], ["In", 852], ["both", 855], ["experiments", 860], [",", 871], ["empagliflozin", 873], ["treatment", 887], ["enhanced", 897], ["glucosuria", 906], [",", 916], ["thereby", 918], ["lowering", 926], ["blood", 935], ["glucose", 941], [".", 948], ["Independently", 950], ["of", 964], ["hypertension", 967], [",", 979], ["empagliflozin", 981], ["reduced", 995], ["albuminuria", 1003], ["in", 1015], ["diabetic", 1018], ["mice", 1027], [".", 1031], ["However", 1033], [",", 1040], ["empagliflozin", 1042], ["treatment", 1056], ["affected", 1066], ["diabetes", 1075], ["-", 1083], ["related", 1084], ["glomerular", 1092], ["hypertrophy", 1103], [",", 1114], ["markers", 1116], ["of", 1124], ["renal", 1127], ["inflammation", 1133], [",", 1145], ["and", 1147], ["mesangial", 1151], ["matrix", 1161], ["expansion", 1168], ["only", 1178], ["in", 1183], ["BTBR", 1186], ["ob", 1191], ["/", 1193], ["ob", 1194], ["mice", 1197], ["without", 1202], ["hypertension", 1210], [".", 1222], ["In", 1224], ["summary", 1227], [",", 1234], ["empagliflozin", 1236], ["demonstrated", 1250], ["significant", 1263], ["antihyperglycemic", 1275], ["effects", 1293], [",", 1300], ["differentially", 1302], ["ameliorating", 1317], ["early", 1330], ["features", 1336], ["of", 1345], ["diabetic", 1348], ["nephropathy", 1357], ["in", 1369], ["BTBR", 1372], ["ob", 1377], ["/", 1379], ["ob", 1380], ["mice", 1383], ["with", 1388], ["and", 1393], ["without", 1397], ["hypertension", 1405], [".", 1417]]}
{"context": "Interleukin-6 (IL-6) is a pleiotropic cytokine implicated in the pathogenesis of many immune-mediated disorders including several types of non-infectious uveitis. These uveitic conditions include Vogt-Koyanagi-Harada syndrome, uveitis associated with Beh\u00e7et disease, and sarcoidosis. This review summarizes the role of IL-6 in immunity, highlighting its effect on Th17, Th1, and plasmablast differentiation. It reviews the downstream mediators activated in the process of IL-6 binding to its receptor complex. This review also summarizes the biologics targeting either IL-6 or the IL-6 receptor, including tocilizumab, sarilumab, sirukumab, olokizumab, clazakizumab, and siltuximab. The target, dosage, potential side effects, and potential uses of these biologics are summarized in this article based on the existing literature. In summary, anti-IL-6 therapy for non-infectious uveitis shows promise in terms of efficacy and side effect profile.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "a00c444bb61f44519190db6046039820", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[0, 0]], "char_spans": [[0, 12]]}]}], "context_tokens": [["Interleukin-6", 0], ["(", 14], ["IL-6", 15], [")", 19], ["is", 21], ["a", 24], ["pleiotropic", 26], ["cytokine", 38], ["implicated", 47], ["in", 58], ["the", 61], ["pathogenesis", 65], ["of", 78], ["many", 81], ["immune", 86], ["-", 92], ["mediated", 93], ["disorders", 102], ["including", 112], ["several", 122], ["types", 130], ["of", 136], ["non", 139], ["-", 142], ["infectious", 143], ["uveitis", 154], [".", 161], ["These", 163], ["uveitic", 169], ["conditions", 177], ["include", 188], ["Vogt", 196], ["-", 200], ["Koyanagi", 201], ["-", 209], ["Harada", 210], ["syndrome", 217], [",", 225], ["uveitis", 227], ["associated", 235], ["with", 246], ["Beh\u00e7et", 251], ["disease", 258], [",", 265], ["and", 267], ["sarcoidosis", 271], [".", 282], ["This", 284], ["review", 289], ["summarizes", 296], ["the", 307], ["role", 311], ["of", 316], ["IL-6", 319], ["in", 324], ["immunity", 327], [",", 335], ["highlighting", 337], ["its", 350], ["effect", 354], ["on", 361], ["Th17", 364], [",", 368], ["Th1", 370], [",", 373], ["and", 375], ["plasmablast", 379], ["differentiation", 391], [".", 406], ["It", 408], ["reviews", 411], ["the", 419], ["downstream", 423], ["mediators", 434], ["activated", 444], ["in", 454], ["the", 457], ["process", 461], ["of", 469], ["IL-6", 472], ["binding", 477], ["to", 485], ["its", 488], ["receptor", 492], ["complex", 501], [".", 508], ["This", 510], ["review", 515], ["also", 522], ["summarizes", 527], ["the", 538], ["biologics", 542], ["targeting", 552], ["either", 562], ["IL-6", 569], ["or", 574], ["the", 577], ["IL-6", 581], ["receptor", 586], [",", 594], ["including", 596], ["tocilizumab", 606], [",", 617], ["sarilumab", 619], [",", 628], ["sirukumab", 630], [",", 639], ["olokizumab", 641], [",", 651], ["clazakizumab", 653], [",", 665], ["and", 667], ["siltuximab", 671], [".", 681], ["The", 683], ["target", 687], [",", 693], ["dosage", 695], [",", 701], ["potential", 703], ["side", 713], ["effects", 718], [",", 725], ["and", 727], ["potential", 731], ["uses", 741], ["of", 746], ["these", 749], ["biologics", 755], ["are", 765], ["summarized", 769], ["in", 780], ["this", 783], ["article", 788], ["based", 796], ["on", 802], ["the", 805], ["existing", 809], ["literature", 818], [".", 828], ["In", 830], ["summary", 833], [",", 840], ["anti", 842], ["-", 846], ["IL-6", 847], ["therapy", 852], ["for", 860], ["non", 864], ["-", 867], ["infectious", 868], ["uveitis", 879], ["shows", 887], ["promise", 893], ["in", 901], ["terms", 904], ["of", 910], ["efficacy", 913], ["and", 922], ["side", 926], ["effect", 931], ["profile", 938], [".", 945]]}
{"context": "Proteins of the Notch family are cell surface receptors that transduce signals between neighbouring cells. The Notch signalling pathway is highly evolutionarily conserved and critical for cell fate determination during embryonic development, including many aspects of vascular development. The interaction of Notch receptors with ligands leads to cleavage of the Notch intracellular domain (NICD) which then translocates to the nucleus and activates the transcription factor CBF1/JBP-Jkappa, regulating downstream gene expression. To date four Notch receptors have been found in mammals. Of these, Notch3 is predominantly expressed in adult arterial smooth muscle cells in human. NOTCH3 gene mutations cause the autosomal dominant condition, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoecephelopathy (CADASIL), an inherited early stroke syndrome leading to dementia due to systemic vascular degeneration. This suggests that Notch3 plays a critical role in maintaining the phenotypic stability of vascular smooth muscle cells (VSMCs). Recent publications indicate that Notch3 is involved in vascular injury and is a determinant of VSMC survival, but its exact function is unknown. The molecular mechanisms underlying CADASIL pathology are therefore intriguing. Investigation of CADASIL mutant Notch3 shows that the majority of mutations do not change CBF1/JBP-Jkappa mediated classic Notch activation, so the pathological consequences of NOTCH3 mutations in CADASIL patients can not be simply explained by loss- or gain-of-function in the classic Notch signalling pathway. This suggests that a novel Notch3-mediated signalling pathway may be present in VSMCs, or cross-regulation of Notch3 to other signalling pathway(s) may play a critical role on VSMCs survival. Alternatively, the mutant Notch3 may gain a novel or toxic function in VSMCs. This review will focus on recent findings of Notch3 in vascular development and in regulating the VSMC behaviour and phenotype, and will use findings on investigating the molecular pathology of the single gene disorder CADASIL to understand the function of Notch3 in VSMCs.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "2c9f414f7a3a499893e29b02c1e7994e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[106, 107]], "char_spans": [[680, 690]]}]}], "context_tokens": [["Proteins", 0], ["of", 9], ["the", 12], ["Notch", 16], ["family", 22], ["are", 29], ["cell", 33], ["surface", 38], ["receptors", 46], ["that", 56], ["transduce", 61], ["signals", 71], ["between", 79], ["neighbouring", 87], ["cells", 100], [".", 105], ["The", 107], ["Notch", 111], ["signalling", 117], ["pathway", 128], ["is", 136], ["highly", 139], ["evolutionarily", 146], ["conserved", 161], ["and", 171], ["critical", 175], ["for", 184], ["cell", 188], ["fate", 193], ["determination", 198], ["during", 212], ["embryonic", 219], ["development", 229], [",", 240], ["including", 242], ["many", 252], ["aspects", 257], ["of", 265], ["vascular", 268], ["development", 277], [".", 288], ["The", 290], ["interaction", 294], ["of", 306], ["Notch", 309], ["receptors", 315], ["with", 325], ["ligands", 330], ["leads", 338], ["to", 344], ["cleavage", 347], ["of", 356], ["the", 359], ["Notch", 363], ["intracellular", 369], ["domain", 383], ["(", 390], ["NICD", 391], [")", 395], ["which", 397], ["then", 403], ["translocates", 408], ["to", 421], ["the", 424], ["nucleus", 428], ["and", 436], ["activates", 440], ["the", 450], ["transcription", 454], ["factor", 468], ["CBF1/JBP", 475], ["-", 483], ["Jkappa", 484], [",", 490], ["regulating", 492], ["downstream", 503], ["gene", 514], ["expression", 519], [".", 529], ["To", 531], ["date", 534], ["four", 539], ["Notch", 544], ["receptors", 550], ["have", 560], ["been", 565], ["found", 570], ["in", 576], ["mammals", 579], [".", 586], ["Of", 588], ["these", 591], [",", 596], ["Notch3", 598], ["is", 605], ["predominantly", 608], ["expressed", 622], ["in", 632], ["adult", 635], ["arterial", 641], ["smooth", 650], ["muscle", 657], ["cells", 664], ["in", 670], ["human", 673], [".", 678], ["NOTCH3", 680], ["gene", 687], ["mutations", 692], ["cause", 702], ["the", 708], ["autosomal", 712], ["dominant", 722], ["condition", 731], [",", 740], ["cerebral", 742], ["autosomal", 751], ["dominant", 761], ["arteriopathy", 770], ["with", 783], ["subcortical", 788], ["infarcts", 800], ["and", 809], ["leukoecephelopathy", 813], ["(", 832], ["CADASIL", 833], [")", 840], [",", 841], ["an", 843], ["inherited", 846], ["early", 856], ["stroke", 862], ["syndrome", 869], ["leading", 878], ["to", 886], ["dementia", 889], ["due", 898], ["to", 902], ["systemic", 905], ["vascular", 914], ["degeneration", 923], [".", 935], ["This", 937], ["suggests", 942], ["that", 951], ["Notch3", 956], ["plays", 963], ["a", 969], ["critical", 971], ["role", 980], ["in", 985], ["maintaining", 988], ["the", 1000], ["phenotypic", 1004], ["stability", 1015], ["of", 1025], ["vascular", 1028], ["smooth", 1037], ["muscle", 1044], ["cells", 1051], ["(", 1057], ["VSMCs", 1058], [")", 1063], [".", 1064], ["Recent", 1066], ["publications", 1073], ["indicate", 1086], ["that", 1095], ["Notch3", 1100], ["is", 1107], ["involved", 1110], ["in", 1119], ["vascular", 1122], ["injury", 1131], ["and", 1138], ["is", 1142], ["a", 1145], ["determinant", 1147], ["of", 1159], ["VSMC", 1162], ["survival", 1167], [",", 1175], ["but", 1177], ["its", 1181], ["exact", 1185], ["function", 1191], ["is", 1200], ["unknown", 1203], [".", 1210], ["The", 1212], ["molecular", 1216], ["mechanisms", 1226], ["underlying", 1237], ["CADASIL", 1248], ["pathology", 1256], ["are", 1266], ["therefore", 1270], ["intriguing", 1280], [".", 1290], ["Investigation", 1292], ["of", 1306], ["CADASIL", 1309], ["mutant", 1317], ["Notch3", 1324], ["shows", 1331], ["that", 1337], ["the", 1342], ["majority", 1346], ["of", 1355], ["mutations", 1358], ["do", 1368], ["not", 1371], ["change", 1375], ["CBF1/JBP", 1382], ["-", 1390], ["Jkappa", 1391], ["mediated", 1398], ["classic", 1407], ["Notch", 1415], ["activation", 1421], [",", 1431], ["so", 1433], ["the", 1436], ["pathological", 1440], ["consequences", 1453], ["of", 1466], ["NOTCH3", 1469], ["mutations", 1476], ["in", 1486], ["CADASIL", 1489], ["patients", 1497], ["can", 1506], ["not", 1510], ["be", 1514], ["simply", 1517], ["explained", 1524], ["by", 1534], ["loss-", 1537], ["or", 1543], ["gain", 1546], ["-", 1550], ["of", 1551], ["-", 1553], ["function", 1554], ["in", 1563], ["the", 1566], ["classic", 1570], ["Notch", 1578], ["signalling", 1584], ["pathway", 1595], [".", 1602], ["This", 1604], ["suggests", 1609], ["that", 1618], ["a", 1623], ["novel", 1625], ["Notch3-mediated", 1631], ["signalling", 1647], ["pathway", 1658], ["may", 1666], ["be", 1670], ["present", 1673], ["in", 1681], ["VSMCs", 1684], [",", 1689], ["or", 1691], ["cross", 1694], ["-", 1699], ["regulation", 1700], ["of", 1711], ["Notch3", 1714], ["to", 1721], ["other", 1724], ["signalling", 1730], ["pathway(s", 1741], [")", 1750], ["may", 1752], ["play", 1756], ["a", 1761], ["critical", 1763], ["role", 1772], ["on", 1777], ["VSMCs", 1780], ["survival", 1786], [".", 1794], ["Alternatively", 1796], [",", 1809], ["the", 1811], ["mutant", 1815], ["Notch3", 1822], ["may", 1829], ["gain", 1833], ["a", 1838], ["novel", 1840], ["or", 1846], ["toxic", 1849], ["function", 1855], ["in", 1864], ["VSMCs", 1867], [".", 1872], ["This", 1874], ["review", 1879], ["will", 1886], ["focus", 1891], ["on", 1897], ["recent", 1900], ["findings", 1907], ["of", 1916], ["Notch3", 1919], ["in", 1926], ["vascular", 1929], ["development", 1938], ["and", 1950], ["in", 1954], ["regulating", 1957], ["the", 1968], ["VSMC", 1972], ["behaviour", 1977], ["and", 1987], ["phenotype", 1991], [",", 2000], ["and", 2002], ["will", 2006], ["use", 2011], ["findings", 2015], ["on", 2024], ["investigating", 2027], ["the", 2041], ["molecular", 2045], ["pathology", 2055], ["of", 2065], ["the", 2068], ["single", 2072], ["gene", 2079], ["disorder", 2084], ["CADASIL", 2093], ["to", 2101], ["understand", 2104], ["the", 2115], ["function", 2119], ["of", 2128], ["Notch3", 2131], ["in", 2138], ["VSMCs", 2141], [".", 2146]]}
{"context": "Amyloid precursor protein (AbetaPP), a precursor of amyloid beta (Abeta) peptide, is one of the molecules involved in the pathogenesis of Alzheimer's disease (AD). Specific mutations in AbetaPP have been found in patients inheriting familial AD (FAD). These mutant AbetaPP proteins cause cell death in neuronal cell lines in vitro, but the molecular mechanism of cytotoxicity has not yet been clarified completely. We analyzed the cytotoxic mechanisms of the London-type AbetaPP mutant, V642I-AbetaPP, in primary cortical neurons utilizing an adenovirus-mediated gene transfer system. Expression of V642I-AbetaPP protein induced degeneration of the primary neurons. This cytotoxicity was blocked by pertussis toxin, a specific inhibitor for heterotrimeric G proteins, Go/i, and was suppressed by an inhibitor of caspase-3/7 and an antioxidant, glutathione ethyl ester. A specific inhibitor for NADPH oxidase, apocynin, but not a xanthine oxidase inhibitor or a nitric oxide inhibitor, blocked V642I-AbetaPP-induced cytotoxicity. Among mitogen-activated protein kinase (MAPK) family proteins, c-Jun N-terminal kinase (JNK) and p38MAPK, but not extracellular regulated kinase (ERK), were involved in this cytotoxic pathway. The V642I-AbetaPP-induced cytotoxicity was not suppressed by two secretase inhibitors, suggesting that Abeta does not play a major role in this cytotoxicity. Two neuroprotective factors, insulin-like growth factor I (IGF-I) and Humanin, protected these primary neurons from V642I-AbetaPP-induced cytotoxicity. Furthermore, interleukin-6 and -11 also attenuated this cytotoxicity. This study demonstrated that the signaling pathway activated by mutated AbetaPP in the primary neurons is the same as that by the other artificial insults such as antibody binding to AbetaPP and the artificial dimerization of cytoplasmic domain of AbetaPP. The potential of neurotrophic factors and cytokines in AD therapy is also indicated.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "67266c29b6f5450a9294e9b1d43aa376", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[27, 29]], "char_spans": [[138, 156]]}, {"text": "AD", "token_spans": [[343, 343], [45, 45], [31, 31]], "char_spans": [[1914, 1915], [242, 243], [159, 160]]}]}], "context_tokens": [["Amyloid", 0], ["precursor", 8], ["protein", 18], ["(", 26], ["AbetaPP", 27], [")", 34], [",", 35], ["a", 37], ["precursor", 39], ["of", 49], ["amyloid", 52], ["beta", 60], ["(", 65], ["Abeta", 66], [")", 71], ["peptide", 73], [",", 80], ["is", 82], ["one", 85], ["of", 89], ["the", 92], ["molecules", 96], ["involved", 106], ["in", 115], ["the", 118], ["pathogenesis", 122], ["of", 135], ["Alzheimer", 138], ["'s", 147], ["disease", 150], ["(", 158], ["AD", 159], [")", 161], [".", 162], ["Specific", 164], ["mutations", 173], ["in", 183], ["AbetaPP", 186], ["have", 194], ["been", 199], ["found", 204], ["in", 210], ["patients", 213], ["inheriting", 222], ["familial", 233], ["AD", 242], ["(", 245], ["FAD", 246], [")", 249], [".", 250], ["These", 252], ["mutant", 258], ["AbetaPP", 265], ["proteins", 273], ["cause", 282], ["cell", 288], ["death", 293], ["in", 299], ["neuronal", 302], ["cell", 311], ["lines", 316], ["in", 322], ["vitro", 325], [",", 330], ["but", 332], ["the", 336], ["molecular", 340], ["mechanism", 350], ["of", 360], ["cytotoxicity", 363], ["has", 376], ["not", 380], ["yet", 384], ["been", 388], ["clarified", 393], ["completely", 403], [".", 413], ["We", 415], ["analyzed", 418], ["the", 427], ["cytotoxic", 431], ["mechanisms", 441], ["of", 452], ["the", 455], ["London", 459], ["-", 465], ["type", 466], ["AbetaPP", 471], ["mutant", 479], [",", 485], ["V642I", 487], ["-", 492], ["AbetaPP", 493], [",", 500], ["in", 502], ["primary", 505], ["cortical", 513], ["neurons", 522], ["utilizing", 530], ["an", 540], ["adenovirus", 543], ["-", 553], ["mediated", 554], ["gene", 563], ["transfer", 568], ["system", 577], [".", 583], ["Expression", 585], ["of", 596], ["V642I", 599], ["-", 604], ["AbetaPP", 605], ["protein", 613], ["induced", 621], ["degeneration", 629], ["of", 642], ["the", 645], ["primary", 649], ["neurons", 657], [".", 664], ["This", 666], ["cytotoxicity", 671], ["was", 684], ["blocked", 688], ["by", 696], ["pertussis", 699], ["toxin", 709], [",", 714], ["a", 716], ["specific", 718], ["inhibitor", 727], ["for", 737], ["heterotrimeric", 741], ["G", 756], ["proteins", 758], [",", 766], ["Go", 768], ["/", 770], ["i", 771], [",", 772], ["and", 774], ["was", 778], ["suppressed", 782], ["by", 793], ["an", 796], ["inhibitor", 799], ["of", 809], ["caspase-3/7", 812], ["and", 824], ["an", 828], ["antioxidant", 831], [",", 842], ["glutathione", 844], ["ethyl", 856], ["ester", 862], [".", 867], ["A", 869], ["specific", 871], ["inhibitor", 880], ["for", 890], ["NADPH", 894], ["oxidase", 900], [",", 907], ["apocynin", 909], [",", 917], ["but", 919], ["not", 923], ["a", 927], ["xanthine", 929], ["oxidase", 938], ["inhibitor", 946], ["or", 956], ["a", 959], ["nitric", 961], ["oxide", 968], ["inhibitor", 974], [",", 983], ["blocked", 985], ["V642I", 993], ["-", 998], ["AbetaPP", 999], ["-", 1006], ["induced", 1007], ["cytotoxicity", 1015], [".", 1027], ["Among", 1029], ["mitogen", 1035], ["-", 1042], ["activated", 1043], ["protein", 1053], ["kinase", 1061], ["(", 1068], ["MAPK", 1069], [")", 1073], ["family", 1075], ["proteins", 1082], [",", 1090], ["c", 1092], ["-", 1093], ["Jun", 1094], ["N", 1098], ["-", 1099], ["terminal", 1100], ["kinase", 1109], ["(", 1116], ["JNK", 1117], [")", 1120], ["and", 1122], ["p38MAPK", 1126], [",", 1133], ["but", 1135], ["not", 1139], ["extracellular", 1143], ["regulated", 1157], ["kinase", 1167], ["(", 1174], ["ERK", 1175], [")", 1178], [",", 1179], ["were", 1181], ["involved", 1186], ["in", 1195], ["this", 1198], ["cytotoxic", 1203], ["pathway", 1213], [".", 1220], ["The", 1222], ["V642I", 1226], ["-", 1231], ["AbetaPP", 1232], ["-", 1239], ["induced", 1240], ["cytotoxicity", 1248], ["was", 1261], ["not", 1265], ["suppressed", 1269], ["by", 1280], ["two", 1283], ["secretase", 1287], ["inhibitors", 1297], [",", 1307], ["suggesting", 1309], ["that", 1320], ["Abeta", 1325], ["does", 1331], ["not", 1336], ["play", 1340], ["a", 1345], ["major", 1347], ["role", 1353], ["in", 1358], ["this", 1361], ["cytotoxicity", 1366], [".", 1378], ["Two", 1380], ["neuroprotective", 1384], ["factors", 1400], [",", 1407], ["insulin", 1409], ["-", 1416], ["like", 1417], ["growth", 1422], ["factor", 1429], ["I", 1436], ["(", 1438], ["IGF", 1439], ["-", 1442], ["I", 1443], [")", 1444], ["and", 1446], ["Humanin", 1450], [",", 1457], ["protected", 1459], ["these", 1469], ["primary", 1475], ["neurons", 1483], ["from", 1491], ["V642I", 1496], ["-", 1501], ["AbetaPP", 1502], ["-", 1509], ["induced", 1510], ["cytotoxicity", 1518], [".", 1530], ["Furthermore", 1532], [",", 1543], ["interleukin-6", 1545], ["and", 1559], ["-11", 1563], ["also", 1567], ["attenuated", 1572], ["this", 1583], ["cytotoxicity", 1588], [".", 1600], ["This", 1602], ["study", 1607], ["demonstrated", 1613], ["that", 1626], ["the", 1631], ["signaling", 1635], ["pathway", 1645], ["activated", 1653], ["by", 1663], ["mutated", 1666], ["AbetaPP", 1674], ["in", 1682], ["the", 1685], ["primary", 1689], ["neurons", 1697], ["is", 1705], ["the", 1708], ["same", 1712], ["as", 1717], ["that", 1720], ["by", 1725], ["the", 1728], ["other", 1732], ["artificial", 1738], ["insults", 1749], ["such", 1757], ["as", 1762], ["antibody", 1765], ["binding", 1774], ["to", 1782], ["AbetaPP", 1785], ["and", 1793], ["the", 1797], ["artificial", 1801], ["dimerization", 1812], ["of", 1825], ["cytoplasmic", 1828], ["domain", 1840], ["of", 1847], ["AbetaPP", 1850], [".", 1857], ["The", 1859], ["potential", 1863], ["of", 1873], ["neurotrophic", 1876], ["factors", 1889], ["and", 1897], ["cytokines", 1901], ["in", 1911], ["AD", 1914], ["therapy", 1917], ["is", 1925], ["also", 1928], ["indicated", 1933], [".", 1942]]}
{"context": "Viroids, satellite RNAs, satellites viruses and the human hepatitis delta virus form the 'brotherhood' of the smallest known infectious RNA agents, known as the subviral RNAs. For most of these species, it is generally accepted that characteristics such as cell movement, replication, host specificity and pathogenicity are encoded in their RNA sequences and their resulting RNA structures. Although many sequences are indexed in publicly available databases, these sequence annotation databases do not provide the advanced searches and data manipulation capability for identifying and characterizing subviral RNA motifs. The Subviral RNA database is a web-based environment that facilitates the research and analysis of viroids, satellite RNAs, satellites viruses, the human hepatitis delta virus, and related RNA sequences. It integrates a large number of Subviral RNA sequences, their respective RNA motifs, analysis tools, related publication links and additional pertinent information (ex. links, conferences, announcements), allowing users to efficiently retrieve and analyze relevant information about these small RNA agents. With its design, the Subviral RNA Database could be considered as a fundamental building block for the study of these related RNAs. It is freely available via a web browser at the URL: http://subviral.med.uottawa.ca.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "2617acecfbd24533a69a8513130d6dde", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[116, 116], [0, 0]], "char_spans": [[721, 727], [0, 6]]}]}], "context_tokens": [["Viroids", 0], [",", 7], ["satellite", 9], ["RNAs", 19], [",", 23], ["satellites", 25], ["viruses", 36], ["and", 44], ["the", 48], ["human", 52], ["hepatitis", 58], ["delta", 68], ["virus", 74], ["form", 80], ["the", 85], ["'", 89], ["brotherhood", 90], ["'", 101], ["of", 103], ["the", 106], ["smallest", 110], ["known", 119], ["infectious", 125], ["RNA", 136], ["agents", 140], [",", 146], ["known", 148], ["as", 154], ["the", 157], ["subviral", 161], ["RNAs", 170], [".", 174], ["For", 176], ["most", 180], ["of", 185], ["these", 188], ["species", 194], [",", 201], ["it", 203], ["is", 206], ["generally", 209], ["accepted", 219], ["that", 228], ["characteristics", 233], ["such", 249], ["as", 254], ["cell", 257], ["movement", 262], [",", 270], ["replication", 272], [",", 283], ["host", 285], ["specificity", 290], ["and", 302], ["pathogenicity", 306], ["are", 320], ["encoded", 324], ["in", 332], ["their", 335], ["RNA", 341], ["sequences", 345], ["and", 355], ["their", 359], ["resulting", 365], ["RNA", 375], ["structures", 379], [".", 389], ["Although", 391], ["many", 400], ["sequences", 405], ["are", 415], ["indexed", 419], ["in", 427], ["publicly", 430], ["available", 439], ["databases", 449], [",", 458], ["these", 460], ["sequence", 466], ["annotation", 475], ["databases", 486], ["do", 496], ["not", 499], ["provide", 503], ["the", 511], ["advanced", 515], ["searches", 524], ["and", 533], ["data", 537], ["manipulation", 542], ["capability", 555], ["for", 566], ["identifying", 570], ["and", 582], ["characterizing", 586], ["subviral", 601], ["RNA", 610], ["motifs", 614], [".", 620], ["The", 622], ["Subviral", 626], ["RNA", 635], ["database", 639], ["is", 648], ["a", 651], ["web", 653], ["-", 656], ["based", 657], ["environment", 663], ["that", 675], ["facilitates", 680], ["the", 692], ["research", 696], ["and", 705], ["analysis", 709], ["of", 718], ["viroids", 721], [",", 728], ["satellite", 730], ["RNAs", 740], [",", 744], ["satellites", 746], ["viruses", 757], [",", 764], ["the", 766], ["human", 770], ["hepatitis", 776], ["delta", 786], ["virus", 792], [",", 797], ["and", 799], ["related", 803], ["RNA", 811], ["sequences", 815], [".", 824], ["It", 826], ["integrates", 829], ["a", 840], ["large", 842], ["number", 848], ["of", 855], ["Subviral", 858], ["RNA", 867], ["sequences", 871], [",", 880], ["their", 882], ["respective", 888], ["RNA", 899], ["motifs", 903], [",", 909], ["analysis", 911], ["tools", 920], [",", 925], ["related", 927], ["publication", 935], ["links", 947], ["and", 953], ["additional", 957], ["pertinent", 968], ["information", 978], ["(", 990], ["ex", 991], [".", 993], ["links", 995], [",", 1000], ["conferences", 1002], [",", 1013], ["announcements", 1015], [")", 1028], [",", 1029], ["allowing", 1031], ["users", 1040], ["to", 1046], ["efficiently", 1049], ["retrieve", 1061], ["and", 1070], ["analyze", 1074], ["relevant", 1082], ["information", 1091], ["about", 1103], ["these", 1109], ["small", 1115], ["RNA", 1121], ["agents", 1125], [".", 1131], ["With", 1133], ["its", 1138], ["design", 1142], [",", 1148], ["the", 1150], ["Subviral", 1154], ["RNA", 1163], ["Database", 1167], ["could", 1176], ["be", 1182], ["considered", 1185], ["as", 1196], ["a", 1199], ["fundamental", 1201], ["building", 1213], ["block", 1222], ["for", 1228], ["the", 1232], ["study", 1236], ["of", 1242], ["these", 1245], ["related", 1251], ["RNAs", 1259], [".", 1263], ["It", 1265], ["is", 1268], ["freely", 1271], ["available", 1278], ["via", 1288], ["a", 1292], ["web", 1294], ["browser", 1298], ["at", 1306], ["the", 1309], ["URL", 1313], [":", 1316], ["http://subviral.med.uottawa.ca", 1318], [".", 1348]]}
{"context": "Interleukin-6 (IL-6) can activate downstream signaling pathways in lung cancer cells, such as the STAT3 pathway, and is reported to be produced by tumor cells with activating EGFR mutations. We examined IL-6/STAT3 in lung cancer tumor tissues and the effects of siltuximab, a neutralizing antibody to human IL-6, in mouse models of lung cancer. IL-6 and STAT3 activation levels were compared with tumor histology and presence of KRAS mutations in snap-frozen, non-small-cell lung cancer tumors. The effects of siltuximab alone or in combination with erlotinib were examined in mouse xenograft models constructed using three cell line xenograft models and one primary explant mouse model. We examined the influence of cancer-associated fibroblasts (CAFs) on tumor growth and siltuximab effects. IL-6 levels were higher in tumors of squamous cell versus adenocarcinoma histology and were not associated with presence of KRAS mutations. Tyrosine phosphorylation status of STAT3 did not correlate with tumor IL-6 levels. Serine phosphorylation of STAT3 was correlated with KRAS mutation status. Both tumor and stromal cells contributed to total IL-6 within tumors. Siltuximab had minimal effect as a single agent in xenografts with tumor cells alone; however, in models coadministered with CAFs, siltuximab had more potent effects on tumor inhibition. We observed no effects of combined erlotinib and siltuximab. IL-6 is elevated in subsets of human NSCLCs, especially with squamous cell histology. Tumors supported by stromal production of IL-6 seem to be the most vulnerable to tumor growth inhibition by siltuximab.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "3e577b5a3ecf46909b53f1b6b6403b89", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[0, 0]], "char_spans": [[0, 12]]}]}], "context_tokens": [["Interleukin-6", 0], ["(", 14], ["IL-6", 15], [")", 19], ["can", 21], ["activate", 25], ["downstream", 34], ["signaling", 45], ["pathways", 55], ["in", 64], ["lung", 67], ["cancer", 72], ["cells", 79], [",", 84], ["such", 86], ["as", 91], ["the", 94], ["STAT3", 98], ["pathway", 104], [",", 111], ["and", 113], ["is", 117], ["reported", 120], ["to", 129], ["be", 132], ["produced", 135], ["by", 144], ["tumor", 147], ["cells", 153], ["with", 159], ["activating", 164], ["EGFR", 175], ["mutations", 180], [".", 189], ["We", 191], ["examined", 194], ["IL-6/STAT3", 203], ["in", 214], ["lung", 217], ["cancer", 222], ["tumor", 229], ["tissues", 235], ["and", 243], ["the", 247], ["effects", 251], ["of", 259], ["siltuximab", 262], [",", 272], ["a", 274], ["neutralizing", 276], ["antibody", 289], ["to", 298], ["human", 301], ["IL-6", 307], [",", 311], ["in", 313], ["mouse", 316], ["models", 322], ["of", 329], ["lung", 332], ["cancer", 337], [".", 343], ["IL-6", 345], ["and", 350], ["STAT3", 354], ["activation", 360], ["levels", 371], ["were", 378], ["compared", 383], ["with", 392], ["tumor", 397], ["histology", 403], ["and", 413], ["presence", 417], ["of", 426], ["KRAS", 429], ["mutations", 434], ["in", 444], ["snap", 447], ["-", 451], ["frozen", 452], [",", 458], ["non", 460], ["-", 463], ["small", 464], ["-", 469], ["cell", 470], ["lung", 475], ["cancer", 480], ["tumors", 487], [".", 493], ["The", 495], ["effects", 499], ["of", 507], ["siltuximab", 510], ["alone", 521], ["or", 527], ["in", 530], ["combination", 533], ["with", 545], ["erlotinib", 550], ["were", 560], ["examined", 565], ["in", 574], ["mouse", 577], ["xenograft", 583], ["models", 593], ["constructed", 600], ["using", 612], ["three", 618], ["cell", 624], ["line", 629], ["xenograft", 634], ["models", 644], ["and", 651], ["one", 655], ["primary", 659], ["explant", 667], ["mouse", 675], ["model", 681], [".", 686], ["We", 688], ["examined", 691], ["the", 700], ["influence", 704], ["of", 714], ["cancer", 717], ["-", 723], ["associated", 724], ["fibroblasts", 735], ["(", 747], ["CAFs", 748], [")", 752], ["on", 754], ["tumor", 757], ["growth", 763], ["and", 770], ["siltuximab", 774], ["effects", 785], [".", 792], ["IL-6", 794], ["levels", 799], ["were", 806], ["higher", 811], ["in", 818], ["tumors", 821], ["of", 828], ["squamous", 831], ["cell", 840], ["versus", 845], ["adenocarcinoma", 852], ["histology", 867], ["and", 877], ["were", 881], ["not", 886], ["associated", 890], ["with", 901], ["presence", 906], ["of", 915], ["KRAS", 918], ["mutations", 923], [".", 932], ["Tyrosine", 934], ["phosphorylation", 943], ["status", 959], ["of", 966], ["STAT3", 969], ["did", 975], ["not", 979], ["correlate", 983], ["with", 993], ["tumor", 998], ["IL-6", 1004], ["levels", 1009], [".", 1015], ["Serine", 1017], ["phosphorylation", 1024], ["of", 1040], ["STAT3", 1043], ["was", 1049], ["correlated", 1053], ["with", 1064], ["KRAS", 1069], ["mutation", 1074], ["status", 1083], [".", 1089], ["Both", 1091], ["tumor", 1096], ["and", 1102], ["stromal", 1106], ["cells", 1114], ["contributed", 1120], ["to", 1132], ["total", 1135], ["IL-6", 1141], ["within", 1146], ["tumors", 1153], [".", 1159], ["Siltuximab", 1161], ["had", 1172], ["minimal", 1176], ["effect", 1184], ["as", 1191], ["a", 1194], ["single", 1196], ["agent", 1203], ["in", 1209], ["xenografts", 1212], ["with", 1223], ["tumor", 1228], ["cells", 1234], ["alone", 1240], [";", 1245], ["however", 1247], [",", 1254], ["in", 1256], ["models", 1259], ["coadministered", 1266], ["with", 1281], ["CAFs", 1286], [",", 1290], ["siltuximab", 1292], ["had", 1303], ["more", 1307], ["potent", 1312], ["effects", 1319], ["on", 1327], ["tumor", 1330], ["inhibition", 1336], [".", 1346], ["We", 1348], ["observed", 1351], ["no", 1360], ["effects", 1363], ["of", 1371], ["combined", 1374], ["erlotinib", 1383], ["and", 1393], ["siltuximab", 1397], [".", 1407], ["IL-6", 1409], ["is", 1414], ["elevated", 1417], ["in", 1426], ["subsets", 1429], ["of", 1437], ["human", 1440], ["NSCLCs", 1446], [",", 1452], ["especially", 1454], ["with", 1465], ["squamous", 1470], ["cell", 1479], ["histology", 1484], [".", 1493], ["Tumors", 1495], ["supported", 1502], ["by", 1512], ["stromal", 1515], ["production", 1523], ["of", 1534], ["IL-6", 1537], ["seem", 1542], ["to", 1547], ["be", 1550], ["the", 1553], ["most", 1557], ["vulnerable", 1562], ["to", 1573], ["tumor", 1576], ["growth", 1582], ["inhibition", 1589], ["by", 1600], ["siltuximab", 1603], [".", 1613]]}
{"context": "Using post-embedding immunogold electron microscopy, TAR DNA-binding protein of 43 kDa (TDP-43) was localized to neuronal cytoplasmic (NCI) and intranuclear (NII) inclusions, as well as unmyelinated neurites, in frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U), amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), Pick's disease (PiD) and Lewy body disease (LBD). The TDP-43 immunoreactive structures were morphologically heterogeneous. The most common was characterized by bundles of 10-20 nm diameter straight filaments with electron dense granular material within NCI, NII and neurites. This type of pathology was found in FTLD-U, ALS and some cases of AD. Less often, inclusions in neuritic processes of FTLD-U and some cases of AD contained 10-17 nm diameter straight filaments without granular material. A final type of TDP-43 immunoreactivity was labeling of filaments and granular material associated with tau filaments in neurofibrillary tangles of AD and Pick bodies of PiD or alpha-synuclein filaments in Lewy bodies of LBD. The results suggest that TDP-43 is the primary component of the granulofilamentous inclusions in FTLD-U and ALS. Similar inclusions sometimes accompany filamentous aggregates composed of other abnormal proteins in AD, PiD and LBD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "2f91c196e1e14427999116eb471acf92", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[189, 191]], "char_spans": [[1014, 1028]]}]}], "context_tokens": [["Using", 0], ["post", 6], ["-", 10], ["embedding", 11], ["immunogold", 21], ["electron", 32], ["microscopy", 41], [",", 51], ["TAR", 53], ["DNA", 57], ["-", 60], ["binding", 61], ["protein", 69], ["of", 77], ["43", 80], ["kDa", 83], ["(", 87], ["TDP-43", 88], [")", 94], ["was", 96], ["localized", 100], ["to", 110], ["neuronal", 113], ["cytoplasmic", 122], ["(", 134], ["NCI", 135], [")", 138], ["and", 140], ["intranuclear", 144], ["(", 157], ["NII", 158], [")", 161], ["inclusions", 163], [",", 173], ["as", 175], ["well", 178], ["as", 183], ["unmyelinated", 186], ["neurites", 199], [",", 207], ["in", 209], ["frontotemporal", 212], ["lobar", 227], ["degeneration", 233], ["with", 246], ["ubiquitinated", 251], ["inclusions", 265], ["(", 276], ["FTLD", 277], ["-", 281], ["U", 282], [")", 283], [",", 284], ["amyotrophic", 286], ["lateral", 298], ["sclerosis", 306], ["(", 316], ["ALS", 317], [")", 320], [",", 321], ["Alzheimer", 323], ["'s", 332], ["(", 335], ["AD", 336], [")", 338], [",", 339], ["Pick", 341], ["'s", 345], ["disease", 348], ["(", 356], ["PiD", 357], [")", 360], ["and", 362], ["Lewy", 366], ["body", 371], ["disease", 376], ["(", 384], ["LBD", 385], [")", 388], [".", 389], ["The", 391], ["TDP-43", 395], ["immunoreactive", 402], ["structures", 417], ["were", 428], ["morphologically", 433], ["heterogeneous", 449], [".", 462], ["The", 464], ["most", 468], ["common", 473], ["was", 480], ["characterized", 484], ["by", 498], ["bundles", 501], ["of", 509], ["10", 512], ["-", 514], ["20", 515], ["nm", 518], ["diameter", 521], ["straight", 530], ["filaments", 539], ["with", 549], ["electron", 554], ["dense", 563], ["granular", 569], ["material", 578], ["within", 587], ["NCI", 594], [",", 597], ["NII", 599], ["and", 603], ["neurites", 607], [".", 615], ["This", 617], ["type", 622], ["of", 627], ["pathology", 630], ["was", 640], ["found", 644], ["in", 650], ["FTLD", 653], ["-", 657], ["U", 658], [",", 659], ["ALS", 661], ["and", 665], ["some", 669], ["cases", 674], ["of", 680], ["AD", 683], [".", 685], ["Less", 687], ["often", 692], [",", 697], ["inclusions", 699], ["in", 710], ["neuritic", 713], ["processes", 722], ["of", 732], ["FTLD", 735], ["-", 739], ["U", 740], ["and", 742], ["some", 746], ["cases", 751], ["of", 757], ["AD", 760], ["contained", 763], ["10", 773], ["-", 775], ["17", 776], ["nm", 779], ["diameter", 782], ["straight", 791], ["filaments", 800], ["without", 810], ["granular", 818], ["material", 827], [".", 835], ["A", 837], ["final", 839], ["type", 845], ["of", 850], ["TDP-43", 853], ["immunoreactivity", 860], ["was", 877], ["labeling", 881], ["of", 890], ["filaments", 893], ["and", 903], ["granular", 907], ["material", 916], ["associated", 925], ["with", 936], ["tau", 941], ["filaments", 945], ["in", 955], ["neurofibrillary", 958], ["tangles", 974], ["of", 982], ["AD", 985], ["and", 988], ["Pick", 992], ["bodies", 997], ["of", 1004], ["PiD", 1007], ["or", 1011], ["alpha", 1014], ["-", 1019], ["synuclein", 1020], ["filaments", 1030], ["in", 1040], ["Lewy", 1043], ["bodies", 1048], ["of", 1055], ["LBD", 1058], [".", 1061], ["The", 1063], ["results", 1067], ["suggest", 1075], ["that", 1083], ["TDP-43", 1088], ["is", 1095], ["the", 1098], ["primary", 1102], ["component", 1110], ["of", 1120], ["the", 1123], ["granulofilamentous", 1127], ["inclusions", 1146], ["in", 1157], ["FTLD", 1160], ["-", 1164], ["U", 1165], ["and", 1167], ["ALS", 1171], [".", 1174], ["Similar", 1176], ["inclusions", 1184], ["sometimes", 1195], ["accompany", 1205], ["filamentous", 1215], ["aggregates", 1227], ["composed", 1238], ["of", 1247], ["other", 1250], ["abnormal", 1256], ["proteins", 1265], ["in", 1274], ["AD", 1277], [",", 1279], ["PiD", 1281], ["and", 1285], ["LBD", 1289], [".", 1292]]}
{"context": "Mutations in the human FOXP2 gene cause speech and language impairments. The FOXP2 protein is a transcription factor that regulates the expression of many downstream genes, which may have important roles in nervous system development and function. An adequate amount of functional FOXP2 protein is thought to be critical for the proper development of the neural circuitry underlying speech and language. However, how FOXP2 gene expression is regulated is not clearly understood. The FOXP2 mRNA has an approximately 4-kb-long 3' untranslated region (3' UTR), twice as long as its protein coding region, indicating that FOXP2 can be regulated by microRNAs (miRNAs). We identified multiple miRNAs that regulate the expression of the human FOXP2 gene using sequence analysis and in vitro cell systems. Focusing on let-7a, miR-9, and miR-129-5p, three brain-enriched miRNAs, we show that these miRNAs regulate human FOXP2 expression in a dosage-dependent manner and target specific sequences in the FOXP2 3' UTR. We further show that these three miRNAs are expressed in the cerebellum of the human fetal brain, where FOXP2 is known to be expressed. Our results reveal novel regulatory functions of the human FOXP2 3' UTR sequence and regulatory interactions between multiple miRNAs and the human FOXP2 gene. The expression of let-7a, miR-9, and miR-129-5p in the human fetal cerebellum is consistent with their roles in regulating FOXP2 expression during early cerebellum development. These results suggest that various genetic and environmental factors may contribute to speech and language development and related neural developmental disorders via the miRNA-FOXP2 regulatory network.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "e6f7d1e34eb24319b5b80ce914ab3c03", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[129, 129], [45, 45], [13, 13], [202, 202], [218, 218], [258, 258], [68, 68], [4, 4], [108, 108], [164, 164], [290, 290], [232, 232], [178, 178], [79, 79]], "char_spans": [[736, 740], [281, 285], [77, 81], [1112, 1116], [1203, 1207], [1426, 1430], [417, 421], [23, 27], [618, 622], [911, 915], [1656, 1660], [1291, 1295], [994, 998], [483, 487]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["human", 17], ["FOXP2", 23], ["gene", 29], ["cause", 34], ["speech", 40], ["and", 47], ["language", 51], ["impairments", 60], [".", 71], ["The", 73], ["FOXP2", 77], ["protein", 83], ["is", 91], ["a", 94], ["transcription", 96], ["factor", 110], ["that", 117], ["regulates", 122], ["the", 132], ["expression", 136], ["of", 147], ["many", 150], ["downstream", 155], ["genes", 166], [",", 171], ["which", 173], ["may", 179], ["have", 183], ["important", 188], ["roles", 198], ["in", 204], ["nervous", 207], ["system", 215], ["development", 222], ["and", 234], ["function", 238], [".", 246], ["An", 248], ["adequate", 251], ["amount", 260], ["of", 267], ["functional", 270], ["FOXP2", 281], ["protein", 287], ["is", 295], ["thought", 298], ["to", 306], ["be", 309], ["critical", 312], ["for", 321], ["the", 325], ["proper", 329], ["development", 336], ["of", 348], ["the", 351], ["neural", 355], ["circuitry", 362], ["underlying", 372], ["speech", 383], ["and", 390], ["language", 394], [".", 402], ["However", 404], [",", 411], ["how", 413], ["FOXP2", 417], ["gene", 423], ["expression", 428], ["is", 439], ["regulated", 442], ["is", 452], ["not", 455], ["clearly", 459], ["understood", 467], [".", 477], ["The", 479], ["FOXP2", 483], ["mRNA", 489], ["has", 494], ["an", 498], ["approximately", 501], ["4-kb", 515], ["-", 519], ["long", 520], ["3", 525], ["'", 526], ["untranslated", 528], ["region", 541], ["(", 548], ["3", 549], ["'", 550], ["UTR", 552], [")", 555], [",", 556], ["twice", 558], ["as", 564], ["long", 567], ["as", 572], ["its", 575], ["protein", 579], ["coding", 587], ["region", 594], [",", 600], ["indicating", 602], ["that", 613], ["FOXP2", 618], ["can", 624], ["be", 628], ["regulated", 631], ["by", 641], ["microRNAs", 644], ["(", 654], ["miRNAs", 655], [")", 661], [".", 662], ["We", 664], ["identified", 667], ["multiple", 678], ["miRNAs", 687], ["that", 694], ["regulate", 699], ["the", 708], ["expression", 712], ["of", 723], ["the", 726], ["human", 730], ["FOXP2", 736], ["gene", 742], ["using", 747], ["sequence", 753], ["analysis", 762], ["and", 771], ["in", 775], ["vitro", 778], ["cell", 784], ["systems", 789], [".", 796], ["Focusing", 798], ["on", 807], ["let-7a", 810], [",", 816], ["miR-9", 818], [",", 823], ["and", 825], ["miR-129", 829], ["-", 836], ["5p", 837], [",", 839], ["three", 841], ["brain", 847], ["-", 852], ["enriched", 853], ["miRNAs", 862], [",", 868], ["we", 870], ["show", 873], ["that", 878], ["these", 883], ["miRNAs", 889], ["regulate", 896], ["human", 905], ["FOXP2", 911], ["expression", 917], ["in", 928], ["a", 931], ["dosage", 933], ["-", 939], ["dependent", 940], ["manner", 950], ["and", 957], ["target", 961], ["specific", 968], ["sequences", 977], ["in", 987], ["the", 990], ["FOXP2", 994], ["3", 1000], ["'", 1001], ["UTR", 1003], [".", 1006], ["We", 1008], ["further", 1011], ["show", 1019], ["that", 1024], ["these", 1029], ["three", 1035], ["miRNAs", 1041], ["are", 1048], ["expressed", 1052], ["in", 1062], ["the", 1065], ["cerebellum", 1069], ["of", 1080], ["the", 1083], ["human", 1087], ["fetal", 1093], ["brain", 1099], [",", 1104], ["where", 1106], ["FOXP2", 1112], ["is", 1118], ["known", 1121], ["to", 1127], ["be", 1130], ["expressed", 1133], [".", 1142], ["Our", 1144], ["results", 1148], ["reveal", 1156], ["novel", 1163], ["regulatory", 1169], ["functions", 1180], ["of", 1190], ["the", 1193], ["human", 1197], ["FOXP2", 1203], ["3", 1209], ["'", 1210], ["UTR", 1212], ["sequence", 1216], ["and", 1225], ["regulatory", 1229], ["interactions", 1240], ["between", 1253], ["multiple", 1261], ["miRNAs", 1270], ["and", 1277], ["the", 1281], ["human", 1285], ["FOXP2", 1291], ["gene", 1297], [".", 1301], ["The", 1303], ["expression", 1307], ["of", 1318], ["let-7a", 1321], [",", 1327], ["miR-9", 1329], [",", 1334], ["and", 1336], ["miR-129", 1340], ["-", 1347], ["5p", 1348], ["in", 1351], ["the", 1354], ["human", 1358], ["fetal", 1364], ["cerebellum", 1370], ["is", 1381], ["consistent", 1384], ["with", 1395], ["their", 1400], ["roles", 1406], ["in", 1412], ["regulating", 1415], ["FOXP2", 1426], ["expression", 1432], ["during", 1443], ["early", 1450], ["cerebellum", 1456], ["development", 1467], [".", 1478], ["These", 1480], ["results", 1486], ["suggest", 1494], ["that", 1502], ["various", 1507], ["genetic", 1515], ["and", 1523], ["environmental", 1527], ["factors", 1541], ["may", 1549], ["contribute", 1553], ["to", 1564], ["speech", 1567], ["and", 1574], ["language", 1578], ["development", 1587], ["and", 1599], ["related", 1603], ["neural", 1611], ["developmental", 1618], ["disorders", 1632], ["via", 1642], ["the", 1646], ["miRNA", 1650], ["-", 1655], ["FOXP2", 1656], ["regulatory", 1662], ["network", 1673], [".", 1680]]}
{"context": "Past studies have documented a crosstalk between H2B ubiquitylation (H2Bub) and H3K4 methylation, but little (if any) direct evidence exists explaining the mechanism underlying H2Bub-dependent H3K4 methylation on chromatin templates. Here, we took advantage of an in vitro histone methyltransferase assay employing a reconstituted yeast Set1 complex (ySet1C) and a recombinant chromatin template containing fully ubiquitylated H2B to gain valuable insights. Combined with genetic analyses, we demonstrate that the n-SET domain within Set1, but not Swd2, is essential for H2Bub-dependent H3K4 methylation. Spp1, a homolog of human CFP1, is conditionally involved in this crosstalk. Our findings extend to the human Set1 complex, underscoring the conserved nature of this disease-relevant crosstalk pathway. As not all members of the H3K4 methyltransferase family contain n-SET domains, our studies draw attention to the n-SET domain as a predictor of an H2B ubiquitylation-sensing mechanism that leads to downstream H3K4 methylation.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "0e9ad5ae9db7422d92338cea8e52e210", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[84, 85], [161, 162]], "char_spans": [[516, 525], [921, 930]]}]}], "context_tokens": [["Past", 0], ["studies", 5], ["have", 13], ["documented", 18], ["a", 29], ["crosstalk", 31], ["between", 41], ["H2B", 49], ["ubiquitylation", 53], ["(", 68], ["H2Bub", 69], [")", 74], ["and", 76], ["H3K4", 80], ["methylation", 85], [",", 96], ["but", 98], ["little", 102], ["(", 109], ["if", 110], ["any", 113], [")", 116], ["direct", 118], ["evidence", 125], ["exists", 134], ["explaining", 141], ["the", 152], ["mechanism", 156], ["underlying", 166], ["H2Bub", 177], ["-", 182], ["dependent", 183], ["H3K4", 193], ["methylation", 198], ["on", 210], ["chromatin", 213], ["templates", 223], [".", 232], ["Here", 234], [",", 238], ["we", 240], ["took", 243], ["advantage", 248], ["of", 258], ["an", 261], ["in", 264], ["vitro", 267], ["histone", 273], ["methyltransferase", 281], ["assay", 299], ["employing", 305], ["a", 315], ["reconstituted", 317], ["yeast", 331], ["Set1", 337], ["complex", 342], ["(", 350], ["ySet1C", 351], [")", 357], ["and", 359], ["a", 363], ["recombinant", 365], ["chromatin", 377], ["template", 387], ["containing", 396], ["fully", 407], ["ubiquitylated", 413], ["H2B", 427], ["to", 431], ["gain", 434], ["valuable", 439], ["insights", 448], [".", 456], ["Combined", 458], ["with", 467], ["genetic", 472], ["analyses", 480], [",", 488], ["we", 490], ["demonstrate", 493], ["that", 505], ["the", 510], ["n", 514], ["-", 515], ["SET", 516], ["domain", 520], ["within", 527], ["Set1", 534], [",", 538], ["but", 540], ["not", 544], ["Swd2", 548], [",", 552], ["is", 554], ["essential", 557], ["for", 567], ["H2Bub", 571], ["-", 576], ["dependent", 577], ["H3K4", 587], ["methylation", 592], [".", 603], ["Spp1", 605], [",", 609], ["a", 611], ["homolog", 613], ["of", 621], ["human", 624], ["CFP1", 630], [",", 634], ["is", 636], ["conditionally", 639], ["involved", 653], ["in", 662], ["this", 665], ["crosstalk", 670], [".", 679], ["Our", 681], ["findings", 685], ["extend", 694], ["to", 701], ["the", 704], ["human", 708], ["Set1", 714], ["complex", 719], [",", 726], ["underscoring", 728], ["the", 741], ["conserved", 745], ["nature", 755], ["of", 762], ["this", 765], ["disease", 770], ["-", 777], ["relevant", 778], ["crosstalk", 787], ["pathway", 797], [".", 804], ["As", 806], ["not", 809], ["all", 813], ["members", 817], ["of", 825], ["the", 828], ["H3K4", 832], ["methyltransferase", 837], ["family", 855], ["contain", 862], ["n", 870], ["-", 871], ["SET", 872], ["domains", 876], [",", 883], ["our", 885], ["studies", 889], ["draw", 897], ["attention", 902], ["to", 912], ["the", 915], ["n", 919], ["-", 920], ["SET", 921], ["domain", 925], ["as", 932], ["a", 935], ["predictor", 937], ["of", 947], ["an", 950], ["H2B", 953], ["ubiquitylation", 957], ["-", 971], ["sensing", 972], ["mechanism", 980], ["that", 990], ["leads", 995], ["to", 1001], ["downstream", 1004], ["H3K4", 1015], ["methylation", 1020], [".", 1031]]}
{"context": "Mutations within the NOTCH3 gene cause cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). CADASIL mutations appear to be restricted to the first twenty-four exons, resulting in the gain or loss of a cysteine amino acid. The role of other exonic NOTCH3 variation not involving cysteine residues and mutations in exons 25-33 in ischemic stroke remains unresolved. All 33 exons of NOTCH3 were sequenced in 269 Caucasian probands from the Siblings With Ischemic Stroke Study (SWISS), a 70-center North American affected sibling pair study and 95 healthy Caucasian control subjects. Variants identified by sequencing in the SWISS probands were then tested for association with ischemic stroke using US Caucasian controls collected at the Mayo Clinic (n=654), and further assessed in a Caucasian (n=802) and African American (n=298) patient-control series collected through the Ischemic Stroke Genetics Study (ISGS). Sequencing of the 269 SWISS probands identified one (0.4%) with small vessel type stroke carrying a known CADASIL mutation (p.R558C; Exon 11). Of the 19 common NOTCH3 variants identified, the only variant significantly associated with ischemic stroke after multiple testing adjustment was p.R1560P (rs78501403; Exon 25) in the combined SWISS and ISGS Caucasian series (Odds Ratio [OR] 0.50, P=0.0022) where presence of the minor allele was protective against ischemic stroke. Although only significant prior to adjustment for multiple testing, p.T101T (rs3815188; Exon 3) was associated with an increased risk of small-vessel stroke (OR: 1.56, P=0.008) and p.P380P (rs61749020; Exon 7) was associated with decreased risk of large-vessel stroke (OR: 0.35, P=0.047) in Caucasians. No significant associations were observed in the small African American series. Cysteine-affecting NOTCH3 mutations are rare in patients with typical ischemic stroke, however our observation that common NOTCH3 variants may be associated with risk of ischemic stroke warrants further study.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "5d67f3f3e8fc4a01a62f519db556744e", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[336, 336], [41, 41], [54, 54]], "char_spans": [[1821, 1828], [250, 257], [327, 334]]}]}], "context_tokens": [["Mutations", 0], ["within", 10], ["the", 17], ["NOTCH3", 21], ["gene", 28], ["cause", 33], ["cerebral", 39], ["autosomal", 48], ["dominant", 58], ["arteriopathy", 67], ["with", 80], ["subcortical", 85], ["infarcts", 97], ["and", 106], ["leukoencephalopathy", 110], ["(", 130], ["CADASIL", 131], [")", 138], [".", 139], ["CADASIL", 141], ["mutations", 149], ["appear", 159], ["to", 166], ["be", 169], ["restricted", 172], ["to", 183], ["the", 186], ["first", 190], ["twenty", 196], ["-", 202], ["four", 203], ["exons", 208], [",", 213], ["resulting", 215], ["in", 225], ["the", 228], ["gain", 232], ["or", 237], ["loss", 240], ["of", 245], ["a", 248], ["cysteine", 250], ["amino", 259], ["acid", 265], [".", 269], ["The", 271], ["role", 275], ["of", 280], ["other", 283], ["exonic", 289], ["NOTCH3", 296], ["variation", 303], ["not", 313], ["involving", 317], ["cysteine", 327], ["residues", 336], ["and", 345], ["mutations", 349], ["in", 359], ["exons", 362], ["25", 368], ["-", 370], ["33", 371], ["in", 374], ["ischemic", 377], ["stroke", 386], ["remains", 393], ["unresolved", 401], [".", 411], ["All", 413], ["33", 417], ["exons", 420], ["of", 426], ["NOTCH3", 429], ["were", 436], ["sequenced", 441], ["in", 451], ["269", 454], ["Caucasian", 458], ["probands", 468], ["from", 477], ["the", 482], ["Siblings", 486], ["With", 495], ["Ischemic", 500], ["Stroke", 509], ["Study", 516], ["(", 522], ["SWISS", 523], [")", 528], [",", 529], ["a", 531], ["70-center", 533], ["North", 543], ["American", 549], ["affected", 558], ["sibling", 567], ["pair", 575], ["study", 580], ["and", 586], ["95", 590], ["healthy", 593], ["Caucasian", 601], ["control", 611], ["subjects", 619], [".", 627], ["Variants", 629], ["identified", 638], ["by", 649], ["sequencing", 652], ["in", 663], ["the", 666], ["SWISS", 670], ["probands", 676], ["were", 685], ["then", 690], ["tested", 695], ["for", 702], ["association", 706], ["with", 718], ["ischemic", 723], ["stroke", 732], ["using", 739], ["US", 745], ["Caucasian", 748], ["controls", 758], ["collected", 767], ["at", 777], ["the", 780], ["Mayo", 784], ["Clinic", 789], ["(", 796], ["n=654", 797], [")", 802], [",", 803], ["and", 805], ["further", 809], ["assessed", 817], ["in", 826], ["a", 829], ["Caucasian", 831], ["(", 841], ["n=802", 842], [")", 847], ["and", 849], ["African", 853], ["American", 861], ["(", 870], ["n=298", 871], [")", 876], ["patient", 878], ["-", 885], ["control", 886], ["series", 894], ["collected", 901], ["through", 911], ["the", 919], ["Ischemic", 923], ["Stroke", 932], ["Genetics", 939], ["Study", 948], ["(", 954], ["ISGS", 955], [")", 959], [".", 960], ["Sequencing", 962], ["of", 973], ["the", 976], ["269", 980], ["SWISS", 984], ["probands", 990], ["identified", 999], ["one", 1010], ["(", 1014], ["0.4", 1015], ["%", 1018], [")", 1019], ["with", 1021], ["small", 1026], ["vessel", 1032], ["type", 1039], ["stroke", 1044], ["carrying", 1051], ["a", 1060], ["known", 1062], ["CADASIL", 1068], ["mutation", 1076], ["(", 1085], ["p", 1086], [".", 1087], ["R558C", 1088], [";", 1093], ["Exon", 1095], ["11", 1100], [")", 1102], [".", 1103], ["Of", 1105], ["the", 1108], ["19", 1112], ["common", 1115], ["NOTCH3", 1122], ["variants", 1129], ["identified", 1138], [",", 1148], ["the", 1150], ["only", 1154], ["variant", 1159], ["significantly", 1167], ["associated", 1181], ["with", 1192], ["ischemic", 1197], ["stroke", 1206], ["after", 1213], ["multiple", 1219], ["testing", 1228], ["adjustment", 1236], ["was", 1247], ["p", 1251], [".", 1252], ["R1560P", 1253], ["(", 1260], ["rs78501403", 1261], [";", 1271], ["Exon", 1273], ["25", 1278], [")", 1280], ["in", 1282], ["the", 1285], ["combined", 1289], ["SWISS", 1298], ["and", 1304], ["ISGS", 1308], ["Caucasian", 1313], ["series", 1323], ["(", 1330], ["Odds", 1331], ["Ratio", 1336], ["[", 1342], ["OR", 1343], ["]", 1345], ["0.50", 1347], [",", 1351], ["P=0.0022", 1353], [")", 1361], ["where", 1363], ["presence", 1369], ["of", 1378], ["the", 1381], ["minor", 1385], ["allele", 1391], ["was", 1398], ["protective", 1402], ["against", 1413], ["ischemic", 1421], ["stroke", 1430], [".", 1436], ["Although", 1438], ["only", 1447], ["significant", 1452], ["prior", 1464], ["to", 1470], ["adjustment", 1473], ["for", 1484], ["multiple", 1488], ["testing", 1497], [",", 1504], ["p", 1506], [".", 1507], ["T101", 1508], ["T", 1512], ["(", 1514], ["rs3815188", 1515], [";", 1524], ["Exon", 1526], ["3", 1531], [")", 1532], ["was", 1534], ["associated", 1538], ["with", 1549], ["an", 1554], ["increased", 1557], ["risk", 1567], ["of", 1572], ["small", 1575], ["-", 1580], ["vessel", 1581], ["stroke", 1588], ["(", 1595], ["OR", 1596], [":", 1598], ["1.56", 1600], [",", 1604], ["P=0.008", 1606], [")", 1613], ["and", 1615], ["p", 1619], [".", 1620], ["P380P", 1621], ["(", 1627], ["rs61749020", 1628], [";", 1638], ["Exon", 1640], ["7", 1645], [")", 1646], ["was", 1648], ["associated", 1652], ["with", 1663], ["decreased", 1668], ["risk", 1678], ["of", 1683], ["large", 1686], ["-", 1691], ["vessel", 1692], ["stroke", 1699], ["(", 1706], ["OR", 1707], [":", 1709], ["0.35", 1711], [",", 1715], ["P=0.047", 1717], [")", 1724], ["in", 1726], ["Caucasians", 1729], [".", 1739], ["No", 1741], ["significant", 1744], ["associations", 1756], ["were", 1769], ["observed", 1774], ["in", 1783], ["the", 1786], ["small", 1790], ["African", 1796], ["American", 1804], ["series", 1813], [".", 1819], ["Cysteine", 1821], ["-", 1829], ["affecting", 1830], ["NOTCH3", 1840], ["mutations", 1847], ["are", 1857], ["rare", 1861], ["in", 1866], ["patients", 1869], ["with", 1878], ["typical", 1883], ["ischemic", 1891], ["stroke", 1900], [",", 1906], ["however", 1908], ["our", 1916], ["observation", 1920], ["that", 1932], ["common", 1937], ["NOTCH3", 1944], ["variants", 1951], ["may", 1960], ["be", 1964], ["associated", 1967], ["with", 1978], ["risk", 1983], ["of", 1988], ["ischemic", 1991], ["stroke", 2000], ["warrants", 2007], ["further", 2016], ["study", 2024], [".", 2029]]}
{"context": "The incorporation of histone variant H2A.Z into nucleosomes plays essential roles in regulating chromatin structure and gene expression. A multisubunit complex containing chromatin remodeling protein Swr1 is responsible for the deposition of H2A.Z in budding yeast and mammals. Here, we show that the JmjC domain protein Msc1 is a novel component of the fission yeast Swr1 complex and is required for Swr1-mediated incorporation of H2A.Z into nucleosomes at gene promoters. Loss of Msc1, Swr1, or H2A.Z results in loss of silencing at centromeres and defective chromosome segregation, although centromeric levels of CENP-A, a centromere-specific histone H3 variant that is required for setting up the chromatin structure at centromeres, remain unchanged. Intriguingly, H2A.Z is required for the expression of another centromere protein, CENP-C, and overexpression of CENP-C rescues centromere silencing defects associated with H2A.Z loss. These results demonstrate the importance of H2A.Z and CENP-C in maintaining a silenced chromatin state at centromeres.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "aca0c2813cab4d7ca0129b61b2f3dc20", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[58, 58], [78, 78], [26, 26]], "char_spans": [[368, 371], [488, 491], [200, 203]]}]}], "context_tokens": [["The", 0], ["incorporation", 4], ["of", 18], ["histone", 21], ["variant", 29], ["H2A.Z", 37], ["into", 43], ["nucleosomes", 48], ["plays", 60], ["essential", 66], ["roles", 76], ["in", 82], ["regulating", 85], ["chromatin", 96], ["structure", 106], ["and", 116], ["gene", 120], ["expression", 125], [".", 135], ["A", 137], ["multisubunit", 139], ["complex", 152], ["containing", 160], ["chromatin", 171], ["remodeling", 181], ["protein", 192], ["Swr1", 200], ["is", 205], ["responsible", 208], ["for", 220], ["the", 224], ["deposition", 228], ["of", 239], ["H2A.Z", 242], ["in", 248], ["budding", 251], ["yeast", 259], ["and", 265], ["mammals", 269], [".", 276], ["Here", 278], [",", 282], ["we", 284], ["show", 287], ["that", 292], ["the", 297], ["JmjC", 301], ["domain", 306], ["protein", 313], ["Msc1", 321], ["is", 326], ["a", 329], ["novel", 331], ["component", 337], ["of", 347], ["the", 350], ["fission", 354], ["yeast", 362], ["Swr1", 368], ["complex", 373], ["and", 381], ["is", 385], ["required", 388], ["for", 397], ["Swr1-mediated", 401], ["incorporation", 415], ["of", 429], ["H2A.Z", 432], ["into", 438], ["nucleosomes", 443], ["at", 455], ["gene", 458], ["promoters", 463], [".", 472], ["Loss", 474], ["of", 479], ["Msc1", 482], [",", 486], ["Swr1", 488], [",", 492], ["or", 494], ["H2A.Z", 497], ["results", 503], ["in", 511], ["loss", 514], ["of", 519], ["silencing", 522], ["at", 532], ["centromeres", 535], ["and", 547], ["defective", 551], ["chromosome", 561], ["segregation", 572], [",", 583], ["although", 585], ["centromeric", 594], ["levels", 606], ["of", 613], ["CENP", 616], ["-", 620], ["A", 621], [",", 622], ["a", 624], ["centromere", 626], ["-", 636], ["specific", 637], ["histone", 646], ["H3", 654], ["variant", 657], ["that", 665], ["is", 670], ["required", 673], ["for", 682], ["setting", 686], ["up", 694], ["the", 697], ["chromatin", 701], ["structure", 711], ["at", 721], ["centromeres", 724], [",", 735], ["remain", 737], ["unchanged", 744], [".", 753], ["Intriguingly", 755], [",", 767], ["H2A.Z", 769], ["is", 775], ["required", 778], ["for", 787], ["the", 791], ["expression", 795], ["of", 806], ["another", 809], ["centromere", 817], ["protein", 828], [",", 835], ["CENP", 837], ["-", 841], ["C", 842], [",", 843], ["and", 845], ["overexpression", 849], ["of", 864], ["CENP", 867], ["-", 871], ["C", 872], ["rescues", 874], ["centromere", 882], ["silencing", 893], ["defects", 903], ["associated", 911], ["with", 922], ["H2A.Z", 927], ["loss", 933], [".", 937], ["These", 939], ["results", 945], ["demonstrate", 953], ["the", 965], ["importance", 969], ["of", 980], ["H2A.Z", 983], ["and", 989], ["CENP", 993], ["-", 997], ["C", 998], ["in", 1000], ["maintaining", 1003], ["a", 1015], ["silenced", 1017], ["chromatin", 1026], ["state", 1036], ["at", 1042], ["centromeres", 1045], [".", 1056]]}
{"context": "Coexpression of PU.1 and GATA-1 is required for proper specification of the mast cell lineage; however, in the myeloid and erythroid lineages, PU.1 and GATA-1 are functionally antagonistic. In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development. We isolated a variant mRNA isoform of GATA-1 in murine mast cells that is significantly upregulated during mast cell differentiation. This isoform contains an alternatively spliced first exon (IB) that is distinct from the first exon (IE) incorporated in the major erythroid mRNA transcript. In contrast to erythroid and megakaryocyte cells, in mast cells we show that PU.1 and GATA-2 predominantly occupy potential cis-regulatory elements in the IB exon region in vivo. Using reporter assays, we identify an enhancer flanking the IB exon that is activated by PU.1. Furthermore, we observe that in PU.1(-/-) fetal liver cells, low levels of the IE GATA-1 isoform is expressed, but the variant IB isoform is absent. Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation. Our results are consistent with a transcriptional hierarchy in which PU.1, possibly in concert with GATA-2, activates GATA-1 expression in mast cells in a pathway distinct from that seen in the erythroid and megakaryocytic lineages.", "qas": [{"question": "Which gene controls the expression of GATA-1 isoforms?", "answers": ["PU.1"], "qid": "f6516640f1d44d11963b1679aae29f07", "question_tokens": [["Which", 0], ["gene", 6], ["controls", 11], ["the", 20], ["expression", 24], ["of", 35], ["GATA-1", 38], ["isoforms", 45], ["?", 53]], "detected_answers": [{"text": "PU.1", "token_spans": [[117, 117], [43, 43], [151, 151], [25, 25], [185, 185], [215, 215], [2, 2], [159, 159]], "char_spans": [[689, 692], [250, 253], [880, 883], [143, 146], [1053, 1056], [1256, 1259], [16, 19], [918, 925]]}]}], "context_tokens": [["Coexpression", 0], ["of", 13], ["PU.1", 16], ["and", 21], ["GATA-1", 25], ["is", 32], ["required", 35], ["for", 44], ["proper", 48], ["specification", 55], ["of", 69], ["the", 72], ["mast", 76], ["cell", 81], ["lineage", 86], [";", 93], ["however", 95], [",", 102], ["in", 104], ["the", 107], ["myeloid", 111], ["and", 119], ["erythroid", 123], ["lineages", 133], [",", 141], ["PU.1", 143], ["and", 148], ["GATA-1", 152], ["are", 159], ["functionally", 163], ["antagonistic", 176], [".", 188], ["In", 190], ["this", 193], ["study", 198], [",", 203], ["we", 205], ["report", 208], ["a", 215], ["transcriptional", 217], ["network", 233], ["in", 241], ["which", 244], ["PU.1", 250], ["positively", 255], ["regulates", 266], ["GATA-1", 276], ["expression", 283], ["in", 294], ["mast", 297], ["cell", 302], ["development", 307], [".", 318], ["We", 320], ["isolated", 323], ["a", 332], ["variant", 334], ["mRNA", 342], ["isoform", 347], ["of", 355], ["GATA-1", 358], ["in", 365], ["murine", 368], ["mast", 375], ["cells", 380], ["that", 386], ["is", 391], ["significantly", 394], ["upregulated", 408], ["during", 420], ["mast", 427], ["cell", 432], ["differentiation", 437], [".", 452], ["This", 454], ["isoform", 459], ["contains", 467], ["an", 476], ["alternatively", 479], ["spliced", 493], ["first", 501], ["exon", 507], ["(", 512], ["IB", 513], [")", 515], ["that", 517], ["is", 522], ["distinct", 525], ["from", 534], ["the", 539], ["first", 543], ["exon", 549], ["(", 554], ["IE", 555], [")", 557], ["incorporated", 559], ["in", 572], ["the", 575], ["major", 579], ["erythroid", 585], ["mRNA", 595], ["transcript", 600], [".", 610], ["In", 612], ["contrast", 615], ["to", 624], ["erythroid", 627], ["and", 637], ["megakaryocyte", 641], ["cells", 655], [",", 660], ["in", 662], ["mast", 665], ["cells", 670], ["we", 676], ["show", 679], ["that", 684], ["PU.1", 689], ["and", 694], ["GATA-2", 698], ["predominantly", 705], ["occupy", 719], ["potential", 726], ["cis", 736], ["-", 739], ["regulatory", 740], ["elements", 751], ["in", 760], ["the", 763], ["IB", 767], ["exon", 770], ["region", 775], ["in", 782], ["vivo", 785], [".", 789], ["Using", 791], ["reporter", 797], ["assays", 806], [",", 812], ["we", 814], ["identify", 817], ["an", 826], ["enhancer", 829], ["flanking", 838], ["the", 847], ["IB", 851], ["exon", 854], ["that", 859], ["is", 864], ["activated", 867], ["by", 877], ["PU.1", 880], [".", 884], ["Furthermore", 886], [",", 897], ["we", 899], ["observe", 902], ["that", 910], ["in", 915], ["PU.1(-/-", 918], [")", 926], ["fetal", 928], ["liver", 934], ["cells", 940], [",", 945], ["low", 947], ["levels", 951], ["of", 958], ["the", 961], ["IE", 965], ["GATA-1", 968], ["isoform", 975], ["is", 983], ["expressed", 986], [",", 995], ["but", 997], ["the", 1001], ["variant", 1005], ["IB", 1013], ["isoform", 1016], ["is", 1024], ["absent", 1027], [".", 1033], ["Reintroduction", 1035], ["of", 1050], ["PU.1", 1053], ["restores", 1058], ["variant", 1067], ["IB", 1075], ["isoform", 1078], ["and", 1086], ["upregulates", 1090], ["total", 1102], ["GATA-1", 1108], ["protein", 1115], ["expression", 1123], [",", 1133], ["which", 1135], ["is", 1141], ["concurrent", 1144], ["with", 1155], ["mast", 1160], ["cell", 1165], ["differentiation", 1170], [".", 1185], ["Our", 1187], ["results", 1191], ["are", 1199], ["consistent", 1203], ["with", 1214], ["a", 1219], ["transcriptional", 1221], ["hierarchy", 1237], ["in", 1247], ["which", 1250], ["PU.1", 1256], [",", 1260], ["possibly", 1262], ["in", 1271], ["concert", 1274], ["with", 1282], ["GATA-2", 1287], [",", 1293], ["activates", 1295], ["GATA-1", 1305], ["expression", 1312], ["in", 1323], ["mast", 1326], ["cells", 1331], ["in", 1337], ["a", 1340], ["pathway", 1342], ["distinct", 1350], ["from", 1359], ["that", 1364], ["seen", 1369], ["in", 1374], ["the", 1377], ["erythroid", 1381], ["and", 1391], ["megakaryocytic", 1395], ["lineages", 1410], [".", 1418]]}
{"context": "Chediak-Higashi syndrome (CHS) is an inherited immunodeficiency disease characterized by giant lysosomes and impaired leukocyte degranulation. CHS results from mutations in the lysosomal trafficking regulator (LYST) gene, which encodes a 425-kD cytoplasmic protein of unknown function. The goal of this study was to identify proteins that interact with LYST as a first step in understanding how LYST modulates lysosomal exocytosis. Fourteen cDNA fragments, covering the entire coding domain of LYST, were used as baits to screen five human cDNA libraries by a yeast two-hybrid method, modified to allow screening in the activation and the binding domain, three selectable markers, and more stringent confirmation procedures. Five of the interactions were confirmed by an in vitro binding assay. Twenty-one proteins that interact with LYST were identified in yeast two-hybrid screens. Four interactions, confirmed directly, were with proteins important in vesicular transport and signal transduction (the SNARE-complex protein HRS, 14-3-3, and casein kinase II). On the basis of protein interactions, LYST appears to function as an adapter protein that may juxtapose proteins that mediate intracellular membrane fusion reactions. The pathologic manifestations observed in CHS patients and in mice with the homologous mutation beige suggest that understanding the role of LYST may be relevant to the treatment of not only CHS but also of diseases such as asthma, urticaria, and lupus, as well as to the molecular dissection of the CHS-associated cancer predisposition.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "6a6c0c5ae87d4079ad03b0e1d5ecdd40", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["an", 34], ["inherited", 37], ["immunodeficiency", 47], ["disease", 64], ["characterized", 72], ["by", 86], ["giant", 89], ["lysosomes", 95], ["and", 105], ["impaired", 109], ["leukocyte", 118], ["degranulation", 128], [".", 141], ["CHS", 143], ["results", 147], ["from", 155], ["mutations", 160], ["in", 170], ["the", 173], ["lysosomal", 177], ["trafficking", 187], ["regulator", 199], ["(", 209], ["LYST", 210], [")", 214], ["gene", 216], [",", 220], ["which", 222], ["encodes", 228], ["a", 236], ["425-kD", 238], ["cytoplasmic", 245], ["protein", 257], ["of", 265], ["unknown", 268], ["function", 276], [".", 284], ["The", 286], ["goal", 290], ["of", 295], ["this", 298], ["study", 303], ["was", 309], ["to", 313], ["identify", 316], ["proteins", 325], ["that", 334], ["interact", 339], ["with", 348], ["LYST", 353], ["as", 358], ["a", 361], ["first", 363], ["step", 369], ["in", 374], ["understanding", 377], ["how", 391], ["LYST", 395], ["modulates", 400], ["lysosomal", 410], ["exocytosis", 420], [".", 430], ["Fourteen", 432], ["cDNA", 441], ["fragments", 446], [",", 455], ["covering", 457], ["the", 466], ["entire", 470], ["coding", 477], ["domain", 484], ["of", 491], ["LYST", 494], [",", 498], ["were", 500], ["used", 505], ["as", 510], ["baits", 513], ["to", 519], ["screen", 522], ["five", 529], ["human", 534], ["cDNA", 540], ["libraries", 545], ["by", 555], ["a", 558], ["yeast", 560], ["two", 566], ["-", 569], ["hybrid", 570], ["method", 577], [",", 583], ["modified", 585], ["to", 594], ["allow", 597], ["screening", 603], ["in", 613], ["the", 616], ["activation", 620], ["and", 631], ["the", 635], ["binding", 639], ["domain", 647], [",", 653], ["three", 655], ["selectable", 661], ["markers", 672], [",", 679], ["and", 681], ["more", 685], ["stringent", 690], ["confirmation", 700], ["procedures", 713], [".", 723], ["Five", 725], ["of", 730], ["the", 733], ["interactions", 737], ["were", 750], ["confirmed", 755], ["by", 765], ["an", 768], ["in", 771], ["vitro", 774], ["binding", 780], ["assay", 788], [".", 793], ["Twenty", 795], ["-", 801], ["one", 802], ["proteins", 806], ["that", 815], ["interact", 820], ["with", 829], ["LYST", 834], ["were", 839], ["identified", 844], ["in", 855], ["yeast", 858], ["two", 864], ["-", 867], ["hybrid", 868], ["screens", 875], [".", 882], ["Four", 884], ["interactions", 889], [",", 901], ["confirmed", 903], ["directly", 913], [",", 921], ["were", 923], ["with", 928], ["proteins", 933], ["important", 942], ["in", 952], ["vesicular", 955], ["transport", 965], ["and", 975], ["signal", 979], ["transduction", 986], ["(", 999], ["the", 1000], ["SNARE", 1004], ["-", 1009], ["complex", 1010], ["protein", 1018], ["HRS", 1026], [",", 1029], ["14", 1031], ["-", 1033], ["3", 1034], ["-", 1035], ["3", 1036], [",", 1037], ["and", 1039], ["casein", 1043], ["kinase", 1050], ["II", 1057], [")", 1059], [".", 1060], ["On", 1062], ["the", 1065], ["basis", 1069], ["of", 1075], ["protein", 1078], ["interactions", 1086], [",", 1098], ["LYST", 1100], ["appears", 1105], ["to", 1113], ["function", 1116], ["as", 1125], ["an", 1128], ["adapter", 1131], ["protein", 1139], ["that", 1147], ["may", 1152], ["juxtapose", 1156], ["proteins", 1166], ["that", 1175], ["mediate", 1180], ["intracellular", 1188], ["membrane", 1202], ["fusion", 1211], ["reactions", 1218], [".", 1227], ["The", 1229], ["pathologic", 1233], ["manifestations", 1244], ["observed", 1259], ["in", 1268], ["CHS", 1271], ["patients", 1275], ["and", 1284], ["in", 1288], ["mice", 1291], ["with", 1296], ["the", 1301], ["homologous", 1305], ["mutation", 1316], ["beige", 1325], ["suggest", 1331], ["that", 1339], ["understanding", 1344], ["the", 1358], ["role", 1362], ["of", 1367], ["LYST", 1370], ["may", 1375], ["be", 1379], ["relevant", 1382], ["to", 1391], ["the", 1394], ["treatment", 1398], ["of", 1408], ["not", 1411], ["only", 1415], ["CHS", 1420], ["but", 1424], ["also", 1428], ["of", 1433], ["diseases", 1436], ["such", 1445], ["as", 1450], ["asthma", 1453], [",", 1459], ["urticaria", 1461], [",", 1470], ["and", 1472], ["lupus", 1476], [",", 1481], ["as", 1483], ["well", 1486], ["as", 1491], ["to", 1494], ["the", 1497], ["molecular", 1501], ["dissection", 1511], ["of", 1522], ["the", 1525], ["CHS", 1529], ["-", 1532], ["associated", 1533], ["cancer", 1544], ["predisposition", 1551], [".", 1565]]}
{"context": "To define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography. Body indices (height, weight, and body mass index) were analyzed in 60 healthy adults, and electromyography and sonography were also performed. The cross-sectional areas of the proximal and distal median nerve and carpal tunnel were obtained by sonography. The proximal and distal nerve/tunnel indices were obtained by calculating the ratio between the proximal and distal cross-sectional areas of the median nerve to those of the carpal tunnel and multiplying the value by 100. Although the proximal cross-sectional areas of the median nerve and body indices showed statistically significant relationships with weak positive correlations, the proximal and distal areas of the carpal tunnel showed relatively stronger correlations with body indices. Between sexes, there were significant differences in the proximal median nerve cross-sectional area (mean \u00b1 SD: male, 10.48 \u00b1 3.21 mm(2); female, 8.81 \u00b1 3.21 mm(2); P < .05) and proximal carpal tunnel area (male, 182.50 \u00b1 21.15 mm(2); female, 151.23 \u00b1 21.14 mm(2); P < .05). There was no difference in the proximal nerve/tunnel index (male, 5.80% \u00b1 1.72%; female, 5.91% \u00b1 1.63%). There was a statistically significant difference in the distal carpal tunnel cross-sectional area (male, 138.90 \u00b1 20.95 mm(2); female, 121.50 \u00b1 18.99 mm(2); P < .05) between sexes, but the distal median area (male, 9.99 \u00b1 3.42 mm(2); female, 8.46 \u00b1 1.84 mm(2)) and distal nerve/tunnel index (male, 7.15% \u00b1 2.00%; female, 7.01% \u00b1 1.38%) showed no significant differences. The proximal index was significantly higher than the distal index (proximal, 5.85% \u00b1 1.66%; distal, 7.08% \u00b1 1.71%). The nerve/tunnel index is unaffected by body indices or sex and thus may be a useful and objective standard for diagnosing carpal tunnel syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "75f0878c248e4bbab73420d14772e958", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[181, 181], [310, 310], [116, 116], [140, 140], [20, 20], [81, 81]], "char_spans": [[1072, 1077], [1582, 1587], [658, 663], [786, 791], [117, 122], [453, 458]]}]}], "context_tokens": [["To", 0], ["define", 3], ["the", 10], ["relationship", 14], ["between", 27], ["body", 35], ["indices", 40], ["of", 48], ["healthy", 51], ["adults", 59], ["and", 66], ["cross", 70], ["-", 75], ["sectional", 76], ["areas", 86], ["of", 92], ["the", 95], ["carpal", 99], ["tunnel", 106], ["and", 113], ["median", 117], ["nerve", 124], ["and", 130], ["to", 134], ["obtain", 137], ["the", 144], ["nerve", 148], ["/", 153], ["tunnel", 154], ["index", 161], [",", 166], ["which", 168], ["represents", 174], ["a", 185], ["new", 187], ["standard", 191], ["for", 200], ["diagnosing", 204], ["carpal", 215], ["tunnel", 222], ["syndrome", 229], ["using", 238], ["sonography", 244], [".", 254], ["Body", 256], ["indices", 261], ["(", 269], ["height", 270], [",", 276], ["weight", 278], [",", 284], ["and", 286], ["body", 290], ["mass", 295], ["index", 300], [")", 305], ["were", 307], ["analyzed", 312], ["in", 321], ["60", 324], ["healthy", 327], ["adults", 335], [",", 341], ["and", 343], ["electromyography", 347], ["and", 364], ["sonography", 368], ["were", 379], ["also", 384], ["performed", 389], [".", 398], ["The", 400], ["cross", 404], ["-", 409], ["sectional", 410], ["areas", 420], ["of", 426], ["the", 429], ["proximal", 433], ["and", 442], ["distal", 446], ["median", 453], ["nerve", 460], ["and", 466], ["carpal", 470], ["tunnel", 477], ["were", 484], ["obtained", 489], ["by", 498], ["sonography", 501], [".", 511], ["The", 513], ["proximal", 517], ["and", 526], ["distal", 530], ["nerve", 537], ["/", 542], ["tunnel", 543], ["indices", 550], ["were", 558], ["obtained", 563], ["by", 572], ["calculating", 575], ["the", 587], ["ratio", 591], ["between", 597], ["the", 605], ["proximal", 609], ["and", 618], ["distal", 622], ["cross", 629], ["-", 634], ["sectional", 635], ["areas", 645], ["of", 651], ["the", 654], ["median", 658], ["nerve", 665], ["to", 671], ["those", 674], ["of", 680], ["the", 683], ["carpal", 687], ["tunnel", 694], ["and", 701], ["multiplying", 705], ["the", 717], ["value", 721], ["by", 727], ["100", 730], [".", 733], ["Although", 735], ["the", 744], ["proximal", 748], ["cross", 757], ["-", 762], ["sectional", 763], ["areas", 773], ["of", 779], ["the", 782], ["median", 786], ["nerve", 793], ["and", 799], ["body", 803], ["indices", 808], ["showed", 816], ["statistically", 823], ["significant", 837], ["relationships", 849], ["with", 863], ["weak", 868], ["positive", 873], ["correlations", 882], [",", 894], ["the", 896], ["proximal", 900], ["and", 909], ["distal", 913], ["areas", 920], ["of", 926], ["the", 929], ["carpal", 933], ["tunnel", 940], ["showed", 947], ["relatively", 954], ["stronger", 965], ["correlations", 974], ["with", 987], ["body", 992], ["indices", 997], [".", 1004], ["Between", 1006], ["sexes", 1014], [",", 1019], ["there", 1021], ["were", 1027], ["significant", 1032], ["differences", 1044], ["in", 1056], ["the", 1059], ["proximal", 1063], ["median", 1072], ["nerve", 1079], ["cross", 1085], ["-", 1090], ["sectional", 1091], ["area", 1101], ["(", 1106], ["mean", 1107], ["\u00b1", 1112], ["SD", 1114], [":", 1116], ["male", 1118], [",", 1122], ["10.48", 1124], ["\u00b1", 1130], ["3.21", 1132], ["mm(2", 1137], [")", 1141], [";", 1142], ["female", 1144], [",", 1150], ["8.81", 1152], ["\u00b1", 1157], ["3.21", 1159], ["mm(2", 1164], [")", 1168], [";", 1169], ["P", 1171], ["<", 1173], [".05", 1175], [")", 1178], ["and", 1180], ["proximal", 1184], ["carpal", 1193], ["tunnel", 1200], ["area", 1207], ["(", 1212], ["male", 1213], [",", 1217], ["182.50", 1219], ["\u00b1", 1226], ["21.15", 1228], ["mm(2", 1234], [")", 1238], [";", 1239], ["female", 1241], [",", 1247], ["151.23", 1249], ["\u00b1", 1256], ["21.14", 1258], ["mm(2", 1264], [")", 1268], [";", 1269], ["P", 1271], ["<", 1273], [".05", 1275], [")", 1278], [".", 1279], ["There", 1281], ["was", 1287], ["no", 1291], ["difference", 1294], ["in", 1305], ["the", 1308], ["proximal", 1312], ["nerve", 1321], ["/", 1326], ["tunnel", 1327], ["index", 1334], ["(", 1340], ["male", 1341], [",", 1345], ["5.80", 1347], ["%", 1351], ["\u00b1", 1353], ["1.72", 1355], ["%", 1359], [";", 1360], ["female", 1362], [",", 1368], ["5.91", 1370], ["%", 1374], ["\u00b1", 1376], ["1.63", 1378], ["%", 1382], [")", 1383], [".", 1384], ["There", 1386], ["was", 1392], ["a", 1396], ["statistically", 1398], ["significant", 1412], ["difference", 1424], ["in", 1435], ["the", 1438], ["distal", 1442], ["carpal", 1449], ["tunnel", 1456], ["cross", 1463], ["-", 1468], ["sectional", 1469], ["area", 1479], ["(", 1484], ["male", 1485], [",", 1489], ["138.90", 1491], ["\u00b1", 1498], ["20.95", 1500], ["mm(2", 1506], [")", 1510], [";", 1511], ["female", 1513], [",", 1519], ["121.50", 1521], ["\u00b1", 1528], ["18.99", 1530], ["mm(2", 1536], [")", 1540], [";", 1541], ["P", 1543], ["<", 1545], [".05", 1547], [")", 1550], ["between", 1552], ["sexes", 1560], [",", 1565], ["but", 1567], ["the", 1571], ["distal", 1575], ["median", 1582], ["area", 1589], ["(", 1594], ["male", 1595], [",", 1599], ["9.99", 1601], ["\u00b1", 1606], ["3.42", 1608], ["mm(2", 1613], [")", 1617], [";", 1618], ["female", 1620], [",", 1626], ["8.46", 1628], ["\u00b1", 1633], ["1.84", 1635], ["mm(2", 1640], [")", 1644], [")", 1645], ["and", 1647], ["distal", 1651], ["nerve", 1658], ["/", 1663], ["tunnel", 1664], ["index", 1671], ["(", 1677], ["male", 1678], [",", 1682], ["7.15", 1684], ["%", 1688], ["\u00b1", 1690], ["2.00", 1692], ["%", 1696], [";", 1697], ["female", 1699], [",", 1705], ["7.01", 1707], ["%", 1711], ["\u00b1", 1713], ["1.38", 1715], ["%", 1719], [")", 1720], ["showed", 1722], ["no", 1729], ["significant", 1732], ["differences", 1744], [".", 1755], ["The", 1757], ["proximal", 1761], ["index", 1770], ["was", 1776], ["significantly", 1780], ["higher", 1794], ["than", 1801], ["the", 1806], ["distal", 1810], ["index", 1817], ["(", 1823], ["proximal", 1824], [",", 1832], ["5.85", 1834], ["%", 1838], ["\u00b1", 1840], ["1.66", 1842], ["%", 1846], [";", 1847], ["distal", 1849], [",", 1855], ["7.08", 1857], ["%", 1861], ["\u00b1", 1863], ["1.71", 1865], ["%", 1869], [")", 1870], [".", 1871], ["The", 1873], ["nerve", 1877], ["/", 1882], ["tunnel", 1883], ["index", 1890], ["is", 1896], ["unaffected", 1899], ["by", 1910], ["body", 1913], ["indices", 1918], ["or", 1926], ["sex", 1929], ["and", 1933], ["thus", 1937], ["may", 1942], ["be", 1946], ["a", 1949], ["useful", 1951], ["and", 1958], ["objective", 1962], ["standard", 1972], ["for", 1981], ["diagnosing", 1985], ["carpal", 1996], ["tunnel", 2003], ["syndrome", 2010], [".", 2018]]}
{"context": "Stem cells, one of the progenitors of cancer, exist predominately in a quiescent state. Thus, understanding the mechanisms of DNA repair and mutagenesis in such arrested cells may help unravel the complex process of tumorigenesis. Two major nucleotide excision repair (NER) pathways are known to remove bulky physical or chemical lesions from DNA. Transcription-coupled repair (TCR) acts solely on the transcribed strand of expressed genes, while global genomic repair (GGR) is responsible for the ubiquitous repair of the genome. Indirectly, it has been shown that while TCR functions in quiescent cells GGR does not. To explicitly elucidate this phenomenon, we adapted a quantitative PCR (QPCR) assay to study UV-damage repair via TCR and GGR in quiescent and proliferating cells. We present evidence that repair of untranscribed silent regions of the genome and repair of the non-transcribed strand of active genes proceeds by two discrete mechanisms in quiescent cells; rather than by GGR, which was believed to encompass both. Thus, our findings suggest the existence of an alternate NER pathway in quiescent cells. The proposed subcategories of NER are as follows: (i) TCR, responsible for maintenance of transcribed strands; (ii) GGR, responsible for ubiquitous genome repair; and (iii) non-transcribed strand repair (NTSR), predominantly responsible for the repair of the NTS in arrested cells. In quiescent cells, it is evident that TCR and NTSR function and GGR are arrested. As a consequence, mutation accumulation at temporally silent genes and incomplete or imperfect repair of transcribed genes, in quiescent stem cells, may provide a source of cancer causing mutations.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "d4a589e25b7e41539ef282bbbf96e4a6", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[72, 73], [241, 242], [161, 162]], "char_spans": [[402, 419], [1298, 1315], [883, 900]]}]}], "context_tokens": [["Stem", 0], ["cells", 5], [",", 10], ["one", 12], ["of", 16], ["the", 19], ["progenitors", 23], ["of", 35], ["cancer", 38], [",", 44], ["exist", 46], ["predominately", 52], ["in", 66], ["a", 69], ["quiescent", 71], ["state", 81], [".", 86], ["Thus", 88], [",", 92], ["understanding", 94], ["the", 108], ["mechanisms", 112], ["of", 123], ["DNA", 126], ["repair", 130], ["and", 137], ["mutagenesis", 141], ["in", 153], ["such", 156], ["arrested", 161], ["cells", 170], ["may", 176], ["help", 180], ["unravel", 185], ["the", 193], ["complex", 197], ["process", 205], ["of", 213], ["tumorigenesis", 216], [".", 229], ["Two", 231], ["major", 235], ["nucleotide", 241], ["excision", 252], ["repair", 261], ["(", 268], ["NER", 269], [")", 272], ["pathways", 274], ["are", 283], ["known", 287], ["to", 293], ["remove", 296], ["bulky", 303], ["physical", 309], ["or", 318], ["chemical", 321], ["lesions", 330], ["from", 338], ["DNA", 343], [".", 346], ["Transcription", 348], ["-", 361], ["coupled", 362], ["repair", 370], ["(", 377], ["TCR", 378], [")", 381], ["acts", 383], ["solely", 388], ["on", 395], ["the", 398], ["transcribed", 402], ["strand", 414], ["of", 421], ["expressed", 424], ["genes", 434], [",", 439], ["while", 441], ["global", 447], ["genomic", 454], ["repair", 462], ["(", 469], ["GGR", 470], [")", 473], ["is", 475], ["responsible", 478], ["for", 490], ["the", 494], ["ubiquitous", 498], ["repair", 509], ["of", 516], ["the", 519], ["genome", 523], [".", 529], ["Indirectly", 531], [",", 541], ["it", 543], ["has", 546], ["been", 550], ["shown", 555], ["that", 561], ["while", 566], ["TCR", 572], ["functions", 576], ["in", 586], ["quiescent", 589], ["cells", 599], ["GGR", 605], ["does", 609], ["not", 614], [".", 617], ["To", 619], ["explicitly", 622], ["elucidate", 633], ["this", 643], ["phenomenon", 648], [",", 658], ["we", 660], ["adapted", 663], ["a", 671], ["quantitative", 673], ["PCR", 686], ["(", 690], ["QPCR", 691], [")", 695], ["assay", 697], ["to", 703], ["study", 706], ["UV", 712], ["-", 714], ["damage", 715], ["repair", 722], ["via", 729], ["TCR", 733], ["and", 737], ["GGR", 741], ["in", 745], ["quiescent", 748], ["and", 758], ["proliferating", 762], ["cells", 776], [".", 781], ["We", 783], ["present", 786], ["evidence", 794], ["that", 803], ["repair", 808], ["of", 815], ["untranscribed", 818], ["silent", 832], ["regions", 839], ["of", 847], ["the", 850], ["genome", 854], ["and", 861], ["repair", 865], ["of", 872], ["the", 875], ["non", 879], ["-", 882], ["transcribed", 883], ["strand", 895], ["of", 902], ["active", 905], ["genes", 912], ["proceeds", 918], ["by", 927], ["two", 930], ["discrete", 934], ["mechanisms", 943], ["in", 954], ["quiescent", 957], ["cells", 967], [";", 972], ["rather", 974], ["than", 981], ["by", 986], ["GGR", 989], [",", 992], ["which", 994], ["was", 1000], ["believed", 1004], ["to", 1013], ["encompass", 1016], ["both", 1026], [".", 1030], ["Thus", 1032], [",", 1036], ["our", 1038], ["findings", 1042], ["suggest", 1051], ["the", 1059], ["existence", 1063], ["of", 1073], ["an", 1076], ["alternate", 1079], ["NER", 1089], ["pathway", 1093], ["in", 1101], ["quiescent", 1104], ["cells", 1114], [".", 1119], ["The", 1121], ["proposed", 1125], ["subcategories", 1134], ["of", 1148], ["NER", 1151], ["are", 1155], ["as", 1159], ["follows", 1162], [":", 1169], ["(", 1171], ["i", 1172], [")", 1173], ["TCR", 1175], [",", 1178], ["responsible", 1180], ["for", 1192], ["maintenance", 1196], ["of", 1208], ["transcribed", 1211], ["strands", 1223], [";", 1230], ["(", 1232], ["ii", 1233], [")", 1235], ["GGR", 1237], [",", 1240], ["responsible", 1242], ["for", 1254], ["ubiquitous", 1258], ["genome", 1269], ["repair", 1276], [";", 1282], ["and", 1284], ["(", 1288], ["iii", 1289], [")", 1292], ["non", 1294], ["-", 1297], ["transcribed", 1298], ["strand", 1310], ["repair", 1317], ["(", 1324], ["NTSR", 1325], [")", 1329], [",", 1330], ["predominantly", 1332], ["responsible", 1346], ["for", 1358], ["the", 1362], ["repair", 1366], ["of", 1373], ["the", 1376], ["NTS", 1380], ["in", 1384], ["arrested", 1387], ["cells", 1396], [".", 1401], ["In", 1403], ["quiescent", 1406], ["cells", 1416], [",", 1421], ["it", 1423], ["is", 1426], ["evident", 1429], ["that", 1437], ["TCR", 1442], ["and", 1446], ["NTSR", 1450], ["function", 1455], ["and", 1464], ["GGR", 1468], ["are", 1472], ["arrested", 1476], [".", 1484], ["As", 1486], ["a", 1489], ["consequence", 1491], [",", 1502], ["mutation", 1504], ["accumulation", 1513], ["at", 1526], ["temporally", 1529], ["silent", 1540], ["genes", 1547], ["and", 1553], ["incomplete", 1557], ["or", 1568], ["imperfect", 1571], ["repair", 1581], ["of", 1588], ["transcribed", 1591], ["genes", 1603], [",", 1608], ["in", 1610], ["quiescent", 1613], ["stem", 1623], ["cells", 1628], [",", 1633], ["may", 1635], ["provide", 1639], ["a", 1647], ["source", 1649], ["of", 1656], ["cancer", 1659], ["causing", 1666], ["mutations", 1674], [".", 1683]]}
{"context": "Ehlers-Danlos syndrome is a complex hereditary connective tissue disorder that is characterized by abnormalities of the skin and joints and visceral and neurological manifestations. At present, at least 11 forms are recognized on the basis of their clinical characteristics, methods of transmission, and biochemical defect. The neurologic manifestations include cerebrovascular disease, peripheral neuropathy, plexopathy, periventricular subependymal heterotopias, and epilepsy. Previously, 2 females were reported to be affected with subependimal periventricular heterotopias and Ehlers-Danlos syndrome type 1. The authors report a new case of a 12-year-old girl with similar clinical and neuroradiological features.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "10de1ab61b0a47219444a92bc141d960", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[8, 9]], "char_spans": [[47, 63]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["a", 26], ["complex", 28], ["hereditary", 36], ["connective", 47], ["tissue", 58], ["disorder", 65], ["that", 74], ["is", 79], ["characterized", 82], ["by", 96], ["abnormalities", 99], ["of", 113], ["the", 116], ["skin", 120], ["and", 125], ["joints", 129], ["and", 136], ["visceral", 140], ["and", 149], ["neurological", 153], ["manifestations", 166], [".", 180], ["At", 182], ["present", 185], [",", 192], ["at", 194], ["least", 197], ["11", 203], ["forms", 206], ["are", 212], ["recognized", 216], ["on", 227], ["the", 230], ["basis", 234], ["of", 240], ["their", 243], ["clinical", 249], ["characteristics", 258], [",", 273], ["methods", 275], ["of", 283], ["transmission", 286], [",", 298], ["and", 300], ["biochemical", 304], ["defect", 316], [".", 322], ["The", 324], ["neurologic", 328], ["manifestations", 339], ["include", 354], ["cerebrovascular", 362], ["disease", 378], [",", 385], ["peripheral", 387], ["neuropathy", 398], [",", 408], ["plexopathy", 410], [",", 420], ["periventricular", 422], ["subependymal", 438], ["heterotopias", 451], [",", 463], ["and", 465], ["epilepsy", 469], [".", 477], ["Previously", 479], [",", 489], ["2", 491], ["females", 493], ["were", 501], ["reported", 506], ["to", 515], ["be", 518], ["affected", 521], ["with", 530], ["subependimal", 535], ["periventricular", 548], ["heterotopias", 564], ["and", 577], ["Ehlers", 581], ["-", 587], ["Danlos", 588], ["syndrome", 595], ["type", 604], ["1", 609], [".", 610], ["The", 612], ["authors", 616], ["report", 624], ["a", 631], ["new", 633], ["case", 637], ["of", 642], ["a", 645], ["12-year", 647], ["-", 654], ["old", 655], ["girl", 659], ["with", 664], ["similar", 669], ["clinical", 677], ["and", 686], ["neuroradiological", 690], ["features", 708], [".", 716]]}
{"context": "The organization of chromatin into higher-order structures influences chromosome function and epigenetic gene regulation. Higher-order chromatin has been proposed to be nucleated by the covalent modification of histone tails and the subsequent establishment of chromosomal subdomains by non-histone modifier factors. Here we show that human SUV39H1 and murine Suv39h1--mammalian homologues of Drosophila Su(var)3-9 and of Schizosaccharomyces pombe clr4--encode histone H3-specific methyltransferases that selectively methylate lysine 9 of the amino terminus of histone H3 in vitro. We mapped the catalytic motif to the evolutionarily conserved SET domain, which requires adjacent cysteine-rich regions to confer histone methyltransferase activity. Methylation of lysine 9 interferes with phosphorylation of serine 10, but is also influenced by pre-existing modifications in the amino terminus of H3. In vivo, deregulated SUV39H1 or disrupted Suv39h activity modulate H3 serine 10 phosphorylation in native chromatin and induce aberrant mitotic divisions. Our data reveal a functional interdependence of site-specific H3 tail modifications and suggest a dynamic mechanism for the regulation of higher-order chromatin.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "d2b96659e02a4db4a080036e2a0c4128", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[99, 100]], "char_spans": [[644, 653]]}]}], "context_tokens": [["The", 0], ["organization", 4], ["of", 17], ["chromatin", 20], ["into", 30], ["higher", 35], ["-", 41], ["order", 42], ["structures", 48], ["influences", 59], ["chromosome", 70], ["function", 81], ["and", 90], ["epigenetic", 94], ["gene", 105], ["regulation", 110], [".", 120], ["Higher", 122], ["-", 128], ["order", 129], ["chromatin", 135], ["has", 145], ["been", 149], ["proposed", 154], ["to", 163], ["be", 166], ["nucleated", 169], ["by", 179], ["the", 182], ["covalent", 186], ["modification", 195], ["of", 208], ["histone", 211], ["tails", 219], ["and", 225], ["the", 229], ["subsequent", 233], ["establishment", 244], ["of", 258], ["chromosomal", 261], ["subdomains", 273], ["by", 284], ["non", 287], ["-", 290], ["histone", 291], ["modifier", 299], ["factors", 308], [".", 315], ["Here", 317], ["we", 322], ["show", 325], ["that", 330], ["human", 335], ["SUV39H1", 341], ["and", 349], ["murine", 353], ["Suv39h1", 360], ["-", 367], ["-mammalian", 368], ["homologues", 379], ["of", 390], ["Drosophila", 393], ["Su(var)3", 404], ["-", 412], ["9", 413], ["and", 415], ["of", 419], ["Schizosaccharomyces", 422], ["pombe", 442], ["clr4", 448], ["-", 452], ["-encode", 453], ["histone", 461], ["H3-specific", 469], ["methyltransferases", 481], ["that", 500], ["selectively", 505], ["methylate", 517], ["lysine", 527], ["9", 534], ["of", 536], ["the", 539], ["amino", 543], ["terminus", 549], ["of", 558], ["histone", 561], ["H3", 569], ["in", 572], ["vitro", 575], [".", 580], ["We", 582], ["mapped", 585], ["the", 592], ["catalytic", 596], ["motif", 606], ["to", 612], ["the", 615], ["evolutionarily", 619], ["conserved", 634], ["SET", 644], ["domain", 648], [",", 654], ["which", 656], ["requires", 662], ["adjacent", 671], ["cysteine", 680], ["-", 688], ["rich", 689], ["regions", 694], ["to", 702], ["confer", 705], ["histone", 712], ["methyltransferase", 720], ["activity", 738], [".", 746], ["Methylation", 748], ["of", 760], ["lysine", 763], ["9", 770], ["interferes", 772], ["with", 783], ["phosphorylation", 788], ["of", 804], ["serine", 807], ["10", 814], [",", 816], ["but", 818], ["is", 822], ["also", 825], ["influenced", 830], ["by", 841], ["pre", 844], ["-", 847], ["existing", 848], ["modifications", 857], ["in", 871], ["the", 874], ["amino", 878], ["terminus", 884], ["of", 893], ["H3", 896], [".", 898], ["In", 900], ["vivo", 903], [",", 907], ["deregulated", 909], ["SUV39H1", 921], ["or", 929], ["disrupted", 932], ["Suv39h", 942], ["activity", 949], ["modulate", 958], ["H3", 967], ["serine", 970], ["10", 977], ["phosphorylation", 980], ["in", 996], ["native", 999], ["chromatin", 1006], ["and", 1016], ["induce", 1020], ["aberrant", 1027], ["mitotic", 1036], ["divisions", 1044], [".", 1053], ["Our", 1055], ["data", 1059], ["reveal", 1064], ["a", 1071], ["functional", 1073], ["interdependence", 1084], ["of", 1100], ["site", 1103], ["-", 1107], ["specific", 1108], ["H3", 1117], ["tail", 1120], ["modifications", 1125], ["and", 1139], ["suggest", 1143], ["a", 1151], ["dynamic", 1153], ["mechanism", 1161], ["for", 1171], ["the", 1175], ["regulation", 1179], ["of", 1190], ["higher", 1193], ["-", 1199], ["order", 1200], ["chromatin", 1206], [".", 1215]]}
{"context": "Emotion regulation has been associated with perceived health in rheumatoid arthritis, which is diagnosed three times more often in women than men. Our aim was to examine gender differences in styles of emotion regulation (ambiguity, control, orientation, and expression) and gender-specificity of the associations between emotion regulation and perceived health (psychological well-being, social functioning, physical functioning, and disease activity) in 244 female and 91 male patients with rheumatoid arthritis. Women reported more emotional orientation than men, but did not differ from men with regard to ambiguity, control, and expression. Structural equation modelling showed that relationships between emotion regulation and perceived health were more frequent and stronger for women than men. This held especially for the affective dimension of health, while associations were similar for both women and men with regard to social and physical functioning. Only for women, the association between ambiguity and disease activity was significant, which appeared to be mediated by affective functioning. The observations that women are more emotionally oriented than men and that emotion regulation is more interwoven with psychological health in women than men, support the usefulness of a gender-sensitive approach in research and health care of patients with rheumatoid arthritis.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "33ce31f2b31e434a8646df96cc8b9daa", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[128, 128], [203, 203], [86, 86], [148, 148], [20, 20], [185, 185], [161, 161]], "char_spans": [[786, 790], [1252, 1256], [515, 519], [903, 907], [131, 135], [1131, 1135], [974, 978]]}]}], "context_tokens": [["Emotion", 0], ["regulation", 8], ["has", 19], ["been", 23], ["associated", 28], ["with", 39], ["perceived", 44], ["health", 54], ["in", 61], ["rheumatoid", 64], ["arthritis", 75], [",", 84], ["which", 86], ["is", 92], ["diagnosed", 95], ["three", 105], ["times", 111], ["more", 117], ["often", 122], ["in", 128], ["women", 131], ["than", 137], ["men", 142], [".", 145], ["Our", 147], ["aim", 151], ["was", 155], ["to", 159], ["examine", 162], ["gender", 170], ["differences", 177], ["in", 189], ["styles", 192], ["of", 199], ["emotion", 202], ["regulation", 210], ["(", 221], ["ambiguity", 222], [",", 231], ["control", 233], [",", 240], ["orientation", 242], [",", 253], ["and", 255], ["expression", 259], [")", 269], ["and", 271], ["gender", 275], ["-", 281], ["specificity", 282], ["of", 294], ["the", 297], ["associations", 301], ["between", 314], ["emotion", 322], ["regulation", 330], ["and", 341], ["perceived", 345], ["health", 355], ["(", 362], ["psychological", 363], ["well", 377], ["-", 381], ["being", 382], [",", 387], ["social", 389], ["functioning", 396], [",", 407], ["physical", 409], ["functioning", 418], [",", 429], ["and", 431], ["disease", 435], ["activity", 443], [")", 451], ["in", 453], ["244", 456], ["female", 460], ["and", 467], ["91", 471], ["male", 474], ["patients", 479], ["with", 488], ["rheumatoid", 493], ["arthritis", 504], [".", 513], ["Women", 515], ["reported", 521], ["more", 530], ["emotional", 535], ["orientation", 545], ["than", 557], ["men", 562], [",", 565], ["but", 567], ["did", 571], ["not", 575], ["differ", 579], ["from", 586], ["men", 591], ["with", 595], ["regard", 600], ["to", 607], ["ambiguity", 610], [",", 619], ["control", 621], [",", 628], ["and", 630], ["expression", 634], [".", 644], ["Structural", 646], ["equation", 657], ["modelling", 666], ["showed", 676], ["that", 683], ["relationships", 688], ["between", 702], ["emotion", 710], ["regulation", 718], ["and", 729], ["perceived", 733], ["health", 743], ["were", 750], ["more", 755], ["frequent", 760], ["and", 769], ["stronger", 773], ["for", 782], ["women", 786], ["than", 792], ["men", 797], [".", 800], ["This", 802], ["held", 807], ["especially", 812], ["for", 823], ["the", 827], ["affective", 831], ["dimension", 841], ["of", 851], ["health", 854], [",", 860], ["while", 862], ["associations", 868], ["were", 881], ["similar", 886], ["for", 894], ["both", 898], ["women", 903], ["and", 909], ["men", 913], ["with", 917], ["regard", 922], ["to", 929], ["social", 932], ["and", 939], ["physical", 943], ["functioning", 952], [".", 963], ["Only", 965], ["for", 970], ["women", 974], [",", 979], ["the", 981], ["association", 985], ["between", 997], ["ambiguity", 1005], ["and", 1015], ["disease", 1019], ["activity", 1027], ["was", 1036], ["significant", 1040], [",", 1051], ["which", 1053], ["appeared", 1059], ["to", 1068], ["be", 1071], ["mediated", 1074], ["by", 1083], ["affective", 1086], ["functioning", 1096], [".", 1107], ["The", 1109], ["observations", 1113], ["that", 1126], ["women", 1131], ["are", 1137], ["more", 1141], ["emotionally", 1146], ["oriented", 1158], ["than", 1167], ["men", 1172], ["and", 1176], ["that", 1180], ["emotion", 1185], ["regulation", 1193], ["is", 1204], ["more", 1207], ["interwoven", 1212], ["with", 1223], ["psychological", 1228], ["health", 1242], ["in", 1249], ["women", 1252], ["than", 1258], ["men", 1263], [",", 1266], ["support", 1268], ["the", 1276], ["usefulness", 1280], ["of", 1291], ["a", 1294], ["gender", 1296], ["-", 1302], ["sensitive", 1303], ["approach", 1313], ["in", 1322], ["research", 1325], ["and", 1334], ["health", 1338], ["care", 1345], ["of", 1350], ["patients", 1353], ["with", 1362], ["rheumatoid", 1367], ["arthritis", 1378], [".", 1387]]}
{"context": "The health benefits of leisure-time physical activity are well known, however the effects of engaging in competitive sports on health are uncertain. This literature review examines mortality and longevity of elite athletes and attempts to understand the association between long-term vigorous exercise training and survival rates. Fourteen articles of epidemiological studies were identified and classified by type of sport. Life expectancy, standardised mortality ratio, standardised proportionate mortality ratio, mortality rate, and mortality odds ratio for all causes of death were used to analyse mortality and longevity of elite athletes. It appears that elite endurance (aerobic) athletes and mixed-sports (aerobic and anaerobic) athletes survive longer than the general population, as indicated by lower mortality and higher longevity. Lower cardiovascular disease mortality is likely the primary reason for their better survival rates. On the other hand, there are inconsistent results among studies of power (anaerobic) athletes. When elite athletes engaging in various sports are analysed together, their mortality is lower than that of the general population. In conclusion, long-term vigorous exercise training is associated with increased survival rates of specific groups of athletes.", "qas": [{"question": "What is the life expectancy of professional athletes in respect to the general population?", "answers": ["longer than the general population", "No clear results indicating improved life expectancy in professional athletes"], "qid": "5a537555a5e843839c53a7739cd95f64", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["life", 12], ["expectancy", 17], ["of", 28], ["professional", 31], ["athletes", 44], ["in", 53], ["respect", 56], ["to", 64], ["the", 67], ["general", 71], ["population", 79], ["?", 89]], "detected_answers": [{"text": "longer than the general population", "token_spans": [[122, 126]], "char_spans": [[754, 787]]}]}], "context_tokens": [["The", 0], ["health", 4], ["benefits", 11], ["of", 20], ["leisure", 23], ["-", 30], ["time", 31], ["physical", 36], ["activity", 45], ["are", 54], ["well", 58], ["known", 63], [",", 68], ["however", 70], ["the", 78], ["effects", 82], ["of", 90], ["engaging", 93], ["in", 102], ["competitive", 105], ["sports", 117], ["on", 124], ["health", 127], ["are", 134], ["uncertain", 138], [".", 147], ["This", 149], ["literature", 154], ["review", 165], ["examines", 172], ["mortality", 181], ["and", 191], ["longevity", 195], ["of", 205], ["elite", 208], ["athletes", 214], ["and", 223], ["attempts", 227], ["to", 236], ["understand", 239], ["the", 250], ["association", 254], ["between", 266], ["long", 274], ["-", 278], ["term", 279], ["vigorous", 284], ["exercise", 293], ["training", 302], ["and", 311], ["survival", 315], ["rates", 324], [".", 329], ["Fourteen", 331], ["articles", 340], ["of", 349], ["epidemiological", 352], ["studies", 368], ["were", 376], ["identified", 381], ["and", 392], ["classified", 396], ["by", 407], ["type", 410], ["of", 415], ["sport", 418], [".", 423], ["Life", 425], ["expectancy", 430], [",", 440], ["standardised", 442], ["mortality", 455], ["ratio", 465], [",", 470], ["standardised", 472], ["proportionate", 485], ["mortality", 499], ["ratio", 509], [",", 514], ["mortality", 516], ["rate", 526], [",", 530], ["and", 532], ["mortality", 536], ["odds", 546], ["ratio", 551], ["for", 557], ["all", 561], ["causes", 565], ["of", 572], ["death", 575], ["were", 581], ["used", 586], ["to", 591], ["analyse", 594], ["mortality", 602], ["and", 612], ["longevity", 616], ["of", 626], ["elite", 629], ["athletes", 635], [".", 643], ["It", 645], ["appears", 648], ["that", 656], ["elite", 661], ["endurance", 667], ["(", 677], ["aerobic", 678], [")", 685], ["athletes", 687], ["and", 696], ["mixed", 700], ["-", 705], ["sports", 706], ["(", 713], ["aerobic", 714], ["and", 722], ["anaerobic", 726], [")", 735], ["athletes", 737], ["survive", 746], ["longer", 754], ["than", 761], ["the", 766], ["general", 770], ["population", 778], [",", 788], ["as", 790], ["indicated", 793], ["by", 803], ["lower", 806], ["mortality", 812], ["and", 822], ["higher", 826], ["longevity", 833], [".", 842], ["Lower", 844], ["cardiovascular", 850], ["disease", 865], ["mortality", 873], ["is", 883], ["likely", 886], ["the", 893], ["primary", 897], ["reason", 905], ["for", 912], ["their", 916], ["better", 922], ["survival", 929], ["rates", 938], [".", 943], ["On", 945], ["the", 948], ["other", 952], ["hand", 958], [",", 962], ["there", 964], ["are", 970], ["inconsistent", 974], ["results", 987], ["among", 995], ["studies", 1001], ["of", 1009], ["power", 1012], ["(", 1018], ["anaerobic", 1019], [")", 1028], ["athletes", 1030], [".", 1038], ["When", 1040], ["elite", 1045], ["athletes", 1051], ["engaging", 1060], ["in", 1069], ["various", 1072], ["sports", 1080], ["are", 1087], ["analysed", 1091], ["together", 1100], [",", 1108], ["their", 1110], ["mortality", 1116], ["is", 1126], ["lower", 1129], ["than", 1135], ["that", 1140], ["of", 1145], ["the", 1148], ["general", 1152], ["population", 1160], [".", 1170], ["In", 1172], ["conclusion", 1175], [",", 1185], ["long", 1187], ["-", 1191], ["term", 1192], ["vigorous", 1197], ["exercise", 1206], ["training", 1215], ["is", 1224], ["associated", 1227], ["with", 1238], ["increased", 1243], ["survival", 1253], ["rates", 1262], ["of", 1268], ["specific", 1271], ["groups", 1280], ["of", 1287], ["athletes", 1290], [".", 1298]]}
{"context": "The 2016 Conference on Retroviruses and Opportunistic Infections (CROI) highlighted hot spots in HIV infection. Men who have sex with men (MSM), transgender populations, people who inject drugs, fisherfolk, migrants, adolescents, and older adults are heavily impacted in a number of regions. Stigma contributes to risk behaviors and HIV acquisition across populations. HIV testing is a crucial first step in the HIV care continuum, and several large community-based surveys are underway in Africa to increase HIV testing, linkage to care, and uptake of antiretroviral treatment. Advances in preexposure prophylaxis (PrEP) featured prominently at CROI 2016. Two large efficacy trials of a vaginal ring containing the investigational drug dapivirine demonstrated efficacy and safety in preventing HIV infections in women in Africa. Data on the safety of long-acting injectable PrEP and several investigational PrEP drugs and formulations were also presented. Knowledge and use of PrEP among MSM in the United States appears to be increasing, and high uptake was seen among black MSM when provided as part of a culturally tailored support program. The use of broadly neutralizing antibodies for HIV prevention is a novel and promising approach to be evaluated in efficacy trials.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "b6d97f2cc9864e81ae3ccfefeac8cedd", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[91, 91], [74, 74], [60, 60], [136, 136], [206, 206], [65, 65], [15, 15]], "char_spans": [[509, 511], [412, 414], [333, 335], [795, 797], [1192, 1194], [369, 371], [97, 99]]}]}], "context_tokens": [["The", 0], ["2016", 4], ["Conference", 9], ["on", 20], ["Retroviruses", 23], ["and", 36], ["Opportunistic", 40], ["Infections", 54], ["(", 65], ["CROI", 66], [")", 70], ["highlighted", 72], ["hot", 84], ["spots", 88], ["in", 94], ["HIV", 97], ["infection", 101], [".", 110], ["Men", 112], ["who", 116], ["have", 120], ["sex", 125], ["with", 129], ["men", 134], ["(", 138], ["MSM", 139], [")", 142], [",", 143], ["transgender", 145], ["populations", 157], [",", 168], ["people", 170], ["who", 177], ["inject", 181], ["drugs", 188], [",", 193], ["fisherfolk", 195], [",", 205], ["migrants", 207], [",", 215], ["adolescents", 217], [",", 228], ["and", 230], ["older", 234], ["adults", 240], ["are", 247], ["heavily", 251], ["impacted", 259], ["in", 268], ["a", 271], ["number", 273], ["of", 280], ["regions", 283], [".", 290], ["Stigma", 292], ["contributes", 299], ["to", 311], ["risk", 314], ["behaviors", 319], ["and", 329], ["HIV", 333], ["acquisition", 337], ["across", 349], ["populations", 356], [".", 367], ["HIV", 369], ["testing", 373], ["is", 381], ["a", 384], ["crucial", 386], ["first", 394], ["step", 400], ["in", 405], ["the", 408], ["HIV", 412], ["care", 416], ["continuum", 421], [",", 430], ["and", 432], ["several", 436], ["large", 444], ["community", 450], ["-", 459], ["based", 460], ["surveys", 466], ["are", 474], ["underway", 478], ["in", 487], ["Africa", 490], ["to", 497], ["increase", 500], ["HIV", 509], ["testing", 513], [",", 520], ["linkage", 522], ["to", 530], ["care", 533], [",", 537], ["and", 539], ["uptake", 543], ["of", 550], ["antiretroviral", 553], ["treatment", 568], [".", 577], ["Advances", 579], ["in", 588], ["preexposure", 591], ["prophylaxis", 603], ["(", 615], ["PrEP", 616], [")", 620], ["featured", 622], ["prominently", 631], ["at", 643], ["CROI", 646], ["2016", 651], [".", 655], ["Two", 657], ["large", 661], ["efficacy", 667], ["trials", 676], ["of", 683], ["a", 686], ["vaginal", 688], ["ring", 696], ["containing", 701], ["the", 712], ["investigational", 716], ["drug", 732], ["dapivirine", 737], ["demonstrated", 748], ["efficacy", 761], ["and", 770], ["safety", 774], ["in", 781], ["preventing", 784], ["HIV", 795], ["infections", 799], ["in", 810], ["women", 813], ["in", 819], ["Africa", 822], [".", 828], ["Data", 830], ["on", 835], ["the", 838], ["safety", 842], ["of", 849], ["long", 852], ["-", 856], ["acting", 857], ["injectable", 864], ["PrEP", 875], ["and", 880], ["several", 884], ["investigational", 892], ["PrEP", 908], ["drugs", 913], ["and", 919], ["formulations", 923], ["were", 936], ["also", 941], ["presented", 946], [".", 955], ["Knowledge", 957], ["and", 967], ["use", 971], ["of", 975], ["PrEP", 978], ["among", 983], ["MSM", 989], ["in", 993], ["the", 996], ["United", 1000], ["States", 1007], ["appears", 1014], ["to", 1022], ["be", 1025], ["increasing", 1028], [",", 1038], ["and", 1040], ["high", 1044], ["uptake", 1049], ["was", 1056], ["seen", 1060], ["among", 1065], ["black", 1071], ["MSM", 1077], ["when", 1081], ["provided", 1086], ["as", 1095], ["part", 1098], ["of", 1103], ["a", 1106], ["culturally", 1108], ["tailored", 1119], ["support", 1128], ["program", 1136], [".", 1143], ["The", 1145], ["use", 1149], ["of", 1153], ["broadly", 1156], ["neutralizing", 1164], ["antibodies", 1177], ["for", 1188], ["HIV", 1192], ["prevention", 1196], ["is", 1207], ["a", 1210], ["novel", 1212], ["and", 1218], ["promising", 1222], ["approach", 1232], ["to", 1241], ["be", 1244], ["evaluated", 1247], ["in", 1257], ["efficacy", 1260], ["trials", 1269], [".", 1275]]}
{"context": "Many mutations of the NF1 gene have been reported in patients with neurofibromatosis type 1 (NF1); however, there have been no documented NF1 gene mutations in Japanese NF1 patients. In the present study, we used the polymerase chain reaction (PCR) and DNA sequencing analysis to characterize the NF1 gene in a 53-year-old Japanese patient with NF1 who suffered from neurofibroma, pheochromocytoma, and gastrointestinal stromal tumor (GIST). Direct sequence analyses revealed a single base substitution in the splicing donor site of intron 6 (IVS6 888+1, G --> A) in one NF1 allele, resulting in an altered splice site (ss) in the mutated allele. Splicing at the cryptic 5' ss in the mutated allele generated mRNA with an insertion of 60 nucleotides. In addition, we screened for mutations in exons 9, 11, 13, and 17 of the c-kit gene in GIST and the succinate dehydrogenase subunit D (SDHD) gene in the pheochromocytoma, but we did not detect any somatic mutations. We report here the first case of an NF1 patient with four neoplasms: neurofibroma, pheochromocytoma, astrocytoma and GIST. Our results suggest that the molecular pathogenesis of GISTs in NF1 patients is different from that in non-NF1 patients.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "5976ad62650747a3bc3be03c0e430c7d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[16, 16], [203, 203], [227, 227], [26, 26], [4, 4], [65, 65], [55, 55], [236, 236], [110, 110], [31, 31]], "char_spans": [[93, 95], [1003, 1005], [1154, 1156], [138, 140], [22, 24], [345, 347], [297, 299], [1197, 1199], [571, 573], [169, 171]]}]}], "context_tokens": [["Many", 0], ["mutations", 5], ["of", 15], ["the", 18], ["NF1", 22], ["gene", 26], ["have", 31], ["been", 36], ["reported", 41], ["in", 50], ["patients", 53], ["with", 62], ["neurofibromatosis", 67], ["type", 85], ["1", 90], ["(", 92], ["NF1", 93], [")", 96], [";", 97], ["however", 99], [",", 106], ["there", 108], ["have", 114], ["been", 119], ["no", 124], ["documented", 127], ["NF1", 138], ["gene", 142], ["mutations", 147], ["in", 157], ["Japanese", 160], ["NF1", 169], ["patients", 173], [".", 181], ["In", 183], ["the", 186], ["present", 190], ["study", 198], [",", 203], ["we", 205], ["used", 208], ["the", 213], ["polymerase", 217], ["chain", 228], ["reaction", 234], ["(", 243], ["PCR", 244], [")", 247], ["and", 249], ["DNA", 253], ["sequencing", 257], ["analysis", 268], ["to", 277], ["characterize", 280], ["the", 293], ["NF1", 297], ["gene", 301], ["in", 306], ["a", 309], ["53-year", 311], ["-", 318], ["old", 319], ["Japanese", 323], ["patient", 332], ["with", 340], ["NF1", 345], ["who", 349], ["suffered", 353], ["from", 362], ["neurofibroma", 367], [",", 379], ["pheochromocytoma", 381], [",", 397], ["and", 399], ["gastrointestinal", 403], ["stromal", 420], ["tumor", 428], ["(", 434], ["GIST", 435], [")", 439], [".", 440], ["Direct", 442], ["sequence", 449], ["analyses", 458], ["revealed", 467], ["a", 476], ["single", 478], ["base", 485], ["substitution", 490], ["in", 503], ["the", 506], ["splicing", 510], ["donor", 519], ["site", 525], ["of", 530], ["intron", 533], ["6", 540], ["(", 542], ["IVS6", 543], ["888", 548], ["+", 551], ["1", 552], [",", 553], ["G", 555], ["--", 557], [">", 559], ["A", 561], [")", 562], ["in", 564], ["one", 567], ["NF1", 571], ["allele", 575], [",", 581], ["resulting", 583], ["in", 593], ["an", 596], ["altered", 599], ["splice", 607], ["site", 614], ["(", 619], ["ss", 620], [")", 622], ["in", 624], ["the", 627], ["mutated", 631], ["allele", 639], [".", 645], ["Splicing", 647], ["at", 656], ["the", 659], ["cryptic", 663], ["5", 671], ["'", 672], ["ss", 674], ["in", 677], ["the", 680], ["mutated", 684], ["allele", 692], ["generated", 699], ["mRNA", 709], ["with", 714], ["an", 719], ["insertion", 722], ["of", 732], ["60", 735], ["nucleotides", 738], [".", 749], ["In", 751], ["addition", 754], [",", 762], ["we", 764], ["screened", 767], ["for", 776], ["mutations", 780], ["in", 790], ["exons", 793], ["9", 799], [",", 800], ["11", 802], [",", 804], ["13", 806], [",", 808], ["and", 810], ["17", 814], ["of", 817], ["the", 820], ["c", 824], ["-", 825], ["kit", 826], ["gene", 830], ["in", 835], ["GIST", 838], ["and", 843], ["the", 847], ["succinate", 851], ["dehydrogenase", 861], ["subunit", 875], ["D", 883], ["(", 885], ["SDHD", 886], [")", 890], ["gene", 892], ["in", 897], ["the", 900], ["pheochromocytoma", 904], [",", 920], ["but", 922], ["we", 926], ["did", 929], ["not", 933], ["detect", 937], ["any", 944], ["somatic", 948], ["mutations", 956], [".", 965], ["We", 967], ["report", 970], ["here", 977], ["the", 982], ["first", 986], ["case", 992], ["of", 997], ["an", 1000], ["NF1", 1003], ["patient", 1007], ["with", 1015], ["four", 1020], ["neoplasms", 1025], [":", 1034], ["neurofibroma", 1036], [",", 1048], ["pheochromocytoma", 1050], [",", 1066], ["astrocytoma", 1068], ["and", 1080], ["GIST", 1084], [".", 1088], ["Our", 1090], ["results", 1094], ["suggest", 1102], ["that", 1110], ["the", 1115], ["molecular", 1119], ["pathogenesis", 1129], ["of", 1142], ["GISTs", 1145], ["in", 1151], ["NF1", 1154], ["patients", 1158], ["is", 1167], ["different", 1170], ["from", 1180], ["that", 1185], ["in", 1190], ["non", 1193], ["-", 1196], ["NF1", 1197], ["patients", 1201], [".", 1209]]}
{"context": "Imatinib induces a durable response in most patients with Philadelphia chromosome-positive chronic myeloid leukemia, but it is currently unclear whether imatinib reduces the leukemic stem cell (LSC) burden, which may be an important step toward enabling safe discontinuation of therapy. In this article, we use mathematical models of BCR-ABL levels to make inferences on the dynamics of LSCs. Patients with at least 1 BCR-ABL transcript measurement on imatinib were included (N = 477). Maximum likelihood methods were used to test 3 potential hypotheses of the dynamics of BCR-ABL transcripts on imatinib therapy: (i) monoexponential, in which there is little, if any, decline in BCR-ABL transcripts; (ii) biexponential, in which patients have a rapid initial decrease in BCR-ABL transcripts followed by a more gradual response; and (iii) triexponential, in which patients first exhibit a biphasic decline but then have a third phase when BCR-ABL transcripts increase rapidly. We found that most patients treated with imatinib exhibit a biphasic decrease in BCR-ABL transcript levels, with a rapid decrease during the first few months of treatment, followed by a more gradual decrease that often continues over many years. We show that the only hypothesis consistent with current data on progenitor cell turnover and with the long-term, gradual decrease in the BCR-ABL levels seen in most patients is that these patients exhibit a continual, gradual reduction of the LSCs. This observation may explain the ability to discontinue imatinib therapy without relapse in some cases.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "675a5cb5c500436ea513172bdfcae39c", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[198, 200], [254, 256], [74, 76], [56, 58], [178, 180], [103, 105], [146, 148], [127, 129]], "char_spans": [[1058, 1064], [1361, 1367], [418, 424], [334, 340], [939, 945], [573, 579], [772, 778], [680, 686]]}]}], "context_tokens": [["Imatinib", 0], ["induces", 9], ["a", 17], ["durable", 19], ["response", 27], ["in", 36], ["most", 39], ["patients", 44], ["with", 53], ["Philadelphia", 58], ["chromosome", 71], ["-", 81], ["positive", 82], ["chronic", 91], ["myeloid", 99], ["leukemia", 107], [",", 115], ["but", 117], ["it", 121], ["is", 124], ["currently", 127], ["unclear", 137], ["whether", 145], ["imatinib", 153], ["reduces", 162], ["the", 170], ["leukemic", 174], ["stem", 183], ["cell", 188], ["(", 193], ["LSC", 194], [")", 197], ["burden", 199], [",", 205], ["which", 207], ["may", 213], ["be", 217], ["an", 220], ["important", 223], ["step", 233], ["toward", 238], ["enabling", 245], ["safe", 254], ["discontinuation", 259], ["of", 275], ["therapy", 278], [".", 285], ["In", 287], ["this", 290], ["article", 295], [",", 302], ["we", 304], ["use", 307], ["mathematical", 311], ["models", 324], ["of", 331], ["BCR", 334], ["-", 337], ["ABL", 338], ["levels", 342], ["to", 349], ["make", 352], ["inferences", 357], ["on", 368], ["the", 371], ["dynamics", 375], ["of", 384], ["LSCs", 387], [".", 391], ["Patients", 393], ["with", 402], ["at", 407], ["least", 410], ["1", 416], ["BCR", 418], ["-", 421], ["ABL", 422], ["transcript", 426], ["measurement", 437], ["on", 449], ["imatinib", 452], ["were", 461], ["included", 466], ["(", 475], ["N", 476], ["=", 478], ["477", 480], [")", 483], [".", 484], ["Maximum", 486], ["likelihood", 494], ["methods", 505], ["were", 513], ["used", 518], ["to", 523], ["test", 526], ["3", 531], ["potential", 533], ["hypotheses", 543], ["of", 554], ["the", 557], ["dynamics", 561], ["of", 570], ["BCR", 573], ["-", 576], ["ABL", 577], ["transcripts", 581], ["on", 593], ["imatinib", 596], ["therapy", 605], [":", 612], ["(", 614], ["i", 615], [")", 616], ["monoexponential", 618], [",", 633], ["in", 635], ["which", 638], ["there", 644], ["is", 650], ["little", 653], [",", 659], ["if", 661], ["any", 664], [",", 667], ["decline", 669], ["in", 677], ["BCR", 680], ["-", 683], ["ABL", 684], ["transcripts", 688], [";", 699], ["(", 701], ["ii", 702], [")", 704], ["biexponential", 706], [",", 719], ["in", 721], ["which", 724], ["patients", 730], ["have", 739], ["a", 744], ["rapid", 746], ["initial", 752], ["decrease", 760], ["in", 769], ["BCR", 772], ["-", 775], ["ABL", 776], ["transcripts", 780], ["followed", 792], ["by", 801], ["a", 804], ["more", 806], ["gradual", 811], ["response", 819], [";", 827], ["and", 829], ["(", 833], ["iii", 834], [")", 837], ["triexponential", 839], [",", 853], ["in", 855], ["which", 858], ["patients", 864], ["first", 873], ["exhibit", 879], ["a", 887], ["biphasic", 889], ["decline", 898], ["but", 906], ["then", 910], ["have", 915], ["a", 920], ["third", 922], ["phase", 928], ["when", 934], ["BCR", 939], ["-", 942], ["ABL", 943], ["transcripts", 947], ["increase", 959], ["rapidly", 968], [".", 975], ["We", 977], ["found", 980], ["that", 986], ["most", 991], ["patients", 996], ["treated", 1005], ["with", 1013], ["imatinib", 1018], ["exhibit", 1027], ["a", 1035], ["biphasic", 1037], ["decrease", 1046], ["in", 1055], ["BCR", 1058], ["-", 1061], ["ABL", 1062], ["transcript", 1066], ["levels", 1077], [",", 1083], ["with", 1085], ["a", 1090], ["rapid", 1092], ["decrease", 1098], ["during", 1107], ["the", 1114], ["first", 1118], ["few", 1124], ["months", 1128], ["of", 1135], ["treatment", 1138], [",", 1147], ["followed", 1149], ["by", 1158], ["a", 1161], ["more", 1163], ["gradual", 1168], ["decrease", 1176], ["that", 1185], ["often", 1190], ["continues", 1196], ["over", 1206], ["many", 1211], ["years", 1216], [".", 1221], ["We", 1223], ["show", 1226], ["that", 1231], ["the", 1236], ["only", 1240], ["hypothesis", 1245], ["consistent", 1256], ["with", 1267], ["current", 1272], ["data", 1280], ["on", 1285], ["progenitor", 1288], ["cell", 1299], ["turnover", 1304], ["and", 1313], ["with", 1317], ["the", 1322], ["long", 1326], ["-", 1330], ["term", 1331], [",", 1335], ["gradual", 1337], ["decrease", 1345], ["in", 1354], ["the", 1357], ["BCR", 1361], ["-", 1364], ["ABL", 1365], ["levels", 1369], ["seen", 1376], ["in", 1381], ["most", 1384], ["patients", 1389], ["is", 1398], ["that", 1401], ["these", 1406], ["patients", 1412], ["exhibit", 1421], ["a", 1429], ["continual", 1431], [",", 1440], ["gradual", 1442], ["reduction", 1450], ["of", 1460], ["the", 1463], ["LSCs", 1467], [".", 1471], ["This", 1473], ["observation", 1478], ["may", 1490], ["explain", 1494], ["the", 1502], ["ability", 1506], ["to", 1514], ["discontinue", 1517], ["imatinib", 1529], ["therapy", 1538], ["without", 1546], ["relapse", 1554], ["in", 1562], ["some", 1565], ["cases", 1570], [".", 1575]]}
{"context": "The debate continues with a limited number of publications describing outcomes in patients with vestibular schwannoma (VS) treated with planned subtotal resection (STR) plus stereotactic radiosurgery (SRS). Here we present our experience. This is a retrospective review of 22 patients with VS Koos grade III and IV who were treated with STR followed by SRS. Tumor volumes, facial nerve function, hearing preservation, and the presence of trigeminal neuropathy were noted. Spearman's rank test was used to correlate facial nerve grade with postoperative tumor residual tumor volume. Tumor control was achieved in all patients with a mean follow-up of 28 months. No patient required other treatment beyond the original surgery and adjuvant SRS during this period. After a mean postoperative period of 28 months, 19/22 patients had excellent (House-Brackmann I or II) facial nerve function grading. Improved facial nerve function was positively correlated with larger residual tumor volume (rs = 0.63). Kaplan-Meier curve showed around 80% probability for regaining facial nerve function after initial deterioration. Four patients reported postoperative facial numbness at the side of surgery, with 3 cases showing improvement within a month. Temporary postoperative caudal cranial nerve dysfunction was observed in 2 patients. Hybrid strategy of STR and adjuvant SRS provides patients with large VS excellent tumor control and a good clinical outcome.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "95bb8596ef944c13a5524065ba54cbb9", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[14, 15]], "char_spans": [[96, 116]]}]}], "context_tokens": [["The", 0], ["debate", 4], ["continues", 11], ["with", 21], ["a", 26], ["limited", 28], ["number", 36], ["of", 43], ["publications", 46], ["describing", 59], ["outcomes", 70], ["in", 79], ["patients", 82], ["with", 91], ["vestibular", 96], ["schwannoma", 107], ["(", 118], ["VS", 119], [")", 121], ["treated", 123], ["with", 131], ["planned", 136], ["subtotal", 144], ["resection", 153], ["(", 163], ["STR", 164], [")", 167], ["plus", 169], ["stereotactic", 174], ["radiosurgery", 187], ["(", 200], ["SRS", 201], [")", 204], [".", 205], ["Here", 207], ["we", 212], ["present", 215], ["our", 223], ["experience", 227], [".", 237], ["This", 239], ["is", 244], ["a", 247], ["retrospective", 249], ["review", 263], ["of", 270], ["22", 273], ["patients", 276], ["with", 285], ["VS", 290], ["Koos", 293], ["grade", 298], ["III", 304], ["and", 308], ["IV", 312], ["who", 315], ["were", 319], ["treated", 324], ["with", 332], ["STR", 337], ["followed", 341], ["by", 350], ["SRS", 353], [".", 356], ["Tumor", 358], ["volumes", 364], [",", 371], ["facial", 373], ["nerve", 380], ["function", 386], [",", 394], ["hearing", 396], ["preservation", 404], [",", 416], ["and", 418], ["the", 422], ["presence", 426], ["of", 435], ["trigeminal", 438], ["neuropathy", 449], ["were", 460], ["noted", 465], [".", 470], ["Spearman", 472], ["'s", 480], ["rank", 483], ["test", 488], ["was", 493], ["used", 497], ["to", 502], ["correlate", 505], ["facial", 515], ["nerve", 522], ["grade", 528], ["with", 534], ["postoperative", 539], ["tumor", 553], ["residual", 559], ["tumor", 568], ["volume", 574], [".", 580], ["Tumor", 582], ["control", 588], ["was", 596], ["achieved", 600], ["in", 609], ["all", 612], ["patients", 616], ["with", 625], ["a", 630], ["mean", 632], ["follow", 637], ["-", 643], ["up", 644], ["of", 647], ["28", 650], ["months", 653], [".", 659], ["No", 661], ["patient", 664], ["required", 672], ["other", 681], ["treatment", 687], ["beyond", 697], ["the", 704], ["original", 708], ["surgery", 717], ["and", 725], ["adjuvant", 729], ["SRS", 738], ["during", 742], ["this", 749], ["period", 754], [".", 760], ["After", 762], ["a", 768], ["mean", 770], ["postoperative", 775], ["period", 789], ["of", 796], ["28", 799], ["months", 802], [",", 808], ["19/22", 810], ["patients", 816], ["had", 825], ["excellent", 829], ["(", 839], ["House", 840], ["-", 845], ["Brackmann", 846], ["I", 856], ["or", 858], ["II", 861], [")", 863], ["facial", 865], ["nerve", 872], ["function", 878], ["grading", 887], [".", 894], ["Improved", 896], ["facial", 905], ["nerve", 912], ["function", 918], ["was", 927], ["positively", 931], ["correlated", 942], ["with", 953], ["larger", 958], ["residual", 965], ["tumor", 974], ["volume", 980], ["(", 987], ["rs", 988], ["=", 991], ["0.63", 993], [")", 997], [".", 998], ["Kaplan", 1000], ["-", 1006], ["Meier", 1007], ["curve", 1013], ["showed", 1019], ["around", 1026], ["80", 1033], ["%", 1035], ["probability", 1037], ["for", 1049], ["regaining", 1053], ["facial", 1063], ["nerve", 1070], ["function", 1076], ["after", 1085], ["initial", 1091], ["deterioration", 1099], [".", 1112], ["Four", 1114], ["patients", 1119], ["reported", 1128], ["postoperative", 1137], ["facial", 1151], ["numbness", 1158], ["at", 1167], ["the", 1170], ["side", 1174], ["of", 1179], ["surgery", 1182], [",", 1189], ["with", 1191], ["3", 1196], ["cases", 1198], ["showing", 1204], ["improvement", 1212], ["within", 1224], ["a", 1231], ["month", 1233], [".", 1238], ["Temporary", 1240], ["postoperative", 1250], ["caudal", 1264], ["cranial", 1271], ["nerve", 1279], ["dysfunction", 1285], ["was", 1297], ["observed", 1301], ["in", 1310], ["2", 1313], ["patients", 1315], [".", 1323], ["Hybrid", 1325], ["strategy", 1332], ["of", 1341], ["STR", 1344], ["and", 1348], ["adjuvant", 1352], ["SRS", 1361], ["provides", 1365], ["patients", 1374], ["with", 1383], ["large", 1388], ["VS", 1394], ["excellent", 1397], ["tumor", 1407], ["control", 1413], ["and", 1421], ["a", 1425], ["good", 1427], ["clinical", 1432], ["outcome", 1441], [".", 1448]]}
{"context": "To demonstrate the importance of preventive measures when a case of tuberculosis is detected, identify the causes that favored a tuberculosis outbreak in a school and determine the efficiency of obtaining induced sputum samples. Descriptive, study. The Santa Maria de la Providencia school, located in the municipality of Alcala de Henares in Spain. On April 11, 2005, a case of bacilliform pulmonary tuberculosis was notified in a teacher. Study of contacts in the collective was performed as a programmed intervention. Mantoux skin test and, if positive, chest radiograph were performed in contacts. Treatment of latent or active tuberculosis was recommended according to the result. School exposures were identified and underwent the Mantoux skin test (142 students in years 1, 2, 3, and 4 of compulsory secondary education and 22 teachers). The Mantoux test was positive in 68 students (48 %) and seven teachers (32 %). In seven students with results compatible with active tuberculosis disease, sputum induction was performed and treatment was started. A further two students, identified as contacts, were studied in another center and also started treatment for active tuberculosis disease. Due to the high risk of contagion, study of contacts was extended to the remaining students in compulsory secondary education. In this second phase, 134 students received the Mantoux skin test and seven were Mantoux positive (5.2 %). In all these students, active tuberculosis disease was ruled out. Latent tuberculosis treatment was recommended in all Mantoux-positive contacts.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "432d404973ba41318c6fe93752543d01", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[11, 11], [21, 21], [70, 70], [210, 210], [263, 263], [270, 270], [178, 178], [110, 110]], "char_spans": [[68, 79], [129, 140], [401, 412], [1175, 1186], [1461, 1472], [1504, 1515], [978, 989], [632, 643]]}]}], "context_tokens": [["To", 0], ["demonstrate", 3], ["the", 15], ["importance", 19], ["of", 30], ["preventive", 33], ["measures", 44], ["when", 53], ["a", 58], ["case", 60], ["of", 65], ["tuberculosis", 68], ["is", 81], ["detected", 84], [",", 92], ["identify", 94], ["the", 103], ["causes", 107], ["that", 114], ["favored", 119], ["a", 127], ["tuberculosis", 129], ["outbreak", 142], ["in", 151], ["a", 154], ["school", 156], ["and", 163], ["determine", 167], ["the", 177], ["efficiency", 181], ["of", 192], ["obtaining", 195], ["induced", 205], ["sputum", 213], ["samples", 220], [".", 227], ["Descriptive", 229], [",", 240], ["study", 242], [".", 247], ["The", 249], ["Santa", 253], ["Maria", 259], ["de", 265], ["la", 268], ["Providencia", 271], ["school", 283], [",", 289], ["located", 291], ["in", 299], ["the", 302], ["municipality", 306], ["of", 319], ["Alcala", 322], ["de", 329], ["Henares", 332], ["in", 340], ["Spain", 343], [".", 348], ["On", 350], ["April", 353], ["11", 359], [",", 361], ["2005", 363], [",", 367], ["a", 369], ["case", 371], ["of", 376], ["bacilliform", 379], ["pulmonary", 391], ["tuberculosis", 401], ["was", 414], ["notified", 418], ["in", 427], ["a", 430], ["teacher", 432], [".", 439], ["Study", 441], ["of", 447], ["contacts", 450], ["in", 459], ["the", 462], ["collective", 466], ["was", 477], ["performed", 481], ["as", 491], ["a", 494], ["programmed", 496], ["intervention", 507], [".", 519], ["Mantoux", 521], ["skin", 529], ["test", 534], ["and", 539], [",", 542], ["if", 544], ["positive", 547], [",", 555], ["chest", 557], ["radiograph", 563], ["were", 574], ["performed", 579], ["in", 589], ["contacts", 592], [".", 600], ["Treatment", 602], ["of", 612], ["latent", 615], ["or", 622], ["active", 625], ["tuberculosis", 632], ["was", 645], ["recommended", 649], ["according", 661], ["to", 671], ["the", 674], ["result", 678], [".", 684], ["School", 686], ["exposures", 693], ["were", 703], ["identified", 708], ["and", 719], ["underwent", 723], ["the", 733], ["Mantoux", 737], ["skin", 745], ["test", 750], ["(", 755], ["142", 756], ["students", 760], ["in", 769], ["years", 772], ["1", 778], [",", 779], ["2", 781], [",", 782], ["3", 784], [",", 785], ["and", 787], ["4", 791], ["of", 793], ["compulsory", 796], ["secondary", 807], ["education", 817], ["and", 827], ["22", 831], ["teachers", 834], [")", 842], [".", 843], ["The", 845], ["Mantoux", 849], ["test", 857], ["was", 862], ["positive", 866], ["in", 875], ["68", 878], ["students", 881], ["(", 890], ["48", 891], ["%", 894], [")", 895], ["and", 897], ["seven", 901], ["teachers", 907], ["(", 916], ["32", 917], ["%", 920], [")", 921], [".", 922], ["In", 924], ["seven", 927], ["students", 933], ["with", 942], ["results", 947], ["compatible", 955], ["with", 966], ["active", 971], ["tuberculosis", 978], ["disease", 991], [",", 998], ["sputum", 1000], ["induction", 1007], ["was", 1017], ["performed", 1021], ["and", 1031], ["treatment", 1035], ["was", 1045], ["started", 1049], [".", 1056], ["A", 1058], ["further", 1060], ["two", 1068], ["students", 1072], [",", 1080], ["identified", 1082], ["as", 1093], ["contacts", 1096], [",", 1104], ["were", 1106], ["studied", 1111], ["in", 1119], ["another", 1122], ["center", 1130], ["and", 1137], ["also", 1141], ["started", 1146], ["treatment", 1154], ["for", 1164], ["active", 1168], ["tuberculosis", 1175], ["disease", 1188], [".", 1195], ["Due", 1197], ["to", 1201], ["the", 1204], ["high", 1208], ["risk", 1213], ["of", 1218], ["contagion", 1221], [",", 1230], ["study", 1232], ["of", 1238], ["contacts", 1241], ["was", 1250], ["extended", 1254], ["to", 1263], ["the", 1266], ["remaining", 1270], ["students", 1280], ["in", 1289], ["compulsory", 1292], ["secondary", 1303], ["education", 1313], [".", 1322], ["In", 1324], ["this", 1327], ["second", 1332], ["phase", 1339], [",", 1344], ["134", 1346], ["students", 1350], ["received", 1359], ["the", 1368], ["Mantoux", 1372], ["skin", 1380], ["test", 1385], ["and", 1390], ["seven", 1394], ["were", 1400], ["Mantoux", 1405], ["positive", 1413], ["(", 1422], ["5.2", 1423], ["%", 1427], [")", 1428], [".", 1429], ["In", 1431], ["all", 1434], ["these", 1438], ["students", 1444], [",", 1452], ["active", 1454], ["tuberculosis", 1461], ["disease", 1474], ["was", 1482], ["ruled", 1486], ["out", 1492], [".", 1495], ["Latent", 1497], ["tuberculosis", 1504], ["treatment", 1517], ["was", 1527], ["recommended", 1531], ["in", 1543], ["all", 1546], ["Mantoux", 1550], ["-", 1557], ["positive", 1558], ["contacts", 1567], [".", 1575]]}
{"context": "Restless legs syndrome (RLS), recently renamed Willis-Ekbom disease (WED), is a common movement disorder. It is characterised by the need to move mainly the legs due to uncomfortable, sometimes painful sensations in the legs, which have a diurnal variation and a release with movement. Management is complex. First, centres should establish the severity of RLS using a simple 10-item RLS severity rating scale (IRLS). They should also exclude secondary causes, in particular ensuring normal iron levels. Mild cases can be managed by lifestyle changes, but patients with a IRLS score above 15 usually require pharmacological treatment. Dopaminergic therapies remain the mainstay of medical therapies, with recent evidence suggesting opioids may be particularly effective. This article focuses on the different treatment strategies in RLS, their associated complications and ways to manage them.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "9cce10bf0b6546509cf2de1aba61138e", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["recently", 30], ["renamed", 39], ["Willis", 47], ["-", 53], ["Ekbom", 54], ["disease", 60], ["(", 68], ["WED", 69], [")", 72], [",", 73], ["is", 75], ["a", 78], ["common", 80], ["movement", 87], ["disorder", 96], [".", 104], ["It", 106], ["is", 109], ["characterised", 112], ["by", 126], ["the", 129], ["need", 133], ["to", 138], ["move", 141], ["mainly", 146], ["the", 153], ["legs", 157], ["due", 162], ["to", 166], ["uncomfortable", 169], [",", 182], ["sometimes", 184], ["painful", 194], ["sensations", 202], ["in", 213], ["the", 216], ["legs", 220], [",", 224], ["which", 226], ["have", 232], ["a", 237], ["diurnal", 239], ["variation", 247], ["and", 257], ["a", 261], ["release", 263], ["with", 271], ["movement", 276], [".", 284], ["Management", 286], ["is", 297], ["complex", 300], [".", 307], ["First", 309], [",", 314], ["centres", 316], ["should", 324], ["establish", 331], ["the", 341], ["severity", 345], ["of", 354], ["RLS", 357], ["using", 361], ["a", 367], ["simple", 369], ["10-item", 376], ["RLS", 384], ["severity", 388], ["rating", 397], ["scale", 404], ["(", 410], ["IRLS", 411], [")", 415], [".", 416], ["They", 418], ["should", 423], ["also", 430], ["exclude", 435], ["secondary", 443], ["causes", 453], [",", 459], ["in", 461], ["particular", 464], ["ensuring", 475], ["normal", 484], ["iron", 491], ["levels", 496], [".", 502], ["Mild", 504], ["cases", 509], ["can", 515], ["be", 519], ["managed", 522], ["by", 530], ["lifestyle", 533], ["changes", 543], [",", 550], ["but", 552], ["patients", 556], ["with", 565], ["a", 570], ["IRLS", 572], ["score", 577], ["above", 583], ["15", 589], ["usually", 592], ["require", 600], ["pharmacological", 608], ["treatment", 624], [".", 633], ["Dopaminergic", 635], ["therapies", 648], ["remain", 658], ["the", 665], ["mainstay", 669], ["of", 678], ["medical", 681], ["therapies", 689], [",", 698], ["with", 700], ["recent", 705], ["evidence", 712], ["suggesting", 721], ["opioids", 732], ["may", 740], ["be", 744], ["particularly", 747], ["effective", 760], [".", 769], ["This", 771], ["article", 776], ["focuses", 784], ["on", 792], ["the", 795], ["different", 799], ["treatment", 809], ["strategies", 819], ["in", 830], ["RLS", 833], [",", 836], ["their", 838], ["associated", 844], ["complications", 855], ["and", 869], ["ways", 873], ["to", 878], ["manage", 881], ["them", 888], [".", 892]]}
{"context": "Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium. But there is no consensus as to what constitutes an alpha-proteobacterial gene. Is it a gene found in all or several alpha-proteobacteria, or in only one? Here, we examine the proportion of alpha-proteobacterial genes in alpha-proteobacterial genomes by means of sequence comparisons. We find that each alpha-proteobacterium harbours a particular collection of genes and that, depending upon the lineage examined, between 97 and 33% are alpha-proteobacterial by the nearest-neighbour criterion. Our findings bear upon attempts to reconstruct the mitochondrial ancestor and upon inferences concerning the collection of genes that the mitochondrial ancestor possessed at the time that it became an endosymbiont.", "qas": [{"question": "Which species of bacteria did the mitochondria originate from?", "answers": ["Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium."], "qid": "1bcd341d9896445e8554027ad01ed066", "question_tokens": [["Which", 0], ["species", 6], ["of", 14], ["bacteria", 17], ["did", 26], ["the", 30], ["mitochondria", 34], ["originate", 47], ["from", 57], ["?", 61]], "detected_answers": [{"text": "Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium.", "token_spans": [[0, 11]], "char_spans": [[0, 78]]}]}], "context_tokens": [["Biologists", 0], ["agree", 11], ["that", 17], ["the", 22], ["ancestor", 26], ["of", 35], ["mitochondria", 38], ["was", 51], ["an", 55], ["alpha", 58], ["-", 63], ["proteobacterium", 64], [".", 79], ["But", 81], ["there", 85], ["is", 91], ["no", 94], ["consensus", 97], ["as", 107], ["to", 110], ["what", 113], ["constitutes", 118], ["an", 130], ["alpha", 133], ["-", 138], ["proteobacterial", 139], ["gene", 155], [".", 159], ["Is", 161], ["it", 164], ["a", 167], ["gene", 169], ["found", 174], ["in", 180], ["all", 183], ["or", 187], ["several", 190], ["alpha", 198], ["-", 203], ["proteobacteria", 204], [",", 218], ["or", 220], ["in", 223], ["only", 226], ["one", 231], ["?", 234], ["Here", 236], [",", 240], ["we", 242], ["examine", 245], ["the", 253], ["proportion", 257], ["of", 268], ["alpha", 271], ["-", 276], ["proteobacterial", 277], ["genes", 293], ["in", 299], ["alpha", 302], ["-", 307], ["proteobacterial", 308], ["genomes", 324], ["by", 332], ["means", 335], ["of", 341], ["sequence", 344], ["comparisons", 353], [".", 364], ["We", 366], ["find", 369], ["that", 374], ["each", 379], ["alpha", 384], ["-", 389], ["proteobacterium", 390], ["harbours", 406], ["a", 415], ["particular", 417], ["collection", 428], ["of", 439], ["genes", 442], ["and", 448], ["that", 452], [",", 456], ["depending", 458], ["upon", 468], ["the", 473], ["lineage", 477], ["examined", 485], [",", 493], ["between", 495], ["97", 503], ["and", 506], ["33", 510], ["%", 512], ["are", 514], ["alpha", 518], ["-", 523], ["proteobacterial", 524], ["by", 540], ["the", 543], ["nearest", 547], ["-", 554], ["neighbour", 555], ["criterion", 565], [".", 574], ["Our", 576], ["findings", 580], ["bear", 589], ["upon", 594], ["attempts", 599], ["to", 608], ["reconstruct", 611], ["the", 623], ["mitochondrial", 627], ["ancestor", 641], ["and", 650], ["upon", 654], ["inferences", 659], ["concerning", 670], ["the", 681], ["collection", 685], ["of", 696], ["genes", 699], ["that", 705], ["the", 710], ["mitochondrial", 714], ["ancestor", 728], ["possessed", 737], ["at", 747], ["the", 750], ["time", 754], ["that", 759], ["it", 764], ["became", 767], ["an", 774], ["endosymbiont", 777], [".", 789]]}
{"context": "A 54-y-old man ingested 2 g of bulk laboratory diazepam and was treated with activated charcoal, enhanced diuresis and flumazenil infusion. The treatment resulted in awakening, but the patient had drowsiness, dysarthria, diplopia, and dizziness for 9 d. Blood levels of diazepam and its main metabolite, nordiazepam, were obtained for 1 mo. The half-lives in this benzodiazepine overdose were longer than those seen with therapeutic doses. Benzodiazepines should not be readministrated when patients awake after suicide attempts.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "f11fbd28f9c1426ebef6f55f607da505", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[22, 22]], "char_spans": [[119, 128]]}]}], "context_tokens": [["A", 0], ["54-y", 2], ["-", 6], ["old", 7], ["man", 11], ["ingested", 15], ["2", 24], ["g", 26], ["of", 28], ["bulk", 31], ["laboratory", 36], ["diazepam", 47], ["and", 56], ["was", 60], ["treated", 64], ["with", 72], ["activated", 77], ["charcoal", 87], [",", 95], ["enhanced", 97], ["diuresis", 106], ["and", 115], ["flumazenil", 119], ["infusion", 130], [".", 138], ["The", 140], ["treatment", 144], ["resulted", 154], ["in", 163], ["awakening", 166], [",", 175], ["but", 177], ["the", 181], ["patient", 185], ["had", 193], ["drowsiness", 197], [",", 207], ["dysarthria", 209], [",", 219], ["diplopia", 221], [",", 229], ["and", 231], ["dizziness", 235], ["for", 245], ["9", 249], ["d.", 251], ["Blood", 254], ["levels", 260], ["of", 267], ["diazepam", 270], ["and", 279], ["its", 283], ["main", 287], ["metabolite", 292], [",", 302], ["nordiazepam", 304], [",", 315], ["were", 317], ["obtained", 322], ["for", 331], ["1", 335], ["mo", 337], [".", 339], ["The", 341], ["half", 345], ["-", 349], ["lives", 350], ["in", 356], ["this", 359], ["benzodiazepine", 364], ["overdose", 379], ["were", 388], ["longer", 393], ["than", 400], ["those", 405], ["seen", 411], ["with", 416], ["therapeutic", 421], ["doses", 433], [".", 438], ["Benzodiazepines", 440], ["should", 456], ["not", 463], ["be", 467], ["readministrated", 470], ["when", 486], ["patients", 491], ["awake", 500], ["after", 506], ["suicide", 512], ["attempts", 520], [".", 528]]}
{"context": "Chaperone-mediated autophagy (CMA) is a selective autophagy-lysosome protein degradation pathway. The role of CMA in normal neuronal functions and in neural disease pathogenesis remains unclear, in part because there is no available method to monitor CMA activity at the single-cell level. We sought to establish a single-cell monitoring method by visualizing translocation of CMA substrates from the cytosol to lysosomes using the HaloTag (HT) system. GAPDH, a CMA substrate, was fused to HT (GAPDH-HT); this protein accumulated in the lysosomes of HeLa cells and cultured cerebellar Purkinje cells (PCs) after labeling with fluorescent dye-conjugated HT ligand. Lysosomal accumulation was enhanced by treatments that activate CMA and prevented by siRNA-mediated knockdown of LAMP2A, a lysosomal receptor for CMA, and by treatments that inactivate CMA. These results suggest that lysosomal accumulation of GAPDH-HT reflects CMA activity. Using this method, we revealed that mutant \u03b3PKC, which causes spinocerebellar ataxia type 14, decreased CMA activity in cultured PCs. In the present study, we established a novel fluorescent-based method to evaluate CMA activity in a single neuron. This novel method should be useful and valuable for evaluating the role of CMA in various neuronal functions and neural disease pathogenesis.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "86bd299403624adfa79bf2ac1de79528", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[141, 141]], "char_spans": [[777, 782]]}]}], "context_tokens": [["Chaperone", 0], ["-", 9], ["mediated", 10], ["autophagy", 19], ["(", 29], ["CMA", 30], [")", 33], ["is", 35], ["a", 38], ["selective", 40], ["autophagy", 50], ["-", 59], ["lysosome", 60], ["protein", 69], ["degradation", 77], ["pathway", 89], [".", 96], ["The", 98], ["role", 102], ["of", 107], ["CMA", 110], ["in", 114], ["normal", 117], ["neuronal", 124], ["functions", 133], ["and", 143], ["in", 147], ["neural", 150], ["disease", 157], ["pathogenesis", 165], ["remains", 178], ["unclear", 186], [",", 193], ["in", 195], ["part", 198], ["because", 203], ["there", 211], ["is", 217], ["no", 220], ["available", 223], ["method", 233], ["to", 240], ["monitor", 243], ["CMA", 251], ["activity", 255], ["at", 264], ["the", 267], ["single", 271], ["-", 277], ["cell", 278], ["level", 283], [".", 288], ["We", 290], ["sought", 293], ["to", 300], ["establish", 303], ["a", 313], ["single", 315], ["-", 321], ["cell", 322], ["monitoring", 327], ["method", 338], ["by", 345], ["visualizing", 348], ["translocation", 360], ["of", 374], ["CMA", 377], ["substrates", 381], ["from", 392], ["the", 397], ["cytosol", 401], ["to", 409], ["lysosomes", 412], ["using", 422], ["the", 428], ["HaloTag", 432], ["(", 440], ["HT", 441], [")", 443], ["system", 445], [".", 451], ["GAPDH", 453], [",", 458], ["a", 460], ["CMA", 462], ["substrate", 466], [",", 475], ["was", 477], ["fused", 481], ["to", 487], ["HT", 490], ["(", 493], ["GAPDH", 494], ["-", 499], ["HT", 500], [")", 502], [";", 503], ["this", 505], ["protein", 510], ["accumulated", 518], ["in", 530], ["the", 533], ["lysosomes", 537], ["of", 547], ["HeLa", 550], ["cells", 555], ["and", 561], ["cultured", 565], ["cerebellar", 574], ["Purkinje", 585], ["cells", 594], ["(", 600], ["PCs", 601], [")", 604], ["after", 606], ["labeling", 612], ["with", 621], ["fluorescent", 626], ["dye", 638], ["-", 641], ["conjugated", 642], ["HT", 653], ["ligand", 656], [".", 662], ["Lysosomal", 664], ["accumulation", 674], ["was", 687], ["enhanced", 691], ["by", 700], ["treatments", 703], ["that", 714], ["activate", 719], ["CMA", 728], ["and", 732], ["prevented", 736], ["by", 746], ["siRNA", 749], ["-", 754], ["mediated", 755], ["knockdown", 764], ["of", 774], ["LAMP2A", 777], [",", 783], ["a", 785], ["lysosomal", 787], ["receptor", 797], ["for", 806], ["CMA", 810], [",", 813], ["and", 815], ["by", 819], ["treatments", 822], ["that", 833], ["inactivate", 838], ["CMA", 849], [".", 852], ["These", 854], ["results", 860], ["suggest", 868], ["that", 876], ["lysosomal", 881], ["accumulation", 891], ["of", 904], ["GAPDH", 907], ["-", 912], ["HT", 913], ["reflects", 916], ["CMA", 925], ["activity", 929], [".", 937], ["Using", 939], ["this", 945], ["method", 950], [",", 956], ["we", 958], ["revealed", 961], ["that", 970], ["mutant", 975], ["\u03b3PKC", 982], [",", 986], ["which", 988], ["causes", 994], ["spinocerebellar", 1001], ["ataxia", 1017], ["type", 1024], ["14", 1029], [",", 1031], ["decreased", 1033], ["CMA", 1043], ["activity", 1047], ["in", 1056], ["cultured", 1059], ["PCs", 1068], [".", 1071], ["In", 1073], ["the", 1076], ["present", 1080], ["study", 1088], [",", 1093], ["we", 1095], ["established", 1098], ["a", 1110], ["novel", 1112], ["fluorescent", 1118], ["-", 1129], ["based", 1130], ["method", 1136], ["to", 1143], ["evaluate", 1146], ["CMA", 1155], ["activity", 1159], ["in", 1168], ["a", 1171], ["single", 1173], ["neuron", 1180], [".", 1186], ["This", 1188], ["novel", 1193], ["method", 1199], ["should", 1206], ["be", 1213], ["useful", 1216], ["and", 1223], ["valuable", 1227], ["for", 1236], ["evaluating", 1240], ["the", 1251], ["role", 1255], ["of", 1260], ["CMA", 1263], ["in", 1267], ["various", 1270], ["neuronal", 1278], ["functions", 1287], ["and", 1297], ["neural", 1301], ["disease", 1308], ["pathogenesis", 1316], [".", 1328]]}
{"context": "Rapid laboratory methods provide optimal support for active surveillance efforts to screen for methicillin-resistant Staphylococcus aureus (MRSA). Most laboratories struggle to determine the optimal use of resources, considering options to balance cost, speed, and diagnostic accuracy. To assess the performance of common methods, the first comparison of MRSASelect agar (MS) and CHROMagar MRSA (CA), with and without broth enrichment followed by a 24-h subculture to MS, was performed. Results were compared to those of the Xpert MRSA assay. For direct culture methods, the agreement between MS and CA was 98.8%. At 18 h, direct MS identified 93% of all positive samples from direct culture and 84% of those identified by the Xpert MRSA. For Trypticase soy broth-enriched MS culture, incubated overnight and then subcultured for an additional 24 h, the agreement with Xpert MRSA was 96%. The agreement between direct MS and Xpert MRSA was 100% when semiquantitative culture revealed a bacterial density of 2+ or greater; however, discrepancies between culture and Xpert MRSA arose for MRSA bacterial densities of 1+ or less, indicating low density as a common cause of false-negative culture results. Since 1+ or less was established as the most common MRSA carrier state, broth enrichment or PCR may be critical for the identification of all MRSA carriers who may be reservoirs for transmission. In this active-surveillance convenience sample, the use of broth enrichment followed by subculture to MS offered a low-cost but sensitive method for MRSA screening, with performance similar to that of Xpert MRSA PCR.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "3bb7162086024ef8ac8c5df12b9b21a0", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[64, 64], [93, 93], [19, 19], [198, 198], [235, 235], [251, 251], [201, 201], [297, 297], [136, 136], [287, 287], [162, 162], [174, 174]], "char_spans": [[390, 393], [531, 534], [140, 143], [1071, 1074], [1254, 1257], [1344, 1347], [1086, 1089], [1605, 1608], [733, 736], [1547, 1550], [875, 878], [931, 934]]}]}], "context_tokens": [["Rapid", 0], ["laboratory", 6], ["methods", 17], ["provide", 25], ["optimal", 33], ["support", 41], ["for", 49], ["active", 53], ["surveillance", 60], ["efforts", 73], ["to", 81], ["screen", 84], ["for", 91], ["methicillin", 95], ["-", 106], ["resistant", 107], ["Staphylococcus", 117], ["aureus", 132], ["(", 139], ["MRSA", 140], [")", 144], [".", 145], ["Most", 147], ["laboratories", 152], ["struggle", 165], ["to", 174], ["determine", 177], ["the", 187], ["optimal", 191], ["use", 199], ["of", 203], ["resources", 206], [",", 215], ["considering", 217], ["options", 229], ["to", 237], ["balance", 240], ["cost", 248], [",", 252], ["speed", 254], [",", 259], ["and", 261], ["diagnostic", 265], ["accuracy", 276], [".", 284], ["To", 286], ["assess", 289], ["the", 296], ["performance", 300], ["of", 312], ["common", 315], ["methods", 322], [",", 329], ["the", 331], ["first", 335], ["comparison", 341], ["of", 352], ["MRSASelect", 355], ["agar", 366], ["(", 371], ["MS", 372], [")", 374], ["and", 376], ["CHROMagar", 380], ["MRSA", 390], ["(", 395], ["CA", 396], [")", 398], [",", 399], ["with", 401], ["and", 406], ["without", 410], ["broth", 418], ["enrichment", 424], ["followed", 435], ["by", 444], ["a", 447], ["24-h", 449], ["subculture", 454], ["to", 465], ["MS", 468], [",", 470], ["was", 472], ["performed", 476], [".", 485], ["Results", 487], ["were", 495], ["compared", 500], ["to", 509], ["those", 512], ["of", 518], ["the", 521], ["Xpert", 525], ["MRSA", 531], ["assay", 536], [".", 541], ["For", 543], ["direct", 547], ["culture", 554], ["methods", 562], [",", 569], ["the", 571], ["agreement", 575], ["between", 585], ["MS", 593], ["and", 596], ["CA", 600], ["was", 603], ["98.8", 607], ["%", 611], [".", 612], ["At", 614], ["18", 617], ["h", 620], [",", 621], ["direct", 623], ["MS", 630], ["identified", 633], ["93", 644], ["%", 646], ["of", 648], ["all", 651], ["positive", 655], ["samples", 664], ["from", 672], ["direct", 677], ["culture", 684], ["and", 692], ["84", 696], ["%", 698], ["of", 700], ["those", 703], ["identified", 709], ["by", 720], ["the", 723], ["Xpert", 727], ["MRSA", 733], [".", 737], ["For", 739], ["Trypticase", 743], ["soy", 754], ["broth", 758], ["-", 763], ["enriched", 764], ["MS", 773], ["culture", 776], [",", 783], ["incubated", 785], ["overnight", 795], ["and", 805], ["then", 809], ["subcultured", 814], ["for", 826], ["an", 830], ["additional", 833], ["24", 844], ["h", 847], [",", 848], ["the", 850], ["agreement", 854], ["with", 864], ["Xpert", 869], ["MRSA", 875], ["was", 880], ["96", 884], ["%", 886], [".", 887], ["The", 889], ["agreement", 893], ["between", 903], ["direct", 911], ["MS", 918], ["and", 921], ["Xpert", 925], ["MRSA", 931], ["was", 936], ["100", 940], ["%", 943], ["when", 945], ["semiquantitative", 950], ["culture", 967], ["revealed", 975], ["a", 984], ["bacterial", 986], ["density", 996], ["of", 1004], ["2", 1007], ["+", 1008], ["or", 1010], ["greater", 1013], [";", 1020], ["however", 1022], [",", 1029], ["discrepancies", 1031], ["between", 1045], ["culture", 1053], ["and", 1061], ["Xpert", 1065], ["MRSA", 1071], ["arose", 1076], ["for", 1082], ["MRSA", 1086], ["bacterial", 1091], ["densities", 1101], ["of", 1111], ["1", 1114], ["+", 1115], ["or", 1117], ["less", 1120], [",", 1124], ["indicating", 1126], ["low", 1137], ["density", 1141], ["as", 1149], ["a", 1152], ["common", 1154], ["cause", 1161], ["of", 1167], ["false", 1170], ["-", 1175], ["negative", 1176], ["culture", 1185], ["results", 1193], [".", 1200], ["Since", 1202], ["1", 1208], ["+", 1209], ["or", 1211], ["less", 1214], ["was", 1219], ["established", 1223], ["as", 1235], ["the", 1238], ["most", 1242], ["common", 1247], ["MRSA", 1254], ["carrier", 1259], ["state", 1267], [",", 1272], ["broth", 1274], ["enrichment", 1280], ["or", 1291], ["PCR", 1294], ["may", 1298], ["be", 1302], ["critical", 1305], ["for", 1314], ["the", 1318], ["identification", 1322], ["of", 1337], ["all", 1340], ["MRSA", 1344], ["carriers", 1349], ["who", 1358], ["may", 1362], ["be", 1366], ["reservoirs", 1369], ["for", 1380], ["transmission", 1384], [".", 1396], ["In", 1398], ["this", 1401], ["active", 1406], ["-", 1412], ["surveillance", 1413], ["convenience", 1426], ["sample", 1438], [",", 1444], ["the", 1446], ["use", 1450], ["of", 1454], ["broth", 1457], ["enrichment", 1463], ["followed", 1474], ["by", 1483], ["subculture", 1486], ["to", 1497], ["MS", 1500], ["offered", 1503], ["a", 1511], ["low", 1513], ["-", 1516], ["cost", 1517], ["but", 1522], ["sensitive", 1526], ["method", 1536], ["for", 1543], ["MRSA", 1547], ["screening", 1552], [",", 1561], ["with", 1563], ["performance", 1568], ["similar", 1580], ["to", 1588], ["that", 1591], ["of", 1596], ["Xpert", 1599], ["MRSA", 1605], ["PCR", 1610], [".", 1613]]}
{"context": "In 2005, a distinct clone of methicillin resistant Staphylococcus aureus (MRSA CC398) was found in pigs and people in contact with pigs. The structure of the pig production chain in high technology pig husbandry enables pathogens to spread during animal trading, with an increasing prevalence in herds further down the chain. The objective of this study was to quantify the effect of the MRSA status of the supplying herd on the MRSA status of the receiving herd in order to gain more insight into the role of animal trading as a transmission route for MRSA CC398. Nasal samples (60-80 pigs per herd) were collected from 38 herds; in 20 herds, environmental samples were collected as well. Ten MRSA-positive herds (based on the results of nasal swabs of 10 individual pigs per herd) from a prior study were included in the data analysis. Herds were classified as MRSA positive if at least one sample tested positive. The 48 herds were part of 14 complete (40 herds) and 4 incomplete (8 herds) pig production chains. Fifty-six percent of the herds were classified as MRSA positive. MRSA-positive herds were observed at the start (breeding herds), middle (farrowing herds) and the end (finishing herds) of the pig production chain. All of the herds in 8 chains tested MRSA positive;, all of the herds in 5 chains tested MRSA negative and in the remaining 5 chains, MRSA-positive and MRSA-negative herds were detected. Seven spa types were found, which were all previously confirmed to belong to CC398. All of the isolates were susceptible to mupirocin, linezolid, rifampicin, fusidic acid and cotrimoxazole. Resistance against tetracycline, erythromycin and clindamycin was found in 100, 74 and 76% of the isolates, respectively. Seventy-nine percent of herds with a MRSA-positive supplier of pigs were MRSA positive, whereas 23% of herds with a MRSA-negative supplier were MRSA positive (OR=10.8; 95% CI: 1.5-110.1; P=0.011). The presence of entirely MRSA-positive and MRSA-negative chains and the strong association between the MRSA status of herds and their suppliers illustrates a large risk associated with purchasing pigs from MRSA-positive herds; a top-down strategy for future control programs is, therefore, a basic requirement. However, 23% of herds with a MRSA-negative supplier were MRSA positive and furthermore, 46% of the herds at the top of the pig production chain without a supplier tested MRSA positive. This underlined the need for the identification of additional risk factors for MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "f4ea9fa4a4b04d9bb9a697ce1418abdb", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[208, 208], [272, 272], [403, 403], [77, 77], [211, 211], [454, 454], [491, 491], [12, 12], [276, 276], [263, 263], [364, 364], [69, 69], [131, 131], [251, 251], [389, 389], [369, 369], [449, 449], [165, 165], [347, 347], [419, 419], [100, 100], [476, 476], [393, 393], [354, 354]], "char_spans": [[1066, 1069], [1363, 1366], [2028, 2031], [429, 432], [1081, 1084], [2293, 2296], [2500, 2503], [74, 77], [1381, 1384], [1318, 1321], [1844, 1847], [388, 391], [694, 697], [1266, 1269], [1950, 1953], [1872, 1875], [2265, 2268], [863, 866], [1765, 1768], [2131, 2134], [553, 556], [2406, 2409], [1968, 1971], [1801, 1804]]}]}], "context_tokens": [["In", 0], ["2005", 3], [",", 7], ["a", 9], ["distinct", 11], ["clone", 20], ["of", 26], ["methicillin", 29], ["resistant", 41], ["Staphylococcus", 51], ["aureus", 66], ["(", 73], ["MRSA", 74], ["CC398", 79], [")", 84], ["was", 86], ["found", 90], ["in", 96], ["pigs", 99], ["and", 104], ["people", 108], ["in", 115], ["contact", 118], ["with", 126], ["pigs", 131], [".", 135], ["The", 137], ["structure", 141], ["of", 151], ["the", 154], ["pig", 158], ["production", 162], ["chain", 173], ["in", 179], ["high", 182], ["technology", 187], ["pig", 198], ["husbandry", 202], ["enables", 212], ["pathogens", 220], ["to", 230], ["spread", 233], ["during", 240], ["animal", 247], ["trading", 254], [",", 261], ["with", 263], ["an", 268], ["increasing", 271], ["prevalence", 282], ["in", 293], ["herds", 296], ["further", 302], ["down", 310], ["the", 315], ["chain", 319], [".", 324], ["The", 326], ["objective", 330], ["of", 340], ["this", 343], ["study", 348], ["was", 354], ["to", 358], ["quantify", 361], ["the", 370], ["effect", 374], ["of", 381], ["the", 384], ["MRSA", 388], ["status", 393], ["of", 400], ["the", 403], ["supplying", 407], ["herd", 417], ["on", 422], ["the", 425], ["MRSA", 429], ["status", 434], ["of", 441], ["the", 444], ["receiving", 448], ["herd", 458], ["in", 463], ["order", 466], ["to", 472], ["gain", 475], ["more", 480], ["insight", 485], ["into", 493], ["the", 498], ["role", 502], ["of", 507], ["animal", 510], ["trading", 517], ["as", 525], ["a", 528], ["transmission", 530], ["route", 543], ["for", 549], ["MRSA", 553], ["CC398", 558], [".", 563], ["Nasal", 565], ["samples", 571], ["(", 579], ["60", 580], ["-", 582], ["80", 583], ["pigs", 586], ["per", 591], ["herd", 595], [")", 599], ["were", 601], ["collected", 606], ["from", 616], ["38", 621], ["herds", 624], [";", 629], ["in", 631], ["20", 634], ["herds", 637], [",", 642], ["environmental", 644], ["samples", 658], ["were", 666], ["collected", 671], ["as", 681], ["well", 684], [".", 688], ["Ten", 690], ["MRSA", 694], ["-", 698], ["positive", 699], ["herds", 708], ["(", 714], ["based", 715], ["on", 721], ["the", 724], ["results", 728], ["of", 736], ["nasal", 739], ["swabs", 745], ["of", 751], ["10", 754], ["individual", 757], ["pigs", 768], ["per", 773], ["herd", 777], [")", 781], ["from", 783], ["a", 788], ["prior", 790], ["study", 796], ["were", 802], ["included", 807], ["in", 816], ["the", 819], ["data", 823], ["analysis", 828], [".", 836], ["Herds", 838], ["were", 844], ["classified", 849], ["as", 860], ["MRSA", 863], ["positive", 868], ["if", 877], ["at", 880], ["least", 883], ["one", 889], ["sample", 893], ["tested", 900], ["positive", 907], [".", 915], ["The", 917], ["48", 921], ["herds", 924], ["were", 930], ["part", 935], ["of", 940], ["14", 943], ["complete", 946], ["(", 955], ["40", 956], ["herds", 959], [")", 964], ["and", 966], ["4", 970], ["incomplete", 972], ["(", 983], ["8", 984], ["herds", 986], [")", 991], ["pig", 993], ["production", 997], ["chains", 1008], [".", 1014], ["Fifty", 1016], ["-", 1021], ["six", 1022], ["percent", 1026], ["of", 1034], ["the", 1037], ["herds", 1041], ["were", 1047], ["classified", 1052], ["as", 1063], ["MRSA", 1066], ["positive", 1071], [".", 1079], ["MRSA", 1081], ["-", 1085], ["positive", 1086], ["herds", 1095], ["were", 1101], ["observed", 1106], ["at", 1115], ["the", 1118], ["start", 1122], ["(", 1128], ["breeding", 1129], ["herds", 1138], [")", 1143], [",", 1144], ["middle", 1146], ["(", 1153], ["farrowing", 1154], ["herds", 1164], [")", 1169], ["and", 1171], ["the", 1175], ["end", 1179], ["(", 1183], ["finishing", 1184], ["herds", 1194], [")", 1199], ["of", 1201], ["the", 1204], ["pig", 1208], ["production", 1212], ["chain", 1223], [".", 1228], ["All", 1230], ["of", 1234], ["the", 1237], ["herds", 1241], ["in", 1247], ["8", 1250], ["chains", 1252], ["tested", 1259], ["MRSA", 1266], ["positive", 1271], [";", 1279], [",", 1280], ["all", 1282], ["of", 1286], ["the", 1289], ["herds", 1293], ["in", 1299], ["5", 1302], ["chains", 1304], ["tested", 1311], ["MRSA", 1318], ["negative", 1323], ["and", 1332], ["in", 1336], ["the", 1339], ["remaining", 1343], ["5", 1353], ["chains", 1355], [",", 1361], ["MRSA", 1363], ["-", 1367], ["positive", 1368], ["and", 1377], ["MRSA", 1381], ["-", 1385], ["negative", 1386], ["herds", 1395], ["were", 1401], ["detected", 1406], [".", 1414], ["Seven", 1416], ["spa", 1422], ["types", 1426], ["were", 1432], ["found", 1437], [",", 1442], ["which", 1444], ["were", 1450], ["all", 1455], ["previously", 1459], ["confirmed", 1470], ["to", 1480], ["belong", 1483], ["to", 1490], ["CC398", 1493], [".", 1498], ["All", 1500], ["of", 1504], ["the", 1507], ["isolates", 1511], ["were", 1520], ["susceptible", 1525], ["to", 1537], ["mupirocin", 1540], [",", 1549], ["linezolid", 1551], [",", 1560], ["rifampicin", 1562], [",", 1572], ["fusidic", 1574], ["acid", 1582], ["and", 1587], ["cotrimoxazole", 1591], [".", 1604], ["Resistance", 1606], ["against", 1617], ["tetracycline", 1625], [",", 1637], ["erythromycin", 1639], ["and", 1652], ["clindamycin", 1656], ["was", 1668], ["found", 1672], ["in", 1678], ["100", 1681], [",", 1684], ["74", 1686], ["and", 1689], ["76", 1693], ["%", 1695], ["of", 1697], ["the", 1700], ["isolates", 1704], [",", 1712], ["respectively", 1714], [".", 1726], ["Seventy", 1728], ["-", 1735], ["nine", 1736], ["percent", 1741], ["of", 1749], ["herds", 1752], ["with", 1758], ["a", 1763], ["MRSA", 1765], ["-", 1769], ["positive", 1770], ["supplier", 1779], ["of", 1788], ["pigs", 1791], ["were", 1796], ["MRSA", 1801], ["positive", 1806], [",", 1814], ["whereas", 1816], ["23", 1824], ["%", 1826], ["of", 1828], ["herds", 1831], ["with", 1837], ["a", 1842], ["MRSA", 1844], ["-", 1848], ["negative", 1849], ["supplier", 1858], ["were", 1867], ["MRSA", 1872], ["positive", 1877], ["(", 1886], ["OR=10.8", 1887], [";", 1894], ["95", 1896], ["%", 1898], ["CI", 1900], [":", 1902], ["1.5", 1904], ["-", 1907], ["110.1", 1908], [";", 1913], ["P=0.011", 1915], [")", 1922], [".", 1923], ["The", 1925], ["presence", 1929], ["of", 1938], ["entirely", 1941], ["MRSA", 1950], ["-", 1954], ["positive", 1955], ["and", 1964], ["MRSA", 1968], ["-", 1972], ["negative", 1973], ["chains", 1982], ["and", 1989], ["the", 1993], ["strong", 1997], ["association", 2004], ["between", 2016], ["the", 2024], ["MRSA", 2028], ["status", 2033], ["of", 2040], ["herds", 2043], ["and", 2049], ["their", 2053], ["suppliers", 2059], ["illustrates", 2069], ["a", 2081], ["large", 2083], ["risk", 2089], ["associated", 2094], ["with", 2105], ["purchasing", 2110], ["pigs", 2121], ["from", 2126], ["MRSA", 2131], ["-", 2135], ["positive", 2136], ["herds", 2145], [";", 2150], ["a", 2152], ["top", 2154], ["-", 2157], ["down", 2158], ["strategy", 2163], ["for", 2172], ["future", 2176], ["control", 2183], ["programs", 2191], ["is", 2200], [",", 2202], ["therefore", 2204], [",", 2213], ["a", 2215], ["basic", 2217], ["requirement", 2223], [".", 2234], ["However", 2236], [",", 2243], ["23", 2245], ["%", 2247], ["of", 2249], ["herds", 2252], ["with", 2258], ["a", 2263], ["MRSA", 2265], ["-", 2269], ["negative", 2270], ["supplier", 2279], ["were", 2288], ["MRSA", 2293], ["positive", 2298], ["and", 2307], ["furthermore", 2311], [",", 2322], ["46", 2324], ["%", 2326], ["of", 2328], ["the", 2331], ["herds", 2335], ["at", 2341], ["the", 2344], ["top", 2348], ["of", 2352], ["the", 2355], ["pig", 2359], ["production", 2363], ["chain", 2374], ["without", 2380], ["a", 2388], ["supplier", 2390], ["tested", 2399], ["MRSA", 2406], ["positive", 2411], [".", 2419], ["This", 2421], ["underlined", 2426], ["the", 2437], ["need", 2441], ["for", 2446], ["the", 2450], ["identification", 2454], ["of", 2469], ["additional", 2472], ["risk", 2483], ["factors", 2488], ["for", 2496], ["MRSA", 2500], [".", 2504]]}
{"context": "Eukaryotic centromeres are maintained at specific chromosomal sites over many generations. In the budding yeast Saccharomyces cerevisiae, centromeres are genetic elements defined by a DNA sequence that is both necessary and sufficient for function; whereas, in most other eukaryotes, centromeres are maintained by poorly characterized epigenetic mechanisms in which DNA has a less definitive role. Here we use the pathogenic yeast Candida albicans as a model organism to study the DNA replication properties of centromeric DNA. By determining the genome-wide replication timing program of the C. albicans genome, we discovered that each centromere is associated with a replication origin that is the first to fire on its respective chromosome. Importantly, epigenetic formation of new ectopic centromeres (neocentromeres) was accompanied by shifts in replication timing, such that a neocentromere became the first to replicate and became associated with origin recognition complex (ORC) components. Furthermore, changing the level of the centromere-specific histone H3 isoform led to a concomitant change in levels of ORC association with centromere regions, further supporting the idea that centromere proteins determine origin activity. Finally, analysis of centromere-associated DNA revealed a replication-dependent sequence pattern characteristic of constitutively active replication origins. This strand-biased pattern is conserved, together with centromere position, among related strains and species, in a manner independent of primary DNA sequence. Thus, inheritance of centromere position is correlated with a constitutively active origin of replication that fires at a distinct early time. We suggest a model in which the distinct timing of DNA replication serves as an epigenetic mechanism for the inheritance of centromere position.", "qas": [{"question": "Do origins of replication close to yeast centromeres fire early or late?", "answers": ["Early"], "qid": "f86ba8d933b746bc9dcc170bdad24a09", "question_tokens": [["Do", 0], ["origins", 3], ["of", 11], ["replication", 14], ["close", 26], ["to", 32], ["yeast", 35], ["centromeres", 41], ["fire", 53], ["early", 58], ["or", 64], ["late", 67], ["?", 71]], "detected_answers": [{"text": "Early", "token_spans": [[268, 268]], "char_spans": [[1688, 1692]]}]}], "context_tokens": [["Eukaryotic", 0], ["centromeres", 11], ["are", 23], ["maintained", 27], ["at", 38], ["specific", 41], ["chromosomal", 50], ["sites", 62], ["over", 68], ["many", 73], ["generations", 78], [".", 89], ["In", 91], ["the", 94], ["budding", 98], ["yeast", 106], ["Saccharomyces", 112], ["cerevisiae", 126], [",", 136], ["centromeres", 138], ["are", 150], ["genetic", 154], ["elements", 162], ["defined", 171], ["by", 179], ["a", 182], ["DNA", 184], ["sequence", 188], ["that", 197], ["is", 202], ["both", 205], ["necessary", 210], ["and", 220], ["sufficient", 224], ["for", 235], ["function", 239], [";", 247], ["whereas", 249], [",", 256], ["in", 258], ["most", 261], ["other", 266], ["eukaryotes", 272], [",", 282], ["centromeres", 284], ["are", 296], ["maintained", 300], ["by", 311], ["poorly", 314], ["characterized", 321], ["epigenetic", 335], ["mechanisms", 346], ["in", 357], ["which", 360], ["DNA", 366], ["has", 370], ["a", 374], ["less", 376], ["definitive", 381], ["role", 392], [".", 396], ["Here", 398], ["we", 403], ["use", 406], ["the", 410], ["pathogenic", 414], ["yeast", 425], ["Candida", 431], ["albicans", 439], ["as", 448], ["a", 451], ["model", 453], ["organism", 459], ["to", 468], ["study", 471], ["the", 477], ["DNA", 481], ["replication", 485], ["properties", 497], ["of", 508], ["centromeric", 511], ["DNA", 523], [".", 526], ["By", 528], ["determining", 531], ["the", 543], ["genome", 547], ["-", 553], ["wide", 554], ["replication", 559], ["timing", 571], ["program", 578], ["of", 586], ["the", 589], ["C.", 593], ["albicans", 596], ["genome", 605], [",", 611], ["we", 613], ["discovered", 616], ["that", 627], ["each", 632], ["centromere", 637], ["is", 648], ["associated", 651], ["with", 662], ["a", 667], ["replication", 669], ["origin", 681], ["that", 688], ["is", 693], ["the", 696], ["first", 700], ["to", 706], ["fire", 709], ["on", 714], ["its", 717], ["respective", 721], ["chromosome", 732], [".", 742], ["Importantly", 744], [",", 755], ["epigenetic", 757], ["formation", 768], ["of", 778], ["new", 781], ["ectopic", 785], ["centromeres", 793], ["(", 805], ["neocentromeres", 806], [")", 820], ["was", 822], ["accompanied", 826], ["by", 838], ["shifts", 841], ["in", 848], ["replication", 851], ["timing", 863], [",", 869], ["such", 871], ["that", 876], ["a", 881], ["neocentromere", 883], ["became", 897], ["the", 904], ["first", 908], ["to", 914], ["replicate", 917], ["and", 927], ["became", 931], ["associated", 938], ["with", 949], ["origin", 954], ["recognition", 961], ["complex", 973], ["(", 981], ["ORC", 982], [")", 985], ["components", 987], [".", 997], ["Furthermore", 999], [",", 1010], ["changing", 1012], ["the", 1021], ["level", 1025], ["of", 1031], ["the", 1034], ["centromere", 1038], ["-", 1048], ["specific", 1049], ["histone", 1058], ["H3", 1066], ["isoform", 1069], ["led", 1077], ["to", 1081], ["a", 1084], ["concomitant", 1086], ["change", 1098], ["in", 1105], ["levels", 1108], ["of", 1115], ["ORC", 1118], ["association", 1122], ["with", 1134], ["centromere", 1139], ["regions", 1150], [",", 1157], ["further", 1159], ["supporting", 1167], ["the", 1178], ["idea", 1182], ["that", 1187], ["centromere", 1192], ["proteins", 1203], ["determine", 1212], ["origin", 1222], ["activity", 1229], [".", 1237], ["Finally", 1239], [",", 1246], ["analysis", 1248], ["of", 1257], ["centromere", 1260], ["-", 1270], ["associated", 1271], ["DNA", 1282], ["revealed", 1286], ["a", 1295], ["replication", 1297], ["-", 1308], ["dependent", 1309], ["sequence", 1319], ["pattern", 1328], ["characteristic", 1336], ["of", 1351], ["constitutively", 1354], ["active", 1369], ["replication", 1376], ["origins", 1388], [".", 1395], ["This", 1397], ["strand", 1402], ["-", 1408], ["biased", 1409], ["pattern", 1416], ["is", 1424], ["conserved", 1427], [",", 1436], ["together", 1438], ["with", 1447], ["centromere", 1452], ["position", 1463], [",", 1471], ["among", 1473], ["related", 1479], ["strains", 1487], ["and", 1495], ["species", 1499], [",", 1506], ["in", 1508], ["a", 1511], ["manner", 1513], ["independent", 1520], ["of", 1532], ["primary", 1535], ["DNA", 1543], ["sequence", 1547], [".", 1555], ["Thus", 1557], [",", 1561], ["inheritance", 1563], ["of", 1575], ["centromere", 1578], ["position", 1589], ["is", 1598], ["correlated", 1601], ["with", 1612], ["a", 1617], ["constitutively", 1619], ["active", 1634], ["origin", 1641], ["of", 1648], ["replication", 1651], ["that", 1663], ["fires", 1668], ["at", 1674], ["a", 1677], ["distinct", 1679], ["early", 1688], ["time", 1694], [".", 1698], ["We", 1700], ["suggest", 1703], ["a", 1711], ["model", 1713], ["in", 1719], ["which", 1722], ["the", 1728], ["distinct", 1732], ["timing", 1741], ["of", 1748], ["DNA", 1751], ["replication", 1755], ["serves", 1767], ["as", 1774], ["an", 1777], ["epigenetic", 1780], ["mechanism", 1791], ["for", 1801], ["the", 1805], ["inheritance", 1809], ["of", 1821], ["centromere", 1824], ["position", 1835], [".", 1843]]}
{"context": "Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is increasing in prevalence among asymptomatic carriers and in cases of paediatric soft-tissue infections alike. CA-MRSA may express virulence factors such as Panton-Valentine leukocidin, which makes soft-tissue and hard-tissue infections due to such organisms challenging to treat. We report a case of osteomyelitis of the proximal tibia in a 10-year-old boy and discuss its management in what is to the authors' knowledge the first case report of Panton-Valentine leukocidin-positive CA-MRSA osteomyelitis in a child in the UK.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "aee842a768df4abebce2612c194f1e62", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[33, 33], [104, 104], [11, 11]], "char_spans": [[191, 194], [564, 567], [69, 72]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["associated", 10], ["methicillin", 21], ["-", 32], ["resistant", 33], ["Staphylococcus", 43], ["aureus", 58], ["(", 65], ["CA", 66], ["-", 68], ["MRSA", 69], [")", 73], ["is", 75], ["increasing", 78], ["in", 89], ["prevalence", 92], ["among", 103], ["asymptomatic", 109], ["carriers", 122], ["and", 131], ["in", 135], ["cases", 138], ["of", 144], ["paediatric", 147], ["soft", 158], ["-", 162], ["tissue", 163], ["infections", 170], ["alike", 181], [".", 186], ["CA", 188], ["-", 190], ["MRSA", 191], ["may", 196], ["express", 200], ["virulence", 208], ["factors", 218], ["such", 226], ["as", 231], ["Panton", 234], ["-", 240], ["Valentine", 241], ["leukocidin", 251], [",", 261], ["which", 263], ["makes", 269], ["soft", 275], ["-", 279], ["tissue", 280], ["and", 287], ["hard", 291], ["-", 295], ["tissue", 296], ["infections", 303], ["due", 314], ["to", 318], ["such", 321], ["organisms", 326], ["challenging", 336], ["to", 348], ["treat", 351], [".", 356], ["We", 358], ["report", 361], ["a", 368], ["case", 370], ["of", 375], ["osteomyelitis", 378], ["of", 392], ["the", 395], ["proximal", 399], ["tibia", 408], ["in", 414], ["a", 417], ["10-year", 419], ["-", 426], ["old", 427], ["boy", 431], ["and", 435], ["discuss", 439], ["its", 447], ["management", 451], ["in", 462], ["what", 465], ["is", 470], ["to", 473], ["the", 476], ["authors", 480], ["'", 487], ["knowledge", 489], ["the", 499], ["first", 503], ["case", 509], ["report", 514], ["of", 521], ["Panton", 524], ["-", 530], ["Valentine", 531], ["leukocidin", 541], ["-", 551], ["positive", 552], ["CA", 561], ["-", 563], ["MRSA", 564], ["osteomyelitis", 569], ["in", 583], ["a", 586], ["child", 588], ["in", 594], ["the", 597], ["UK", 601], [".", 603]]}
{"context": "Missense mutations in ubiquilin 2 (UBQLN2) cause ALS with frontotemporal dementia (ALS-FTD). Animal models of ALS are useful for understanding the mechanisms of pathogenesis and for preclinical investigations. However, previous rodent models carrying UBQLN2 mutations failed to manifest any sign of motor neuron disease. Here, we show that lines of mice expressing either the ALS-FTD-linked P497S or P506T UBQLN2 mutations have cognitive deficits, shortened lifespans, and develop motor neuron disease, mimicking the human disease. Neuropathologic analysis of the mice with end-stage disease revealed the accumulation of ubiquitinated inclusions in the brain and spinal cord, astrocytosis, a reduction in the number of hippocampal neurons, and reduced staining of TAR-DNA binding protein 43 in the nucleus, with concomitant formation of ubiquitin", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "020cf00b943b468f9e50ce04bee47b9f", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[65, 65], [22, 22], [9, 9], [14, 14]], "char_spans": [[376, 378], [110, 112], [49, 51], [83, 85]]}]}], "context_tokens": [["Missense", 0], ["mutations", 9], ["in", 19], ["ubiquilin", 22], ["2", 32], ["(", 34], ["UBQLN2", 35], [")", 41], ["cause", 43], ["ALS", 49], ["with", 53], ["frontotemporal", 58], ["dementia", 73], ["(", 82], ["ALS", 83], ["-", 86], ["FTD", 87], [")", 90], [".", 91], ["Animal", 93], ["models", 100], ["of", 107], ["ALS", 110], ["are", 114], ["useful", 118], ["for", 125], ["understanding", 129], ["the", 143], ["mechanisms", 147], ["of", 158], ["pathogenesis", 161], ["and", 174], ["for", 178], ["preclinical", 182], ["investigations", 194], [".", 208], ["However", 210], [",", 217], ["previous", 219], ["rodent", 228], ["models", 235], ["carrying", 242], ["UBQLN2", 251], ["mutations", 258], ["failed", 268], ["to", 275], ["manifest", 278], ["any", 287], ["sign", 291], ["of", 296], ["motor", 299], ["neuron", 305], ["disease", 312], [".", 319], ["Here", 321], [",", 325], ["we", 327], ["show", 330], ["that", 335], ["lines", 340], ["of", 346], ["mice", 349], ["expressing", 354], ["either", 365], ["the", 372], ["ALS", 376], ["-", 379], ["FTD", 380], ["-", 383], ["linked", 384], ["P497S", 391], ["or", 397], ["P506", 400], ["T", 404], ["UBQLN2", 406], ["mutations", 413], ["have", 423], ["cognitive", 428], ["deficits", 438], [",", 446], ["shortened", 448], ["lifespans", 458], [",", 467], ["and", 469], ["develop", 473], ["motor", 481], ["neuron", 487], ["disease", 494], [",", 501], ["mimicking", 503], ["the", 513], ["human", 517], ["disease", 523], [".", 530], ["Neuropathologic", 532], ["analysis", 548], ["of", 557], ["the", 560], ["mice", 564], ["with", 569], ["end", 574], ["-", 577], ["stage", 578], ["disease", 584], ["revealed", 592], ["the", 601], ["accumulation", 605], ["of", 618], ["ubiquitinated", 621], ["inclusions", 635], ["in", 646], ["the", 649], ["brain", 653], ["and", 659], ["spinal", 663], ["cord", 670], [",", 674], ["astrocytosis", 676], [",", 688], ["a", 690], ["reduction", 692], ["in", 702], ["the", 705], ["number", 709], ["of", 716], ["hippocampal", 719], ["neurons", 731], [",", 738], ["and", 740], ["reduced", 744], ["staining", 752], ["of", 761], ["TAR", 764], ["-", 767], ["DNA", 768], ["binding", 772], ["protein", 780], ["43", 788], ["in", 791], ["the", 794], ["nucleus", 798], [",", 805], ["with", 807], ["concomitant", 812], ["formation", 824], ["of", 834], ["ubiquitin", 837]]}
{"context": "Flumazenil, a potent benzodiazepine antagonist, is a newly synthetic imidazo-benzodiazepine, which blocks the neurological effects of benzodiazepines. The purpose of this study was to evaluate the effects of this agent in reversal of benzodiazepine overdose and differentiation of comatous patients with drug overdose. Fifteen comatous patients with suspected sedatives/hypnotics overdose were included in this study and flumazenil 0.25 mg per dose was administrated intravenously. The average score of Glasgow Coma Scale increased from 7.13 +/- 2.92 to 10.93 +/- 3.67 after one dose of flumazenil. Clear consciousness was restored after multiple doses of flumazenil administration. Three cases with different drug history and variant response after flumazenil treatment were also illustrated and discussed. The dosage of flumazenil used in this study ranged from 0.25 mg to 3 mg (average 0.87 +/- 0.74 mg). We concluded that flumazenil is an excellent antidote for benzodiazepine overdose and valuable for differentiating the patients in comatose.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "ebb1ae34a73c4a5d839b1240da0af1a4", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [96, 96], [106, 106], [154, 154], [119, 119], [130, 130], [65, 65]], "char_spans": [[0, 9], [587, 596], [656, 665], [926, 935], [750, 759], [822, 831], [421, 430]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["potent", 14], ["benzodiazepine", 21], ["antagonist", 36], [",", 46], ["is", 48], ["a", 51], ["newly", 53], ["synthetic", 59], ["imidazo", 69], ["-", 76], ["benzodiazepine", 77], [",", 91], ["which", 93], ["blocks", 99], ["the", 106], ["neurological", 110], ["effects", 123], ["of", 131], ["benzodiazepines", 134], [".", 149], ["The", 151], ["purpose", 155], ["of", 163], ["this", 166], ["study", 171], ["was", 177], ["to", 181], ["evaluate", 184], ["the", 193], ["effects", 197], ["of", 205], ["this", 208], ["agent", 213], ["in", 219], ["reversal", 222], ["of", 231], ["benzodiazepine", 234], ["overdose", 249], ["and", 258], ["differentiation", 262], ["of", 278], ["comatous", 281], ["patients", 290], ["with", 299], ["drug", 304], ["overdose", 309], [".", 317], ["Fifteen", 319], ["comatous", 327], ["patients", 336], ["with", 345], ["suspected", 350], ["sedatives", 360], ["/", 369], ["hypnotics", 370], ["overdose", 380], ["were", 389], ["included", 394], ["in", 403], ["this", 406], ["study", 411], ["and", 417], ["flumazenil", 421], ["0.25", 432], ["mg", 437], ["per", 440], ["dose", 444], ["was", 449], ["administrated", 453], ["intravenously", 467], [".", 480], ["The", 482], ["average", 486], ["score", 494], ["of", 500], ["Glasgow", 503], ["Coma", 511], ["Scale", 516], ["increased", 522], ["from", 532], ["7.13", 537], ["+", 542], ["/-", 543], ["2.92", 546], ["to", 551], ["10.93", 554], ["+", 560], ["/-", 561], ["3.67", 564], ["after", 569], ["one", 575], ["dose", 579], ["of", 584], ["flumazenil", 587], [".", 597], ["Clear", 599], ["consciousness", 605], ["was", 619], ["restored", 623], ["after", 632], ["multiple", 638], ["doses", 647], ["of", 653], ["flumazenil", 656], ["administration", 667], [".", 681], ["Three", 683], ["cases", 689], ["with", 695], ["different", 700], ["drug", 710], ["history", 715], ["and", 723], ["variant", 727], ["response", 735], ["after", 744], ["flumazenil", 750], ["treatment", 761], ["were", 771], ["also", 776], ["illustrated", 781], ["and", 793], ["discussed", 797], [".", 806], ["The", 808], ["dosage", 812], ["of", 819], ["flumazenil", 822], ["used", 833], ["in", 838], ["this", 841], ["study", 846], ["ranged", 852], ["from", 859], ["0.25", 864], ["mg", 869], ["to", 872], ["3", 875], ["mg", 877], ["(", 880], ["average", 881], ["0.87", 889], ["+", 894], ["/-", 895], ["0.74", 898], ["mg", 903], [")", 905], [".", 906], ["We", 908], ["concluded", 911], ["that", 921], ["flumazenil", 926], ["is", 937], ["an", 940], ["excellent", 943], ["antidote", 953], ["for", 962], ["benzodiazepine", 966], ["overdose", 981], ["and", 990], ["valuable", 994], ["for", 1003], ["differentiating", 1007], ["the", 1023], ["patients", 1027], ["in", 1036], ["comatose", 1039], [".", 1047]]}
{"context": "RNA editing is proposed as a modulator of transcriptomes, but its biological impact has not been fully elucidated. In particular, its importance for transposable elements is controversial. We found RNA editing on antisense read-through transcripts of KP elements, one of the deletion derivatives of P transposable elements in Drosophila melanogaster. Three kinds of RNA editing were detected at 20 sites around the terminal inverted repeats (TIR); 15 A-to-G, four U-to-C, and one C-to-U conversions. A-to-G conversions are suggested to be attributed to A-to-I RNA editing on KP element RNAs, because inosine (I) in RNA is recognized as G by reverse transcriptase. TIRs were deduced to form dsRNAs as a putative target of ADAR. This is the first report of RNA editing on mobile elements of Drosophila.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "ed3c30f4b2954727ac67c7b6e40750c9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[150, 150]], "char_spans": [[721, 724]]}]}], "context_tokens": [["RNA", 0], ["editing", 4], ["is", 12], ["proposed", 15], ["as", 24], ["a", 27], ["modulator", 29], ["of", 39], ["transcriptomes", 42], [",", 56], ["but", 58], ["its", 62], ["biological", 66], ["impact", 77], ["has", 84], ["not", 88], ["been", 92], ["fully", 97], ["elucidated", 103], [".", 113], ["In", 115], ["particular", 118], [",", 128], ["its", 130], ["importance", 134], ["for", 145], ["transposable", 149], ["elements", 162], ["is", 171], ["controversial", 174], [".", 187], ["We", 189], ["found", 192], ["RNA", 198], ["editing", 202], ["on", 210], ["antisense", 213], ["read", 223], ["-", 227], ["through", 228], ["transcripts", 236], ["of", 248], ["KP", 251], ["elements", 254], [",", 262], ["one", 264], ["of", 268], ["the", 271], ["deletion", 275], ["derivatives", 284], ["of", 296], ["P", 299], ["transposable", 301], ["elements", 314], ["in", 323], ["Drosophila", 326], ["melanogaster", 337], [".", 349], ["Three", 351], ["kinds", 357], ["of", 363], ["RNA", 366], ["editing", 370], ["were", 378], ["detected", 383], ["at", 392], ["20", 395], ["sites", 398], ["around", 404], ["the", 411], ["terminal", 415], ["inverted", 424], ["repeats", 433], ["(", 441], ["TIR", 442], [")", 445], [";", 446], ["15", 448], ["A", 451], ["-", 452], ["to", 453], ["-", 455], ["G", 456], [",", 457], ["four", 459], ["U", 464], ["-", 465], ["to", 466], ["-", 468], ["C", 469], [",", 470], ["and", 472], ["one", 476], ["C", 480], ["-", 481], ["to", 482], ["-", 484], ["U", 485], ["conversions", 487], [".", 498], ["A", 500], ["-", 501], ["to", 502], ["-", 504], ["G", 505], ["conversions", 507], ["are", 519], ["suggested", 523], ["to", 533], ["be", 536], ["attributed", 539], ["to", 550], ["A", 553], ["-", 554], ["to", 555], ["-", 557], ["I", 558], ["RNA", 560], ["editing", 564], ["on", 572], ["KP", 575], ["element", 578], ["RNAs", 586], [",", 590], ["because", 592], ["inosine", 600], ["(", 608], ["I", 609], [")", 610], ["in", 612], ["RNA", 615], ["is", 619], ["recognized", 622], ["as", 633], ["G", 636], ["by", 638], ["reverse", 641], ["transcriptase", 649], [".", 662], ["TIRs", 664], ["were", 669], ["deduced", 674], ["to", 682], ["form", 685], ["dsRNAs", 690], ["as", 697], ["a", 700], ["putative", 702], ["target", 711], ["of", 718], ["ADAR", 721], [".", 725], ["This", 727], ["is", 732], ["the", 735], ["first", 739], ["report", 745], ["of", 752], ["RNA", 755], ["editing", 759], ["on", 767], ["mobile", 770], ["elements", 777], ["of", 786], ["Drosophila", 789], [".", 799]]}
{"context": "The Swc4p protein, encoded by an essential gene, is shared by two chromatin-remodeling complexes in Saccharomyces cerevisiae cells: NuA4 (nucleosome acetyltransferase of H4) and SWR1. The SWR1 complex catalyzes ATP-dependent exchange of the nucleosomal histone H2A for H2AZ (Htz1p). The activity of NuA4 is responsible mainly for the acetylation of the H4 histone but also for the acetylation of H2A and H2AZ. In this work we investigated the role of the Swc4p protein. Using random mutagenesis we isolated a collection of swc4 mutants and showed that the essential function of Swc4p resides in its N-terminal part, within the first 269 amino acids of the 476-amino acid-long protein. We also demonstrated that Swc4p is able to accommodate numerous mutations without losing its functionality under standard growth conditions. However, when swc4 mutants were exposed to methyl methanesulfonate (MMS), hydroxyurea or benomyl, severe growth deficiencies appeared, pointing to an involvement of Swc4p in many chromatin-based processes. The mutants' phenotypes did not result from an impairment of histone acetylation, as in the mutant which bears the shortest isolated variant of truncated Swc4p, the level of overall H4 acetylation was unchanged.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "464136c1262c4537a73e251dcc6d6f54", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[31, 31], [34, 34]], "char_spans": [[178, 181], [188, 191]]}]}], "context_tokens": [["The", 0], ["Swc4p", 4], ["protein", 10], [",", 17], ["encoded", 19], ["by", 27], ["an", 30], ["essential", 33], ["gene", 43], [",", 47], ["is", 49], ["shared", 52], ["by", 59], ["two", 62], ["chromatin", 66], ["-", 75], ["remodeling", 76], ["complexes", 87], ["in", 97], ["Saccharomyces", 100], ["cerevisiae", 114], ["cells", 125], [":", 130], ["NuA4", 132], ["(", 137], ["nucleosome", 138], ["acetyltransferase", 149], ["of", 167], ["H4", 170], [")", 172], ["and", 174], ["SWR1", 178], [".", 182], ["The", 184], ["SWR1", 188], ["complex", 193], ["catalyzes", 201], ["ATP", 211], ["-", 214], ["dependent", 215], ["exchange", 225], ["of", 234], ["the", 237], ["nucleosomal", 241], ["histone", 253], ["H2A", 261], ["for", 265], ["H2AZ", 269], ["(", 274], ["Htz1p", 275], [")", 280], [".", 281], ["The", 283], ["activity", 287], ["of", 296], ["NuA4", 299], ["is", 304], ["responsible", 307], ["mainly", 319], ["for", 326], ["the", 330], ["acetylation", 334], ["of", 346], ["the", 349], ["H4", 353], ["histone", 356], ["but", 364], ["also", 368], ["for", 373], ["the", 377], ["acetylation", 381], ["of", 393], ["H2A", 396], ["and", 400], ["H2AZ", 404], [".", 408], ["In", 410], ["this", 413], ["work", 418], ["we", 423], ["investigated", 426], ["the", 439], ["role", 443], ["of", 448], ["the", 451], ["Swc4p", 455], ["protein", 461], [".", 468], ["Using", 470], ["random", 476], ["mutagenesis", 483], ["we", 495], ["isolated", 498], ["a", 507], ["collection", 509], ["of", 520], ["swc4", 523], ["mutants", 528], ["and", 536], ["showed", 540], ["that", 547], ["the", 552], ["essential", 556], ["function", 566], ["of", 575], ["Swc4p", 578], ["resides", 584], ["in", 592], ["its", 595], ["N", 599], ["-", 600], ["terminal", 601], ["part", 610], [",", 614], ["within", 616], ["the", 623], ["first", 627], ["269", 633], ["amino", 637], ["acids", 643], ["of", 649], ["the", 652], ["476-amino", 656], ["acid", 666], ["-", 670], ["long", 671], ["protein", 676], [".", 683], ["We", 685], ["also", 688], ["demonstrated", 693], ["that", 706], ["Swc4p", 711], ["is", 717], ["able", 720], ["to", 725], ["accommodate", 728], ["numerous", 740], ["mutations", 749], ["without", 759], ["losing", 767], ["its", 774], ["functionality", 778], ["under", 792], ["standard", 798], ["growth", 807], ["conditions", 814], [".", 824], ["However", 826], [",", 833], ["when", 835], ["swc4", 840], ["mutants", 845], ["were", 853], ["exposed", 858], ["to", 866], ["methyl", 869], ["methanesulfonate", 876], ["(", 893], ["MMS", 894], [")", 897], [",", 898], ["hydroxyurea", 900], ["or", 912], ["benomyl", 915], [",", 922], ["severe", 924], ["growth", 931], ["deficiencies", 938], ["appeared", 951], [",", 959], ["pointing", 961], ["to", 970], ["an", 973], ["involvement", 976], ["of", 988], ["Swc4p", 991], ["in", 997], ["many", 1000], ["chromatin", 1005], ["-", 1014], ["based", 1015], ["processes", 1021], [".", 1030], ["The", 1032], ["mutants", 1036], ["'", 1043], ["phenotypes", 1045], ["did", 1056], ["not", 1060], ["result", 1064], ["from", 1071], ["an", 1076], ["impairment", 1079], ["of", 1090], ["histone", 1093], ["acetylation", 1101], [",", 1112], ["as", 1114], ["in", 1117], ["the", 1120], ["mutant", 1124], ["which", 1131], ["bears", 1137], ["the", 1143], ["shortest", 1147], ["isolated", 1156], ["variant", 1165], ["of", 1173], ["truncated", 1176], ["Swc4p", 1186], [",", 1191], ["the", 1193], ["level", 1197], ["of", 1203], ["overall", 1206], ["H4", 1214], ["acetylation", 1217], ["was", 1229], ["unchanged", 1233], [".", 1242]]}
{"context": "The mechanism of neurodegeneration in CAG/polyglutamine repeat expansion diseases is unknown but is thought to occur at the protein level. Here, in studies of spinocerebellar ataxia type 3, also known as Machado-Joseph disease (SCA3/MJD), we show that the disease protein ataxin-3 accumulates in ubiquitinated intranuclear inclusions selectively in neurons of affected brain regions. We further provide evidence in vitro for a model of disease in which an expanded polyglutamine-containing fragment recruits full-length protein into insoluble aggregates. Together with recent findings from transgenic models, our results suggest that intranuclear aggregation of the expanded protein is a unifying feature of CAG/polyglutamine diseases and may be initiated or catalyzed by a glutamine-containing fragment of the disease protein.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "353a222964794361bdaaf8ea481c12ee", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[50, 50]], "char_spans": [[272, 279]]}]}], "context_tokens": [["The", 0], ["mechanism", 4], ["of", 14], ["neurodegeneration", 17], ["in", 35], ["CAG", 38], ["/", 41], ["polyglutamine", 42], ["repeat", 56], ["expansion", 63], ["diseases", 73], ["is", 82], ["unknown", 85], ["but", 93], ["is", 97], ["thought", 100], ["to", 108], ["occur", 111], ["at", 117], ["the", 120], ["protein", 124], ["level", 132], [".", 137], ["Here", 139], [",", 143], ["in", 145], ["studies", 148], ["of", 156], ["spinocerebellar", 159], ["ataxia", 175], ["type", 182], ["3", 187], [",", 188], ["also", 190], ["known", 195], ["as", 201], ["Machado", 204], ["-", 211], ["Joseph", 212], ["disease", 219], ["(", 227], ["SCA3/MJD", 228], [")", 236], [",", 237], ["we", 239], ["show", 242], ["that", 247], ["the", 252], ["disease", 256], ["protein", 264], ["ataxin-3", 272], ["accumulates", 281], ["in", 293], ["ubiquitinated", 296], ["intranuclear", 310], ["inclusions", 323], ["selectively", 334], ["in", 346], ["neurons", 349], ["of", 357], ["affected", 360], ["brain", 369], ["regions", 375], [".", 382], ["We", 384], ["further", 387], ["provide", 395], ["evidence", 403], ["in", 412], ["vitro", 415], ["for", 421], ["a", 425], ["model", 427], ["of", 433], ["disease", 436], ["in", 444], ["which", 447], ["an", 453], ["expanded", 456], ["polyglutamine", 465], ["-", 478], ["containing", 479], ["fragment", 490], ["recruits", 499], ["full", 508], ["-", 512], ["length", 513], ["protein", 520], ["into", 528], ["insoluble", 533], ["aggregates", 543], [".", 553], ["Together", 555], ["with", 564], ["recent", 569], ["findings", 576], ["from", 585], ["transgenic", 590], ["models", 601], [",", 607], ["our", 609], ["results", 613], ["suggest", 621], ["that", 629], ["intranuclear", 634], ["aggregation", 647], ["of", 659], ["the", 662], ["expanded", 666], ["protein", 675], ["is", 683], ["a", 686], ["unifying", 688], ["feature", 697], ["of", 705], ["CAG", 708], ["/", 711], ["polyglutamine", 712], ["diseases", 726], ["and", 735], ["may", 739], ["be", 743], ["initiated", 746], ["or", 756], ["catalyzed", 759], ["by", 769], ["a", 772], ["glutamine", 774], ["-", 783], ["containing", 784], ["fragment", 795], ["of", 804], ["the", 807], ["disease", 811], ["protein", 819], [".", 826]]}
{"context": "Erythrasma is a superficial cutaneous infection caused by Corynebacterium minutissimum and is characterized by fluorescence under Wood's light (UV) because of the presence of porphyrins. These molecules are photosensitizing and we propose to assess efficacy of red light that activates porphyrins (photodynamic reaction) in treatment of this pathology. Assessment of effects of photodynamic action of red light for treatment of erythrasma without exogenous photosensitizing molecules. Thirteen patients with erythrasma were treated by one illumination (80 J/cm2) by red light (broad band, peak at 635 nm) without exogenous photosensitizing molecules. Disappearance or reduction of extent of lesions were observed 2 weeks later. If lesions were still present, a second irradiation was conducted with the same method. Preliminary results are presented. As a result of red light irradiation, we noticed a complete recovery for three patients and, in most other cases, reduction of extent of lesions (mean: -29% after one session). The treatment was well tolerated. We report first cases of photodynamic treatment of erythrasma. There are other reports of clinical applications of antimicrobial action of photodynamic therapy in dermatology (acne vulgaris, leishmaniasis, warts, etc.). But there are few applications without addition of exogenous photosensitizing agent. The originality and interest of our study is to use spontaneous presence of porphyrins in the lesions. This technique seems to be an interesting alternative, inexpensive and easy, for the treatment of this localized infection. But an optimal method is still to be determined to improve efficacy.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "6216a4e8801a4b69bc9d147d4f205120", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[8, 9]], "char_spans": [[58, 85]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["cutaneous", 28], ["infection", 38], ["caused", 48], ["by", 55], ["Corynebacterium", 58], ["minutissimum", 74], ["and", 87], ["is", 91], ["characterized", 94], ["by", 108], ["fluorescence", 111], ["under", 124], ["Wood", 130], ["'s", 134], ["light", 137], ["(", 143], ["UV", 144], [")", 146], ["because", 148], ["of", 156], ["the", 159], ["presence", 163], ["of", 172], ["porphyrins", 175], [".", 185], ["These", 187], ["molecules", 193], ["are", 203], ["photosensitizing", 207], ["and", 224], ["we", 228], ["propose", 231], ["to", 239], ["assess", 242], ["efficacy", 249], ["of", 258], ["red", 261], ["light", 265], ["that", 271], ["activates", 276], ["porphyrins", 286], ["(", 297], ["photodynamic", 298], ["reaction", 311], [")", 319], ["in", 321], ["treatment", 324], ["of", 334], ["this", 337], ["pathology", 342], [".", 351], ["Assessment", 353], ["of", 364], ["effects", 367], ["of", 375], ["photodynamic", 378], ["action", 391], ["of", 398], ["red", 401], ["light", 405], ["for", 411], ["treatment", 415], ["of", 425], ["erythrasma", 428], ["without", 439], ["exogenous", 447], ["photosensitizing", 457], ["molecules", 474], [".", 483], ["Thirteen", 485], ["patients", 494], ["with", 503], ["erythrasma", 508], ["were", 519], ["treated", 524], ["by", 532], ["one", 535], ["illumination", 539], ["(", 552], ["80", 553], ["J", 556], ["/", 557], ["cm2", 558], [")", 561], ["by", 563], ["red", 566], ["light", 570], ["(", 576], ["broad", 577], ["band", 583], [",", 587], ["peak", 589], ["at", 594], ["635", 597], ["nm", 601], [")", 603], ["without", 605], ["exogenous", 613], ["photosensitizing", 623], ["molecules", 640], [".", 649], ["Disappearance", 651], ["or", 665], ["reduction", 668], ["of", 678], ["extent", 681], ["of", 688], ["lesions", 691], ["were", 699], ["observed", 704], ["2", 713], ["weeks", 715], ["later", 721], [".", 726], ["If", 728], ["lesions", 731], ["were", 739], ["still", 744], ["present", 750], [",", 757], ["a", 759], ["second", 761], ["irradiation", 768], ["was", 780], ["conducted", 784], ["with", 794], ["the", 799], ["same", 803], ["method", 808], [".", 814], ["Preliminary", 816], ["results", 828], ["are", 836], ["presented", 840], [".", 849], ["As", 851], ["a", 854], ["result", 856], ["of", 863], ["red", 866], ["light", 870], ["irradiation", 876], [",", 887], ["we", 889], ["noticed", 892], ["a", 900], ["complete", 902], ["recovery", 911], ["for", 920], ["three", 924], ["patients", 930], ["and", 939], [",", 942], ["in", 944], ["most", 947], ["other", 952], ["cases", 958], [",", 963], ["reduction", 965], ["of", 975], ["extent", 978], ["of", 985], ["lesions", 988], ["(", 996], ["mean", 997], [":", 1001], ["-29", 1003], ["%", 1006], ["after", 1008], ["one", 1014], ["session", 1018], [")", 1025], [".", 1026], ["The", 1028], ["treatment", 1032], ["was", 1042], ["well", 1046], ["tolerated", 1051], [".", 1060], ["We", 1062], ["report", 1065], ["first", 1072], ["cases", 1078], ["of", 1084], ["photodynamic", 1087], ["treatment", 1100], ["of", 1110], ["erythrasma", 1113], [".", 1123], ["There", 1125], ["are", 1131], ["other", 1135], ["reports", 1141], ["of", 1149], ["clinical", 1152], ["applications", 1161], ["of", 1174], ["antimicrobial", 1177], ["action", 1191], ["of", 1198], ["photodynamic", 1201], ["therapy", 1214], ["in", 1222], ["dermatology", 1225], ["(", 1237], ["acne", 1238], ["vulgaris", 1243], [",", 1251], ["leishmaniasis", 1253], [",", 1266], ["warts", 1268], [",", 1273], ["etc", 1275], [".", 1278], [")", 1279], [".", 1280], ["But", 1282], ["there", 1286], ["are", 1292], ["few", 1296], ["applications", 1300], ["without", 1313], ["addition", 1321], ["of", 1330], ["exogenous", 1333], ["photosensitizing", 1343], ["agent", 1360], [".", 1365], ["The", 1367], ["originality", 1371], ["and", 1383], ["interest", 1387], ["of", 1396], ["our", 1399], ["study", 1403], ["is", 1409], ["to", 1412], ["use", 1415], ["spontaneous", 1419], ["presence", 1431], ["of", 1440], ["porphyrins", 1443], ["in", 1454], ["the", 1457], ["lesions", 1461], [".", 1468], ["This", 1470], ["technique", 1475], ["seems", 1485], ["to", 1491], ["be", 1494], ["an", 1497], ["interesting", 1500], ["alternative", 1512], [",", 1523], ["inexpensive", 1525], ["and", 1537], ["easy", 1541], [",", 1545], ["for", 1547], ["the", 1551], ["treatment", 1555], ["of", 1565], ["this", 1568], ["localized", 1573], ["infection", 1583], [".", 1592], ["But", 1594], ["an", 1598], ["optimal", 1601], ["method", 1609], ["is", 1616], ["still", 1619], ["to", 1625], ["be", 1628], ["determined", 1631], ["to", 1642], ["improve", 1645], ["efficacy", 1653], [".", 1661]]}
{"context": "Both restless legs syndrome ([RLS], also known as Willis-Ekbom Disease [WED]) and depression are common during pregnancy. However, no prior studies have assessed if pregnant women with RLS have an elevated risk of depression during and/or after pregnancy. 1,428 women who were pregnant in gestational week 16-17 were asked to participate in a longitudinal survey. They were followed by web-based questionnaires in gestational week 17 and 32, and 6 weeks after delivery. Data were also retrieved from prenatal and birth records. Two different sets of criteria were used to examine the prevalence of RLS in the cohort (International Restless Legs Syndrome Society Group standard criteria and the later developed CH-RLSQ11 questionnaire). The latter questionnaire attempts to exclude those with common \"mimics\" of RLS. Adjusted odds ratio for depression in gestational week 17, 32, and postpartum week 6 in relation to pre-pregnancy RLS onset and moderate to severe symptom severity were 4.74 (2.30 - 9.76), 3.67 (1.85 - 7.28), and 2.58 (1.28 - 5.21), respectively. No significant associations were seen in pregnant women with de novo RLS during pregnancy. When using the standard diagnostic RLS criteria and frequency of symptoms more than 2-3 days per week, the prevalence of RLS was 12.3%. With the CH-RLSQ11 questionnaire and the same threshold for frequency of symptoms the prevalence was 6.5%. Women with RLS onset before pregnancy with moderate or severe symptoms had an increased risk of both antenatal and postnatal depression. The self-reported prevalence of RLS during pregnancy is lower when a questionnaire dealing with \"mimics\" is used.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "c1bbf8276dad42dc8e9a68753159154e", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[1, 3], [119, 121]], "char_spans": [[5, 26], [631, 652]]}]}], "context_tokens": [["Both", 0], ["restless", 5], ["legs", 14], ["syndrome", 19], ["(", 28], ["[", 29], ["RLS", 30], ["]", 33], [",", 34], ["also", 36], ["known", 41], ["as", 47], ["Willis", 50], ["-", 56], ["Ekbom", 57], ["Disease", 63], ["[", 71], ["WED", 72], ["]", 75], [")", 76], ["and", 78], ["depression", 82], ["are", 93], ["common", 97], ["during", 104], ["pregnancy", 111], [".", 120], ["However", 122], [",", 129], ["no", 131], ["prior", 134], ["studies", 140], ["have", 148], ["assessed", 153], ["if", 162], ["pregnant", 165], ["women", 174], ["with", 180], ["RLS", 185], ["have", 189], ["an", 194], ["elevated", 197], ["risk", 206], ["of", 211], ["depression", 214], ["during", 225], ["and/or", 232], ["after", 239], ["pregnancy", 245], [".", 254], ["1,428", 256], ["women", 262], ["who", 268], ["were", 272], ["pregnant", 277], ["in", 286], ["gestational", 289], ["week", 301], ["16", 306], ["-", 308], ["17", 309], ["were", 312], ["asked", 317], ["to", 323], ["participate", 326], ["in", 338], ["a", 341], ["longitudinal", 343], ["survey", 356], [".", 362], ["They", 364], ["were", 369], ["followed", 374], ["by", 383], ["web", 386], ["-", 389], ["based", 390], ["questionnaires", 396], ["in", 411], ["gestational", 414], ["week", 426], ["17", 431], ["and", 434], ["32", 438], [",", 440], ["and", 442], ["6", 446], ["weeks", 448], ["after", 454], ["delivery", 460], [".", 468], ["Data", 470], ["were", 475], ["also", 480], ["retrieved", 485], ["from", 495], ["prenatal", 500], ["and", 509], ["birth", 513], ["records", 519], [".", 526], ["Two", 528], ["different", 532], ["sets", 542], ["of", 547], ["criteria", 550], ["were", 559], ["used", 564], ["to", 569], ["examine", 572], ["the", 580], ["prevalence", 584], ["of", 595], ["RLS", 598], ["in", 602], ["the", 605], ["cohort", 609], ["(", 616], ["International", 617], ["Restless", 631], ["Legs", 640], ["Syndrome", 645], ["Society", 654], ["Group", 662], ["standard", 668], ["criteria", 677], ["and", 686], ["the", 690], ["later", 694], ["developed", 700], ["CH", 710], ["-", 712], ["RLSQ11", 713], ["questionnaire", 720], [")", 733], [".", 734], ["The", 736], ["latter", 740], ["questionnaire", 747], ["attempts", 761], ["to", 770], ["exclude", 773], ["those", 781], ["with", 787], ["common", 792], ["\"", 799], ["mimics", 800], ["\"", 806], ["of", 808], ["RLS", 811], [".", 814], ["Adjusted", 816], ["odds", 825], ["ratio", 830], ["for", 836], ["depression", 840], ["in", 851], ["gestational", 854], ["week", 866], ["17", 871], [",", 873], ["32", 875], [",", 877], ["and", 879], ["postpartum", 883], ["week", 894], ["6", 899], ["in", 901], ["relation", 904], ["to", 913], ["pre", 916], ["-", 919], ["pregnancy", 920], ["RLS", 930], ["onset", 934], ["and", 940], ["moderate", 944], ["to", 953], ["severe", 956], ["symptom", 963], ["severity", 971], ["were", 980], ["4.74", 985], ["(", 990], ["2.30", 991], ["-", 996], ["9.76", 998], [")", 1002], [",", 1003], ["3.67", 1005], ["(", 1010], ["1.85", 1011], ["-", 1016], ["7.28", 1018], [")", 1022], [",", 1023], ["and", 1025], ["2.58", 1029], ["(", 1034], ["1.28", 1035], ["-", 1040], ["5.21", 1042], [")", 1046], [",", 1047], ["respectively", 1049], [".", 1061], ["No", 1063], ["significant", 1066], ["associations", 1078], ["were", 1091], ["seen", 1096], ["in", 1101], ["pregnant", 1104], ["women", 1113], ["with", 1119], ["de", 1124], ["novo", 1127], ["RLS", 1132], ["during", 1136], ["pregnancy", 1143], [".", 1152], ["When", 1154], ["using", 1159], ["the", 1165], ["standard", 1169], ["diagnostic", 1178], ["RLS", 1189], ["criteria", 1193], ["and", 1202], ["frequency", 1206], ["of", 1216], ["symptoms", 1219], ["more", 1228], ["than", 1233], ["2", 1238], ["-", 1239], ["3", 1240], ["days", 1242], ["per", 1247], ["week", 1251], [",", 1255], ["the", 1257], ["prevalence", 1261], ["of", 1272], ["RLS", 1275], ["was", 1279], ["12.3", 1283], ["%", 1287], [".", 1288], ["With", 1290], ["the", 1295], ["CH", 1299], ["-", 1301], ["RLSQ11", 1302], ["questionnaire", 1309], ["and", 1323], ["the", 1327], ["same", 1331], ["threshold", 1336], ["for", 1346], ["frequency", 1350], ["of", 1360], ["symptoms", 1363], ["the", 1372], ["prevalence", 1376], ["was", 1387], ["6.5", 1391], ["%", 1394], [".", 1395], ["Women", 1397], ["with", 1403], ["RLS", 1408], ["onset", 1412], ["before", 1418], ["pregnancy", 1425], ["with", 1435], ["moderate", 1440], ["or", 1449], ["severe", 1452], ["symptoms", 1459], ["had", 1468], ["an", 1472], ["increased", 1475], ["risk", 1485], ["of", 1490], ["both", 1493], ["antenatal", 1498], ["and", 1508], ["postnatal", 1512], ["depression", 1522], [".", 1532], ["The", 1534], ["self", 1538], ["-", 1542], ["reported", 1543], ["prevalence", 1552], ["of", 1563], ["RLS", 1566], ["during", 1570], ["pregnancy", 1577], ["is", 1587], ["lower", 1590], ["when", 1596], ["a", 1601], ["questionnaire", 1603], ["dealing", 1617], ["with", 1625], ["\"", 1630], ["mimics", 1631], ["\"", 1637], ["is", 1639], ["used", 1642], [".", 1646]]}
{"context": "Cep135 is a 135-kDa, coiled-coil centrosome protein important for microtubule organization in mammalian cells [Ohta et al., 2002: J. Cell Biol. 156:87-99]. To identify Cep135-interacting molecules, we screened yeast two-hybrid libraries. One clone encoded dynamitin, a p50 dynactin subunit, which localized at the centrosome and has been shown to be involved in anchoring microtubules to centrosomes. The central domain of p50 binds to the C-terminal sequence of Cep135; this was further confirmed by immunoprecipitation and immunostaining of CHO cells co-expressing the binding domains for Cep135 and p50. Exogenous p50 lacking the Cep 135-binding domain failed to locate at the centrosome, suggesting that Cep135 is required for initial targeting of the centrosome. Altered levels of Cep135 and p50 by RNAi and protein overexpression caused the release of endogenous partner molecules from centrosomes. This also resulted in dislocation of other centrosomal molecules, such as gamma-tubulin and pericentrin, ultimately leading to disorganization of microtubule patterns. These results suggest that Cep135 and p50 play an important role in assembly and maintenance of functional microtubule-organizing centers.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "08c3aa54125445ca90f9fe4a6632bcf7", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[134, 134], [8, 8], [59, 59], [122, 122]], "char_spans": [[756, 765], [33, 42], [314, 323], [680, 689]]}]}], "context_tokens": [["Cep135", 0], ["is", 7], ["a", 10], ["135-kDa", 12], [",", 19], ["coiled", 21], ["-", 27], ["coil", 28], ["centrosome", 33], ["protein", 44], ["important", 52], ["for", 62], ["microtubule", 66], ["organization", 78], ["in", 91], ["mammalian", 94], ["cells", 104], ["[", 110], ["Ohta", 111], ["et", 116], ["al", 119], [".", 121], [",", 122], ["2002", 124], [":", 128], ["J.", 130], ["Cell", 133], ["Biol", 138], [".", 142], ["156:87", 144], ["-", 150], ["99].", 151], ["To", 156], ["identify", 159], ["Cep135-interacting", 168], ["molecules", 187], [",", 196], ["we", 198], ["screened", 201], ["yeast", 210], ["two", 216], ["-", 219], ["hybrid", 220], ["libraries", 227], [".", 236], ["One", 238], ["clone", 242], ["encoded", 248], ["dynamitin", 256], [",", 265], ["a", 267], ["p50", 269], ["dynactin", 273], ["subunit", 282], [",", 289], ["which", 291], ["localized", 297], ["at", 307], ["the", 310], ["centrosome", 314], ["and", 325], ["has", 329], ["been", 333], ["shown", 338], ["to", 344], ["be", 347], ["involved", 350], ["in", 359], ["anchoring", 362], ["microtubules", 372], ["to", 385], ["centrosomes", 388], [".", 399], ["The", 401], ["central", 405], ["domain", 413], ["of", 420], ["p50", 423], ["binds", 427], ["to", 433], ["the", 436], ["C", 440], ["-", 441], ["terminal", 442], ["sequence", 451], ["of", 460], ["Cep135", 463], [";", 469], ["this", 471], ["was", 476], ["further", 480], ["confirmed", 488], ["by", 498], ["immunoprecipitation", 501], ["and", 521], ["immunostaining", 525], ["of", 540], ["CHO", 543], ["cells", 547], ["co", 553], ["-", 555], ["expressing", 556], ["the", 567], ["binding", 571], ["domains", 579], ["for", 587], ["Cep135", 591], ["and", 598], ["p50", 602], [".", 605], ["Exogenous", 607], ["p50", 617], ["lacking", 621], ["the", 629], ["Cep", 633], ["135-binding", 637], ["domain", 649], ["failed", 656], ["to", 663], ["locate", 666], ["at", 673], ["the", 676], ["centrosome", 680], [",", 690], ["suggesting", 692], ["that", 703], ["Cep135", 708], ["is", 715], ["required", 718], ["for", 727], ["initial", 731], ["targeting", 739], ["of", 749], ["the", 752], ["centrosome", 756], [".", 766], ["Altered", 768], ["levels", 776], ["of", 783], ["Cep135", 786], ["and", 793], ["p50", 797], ["by", 801], ["RNAi", 804], ["and", 809], ["protein", 813], ["overexpression", 821], ["caused", 836], ["the", 843], ["release", 847], ["of", 855], ["endogenous", 858], ["partner", 869], ["molecules", 877], ["from", 887], ["centrosomes", 892], [".", 903], ["This", 905], ["also", 910], ["resulted", 915], ["in", 924], ["dislocation", 927], ["of", 939], ["other", 942], ["centrosomal", 948], ["molecules", 960], [",", 969], ["such", 971], ["as", 976], ["gamma", 979], ["-", 984], ["tubulin", 985], ["and", 993], ["pericentrin", 997], [",", 1008], ["ultimately", 1010], ["leading", 1021], ["to", 1029], ["disorganization", 1032], ["of", 1048], ["microtubule", 1051], ["patterns", 1063], [".", 1071], ["These", 1073], ["results", 1079], ["suggest", 1087], ["that", 1095], ["Cep135", 1100], ["and", 1107], ["p50", 1111], ["play", 1115], ["an", 1120], ["important", 1123], ["role", 1133], ["in", 1138], ["assembly", 1141], ["and", 1150], ["maintenance", 1154], ["of", 1166], ["functional", 1169], ["microtubule", 1180], ["-", 1191], ["organizing", 1192], ["centers", 1203], [".", 1210]]}
{"context": "Imatinib mesylate is a new drug that can inhibit the tyrosine kinase activity of Bcr-Abl, the receptors for platelet-derived growth factor receptor(PDGF) and stem cell factor, or c-kit. Chronic myeloid leukemia (CML) is distinguished by the presence of a reciprocal translocation between chromosomes 9 and 22 that results in a shortened chromosome 22, termed the Philadelphia(Ph) chromosome. As a result of the translocation, a fusion gene called the Bcr-Abl gene is created from two normal cellular genes, encoding a chimeric Bcr-Abl protein with a deregulated tyrosine kinase activity. The expression of Bcr-Abl tyrosine kinase has been shown to be necessary and sufficient for the transformed phenotype of CML cells. Imatinib can block the kinase activity of Bcr-Abl, thus inhibiting the proliferation of Ph-positive progenitors, and has shown activity against all phases of CML, though responses are most substantial and durable in patients in the chronic phase. An international phase III study which compared the efficacy of imatinib with that of interferon alpha combined with low-dose cytarabine in newly diagnosed chronic-phase CML showed the rate of major cytogenetic response at 24 months was 90%, including 82% of complete cytogenetic response. These results indicated that imatinib was superior to interferon-containing treatment as a first-line therapy. More than 10,000 patients worldwide, including those in Japan, have been treated with imatinib in clinical trials, and a lot of information has been accumulated on the use of this drug. The aim of this article is to review the use of this drug and the practical management of patients with chronic myeloid leukemia.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7eb603c02b0c40579e66fe97ee76c19f", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[113, 115], [84, 86], [14, 16], [141, 143], [99, 101]], "char_spans": [[606, 612], [451, 457], [81, 87], [762, 768], [527, 533]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["is", 18], ["a", 21], ["new", 23], ["drug", 27], ["that", 32], ["can", 37], ["inhibit", 41], ["the", 49], ["tyrosine", 53], ["kinase", 62], ["activity", 69], ["of", 78], ["Bcr", 81], ["-", 84], ["Abl", 85], [",", 88], ["the", 90], ["receptors", 94], ["for", 104], ["platelet", 108], ["-", 116], ["derived", 117], ["growth", 125], ["factor", 132], ["receptor(PDGF", 139], [")", 152], ["and", 154], ["stem", 158], ["cell", 163], ["factor", 168], [",", 174], ["or", 176], ["c", 179], ["-", 180], ["kit", 181], [".", 184], ["Chronic", 186], ["myeloid", 194], ["leukemia", 202], ["(", 211], ["CML", 212], [")", 215], ["is", 217], ["distinguished", 220], ["by", 234], ["the", 237], ["presence", 241], ["of", 250], ["a", 253], ["reciprocal", 255], ["translocation", 266], ["between", 280], ["chromosomes", 288], ["9", 300], ["and", 302], ["22", 306], ["that", 309], ["results", 314], ["in", 322], ["a", 325], ["shortened", 327], ["chromosome", 337], ["22", 348], [",", 350], ["termed", 352], ["the", 359], ["Philadelphia(Ph", 363], [")", 378], ["chromosome", 380], [".", 390], ["As", 392], ["a", 395], ["result", 397], ["of", 404], ["the", 407], ["translocation", 411], [",", 424], ["a", 426], ["fusion", 428], ["gene", 435], ["called", 440], ["the", 447], ["Bcr", 451], ["-", 454], ["Abl", 455], ["gene", 459], ["is", 464], ["created", 467], ["from", 475], ["two", 480], ["normal", 484], ["cellular", 491], ["genes", 500], [",", 505], ["encoding", 507], ["a", 516], ["chimeric", 518], ["Bcr", 527], ["-", 530], ["Abl", 531], ["protein", 535], ["with", 543], ["a", 548], ["deregulated", 550], ["tyrosine", 562], ["kinase", 571], ["activity", 578], [".", 586], ["The", 588], ["expression", 592], ["of", 603], ["Bcr", 606], ["-", 609], ["Abl", 610], ["tyrosine", 614], ["kinase", 623], ["has", 630], ["been", 634], ["shown", 639], ["to", 645], ["be", 648], ["necessary", 651], ["and", 661], ["sufficient", 665], ["for", 676], ["the", 680], ["transformed", 684], ["phenotype", 696], ["of", 706], ["CML", 709], ["cells", 713], [".", 718], ["Imatinib", 720], ["can", 729], ["block", 733], ["the", 739], ["kinase", 743], ["activity", 750], ["of", 759], ["Bcr", 762], ["-", 765], ["Abl", 766], [",", 769], ["thus", 771], ["inhibiting", 776], ["the", 787], ["proliferation", 791], ["of", 805], ["Ph", 808], ["-", 810], ["positive", 811], ["progenitors", 820], [",", 831], ["and", 833], ["has", 837], ["shown", 841], ["activity", 847], ["against", 856], ["all", 864], ["phases", 868], ["of", 875], ["CML", 878], [",", 881], ["though", 883], ["responses", 890], ["are", 900], ["most", 904], ["substantial", 909], ["and", 921], ["durable", 925], ["in", 933], ["patients", 936], ["in", 945], ["the", 948], ["chronic", 952], ["phase", 960], [".", 965], ["An", 967], ["international", 970], ["phase", 984], ["III", 990], ["study", 994], ["which", 1000], ["compared", 1006], ["the", 1015], ["efficacy", 1019], ["of", 1028], ["imatinib", 1031], ["with", 1040], ["that", 1045], ["of", 1050], ["interferon", 1053], ["alpha", 1064], ["combined", 1070], ["with", 1079], ["low", 1084], ["-", 1087], ["dose", 1088], ["cytarabine", 1093], ["in", 1104], ["newly", 1107], ["diagnosed", 1113], ["chronic", 1123], ["-", 1130], ["phase", 1131], ["CML", 1137], ["showed", 1141], ["the", 1148], ["rate", 1152], ["of", 1157], ["major", 1160], ["cytogenetic", 1166], ["response", 1178], ["at", 1187], ["24", 1190], ["months", 1193], ["was", 1200], ["90", 1204], ["%", 1206], [",", 1207], ["including", 1209], ["82", 1219], ["%", 1221], ["of", 1223], ["complete", 1226], ["cytogenetic", 1235], ["response", 1247], [".", 1255], ["These", 1257], ["results", 1263], ["indicated", 1271], ["that", 1281], ["imatinib", 1286], ["was", 1295], ["superior", 1299], ["to", 1308], ["interferon", 1311], ["-", 1321], ["containing", 1322], ["treatment", 1333], ["as", 1343], ["a", 1346], ["first", 1348], ["-", 1353], ["line", 1354], ["therapy", 1359], [".", 1366], ["More", 1368], ["than", 1373], ["10,000", 1378], ["patients", 1385], ["worldwide", 1394], [",", 1403], ["including", 1405], ["those", 1415], ["in", 1421], ["Japan", 1424], [",", 1429], ["have", 1431], ["been", 1436], ["treated", 1441], ["with", 1449], ["imatinib", 1454], ["in", 1463], ["clinical", 1466], ["trials", 1475], [",", 1481], ["and", 1483], ["a", 1487], ["lot", 1489], ["of", 1493], ["information", 1496], ["has", 1508], ["been", 1512], ["accumulated", 1517], ["on", 1529], ["the", 1532], ["use", 1536], ["of", 1540], ["this", 1543], ["drug", 1548], [".", 1552], ["The", 1554], ["aim", 1558], ["of", 1562], ["this", 1565], ["article", 1570], ["is", 1578], ["to", 1581], ["review", 1584], ["the", 1591], ["use", 1595], ["of", 1599], ["this", 1602], ["drug", 1607], ["and", 1612], ["the", 1616], ["practical", 1620], ["management", 1630], ["of", 1641], ["patients", 1644], ["with", 1653], ["chronic", 1658], ["myeloid", 1666], ["leukemia", 1674], [".", 1682]]}
{"context": "Contrary to earlier beliefs, viruses are not the smallest causative agents of infectious diseases. Single-stranded RNAs as small as 246 nucleotides exist in certain higher plants and cause more than a dozen crop diseases. These RNAs have been termed viroids. Despite their extremely limited information content, viroids replicate autonomously in susceptible cells--that is, they do not require helper functions from simultaneously replicating conventional viruses. Viroids are covalently closed circular molecules with a characteristic rodlike secondary structure in which short helical regions are interrupted by internal and bulge loops. Viroids are not translated; they are replicated by a host enzyme (or enzymes) (probably RNA polymerase II) via oligomeric RNA intermediates by a rolling circle mechanism. Viroidlike satellite RNAs resemble viroids in size and molecular structure, but are found within the capsids of specific helper viruses on which they depend for their own replication. These RNAs are of great interest to molecular biology for at least two reasons: 1) they are the smallest and simplest replicating molecules known, and 2) they may represent living fossils of precellular evolution in a hypothetical RNA world.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "2f0016f1f1004c60afce22d6816d93e1", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[75, 75], [53, 53], [100, 100], [44, 44], [136, 136]], "char_spans": [[465, 471], [312, 318], [640, 646], [250, 256], [846, 852]]}]}], "context_tokens": [["Contrary", 0], ["to", 9], ["earlier", 12], ["beliefs", 20], [",", 27], ["viruses", 29], ["are", 37], ["not", 41], ["the", 45], ["smallest", 49], ["causative", 58], ["agents", 68], ["of", 75], ["infectious", 78], ["diseases", 89], [".", 97], ["Single", 99], ["-", 105], ["stranded", 106], ["RNAs", 115], ["as", 120], ["small", 123], ["as", 129], ["246", 132], ["nucleotides", 136], ["exist", 148], ["in", 154], ["certain", 157], ["higher", 165], ["plants", 172], ["and", 179], ["cause", 183], ["more", 189], ["than", 194], ["a", 199], ["dozen", 201], ["crop", 207], ["diseases", 212], [".", 220], ["These", 222], ["RNAs", 228], ["have", 233], ["been", 238], ["termed", 243], ["viroids", 250], [".", 257], ["Despite", 259], ["their", 267], ["extremely", 273], ["limited", 283], ["information", 291], ["content", 303], [",", 310], ["viroids", 312], ["replicate", 320], ["autonomously", 330], ["in", 343], ["susceptible", 346], ["cells", 358], ["--", 363], ["that", 365], ["is", 370], [",", 372], ["they", 374], ["do", 379], ["not", 382], ["require", 386], ["helper", 394], ["functions", 401], ["from", 411], ["simultaneously", 416], ["replicating", 431], ["conventional", 443], ["viruses", 456], [".", 463], ["Viroids", 465], ["are", 473], ["covalently", 477], ["closed", 488], ["circular", 495], ["molecules", 504], ["with", 514], ["a", 519], ["characteristic", 521], ["rodlike", 536], ["secondary", 544], ["structure", 554], ["in", 564], ["which", 567], ["short", 573], ["helical", 579], ["regions", 587], ["are", 595], ["interrupted", 599], ["by", 611], ["internal", 614], ["and", 623], ["bulge", 627], ["loops", 633], [".", 638], ["Viroids", 640], ["are", 648], ["not", 652], ["translated", 656], [";", 666], ["they", 668], ["are", 673], ["replicated", 677], ["by", 688], ["a", 691], ["host", 693], ["enzyme", 698], ["(", 705], ["or", 706], ["enzymes", 709], [")", 716], ["(", 718], ["probably", 719], ["RNA", 728], ["polymerase", 732], ["II", 743], [")", 745], ["via", 747], ["oligomeric", 751], ["RNA", 762], ["intermediates", 766], ["by", 780], ["a", 783], ["rolling", 785], ["circle", 793], ["mechanism", 800], [".", 809], ["Viroidlike", 811], ["satellite", 822], ["RNAs", 832], ["resemble", 837], ["viroids", 846], ["in", 854], ["size", 857], ["and", 862], ["molecular", 866], ["structure", 876], [",", 885], ["but", 887], ["are", 891], ["found", 895], ["within", 901], ["the", 908], ["capsids", 912], ["of", 920], ["specific", 923], ["helper", 932], ["viruses", 939], ["on", 947], ["which", 950], ["they", 956], ["depend", 961], ["for", 968], ["their", 972], ["own", 978], ["replication", 982], [".", 993], ["These", 995], ["RNAs", 1001], ["are", 1006], ["of", 1010], ["great", 1013], ["interest", 1019], ["to", 1028], ["molecular", 1031], ["biology", 1041], ["for", 1049], ["at", 1053], ["least", 1056], ["two", 1062], ["reasons", 1066], [":", 1073], ["1", 1075], [")", 1076], ["they", 1078], ["are", 1083], ["the", 1087], ["smallest", 1091], ["and", 1100], ["simplest", 1104], ["replicating", 1113], ["molecules", 1125], ["known", 1135], [",", 1140], ["and", 1142], ["2", 1146], [")", 1147], ["they", 1149], ["may", 1154], ["represent", 1158], ["living", 1168], ["fossils", 1175], ["of", 1183], ["precellular", 1186], ["evolution", 1198], ["in", 1208], ["a", 1211], ["hypothetical", 1213], ["RNA", 1226], ["world", 1230], [".", 1235]]}
{"context": "Henoch-Sch\u00f6nlein purpura (HSP) is the most common form of childhood vasculitis. Various viral and bacterial infections, drugs, vaccines, food allergy and even insect bites have been considered as triggering factors in pathogenesis of HSP. Epstein-Barr virus (EBV) infection, which is associated with HSP, have been rarely reported. Herein we present HSP patient possibly caused by EBV infection. A 8-year old boy was admitted to our department with fever, rashes on legs and arms and intermittent mild abdominal pain. Multiple purpuric rashes were on his extremities, abdomen and buttock. Laboratory investigations revealed that monospot test was positive, EBV serology tests; Anti-EA-D Ig G: 3+, Anti-VCA gp125 Ig G: 3+, Anti-VCA p19 Ig M: 2+, Anti EBNA-1 Ig M: negative, Anti EBNA-1 Ig M: negative, Anti EBNA-1 Ig G: negative. The patient was interpreted as the primary active acute EBV infection. A skin biopsy showed leucocytoclastic vasculitis. The other viral and bacterial investigations were negative. The patient was diagnosed as HSP vasculitis according to EULAR criteria and treated with intravenous hydration and ibuprofen. He was discharged after 15 days with normal laboratory findings and physical examination. We think that EBV infection may be stimulant factor for autoimmune reactions and may cause HSP vasculitis. Hence, it may be useful to investigate the EBV infection in etiology of HSP cases.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "0e6c87f5f0c94291853b04cbabd336bd", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[43, 46]], "char_spans": [[239, 256]]}]}], "context_tokens": [["Henoch", 0], ["-", 6], ["Sch\u00f6nlein", 7], ["purpura", 17], ["(", 25], ["HSP", 26], [")", 29], ["is", 31], ["the", 34], ["most", 38], ["common", 43], ["form", 50], ["of", 55], ["childhood", 58], ["vasculitis", 68], [".", 78], ["Various", 80], ["viral", 88], ["and", 94], ["bacterial", 98], ["infections", 108], [",", 118], ["drugs", 120], [",", 125], ["vaccines", 127], [",", 135], ["food", 137], ["allergy", 142], ["and", 150], ["even", 154], ["insect", 159], ["bites", 166], ["have", 172], ["been", 177], ["considered", 182], ["as", 193], ["triggering", 196], ["factors", 207], ["in", 215], ["pathogenesis", 218], ["of", 231], ["HSP", 234], [".", 237], ["Epstein", 239], ["-", 246], ["Barr", 247], ["virus", 252], ["(", 258], ["EBV", 259], [")", 262], ["infection", 264], [",", 273], ["which", 275], ["is", 281], ["associated", 284], ["with", 295], ["HSP", 300], [",", 303], ["have", 305], ["been", 310], ["rarely", 315], ["reported", 322], [".", 330], ["Herein", 332], ["we", 339], ["present", 342], ["HSP", 350], ["patient", 354], ["possibly", 362], ["caused", 371], ["by", 378], ["EBV", 381], ["infection", 385], [".", 394], ["A", 396], ["8-year", 398], ["old", 405], ["boy", 409], ["was", 413], ["admitted", 417], ["to", 426], ["our", 429], ["department", 433], ["with", 444], ["fever", 449], [",", 454], ["rashes", 456], ["on", 463], ["legs", 466], ["and", 471], ["arms", 475], ["and", 480], ["intermittent", 484], ["mild", 497], ["abdominal", 502], ["pain", 512], [".", 516], ["Multiple", 518], ["purpuric", 527], ["rashes", 536], ["were", 543], ["on", 548], ["his", 551], ["extremities", 555], [",", 566], ["abdomen", 568], ["and", 576], ["buttock", 580], [".", 587], ["Laboratory", 589], ["investigations", 600], ["revealed", 615], ["that", 624], ["monospot", 629], ["test", 638], ["was", 643], ["positive", 647], [",", 655], ["EBV", 657], ["serology", 661], ["tests", 670], [";", 675], ["Anti", 677], ["-", 681], ["EA", 682], ["-", 684], ["D", 685], ["Ig", 687], ["G", 690], [":", 691], ["3", 693], ["+", 694], [",", 695], ["Anti", 697], ["-", 701], ["VCA", 702], ["gp125", 706], ["Ig", 712], ["G", 715], [":", 716], ["3", 718], ["+", 719], [",", 720], ["Anti", 722], ["-", 726], ["VCA", 727], ["p19", 731], ["Ig", 735], ["M", 738], [":", 739], ["2", 741], ["+", 742], [",", 743], ["Anti", 745], ["EBNA-1", 750], ["Ig", 757], ["M", 760], [":", 761], ["negative", 763], [",", 771], ["Anti", 773], ["EBNA-1", 778], ["Ig", 785], ["M", 788], [":", 789], ["negative", 791], [",", 799], ["Anti", 801], ["EBNA-1", 806], ["Ig", 813], ["G", 816], [":", 817], ["negative", 819], [".", 827], ["The", 829], ["patient", 833], ["was", 841], ["interpreted", 845], ["as", 857], ["the", 860], ["primary", 864], ["active", 872], ["acute", 879], ["EBV", 885], ["infection", 889], [".", 898], ["A", 900], ["skin", 902], ["biopsy", 907], ["showed", 914], ["leucocytoclastic", 921], ["vasculitis", 938], [".", 948], ["The", 950], ["other", 954], ["viral", 960], ["and", 966], ["bacterial", 970], ["investigations", 980], ["were", 995], ["negative", 1000], [".", 1008], ["The", 1010], ["patient", 1014], ["was", 1022], ["diagnosed", 1026], ["as", 1036], ["HSP", 1039], ["vasculitis", 1043], ["according", 1054], ["to", 1064], ["EULAR", 1067], ["criteria", 1073], ["and", 1082], ["treated", 1086], ["with", 1094], ["intravenous", 1099], ["hydration", 1111], ["and", 1121], ["ibuprofen", 1125], [".", 1134], ["He", 1136], ["was", 1139], ["discharged", 1143], ["after", 1154], ["15", 1160], ["days", 1163], ["with", 1168], ["normal", 1173], ["laboratory", 1180], ["findings", 1191], ["and", 1200], ["physical", 1204], ["examination", 1213], [".", 1224], ["We", 1226], ["think", 1229], ["that", 1235], ["EBV", 1240], ["infection", 1244], ["may", 1254], ["be", 1258], ["stimulant", 1261], ["factor", 1271], ["for", 1278], ["autoimmune", 1282], ["reactions", 1293], ["and", 1303], ["may", 1307], ["cause", 1311], ["HSP", 1317], ["vasculitis", 1321], [".", 1331], ["Hence", 1333], [",", 1338], ["it", 1340], ["may", 1343], ["be", 1347], ["useful", 1350], ["to", 1357], ["investigate", 1360], ["the", 1372], ["EBV", 1376], ["infection", 1380], ["in", 1390], ["etiology", 1393], ["of", 1402], ["HSP", 1405], ["cases", 1409], [".", 1414]]}
{"context": "This was a 12-week randomized, placebo-controlled trial to assess the efficacy of quetiapine monotherapy in the treatment of posttraumatic stress disorder (PTSD). Eighty patients were randomly assigned to treatment with either quetiapine or placebo. The primary outcome measure was the Clinician-Administered PTSD Scale (CAPS). Secondary efficacy measures included the CAPS subscales, the Davidson Trauma Scale, the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions (CGI) scales for severity of Illness and improvement, the Hamilton Depression Rating Scale (HAM-D), and the Hamilton Anxiety Rating Scale (HAM-A). Safety measurements included adverse events, vital signs, the Abnormal Involuntary Movement Scale, the Barnes Akathisia Scale, the Simpson-Angus Scale, and the Arizona Sexual Experiences Scale. After a 1-week placebo run-in, quetiapine was started at a daily dosage of 25 mg and increased to a maximum of 800 mg; the average was 258 mg (range, 50-800 mg). Reductions in CAPS total, re-experiencing, and hyperarousal scores were significantly greater for the quetiapine group than for the placebo group. Greater improvements were also observed for quetiapine in scores on the Davidson Trauma Scale, CGI severity and improvement ratings, PANSS positive symptom and general psychopathology subscales, HAM-A, and HAM-D than for placebo. Adverse events were generally mild and expected based on prior studies of quetiapine in this and other patient population. There were no differences in safety measures between groups. Quetiapine monotherapy was efficacious in the treatment of PTSD. These findings suggest quetiapine as a single agent is effective in treating military PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "9dafa681f75c4bb190fa51f4757a6056", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[295, 295], [25, 25], [310, 310], [50, 50]], "char_spans": [[1617, 1620], [156, 159], [1709, 1712], [309, 312]]}]}], "context_tokens": [["This", 0], ["was", 5], ["a", 9], ["12-week", 11], ["randomized", 19], [",", 29], ["placebo", 31], ["-", 38], ["controlled", 39], ["trial", 50], ["to", 56], ["assess", 59], ["the", 66], ["efficacy", 70], ["of", 79], ["quetiapine", 82], ["monotherapy", 93], ["in", 105], ["the", 108], ["treatment", 112], ["of", 122], ["posttraumatic", 125], ["stress", 139], ["disorder", 146], ["(", 155], ["PTSD", 156], [")", 160], [".", 161], ["Eighty", 163], ["patients", 170], ["were", 179], ["randomly", 184], ["assigned", 193], ["to", 202], ["treatment", 205], ["with", 215], ["either", 220], ["quetiapine", 227], ["or", 238], ["placebo", 241], [".", 248], ["The", 250], ["primary", 254], ["outcome", 262], ["measure", 270], ["was", 278], ["the", 282], ["Clinician", 286], ["-", 295], ["Administered", 296], ["PTSD", 309], ["Scale", 314], ["(", 320], ["CAPS", 321], [")", 325], [".", 326], ["Secondary", 328], ["efficacy", 338], ["measures", 347], ["included", 356], ["the", 365], ["CAPS", 369], ["subscales", 374], [",", 383], ["the", 385], ["Davidson", 389], ["Trauma", 398], ["Scale", 405], [",", 410], ["the", 412], ["Positive", 416], ["and", 425], ["Negative", 429], ["Syndrome", 438], ["Scale", 447], ["(", 453], ["PANSS", 454], [")", 459], [",", 460], ["the", 462], ["Clinical", 466], ["Global", 475], ["Impressions", 482], ["(", 494], ["CGI", 495], [")", 498], ["scales", 500], ["for", 507], ["severity", 511], ["of", 520], ["Illness", 523], ["and", 531], ["improvement", 535], [",", 546], ["the", 548], ["Hamilton", 552], ["Depression", 561], ["Rating", 572], ["Scale", 579], ["(", 585], ["HAM", 586], ["-", 589], ["D", 590], [")", 591], [",", 592], ["and", 594], ["the", 598], ["Hamilton", 602], ["Anxiety", 611], ["Rating", 619], ["Scale", 626], ["(", 632], ["HAM", 633], ["-", 636], ["A", 637], [")", 638], [".", 639], ["Safety", 641], ["measurements", 648], ["included", 661], ["adverse", 670], ["events", 678], [",", 684], ["vital", 686], ["signs", 692], [",", 697], ["the", 699], ["Abnormal", 703], ["Involuntary", 712], ["Movement", 724], ["Scale", 733], [",", 738], ["the", 740], ["Barnes", 744], ["Akathisia", 751], ["Scale", 761], [",", 766], ["the", 768], ["Simpson", 772], ["-", 779], ["Angus", 780], ["Scale", 786], [",", 791], ["and", 793], ["the", 797], ["Arizona", 801], ["Sexual", 809], ["Experiences", 816], ["Scale", 828], [".", 833], ["After", 835], ["a", 841], ["1-week", 843], ["placebo", 850], ["run", 858], ["-", 861], ["in", 862], [",", 864], ["quetiapine", 866], ["was", 877], ["started", 881], ["at", 889], ["a", 892], ["daily", 894], ["dosage", 900], ["of", 907], ["25", 910], ["mg", 913], ["and", 916], ["increased", 920], ["to", 930], ["a", 933], ["maximum", 935], ["of", 943], ["800", 946], ["mg", 950], [";", 952], ["the", 954], ["average", 958], ["was", 966], ["258", 970], ["mg", 974], ["(", 977], ["range", 978], [",", 983], ["50", 985], ["-", 987], ["800", 988], ["mg", 992], [")", 994], [".", 995], ["Reductions", 997], ["in", 1008], ["CAPS", 1011], ["total", 1016], [",", 1021], ["re", 1023], ["-", 1025], ["experiencing", 1026], [",", 1038], ["and", 1040], ["hyperarousal", 1044], ["scores", 1057], ["were", 1064], ["significantly", 1069], ["greater", 1083], ["for", 1091], ["the", 1095], ["quetiapine", 1099], ["group", 1110], ["than", 1116], ["for", 1121], ["the", 1125], ["placebo", 1129], ["group", 1137], [".", 1142], ["Greater", 1144], ["improvements", 1152], ["were", 1165], ["also", 1170], ["observed", 1175], ["for", 1184], ["quetiapine", 1188], ["in", 1199], ["scores", 1202], ["on", 1209], ["the", 1212], ["Davidson", 1216], ["Trauma", 1225], ["Scale", 1232], [",", 1237], ["CGI", 1239], ["severity", 1243], ["and", 1252], ["improvement", 1256], ["ratings", 1268], [",", 1275], ["PANSS", 1277], ["positive", 1283], ["symptom", 1292], ["and", 1300], ["general", 1304], ["psychopathology", 1312], ["subscales", 1328], [",", 1337], ["HAM", 1339], ["-", 1342], ["A", 1343], [",", 1344], ["and", 1346], ["HAM", 1350], ["-", 1353], ["D", 1354], ["than", 1356], ["for", 1361], ["placebo", 1365], [".", 1372], ["Adverse", 1374], ["events", 1382], ["were", 1389], ["generally", 1394], ["mild", 1404], ["and", 1409], ["expected", 1413], ["based", 1422], ["on", 1428], ["prior", 1431], ["studies", 1437], ["of", 1445], ["quetiapine", 1448], ["in", 1459], ["this", 1462], ["and", 1467], ["other", 1471], ["patient", 1477], ["population", 1485], [".", 1495], ["There", 1497], ["were", 1503], ["no", 1508], ["differences", 1511], ["in", 1523], ["safety", 1526], ["measures", 1533], ["between", 1542], ["groups", 1550], [".", 1556], ["Quetiapine", 1558], ["monotherapy", 1569], ["was", 1581], ["efficacious", 1585], ["in", 1597], ["the", 1600], ["treatment", 1604], ["of", 1614], ["PTSD", 1617], [".", 1621], ["These", 1623], ["findings", 1629], ["suggest", 1638], ["quetiapine", 1646], ["as", 1657], ["a", 1660], ["single", 1662], ["agent", 1669], ["is", 1675], ["effective", 1678], ["in", 1688], ["treating", 1691], ["military", 1700], ["PTSD", 1709], [".", 1713]]}
{"context": "The aim of the study was to determine the frequency and type of MRSA strains and antibiotic susceptibility in Al-Zahra Hospital, Isfahan, Iran. In an analytic descriptive survey in 2005 and early 2006, patients admitted to the hospital who contracted S. aureus nosocomial infections were enrolled in the study. All isolates were identified by the conventional laboratory tests. Minimal Inhibitory Concentration (MIC) of oxacillin on isolated bacteria was determined by E-Test method. According to Clinical and Laboratory Standard Institute (CLSI) criteria all strains with MIC of > or = 4 microg for oxacillin were identified as MRSA. Intrinsic high level resistance (mecA positive) and borderline oxacillin resistant Staphylococcus aureus (BORSA) were detected by amoxicillin-clavulanate E-test strips. Strains with MIC of > or = 4 microg for oxacillin and > or = 8 microg for amoxicillin-clavulanate were identified as mecA positive MRSA. Other staphylococcus with MIC > or = 4 microg for oxacillin and < or = 4 for amoxicillin-clavulanate were identified as mecA negative MRSA (BORSA). MIC of vancomycin also was determined on isolated bacteria. Data were analyzed by SPSS version 13 and Who net version 5. Out of 134 Staphylococcus aureus samples which were isolated from nosocomial infections 90 (67.2%) were MRSA. Sixty seven out of 90 (74.5%) MRSA were mecA positive and 23 out of 90 (25.5%) were mecA negative (BORSA). Although most of the MRSA strains were isolated from surgical site infections, there were no statistically significant differences between types of Staphylococcus aureus growing from variant sites of infections. Only one (1.49) of the mecA positive MRSA had reduced susceptibility to vancomycin but all of the mecA-negative MRSA (BORSA) were sensitive to it. Because one fourth of our staphylococcus strains are mecA negative BORSA and there is no alternative for vancomycin against mecA positive MRSA and Enterococcus spp. in our hospital, vancomycin should be reserved only for life threatening infections due to these organisms. Thus MRSA typing should be done to choose appropriate antibiotic for optimal treatment of MRSA infections.", "qas": [{"question": "What is BORSA?", "answers": ["borderline oxacillin resistant Staphylococcus aureus", "Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "d3cb2ae20ed644fa9da62fd47344b395", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[122, 126]], "char_spans": [[687, 738]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["the", 11], ["study", 15], ["was", 21], ["to", 25], ["determine", 28], ["the", 38], ["frequency", 42], ["and", 52], ["type", 56], ["of", 61], ["MRSA", 64], ["strains", 69], ["and", 77], ["antibiotic", 81], ["susceptibility", 92], ["in", 107], ["Al", 110], ["-", 112], ["Zahra", 113], ["Hospital", 119], [",", 127], ["Isfahan", 129], [",", 136], ["Iran", 138], [".", 142], ["In", 144], ["an", 147], ["analytic", 150], ["descriptive", 159], ["survey", 171], ["in", 178], ["2005", 181], ["and", 186], ["early", 190], ["2006", 196], [",", 200], ["patients", 202], ["admitted", 211], ["to", 220], ["the", 223], ["hospital", 227], ["who", 236], ["contracted", 240], ["S.", 251], ["aureus", 254], ["nosocomial", 261], ["infections", 272], ["were", 283], ["enrolled", 288], ["in", 297], ["the", 300], ["study", 304], [".", 309], ["All", 311], ["isolates", 315], ["were", 324], ["identified", 329], ["by", 340], ["the", 343], ["conventional", 347], ["laboratory", 360], ["tests", 371], [".", 376], ["Minimal", 378], ["Inhibitory", 386], ["Concentration", 397], ["(", 411], ["MIC", 412], [")", 415], ["of", 417], ["oxacillin", 420], ["on", 430], ["isolated", 433], ["bacteria", 442], ["was", 451], ["determined", 455], ["by", 466], ["E", 469], ["-", 470], ["Test", 471], ["method", 476], [".", 482], ["According", 484], ["to", 494], ["Clinical", 497], ["and", 506], ["Laboratory", 510], ["Standard", 521], ["Institute", 530], ["(", 540], ["CLSI", 541], [")", 545], ["criteria", 547], ["all", 556], ["strains", 560], ["with", 568], ["MIC", 573], ["of", 577], [">", 580], ["or", 582], ["=", 585], ["4", 587], ["microg", 589], ["for", 596], ["oxacillin", 600], ["were", 610], ["identified", 615], ["as", 626], ["MRSA", 629], [".", 633], ["Intrinsic", 635], ["high", 645], ["level", 650], ["resistance", 656], ["(", 667], ["mecA", 668], ["positive", 673], [")", 681], ["and", 683], ["borderline", 687], ["oxacillin", 698], ["resistant", 708], ["Staphylococcus", 718], ["aureus", 733], ["(", 740], ["BORSA", 741], [")", 746], ["were", 748], ["detected", 753], ["by", 762], ["amoxicillin", 765], ["-", 776], ["clavulanate", 777], ["E", 789], ["-", 790], ["test", 791], ["strips", 796], [".", 802], ["Strains", 804], ["with", 812], ["MIC", 817], ["of", 821], [">", 824], ["or", 826], ["=", 829], ["4", 831], ["microg", 833], ["for", 840], ["oxacillin", 844], ["and", 854], [">", 858], ["or", 860], ["=", 863], ["8", 865], ["microg", 867], ["for", 874], ["amoxicillin", 878], ["-", 889], ["clavulanate", 890], ["were", 902], ["identified", 907], ["as", 918], ["mecA", 921], ["positive", 926], ["MRSA", 935], [".", 939], ["Other", 941], ["staphylococcus", 947], ["with", 962], ["MIC", 967], [">", 971], ["or", 973], ["=", 976], ["4", 978], ["microg", 980], ["for", 987], ["oxacillin", 991], ["and", 1001], ["<", 1005], ["or", 1007], ["=", 1010], ["4", 1012], ["for", 1014], ["amoxicillin", 1018], ["-", 1029], ["clavulanate", 1030], ["were", 1042], ["identified", 1047], ["as", 1058], ["mecA", 1061], ["negative", 1066], ["MRSA", 1075], ["(", 1080], ["BORSA", 1081], [")", 1086], [".", 1087], ["MIC", 1089], ["of", 1093], ["vancomycin", 1096], ["also", 1107], ["was", 1112], ["determined", 1116], ["on", 1127], ["isolated", 1130], ["bacteria", 1139], [".", 1147], ["Data", 1149], ["were", 1154], ["analyzed", 1159], ["by", 1168], ["SPSS", 1171], ["version", 1176], ["13", 1184], ["and", 1187], ["Who", 1191], ["net", 1195], ["version", 1199], ["5", 1207], [".", 1208], ["Out", 1210], ["of", 1214], ["134", 1217], ["Staphylococcus", 1221], ["aureus", 1236], ["samples", 1243], ["which", 1251], ["were", 1257], ["isolated", 1262], ["from", 1271], ["nosocomial", 1276], ["infections", 1287], ["90", 1298], ["(", 1301], ["67.2", 1302], ["%", 1306], [")", 1307], ["were", 1309], ["MRSA", 1314], [".", 1318], ["Sixty", 1320], ["seven", 1326], ["out", 1332], ["of", 1336], ["90", 1339], ["(", 1342], ["74.5", 1343], ["%", 1347], [")", 1348], ["MRSA", 1350], ["were", 1355], ["mecA", 1360], ["positive", 1365], ["and", 1374], ["23", 1378], ["out", 1381], ["of", 1385], ["90", 1388], ["(", 1391], ["25.5", 1392], ["%", 1396], [")", 1397], ["were", 1399], ["mecA", 1404], ["negative", 1409], ["(", 1418], ["BORSA", 1419], [")", 1424], [".", 1425], ["Although", 1427], ["most", 1436], ["of", 1441], ["the", 1444], ["MRSA", 1448], ["strains", 1453], ["were", 1461], ["isolated", 1466], ["from", 1475], ["surgical", 1480], ["site", 1489], ["infections", 1494], [",", 1504], ["there", 1506], ["were", 1512], ["no", 1517], ["statistically", 1520], ["significant", 1534], ["differences", 1546], ["between", 1558], ["types", 1566], ["of", 1572], ["Staphylococcus", 1575], ["aureus", 1590], ["growing", 1597], ["from", 1605], ["variant", 1610], ["sites", 1618], ["of", 1624], ["infections", 1627], [".", 1637], ["Only", 1639], ["one", 1644], ["(", 1648], ["1.49", 1649], [")", 1653], ["of", 1655], ["the", 1658], ["mecA", 1662], ["positive", 1667], ["MRSA", 1676], ["had", 1681], ["reduced", 1685], ["susceptibility", 1693], ["to", 1708], ["vancomycin", 1711], ["but", 1722], ["all", 1726], ["of", 1730], ["the", 1733], ["mecA", 1737], ["-", 1741], ["negative", 1742], ["MRSA", 1751], ["(", 1756], ["BORSA", 1757], [")", 1762], ["were", 1764], ["sensitive", 1769], ["to", 1779], ["it", 1782], [".", 1784], ["Because", 1786], ["one", 1794], ["fourth", 1798], ["of", 1805], ["our", 1808], ["staphylococcus", 1812], ["strains", 1827], ["are", 1835], ["mecA", 1839], ["negative", 1844], ["BORSA", 1853], ["and", 1859], ["there", 1863], ["is", 1869], ["no", 1872], ["alternative", 1875], ["for", 1887], ["vancomycin", 1891], ["against", 1902], ["mecA", 1910], ["positive", 1915], ["MRSA", 1924], ["and", 1929], ["Enterococcus", 1933], ["spp", 1946], [".", 1949], ["in", 1951], ["our", 1954], ["hospital", 1958], [",", 1966], ["vancomycin", 1968], ["should", 1979], ["be", 1986], ["reserved", 1989], ["only", 1998], ["for", 2003], ["life", 2007], ["threatening", 2012], ["infections", 2024], ["due", 2035], ["to", 2039], ["these", 2042], ["organisms", 2048], [".", 2057], ["Thus", 2059], ["MRSA", 2064], ["typing", 2069], ["should", 2076], ["be", 2083], ["done", 2086], ["to", 2091], ["choose", 2094], ["appropriate", 2101], ["antibiotic", 2113], ["for", 2124], ["optimal", 2128], ["treatment", 2136], ["of", 2146], ["MRSA", 2149], ["infections", 2154], [".", 2164]]}
{"context": "Chronic myeloid leukemia (CML) is a clonal malignant myeloproliferative disorder characterized by the expansion of hematopoietic cells carrying the Philadelphia chromosome (t 9.22). Our main objective was to assess the efficacy of imatinib in CML patients, measured by their survival. Over a six-year period (June 2003 through May 2009), 25 patients were seen regularly for CML at the Lom\u00e9 Campus teaching hospital. Patients received imatinib after diagnosis and underwent regular laboratory monitoring (quantification of BCR-ABL ratio by RT-PCR). Patients' survival and treatment response were evaluated. Patients' mean age at diagnosis was 40 years (range: 9 to 72 years). Men predominated (17 compared with 7 women). Splenomegaly was found in 80% of cases. The mean leukocyte level was 188.71 g/L (24.4-350). Six patients (24%) had thrombocytosis with a mean platelet count of 491.15 g/L (108-2000). Six patients (24%) died after developing accelerated-phase CML or blast crisis. Estimated overall survival of patients at 6 years was 60%. Molecular biology monitoring detected a secondary G250E mutation with resistance to imatinib in one patient. Standard hematological side effects led to reduction in imatinib doses. The principal nonhematological side effects were weight gain and transient digestible disorders. At six years after diagnosis, imatinib was effective in treating patients with CML, even in sub-Saharan Africa. Mutation-induced resistance required regular molecular biological monitoring to determine the need to switch to later-generation tyrosine kinase inhibitors.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "5d0e918abb8649f49a8cdb096d471c53", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[88, 90]], "char_spans": [[522, 528]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["clonal", 36], ["malignant", 43], ["myeloproliferative", 53], ["disorder", 72], ["characterized", 81], ["by", 95], ["the", 98], ["expansion", 102], ["of", 112], ["hematopoietic", 115], ["cells", 129], ["carrying", 135], ["the", 144], ["Philadelphia", 148], ["chromosome", 161], ["(", 172], ["t", 173], ["9.22", 175], [")", 179], [".", 180], ["Our", 182], ["main", 186], ["objective", 191], ["was", 201], ["to", 205], ["assess", 208], ["the", 215], ["efficacy", 219], ["of", 228], ["imatinib", 231], ["in", 240], ["CML", 243], ["patients", 247], [",", 255], ["measured", 257], ["by", 266], ["their", 269], ["survival", 275], [".", 283], ["Over", 285], ["a", 290], ["six", 292], ["-", 295], ["year", 296], ["period", 301], ["(", 308], ["June", 309], ["2003", 314], ["through", 319], ["May", 327], ["2009", 331], [")", 335], [",", 336], ["25", 338], ["patients", 341], ["were", 350], ["seen", 355], ["regularly", 360], ["for", 370], ["CML", 374], ["at", 378], ["the", 381], ["Lom\u00e9", 385], ["Campus", 390], ["teaching", 397], ["hospital", 406], [".", 414], ["Patients", 416], ["received", 425], ["imatinib", 434], ["after", 443], ["diagnosis", 449], ["and", 459], ["underwent", 463], ["regular", 473], ["laboratory", 481], ["monitoring", 492], ["(", 503], ["quantification", 504], ["of", 519], ["BCR", 522], ["-", 525], ["ABL", 526], ["ratio", 530], ["by", 536], ["RT", 539], ["-", 541], ["PCR", 542], [")", 545], [".", 546], ["Patients", 548], ["'", 556], ["survival", 558], ["and", 567], ["treatment", 571], ["response", 581], ["were", 590], ["evaluated", 595], [".", 604], ["Patients", 606], ["'", 614], ["mean", 616], ["age", 621], ["at", 625], ["diagnosis", 628], ["was", 638], ["40", 642], ["years", 645], ["(", 651], ["range", 652], [":", 657], ["9", 659], ["to", 661], ["72", 664], ["years", 667], [")", 672], [".", 673], ["Men", 675], ["predominated", 679], ["(", 692], ["17", 693], ["compared", 696], ["with", 705], ["7", 710], ["women", 712], [")", 717], [".", 718], ["Splenomegaly", 720], ["was", 733], ["found", 737], ["in", 743], ["80", 746], ["%", 748], ["of", 750], ["cases", 753], [".", 758], ["The", 760], ["mean", 764], ["leukocyte", 769], ["level", 779], ["was", 785], ["188.71", 789], ["g", 796], ["/", 797], ["L", 798], ["(", 800], ["24.4", 801], ["-", 805], ["350", 806], [")", 809], [".", 810], ["Six", 812], ["patients", 816], ["(", 825], ["24", 826], ["%", 828], [")", 829], ["had", 831], ["thrombocytosis", 835], ["with", 850], ["a", 855], ["mean", 857], ["platelet", 862], ["count", 871], ["of", 877], ["491.15", 880], ["g", 887], ["/", 888], ["L", 889], ["(", 891], ["108", 892], ["-", 895], ["2000", 896], [")", 900], [".", 901], ["Six", 903], ["patients", 907], ["(", 916], ["24", 917], ["%", 919], [")", 920], ["died", 922], ["after", 927], ["developing", 933], ["accelerated", 944], ["-", 955], ["phase", 956], ["CML", 962], ["or", 966], ["blast", 969], ["crisis", 975], [".", 981], ["Estimated", 983], ["overall", 993], ["survival", 1001], ["of", 1010], ["patients", 1013], ["at", 1022], ["6", 1025], ["years", 1027], ["was", 1033], ["60", 1037], ["%", 1039], [".", 1040], ["Molecular", 1042], ["biology", 1052], ["monitoring", 1060], ["detected", 1071], ["a", 1080], ["secondary", 1082], ["G250E", 1092], ["mutation", 1098], ["with", 1107], ["resistance", 1112], ["to", 1123], ["imatinib", 1126], ["in", 1135], ["one", 1138], ["patient", 1142], [".", 1149], ["Standard", 1151], ["hematological", 1160], ["side", 1174], ["effects", 1179], ["led", 1187], ["to", 1191], ["reduction", 1194], ["in", 1204], ["imatinib", 1207], ["doses", 1216], [".", 1221], ["The", 1223], ["principal", 1227], ["nonhematological", 1237], ["side", 1254], ["effects", 1259], ["were", 1267], ["weight", 1272], ["gain", 1279], ["and", 1284], ["transient", 1288], ["digestible", 1298], ["disorders", 1309], [".", 1318], ["At", 1320], ["six", 1323], ["years", 1327], ["after", 1333], ["diagnosis", 1339], [",", 1348], ["imatinib", 1350], ["was", 1359], ["effective", 1363], ["in", 1373], ["treating", 1376], ["patients", 1385], ["with", 1394], ["CML", 1399], [",", 1402], ["even", 1404], ["in", 1409], ["sub", 1412], ["-", 1415], ["Saharan", 1416], ["Africa", 1424], [".", 1430], ["Mutation", 1432], ["-", 1440], ["induced", 1441], ["resistance", 1449], ["required", 1460], ["regular", 1469], ["molecular", 1477], ["biological", 1487], ["monitoring", 1498], ["to", 1509], ["determine", 1512], ["the", 1522], ["need", 1526], ["to", 1531], ["switch", 1534], ["to", 1541], ["later", 1544], ["-", 1549], ["generation", 1550], ["tyrosine", 1561], ["kinase", 1570], ["inhibitors", 1577], [".", 1587]]}
{"context": "Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the development and progression of Philadelphia chromosome-positive (Ph(+)) chronic myelogenous leukemia (CML). Imatinib mesylate (STI571), a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor, has shown encouraging activity in phase I and II studies of CML. Here, we describe the use of imatinib mesylate to treat 75 patients in blast-phase CML (median age, 53 years; 65 with nonlymphoid and 10 with lymphoid blasts), and compare the results with those of a historical control group treated with standard cytarabine-based therapy. Imatinib mesylate was given as oral doses at 300 to 1000 mg per day and was the first salvage therapy for 47 patients. The objective response rate was 52% (39 of 75 patients: 16 had complete and 3 had partial hematologic response; 12 had hematologic improvement; 7 returned to second chronic phase; and 1 had a complete response in extramedullary blastic disease). Response rates were not different between nonlymphoid and lymphoid groups. The cytogenetic response rate was 16% (12 patients: 5 complete, 3 partial [Ph(+) below 35%], and 4 minor [Ph(+), 34% to 90%]). The estimated median overall survival was 6.5 months; the estimated 1-year survival was 22%. Response to therapy (landmark analysis at 8 weeks) was associated with survival prolongation. Compared with standard cytarabine combinations, imatinib mesylate therapy was less toxic and produced a higher response rate (55% versus 29%, P =.001), longer median survival (7 versus 4 months, P =.04), and lower 4-week induction mortality (4% versus 15%, P =.07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "130270c72b1842a69ae47929d7075090", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[42, 44], [6, 8]], "char_spans": [[238, 244], [45, 51]]}]}], "context_tokens": [["Molecular", 0], ["abnormalities", 10], ["caused", 24], ["by", 31], ["the", 34], ["hybrid", 38], ["Bcr", 45], ["-", 48], ["Abl", 49], ["gene", 53], ["are", 58], ["causally", 62], ["associated", 71], ["with", 82], ["the", 87], ["development", 91], ["and", 103], ["progression", 107], ["of", 119], ["Philadelphia", 122], ["chromosome", 135], ["-", 145], ["positive", 146], ["(", 155], ["Ph(+", 156], [")", 160], [")", 161], ["chronic", 163], ["myelogenous", 171], ["leukemia", 183], ["(", 192], ["CML", 193], [")", 196], [".", 197], ["Imatinib", 199], ["mesylate", 208], ["(", 217], ["STI571", 218], [")", 224], [",", 225], ["a", 227], ["specific", 229], ["Bcr", 238], ["-", 241], ["Abl", 242], ["tyrosine", 246], ["-", 254], ["kinase", 255], ["signal", 262], ["-", 268], ["transduction", 269], ["inhibitor", 282], [",", 291], ["has", 293], ["shown", 297], ["encouraging", 303], ["activity", 315], ["in", 324], ["phase", 327], ["I", 333], ["and", 335], ["II", 339], ["studies", 342], ["of", 350], ["CML", 353], [".", 356], ["Here", 358], [",", 362], ["we", 364], ["describe", 367], ["the", 376], ["use", 380], ["of", 384], ["imatinib", 387], ["mesylate", 396], ["to", 405], ["treat", 408], ["75", 414], ["patients", 417], ["in", 426], ["blast", 429], ["-", 434], ["phase", 435], ["CML", 441], ["(", 445], ["median", 446], ["age", 453], [",", 456], ["53", 458], ["years", 461], [";", 466], ["65", 468], ["with", 471], ["nonlymphoid", 476], ["and", 488], ["10", 492], ["with", 495], ["lymphoid", 500], ["blasts", 509], [")", 515], [",", 516], ["and", 518], ["compare", 522], ["the", 530], ["results", 534], ["with", 542], ["those", 547], ["of", 553], ["a", 556], ["historical", 558], ["control", 569], ["group", 577], ["treated", 583], ["with", 591], ["standard", 596], ["cytarabine", 605], ["-", 615], ["based", 616], ["therapy", 622], [".", 629], ["Imatinib", 631], ["mesylate", 640], ["was", 649], ["given", 653], ["as", 659], ["oral", 662], ["doses", 667], ["at", 673], ["300", 676], ["to", 680], ["1000", 683], ["mg", 688], ["per", 691], ["day", 695], ["and", 699], ["was", 703], ["the", 707], ["first", 711], ["salvage", 717], ["therapy", 725], ["for", 733], ["47", 737], ["patients", 740], [".", 748], ["The", 750], ["objective", 754], ["response", 764], ["rate", 773], ["was", 778], ["52", 782], ["%", 784], ["(", 786], ["39", 787], ["of", 790], ["75", 793], ["patients", 796], [":", 804], ["16", 806], ["had", 809], ["complete", 813], ["and", 822], ["3", 826], ["had", 828], ["partial", 832], ["hematologic", 840], ["response", 852], [";", 860], ["12", 862], ["had", 865], ["hematologic", 869], ["improvement", 881], [";", 892], ["7", 894], ["returned", 896], ["to", 905], ["second", 908], ["chronic", 915], ["phase", 923], [";", 928], ["and", 930], ["1", 934], ["had", 936], ["a", 940], ["complete", 942], ["response", 951], ["in", 960], ["extramedullary", 963], ["blastic", 978], ["disease", 986], [")", 993], [".", 994], ["Response", 996], ["rates", 1005], ["were", 1011], ["not", 1016], ["different", 1020], ["between", 1030], ["nonlymphoid", 1038], ["and", 1050], ["lymphoid", 1054], ["groups", 1063], [".", 1069], ["The", 1071], ["cytogenetic", 1075], ["response", 1087], ["rate", 1096], ["was", 1101], ["16", 1105], ["%", 1107], ["(", 1109], ["12", 1110], ["patients", 1113], [":", 1121], ["5", 1123], ["complete", 1125], [",", 1133], ["3", 1135], ["partial", 1137], ["[", 1145], ["Ph(+", 1146], [")", 1150], ["below", 1152], ["35", 1158], ["%", 1160], ["]", 1161], [",", 1162], ["and", 1164], ["4", 1168], ["minor", 1170], ["[", 1176], ["Ph(+", 1177], [")", 1181], [",", 1182], ["34", 1184], ["%", 1186], ["to", 1188], ["90", 1191], ["%", 1193], ["]", 1194], [")", 1195], [".", 1196], ["The", 1198], ["estimated", 1202], ["median", 1212], ["overall", 1219], ["survival", 1227], ["was", 1236], ["6.5", 1240], ["months", 1244], [";", 1250], ["the", 1252], ["estimated", 1256], ["1-year", 1266], ["survival", 1273], ["was", 1282], ["22", 1286], ["%", 1288], [".", 1289], ["Response", 1291], ["to", 1300], ["therapy", 1303], ["(", 1311], ["landmark", 1312], ["analysis", 1321], ["at", 1330], ["8", 1333], ["weeks", 1335], [")", 1340], ["was", 1342], ["associated", 1346], ["with", 1357], ["survival", 1362], ["prolongation", 1371], [".", 1383], ["Compared", 1385], ["with", 1394], ["standard", 1399], ["cytarabine", 1408], ["combinations", 1419], [",", 1431], ["imatinib", 1433], ["mesylate", 1442], ["therapy", 1451], ["was", 1459], ["less", 1463], ["toxic", 1468], ["and", 1474], ["produced", 1478], ["a", 1487], ["higher", 1489], ["response", 1496], ["rate", 1505], ["(", 1510], ["55", 1511], ["%", 1513], ["versus", 1515], ["29", 1522], ["%", 1524], [",", 1525], ["P", 1527], ["=", 1529], [".001", 1530], [")", 1534], [",", 1535], ["longer", 1537], ["median", 1544], ["survival", 1551], ["(", 1560], ["7", 1561], ["versus", 1563], ["4", 1570], ["months", 1572], [",", 1578], ["P", 1580], ["=", 1582], [".04", 1583], [")", 1586], [",", 1587], ["and", 1589], ["lower", 1593], ["4-week", 1599], ["induction", 1606], ["mortality", 1616], ["(", 1626], ["4", 1627], ["%", 1628], ["versus", 1630], ["15", 1637], ["%", 1639], [",", 1640], ["P", 1642], ["=", 1644], [".07", 1645], [")", 1648], [".", 1649], ["Imatinib", 1651], ["mesylate", 1660], ["is", 1669], ["currently", 1672], ["being", 1682], ["tested", 1688], ["in", 1695], ["combination", 1698], ["with", 1710], ["other", 1715], ["drugs", 1721], ["to", 1727], ["improve", 1730], ["the", 1738], ["prognosis", 1742], ["for", 1752], ["blast", 1756], ["-", 1761], ["phase", 1762], ["CML", 1768], [".", 1771]]}
{"context": "Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are present in lung adenocarcinomas that respond to the EGFR inhibitors gefitinib and erlotinib. Two types of mutations account for approximately 90% of mutated cases: short in-frame deletions in exon 19 and a specific point mutation in exon 21 at codon 858 (L858R). Screening for these mutations has been based mainly on direct sequencing. We report here the development and validation of polymerase chain reaction-based assays for these two predominant types of EGFR mutations. The assay for exon 19 mutations is based on length analysis of fluorescently labeled polymerase chain reaction products, and the assay for the exon 21 L858R mutation is based on a new Sau96I restriction site created by this mutation. Using serial dilutions of DNAs from lung cancer cell lines harboring either exon 19 or 21 mutations, we detected these mutations in the presence of up to approximately 90% normal DNA. In a test set of 39 lung cancer samples, direct sequencing detected mutations in 25 cases whereas our assays were positive in 29 cases, including 4 cases in which mutations were not apparent by sequencing. These assays offer higher sensitivity and ease of scoring and eliminate the need for sequencing, providing a robust and accessible approach to the rapid identification of most lung cancer patients likely to respond to EGFR inhibitors.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "a19945a83e2d457caf189e2614c1ac05", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[9, 16]], "char_spans": [[55, 98]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["the", 21], ["tyrosine", 25], ["kinase", 34], ["domain", 41], ["of", 48], ["the", 51], ["epidermal", 55], ["growth", 65], ["factor", 72], ["receptor", 79], ["(", 88], ["EGFR", 89], [")", 93], ["gene", 95], ["are", 100], ["present", 104], ["in", 112], ["lung", 115], ["adenocarcinomas", 120], ["that", 136], ["respond", 141], ["to", 149], ["the", 152], ["EGFR", 156], ["inhibitors", 161], ["gefitinib", 172], ["and", 182], ["erlotinib", 186], [".", 195], ["Two", 197], ["types", 201], ["of", 207], ["mutations", 210], ["account", 220], ["for", 228], ["approximately", 232], ["90", 246], ["%", 248], ["of", 250], ["mutated", 253], ["cases", 261], [":", 266], ["short", 268], ["in", 274], ["-", 276], ["frame", 277], ["deletions", 283], ["in", 293], ["exon", 296], ["19", 301], ["and", 304], ["a", 308], ["specific", 310], ["point", 319], ["mutation", 325], ["in", 334], ["exon", 337], ["21", 342], ["at", 345], ["codon", 348], ["858", 354], ["(", 358], ["L858R", 359], [")", 364], [".", 365], ["Screening", 367], ["for", 377], ["these", 381], ["mutations", 387], ["has", 397], ["been", 401], ["based", 406], ["mainly", 412], ["on", 419], ["direct", 422], ["sequencing", 429], [".", 439], ["We", 441], ["report", 444], ["here", 451], ["the", 456], ["development", 460], ["and", 472], ["validation", 476], ["of", 487], ["polymerase", 490], ["chain", 501], ["reaction", 507], ["-", 515], ["based", 516], ["assays", 522], ["for", 529], ["these", 533], ["two", 539], ["predominant", 543], ["types", 555], ["of", 561], ["EGFR", 564], ["mutations", 569], [".", 578], ["The", 580], ["assay", 584], ["for", 590], ["exon", 594], ["19", 599], ["mutations", 602], ["is", 612], ["based", 615], ["on", 621], ["length", 624], ["analysis", 631], ["of", 640], ["fluorescently", 643], ["labeled", 657], ["polymerase", 665], ["chain", 676], ["reaction", 682], ["products", 691], [",", 699], ["and", 701], ["the", 705], ["assay", 709], ["for", 715], ["the", 719], ["exon", 723], ["21", 728], ["L858R", 731], ["mutation", 737], ["is", 746], ["based", 749], ["on", 755], ["a", 758], ["new", 760], ["Sau96I", 764], ["restriction", 771], ["site", 783], ["created", 788], ["by", 796], ["this", 799], ["mutation", 804], [".", 812], ["Using", 814], ["serial", 820], ["dilutions", 827], ["of", 837], ["DNAs", 840], ["from", 845], ["lung", 850], ["cancer", 855], ["cell", 862], ["lines", 867], ["harboring", 873], ["either", 883], ["exon", 890], ["19", 895], ["or", 898], ["21", 901], ["mutations", 904], [",", 913], ["we", 915], ["detected", 918], ["these", 927], ["mutations", 933], ["in", 943], ["the", 946], ["presence", 950], ["of", 959], ["up", 962], ["to", 965], ["approximately", 968], ["90", 982], ["%", 984], ["normal", 986], ["DNA", 993], [".", 996], ["In", 998], ["a", 1001], ["test", 1003], ["set", 1008], ["of", 1012], ["39", 1015], ["lung", 1018], ["cancer", 1023], ["samples", 1030], [",", 1037], ["direct", 1039], ["sequencing", 1046], ["detected", 1057], ["mutations", 1066], ["in", 1076], ["25", 1079], ["cases", 1082], ["whereas", 1088], ["our", 1096], ["assays", 1100], ["were", 1107], ["positive", 1112], ["in", 1121], ["29", 1124], ["cases", 1127], [",", 1132], ["including", 1134], ["4", 1144], ["cases", 1146], ["in", 1152], ["which", 1155], ["mutations", 1161], ["were", 1171], ["not", 1176], ["apparent", 1180], ["by", 1189], ["sequencing", 1192], [".", 1202], ["These", 1204], ["assays", 1210], ["offer", 1217], ["higher", 1223], ["sensitivity", 1230], ["and", 1242], ["ease", 1246], ["of", 1251], ["scoring", 1254], ["and", 1262], ["eliminate", 1266], ["the", 1276], ["need", 1280], ["for", 1285], ["sequencing", 1289], [",", 1299], ["providing", 1301], ["a", 1311], ["robust", 1313], ["and", 1320], ["accessible", 1324], ["approach", 1335], ["to", 1344], ["the", 1347], ["rapid", 1351], ["identification", 1357], ["of", 1372], ["most", 1375], ["lung", 1380], ["cancer", 1385], ["patients", 1392], ["likely", 1401], ["to", 1408], ["respond", 1411], ["to", 1419], ["EGFR", 1422], ["inhibitors", 1427], [".", 1437]]}
{"context": "Peripheral neuropathy (PN) has been reported in idiopathic and hereditary forms of parkinsonism, but the pathogenic mechanisms are unclear and likely heterogeneous. Levodopa-induced vitamin B12 deficiency has been discussed as a causal factor of PN in idiopathic Parkinson's disease, but peripheral nervous system involvement might also be a consequence of the underlying neurodegenerative process. Occurrence of PN with parkinsonism has been associated with a panel of mitochondrial cytopathies, more frequently related to a nuclear gene defect and mainly polymerase gamma (POLG1) gene. Parkin (PARK2) gene mutations are responsible for juvenile parkinsonism, and possible peripheral nervous system involvement has been reported. Rarely, an association of parkinsonism with PN may be encountered in other neurodegenerative diseases such as fragile X-associated tremor and ataxia syndrome related to premutation CGG repeat expansion in the fragile X mental retardation (FMR1) gene, Machado-Joseph disease related to an abnormal CAG repeat expansion in ataxin-3 (ATXN3) gene, Kufor-Rakeb syndrome caused by mutations in ATP13A2 gene, or in hereditary systemic disorders such as Gaucher disease due to mutations in the \u03b2-glucocerebrosidase (GBA) gene and Chediak-Higashi syndrome due to LYST gene mutations. This article reviews conditions in which PN may coexist with parkinsonism.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "ccaf40e8947045dbb86dafd325b2f626", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[216, 217]], "char_spans": [[1285, 1293]]}]}], "context_tokens": [["Peripheral", 0], ["neuropathy", 11], ["(", 22], ["PN", 23], [")", 25], ["has", 27], ["been", 31], ["reported", 36], ["in", 45], ["idiopathic", 48], ["and", 59], ["hereditary", 63], ["forms", 74], ["of", 80], ["parkinsonism", 83], [",", 95], ["but", 97], ["the", 101], ["pathogenic", 105], ["mechanisms", 116], ["are", 127], ["unclear", 131], ["and", 139], ["likely", 143], ["heterogeneous", 150], [".", 163], ["Levodopa", 165], ["-", 173], ["induced", 174], ["vitamin", 182], ["B12", 190], ["deficiency", 194], ["has", 205], ["been", 209], ["discussed", 214], ["as", 224], ["a", 227], ["causal", 229], ["factor", 236], ["of", 243], ["PN", 246], ["in", 249], ["idiopathic", 252], ["Parkinson", 263], ["'s", 272], ["disease", 275], [",", 282], ["but", 284], ["peripheral", 288], ["nervous", 299], ["system", 307], ["involvement", 314], ["might", 326], ["also", 332], ["be", 337], ["a", 340], ["consequence", 342], ["of", 354], ["the", 357], ["underlying", 361], ["neurodegenerative", 372], ["process", 390], [".", 397], ["Occurrence", 399], ["of", 410], ["PN", 413], ["with", 416], ["parkinsonism", 421], ["has", 434], ["been", 438], ["associated", 443], ["with", 454], ["a", 459], ["panel", 461], ["of", 467], ["mitochondrial", 470], ["cytopathies", 484], [",", 495], ["more", 497], ["frequently", 502], ["related", 513], ["to", 521], ["a", 524], ["nuclear", 526], ["gene", 534], ["defect", 539], ["and", 546], ["mainly", 550], ["polymerase", 557], ["gamma", 568], ["(", 574], ["POLG1", 575], [")", 580], ["gene", 582], [".", 586], ["Parkin", 588], ["(", 595], ["PARK2", 596], [")", 601], ["gene", 603], ["mutations", 608], ["are", 618], ["responsible", 622], ["for", 634], ["juvenile", 638], ["parkinsonism", 647], [",", 659], ["and", 661], ["possible", 665], ["peripheral", 674], ["nervous", 685], ["system", 693], ["involvement", 700], ["has", 712], ["been", 716], ["reported", 721], [".", 729], ["Rarely", 731], [",", 737], ["an", 739], ["association", 742], ["of", 754], ["parkinsonism", 757], ["with", 770], ["PN", 775], ["may", 778], ["be", 782], ["encountered", 785], ["in", 797], ["other", 800], ["neurodegenerative", 806], ["diseases", 824], ["such", 833], ["as", 838], ["fragile", 841], ["X", 849], ["-", 850], ["associated", 851], ["tremor", 862], ["and", 869], ["ataxia", 873], ["syndrome", 880], ["related", 889], ["to", 897], ["premutation", 900], ["CGG", 912], ["repeat", 916], ["expansion", 923], ["in", 933], ["the", 936], ["fragile", 940], ["X", 948], ["mental", 950], ["retardation", 957], ["(", 969], ["FMR1", 970], [")", 974], ["gene", 976], [",", 980], ["Machado", 982], ["-", 989], ["Joseph", 990], ["disease", 997], ["related", 1005], ["to", 1013], ["an", 1016], ["abnormal", 1019], ["CAG", 1028], ["repeat", 1032], ["expansion", 1039], ["in", 1049], ["ataxin-3", 1052], ["(", 1061], ["ATXN3", 1062], [")", 1067], ["gene", 1069], [",", 1073], ["Kufor", 1075], ["-", 1080], ["Rakeb", 1081], ["syndrome", 1087], ["caused", 1096], ["by", 1103], ["mutations", 1106], ["in", 1116], ["ATP13A2", 1119], ["gene", 1127], [",", 1131], ["or", 1133], ["in", 1136], ["hereditary", 1139], ["systemic", 1150], ["disorders", 1159], ["such", 1169], ["as", 1174], ["Gaucher", 1177], ["disease", 1185], ["due", 1193], ["to", 1197], ["mutations", 1200], ["in", 1210], ["the", 1213], ["\u03b2", 1217], ["-", 1218], ["glucocerebrosidase", 1219], ["(", 1238], ["GBA", 1239], [")", 1242], ["gene", 1244], ["and", 1249], ["Chediak", 1253], ["-", 1260], ["Higashi", 1261], ["syndrome", 1269], ["due", 1278], ["to", 1282], ["LYST", 1285], ["gene", 1290], ["mutations", 1295], [".", 1304], ["This", 1306], ["article", 1311], ["reviews", 1319], ["conditions", 1327], ["in", 1338], ["which", 1341], ["PN", 1347], ["may", 1350], ["coexist", 1354], ["with", 1362], ["parkinsonism", 1367], [".", 1379]]}
{"context": "Erythrasma is a superficial infection caused by Corynebacterium minutissimum and affects the major skin folds and the interdigital regions of the feet. It is characterized by erythematous, brown, scaly patches and maceration, and exhibits coral-red fluorescence under Wood light. The aim of this study was to determine the frequency of erythrasma in patients with interdigital lesions. An open, prospective, longitudinal, observational study was performed in a hospital in Mexico City between March and December, 2006. All patients with interdigital lesions were examined with a Wood lamp and direct examination was performed with 20 % potassium hydroxide. Cultures were done in Sabouraud dextrose agar and brain heart infusion agar, and smears were analyzed. General characteristics and concomitant diseases were recorded. We examined 73 patients, of whom 24 (32.8 %) were diagnosed with erythrasma based on coral-red fluorescence under Wood light and identification of corynebacteria by Gram staining. The disease was more common in women (83.33 %) and the mean age of the patients was 43.5 years. The main clinical findings were scaling and maceration, and the fourth interdigital web was the most commonly affected. Corynebacterium could not be isolated in any of the cases. Mycology was positive in 15 cases (62.5 %) and the following microorganisms were isolated: Candida (16.6 %), dermatophytes (12.5 %), and Trichosporon (4.1 %). Interdigital erythrasma is a common condition and can be easily confused with interdigital tinea. It persists if not treated appropriately. Rapid diagnosis is easily obtained by examination with a Wood lamp, while culture is difficult and unnecessary for diagnosis. The coexistence of erythrasma with dermatophytes and Candida should be considered when the interdigital webs are affected.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "c5a3515ce38440f0bf803e4cbe2c9b10", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[7, 8]], "char_spans": [[48, 75]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["infection", 28], ["caused", 38], ["by", 45], ["Corynebacterium", 48], ["minutissimum", 64], ["and", 77], ["affects", 81], ["the", 89], ["major", 93], ["skin", 99], ["folds", 104], ["and", 110], ["the", 114], ["interdigital", 118], ["regions", 131], ["of", 139], ["the", 142], ["feet", 146], [".", 150], ["It", 152], ["is", 155], ["characterized", 158], ["by", 172], ["erythematous", 175], [",", 187], ["brown", 189], [",", 194], ["scaly", 196], ["patches", 202], ["and", 210], ["maceration", 214], [",", 224], ["and", 226], ["exhibits", 230], ["coral", 239], ["-", 244], ["red", 245], ["fluorescence", 249], ["under", 262], ["Wood", 268], ["light", 273], [".", 278], ["The", 280], ["aim", 284], ["of", 288], ["this", 291], ["study", 296], ["was", 302], ["to", 306], ["determine", 309], ["the", 319], ["frequency", 323], ["of", 333], ["erythrasma", 336], ["in", 347], ["patients", 350], ["with", 359], ["interdigital", 364], ["lesions", 377], [".", 384], ["An", 386], ["open", 389], [",", 393], ["prospective", 395], [",", 406], ["longitudinal", 408], [",", 420], ["observational", 422], ["study", 436], ["was", 442], ["performed", 446], ["in", 456], ["a", 459], ["hospital", 461], ["in", 470], ["Mexico", 473], ["City", 480], ["between", 485], ["March", 493], ["and", 499], ["December", 503], [",", 511], ["2006", 513], [".", 517], ["All", 519], ["patients", 523], ["with", 532], ["interdigital", 537], ["lesions", 550], ["were", 558], ["examined", 563], ["with", 572], ["a", 577], ["Wood", 579], ["lamp", 584], ["and", 589], ["direct", 593], ["examination", 600], ["was", 612], ["performed", 616], ["with", 626], ["20", 631], ["%", 634], ["potassium", 636], ["hydroxide", 646], [".", 655], ["Cultures", 657], ["were", 666], ["done", 671], ["in", 676], ["Sabouraud", 679], ["dextrose", 689], ["agar", 698], ["and", 703], ["brain", 707], ["heart", 713], ["infusion", 719], ["agar", 728], [",", 732], ["and", 734], ["smears", 738], ["were", 745], ["analyzed", 750], [".", 758], ["General", 760], ["characteristics", 768], ["and", 784], ["concomitant", 788], ["diseases", 800], ["were", 809], ["recorded", 814], [".", 822], ["We", 824], ["examined", 827], ["73", 836], ["patients", 839], [",", 847], ["of", 849], ["whom", 852], ["24", 857], ["(", 860], ["32.8", 861], ["%", 866], [")", 867], ["were", 869], ["diagnosed", 874], ["with", 884], ["erythrasma", 889], ["based", 900], ["on", 906], ["coral", 909], ["-", 914], ["red", 915], ["fluorescence", 919], ["under", 932], ["Wood", 938], ["light", 943], ["and", 949], ["identification", 953], ["of", 968], ["corynebacteria", 971], ["by", 986], ["Gram", 989], ["staining", 994], [".", 1002], ["The", 1004], ["disease", 1008], ["was", 1016], ["more", 1020], ["common", 1025], ["in", 1032], ["women", 1035], ["(", 1041], ["83.33", 1042], ["%", 1048], [")", 1049], ["and", 1051], ["the", 1055], ["mean", 1059], ["age", 1064], ["of", 1068], ["the", 1071], ["patients", 1075], ["was", 1084], ["43.5", 1088], ["years", 1093], [".", 1098], ["The", 1100], ["main", 1104], ["clinical", 1109], ["findings", 1118], ["were", 1127], ["scaling", 1132], ["and", 1140], ["maceration", 1144], [",", 1154], ["and", 1156], ["the", 1160], ["fourth", 1164], ["interdigital", 1171], ["web", 1184], ["was", 1188], ["the", 1192], ["most", 1196], ["commonly", 1201], ["affected", 1210], [".", 1218], ["Corynebacterium", 1220], ["could", 1236], ["not", 1242], ["be", 1246], ["isolated", 1249], ["in", 1258], ["any", 1261], ["of", 1265], ["the", 1268], ["cases", 1272], [".", 1277], ["Mycology", 1279], ["was", 1288], ["positive", 1292], ["in", 1301], ["15", 1304], ["cases", 1307], ["(", 1313], ["62.5", 1314], ["%", 1319], [")", 1320], ["and", 1322], ["the", 1326], ["following", 1330], ["microorganisms", 1340], ["were", 1355], ["isolated", 1360], [":", 1368], ["Candida", 1370], ["(", 1378], ["16.6", 1379], ["%", 1384], [")", 1385], [",", 1386], ["dermatophytes", 1388], ["(", 1402], ["12.5", 1403], ["%", 1408], [")", 1409], [",", 1410], ["and", 1412], ["Trichosporon", 1416], ["(", 1429], ["4.1", 1430], ["%", 1434], [")", 1435], [".", 1436], ["Interdigital", 1438], ["erythrasma", 1451], ["is", 1462], ["a", 1465], ["common", 1467], ["condition", 1474], ["and", 1484], ["can", 1488], ["be", 1492], ["easily", 1495], ["confused", 1502], ["with", 1511], ["interdigital", 1516], ["tinea", 1529], [".", 1534], ["It", 1536], ["persists", 1539], ["if", 1548], ["not", 1551], ["treated", 1555], ["appropriately", 1563], [".", 1576], ["Rapid", 1578], ["diagnosis", 1584], ["is", 1594], ["easily", 1597], ["obtained", 1604], ["by", 1613], ["examination", 1616], ["with", 1628], ["a", 1633], ["Wood", 1635], ["lamp", 1640], [",", 1644], ["while", 1646], ["culture", 1652], ["is", 1660], ["difficult", 1663], ["and", 1673], ["unnecessary", 1677], ["for", 1689], ["diagnosis", 1693], [".", 1702], ["The", 1704], ["coexistence", 1708], ["of", 1720], ["erythrasma", 1723], ["with", 1734], ["dermatophytes", 1739], ["and", 1753], ["Candida", 1757], ["should", 1765], ["be", 1772], ["considered", 1775], ["when", 1786], ["the", 1791], ["interdigital", 1795], ["webs", 1808], ["are", 1813], ["affected", 1817], [".", 1825]]}
{"context": "Dystrophic myotonia is a sufficiently rare disease inherited mainly by the autosomal dominant type. Clinical picture is characterized by the myotonic, myopathic, and endocrine-autonomic syndrome. A clinical, genetic, and electromyographic study was carried out to elucidate the problem of this condition inheritance, its intra- and interfamilial clinical polymorphism, and effects of environmental factors on its course and outcomes.", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "52cd8f90006a41c999627c367f252ff3", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[11, 12]], "char_spans": [[75, 92]]}]}], "context_tokens": [["Dystrophic", 0], ["myotonia", 11], ["is", 20], ["a", 23], ["sufficiently", 25], ["rare", 38], ["disease", 43], ["inherited", 51], ["mainly", 61], ["by", 68], ["the", 71], ["autosomal", 75], ["dominant", 85], ["type", 94], [".", 98], ["Clinical", 100], ["picture", 109], ["is", 117], ["characterized", 120], ["by", 134], ["the", 137], ["myotonic", 141], [",", 149], ["myopathic", 151], [",", 160], ["and", 162], ["endocrine", 166], ["-", 175], ["autonomic", 176], ["syndrome", 186], [".", 194], ["A", 196], ["clinical", 198], [",", 206], ["genetic", 208], [",", 215], ["and", 217], ["electromyographic", 221], ["study", 239], ["was", 245], ["carried", 249], ["out", 257], ["to", 261], ["elucidate", 264], ["the", 274], ["problem", 278], ["of", 286], ["this", 289], ["condition", 294], ["inheritance", 304], [",", 315], ["its", 317], ["intra-", 321], ["and", 328], ["interfamilial", 332], ["clinical", 346], ["polymorphism", 355], [",", 367], ["and", 369], ["effects", 373], ["of", 381], ["environmental", 384], ["factors", 398], ["on", 406], ["its", 409], ["course", 413], ["and", 420], ["outcomes", 424], [".", 432]]}
{"context": "We investigated high- or low-dose irradiation-responsive proteins using proteomics on two-dimensional (2D) PAGE, and the effects of ageing on cell responses to radiation in variously aged rat astrocytes. After 5 Gy irradiation, the relative abundance of peroxiredoxin 2, an antioxidant enzyme, and latexin, an inhibitor of carboxypeptidase, increased. The induction of these proteins was suppressed by ageing, suggesting that the response to high-dose radiation decreased with ageing. The relative abundance of elongation factor 2 (EF-2) fragment increased 3 h and reduced 24 h after 0.1 Gy irradiation. Temporal enhancement of the EF-2 fragment due to low-dose irradiation was suppressed by ageing. Since radiation adaptive response in cultured astrocytes was observed 3 h but not 24 h after 0.1 Gy irradiation and suppressed by ageing as previously reported, alteration of the EF-2 fragment corresponded to the radiation adaptive response. We also examined phospho-protein profiles, resulting in the relative abundance of phospho-EF-1beta and phospho-beta-actin being altered by 0.1 Gy irradiation; however, ageing did not affect the alteration of phospho-EF-1beta and phospho-beta-actin, unlike the EF-2 fragment. The results suggested that the EF-2 fragment was a possible candidate for the protein responsible for the radiation adaptive response in cultured astrocytes.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "b7cd2f0a380d4d14b488e20ddf88b204", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[51, 51]], "char_spans": [[274, 284]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["high-", 16], ["or", 22], ["low", 25], ["-", 28], ["dose", 29], ["irradiation", 34], ["-", 45], ["responsive", 46], ["proteins", 57], ["using", 66], ["proteomics", 72], ["on", 83], ["two", 86], ["-", 89], ["dimensional", 90], ["(", 102], ["2D", 103], [")", 105], ["PAGE", 107], [",", 111], ["and", 113], ["the", 117], ["effects", 121], ["of", 129], ["ageing", 132], ["on", 139], ["cell", 142], ["responses", 147], ["to", 157], ["radiation", 160], ["in", 170], ["variously", 173], ["aged", 183], ["rat", 188], ["astrocytes", 192], [".", 202], ["After", 204], ["5", 210], ["Gy", 212], ["irradiation", 215], [",", 226], ["the", 228], ["relative", 232], ["abundance", 241], ["of", 251], ["peroxiredoxin", 254], ["2", 268], [",", 269], ["an", 271], ["antioxidant", 274], ["enzyme", 286], [",", 292], ["and", 294], ["latexin", 298], [",", 305], ["an", 307], ["inhibitor", 310], ["of", 320], ["carboxypeptidase", 323], [",", 339], ["increased", 341], [".", 350], ["The", 352], ["induction", 356], ["of", 366], ["these", 369], ["proteins", 375], ["was", 384], ["suppressed", 388], ["by", 399], ["ageing", 402], [",", 408], ["suggesting", 410], ["that", 421], ["the", 426], ["response", 430], ["to", 439], ["high", 442], ["-", 446], ["dose", 447], ["radiation", 452], ["decreased", 462], ["with", 472], ["ageing", 477], [".", 483], ["The", 485], ["relative", 489], ["abundance", 498], ["of", 508], ["elongation", 511], ["factor", 522], ["2", 529], ["(", 531], ["EF-2", 532], [")", 536], ["fragment", 538], ["increased", 547], ["3", 557], ["h", 559], ["and", 561], ["reduced", 565], ["24", 573], ["h", 576], ["after", 578], ["0.1", 584], ["Gy", 588], ["irradiation", 591], [".", 602], ["Temporal", 604], ["enhancement", 613], ["of", 625], ["the", 628], ["EF-2", 632], ["fragment", 637], ["due", 646], ["to", 650], ["low", 653], ["-", 656], ["dose", 657], ["irradiation", 662], ["was", 674], ["suppressed", 678], ["by", 689], ["ageing", 692], [".", 698], ["Since", 700], ["radiation", 706], ["adaptive", 716], ["response", 725], ["in", 734], ["cultured", 737], ["astrocytes", 746], ["was", 757], ["observed", 761], ["3", 770], ["h", 772], ["but", 774], ["not", 778], ["24", 782], ["h", 785], ["after", 787], ["0.1", 793], ["Gy", 797], ["irradiation", 800], ["and", 812], ["suppressed", 816], ["by", 827], ["ageing", 830], ["as", 837], ["previously", 840], ["reported", 851], [",", 859], ["alteration", 861], ["of", 872], ["the", 875], ["EF-2", 879], ["fragment", 884], ["corresponded", 893], ["to", 906], ["the", 909], ["radiation", 913], ["adaptive", 923], ["response", 932], [".", 940], ["We", 942], ["also", 945], ["examined", 950], ["phospho", 959], ["-", 966], ["protein", 967], ["profiles", 975], [",", 983], ["resulting", 985], ["in", 995], ["the", 998], ["relative", 1002], ["abundance", 1011], ["of", 1021], ["phospho", 1024], ["-", 1031], ["EF-1beta", 1032], ["and", 1041], ["phospho", 1045], ["-", 1052], ["beta", 1053], ["-", 1057], ["actin", 1058], ["being", 1064], ["altered", 1070], ["by", 1078], ["0.1", 1081], ["Gy", 1085], ["irradiation", 1088], [";", 1099], ["however", 1101], [",", 1108], ["ageing", 1110], ["did", 1117], ["not", 1121], ["affect", 1125], ["the", 1132], ["alteration", 1136], ["of", 1147], ["phospho", 1150], ["-", 1157], ["EF-1beta", 1158], ["and", 1167], ["phospho", 1171], ["-", 1178], ["beta", 1179], ["-", 1183], ["actin", 1184], [",", 1189], ["unlike", 1191], ["the", 1198], ["EF-2", 1202], ["fragment", 1207], [".", 1215], ["The", 1217], ["results", 1221], ["suggested", 1229], ["that", 1239], ["the", 1244], ["EF-2", 1248], ["fragment", 1253], ["was", 1262], ["a", 1266], ["possible", 1268], ["candidate", 1277], ["for", 1287], ["the", 1291], ["protein", 1295], ["responsible", 1303], ["for", 1315], ["the", 1319], ["radiation", 1323], ["adaptive", 1333], ["response", 1342], ["in", 1351], ["cultured", 1354], ["astrocytes", 1363], [".", 1373]]}
{"context": "To determine whether voxel-based morphometry (VBM) might contribute to the detection of cortical dysplasia within the temporal pole in patients with mesial temporal lobe epilepsy and hippocampal sclerosis (MTLE/HS). Eighteen patients with intractable MTLE/HS and 30 sex- and age-matched healthy controls were included in the study. All of the patients fulfilled the diagnostic criteria for MTLE/HS and underwent anteromedial temporal resection. VBM without a modulation step was applied to the magnetic resonance (MR) images of the brain. Statistical parametric maps were used to compare structural characteristics such as gray matter concentration (GMC) within the temporal pole among patients and controls separately. The acquired data were then statistically analyzed to determine the congruency between visually inspected MR imaging (MRI) scans and VBM results in the detection of morphologic abnormalities in the temporal pole compared to postoperative histopathologic findings of cortical dysplasia. Histopathologic examination revealed cortical dysplasia within the temporal pole in 11 patients. In detail, according to Palmini's classification, mild malformations of cortical development (mMCDs) were disclosed in three patients, focal cortical dysplasia (FCD) type Ia in three patients, and FCD type Ib in five patients. Some type of structural temporal pole abnormality was suggested by VBM in 14 patients and by visually inspected MRI scans in 11 patients. The results of VBM were in agreement with the presence/absence of cortical dysplasia in 13 patients (72.2%); this correspondence was significant (p = 0.047). In one case, VBM was false negative and in four cases it was false positive. There was congruence between the results of visual analysis and histologic proof in 55.6% of examined patients, which was not significant. We found that VBM made a superior contribution to the detection of temporopolar structural malformations (cortical dysplasia) compared to visual inspection. The agreement with postoperative histopathologic proof was clearly significant for VBM results and nonsignificant for visual inspection.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "83d14fe95f5740f0a8febe5c79a52938", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[202, 204]], "char_spans": [[1238, 1261]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["whether", 13], ["voxel", 21], ["-", 26], ["based", 27], ["morphometry", 33], ["(", 45], ["VBM", 46], [")", 49], ["might", 51], ["contribute", 57], ["to", 68], ["the", 71], ["detection", 75], ["of", 85], ["cortical", 88], ["dysplasia", 97], ["within", 107], ["the", 114], ["temporal", 118], ["pole", 127], ["in", 132], ["patients", 135], ["with", 144], ["mesial", 149], ["temporal", 156], ["lobe", 165], ["epilepsy", 170], ["and", 179], ["hippocampal", 183], ["sclerosis", 195], ["(", 205], ["MTLE", 206], ["/", 210], ["HS", 211], [")", 213], [".", 214], ["Eighteen", 216], ["patients", 225], ["with", 234], ["intractable", 239], ["MTLE", 251], ["/", 255], ["HS", 256], ["and", 259], ["30", 263], ["sex-", 266], ["and", 271], ["age", 275], ["-", 278], ["matched", 279], ["healthy", 287], ["controls", 295], ["were", 304], ["included", 309], ["in", 318], ["the", 321], ["study", 325], [".", 330], ["All", 332], ["of", 336], ["the", 339], ["patients", 343], ["fulfilled", 352], ["the", 362], ["diagnostic", 366], ["criteria", 377], ["for", 386], ["MTLE", 390], ["/", 394], ["HS", 395], ["and", 398], ["underwent", 402], ["anteromedial", 412], ["temporal", 425], ["resection", 434], [".", 443], ["VBM", 445], ["without", 449], ["a", 457], ["modulation", 459], ["step", 470], ["was", 475], ["applied", 479], ["to", 487], ["the", 490], ["magnetic", 494], ["resonance", 503], ["(", 513], ["MR", 514], [")", 516], ["images", 518], ["of", 525], ["the", 528], ["brain", 532], [".", 537], ["Statistical", 539], ["parametric", 551], ["maps", 562], ["were", 567], ["used", 572], ["to", 577], ["compare", 580], ["structural", 588], ["characteristics", 599], ["such", 615], ["as", 620], ["gray", 623], ["matter", 628], ["concentration", 635], ["(", 649], ["GMC", 650], [")", 653], ["within", 655], ["the", 662], ["temporal", 666], ["pole", 675], ["among", 680], ["patients", 686], ["and", 695], ["controls", 699], ["separately", 708], [".", 718], ["The", 720], ["acquired", 724], ["data", 733], ["were", 738], ["then", 743], ["statistically", 748], ["analyzed", 762], ["to", 771], ["determine", 774], ["the", 784], ["congruency", 788], ["between", 799], ["visually", 807], ["inspected", 816], ["MR", 826], ["imaging", 829], ["(", 837], ["MRI", 838], [")", 841], ["scans", 843], ["and", 849], ["VBM", 853], ["results", 857], ["in", 865], ["the", 868], ["detection", 872], ["of", 882], ["morphologic", 885], ["abnormalities", 897], ["in", 911], ["the", 914], ["temporal", 918], ["pole", 927], ["compared", 932], ["to", 941], ["postoperative", 944], ["histopathologic", 958], ["findings", 974], ["of", 983], ["cortical", 986], ["dysplasia", 995], [".", 1004], ["Histopathologic", 1006], ["examination", 1022], ["revealed", 1034], ["cortical", 1043], ["dysplasia", 1052], ["within", 1062], ["the", 1069], ["temporal", 1073], ["pole", 1082], ["in", 1087], ["11", 1090], ["patients", 1093], [".", 1101], ["In", 1103], ["detail", 1106], [",", 1112], ["according", 1114], ["to", 1124], ["Palmini", 1127], ["'s", 1134], ["classification", 1137], [",", 1151], ["mild", 1153], ["malformations", 1158], ["of", 1172], ["cortical", 1175], ["development", 1184], ["(", 1196], ["mMCDs", 1197], [")", 1202], ["were", 1204], ["disclosed", 1209], ["in", 1219], ["three", 1222], ["patients", 1228], [",", 1236], ["focal", 1238], ["cortical", 1244], ["dysplasia", 1253], ["(", 1263], ["FCD", 1264], [")", 1267], ["type", 1269], ["Ia", 1274], ["in", 1277], ["three", 1280], ["patients", 1286], [",", 1294], ["and", 1296], ["FCD", 1300], ["type", 1304], ["Ib", 1309], ["in", 1312], ["five", 1315], ["patients", 1320], [".", 1328], ["Some", 1330], ["type", 1335], ["of", 1340], ["structural", 1343], ["temporal", 1354], ["pole", 1363], ["abnormality", 1368], ["was", 1380], ["suggested", 1384], ["by", 1394], ["VBM", 1397], ["in", 1401], ["14", 1404], ["patients", 1407], ["and", 1416], ["by", 1420], ["visually", 1423], ["inspected", 1432], ["MRI", 1442], ["scans", 1446], ["in", 1452], ["11", 1455], ["patients", 1458], [".", 1466], ["The", 1468], ["results", 1472], ["of", 1480], ["VBM", 1483], ["were", 1487], ["in", 1492], ["agreement", 1495], ["with", 1505], ["the", 1510], ["presence", 1514], ["/", 1522], ["absence", 1523], ["of", 1531], ["cortical", 1534], ["dysplasia", 1543], ["in", 1553], ["13", 1556], ["patients", 1559], ["(", 1568], ["72.2", 1569], ["%", 1573], [")", 1574], [";", 1575], ["this", 1577], ["correspondence", 1582], ["was", 1597], ["significant", 1601], ["(", 1613], ["p", 1614], ["=", 1616], ["0.047", 1618], [")", 1623], [".", 1624], ["In", 1626], ["one", 1629], ["case", 1633], [",", 1637], ["VBM", 1639], ["was", 1643], ["false", 1647], ["negative", 1653], ["and", 1662], ["in", 1666], ["four", 1669], ["cases", 1674], ["it", 1680], ["was", 1683], ["false", 1687], ["positive", 1693], [".", 1701], ["There", 1703], ["was", 1709], ["congruence", 1713], ["between", 1724], ["the", 1732], ["results", 1736], ["of", 1744], ["visual", 1747], ["analysis", 1754], ["and", 1763], ["histologic", 1767], ["proof", 1778], ["in", 1784], ["55.6", 1787], ["%", 1791], ["of", 1793], ["examined", 1796], ["patients", 1805], [",", 1813], ["which", 1815], ["was", 1821], ["not", 1825], ["significant", 1829], [".", 1840], ["We", 1842], ["found", 1845], ["that", 1851], ["VBM", 1856], ["made", 1860], ["a", 1865], ["superior", 1867], ["contribution", 1876], ["to", 1889], ["the", 1892], ["detection", 1896], ["of", 1906], ["temporopolar", 1909], ["structural", 1922], ["malformations", 1933], ["(", 1947], ["cortical", 1948], ["dysplasia", 1957], [")", 1966], ["compared", 1968], ["to", 1977], ["visual", 1980], ["inspection", 1987], [".", 1997], ["The", 1999], ["agreement", 2003], ["with", 2013], ["postoperative", 2018], ["histopathologic", 2032], ["proof", 2048], ["was", 2054], ["clearly", 2058], ["significant", 2066], ["for", 2078], ["VBM", 2082], ["results", 2086], ["and", 2094], ["nonsignificant", 2098], ["for", 2113], ["visual", 2117], ["inspection", 2124], [".", 2134]]}
{"context": "Upon infection of a mammalian host, Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer. This response requires the presence of the pXO1 virulence plasmid-encoded pleiotropic regulator AtxA. To better understand the genetic basis of this response, we utilized a controlled in vitro system and Next Generation sequencing to determine and compare RNA expression profiles of the parental strain and an isogenic AtxA-deficient strain in a 2 \u00d7 2 factorial design with growth environments containing or lacking carbon dioxide. We found 15 pXO1-encoded genes and 3 chromosomal genes that were strongly regulated by the separate or synergistic actions of AtxA and carbon dioxide. The majority of the regulated genes responded to both AtxA and carbon dioxide rather than to just one of these factors. Interestingly, we identified two previously unrecognized small RNAs that are highly expressed under physiological carbon dioxide concentrations in an AtxA-dependent manner. Expression levels of the two small RNAs were found to be higher than that of any other gene differentially expressed in response to these conditions. Secondary structure and small RNA-mRNA binding predictions for the two small RNAs suggest that they may perform important functions in regulating B. anthracis virulence. A majority of genes on the virulence plasmid pXO1 that are regulated by the presence of either CO2 or AtxA separately are also regulated synergistically in the presence of both. These results also elucidate novel pXO1-encoded small RNAs that are associated with virulence conditions.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "2ef046659f484e2c81027f2213ef0759", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "CO2", "token_spans": [[27, 27], [258, 258]], "char_spans": [[142, 144], [1566, 1568]]}, {"text": "bicarbonate", "token_spans": [[25, 25]], "char_spans": [[130, 140]]}]}], "context_tokens": [["Upon", 0], ["infection", 5], ["of", 15], ["a", 18], ["mammalian", 20], ["host", 30], [",", 34], ["Bacillus", 36], ["anthracis", 45], ["responds", 55], ["to", 64], ["host", 67], ["cues", 72], [",", 76], ["and", 78], ["particularly", 82], ["to", 95], ["elevated", 98], ["temperature", 107], ["(", 119], ["37", 120], ["\u00b0", 122], ["C", 123], [")", 124], ["and", 126], ["bicarbonate", 130], ["/", 141], ["CO2", 142], ["concentrations", 146], [",", 160], ["with", 162], ["increased", 167], ["expression", 177], ["of", 188], ["virulence", 191], ["factors", 201], ["that", 209], ["include", 214], ["the", 222], ["anthrax", 226], ["toxins", 234], ["and", 241], ["extracellular", 245], ["capsular", 259], ["layer", 268], [".", 273], ["This", 275], ["response", 280], ["requires", 289], ["the", 298], ["presence", 302], ["of", 311], ["the", 314], ["pXO1", 318], ["virulence", 323], ["plasmid", 333], ["-", 340], ["encoded", 341], ["pleiotropic", 349], ["regulator", 361], ["AtxA.", 371], ["To", 377], ["better", 380], ["understand", 387], ["the", 398], ["genetic", 402], ["basis", 410], ["of", 416], ["this", 419], ["response", 424], [",", 432], ["we", 434], ["utilized", 437], ["a", 446], ["controlled", 448], ["in", 459], ["vitro", 462], ["system", 468], ["and", 475], ["Next", 479], ["Generation", 484], ["sequencing", 495], ["to", 506], ["determine", 509], ["and", 519], ["compare", 523], ["RNA", 531], ["expression", 535], ["profiles", 546], ["of", 555], ["the", 558], ["parental", 562], ["strain", 571], ["and", 578], ["an", 582], ["isogenic", 585], ["AtxA", 594], ["-", 598], ["deficient", 599], ["strain", 609], ["in", 616], ["a", 619], ["2", 621], ["\u00d7", 623], ["2", 625], ["factorial", 627], ["design", 637], ["with", 644], ["growth", 649], ["environments", 656], ["containing", 669], ["or", 680], ["lacking", 683], ["carbon", 691], ["dioxide", 698], [".", 705], ["We", 707], ["found", 710], ["15", 716], ["pXO1-encoded", 719], ["genes", 732], ["and", 738], ["3", 742], ["chromosomal", 744], ["genes", 756], ["that", 762], ["were", 767], ["strongly", 772], ["regulated", 781], ["by", 791], ["the", 794], ["separate", 798], ["or", 807], ["synergistic", 810], ["actions", 822], ["of", 830], ["AtxA", 833], ["and", 838], ["carbon", 842], ["dioxide", 849], [".", 856], ["The", 858], ["majority", 862], ["of", 871], ["the", 874], ["regulated", 878], ["genes", 888], ["responded", 894], ["to", 904], ["both", 907], ["AtxA", 912], ["and", 917], ["carbon", 921], ["dioxide", 928], ["rather", 936], ["than", 943], ["to", 948], ["just", 951], ["one", 956], ["of", 960], ["these", 963], ["factors", 969], [".", 976], ["Interestingly", 978], [",", 991], ["we", 993], ["identified", 996], ["two", 1007], ["previously", 1011], ["unrecognized", 1022], ["small", 1035], ["RNAs", 1041], ["that", 1046], ["are", 1051], ["highly", 1055], ["expressed", 1062], ["under", 1072], ["physiological", 1078], ["carbon", 1092], ["dioxide", 1099], ["concentrations", 1107], ["in", 1122], ["an", 1125], ["AtxA", 1128], ["-", 1132], ["dependent", 1133], ["manner", 1143], [".", 1149], ["Expression", 1151], ["levels", 1162], ["of", 1169], ["the", 1172], ["two", 1176], ["small", 1180], ["RNAs", 1186], ["were", 1191], ["found", 1196], ["to", 1202], ["be", 1205], ["higher", 1208], ["than", 1215], ["that", 1220], ["of", 1225], ["any", 1228], ["other", 1232], ["gene", 1238], ["differentially", 1243], ["expressed", 1258], ["in", 1268], ["response", 1271], ["to", 1280], ["these", 1283], ["conditions", 1289], [".", 1299], ["Secondary", 1301], ["structure", 1311], ["and", 1321], ["small", 1325], ["RNA", 1331], ["-", 1334], ["mRNA", 1335], ["binding", 1340], ["predictions", 1348], ["for", 1360], ["the", 1364], ["two", 1368], ["small", 1372], ["RNAs", 1378], ["suggest", 1383], ["that", 1391], ["they", 1396], ["may", 1401], ["perform", 1405], ["important", 1413], ["functions", 1423], ["in", 1433], ["regulating", 1436], ["B.", 1447], ["anthracis", 1450], ["virulence", 1460], [".", 1469], ["A", 1471], ["majority", 1473], ["of", 1482], ["genes", 1485], ["on", 1491], ["the", 1494], ["virulence", 1498], ["plasmid", 1508], ["pXO1", 1516], ["that", 1521], ["are", 1526], ["regulated", 1530], ["by", 1540], ["the", 1543], ["presence", 1547], ["of", 1556], ["either", 1559], ["CO2", 1566], ["or", 1570], ["AtxA", 1573], ["separately", 1578], ["are", 1589], ["also", 1593], ["regulated", 1598], ["synergistically", 1608], ["in", 1624], ["the", 1627], ["presence", 1631], ["of", 1640], ["both", 1643], [".", 1647], ["These", 1649], ["results", 1655], ["also", 1663], ["elucidate", 1668], ["novel", 1678], ["pXO1-encoded", 1684], ["small", 1697], ["RNAs", 1703], ["that", 1708], ["are", 1713], ["associated", 1717], ["with", 1728], ["virulence", 1733], ["conditions", 1743], [".", 1753]]}
{"context": "Chronic myeloid leukemia (CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by imatinib is effective to control the tyrosyl phosphorylation of the protein related to the cell signaling. BCR-ABL mRNA is overexpressed in the minimal residual disease (MRD), known as an early sign of relapse. Between December 2005 and June 2008, we measured BCR-ABL mRNA levels in the bone marrow (BM) from patients by quantitative real-time polymerase chain reaction (RQ-PCR) in Aomori Prefectural Central Hospital. Eighty-six samples from 26 patients were collected. Among the 26 CML patients, 11 patients (42%) were in the pretreatment group. Seven (64%) of the 11 patients achieved complete molecular response (CMR). In the post-treatment group consisting of the remaining 15 patients, 9 (60%) patients achieved CMR. The patients receiving imatinib at a dose over 300 mg per day required 13 (6-77) months [median (range)] to achieve CMR. On the other hand, the patients receiving a dose below 300 mg per day required 29.5 (11-84) months [median (range)]. When BCR-ABL mRNA was detected during the treatment course of patients with CMR, careful observation of BCR-ABL mRNA was useful for tracking the clinical course of patients. In conclusion, the BCR-ABL mRNA level was useful for monitoring the clinical course in 26 patients with CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "412a49803a00424099cd84a75d92bd63", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[295, 297], [36, 38], [101, 103], [69, 71], [10, 12], [277, 279], [259, 261]], "char_spans": [[1409, 1415], [172, 178], [515, 521], [362, 368], [48, 54], [1320, 1326], [1221, 1227]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["caused", 34], ["by", 41], ["the", 44], ["BCR", 48], ["-", 51], ["ABL", 52], ["oncogene", 56], [".", 64], ["The", 66], ["Philadelphia", 70], ["chromosome", 83], ["(", 94], ["Ph", 95], [")", 97], ["from", 99], ["a", 104], ["reciprocal", 106], ["translocation", 117], [",", 130], ["t(9;22", 132], [")", 138], ["(", 140], ["q34;q11", 141], [")", 148], ["causes", 150], ["a", 157], ["fusion", 159], ["gene", 166], [",", 170], ["BCR", 172], ["-", 175], ["ABL", 176], [",", 179], ["that", 181], ["encodes", 186], ["a", 194], ["constitutively", 196], ["active", 211], ["tyrosine", 218], ["kinase", 227], [".", 233], ["Treatment", 235], ["of", 245], ["CML", 248], ["by", 252], ["imatinib", 255], ["is", 264], ["effective", 267], ["to", 277], ["control", 280], ["the", 288], ["tyrosyl", 292], ["phosphorylation", 300], ["of", 316], ["the", 319], ["protein", 323], ["related", 331], ["to", 339], ["the", 342], ["cell", 346], ["signaling", 351], [".", 360], ["BCR", 362], ["-", 365], ["ABL", 366], ["mRNA", 370], ["is", 375], ["overexpressed", 378], ["in", 392], ["the", 395], ["minimal", 399], ["residual", 407], ["disease", 416], ["(", 424], ["MRD", 425], [")", 428], [",", 429], ["known", 431], ["as", 437], ["an", 440], ["early", 443], ["sign", 449], ["of", 454], ["relapse", 457], [".", 464], ["Between", 466], ["December", 474], ["2005", 483], ["and", 488], ["June", 492], ["2008", 497], [",", 501], ["we", 503], ["measured", 506], ["BCR", 515], ["-", 518], ["ABL", 519], ["mRNA", 523], ["levels", 528], ["in", 535], ["the", 538], ["bone", 542], ["marrow", 547], ["(", 554], ["BM", 555], [")", 557], ["from", 559], ["patients", 564], ["by", 573], ["quantitative", 576], ["real", 589], ["-", 593], ["time", 594], ["polymerase", 599], ["chain", 610], ["reaction", 616], ["(", 625], ["RQ", 626], ["-", 628], ["PCR", 629], [")", 632], ["in", 634], ["Aomori", 637], ["Prefectural", 644], ["Central", 656], ["Hospital", 664], [".", 672], ["Eighty", 674], ["-", 680], ["six", 681], ["samples", 685], ["from", 693], ["26", 698], ["patients", 701], ["were", 710], ["collected", 715], [".", 724], ["Among", 726], ["the", 732], ["26", 736], ["CML", 739], ["patients", 743], [",", 751], ["11", 753], ["patients", 756], ["(", 765], ["42", 766], ["%", 768], [")", 769], ["were", 771], ["in", 776], ["the", 779], ["pretreatment", 783], ["group", 796], [".", 801], ["Seven", 803], ["(", 809], ["64", 810], ["%", 812], [")", 813], ["of", 815], ["the", 818], ["11", 822], ["patients", 825], ["achieved", 834], ["complete", 843], ["molecular", 852], ["response", 862], ["(", 871], ["CMR", 872], [")", 875], [".", 876], ["In", 878], ["the", 881], ["post", 885], ["-", 889], ["treatment", 890], ["group", 900], ["consisting", 906], ["of", 917], ["the", 920], ["remaining", 924], ["15", 934], ["patients", 937], [",", 945], ["9", 947], ["(", 949], ["60", 950], ["%", 952], [")", 953], ["patients", 955], ["achieved", 964], ["CMR", 973], [".", 976], ["The", 978], ["patients", 982], ["receiving", 991], ["imatinib", 1001], ["at", 1010], ["a", 1013], ["dose", 1015], ["over", 1020], ["300", 1025], ["mg", 1029], ["per", 1032], ["day", 1036], ["required", 1040], ["13", 1049], ["(", 1052], ["6", 1053], ["-", 1054], ["77", 1055], [")", 1057], ["months", 1059], ["[", 1066], ["median", 1067], ["(", 1074], ["range", 1075], [")", 1080], ["]", 1081], ["to", 1083], ["achieve", 1086], ["CMR", 1094], [".", 1097], ["On", 1099], ["the", 1102], ["other", 1106], ["hand", 1112], [",", 1116], ["the", 1118], ["patients", 1122], ["receiving", 1131], ["a", 1141], ["dose", 1143], ["below", 1148], ["300", 1154], ["mg", 1158], ["per", 1161], ["day", 1165], ["required", 1169], ["29.5", 1178], ["(", 1183], ["11", 1184], ["-", 1186], ["84", 1187], [")", 1189], ["months", 1191], ["[", 1198], ["median", 1199], ["(", 1206], ["range)].", 1207], ["When", 1216], ["BCR", 1221], ["-", 1224], ["ABL", 1225], ["mRNA", 1229], ["was", 1234], ["detected", 1238], ["during", 1247], ["the", 1254], ["treatment", 1258], ["course", 1268], ["of", 1275], ["patients", 1278], ["with", 1287], ["CMR", 1292], [",", 1295], ["careful", 1297], ["observation", 1305], ["of", 1317], ["BCR", 1320], ["-", 1323], ["ABL", 1324], ["mRNA", 1328], ["was", 1333], ["useful", 1337], ["for", 1344], ["tracking", 1348], ["the", 1357], ["clinical", 1361], ["course", 1370], ["of", 1377], ["patients", 1380], [".", 1388], ["In", 1390], ["conclusion", 1393], [",", 1403], ["the", 1405], ["BCR", 1409], ["-", 1412], ["ABL", 1413], ["mRNA", 1417], ["level", 1422], ["was", 1428], ["useful", 1432], ["for", 1439], ["monitoring", 1443], ["the", 1454], ["clinical", 1458], ["course", 1467], ["in", 1474], ["26", 1477], ["patients", 1480], ["with", 1489], ["CML", 1494], [".", 1497]]}
{"context": "Abnormal accumulation of Abeta and tau in senile plaques (SP) and neurofibrillary tangles (NFTs) is a key event in Alzheimer's disease (AD). Here, we show that T668-phosphorylated cytoplasmic domain of APP (pT668-ACD) accumulates Abeta and tau in AD and its transgenic models. Anti-pT668 immunostaining of AD brain sections with hydrated autoclave enhancement identified SP neurites and NFTs in which pT668-ACD colocalizes with tau. We produced and examined transgenic (Tg) mice that overexpress human APP695, harboring the double Swedish/London mutation, and develop age-dependently Abeta plaques in the brain. All Abeta plaques contain co-accumulations of pT668-ACD, but co-accumulation of tau appears in only a fraction of Abeta plaques in older animals. We also examined the established tau Tg mice that overexpress the smallest human brain tau isoform and develop neuronal accumulations of tau in older animals. Examination of the old tau Tg mice showed that neuronal cells affected by tau accumulation induce co-accumulation of pT668-ACD. We speculate that in AD brains, extracellular Abeta deposition is accompanied by intracellular accumulation of pT668-ACD, followed by tau accumulation in the SP with dystrophic neurites and that neuronal cells affected by tau accumulation induce co-accumulation of pT668-ACD in NFTs. Thus, pT668-ACD is likely to mediate pathological interaction between Abeta and tau.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "359b351dab714a9eb679ec9eef3d8227", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[23, 25]], "char_spans": [[115, 133]]}, {"text": "AD", "token_spans": [[191, 191], [59, 59], [48, 48], [27, 27]], "char_spans": [[1066, 1067], [306, 307], [247, 248], [136, 137]]}]}], "context_tokens": [["Abnormal", 0], ["accumulation", 9], ["of", 22], ["Abeta", 25], ["and", 31], ["tau", 35], ["in", 39], ["senile", 42], ["plaques", 49], ["(", 57], ["SP", 58], [")", 60], ["and", 62], ["neurofibrillary", 66], ["tangles", 82], ["(", 90], ["NFTs", 91], [")", 95], ["is", 97], ["a", 100], ["key", 102], ["event", 106], ["in", 112], ["Alzheimer", 115], ["'s", 124], ["disease", 127], ["(", 135], ["AD", 136], [")", 138], [".", 139], ["Here", 141], [",", 145], ["we", 147], ["show", 150], ["that", 155], ["T668-phosphorylated", 160], ["cytoplasmic", 180], ["domain", 192], ["of", 199], ["APP", 202], ["(", 206], ["pT668-ACD", 207], [")", 216], ["accumulates", 218], ["Abeta", 230], ["and", 236], ["tau", 240], ["in", 244], ["AD", 247], ["and", 250], ["its", 254], ["transgenic", 258], ["models", 269], [".", 275], ["Anti", 277], ["-", 281], ["pT668", 282], ["immunostaining", 288], ["of", 303], ["AD", 306], ["brain", 309], ["sections", 315], ["with", 324], ["hydrated", 329], ["autoclave", 338], ["enhancement", 348], ["identified", 360], ["SP", 371], ["neurites", 374], ["and", 383], ["NFTs", 387], ["in", 392], ["which", 395], ["pT668-ACD", 401], ["colocalizes", 411], ["with", 423], ["tau", 428], [".", 431], ["We", 433], ["produced", 436], ["and", 445], ["examined", 449], ["transgenic", 458], ["(", 469], ["Tg", 470], [")", 472], ["mice", 474], ["that", 479], ["overexpress", 484], ["human", 496], ["APP695", 502], [",", 508], ["harboring", 510], ["the", 520], ["double", 524], ["Swedish", 531], ["/", 538], ["London", 539], ["mutation", 546], [",", 554], ["and", 556], ["develop", 560], ["age", 568], ["-", 571], ["dependently", 572], ["Abeta", 584], ["plaques", 590], ["in", 598], ["the", 601], ["brain", 605], [".", 610], ["All", 612], ["Abeta", 616], ["plaques", 622], ["contain", 630], ["co", 638], ["-", 640], ["accumulations", 641], ["of", 655], ["pT668-ACD", 658], [",", 667], ["but", 669], ["co", 673], ["-", 675], ["accumulation", 676], ["of", 689], ["tau", 692], ["appears", 696], ["in", 704], ["only", 707], ["a", 712], ["fraction", 714], ["of", 723], ["Abeta", 726], ["plaques", 732], ["in", 740], ["older", 743], ["animals", 749], [".", 756], ["We", 758], ["also", 761], ["examined", 766], ["the", 775], ["established", 779], ["tau", 791], ["Tg", 795], ["mice", 798], ["that", 803], ["overexpress", 808], ["the", 820], ["smallest", 824], ["human", 833], ["brain", 839], ["tau", 845], ["isoform", 849], ["and", 857], ["develop", 861], ["neuronal", 869], ["accumulations", 878], ["of", 892], ["tau", 895], ["in", 899], ["older", 902], ["animals", 908], [".", 915], ["Examination", 917], ["of", 929], ["the", 932], ["old", 936], ["tau", 940], ["Tg", 944], ["mice", 947], ["showed", 952], ["that", 959], ["neuronal", 964], ["cells", 973], ["affected", 979], ["by", 988], ["tau", 991], ["accumulation", 995], ["induce", 1008], ["co", 1015], ["-", 1017], ["accumulation", 1018], ["of", 1031], ["pT668-ACD", 1034], [".", 1043], ["We", 1045], ["speculate", 1048], ["that", 1058], ["in", 1063], ["AD", 1066], ["brains", 1069], [",", 1075], ["extracellular", 1077], ["Abeta", 1091], ["deposition", 1097], ["is", 1108], ["accompanied", 1111], ["by", 1123], ["intracellular", 1126], ["accumulation", 1140], ["of", 1153], ["pT668-ACD", 1156], [",", 1165], ["followed", 1167], ["by", 1176], ["tau", 1179], ["accumulation", 1183], ["in", 1196], ["the", 1199], ["SP", 1203], ["with", 1206], ["dystrophic", 1211], ["neurites", 1222], ["and", 1231], ["that", 1235], ["neuronal", 1240], ["cells", 1249], ["affected", 1255], ["by", 1264], ["tau", 1267], ["accumulation", 1271], ["induce", 1284], ["co", 1291], ["-", 1293], ["accumulation", 1294], ["of", 1307], ["pT668-ACD", 1310], ["in", 1320], ["NFTs", 1323], [".", 1327], ["Thus", 1329], [",", 1333], ["pT668-ACD", 1335], ["is", 1345], ["likely", 1348], ["to", 1355], ["mediate", 1358], ["pathological", 1366], ["interaction", 1379], ["between", 1391], ["Abeta", 1399], ["and", 1405], ["tau", 1409], [".", 1412]]}
{"context": "Opicapone (OPC) is a novel catechol-O-methyltransferase (COMT) inhibitor to be used as adjunctive therapy in levodopa-treated patients with Parkinson's disease. The purpose of this study was to evaluate the effect of moderate liver impairment on the pharmacokinetics (PK) and pharmacodynamics (PD; effect on COMT activity) of OPC. An open-label, parallel-group study in patients (n\u2009=\u20098) with moderate liver impairment (Child-Pugh category B, score of 7 to 9) and matched healthy subjects (n\u2009=\u20098, control) with normal liver function. All subjects received a single 50-mg oral dose of OPC, with plasma and urine concentrations of opicapone and its metabolites measured up to 72\u00a0h post-dose, including soluble COMT (S-COMT) activity. A one-way analysis of variance (ANOVA) was used to compare the main PK and PD parameters between groups. Point estimates (PE) of geometric mean ratios (GMR) and corresponding 90\u00a0% confidence intervals (90%CI) for the ratio hepatic/control subjects of each parameter were calculated and compared with the reference interval (80-125\u00a0%). Exposure to opicapone (AUC and Cmax) increased significantly in patients with moderate hepatic impairment (PE [90%CI]: AUC0-\u221e, 184\u00a0% [135-250\u00a0%]; Cmax, 189\u00a0% [144-249\u00a0%]). Although apparent total clearance (CL/F) of opicapone was decreased by \u223c35\u00a0%, similar elimination half-life and unbound/bound fractions of opicapone were observed between the two groups. Both rate and extent of exposure to BIA 9-1103 were higher in the hepatically impaired group, but not statistically significant compared with the control group. Similar to the parent (opicapone), the observed increase in exposure to BIA 9-1106 was statistically significant in the hepatically impaired group over the control group. BIA 9-1106 was the only metabolite detected in urine and its urine PK parameters were in accordance with plasma data. Maximum S-COMT inhibition (Emax) occurred earlier for the hepatically impaired group with values of 100\u00a0% and 91.2\u00a0% for the hepatically impaired and control groups respectively. Both Emax and AUEC for the hepatically impaired group reached statistical significance over the control group. OPC was well tolerated in both hepatically impaired and control groups. The bioavailability of an orally administered single dose of 50\u00a0mg OPC was significantly higher in patients with moderate chronic hepatic impairment, perhaps by a reduced first-pass effect. As the tolerability profile of OPC was favourable under the conditions of this study and its exposure is completely purged from systemic circulation before the subsequent dose administration, no OPC dose adjustment is needed in patients with mild to moderate chronic hepatic impairment. However, as OPC is under clinical development for use as adjunctive therapy in levodopa-treated patients with Parkinson's disease, an adjustment of levodopa and/or OPC regimens in patients should be carefully considered based on a potentially enhanced levodopa dopaminergic response and the associated tolerability.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "6bedca90e5b9429482c8374aa747b8c4", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[7, 11]], "char_spans": [[27, 54]]}]}], "context_tokens": [["Opicapone", 0], ["(", 10], ["OPC", 11], [")", 14], ["is", 16], ["a", 19], ["novel", 21], ["catechol", 27], ["-", 35], ["O", 36], ["-", 37], ["methyltransferase", 38], ["(", 56], ["COMT", 57], [")", 61], ["inhibitor", 63], ["to", 73], ["be", 76], ["used", 79], ["as", 84], ["adjunctive", 87], ["therapy", 98], ["in", 106], ["levodopa", 109], ["-", 117], ["treated", 118], ["patients", 126], ["with", 135], ["Parkinson", 140], ["'s", 149], ["disease", 152], [".", 159], ["The", 161], ["purpose", 165], ["of", 173], ["this", 176], ["study", 181], ["was", 187], ["to", 191], ["evaluate", 194], ["the", 203], ["effect", 207], ["of", 214], ["moderate", 217], ["liver", 226], ["impairment", 232], ["on", 243], ["the", 246], ["pharmacokinetics", 250], ["(", 267], ["PK", 268], [")", 270], ["and", 272], ["pharmacodynamics", 276], ["(", 293], ["PD", 294], [";", 296], ["effect", 298], ["on", 305], ["COMT", 308], ["activity", 313], [")", 321], ["of", 323], ["OPC", 326], [".", 329], ["An", 331], ["open", 334], ["-", 338], ["label", 339], [",", 344], ["parallel", 346], ["-", 354], ["group", 355], ["study", 361], ["in", 367], ["patients", 370], ["(", 379], ["n", 380], ["=", 382], ["8)", 384], ["with", 387], ["moderate", 392], ["liver", 401], ["impairment", 407], ["(", 418], ["Child", 419], ["-", 424], ["Pugh", 425], ["category", 430], ["B", 439], [",", 440], ["score", 442], ["of", 448], ["7", 451], ["to", 453], ["9", 456], [")", 457], ["and", 459], ["matched", 463], ["healthy", 471], ["subjects", 479], ["(", 488], ["n", 489], ["=", 491], ["8", 493], [",", 494], ["control", 496], [")", 503], ["with", 505], ["normal", 510], ["liver", 517], ["function", 523], [".", 531], ["All", 533], ["subjects", 537], ["received", 546], ["a", 555], ["single", 557], ["50-mg", 564], ["oral", 570], ["dose", 575], ["of", 580], ["OPC", 583], [",", 586], ["with", 588], ["plasma", 593], ["and", 600], ["urine", 604], ["concentrations", 610], ["of", 625], ["opicapone", 628], ["and", 638], ["its", 642], ["metabolites", 646], ["measured", 658], ["up", 667], ["to", 670], ["72", 673], ["h", 676], ["post", 678], ["-", 682], ["dose", 683], [",", 687], ["including", 689], ["soluble", 699], ["COMT", 707], ["(", 712], ["S", 713], ["-", 714], ["COMT", 715], [")", 719], ["activity", 721], [".", 729], ["A", 731], ["one", 733], ["-", 736], ["way", 737], ["analysis", 741], ["of", 750], ["variance", 753], ["(", 762], ["ANOVA", 763], [")", 768], ["was", 770], ["used", 774], ["to", 779], ["compare", 782], ["the", 790], ["main", 794], ["PK", 799], ["and", 802], ["PD", 806], ["parameters", 809], ["between", 820], ["groups", 828], [".", 834], ["Point", 836], ["estimates", 842], ["(", 852], ["PE", 853], [")", 855], ["of", 857], ["geometric", 860], ["mean", 870], ["ratios", 875], ["(", 882], ["GMR", 883], [")", 886], ["and", 888], ["corresponding", 892], ["90", 906], ["%", 909], ["confidence", 911], ["intervals", 922], ["(", 932], ["90%CI", 933], [")", 938], ["for", 940], ["the", 944], ["ratio", 948], ["hepatic", 954], ["/", 961], ["control", 962], ["subjects", 970], ["of", 979], ["each", 982], ["parameter", 987], ["were", 997], ["calculated", 1002], ["and", 1013], ["compared", 1017], ["with", 1026], ["the", 1031], ["reference", 1035], ["interval", 1045], ["(", 1054], ["80", 1055], ["-", 1057], ["125", 1058], ["%", 1062], [")", 1063], [".", 1064], ["Exposure", 1066], ["to", 1075], ["opicapone", 1078], ["(", 1088], ["AUC", 1089], ["and", 1093], ["Cmax", 1097], [")", 1101], ["increased", 1103], ["significantly", 1113], ["in", 1127], ["patients", 1130], ["with", 1139], ["moderate", 1144], ["hepatic", 1153], ["impairment", 1161], ["(", 1172], ["PE", 1173], ["[", 1176], ["90%CI", 1177], ["]", 1182], [":", 1183], ["AUC0-\u221e", 1185], [",", 1191], ["184", 1193], ["%", 1197], ["[", 1199], ["135", 1200], ["-", 1203], ["250", 1204], ["%", 1208], ["]", 1209], [";", 1210], ["Cmax", 1212], [",", 1216], ["189", 1218], ["%", 1222], ["[", 1224], ["144", 1225], ["-", 1228], ["249", 1229], ["%", 1233], ["]", 1234], [")", 1235], [".", 1236], ["Although", 1238], ["apparent", 1247], ["total", 1256], ["clearance", 1262], ["(", 1272], ["CL", 1273], ["/", 1275], ["F", 1276], [")", 1277], ["of", 1279], ["opicapone", 1282], ["was", 1292], ["decreased", 1296], ["by", 1306], ["\u223c35", 1309], ["%", 1313], [",", 1314], ["similar", 1316], ["elimination", 1324], ["half", 1336], ["-", 1340], ["life", 1341], ["and", 1346], ["unbound", 1350], ["/", 1357], ["bound", 1358], ["fractions", 1364], ["of", 1374], ["opicapone", 1377], ["were", 1387], ["observed", 1392], ["between", 1401], ["the", 1409], ["two", 1413], ["groups", 1417], [".", 1423], ["Both", 1425], ["rate", 1430], ["and", 1435], ["extent", 1439], ["of", 1446], ["exposure", 1449], ["to", 1458], ["BIA", 1461], ["9", 1465], ["-", 1466], ["1103", 1467], ["were", 1472], ["higher", 1477], ["in", 1484], ["the", 1487], ["hepatically", 1491], ["impaired", 1503], ["group", 1512], [",", 1517], ["but", 1519], ["not", 1523], ["statistically", 1527], ["significant", 1541], ["compared", 1553], ["with", 1562], ["the", 1567], ["control", 1571], ["group", 1579], [".", 1584], ["Similar", 1586], ["to", 1594], ["the", 1597], ["parent", 1601], ["(", 1608], ["opicapone", 1609], [")", 1618], [",", 1619], ["the", 1621], ["observed", 1625], ["increase", 1634], ["in", 1643], ["exposure", 1646], ["to", 1655], ["BIA", 1658], ["9", 1662], ["-", 1663], ["1106", 1664], ["was", 1669], ["statistically", 1673], ["significant", 1687], ["in", 1699], ["the", 1702], ["hepatically", 1706], ["impaired", 1718], ["group", 1727], ["over", 1733], ["the", 1738], ["control", 1742], ["group", 1750], [".", 1755], ["BIA", 1757], ["9", 1761], ["-", 1762], ["1106", 1763], ["was", 1768], ["the", 1772], ["only", 1776], ["metabolite", 1781], ["detected", 1792], ["in", 1801], ["urine", 1804], ["and", 1810], ["its", 1814], ["urine", 1818], ["PK", 1824], ["parameters", 1827], ["were", 1838], ["in", 1843], ["accordance", 1846], ["with", 1857], ["plasma", 1862], ["data", 1869], [".", 1873], ["Maximum", 1875], ["S", 1883], ["-", 1884], ["COMT", 1885], ["inhibition", 1890], ["(", 1901], ["Emax", 1902], [")", 1906], ["occurred", 1908], ["earlier", 1917], ["for", 1925], ["the", 1929], ["hepatically", 1933], ["impaired", 1945], ["group", 1954], ["with", 1960], ["values", 1965], ["of", 1972], ["100", 1975], ["%", 1979], ["and", 1981], ["91.2", 1985], ["%", 1990], ["for", 1992], ["the", 1996], ["hepatically", 2000], ["impaired", 2012], ["and", 2021], ["control", 2025], ["groups", 2033], ["respectively", 2040], [".", 2052], ["Both", 2054], ["Emax", 2059], ["and", 2064], ["AUEC", 2068], ["for", 2073], ["the", 2077], ["hepatically", 2081], ["impaired", 2093], ["group", 2102], ["reached", 2108], ["statistical", 2116], ["significance", 2128], ["over", 2141], ["the", 2146], ["control", 2150], ["group", 2158], [".", 2163], ["OPC", 2165], ["was", 2169], ["well", 2173], ["tolerated", 2178], ["in", 2188], ["both", 2191], ["hepatically", 2196], ["impaired", 2208], ["and", 2217], ["control", 2221], ["groups", 2229], [".", 2235], ["The", 2237], ["bioavailability", 2241], ["of", 2257], ["an", 2260], ["orally", 2263], ["administered", 2270], ["single", 2283], ["dose", 2290], ["of", 2295], ["50", 2298], ["mg", 2301], ["OPC", 2304], ["was", 2308], ["significantly", 2312], ["higher", 2326], ["in", 2333], ["patients", 2336], ["with", 2345], ["moderate", 2350], ["chronic", 2359], ["hepatic", 2367], ["impairment", 2375], [",", 2385], ["perhaps", 2387], ["by", 2395], ["a", 2398], ["reduced", 2400], ["first", 2408], ["-", 2413], ["pass", 2414], ["effect", 2419], [".", 2425], ["As", 2427], ["the", 2430], ["tolerability", 2434], ["profile", 2447], ["of", 2455], ["OPC", 2458], ["was", 2462], ["favourable", 2466], ["under", 2477], ["the", 2483], ["conditions", 2487], ["of", 2498], ["this", 2501], ["study", 2506], ["and", 2512], ["its", 2516], ["exposure", 2520], ["is", 2529], ["completely", 2532], ["purged", 2543], ["from", 2550], ["systemic", 2555], ["circulation", 2564], ["before", 2576], ["the", 2583], ["subsequent", 2587], ["dose", 2598], ["administration", 2603], [",", 2617], ["no", 2619], ["OPC", 2622], ["dose", 2626], ["adjustment", 2631], ["is", 2642], ["needed", 2645], ["in", 2652], ["patients", 2655], ["with", 2664], ["mild", 2669], ["to", 2674], ["moderate", 2677], ["chronic", 2686], ["hepatic", 2694], ["impairment", 2702], [".", 2712], ["However", 2714], [",", 2721], ["as", 2723], ["OPC", 2726], ["is", 2730], ["under", 2733], ["clinical", 2739], ["development", 2748], ["for", 2760], ["use", 2764], ["as", 2768], ["adjunctive", 2771], ["therapy", 2782], ["in", 2790], ["levodopa", 2793], ["-", 2801], ["treated", 2802], ["patients", 2810], ["with", 2819], ["Parkinson", 2824], ["'s", 2833], ["disease", 2836], [",", 2843], ["an", 2845], ["adjustment", 2848], ["of", 2859], ["levodopa", 2862], ["and/or", 2871], ["OPC", 2878], ["regimens", 2882], ["in", 2891], ["patients", 2894], ["should", 2903], ["be", 2910], ["carefully", 2913], ["considered", 2923], ["based", 2934], ["on", 2940], ["a", 2943], ["potentially", 2945], ["enhanced", 2957], ["levodopa", 2966], ["dopaminergic", 2975], ["response", 2988], ["and", 2997], ["the", 3001], ["associated", 3005], ["tolerability", 3016], [".", 3028]]}
{"context": "The enzyme telomerase is activated in 80-90% of all human malignancies and immortal cell lines, where it functions to maintain the integrity of chromosomal-end structures called telomeres. Telomerase enzyme activity can be detected in whole cell lysates by a polymerase chain reaction (PCR)-based method referred to as the telomeric repeat amplification protocol (TRAP). The TRAP assay involves extension of an oligonucleotide through telomerase-mediated enzymatic addition of telomeric DNA repeats and subsequent PCR amplification of the extension products. While the TRAP assay as originally developed utilizes radioactively labelled nucleotides, protocols are provided herein for nonradioactive versions of the TRAP assay, with options for either qualitative assessment of TRAP products by polyacrylamide gel electrophoresis (standard TRAP), or quantitative analysis by real-time PCR (Q-TRAP). The Q-TRAP method poses the additional advantages of exquisite sensitivity, rapidity, and potential for adoption to a high-throughput format.", "qas": [{"question": "What is the aim of the TRAP assay?", "answers": ["Telomerase enzyme activity can be detected in whole cell lysates by a polymerase chain reaction (PCR)-based method referred to as the telomeric repeat amplification protocol (TRAP)."], "qid": "8076404cfda8488c9fbc09080b95dccf", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["aim", 12], ["of", 16], ["the", 19], ["TRAP", 23], ["assay", 28], ["?", 33]], "detected_answers": [{"text": "Telomerase enzyme activity can be detected in whole cell lysates by a polymerase chain reaction (PCR)-based method referred to as the telomeric repeat amplification protocol (TRAP).", "token_spans": [[34, 61]], "char_spans": [[189, 367]]}]}], "context_tokens": [["The", 0], ["enzyme", 4], ["telomerase", 11], ["is", 22], ["activated", 25], ["in", 35], ["80", 38], ["-", 40], ["90", 41], ["%", 43], ["of", 45], ["all", 48], ["human", 52], ["malignancies", 58], ["and", 71], ["immortal", 75], ["cell", 84], ["lines", 89], [",", 94], ["where", 96], ["it", 102], ["functions", 105], ["to", 115], ["maintain", 118], ["the", 127], ["integrity", 131], ["of", 141], ["chromosomal", 144], ["-", 155], ["end", 156], ["structures", 160], ["called", 171], ["telomeres", 178], [".", 187], ["Telomerase", 189], ["enzyme", 200], ["activity", 207], ["can", 216], ["be", 220], ["detected", 223], ["in", 232], ["whole", 235], ["cell", 241], ["lysates", 246], ["by", 254], ["a", 257], ["polymerase", 259], ["chain", 270], ["reaction", 276], ["(", 285], ["PCR)-based", 286], ["method", 297], ["referred", 304], ["to", 313], ["as", 316], ["the", 319], ["telomeric", 323], ["repeat", 333], ["amplification", 340], ["protocol", 354], ["(", 363], ["TRAP", 364], [")", 368], [".", 369], ["The", 371], ["TRAP", 375], ["assay", 380], ["involves", 386], ["extension", 395], ["of", 405], ["an", 408], ["oligonucleotide", 411], ["through", 427], ["telomerase", 435], ["-", 445], ["mediated", 446], ["enzymatic", 455], ["addition", 465], ["of", 474], ["telomeric", 477], ["DNA", 487], ["repeats", 491], ["and", 499], ["subsequent", 503], ["PCR", 514], ["amplification", 518], ["of", 532], ["the", 535], ["extension", 539], ["products", 549], [".", 557], ["While", 559], ["the", 565], ["TRAP", 569], ["assay", 574], ["as", 580], ["originally", 583], ["developed", 594], ["utilizes", 604], ["radioactively", 613], ["labelled", 627], ["nucleotides", 636], [",", 647], ["protocols", 649], ["are", 659], ["provided", 663], ["herein", 672], ["for", 679], ["nonradioactive", 683], ["versions", 698], ["of", 707], ["the", 710], ["TRAP", 714], ["assay", 719], [",", 724], ["with", 726], ["options", 731], ["for", 739], ["either", 743], ["qualitative", 750], ["assessment", 762], ["of", 773], ["TRAP", 776], ["products", 781], ["by", 790], ["polyacrylamide", 793], ["gel", 808], ["electrophoresis", 812], ["(", 828], ["standard", 829], ["TRAP", 838], [")", 842], [",", 843], ["or", 845], ["quantitative", 848], ["analysis", 861], ["by", 870], ["real", 873], ["-", 877], ["time", 878], ["PCR", 883], ["(", 887], ["Q", 888], ["-", 889], ["TRAP", 890], [")", 894], [".", 895], ["The", 897], ["Q", 901], ["-", 902], ["TRAP", 903], ["method", 908], ["poses", 915], ["the", 921], ["additional", 925], ["advantages", 936], ["of", 947], ["exquisite", 950], ["sensitivity", 960], [",", 971], ["rapidity", 973], [",", 981], ["and", 983], ["potential", 987], ["for", 997], ["adoption", 1001], ["to", 1010], ["a", 1013], ["high", 1015], ["-", 1019], ["throughput", 1020], ["format", 1031], [".", 1037]]}
{"context": "Community-acquired pneumonia (CAP) is the leading cause of infectious death in the world. Immune dysregulation during acute lung infection plays a role in lung injury and the systemic inflammatory response. Cytokines seem to be major players in severe lung infection cases. Here, we present a review of published papers in the last 3\u00a0years regarding this topic. The cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as CURB65 or SOFA. Treatment focused in the cytokine environment is an interesting area that could impact the prognosis of CAP. Some of the agents that have been studied as co-adjuvant therapy are corticosteroids, macrolides, and linezolid, but anyone of those have shown a clear or proven efficacy or have been recommended as a part of the standard of care for CAP. More studies designed to define the role of immunomodulatory agents, such as co-adjuvant therapy in pneumonia, are needed.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "77c8c610c2b44cfdadd28ce51c2e8c6b", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[177, 177], [3, 3], [70, 70]], "char_spans": [[984, 992], [19, 27], [391, 399]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["acquired", 10], ["pneumonia", 19], ["(", 29], ["CAP", 30], [")", 33], ["is", 35], ["the", 38], ["leading", 42], ["cause", 50], ["of", 56], ["infectious", 59], ["death", 70], ["in", 76], ["the", 79], ["world", 83], [".", 88], ["Immune", 90], ["dysregulation", 97], ["during", 111], ["acute", 118], ["lung", 124], ["infection", 129], ["plays", 139], ["a", 145], ["role", 147], ["in", 152], ["lung", 155], ["injury", 160], ["and", 167], ["the", 171], ["systemic", 175], ["inflammatory", 184], ["response", 197], [".", 205], ["Cytokines", 207], ["seem", 217], ["to", 222], ["be", 225], ["major", 228], ["players", 234], ["in", 242], ["severe", 245], ["lung", 252], ["infection", 257], ["cases", 267], [".", 272], ["Here", 274], [",", 278], ["we", 280], ["present", 283], ["a", 291], ["review", 293], ["of", 300], ["published", 303], ["papers", 313], ["in", 320], ["the", 323], ["last", 327], ["3", 332], ["years", 334], ["regarding", 340], ["this", 350], ["topic", 355], [".", 360], ["The", 362], ["cytokine", 366], ["response", 375], ["during", 384], ["pneumonia", 391], ["is", 401], ["different", 404], ["in", 414], ["bacterial", 417], ["vs", 427], ["viral", 430], ["infections", 436], [";", 446], ["some", 448], ["of", 453], ["these", 456], ["cytokines", 462], ["correlate", 472], ["with", 482], ["clinical", 487], ["severity", 496], ["scales", 505], ["such", 512], ["as", 517], ["CURB65", 520], ["or", 527], ["SOFA", 530], [".", 534], ["Treatment", 536], ["focused", 546], ["in", 554], ["the", 557], ["cytokine", 561], ["environment", 570], ["is", 582], ["an", 585], ["interesting", 588], ["area", 600], ["that", 605], ["could", 610], ["impact", 616], ["the", 623], ["prognosis", 627], ["of", 637], ["CAP", 640], [".", 643], ["Some", 645], ["of", 650], ["the", 653], ["agents", 657], ["that", 664], ["have", 669], ["been", 674], ["studied", 679], ["as", 687], ["co", 690], ["-", 692], ["adjuvant", 693], ["therapy", 702], ["are", 710], ["corticosteroids", 714], [",", 729], ["macrolides", 731], [",", 741], ["and", 743], ["linezolid", 747], [",", 756], ["but", 758], ["anyone", 762], ["of", 769], ["those", 772], ["have", 778], ["shown", 783], ["a", 789], ["clear", 791], ["or", 797], ["proven", 800], ["efficacy", 807], ["or", 816], ["have", 819], ["been", 824], ["recommended", 829], ["as", 841], ["a", 844], ["part", 846], ["of", 851], ["the", 854], ["standard", 858], ["of", 867], ["care", 870], ["for", 875], ["CAP", 879], [".", 882], ["More", 884], ["studies", 889], ["designed", 897], ["to", 906], ["define", 909], ["the", 916], ["role", 920], ["of", 925], ["immunomodulatory", 928], ["agents", 945], [",", 951], ["such", 953], ["as", 958], ["co", 961], ["-", 963], ["adjuvant", 964], ["therapy", 973], ["in", 981], ["pneumonia", 984], [",", 993], ["are", 995], ["needed", 999], [".", 1005]]}
{"context": "Infection with Epstein-Barr virus (EBV) is almost ubiquitous in humans and generally occurs at two ages: infantile, which is usually asymptomatic and associated with poorer socioeconomic conditions, and adolescent, which causes infectious mononucleosis (IM) in ~25% cases. The determinants of whether the infection causes IM remain uncertain. We aimed to evaluate seasonality and temporal trends in IM. Data from all Monospot tests, used as a marker for IM, were collected from the Grampian population over 16 years. Positive Monospot test results peaked at 17 years in females and 19 in males. Females had 16% more diagnoses, although 55% more tests. IM was ~38% more common in winter than summer. The annual rate of positive tests decreased progressively over the study period, from 174/100 000 (95% CI 171-178) in 1997 to 67/100 000 (95% CI 65-69) in 2012. IM appears to be decreasing in incidence, which may be caused by changing environmental influences on immune systems. One such factor may be exposure to sunlight.Words 168. The Medical Research Council and NHS Grampian-MS endowments.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "80319100e57e4e6bae3dd5bfdc5b1543", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[2, 5]], "char_spans": [[15, 32]]}]}], "context_tokens": [["Infection", 0], ["with", 10], ["Epstein", 15], ["-", 22], ["Barr", 23], ["virus", 28], ["(", 34], ["EBV", 35], [")", 38], ["is", 40], ["almost", 43], ["ubiquitous", 50], ["in", 61], ["humans", 64], ["and", 71], ["generally", 75], ["occurs", 85], ["at", 92], ["two", 95], ["ages", 99], [":", 103], ["infantile", 105], [",", 114], ["which", 116], ["is", 122], ["usually", 125], ["asymptomatic", 133], ["and", 146], ["associated", 150], ["with", 161], ["poorer", 166], ["socioeconomic", 173], ["conditions", 187], [",", 197], ["and", 199], ["adolescent", 203], [",", 213], ["which", 215], ["causes", 221], ["infectious", 228], ["mononucleosis", 239], ["(", 253], ["IM", 254], [")", 256], ["in", 258], ["~25", 261], ["%", 264], ["cases", 266], [".", 271], ["The", 273], ["determinants", 277], ["of", 290], ["whether", 293], ["the", 301], ["infection", 305], ["causes", 315], ["IM", 322], ["remain", 325], ["uncertain", 332], [".", 341], ["We", 343], ["aimed", 346], ["to", 352], ["evaluate", 355], ["seasonality", 364], ["and", 376], ["temporal", 380], ["trends", 389], ["in", 396], ["IM", 399], [".", 401], ["Data", 403], ["from", 408], ["all", 413], ["Monospot", 417], ["tests", 426], [",", 431], ["used", 433], ["as", 438], ["a", 441], ["marker", 443], ["for", 450], ["IM", 454], [",", 456], ["were", 458], ["collected", 463], ["from", 473], ["the", 478], ["Grampian", 482], ["population", 491], ["over", 502], ["16", 507], ["years", 510], [".", 515], ["Positive", 517], ["Monospot", 526], ["test", 535], ["results", 540], ["peaked", 548], ["at", 555], ["17", 558], ["years", 561], ["in", 567], ["females", 570], ["and", 578], ["19", 582], ["in", 585], ["males", 588], [".", 593], ["Females", 595], ["had", 603], ["16", 607], ["%", 609], ["more", 611], ["diagnoses", 616], [",", 625], ["although", 627], ["55", 636], ["%", 638], ["more", 640], ["tests", 645], [".", 650], ["IM", 652], ["was", 655], ["~38", 659], ["%", 662], ["more", 664], ["common", 669], ["in", 676], ["winter", 679], ["than", 686], ["summer", 691], [".", 697], ["The", 699], ["annual", 703], ["rate", 710], ["of", 715], ["positive", 718], ["tests", 727], ["decreased", 733], ["progressively", 743], ["over", 757], ["the", 762], ["study", 766], ["period", 772], [",", 778], ["from", 780], ["174/100", 785], ["000", 793], ["(", 797], ["95", 798], ["%", 800], ["CI", 802], ["171", 805], ["-", 808], ["178", 809], [")", 812], ["in", 814], ["1997", 817], ["to", 822], ["67/100", 825], ["000", 832], ["(", 836], ["95", 837], ["%", 839], ["CI", 841], ["65", 844], ["-", 846], ["69", 847], [")", 849], ["in", 851], ["2012", 854], [".", 858], ["IM", 860], ["appears", 863], ["to", 871], ["be", 874], ["decreasing", 877], ["in", 888], ["incidence", 891], [",", 900], ["which", 902], ["may", 908], ["be", 912], ["caused", 915], ["by", 922], ["changing", 925], ["environmental", 934], ["influences", 948], ["on", 959], ["immune", 962], ["systems", 969], [".", 976], ["One", 978], ["such", 982], ["factor", 987], ["may", 994], ["be", 998], ["exposure", 1001], ["to", 1010], ["sunlight", 1013], [".", 1021], ["Words", 1022], ["168", 1028], [".", 1031], ["The", 1033], ["Medical", 1037], ["Research", 1045], ["Council", 1054], ["and", 1062], ["NHS", 1066], ["Grampian", 1070], ["-", 1078], ["MS", 1079], ["endowments", 1082], [".", 1092]]}
{"context": "Protein kinases (PKs) and lipid kinases (LKs) are good choices for targets of signal transduction therapy as these enzymes are involved in signaling pathways, and are often related to the pathogenesis of lymphoid malignancies. The attractiveness of PKs and LKs as drug able targets is enhanced by the fact that they are enzymes whose biological activity can be turned off by drugs that block their catalytic site. In the last few years small molecular kinase inhibitors (KIs) have been synthesized and become available for preclinical studies and clinical trials. The first KI, introduced into clinical practice in 1998, was imatinib mesylate, which became the first choice drug in chronic myeloid leukemia. More recently, several KIs have been developed to target the proximal B-cell receptor (BCR) signaling pathway including spleen tyrosine kinase inhibitor (Fostamatinib) and Bruton's tyrosine kinase inhibitors (Ibrutinib, AVL-263). These agents are currently evaluated in early clinical trials in chronic lymphocytic leukemia (CLL) and other diseases. Cyclin-dependent kinase (Cdk) inhibitors, flavopiridol (alvocidib), BMS-387032 (SNS-032), sunitinib and sorafenib are currently under evaluation in clinical trials for relapsed/refractory CLL. Multi-tyrosine kinase inhibitors including vandetanib (ZD6474) bosutinib (SKI-606), TKI258 (CHIR-258), pazopanib (GW786034) and axitinib (AG013736) have been also developed for the treatment of lymphoid malignancies. Phosphatidylinositol 3-kinases (PI3K ) are a family of lipid kinases that mediate signals from cell surface receptors. CAL-101 (GS-1101) is an oral PI3K\u03b4-specific inhibitor which has shown preclinical and clinical activity against CLL. This article summarizes recent achievements in the mechanism of action, pharmacological properties and clinical activity and toxicity of PK and LK inhibitors in CLL.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "1eb2d0fe88414c37812859c1e4d6e1b5", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[161, 161]], "char_spans": [[917, 925]]}]}], "context_tokens": [["Protein", 0], ["kinases", 8], ["(", 16], ["PKs", 17], [")", 20], ["and", 22], ["lipid", 26], ["kinases", 32], ["(", 40], ["LKs", 41], [")", 44], ["are", 46], ["good", 50], ["choices", 55], ["for", 63], ["targets", 67], ["of", 75], ["signal", 78], ["transduction", 85], ["therapy", 98], ["as", 106], ["these", 109], ["enzymes", 115], ["are", 123], ["involved", 127], ["in", 136], ["signaling", 139], ["pathways", 149], [",", 157], ["and", 159], ["are", 163], ["often", 167], ["related", 173], ["to", 181], ["the", 184], ["pathogenesis", 188], ["of", 201], ["lymphoid", 204], ["malignancies", 213], [".", 225], ["The", 227], ["attractiveness", 231], ["of", 246], ["PKs", 249], ["and", 253], ["LKs", 257], ["as", 261], ["drug", 264], ["able", 269], ["targets", 274], ["is", 282], ["enhanced", 285], ["by", 294], ["the", 297], ["fact", 301], ["that", 306], ["they", 311], ["are", 316], ["enzymes", 320], ["whose", 328], ["biological", 334], ["activity", 345], ["can", 354], ["be", 358], ["turned", 361], ["off", 368], ["by", 372], ["drugs", 375], ["that", 381], ["block", 386], ["their", 392], ["catalytic", 398], ["site", 408], [".", 412], ["In", 414], ["the", 417], ["last", 421], ["few", 426], ["years", 430], ["small", 436], ["molecular", 442], ["kinase", 452], ["inhibitors", 459], ["(", 470], ["KIs", 471], [")", 474], ["have", 476], ["been", 481], ["synthesized", 486], ["and", 498], ["become", 502], ["available", 509], ["for", 519], ["preclinical", 523], ["studies", 535], ["and", 543], ["clinical", 547], ["trials", 556], [".", 562], ["The", 564], ["first", 568], ["KI", 574], [",", 576], ["introduced", 578], ["into", 589], ["clinical", 594], ["practice", 603], ["in", 612], ["1998", 615], [",", 619], ["was", 621], ["imatinib", 625], ["mesylate", 634], [",", 642], ["which", 644], ["became", 650], ["the", 657], ["first", 661], ["choice", 667], ["drug", 674], ["in", 679], ["chronic", 682], ["myeloid", 690], ["leukemia", 698], [".", 706], ["More", 708], ["recently", 713], [",", 721], ["several", 723], ["KIs", 731], ["have", 735], ["been", 740], ["developed", 745], ["to", 755], ["target", 758], ["the", 765], ["proximal", 769], ["B", 778], ["-", 779], ["cell", 780], ["receptor", 785], ["(", 794], ["BCR", 795], [")", 798], ["signaling", 800], ["pathway", 810], ["including", 818], ["spleen", 828], ["tyrosine", 835], ["kinase", 844], ["inhibitor", 851], ["(", 861], ["Fostamatinib", 862], [")", 874], ["and", 876], ["Bruton", 880], ["'s", 886], ["tyrosine", 889], ["kinase", 898], ["inhibitors", 905], ["(", 916], ["Ibrutinib", 917], [",", 926], ["AVL-263", 928], [")", 935], [".", 936], ["These", 938], ["agents", 944], ["are", 951], ["currently", 955], ["evaluated", 965], ["in", 975], ["early", 978], ["clinical", 984], ["trials", 993], ["in", 1000], ["chronic", 1003], ["lymphocytic", 1011], ["leukemia", 1023], ["(", 1032], ["CLL", 1033], [")", 1036], ["and", 1038], ["other", 1042], ["diseases", 1048], [".", 1056], ["Cyclin", 1058], ["-", 1064], ["dependent", 1065], ["kinase", 1075], ["(", 1082], ["Cdk", 1083], [")", 1086], ["inhibitors", 1088], [",", 1098], ["flavopiridol", 1100], ["(", 1113], ["alvocidib", 1114], [")", 1123], [",", 1124], ["BMS-387032", 1126], ["(", 1137], ["SNS-032", 1138], [")", 1145], [",", 1146], ["sunitinib", 1148], ["and", 1158], ["sorafenib", 1162], ["are", 1172], ["currently", 1176], ["under", 1186], ["evaluation", 1192], ["in", 1203], ["clinical", 1206], ["trials", 1215], ["for", 1222], ["relapsed", 1226], ["/", 1234], ["refractory", 1235], ["CLL", 1246], [".", 1249], ["Multi", 1251], ["-", 1256], ["tyrosine", 1257], ["kinase", 1266], ["inhibitors", 1273], ["including", 1284], ["vandetanib", 1294], ["(", 1305], ["ZD6474", 1306], [")", 1312], ["bosutinib", 1314], ["(", 1324], ["SKI-606", 1325], [")", 1332], [",", 1333], ["TKI258", 1335], ["(", 1342], ["CHIR-258", 1343], [")", 1351], [",", 1352], ["pazopanib", 1354], ["(", 1364], ["GW786034", 1365], [")", 1373], ["and", 1375], ["axitinib", 1379], ["(", 1388], ["AG013736", 1389], [")", 1397], ["have", 1399], ["been", 1404], ["also", 1409], ["developed", 1414], ["for", 1424], ["the", 1428], ["treatment", 1432], ["of", 1442], ["lymphoid", 1445], ["malignancies", 1454], [".", 1466], ["Phosphatidylinositol", 1468], ["3-kinases", 1489], ["(", 1499], ["PI3", 1500], ["K", 1503], [")", 1505], ["are", 1507], ["a", 1511], ["family", 1513], ["of", 1520], ["lipid", 1523], ["kinases", 1529], ["that", 1537], ["mediate", 1542], ["signals", 1550], ["from", 1558], ["cell", 1563], ["surface", 1568], ["receptors", 1576], [".", 1585], ["CAL-101", 1587], ["(", 1595], ["GS-1101", 1596], [")", 1603], ["is", 1605], ["an", 1608], ["oral", 1611], ["PI3K\u03b4", 1616], ["-", 1621], ["specific", 1622], ["inhibitor", 1631], ["which", 1641], ["has", 1647], ["shown", 1651], ["preclinical", 1657], ["and", 1669], ["clinical", 1673], ["activity", 1682], ["against", 1691], ["CLL", 1699], [".", 1702], ["This", 1704], ["article", 1709], ["summarizes", 1717], ["recent", 1728], ["achievements", 1735], ["in", 1748], ["the", 1751], ["mechanism", 1755], ["of", 1765], ["action", 1768], [",", 1774], ["pharmacological", 1776], ["properties", 1792], ["and", 1803], ["clinical", 1807], ["activity", 1816], ["and", 1825], ["toxicity", 1829], ["of", 1838], ["PK", 1841], ["and", 1844], ["LK", 1848], ["inhibitors", 1851], ["in", 1862], ["CLL", 1865], [".", 1868]]}
{"context": "Fostamatinib (R788) is a prodrug rapidly converted to its active metabolite on oral administration. This (known as R406) is a potent inhibitor of spleen tyrosine kinase, required for the expression of a number of proinflammatory cytokines. Fostamatinib has shown significantly superior efficacy (when compared with placebo) in the control of patients with rheumatoid arthritis not responding to methotrexate in Phase II clinical trials. Treatment emergent adverse events with a higher frequency than in those on placebo included diarrhea, hypertension, urinary tract infections, neutropenia and elevated transaminases. The studied doses have shown a linear pharmacokinetic pattern and the administration of methotrexate does not affect it. Fostamatinib may have a role in the therapy of patients with rheumatoid arthritis with poor response to conventional therapy. If these results are confirmed once Phase III studies are completed, it may find a place in the evolving treatment algorithm for rheumatoid arthritis.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "7c88f7862dc74ae8bded750a958b2e65", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[28, 30]], "char_spans": [[146, 167]]}]}], "context_tokens": [["Fostamatinib", 0], ["(", 13], ["R788", 14], [")", 18], ["is", 20], ["a", 23], ["prodrug", 25], ["rapidly", 33], ["converted", 41], ["to", 51], ["its", 54], ["active", 58], ["metabolite", 65], ["on", 76], ["oral", 79], ["administration", 84], [".", 98], ["This", 100], ["(", 105], ["known", 106], ["as", 112], ["R406", 115], [")", 119], ["is", 121], ["a", 124], ["potent", 126], ["inhibitor", 133], ["of", 143], ["spleen", 146], ["tyrosine", 153], ["kinase", 162], [",", 168], ["required", 170], ["for", 179], ["the", 183], ["expression", 187], ["of", 198], ["a", 201], ["number", 203], ["of", 210], ["proinflammatory", 213], ["cytokines", 229], [".", 238], ["Fostamatinib", 240], ["has", 253], ["shown", 257], ["significantly", 263], ["superior", 277], ["efficacy", 286], ["(", 295], ["when", 296], ["compared", 301], ["with", 310], ["placebo", 315], [")", 322], ["in", 324], ["the", 327], ["control", 331], ["of", 339], ["patients", 342], ["with", 351], ["rheumatoid", 356], ["arthritis", 367], ["not", 377], ["responding", 381], ["to", 392], ["methotrexate", 395], ["in", 408], ["Phase", 411], ["II", 417], ["clinical", 420], ["trials", 429], [".", 435], ["Treatment", 437], ["emergent", 447], ["adverse", 456], ["events", 464], ["with", 471], ["a", 476], ["higher", 478], ["frequency", 485], ["than", 495], ["in", 500], ["those", 503], ["on", 509], ["placebo", 512], ["included", 520], ["diarrhea", 529], [",", 537], ["hypertension", 539], [",", 551], ["urinary", 553], ["tract", 561], ["infections", 567], [",", 577], ["neutropenia", 579], ["and", 591], ["elevated", 595], ["transaminases", 604], [".", 617], ["The", 619], ["studied", 623], ["doses", 631], ["have", 637], ["shown", 642], ["a", 648], ["linear", 650], ["pharmacokinetic", 657], ["pattern", 673], ["and", 681], ["the", 685], ["administration", 689], ["of", 704], ["methotrexate", 707], ["does", 720], ["not", 725], ["affect", 729], ["it", 736], [".", 738], ["Fostamatinib", 740], ["may", 753], ["have", 757], ["a", 762], ["role", 764], ["in", 769], ["the", 772], ["therapy", 776], ["of", 784], ["patients", 787], ["with", 796], ["rheumatoid", 801], ["arthritis", 812], ["with", 822], ["poor", 827], ["response", 832], ["to", 841], ["conventional", 844], ["therapy", 857], [".", 864], ["If", 866], ["these", 869], ["results", 875], ["are", 883], ["confirmed", 887], ["once", 897], ["Phase", 902], ["III", 908], ["studies", 912], ["are", 920], ["completed", 924], [",", 933], ["it", 935], ["may", 938], ["find", 942], ["a", 947], ["place", 949], ["in", 955], ["the", 958], ["evolving", 962], ["treatment", 971], ["algorithm", 981], ["for", 991], ["rheumatoid", 995], ["arthritis", 1006], [".", 1015]]}
{"context": "Change in gene expression associated with pancreatic cancer could be attributed to the variation in histone posttranslational modifications leading to subsequent remodeling of the chromatin template during transcription. However, the interconnected network of molecules involved in regulating such processes remains elusive. hPaf1/PD2, a subunit of the human PAF-complex, involved in the regulation of transcriptional elongation has oncogenic potential. Our study explores the possibility that regulation of histone methylation by hPaf1 can contribute towards alteration in gene expression by nucleosomal rearrangement. Here, we show that knockdown of hPaf1/PD2 leads to decreased di- and tri-methylation at histone H3 lysine 4 residues in pancreatic cancer cells. Interestingly, hPaf1/PD2 colocalizes with MLL1 (Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K4 residues. Also, a reduction in hPaf1 level resulted in reduced MLL1 expression and a corresponding decrease in the level of CHD1 (Chromohelicase DNA-binding protein 1), an ATPase dependent chromatin remodeling enzyme that specifically binds to H3K4 di and trimethyl marks. hPaf1/PD2 was also found to interact and colocalize with CHD1 in both cytoplasmic and nuclear extracts of pancreatic cancer cells. Further, reduced level of CHD1 localization in the nucleus in hPaf1/PD2 Knockdown cells could be rescued by ectopic expression of hPaf1/PD2. Micrococcal nuclease digestion showed an altered chromatin structure in hPaf1/PD2-KD cells. Overall, our results suggest that hPaf1/PD2 in association with MLL1 regulates methylation of H3K4 residues, as well as interacts and regulates nuclear shuttling of chromatin remodeling protein CHD1, facilitating its function in pancreatic cancer cells.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "98cb43e4ec95414598cd781412a5d3b8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[253, 253], [177, 177], [134, 134]], "char_spans": [[1620, 1623], [1133, 1136], [884, 887]]}]}], "context_tokens": [["Change", 0], ["in", 7], ["gene", 10], ["expression", 15], ["associated", 26], ["with", 37], ["pancreatic", 42], ["cancer", 53], ["could", 60], ["be", 66], ["attributed", 69], ["to", 80], ["the", 83], ["variation", 87], ["in", 97], ["histone", 100], ["posttranslational", 108], ["modifications", 126], ["leading", 140], ["to", 148], ["subsequent", 151], ["remodeling", 162], ["of", 173], ["the", 176], ["chromatin", 180], ["template", 190], ["during", 199], ["transcription", 206], [".", 219], ["However", 221], [",", 228], ["the", 230], ["interconnected", 234], ["network", 249], ["of", 257], ["molecules", 260], ["involved", 270], ["in", 279], ["regulating", 282], ["such", 293], ["processes", 298], ["remains", 308], ["elusive", 316], [".", 323], ["hPaf1/PD2", 325], [",", 334], ["a", 336], ["subunit", 338], ["of", 346], ["the", 349], ["human", 353], ["PAF", 359], ["-", 362], ["complex", 363], [",", 370], ["involved", 372], ["in", 381], ["the", 384], ["regulation", 388], ["of", 399], ["transcriptional", 402], ["elongation", 418], ["has", 429], ["oncogenic", 433], ["potential", 443], [".", 452], ["Our", 454], ["study", 458], ["explores", 464], ["the", 473], ["possibility", 477], ["that", 489], ["regulation", 494], ["of", 505], ["histone", 508], ["methylation", 516], ["by", 528], ["hPaf1", 531], ["can", 537], ["contribute", 541], ["towards", 552], ["alteration", 560], ["in", 571], ["gene", 574], ["expression", 579], ["by", 590], ["nucleosomal", 593], ["rearrangement", 605], [".", 618], ["Here", 620], [",", 624], ["we", 626], ["show", 629], ["that", 634], ["knockdown", 639], ["of", 649], ["hPaf1/PD2", 652], ["leads", 662], ["to", 668], ["decreased", 671], ["di-", 681], ["and", 685], ["tri", 689], ["-", 692], ["methylation", 693], ["at", 705], ["histone", 708], ["H3", 716], ["lysine", 719], ["4", 726], ["residues", 728], ["in", 737], ["pancreatic", 740], ["cancer", 751], ["cells", 758], [".", 763], ["Interestingly", 765], [",", 778], ["hPaf1/PD2", 780], ["colocalizes", 790], ["with", 802], ["MLL1", 807], ["(", 812], ["Mixed", 813], ["Lineage", 819], ["Leukemia", 827], ["1", 836], [")", 837], [",", 838], ["a", 840], ["histone", 842], ["methyltransferase", 850], ["that", 868], ["methylates", 873], ["H3K4", 884], ["residues", 889], [".", 897], ["Also", 899], [",", 903], ["a", 905], ["reduction", 907], ["in", 917], ["hPaf1", 920], ["level", 926], ["resulted", 932], ["in", 941], ["reduced", 944], ["MLL1", 952], ["expression", 957], ["and", 968], ["a", 972], ["corresponding", 974], ["decrease", 988], ["in", 997], ["the", 1000], ["level", 1004], ["of", 1010], ["CHD1", 1013], ["(", 1018], ["Chromohelicase", 1019], ["DNA", 1034], ["-", 1037], ["binding", 1038], ["protein", 1046], ["1", 1054], [")", 1055], [",", 1056], ["an", 1058], ["ATPase", 1061], ["dependent", 1068], ["chromatin", 1078], ["remodeling", 1088], ["enzyme", 1099], ["that", 1106], ["specifically", 1111], ["binds", 1124], ["to", 1130], ["H3K4", 1133], ["di", 1138], ["and", 1141], ["trimethyl", 1145], ["marks", 1155], [".", 1160], ["hPaf1/PD2", 1162], ["was", 1172], ["also", 1176], ["found", 1181], ["to", 1187], ["interact", 1190], ["and", 1199], ["colocalize", 1203], ["with", 1214], ["CHD1", 1219], ["in", 1224], ["both", 1227], ["cytoplasmic", 1232], ["and", 1244], ["nuclear", 1248], ["extracts", 1256], ["of", 1265], ["pancreatic", 1268], ["cancer", 1279], ["cells", 1286], [".", 1291], ["Further", 1293], [",", 1300], ["reduced", 1302], ["level", 1310], ["of", 1316], ["CHD1", 1319], ["localization", 1324], ["in", 1337], ["the", 1340], ["nucleus", 1344], ["in", 1352], ["hPaf1/PD2", 1355], ["Knockdown", 1365], ["cells", 1375], ["could", 1381], ["be", 1387], ["rescued", 1390], ["by", 1398], ["ectopic", 1401], ["expression", 1409], ["of", 1420], ["hPaf1/PD2", 1423], [".", 1432], ["Micrococcal", 1434], ["nuclease", 1446], ["digestion", 1455], ["showed", 1465], ["an", 1472], ["altered", 1475], ["chromatin", 1483], ["structure", 1493], ["in", 1503], ["hPaf1/PD2-KD", 1506], ["cells", 1519], [".", 1524], ["Overall", 1526], [",", 1533], ["our", 1535], ["results", 1539], ["suggest", 1547], ["that", 1555], ["hPaf1/PD2", 1560], ["in", 1570], ["association", 1573], ["with", 1585], ["MLL1", 1590], ["regulates", 1595], ["methylation", 1605], ["of", 1617], ["H3K4", 1620], ["residues", 1625], [",", 1633], ["as", 1635], ["well", 1638], ["as", 1643], ["interacts", 1646], ["and", 1656], ["regulates", 1660], ["nuclear", 1670], ["shuttling", 1678], ["of", 1688], ["chromatin", 1691], ["remodeling", 1701], ["protein", 1712], ["CHD1", 1720], [",", 1724], ["facilitating", 1726], ["its", 1739], ["function", 1743], ["in", 1752], ["pancreatic", 1755], ["cancer", 1766], ["cells", 1773], [".", 1778]]}
{"context": "Previously, using a chromosomal reversion assay system, we established that an adaptive mutagenic process occurs in nongrowing Bacillus subtilis cells under stress, and we demonstrated that multiple mechanisms are involved in generating these mutations (41, 43). In an attempt to delineate how these mutations are generated, we began an investigation into whether or not transcription and transcription-associated proteins influence adaptive mutagenesis. In B. subtilis, the Mfd protein (transcription repair coupling factor) facilitates removal of RNA polymerase stalled at transcriptional blockages and recruitment of repair proteins to DNA lesions on the transcribed strand. Here we demonstrate that the loss of Mfd has a depressive effect on stationary-phase mutagenesis. An association between Mfd mutagenesis and aspects of transcription is discussed.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "91db4f5a6e754a4889b60c8eb22bc009", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[120, 122]], "char_spans": [[746, 761]]}]}], "context_tokens": [["Previously", 0], [",", 10], ["using", 12], ["a", 18], ["chromosomal", 20], ["reversion", 32], ["assay", 42], ["system", 48], [",", 54], ["we", 56], ["established", 59], ["that", 71], ["an", 76], ["adaptive", 79], ["mutagenic", 88], ["process", 98], ["occurs", 106], ["in", 113], ["nongrowing", 116], ["Bacillus", 127], ["subtilis", 136], ["cells", 145], ["under", 151], ["stress", 157], [",", 163], ["and", 165], ["we", 169], ["demonstrated", 172], ["that", 185], ["multiple", 190], ["mechanisms", 199], ["are", 210], ["involved", 214], ["in", 223], ["generating", 226], ["these", 237], ["mutations", 243], ["(", 253], ["41", 254], [",", 256], ["43", 258], [")", 260], [".", 261], ["In", 263], ["an", 266], ["attempt", 269], ["to", 277], ["delineate", 280], ["how", 290], ["these", 294], ["mutations", 300], ["are", 310], ["generated", 314], [",", 323], ["we", 325], ["began", 328], ["an", 334], ["investigation", 337], ["into", 351], ["whether", 356], ["or", 364], ["not", 367], ["transcription", 371], ["and", 385], ["transcription", 389], ["-", 402], ["associated", 403], ["proteins", 414], ["influence", 423], ["adaptive", 433], ["mutagenesis", 442], [".", 453], ["In", 455], ["B.", 458], ["subtilis", 461], [",", 469], ["the", 471], ["Mfd", 475], ["protein", 479], ["(", 487], ["transcription", 488], ["repair", 502], ["coupling", 509], ["factor", 518], [")", 524], ["facilitates", 526], ["removal", 538], ["of", 546], ["RNA", 549], ["polymerase", 553], ["stalled", 564], ["at", 572], ["transcriptional", 575], ["blockages", 591], ["and", 601], ["recruitment", 605], ["of", 617], ["repair", 620], ["proteins", 627], ["to", 636], ["DNA", 639], ["lesions", 643], ["on", 651], ["the", 654], ["transcribed", 658], ["strand", 670], [".", 676], ["Here", 678], ["we", 683], ["demonstrate", 686], ["that", 698], ["the", 703], ["loss", 707], ["of", 712], ["Mfd", 715], ["has", 719], ["a", 723], ["depressive", 725], ["effect", 736], ["on", 743], ["stationary", 746], ["-", 756], ["phase", 757], ["mutagenesis", 763], [".", 774], ["An", 776], ["association", 779], ["between", 791], ["Mfd", 799], ["mutagenesis", 803], ["and", 815], ["aspects", 819], ["of", 827], ["transcription", 830], ["is", 844], ["discussed", 847], [".", 856]]}
{"context": "Fluorescence in situ hybridization (FISH) technique has been successfully used to detect the BCR-ABL gene fusion in chronic myeloid leukemia (CML) with the classic form of the Philadelphia chromosome (Ph). We applied FISH to study three CML patients showing variant Ph chromosome (either complex or simple type). The results demonstrate that the use of a yeast artificial chromosome (YAC)-derived probe (D107F9) and a cosmid probe (cos-abl 8), specific for BCR and ABL genes respectively, allows also the detection of the BCR-ABL fusion in CML patients with variant Ph.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "97cb4d97afcb4eb2952fd63b3de90dbf", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[15, 19]], "char_spans": [[93, 111]]}]}], "context_tokens": [["Fluorescence", 0], ["in", 13], ["situ", 16], ["hybridization", 21], ["(", 35], ["FISH", 36], [")", 40], ["technique", 42], ["has", 52], ["been", 56], ["successfully", 61], ["used", 74], ["to", 79], ["detect", 82], ["the", 89], ["BCR", 93], ["-", 96], ["ABL", 97], ["gene", 101], ["fusion", 106], ["in", 113], ["chronic", 116], ["myeloid", 124], ["leukemia", 132], ["(", 141], ["CML", 142], [")", 145], ["with", 147], ["the", 152], ["classic", 156], ["form", 164], ["of", 169], ["the", 172], ["Philadelphia", 176], ["chromosome", 189], ["(", 200], ["Ph", 201], [")", 203], [".", 204], ["We", 206], ["applied", 209], ["FISH", 217], ["to", 222], ["study", 225], ["three", 231], ["CML", 237], ["patients", 241], ["showing", 250], ["variant", 258], ["Ph", 266], ["chromosome", 269], ["(", 280], ["either", 281], ["complex", 288], ["or", 296], ["simple", 299], ["type", 306], [")", 310], [".", 311], ["The", 313], ["results", 317], ["demonstrate", 325], ["that", 337], ["the", 342], ["use", 346], ["of", 350], ["a", 353], ["yeast", 355], ["artificial", 361], ["chromosome", 372], ["(", 383], ["YAC)-derived", 384], ["probe", 397], ["(", 403], ["D107F9", 404], [")", 410], ["and", 412], ["a", 416], ["cosmid", 418], ["probe", 425], ["(", 431], ["cos", 432], ["-", 435], ["abl", 436], ["8)", 440], [",", 442], ["specific", 444], ["for", 453], ["BCR", 457], ["and", 461], ["ABL", 465], ["genes", 469], ["respectively", 475], [",", 487], ["allows", 489], ["also", 496], ["the", 501], ["detection", 505], ["of", 515], ["the", 518], ["BCR", 522], ["-", 525], ["ABL", 526], ["fusion", 530], ["in", 537], ["CML", 540], ["patients", 544], ["with", 553], ["variant", 558], ["Ph", 566], [".", 568]]}
{"context": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis. In the present study, we analyzed the CaSR gene in a Korean family with familial hypocalciuric hypercalcemia (FHH). Genetic studies were performed by direct sequence analysis of the CaSR gene in genomic DNA obtained from peripheral leukocytes. A novel heterozygous G to T substitution at nucleotide position 1711 in exon 6, resulting in the G571W mutation, was identified in the CaSR gene in a 26-year-old female with asymptomatic hypercalcemia, a low calcium/creatinine clearance ratio, and normal intact parathyroid hormone. To study CaSR expression, the mutation was introduced by site-directed mutagenesis into a wild-type (WT) CaSR-expressing pCR3.1 vector, and COS-7 cells were transfected with either the WT or mutant CaSR-containing vector. Transfected cells loaded with Fura-2/AM, a fluorescent indicator of Ca", "qas": [{"question": "What is the function of calcium-sensing receptor (CaSR)?", "answers": ["The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis."], "qid": "1f0adb77304f4c188ae40ccb27db4e56", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["function", 12], ["of", 21], ["calcium", 24], ["-", 31], ["sensing", 32], ["receptor", 40], ["(", 49], ["CaSR", 50], [")", 54], ["?", 55]], "detected_answers": [{"text": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis.", "token_spans": [[1, 24]], "char_spans": [[4, 130]]}]}], "context_tokens": [["The", 0], ["calcium", 4], ["-", 11], ["sensing", 12], ["receptor", 20], ["(", 29], ["CaSR", 30], [")", 34], ["is", 36], ["a", 39], ["G", 41], ["-", 42], ["protein", 43], ["-", 50], ["coupled", 51], ["receptor", 59], ["that", 68], ["plays", 73], ["an", 79], ["essential", 82], ["role", 92], ["in", 97], ["maintaining", 100], ["calcium", 112], ["homeostasis", 120], [".", 131], ["In", 133], ["the", 136], ["present", 140], ["study", 148], [",", 153], ["we", 155], ["analyzed", 158], ["the", 167], ["CaSR", 171], ["gene", 176], ["in", 181], ["a", 184], ["Korean", 186], ["family", 193], ["with", 200], ["familial", 205], ["hypocalciuric", 214], ["hypercalcemia", 228], ["(", 242], ["FHH", 243], [")", 246], [".", 247], ["Genetic", 249], ["studies", 257], ["were", 265], ["performed", 270], ["by", 280], ["direct", 283], ["sequence", 290], ["analysis", 299], ["of", 308], ["the", 311], ["CaSR", 315], ["gene", 320], ["in", 325], ["genomic", 328], ["DNA", 336], ["obtained", 340], ["from", 349], ["peripheral", 354], ["leukocytes", 365], [".", 375], ["A", 377], ["novel", 379], ["heterozygous", 385], ["G", 398], ["to", 400], ["T", 403], ["substitution", 405], ["at", 418], ["nucleotide", 421], ["position", 432], ["1711", 441], ["in", 446], ["exon", 449], ["6", 454], [",", 455], ["resulting", 457], ["in", 467], ["the", 470], ["G571W", 474], ["mutation", 480], [",", 488], ["was", 490], ["identified", 494], ["in", 505], ["the", 508], ["CaSR", 512], ["gene", 517], ["in", 522], ["a", 525], ["26-year", 527], ["-", 534], ["old", 535], ["female", 539], ["with", 546], ["asymptomatic", 551], ["hypercalcemia", 564], [",", 577], ["a", 579], ["low", 581], ["calcium", 585], ["/", 592], ["creatinine", 593], ["clearance", 604], ["ratio", 614], [",", 619], ["and", 621], ["normal", 625], ["intact", 632], ["parathyroid", 639], ["hormone", 651], [".", 658], ["To", 660], ["study", 663], ["CaSR", 669], ["expression", 674], [",", 684], ["the", 686], ["mutation", 690], ["was", 699], ["introduced", 703], ["by", 714], ["site", 717], ["-", 721], ["directed", 722], ["mutagenesis", 731], ["into", 743], ["a", 748], ["wild", 750], ["-", 754], ["type", 755], ["(", 760], ["WT", 761], [")", 763], ["CaSR", 765], ["-", 769], ["expressing", 770], ["pCR3.1", 781], ["vector", 788], [",", 794], ["and", 796], ["COS-7", 800], ["cells", 806], ["were", 812], ["transfected", 817], ["with", 829], ["either", 834], ["the", 841], ["WT", 845], ["or", 848], ["mutant", 851], ["CaSR", 858], ["-", 862], ["containing", 863], ["vector", 874], [".", 880], ["Transfected", 882], ["cells", 894], ["loaded", 900], ["with", 907], ["Fura-2/AM", 912], [",", 921], ["a", 923], ["fluorescent", 925], ["indicator", 937], ["of", 947], ["Ca", 950]]}
{"context": "Although methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to vancomycin (RVS-MRSA; including vancomycin-intermediate S. aureus [VISA] and heterogeneous VISA [hVISA]) have been linked with vancomycin treatment failure, it is unclear whether they are more pathogenic than vancomycin-susceptible MRSA (VS-MRSA). We prospectively assessed patients with clinical MRSA isolates during a 10-month period to determine clinical status (infection versus colonization) and therapeutic outcome before correlating these findings with the results of detailed in vitro assessment of vancomycin susceptibility, including population analysis profile (PAP) testing. hVISA and VISA were defined by standard PAP criteria (area-under-the-curve ratio compared to that of the reference hVISA strain Mu3 [>or=0.9]) and routine CLSI criteria (vancomycin MIC, 4 to 8 microg/ml), respectively. Among the 117 patients assessed, 58 had RVS-MRSA isolates (56 hVISA and 2 VISA) and 59 had VS-MRSA isolates; the patient demographics and comorbidities were similar. RVS-MRSA was associated with a lower rate of infection than VS-MRSA (29/58 versus 46/59; P = 0.003), including a lower rate of bacteremia (3/58 versus 20/59, respectively; P < 0.001). The cure rates in RVS-MRSA and VS-MRSA groups were not statistically different (16/26 versus 31/42; P = 0.43), but the post hoc assessment of treatment regimes and study size made detailed conclusions difficult. The results of the macro method Etest correlated well with the PAP results (sensitivity, 98.3%, and specificity, 91.5%), but broth microdilution and our preliminary RVS-MRSA detection method correlated poorly. All isolates were susceptible to linezolid and daptomycin. These data suggest that detailed prospective laboratory identification of RVS-MRSA isolates may be of limited value and that, instead, such in vitro investigation should be reserved for isolates from patients who are failing appropriate anti-MRSA therapy.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "ceea58daf75a47a2a1f4006fe10ba779", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[69, 69], [211, 211], [186, 186], [246, 246], [250, 250], [342, 342], [60, 60], [172, 172], [7, 7], [199, 199], [316, 316], [371, 371], [56, 56], [18, 18]], "char_spans": [[409, 412], [1147, 1150], [1012, 1015], [1290, 1293], [1302, 1305], [1827, 1830], [353, 356], [962, 965], [67, 70], [1088, 1091], [1649, 1652], [1991, 1994], [344, 347], [128, 131]]}]}], "context_tokens": [["Although", 0], ["methicillin", 9], ["(", 21], ["meticillin)-resistant", 22], ["Staphylococcus", 44], ["aureus", 59], ["(", 66], ["MRSA", 67], [")", 71], ["strains", 73], ["with", 81], ["reduced", 86], ["susceptibility", 94], ["to", 109], ["vancomycin", 112], ["(", 123], ["RVS", 124], ["-", 127], ["MRSA", 128], [";", 132], ["including", 134], ["vancomycin", 144], ["-", 154], ["intermediate", 155], ["S.", 168], ["aureus", 171], ["[", 178], ["VISA", 179], ["]", 183], ["and", 185], ["heterogeneous", 189], ["VISA", 203], ["[", 208], ["hVISA", 209], ["]", 214], [")", 215], ["have", 217], ["been", 222], ["linked", 227], ["with", 234], ["vancomycin", 239], ["treatment", 250], ["failure", 260], [",", 267], ["it", 269], ["is", 272], ["unclear", 275], ["whether", 283], ["they", 291], ["are", 296], ["more", 300], ["pathogenic", 305], ["than", 316], ["vancomycin", 321], ["-", 331], ["susceptible", 332], ["MRSA", 344], ["(", 349], ["VS", 350], ["-", 352], ["MRSA", 353], [")", 357], [".", 358], ["We", 360], ["prospectively", 363], ["assessed", 377], ["patients", 386], ["with", 395], ["clinical", 400], ["MRSA", 409], ["isolates", 414], ["during", 423], ["a", 430], ["10-month", 432], ["period", 441], ["to", 448], ["determine", 451], ["clinical", 461], ["status", 470], ["(", 477], ["infection", 478], ["versus", 488], ["colonization", 495], [")", 507], ["and", 509], ["therapeutic", 513], ["outcome", 525], ["before", 533], ["correlating", 540], ["these", 552], ["findings", 558], ["with", 567], ["the", 572], ["results", 576], ["of", 584], ["detailed", 587], ["in", 596], ["vitro", 599], ["assessment", 605], ["of", 616], ["vancomycin", 619], ["susceptibility", 630], [",", 644], ["including", 646], ["population", 656], ["analysis", 667], ["profile", 676], ["(", 684], ["PAP", 685], [")", 688], ["testing", 690], [".", 697], ["hVISA", 699], ["and", 705], ["VISA", 709], ["were", 714], ["defined", 719], ["by", 727], ["standard", 730], ["PAP", 739], ["criteria", 743], ["(", 752], ["area", 753], ["-", 757], ["under", 758], ["-", 763], ["the", 764], ["-", 767], ["curve", 768], ["ratio", 774], ["compared", 780], ["to", 789], ["that", 792], ["of", 797], ["the", 800], ["reference", 804], ["hVISA", 814], ["strain", 820], ["Mu3", 827], ["[", 831], [">", 832], ["or=0.9", 833], ["]", 839], [")", 840], ["and", 842], ["routine", 846], ["CLSI", 854], ["criteria", 859], ["(", 868], ["vancomycin", 869], ["MIC", 880], [",", 883], ["4", 885], ["to", 887], ["8", 890], ["microg", 892], ["/", 898], ["ml", 899], [")", 901], [",", 902], ["respectively", 904], [".", 916], ["Among", 918], ["the", 924], ["117", 928], ["patients", 932], ["assessed", 941], [",", 949], ["58", 951], ["had", 954], ["RVS", 958], ["-", 961], ["MRSA", 962], ["isolates", 967], ["(", 976], ["56", 977], ["hVISA", 980], ["and", 986], ["2", 990], ["VISA", 992], [")", 996], ["and", 998], ["59", 1002], ["had", 1005], ["VS", 1009], ["-", 1011], ["MRSA", 1012], ["isolates", 1017], [";", 1025], ["the", 1027], ["patient", 1031], ["demographics", 1039], ["and", 1052], ["comorbidities", 1056], ["were", 1070], ["similar", 1075], [".", 1082], ["RVS", 1084], ["-", 1087], ["MRSA", 1088], ["was", 1093], ["associated", 1097], ["with", 1108], ["a", 1113], ["lower", 1115], ["rate", 1121], ["of", 1126], ["infection", 1129], ["than", 1139], ["VS", 1144], ["-", 1146], ["MRSA", 1147], ["(", 1152], ["29/58", 1153], ["versus", 1159], ["46/59", 1166], [";", 1171], ["P", 1173], ["=", 1175], ["0.003", 1177], [")", 1182], [",", 1183], ["including", 1185], ["a", 1195], ["lower", 1197], ["rate", 1203], ["of", 1208], ["bacteremia", 1211], ["(", 1222], ["3/58", 1223], ["versus", 1228], ["20/59", 1235], [",", 1240], ["respectively", 1242], [";", 1254], ["P", 1256], ["<", 1258], ["0.001", 1260], [")", 1265], [".", 1266], ["The", 1268], ["cure", 1272], ["rates", 1277], ["in", 1283], ["RVS", 1286], ["-", 1289], ["MRSA", 1290], ["and", 1295], ["VS", 1299], ["-", 1301], ["MRSA", 1302], ["groups", 1307], ["were", 1314], ["not", 1319], ["statistically", 1323], ["different", 1337], ["(", 1347], ["16/26", 1348], ["versus", 1354], ["31/42", 1361], [";", 1366], ["P", 1368], ["=", 1370], ["0.43", 1372], [")", 1376], [",", 1377], ["but", 1379], ["the", 1383], ["post", 1387], ["hoc", 1392], ["assessment", 1396], ["of", 1407], ["treatment", 1410], ["regimes", 1420], ["and", 1428], ["study", 1432], ["size", 1438], ["made", 1443], ["detailed", 1448], ["conclusions", 1457], ["difficult", 1469], [".", 1478], ["The", 1480], ["results", 1484], ["of", 1492], ["the", 1495], ["macro", 1499], ["method", 1505], ["Etest", 1512], ["correlated", 1518], ["well", 1529], ["with", 1534], ["the", 1539], ["PAP", 1543], ["results", 1547], ["(", 1555], ["sensitivity", 1556], [",", 1567], ["98.3", 1569], ["%", 1573], [",", 1574], ["and", 1576], ["specificity", 1580], [",", 1591], ["91.5", 1593], ["%", 1597], [")", 1598], [",", 1599], ["but", 1601], ["broth", 1605], ["microdilution", 1611], ["and", 1625], ["our", 1629], ["preliminary", 1633], ["RVS", 1645], ["-", 1648], ["MRSA", 1649], ["detection", 1654], ["method", 1664], ["correlated", 1671], ["poorly", 1682], [".", 1688], ["All", 1690], ["isolates", 1694], ["were", 1703], ["susceptible", 1708], ["to", 1720], ["linezolid", 1723], ["and", 1733], ["daptomycin", 1737], [".", 1747], ["These", 1749], ["data", 1755], ["suggest", 1760], ["that", 1768], ["detailed", 1773], ["prospective", 1782], ["laboratory", 1794], ["identification", 1805], ["of", 1820], ["RVS", 1823], ["-", 1826], ["MRSA", 1827], ["isolates", 1832], ["may", 1841], ["be", 1845], ["of", 1848], ["limited", 1851], ["value", 1859], ["and", 1865], ["that", 1869], [",", 1873], ["instead", 1875], [",", 1882], ["such", 1884], ["in", 1889], ["vitro", 1892], ["investigation", 1898], ["should", 1912], ["be", 1919], ["reserved", 1922], ["for", 1931], ["isolates", 1935], ["from", 1944], ["patients", 1949], ["who", 1958], ["are", 1962], ["failing", 1966], ["appropriate", 1974], ["anti", 1986], ["-", 1990], ["MRSA", 1991], ["therapy", 1996], [".", 2003]]}
{"context": "Chronic myelogenous leukemia (CML) is characterized by Philadelphia (Ph) chromosome with a chimeric gene BCR-ABL created by reciprocal t(9:22) (q34;q11) translocation. Variant Ph chromosome translocations involving chromosomes other than 9 and 22 are found in 5-10% of CML cases. We here report a CML patient who carries a four-way Ph chromosome translocation, t(9;22;15;19) (q34;q11;q15;q13). The patient was diagnosed in 1997 and initially treated with hydroxyurea. In 2002, treatment with imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was started but Ph-positive chromosomes remained at the levels of 42-65%, indicating imatinib failure. In 2006, the point mutations of F359I and L387M were detected in BCR/ABL gene, which may be related to imatinib failure. Treatment with nilotinib, a TKI with high target specificity, was then started which resulted in durable major molecular response. Administration of nilotinib offered an effective treatment in a CML patient with variant Ph chromosome translocations and BCR-ABL point mutations after imatinib failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "fdeaba7b6cb142ef8d135fd8ca5d8c0a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[193, 195], [141, 143], [18, 20], [96, 98]], "char_spans": [[1032, 1038], [723, 729], [105, 111], [514, 520]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["Philadelphia", 55], ["(", 68], ["Ph", 69], [")", 71], ["chromosome", 73], ["with", 84], ["a", 89], ["chimeric", 91], ["gene", 100], ["BCR", 105], ["-", 108], ["ABL", 109], ["created", 113], ["by", 121], ["reciprocal", 124], ["t(9:22", 135], [")", 141], ["(", 143], ["q34;q11", 144], [")", 151], ["translocation", 153], [".", 166], ["Variant", 168], ["Ph", 176], ["chromosome", 179], ["translocations", 190], ["involving", 205], ["chromosomes", 215], ["other", 227], ["than", 233], ["9", 238], ["and", 240], ["22", 244], ["are", 247], ["found", 251], ["in", 257], ["5", 260], ["-", 261], ["10", 262], ["%", 264], ["of", 266], ["CML", 269], ["cases", 273], [".", 278], ["We", 280], ["here", 283], ["report", 288], ["a", 295], ["CML", 297], ["patient", 301], ["who", 309], ["carries", 313], ["a", 321], ["four", 323], ["-", 327], ["way", 328], ["Ph", 332], ["chromosome", 335], ["translocation", 346], [",", 359], ["t(9;22;15;19", 361], [")", 373], ["(", 375], ["q34;q11;q15;q13", 376], [")", 391], [".", 392], ["The", 394], ["patient", 398], ["was", 406], ["diagnosed", 410], ["in", 420], ["1997", 423], ["and", 428], ["initially", 432], ["treated", 442], ["with", 450], ["hydroxyurea", 455], [".", 466], ["In", 468], ["2002", 471], [",", 475], ["treatment", 477], ["with", 487], ["imatinib", 492], [",", 500], ["a", 502], ["selective", 504], ["BCR", 514], ["-", 517], ["ABL", 518], ["tyrosine", 522], ["kinase", 531], ["inhibitor", 538], ["(", 548], ["TKI", 549], [")", 552], [",", 553], ["was", 555], ["started", 559], ["but", 567], ["Ph", 571], ["-", 573], ["positive", 574], ["chromosomes", 583], ["remained", 595], ["at", 604], ["the", 607], ["levels", 611], ["of", 618], ["42", 621], ["-", 623], ["65", 624], ["%", 626], [",", 627], ["indicating", 629], ["imatinib", 640], ["failure", 649], [".", 656], ["In", 658], ["2006", 661], [",", 665], ["the", 667], ["point", 671], ["mutations", 677], ["of", 687], ["F359I", 690], ["and", 696], ["L387", 700], ["M", 704], ["were", 706], ["detected", 711], ["in", 720], ["BCR", 723], ["/", 726], ["ABL", 727], ["gene", 731], [",", 735], ["which", 737], ["may", 743], ["be", 747], ["related", 750], ["to", 758], ["imatinib", 761], ["failure", 770], [".", 777], ["Treatment", 779], ["with", 789], ["nilotinib", 794], [",", 803], ["a", 805], ["TKI", 807], ["with", 811], ["high", 816], ["target", 821], ["specificity", 828], [",", 839], ["was", 841], ["then", 845], ["started", 850], ["which", 858], ["resulted", 864], ["in", 873], ["durable", 876], ["major", 884], ["molecular", 890], ["response", 900], [".", 908], ["Administration", 910], ["of", 925], ["nilotinib", 928], ["offered", 938], ["an", 946], ["effective", 949], ["treatment", 959], ["in", 969], ["a", 972], ["CML", 974], ["patient", 978], ["with", 986], ["variant", 991], ["Ph", 999], ["chromosome", 1002], ["translocations", 1013], ["and", 1028], ["BCR", 1032], ["-", 1035], ["ABL", 1036], ["point", 1040], ["mutations", 1046], ["after", 1056], ["imatinib", 1062], ["failure", 1071], [".", 1078]]}
{"context": "The BCR/ABL gene fusion, the hallmark of chronic myelogenous leukemia (CML) is generated in 2-10% of patients by a variant Ph translocation involving 9q34, 22q11.2, and one or more additional genomic regions. The objective of this study was the characterization by conventional and molecular cytogenetics of complex variant Ph translocations present at diagnosis. FISH studies were performed in 7 cases using the LSI BCR/ABL ES probe allowing the detection of the fusion BCR/ABL gene on the Ph chromosome in all of them and 9q34 deletions in 2 cases. Three cryptic complex rearrangements were detected by FISH studies. The third and the fourth chromosome regions involved in the 8 complex variant translocations were: 1q21, 1p36, 5q31, 11q13, 12q13, 12p13, and 20q12. In conclusion, FISH studies have been useful in the detection of the BCR/ABL rearrangements and 9q34 deletions, and to identify complex rearrangements that differ from the ones previously established by conventional cytogenetics.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "85a18e64fb2d47b0afeee4832c599891", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[1, 5]], "char_spans": [[4, 22]]}]}], "context_tokens": [["The", 0], ["BCR", 4], ["/", 7], ["ABL", 8], ["gene", 12], ["fusion", 17], [",", 23], ["the", 25], ["hallmark", 29], ["of", 38], ["chronic", 41], ["myelogenous", 49], ["leukemia", 61], ["(", 70], ["CML", 71], [")", 74], ["is", 76], ["generated", 79], ["in", 89], ["2", 92], ["-", 93], ["10", 94], ["%", 96], ["of", 98], ["patients", 101], ["by", 110], ["a", 113], ["variant", 115], ["Ph", 123], ["translocation", 126], ["involving", 140], ["9q34", 150], [",", 154], ["22q11.2", 156], [",", 163], ["and", 165], ["one", 169], ["or", 173], ["more", 176], ["additional", 181], ["genomic", 192], ["regions", 200], [".", 207], ["The", 209], ["objective", 213], ["of", 223], ["this", 226], ["study", 231], ["was", 237], ["the", 241], ["characterization", 245], ["by", 262], ["conventional", 265], ["and", 278], ["molecular", 282], ["cytogenetics", 292], ["of", 305], ["complex", 308], ["variant", 316], ["Ph", 324], ["translocations", 327], ["present", 342], ["at", 350], ["diagnosis", 353], [".", 362], ["FISH", 364], ["studies", 369], ["were", 377], ["performed", 382], ["in", 392], ["7", 395], ["cases", 397], ["using", 403], ["the", 409], ["LSI", 413], ["BCR", 417], ["/", 420], ["ABL", 421], ["ES", 425], ["probe", 428], ["allowing", 434], ["the", 443], ["detection", 447], ["of", 457], ["the", 460], ["fusion", 464], ["BCR", 471], ["/", 474], ["ABL", 475], ["gene", 479], ["on", 484], ["the", 487], ["Ph", 491], ["chromosome", 494], ["in", 505], ["all", 508], ["of", 512], ["them", 515], ["and", 520], ["9q34", 524], ["deletions", 529], ["in", 539], ["2", 542], ["cases", 544], [".", 549], ["Three", 551], ["cryptic", 557], ["complex", 565], ["rearrangements", 573], ["were", 588], ["detected", 593], ["by", 602], ["FISH", 605], ["studies", 610], [".", 617], ["The", 619], ["third", 623], ["and", 629], ["the", 633], ["fourth", 637], ["chromosome", 644], ["regions", 655], ["involved", 663], ["in", 672], ["the", 675], ["8", 679], ["complex", 681], ["variant", 689], ["translocations", 697], ["were", 712], [":", 716], ["1q21", 718], [",", 722], ["1p36", 724], [",", 728], ["5q31", 730], [",", 734], ["11q13", 736], [",", 741], ["12q13", 743], [",", 748], ["12p13", 750], [",", 755], ["and", 757], ["20q12", 761], [".", 766], ["In", 768], ["conclusion", 771], [",", 781], ["FISH", 783], ["studies", 788], ["have", 796], ["been", 801], ["useful", 806], ["in", 813], ["the", 816], ["detection", 820], ["of", 830], ["the", 833], ["BCR", 837], ["/", 840], ["ABL", 841], ["rearrangements", 845], ["and", 860], ["9q34", 864], ["deletions", 869], [",", 878], ["and", 880], ["to", 884], ["identify", 887], ["complex", 896], ["rearrangements", 904], ["that", 919], ["differ", 924], ["from", 931], ["the", 936], ["ones", 940], ["previously", 945], ["established", 956], ["by", 968], ["conventional", 971], ["cytogenetics", 984], [".", 996]]}
{"context": "Ubiquilin proteins facilitate delivery of ubiquitinated proteins to the proteasome for degradation. Interest in the proteins has been heightened by the discovery that gene mutations in UBQLN2 cause dominant inheritance of amyotrophic lateral sclerosis (ALS). However, the mechanisms by which the mutations cause ALS are not known. Here we report on the underlying defect of ubiquilin-2 proteins containing ALS-linked mutations in affecting proteasome-mediated degradation. We found that overexpression of ubiquilin-2 proteins containing any one of five different ALS mutations slow degradation of Myc, a prototypic proteasome substrate. Examination of coprecipitating proteins indicated that the mutant proteins are generally capable of binding polyubiquitinated proteins, but defective in binding the proteasome. GST-pulldown studies revealed that many of the mutants bind weaker to the S5a subunit of the proteasome, compared with wild type (WT) ubiquilin-2 protein. The results suggest the mutant proteins are unable to deliver their captured cargo to the proteasome for degradation, which presumably leads to toxicity. Quantification of cell death is consistent with this idea. Measurement of protein turnover further indicated the mutant proteins have longer half-lives than WT ubiquilin-2. Our studies provide novel insight into the mechanism by which ALS-linked mutations in UBQLN2 interfere with protein degradation.", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "512ddca4bf4d4b0b858b5f2fc87b8f28", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[48, 48], [64, 64], [36, 36], [217, 217], [88, 88]], "char_spans": [[312, 314], [406, 408], [253, 255], [1358, 1360], [563, 565]]}, {"text": "amyotrophic lateral sclerosis", "token_spans": [[32, 34]], "char_spans": [[222, 250]]}]}], "context_tokens": [["Ubiquilin", 0], ["proteins", 10], ["facilitate", 19], ["delivery", 30], ["of", 39], ["ubiquitinated", 42], ["proteins", 56], ["to", 65], ["the", 68], ["proteasome", 72], ["for", 83], ["degradation", 87], [".", 98], ["Interest", 100], ["in", 109], ["the", 112], ["proteins", 116], ["has", 125], ["been", 129], ["heightened", 134], ["by", 145], ["the", 148], ["discovery", 152], ["that", 162], ["gene", 167], ["mutations", 172], ["in", 182], ["UBQLN2", 185], ["cause", 192], ["dominant", 198], ["inheritance", 207], ["of", 219], ["amyotrophic", 222], ["lateral", 234], ["sclerosis", 242], ["(", 252], ["ALS", 253], [")", 256], [".", 257], ["However", 259], [",", 266], ["the", 268], ["mechanisms", 272], ["by", 283], ["which", 286], ["the", 292], ["mutations", 296], ["cause", 306], ["ALS", 312], ["are", 316], ["not", 320], ["known", 324], [".", 329], ["Here", 331], ["we", 336], ["report", 339], ["on", 346], ["the", 349], ["underlying", 353], ["defect", 364], ["of", 371], ["ubiquilin-2", 374], ["proteins", 386], ["containing", 395], ["ALS", 406], ["-", 409], ["linked", 410], ["mutations", 417], ["in", 427], ["affecting", 430], ["proteasome", 440], ["-", 450], ["mediated", 451], ["degradation", 460], [".", 471], ["We", 473], ["found", 476], ["that", 482], ["overexpression", 487], ["of", 502], ["ubiquilin-2", 505], ["proteins", 517], ["containing", 526], ["any", 537], ["one", 541], ["of", 545], ["five", 548], ["different", 553], ["ALS", 563], ["mutations", 567], ["slow", 577], ["degradation", 582], ["of", 594], ["Myc", 597], [",", 600], ["a", 602], ["prototypic", 604], ["proteasome", 615], ["substrate", 626], [".", 635], ["Examination", 637], ["of", 649], ["coprecipitating", 652], ["proteins", 668], ["indicated", 677], ["that", 687], ["the", 692], ["mutant", 696], ["proteins", 703], ["are", 712], ["generally", 716], ["capable", 726], ["of", 734], ["binding", 737], ["polyubiquitinated", 745], ["proteins", 763], [",", 771], ["but", 773], ["defective", 777], ["in", 787], ["binding", 790], ["the", 798], ["proteasome", 802], [".", 812], ["GST", 814], ["-", 817], ["pulldown", 818], ["studies", 827], ["revealed", 835], ["that", 844], ["many", 849], ["of", 854], ["the", 857], ["mutants", 861], ["bind", 869], ["weaker", 874], ["to", 881], ["the", 884], ["S5a", 888], ["subunit", 892], ["of", 900], ["the", 903], ["proteasome", 907], [",", 917], ["compared", 919], ["with", 928], ["wild", 933], ["type", 938], ["(", 943], ["WT", 944], [")", 946], ["ubiquilin-2", 948], ["protein", 960], [".", 967], ["The", 969], ["results", 973], ["suggest", 981], ["the", 989], ["mutant", 993], ["proteins", 1000], ["are", 1009], ["unable", 1013], ["to", 1020], ["deliver", 1023], ["their", 1031], ["captured", 1037], ["cargo", 1046], ["to", 1052], ["the", 1055], ["proteasome", 1059], ["for", 1070], ["degradation", 1074], [",", 1085], ["which", 1087], ["presumably", 1093], ["leads", 1104], ["to", 1110], ["toxicity", 1113], [".", 1121], ["Quantification", 1123], ["of", 1138], ["cell", 1141], ["death", 1146], ["is", 1152], ["consistent", 1155], ["with", 1166], ["this", 1171], ["idea", 1176], [".", 1180], ["Measurement", 1182], ["of", 1194], ["protein", 1197], ["turnover", 1205], ["further", 1214], ["indicated", 1222], ["the", 1232], ["mutant", 1236], ["proteins", 1243], ["have", 1252], ["longer", 1257], ["half", 1264], ["-", 1268], ["lives", 1269], ["than", 1275], ["WT", 1280], ["ubiquilin-2", 1283], [".", 1294], ["Our", 1296], ["studies", 1300], ["provide", 1308], ["novel", 1316], ["insight", 1322], ["into", 1330], ["the", 1335], ["mechanism", 1339], ["by", 1349], ["which", 1352], ["ALS", 1358], ["-", 1361], ["linked", 1362], ["mutations", 1369], ["in", 1379], ["UBQLN2", 1382], ["interfere", 1389], ["with", 1399], ["protein", 1404], ["degradation", 1412], [".", 1423]]}
{"context": "Purpose To determine the frequency of, and yield after, provider overrides of evidence-based clinical decision support (CDS) for ordering computed tomographic (CT) pulmonary angiography in the emergency department (ED). Materials and Methods This HIPAA-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ED with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (PE) and who underwent CT pulmonary angiography between January 1, 2011, and August 31, 2013. The requirement to obtain informed consent was waived. Each CT order for pulmonary angiography was exposed to CDS on the basis of the Wells criteria. For patients with a Wells score of 4 or less, CDS alerts suggested d-dimer testing because acute PE is highly unlikely in these patients if d-dimer levels are normal. The yield of CT pulmonary angiography (number of positive PE diagnoses/total number of CT pulmonary angiographic examinations) was compared in patients in whom providers overrode CDS alerts (by performing CT pulmonary angiography in patients with a Wells score \u22644 and a normal d-dimer level or no d-dimer testing) (override group) and those in whom providers followed Wells criteria (CT pulmonary angiography only in patients with Wells score >4 or \u22644 with elevated d-dimer level) (adherent group). A validated natural language processing tool identified positive PE diagnoses, with subsegmental and/or indeterminate diagnoses removed by means of chart review. Statistical analysis was performed with the \u03c7", "qas": [{"question": "What can be predicted with the Wells criteria?", "answers": ["pulmonary embolism"], "qid": "0e98ec9fa2fc434f89b5688800607a86", "question_tokens": [["What", 0], ["can", 5], ["be", 9], ["predicted", 12], ["with", 22], ["the", 27], ["Wells", 31], ["criteria", 37], ["?", 45]], "detected_answers": [{"text": "pulmonary embolism", "token_spans": [[80, 81]], "char_spans": [[462, 479]]}]}], "context_tokens": [["Purpose", 0], ["To", 8], ["determine", 11], ["the", 21], ["frequency", 25], ["of", 35], [",", 37], ["and", 39], ["yield", 43], ["after", 49], [",", 54], ["provider", 56], ["overrides", 65], ["of", 75], ["evidence", 78], ["-", 86], ["based", 87], ["clinical", 93], ["decision", 102], ["support", 111], ["(", 119], ["CDS", 120], [")", 123], ["for", 125], ["ordering", 129], ["computed", 138], ["tomographic", 147], ["(", 159], ["CT", 160], [")", 162], ["pulmonary", 164], ["angiography", 174], ["in", 186], ["the", 189], ["emergency", 193], ["department", 203], ["(", 214], ["ED", 215], [")", 217], [".", 218], ["Materials", 220], ["and", 230], ["Methods", 234], ["This", 242], ["HIPAA", 247], ["-", 252], ["compliant", 253], [",", 262], ["institutional", 264], ["review", 278], ["board", 285], ["-", 290], ["approved", 291], ["study", 300], ["was", 306], ["performed", 310], ["at", 320], ["a", 323], ["tertiary", 325], ["care", 334], [",", 338], ["academic", 340], ["medical", 349], ["center", 357], ["ED", 364], ["with", 367], ["approximately", 372], ["60", 386], ["000", 389], ["annual", 393], ["visits", 400], ["and", 407], ["included", 411], ["all", 420], ["patients", 424], ["who", 433], ["were", 437], ["suspected", 442], ["of", 452], ["having", 455], ["pulmonary", 462], ["embolism", 472], ["(", 481], ["PE", 482], [")", 484], ["and", 486], ["who", 490], ["underwent", 494], ["CT", 504], ["pulmonary", 507], ["angiography", 517], ["between", 529], ["January", 537], ["1", 545], [",", 546], ["2011", 548], [",", 552], ["and", 554], ["August", 558], ["31", 565], [",", 567], ["2013", 569], [".", 573], ["The", 575], ["requirement", 579], ["to", 591], ["obtain", 594], ["informed", 601], ["consent", 610], ["was", 618], ["waived", 622], [".", 628], ["Each", 630], ["CT", 635], ["order", 638], ["for", 644], ["pulmonary", 648], ["angiography", 658], ["was", 670], ["exposed", 674], ["to", 682], ["CDS", 685], ["on", 689], ["the", 692], ["basis", 696], ["of", 702], ["the", 705], ["Wells", 709], ["criteria", 715], [".", 723], ["For", 725], ["patients", 729], ["with", 738], ["a", 743], ["Wells", 745], ["score", 751], ["of", 757], ["4", 760], ["or", 762], ["less", 765], [",", 769], ["CDS", 771], ["alerts", 775], ["suggested", 782], ["d", 792], ["-", 793], ["dimer", 794], ["testing", 800], ["because", 808], ["acute", 816], ["PE", 822], ["is", 825], ["highly", 828], ["unlikely", 835], ["in", 844], ["these", 847], ["patients", 853], ["if", 862], ["d", 865], ["-", 866], ["dimer", 867], ["levels", 873], ["are", 880], ["normal", 884], [".", 890], ["The", 892], ["yield", 896], ["of", 902], ["CT", 905], ["pulmonary", 908], ["angiography", 918], ["(", 930], ["number", 931], ["of", 938], ["positive", 941], ["PE", 950], ["diagnoses", 953], ["/", 962], ["total", 963], ["number", 969], ["of", 976], ["CT", 979], ["pulmonary", 982], ["angiographic", 992], ["examinations", 1005], [")", 1017], ["was", 1019], ["compared", 1023], ["in", 1032], ["patients", 1035], ["in", 1044], ["whom", 1047], ["providers", 1052], ["overrode", 1062], ["CDS", 1071], ["alerts", 1075], ["(", 1082], ["by", 1083], ["performing", 1086], ["CT", 1097], ["pulmonary", 1100], ["angiography", 1110], ["in", 1122], ["patients", 1125], ["with", 1134], ["a", 1139], ["Wells", 1141], ["score", 1147], ["\u22644", 1153], ["and", 1156], ["a", 1160], ["normal", 1162], ["d", 1169], ["-", 1170], ["dimer", 1171], ["level", 1177], ["or", 1183], ["no", 1186], ["d", 1189], ["-", 1190], ["dimer", 1191], ["testing", 1197], [")", 1204], ["(", 1206], ["override", 1207], ["group", 1216], [")", 1221], ["and", 1223], ["those", 1227], ["in", 1233], ["whom", 1236], ["providers", 1241], ["followed", 1251], ["Wells", 1260], ["criteria", 1266], ["(", 1275], ["CT", 1276], ["pulmonary", 1279], ["angiography", 1289], ["only", 1301], ["in", 1306], ["patients", 1309], ["with", 1318], ["Wells", 1323], ["score", 1329], [">", 1335], ["4", 1336], ["or", 1338], ["\u22644", 1341], ["with", 1344], ["elevated", 1349], ["d", 1358], ["-", 1359], ["dimer", 1360], ["level", 1366], [")", 1371], ["(", 1373], ["adherent", 1374], ["group", 1383], [")", 1388], [".", 1389], ["A", 1391], ["validated", 1393], ["natural", 1403], ["language", 1411], ["processing", 1420], ["tool", 1431], ["identified", 1436], ["positive", 1447], ["PE", 1456], ["diagnoses", 1459], [",", 1468], ["with", 1470], ["subsegmental", 1475], ["and/or", 1488], ["indeterminate", 1495], ["diagnoses", 1509], ["removed", 1519], ["by", 1527], ["means", 1530], ["of", 1536], ["chart", 1539], ["review", 1545], [".", 1551], ["Statistical", 1553], ["analysis", 1565], ["was", 1574], ["performed", 1578], ["with", 1588], ["the", 1593], ["\u03c7", 1597]]}
{"context": "Here, we report the biochemical and genetic basis of the Vel blood group antigen, which has been a vexing mystery for decades, especially as anti-Vel regularly causes severe haemolytic transfusion reactions. The protein carrying the Vel blood group antigen was biochemically purified from red blood cell membranes. Mass spectrometry-based de novo peptide sequencing identified this protein to be small integral membrane protein 1 (SMIM1), a previously uncharacterized single-pass membrane protein. Expression of SMIM1 cDNA in Vel- cultured cells generated anti-Vel cell surface reactivity, confirming that SMIM1 encoded the Vel blood group antigen. A cohort of 70 Vel- individuals was found to be uniformly homozygous for a 17 nucleotide deletion in the coding sequence of SMIM1. The genetic homogeneity of the Vel- blood type, likely having a common origin, facilitated the development of two highly specific DNA-based tests for rapid Vel genotyping, which can be easily integrated into blood group genotyping platforms. These results answer a 60-year-old riddle and provide tools of immediate assistance to all clinicians involved in the care of Vel- patients.", "qas": [{"question": "Which gene-defect causes the Vel-blood type?", "answers": ["a 17 nucleotide deletion"], "qid": "1a0f88859ac041309e802081a92d69d7", "question_tokens": [["Which", 0], ["gene", 6], ["-", 10], ["defect", 11], ["causes", 18], ["the", 25], ["Vel", 29], ["-", 32], ["blood", 33], ["type", 39], ["?", 43]], "detected_answers": [{"text": "a 17 nucleotide deletion", "token_spans": [[125, 127]], "char_spans": [[724, 745]]}]}], "context_tokens": [["Here", 0], [",", 4], ["we", 6], ["report", 9], ["the", 16], ["biochemical", 20], ["and", 32], ["genetic", 36], ["basis", 44], ["of", 50], ["the", 53], ["Vel", 57], ["blood", 61], ["group", 67], ["antigen", 73], [",", 80], ["which", 82], ["has", 88], ["been", 92], ["a", 97], ["vexing", 99], ["mystery", 106], ["for", 114], ["decades", 118], [",", 125], ["especially", 127], ["as", 138], ["anti", 141], ["-", 145], ["Vel", 146], ["regularly", 150], ["causes", 160], ["severe", 167], ["haemolytic", 174], ["transfusion", 185], ["reactions", 197], [".", 206], ["The", 208], ["protein", 212], ["carrying", 220], ["the", 229], ["Vel", 233], ["blood", 237], ["group", 243], ["antigen", 249], ["was", 257], ["biochemically", 261], ["purified", 275], ["from", 284], ["red", 289], ["blood", 293], ["cell", 299], ["membranes", 304], [".", 313], ["Mass", 315], ["spectrometry", 320], ["-", 332], ["based", 333], ["de", 339], ["novo", 342], ["peptide", 347], ["sequencing", 355], ["identified", 366], ["this", 377], ["protein", 382], ["to", 390], ["be", 393], ["small", 396], ["integral", 402], ["membrane", 411], ["protein", 420], ["1", 428], ["(", 430], ["SMIM1", 431], [")", 436], [",", 437], ["a", 439], ["previously", 441], ["uncharacterized", 452], ["single", 468], ["-", 474], ["pass", 475], ["membrane", 480], ["protein", 489], [".", 496], ["Expression", 498], ["of", 509], ["SMIM1", 512], ["cDNA", 518], ["in", 523], ["Vel-", 526], ["cultured", 531], ["cells", 540], ["generated", 546], ["anti", 556], ["-", 560], ["Vel", 561], ["cell", 565], ["surface", 570], ["reactivity", 578], [",", 588], ["confirming", 590], ["that", 601], ["SMIM1", 606], ["encoded", 612], ["the", 620], ["Vel", 624], ["blood", 628], ["group", 634], ["antigen", 640], [".", 647], ["A", 649], ["cohort", 651], ["of", 658], ["70", 661], ["Vel-", 664], ["individuals", 669], ["was", 681], ["found", 685], ["to", 691], ["be", 694], ["uniformly", 697], ["homozygous", 707], ["for", 718], ["a", 722], ["17", 724], ["nucleotide", 727], ["deletion", 738], ["in", 747], ["the", 750], ["coding", 754], ["sequence", 761], ["of", 770], ["SMIM1", 773], [".", 778], ["The", 780], ["genetic", 784], ["homogeneity", 792], ["of", 804], ["the", 807], ["Vel-", 811], ["blood", 816], ["type", 822], [",", 826], ["likely", 828], ["having", 835], ["a", 842], ["common", 844], ["origin", 851], [",", 857], ["facilitated", 859], ["the", 871], ["development", 875], ["of", 887], ["two", 890], ["highly", 894], ["specific", 901], ["DNA", 910], ["-", 913], ["based", 914], ["tests", 920], ["for", 926], ["rapid", 930], ["Vel", 936], ["genotyping", 940], [",", 950], ["which", 952], ["can", 958], ["be", 962], ["easily", 965], ["integrated", 972], ["into", 983], ["blood", 988], ["group", 994], ["genotyping", 1000], ["platforms", 1011], [".", 1020], ["These", 1022], ["results", 1028], ["answer", 1036], ["a", 1043], ["60-year", 1045], ["-", 1052], ["old", 1053], ["riddle", 1057], ["and", 1064], ["provide", 1068], ["tools", 1076], ["of", 1082], ["immediate", 1085], ["assistance", 1095], ["to", 1106], ["all", 1109], ["clinicians", 1113], ["involved", 1124], ["in", 1133], ["the", 1136], ["care", 1140], ["of", 1145], ["Vel-", 1148], ["patients", 1153], [".", 1161]]}
{"context": "Sodium glucose cotransporter 2 (SGLT2) is the main luminal glucose transporter in the kidney. SGLT2 inhibition results in glycosuria and improved glycaemic control. Drugs inhibiting this transporter have recently been approved for clinical use and have been suggested to have potential renoprotective benefits by limiting glycotoxicity in the proximal tubule. We aimed to determine the renoprotective benefits of empagliflozin, an SGLT2 inhibitor, independent of its glucose lowering effect. We induced diabetes using a low dose streptozotocin protocol in 7-8 week old endothelial nitric oxide (eNOS) synthase knockout mice. We measured fasting blood glucose on a monthly basis, terminal urinary albumin/creatinine ratio. Renal histology was assessed for inflammatory and fibrotic changes. Renal cortical mRNA transcription of inflammatory and profibrotic cytokines, glucose transporters and protein expression of SGLT2 and GLUT1 were determined. Outcomes were compared to diabetic animals receiving the angiotensin receptor blocker telmisartan (current best practice). Diabetic mice had high matched blood glucose levels. Empagliflozin did not attenuate diabetes-induced albuminuria, unlike telmisartan. Empagliflozin did not improve glomerulosclerosis, tubular atrophy, tubulointerstitial inflammation or fibrosis, while telmisartan attenuated these. Empagliflozin did not modify tubular toll-like receptor-2 expression in diabetic mice. Empagliflozin did not reduce the upregulation of macrophage chemoattractant protein-1 (MCP-1), transforming growth factor \u03b21 and fibronectin mRNA observed in the diabetic animals, while telmisartan decreased transcription of MCP-1 and fibronectin. Empagliflozin increased GLUT1 mRNA expression and telmisartan increased SGLT2 mRNA expression in comparison to untreated diabetic mice. However no significant difference was found in protein expression of GLUT1 or SGLT2 among the different groups. Hence SGLT2 inhibition does not have renoprotective benefits independent of glucose lowering.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "7319749c99d7437480b077f9c67163c7", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[144, 144], [288, 288], [5, 5], [266, 266], [295, 295], [66, 66], [17, 17]], "char_spans": [[914, 918], [1902, 1906], [32, 36], [1760, 1764], [1942, 1946], [431, 435], [94, 98]]}]}], "context_tokens": [["Sodium", 0], ["glucose", 7], ["cotransporter", 15], ["2", 29], ["(", 31], ["SGLT2", 32], [")", 37], ["is", 39], ["the", 42], ["main", 46], ["luminal", 51], ["glucose", 59], ["transporter", 67], ["in", 79], ["the", 82], ["kidney", 86], [".", 92], ["SGLT2", 94], ["inhibition", 100], ["results", 111], ["in", 119], ["glycosuria", 122], ["and", 133], ["improved", 137], ["glycaemic", 146], ["control", 156], [".", 163], ["Drugs", 165], ["inhibiting", 171], ["this", 182], ["transporter", 187], ["have", 199], ["recently", 204], ["been", 213], ["approved", 218], ["for", 227], ["clinical", 231], ["use", 240], ["and", 244], ["have", 248], ["been", 253], ["suggested", 258], ["to", 268], ["have", 271], ["potential", 276], ["renoprotective", 286], ["benefits", 301], ["by", 310], ["limiting", 313], ["glycotoxicity", 322], ["in", 336], ["the", 339], ["proximal", 343], ["tubule", 352], [".", 358], ["We", 360], ["aimed", 363], ["to", 369], ["determine", 372], ["the", 382], ["renoprotective", 386], ["benefits", 401], ["of", 410], ["empagliflozin", 413], [",", 426], ["an", 428], ["SGLT2", 431], ["inhibitor", 437], [",", 446], ["independent", 448], ["of", 460], ["its", 463], ["glucose", 467], ["lowering", 475], ["effect", 484], [".", 490], ["We", 492], ["induced", 495], ["diabetes", 503], ["using", 512], ["a", 518], ["low", 520], ["dose", 524], ["streptozotocin", 529], ["protocol", 544], ["in", 553], ["7", 556], ["-", 557], ["8", 558], ["week", 560], ["old", 565], ["endothelial", 569], ["nitric", 581], ["oxide", 588], ["(", 594], ["eNOS", 595], [")", 599], ["synthase", 601], ["knockout", 610], ["mice", 619], [".", 623], ["We", 625], ["measured", 628], ["fasting", 637], ["blood", 645], ["glucose", 651], ["on", 659], ["a", 662], ["monthly", 664], ["basis", 672], [",", 677], ["terminal", 679], ["urinary", 688], ["albumin", 696], ["/", 703], ["creatinine", 704], ["ratio", 715], [".", 720], ["Renal", 722], ["histology", 728], ["was", 738], ["assessed", 742], ["for", 751], ["inflammatory", 755], ["and", 768], ["fibrotic", 772], ["changes", 781], [".", 788], ["Renal", 790], ["cortical", 796], ["mRNA", 805], ["transcription", 810], ["of", 824], ["inflammatory", 827], ["and", 840], ["profibrotic", 844], ["cytokines", 856], [",", 865], ["glucose", 867], ["transporters", 875], ["and", 888], ["protein", 892], ["expression", 900], ["of", 911], ["SGLT2", 914], ["and", 920], ["GLUT1", 924], ["were", 930], ["determined", 935], [".", 945], ["Outcomes", 947], ["were", 956], ["compared", 961], ["to", 970], ["diabetic", 973], ["animals", 982], ["receiving", 990], ["the", 1000], ["angiotensin", 1004], ["receptor", 1016], ["blocker", 1025], ["telmisartan", 1033], ["(", 1045], ["current", 1046], ["best", 1054], ["practice", 1059], [")", 1067], [".", 1068], ["Diabetic", 1070], ["mice", 1079], ["had", 1084], ["high", 1088], ["matched", 1093], ["blood", 1101], ["glucose", 1107], ["levels", 1115], [".", 1121], ["Empagliflozin", 1123], ["did", 1137], ["not", 1141], ["attenuate", 1145], ["diabetes", 1155], ["-", 1163], ["induced", 1164], ["albuminuria", 1172], [",", 1183], ["unlike", 1185], ["telmisartan", 1192], [".", 1203], ["Empagliflozin", 1205], ["did", 1219], ["not", 1223], ["improve", 1227], ["glomerulosclerosis", 1235], [",", 1253], ["tubular", 1255], ["atrophy", 1263], [",", 1270], ["tubulointerstitial", 1272], ["inflammation", 1291], ["or", 1304], ["fibrosis", 1307], [",", 1315], ["while", 1317], ["telmisartan", 1323], ["attenuated", 1335], ["these", 1346], [".", 1351], ["Empagliflozin", 1353], ["did", 1367], ["not", 1371], ["modify", 1375], ["tubular", 1382], ["toll", 1390], ["-", 1394], ["like", 1395], ["receptor-2", 1400], ["expression", 1411], ["in", 1422], ["diabetic", 1425], ["mice", 1434], [".", 1438], ["Empagliflozin", 1440], ["did", 1454], ["not", 1458], ["reduce", 1462], ["the", 1469], ["upregulation", 1473], ["of", 1486], ["macrophage", 1489], ["chemoattractant", 1500], ["protein-1", 1516], ["(", 1526], ["MCP-1", 1527], [")", 1532], [",", 1533], ["transforming", 1535], ["growth", 1548], ["factor", 1555], ["\u03b21", 1562], ["and", 1565], ["fibronectin", 1569], ["mRNA", 1581], ["observed", 1586], ["in", 1595], ["the", 1598], ["diabetic", 1602], ["animals", 1611], [",", 1618], ["while", 1620], ["telmisartan", 1626], ["decreased", 1638], ["transcription", 1648], ["of", 1662], ["MCP-1", 1665], ["and", 1671], ["fibronectin", 1675], [".", 1686], ["Empagliflozin", 1688], ["increased", 1702], ["GLUT1", 1712], ["mRNA", 1718], ["expression", 1723], ["and", 1734], ["telmisartan", 1738], ["increased", 1750], ["SGLT2", 1760], ["mRNA", 1766], ["expression", 1771], ["in", 1782], ["comparison", 1785], ["to", 1796], ["untreated", 1799], ["diabetic", 1809], ["mice", 1818], [".", 1822], ["However", 1824], ["no", 1832], ["significant", 1835], ["difference", 1847], ["was", 1858], ["found", 1862], ["in", 1868], ["protein", 1871], ["expression", 1879], ["of", 1890], ["GLUT1", 1893], ["or", 1899], ["SGLT2", 1902], ["among", 1908], ["the", 1914], ["different", 1918], ["groups", 1928], [".", 1934], ["Hence", 1936], ["SGLT2", 1942], ["inhibition", 1948], ["does", 1959], ["not", 1964], ["have", 1968], ["renoprotective", 1973], ["benefits", 1988], ["independent", 1997], ["of", 2009], ["glucose", 2012], ["lowering", 2020], [".", 2028]]}
{"context": "Although malaria has become a serious public health problem in Mauritania since the late 1990s, few documented data on its epidemiology exist. The objective of this study was to assess the morbidity of clinical malaria among children in Nouakchott. Three hundred and one febrile children, consulting at three health facilities of Nouakchott, were screened for malaria in 2009 (n=216) and 2010 (n=85). Plasmodium species identification and parasite density were determined by microscopic examination of Giemsa-stained thin and thick films and confirmed by rapid diagnostic test and nested PCR. Of 301 febrile children, 105 (34.9%) were malaria-positive by nested PCR and 87 (28.9%) by microscopy. Plasmodium vivax represented 97.1% (102/105) and P. falciparum accounted for 2.9% (3/105) of positive cases. All positive children under five years old were infected with P. vivax. The highest numbers of malaria positives were found during or shortly after the rainy season and the lowest during the dry season. Fifty-four of 105 (51.4%) malaria cases, all with P. vivax, had never travelled outside Nouakchott. Individuals belonging to the Moors ethnic group represented 97.0% of P. vivax cases. Results of the present study indicate that malaria is endemic in Nouakchott and that P. vivax is the principal causative agent. Regular surveillance is required to monitor malaria prevalence and incidence, and further measures are needed to counter the possible spread of malaria in the country.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "03a16d0eb3134070ad262ad943d2c738", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium species", "token_spans": [[72, 73]], "char_spans": [[401, 418]]}]}], "context_tokens": [["Although", 0], ["malaria", 9], ["has", 17], ["become", 21], ["a", 28], ["serious", 30], ["public", 38], ["health", 45], ["problem", 52], ["in", 60], ["Mauritania", 63], ["since", 74], ["the", 80], ["late", 84], ["1990s", 89], [",", 94], ["few", 96], ["documented", 100], ["data", 111], ["on", 116], ["its", 119], ["epidemiology", 123], ["exist", 136], [".", 141], ["The", 143], ["objective", 147], ["of", 157], ["this", 160], ["study", 165], ["was", 171], ["to", 175], ["assess", 178], ["the", 185], ["morbidity", 189], ["of", 199], ["clinical", 202], ["malaria", 211], ["among", 219], ["children", 225], ["in", 234], ["Nouakchott", 237], [".", 247], ["Three", 249], ["hundred", 255], ["and", 263], ["one", 267], ["febrile", 271], ["children", 279], [",", 287], ["consulting", 289], ["at", 300], ["three", 303], ["health", 309], ["facilities", 316], ["of", 327], ["Nouakchott", 330], [",", 340], ["were", 342], ["screened", 347], ["for", 356], ["malaria", 360], ["in", 368], ["2009", 371], ["(", 376], ["n=216", 377], [")", 382], ["and", 384], ["2010", 388], ["(", 393], ["n=85", 394], [")", 398], [".", 399], ["Plasmodium", 401], ["species", 412], ["identification", 420], ["and", 435], ["parasite", 439], ["density", 448], ["were", 456], ["determined", 461], ["by", 472], ["microscopic", 475], ["examination", 487], ["of", 499], ["Giemsa", 502], ["-", 508], ["stained", 509], ["thin", 517], ["and", 522], ["thick", 526], ["films", 532], ["and", 538], ["confirmed", 542], ["by", 552], ["rapid", 555], ["diagnostic", 561], ["test", 572], ["and", 577], ["nested", 581], ["PCR", 588], [".", 591], ["Of", 593], ["301", 596], ["febrile", 600], ["children", 608], [",", 616], ["105", 618], ["(", 622], ["34.9", 623], ["%", 627], [")", 628], ["were", 630], ["malaria", 635], ["-", 642], ["positive", 643], ["by", 652], ["nested", 655], ["PCR", 662], ["and", 666], ["87", 670], ["(", 673], ["28.9", 674], ["%", 678], [")", 679], ["by", 681], ["microscopy", 684], [".", 694], ["Plasmodium", 696], ["vivax", 707], ["represented", 713], ["97.1", 725], ["%", 729], ["(", 731], ["102/105", 732], [")", 739], ["and", 741], ["P.", 745], ["falciparum", 748], ["accounted", 759], ["for", 769], ["2.9", 773], ["%", 776], ["(", 778], ["3/105", 779], [")", 784], ["of", 786], ["positive", 789], ["cases", 798], [".", 803], ["All", 805], ["positive", 809], ["children", 818], ["under", 827], ["five", 833], ["years", 838], ["old", 844], ["were", 848], ["infected", 853], ["with", 862], ["P.", 867], ["vivax", 870], [".", 875], ["The", 877], ["highest", 881], ["numbers", 889], ["of", 897], ["malaria", 900], ["positives", 908], ["were", 918], ["found", 923], ["during", 929], ["or", 936], ["shortly", 939], ["after", 947], ["the", 953], ["rainy", 957], ["season", 963], ["and", 970], ["the", 974], ["lowest", 978], ["during", 985], ["the", 992], ["dry", 996], ["season", 1000], [".", 1006], ["Fifty", 1008], ["-", 1013], ["four", 1014], ["of", 1019], ["105", 1022], ["(", 1026], ["51.4", 1027], ["%", 1031], [")", 1032], ["malaria", 1034], ["cases", 1042], [",", 1047], ["all", 1049], ["with", 1053], ["P.", 1058], ["vivax", 1061], [",", 1066], ["had", 1068], ["never", 1072], ["travelled", 1078], ["outside", 1088], ["Nouakchott", 1096], [".", 1106], ["Individuals", 1108], ["belonging", 1120], ["to", 1130], ["the", 1133], ["Moors", 1137], ["ethnic", 1143], ["group", 1150], ["represented", 1156], ["97.0", 1168], ["%", 1172], ["of", 1174], ["P.", 1177], ["vivax", 1180], ["cases", 1186], [".", 1191], ["Results", 1193], ["of", 1201], ["the", 1204], ["present", 1208], ["study", 1216], ["indicate", 1222], ["that", 1231], ["malaria", 1236], ["is", 1244], ["endemic", 1247], ["in", 1255], ["Nouakchott", 1258], ["and", 1269], ["that", 1273], ["P.", 1278], ["vivax", 1281], ["is", 1287], ["the", 1290], ["principal", 1294], ["causative", 1304], ["agent", 1314], [".", 1319], ["Regular", 1321], ["surveillance", 1329], ["is", 1342], ["required", 1345], ["to", 1354], ["monitor", 1357], ["malaria", 1365], ["prevalence", 1373], ["and", 1384], ["incidence", 1388], [",", 1397], ["and", 1399], ["further", 1403], ["measures", 1411], ["are", 1420], ["needed", 1424], ["to", 1431], ["counter", 1434], ["the", 1442], ["possible", 1446], ["spread", 1455], ["of", 1462], ["malaria", 1465], ["in", 1473], ["the", 1476], ["country", 1480], [".", 1487]]}
{"context": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator 1, and Rac1. Interleukin-1beta, flagellin, interferon-gamma, and tumor necrosis factor alpha (TNF-alpha) similarly induced Nox1 in a colon cancer cell line (T84), whereas only TNF-alpha fully induced NOXO1 and upregulated superoxide-producing activity by ninefold. This upregulation was canceled by knockdown of NOXO1 with small interfering RNAs. TNF-alpha rapidly phosphorylated p38 mitogen-activated protein kinase and c-Jun N-terminal kinase 1/2, followed by phosphorylation of c-Jun and c-Fos and appearance of an AP-1 binding activity within 30 min. We cloned the 5' flank of the human NOXO1 gene (-3888 to +263 bp), and found that the region between -585 and -452 bp, which contains consensus elements of YY-1, AP-1, and Ets, and the GC-rich region encoding three putative binding sites for SP-1, was crucial for TNF-alpha-dependent promoter activity. Serial mutation analysis of the elements identified an AP-1 binding site (from -561 to -551 bp, agtAAGtcatg) as a crucial element for TNF-alpha-stimulated transcription of the human NOXO1 gene, which was also confirmed by the AP-1 decoy experiments. Thus, TNF-alpha acts as a potent activator of Nox1-based oxidase in colon epithelial cells, suggesting a potential role of this oxidase in inflammation of the colon.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "6779bef390824d269a423840772240f6", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}, {"text": "NOX1", "token_spans": [[4, 4], [49, 49], [22, 22]], "char_spans": [[17, 20], [238, 241], [100, 103]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["1", 14], ["(", 16], ["Nox1", 17], [")", 21], ["is", 23], ["a", 26], ["multicomponent", 28], ["enzyme", 43], ["consisting", 50], ["of", 61], ["p22(phox", 64], [")", 72], [",", 73], ["Nox", 75], ["organizer", 79], ["1", 89], ["(", 91], ["NOXO1", 92], [")", 97], [",", 98], ["Nox1", 100], ["activator", 105], ["1", 115], [",", 116], ["and", 118], ["Rac1", 122], [".", 126], ["Interleukin-1beta", 128], [",", 145], ["flagellin", 147], [",", 156], ["interferon", 158], ["-", 168], ["gamma", 169], [",", 174], ["and", 176], ["tumor", 180], ["necrosis", 186], ["factor", 195], ["alpha", 202], ["(", 208], ["TNF", 209], ["-", 212], ["alpha", 213], [")", 218], ["similarly", 220], ["induced", 230], ["Nox1", 238], ["in", 243], ["a", 246], ["colon", 248], ["cancer", 254], ["cell", 261], ["line", 266], ["(", 271], ["T84", 272], [")", 275], [",", 276], ["whereas", 278], ["only", 286], ["TNF", 291], ["-", 294], ["alpha", 295], ["fully", 301], ["induced", 307], ["NOXO1", 315], ["and", 321], ["upregulated", 325], ["superoxide", 337], ["-", 347], ["producing", 348], ["activity", 358], ["by", 367], ["ninefold", 370], [".", 378], ["This", 380], ["upregulation", 385], ["was", 398], ["canceled", 402], ["by", 411], ["knockdown", 414], ["of", 424], ["NOXO1", 427], ["with", 433], ["small", 438], ["interfering", 444], ["RNAs", 456], [".", 460], ["TNF", 462], ["-", 465], ["alpha", 466], ["rapidly", 472], ["phosphorylated", 480], ["p38", 495], ["mitogen", 499], ["-", 506], ["activated", 507], ["protein", 517], ["kinase", 525], ["and", 532], ["c", 536], ["-", 537], ["Jun", 538], ["N", 542], ["-", 543], ["terminal", 544], ["kinase", 553], ["1/2", 560], [",", 563], ["followed", 565], ["by", 574], ["phosphorylation", 577], ["of", 593], ["c", 596], ["-", 597], ["Jun", 598], ["and", 602], ["c", 606], ["-", 607], ["Fos", 608], ["and", 612], ["appearance", 616], ["of", 627], ["an", 630], ["AP-1", 633], ["binding", 638], ["activity", 646], ["within", 655], ["30", 662], ["min", 665], [".", 668], ["We", 670], ["cloned", 673], ["the", 680], ["5", 684], ["'", 685], ["flank", 687], ["of", 693], ["the", 696], ["human", 700], ["NOXO1", 706], ["gene", 712], ["(", 717], ["-3888", 718], ["to", 724], ["+263", 727], ["bp", 732], [")", 734], [",", 735], ["and", 737], ["found", 741], ["that", 747], ["the", 752], ["region", 756], ["between", 763], ["-585", 771], ["and", 776], ["-452", 780], ["bp", 785], [",", 787], ["which", 789], ["contains", 795], ["consensus", 804], ["elements", 814], ["of", 823], ["YY-1", 826], [",", 830], ["AP-1", 832], [",", 836], ["and", 838], ["Ets", 842], [",", 845], ["and", 847], ["the", 851], ["GC", 855], ["-", 857], ["rich", 858], ["region", 863], ["encoding", 870], ["three", 879], ["putative", 885], ["binding", 894], ["sites", 902], ["for", 908], ["SP-1", 912], [",", 916], ["was", 918], ["crucial", 922], ["for", 930], ["TNF", 934], ["-", 937], ["alpha", 938], ["-", 943], ["dependent", 944], ["promoter", 954], ["activity", 963], [".", 971], ["Serial", 973], ["mutation", 980], ["analysis", 989], ["of", 998], ["the", 1001], ["elements", 1005], ["identified", 1014], ["an", 1025], ["AP-1", 1028], ["binding", 1033], ["site", 1041], ["(", 1046], ["from", 1047], ["-561", 1052], ["to", 1057], ["-551", 1060], ["bp", 1065], [",", 1067], ["agtAAGtcatg", 1069], [")", 1080], ["as", 1082], ["a", 1085], ["crucial", 1087], ["element", 1095], ["for", 1103], ["TNF", 1107], ["-", 1110], ["alpha", 1111], ["-", 1116], ["stimulated", 1117], ["transcription", 1128], ["of", 1142], ["the", 1145], ["human", 1149], ["NOXO1", 1155], ["gene", 1161], [",", 1165], ["which", 1167], ["was", 1173], ["also", 1177], ["confirmed", 1182], ["by", 1192], ["the", 1195], ["AP-1", 1199], ["decoy", 1204], ["experiments", 1210], [".", 1221], ["Thus", 1223], [",", 1227], ["TNF", 1229], ["-", 1232], ["alpha", 1233], ["acts", 1239], ["as", 1244], ["a", 1247], ["potent", 1249], ["activator", 1256], ["of", 1266], ["Nox1-based", 1269], ["oxidase", 1280], ["in", 1288], ["colon", 1291], ["epithelial", 1297], ["cells", 1308], [",", 1313], ["suggesting", 1315], ["a", 1326], ["potential", 1328], ["role", 1338], ["of", 1343], ["this", 1346], ["oxidase", 1351], ["in", 1359], ["inflammation", 1362], ["of", 1375], ["the", 1378], ["colon", 1382], [".", 1387]]}
{"context": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA) in the clinical laboratory. Under disk diffusion testing conditions designed to maximize detection of MRSA (incubation at 32 degrees C, pre-induction with methicillin, or plating on 4% NaCl-supplemented agar), BORSA strains also tend to appear resistant to semisynthetic penicillins. Under these conditions, ampicillin/sulbactam appears to be more accurate than amoxicillin/clavulanic acid for differentiating BORSA from MRSA.", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "a859d7dd48d14f7ba82f37892f524538", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[0, 5]], "char_spans": [[0, 51]]}]}], "context_tokens": [["Borderline", 0], ["oxacillin", 11], ["-", 20], ["resistant", 21], ["Staphylococcus", 31], ["aureus", 46], ["(", 53], ["BORSA", 54], [")", 59], ["may", 61], ["be", 65], ["misidentified", 68], ["as", 82], ["intrinsically", 85], ["methicillin", 99], ["-", 110], ["resistant", 111], ["Staphylococcus", 121], ["aureus", 136], ["(", 143], ["MRSA", 144], [")", 148], ["in", 150], ["the", 153], ["clinical", 157], ["laboratory", 166], [".", 176], ["Under", 178], ["disk", 184], ["diffusion", 189], ["testing", 199], ["conditions", 207], ["designed", 218], ["to", 227], ["maximize", 230], ["detection", 239], ["of", 249], ["MRSA", 252], ["(", 257], ["incubation", 258], ["at", 269], ["32", 272], ["degrees", 275], ["C", 283], [",", 284], ["pre", 286], ["-", 289], ["induction", 290], ["with", 300], ["methicillin", 305], [",", 316], ["or", 318], ["plating", 321], ["on", 329], ["4", 332], ["%", 333], ["NaCl", 335], ["-", 339], ["supplemented", 340], ["agar", 353], [")", 357], [",", 358], ["BORSA", 360], ["strains", 366], ["also", 374], ["tend", 379], ["to", 384], ["appear", 387], ["resistant", 394], ["to", 404], ["semisynthetic", 407], ["penicillins", 421], [".", 432], ["Under", 434], ["these", 440], ["conditions", 446], [",", 456], ["ampicillin", 458], ["/", 468], ["sulbactam", 469], ["appears", 479], ["to", 487], ["be", 490], ["more", 493], ["accurate", 498], ["than", 507], ["amoxicillin", 512], ["/", 523], ["clavulanic", 524], ["acid", 535], ["for", 540], ["differentiating", 544], ["BORSA", 560], ["from", 566], ["MRSA", 571], [".", 575]]}
{"context": "The mammalian radiation has corresponded with rapid changes in noncoding regions of the genome, but we lack a comprehensive understanding of regulatory evolution in mammals. Here, we track the evolution of promoters and enhancers active in liver across 20 mammalian species from six diverse orders by profiling genomic enrichment of H3K27 acetylation and H3K4 trimethylation. We report that rapid evolution of enhancers is a universal feature of mammalian genomes. Most of the recently evolved enhancers arise from ancestral DNA exaptation, rather than lineage-specific expansions of repeat elements. In contrast, almost all liver promoters are partially or fully conserved across these species. Our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences. These results provide important insight into the functional genetics underpinning mammalian regulatory evolution.", "qas": [{"question": "Are human enhancers or promoters evolving faster?", "answers": ["enhancers"], "qid": "ce06b70fdbb149389828f705b0d6faaf", "question_tokens": [["Are", 0], ["human", 4], ["enhancers", 10], ["or", 20], ["promoters", 23], ["evolving", 33], ["faster", 42], ["?", 48]], "detected_answers": [{"text": "enhancers", "token_spans": [[119, 119], [36, 36], [65, 65], [79, 79]], "char_spans": [[742, 750], [220, 228], [410, 418], [494, 502]]}]}], "context_tokens": [["The", 0], ["mammalian", 4], ["radiation", 14], ["has", 24], ["corresponded", 28], ["with", 41], ["rapid", 46], ["changes", 52], ["in", 60], ["noncoding", 63], ["regions", 73], ["of", 81], ["the", 84], ["genome", 88], [",", 94], ["but", 96], ["we", 100], ["lack", 103], ["a", 108], ["comprehensive", 110], ["understanding", 124], ["of", 138], ["regulatory", 141], ["evolution", 152], ["in", 162], ["mammals", 165], [".", 172], ["Here", 174], [",", 178], ["we", 180], ["track", 183], ["the", 189], ["evolution", 193], ["of", 203], ["promoters", 206], ["and", 216], ["enhancers", 220], ["active", 230], ["in", 237], ["liver", 240], ["across", 246], ["20", 253], ["mammalian", 256], ["species", 266], ["from", 274], ["six", 279], ["diverse", 283], ["orders", 291], ["by", 298], ["profiling", 301], ["genomic", 311], ["enrichment", 319], ["of", 330], ["H3K27", 333], ["acetylation", 339], ["and", 351], ["H3K4", 355], ["trimethylation", 360], [".", 374], ["We", 376], ["report", 379], ["that", 386], ["rapid", 391], ["evolution", 397], ["of", 407], ["enhancers", 410], ["is", 420], ["a", 423], ["universal", 425], ["feature", 435], ["of", 443], ["mammalian", 446], ["genomes", 456], [".", 463], ["Most", 465], ["of", 470], ["the", 473], ["recently", 477], ["evolved", 486], ["enhancers", 494], ["arise", 504], ["from", 510], ["ancestral", 515], ["DNA", 525], ["exaptation", 529], [",", 539], ["rather", 541], ["than", 548], ["lineage", 553], ["-", 560], ["specific", 561], ["expansions", 570], ["of", 581], ["repeat", 584], ["elements", 591], [".", 599], ["In", 601], ["contrast", 604], [",", 612], ["almost", 614], ["all", 621], ["liver", 625], ["promoters", 631], ["are", 641], ["partially", 645], ["or", 655], ["fully", 658], ["conserved", 664], ["across", 674], ["these", 681], ["species", 687], [".", 694], ["Our", 696], ["data", 700], ["further", 705], ["reveal", 713], ["that", 720], ["recently", 725], ["evolved", 734], ["enhancers", 742], ["can", 752], ["be", 756], ["associated", 759], ["with", 770], ["genes", 775], ["under", 781], ["positive", 787], ["selection", 796], [",", 805], ["demonstrating", 807], ["the", 821], ["power", 825], ["of", 831], ["this", 834], ["approach", 839], ["for", 848], ["annotating", 852], ["regulatory", 863], ["adaptations", 874], ["in", 886], ["genomic", 889], ["sequences", 897], [".", 906], ["These", 908], ["results", 914], ["provide", 922], ["important", 930], ["insight", 940], ["into", 948], ["the", 953], ["functional", 957], ["genetics", 968], ["underpinning", 977], ["mammalian", 990], ["regulatory", 1000], ["evolution", 1011], [".", 1020]]}
{"context": "Oxidatively damaged proteins accumulate with age in almost all cell types and tissues. The activity of chaperone-mediated autophagy (CMA), a selective pathway for the degradation of cytosolic proteins in lysosomes, decreases with age. We have analyzed the possible participation of CMA in the removal of oxidized proteins in rat liver and cultured mouse fibroblasts. Added to the fact that CMA substrates, when oxidized, are more efficiently internalized into lysosomes, we have found a constitutive activation of CMA during oxidative stress. Oxidation-induced activation of CMA correlates with higher levels of several components of the lysosomal translocation complex, but in particular of the lumenal chaperone, required for substrate uptake, and of the lysosomal membrane protein (lamp) type 2a, previously identified as a receptor for this pathway. In contrast with the well characterized mechanism of CMA activation during nutritional stress, which does not require de novo synthesis of the receptor, oxidation-induced activation of CMA is attained through transcriptional up-regulation of lamp2a. We conclude that CMA is activated during oxidative stress and that the higher activity of this pathway under these conditions, along with the higher susceptibility of the oxidized proteins to be taken up by lysosomes, both contribute to the efficient removal of oxidized proteins.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "231d54cde09548338f239c48ff1fd357", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[185, 185]], "char_spans": [[1096, 1101]]}]}], "context_tokens": [["Oxidatively", 0], ["damaged", 12], ["proteins", 20], ["accumulate", 29], ["with", 40], ["age", 45], ["in", 49], ["almost", 52], ["all", 59], ["cell", 63], ["types", 68], ["and", 74], ["tissues", 78], [".", 85], ["The", 87], ["activity", 91], ["of", 100], ["chaperone", 103], ["-", 112], ["mediated", 113], ["autophagy", 122], ["(", 132], ["CMA", 133], [")", 136], [",", 137], ["a", 139], ["selective", 141], ["pathway", 151], ["for", 159], ["the", 163], ["degradation", 167], ["of", 179], ["cytosolic", 182], ["proteins", 192], ["in", 201], ["lysosomes", 204], [",", 213], ["decreases", 215], ["with", 225], ["age", 230], [".", 233], ["We", 235], ["have", 238], ["analyzed", 243], ["the", 252], ["possible", 256], ["participation", 265], ["of", 279], ["CMA", 282], ["in", 286], ["the", 289], ["removal", 293], ["of", 301], ["oxidized", 304], ["proteins", 313], ["in", 322], ["rat", 325], ["liver", 329], ["and", 335], ["cultured", 339], ["mouse", 348], ["fibroblasts", 354], [".", 365], ["Added", 367], ["to", 373], ["the", 376], ["fact", 380], ["that", 385], ["CMA", 390], ["substrates", 394], [",", 404], ["when", 406], ["oxidized", 411], [",", 419], ["are", 421], ["more", 425], ["efficiently", 430], ["internalized", 442], ["into", 455], ["lysosomes", 460], [",", 469], ["we", 471], ["have", 474], ["found", 479], ["a", 485], ["constitutive", 487], ["activation", 500], ["of", 511], ["CMA", 514], ["during", 518], ["oxidative", 525], ["stress", 535], [".", 541], ["Oxidation", 543], ["-", 552], ["induced", 553], ["activation", 561], ["of", 572], ["CMA", 575], ["correlates", 579], ["with", 590], ["higher", 595], ["levels", 602], ["of", 609], ["several", 612], ["components", 620], ["of", 631], ["the", 634], ["lysosomal", 638], ["translocation", 648], ["complex", 662], [",", 669], ["but", 671], ["in", 675], ["particular", 678], ["of", 689], ["the", 692], ["lumenal", 696], ["chaperone", 704], [",", 713], ["required", 715], ["for", 724], ["substrate", 728], ["uptake", 738], [",", 744], ["and", 746], ["of", 750], ["the", 753], ["lysosomal", 757], ["membrane", 767], ["protein", 776], ["(", 784], ["lamp", 785], [")", 789], ["type", 791], ["2a", 796], [",", 798], ["previously", 800], ["identified", 811], ["as", 822], ["a", 825], ["receptor", 827], ["for", 836], ["this", 840], ["pathway", 845], [".", 852], ["In", 854], ["contrast", 857], ["with", 866], ["the", 871], ["well", 875], ["characterized", 880], ["mechanism", 894], ["of", 904], ["CMA", 907], ["activation", 911], ["during", 922], ["nutritional", 929], ["stress", 941], [",", 947], ["which", 949], ["does", 955], ["not", 960], ["require", 964], ["de", 972], ["novo", 975], ["synthesis", 980], ["of", 990], ["the", 993], ["receptor", 997], [",", 1005], ["oxidation", 1007], ["-", 1016], ["induced", 1017], ["activation", 1025], ["of", 1036], ["CMA", 1039], ["is", 1043], ["attained", 1046], ["through", 1055], ["transcriptional", 1063], ["up", 1079], ["-", 1081], ["regulation", 1082], ["of", 1093], ["lamp2a", 1096], [".", 1102], ["We", 1104], ["conclude", 1107], ["that", 1116], ["CMA", 1121], ["is", 1125], ["activated", 1128], ["during", 1138], ["oxidative", 1145], ["stress", 1155], ["and", 1162], ["that", 1166], ["the", 1171], ["higher", 1175], ["activity", 1182], ["of", 1191], ["this", 1194], ["pathway", 1199], ["under", 1207], ["these", 1213], ["conditions", 1219], [",", 1229], ["along", 1231], ["with", 1237], ["the", 1242], ["higher", 1246], ["susceptibility", 1253], ["of", 1268], ["the", 1271], ["oxidized", 1275], ["proteins", 1284], ["to", 1293], ["be", 1296], ["taken", 1299], ["up", 1305], ["by", 1308], ["lysosomes", 1311], [",", 1320], ["both", 1322], ["contribute", 1327], ["to", 1338], ["the", 1341], ["efficient", 1345], ["removal", 1355], ["of", 1363], ["oxidized", 1366], ["proteins", 1375], [".", 1383]]}
{"context": "Lewy bodies, neuropathological hallmarks of Parkinson's disease and dementia with Lewy bodies, comprise alpha-synuclein filaments and other less defined proteins. Characterization of Lewy body proteins that interact with alpha-synuclein may provide insight into the mechanism of Lewy body formation. Double immunofluorescence labeling and confocal microscopy revealed approximately 80% of cortical Lewy bodies contained microtubule-associated protein 1B (MAP-1B) that overlapped with alpha-synuclein. Lewy bodies were isolated using an immunomagnetic technique from brain tissue of patients dying with dementia with Lewy bodies. Lewy body proteins were resolved by polyacrylamide gel electrophoresis. Immunoblotting confirmed the presence of MAP-1B and alpha-synuclein in purified Lewy bodies. Direct binding studies revealed a high affinity interaction (IC(50) approximately 20 nm) between MAP-1B and alpha-synuclein. The MAP-1B-binding sites were mapped to the last 45 amino acids of the alpha-synuclein C terminus. MAP-1B also bound in vitro assembled alpha-synuclein fibrils. Thus, MAP-1B may be involved in the pathogenesis of Lewy bodies via its interaction with monomeric and fibrillar alpha-synuclein.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "61399ac72d9a4c4397aa7b80ee902d25", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[172, 174], [196, 198], [141, 143], [74, 76], [16, 18], [160, 162], [34, 36], [115, 117]], "char_spans": [[1055, 1069], [1193, 1207], [902, 916], [484, 498], [104, 118], [990, 1004], [221, 235], [753, 767]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], [",", 11], ["neuropathological", 13], ["hallmarks", 31], ["of", 41], ["Parkinson", 44], ["'s", 53], ["disease", 56], ["and", 64], ["dementia", 68], ["with", 77], ["Lewy", 82], ["bodies", 87], [",", 93], ["comprise", 95], ["alpha", 104], ["-", 109], ["synuclein", 110], ["filaments", 120], ["and", 130], ["other", 134], ["less", 140], ["defined", 145], ["proteins", 153], [".", 161], ["Characterization", 163], ["of", 180], ["Lewy", 183], ["body", 188], ["proteins", 193], ["that", 202], ["interact", 207], ["with", 216], ["alpha", 221], ["-", 226], ["synuclein", 227], ["may", 237], ["provide", 241], ["insight", 249], ["into", 257], ["the", 262], ["mechanism", 266], ["of", 276], ["Lewy", 279], ["body", 284], ["formation", 289], [".", 298], ["Double", 300], ["immunofluorescence", 307], ["labeling", 326], ["and", 335], ["confocal", 339], ["microscopy", 348], ["revealed", 359], ["approximately", 368], ["80", 382], ["%", 384], ["of", 386], ["cortical", 389], ["Lewy", 398], ["bodies", 403], ["contained", 410], ["microtubule", 420], ["-", 431], ["associated", 432], ["protein", 443], ["1B", 451], ["(", 454], ["MAP-1B", 455], [")", 461], ["that", 463], ["overlapped", 468], ["with", 479], ["alpha", 484], ["-", 489], ["synuclein", 490], [".", 499], ["Lewy", 501], ["bodies", 506], ["were", 513], ["isolated", 518], ["using", 527], ["an", 533], ["immunomagnetic", 536], ["technique", 551], ["from", 561], ["brain", 566], ["tissue", 572], ["of", 579], ["patients", 582], ["dying", 591], ["with", 597], ["dementia", 602], ["with", 611], ["Lewy", 616], ["bodies", 621], [".", 627], ["Lewy", 629], ["body", 634], ["proteins", 639], ["were", 648], ["resolved", 653], ["by", 662], ["polyacrylamide", 665], ["gel", 680], ["electrophoresis", 684], [".", 699], ["Immunoblotting", 701], ["confirmed", 716], ["the", 726], ["presence", 730], ["of", 739], ["MAP-1B", 742], ["and", 749], ["alpha", 753], ["-", 758], ["synuclein", 759], ["in", 769], ["purified", 772], ["Lewy", 781], ["bodies", 786], [".", 792], ["Direct", 794], ["binding", 801], ["studies", 809], ["revealed", 817], ["a", 826], ["high", 828], ["affinity", 833], ["interaction", 842], ["(", 854], ["IC(50", 855], [")", 860], ["approximately", 862], ["20", 876], ["nm", 879], [")", 881], ["between", 883], ["MAP-1B", 891], ["and", 898], ["alpha", 902], ["-", 907], ["synuclein", 908], [".", 917], ["The", 919], ["MAP-1B", 923], ["-", 929], ["binding", 930], ["sites", 938], ["were", 944], ["mapped", 949], ["to", 956], ["the", 959], ["last", 963], ["45", 968], ["amino", 971], ["acids", 977], ["of", 983], ["the", 986], ["alpha", 990], ["-", 995], ["synuclein", 996], ["C", 1006], ["terminus", 1008], [".", 1016], ["MAP-1B", 1018], ["also", 1025], ["bound", 1030], ["in", 1036], ["vitro", 1039], ["assembled", 1045], ["alpha", 1055], ["-", 1060], ["synuclein", 1061], ["fibrils", 1071], [".", 1078], ["Thus", 1080], [",", 1084], ["MAP-1B", 1086], ["may", 1093], ["be", 1097], ["involved", 1100], ["in", 1109], ["the", 1112], ["pathogenesis", 1116], ["of", 1129], ["Lewy", 1132], ["bodies", 1137], ["via", 1144], ["its", 1148], ["interaction", 1152], ["with", 1164], ["monomeric", 1169], ["and", 1179], ["fibrillar", 1183], ["alpha", 1193], ["-", 1198], ["synuclein", 1199], [".", 1208]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) is a common multidrug-resistant (MDR) pathogen. We herein discussed MRSA and its infections in Krasnoyarsk, Siberian Russia between 2007 and 2011. The incidence of MRSA in 3,662 subjects was 22.0% and 2.9% for healthcare- and community-associated MRSA (HA- and CA-MRSA), respectively. The 15-day mortality rates for MRSA hospital- and community-acquired pneumonia (HAP and CAP) were 6.5% and 50%, respectively. MRSA CAP cases included pediatric deaths; of the MRSA pneumonia episodes available, \u226527.3% were associated with bacteremia. Most cases of HA-MRSA examined exhibited ST239/spa3(t037)/SCCmecIII.1.1.2 (designated as ST239Kras), while all CA-MRSA cases examined were ST8/spa1(t008)/SCCmecIV.3.1.1(IVc) (designated as ST8Kras). ST239Kras and ST8Kras strongly expressed cytolytic peptide (phenol-soluble modulin \u03b1, PSM\u03b1; and \u03b4-hemolysin, Hld) genes, similar to CA-MRSA. ST239Kras pneumonia may have been attributed to a unique set of multiple virulence factors (MVFs): toxic shock syndrome toxin-1 (TSST-1), elevated PSM\u03b1/Hld expression, \u03b1-hemolysin, the staphylococcal enterotoxin SEK/SEQ, the immune evasion factor SCIN/SAK, and collagen adhesin. Regarding ST8Kras, SEA was included in MVFs, some of which were common to ST239Kras. The ST239Kras (strain OC3) genome contained: a completely unique phage, \u03c6Sa7-like (W), with no att repetition; S. aureus pathogenicity island SaPI2R, the first TSST-1 gene-positive (tst+) SaPI in the ST239 lineage; and a super copy of IS256 (\u226522 copies/genome). ST239Kras carried the Brazilian SCCmecIII.1.1.2 and United Kingdom-type tst. ST239Kras and ST8Kras were MDR, with the same levofloxacin resistance mutations; small, but transmissible chloramphenicol resistance plasmids spread widely enough to not be ignored. These results suggest that novel MDR and MVF+ HA- and CA-MRSA (ST239Kras and ST8Kras) emerged in Siberian Russia (Krasnoyarsk) associated with fatal pneumonia, and also with ST239Kras, a new (Siberian Russian) clade of the ST239 lineage, which was created through stepwise evolution during its potential transmission route of Brazil-Europe-Russia/Krasnoyarsk, thereby selective advantages from unique MVFs and the MDR.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "b720f34ec0e14433b46b51f2661ed750", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[61, 61], [101, 101], [22, 22], [6, 6], [118, 118], [173, 173], [92, 92], [132, 132], [55, 55], [39, 39], [71, 71], [357, 357]], "char_spans": [[315, 318], [511, 514], [119, 122], [45, 48], [603, 606], [920, 923], [462, 465], [700, 703], [298, 301], [215, 218], [367, 370], [1868, 1871]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["is", 51], ["a", 54], ["common", 56], ["multidrug", 63], ["-", 72], ["resistant", 73], ["(", 83], ["MDR", 84], [")", 87], ["pathogen", 89], [".", 97], ["We", 99], ["herein", 102], ["discussed", 109], ["MRSA", 119], ["and", 124], ["its", 128], ["infections", 132], ["in", 143], ["Krasnoyarsk", 146], [",", 157], ["Siberian", 159], ["Russia", 168], ["between", 175], ["2007", 183], ["and", 188], ["2011", 192], [".", 196], ["The", 198], ["incidence", 202], ["of", 212], ["MRSA", 215], ["in", 220], ["3,662", 223], ["subjects", 229], ["was", 238], ["22.0", 242], ["%", 246], ["and", 248], ["2.9", 252], ["%", 255], ["for", 257], ["healthcare-", 261], ["and", 273], ["community", 277], ["-", 286], ["associated", 287], ["MRSA", 298], ["(", 303], ["HA-", 304], ["and", 308], ["CA", 312], ["-", 314], ["MRSA", 315], [")", 319], [",", 320], ["respectively", 322], [".", 334], ["The", 336], ["15-day", 340], ["mortality", 347], ["rates", 357], ["for", 363], ["MRSA", 367], ["hospital-", 372], ["and", 382], ["community", 386], ["-", 395], ["acquired", 396], ["pneumonia", 405], ["(", 415], ["HAP", 416], ["and", 420], ["CAP", 424], [")", 427], ["were", 429], ["6.5", 434], ["%", 437], ["and", 439], ["50", 443], ["%", 445], [",", 446], ["respectively", 448], [".", 460], ["MRSA", 462], ["CAP", 467], ["cases", 471], ["included", 477], ["pediatric", 486], ["deaths", 496], [";", 502], ["of", 504], ["the", 507], ["MRSA", 511], ["pneumonia", 516], ["episodes", 526], ["available", 535], [",", 544], ["\u226527.3", 546], ["%", 551], ["were", 553], ["associated", 558], ["with", 569], ["bacteremia", 574], [".", 584], ["Most", 586], ["cases", 591], ["of", 597], ["HA", 600], ["-", 602], ["MRSA", 603], ["examined", 608], ["exhibited", 617], ["ST239/spa3(t037)/SCCmecIII.1.1.2", 627], ["(", 660], ["designated", 661], ["as", 672], ["ST239Kras", 675], [")", 684], [",", 685], ["while", 687], ["all", 693], ["CA", 697], ["-", 699], ["MRSA", 700], ["cases", 705], ["examined", 711], ["were", 720], ["ST8/spa1(t008)/SCCmecIV.3.1.1(IVc", 725], [")", 758], ["(", 760], ["designated", 761], ["as", 772], ["ST8Kras", 775], [")", 782], [".", 783], ["ST239Kras", 785], ["and", 795], ["ST8Kras", 799], ["strongly", 807], ["expressed", 816], ["cytolytic", 826], ["peptide", 836], ["(", 844], ["phenol", 845], ["-", 851], ["soluble", 852], ["modulin", 860], ["\u03b1", 868], [",", 869], ["PSM\u03b1", 871], [";", 875], ["and", 877], ["\u03b4", 881], ["-", 882], ["hemolysin", 883], [",", 892], ["Hld", 894], [")", 897], ["genes", 899], [",", 904], ["similar", 906], ["to", 914], ["CA", 917], ["-", 919], ["MRSA", 920], [".", 924], ["ST239Kras", 926], ["pneumonia", 936], ["may", 946], ["have", 950], ["been", 955], ["attributed", 960], ["to", 971], ["a", 974], ["unique", 976], ["set", 983], ["of", 987], ["multiple", 990], ["virulence", 999], ["factors", 1009], ["(", 1017], ["MVFs", 1018], [")", 1022], [":", 1023], ["toxic", 1025], ["shock", 1031], ["syndrome", 1037], ["toxin-1", 1046], ["(", 1054], ["TSST-1", 1055], [")", 1061], [",", 1062], ["elevated", 1064], ["PSM\u03b1", 1073], ["/", 1077], ["Hld", 1078], ["expression", 1082], [",", 1092], ["\u03b1", 1094], ["-", 1095], ["hemolysin", 1096], [",", 1105], ["the", 1107], ["staphylococcal", 1111], ["enterotoxin", 1126], ["SEK", 1138], ["/", 1141], ["SEQ", 1142], [",", 1145], ["the", 1147], ["immune", 1151], ["evasion", 1158], ["factor", 1166], ["SCIN", 1173], ["/", 1177], ["SAK", 1178], [",", 1181], ["and", 1183], ["collagen", 1187], ["adhesin", 1196], [".", 1203], ["Regarding", 1205], ["ST8Kras", 1215], [",", 1222], ["SEA", 1224], ["was", 1228], ["included", 1232], ["in", 1241], ["MVFs", 1244], [",", 1248], ["some", 1250], ["of", 1255], ["which", 1258], ["were", 1264], ["common", 1269], ["to", 1276], ["ST239Kras", 1279], [".", 1288], ["The", 1290], ["ST239Kras", 1294], ["(", 1304], ["strain", 1305], ["OC3", 1312], [")", 1315], ["genome", 1317], ["contained", 1324], [":", 1333], ["a", 1335], ["completely", 1337], ["unique", 1348], ["phage", 1355], [",", 1360], ["\u03c6Sa7-like", 1362], ["(", 1372], ["W", 1373], [")", 1374], [",", 1375], ["with", 1377], ["no", 1382], ["att", 1385], ["repetition", 1389], [";", 1399], ["S.", 1401], ["aureus", 1404], ["pathogenicity", 1411], ["island", 1425], ["SaPI2R", 1432], [",", 1438], ["the", 1440], ["first", 1444], ["TSST-1", 1450], ["gene", 1457], ["-", 1461], ["positive", 1462], ["(", 1471], ["tst+", 1472], [")", 1476], ["SaPI", 1478], ["in", 1483], ["the", 1486], ["ST239", 1490], ["lineage", 1496], [";", 1503], ["and", 1505], ["a", 1509], ["super", 1511], ["copy", 1517], ["of", 1522], ["IS256", 1525], ["(", 1531], ["\u226522", 1532], ["copies", 1536], ["/", 1542], ["genome", 1543], [")", 1549], [".", 1550], ["ST239Kras", 1552], ["carried", 1562], ["the", 1570], ["Brazilian", 1574], ["SCCmecIII.1.1.2", 1584], ["and", 1600], ["United", 1604], ["Kingdom", 1611], ["-", 1618], ["type", 1619], ["tst", 1624], [".", 1627], ["ST239Kras", 1629], ["and", 1639], ["ST8Kras", 1643], ["were", 1651], ["MDR", 1656], [",", 1659], ["with", 1661], ["the", 1666], ["same", 1670], ["levofloxacin", 1675], ["resistance", 1688], ["mutations", 1699], [";", 1708], ["small", 1710], [",", 1715], ["but", 1717], ["transmissible", 1721], ["chloramphenicol", 1735], ["resistance", 1751], ["plasmids", 1762], ["spread", 1771], ["widely", 1778], ["enough", 1785], ["to", 1792], ["not", 1795], ["be", 1799], ["ignored", 1802], [".", 1809], ["These", 1811], ["results", 1817], ["suggest", 1825], ["that", 1833], ["novel", 1838], ["MDR", 1844], ["and", 1848], ["MVF+", 1852], ["HA-", 1857], ["and", 1861], ["CA", 1865], ["-", 1867], ["MRSA", 1868], ["(", 1873], ["ST239Kras", 1874], ["and", 1884], ["ST8Kras", 1888], [")", 1895], ["emerged", 1897], ["in", 1905], ["Siberian", 1908], ["Russia", 1917], ["(", 1924], ["Krasnoyarsk", 1925], [")", 1936], ["associated", 1938], ["with", 1949], ["fatal", 1954], ["pneumonia", 1960], [",", 1969], ["and", 1971], ["also", 1975], ["with", 1980], ["ST239Kras", 1985], [",", 1994], ["a", 1996], ["new", 1998], ["(", 2002], ["Siberian", 2003], ["Russian", 2012], [")", 2019], ["clade", 2021], ["of", 2027], ["the", 2030], ["ST239", 2034], ["lineage", 2040], [",", 2047], ["which", 2049], ["was", 2055], ["created", 2059], ["through", 2067], ["stepwise", 2075], ["evolution", 2084], ["during", 2094], ["its", 2101], ["potential", 2105], ["transmission", 2115], ["route", 2128], ["of", 2134], ["Brazil", 2137], ["-", 2143], ["Europe", 2144], ["-", 2150], ["Russia", 2151], ["/", 2157], ["Krasnoyarsk", 2158], [",", 2169], ["thereby", 2171], ["selective", 2179], ["advantages", 2189], ["from", 2200], ["unique", 2205], ["MVFs", 2212], ["and", 2217], ["the", 2221], ["MDR", 2225], [".", 2228]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common familial tumour syndrome with multiple clinical features such as neurofibromas, caf\u00e9-au-lait spots (CLS), iris Lisch nodules, axillary freckling, optic glioma, specific bone lesions and an increased risk of malignant tumours. It is caused by a wide spectrum of mutations affecting the NF1 gene. Most mutations result in the loss of one allele at the DNA, mRNA or protein level and thus in the loss of any function of the gene product neurofibromin. The idea of the simultaneous loss of several different neurofibromin functions has been postulated to explain the pleiotropic effects of its loss. However, we have identified a novel missense mutation in a family with a classical multi-symptomatic NF1 phenotype, including a malignant schwannoma, that specifically abolishes the Ras-GTPase-activating function of neurofibromin. In this family, Arg1276 had mutated into proline. Based on complex biochemical studies as well as the analysis of the crystal structure of the GTPase-activating protein (GAP) domain of p120GAP in the presence of Ras, we unequivocally identified this amino acid as the arginine finger of the neurofibromin GAP-related domain (GRD)-the most essential catalytic element for RasGAP activity. Here, we present data demonstrating that the mutation R1276P, unlike previously reported missense mutations of the GRD region, does not impair the secondary and tertiary protein structure. It neither reduces the level of cellular neurofibromin nor influences its binding to Ras substantially, but it does completely disable GAP activity. Our findings provide direct evidence that failure of neurofibromin GAP activity is the critical element of NF1 pathogenesis. Thus, therapeutic approaches aimed at the reduction of Ras.GTP levels in neural crest-derived cells can be expected to relieve most of the NF1 symptoms.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "6f4df195db2e4569b74922aec8abb058", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[298, 298], [4, 4], [137, 137], [328, 328], [62, 62]], "char_spans": [[1703, 1705], [26, 28], [740, 742], [1860, 1862], [328, 330]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["familial", 43], ["tumour", 52], ["syndrome", 59], ["with", 68], ["multiple", 73], ["clinical", 82], ["features", 91], ["such", 100], ["as", 105], ["neurofibromas", 108], [",", 121], ["caf\u00e9", 123], ["-", 127], ["au", 128], ["-", 130], ["lait", 131], ["spots", 136], ["(", 142], ["CLS", 143], [")", 146], [",", 147], ["iris", 149], ["Lisch", 154], ["nodules", 160], [",", 167], ["axillary", 169], ["freckling", 178], [",", 187], ["optic", 189], ["glioma", 195], [",", 201], ["specific", 203], ["bone", 212], ["lesions", 217], ["and", 225], ["an", 229], ["increased", 232], ["risk", 242], ["of", 247], ["malignant", 250], ["tumours", 260], [".", 267], ["It", 269], ["is", 272], ["caused", 275], ["by", 282], ["a", 285], ["wide", 287], ["spectrum", 292], ["of", 301], ["mutations", 304], ["affecting", 314], ["the", 324], ["NF1", 328], ["gene", 332], [".", 336], ["Most", 338], ["mutations", 343], ["result", 353], ["in", 360], ["the", 363], ["loss", 367], ["of", 372], ["one", 375], ["allele", 379], ["at", 386], ["the", 389], ["DNA", 393], [",", 396], ["mRNA", 398], ["or", 403], ["protein", 406], ["level", 414], ["and", 420], ["thus", 424], ["in", 429], ["the", 432], ["loss", 436], ["of", 441], ["any", 444], ["function", 448], ["of", 457], ["the", 460], ["gene", 464], ["product", 469], ["neurofibromin", 477], [".", 490], ["The", 492], ["idea", 496], ["of", 501], ["the", 504], ["simultaneous", 508], ["loss", 521], ["of", 526], ["several", 529], ["different", 537], ["neurofibromin", 547], ["functions", 561], ["has", 571], ["been", 575], ["postulated", 580], ["to", 591], ["explain", 594], ["the", 602], ["pleiotropic", 606], ["effects", 618], ["of", 626], ["its", 629], ["loss", 633], [".", 637], ["However", 639], [",", 646], ["we", 648], ["have", 651], ["identified", 656], ["a", 667], ["novel", 669], ["missense", 675], ["mutation", 684], ["in", 693], ["a", 696], ["family", 698], ["with", 705], ["a", 710], ["classical", 712], ["multi", 722], ["-", 727], ["symptomatic", 728], ["NF1", 740], ["phenotype", 744], [",", 753], ["including", 755], ["a", 765], ["malignant", 767], ["schwannoma", 777], [",", 787], ["that", 789], ["specifically", 794], ["abolishes", 807], ["the", 817], ["Ras", 821], ["-", 824], ["GTPase", 825], ["-", 831], ["activating", 832], ["function", 843], ["of", 852], ["neurofibromin", 855], [".", 868], ["In", 870], ["this", 873], ["family", 878], [",", 884], ["Arg1276", 886], ["had", 894], ["mutated", 898], ["into", 906], ["proline", 911], [".", 918], ["Based", 920], ["on", 926], ["complex", 929], ["biochemical", 937], ["studies", 949], ["as", 957], ["well", 960], ["as", 965], ["the", 968], ["analysis", 972], ["of", 981], ["the", 984], ["crystal", 988], ["structure", 996], ["of", 1006], ["the", 1009], ["GTPase", 1013], ["-", 1019], ["activating", 1020], ["protein", 1031], ["(", 1039], ["GAP", 1040], [")", 1043], ["domain", 1045], ["of", 1052], ["p120GAP", 1055], ["in", 1063], ["the", 1066], ["presence", 1070], ["of", 1079], ["Ras", 1082], [",", 1085], ["we", 1087], ["unequivocally", 1090], ["identified", 1104], ["this", 1115], ["amino", 1120], ["acid", 1126], ["as", 1131], ["the", 1134], ["arginine", 1138], ["finger", 1147], ["of", 1154], ["the", 1157], ["neurofibromin", 1161], ["GAP", 1175], ["-", 1178], ["related", 1179], ["domain", 1187], ["(", 1194], ["GRD)-the", 1195], ["most", 1204], ["essential", 1209], ["catalytic", 1219], ["element", 1229], ["for", 1237], ["RasGAP", 1241], ["activity", 1248], [".", 1256], ["Here", 1258], [",", 1262], ["we", 1264], ["present", 1267], ["data", 1275], ["demonstrating", 1280], ["that", 1294], ["the", 1299], ["mutation", 1303], ["R1276P", 1312], [",", 1318], ["unlike", 1320], ["previously", 1327], ["reported", 1338], ["missense", 1347], ["mutations", 1356], ["of", 1366], ["the", 1369], ["GRD", 1373], ["region", 1377], [",", 1383], ["does", 1385], ["not", 1390], ["impair", 1394], ["the", 1401], ["secondary", 1405], ["and", 1415], ["tertiary", 1419], ["protein", 1428], ["structure", 1436], [".", 1445], ["It", 1447], ["neither", 1450], ["reduces", 1458], ["the", 1466], ["level", 1470], ["of", 1476], ["cellular", 1479], ["neurofibromin", 1488], ["nor", 1502], ["influences", 1506], ["its", 1517], ["binding", 1521], ["to", 1529], ["Ras", 1532], ["substantially", 1536], [",", 1549], ["but", 1551], ["it", 1555], ["does", 1558], ["completely", 1563], ["disable", 1574], ["GAP", 1582], ["activity", 1586], [".", 1594], ["Our", 1596], ["findings", 1600], ["provide", 1609], ["direct", 1617], ["evidence", 1624], ["that", 1633], ["failure", 1638], ["of", 1646], ["neurofibromin", 1649], ["GAP", 1663], ["activity", 1667], ["is", 1676], ["the", 1679], ["critical", 1683], ["element", 1692], ["of", 1700], ["NF1", 1703], ["pathogenesis", 1707], [".", 1719], ["Thus", 1721], [",", 1725], ["therapeutic", 1727], ["approaches", 1739], ["aimed", 1750], ["at", 1756], ["the", 1759], ["reduction", 1763], ["of", 1773], ["Ras", 1776], [".", 1779], ["GTP", 1780], ["levels", 1784], ["in", 1791], ["neural", 1794], ["crest", 1801], ["-", 1806], ["derived", 1807], ["cells", 1815], ["can", 1821], ["be", 1825], ["expected", 1828], ["to", 1837], ["relieve", 1840], ["most", 1848], ["of", 1853], ["the", 1856], ["NF1", 1860], ["symptoms", 1864], [".", 1872]]}
{"context": "Spleen tyrosine kinase (SYK) has come into focus as a potential therapeutic target in chronic inflammatory diseases, such as rheumatoid arthritis and asthma, as well as in B-cell lymphomas. SYK has also been involved in the signaling of immunoreceptors, cytokine receptors, and integrins. We therefore hypothesized that inhibition of SYK attenuates the inflammatory process underlying atherosclerosis and reduces plaque development. Low-density lipoprotein receptor-deficient mice consuming a high-cholesterol diet supplemented with 2 doses of the orally available SYK inhibitor fostamatinib for 16 weeks showed a dose-dependent reduction in atherosclerotic lesion size by up to 59\u00b16% compared with the respective controls. Lesions of fostamatinib-treated animals contained fewer macrophages but more smooth muscle cells and collagen-characteristics associated with more stable plaques in humans. Mechanistically, fostamatinib attenuated adhesion and migration of inflammatory cells and limited macrophage survival. Furthermore, fostamatinib normalized high-cholesterol diet -induced monocytosis and inflammatory gene expression. We present the novel finding that the SYK inhibitor fostamatinib attenuates atherogenesis in mice. Our data identify SYK inhibition as a potentially fruitful antiinflammatory therapeutic strategy in atherosclerosis.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "89a7ef2839a844569cd9d4d936eba6c3", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["SYK", 24], [")", 27], ["has", 29], ["come", 33], ["into", 38], ["focus", 43], ["as", 49], ["a", 52], ["potential", 54], ["therapeutic", 64], ["target", 76], ["in", 83], ["chronic", 86], ["inflammatory", 94], ["diseases", 107], [",", 115], ["such", 117], ["as", 122], ["rheumatoid", 125], ["arthritis", 136], ["and", 146], ["asthma", 150], [",", 156], ["as", 158], ["well", 161], ["as", 166], ["in", 169], ["B", 172], ["-", 173], ["cell", 174], ["lymphomas", 179], [".", 188], ["SYK", 190], ["has", 194], ["also", 198], ["been", 203], ["involved", 208], ["in", 217], ["the", 220], ["signaling", 224], ["of", 234], ["immunoreceptors", 237], [",", 252], ["cytokine", 254], ["receptors", 263], [",", 272], ["and", 274], ["integrins", 278], [".", 287], ["We", 289], ["therefore", 292], ["hypothesized", 302], ["that", 315], ["inhibition", 320], ["of", 331], ["SYK", 334], ["attenuates", 338], ["the", 349], ["inflammatory", 353], ["process", 366], ["underlying", 374], ["atherosclerosis", 385], ["and", 401], ["reduces", 405], ["plaque", 413], ["development", 420], [".", 431], ["Low", 433], ["-", 436], ["density", 437], ["lipoprotein", 445], ["receptor", 457], ["-", 465], ["deficient", 466], ["mice", 476], ["consuming", 481], ["a", 491], ["high", 493], ["-", 497], ["cholesterol", 498], ["diet", 510], ["supplemented", 515], ["with", 528], ["2", 533], ["doses", 535], ["of", 541], ["the", 544], ["orally", 548], ["available", 555], ["SYK", 565], ["inhibitor", 569], ["fostamatinib", 579], ["for", 592], ["16", 596], ["weeks", 599], ["showed", 605], ["a", 612], ["dose", 614], ["-", 618], ["dependent", 619], ["reduction", 629], ["in", 639], ["atherosclerotic", 642], ["lesion", 658], ["size", 665], ["by", 670], ["up", 673], ["to", 676], ["59\u00b16", 679], ["%", 683], ["compared", 685], ["with", 694], ["the", 699], ["respective", 703], ["controls", 714], [".", 722], ["Lesions", 724], ["of", 732], ["fostamatinib", 735], ["-", 747], ["treated", 748], ["animals", 756], ["contained", 764], ["fewer", 774], ["macrophages", 780], ["but", 792], ["more", 796], ["smooth", 801], ["muscle", 808], ["cells", 815], ["and", 821], ["collagen", 825], ["-", 833], ["characteristics", 834], ["associated", 850], ["with", 861], ["more", 866], ["stable", 871], ["plaques", 878], ["in", 886], ["humans", 889], [".", 895], ["Mechanistically", 897], [",", 912], ["fostamatinib", 914], ["attenuated", 927], ["adhesion", 938], ["and", 947], ["migration", 951], ["of", 961], ["inflammatory", 964], ["cells", 977], ["and", 983], ["limited", 987], ["macrophage", 995], ["survival", 1006], [".", 1014], ["Furthermore", 1016], [",", 1027], ["fostamatinib", 1029], ["normalized", 1042], ["high", 1053], ["-", 1057], ["cholesterol", 1058], ["diet", 1070], ["-induced", 1075], ["monocytosis", 1084], ["and", 1096], ["inflammatory", 1100], ["gene", 1113], ["expression", 1118], [".", 1128], ["We", 1130], ["present", 1133], ["the", 1141], ["novel", 1145], ["finding", 1151], ["that", 1159], ["the", 1164], ["SYK", 1168], ["inhibitor", 1172], ["fostamatinib", 1182], ["attenuates", 1195], ["atherogenesis", 1206], ["in", 1220], ["mice", 1223], [".", 1227], ["Our", 1229], ["data", 1233], ["identify", 1238], ["SYK", 1247], ["inhibition", 1251], ["as", 1262], ["a", 1265], ["potentially", 1267], ["fruitful", 1279], ["antiinflammatory", 1288], ["therapeutic", 1305], ["strategy", 1317], ["in", 1326], ["atherosclerosis", 1329], [".", 1344]]}
{"context": "Many neurodegenerative diseases are associated with the aggregation of misfolded proteins into amyloid oligomers or fibrils that are deposited as pathological lesions within areas of the brain. An attractive therapeutic strategy for preventing or ameliorating amyloid formation is to identify agents that inhibit the onset or propagation of protein aggregation. Here we demonstrate how solid-state nuclear magnetic resonance (ssNMR) may be used to identify key residues within amyloidogenic protein sequences that may be targeted to inhibit the aggregation of the host protein. For alpha-synuclein, the major protein component of Lewy bodies associated with Parkinson's disease, we have used a combination of ssNMR and biochemical data to identify the key region for self-aggregation of the protein as residues 77-82 (VAQKTV). We used our new structural information to design a peptide derived from residues 77 to 82 of alpha-synuclein with an N-methyl group at the C-terminal residue, which was able to disrupt the aggregation of alpha-synuclein. Thus, we have shown how structural data obtained from ssNMR can guide the design of modified peptides for use as amyloid inhibitors, as a primary step toward developing therapeutic compounds for prevention and/or treatment of amyloid diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "ec3fbfeea1b541fd86801d3f230fe7ac", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[179, 181], [90, 92], [155, 157]], "char_spans": [[1031, 1045], [582, 596], [920, 934]]}]}], "context_tokens": [["Many", 0], ["neurodegenerative", 5], ["diseases", 23], ["are", 32], ["associated", 36], ["with", 47], ["the", 52], ["aggregation", 56], ["of", 68], ["misfolded", 71], ["proteins", 81], ["into", 90], ["amyloid", 95], ["oligomers", 103], ["or", 113], ["fibrils", 116], ["that", 124], ["are", 129], ["deposited", 133], ["as", 143], ["pathological", 146], ["lesions", 159], ["within", 167], ["areas", 174], ["of", 180], ["the", 183], ["brain", 187], [".", 192], ["An", 194], ["attractive", 197], ["therapeutic", 208], ["strategy", 220], ["for", 229], ["preventing", 233], ["or", 244], ["ameliorating", 247], ["amyloid", 260], ["formation", 268], ["is", 278], ["to", 281], ["identify", 284], ["agents", 293], ["that", 300], ["inhibit", 305], ["the", 313], ["onset", 317], ["or", 323], ["propagation", 326], ["of", 338], ["protein", 341], ["aggregation", 349], [".", 360], ["Here", 362], ["we", 367], ["demonstrate", 370], ["how", 382], ["solid", 386], ["-", 391], ["state", 392], ["nuclear", 398], ["magnetic", 406], ["resonance", 415], ["(", 425], ["ssNMR", 426], [")", 431], ["may", 433], ["be", 437], ["used", 440], ["to", 445], ["identify", 448], ["key", 457], ["residues", 461], ["within", 470], ["amyloidogenic", 477], ["protein", 491], ["sequences", 499], ["that", 509], ["may", 514], ["be", 518], ["targeted", 521], ["to", 530], ["inhibit", 533], ["the", 541], ["aggregation", 545], ["of", 557], ["the", 560], ["host", 564], ["protein", 569], [".", 576], ["For", 578], ["alpha", 582], ["-", 587], ["synuclein", 588], [",", 597], ["the", 599], ["major", 603], ["protein", 609], ["component", 617], ["of", 627], ["Lewy", 630], ["bodies", 635], ["associated", 642], ["with", 653], ["Parkinson", 658], ["'s", 667], ["disease", 670], [",", 677], ["we", 679], ["have", 682], ["used", 687], ["a", 692], ["combination", 694], ["of", 706], ["ssNMR", 709], ["and", 715], ["biochemical", 719], ["data", 731], ["to", 736], ["identify", 739], ["the", 748], ["key", 752], ["region", 756], ["for", 763], ["self", 767], ["-", 771], ["aggregation", 772], ["of", 784], ["the", 787], ["protein", 791], ["as", 799], ["residues", 802], ["77", 811], ["-", 813], ["82", 814], ["(", 817], ["VAQKTV", 818], [")", 824], [".", 825], ["We", 827], ["used", 830], ["our", 835], ["new", 839], ["structural", 843], ["information", 854], ["to", 866], ["design", 869], ["a", 876], ["peptide", 878], ["derived", 886], ["from", 894], ["residues", 899], ["77", 908], ["to", 911], ["82", 914], ["of", 917], ["alpha", 920], ["-", 925], ["synuclein", 926], ["with", 936], ["an", 941], ["N", 944], ["-", 945], ["methyl", 946], ["group", 953], ["at", 959], ["the", 962], ["C", 966], ["-", 967], ["terminal", 968], ["residue", 977], [",", 984], ["which", 986], ["was", 992], ["able", 996], ["to", 1001], ["disrupt", 1004], ["the", 1012], ["aggregation", 1016], ["of", 1028], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], [".", 1046], ["Thus", 1048], [",", 1052], ["we", 1054], ["have", 1057], ["shown", 1062], ["how", 1068], ["structural", 1072], ["data", 1083], ["obtained", 1088], ["from", 1097], ["ssNMR", 1102], ["can", 1108], ["guide", 1112], ["the", 1118], ["design", 1122], ["of", 1129], ["modified", 1132], ["peptides", 1141], ["for", 1150], ["use", 1154], ["as", 1158], ["amyloid", 1161], ["inhibitors", 1169], [",", 1179], ["as", 1181], ["a", 1184], ["primary", 1186], ["step", 1194], ["toward", 1199], ["developing", 1206], ["therapeutic", 1217], ["compounds", 1229], ["for", 1239], ["prevention", 1243], ["and/or", 1254], ["treatment", 1261], ["of", 1271], ["amyloid", 1274], ["diseases", 1282], [".", 1290]]}
{"context": "Fostamatinib (R788) is an orally dosed prodrug designed to deliver the active metabolite R940406 (R406), a spleen tyrosine kinase (SYK) inhibitor, for the treatment of rheumatoid arthritis. The objectives were to evaluate the human pharmacokinetic properties of fostamatinib and R406. Three clinical studies were conducted in healthy subjects: (A) A single ascending dose study for R406 with doses ranging from 80-600\u2009mg, (B) a single- and multiple-dose study of fostamatinib in aqueous suspension, with single doses ranging from 80-400\u2009mg and multiple doses at 160\u2009mg twice daily and (C) a study comparing suspension and tablet of fostamatinib, with the latter tested in both fed and fasted states. These studies demonstrated that when administered as a solution, R406 was rapidly absorbed. Increases in exposure were observed with doses up to 400\u2009mg. A terminal half-life of 12-21\u2009h was observed. Similar R406 exposure could be achieved with fostamatinib suspension and steady-state was achieved after 3-4 days following twice daily administration. Fostamatinib tablet and suspension exhibited similar R406 exposure. Upon co-administration with food, a delay in peak time and lower peak concentrations of R406 were observed but at the same time the overall exposure did not change. Fostamatinib demonstrates rapid and extensive conversion to R406, an inhibitor of SYK. Solid dosage forms of fostamatinib overcome the challenge of low aqueous solubility of R406. The PK profile of R406 could potentially allow once daily or twice daily oral administration of fostamatinib.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "68d14ce5231c4bba93f1b52c90dd2f8c", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[21, 23]], "char_spans": [[107, 128]]}]}], "context_tokens": [["Fostamatinib", 0], ["(", 13], ["R788", 14], [")", 18], ["is", 20], ["an", 23], ["orally", 26], ["dosed", 33], ["prodrug", 39], ["designed", 47], ["to", 56], ["deliver", 59], ["the", 67], ["active", 71], ["metabolite", 78], ["R940406", 89], ["(", 97], ["R406", 98], [")", 102], [",", 103], ["a", 105], ["spleen", 107], ["tyrosine", 114], ["kinase", 123], ["(", 130], ["SYK", 131], [")", 134], ["inhibitor", 136], [",", 145], ["for", 147], ["the", 151], ["treatment", 155], ["of", 165], ["rheumatoid", 168], ["arthritis", 179], [".", 188], ["The", 190], ["objectives", 194], ["were", 205], ["to", 210], ["evaluate", 213], ["the", 222], ["human", 226], ["pharmacokinetic", 232], ["properties", 248], ["of", 259], ["fostamatinib", 262], ["and", 275], ["R406", 279], [".", 283], ["Three", 285], ["clinical", 291], ["studies", 300], ["were", 308], ["conducted", 313], ["in", 323], ["healthy", 326], ["subjects", 334], [":", 342], ["(", 344], ["A", 345], [")", 346], ["A", 348], ["single", 350], ["ascending", 357], ["dose", 367], ["study", 372], ["for", 378], ["R406", 382], ["with", 387], ["doses", 392], ["ranging", 398], ["from", 406], ["80", 411], ["-", 413], ["600", 414], ["mg", 418], [",", 420], ["(", 422], ["B", 423], [")", 424], ["a", 426], ["single-", 428], ["and", 436], ["multiple", 440], ["-", 448], ["dose", 449], ["study", 454], ["of", 460], ["fostamatinib", 463], ["in", 476], ["aqueous", 479], ["suspension", 487], [",", 497], ["with", 499], ["single", 504], ["doses", 511], ["ranging", 517], ["from", 525], ["80", 530], ["-", 532], ["400", 533], ["mg", 537], ["and", 540], ["multiple", 544], ["doses", 553], ["at", 559], ["160", 562], ["mg", 566], ["twice", 569], ["daily", 575], ["and", 581], ["(", 585], ["C", 586], [")", 587], ["a", 589], ["study", 591], ["comparing", 597], ["suspension", 607], ["and", 618], ["tablet", 622], ["of", 629], ["fostamatinib", 632], [",", 644], ["with", 646], ["the", 651], ["latter", 655], ["tested", 662], ["in", 669], ["both", 672], ["fed", 677], ["and", 681], ["fasted", 685], ["states", 692], [".", 698], ["These", 700], ["studies", 706], ["demonstrated", 714], ["that", 727], ["when", 732], ["administered", 737], ["as", 750], ["a", 753], ["solution", 755], [",", 763], ["R406", 765], ["was", 770], ["rapidly", 774], ["absorbed", 782], [".", 790], ["Increases", 792], ["in", 802], ["exposure", 805], ["were", 814], ["observed", 819], ["with", 828], ["doses", 833], ["up", 839], ["to", 842], ["400", 845], ["mg", 849], [".", 851], ["A", 853], ["terminal", 855], ["half", 864], ["-", 868], ["life", 869], ["of", 874], ["12", 877], ["-", 879], ["21", 880], ["h", 883], ["was", 885], ["observed", 889], [".", 897], ["Similar", 899], ["R406", 907], ["exposure", 912], ["could", 921], ["be", 927], ["achieved", 930], ["with", 939], ["fostamatinib", 944], ["suspension", 957], ["and", 968], ["steady", 972], ["-", 978], ["state", 979], ["was", 985], ["achieved", 989], ["after", 998], ["3", 1004], ["-", 1005], ["4", 1006], ["days", 1008], ["following", 1013], ["twice", 1023], ["daily", 1029], ["administration", 1035], [".", 1049], ["Fostamatinib", 1051], ["tablet", 1064], ["and", 1071], ["suspension", 1075], ["exhibited", 1086], ["similar", 1096], ["R406", 1104], ["exposure", 1109], [".", 1117], ["Upon", 1119], ["co", 1124], ["-", 1126], ["administration", 1127], ["with", 1142], ["food", 1147], [",", 1151], ["a", 1153], ["delay", 1155], ["in", 1161], ["peak", 1164], ["time", 1169], ["and", 1174], ["lower", 1178], ["peak", 1184], ["concentrations", 1189], ["of", 1204], ["R406", 1207], ["were", 1212], ["observed", 1217], ["but", 1226], ["at", 1230], ["the", 1233], ["same", 1237], ["time", 1242], ["the", 1247], ["overall", 1251], ["exposure", 1259], ["did", 1268], ["not", 1272], ["change", 1276], [".", 1282], ["Fostamatinib", 1284], ["demonstrates", 1297], ["rapid", 1310], ["and", 1316], ["extensive", 1320], ["conversion", 1330], ["to", 1341], ["R406", 1344], [",", 1348], ["an", 1350], ["inhibitor", 1353], ["of", 1363], ["SYK", 1366], [".", 1369], ["Solid", 1371], ["dosage", 1377], ["forms", 1384], ["of", 1390], ["fostamatinib", 1393], ["overcome", 1406], ["the", 1415], ["challenge", 1419], ["of", 1429], ["low", 1432], ["aqueous", 1436], ["solubility", 1444], ["of", 1455], ["R406", 1458], [".", 1462], ["The", 1464], ["PK", 1468], ["profile", 1471], ["of", 1479], ["R406", 1482], ["could", 1487], ["potentially", 1493], ["allow", 1505], ["once", 1511], ["daily", 1516], ["or", 1522], ["twice", 1525], ["daily", 1531], ["oral", 1537], ["administration", 1542], ["of", 1557], ["fostamatinib", 1560], [".", 1572]]}
{"context": "Spleen tyrosine kinase (Syk) has been identified as an important modulator of immune signaling in B cells and cells bearing Fcgamma-activating receptors. R788, a prodrug of active metabolite R406, has been shown to be an inhibitor of Syk kinase, active in a variety of in vitro and in vivo models, suggesting potential activity in the treatment of rheumatoid arthritis (RA). We enrolled 189 patients with active RA despite methotrexate therapy in a 3-month, multicenter, ascending-dose, double-blind, placebo-controlled trial. The primary end point was the American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 12. Twice-daily oral doses of 100 mg and 150 mg of R788 were significantly superior to placebo or twice-daily oral doses of 50 mg at week 12 (ACR20 achieved in 65% and 72% versus 38% and 32% of patients, respectively [P < 0.01]). ACR50 (achieved in 49% and 57% versus 19% and 17% of patients, respectively) and ACR70 (achieved in 33% and 40% versus 4% and 2% of patients, respectively) scores showed a similar pattern. Clinical effect was noted as early as 1 week after initiation of therapy. Reductions in serum interleukin-6 and matrix metalloproteinase 3 levels also occurred as early as week 1 in the groups receiving 100 mg and 150 mg R788. The major adverse effects were gastrointestinal side effects (predominantly diarrhea) and neutropenia (<1,500/mm3), both of which were dose related. These results indicate that an inhibitor of Syk kinase produces significant clinical benefits at 12 weeks in a population of patients with active RA receiving methotrexate therapy. Syk kinase may be an important new therapeutic target in RA and related autoimmune conditions.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "782a069dddc14cda828565a5f8c628ff", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["Syk", 24], [")", 27], ["has", 29], ["been", 33], ["identified", 38], ["as", 49], ["an", 52], ["important", 55], ["modulator", 65], ["of", 75], ["immune", 78], ["signaling", 85], ["in", 95], ["B", 98], ["cells", 100], ["and", 106], ["cells", 110], ["bearing", 116], ["Fcgamma", 124], ["-", 131], ["activating", 132], ["receptors", 143], [".", 152], ["R788", 154], [",", 158], ["a", 160], ["prodrug", 162], ["of", 170], ["active", 173], ["metabolite", 180], ["R406", 191], [",", 195], ["has", 197], ["been", 201], ["shown", 206], ["to", 212], ["be", 215], ["an", 218], ["inhibitor", 221], ["of", 231], ["Syk", 234], ["kinase", 238], [",", 244], ["active", 246], ["in", 253], ["a", 256], ["variety", 258], ["of", 266], ["in", 269], ["vitro", 272], ["and", 278], ["in", 282], ["vivo", 285], ["models", 290], [",", 296], ["suggesting", 298], ["potential", 309], ["activity", 319], ["in", 328], ["the", 331], ["treatment", 335], ["of", 345], ["rheumatoid", 348], ["arthritis", 359], ["(", 369], ["RA", 370], [")", 372], [".", 373], ["We", 375], ["enrolled", 378], ["189", 387], ["patients", 391], ["with", 400], ["active", 405], ["RA", 412], ["despite", 415], ["methotrexate", 423], ["therapy", 436], ["in", 444], ["a", 447], ["3-month", 449], [",", 456], ["multicenter", 458], [",", 469], ["ascending", 471], ["-", 480], ["dose", 481], [",", 485], ["double", 487], ["-", 493], ["blind", 494], [",", 499], ["placebo", 501], ["-", 508], ["controlled", 509], ["trial", 520], [".", 525], ["The", 527], ["primary", 531], ["end", 539], ["point", 543], ["was", 549], ["the", 553], ["American", 557], ["College", 566], ["of", 574], ["Rheumatology", 577], ["20", 590], ["%", 592], ["improvement", 594], ["criteria", 606], ["(", 615], ["ACR20", 616], [")", 621], ["response", 623], ["rate", 632], ["at", 637], ["week", 640], ["12", 645], [".", 647], ["Twice", 649], ["-", 654], ["daily", 655], ["oral", 661], ["doses", 666], ["of", 672], ["100", 675], ["mg", 679], ["and", 682], ["150", 686], ["mg", 690], ["of", 693], ["R788", 696], ["were", 701], ["significantly", 706], ["superior", 720], ["to", 729], ["placebo", 732], ["or", 740], ["twice", 743], ["-", 748], ["daily", 749], ["oral", 755], ["doses", 760], ["of", 766], ["50", 769], ["mg", 772], ["at", 775], ["week", 778], ["12", 783], ["(", 786], ["ACR20", 787], ["achieved", 793], ["in", 802], ["65", 805], ["%", 807], ["and", 809], ["72", 813], ["%", 815], ["versus", 817], ["38", 824], ["%", 826], ["and", 828], ["32", 832], ["%", 834], ["of", 836], ["patients", 839], [",", 847], ["respectively", 849], ["[", 862], ["P", 863], ["<", 865], ["0.01", 867], ["]", 871], [")", 872], [".", 873], ["ACR50", 875], ["(", 881], ["achieved", 882], ["in", 891], ["49", 894], ["%", 896], ["and", 898], ["57", 902], ["%", 904], ["versus", 906], ["19", 913], ["%", 915], ["and", 917], ["17", 921], ["%", 923], ["of", 925], ["patients", 928], [",", 936], ["respectively", 938], [")", 950], ["and", 952], ["ACR70", 956], ["(", 962], ["achieved", 963], ["in", 972], ["33", 975], ["%", 977], ["and", 979], ["40", 983], ["%", 985], ["versus", 987], ["4", 994], ["%", 995], ["and", 997], ["2", 1001], ["%", 1002], ["of", 1004], ["patients", 1007], [",", 1015], ["respectively", 1017], [")", 1029], ["scores", 1031], ["showed", 1038], ["a", 1045], ["similar", 1047], ["pattern", 1055], [".", 1062], ["Clinical", 1064], ["effect", 1073], ["was", 1080], ["noted", 1084], ["as", 1090], ["early", 1093], ["as", 1099], ["1", 1102], ["week", 1104], ["after", 1109], ["initiation", 1115], ["of", 1126], ["therapy", 1129], [".", 1136], ["Reductions", 1138], ["in", 1149], ["serum", 1152], ["interleukin-6", 1158], ["and", 1172], ["matrix", 1176], ["metalloproteinase", 1183], ["3", 1201], ["levels", 1203], ["also", 1210], ["occurred", 1215], ["as", 1224], ["early", 1227], ["as", 1233], ["week", 1236], ["1", 1241], ["in", 1243], ["the", 1246], ["groups", 1250], ["receiving", 1257], ["100", 1267], ["mg", 1271], ["and", 1274], ["150", 1278], ["mg", 1282], ["R788", 1285], [".", 1289], ["The", 1291], ["major", 1295], ["adverse", 1301], ["effects", 1309], ["were", 1317], ["gastrointestinal", 1322], ["side", 1339], ["effects", 1344], ["(", 1352], ["predominantly", 1353], ["diarrhea", 1367], [")", 1375], ["and", 1377], ["neutropenia", 1381], ["(", 1393], ["<", 1394], ["1,500/mm3", 1395], [")", 1404], [",", 1405], ["both", 1407], ["of", 1412], ["which", 1415], ["were", 1421], ["dose", 1426], ["related", 1431], [".", 1438], ["These", 1440], ["results", 1446], ["indicate", 1454], ["that", 1463], ["an", 1468], ["inhibitor", 1471], ["of", 1481], ["Syk", 1484], ["kinase", 1488], ["produces", 1495], ["significant", 1504], ["clinical", 1516], ["benefits", 1525], ["at", 1534], ["12", 1537], ["weeks", 1540], ["in", 1546], ["a", 1549], ["population", 1551], ["of", 1562], ["patients", 1565], ["with", 1574], ["active", 1579], ["RA", 1586], ["receiving", 1589], ["methotrexate", 1599], ["therapy", 1612], [".", 1619], ["Syk", 1621], ["kinase", 1625], ["may", 1632], ["be", 1636], ["an", 1639], ["important", 1642], ["new", 1652], ["therapeutic", 1656], ["target", 1668], ["in", 1675], ["RA", 1678], ["and", 1681], ["related", 1685], ["autoimmune", 1693], ["conditions", 1704], [".", 1714]]}
{"context": "The RTS,S/AS01(E) malaria vaccine candidate has recently entered Phase 3 testing. Reaching this important milestone is the culmination of more than 20 years of research and development by GlaxoSmithKline and partners and collaborators. The vaccine has been developed to protect young children and infants living in Sub-Saharan Africa against clinical and severe disease caused by Plasmodium falciparum infection. Over the past 9 years, RTS,S/AS has been evaluated in multiple Phase 2 studies. The vaccine was shown to have a favorable safety profile and to be well tolerated in all age groups in which it was tested, including the intended target population of infants and young children in Sub-Saharan Africa. Data obtained so far suggest that RTS,S/AS can be co-administered with other vaccines included in the routine Expanded Program of Immunization (EPI). In Phase 2 testing, the vaccine candidate was shown to confer significant protection against P. falciparum infection and clinical disease, including severe malaria. Furthermore, a trend towards an indirect beneficial effect of the vaccine on non-malarial morbidities has been observed in several trials. In this paper, we will describe the genesis of the RTS,S/AS concept, including the rationale for selecting the circumsporozoite protein (CSP) as the target antigen. Early development history of the vaccine will be briefly described. We will present the most salient results from recent Phase 2 studies conducted in the target pediatric population, which have led to the decision to progress RTS,S/AS to Phase 3 testing. If the Phase 3 results confirm the observations made during Phase 2 testing, the RTS,S/AS vaccine, when broadly implemented and judiciously integrated with other malaria-prevention measures, would have a major public-health impact in Sub-Saharan Africa.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "3926de0ae12f43be8eb6f2e7dbc0cee7", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[184, 184], [7, 7], [322, 322]], "char_spans": [[1017, 1023], [18, 24], [1747, 1753]]}]}], "context_tokens": [["The", 0], ["RTS", 4], [",", 7], ["S", 8], ["/", 9], ["AS01(E", 10], [")", 16], ["malaria", 18], ["vaccine", 26], ["candidate", 34], ["has", 44], ["recently", 48], ["entered", 57], ["Phase", 65], ["3", 71], ["testing", 73], [".", 80], ["Reaching", 82], ["this", 91], ["important", 96], ["milestone", 106], ["is", 116], ["the", 119], ["culmination", 123], ["of", 135], ["more", 138], ["than", 143], ["20", 148], ["years", 151], ["of", 157], ["research", 160], ["and", 169], ["development", 173], ["by", 185], ["GlaxoSmithKline", 188], ["and", 204], ["partners", 208], ["and", 217], ["collaborators", 221], [".", 234], ["The", 236], ["vaccine", 240], ["has", 248], ["been", 252], ["developed", 257], ["to", 267], ["protect", 270], ["young", 278], ["children", 284], ["and", 293], ["infants", 297], ["living", 305], ["in", 312], ["Sub", 315], ["-", 318], ["Saharan", 319], ["Africa", 327], ["against", 334], ["clinical", 342], ["and", 351], ["severe", 355], ["disease", 362], ["caused", 370], ["by", 377], ["Plasmodium", 380], ["falciparum", 391], ["infection", 402], [".", 411], ["Over", 413], ["the", 418], ["past", 422], ["9", 427], ["years", 429], [",", 434], ["RTS", 436], [",", 439], ["S", 440], ["/", 441], ["AS", 442], ["has", 445], ["been", 449], ["evaluated", 454], ["in", 464], ["multiple", 467], ["Phase", 476], ["2", 482], ["studies", 484], [".", 491], ["The", 493], ["vaccine", 497], ["was", 505], ["shown", 509], ["to", 515], ["have", 518], ["a", 523], ["favorable", 525], ["safety", 535], ["profile", 542], ["and", 550], ["to", 554], ["be", 557], ["well", 560], ["tolerated", 565], ["in", 575], ["all", 578], ["age", 582], ["groups", 586], ["in", 593], ["which", 596], ["it", 602], ["was", 605], ["tested", 609], [",", 615], ["including", 617], ["the", 627], ["intended", 631], ["target", 640], ["population", 647], ["of", 658], ["infants", 661], ["and", 669], ["young", 673], ["children", 679], ["in", 688], ["Sub", 691], ["-", 694], ["Saharan", 695], ["Africa", 703], [".", 709], ["Data", 711], ["obtained", 716], ["so", 725], ["far", 728], ["suggest", 732], ["that", 740], ["RTS", 745], [",", 748], ["S", 749], ["/", 750], ["AS", 751], ["can", 754], ["be", 758], ["co", 761], ["-", 763], ["administered", 764], ["with", 777], ["other", 782], ["vaccines", 788], ["included", 797], ["in", 806], ["the", 809], ["routine", 813], ["Expanded", 821], ["Program", 830], ["of", 838], ["Immunization", 841], ["(", 854], ["EPI", 855], [")", 858], [".", 859], ["In", 861], ["Phase", 864], ["2", 870], ["testing", 872], [",", 879], ["the", 881], ["vaccine", 885], ["candidate", 893], ["was", 903], ["shown", 907], ["to", 913], ["confer", 916], ["significant", 923], ["protection", 935], ["against", 946], ["P.", 954], ["falciparum", 957], ["infection", 968], ["and", 978], ["clinical", 982], ["disease", 991], [",", 998], ["including", 1000], ["severe", 1010], ["malaria", 1017], [".", 1024], ["Furthermore", 1026], [",", 1037], ["a", 1039], ["trend", 1041], ["towards", 1047], ["an", 1055], ["indirect", 1058], ["beneficial", 1067], ["effect", 1078], ["of", 1085], ["the", 1088], ["vaccine", 1092], ["on", 1100], ["non", 1103], ["-", 1106], ["malarial", 1107], ["morbidities", 1116], ["has", 1128], ["been", 1132], ["observed", 1137], ["in", 1146], ["several", 1149], ["trials", 1157], [".", 1163], ["In", 1165], ["this", 1168], ["paper", 1173], [",", 1178], ["we", 1180], ["will", 1183], ["describe", 1188], ["the", 1197], ["genesis", 1201], ["of", 1209], ["the", 1212], ["RTS", 1216], [",", 1219], ["S", 1220], ["/", 1221], ["AS", 1222], ["concept", 1225], [",", 1232], ["including", 1234], ["the", 1244], ["rationale", 1248], ["for", 1258], ["selecting", 1262], ["the", 1272], ["circumsporozoite", 1276], ["protein", 1293], ["(", 1301], ["CSP", 1302], [")", 1305], ["as", 1307], ["the", 1310], ["target", 1314], ["antigen", 1321], [".", 1328], ["Early", 1330], ["development", 1336], ["history", 1348], ["of", 1356], ["the", 1359], ["vaccine", 1363], ["will", 1371], ["be", 1376], ["briefly", 1379], ["described", 1387], [".", 1396], ["We", 1398], ["will", 1401], ["present", 1406], ["the", 1414], ["most", 1418], ["salient", 1423], ["results", 1431], ["from", 1439], ["recent", 1444], ["Phase", 1451], ["2", 1457], ["studies", 1459], ["conducted", 1467], ["in", 1477], ["the", 1480], ["target", 1484], ["pediatric", 1491], ["population", 1501], [",", 1511], ["which", 1513], ["have", 1519], ["led", 1524], ["to", 1528], ["the", 1531], ["decision", 1535], ["to", 1544], ["progress", 1547], ["RTS", 1556], [",", 1559], ["S", 1560], ["/", 1561], ["AS", 1562], ["to", 1565], ["Phase", 1568], ["3", 1574], ["testing", 1576], [".", 1583], ["If", 1585], ["the", 1588], ["Phase", 1592], ["3", 1598], ["results", 1600], ["confirm", 1608], ["the", 1616], ["observations", 1620], ["made", 1633], ["during", 1638], ["Phase", 1645], ["2", 1651], ["testing", 1653], [",", 1660], ["the", 1662], ["RTS", 1666], [",", 1669], ["S", 1670], ["/", 1671], ["AS", 1672], ["vaccine", 1675], [",", 1682], ["when", 1684], ["broadly", 1689], ["implemented", 1697], ["and", 1709], ["judiciously", 1713], ["integrated", 1725], ["with", 1736], ["other", 1741], ["malaria", 1747], ["-", 1754], ["prevention", 1755], ["measures", 1766], [",", 1774], ["would", 1776], ["have", 1782], ["a", 1787], ["major", 1789], ["public", 1795], ["-", 1801], ["health", 1802], ["impact", 1809], ["in", 1816], ["Sub", 1819], ["-", 1822], ["Saharan", 1823], ["Africa", 1831], [".", 1837]]}
{"context": "Chronic myelogenous leukemia (CML) is a clonal hematopoietic disorder caused by the reciprocal translocation between chromosome 9 and 22. As a result of this translocation, a novel fusion gene, BCR-ABL, is created on Philadelphia (Ph) chromosome, and the constitutive activity of the BCR-ABL protein tyrosine kinase plays a critical role in the disease pathogenesis. Imatinib mesylate, a selective BCR-ABL tyrosine kinase inhibitor, was first given to a patient with CML in June 1998. Since then, it has continued to demonstrate remarkable efficacy in treating patients with CML. Based upon the results of early phase I and II studies, a phase III study (IRIS Study) that was randomized to first-line imatinib (400 mg/day) or to standard treatment with interferon+low-dose Ara-C, was conducted on 1,106 patients newly diagnosed (within 6 months) with chronic-phase CML. After median follow-up of 30 months, imatinib showed significantly superior tolerability, hematologic and cytogenetic responses (major cytogenetic response, 90%; complete cytogenetic response, 82%), and overall survival (95% without censoring allo-HSCT). Although imatinib is the first-line therapy and has changed the paradigm of CML treatment strategy, questions remain as to the meaning of cytogenetic and molecular response, curability, optimal dose, and relation with allo-HSCT.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "90bd5d6d1bbd4a51af5bf2328d5aebb7", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[73, 75], [53, 55], [34, 36]], "char_spans": [[398, 404], [284, 290], [194, 200]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["a", 38], ["clonal", 40], ["hematopoietic", 47], ["disorder", 61], ["caused", 70], ["by", 77], ["the", 80], ["reciprocal", 84], ["translocation", 95], ["between", 109], ["chromosome", 117], ["9", 128], ["and", 130], ["22", 134], [".", 136], ["As", 138], ["a", 141], ["result", 143], ["of", 150], ["this", 153], ["translocation", 158], [",", 171], ["a", 173], ["novel", 175], ["fusion", 181], ["gene", 188], [",", 192], ["BCR", 194], ["-", 197], ["ABL", 198], [",", 201], ["is", 203], ["created", 206], ["on", 214], ["Philadelphia", 217], ["(", 230], ["Ph", 231], [")", 233], ["chromosome", 235], [",", 245], ["and", 247], ["the", 251], ["constitutive", 255], ["activity", 268], ["of", 277], ["the", 280], ["BCR", 284], ["-", 287], ["ABL", 288], ["protein", 292], ["tyrosine", 300], ["kinase", 309], ["plays", 316], ["a", 322], ["critical", 324], ["role", 333], ["in", 338], ["the", 341], ["disease", 345], ["pathogenesis", 353], [".", 365], ["Imatinib", 367], ["mesylate", 376], [",", 384], ["a", 386], ["selective", 388], ["BCR", 398], ["-", 401], ["ABL", 402], ["tyrosine", 406], ["kinase", 415], ["inhibitor", 422], [",", 431], ["was", 433], ["first", 437], ["given", 443], ["to", 449], ["a", 452], ["patient", 454], ["with", 462], ["CML", 467], ["in", 471], ["June", 474], ["1998", 479], [".", 483], ["Since", 485], ["then", 491], [",", 495], ["it", 497], ["has", 500], ["continued", 504], ["to", 514], ["demonstrate", 517], ["remarkable", 529], ["efficacy", 540], ["in", 549], ["treating", 552], ["patients", 561], ["with", 570], ["CML", 575], [".", 578], ["Based", 580], ["upon", 586], ["the", 591], ["results", 595], ["of", 603], ["early", 606], ["phase", 612], ["I", 618], ["and", 620], ["II", 624], ["studies", 627], [",", 634], ["a", 636], ["phase", 638], ["III", 644], ["study", 648], ["(", 654], ["IRIS", 655], ["Study", 660], [")", 665], ["that", 667], ["was", 672], ["randomized", 676], ["to", 687], ["first", 690], ["-", 695], ["line", 696], ["imatinib", 701], ["(", 710], ["400", 711], ["mg", 715], ["/", 717], ["day", 718], [")", 721], ["or", 723], ["to", 726], ["standard", 729], ["treatment", 738], ["with", 748], ["interferon+low", 753], ["-", 767], ["dose", 768], ["Ara", 773], ["-", 776], ["C", 777], [",", 778], ["was", 780], ["conducted", 784], ["on", 794], ["1,106", 797], ["patients", 803], ["newly", 812], ["diagnosed", 818], ["(", 828], ["within", 829], ["6", 836], ["months", 838], [")", 844], ["with", 846], ["chronic", 851], ["-", 858], ["phase", 859], ["CML", 865], [".", 868], ["After", 870], ["median", 876], ["follow", 883], ["-", 889], ["up", 890], ["of", 893], ["30", 896], ["months", 899], [",", 905], ["imatinib", 907], ["showed", 916], ["significantly", 923], ["superior", 937], ["tolerability", 946], [",", 958], ["hematologic", 960], ["and", 972], ["cytogenetic", 976], ["responses", 988], ["(", 998], ["major", 999], ["cytogenetic", 1005], ["response", 1017], [",", 1025], ["90", 1027], ["%", 1029], [";", 1030], ["complete", 1032], ["cytogenetic", 1041], ["response", 1053], [",", 1061], ["82", 1063], ["%", 1065], [")", 1066], [",", 1067], ["and", 1069], ["overall", 1073], ["survival", 1081], ["(", 1090], ["95", 1091], ["%", 1093], ["without", 1095], ["censoring", 1103], ["allo", 1113], ["-", 1117], ["HSCT", 1118], [")", 1122], [".", 1123], ["Although", 1125], ["imatinib", 1134], ["is", 1143], ["the", 1146], ["first", 1150], ["-", 1155], ["line", 1156], ["therapy", 1161], ["and", 1169], ["has", 1173], ["changed", 1177], ["the", 1185], ["paradigm", 1189], ["of", 1198], ["CML", 1201], ["treatment", 1205], ["strategy", 1215], [",", 1223], ["questions", 1225], ["remain", 1235], ["as", 1242], ["to", 1245], ["the", 1248], ["meaning", 1252], ["of", 1260], ["cytogenetic", 1263], ["and", 1275], ["molecular", 1279], ["response", 1289], [",", 1297], ["curability", 1299], [",", 1309], ["optimal", 1311], ["dose", 1319], [",", 1323], ["and", 1325], ["relation", 1329], ["with", 1338], ["allo", 1343], ["-", 1347], ["HSCT", 1348], [".", 1352]]}
{"context": "Plague is still an endemic disease in different regions of the world. Increasing reports of incidence, the discovery of antibiotic resistance strains, and concern about a potential use of the causative bacteria Yersinia pestis as an agent of biological warfare have highlighted the need for a safe, efficacious, and rapidly producible vaccine. The use of F1 and V antigens and the derived protein fusion F1-V has shown great potential as a protective vaccine in animal studies. Plants have been extensively studied for the production of pharmaceutical proteins as an inexpensive and scalable alternative to common expression systems. In the current study the recombinant plague antigens F1, V, and fusion protein F1-V were produced by transient expression in Nicotiana benthamiana by using a deconstructed tobacco mosaic virus-based system that allowed very rapid and extremely high levels of expression. All of the plant-derived purified antigens, administered s.c. to guinea pigs, generated systemic immune responses and provided protection against an aerosol challenge of virulent Y. pestis.", "qas": [{"question": "Which bacteria caused plague?", "answers": ["Yersinia pestis"], "qid": "4ce4a14391204eb893a5d9a49f0652af", "question_tokens": [["Which", 0], ["bacteria", 6], ["caused", 15], ["plague", 22], ["?", 28]], "detected_answers": [{"text": "Yersinia pestis", "token_spans": [[35, 36]], "char_spans": [[211, 225]]}]}], "context_tokens": [["Plague", 0], ["is", 7], ["still", 10], ["an", 16], ["endemic", 19], ["disease", 27], ["in", 35], ["different", 38], ["regions", 48], ["of", 56], ["the", 59], ["world", 63], [".", 68], ["Increasing", 70], ["reports", 81], ["of", 89], ["incidence", 92], [",", 101], ["the", 103], ["discovery", 107], ["of", 117], ["antibiotic", 120], ["resistance", 131], ["strains", 142], [",", 149], ["and", 151], ["concern", 155], ["about", 163], ["a", 169], ["potential", 171], ["use", 181], ["of", 185], ["the", 188], ["causative", 192], ["bacteria", 202], ["Yersinia", 211], ["pestis", 220], ["as", 227], ["an", 230], ["agent", 233], ["of", 239], ["biological", 242], ["warfare", 253], ["have", 261], ["highlighted", 266], ["the", 278], ["need", 282], ["for", 287], ["a", 291], ["safe", 293], [",", 297], ["efficacious", 299], [",", 310], ["and", 312], ["rapidly", 316], ["producible", 324], ["vaccine", 335], [".", 342], ["The", 344], ["use", 348], ["of", 352], ["F1", 355], ["and", 358], ["V", 362], ["antigens", 364], ["and", 373], ["the", 377], ["derived", 381], ["protein", 389], ["fusion", 397], ["F1-V", 404], ["has", 409], ["shown", 413], ["great", 419], ["potential", 425], ["as", 435], ["a", 438], ["protective", 440], ["vaccine", 451], ["in", 459], ["animal", 462], ["studies", 469], [".", 476], ["Plants", 478], ["have", 485], ["been", 490], ["extensively", 495], ["studied", 507], ["for", 515], ["the", 519], ["production", 523], ["of", 534], ["pharmaceutical", 537], ["proteins", 552], ["as", 561], ["an", 564], ["inexpensive", 567], ["and", 579], ["scalable", 583], ["alternative", 592], ["to", 604], ["common", 607], ["expression", 614], ["systems", 625], [".", 632], ["In", 634], ["the", 637], ["current", 641], ["study", 649], ["the", 655], ["recombinant", 659], ["plague", 671], ["antigens", 678], ["F1", 687], [",", 689], ["V", 691], [",", 692], ["and", 694], ["fusion", 698], ["protein", 705], ["F1-V", 713], ["were", 718], ["produced", 723], ["by", 732], ["transient", 735], ["expression", 745], ["in", 756], ["Nicotiana", 759], ["benthamiana", 769], ["by", 781], ["using", 784], ["a", 790], ["deconstructed", 792], ["tobacco", 806], ["mosaic", 814], ["virus", 821], ["-", 826], ["based", 827], ["system", 833], ["that", 840], ["allowed", 845], ["very", 853], ["rapid", 858], ["and", 864], ["extremely", 868], ["high", 878], ["levels", 883], ["of", 890], ["expression", 893], [".", 903], ["All", 905], ["of", 909], ["the", 912], ["plant", 916], ["-", 921], ["derived", 922], ["purified", 930], ["antigens", 939], [",", 947], ["administered", 949], ["s.c", 962], [".", 965], ["to", 967], ["guinea", 970], ["pigs", 977], [",", 981], ["generated", 983], ["systemic", 993], ["immune", 1002], ["responses", 1009], ["and", 1019], ["provided", 1023], ["protection", 1032], ["against", 1043], ["an", 1051], ["aerosol", 1054], ["challenge", 1062], ["of", 1072], ["virulent", 1075], ["Y.", 1084], ["pestis", 1087], [".", 1093]]}
{"context": "Protection and replenishment of a functional pancreatic \u03b2-cell mass (BCM) are key goals of all diabetes therapies. Apelin, a small regulatory peptide, is the endogenous ligand for the apelin receptor (APJ) receptor. The apelin-APJ signaling system is expressed in rodent and human islet cells. Apelin exposure has been shown to inhibit and to stimulate insulin secretion. Our aim was to assess the influence of a selective APJ deletion in pancreatic islet cells on islet homeostasis and glucose tolerance in mice. Cre-LoxP strategy was utilized to mediate islet APJ deletion. APJ deletion in islet cells (APJ(\u0394islet)) resulted in a significantly reduced islet size, density and BCM. An ip glucose tolerance test showed significantly impaired glucose clearance in APJ(\u0394islet) mice. APJ(\u0394islet) mice were not insulin resistant and in vivo glucose-stimulated insulin secretion was reduced modestly. In vitro glucose-stimulated insulin secretion showed a significantly reduced insulin secretion by islets from APJ(\u0394islet) mice. Glucose clearance in response to ip glucose tolerance test in obese APJ(\u0394islet) mice fed a chronic high-fat (HF) diet, but not pregnant APJ(\u0394islet) mice, was impaired significantly. In addition, the obesity-induced adaptive elevations in mean islet size and fractional islet area were reduced significantly in obese APJ(\u0394islet) mice when compared with wild-type mice. Together, these findings demonstrate a stimulatory role for the islet cell apelin-APJ signaling axis in regulation of pancreatic islet homeostasis and in metabolic induced \u03b2-cell hyperplasia. The results indicate the apelin-APJ system can be exploited for replenishment of BCM.", "qas": [{"question": "What is apelin?", "answers": ["Apelin, a small regulatory peptide, is the endogenous ligand for the apelin receptor (APJ) receptor."], "qid": "22b639b52f25417c920ceec18fc765f2", "question_tokens": [["What", 0], ["is", 5], ["apelin", 8], ["?", 14]], "detected_answers": [{"text": "Apelin, a small regulatory peptide, is the endogenous ligand for the apelin receptor (APJ) receptor.", "token_spans": [[22, 40]], "char_spans": [[115, 213]]}]}], "context_tokens": [["Protection", 0], ["and", 11], ["replenishment", 15], ["of", 29], ["a", 32], ["functional", 34], ["pancreatic", 45], ["\u03b2", 56], ["-", 57], ["cell", 58], ["mass", 63], ["(", 68], ["BCM", 69], [")", 72], ["are", 74], ["key", 78], ["goals", 82], ["of", 88], ["all", 91], ["diabetes", 95], ["therapies", 104], [".", 113], ["Apelin", 115], [",", 121], ["a", 123], ["small", 125], ["regulatory", 131], ["peptide", 142], [",", 149], ["is", 151], ["the", 154], ["endogenous", 158], ["ligand", 169], ["for", 176], ["the", 180], ["apelin", 184], ["receptor", 191], ["(", 200], ["APJ", 201], [")", 204], ["receptor", 206], [".", 214], ["The", 216], ["apelin", 220], ["-", 226], ["APJ", 227], ["signaling", 231], ["system", 241], ["is", 248], ["expressed", 251], ["in", 261], ["rodent", 264], ["and", 271], ["human", 275], ["islet", 281], ["cells", 287], [".", 292], ["Apelin", 294], ["exposure", 301], ["has", 310], ["been", 314], ["shown", 319], ["to", 325], ["inhibit", 328], ["and", 336], ["to", 340], ["stimulate", 343], ["insulin", 353], ["secretion", 361], [".", 370], ["Our", 372], ["aim", 376], ["was", 380], ["to", 384], ["assess", 387], ["the", 394], ["influence", 398], ["of", 408], ["a", 411], ["selective", 413], ["APJ", 423], ["deletion", 427], ["in", 436], ["pancreatic", 439], ["islet", 450], ["cells", 456], ["on", 462], ["islet", 465], ["homeostasis", 471], ["and", 483], ["glucose", 487], ["tolerance", 495], ["in", 505], ["mice", 508], [".", 512], ["Cre", 514], ["-", 517], ["LoxP", 518], ["strategy", 523], ["was", 532], ["utilized", 536], ["to", 545], ["mediate", 548], ["islet", 556], ["APJ", 562], ["deletion", 566], [".", 574], ["APJ", 576], ["deletion", 580], ["in", 589], ["islet", 592], ["cells", 598], ["(", 604], ["APJ(\u0394islet", 605], [")", 615], [")", 616], ["resulted", 618], ["in", 627], ["a", 630], ["significantly", 632], ["reduced", 646], ["islet", 654], ["size", 660], [",", 664], ["density", 666], ["and", 674], ["BCM", 678], [".", 681], ["An", 683], ["ip", 686], ["glucose", 689], ["tolerance", 697], ["test", 707], ["showed", 712], ["significantly", 719], ["impaired", 733], ["glucose", 742], ["clearance", 750], ["in", 760], ["APJ(\u0394islet", 763], [")", 773], ["mice", 775], [".", 779], ["APJ(\u0394islet", 781], [")", 791], ["mice", 793], ["were", 798], ["not", 803], ["insulin", 807], ["resistant", 815], ["and", 825], ["in", 829], ["vivo", 832], ["glucose", 837], ["-", 844], ["stimulated", 845], ["insulin", 856], ["secretion", 864], ["was", 874], ["reduced", 878], ["modestly", 886], [".", 894], ["In", 896], ["vitro", 899], ["glucose", 905], ["-", 912], ["stimulated", 913], ["insulin", 924], ["secretion", 932], ["showed", 942], ["a", 949], ["significantly", 951], ["reduced", 965], ["insulin", 973], ["secretion", 981], ["by", 991], ["islets", 994], ["from", 1001], ["APJ(\u0394islet", 1006], [")", 1016], ["mice", 1018], [".", 1022], ["Glucose", 1024], ["clearance", 1032], ["in", 1042], ["response", 1045], ["to", 1054], ["ip", 1057], ["glucose", 1060], ["tolerance", 1068], ["test", 1078], ["in", 1083], ["obese", 1086], ["APJ(\u0394islet", 1092], [")", 1102], ["mice", 1104], ["fed", 1109], ["a", 1113], ["chronic", 1115], ["high", 1123], ["-", 1127], ["fat", 1128], ["(", 1132], ["HF", 1133], [")", 1135], ["diet", 1137], [",", 1141], ["but", 1143], ["not", 1147], ["pregnant", 1151], ["APJ(\u0394islet", 1160], [")", 1170], ["mice", 1172], [",", 1176], ["was", 1178], ["impaired", 1182], ["significantly", 1191], [".", 1204], ["In", 1206], ["addition", 1209], [",", 1217], ["the", 1219], ["obesity", 1223], ["-", 1230], ["induced", 1231], ["adaptive", 1239], ["elevations", 1248], ["in", 1259], ["mean", 1262], ["islet", 1267], ["size", 1273], ["and", 1278], ["fractional", 1282], ["islet", 1293], ["area", 1299], ["were", 1304], ["reduced", 1309], ["significantly", 1317], ["in", 1331], ["obese", 1334], ["APJ(\u0394islet", 1340], [")", 1350], ["mice", 1352], ["when", 1357], ["compared", 1362], ["with", 1371], ["wild", 1376], ["-", 1380], ["type", 1381], ["mice", 1386], [".", 1390], ["Together", 1392], [",", 1400], ["these", 1402], ["findings", 1408], ["demonstrate", 1417], ["a", 1429], ["stimulatory", 1431], ["role", 1443], ["for", 1448], ["the", 1452], ["islet", 1456], ["cell", 1462], ["apelin", 1467], ["-", 1473], ["APJ", 1474], ["signaling", 1478], ["axis", 1488], ["in", 1493], ["regulation", 1496], ["of", 1507], ["pancreatic", 1510], ["islet", 1521], ["homeostasis", 1527], ["and", 1539], ["in", 1543], ["metabolic", 1546], ["induced", 1556], ["\u03b2", 1564], ["-", 1565], ["cell", 1566], ["hyperplasia", 1571], [".", 1582], ["The", 1584], ["results", 1588], ["indicate", 1596], ["the", 1605], ["apelin", 1609], ["-", 1615], ["APJ", 1616], ["system", 1620], ["can", 1627], ["be", 1631], ["exploited", 1634], ["for", 1644], ["replenishment", 1648], ["of", 1662], ["BCM", 1665], [".", 1668]]}
{"context": "The lysosomal storage disorder Fabry disease is characterized by excessive globotriaosylceramide (Gb3) accumulation in major organs such as the heart and kidney. Defective lysosomal alpha-galactosidase A (Gla) is responsible for excessive Gb3 accumulation, and one cell sensitive to the effects of Gb3 accumulation is vascular endothelium. Endothelial dysfunction is associated with Fabry disease and excessive cellular Gb3. We previously demonstrated that excessive vascular Gb3 in a mouse model of Fabry disease, the Gla-knockout (Gla(-/0)) mouse, results in abnormal vascular function, which includes abnormal endothelium-dependent contractions, a vascular phenomenon known to involve cyclooxygenase (COX). Therefore, we hypothesized that the vasculopathy in the Gla knockout mouse may be due to a vasoactive COX-derived product. To test this hypothesis, vascular reactivity experiments were performed in aortic rings from wild-type (Gla(+/0)) and Gla(-/0) mice in the presence and absence of specific and nonspecific COX inhibitors. Specific inhibition of COX1 or COX2 in endothelium-intact rings from Gla(-/0) mice decreased overall phenylephrine contractility compared with untreated Gla(-/0) rings, whereas COX inhibitors had no effect on contractility in endothelium-denuded rings. Nonspecific inhibition of COX with indomethacin (10 micromol/l) or COX1 inhibition with valeryl salicylate (3 mmol/l) improved endothelial function in rings from Gla(-/0) mice, but COX2 inhibition with NS-398 (1 micromol/l) further increased endothelial dysfunction in rings from Gla(-/0) mice. These results suggest that, in the Gla(-/0) mice, COX1 and COX2 activity are increased and localized in the endothelium, producing vasopressor and vasorelaxant products, which contribute to the Fabry-related vasculopathy.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "16952fa330f540e6884c87a1a0567566", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[27, 29]], "char_spans": [[182, 200]]}]}], "context_tokens": [["The", 0], ["lysosomal", 4], ["storage", 14], ["disorder", 22], ["Fabry", 31], ["disease", 37], ["is", 45], ["characterized", 48], ["by", 62], ["excessive", 65], ["globotriaosylceramide", 75], ["(", 97], ["Gb3", 98], [")", 101], ["accumulation", 103], ["in", 116], ["major", 119], ["organs", 125], ["such", 132], ["as", 137], ["the", 140], ["heart", 144], ["and", 150], ["kidney", 154], [".", 160], ["Defective", 162], ["lysosomal", 172], ["alpha", 182], ["-", 187], ["galactosidase", 188], ["A", 202], ["(", 204], ["Gla", 205], [")", 208], ["is", 210], ["responsible", 213], ["for", 225], ["excessive", 229], ["Gb3", 239], ["accumulation", 243], [",", 255], ["and", 257], ["one", 261], ["cell", 265], ["sensitive", 270], ["to", 280], ["the", 283], ["effects", 287], ["of", 295], ["Gb3", 298], ["accumulation", 302], ["is", 315], ["vascular", 318], ["endothelium", 327], [".", 338], ["Endothelial", 340], ["dysfunction", 352], ["is", 364], ["associated", 367], ["with", 378], ["Fabry", 383], ["disease", 389], ["and", 397], ["excessive", 401], ["cellular", 411], ["Gb3", 420], [".", 423], ["We", 425], ["previously", 428], ["demonstrated", 439], ["that", 452], ["excessive", 457], ["vascular", 467], ["Gb3", 476], ["in", 480], ["a", 483], ["mouse", 485], ["model", 491], ["of", 497], ["Fabry", 500], ["disease", 506], [",", 513], ["the", 515], ["Gla", 519], ["-", 522], ["knockout", 523], ["(", 532], ["Gla(-/0", 533], [")", 540], [")", 541], ["mouse", 543], [",", 548], ["results", 550], ["in", 558], ["abnormal", 561], ["vascular", 570], ["function", 579], [",", 587], ["which", 589], ["includes", 595], ["abnormal", 604], ["endothelium", 613], ["-", 624], ["dependent", 625], ["contractions", 635], [",", 647], ["a", 649], ["vascular", 651], ["phenomenon", 660], ["known", 671], ["to", 677], ["involve", 680], ["cyclooxygenase", 688], ["(", 703], ["COX", 704], [")", 707], [".", 708], ["Therefore", 710], [",", 719], ["we", 721], ["hypothesized", 724], ["that", 737], ["the", 742], ["vasculopathy", 746], ["in", 759], ["the", 762], ["Gla", 766], ["knockout", 770], ["mouse", 779], ["may", 785], ["be", 789], ["due", 792], ["to", 796], ["a", 799], ["vasoactive", 801], ["COX", 812], ["-", 815], ["derived", 816], ["product", 824], [".", 831], ["To", 833], ["test", 836], ["this", 841], ["hypothesis", 846], [",", 856], ["vascular", 858], ["reactivity", 867], ["experiments", 878], ["were", 890], ["performed", 895], ["in", 905], ["aortic", 908], ["rings", 915], ["from", 921], ["wild", 926], ["-", 930], ["type", 931], ["(", 936], ["Gla(+/0", 937], [")", 944], [")", 945], ["and", 947], ["Gla(-/0", 951], [")", 958], ["mice", 960], ["in", 965], ["the", 968], ["presence", 972], ["and", 981], ["absence", 985], ["of", 993], ["specific", 996], ["and", 1005], ["nonspecific", 1009], ["COX", 1021], ["inhibitors", 1025], [".", 1035], ["Specific", 1037], ["inhibition", 1046], ["of", 1057], ["COX1", 1060], ["or", 1065], ["COX2", 1068], ["in", 1073], ["endothelium", 1076], ["-", 1087], ["intact", 1088], ["rings", 1095], ["from", 1101], ["Gla(-/0", 1106], [")", 1113], ["mice", 1115], ["decreased", 1120], ["overall", 1130], ["phenylephrine", 1138], ["contractility", 1152], ["compared", 1166], ["with", 1175], ["untreated", 1180], ["Gla(-/0", 1190], [")", 1197], ["rings", 1199], [",", 1204], ["whereas", 1206], ["COX", 1214], ["inhibitors", 1218], ["had", 1229], ["no", 1233], ["effect", 1236], ["on", 1243], ["contractility", 1246], ["in", 1260], ["endothelium", 1263], ["-", 1274], ["denuded", 1275], ["rings", 1283], [".", 1288], ["Nonspecific", 1290], ["inhibition", 1302], ["of", 1313], ["COX", 1316], ["with", 1320], ["indomethacin", 1325], ["(", 1338], ["10", 1339], ["micromol", 1342], ["/", 1350], ["l", 1351], [")", 1352], ["or", 1354], ["COX1", 1357], ["inhibition", 1362], ["with", 1373], ["valeryl", 1378], ["salicylate", 1386], ["(", 1397], ["3", 1398], ["mmol", 1400], ["/", 1404], ["l", 1405], [")", 1406], ["improved", 1408], ["endothelial", 1417], ["function", 1429], ["in", 1438], ["rings", 1441], ["from", 1447], ["Gla(-/0", 1452], [")", 1459], ["mice", 1461], [",", 1465], ["but", 1467], ["COX2", 1471], ["inhibition", 1476], ["with", 1487], ["NS-398", 1492], ["(", 1499], ["1", 1500], ["micromol", 1502], ["/", 1510], ["l", 1511], [")", 1512], ["further", 1514], ["increased", 1522], ["endothelial", 1532], ["dysfunction", 1544], ["in", 1556], ["rings", 1559], ["from", 1565], ["Gla(-/0", 1570], [")", 1577], ["mice", 1579], [".", 1583], ["These", 1585], ["results", 1591], ["suggest", 1599], ["that", 1607], [",", 1611], ["in", 1613], ["the", 1616], ["Gla(-/0", 1620], [")", 1627], ["mice", 1629], [",", 1633], ["COX1", 1635], ["and", 1640], ["COX2", 1644], ["activity", 1649], ["are", 1658], ["increased", 1662], ["and", 1672], ["localized", 1676], ["in", 1686], ["the", 1689], ["endothelium", 1693], [",", 1704], ["producing", 1706], ["vasopressor", 1716], ["and", 1728], ["vasorelaxant", 1732], ["products", 1745], [",", 1753], ["which", 1755], ["contribute", 1761], ["to", 1772], ["the", 1775], ["Fabry", 1779], ["-", 1784], ["related", 1785], ["vasculopathy", 1793], [".", 1805]]}
{"context": "Fibrillar \u03b1-synuclein (\u03b1-Syn) is the principal component of Lewy bodies, which are evident in individuals affected by Parkinson disease (PD). This neuropathologic form of \u03b1-Syn plays a central role in PD progression as it has been shown to propagate between neurons. Tools that interfere with \u03b1-Syn assembly or change the physicochemical properties of the fibrils have potential therapeutic properties as they may be sufficient to interfere with and/or halt cell-to-cell transmission and the systematic spread of \u03b1-Syn assemblies within the central nervous system. Vertebrate molecular chaperones from the constitutive/heat-inducible heat shock protein 70 (Hsc/p70) family have been shown to hinder the assembly of soluble \u03b1-Syn into fibrils and to bind to the fibrils and very significantly reduce their toxicity. To understand how Hsc70 family members sequester soluble \u03b1-Syn, we set up experiments to identify the molecular chaperone-\u03b1-Syn surface interfaces. We cross-linked human Hsc70 and its yeast homologue Ssa1p and \u03b1-Syn using a chemical cross-linker and mapped the Hsc70- and Ssa1p-\u03b1-Syn interface. We show that the client binding domain of Hsc70 and Ssa1p binds two regions within \u03b1-Syn similar to a tweezer, with the first spanning residues 10-45 and the second spanning residues 97-102. Our findings define what is necessary and sufficient for engineering Hsc70- and Ssa1p-derived polypeptide with minichaperone properties with a potential as therapeutic agents in Parkinson disease through their ability to affect \u03b1-Syn assembly and/or toxicity.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "344f79431db040ea8cbbb6cb3a1b171a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[1, 3]], "char_spans": [[10, 20]]}]}], "context_tokens": [["Fibrillar", 0], ["\u03b1", 10], ["-", 11], ["synuclein", 12], ["(", 22], ["\u03b1", 23], ["-", 24], ["Syn", 25], [")", 28], ["is", 30], ["the", 33], ["principal", 37], ["component", 47], ["of", 57], ["Lewy", 60], ["bodies", 65], [",", 71], ["which", 73], ["are", 79], ["evident", 83], ["in", 91], ["individuals", 94], ["affected", 106], ["by", 115], ["Parkinson", 118], ["disease", 128], ["(", 136], ["PD", 137], [")", 139], [".", 140], ["This", 142], ["neuropathologic", 147], ["form", 163], ["of", 168], ["\u03b1", 171], ["-", 172], ["Syn", 173], ["plays", 177], ["a", 183], ["central", 185], ["role", 193], ["in", 198], ["PD", 201], ["progression", 204], ["as", 216], ["it", 219], ["has", 222], ["been", 226], ["shown", 231], ["to", 237], ["propagate", 240], ["between", 250], ["neurons", 258], [".", 265], ["Tools", 267], ["that", 273], ["interfere", 278], ["with", 288], ["\u03b1", 293], ["-", 294], ["Syn", 295], ["assembly", 299], ["or", 308], ["change", 311], ["the", 318], ["physicochemical", 322], ["properties", 338], ["of", 349], ["the", 352], ["fibrils", 356], ["have", 364], ["potential", 369], ["therapeutic", 379], ["properties", 391], ["as", 402], ["they", 405], ["may", 410], ["be", 414], ["sufficient", 417], ["to", 428], ["interfere", 431], ["with", 441], ["and/or", 446], ["halt", 453], ["cell", 458], ["-", 462], ["to", 463], ["-", 465], ["cell", 466], ["transmission", 471], ["and", 484], ["the", 488], ["systematic", 492], ["spread", 503], ["of", 510], ["\u03b1", 513], ["-", 514], ["Syn", 515], ["assemblies", 519], ["within", 530], ["the", 537], ["central", 541], ["nervous", 549], ["system", 557], [".", 563], ["Vertebrate", 565], ["molecular", 576], ["chaperones", 586], ["from", 597], ["the", 602], ["constitutive", 606], ["/", 618], ["heat", 619], ["-", 623], ["inducible", 624], ["heat", 634], ["shock", 639], ["protein", 645], ["70", 653], ["(", 656], ["Hsc", 657], ["/", 660], ["p70", 661], [")", 664], ["family", 666], ["have", 673], ["been", 678], ["shown", 683], ["to", 689], ["hinder", 692], ["the", 699], ["assembly", 703], ["of", 712], ["soluble", 715], ["\u03b1", 723], ["-", 724], ["Syn", 725], ["into", 729], ["fibrils", 734], ["and", 742], ["to", 746], ["bind", 749], ["to", 754], ["the", 757], ["fibrils", 761], ["and", 769], ["very", 773], ["significantly", 778], ["reduce", 792], ["their", 799], ["toxicity", 805], [".", 813], ["To", 815], ["understand", 818], ["how", 829], ["Hsc70", 833], ["family", 839], ["members", 846], ["sequester", 854], ["soluble", 864], ["\u03b1", 872], ["-", 873], ["Syn", 874], [",", 877], ["we", 879], ["set", 882], ["up", 886], ["experiments", 889], ["to", 901], ["identify", 904], ["the", 913], ["molecular", 917], ["chaperone", 927], ["-", 936], ["\u03b1", 937], ["-", 938], ["Syn", 939], ["surface", 943], ["interfaces", 951], [".", 961], ["We", 963], ["cross", 966], ["-", 971], ["linked", 972], ["human", 979], ["Hsc70", 985], ["and", 991], ["its", 995], ["yeast", 999], ["homologue", 1005], ["Ssa1p", 1015], ["and", 1021], ["\u03b1", 1025], ["-", 1026], ["Syn", 1027], ["using", 1031], ["a", 1037], ["chemical", 1039], ["cross", 1048], ["-", 1053], ["linker", 1054], ["and", 1061], ["mapped", 1065], ["the", 1072], ["Hsc70-", 1076], ["and", 1083], ["Ssa1p", 1087], ["-", 1092], ["\u03b1", 1093], ["-", 1094], ["Syn", 1095], ["interface", 1099], [".", 1108], ["We", 1110], ["show", 1113], ["that", 1118], ["the", 1123], ["client", 1127], ["binding", 1134], ["domain", 1142], ["of", 1149], ["Hsc70", 1152], ["and", 1158], ["Ssa1p", 1162], ["binds", 1168], ["two", 1174], ["regions", 1178], ["within", 1186], ["\u03b1", 1193], ["-", 1194], ["Syn", 1195], ["similar", 1199], ["to", 1207], ["a", 1210], ["tweezer", 1212], [",", 1219], ["with", 1221], ["the", 1226], ["first", 1230], ["spanning", 1236], ["residues", 1245], ["10", 1254], ["-", 1256], ["45", 1257], ["and", 1260], ["the", 1264], ["second", 1268], ["spanning", 1275], ["residues", 1284], ["97", 1293], ["-", 1295], ["102", 1296], [".", 1299], ["Our", 1301], ["findings", 1305], ["define", 1314], ["what", 1321], ["is", 1326], ["necessary", 1329], ["and", 1339], ["sufficient", 1343], ["for", 1354], ["engineering", 1358], ["Hsc70-", 1370], ["and", 1377], ["Ssa1p", 1381], ["-", 1386], ["derived", 1387], ["polypeptide", 1395], ["with", 1407], ["minichaperone", 1412], ["properties", 1426], ["with", 1437], ["a", 1442], ["potential", 1444], ["as", 1454], ["therapeutic", 1457], ["agents", 1469], ["in", 1476], ["Parkinson", 1479], ["disease", 1489], ["through", 1497], ["their", 1505], ["ability", 1511], ["to", 1519], ["affect", 1522], ["\u03b1", 1529], ["-", 1530], ["Syn", 1531], ["assembly", 1535], ["and/or", 1544], ["toxicity", 1551], [".", 1559]]}
{"context": "The Shprintzen-Goldberg syndrome is an extremely rare syndrome with a characteristic face. This is one of a group of disorders characterized by craniosynostosis and marfanoid features. The aim of this study was to present a new sporadic case of the syndrome and describe in detail the findings at the maxillofacial region.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "0e334455b93e49ba8dc2280657d82443", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[25, 25]], "char_spans": [[144, 159]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["is", 33], ["an", 36], ["extremely", 39], ["rare", 49], ["syndrome", 54], ["with", 63], ["a", 68], ["characteristic", 70], ["face", 85], [".", 89], ["This", 91], ["is", 96], ["one", 99], ["of", 103], ["a", 106], ["group", 108], ["of", 114], ["disorders", 117], ["characterized", 127], ["by", 141], ["craniosynostosis", 144], ["and", 161], ["marfanoid", 165], ["features", 175], [".", 183], ["The", 185], ["aim", 189], ["of", 193], ["this", 196], ["study", 201], ["was", 207], ["to", 211], ["present", 214], ["a", 222], ["new", 224], ["sporadic", 228], ["case", 237], ["of", 242], ["the", 245], ["syndrome", 249], ["and", 258], ["describe", 262], ["in", 271], ["detail", 274], ["the", 281], ["findings", 285], ["at", 294], ["the", 297], ["maxillofacial", 301], ["region", 315], [".", 321]]}
{"context": "Psychiatric disorders have a great impact on morbidity and mortality. Genotype-phenotype resources for psychiatric diseases are key to enable the translation of research findings to a better care of patients. PsyGeNET is a knowledge resource on psychiatric diseases and their genes, developed by text mining and curated by domain experts. We present psygenet2r, an R package that contains a variety of functions for leveraging PsyGeNET database and facilitating its analysis and interpretation. The package offers different types of queries to the database along with variety of analysis and visualization tools, including the study of the anatomical structures in which the genes are expressed and gaining insight of gene's molecular function. Psygenet2r is especially suited for network medicine analysis of psychiatric disorders. The package is implemented in R and is available under MIT license from Bioconductor (http://bioconductor.org/packages/release/bioc/html/psygenet2r.html). juanr.gonzalez@isglobal.org or laura.furlong@upf.edu. Supplementary data are available at Bioinformatics online.", "qas": [{"question": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?", "answers": ["Psygenet2r"], "qid": "4d4e76e2c6944123bd9d9709e0e9d250", "question_tokens": [["Which", 0], ["R", 6], ["/", 7], ["Bioconductor", 8], ["package", 21], ["has", 29], ["been", 33], ["developed", 38], ["for", 48], ["the", 52], ["analysis", 56], ["of", 65], ["psychiatric", 68], ["disease", 80], ["genes", 88], ["?", 93]], "detected_answers": [{"text": "Psygenet2r", "token_spans": [[121, 121], [58, 58]], "char_spans": [[745, 754], [350, 359]]}]}], "context_tokens": [["Psychiatric", 0], ["disorders", 12], ["have", 22], ["a", 27], ["great", 29], ["impact", 35], ["on", 42], ["morbidity", 45], ["and", 55], ["mortality", 59], [".", 68], ["Genotype", 70], ["-", 78], ["phenotype", 79], ["resources", 89], ["for", 99], ["psychiatric", 103], ["diseases", 115], ["are", 124], ["key", 128], ["to", 132], ["enable", 135], ["the", 142], ["translation", 146], ["of", 158], ["research", 161], ["findings", 170], ["to", 179], ["a", 182], ["better", 184], ["care", 191], ["of", 196], ["patients", 199], [".", 207], ["PsyGeNET", 209], ["is", 218], ["a", 221], ["knowledge", 223], ["resource", 233], ["on", 242], ["psychiatric", 245], ["diseases", 257], ["and", 266], ["their", 270], ["genes", 276], [",", 281], ["developed", 283], ["by", 293], ["text", 296], ["mining", 301], ["and", 308], ["curated", 312], ["by", 320], ["domain", 323], ["experts", 330], [".", 337], ["We", 339], ["present", 342], ["psygenet2r", 350], [",", 360], ["an", 362], ["R", 365], ["package", 367], ["that", 375], ["contains", 380], ["a", 389], ["variety", 391], ["of", 399], ["functions", 402], ["for", 412], ["leveraging", 416], ["PsyGeNET", 427], ["database", 436], ["and", 445], ["facilitating", 449], ["its", 462], ["analysis", 466], ["and", 475], ["interpretation", 479], [".", 493], ["The", 495], ["package", 499], ["offers", 507], ["different", 514], ["types", 524], ["of", 530], ["queries", 533], ["to", 541], ["the", 544], ["database", 548], ["along", 557], ["with", 563], ["variety", 568], ["of", 576], ["analysis", 579], ["and", 588], ["visualization", 592], ["tools", 606], [",", 611], ["including", 613], ["the", 623], ["study", 627], ["of", 633], ["the", 636], ["anatomical", 640], ["structures", 651], ["in", 662], ["which", 665], ["the", 671], ["genes", 675], ["are", 681], ["expressed", 685], ["and", 695], ["gaining", 699], ["insight", 707], ["of", 715], ["gene", 718], ["'s", 722], ["molecular", 725], ["function", 735], [".", 743], ["Psygenet2r", 745], ["is", 756], ["especially", 759], ["suited", 770], ["for", 777], ["network", 781], ["medicine", 789], ["analysis", 798], ["of", 807], ["psychiatric", 810], ["disorders", 822], [".", 831], ["The", 833], ["package", 837], ["is", 845], ["implemented", 848], ["in", 860], ["R", 863], ["and", 865], ["is", 869], ["available", 872], ["under", 882], ["MIT", 888], ["license", 892], ["from", 900], ["Bioconductor", 905], ["(", 918], ["http://bioconductor.org/packages/release/bioc/html/psygenet2r.html", 919], [")", 985], [".", 986], ["juanr.gonzalez@isglobal.org", 988], ["or", 1016], ["laura.furlong@upf.edu", 1019], [".", 1040], ["Supplementary", 1042], ["data", 1056], ["are", 1061], ["available", 1065], ["at", 1075], ["Bioinformatics", 1078], ["online", 1093], [".", 1099]]}
{"context": "NuA4 (nucleosome acetyltransferase of H4) promotes transcriptional initiation of TFIID (a complex of TBP and TBP-associated factors [TAFs])-dependent ribosomal protein genes involved in ribosome biogenesis. However, it is not clearly understood how NuA4 regulates the transcription of ribosomal protein genes. Here, we show that NuA4 is recruited to the promoters of ribosomal protein genes, such as RPS5, RPL2B, and RPS11B, for TFIID recruitment to initiate transcription, and the recruitment of NuA4 to these promoters is impaired in the absence of its Eaf1p component. Intriguingly, impaired NuA4 recruitment in a \u0394eaf1 strain depletes recruitment of TFIID (a TAF-dependent form of TBP) but not the TAF-independent form of TBP to the promoters of ribosomal protein genes. However, in the absence of NuA4, SAGA (Spt-Ada-Gcn5-acetyltransferase) is involved in targeting the TAF-independent form of TBP to the promoters of ribosomal protein genes for transcriptional initiation. Thus, NuA4 plays an important role in targeting TFIID to the promoters of ribosomal protein genes for transcriptional initiation in vivo. Such a function is mediated via its targeted histone acetyltransferase activity. In the absence of NuA4, ribosomal protein genes lose TFIID dependency and become SAGA dependent for transcriptional initiation. Collectively, these results provide significant insights into the regulation of ribosomal protein gene expression and, hence, ribosome biogenesis and functions.", "qas": [{"question": "What does the SAGA complex acronym stands for?", "answers": ["Spt-Ada-Gcn5-acetyltransferase"], "qid": "513f317b2bbb49a488431854ec8b1291", "question_tokens": [["What", 0], ["does", 5], ["the", 10], ["SAGA", 14], ["complex", 19], ["acronym", 27], ["stands", 35], ["for", 42], ["?", 45]], "detected_answers": [{"text": "Spt-Ada-Gcn5-acetyltransferase", "token_spans": [[148, 152]], "char_spans": [[814, 843]]}]}], "context_tokens": [["NuA4", 0], ["(", 5], ["nucleosome", 6], ["acetyltransferase", 17], ["of", 35], ["H4", 38], [")", 40], ["promotes", 42], ["transcriptional", 51], ["initiation", 67], ["of", 78], ["TFIID", 81], ["(", 87], ["a", 88], ["complex", 90], ["of", 98], ["TBP", 101], ["and", 105], ["TBP", 109], ["-", 112], ["associated", 113], ["factors", 124], ["[", 132], ["TAFs])-dependent", 133], ["ribosomal", 150], ["protein", 160], ["genes", 168], ["involved", 174], ["in", 183], ["ribosome", 186], ["biogenesis", 195], [".", 205], ["However", 207], [",", 214], ["it", 216], ["is", 219], ["not", 222], ["clearly", 226], ["understood", 234], ["how", 245], ["NuA4", 249], ["regulates", 254], ["the", 264], ["transcription", 268], ["of", 282], ["ribosomal", 285], ["protein", 295], ["genes", 303], [".", 308], ["Here", 310], [",", 314], ["we", 316], ["show", 319], ["that", 324], ["NuA4", 329], ["is", 334], ["recruited", 337], ["to", 347], ["the", 350], ["promoters", 354], ["of", 364], ["ribosomal", 367], ["protein", 377], ["genes", 385], [",", 390], ["such", 392], ["as", 397], ["RPS5", 400], [",", 404], ["RPL2B", 406], [",", 411], ["and", 413], ["RPS11B", 417], [",", 423], ["for", 425], ["TFIID", 429], ["recruitment", 435], ["to", 447], ["initiate", 450], ["transcription", 459], [",", 472], ["and", 474], ["the", 478], ["recruitment", 482], ["of", 494], ["NuA4", 497], ["to", 502], ["these", 505], ["promoters", 511], ["is", 521], ["impaired", 524], ["in", 533], ["the", 536], ["absence", 540], ["of", 548], ["its", 551], ["Eaf1p", 555], ["component", 561], [".", 570], ["Intriguingly", 572], [",", 584], ["impaired", 586], ["NuA4", 595], ["recruitment", 600], ["in", 612], ["a", 615], ["\u0394eaf1", 617], ["strain", 623], ["depletes", 630], ["recruitment", 639], ["of", 651], ["TFIID", 654], ["(", 660], ["a", 661], ["TAF", 663], ["-", 666], ["dependent", 667], ["form", 677], ["of", 682], ["TBP", 685], [")", 688], ["but", 690], ["not", 694], ["the", 698], ["TAF", 702], ["-", 705], ["independent", 706], ["form", 718], ["of", 723], ["TBP", 726], ["to", 730], ["the", 733], ["promoters", 737], ["of", 747], ["ribosomal", 750], ["protein", 760], ["genes", 768], [".", 773], ["However", 775], [",", 782], ["in", 784], ["the", 787], ["absence", 791], ["of", 799], ["NuA4", 802], [",", 806], ["SAGA", 808], ["(", 813], ["Spt", 814], ["-", 817], ["Ada", 818], ["-", 821], ["Gcn5-acetyltransferase", 822], [")", 844], ["is", 846], ["involved", 849], ["in", 858], ["targeting", 861], ["the", 871], ["TAF", 875], ["-", 878], ["independent", 879], ["form", 891], ["of", 896], ["TBP", 899], ["to", 903], ["the", 906], ["promoters", 910], ["of", 920], ["ribosomal", 923], ["protein", 933], ["genes", 941], ["for", 947], ["transcriptional", 951], ["initiation", 967], [".", 977], ["Thus", 979], [",", 983], ["NuA4", 985], ["plays", 990], ["an", 996], ["important", 999], ["role", 1009], ["in", 1014], ["targeting", 1017], ["TFIID", 1027], ["to", 1033], ["the", 1036], ["promoters", 1040], ["of", 1050], ["ribosomal", 1053], ["protein", 1063], ["genes", 1071], ["for", 1077], ["transcriptional", 1081], ["initiation", 1097], ["in", 1108], ["vivo", 1111], [".", 1115], ["Such", 1117], ["a", 1122], ["function", 1124], ["is", 1133], ["mediated", 1136], ["via", 1145], ["its", 1149], ["targeted", 1153], ["histone", 1162], ["acetyltransferase", 1170], ["activity", 1188], [".", 1196], ["In", 1198], ["the", 1201], ["absence", 1205], ["of", 1213], ["NuA4", 1216], [",", 1220], ["ribosomal", 1222], ["protein", 1232], ["genes", 1240], ["lose", 1246], ["TFIID", 1251], ["dependency", 1257], ["and", 1268], ["become", 1272], ["SAGA", 1279], ["dependent", 1284], ["for", 1294], ["transcriptional", 1298], ["initiation", 1314], [".", 1324], ["Collectively", 1326], [",", 1338], ["these", 1340], ["results", 1346], ["provide", 1354], ["significant", 1362], ["insights", 1374], ["into", 1383], ["the", 1388], ["regulation", 1392], ["of", 1403], ["ribosomal", 1406], ["protein", 1416], ["gene", 1424], ["expression", 1429], ["and", 1440], [",", 1443], ["hence", 1445], [",", 1450], ["ribosome", 1452], ["biogenesis", 1461], ["and", 1472], ["functions", 1476], [".", 1485]]}
{"context": "In breast cancer the development of metastasis is a major turning point in the treatment and outcome of the disease. Throughout tumour development, and especially in the development of metastasis, epithelial mesenchymal transition takes place. During this transformation into a mesenchymal phenotype, the tumour cells undergo a series of structural changes. The loss of structural integrity and adoption of mesenchymal filaments enables cells to detach from the epithelial cell layer and metastasise. Keratins form the intermediate filaments of the cytoskeleton and provide scaffold structures within cells. During cancer progression the intermediate filaments are reorganised, and dramatic changes are seen in their protein components. Keratins K8, K18, K19 and vimentin are intermediate filament proteins with altered expression profiles during tumour development. We have used in vivo and in vitro models to analyse changes in intermediate filament proteins. Antibody-based methods were used to study K8 levels and proteomic analysis to profile the protein content of metastatic breast cancer cell variants. K8 expression declines as human breast tumours progress into an invasive phenotype. Analysis of IF proteins indicated altered expression profiles of K8, K18, K19 and vimentin, with K8, K18, K19 expressed in high levels in the T47D and MCF-7 cell lines, whereas the highly metastatic cell lines expressed lower levels of K8 and K18 and no detectable K19. Vimentin showed reverse expression profile with T47D and MCF-7 cells having no detectable vimentin expression whereas the highly metastatic MDA-MB-231 and MDA-MB-436 showed high levels. Analysis of acetylation status using specific antibodies suggested acetylation occurred within the central coiled domain in the MCF-7 and T47D cells. Inhibition of tumour growth by tissue factor (TF) shRNA resulted in a dramatic re-elevation of expression of K8 in xenographs of the highly metastatic MDA-MB-436 line. Intermediate filament expression alters during epithelial mesenchymal transition. Identified post translational modifications may play a role in alterations seen in the organisation, solubility and stability of these filaments. Epithelial mesenchymal transition can be reversed and an epithelial phenotype re-established.", "qas": [{"question": "What are the structures formed when keratin molecules come together?", "answers": ["Intermediate filaments"], "qid": "0b44e46a198e44a3a793781a09543148", "question_tokens": [["What", 0], ["are", 5], ["the", 9], ["structures", 13], ["formed", 24], ["when", 31], ["keratin", 36], ["molecules", 44], ["come", 54], ["together", 59], ["?", 67]], "detected_answers": [{"text": "Intermediate filaments", "token_spans": [[82, 83], [98, 99]], "char_spans": [[519, 540], [638, 659]]}]}], "context_tokens": [["In", 0], ["breast", 3], ["cancer", 10], ["the", 17], ["development", 21], ["of", 33], ["metastasis", 36], ["is", 47], ["a", 50], ["major", 52], ["turning", 58], ["point", 66], ["in", 72], ["the", 75], ["treatment", 79], ["and", 89], ["outcome", 93], ["of", 101], ["the", 104], ["disease", 108], [".", 115], ["Throughout", 117], ["tumour", 128], ["development", 135], [",", 146], ["and", 148], ["especially", 152], ["in", 163], ["the", 166], ["development", 170], ["of", 182], ["metastasis", 185], [",", 195], ["epithelial", 197], ["mesenchymal", 208], ["transition", 220], ["takes", 231], ["place", 237], [".", 242], ["During", 244], ["this", 251], ["transformation", 256], ["into", 271], ["a", 276], ["mesenchymal", 278], ["phenotype", 290], [",", 299], ["the", 301], ["tumour", 305], ["cells", 312], ["undergo", 318], ["a", 326], ["series", 328], ["of", 335], ["structural", 338], ["changes", 349], [".", 356], ["The", 358], ["loss", 362], ["of", 367], ["structural", 370], ["integrity", 381], ["and", 391], ["adoption", 395], ["of", 404], ["mesenchymal", 407], ["filaments", 419], ["enables", 429], ["cells", 437], ["to", 443], ["detach", 446], ["from", 453], ["the", 458], ["epithelial", 462], ["cell", 473], ["layer", 478], ["and", 484], ["metastasise", 488], [".", 499], ["Keratins", 501], ["form", 510], ["the", 515], ["intermediate", 519], ["filaments", 532], ["of", 542], ["the", 545], ["cytoskeleton", 549], ["and", 562], ["provide", 566], ["scaffold", 574], ["structures", 583], ["within", 594], ["cells", 601], [".", 606], ["During", 608], ["cancer", 615], ["progression", 622], ["the", 634], ["intermediate", 638], ["filaments", 651], ["are", 661], ["reorganised", 665], [",", 676], ["and", 678], ["dramatic", 682], ["changes", 691], ["are", 699], ["seen", 703], ["in", 708], ["their", 711], ["protein", 717], ["components", 725], [".", 735], ["Keratins", 737], ["K8", 746], [",", 748], ["K18", 750], [",", 753], ["K19", 755], ["and", 759], ["vimentin", 763], ["are", 772], ["intermediate", 776], ["filament", 789], ["proteins", 798], ["with", 807], ["altered", 812], ["expression", 820], ["profiles", 831], ["during", 840], ["tumour", 847], ["development", 854], [".", 865], ["We", 867], ["have", 870], ["used", 875], ["in", 880], ["vivo", 883], ["and", 888], ["in", 892], ["vitro", 895], ["models", 901], ["to", 908], ["analyse", 911], ["changes", 919], ["in", 927], ["intermediate", 930], ["filament", 943], ["proteins", 952], [".", 960], ["Antibody", 962], ["-", 970], ["based", 971], ["methods", 977], ["were", 985], ["used", 990], ["to", 995], ["study", 998], ["K8", 1004], ["levels", 1007], ["and", 1014], ["proteomic", 1018], ["analysis", 1028], ["to", 1037], ["profile", 1040], ["the", 1048], ["protein", 1052], ["content", 1060], ["of", 1068], ["metastatic", 1071], ["breast", 1082], ["cancer", 1089], ["cell", 1096], ["variants", 1101], [".", 1109], ["K8", 1111], ["expression", 1114], ["declines", 1125], ["as", 1134], ["human", 1137], ["breast", 1143], ["tumours", 1150], ["progress", 1158], ["into", 1167], ["an", 1172], ["invasive", 1175], ["phenotype", 1184], [".", 1193], ["Analysis", 1195], ["of", 1204], ["IF", 1207], ["proteins", 1210], ["indicated", 1219], ["altered", 1229], ["expression", 1237], ["profiles", 1248], ["of", 1257], ["K8", 1260], [",", 1262], ["K18", 1264], [",", 1267], ["K19", 1269], ["and", 1273], ["vimentin", 1277], [",", 1285], ["with", 1287], ["K8", 1292], [",", 1294], ["K18", 1296], [",", 1299], ["K19", 1301], ["expressed", 1305], ["in", 1315], ["high", 1318], ["levels", 1323], ["in", 1330], ["the", 1333], ["T47D", 1337], ["and", 1342], ["MCF-7", 1346], ["cell", 1352], ["lines", 1357], [",", 1362], ["whereas", 1364], ["the", 1372], ["highly", 1376], ["metastatic", 1383], ["cell", 1394], ["lines", 1399], ["expressed", 1405], ["lower", 1415], ["levels", 1421], ["of", 1428], ["K8", 1431], ["and", 1434], ["K18", 1438], ["and", 1442], ["no", 1446], ["detectable", 1449], ["K19", 1460], [".", 1463], ["Vimentin", 1465], ["showed", 1474], ["reverse", 1481], ["expression", 1489], ["profile", 1500], ["with", 1508], ["T47D", 1513], ["and", 1518], ["MCF-7", 1522], ["cells", 1528], ["having", 1534], ["no", 1541], ["detectable", 1544], ["vimentin", 1555], ["expression", 1564], ["whereas", 1575], ["the", 1583], ["highly", 1587], ["metastatic", 1594], ["MDA", 1605], ["-", 1608], ["MB-231", 1609], ["and", 1616], ["MDA", 1620], ["-", 1623], ["MB-436", 1624], ["showed", 1631], ["high", 1638], ["levels", 1643], [".", 1649], ["Analysis", 1651], ["of", 1660], ["acetylation", 1663], ["status", 1675], ["using", 1682], ["specific", 1688], ["antibodies", 1697], ["suggested", 1708], ["acetylation", 1718], ["occurred", 1730], ["within", 1739], ["the", 1746], ["central", 1750], ["coiled", 1758], ["domain", 1765], ["in", 1772], ["the", 1775], ["MCF-7", 1779], ["and", 1785], ["T47D", 1789], ["cells", 1794], [".", 1799], ["Inhibition", 1801], ["of", 1812], ["tumour", 1815], ["growth", 1822], ["by", 1829], ["tissue", 1832], ["factor", 1839], ["(", 1846], ["TF", 1847], [")", 1849], ["shRNA", 1851], ["resulted", 1857], ["in", 1866], ["a", 1869], ["dramatic", 1871], ["re", 1880], ["-", 1882], ["elevation", 1883], ["of", 1893], ["expression", 1896], ["of", 1907], ["K8", 1910], ["in", 1913], ["xenographs", 1916], ["of", 1927], ["the", 1930], ["highly", 1934], ["metastatic", 1941], ["MDA", 1952], ["-", 1955], ["MB-436", 1956], ["line", 1963], [".", 1967], ["Intermediate", 1969], ["filament", 1982], ["expression", 1991], ["alters", 2002], ["during", 2009], ["epithelial", 2016], ["mesenchymal", 2027], ["transition", 2039], [".", 2049], ["Identified", 2051], ["post", 2062], ["translational", 2067], ["modifications", 2081], ["may", 2095], ["play", 2099], ["a", 2104], ["role", 2106], ["in", 2111], ["alterations", 2114], ["seen", 2126], ["in", 2131], ["the", 2134], ["organisation", 2138], [",", 2150], ["solubility", 2152], ["and", 2163], ["stability", 2167], ["of", 2177], ["these", 2180], ["filaments", 2186], [".", 2195], ["Epithelial", 2197], ["mesenchymal", 2208], ["transition", 2220], ["can", 2231], ["be", 2235], ["reversed", 2238], ["and", 2247], ["an", 2251], ["epithelial", 2254], ["phenotype", 2265], ["re", 2275], ["-", 2277], ["established", 2278], [".", 2289]]}
{"context": "A novel 135 kDa centrosomal component (Cep135) was identified by immunoscreening of a mammalian expression library with monoclonal antibodies raised against clam centrosomes. It is predicted to be a highly coiled-coil protein with an extensive alpha-helix, suggesting that Cep135 is a structural component of the centrosome. To evaluate how the protein is arranged in the centrosomal structure, we overexpressed Cep135 polypeptides in CHO cells by transient transfection. HA- or GFP-tagged full (amino acids 1-1144) as well as truncated (#10, 29-1144; Delta3, 29-812) polypeptides become localized at the centrosome and induce cytoplasmic dots of various size and number in CHO cells. Centrosomes are associated with massive approximately 7 nm filaments and dense particles organized in a whorl-like arrangement in which parallel-oriented dense lines appear with a regular approximately 7 nm periodicity. The same filamentous aggregates are also detected in cytoplasmic dots, indicating that overexpressed Cep135 can assemble into elaborate higher-ordered structures in and outside the centrosome. Sf9 cells infected with baculovirus containing Cep135 sequences induce filamentous polymers which are distinctive from the whorl seen in CHO cells; #10 forms highly packed spheroids, but the Delta3-containing structure looks loose. Both structures show an internal repeating unit of dense and less dense stripes. Although the distance between the outer end of two adjacent dense lines is similar between two types of polymers ( approximately 120 nm), the dense stripe of Delta3 polymers ( approximately 40 nm) is wider than #10 ( approximately 30 nm). The light band of Delta3 ( approximately 40 nm) is thus narrower than #10 ( approximately 60 nm). Since thin fibers are frequently seen to extend from one dense line to the next, the coiled-coil rod of Cep135 may span the light band. These results suggest that overexpressed Cep135 assemble into distinctive polymers in a domain-specific manner.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "62f547c5c52345068b263ed7bbd85032", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[190, 190], [53, 53], [114, 114]], "char_spans": [[1086, 1095], [313, 322], [605, 614]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["135", 8], ["kDa", 12], ["centrosomal", 16], ["component", 28], ["(", 38], ["Cep135", 39], [")", 45], ["was", 47], ["identified", 51], ["by", 62], ["immunoscreening", 65], ["of", 81], ["a", 84], ["mammalian", 86], ["expression", 96], ["library", 107], ["with", 115], ["monoclonal", 120], ["antibodies", 131], ["raised", 142], ["against", 149], ["clam", 157], ["centrosomes", 162], [".", 173], ["It", 175], ["is", 178], ["predicted", 181], ["to", 191], ["be", 194], ["a", 197], ["highly", 199], ["coiled", 206], ["-", 212], ["coil", 213], ["protein", 218], ["with", 226], ["an", 231], ["extensive", 234], ["alpha", 244], ["-", 249], ["helix", 250], [",", 255], ["suggesting", 257], ["that", 268], ["Cep135", 273], ["is", 280], ["a", 283], ["structural", 285], ["component", 296], ["of", 306], ["the", 309], ["centrosome", 313], [".", 323], ["To", 325], ["evaluate", 328], ["how", 337], ["the", 341], ["protein", 345], ["is", 353], ["arranged", 356], ["in", 365], ["the", 368], ["centrosomal", 372], ["structure", 384], [",", 393], ["we", 395], ["overexpressed", 398], ["Cep135", 412], ["polypeptides", 419], ["in", 432], ["CHO", 435], ["cells", 439], ["by", 445], ["transient", 448], ["transfection", 458], [".", 470], ["HA-", 472], ["or", 476], ["GFP", 479], ["-", 482], ["tagged", 483], ["full", 490], ["(", 495], ["amino", 496], ["acids", 502], ["1", 508], ["-", 509], ["1144", 510], [")", 514], ["as", 516], ["well", 519], ["as", 524], ["truncated", 527], ["(", 537], ["#", 538], ["10", 539], [",", 541], ["29", 543], ["-", 545], ["1144", 546], [";", 550], ["Delta3", 552], [",", 558], ["29", 560], ["-", 562], ["812", 563], [")", 566], ["polypeptides", 568], ["become", 581], ["localized", 588], ["at", 598], ["the", 601], ["centrosome", 605], ["and", 616], ["induce", 620], ["cytoplasmic", 627], ["dots", 639], ["of", 644], ["various", 647], ["size", 655], ["and", 660], ["number", 664], ["in", 671], ["CHO", 674], ["cells", 678], [".", 683], ["Centrosomes", 685], ["are", 697], ["associated", 701], ["with", 712], ["massive", 717], ["approximately", 725], ["7", 739], ["nm", 741], ["filaments", 744], ["and", 754], ["dense", 758], ["particles", 764], ["organized", 774], ["in", 784], ["a", 787], ["whorl", 789], ["-", 794], ["like", 795], ["arrangement", 800], ["in", 812], ["which", 815], ["parallel", 821], ["-", 829], ["oriented", 830], ["dense", 839], ["lines", 845], ["appear", 851], ["with", 858], ["a", 863], ["regular", 865], ["approximately", 873], ["7", 887], ["nm", 889], ["periodicity", 892], [".", 903], ["The", 905], ["same", 909], ["filamentous", 914], ["aggregates", 926], ["are", 937], ["also", 941], ["detected", 946], ["in", 955], ["cytoplasmic", 958], ["dots", 970], [",", 974], ["indicating", 976], ["that", 987], ["overexpressed", 992], ["Cep135", 1006], ["can", 1013], ["assemble", 1017], ["into", 1026], ["elaborate", 1031], ["higher", 1041], ["-", 1047], ["ordered", 1048], ["structures", 1056], ["in", 1067], ["and", 1070], ["outside", 1074], ["the", 1082], ["centrosome", 1086], [".", 1096], ["Sf9", 1098], ["cells", 1102], ["infected", 1108], ["with", 1117], ["baculovirus", 1122], ["containing", 1134], ["Cep135", 1145], ["sequences", 1152], ["induce", 1162], ["filamentous", 1169], ["polymers", 1181], ["which", 1190], ["are", 1196], ["distinctive", 1200], ["from", 1212], ["the", 1217], ["whorl", 1221], ["seen", 1227], ["in", 1232], ["CHO", 1235], ["cells", 1239], [";", 1244], ["#", 1246], ["10", 1247], ["forms", 1250], ["highly", 1256], ["packed", 1263], ["spheroids", 1270], [",", 1279], ["but", 1281], ["the", 1285], ["Delta3-containing", 1289], ["structure", 1307], ["looks", 1317], ["loose", 1323], [".", 1328], ["Both", 1330], ["structures", 1335], ["show", 1346], ["an", 1351], ["internal", 1354], ["repeating", 1363], ["unit", 1373], ["of", 1378], ["dense", 1381], ["and", 1387], ["less", 1391], ["dense", 1396], ["stripes", 1402], [".", 1409], ["Although", 1411], ["the", 1420], ["distance", 1424], ["between", 1433], ["the", 1441], ["outer", 1445], ["end", 1451], ["of", 1455], ["two", 1458], ["adjacent", 1462], ["dense", 1471], ["lines", 1477], ["is", 1483], ["similar", 1486], ["between", 1494], ["two", 1502], ["types", 1506], ["of", 1512], ["polymers", 1515], ["(", 1524], ["approximately", 1526], ["120", 1540], ["nm", 1544], [")", 1546], [",", 1547], ["the", 1549], ["dense", 1553], ["stripe", 1559], ["of", 1566], ["Delta3", 1569], ["polymers", 1576], ["(", 1585], ["approximately", 1587], ["40", 1601], ["nm", 1604], [")", 1606], ["is", 1608], ["wider", 1611], ["than", 1617], ["#", 1622], ["10", 1623], ["(", 1626], ["approximately", 1628], ["30", 1642], ["nm", 1645], [")", 1647], [".", 1648], ["The", 1650], ["light", 1654], ["band", 1660], ["of", 1665], ["Delta3", 1668], ["(", 1675], ["approximately", 1677], ["40", 1691], ["nm", 1694], [")", 1696], ["is", 1698], ["thus", 1701], ["narrower", 1706], ["than", 1715], ["#", 1720], ["10", 1721], ["(", 1724], ["approximately", 1726], ["60", 1740], ["nm", 1743], [")", 1745], [".", 1746], ["Since", 1748], ["thin", 1754], ["fibers", 1759], ["are", 1766], ["frequently", 1770], ["seen", 1781], ["to", 1786], ["extend", 1789], ["from", 1796], ["one", 1801], ["dense", 1805], ["line", 1811], ["to", 1816], ["the", 1819], ["next", 1823], [",", 1827], ["the", 1829], ["coiled", 1833], ["-", 1839], ["coil", 1840], ["rod", 1845], ["of", 1849], ["Cep135", 1852], ["may", 1859], ["span", 1863], ["the", 1868], ["light", 1872], ["band", 1878], [".", 1882], ["These", 1884], ["results", 1890], ["suggest", 1898], ["that", 1906], ["overexpressed", 1911], ["Cep135", 1925], ["assemble", 1932], ["into", 1941], ["distinctive", 1946], ["polymers", 1958], ["in", 1967], ["a", 1970], ["domain", 1972], ["-", 1978], ["specific", 1979], ["manner", 1988], [".", 1994]]}
{"context": "Spleen tyrosine kinase (Syk) is involved in the development of the adaptive immune system and has been recognized as being important in the function of additional cell types, including platelets, phagocytes, fibroblasts, and osteoclasts, and in the generation of the inflammasome. Preclinical studies presented compelling evidence that Syk inhibition may have therapeutic value in the treatment of rheumatoid arthritis and other forms of arthritis, systemic lupus erythematosus, autoimmune cytopenias, and allergic and autoinflammatory diseases. In addition, Syk inhibition may have a place in limiting tissue injury associated with organ transplant and revascularization procedures. Clinical trials have documented exciting success in the treatment of patients with rheumatoid arthritis, autoimmune cytopenias, and allergic rhinitis. While the extent and severity of side effects appear to be limited so far, larger studies will unravel the risk involved with the clinical benefit.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "4f5281fae53d4f948abc936704d3dab3", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["Syk", 24], [")", 27], ["is", 29], ["involved", 32], ["in", 41], ["the", 44], ["development", 48], ["of", 60], ["the", 63], ["adaptive", 67], ["immune", 76], ["system", 83], ["and", 90], ["has", 94], ["been", 98], ["recognized", 103], ["as", 114], ["being", 117], ["important", 123], ["in", 133], ["the", 136], ["function", 140], ["of", 149], ["additional", 152], ["cell", 163], ["types", 168], [",", 173], ["including", 175], ["platelets", 185], [",", 194], ["phagocytes", 196], [",", 206], ["fibroblasts", 208], [",", 219], ["and", 221], ["osteoclasts", 225], [",", 236], ["and", 238], ["in", 242], ["the", 245], ["generation", 249], ["of", 260], ["the", 263], ["inflammasome", 267], [".", 279], ["Preclinical", 281], ["studies", 293], ["presented", 301], ["compelling", 311], ["evidence", 322], ["that", 331], ["Syk", 336], ["inhibition", 340], ["may", 351], ["have", 355], ["therapeutic", 360], ["value", 372], ["in", 378], ["the", 381], ["treatment", 385], ["of", 395], ["rheumatoid", 398], ["arthritis", 409], ["and", 419], ["other", 423], ["forms", 429], ["of", 435], ["arthritis", 438], [",", 447], ["systemic", 449], ["lupus", 458], ["erythematosus", 464], [",", 477], ["autoimmune", 479], ["cytopenias", 490], [",", 500], ["and", 502], ["allergic", 506], ["and", 515], ["autoinflammatory", 519], ["diseases", 536], [".", 544], ["In", 546], ["addition", 549], [",", 557], ["Syk", 559], ["inhibition", 563], ["may", 574], ["have", 578], ["a", 583], ["place", 585], ["in", 591], ["limiting", 594], ["tissue", 603], ["injury", 610], ["associated", 617], ["with", 628], ["organ", 633], ["transplant", 639], ["and", 650], ["revascularization", 654], ["procedures", 672], [".", 682], ["Clinical", 684], ["trials", 693], ["have", 700], ["documented", 705], ["exciting", 716], ["success", 725], ["in", 733], ["the", 736], ["treatment", 740], ["of", 750], ["patients", 753], ["with", 762], ["rheumatoid", 767], ["arthritis", 778], [",", 787], ["autoimmune", 789], ["cytopenias", 800], [",", 810], ["and", 812], ["allergic", 816], ["rhinitis", 825], [".", 833], ["While", 835], ["the", 841], ["extent", 845], ["and", 852], ["severity", 856], ["of", 865], ["side", 868], ["effects", 873], ["appear", 881], ["to", 888], ["be", 891], ["limited", 894], ["so", 902], ["far", 905], [",", 908], ["larger", 910], ["studies", 917], ["will", 925], ["unravel", 930], ["the", 938], ["risk", 942], ["involved", 947], ["with", 956], ["the", 961], ["clinical", 965], ["benefit", 974], [".", 981]]}
{"context": "We evaluated the predictive value of serum biomarkers and various clinical risk scales for the 28-day mortality of community-acquired pneumonia (CAP). Serum biomarkers including procalcitonin (PCT) and C-reactive protein (CRP) were evaluated in the emergency department. Scores for the pneumonia severity index (PSI); CURB65 (confusion, urea, respiration, blood pressure; age >65\u2009years); Infectious Disease Society of America (IDSA) and American Thoracic Society (ATS) guidelines for severe CAP; Acute Physiology, Chronic Health Evaluation (APACHE) II; Sequential Organ Failure Assessment (SOFA); and quick SOFA (qSOFA) were calculated. Receiver-operating characteristic curves for 28-day mortality were calculated for each predictor using cut-off values, and we applied logistic regression models and area under the curve (AUC) analysis to compare the performance of predictors. Of the 125 enrolled patients, 13 died within 28\u2009days. The AUCs of the PCT and CRP were 0.83 and 0.77, respectively. Using a PCT level >5.6\u2009\u03bcg/L as the cut-off, the sensitivity and specificity for mortality were 76.9% and 90.2%, respectively. The three pneumonia severity scales showed an AUC of 0.86 (PSI), 0.87 (IDSA/ATS) and 0.77 (CURB65). The AUCs of the APACHE II, SOFA and qSOFA scores were 0.85, 0.83 and 0.81, respectively. The models combining CRP and/or PCT with PSI or the IDSA/ATS guidelines demonstrated superior performance to those of either PSI or the IDAS/ATS guidelines alone. In conclusion, serum PCT is a reliable single predictor for short-term mortality. Inclusion of CRP and/or PCT could significantly improve the performance of the PSI and IDAS/ATS guidelines.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "7c707712084d4ceda79cb8580017408e", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[21, 21], [51, 51], [222, 222]], "char_spans": [[134, 142], [286, 294], [1132, 1140]]}]}], "context_tokens": [["We", 0], ["evaluated", 3], ["the", 13], ["predictive", 17], ["value", 28], ["of", 34], ["serum", 37], ["biomarkers", 43], ["and", 54], ["various", 58], ["clinical", 66], ["risk", 75], ["scales", 80], ["for", 87], ["the", 91], ["28-day", 95], ["mortality", 102], ["of", 112], ["community", 115], ["-", 124], ["acquired", 125], ["pneumonia", 134], ["(", 144], ["CAP", 145], [")", 148], [".", 149], ["Serum", 151], ["biomarkers", 157], ["including", 168], ["procalcitonin", 178], ["(", 192], ["PCT", 193], [")", 196], ["and", 198], ["C", 202], ["-", 203], ["reactive", 204], ["protein", 213], ["(", 221], ["CRP", 222], [")", 225], ["were", 227], ["evaluated", 232], ["in", 242], ["the", 245], ["emergency", 249], ["department", 259], [".", 269], ["Scores", 271], ["for", 278], ["the", 282], ["pneumonia", 286], ["severity", 296], ["index", 305], ["(", 311], ["PSI", 312], [")", 315], [";", 316], ["CURB65", 318], ["(", 325], ["confusion", 326], [",", 335], ["urea", 337], [",", 341], ["respiration", 343], [",", 354], ["blood", 356], ["pressure", 362], [";", 370], ["age", 372], [">", 376], ["65", 377], ["years", 380], [")", 385], [";", 386], ["Infectious", 388], ["Disease", 399], ["Society", 407], ["of", 415], ["America", 418], ["(", 426], ["IDSA", 427], [")", 431], ["and", 433], ["American", 437], ["Thoracic", 446], ["Society", 455], ["(", 463], ["ATS", 464], [")", 467], ["guidelines", 469], ["for", 480], ["severe", 484], ["CAP", 491], [";", 494], ["Acute", 496], ["Physiology", 502], [",", 512], ["Chronic", 514], ["Health", 522], ["Evaluation", 529], ["(", 540], ["APACHE", 541], [")", 547], ["II", 549], [";", 551], ["Sequential", 553], ["Organ", 564], ["Failure", 570], ["Assessment", 578], ["(", 589], ["SOFA", 590], [")", 594], [";", 595], ["and", 597], ["quick", 601], ["SOFA", 607], ["(", 612], ["qSOFA", 613], [")", 618], ["were", 620], ["calculated", 625], [".", 635], ["Receiver", 637], ["-", 645], ["operating", 646], ["characteristic", 656], ["curves", 671], ["for", 678], ["28-day", 682], ["mortality", 689], ["were", 699], ["calculated", 704], ["for", 715], ["each", 719], ["predictor", 724], ["using", 734], ["cut", 740], ["-", 743], ["off", 744], ["values", 748], [",", 754], ["and", 756], ["we", 760], ["applied", 763], ["logistic", 771], ["regression", 780], ["models", 791], ["and", 798], ["area", 802], ["under", 807], ["the", 813], ["curve", 817], ["(", 823], ["AUC", 824], [")", 827], ["analysis", 829], ["to", 838], ["compare", 841], ["the", 849], ["performance", 853], ["of", 865], ["predictors", 868], [".", 878], ["Of", 880], ["the", 883], ["125", 887], ["enrolled", 891], ["patients", 900], [",", 908], ["13", 910], ["died", 913], ["within", 918], ["28", 925], ["days", 928], [".", 932], ["The", 934], ["AUCs", 938], ["of", 943], ["the", 946], ["PCT", 950], ["and", 954], ["CRP", 958], ["were", 962], ["0.83", 967], ["and", 972], ["0.77", 976], [",", 980], ["respectively", 982], [".", 994], ["Using", 996], ["a", 1002], ["PCT", 1004], ["level", 1008], [">", 1014], ["5.6", 1015], ["\u03bcg", 1019], ["/", 1021], ["L", 1022], ["as", 1024], ["the", 1027], ["cut", 1031], ["-", 1034], ["off", 1035], [",", 1038], ["the", 1040], ["sensitivity", 1044], ["and", 1056], ["specificity", 1060], ["for", 1072], ["mortality", 1076], ["were", 1086], ["76.9", 1091], ["%", 1095], ["and", 1097], ["90.2", 1101], ["%", 1105], [",", 1106], ["respectively", 1108], [".", 1120], ["The", 1122], ["three", 1126], ["pneumonia", 1132], ["severity", 1142], ["scales", 1151], ["showed", 1158], ["an", 1165], ["AUC", 1168], ["of", 1172], ["0.86", 1175], ["(", 1180], ["PSI", 1181], [")", 1184], [",", 1185], ["0.87", 1187], ["(", 1192], ["IDSA", 1193], ["/", 1197], ["ATS", 1198], [")", 1201], ["and", 1203], ["0.77", 1207], ["(", 1212], ["CURB65", 1213], [")", 1219], [".", 1220], ["The", 1222], ["AUCs", 1226], ["of", 1231], ["the", 1234], ["APACHE", 1238], ["II", 1245], [",", 1247], ["SOFA", 1249], ["and", 1254], ["qSOFA", 1258], ["scores", 1264], ["were", 1271], ["0.85", 1276], [",", 1280], ["0.83", 1282], ["and", 1287], ["0.81", 1291], [",", 1295], ["respectively", 1297], [".", 1309], ["The", 1311], ["models", 1315], ["combining", 1322], ["CRP", 1332], ["and/or", 1336], ["PCT", 1343], ["with", 1347], ["PSI", 1352], ["or", 1356], ["the", 1359], ["IDSA", 1363], ["/", 1367], ["ATS", 1368], ["guidelines", 1372], ["demonstrated", 1383], ["superior", 1396], ["performance", 1405], ["to", 1417], ["those", 1420], ["of", 1426], ["either", 1429], ["PSI", 1436], ["or", 1440], ["the", 1443], ["IDAS", 1447], ["/", 1451], ["ATS", 1452], ["guidelines", 1456], ["alone", 1467], [".", 1472], ["In", 1474], ["conclusion", 1477], [",", 1487], ["serum", 1489], ["PCT", 1495], ["is", 1499], ["a", 1502], ["reliable", 1504], ["single", 1513], ["predictor", 1520], ["for", 1530], ["short", 1534], ["-", 1539], ["term", 1540], ["mortality", 1545], [".", 1554], ["Inclusion", 1556], ["of", 1566], ["CRP", 1569], ["and/or", 1573], ["PCT", 1580], ["could", 1584], ["significantly", 1590], ["improve", 1604], ["the", 1612], ["performance", 1616], ["of", 1628], ["the", 1631], ["PSI", 1635], ["and", 1639], ["IDAS", 1643], ["/", 1647], ["ATS", 1648], ["guidelines", 1652], [".", 1662]]}
{"context": "The spleen tyrosine kinase (Syk) inhibitor R406 is orally administered as the prodrug R788. Following administration of R788 (12.5 mg kg(-1), 20 microCi kg(-1 14)C-R788) to intact and bile duct-cannulated cynomolgus monkeys, drug-related radioactivity was rapidly observed in plasma. No R788 was observed in plasma, while R406 was the major radioactive peak observed at all time points. Only low levels of metabolites were observed in plasma. The half-life for plasma radioactivity was 2.0-2.8 h. The majority (68.9%) of drug-related radioactivity was eliminated into bile. No intact R406 was observed in excreta. Biliary and urinary metabolites consisted of glucuronide and sulfate conjugates of the para-O-demethylated metabolite of R406 (R529), and a direct N-glucuronide of R406. The major metabolite in faeces from intact and bile duct-cannulated monkeys was a unique 3,5-benzene diol metabolite of R406. This metabolite was formed following the sequential O-demethylation and para-dehydroxylation of R529 by anaerobic gut bacteria.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "ea2c422448e642a6989d21e8c090f77a", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[1, 3]], "char_spans": [[4, 25]]}]}], "context_tokens": [["The", 0], ["spleen", 4], ["tyrosine", 11], ["kinase", 20], ["(", 27], ["Syk", 28], [")", 31], ["inhibitor", 33], ["R406", 43], ["is", 48], ["orally", 51], ["administered", 58], ["as", 71], ["the", 74], ["prodrug", 78], ["R788", 86], [".", 90], ["Following", 92], ["administration", 102], ["of", 117], ["R788", 120], ["(", 125], ["12.5", 126], ["mg", 131], ["kg(-1", 134], [")", 139], [",", 140], ["20", 142], ["microCi", 145], ["kg(-1", 153], ["14)C", 159], ["-", 163], ["R788", 164], [")", 168], ["to", 170], ["intact", 173], ["and", 180], ["bile", 184], ["duct", 189], ["-", 193], ["cannulated", 194], ["cynomolgus", 205], ["monkeys", 216], [",", 223], ["drug", 225], ["-", 229], ["related", 230], ["radioactivity", 238], ["was", 252], ["rapidly", 256], ["observed", 264], ["in", 273], ["plasma", 276], [".", 282], ["No", 284], ["R788", 287], ["was", 292], ["observed", 296], ["in", 305], ["plasma", 308], [",", 314], ["while", 316], ["R406", 322], ["was", 327], ["the", 331], ["major", 335], ["radioactive", 341], ["peak", 353], ["observed", 358], ["at", 367], ["all", 370], ["time", 374], ["points", 379], [".", 385], ["Only", 387], ["low", 392], ["levels", 396], ["of", 403], ["metabolites", 406], ["were", 418], ["observed", 423], ["in", 432], ["plasma", 435], [".", 441], ["The", 443], ["half", 447], ["-", 451], ["life", 452], ["for", 457], ["plasma", 461], ["radioactivity", 468], ["was", 482], ["2.0", 486], ["-", 489], ["2.8", 490], ["h.", 494], ["The", 497], ["majority", 501], ["(", 510], ["68.9", 511], ["%", 515], [")", 516], ["of", 518], ["drug", 521], ["-", 525], ["related", 526], ["radioactivity", 534], ["was", 548], ["eliminated", 552], ["into", 563], ["bile", 568], [".", 572], ["No", 574], ["intact", 577], ["R406", 584], ["was", 589], ["observed", 593], ["in", 602], ["excreta", 605], [".", 612], ["Biliary", 614], ["and", 622], ["urinary", 626], ["metabolites", 634], ["consisted", 646], ["of", 656], ["glucuronide", 659], ["and", 671], ["sulfate", 675], ["conjugates", 683], ["of", 694], ["the", 697], ["para", 701], ["-", 705], ["O", 706], ["-", 707], ["demethylated", 708], ["metabolite", 721], ["of", 732], ["R406", 735], ["(", 740], ["R529", 741], [")", 745], [",", 746], ["and", 748], ["a", 752], ["direct", 754], ["N", 761], ["-", 762], ["glucuronide", 763], ["of", 775], ["R406", 778], [".", 782], ["The", 784], ["major", 788], ["metabolite", 794], ["in", 805], ["faeces", 808], ["from", 815], ["intact", 820], ["and", 827], ["bile", 831], ["duct", 836], ["-", 840], ["cannulated", 841], ["monkeys", 852], ["was", 860], ["a", 864], ["unique", 866], ["3,5-benzene", 873], ["diol", 885], ["metabolite", 890], ["of", 901], ["R406", 904], [".", 908], ["This", 910], ["metabolite", 915], ["was", 926], ["formed", 930], ["following", 937], ["the", 947], ["sequential", 951], ["O", 962], ["-", 963], ["demethylation", 964], ["and", 978], ["para", 982], ["-", 986], ["dehydroxylation", 987], ["of", 1003], ["R529", 1006], ["by", 1011], ["anaerobic", 1014], ["gut", 1024], ["bacteria", 1028], [".", 1036]]}
{"context": "The literature is divided as to the necessity of an intact posterior cruciate ligament for functional stability. Presented here is a prospective study of isolated posterior cruciate injuries seen in the acute stage in 13 patients, 6 males and 7 females. The diagnosis of posterior cruciate ligament tear was made clinically and confirmed by arthroscopy. The average age at injury was 22 years. The athletic activity at injury was varied. Hyperflexion was the most common mechanism of injury, followed by pretibial trauma in the hyperflexed knee or in the \"dashboard\" injury. There were seven complete midsubstance tears and five partial tears. Direct visualization of the posterior cruciate ligament was not attained in one patient. All patients were treated nonoperatively on a physiotherapy routine. Average followup was 2.6 years. Patients were clinically examined and subjected to KT-1000 and Cybex testing. All patients were able to return to their previous activity and experienced no limitations with their injured knees. Using Hughston's criteria, subjective and functional ratings were all good. However, only 3 rated good and 10 fair when assessed objectively. We conclude that acceptable functional stability in these patients does not necessarily require absolute static stability. Nonoperative treatment of the isolated posterior cruciate ligament midsubstance injury may be a viable alternative to the difficult repair/reconstruction procedure.", "qas": [{"question": "Which ligament is most commonly injured in dashboard injury?", "answers": ["Posterior cruciate ligament"], "qid": "227ac45c39224b96946662810578c154", "question_tokens": [["Which", 0], ["ligament", 6], ["is", 15], ["most", 18], ["commonly", 23], ["injured", 32], ["in", 40], ["dashboard", 43], ["injury", 53], ["?", 59]], "detected_answers": [{"text": "Posterior cruciate ligament", "token_spans": [[47, 49], [221, 223], [116, 118], [11, 13]], "char_spans": [[271, 297], [1333, 1359], [672, 698], [59, 85]]}]}], "context_tokens": [["The", 0], ["literature", 4], ["is", 15], ["divided", 18], ["as", 26], ["to", 29], ["the", 32], ["necessity", 36], ["of", 46], ["an", 49], ["intact", 52], ["posterior", 59], ["cruciate", 69], ["ligament", 78], ["for", 87], ["functional", 91], ["stability", 102], [".", 111], ["Presented", 113], ["here", 123], ["is", 128], ["a", 131], ["prospective", 133], ["study", 145], ["of", 151], ["isolated", 154], ["posterior", 163], ["cruciate", 173], ["injuries", 182], ["seen", 191], ["in", 196], ["the", 199], ["acute", 203], ["stage", 209], ["in", 215], ["13", 218], ["patients", 221], [",", 229], ["6", 231], ["males", 233], ["and", 239], ["7", 243], ["females", 245], [".", 252], ["The", 254], ["diagnosis", 258], ["of", 268], ["posterior", 271], ["cruciate", 281], ["ligament", 290], ["tear", 299], ["was", 304], ["made", 308], ["clinically", 313], ["and", 324], ["confirmed", 328], ["by", 338], ["arthroscopy", 341], [".", 352], ["The", 354], ["average", 358], ["age", 366], ["at", 370], ["injury", 373], ["was", 380], ["22", 384], ["years", 387], [".", 392], ["The", 394], ["athletic", 398], ["activity", 407], ["at", 416], ["injury", 419], ["was", 426], ["varied", 430], [".", 436], ["Hyperflexion", 438], ["was", 451], ["the", 455], ["most", 459], ["common", 464], ["mechanism", 471], ["of", 481], ["injury", 484], [",", 490], ["followed", 492], ["by", 501], ["pretibial", 504], ["trauma", 514], ["in", 521], ["the", 524], ["hyperflexed", 528], ["knee", 540], ["or", 545], ["in", 548], ["the", 551], ["\"", 555], ["dashboard", 556], ["\"", 565], ["injury", 567], [".", 573], ["There", 575], ["were", 581], ["seven", 586], ["complete", 592], ["midsubstance", 601], ["tears", 614], ["and", 620], ["five", 624], ["partial", 629], ["tears", 637], [".", 642], ["Direct", 644], ["visualization", 651], ["of", 665], ["the", 668], ["posterior", 672], ["cruciate", 682], ["ligament", 691], ["was", 700], ["not", 704], ["attained", 708], ["in", 717], ["one", 720], ["patient", 724], [".", 731], ["All", 733], ["patients", 737], ["were", 746], ["treated", 751], ["nonoperatively", 759], ["on", 774], ["a", 777], ["physiotherapy", 779], ["routine", 793], [".", 800], ["Average", 802], ["followup", 810], ["was", 819], ["2.6", 823], ["years", 827], [".", 832], ["Patients", 834], ["were", 843], ["clinically", 848], ["examined", 859], ["and", 868], ["subjected", 872], ["to", 882], ["KT-1000", 885], ["and", 893], ["Cybex", 897], ["testing", 903], [".", 910], ["All", 912], ["patients", 916], ["were", 925], ["able", 930], ["to", 935], ["return", 938], ["to", 945], ["their", 948], ["previous", 954], ["activity", 963], ["and", 972], ["experienced", 976], ["no", 988], ["limitations", 991], ["with", 1003], ["their", 1008], ["injured", 1014], ["knees", 1022], [".", 1027], ["Using", 1029], ["Hughston", 1035], ["'s", 1043], ["criteria", 1046], [",", 1054], ["subjective", 1056], ["and", 1067], ["functional", 1071], ["ratings", 1082], ["were", 1090], ["all", 1095], ["good", 1099], [".", 1103], ["However", 1105], [",", 1112], ["only", 1114], ["3", 1119], ["rated", 1121], ["good", 1127], ["and", 1132], ["10", 1136], ["fair", 1139], ["when", 1144], ["assessed", 1149], ["objectively", 1158], [".", 1169], ["We", 1171], ["conclude", 1174], ["that", 1183], ["acceptable", 1188], ["functional", 1199], ["stability", 1210], ["in", 1220], ["these", 1223], ["patients", 1229], ["does", 1238], ["not", 1243], ["necessarily", 1247], ["require", 1259], ["absolute", 1267], ["static", 1276], ["stability", 1283], [".", 1292], ["Nonoperative", 1294], ["treatment", 1307], ["of", 1317], ["the", 1320], ["isolated", 1324], ["posterior", 1333], ["cruciate", 1343], ["ligament", 1352], ["midsubstance", 1361], ["injury", 1374], ["may", 1381], ["be", 1385], ["a", 1388], ["viable", 1390], ["alternative", 1397], ["to", 1409], ["the", 1412], ["difficult", 1416], ["repair", 1426], ["/", 1432], ["reconstruction", 1433], ["procedure", 1448], [".", 1457]]}
{"context": "Chediak-Higashi syndrome (CHS) is a rare multiorgan disease entity with autosomal recessive inheritance characterized by oculocutaneous albinism, bleeding tendency, recurrent bacterial infections and various neurological symptoms. Intracellular vesicle formation is deficient, resulting in giant granules in many cells, e.g. giant melanosomes in the melanocytes. Diagnosis has been based on morphological examination of peripheral blood and bone marrow, with giant granules seen in cells of the myeloid lineage and in lymphocytes. The ultimate diagnostic test is to look for a mutated LYST gene. Most patients develop an accelerated phase of the disease with deposition of lymphohistiocytes in the liver, spleen, lymph nodes and bone marrow, resulting in hepatosplenomegaly, bone marrow infiltration and haemophagocytosis. Peripheral blood neutropenia becomes more profound as anaemia and thrombocytopenia develop. Most patients succumb before the age of 10 years. Four patients with CHS are described, one of whom is a long-term survivor after successful allogeneic bone marrow transplantation, two succumbed during the accelerated phase and one is living with a chronic form of the disease. Allogeneic bone marrow transplantation from an HLA-matched sibling is the therapy of choice and should be performed early. If there is no matched family donor, an unrelated donor or a placental blood graft is a good alternative. The clinical picture of CHS is heterogeneous and therapeutic decisions need to be made on an individual basis.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "9d193028d5e04fa68360de77146992cd", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[92, 93]], "char_spans": [[585, 593]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["multiorgan", 41], ["disease", 52], ["entity", 60], ["with", 67], ["autosomal", 72], ["recessive", 82], ["inheritance", 92], ["characterized", 104], ["by", 118], ["oculocutaneous", 121], ["albinism", 136], [",", 144], ["bleeding", 146], ["tendency", 155], [",", 163], ["recurrent", 165], ["bacterial", 175], ["infections", 185], ["and", 196], ["various", 200], ["neurological", 208], ["symptoms", 221], [".", 229], ["Intracellular", 231], ["vesicle", 245], ["formation", 253], ["is", 263], ["deficient", 266], [",", 275], ["resulting", 277], ["in", 287], ["giant", 290], ["granules", 296], ["in", 305], ["many", 308], ["cells", 313], [",", 318], ["e.g.", 320], ["giant", 325], ["melanosomes", 331], ["in", 343], ["the", 346], ["melanocytes", 350], [".", 361], ["Diagnosis", 363], ["has", 373], ["been", 377], ["based", 382], ["on", 388], ["morphological", 391], ["examination", 405], ["of", 417], ["peripheral", 420], ["blood", 431], ["and", 437], ["bone", 441], ["marrow", 446], [",", 452], ["with", 454], ["giant", 459], ["granules", 465], ["seen", 474], ["in", 479], ["cells", 482], ["of", 488], ["the", 491], ["myeloid", 495], ["lineage", 503], ["and", 511], ["in", 515], ["lymphocytes", 518], [".", 529], ["The", 531], ["ultimate", 535], ["diagnostic", 544], ["test", 555], ["is", 560], ["to", 563], ["look", 566], ["for", 571], ["a", 575], ["mutated", 577], ["LYST", 585], ["gene", 590], [".", 594], ["Most", 596], ["patients", 601], ["develop", 610], ["an", 618], ["accelerated", 621], ["phase", 633], ["of", 639], ["the", 642], ["disease", 646], ["with", 654], ["deposition", 659], ["of", 670], ["lymphohistiocytes", 673], ["in", 691], ["the", 694], ["liver", 698], [",", 703], ["spleen", 705], [",", 711], ["lymph", 713], ["nodes", 719], ["and", 725], ["bone", 729], ["marrow", 734], [",", 740], ["resulting", 742], ["in", 752], ["hepatosplenomegaly", 755], [",", 773], ["bone", 775], ["marrow", 780], ["infiltration", 787], ["and", 800], ["haemophagocytosis", 804], [".", 821], ["Peripheral", 823], ["blood", 834], ["neutropenia", 840], ["becomes", 852], ["more", 860], ["profound", 865], ["as", 874], ["anaemia", 877], ["and", 885], ["thrombocytopenia", 889], ["develop", 906], [".", 913], ["Most", 915], ["patients", 920], ["succumb", 929], ["before", 937], ["the", 944], ["age", 948], ["of", 952], ["10", 955], ["years", 958], [".", 963], ["Four", 965], ["patients", 970], ["with", 979], ["CHS", 984], ["are", 988], ["described", 992], [",", 1001], ["one", 1003], ["of", 1007], ["whom", 1010], ["is", 1015], ["a", 1018], ["long", 1020], ["-", 1024], ["term", 1025], ["survivor", 1030], ["after", 1039], ["successful", 1045], ["allogeneic", 1056], ["bone", 1067], ["marrow", 1072], ["transplantation", 1079], [",", 1094], ["two", 1096], ["succumbed", 1100], ["during", 1110], ["the", 1117], ["accelerated", 1121], ["phase", 1133], ["and", 1139], ["one", 1143], ["is", 1147], ["living", 1150], ["with", 1157], ["a", 1162], ["chronic", 1164], ["form", 1172], ["of", 1177], ["the", 1180], ["disease", 1184], [".", 1191], ["Allogeneic", 1193], ["bone", 1204], ["marrow", 1209], ["transplantation", 1216], ["from", 1232], ["an", 1237], ["HLA", 1240], ["-", 1243], ["matched", 1244], ["sibling", 1252], ["is", 1260], ["the", 1263], ["therapy", 1267], ["of", 1275], ["choice", 1278], ["and", 1285], ["should", 1289], ["be", 1296], ["performed", 1299], ["early", 1309], [".", 1314], ["If", 1316], ["there", 1319], ["is", 1325], ["no", 1328], ["matched", 1331], ["family", 1339], ["donor", 1346], [",", 1351], ["an", 1353], ["unrelated", 1356], ["donor", 1366], ["or", 1372], ["a", 1375], ["placental", 1377], ["blood", 1387], ["graft", 1393], ["is", 1399], ["a", 1402], ["good", 1404], ["alternative", 1409], [".", 1420], ["The", 1422], ["clinical", 1426], ["picture", 1435], ["of", 1443], ["CHS", 1446], ["is", 1450], ["heterogeneous", 1453], ["and", 1467], ["therapeutic", 1471], ["decisions", 1483], ["need", 1493], ["to", 1498], ["be", 1501], ["made", 1504], ["on", 1509], ["an", 1512], ["individual", 1515], ["basis", 1526], [".", 1531]]}
{"context": "Alpha-synuclein forms the major component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies. Here we show that alpha-synuclein is also the major component of the filamentous inclusions of multiple system atrophy which comprises several neurodegenerative diseases with a shared filamentous pathology in nerve cells and glial cells. These findings provide an unexpected link between multiple system atrophy and Lewy body disorders and establish that alpha-synucleinopathies constitute a major class of human neurodegenerative disorder.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a4da3f3b9ad440b69aaf79b7d6f6f893", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2], [32, 34]], "char_spans": [[0, 14], [195, 209]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["forms", 16], ["the", 22], ["major", 26], ["component", 32], ["of", 42], ["Lewy", 45], ["bodies", 50], ["and", 57], ["Lewy", 61], ["neurites", 66], [",", 74], ["the", 76], ["defining", 80], ["neuropathological", 89], ["characteristics", 107], ["of", 123], ["Parkinson", 126], ["'s", 135], ["disease", 138], ["and", 146], ["dementia", 150], ["with", 159], ["Lewy", 164], ["bodies", 169], [".", 175], ["Here", 177], ["we", 182], ["show", 185], ["that", 190], ["alpha", 195], ["-", 200], ["synuclein", 201], ["is", 211], ["also", 214], ["the", 219], ["major", 223], ["component", 229], ["of", 239], ["the", 242], ["filamentous", 246], ["inclusions", 258], ["of", 269], ["multiple", 272], ["system", 281], ["atrophy", 288], ["which", 296], ["comprises", 302], ["several", 312], ["neurodegenerative", 320], ["diseases", 338], ["with", 347], ["a", 352], ["shared", 354], ["filamentous", 361], ["pathology", 373], ["in", 383], ["nerve", 386], ["cells", 392], ["and", 398], ["glial", 402], ["cells", 408], [".", 413], ["These", 415], ["findings", 421], ["provide", 430], ["an", 438], ["unexpected", 441], ["link", 452], ["between", 457], ["multiple", 465], ["system", 474], ["atrophy", 481], ["and", 489], ["Lewy", 493], ["body", 498], ["disorders", 503], ["and", 513], ["establish", 517], ["that", 527], ["alpha", 532], ["-", 537], ["synucleinopathies", 538], ["constitute", 556], ["a", 567], ["major", 569], ["class", 575], ["of", 581], ["human", 584], ["neurodegenerative", 590], ["disorder", 608], [".", 616]]}
{"context": "Chronic myeloid leukaemia (CML) is a genetically associated malignancy of haematopoietic stem cells, characterized by a t(9;22) translocation that forms the Philadelphia chromosome and creates a novel fusion gene, BCR-ABL. Treatment with molecular-targeted therapy is usually initiated with imatinib, an inhibitor of BCR-ABL tyrosine kinase. Imatinib resistance is, however, observed in some CML patients, especially in those with advanced disease. Through computerized literature searches, a systematic analysis was conducted to examine the efficacy and benefits of dasatinib therapy for imatinib resistant or intolerant CML patients in the chronic phase (CP), accelerated phase (AP) and fatal blast crisis phase (BC). In terms of major haematological and cytogenetic responses, this meta-analysis showed no significant differences in dasatinib treatment between myeloid BC-CML and lymphoid BC-CML patients with imatinib resistance or intolerance. Dasatinib therapy was, however, significantly more effective in improving major haematological and cytogenetic responses for CP-CML patients than for AP-CML patients with imatinib resistance or intolerance.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "4039d749db1e402c81b273c51d21f59b", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[53, 55], [34, 36]], "char_spans": [[317, 323], [214, 220]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukaemia", 16], ["(", 26], ["CML", 27], [")", 30], ["is", 32], ["a", 35], ["genetically", 37], ["associated", 49], ["malignancy", 60], ["of", 71], ["haematopoietic", 74], ["stem", 89], ["cells", 94], [",", 99], ["characterized", 101], ["by", 115], ["a", 118], ["t(9;22", 120], [")", 126], ["translocation", 128], ["that", 142], ["forms", 147], ["the", 153], ["Philadelphia", 157], ["chromosome", 170], ["and", 181], ["creates", 185], ["a", 193], ["novel", 195], ["fusion", 201], ["gene", 208], [",", 212], ["BCR", 214], ["-", 217], ["ABL", 218], [".", 221], ["Treatment", 223], ["with", 233], ["molecular", 238], ["-", 247], ["targeted", 248], ["therapy", 257], ["is", 265], ["usually", 268], ["initiated", 276], ["with", 286], ["imatinib", 291], [",", 299], ["an", 301], ["inhibitor", 304], ["of", 314], ["BCR", 317], ["-", 320], ["ABL", 321], ["tyrosine", 325], ["kinase", 334], [".", 340], ["Imatinib", 342], ["resistance", 351], ["is", 362], [",", 364], ["however", 366], [",", 373], ["observed", 375], ["in", 384], ["some", 387], ["CML", 392], ["patients", 396], [",", 404], ["especially", 406], ["in", 417], ["those", 420], ["with", 426], ["advanced", 431], ["disease", 440], [".", 447], ["Through", 449], ["computerized", 457], ["literature", 470], ["searches", 481], [",", 489], ["a", 491], ["systematic", 493], ["analysis", 504], ["was", 513], ["conducted", 517], ["to", 527], ["examine", 530], ["the", 538], ["efficacy", 542], ["and", 551], ["benefits", 555], ["of", 564], ["dasatinib", 567], ["therapy", 577], ["for", 585], ["imatinib", 589], ["resistant", 598], ["or", 608], ["intolerant", 611], ["CML", 622], ["patients", 626], ["in", 635], ["the", 638], ["chronic", 642], ["phase", 650], ["(", 656], ["CP", 657], [")", 659], [",", 660], ["accelerated", 662], ["phase", 674], ["(", 680], ["AP", 681], [")", 683], ["and", 685], ["fatal", 689], ["blast", 695], ["crisis", 701], ["phase", 708], ["(", 714], ["BC", 715], [")", 717], [".", 718], ["In", 720], ["terms", 723], ["of", 729], ["major", 732], ["haematological", 738], ["and", 753], ["cytogenetic", 757], ["responses", 769], [",", 778], ["this", 780], ["meta", 785], ["-", 789], ["analysis", 790], ["showed", 799], ["no", 806], ["significant", 809], ["differences", 821], ["in", 833], ["dasatinib", 836], ["treatment", 846], ["between", 856], ["myeloid", 864], ["BC", 872], ["-", 874], ["CML", 875], ["and", 879], ["lymphoid", 883], ["BC", 892], ["-", 894], ["CML", 895], ["patients", 899], ["with", 908], ["imatinib", 913], ["resistance", 922], ["or", 933], ["intolerance", 936], [".", 947], ["Dasatinib", 949], ["therapy", 959], ["was", 967], [",", 970], ["however", 972], [",", 979], ["significantly", 981], ["more", 995], ["effective", 1000], ["in", 1010], ["improving", 1013], ["major", 1023], ["haematological", 1029], ["and", 1044], ["cytogenetic", 1048], ["responses", 1060], ["for", 1070], ["CP", 1074], ["-", 1076], ["CML", 1077], ["patients", 1081], ["than", 1090], ["for", 1095], ["AP", 1099], ["-", 1101], ["CML", 1102], ["patients", 1106], ["with", 1115], ["imatinib", 1120], ["resistance", 1129], ["or", 1140], ["intolerance", 1143], [".", 1154]]}
{"context": "Willis-Ekbom disease/restless legs syndrome (WED/RLS) seems to be a frequent cause of intractable chronic insomnia (ICI) but is under-recognized in children/adolescents with neurodevelopmental conditions (NDCs), as many patients do not have the ability to express the underlying \"urge-to-move\". In light of this, we aim to develop a protocol for behavioral observations supporting the diagnosis of WED/RLS. We investigated 26 pediatric patients (age 1-16 years, median 8) with NDCs, ICI and evidence of familial WED/RLS employing (1) \"emplotted narratives\" for description of the various \"urge-to-move\" presentations and (2) self-description and \"behavioral observations\" during a \"suggested clinical immobilization test\" (SCIT). Parental narratives reflected typical WED/RLS-related \"urge-to-move\" symptoms during day-, bed-, and nighttime in all patients. Fifteen out of 26 patients could describe the \"urge-to-move\" during the SCIT. Ten out of 26 patients, unable to describe their symptoms due to cognitive disabilities, showed patterns of \"relieving-movements\" upon observation. Sensory processing abnormalities were reported in all patients, with tactile sensitivities (26/26) (including shifted pain threshold) as the most common sensory domain. \"Emplotted narratives\" and structured \"behavioral observations\" support recognition of familial WED/RLS associated movement patterns and provide a useful tool for the diagnosis of WED/RLS in children with NDCs in a clinical office setting.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "b7c3669e630a465892c5b64dbd7a9d82", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[5, 7]], "char_spans": [[21, 42]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["/", 20], ["restless", 21], ["legs", 30], ["syndrome", 35], ["(", 44], ["WED", 45], ["/", 48], ["RLS", 49], [")", 52], ["seems", 54], ["to", 60], ["be", 63], ["a", 66], ["frequent", 68], ["cause", 77], ["of", 83], ["intractable", 86], ["chronic", 98], ["insomnia", 106], ["(", 115], ["ICI", 116], [")", 119], ["but", 121], ["is", 125], ["under", 128], ["-", 133], ["recognized", 134], ["in", 145], ["children", 148], ["/", 156], ["adolescents", 157], ["with", 169], ["neurodevelopmental", 174], ["conditions", 193], ["(", 204], ["NDCs", 205], [")", 209], [",", 210], ["as", 212], ["many", 215], ["patients", 220], ["do", 229], ["not", 232], ["have", 236], ["the", 241], ["ability", 245], ["to", 253], ["express", 256], ["the", 264], ["underlying", 268], ["\"", 279], ["urge", 280], ["-", 284], ["to", 285], ["-", 287], ["move", 288], ["\"", 292], [".", 293], ["In", 295], ["light", 298], ["of", 304], ["this", 307], [",", 311], ["we", 313], ["aim", 316], ["to", 320], ["develop", 323], ["a", 331], ["protocol", 333], ["for", 342], ["behavioral", 346], ["observations", 357], ["supporting", 370], ["the", 381], ["diagnosis", 385], ["of", 395], ["WED", 398], ["/", 401], ["RLS", 402], [".", 405], ["We", 407], ["investigated", 410], ["26", 423], ["pediatric", 426], ["patients", 436], ["(", 445], ["age", 446], ["1", 450], ["-", 451], ["16", 452], ["years", 455], [",", 460], ["median", 462], ["8)", 469], ["with", 472], ["NDCs", 477], [",", 481], ["ICI", 483], ["and", 487], ["evidence", 491], ["of", 500], ["familial", 503], ["WED", 512], ["/", 515], ["RLS", 516], ["employing", 520], ["(", 530], ["1", 531], [")", 532], ["\"", 534], ["emplotted", 535], ["narratives", 545], ["\"", 555], ["for", 557], ["description", 561], ["of", 573], ["the", 576], ["various", 580], ["\"", 588], ["urge", 589], ["-", 593], ["to", 594], ["-", 596], ["move", 597], ["\"", 601], ["presentations", 603], ["and", 617], ["(", 621], ["2", 622], [")", 623], ["self", 625], ["-", 629], ["description", 630], ["and", 642], ["\"", 646], ["behavioral", 647], ["observations", 658], ["\"", 670], ["during", 672], ["a", 679], ["\"", 681], ["suggested", 682], ["clinical", 692], ["immobilization", 701], ["test", 716], ["\"", 720], ["(", 722], ["SCIT", 723], [")", 727], [".", 728], ["Parental", 730], ["narratives", 739], ["reflected", 750], ["typical", 760], ["WED", 768], ["/", 771], ["RLS", 772], ["-", 775], ["related", 776], ["\"", 784], ["urge", 785], ["-", 789], ["to", 790], ["-", 792], ["move", 793], ["\"", 797], ["symptoms", 799], ["during", 808], ["day-", 815], [",", 819], ["bed-", 821], [",", 825], ["and", 827], ["nighttime", 831], ["in", 841], ["all", 844], ["patients", 848], [".", 856], ["Fifteen", 858], ["out", 866], ["of", 870], ["26", 873], ["patients", 876], ["could", 885], ["describe", 891], ["the", 900], ["\"", 904], ["urge", 905], ["-", 909], ["to", 910], ["-", 912], ["move", 913], ["\"", 917], ["during", 919], ["the", 926], ["SCIT", 930], [".", 934], ["Ten", 936], ["out", 940], ["of", 944], ["26", 947], ["patients", 950], [",", 958], ["unable", 960], ["to", 967], ["describe", 970], ["their", 979], ["symptoms", 985], ["due", 994], ["to", 998], ["cognitive", 1001], ["disabilities", 1011], [",", 1023], ["showed", 1025], ["patterns", 1032], ["of", 1041], ["\"", 1044], ["relieving", 1045], ["-", 1054], ["movements", 1055], ["\"", 1064], ["upon", 1066], ["observation", 1071], [".", 1082], ["Sensory", 1084], ["processing", 1092], ["abnormalities", 1103], ["were", 1117], ["reported", 1122], ["in", 1131], ["all", 1134], ["patients", 1138], [",", 1146], ["with", 1148], ["tactile", 1153], ["sensitivities", 1161], ["(", 1175], ["26/26", 1176], [")", 1181], ["(", 1183], ["including", 1184], ["shifted", 1194], ["pain", 1202], ["threshold", 1207], [")", 1216], ["as", 1218], ["the", 1221], ["most", 1225], ["common", 1230], ["sensory", 1237], ["domain", 1245], [".", 1251], ["\"", 1253], ["Emplotted", 1254], ["narratives", 1264], ["\"", 1274], ["and", 1276], ["structured", 1280], ["\"", 1291], ["behavioral", 1292], ["observations", 1303], ["\"", 1315], ["support", 1317], ["recognition", 1325], ["of", 1337], ["familial", 1340], ["WED", 1349], ["/", 1352], ["RLS", 1353], ["associated", 1357], ["movement", 1368], ["patterns", 1377], ["and", 1386], ["provide", 1390], ["a", 1398], ["useful", 1400], ["tool", 1407], ["for", 1412], ["the", 1416], ["diagnosis", 1420], ["of", 1430], ["WED", 1433], ["/", 1436], ["RLS", 1437], ["in", 1441], ["children", 1444], ["with", 1453], ["NDCs", 1458], ["in", 1463], ["a", 1466], ["clinical", 1468], ["office", 1477], ["setting", 1484], [".", 1491]]}
{"context": "Mutations in the amyloid precursor protein gene were the first to be recognized as a cause of Alzheimer's disease (AD). We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile), known as London mutation. In 1 family, this mutation was responsible for AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far. Two subjects of the other family with AD diagnosis were carriers of the same mutation. All AD subjects showed a cognitive profile characterized by early impairment in long-term memory, shifting abilities and affective symptoms beginning in the fifth decade of life.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "f9dd23b8836640968364324126b3087b", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[17, 19]], "char_spans": [[94, 112]]}, {"text": "AD", "token_spans": [[107, 107], [63, 63], [21, 21], [97, 97]], "char_spans": [[551, 552], [333, 334], [115, 116], [498, 499]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["amyloid", 17], ["precursor", 25], ["protein", 35], ["gene", 43], ["were", 48], ["the", 53], ["first", 57], ["to", 63], ["be", 66], ["recognized", 69], ["as", 80], ["a", 83], ["cause", 85], ["of", 91], ["Alzheimer", 94], ["'s", 103], ["disease", 106], ["(", 114], ["AD", 115], [")", 117], [".", 118], ["We", 120], ["describe", 123], ["2", 132], ["Italian", 134], ["families", 142], ["showing", 151], ["the", 159], ["missense", 163], ["mutation", 172], ["in", 181], ["exon", 184], ["17", 189], ["of", 192], ["the", 195], ["amyloid", 199], ["precursor", 207], ["protein", 217], ["gene", 225], ["on", 230], ["chromosome", 233], ["21", 244], ["(", 247], ["Val717Ile", 248], [")", 257], [",", 258], ["known", 260], ["as", 266], ["London", 269], ["mutation", 276], [".", 284], ["In", 286], ["1", 289], ["family", 291], [",", 297], ["this", 299], ["mutation", 304], ["was", 313], ["responsible", 317], ["for", 329], ["AD", 333], ["in", 336], ["3", 339], ["out", 341], ["of", 345], ["7", 348], ["siblings", 350], ["and", 359], ["it", 363], ["is", 366], ["also", 369], ["present", 374], ["in", 382], ["a", 385], ["fourth", 387], ["sibling", 394], ["who", 402], ["has", 406], ["only", 410], ["shown", 415], ["signs", 421], ["of", 427], ["executive", 430], ["dysfunction", 440], ["so", 452], ["far", 455], [".", 458], ["Two", 460], ["subjects", 464], ["of", 473], ["the", 476], ["other", 480], ["family", 486], ["with", 493], ["AD", 498], ["diagnosis", 501], ["were", 511], ["carriers", 516], ["of", 525], ["the", 528], ["same", 532], ["mutation", 537], [".", 545], ["All", 547], ["AD", 551], ["subjects", 554], ["showed", 563], ["a", 570], ["cognitive", 572], ["profile", 582], ["characterized", 590], ["by", 604], ["early", 607], ["impairment", 613], ["in", 624], ["long", 627], ["-", 631], ["term", 632], ["memory", 637], [",", 643], ["shifting", 645], ["abilities", 654], ["and", 664], ["affective", 668], ["symptoms", 678], ["beginning", 687], ["in", 697], ["the", 700], ["fifth", 704], ["decade", 710], ["of", 717], ["life", 720], [".", 724]]}
{"context": "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is triggered by constitutively activated BCR-ABL and SRC family tyrosine kinases.They account for the activations of multiple growth-signaling pathways, including Raf/MEK/ERK, Akt/mTOR and STAT5 pathways. The BCR-ABL tyrosine kinase inhibitor imatinib is the standard treatment for Ph+ leukemia and plays efficacious role in CML. However, imatinib has few inhibitory effects on SRC tyrosine kinase with response rate of Ph+ ALL lower and relapse more frequent and quicker compared with CML. Previous studies showed that oridonin inhibits proliferation and induces apoptosis in many tumor cells. However, the anticancer activity and mechanism of oridonin in Ph+ ALL is unknown. To investigate the anticancer activity of oridonin, we examined its role in constitutively activated Akt/mTOR, Raf/MEK/ERK, STAT5 and SRC pathway, mRNA level of bcr/abl gene, cell viability and apoptosis in Ph+ ALL SUP-B15 cells. Furthermore, we detected synergetic effect of oridonin plus imatinib. Our results showed that oridonin inhibiting activations of LYN (one of SRC family kinases) and ABL and their downstream Akt/mTOR, Raf/MEK/ERK and STAT5 pathways, downregulated Bcl-2 but upregulated Bax protein and then induced apoptosis in Ph+ ALL cells. Oridonin plus imatinib exerted synergetic effects by overcoming imatinib defect of upregulating Akt/mTOR and LYN signaling. Additionally, we examined the effect of oridonin on the signaling pathways in the primary specimens from Ph+ ALL patients. Our data showed that oridonin remarkably suppressed activations of Akt/mTOR, Raf/MEK and STAT5 pathway in these primary specimens and oridonin with imatinib exerted synergetic suppressive effects on mTOR, STAT5 and LYN signaling in one imatinib resistant patient specimen. Additional evaluation of oridonin as a potential therapeutic agent for Ph+ ALL seems warranted.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "86cf7cabdc464986812d7f76361ff136", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[52, 54], [16, 18], [164, 166]], "char_spans": [[281, 287], [113, 119], [910, 916]]}]}], "context_tokens": [["Philadelphia", 0], ["chromosome", 13], ["-", 23], ["positive", 24], ["acute", 33], ["lymphoblastic", 39], ["leukemia", 53], ["(", 62], ["Ph+", 63], ["ALL", 67], [")", 70], ["is", 72], ["triggered", 75], ["by", 85], ["constitutively", 88], ["activated", 103], ["BCR", 113], ["-", 116], ["ABL", 117], ["and", 121], ["SRC", 125], ["family", 129], ["tyrosine", 136], ["kinases", 145], [".", 152], ["They", 153], ["account", 158], ["for", 166], ["the", 170], ["activations", 174], ["of", 186], ["multiple", 189], ["growth", 198], ["-", 204], ["signaling", 205], ["pathways", 215], [",", 223], ["including", 225], ["Raf", 235], ["/", 238], ["MEK", 239], ["/", 242], ["ERK", 243], [",", 246], ["Akt", 248], ["/", 251], ["mTOR", 252], ["and", 257], ["STAT5", 261], ["pathways", 267], [".", 275], ["The", 277], ["BCR", 281], ["-", 284], ["ABL", 285], ["tyrosine", 289], ["kinase", 298], ["inhibitor", 305], ["imatinib", 315], ["is", 324], ["the", 327], ["standard", 331], ["treatment", 340], ["for", 350], ["Ph+", 354], ["leukemia", 358], ["and", 367], ["plays", 371], ["efficacious", 377], ["role", 389], ["in", 394], ["CML", 397], [".", 400], ["However", 402], [",", 409], ["imatinib", 411], ["has", 420], ["few", 424], ["inhibitory", 428], ["effects", 439], ["on", 447], ["SRC", 450], ["tyrosine", 454], ["kinase", 463], ["with", 470], ["response", 475], ["rate", 484], ["of", 489], ["Ph+", 492], ["ALL", 496], ["lower", 500], ["and", 506], ["relapse", 510], ["more", 518], ["frequent", 523], ["and", 532], ["quicker", 536], ["compared", 544], ["with", 553], ["CML", 558], [".", 561], ["Previous", 563], ["studies", 572], ["showed", 580], ["that", 587], ["oridonin", 592], ["inhibits", 601], ["proliferation", 610], ["and", 624], ["induces", 628], ["apoptosis", 636], ["in", 646], ["many", 649], ["tumor", 654], ["cells", 660], [".", 665], ["However", 667], [",", 674], ["the", 676], ["anticancer", 680], ["activity", 691], ["and", 700], ["mechanism", 704], ["of", 714], ["oridonin", 717], ["in", 726], ["Ph+", 729], ["ALL", 733], ["is", 737], ["unknown", 740], [".", 747], ["To", 749], ["investigate", 752], ["the", 764], ["anticancer", 768], ["activity", 779], ["of", 788], ["oridonin", 791], [",", 799], ["we", 801], ["examined", 804], ["its", 813], ["role", 817], ["in", 822], ["constitutively", 825], ["activated", 840], ["Akt", 850], ["/", 853], ["mTOR", 854], [",", 858], ["Raf", 860], ["/", 863], ["MEK", 864], ["/", 867], ["ERK", 868], [",", 871], ["STAT5", 873], ["and", 879], ["SRC", 883], ["pathway", 887], [",", 894], ["mRNA", 896], ["level", 901], ["of", 907], ["bcr", 910], ["/", 913], ["abl", 914], ["gene", 918], [",", 922], ["cell", 924], ["viability", 929], ["and", 939], ["apoptosis", 943], ["in", 953], ["Ph+", 956], ["ALL", 960], ["SUP", 964], ["-", 967], ["B15", 968], ["cells", 972], [".", 977], ["Furthermore", 979], [",", 990], ["we", 992], ["detected", 995], ["synergetic", 1004], ["effect", 1015], ["of", 1022], ["oridonin", 1025], ["plus", 1034], ["imatinib", 1039], [".", 1047], ["Our", 1049], ["results", 1053], ["showed", 1061], ["that", 1068], ["oridonin", 1073], ["inhibiting", 1082], ["activations", 1093], ["of", 1105], ["LYN", 1108], ["(", 1112], ["one", 1113], ["of", 1117], ["SRC", 1120], ["family", 1124], ["kinases", 1131], [")", 1138], ["and", 1140], ["ABL", 1144], ["and", 1148], ["their", 1152], ["downstream", 1158], ["Akt", 1169], ["/", 1172], ["mTOR", 1173], [",", 1177], ["Raf", 1179], ["/", 1182], ["MEK", 1183], ["/", 1186], ["ERK", 1187], ["and", 1191], ["STAT5", 1195], ["pathways", 1201], [",", 1209], ["downregulated", 1211], ["Bcl-2", 1225], ["but", 1231], ["upregulated", 1235], ["Bax", 1247], ["protein", 1251], ["and", 1259], ["then", 1263], ["induced", 1268], ["apoptosis", 1276], ["in", 1286], ["Ph+", 1289], ["ALL", 1293], ["cells", 1297], [".", 1302], ["Oridonin", 1304], ["plus", 1313], ["imatinib", 1318], ["exerted", 1327], ["synergetic", 1335], ["effects", 1346], ["by", 1354], ["overcoming", 1357], ["imatinib", 1368], ["defect", 1377], ["of", 1384], ["upregulating", 1387], ["Akt", 1400], ["/", 1403], ["mTOR", 1404], ["and", 1409], ["LYN", 1413], ["signaling", 1417], [".", 1426], ["Additionally", 1428], [",", 1440], ["we", 1442], ["examined", 1445], ["the", 1454], ["effect", 1458], ["of", 1465], ["oridonin", 1468], ["on", 1477], ["the", 1480], ["signaling", 1484], ["pathways", 1494], ["in", 1503], ["the", 1506], ["primary", 1510], ["specimens", 1518], ["from", 1528], ["Ph+", 1533], ["ALL", 1537], ["patients", 1541], [".", 1549], ["Our", 1551], ["data", 1555], ["showed", 1560], ["that", 1567], ["oridonin", 1572], ["remarkably", 1581], ["suppressed", 1592], ["activations", 1603], ["of", 1615], ["Akt", 1618], ["/", 1621], ["mTOR", 1622], [",", 1626], ["Raf", 1628], ["/", 1631], ["MEK", 1632], ["and", 1636], ["STAT5", 1640], ["pathway", 1646], ["in", 1654], ["these", 1657], ["primary", 1663], ["specimens", 1671], ["and", 1681], ["oridonin", 1685], ["with", 1694], ["imatinib", 1699], ["exerted", 1708], ["synergetic", 1716], ["suppressive", 1727], ["effects", 1739], ["on", 1747], ["mTOR", 1750], [",", 1754], ["STAT5", 1756], ["and", 1762], ["LYN", 1766], ["signaling", 1770], ["in", 1780], ["one", 1783], ["imatinib", 1787], ["resistant", 1796], ["patient", 1806], ["specimen", 1814], [".", 1822], ["Additional", 1824], ["evaluation", 1835], ["of", 1846], ["oridonin", 1849], ["as", 1858], ["a", 1861], ["potential", 1863], ["therapeutic", 1873], ["agent", 1885], ["for", 1891], ["Ph+", 1895], ["ALL", 1899], ["seems", 1903], ["warranted", 1909], [".", 1918]]}
{"context": "Nucleotide excision repair (NER) is a multistep process capable to remove a variety of DNA distorting lesions from prokaryotic and eukaryotic genomes. In eukaryotic cells, the process requires more than 30 proteins to perform the different steps, i.e. recognition of DNA damage, single strand incisions and excision of the lesion-containing DNA fragment and DNA repair synthesis/ligation. NER can operate via two subpathways: global genome repair (GGR) and a specialized pathway coupled to active transcription (transcription-coupled repair, TCR) and directed to DNA lesions in the transcribed strand of active genes. Both in vivo as well as in cultured cells the fast removal of transcription blocking lesions by TCR is crucial to escape from lethal effects of inhibited transcription inhibition The most delicate step in NER is the recognition of the DNA lesions in their different chromatin context and the mechanism of damage recognition in GGR and TCR is principally different and requires specific proteins. In GGR, the XPC-HR23B is essential for the formation of the incision complex. In TCR the Cockayne syndrome (CS) gene products are key players in the recognition of a stalled RNA polymerase the presumed signaling structure for repair of transcribed strands. In this study, we show that the extent of recovery of UV-inhibited transcription and TCR strictly depends on the amount of CSB protein as well as the amount of DNA damage present in the cell. This indicates that the ratio between DNA damage frequency and CSB protein concentration in the cell is rather critical for acute cellular response, i.e. recovery of inhibited transcription upon DNA damage infliction, and hence cellular survival.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "dfc374abfd1246c8bd30686662c51d05", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[103, 104]], "char_spans": [[582, 599]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], ["is", 33], ["a", 36], ["multistep", 38], ["process", 48], ["capable", 56], ["to", 64], ["remove", 67], ["a", 74], ["variety", 76], ["of", 84], ["DNA", 87], ["distorting", 91], ["lesions", 102], ["from", 110], ["prokaryotic", 115], ["and", 127], ["eukaryotic", 131], ["genomes", 142], [".", 149], ["In", 151], ["eukaryotic", 154], ["cells", 165], [",", 170], ["the", 172], ["process", 176], ["requires", 184], ["more", 193], ["than", 198], ["30", 203], ["proteins", 206], ["to", 215], ["perform", 218], ["the", 226], ["different", 230], ["steps", 240], [",", 245], ["i.e.", 247], ["recognition", 252], ["of", 264], ["DNA", 267], ["damage", 271], [",", 277], ["single", 279], ["strand", 286], ["incisions", 293], ["and", 303], ["excision", 307], ["of", 316], ["the", 319], ["lesion", 323], ["-", 329], ["containing", 330], ["DNA", 341], ["fragment", 345], ["and", 354], ["DNA", 358], ["repair", 362], ["synthesis", 369], ["/", 378], ["ligation", 379], [".", 387], ["NER", 389], ["can", 393], ["operate", 397], ["via", 405], ["two", 409], ["subpathways", 413], [":", 424], ["global", 426], ["genome", 433], ["repair", 440], ["(", 447], ["GGR", 448], [")", 451], ["and", 453], ["a", 457], ["specialized", 459], ["pathway", 471], ["coupled", 479], ["to", 487], ["active", 490], ["transcription", 497], ["(", 511], ["transcription", 512], ["-", 525], ["coupled", 526], ["repair", 534], [",", 540], ["TCR", 542], [")", 545], ["and", 547], ["directed", 551], ["to", 560], ["DNA", 563], ["lesions", 567], ["in", 575], ["the", 578], ["transcribed", 582], ["strand", 594], ["of", 601], ["active", 604], ["genes", 611], [".", 616], ["Both", 618], ["in", 623], ["vivo", 626], ["as", 631], ["well", 634], ["as", 639], ["in", 642], ["cultured", 645], ["cells", 654], ["the", 660], ["fast", 664], ["removal", 669], ["of", 677], ["transcription", 680], ["blocking", 694], ["lesions", 703], ["by", 711], ["TCR", 714], ["is", 718], ["crucial", 721], ["to", 729], ["escape", 732], ["from", 739], ["lethal", 744], ["effects", 751], ["of", 759], ["inhibited", 762], ["transcription", 772], ["inhibition", 786], ["The", 797], ["most", 801], ["delicate", 806], ["step", 815], ["in", 820], ["NER", 823], ["is", 827], ["the", 830], ["recognition", 834], ["of", 846], ["the", 849], ["DNA", 853], ["lesions", 857], ["in", 865], ["their", 868], ["different", 874], ["chromatin", 884], ["context", 894], ["and", 902], ["the", 906], ["mechanism", 910], ["of", 920], ["damage", 923], ["recognition", 930], ["in", 942], ["GGR", 945], ["and", 949], ["TCR", 953], ["is", 957], ["principally", 960], ["different", 972], ["and", 982], ["requires", 986], ["specific", 995], ["proteins", 1004], [".", 1012], ["In", 1014], ["GGR", 1017], [",", 1020], ["the", 1022], ["XPC", 1026], ["-", 1029], ["HR23B", 1030], ["is", 1036], ["essential", 1039], ["for", 1049], ["the", 1053], ["formation", 1057], ["of", 1067], ["the", 1070], ["incision", 1074], ["complex", 1083], [".", 1090], ["In", 1092], ["TCR", 1095], ["the", 1099], ["Cockayne", 1103], ["syndrome", 1112], ["(", 1121], ["CS", 1122], [")", 1124], ["gene", 1126], ["products", 1131], ["are", 1140], ["key", 1144], ["players", 1148], ["in", 1156], ["the", 1159], ["recognition", 1163], ["of", 1175], ["a", 1178], ["stalled", 1180], ["RNA", 1188], ["polymerase", 1192], ["the", 1203], ["presumed", 1207], ["signaling", 1216], ["structure", 1226], ["for", 1236], ["repair", 1240], ["of", 1247], ["transcribed", 1250], ["strands", 1262], [".", 1269], ["In", 1271], ["this", 1274], ["study", 1279], [",", 1284], ["we", 1286], ["show", 1289], ["that", 1294], ["the", 1299], ["extent", 1303], ["of", 1310], ["recovery", 1313], ["of", 1322], ["UV", 1325], ["-", 1327], ["inhibited", 1328], ["transcription", 1338], ["and", 1352], ["TCR", 1356], ["strictly", 1360], ["depends", 1369], ["on", 1377], ["the", 1380], ["amount", 1384], ["of", 1391], ["CSB", 1394], ["protein", 1398], ["as", 1406], ["well", 1409], ["as", 1414], ["the", 1417], ["amount", 1421], ["of", 1428], ["DNA", 1431], ["damage", 1435], ["present", 1442], ["in", 1450], ["the", 1453], ["cell", 1457], [".", 1461], ["This", 1463], ["indicates", 1468], ["that", 1478], ["the", 1483], ["ratio", 1487], ["between", 1493], ["DNA", 1501], ["damage", 1505], ["frequency", 1512], ["and", 1522], ["CSB", 1526], ["protein", 1530], ["concentration", 1538], ["in", 1552], ["the", 1555], ["cell", 1559], ["is", 1564], ["rather", 1567], ["critical", 1574], ["for", 1583], ["acute", 1587], ["cellular", 1593], ["response", 1602], [",", 1610], ["i.e.", 1612], ["recovery", 1617], ["of", 1626], ["inhibited", 1629], ["transcription", 1639], ["upon", 1653], ["DNA", 1658], ["damage", 1662], ["infliction", 1669], [",", 1679], ["and", 1681], ["hence", 1685], ["cellular", 1691], ["survival", 1700], [".", 1708]]}
{"context": "Histone H3 lysine 4 (K4) methylation is a prevalent mark associated with transcription activation and is mainly catalyzed by the MLL/SET1 family histone methyltransferases. A common feature of the mammalian MLL/SET1 complexes is the presence of three core components (RbBP5, Ash2L and WDR5) and a catalytic subunit containing a SET domain. Unlike most other histone lysine methyltransferases, all four proteins are required for efficient H3 K4 methylation. Despite extensive efforts, mechanisms for how three core components regulate MLL/SET1 methyltransferase activity remain elusive. Here we show that a heterodimer of Ash2L and RbBP5 has intrinsic histone methyltransferase activity. This activity requires the highly conserved SPRY domain of Ash2L and a short peptide of RbBP5. We demonstrate that both Ash2L and the MLL1 SET domain are capable of binding to S-adenosyl-L- [methyl-(3)H] methionine in the MLL1 core complex. Mutations in the MLL1 SET domain that fail to support overall H3 K4 methylation also compromise SAM binding by Ash2L. Taken together, our results show that the Ash2L/RbBP5 heterodimer plays a critical role in the overall catalysis of MLL1 mediated H3 K4 methylation. The results we describe here provide mechanistic insights for unique regulation of the MLL1 methyltransferase activity. It suggests that both Ash2L/RbBP5 and the MLL1 SET domain make direct contacts with the substrates and contribute to the formation of a joint catalytic center. Given the shared core configuration among all MLL/SET1 family HMTs, it will be interesting to test whether the mechanism we describe here can be generalized to other MLL/SET1 family members in the future.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "e1caec128d5f4cb4a20159f0430b80d1", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[140, 141], [59, 60], [166, 167], [236, 237]], "char_spans": [[826, 835], [328, 337], [950, 959], [1362, 1371]]}]}], "context_tokens": [["Histone", 0], ["H3", 8], ["lysine", 11], ["4", 18], ["(", 20], ["K4", 21], [")", 23], ["methylation", 25], ["is", 37], ["a", 40], ["prevalent", 42], ["mark", 52], ["associated", 57], ["with", 68], ["transcription", 73], ["activation", 87], ["and", 98], ["is", 102], ["mainly", 105], ["catalyzed", 112], ["by", 122], ["the", 125], ["MLL", 129], ["/", 132], ["SET1", 133], ["family", 138], ["histone", 145], ["methyltransferases", 153], [".", 171], ["A", 173], ["common", 175], ["feature", 182], ["of", 190], ["the", 193], ["mammalian", 197], ["MLL", 207], ["/", 210], ["SET1", 211], ["complexes", 216], ["is", 226], ["the", 229], ["presence", 233], ["of", 242], ["three", 245], ["core", 251], ["components", 256], ["(", 267], ["RbBP5", 268], [",", 273], ["Ash2L", 275], ["and", 281], ["WDR5", 285], [")", 289], ["and", 291], ["a", 295], ["catalytic", 297], ["subunit", 307], ["containing", 315], ["a", 326], ["SET", 328], ["domain", 332], [".", 338], ["Unlike", 340], ["most", 347], ["other", 352], ["histone", 358], ["lysine", 366], ["methyltransferases", 373], [",", 391], ["all", 393], ["four", 397], ["proteins", 402], ["are", 411], ["required", 415], ["for", 424], ["efficient", 428], ["H3", 438], ["K4", 441], ["methylation", 444], [".", 455], ["Despite", 457], ["extensive", 465], ["efforts", 475], [",", 482], ["mechanisms", 484], ["for", 495], ["how", 499], ["three", 503], ["core", 509], ["components", 514], ["regulate", 525], ["MLL", 534], ["/", 537], ["SET1", 538], ["methyltransferase", 543], ["activity", 561], ["remain", 570], ["elusive", 577], [".", 584], ["Here", 586], ["we", 591], ["show", 594], ["that", 599], ["a", 604], ["heterodimer", 606], ["of", 618], ["Ash2L", 621], ["and", 627], ["RbBP5", 631], ["has", 637], ["intrinsic", 641], ["histone", 651], ["methyltransferase", 659], ["activity", 677], [".", 685], ["This", 687], ["activity", 692], ["requires", 701], ["the", 710], ["highly", 714], ["conserved", 721], ["SPRY", 731], ["domain", 736], ["of", 743], ["Ash2L", 746], ["and", 752], ["a", 756], ["short", 758], ["peptide", 764], ["of", 772], ["RbBP5", 775], [".", 780], ["We", 782], ["demonstrate", 785], ["that", 797], ["both", 802], ["Ash2L", 807], ["and", 813], ["the", 817], ["MLL1", 821], ["SET", 826], ["domain", 830], ["are", 837], ["capable", 841], ["of", 849], ["binding", 852], ["to", 860], ["S", 863], ["-", 864], ["adenosyl", 865], ["-", 873], ["L-", 874], ["[", 877], ["methyl-(3)H", 878], ["]", 889], ["methionine", 891], ["in", 902], ["the", 905], ["MLL1", 909], ["core", 914], ["complex", 919], [".", 926], ["Mutations", 928], ["in", 938], ["the", 941], ["MLL1", 945], ["SET", 950], ["domain", 954], ["that", 961], ["fail", 966], ["to", 971], ["support", 974], ["overall", 982], ["H3", 990], ["K4", 993], ["methylation", 996], ["also", 1008], ["compromise", 1013], ["SAM", 1024], ["binding", 1028], ["by", 1036], ["Ash2L.", 1039], ["Taken", 1046], ["together", 1052], [",", 1060], ["our", 1062], ["results", 1066], ["show", 1074], ["that", 1079], ["the", 1084], ["Ash2L", 1088], ["/", 1093], ["RbBP5", 1094], ["heterodimer", 1100], ["plays", 1112], ["a", 1118], ["critical", 1120], ["role", 1129], ["in", 1134], ["the", 1137], ["overall", 1141], ["catalysis", 1149], ["of", 1159], ["MLL1", 1162], ["mediated", 1167], ["H3", 1176], ["K4", 1179], ["methylation", 1182], [".", 1193], ["The", 1195], ["results", 1199], ["we", 1207], ["describe", 1210], ["here", 1219], ["provide", 1224], ["mechanistic", 1232], ["insights", 1244], ["for", 1253], ["unique", 1257], ["regulation", 1264], ["of", 1275], ["the", 1278], ["MLL1", 1282], ["methyltransferase", 1287], ["activity", 1305], [".", 1313], ["It", 1315], ["suggests", 1318], ["that", 1327], ["both", 1332], ["Ash2L", 1337], ["/", 1342], ["RbBP5", 1343], ["and", 1349], ["the", 1353], ["MLL1", 1357], ["SET", 1362], ["domain", 1366], ["make", 1373], ["direct", 1378], ["contacts", 1385], ["with", 1394], ["the", 1399], ["substrates", 1403], ["and", 1414], ["contribute", 1418], ["to", 1429], ["the", 1432], ["formation", 1436], ["of", 1446], ["a", 1449], ["joint", 1451], ["catalytic", 1457], ["center", 1467], [".", 1473], ["Given", 1475], ["the", 1481], ["shared", 1485], ["core", 1492], ["configuration", 1497], ["among", 1511], ["all", 1517], ["MLL", 1521], ["/", 1524], ["SET1", 1525], ["family", 1530], ["HMTs", 1537], [",", 1541], ["it", 1543], ["will", 1546], ["be", 1551], ["interesting", 1554], ["to", 1566], ["test", 1569], ["whether", 1574], ["the", 1582], ["mechanism", 1586], ["we", 1596], ["describe", 1599], ["here", 1608], ["can", 1613], ["be", 1617], ["generalized", 1620], ["to", 1632], ["other", 1635], ["MLL", 1641], ["/", 1644], ["SET1", 1645], ["family", 1650], ["members", 1657], ["in", 1665], ["the", 1668], ["future", 1672], [".", 1678]]}
{"context": "Chronic myelogenous leukemia (CML) results from the neoplastic transformation of primitive hematopoietic stem cells, and has been classified as a myeloproliferative disorder. The hallmark of CML is the presence of a balanced translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11.2), which is known as the Philadelphia (Ph) chromosome. This translocation results in the formation of the bcr-abl fusion gene, which, in turn, is translated into a chimeric Bcr-Abl protein with deregulated tyrosine kinase activity. Constitutive Bcr-Abl expression has been shown to be necessary and sufficient for the transformed phenotype of CML cells. CML is unique among human cancers in that a single genetic defect, the Ph chromosome, is responsible for the transformed phenotype. Since this discovery more than 40 years ago, our understanding of the clinical course, therapy, and prognosis of patients with CML has changed significantly. These changes have culminated in the emergence of imatinib, the first rationally designed, molecularly targeted therapy for human malignancy. In this review, the authors describe the molecular biology of CML and the development of imatinib as a therapeutic agent for the treatment of CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "d4a15945d8304a3898c6f391152041af", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[85, 87], [69, 71], [96, 98]], "char_spans": [[476, 482], [409, 415], [548, 554]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["results", 35], ["from", 43], ["the", 48], ["neoplastic", 52], ["transformation", 63], ["of", 78], ["primitive", 81], ["hematopoietic", 91], ["stem", 105], ["cells", 110], [",", 115], ["and", 117], ["has", 121], ["been", 125], ["classified", 130], ["as", 141], ["a", 144], ["myeloproliferative", 146], ["disorder", 165], [".", 173], ["The", 175], ["hallmark", 179], ["of", 188], ["CML", 191], ["is", 195], ["the", 198], ["presence", 202], ["of", 211], ["a", 214], ["balanced", 216], ["translocation", 225], ["between", 239], ["the", 247], ["long", 251], ["arms", 256], ["of", 261], ["chromosomes", 264], ["9", 276], ["and", 278], ["22", 282], [",", 284], ["t(9;22)(q34;q11.2", 286], [")", 303], [",", 304], ["which", 306], ["is", 312], ["known", 315], ["as", 321], ["the", 324], ["Philadelphia", 328], ["(", 341], ["Ph", 342], [")", 344], ["chromosome", 346], [".", 356], ["This", 358], ["translocation", 363], ["results", 377], ["in", 385], ["the", 388], ["formation", 392], ["of", 402], ["the", 405], ["bcr", 409], ["-", 412], ["abl", 413], ["fusion", 417], ["gene", 424], [",", 428], ["which", 430], [",", 435], ["in", 437], ["turn", 440], [",", 444], ["is", 446], ["translated", 449], ["into", 460], ["a", 465], ["chimeric", 467], ["Bcr", 476], ["-", 479], ["Abl", 480], ["protein", 484], ["with", 492], ["deregulated", 497], ["tyrosine", 509], ["kinase", 518], ["activity", 525], [".", 533], ["Constitutive", 535], ["Bcr", 548], ["-", 551], ["Abl", 552], ["expression", 556], ["has", 567], ["been", 571], ["shown", 576], ["to", 582], ["be", 585], ["necessary", 588], ["and", 598], ["sufficient", 602], ["for", 613], ["the", 617], ["transformed", 621], ["phenotype", 633], ["of", 643], ["CML", 646], ["cells", 650], [".", 655], ["CML", 657], ["is", 661], ["unique", 664], ["among", 671], ["human", 677], ["cancers", 683], ["in", 691], ["that", 694], ["a", 699], ["single", 701], ["genetic", 708], ["defect", 716], [",", 722], ["the", 724], ["Ph", 728], ["chromosome", 731], [",", 741], ["is", 743], ["responsible", 746], ["for", 758], ["the", 762], ["transformed", 766], ["phenotype", 778], [".", 787], ["Since", 789], ["this", 795], ["discovery", 800], ["more", 810], ["than", 815], ["40", 820], ["years", 823], ["ago", 829], [",", 832], ["our", 834], ["understanding", 838], ["of", 852], ["the", 855], ["clinical", 859], ["course", 868], [",", 874], ["therapy", 876], [",", 883], ["and", 885], ["prognosis", 889], ["of", 899], ["patients", 902], ["with", 911], ["CML", 916], ["has", 920], ["changed", 924], ["significantly", 932], [".", 945], ["These", 947], ["changes", 953], ["have", 961], ["culminated", 966], ["in", 977], ["the", 980], ["emergence", 984], ["of", 994], ["imatinib", 997], [",", 1005], ["the", 1007], ["first", 1011], ["rationally", 1017], ["designed", 1028], [",", 1036], ["molecularly", 1038], ["targeted", 1050], ["therapy", 1059], ["for", 1067], ["human", 1071], ["malignancy", 1077], [".", 1087], ["In", 1089], ["this", 1092], ["review", 1097], [",", 1103], ["the", 1105], ["authors", 1109], ["describe", 1117], ["the", 1126], ["molecular", 1130], ["biology", 1140], ["of", 1148], ["CML", 1151], ["and", 1155], ["the", 1159], ["development", 1163], ["of", 1175], ["imatinib", 1178], ["as", 1187], ["a", 1190], ["therapeutic", 1192], ["agent", 1204], ["for", 1210], ["the", 1214], ["treatment", 1218], ["of", 1228], ["CML", 1231], [".", 1234]]}
{"context": "Methylation of histone H3 lysine 4 (H3K4) in Saccharomyces cerevisiae is implemented by Set1/COMPASS, which was originally purified based on the similarity of yeast Set1 to human MLL1 and Drosophila melanogaster Trithorax (Trx). While humans have six COMPASS family members, Drosophila possesses a representative of the three subclasses within COMPASS-like complexes: dSet1 (human SET1A/SET1B), Trx (human MLL1/2), and Trr (human MLL3/4). Here, we report the biochemical purification and molecular characterization of the Drosophila COMPASS family. We observed a one-to-one similarity in subunit composition with their mammalian counterparts, with the exception of LPT (lost plant homeodomains [PHDs] of Trr), which copurifies with the Trr complex. LPT is a previously uncharacterized protein that is homologous to the multiple PHD fingers found in the N-terminal regions of mammalian MLL3/4 but not Drosophila Trr, indicating that Trr and LPT constitute a split gene of an MLL3/4 ancestor. Our study demonstrates that all three complexes in Drosophila are H3K4 methyltransferases; however, dSet1/COMPASS is the major monoubiquitination-dependent H3K4 di- and trimethylase in Drosophila. Taken together, this study provides a springboard for the functional dissection of the COMPASS family members and their role in the regulation of histone H3K4 methylation throughout development in Drosophila.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "3288fb6fd40c44d78d4fdd8b337240a0", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[203, 203], [191, 191], [7, 7], [235, 235]], "char_spans": [[1147, 1150], [1057, 1060], [36, 39], [1342, 1345]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["histone", 15], ["H3", 23], ["lysine", 26], ["4", 33], ["(", 35], ["H3K4", 36], [")", 40], ["in", 42], ["Saccharomyces", 45], ["cerevisiae", 59], ["is", 70], ["implemented", 73], ["by", 85], ["Set1/COMPASS", 88], [",", 100], ["which", 102], ["was", 108], ["originally", 112], ["purified", 123], ["based", 132], ["on", 138], ["the", 141], ["similarity", 145], ["of", 156], ["yeast", 159], ["Set1", 165], ["to", 170], ["human", 173], ["MLL1", 179], ["and", 184], ["Drosophila", 188], ["melanogaster", 199], ["Trithorax", 212], ["(", 222], ["Trx", 223], [")", 226], [".", 227], ["While", 229], ["humans", 235], ["have", 242], ["six", 247], ["COMPASS", 251], ["family", 259], ["members", 266], [",", 273], ["Drosophila", 275], ["possesses", 286], ["a", 296], ["representative", 298], ["of", 313], ["the", 316], ["three", 320], ["subclasses", 326], ["within", 337], ["COMPASS", 344], ["-", 351], ["like", 352], ["complexes", 357], [":", 366], ["dSet1", 368], ["(", 374], ["human", 375], ["SET1A", 381], ["/", 386], ["SET1B", 387], [")", 392], [",", 393], ["Trx", 395], ["(", 399], ["human", 400], ["MLL1/2", 406], [")", 412], [",", 413], ["and", 415], ["Trr", 419], ["(", 423], ["human", 424], ["MLL3/4", 430], [")", 436], [".", 437], ["Here", 439], [",", 443], ["we", 445], ["report", 448], ["the", 455], ["biochemical", 459], ["purification", 471], ["and", 484], ["molecular", 488], ["characterization", 498], ["of", 515], ["the", 518], ["Drosophila", 522], ["COMPASS", 533], ["family", 541], [".", 547], ["We", 549], ["observed", 552], ["a", 561], ["one", 563], ["-", 566], ["to", 567], ["-", 569], ["one", 570], ["similarity", 574], ["in", 585], ["subunit", 588], ["composition", 596], ["with", 608], ["their", 613], ["mammalian", 619], ["counterparts", 629], [",", 641], ["with", 643], ["the", 648], ["exception", 652], ["of", 662], ["LPT", 665], ["(", 669], ["lost", 670], ["plant", 675], ["homeodomains", 681], ["[", 694], ["PHDs", 695], ["]", 699], ["of", 701], ["Trr", 704], [")", 707], [",", 708], ["which", 710], ["copurifies", 716], ["with", 727], ["the", 732], ["Trr", 736], ["complex", 740], [".", 747], ["LPT", 749], ["is", 753], ["a", 756], ["previously", 758], ["uncharacterized", 769], ["protein", 785], ["that", 793], ["is", 798], ["homologous", 801], ["to", 812], ["the", 815], ["multiple", 819], ["PHD", 828], ["fingers", 832], ["found", 840], ["in", 846], ["the", 849], ["N", 853], ["-", 854], ["terminal", 855], ["regions", 864], ["of", 872], ["mammalian", 875], ["MLL3/4", 885], ["but", 892], ["not", 896], ["Drosophila", 900], ["Trr", 911], [",", 914], ["indicating", 916], ["that", 927], ["Trr", 932], ["and", 936], ["LPT", 940], ["constitute", 944], ["a", 955], ["split", 957], ["gene", 963], ["of", 968], ["an", 971], ["MLL3/4", 974], ["ancestor", 981], [".", 989], ["Our", 991], ["study", 995], ["demonstrates", 1001], ["that", 1014], ["all", 1019], ["three", 1023], ["complexes", 1029], ["in", 1039], ["Drosophila", 1042], ["are", 1053], ["H3K4", 1057], ["methyltransferases", 1062], [";", 1080], ["however", 1082], [",", 1089], ["dSet1/COMPASS", 1091], ["is", 1105], ["the", 1108], ["major", 1112], ["monoubiquitination", 1118], ["-", 1136], ["dependent", 1137], ["H3K4", 1147], ["di-", 1152], ["and", 1156], ["trimethylase", 1160], ["in", 1173], ["Drosophila", 1176], [".", 1186], ["Taken", 1188], ["together", 1194], [",", 1202], ["this", 1204], ["study", 1209], ["provides", 1215], ["a", 1224], ["springboard", 1226], ["for", 1238], ["the", 1242], ["functional", 1246], ["dissection", 1257], ["of", 1268], ["the", 1271], ["COMPASS", 1275], ["family", 1283], ["members", 1290], ["and", 1298], ["their", 1302], ["role", 1308], ["in", 1313], ["the", 1316], ["regulation", 1320], ["of", 1331], ["histone", 1334], ["H3K4", 1342], ["methylation", 1347], ["throughout", 1359], ["development", 1370], ["in", 1382], ["Drosophila", 1385], [".", 1395]]}
{"context": "We immunohistochemically investigated the degeneration processes of the nigro-striatal and nigro-amygdaloid pathways and the relationship between the loss of dopaminergic neurons and Lewy bodies (LB) formation in the substantia nigra using 15 autopsied cases of dementia with Lewy bodies (DLB). The number of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra and TH-positive axonal terminals in the putamen decreased with a specific pattern. The substantia nigra possessed alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen exhibited diffuse or granular alpha-synuclein-immunostaining. Most of the granular stains were positive for anti-phosphorylated alpha-synuclein antibody, whereas the diffuse stains were negative. These findings suggest that the axonal terminals in the putamen undergo abnormal alpha-synuclein accumulation, but may not always originate from LB-bearing neurons in the substantia nigra. The central amygdaloid nucleus contained anti-alpha-synuclein- and -phosphorylated alpha-synuclein-positive dystrophic axonal terminals, the degree of which was greater for cases with granular staining in the putamen, and which was proportional to the number of alpha-synuclein-positive neurons in the substantia nigra. Thus, the axonal terminals in the central amygdaloid nucleus may have originated from LB-bearing neurons in the substantia nigra. The results of the present study indicate that the nigro-striatal and nigro-amygdaloid pathways undergo different degeneration processes in DLB, and suggest that the degeneration of the nigro-amygdaloid pathway more strongly reflects LB formation in dopaminergic neurons of the substantia nigra than that of the nigro-striatal pathway. In addition, they indicate that there is no direct relationship between the loss of dopaminergic neurons and LB formation in the substantia nigra.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "838f259cf3d94ed1a4628e26a79fa183", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[102, 104], [170, 172], [175, 177], [119, 121], [207, 209], [80, 82], [143, 145]], "char_spans": [[619, 633], [1020, 1035], [1057, 1071], [717, 731], [1236, 1250], [490, 504], [866, 880]]}]}], "context_tokens": [["We", 0], ["immunohistochemically", 3], ["investigated", 25], ["the", 38], ["degeneration", 42], ["processes", 55], ["of", 65], ["the", 68], ["nigro", 72], ["-", 77], ["striatal", 78], ["and", 87], ["nigro", 91], ["-", 96], ["amygdaloid", 97], ["pathways", 108], ["and", 117], ["the", 121], ["relationship", 125], ["between", 138], ["the", 146], ["loss", 150], ["of", 155], ["dopaminergic", 158], ["neurons", 171], ["and", 179], ["Lewy", 183], ["bodies", 188], ["(", 195], ["LB", 196], [")", 198], ["formation", 200], ["in", 210], ["the", 213], ["substantia", 217], ["nigra", 228], ["using", 234], ["15", 240], ["autopsied", 243], ["cases", 253], ["of", 259], ["dementia", 262], ["with", 271], ["Lewy", 276], ["bodies", 281], ["(", 288], ["DLB", 289], [")", 292], [".", 293], ["The", 295], ["number", 299], ["of", 306], ["tyrosine", 309], ["hydroxylase", 318], ["(", 330], ["TH)-positive", 331], ["neurons", 344], ["in", 352], ["the", 355], ["substantia", 359], ["nigra", 370], ["and", 376], ["TH", 380], ["-", 382], ["positive", 383], ["axonal", 392], ["terminals", 399], ["in", 409], ["the", 412], ["putamen", 416], ["decreased", 424], ["with", 434], ["a", 439], ["specific", 441], ["pattern", 450], [".", 457], ["The", 459], ["substantia", 463], ["nigra", 474], ["possessed", 480], ["alpha", 490], ["-", 495], ["synuclein", 496], ["-", 505], ["positive", 506], ["LB", 515], ["-", 517], ["bearing", 518], ["neurons", 526], ["that", 534], ["were", 539], ["almost", 544], ["evenly", 551], ["distributed", 558], [",", 569], ["while", 571], ["the", 577], ["putamen", 581], ["exhibited", 589], ["diffuse", 599], ["or", 607], ["granular", 610], ["alpha", 619], ["-", 624], ["synuclein", 625], ["-", 634], ["immunostaining", 635], [".", 649], ["Most", 651], ["of", 656], ["the", 659], ["granular", 663], ["stains", 672], ["were", 679], ["positive", 684], ["for", 693], ["anti", 697], ["-", 701], ["phosphorylated", 702], ["alpha", 717], ["-", 722], ["synuclein", 723], ["antibody", 733], [",", 741], ["whereas", 743], ["the", 751], ["diffuse", 755], ["stains", 763], ["were", 770], ["negative", 775], [".", 783], ["These", 785], ["findings", 791], ["suggest", 800], ["that", 808], ["the", 813], ["axonal", 817], ["terminals", 824], ["in", 834], ["the", 837], ["putamen", 841], ["undergo", 849], ["abnormal", 857], ["alpha", 866], ["-", 871], ["synuclein", 872], ["accumulation", 882], [",", 894], ["but", 896], ["may", 900], ["not", 904], ["always", 908], ["originate", 915], ["from", 925], ["LB", 930], ["-", 932], ["bearing", 933], ["neurons", 941], ["in", 949], ["the", 952], ["substantia", 956], ["nigra", 967], [".", 972], ["The", 974], ["central", 978], ["amygdaloid", 986], ["nucleus", 997], ["contained", 1005], ["anti", 1015], ["-", 1019], ["alpha", 1020], ["-", 1025], ["synuclein-", 1026], ["and", 1037], ["-phosphorylated", 1041], ["alpha", 1057], ["-", 1062], ["synuclein", 1063], ["-", 1072], ["positive", 1073], ["dystrophic", 1082], ["axonal", 1093], ["terminals", 1100], [",", 1109], ["the", 1111], ["degree", 1115], ["of", 1122], ["which", 1125], ["was", 1131], ["greater", 1135], ["for", 1143], ["cases", 1147], ["with", 1153], ["granular", 1158], ["staining", 1167], ["in", 1176], ["the", 1179], ["putamen", 1183], [",", 1190], ["and", 1192], ["which", 1196], ["was", 1202], ["proportional", 1206], ["to", 1219], ["the", 1222], ["number", 1226], ["of", 1233], ["alpha", 1236], ["-", 1241], ["synuclein", 1242], ["-", 1251], ["positive", 1252], ["neurons", 1261], ["in", 1269], ["the", 1272], ["substantia", 1276], ["nigra", 1287], [".", 1292], ["Thus", 1294], [",", 1298], ["the", 1300], ["axonal", 1304], ["terminals", 1311], ["in", 1321], ["the", 1324], ["central", 1328], ["amygdaloid", 1336], ["nucleus", 1347], ["may", 1355], ["have", 1359], ["originated", 1364], ["from", 1375], ["LB", 1380], ["-", 1382], ["bearing", 1383], ["neurons", 1391], ["in", 1399], ["the", 1402], ["substantia", 1406], ["nigra", 1417], [".", 1422], ["The", 1424], ["results", 1428], ["of", 1436], ["the", 1439], ["present", 1443], ["study", 1451], ["indicate", 1457], ["that", 1466], ["the", 1471], ["nigro", 1475], ["-", 1480], ["striatal", 1481], ["and", 1490], ["nigro", 1494], ["-", 1499], ["amygdaloid", 1500], ["pathways", 1511], ["undergo", 1520], ["different", 1528], ["degeneration", 1538], ["processes", 1551], ["in", 1561], ["DLB", 1564], [",", 1567], ["and", 1569], ["suggest", 1573], ["that", 1581], ["the", 1586], ["degeneration", 1590], ["of", 1603], ["the", 1606], ["nigro", 1610], ["-", 1615], ["amygdaloid", 1616], ["pathway", 1627], ["more", 1635], ["strongly", 1640], ["reflects", 1649], ["LB", 1658], ["formation", 1661], ["in", 1671], ["dopaminergic", 1674], ["neurons", 1687], ["of", 1695], ["the", 1698], ["substantia", 1702], ["nigra", 1713], ["than", 1719], ["that", 1724], ["of", 1729], ["the", 1732], ["nigro", 1736], ["-", 1741], ["striatal", 1742], ["pathway", 1751], [".", 1758], ["In", 1760], ["addition", 1763], [",", 1771], ["they", 1773], ["indicate", 1778], ["that", 1787], ["there", 1792], ["is", 1798], ["no", 1801], ["direct", 1804], ["relationship", 1811], ["between", 1824], ["the", 1832], ["loss", 1836], ["of", 1841], ["dopaminergic", 1844], ["neurons", 1857], ["and", 1865], ["LB", 1869], ["formation", 1872], ["in", 1882], ["the", 1885], ["substantia", 1889], ["nigra", 1900], [".", 1905]]}
{"context": "We have previously shown that NADPH oxidase (NOX) lies upstream of uncoupled endothelial nitric oxide synthase (eNOS), which is known to occur in diabetic endothelium. However, it remains unclear which specific NOX isoform(s) is responsible for eNOS uncoupling and endothelial dysfunction in diabetic mouse models. The aim of the present study was to test the hypothesis that one or more NOX isoform(s) mediate(s) diabetic uncoupling of eNOS, which has been shown to occur in patients with diabetes to contribute to endothelial dysfunction. Diabetes was induced by streptozotocin administration. The N (\u03c9)-nitro-L-arginine methyl ester (L-NAME)-sensitive superoxide production of aortic segments, reflective of eNOS uncoupling activity, was determined by electron spin resonance. The L-NAME-sensitive superoxide production was more than doubled in wild-type diabetic mice, implicating uncoupling of eNOS. This was abolished in diabetic p47 ( phox-/-) (also known as Ncf1 (-/-)) mice, but preserved in Nox2 (-/y) (also known as Cybb (-/-)) mice made diabetic. The eNOS uncoupling activity was markedly attenuated in diabetic mice transfected with Nox1 or Nox1 organiser 1 (Noxo1) short interfering RNA (siRNA), and abolished in Nox1 (-/y) diabetic mice. Diabetes-induced impairment in endothelium-dependent vasorelaxation was also significantly attenuated in the Nox1 (-/y) mice made diabetic. By contrast, Nox4 siRNA, or inhibition of mitochondrial complex I or III with rotenone or siRNA, respectively, had no effect on diabetic uncoupling of eNOS. Overexpression of Dhfr, or oral administration of folic acid to improve dihydrofolate reductase (DHFR) function, recoupled eNOS in diabetes to improve endothelial function. Our data demonstrate for the first time that the p47(phox) and NOXO1-dependent activation of NOX1, but not that of NOX2, NOX4 or mitochondrion, mediates diabetic uncoupling of eNOS. NOX1-null mice are protected from diabetic endothelial dysfunction. Novel approaches to inhibit NOX1 and/or improve DHFR function, may prove to have therapeutic potential for diabetic endothelial dysfunction.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "33aa8ce035c44ae2b854b9bd20914504", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[251, 251], [229, 229], [211, 211], [213, 213], [363, 363], [332, 332]], "char_spans": [[1362, 1365], [1227, 1230], [1146, 1149], [1154, 1157], [2001, 2004], [1816, 1819]]}]}], "context_tokens": [["We", 0], ["have", 3], ["previously", 8], ["shown", 19], ["that", 25], ["NADPH", 30], ["oxidase", 36], ["(", 44], ["NOX", 45], [")", 48], ["lies", 50], ["upstream", 55], ["of", 64], ["uncoupled", 67], ["endothelial", 77], ["nitric", 89], ["oxide", 96], ["synthase", 102], ["(", 111], ["eNOS", 112], [")", 116], [",", 117], ["which", 119], ["is", 125], ["known", 128], ["to", 134], ["occur", 137], ["in", 143], ["diabetic", 146], ["endothelium", 155], [".", 166], ["However", 168], [",", 175], ["it", 177], ["remains", 180], ["unclear", 188], ["which", 196], ["specific", 202], ["NOX", 211], ["isoform(s", 215], [")", 224], ["is", 226], ["responsible", 229], ["for", 241], ["eNOS", 245], ["uncoupling", 250], ["and", 261], ["endothelial", 265], ["dysfunction", 277], ["in", 289], ["diabetic", 292], ["mouse", 301], ["models", 307], [".", 313], ["The", 315], ["aim", 319], ["of", 323], ["the", 326], ["present", 330], ["study", 338], ["was", 344], ["to", 348], ["test", 351], ["the", 356], ["hypothesis", 360], ["that", 371], ["one", 376], ["or", 380], ["more", 383], ["NOX", 388], ["isoform(s", 392], [")", 401], ["mediate(s", 403], [")", 412], ["diabetic", 414], ["uncoupling", 423], ["of", 434], ["eNOS", 437], [",", 441], ["which", 443], ["has", 449], ["been", 453], ["shown", 458], ["to", 464], ["occur", 467], ["in", 473], ["patients", 476], ["with", 485], ["diabetes", 490], ["to", 499], ["contribute", 502], ["to", 513], ["endothelial", 516], ["dysfunction", 528], [".", 539], ["Diabetes", 541], ["was", 550], ["induced", 554], ["by", 562], ["streptozotocin", 565], ["administration", 580], [".", 594], ["The", 596], ["N", 600], ["(", 602], ["\u03c9)-nitro", 603], ["-", 611], ["L", 612], ["-", 613], ["arginine", 614], ["methyl", 623], ["ester", 630], ["(", 636], ["L", 637], ["-", 638], ["NAME)-sensitive", 639], ["superoxide", 655], ["production", 666], ["of", 677], ["aortic", 680], ["segments", 687], [",", 695], ["reflective", 697], ["of", 708], ["eNOS", 711], ["uncoupling", 716], ["activity", 727], [",", 735], ["was", 737], ["determined", 741], ["by", 752], ["electron", 755], ["spin", 764], ["resonance", 769], [".", 778], ["The", 780], ["L", 784], ["-", 785], ["NAME", 786], ["-", 790], ["sensitive", 791], ["superoxide", 801], ["production", 812], ["was", 823], ["more", 827], ["than", 832], ["doubled", 837], ["in", 845], ["wild", 848], ["-", 852], ["type", 853], ["diabetic", 858], ["mice", 867], [",", 871], ["implicating", 873], ["uncoupling", 885], ["of", 896], ["eNOS", 899], [".", 903], ["This", 905], ["was", 910], ["abolished", 914], ["in", 924], ["diabetic", 927], ["p47", 936], ["(", 940], ["phox-/-", 942], [")", 949], ["(", 951], ["also", 952], ["known", 957], ["as", 963], ["Ncf1", 966], ["(", 971], ["-/-", 972], [")", 975], [")", 976], ["mice", 978], [",", 982], ["but", 984], ["preserved", 988], ["in", 998], ["Nox2", 1001], ["(", 1006], ["-/y", 1007], [")", 1010], ["(", 1012], ["also", 1013], ["known", 1018], ["as", 1024], ["Cybb", 1027], ["(", 1032], ["-/-", 1033], [")", 1036], [")", 1037], ["mice", 1039], ["made", 1044], ["diabetic", 1049], [".", 1057], ["The", 1059], ["eNOS", 1063], ["uncoupling", 1068], ["activity", 1079], ["was", 1088], ["markedly", 1092], ["attenuated", 1101], ["in", 1112], ["diabetic", 1115], ["mice", 1124], ["transfected", 1129], ["with", 1141], ["Nox1", 1146], ["or", 1151], ["Nox1", 1154], ["organiser", 1159], ["1", 1169], ["(", 1171], ["Noxo1", 1172], [")", 1177], ["short", 1179], ["interfering", 1185], ["RNA", 1197], ["(", 1201], ["siRNA", 1202], [")", 1207], [",", 1208], ["and", 1210], ["abolished", 1214], ["in", 1224], ["Nox1", 1227], ["(", 1232], ["-/y", 1233], [")", 1236], ["diabetic", 1238], ["mice", 1247], [".", 1251], ["Diabetes", 1253], ["-", 1261], ["induced", 1262], ["impairment", 1270], ["in", 1281], ["endothelium", 1284], ["-", 1295], ["dependent", 1296], ["vasorelaxation", 1306], ["was", 1321], ["also", 1325], ["significantly", 1330], ["attenuated", 1344], ["in", 1355], ["the", 1358], ["Nox1", 1362], ["(", 1367], ["-/y", 1368], [")", 1371], ["mice", 1373], ["made", 1378], ["diabetic", 1383], [".", 1391], ["By", 1393], ["contrast", 1396], [",", 1404], ["Nox4", 1406], ["siRNA", 1411], [",", 1416], ["or", 1418], ["inhibition", 1421], ["of", 1432], ["mitochondrial", 1435], ["complex", 1449], ["I", 1457], ["or", 1459], ["III", 1462], ["with", 1466], ["rotenone", 1471], ["or", 1480], ["siRNA", 1483], [",", 1488], ["respectively", 1490], [",", 1502], ["had", 1504], ["no", 1508], ["effect", 1511], ["on", 1518], ["diabetic", 1521], ["uncoupling", 1530], ["of", 1541], ["eNOS", 1544], [".", 1548], ["Overexpression", 1550], ["of", 1565], ["Dhfr", 1568], [",", 1572], ["or", 1574], ["oral", 1577], ["administration", 1582], ["of", 1597], ["folic", 1600], ["acid", 1606], ["to", 1611], ["improve", 1614], ["dihydrofolate", 1622], ["reductase", 1636], ["(", 1646], ["DHFR", 1647], [")", 1651], ["function", 1653], [",", 1661], ["recoupled", 1663], ["eNOS", 1673], ["in", 1678], ["diabetes", 1681], ["to", 1690], ["improve", 1693], ["endothelial", 1701], ["function", 1713], [".", 1721], ["Our", 1723], ["data", 1727], ["demonstrate", 1732], ["for", 1744], ["the", 1748], ["first", 1752], ["time", 1758], ["that", 1763], ["the", 1768], ["p47(phox", 1772], [")", 1780], ["and", 1782], ["NOXO1-dependent", 1786], ["activation", 1802], ["of", 1813], ["NOX1", 1816], [",", 1820], ["but", 1822], ["not", 1826], ["that", 1830], ["of", 1835], ["NOX2", 1838], [",", 1842], ["NOX4", 1844], ["or", 1849], ["mitochondrion", 1852], [",", 1865], ["mediates", 1867], ["diabetic", 1876], ["uncoupling", 1885], ["of", 1896], ["eNOS", 1899], [".", 1903], ["NOX1-null", 1905], ["mice", 1915], ["are", 1920], ["protected", 1924], ["from", 1934], ["diabetic", 1939], ["endothelial", 1948], ["dysfunction", 1960], [".", 1971], ["Novel", 1973], ["approaches", 1979], ["to", 1990], ["inhibit", 1993], ["NOX1", 2001], ["and/or", 2006], ["improve", 2013], ["DHFR", 2021], ["function", 2026], [",", 2034], ["may", 2036], ["prove", 2040], ["to", 2046], ["have", 2049], ["therapeutic", 2054], ["potential", 2066], ["for", 2076], ["diabetic", 2080], ["endothelial", 2089], ["dysfunction", 2101], [".", 2112]]}
{"context": "Hospitalization for exacerbation of COPD is associated with a high risk of mortality. A risk-prediction model using information easily obtained on admission could help to identify high-risk individuals. The CURB65 score was developed to predict mortality risk in community acquired pneumonia. A retrospective study found that this score was also associated with mortality in COPD exacerbations. We conducted a prospective study to assess the utility of the CURB65 score in acute COPD exacerbations. Consecutive patients with physician diagnosed COPD exacerbations admitted to a public hospital during a 1-year period were studied prospectively. The CURB65 scores were calculated from information obtained at initial hospital presentation. CURB65\u2003=\u2003one point each for Confusion, Urea\u2003>\u20037 mmol/L, Respiratory rate\u2003\u2265\u200330/min, low Blood pressure, age\u2003\u2265\u200365 years. 30-day mortality data were available for 249 of 252 patients. CURB65 scores on admission significantly predicted risk of death during the hospital admission and at 30\u2003days. The 30-day mortality by score groups were: low risk (scores 0-1) 2.0% (2/98), moderate risk (score 2) 6.7% (6/90) and high risk (scores 3-5) 21.3% (13/61). CURB65 scores were not predictive of 1-year mortality. A simple 6-point score based on confusion, blood urea, respiratory rate, blood pressure and age can be used to stratify patients with COPD exacerbation into different management groups. The CURB65 score was as effective in predicting early mortality in our cohort of acute COPD exacerbations as it was in previous cohorts with community acquired pneumonia. Our findings suggest that CURB65 scores can help clinicians to assess patients with exacerbation of COPD.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "930ebd41e49942059fff966207ce5c03", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[288, 288], [46, 46]], "char_spans": [[1588, 1596], [282, 290]]}]}], "context_tokens": [["Hospitalization", 0], ["for", 16], ["exacerbation", 20], ["of", 33], ["COPD", 36], ["is", 41], ["associated", 44], ["with", 55], ["a", 60], ["high", 62], ["risk", 67], ["of", 72], ["mortality", 75], [".", 84], ["A", 86], ["risk", 88], ["-", 92], ["prediction", 93], ["model", 104], ["using", 110], ["information", 116], ["easily", 128], ["obtained", 135], ["on", 144], ["admission", 147], ["could", 157], ["help", 163], ["to", 168], ["identify", 171], ["high", 180], ["-", 184], ["risk", 185], ["individuals", 190], [".", 201], ["The", 203], ["CURB65", 207], ["score", 214], ["was", 220], ["developed", 224], ["to", 234], ["predict", 237], ["mortality", 245], ["risk", 255], ["in", 260], ["community", 263], ["acquired", 273], ["pneumonia", 282], [".", 291], ["A", 293], ["retrospective", 295], ["study", 309], ["found", 315], ["that", 321], ["this", 326], ["score", 331], ["was", 337], ["also", 341], ["associated", 346], ["with", 357], ["mortality", 362], ["in", 372], ["COPD", 375], ["exacerbations", 380], [".", 393], ["We", 395], ["conducted", 398], ["a", 408], ["prospective", 410], ["study", 422], ["to", 428], ["assess", 431], ["the", 438], ["utility", 442], ["of", 450], ["the", 453], ["CURB65", 457], ["score", 464], ["in", 470], ["acute", 473], ["COPD", 479], ["exacerbations", 484], [".", 497], ["Consecutive", 499], ["patients", 511], ["with", 520], ["physician", 525], ["diagnosed", 535], ["COPD", 545], ["exacerbations", 550], ["admitted", 564], ["to", 573], ["a", 576], ["public", 578], ["hospital", 585], ["during", 594], ["a", 601], ["1-year", 603], ["period", 610], ["were", 617], ["studied", 622], ["prospectively", 630], [".", 643], ["The", 645], ["CURB65", 649], ["scores", 656], ["were", 663], ["calculated", 668], ["from", 679], ["information", 684], ["obtained", 696], ["at", 705], ["initial", 708], ["hospital", 716], ["presentation", 725], [".", 737], ["CURB65", 739], ["=", 746], ["one", 748], ["point", 752], ["each", 758], ["for", 763], ["Confusion", 767], [",", 776], ["Urea", 778], [">", 783], ["7", 785], ["mmol", 787], ["/", 791], ["L", 792], [",", 793], ["Respiratory", 795], ["rate", 807], ["\u2265", 812], ["30/min", 814], [",", 820], ["low", 822], ["Blood", 826], ["pressure", 832], [",", 840], ["age", 842], ["\u2265", 846], ["65", 848], ["years", 851], [".", 856], ["30-day", 858], ["mortality", 865], ["data", 875], ["were", 880], ["available", 885], ["for", 895], ["249", 899], ["of", 903], ["252", 906], ["patients", 910], [".", 918], ["CURB65", 920], ["scores", 927], ["on", 934], ["admission", 937], ["significantly", 947], ["predicted", 961], ["risk", 971], ["of", 976], ["death", 979], ["during", 985], ["the", 992], ["hospital", 996], ["admission", 1005], ["and", 1015], ["at", 1019], ["30", 1022], ["days", 1025], [".", 1029], ["The", 1031], ["30-day", 1035], ["mortality", 1042], ["by", 1052], ["score", 1055], ["groups", 1061], ["were", 1068], [":", 1072], ["low", 1074], ["risk", 1078], ["(", 1083], ["scores", 1084], ["0", 1091], ["-", 1092], ["1", 1093], [")", 1094], ["2.0", 1096], ["%", 1099], ["(", 1101], ["2/98", 1102], [")", 1106], [",", 1107], ["moderate", 1109], ["risk", 1118], ["(", 1123], ["score", 1124], ["2", 1130], [")", 1131], ["6.7", 1133], ["%", 1136], ["(", 1138], ["6/90", 1139], [")", 1143], ["and", 1145], ["high", 1149], ["risk", 1154], ["(", 1159], ["scores", 1160], ["3", 1167], ["-", 1168], ["5", 1169], [")", 1170], ["21.3", 1172], ["%", 1176], ["(", 1178], ["13/61", 1179], [")", 1184], [".", 1185], ["CURB65", 1187], ["scores", 1194], ["were", 1201], ["not", 1206], ["predictive", 1210], ["of", 1221], ["1-year", 1224], ["mortality", 1231], [".", 1240], ["A", 1242], ["simple", 1244], ["6-point", 1251], ["score", 1259], ["based", 1265], ["on", 1271], ["confusion", 1274], [",", 1283], ["blood", 1285], ["urea", 1291], [",", 1295], ["respiratory", 1297], ["rate", 1309], [",", 1313], ["blood", 1315], ["pressure", 1321], ["and", 1330], ["age", 1334], ["can", 1338], ["be", 1342], ["used", 1345], ["to", 1350], ["stratify", 1353], ["patients", 1362], ["with", 1371], ["COPD", 1376], ["exacerbation", 1381], ["into", 1394], ["different", 1399], ["management", 1409], ["groups", 1420], [".", 1426], ["The", 1428], ["CURB65", 1432], ["score", 1439], ["was", 1445], ["as", 1449], ["effective", 1452], ["in", 1462], ["predicting", 1465], ["early", 1476], ["mortality", 1482], ["in", 1492], ["our", 1495], ["cohort", 1499], ["of", 1506], ["acute", 1509], ["COPD", 1515], ["exacerbations", 1520], ["as", 1534], ["it", 1537], ["was", 1540], ["in", 1544], ["previous", 1547], ["cohorts", 1556], ["with", 1564], ["community", 1569], ["acquired", 1579], ["pneumonia", 1588], [".", 1597], ["Our", 1599], ["findings", 1603], ["suggest", 1612], ["that", 1620], ["CURB65", 1625], ["scores", 1632], ["can", 1639], ["help", 1643], ["clinicians", 1648], ["to", 1659], ["assess", 1662], ["patients", 1669], ["with", 1678], ["exacerbation", 1683], ["of", 1696], ["COPD", 1699], [".", 1703]]}
{"context": "Accumulation and deposition of \u03b2-amyloid peptides (A\u03b2) in the brain is a central event in the pathogenesis of Alzheimer's disease (AD). Besides the parenchymal pathology, A\u03b2 is known to undergo active transport across the blood-brain barrier and cerebral amyloid angiopathy (CAA) is a prominent feature in the majority of AD. Although impaired cerebral blood flow (CBF) has been implicated in faulty A\u03b2 transport and clearance, and cerebral hypoperfusion can exist in the pre-clinical phase of Alzheimer's disease (AD), it is still unclear whether it is one of the causal factors for AD pathogenesis, or an early consequence of a multi-factor condition that would lead to AD at late stage. To study the potential interaction between faulty CBF and amyloid accumulation in clinical-relevant situation, we generated a new amyloid precursor protein (APP) knock-in allele that expresses humanized A\u03b2 and a Dutch mutation in addition to Swedish/London mutations and compared this line with an equivalent knock-in line but in the absence of the Dutch mutation, both crossed onto the PS1M146V knock-in background. Introduction of the Dutch mutation results in robust CAA and parenchymal A\u03b2 pathology, age-dependent reduction of spatial learning and memory deficits, and CBF reduction as detected by fMRI. Direct manipulation of CBF by transverse aortic constriction surgery on the left common carotid artery caused differential changes in CBF in the anterior and middle region of the cortex, where it is reduced on the left side and increased on the right side. However these perturbations in CBF resulted in the same effect: both significantly exacerbate CAA and amyloid pathology. Our study reveals a direct and positive link between vascular and parenchymal A\u03b2; both can be modulated by CBF. The new APP knock-in mouse model recapitulates many symptoms of AD including progressive vascular and parenchymal A\u03b2 pathology and behavioral deficits in the absence of APP overexpression.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "fd787f32d19848dbb65fe34c00222562", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[22, 24], [94, 96]], "char_spans": [[110, 128], [494, 512]]}, {"text": "AD", "token_spans": [[131, 131], [98, 98], [26, 26], [342, 342], [62, 62], [114, 114]], "char_spans": [[672, 673], [515, 516], [131, 132], [1852, 1853], [322, 323], [584, 585]]}]}], "context_tokens": [["Accumulation", 0], ["and", 13], ["deposition", 17], ["of", 28], ["\u03b2", 31], ["-", 32], ["amyloid", 33], ["peptides", 41], ["(", 50], ["A\u03b2", 51], [")", 53], ["in", 55], ["the", 58], ["brain", 62], ["is", 68], ["a", 71], ["central", 73], ["event", 81], ["in", 87], ["the", 90], ["pathogenesis", 94], ["of", 107], ["Alzheimer", 110], ["'s", 119], ["disease", 122], ["(", 130], ["AD", 131], [")", 133], [".", 134], ["Besides", 136], ["the", 144], ["parenchymal", 148], ["pathology", 160], [",", 169], ["A\u03b2", 171], ["is", 174], ["known", 177], ["to", 183], ["undergo", 186], ["active", 194], ["transport", 201], ["across", 211], ["the", 218], ["blood", 222], ["-", 227], ["brain", 228], ["barrier", 234], ["and", 242], ["cerebral", 246], ["amyloid", 255], ["angiopathy", 263], ["(", 274], ["CAA", 275], [")", 278], ["is", 280], ["a", 283], ["prominent", 285], ["feature", 295], ["in", 303], ["the", 306], ["majority", 310], ["of", 319], ["AD", 322], [".", 324], ["Although", 326], ["impaired", 335], ["cerebral", 344], ["blood", 353], ["flow", 359], ["(", 364], ["CBF", 365], [")", 368], ["has", 370], ["been", 374], ["implicated", 379], ["in", 390], ["faulty", 393], ["A\u03b2", 400], ["transport", 403], ["and", 413], ["clearance", 417], [",", 426], ["and", 428], ["cerebral", 432], ["hypoperfusion", 441], ["can", 455], ["exist", 459], ["in", 465], ["the", 468], ["pre", 472], ["-", 475], ["clinical", 476], ["phase", 485], ["of", 491], ["Alzheimer", 494], ["'s", 503], ["disease", 506], ["(", 514], ["AD", 515], [")", 517], [",", 518], ["it", 520], ["is", 523], ["still", 526], ["unclear", 532], ["whether", 540], ["it", 548], ["is", 551], ["one", 554], ["of", 558], ["the", 561], ["causal", 565], ["factors", 572], ["for", 580], ["AD", 584], ["pathogenesis", 587], [",", 599], ["or", 601], ["an", 604], ["early", 607], ["consequence", 613], ["of", 625], ["a", 628], ["multi", 630], ["-", 635], ["factor", 636], ["condition", 643], ["that", 653], ["would", 658], ["lead", 664], ["to", 669], ["AD", 672], ["at", 675], ["late", 678], ["stage", 683], [".", 688], ["To", 690], ["study", 693], ["the", 699], ["potential", 703], ["interaction", 713], ["between", 725], ["faulty", 733], ["CBF", 740], ["and", 744], ["amyloid", 748], ["accumulation", 756], ["in", 769], ["clinical", 772], ["-", 780], ["relevant", 781], ["situation", 790], [",", 799], ["we", 801], ["generated", 804], ["a", 814], ["new", 816], ["amyloid", 820], ["precursor", 828], ["protein", 838], ["(", 846], ["APP", 847], [")", 850], ["knock", 852], ["-", 857], ["in", 858], ["allele", 861], ["that", 868], ["expresses", 873], ["humanized", 883], ["A\u03b2", 893], ["and", 896], ["a", 900], ["Dutch", 902], ["mutation", 908], ["in", 917], ["addition", 920], ["to", 929], ["Swedish", 932], ["/", 939], ["London", 940], ["mutations", 947], ["and", 957], ["compared", 961], ["this", 970], ["line", 975], ["with", 980], ["an", 985], ["equivalent", 988], ["knock", 999], ["-", 1004], ["in", 1005], ["line", 1008], ["but", 1013], ["in", 1017], ["the", 1020], ["absence", 1024], ["of", 1032], ["the", 1035], ["Dutch", 1039], ["mutation", 1045], [",", 1053], ["both", 1055], ["crossed", 1060], ["onto", 1068], ["the", 1073], ["PS1M146V", 1077], ["knock", 1086], ["-", 1091], ["in", 1092], ["background", 1095], [".", 1105], ["Introduction", 1107], ["of", 1120], ["the", 1123], ["Dutch", 1127], ["mutation", 1133], ["results", 1142], ["in", 1150], ["robust", 1153], ["CAA", 1160], ["and", 1164], ["parenchymal", 1168], ["A\u03b2", 1180], ["pathology", 1183], [",", 1192], ["age", 1194], ["-", 1197], ["dependent", 1198], ["reduction", 1208], ["of", 1218], ["spatial", 1221], ["learning", 1229], ["and", 1238], ["memory", 1242], ["deficits", 1249], [",", 1257], ["and", 1259], ["CBF", 1263], ["reduction", 1267], ["as", 1277], ["detected", 1280], ["by", 1289], ["fMRI", 1292], [".", 1296], ["Direct", 1298], ["manipulation", 1305], ["of", 1318], ["CBF", 1321], ["by", 1325], ["transverse", 1328], ["aortic", 1339], ["constriction", 1346], ["surgery", 1359], ["on", 1367], ["the", 1370], ["left", 1374], ["common", 1379], ["carotid", 1386], ["artery", 1394], ["caused", 1401], ["differential", 1408], ["changes", 1421], ["in", 1429], ["CBF", 1432], ["in", 1436], ["the", 1439], ["anterior", 1443], ["and", 1452], ["middle", 1456], ["region", 1463], ["of", 1470], ["the", 1473], ["cortex", 1477], [",", 1483], ["where", 1485], ["it", 1491], ["is", 1494], ["reduced", 1497], ["on", 1505], ["the", 1508], ["left", 1512], ["side", 1517], ["and", 1522], ["increased", 1526], ["on", 1536], ["the", 1539], ["right", 1543], ["side", 1549], [".", 1553], ["However", 1555], ["these", 1563], ["perturbations", 1569], ["in", 1583], ["CBF", 1586], ["resulted", 1590], ["in", 1599], ["the", 1602], ["same", 1606], ["effect", 1611], [":", 1617], ["both", 1619], ["significantly", 1624], ["exacerbate", 1638], ["CAA", 1649], ["and", 1653], ["amyloid", 1657], ["pathology", 1665], [".", 1674], ["Our", 1676], ["study", 1680], ["reveals", 1686], ["a", 1694], ["direct", 1696], ["and", 1703], ["positive", 1707], ["link", 1716], ["between", 1721], ["vascular", 1729], ["and", 1738], ["parenchymal", 1742], ["A\u03b2", 1754], [";", 1756], ["both", 1758], ["can", 1763], ["be", 1767], ["modulated", 1770], ["by", 1780], ["CBF", 1783], [".", 1786], ["The", 1788], ["new", 1792], ["APP", 1796], ["knock", 1800], ["-", 1805], ["in", 1806], ["mouse", 1809], ["model", 1815], ["recapitulates", 1821], ["many", 1835], ["symptoms", 1840], ["of", 1849], ["AD", 1852], ["including", 1855], ["progressive", 1865], ["vascular", 1877], ["and", 1886], ["parenchymal", 1890], ["A\u03b2", 1902], ["pathology", 1905], ["and", 1915], ["behavioral", 1919], ["deficits", 1930], ["in", 1939], ["the", 1942], ["absence", 1946], ["of", 1954], ["APP", 1957], ["overexpression", 1961], [".", 1975]]}
{"context": "Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility. It comprises Ehlers-Danlos syndrome type I and Ehlers-Danlos syndrome type II, but it is now apparent that these form a continuum of clinical findings and differ only in phenotypic severity. It is currently estimated that approximately 50% of patients with a clinical diagnosis of classic Ehlers-Danlos syndrome harbor mutations in the COL5A1 and the COL5A2 gene, encoding the \u03b11 and the \u03b12-chain of type V collagen, respectively. However, because no prospective molecular studies of COL5A1 and COL5A2 have been performed in a clinically well-defined patient group, this number may underestimate the real proportion of patients with classic Ehlers-Danlos syndrome harboring a mutation in one of these genes. In the majority of patients with molecularly characterized classic Ehlers-Danlos syndrome, the disease is caused by a mutation leading to a nonfunctional COL5A1 allele and resulting in haploinsufficiency of type V collagen. A smaller proportion of patients harbor a structural mutation in COL5A1 or COL5A2, causing the production of a functionally defective type V collagen protein. Most mutations identified so far result in a reduced amount of type V collagen in the connective tissues available for collagen fibrillogenesis. Inter- and intrafamilial phenotypic variability is observed, but no genotype-phenotype correlations have been observed. No treatment for the underlying defect is presently available for Ehlers-Danlos syndrome. However, a series of preventive guidelines are applicable.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "90435bdf04fb46fd88c52fcb14d2c478", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[8, 9]], "char_spans": [[46, 62]]}]}], "context_tokens": [["Classic", 0], ["Ehlers", 8], ["-", 14], ["Danlos", 15], ["syndrome", 22], ["is", 31], ["a", 34], ["heritable", 36], ["connective", 46], ["tissue", 57], ["disorder", 64], ["characterized", 73], ["by", 87], ["skin", 90], ["hyperextensibility", 95], [",", 113], ["fragile", 115], ["and", 123], ["soft", 127], ["skin", 132], [",", 136], ["delayed", 138], ["wound", 146], ["healing", 152], ["with", 160], ["formation", 165], ["of", 175], ["atrophic", 178], ["scars", 187], [",", 192], ["easy", 194], ["bruising", 199], [",", 207], ["and", 209], ["generalized", 213], ["joint", 225], ["hypermobility", 231], [".", 244], ["It", 246], ["comprises", 249], ["Ehlers", 259], ["-", 265], ["Danlos", 266], ["syndrome", 273], ["type", 282], ["I", 287], ["and", 289], ["Ehlers", 293], ["-", 299], ["Danlos", 300], ["syndrome", 307], ["type", 316], ["II", 321], [",", 323], ["but", 325], ["it", 329], ["is", 332], ["now", 335], ["apparent", 339], ["that", 348], ["these", 353], ["form", 359], ["a", 364], ["continuum", 366], ["of", 376], ["clinical", 379], ["findings", 388], ["and", 397], ["differ", 401], ["only", 408], ["in", 413], ["phenotypic", 416], ["severity", 427], [".", 435], ["It", 437], ["is", 440], ["currently", 443], ["estimated", 453], ["that", 463], ["approximately", 468], ["50", 482], ["%", 484], ["of", 486], ["patients", 489], ["with", 498], ["a", 503], ["clinical", 505], ["diagnosis", 514], ["of", 524], ["classic", 527], ["Ehlers", 535], ["-", 541], ["Danlos", 542], ["syndrome", 549], ["harbor", 558], ["mutations", 565], ["in", 575], ["the", 578], ["COL5A1", 582], ["and", 589], ["the", 593], ["COL5A2", 597], ["gene", 604], [",", 608], ["encoding", 610], ["the", 619], ["\u03b11", 623], ["and", 626], ["the", 630], ["\u03b12-chain", 634], ["of", 643], ["type", 646], ["V", 651], ["collagen", 653], [",", 661], ["respectively", 663], [".", 675], ["However", 677], [",", 684], ["because", 686], ["no", 694], ["prospective", 697], ["molecular", 709], ["studies", 719], ["of", 727], ["COL5A1", 730], ["and", 737], ["COL5A2", 741], ["have", 748], ["been", 753], ["performed", 758], ["in", 768], ["a", 771], ["clinically", 773], ["well", 784], ["-", 788], ["defined", 789], ["patient", 797], ["group", 805], [",", 810], ["this", 812], ["number", 817], ["may", 824], ["underestimate", 828], ["the", 842], ["real", 846], ["proportion", 851], ["of", 862], ["patients", 865], ["with", 874], ["classic", 879], ["Ehlers", 887], ["-", 893], ["Danlos", 894], ["syndrome", 901], ["harboring", 910], ["a", 920], ["mutation", 922], ["in", 931], ["one", 934], ["of", 938], ["these", 941], ["genes", 947], [".", 952], ["In", 954], ["the", 957], ["majority", 961], ["of", 970], ["patients", 973], ["with", 982], ["molecularly", 987], ["characterized", 999], ["classic", 1013], ["Ehlers", 1021], ["-", 1027], ["Danlos", 1028], ["syndrome", 1035], [",", 1043], ["the", 1045], ["disease", 1049], ["is", 1057], ["caused", 1060], ["by", 1067], ["a", 1070], ["mutation", 1072], ["leading", 1081], ["to", 1089], ["a", 1092], ["nonfunctional", 1094], ["COL5A1", 1108], ["allele", 1115], ["and", 1122], ["resulting", 1126], ["in", 1136], ["haploinsufficiency", 1139], ["of", 1158], ["type", 1161], ["V", 1166], ["collagen", 1168], [".", 1176], ["A", 1178], ["smaller", 1180], ["proportion", 1188], ["of", 1199], ["patients", 1202], ["harbor", 1211], ["a", 1218], ["structural", 1220], ["mutation", 1231], ["in", 1240], ["COL5A1", 1243], ["or", 1250], ["COL5A2", 1253], [",", 1259], ["causing", 1261], ["the", 1269], ["production", 1273], ["of", 1284], ["a", 1287], ["functionally", 1289], ["defective", 1302], ["type", 1312], ["V", 1317], ["collagen", 1319], ["protein", 1328], [".", 1335], ["Most", 1337], ["mutations", 1342], ["identified", 1352], ["so", 1363], ["far", 1366], ["result", 1370], ["in", 1377], ["a", 1380], ["reduced", 1382], ["amount", 1390], ["of", 1397], ["type", 1400], ["V", 1405], ["collagen", 1407], ["in", 1416], ["the", 1419], ["connective", 1423], ["tissues", 1434], ["available", 1442], ["for", 1452], ["collagen", 1456], ["fibrillogenesis", 1465], [".", 1480], ["Inter-", 1482], ["and", 1489], ["intrafamilial", 1493], ["phenotypic", 1507], ["variability", 1518], ["is", 1530], ["observed", 1533], [",", 1541], ["but", 1543], ["no", 1547], ["genotype", 1550], ["-", 1558], ["phenotype", 1559], ["correlations", 1569], ["have", 1582], ["been", 1587], ["observed", 1592], [".", 1600], ["No", 1602], ["treatment", 1605], ["for", 1615], ["the", 1619], ["underlying", 1623], ["defect", 1634], ["is", 1641], ["presently", 1644], ["available", 1654], ["for", 1664], ["Ehlers", 1668], ["-", 1674], ["Danlos", 1675], ["syndrome", 1682], [".", 1690], ["However", 1692], [",", 1699], ["a", 1701], ["series", 1703], ["of", 1710], ["preventive", 1713], ["guidelines", 1724], ["are", 1735], ["applicable", 1739], [".", 1749]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a key orchestrator in inflammatory and several immune responses. IL-1\u03b2 exerts its effects through interleukin-1 receptor type I (IL-1RI) and interleukin-1 receptor accessory protein (IL-1RAcP), which together form a heterotrimeric signaling-competent complex. Canakinumab and gevokizumab are highly specific IL-1\u03b2 monoclonal antibodies. Canakinumab is known to neutralize IL-1\u03b2 by competing for binding to IL-1R and therefore blocking signaling by the antigen:antibody complex. Gevokizumab is claimed to be a regulatory therapeutic antibody that modulates IL-1\u03b2 bioactivity by reducing the affinity for its IL-1RI:IL-1RAcP signaling complex. How IL-1\u03b2 signaling is affected by both canakinumab and gevokizumab was not yet experimentally determined. We have analyzed the crystal structures of canakinumab and gevokizumab antibody binding fragment (Fab) as well as of their binary complexes with IL-1\u03b2. Furthermore, we characterized the epitopes on IL-1\u03b2 employed by the antibodies by NMR epitope mapping studies. The direct comparison of NMR and X-ray data shows that the epitope defined by the crystal structure encompasses predominantly those residues whose NMR resonances are severely perturbed upon complex formation. The antigen:Fab co-structures confirm the previously identified key contact residues on IL-1\u03b2 and provide insight into the mechanisms leading to their distinct modulation of IL-1\u03b2 signaling. A significant steric overlap of the binding interfaces of IL-1R and canakinumab on IL-1\u03b2 causes competitive inhibition of the association of IL-1\u03b2 and its receptor. In contrast, gevokizumab occupies an allosteric site on IL-1\u03b2 and complex formation results in a minor reduction of binding affinity to IL-1RI. This suggests two different mechanisms of IL-1\u03b2 pathway attenuation.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "2f0cee196ddb4065924495ca24e444df", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[144, 144], [61, 61], [90, 90], [52, 52], [212, 212], [105, 105], [153, 153], [249, 249], [263, 263], [284, 284], [225, 225], [2, 2], [15, 15], [241, 241]], "char_spans": [[920, 924], [398, 402], [582, 586], [334, 338], [1335, 1339], [672, 676], [973, 977], [1579, 1583], [1659, 1663], [1789, 1793], [1421, 1425], [16, 20], [91, 95], [1521, 1525]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["key", 28], ["orchestrator", 32], ["in", 45], ["inflammatory", 48], ["and", 61], ["several", 65], ["immune", 73], ["responses", 80], [".", 89], ["IL-1\u03b2", 91], ["exerts", 97], ["its", 104], ["effects", 108], ["through", 116], ["interleukin-1", 124], ["receptor", 138], ["type", 147], ["I", 152], ["(", 154], ["IL-1RI", 155], [")", 161], ["and", 163], ["interleukin-1", 167], ["receptor", 181], ["accessory", 190], ["protein", 200], ["(", 208], ["IL-1RAcP", 209], [")", 217], [",", 218], ["which", 220], ["together", 226], ["form", 235], ["a", 240], ["heterotrimeric", 242], ["signaling", 257], ["-", 266], ["competent", 267], ["complex", 277], [".", 284], ["Canakinumab", 286], ["and", 298], ["gevokizumab", 302], ["are", 314], ["highly", 318], ["specific", 325], ["IL-1\u03b2", 334], ["monoclonal", 340], ["antibodies", 351], [".", 361], ["Canakinumab", 363], ["is", 375], ["known", 378], ["to", 384], ["neutralize", 387], ["IL-1\u03b2", 398], ["by", 404], ["competing", 407], ["for", 417], ["binding", 421], ["to", 429], ["IL-1R", 432], ["and", 438], ["therefore", 442], ["blocking", 452], ["signaling", 461], ["by", 471], ["the", 474], ["antigen", 478], [":", 485], ["antibody", 486], ["complex", 495], [".", 502], ["Gevokizumab", 504], ["is", 516], ["claimed", 519], ["to", 527], ["be", 530], ["a", 533], ["regulatory", 535], ["therapeutic", 546], ["antibody", 558], ["that", 567], ["modulates", 572], ["IL-1\u03b2", 582], ["bioactivity", 588], ["by", 600], ["reducing", 603], ["the", 612], ["affinity", 616], ["for", 625], ["its", 629], ["IL-1RI", 633], [":", 639], ["IL-1RAcP", 640], ["signaling", 649], ["complex", 659], [".", 666], ["How", 668], ["IL-1\u03b2", 672], ["signaling", 678], ["is", 688], ["affected", 691], ["by", 700], ["both", 703], ["canakinumab", 708], ["and", 720], ["gevokizumab", 724], ["was", 736], ["not", 740], ["yet", 744], ["experimentally", 748], ["determined", 763], [".", 773], ["We", 775], ["have", 778], ["analyzed", 783], ["the", 792], ["crystal", 796], ["structures", 804], ["of", 815], ["canakinumab", 818], ["and", 830], ["gevokizumab", 834], ["antibody", 846], ["binding", 855], ["fragment", 863], ["(", 872], ["Fab", 873], [")", 876], ["as", 878], ["well", 881], ["as", 886], ["of", 889], ["their", 892], ["binary", 898], ["complexes", 905], ["with", 915], ["IL-1\u03b2", 920], [".", 925], ["Furthermore", 927], [",", 938], ["we", 940], ["characterized", 943], ["the", 957], ["epitopes", 961], ["on", 970], ["IL-1\u03b2", 973], ["employed", 979], ["by", 988], ["the", 991], ["antibodies", 995], ["by", 1006], ["NMR", 1009], ["epitope", 1013], ["mapping", 1021], ["studies", 1029], [".", 1036], ["The", 1038], ["direct", 1042], ["comparison", 1049], ["of", 1060], ["NMR", 1063], ["and", 1067], ["X", 1071], ["-", 1072], ["ray", 1073], ["data", 1077], ["shows", 1082], ["that", 1088], ["the", 1093], ["epitope", 1097], ["defined", 1105], ["by", 1113], ["the", 1116], ["crystal", 1120], ["structure", 1128], ["encompasses", 1138], ["predominantly", 1150], ["those", 1164], ["residues", 1170], ["whose", 1179], ["NMR", 1185], ["resonances", 1189], ["are", 1200], ["severely", 1204], ["perturbed", 1213], ["upon", 1223], ["complex", 1228], ["formation", 1236], [".", 1245], ["The", 1247], ["antigen", 1251], [":", 1258], ["Fab", 1259], ["co", 1263], ["-", 1265], ["structures", 1266], ["confirm", 1277], ["the", 1285], ["previously", 1289], ["identified", 1300], ["key", 1311], ["contact", 1315], ["residues", 1323], ["on", 1332], ["IL-1\u03b2", 1335], ["and", 1341], ["provide", 1345], ["insight", 1353], ["into", 1361], ["the", 1366], ["mechanisms", 1370], ["leading", 1381], ["to", 1389], ["their", 1392], ["distinct", 1398], ["modulation", 1407], ["of", 1418], ["IL-1\u03b2", 1421], ["signaling", 1427], [".", 1436], ["A", 1438], ["significant", 1440], ["steric", 1452], ["overlap", 1459], ["of", 1467], ["the", 1470], ["binding", 1474], ["interfaces", 1482], ["of", 1493], ["IL-1R", 1496], ["and", 1502], ["canakinumab", 1506], ["on", 1518], ["IL-1\u03b2", 1521], ["causes", 1527], ["competitive", 1534], ["inhibition", 1546], ["of", 1557], ["the", 1560], ["association", 1564], ["of", 1576], ["IL-1\u03b2", 1579], ["and", 1585], ["its", 1589], ["receptor", 1593], [".", 1601], ["In", 1603], ["contrast", 1606], [",", 1614], ["gevokizumab", 1616], ["occupies", 1628], ["an", 1637], ["allosteric", 1640], ["site", 1651], ["on", 1656], ["IL-1\u03b2", 1659], ["and", 1665], ["complex", 1669], ["formation", 1677], ["results", 1687], ["in", 1695], ["a", 1698], ["minor", 1700], ["reduction", 1706], ["of", 1716], ["binding", 1719], ["affinity", 1727], ["to", 1736], ["IL-1RI", 1739], [".", 1745], ["This", 1747], ["suggests", 1752], ["two", 1761], ["different", 1765], ["mechanisms", 1775], ["of", 1786], ["IL-1\u03b2", 1789], ["pathway", 1795], ["attenuation", 1803], [".", 1814]]}
{"context": "MicroRNAs (miRNAs) regulate many biological processes such as development, metabolism, and others. They are processed from their primary transcripts called primary miRNA transcripts (pri-miRNAs) by the processor complex containing the RNAse III enzyme, DICER-LIKE1 (DCL1), in plants. Consequently, miRNA biogenesis is controlled through altering pri-miRNA accumulation and processing, which is crucial for plant development and adaptation to environmental changes. Plant pri-miRNAs are transcribed by DNA-dependent RNA polymerase II (Pol II) and their levels are determined through transcription and degradation, whereas pri-miRNA processing is affected by its structure, splicing, alternative splicing, loading to the processor and the processor activity, which involve in many accessory proteins. Here, we summarize recent progresses related to pri-miRNA transcription, stability, and processing in plants.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "900bfac64b0f4a6b8c03e872ceb0fbf1", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[90, 92]], "char_spans": [[515, 531]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["regulate", 19], ["many", 28], ["biological", 33], ["processes", 44], ["such", 54], ["as", 59], ["development", 62], [",", 73], ["metabolism", 75], [",", 85], ["and", 87], ["others", 91], [".", 97], ["They", 99], ["are", 104], ["processed", 108], ["from", 118], ["their", 123], ["primary", 129], ["transcripts", 137], ["called", 149], ["primary", 156], ["miRNA", 164], ["transcripts", 170], ["(", 182], ["pri", 183], ["-", 186], ["miRNAs", 187], [")", 193], ["by", 195], ["the", 198], ["processor", 202], ["complex", 212], ["containing", 220], ["the", 231], ["RNAse", 235], ["III", 241], ["enzyme", 245], [",", 251], ["DICER", 253], ["-", 258], ["LIKE1", 259], ["(", 265], ["DCL1", 266], [")", 270], [",", 271], ["in", 273], ["plants", 276], [".", 282], ["Consequently", 284], [",", 296], ["miRNA", 298], ["biogenesis", 304], ["is", 315], ["controlled", 318], ["through", 329], ["altering", 337], ["pri", 346], ["-", 349], ["miRNA", 350], ["accumulation", 356], ["and", 369], ["processing", 373], [",", 383], ["which", 385], ["is", 391], ["crucial", 394], ["for", 402], ["plant", 406], ["development", 412], ["and", 424], ["adaptation", 428], ["to", 439], ["environmental", 442], ["changes", 456], [".", 463], ["Plant", 465], ["pri", 471], ["-", 474], ["miRNAs", 475], ["are", 482], ["transcribed", 486], ["by", 498], ["DNA", 501], ["-", 504], ["dependent", 505], ["RNA", 515], ["polymerase", 519], ["II", 530], ["(", 533], ["Pol", 534], ["II", 538], [")", 540], ["and", 542], ["their", 546], ["levels", 552], ["are", 559], ["determined", 563], ["through", 574], ["transcription", 582], ["and", 596], ["degradation", 600], [",", 611], ["whereas", 613], ["pri", 621], ["-", 624], ["miRNA", 625], ["processing", 631], ["is", 642], ["affected", 645], ["by", 654], ["its", 657], ["structure", 661], [",", 670], ["splicing", 672], [",", 680], ["alternative", 682], ["splicing", 694], [",", 702], ["loading", 704], ["to", 712], ["the", 715], ["processor", 719], ["and", 729], ["the", 733], ["processor", 737], ["activity", 747], [",", 755], ["which", 757], ["involve", 763], ["in", 771], ["many", 774], ["accessory", 779], ["proteins", 789], [".", 797], ["Here", 799], [",", 803], ["we", 805], ["summarize", 808], ["recent", 818], ["progresses", 825], ["related", 836], ["to", 844], ["pri", 847], ["-", 850], ["miRNA", 851], ["transcription", 857], [",", 870], ["stability", 872], [",", 881], ["and", 883], ["processing", 887], ["in", 898], ["plants", 901], [".", 907]]}
{"context": "The susceptibility to arbekacin (ABK) of methicillin-resistant Staphylococcus aureus (MRSA) was investigated to find out how it related to aac(6')/aph(2\") gene. In 49 isolates of MRSA for which MIC of ABK ranged from 0.125 to 64 micrograms/ml, the MICs of ABK for 38 strains carrying aac(6')/aph(2\") gene were widely distributed from 0.25 to 64, whereas those for 11 strains without that gene were all < or = 0.5 microgram/ml. Residual rate of ABK activity was higher than that of gentamicin after the reaction with each crude enzyme preparation extracted from 3 isolates of MRSA, carrying aac(6')/aph(2\") and aad(4',4\") genes. Furthermore, 97 strains of MRSA isolated at Kanagawa prefecture in Japan in 1999 were all sensitive to ABK, although 28 strains of them carried aac(6')/aph(2\") gene. These results showed that ABK resistance was not necessarily related to carrying aac(6')/aph(2\") gene in clinical isolates of MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "c28f41488c09478c988e4e82f733d188", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[14, 14], [128, 128], [34, 34], [174, 174], [111, 111]], "char_spans": [[86, 89], [655, 658], [179, 182], [920, 923], [575, 578]]}]}], "context_tokens": [["The", 0], ["susceptibility", 4], ["to", 19], ["arbekacin", 22], ["(", 32], ["ABK", 33], [")", 36], ["of", 38], ["methicillin", 41], ["-", 52], ["resistant", 53], ["Staphylococcus", 63], ["aureus", 78], ["(", 85], ["MRSA", 86], [")", 90], ["was", 92], ["investigated", 96], ["to", 109], ["find", 112], ["out", 117], ["how", 121], ["it", 125], ["related", 128], ["to", 136], ["aac(6')/aph(2", 139], ["\"", 152], [")", 153], ["gene", 155], [".", 159], ["In", 161], ["49", 164], ["isolates", 167], ["of", 176], ["MRSA", 179], ["for", 184], ["which", 188], ["MIC", 194], ["of", 198], ["ABK", 201], ["ranged", 205], ["from", 212], ["0.125", 217], ["to", 223], ["64", 226], ["micrograms", 229], ["/", 239], ["ml", 240], [",", 242], ["the", 244], ["MICs", 248], ["of", 253], ["ABK", 256], ["for", 260], ["38", 264], ["strains", 267], ["carrying", 275], ["aac(6')/aph(2", 284], ["\"", 297], [")", 298], ["gene", 300], ["were", 305], ["widely", 310], ["distributed", 317], ["from", 329], ["0.25", 334], ["to", 339], ["64", 342], [",", 344], ["whereas", 346], ["those", 354], ["for", 360], ["11", 364], ["strains", 367], ["without", 375], ["that", 383], ["gene", 388], ["were", 393], ["all", 398], ["<", 402], ["or", 404], ["=", 407], ["0.5", 409], ["microgram", 413], ["/", 422], ["ml", 423], [".", 425], ["Residual", 427], ["rate", 436], ["of", 441], ["ABK", 444], ["activity", 448], ["was", 457], ["higher", 461], ["than", 468], ["that", 473], ["of", 478], ["gentamicin", 481], ["after", 492], ["the", 498], ["reaction", 502], ["with", 511], ["each", 516], ["crude", 521], ["enzyme", 527], ["preparation", 534], ["extracted", 546], ["from", 556], ["3", 561], ["isolates", 563], ["of", 572], ["MRSA", 575], [",", 579], ["carrying", 581], ["aac(6')/aph(2", 590], ["\"", 603], [")", 604], ["and", 606], ["aad(4',4", 610], ["\"", 618], [")", 619], ["genes", 621], [".", 626], ["Furthermore", 628], [",", 639], ["97", 641], ["strains", 644], ["of", 652], ["MRSA", 655], ["isolated", 660], ["at", 669], ["Kanagawa", 672], ["prefecture", 681], ["in", 692], ["Japan", 695], ["in", 701], ["1999", 704], ["were", 709], ["all", 714], ["sensitive", 718], ["to", 728], ["ABK", 731], [",", 734], ["although", 736], ["28", 745], ["strains", 748], ["of", 756], ["them", 759], ["carried", 764], ["aac(6')/aph(2", 772], ["\"", 785], [")", 786], ["gene", 788], [".", 792], ["These", 794], ["results", 800], ["showed", 808], ["that", 815], ["ABK", 820], ["resistance", 824], ["was", 835], ["not", 839], ["necessarily", 843], ["related", 855], ["to", 863], ["carrying", 866], ["aac(6')/aph(2", 875], ["\"", 888], [")", 889], ["gene", 891], ["in", 896], ["clinical", 899], ["isolates", 908], ["of", 917], ["MRSA", 920], [".", 924]]}
{"context": "Centrosome forms the backbone of cell cycle progression mechanism. Recent debates have occurred regarding the essentiality of centrosome in cell cycle regulation. CEP family protein is the active component of centrosome and plays a vital role in centriole biogenesis and cell cycle progression control. A total of 31 proteins have been categorized into CEP family protein category and many more are under candidate evaluation. Furthermore, by the recent advancements in genomics and proteomics researches, several new CEP proteins have also been characterized. Here we have summarized the importance of CEP family proteins and their regulation mechanism involved in proper cell cycle progression. Further, we have reviewed the detailed molecular mechanism behind the associated pathological phenotypes and the possible therapeutic approaches. Proteins such as CEP57, CEP63, CEP152, CEP164, and CEP215 have been extensively studied with a detailed description of their molecular mechanisms, which are among the primary targets for drug discovery. Moreover, CEP27, CEP55, CEP70, CEP110, CEP120, CEP135, CEP192, CEP250, CEP290, and CEP350 also seem promising for future drug discovery approaches. Since the overview implicates that the overall researches on CEP proteins are not yet able to present significant details required for effective therapeutics development, thus, it is timely to discuss the importance of future investigations in this field.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "bc41177a6b044b729aab22fd26e9d225", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[0, 0], [32, 32], [18, 18]], "char_spans": [[0, 9], [209, 218], [126, 135]]}]}], "context_tokens": [["Centrosome", 0], ["forms", 11], ["the", 17], ["backbone", 21], ["of", 30], ["cell", 33], ["cycle", 38], ["progression", 44], ["mechanism", 56], [".", 65], ["Recent", 67], ["debates", 74], ["have", 82], ["occurred", 87], ["regarding", 96], ["the", 106], ["essentiality", 110], ["of", 123], ["centrosome", 126], ["in", 137], ["cell", 140], ["cycle", 145], ["regulation", 151], [".", 161], ["CEP", 163], ["family", 167], ["protein", 174], ["is", 182], ["the", 185], ["active", 189], ["component", 196], ["of", 206], ["centrosome", 209], ["and", 220], ["plays", 224], ["a", 230], ["vital", 232], ["role", 238], ["in", 243], ["centriole", 246], ["biogenesis", 256], ["and", 267], ["cell", 271], ["cycle", 276], ["progression", 282], ["control", 294], [".", 301], ["A", 303], ["total", 305], ["of", 311], ["31", 314], ["proteins", 317], ["have", 326], ["been", 331], ["categorized", 336], ["into", 348], ["CEP", 353], ["family", 357], ["protein", 364], ["category", 372], ["and", 381], ["many", 385], ["more", 390], ["are", 395], ["under", 399], ["candidate", 405], ["evaluation", 415], [".", 425], ["Furthermore", 427], [",", 438], ["by", 440], ["the", 443], ["recent", 447], ["advancements", 454], ["in", 467], ["genomics", 470], ["and", 479], ["proteomics", 483], ["researches", 494], [",", 504], ["several", 506], ["new", 514], ["CEP", 518], ["proteins", 522], ["have", 531], ["also", 536], ["been", 541], ["characterized", 546], [".", 559], ["Here", 561], ["we", 566], ["have", 569], ["summarized", 574], ["the", 585], ["importance", 589], ["of", 600], ["CEP", 603], ["family", 607], ["proteins", 614], ["and", 623], ["their", 627], ["regulation", 633], ["mechanism", 644], ["involved", 654], ["in", 663], ["proper", 666], ["cell", 673], ["cycle", 678], ["progression", 684], [".", 695], ["Further", 697], [",", 704], ["we", 706], ["have", 709], ["reviewed", 714], ["the", 723], ["detailed", 727], ["molecular", 736], ["mechanism", 746], ["behind", 756], ["the", 763], ["associated", 767], ["pathological", 778], ["phenotypes", 791], ["and", 802], ["the", 806], ["possible", 810], ["therapeutic", 819], ["approaches", 831], [".", 841], ["Proteins", 843], ["such", 852], ["as", 857], ["CEP57", 860], [",", 865], ["CEP63", 867], [",", 872], ["CEP152", 874], [",", 880], ["CEP164", 882], [",", 888], ["and", 890], ["CEP215", 894], ["have", 901], ["been", 906], ["extensively", 911], ["studied", 923], ["with", 931], ["a", 936], ["detailed", 938], ["description", 947], ["of", 959], ["their", 962], ["molecular", 968], ["mechanisms", 978], [",", 988], ["which", 990], ["are", 996], ["among", 1000], ["the", 1006], ["primary", 1010], ["targets", 1018], ["for", 1026], ["drug", 1030], ["discovery", 1035], [".", 1044], ["Moreover", 1046], [",", 1054], ["CEP27", 1056], [",", 1061], ["CEP55", 1063], [",", 1068], ["CEP70", 1070], [",", 1075], ["CEP110", 1077], [",", 1083], ["CEP120", 1085], [",", 1091], ["CEP135", 1093], [",", 1099], ["CEP192", 1101], [",", 1107], ["CEP250", 1109], [",", 1115], ["CEP290", 1117], [",", 1123], ["and", 1125], ["CEP350", 1129], ["also", 1136], ["seem", 1141], ["promising", 1146], ["for", 1156], ["future", 1160], ["drug", 1167], ["discovery", 1172], ["approaches", 1182], [".", 1192], ["Since", 1194], ["the", 1200], ["overview", 1204], ["implicates", 1213], ["that", 1224], ["the", 1229], ["overall", 1233], ["researches", 1241], ["on", 1252], ["CEP", 1255], ["proteins", 1259], ["are", 1268], ["not", 1272], ["yet", 1276], ["able", 1280], ["to", 1285], ["present", 1288], ["significant", 1296], ["details", 1308], ["required", 1316], ["for", 1325], ["effective", 1329], ["therapeutics", 1339], ["development", 1352], [",", 1363], ["thus", 1365], [",", 1369], ["it", 1371], ["is", 1374], ["timely", 1377], ["to", 1384], ["discuss", 1387], ["the", 1395], ["importance", 1399], ["of", 1410], ["future", 1413], ["investigations", 1420], ["in", 1435], ["this", 1438], ["field", 1443], [".", 1448]]}
{"context": "To evaluate the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin added to metformin for 12\u2009weeks in patients with type 2 diabetes. This dose-ranging, double-blind, placebo-controlled trial randomized 495 participants with type 2 diabetes inadequately controlled on metformin [haemoglobin A1c (HbA1c) >7 to \u226410%] to receive 1, 5, 10, 25, or 50\u2009mg empagliflozin once daily (QD), or placebo, or open-label sitagliptin (100\u2009mg QD), added to metformin for 12\u2009weeks. The primary endpoint was change in HbA1c from baseline to week 12 (empagliflozin groups versus placebo). Reductions in HbA1c of -0.09 to -0.56% were observed with empagliflozin after 12\u2009weeks, versus an increase of 0.15% with placebo (baseline: 7.8-8.1%). Compared with placebo, empagliflozin doses from 5 to 50\u2009mg resulted in reductions in fasting plasma glucose (-2 to -28\u2009mg/dl vs. 5\u2009mg/dl with placebo; p\u2009<\u20090.0001) and body weight (-2.3 to -2.9\u2009kg vs. -1.2\u2009kg; p\u2009<\u20090.01). Frequency of adverse events was generally similar with empagliflozin (29.6-48.6%), placebo (36.6%) and sitagliptin (35.2%). Hypoglycaemia rates were very low and balanced among groups. Most frequent adverse events with empagliflozin were urinary tract infections (4.0% vs. 2.8% with placebo) and pollakiuria (2.5% vs. 1.4% with placebo). Genital infections were reported only with empagliflozin (4.0%). Once daily empagliflozin as add-on therapy to metformin was well tolerated except for increased genital infections and resulted in reductions in HbA1c, fasting plasma glucose and body weight in patients with type 2 diabetes inadequately controlled on metformin monotherapy.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "42c9f1c1eae84fa0885493a31db38248", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[11, 11]], "char_spans": [[63, 67]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["effects", 16], ["of", 24], ["the", 27], ["sodium", 31], ["glucose", 38], ["cotransporter", 46], ["2", 60], ["(", 62], ["SGLT2", 63], [")", 68], ["inhibitor", 70], ["empagliflozin", 80], ["added", 94], ["to", 100], ["metformin", 103], ["for", 113], ["12", 117], ["weeks", 120], ["in", 126], ["patients", 129], ["with", 138], ["type", 143], ["2", 148], ["diabetes", 150], [".", 158], ["This", 160], ["dose", 165], ["-", 169], ["ranging", 170], [",", 177], ["double", 179], ["-", 185], ["blind", 186], [",", 191], ["placebo", 193], ["-", 200], ["controlled", 201], ["trial", 212], ["randomized", 218], ["495", 229], ["participants", 233], ["with", 246], ["type", 251], ["2", 256], ["diabetes", 258], ["inadequately", 267], ["controlled", 280], ["on", 291], ["metformin", 294], ["[", 304], ["haemoglobin", 305], ["A1c", 317], ["(", 321], ["HbA1c", 322], [")", 327], [">", 329], ["7", 330], ["to", 332], ["\u226410", 335], ["%", 338], ["]", 339], ["to", 341], ["receive", 344], ["1", 352], [",", 353], ["5", 355], [",", 356], ["10", 358], [",", 360], ["25", 362], [",", 364], ["or", 366], ["50", 369], ["mg", 372], ["empagliflozin", 375], ["once", 389], ["daily", 394], ["(", 400], ["QD", 401], [")", 403], [",", 404], ["or", 406], ["placebo", 409], [",", 416], ["or", 418], ["open", 421], ["-", 425], ["label", 426], ["sitagliptin", 432], ["(", 444], ["100", 445], ["mg", 449], ["QD", 452], [")", 454], [",", 455], ["added", 457], ["to", 463], ["metformin", 466], ["for", 476], ["12", 480], ["weeks", 483], [".", 488], ["The", 490], ["primary", 494], ["endpoint", 502], ["was", 511], ["change", 515], ["in", 522], ["HbA1c", 525], ["from", 531], ["baseline", 536], ["to", 545], ["week", 548], ["12", 553], ["(", 556], ["empagliflozin", 557], ["groups", 571], ["versus", 578], ["placebo", 585], [")", 592], [".", 593], ["Reductions", 595], ["in", 606], ["HbA1c", 609], ["of", 615], ["-0.09", 618], ["to", 624], ["-0.56", 627], ["%", 632], ["were", 634], ["observed", 639], ["with", 648], ["empagliflozin", 653], ["after", 667], ["12", 673], ["weeks", 676], [",", 681], ["versus", 683], ["an", 690], ["increase", 693], ["of", 702], ["0.15", 705], ["%", 709], ["with", 711], ["placebo", 716], ["(", 724], ["baseline", 725], [":", 733], ["7.8", 735], ["-", 738], ["8.1", 739], ["%", 742], [")", 743], [".", 744], ["Compared", 746], ["with", 755], ["placebo", 760], [",", 767], ["empagliflozin", 769], ["doses", 783], ["from", 789], ["5", 794], ["to", 796], ["50", 799], ["mg", 802], ["resulted", 805], ["in", 814], ["reductions", 817], ["in", 828], ["fasting", 831], ["plasma", 839], ["glucose", 846], ["(", 854], ["-2", 855], ["to", 858], ["-28", 861], ["mg", 865], ["/", 867], ["dl", 868], ["vs.", 871], ["5", 875], ["mg", 877], ["/", 879], ["dl", 880], ["with", 883], ["placebo", 888], [";", 895], ["p", 897], ["<", 899], ["0.0001", 901], [")", 907], ["and", 909], ["body", 913], ["weight", 918], ["(", 925], ["-2.3", 926], ["to", 931], ["-2.9", 934], ["kg", 939], ["vs.", 942], ["-1.2", 946], ["kg", 951], [";", 953], ["p", 955], ["<", 957], ["0.01", 959], [")", 963], [".", 964], ["Frequency", 966], ["of", 976], ["adverse", 979], ["events", 987], ["was", 994], ["generally", 998], ["similar", 1008], ["with", 1016], ["empagliflozin", 1021], ["(", 1035], ["29.6", 1036], ["-", 1040], ["48.6", 1041], ["%", 1045], [")", 1046], [",", 1047], ["placebo", 1049], ["(", 1057], ["36.6", 1058], ["%", 1062], [")", 1063], ["and", 1065], ["sitagliptin", 1069], ["(", 1081], ["35.2", 1082], ["%", 1086], [")", 1087], [".", 1088], ["Hypoglycaemia", 1090], ["rates", 1104], ["were", 1110], ["very", 1115], ["low", 1120], ["and", 1124], ["balanced", 1128], ["among", 1137], ["groups", 1143], [".", 1149], ["Most", 1151], ["frequent", 1156], ["adverse", 1165], ["events", 1173], ["with", 1180], ["empagliflozin", 1185], ["were", 1199], ["urinary", 1204], ["tract", 1212], ["infections", 1218], ["(", 1229], ["4.0", 1230], ["%", 1233], ["vs.", 1235], ["2.8", 1239], ["%", 1242], ["with", 1244], ["placebo", 1249], [")", 1256], ["and", 1258], ["pollakiuria", 1262], ["(", 1274], ["2.5", 1275], ["%", 1278], ["vs.", 1280], ["1.4", 1284], ["%", 1287], ["with", 1289], ["placebo", 1294], [")", 1301], [".", 1302], ["Genital", 1304], ["infections", 1312], ["were", 1323], ["reported", 1328], ["only", 1337], ["with", 1342], ["empagliflozin", 1347], ["(", 1361], ["4.0", 1362], ["%", 1365], [")", 1366], [".", 1367], ["Once", 1369], ["daily", 1374], ["empagliflozin", 1380], ["as", 1394], ["add", 1397], ["-", 1400], ["on", 1401], ["therapy", 1404], ["to", 1412], ["metformin", 1415], ["was", 1425], ["well", 1429], ["tolerated", 1434], ["except", 1444], ["for", 1451], ["increased", 1455], ["genital", 1465], ["infections", 1473], ["and", 1484], ["resulted", 1488], ["in", 1497], ["reductions", 1500], ["in", 1511], ["HbA1c", 1514], [",", 1519], ["fasting", 1521], ["plasma", 1529], ["glucose", 1536], ["and", 1544], ["body", 1548], ["weight", 1553], ["in", 1560], ["patients", 1563], ["with", 1572], ["type", 1577], ["2", 1582], ["diabetes", 1584], ["inadequately", 1593], ["controlled", 1606], ["on", 1617], ["metformin", 1620], ["monotherapy", 1630], [".", 1641]]}
{"context": "Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to evaluate the tolerability, pharmacokinetics (including the effect of food) and pharmacodynamics (effect on COMT activity) following single oral doses of opicapone in young healthy male volunteers. Single rising oral doses of opicapone (10, 25, 50, 100, 200, 400, 800 and 1,200 mg) were administered to eight groups of eight subjects per group (two subjects randomized to placebo and six subjects to opicapone), under a double-blind, randomized, placebo-controlled design. In an additional group of 12 subjects, a 50 mg single dose of opicapone was administered on two occasions, once having fasted overnight and once with a high-fat high-calorie meal. Opicapone was well tolerated at all doses tested. The extent of systemic exposure (area under the plasma concentration-time curve and maximum plasma concentration) to opicapone and metabolites increased in an approximately dose-proportional manner and showed a decrease following concomitant ingestion of a high-fat high-calorie meal. The apparent terminal elimination half-life of opicapone was 0.8-3.2 h. Sulphation appeared to be the main metabolic pathway for opicapone, and both opicapone and the main sulphated metabolite are likely excreted by the biliary route. Maximum COMT inhibition by opicapone was dose dependent, ranged from 36.1% (10 mg) to 100% (200 mg and above), and reached statistical significance at all doses tested. The long duration of COMT inhibition by opicapone, however, tended to be independent from the dose taken. The observed half-life of opicapone-induced COMT inhibition in human erythrocytes was 61.6 h (standard deviation [SD] = 37.6 h), which reflects an underlying dissociative process with a kinetic rate constant of 3.1 \u00d7 10(-6) s(-1) (SD = 1.9 \u00d7 10(-6) s(-1)). Such a process compares well to the estimated dissociation rate constant (k(off)) of the COMT-opicapone molecular complex (k(off) = 1.9 \u00d7 10(-6) s(-1)). Opicapone was well-tolerated and presented dose-proportional kinetics. Opicapone demonstrated marked and sustained inhibition of erythrocyte soluble COMT activity. Based on the observation that the half-life of COMT inhibition is independent of the dose and that it reflects an underlying kinetic process that is consistent with the k(off) value of the COMT-opicapone complex, we propose that the sustained COMT inhibition, far beyond the observable point of clearance of circulating drug, is due to the long residence time of the reversible complex formed between COMT and opicapone. Globally, these promising results provide a basis for further clinical development of opicapone.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "27c5cce16a694b1292f9a384c43beab6", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[4, 8]], "char_spans": [[21, 48]]}]}], "context_tokens": [["Opicapone", 0], ["is", 10], ["a", 13], ["novel", 15], ["catechol", 21], ["-", 29], ["O", 30], ["-", 31], ["methyltransferase", 32], ["(", 50], ["COMT", 51], [")", 55], ["inhibitor", 57], [".", 66], ["The", 68], ["purpose", 72], ["of", 80], ["this", 83], ["study", 88], ["was", 94], ["to", 98], ["evaluate", 101], ["the", 110], ["tolerability", 114], [",", 126], ["pharmacokinetics", 128], ["(", 145], ["including", 146], ["the", 156], ["effect", 160], ["of", 167], ["food", 170], [")", 174], ["and", 176], ["pharmacodynamics", 180], ["(", 197], ["effect", 198], ["on", 205], ["COMT", 208], ["activity", 213], [")", 221], ["following", 223], ["single", 233], ["oral", 240], ["doses", 245], ["of", 251], ["opicapone", 254], ["in", 264], ["young", 267], ["healthy", 273], ["male", 281], ["volunteers", 286], [".", 296], ["Single", 298], ["rising", 305], ["oral", 312], ["doses", 317], ["of", 323], ["opicapone", 326], ["(", 336], ["10", 337], [",", 339], ["25", 341], [",", 343], ["50", 345], [",", 347], ["100", 349], [",", 352], ["200", 354], [",", 357], ["400", 359], [",", 362], ["800", 364], ["and", 368], ["1,200", 372], ["mg", 378], [")", 380], ["were", 382], ["administered", 387], ["to", 400], ["eight", 403], ["groups", 409], ["of", 416], ["eight", 419], ["subjects", 425], ["per", 434], ["group", 438], ["(", 444], ["two", 445], ["subjects", 449], ["randomized", 458], ["to", 469], ["placebo", 472], ["and", 480], ["six", 484], ["subjects", 488], ["to", 497], ["opicapone", 500], [")", 509], [",", 510], ["under", 512], ["a", 518], ["double", 520], ["-", 526], ["blind", 527], [",", 532], ["randomized", 534], [",", 544], ["placebo", 546], ["-", 553], ["controlled", 554], ["design", 565], [".", 571], ["In", 573], ["an", 576], ["additional", 579], ["group", 590], ["of", 596], ["12", 599], ["subjects", 602], [",", 610], ["a", 612], ["50", 614], ["mg", 617], ["single", 620], ["dose", 627], ["of", 632], ["opicapone", 635], ["was", 645], ["administered", 649], ["on", 662], ["two", 665], ["occasions", 669], [",", 678], ["once", 680], ["having", 685], ["fasted", 692], ["overnight", 699], ["and", 709], ["once", 713], ["with", 718], ["a", 723], ["high", 725], ["-", 729], ["fat", 730], ["high", 734], ["-", 738], ["calorie", 739], ["meal", 747], [".", 751], ["Opicapone", 753], ["was", 763], ["well", 767], ["tolerated", 772], ["at", 782], ["all", 785], ["doses", 789], ["tested", 795], [".", 801], ["The", 803], ["extent", 807], ["of", 814], ["systemic", 817], ["exposure", 826], ["(", 835], ["area", 836], ["under", 841], ["the", 847], ["plasma", 851], ["concentration", 858], ["-", 871], ["time", 872], ["curve", 877], ["and", 883], ["maximum", 887], ["plasma", 895], ["concentration", 902], [")", 915], ["to", 917], ["opicapone", 920], ["and", 930], ["metabolites", 934], ["increased", 946], ["in", 956], ["an", 959], ["approximately", 962], ["dose", 976], ["-", 980], ["proportional", 981], ["manner", 994], ["and", 1001], ["showed", 1005], ["a", 1012], ["decrease", 1014], ["following", 1023], ["concomitant", 1033], ["ingestion", 1045], ["of", 1055], ["a", 1058], ["high", 1060], ["-", 1064], ["fat", 1065], ["high", 1069], ["-", 1073], ["calorie", 1074], ["meal", 1082], [".", 1086], ["The", 1088], ["apparent", 1092], ["terminal", 1101], ["elimination", 1110], ["half", 1122], ["-", 1126], ["life", 1127], ["of", 1132], ["opicapone", 1135], ["was", 1145], ["0.8", 1149], ["-", 1152], ["3.2", 1153], ["h.", 1157], ["Sulphation", 1160], ["appeared", 1171], ["to", 1180], ["be", 1183], ["the", 1186], ["main", 1190], ["metabolic", 1195], ["pathway", 1205], ["for", 1213], ["opicapone", 1217], [",", 1226], ["and", 1228], ["both", 1232], ["opicapone", 1237], ["and", 1247], ["the", 1251], ["main", 1255], ["sulphated", 1260], ["metabolite", 1270], ["are", 1281], ["likely", 1285], ["excreted", 1292], ["by", 1301], ["the", 1304], ["biliary", 1308], ["route", 1316], [".", 1321], ["Maximum", 1323], ["COMT", 1331], ["inhibition", 1336], ["by", 1347], ["opicapone", 1350], ["was", 1360], ["dose", 1364], ["dependent", 1369], [",", 1378], ["ranged", 1380], ["from", 1387], ["36.1", 1392], ["%", 1396], ["(", 1398], ["10", 1399], ["mg", 1402], [")", 1404], ["to", 1406], ["100", 1409], ["%", 1412], ["(", 1414], ["200", 1415], ["mg", 1419], ["and", 1422], ["above", 1426], [")", 1431], [",", 1432], ["and", 1434], ["reached", 1438], ["statistical", 1446], ["significance", 1458], ["at", 1471], ["all", 1474], ["doses", 1478], ["tested", 1484], [".", 1490], ["The", 1492], ["long", 1496], ["duration", 1501], ["of", 1510], ["COMT", 1513], ["inhibition", 1518], ["by", 1529], ["opicapone", 1532], [",", 1541], ["however", 1543], [",", 1550], ["tended", 1552], ["to", 1559], ["be", 1562], ["independent", 1565], ["from", 1577], ["the", 1582], ["dose", 1586], ["taken", 1591], [".", 1596], ["The", 1598], ["observed", 1602], ["half", 1611], ["-", 1615], ["life", 1616], ["of", 1621], ["opicapone", 1624], ["-", 1633], ["induced", 1634], ["COMT", 1642], ["inhibition", 1647], ["in", 1658], ["human", 1661], ["erythrocytes", 1667], ["was", 1680], ["61.6", 1684], ["h", 1689], ["(", 1691], ["standard", 1692], ["deviation", 1701], ["[", 1711], ["SD", 1712], ["]", 1714], ["=", 1716], ["37.6", 1718], ["h", 1723], [")", 1724], [",", 1725], ["which", 1727], ["reflects", 1733], ["an", 1742], ["underlying", 1745], ["dissociative", 1756], ["process", 1769], ["with", 1777], ["a", 1782], ["kinetic", 1784], ["rate", 1792], ["constant", 1797], ["of", 1806], ["3.1", 1809], ["\u00d7", 1813], ["10(-6", 1815], [")", 1820], ["s(-1", 1822], [")", 1826], ["(", 1828], ["SD", 1829], ["=", 1832], ["1.9", 1834], ["\u00d7", 1838], ["10(-6", 1840], [")", 1845], ["s(-1", 1847], [")", 1851], [")", 1852], [".", 1853], ["Such", 1855], ["a", 1860], ["process", 1862], ["compares", 1870], ["well", 1879], ["to", 1884], ["the", 1887], ["estimated", 1891], ["dissociation", 1901], ["rate", 1914], ["constant", 1919], ["(", 1928], ["k(off", 1929], [")", 1934], [")", 1935], ["of", 1937], ["the", 1940], ["COMT", 1944], ["-", 1948], ["opicapone", 1949], ["molecular", 1959], ["complex", 1969], ["(", 1977], ["k(off", 1978], [")", 1983], ["=", 1985], ["1.9", 1987], ["\u00d7", 1991], ["10(-6", 1993], [")", 1998], ["s(-1", 2000], [")", 2004], [")", 2005], [".", 2006], ["Opicapone", 2008], ["was", 2018], ["well", 2022], ["-", 2026], ["tolerated", 2027], ["and", 2037], ["presented", 2041], ["dose", 2051], ["-", 2055], ["proportional", 2056], ["kinetics", 2069], [".", 2077], ["Opicapone", 2079], ["demonstrated", 2089], ["marked", 2102], ["and", 2109], ["sustained", 2113], ["inhibition", 2123], ["of", 2134], ["erythrocyte", 2137], ["soluble", 2149], ["COMT", 2157], ["activity", 2162], [".", 2170], ["Based", 2172], ["on", 2178], ["the", 2181], ["observation", 2185], ["that", 2197], ["the", 2202], ["half", 2206], ["-", 2210], ["life", 2211], ["of", 2216], ["COMT", 2219], ["inhibition", 2224], ["is", 2235], ["independent", 2238], ["of", 2250], ["the", 2253], ["dose", 2257], ["and", 2262], ["that", 2266], ["it", 2271], ["reflects", 2274], ["an", 2283], ["underlying", 2286], ["kinetic", 2297], ["process", 2305], ["that", 2313], ["is", 2318], ["consistent", 2321], ["with", 2332], ["the", 2337], ["k(off", 2341], [")", 2346], ["value", 2348], ["of", 2354], ["the", 2357], ["COMT", 2361], ["-", 2365], ["opicapone", 2366], ["complex", 2376], [",", 2383], ["we", 2385], ["propose", 2388], ["that", 2396], ["the", 2401], ["sustained", 2405], ["COMT", 2415], ["inhibition", 2420], [",", 2430], ["far", 2432], ["beyond", 2436], ["the", 2443], ["observable", 2447], ["point", 2458], ["of", 2464], ["clearance", 2467], ["of", 2477], ["circulating", 2480], ["drug", 2492], [",", 2496], ["is", 2498], ["due", 2501], ["to", 2505], ["the", 2508], ["long", 2512], ["residence", 2517], ["time", 2527], ["of", 2532], ["the", 2535], ["reversible", 2539], ["complex", 2550], ["formed", 2558], ["between", 2565], ["COMT", 2573], ["and", 2578], ["opicapone", 2582], [".", 2591], ["Globally", 2593], [",", 2601], ["these", 2603], ["promising", 2609], ["results", 2619], ["provide", 2627], ["a", 2635], ["basis", 2637], ["for", 2643], ["further", 2647], ["clinical", 2655], ["development", 2664], ["of", 2676], ["opicapone", 2679], [".", 2688]]}
{"context": "Romano-Ward syndrome is a subtype of prolonged QT syndrome with autosomal dominant inheritance. Stress-induced syncope and sudden death are secondary to ventricular tachydysrhythmias. A case report of Romano-Ward syndrome complicating pregnancy is presented. Successful therapy with propranolol for life-threatening dysrhythmias was achieved. An excellent neonatal outcome occurred.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "34757c8e5ca444a192856060543f7791", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[12, 13]], "char_spans": [[64, 81]]}]}], "context_tokens": [["Romano", 0], ["-", 6], ["Ward", 7], ["syndrome", 12], ["is", 21], ["a", 24], ["subtype", 26], ["of", 34], ["prolonged", 37], ["QT", 47], ["syndrome", 50], ["with", 59], ["autosomal", 64], ["dominant", 74], ["inheritance", 83], [".", 94], ["Stress", 96], ["-", 102], ["induced", 103], ["syncope", 111], ["and", 119], ["sudden", 123], ["death", 130], ["are", 136], ["secondary", 140], ["to", 150], ["ventricular", 153], ["tachydysrhythmias", 165], [".", 182], ["A", 184], ["case", 186], ["report", 191], ["of", 198], ["Romano", 201], ["-", 207], ["Ward", 208], ["syndrome", 213], ["complicating", 222], ["pregnancy", 235], ["is", 245], ["presented", 248], [".", 257], ["Successful", 259], ["therapy", 270], ["with", 278], ["propranolol", 283], ["for", 295], ["life", 299], ["-", 303], ["threatening", 304], ["dysrhythmias", 316], ["was", 329], ["achieved", 333], [".", 341], ["An", 343], ["excellent", 346], ["neonatal", 356], ["outcome", 365], ["occurred", 373], [".", 381]]}
{"context": "To evaluate the role of apoptosis in the pathogenesis of brain lesions in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary microangiopathy leading to cognitive decline and dementia, caused by mutations in the NOTCH3 gene. Detection of apoptotic nuclei in temporal lobe, brain stem, medulla oblongata, hippocampus and basal ganglia from one young CADASIL patient was performed by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL). Our results showed a great involvement of glial cells in apoptotic cell death in the majority of the brain regions examined; neuronal apoptosis was significantly present only in the brain stem region. We hypothesized that in the early stages of the disease neuronal involvement of apoptosis is limited to the cells of the brain stem, sparing the cortical area which is involved in neuronal apoptosis and cognitive decline later.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "63bd935131b94b97a6120e16b7ff3249", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[41, 42]], "char_spans": [[275, 285]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["role", 16], ["of", 21], ["apoptosis", 24], ["in", 34], ["the", 37], ["pathogenesis", 41], ["of", 54], ["brain", 57], ["lesions", 63], ["in", 71], ["cerebral", 74], ["autosomal", 83], ["dominant", 93], ["arteriopathy", 102], ["with", 115], ["subcortical", 120], ["infarcts", 132], ["and", 141], ["leukoencephalopathy", 145], ["(", 165], ["CADASIL", 166], [")", 173], [",", 174], ["a", 176], ["hereditary", 178], ["microangiopathy", 189], ["leading", 205], ["to", 213], ["cognitive", 216], ["decline", 226], ["and", 234], ["dementia", 238], [",", 246], ["caused", 248], ["by", 255], ["mutations", 258], ["in", 268], ["the", 271], ["NOTCH3", 275], ["gene", 282], [".", 286], ["Detection", 288], ["of", 298], ["apoptotic", 301], ["nuclei", 311], ["in", 318], ["temporal", 321], ["lobe", 330], [",", 334], ["brain", 336], ["stem", 342], [",", 346], ["medulla", 348], ["oblongata", 356], [",", 365], ["hippocampus", 367], ["and", 379], ["basal", 383], ["ganglia", 389], ["from", 397], ["one", 402], ["young", 406], ["CADASIL", 412], ["patient", 420], ["was", 428], ["performed", 432], ["by", 442], ["terminal", 445], ["deoxynucleotidyl", 454], ["transferase", 471], ["(", 483], ["TdT)-mediated", 484], ["dUTP", 498], ["nick", 503], ["end", 508], ["-", 511], ["labeling", 512], ["(", 521], ["TUNEL", 522], [")", 527], [".", 528], ["Our", 530], ["results", 534], ["showed", 542], ["a", 549], ["great", 551], ["involvement", 557], ["of", 569], ["glial", 572], ["cells", 578], ["in", 584], ["apoptotic", 587], ["cell", 597], ["death", 602], ["in", 608], ["the", 611], ["majority", 615], ["of", 624], ["the", 627], ["brain", 631], ["regions", 637], ["examined", 645], [";", 653], ["neuronal", 655], ["apoptosis", 664], ["was", 674], ["significantly", 678], ["present", 692], ["only", 700], ["in", 705], ["the", 708], ["brain", 712], ["stem", 718], ["region", 723], [".", 729], ["We", 731], ["hypothesized", 734], ["that", 747], ["in", 752], ["the", 755], ["early", 759], ["stages", 765], ["of", 772], ["the", 775], ["disease", 779], ["neuronal", 787], ["involvement", 796], ["of", 808], ["apoptosis", 811], ["is", 821], ["limited", 824], ["to", 832], ["the", 835], ["cells", 839], ["of", 845], ["the", 848], ["brain", 852], ["stem", 858], [",", 862], ["sparing", 864], ["the", 872], ["cortical", 876], ["area", 885], ["which", 890], ["is", 896], ["involved", 899], ["in", 908], ["neuronal", 911], ["apoptosis", 920], ["and", 930], ["cognitive", 934], ["decline", 944], ["later", 952], [".", 957]]}
{"context": "Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "93b3fce4ac844f3493818175471378b0", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[7, 7]], "char_spans": [[35, 39]]}]}], "context_tokens": [["Empagliflozin", 0], ["(", 14], ["Jardiance", 15], [")", 24], [":", 25], ["a", 27], ["novel", 29], ["SGLT2", 35], ["inhibitor", 41], ["for", 51], ["the", 55], ["treatment", 59], ["of", 69], ["type-2", 72], ["diabetes", 79], [".", 87]]}
{"context": "Selenoprotein P (SeP) is an extracellular glycoprotein with 8-10 selenocysteines per molecule, containing approximately 50% of total selenium in human serum. An antioxidant function of SeP has been postulated. In the present study, we show that SeP protects low-density lipoproteins (LDL) against oxidation in a cell-free in-vitro system. LDL were isolated from human blood plasma and oxidized with CuCl2, 2,2'-azobis(2-amidinopropane) (AAPH) or peroxynitrite in the presence or absence of SeP, using the formation of conjugated dienes as parameter for lipid peroxidation. SeP delayed the CuCl2- and AAPH-induced LDL oxidation significantly and more efficiently than bovine serum albumin used as control. In contrast, SeP was not capable of inhibiting peroxynitrite-induced LDL oxidation. The protection of LDL against CuCl2- and AAPH-induced oxidation provides evidence for the antioxidant capacity of SeP. Because SeP associates with endothelial membranes, it may act in vivo as a protective factor inhibiting the oxidation of LDL by reactive oxygen species.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "bc72c59b993848e78839cf94591aaa7c", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[0, 1]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Selenoprotein", 0], ["P", 14], ["(", 16], ["SeP", 17], [")", 20], ["is", 22], ["an", 25], ["extracellular", 28], ["glycoprotein", 42], ["with", 55], ["8", 60], ["-", 61], ["10", 62], ["selenocysteines", 65], ["per", 81], ["molecule", 85], [",", 93], ["containing", 95], ["approximately", 106], ["50", 120], ["%", 122], ["of", 124], ["total", 127], ["selenium", 133], ["in", 142], ["human", 145], ["serum", 151], [".", 156], ["An", 158], ["antioxidant", 161], ["function", 173], ["of", 182], ["SeP", 185], ["has", 189], ["been", 193], ["postulated", 198], [".", 208], ["In", 210], ["the", 213], ["present", 217], ["study", 225], [",", 230], ["we", 232], ["show", 235], ["that", 240], ["SeP", 245], ["protects", 249], ["low", 258], ["-", 261], ["density", 262], ["lipoproteins", 270], ["(", 283], ["LDL", 284], [")", 287], ["against", 289], ["oxidation", 297], ["in", 307], ["a", 310], ["cell", 312], ["-", 316], ["free", 317], ["in", 322], ["-", 324], ["vitro", 325], ["system", 331], [".", 337], ["LDL", 339], ["were", 343], ["isolated", 348], ["from", 357], ["human", 362], ["blood", 368], ["plasma", 374], ["and", 381], ["oxidized", 385], ["with", 394], ["CuCl2", 399], [",", 404], ["2,2'-azobis(2-amidinopropane", 406], [")", 434], ["(", 436], ["AAPH", 437], [")", 441], ["or", 443], ["peroxynitrite", 446], ["in", 460], ["the", 463], ["presence", 467], ["or", 476], ["absence", 479], ["of", 487], ["SeP", 490], [",", 493], ["using", 495], ["the", 501], ["formation", 505], ["of", 515], ["conjugated", 518], ["dienes", 529], ["as", 536], ["parameter", 539], ["for", 549], ["lipid", 553], ["peroxidation", 559], [".", 571], ["SeP", 573], ["delayed", 577], ["the", 585], ["CuCl2-", 589], ["and", 596], ["AAPH", 600], ["-", 604], ["induced", 605], ["LDL", 613], ["oxidation", 617], ["significantly", 627], ["and", 641], ["more", 645], ["efficiently", 650], ["than", 662], ["bovine", 667], ["serum", 674], ["albumin", 680], ["used", 688], ["as", 693], ["control", 696], [".", 703], ["In", 705], ["contrast", 708], [",", 716], ["SeP", 718], ["was", 722], ["not", 726], ["capable", 730], ["of", 738], ["inhibiting", 741], ["peroxynitrite", 752], ["-", 765], ["induced", 766], ["LDL", 774], ["oxidation", 778], [".", 787], ["The", 789], ["protection", 793], ["of", 804], ["LDL", 807], ["against", 811], ["CuCl2-", 819], ["and", 826], ["AAPH", 830], ["-", 834], ["induced", 835], ["oxidation", 843], ["provides", 853], ["evidence", 862], ["for", 871], ["the", 875], ["antioxidant", 879], ["capacity", 891], ["of", 900], ["SeP.", 903], ["Because", 908], ["SeP", 916], ["associates", 920], ["with", 931], ["endothelial", 936], ["membranes", 948], [",", 957], ["it", 959], ["may", 962], ["act", 966], ["in", 970], ["vivo", 973], ["as", 978], ["a", 981], ["protective", 983], ["factor", 994], ["inhibiting", 1001], ["the", 1012], ["oxidation", 1016], ["of", 1026], ["LDL", 1029], ["by", 1033], ["reactive", 1036], ["oxygen", 1045], ["species", 1052], [".", 1059]]}
{"context": "A novel Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II) inhibitor, KN-93 potently inhibits gastric acid secretion from parietal cells. As previously reported (1), treatment of parietal cells with a selective inhibitor of CaM kinase II, KN-62 resulted in the inhibition of cholinergic-stimulated rabbit parietal cell secretion, whereas it failed to inhibit the histamine and forskolin response. In contrast effects of carbachol, histamine and forskolin were significantly inhibited by KN-93 with an IC50 of 0.15, 0.3 and 1 microM, respectively; these effects occurred without any changes in intracellular cyclic AMP and Ca2+ levels. In the present study we investigated the mechanism by which KN-93 acts upon the acid-secreting machinery of gastric parietal cells. Neither redistribution of the proton pump activity nor the morphological transformation were affected by KN-93. The drug only weakly inhibited the H+, K(+)-ATPase activity but strongly dissipated the proton gradient formed in the gastric membrane vesicles and reduced the volume of luminal space. Thus KN-93 acts at pH gradient formation whereas KN-62 acts only at CaM Kinase II.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II", "CAMK2"], "qid": "b747f9b082a644009fdd2023df633b19", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "CaM kinase II", "token_spans": [[193, 195], [9, 11], [41, 43]], "char_spans": [[1141, 1153], [53, 65], [233, 245]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["Ca2+/calmodulin", 8], ["-", 23], ["dependent", 24], ["protein", 34], ["kinase", 42], ["II", 49], ["(", 52], ["CaM", 53], ["Kinase", 57], ["II", 64], [")", 66], ["inhibitor", 68], [",", 77], ["KN-93", 79], ["potently", 85], ["inhibits", 94], ["gastric", 103], ["acid", 111], ["secretion", 116], ["from", 126], ["parietal", 131], ["cells", 140], [".", 145], ["As", 147], ["previously", 150], ["reported", 161], ["(", 170], ["1", 171], [")", 172], [",", 173], ["treatment", 175], ["of", 185], ["parietal", 188], ["cells", 197], ["with", 203], ["a", 208], ["selective", 210], ["inhibitor", 220], ["of", 230], ["CaM", 233], ["kinase", 237], ["II", 244], [",", 246], ["KN-62", 248], ["resulted", 254], ["in", 263], ["the", 266], ["inhibition", 270], ["of", 281], ["cholinergic", 284], ["-", 295], ["stimulated", 296], ["rabbit", 307], ["parietal", 314], ["cell", 323], ["secretion", 328], [",", 337], ["whereas", 339], ["it", 347], ["failed", 350], ["to", 357], ["inhibit", 360], ["the", 368], ["histamine", 372], ["and", 382], ["forskolin", 386], ["response", 396], [".", 404], ["In", 406], ["contrast", 409], ["effects", 418], ["of", 426], ["carbachol", 429], [",", 438], ["histamine", 440], ["and", 450], ["forskolin", 454], ["were", 464], ["significantly", 469], ["inhibited", 483], ["by", 493], ["KN-93", 496], ["with", 502], ["an", 507], ["IC50", 510], ["of", 515], ["0.15", 518], [",", 522], ["0.3", 524], ["and", 528], ["1", 532], ["microM", 534], [",", 540], ["respectively", 542], [";", 554], ["these", 556], ["effects", 562], ["occurred", 570], ["without", 579], ["any", 587], ["changes", 591], ["in", 599], ["intracellular", 602], ["cyclic", 616], ["AMP", 623], ["and", 627], ["Ca2", 631], ["+", 634], ["levels", 636], [".", 642], ["In", 644], ["the", 647], ["present", 651], ["study", 659], ["we", 665], ["investigated", 668], ["the", 681], ["mechanism", 685], ["by", 695], ["which", 698], ["KN-93", 704], ["acts", 710], ["upon", 715], ["the", 720], ["acid", 724], ["-", 728], ["secreting", 729], ["machinery", 739], ["of", 749], ["gastric", 752], ["parietal", 760], ["cells", 769], [".", 774], ["Neither", 776], ["redistribution", 784], ["of", 799], ["the", 802], ["proton", 806], ["pump", 813], ["activity", 818], ["nor", 827], ["the", 831], ["morphological", 835], ["transformation", 849], ["were", 864], ["affected", 869], ["by", 878], ["KN-93", 881], [".", 886], ["The", 888], ["drug", 892], ["only", 897], ["weakly", 902], ["inhibited", 909], ["the", 919], ["H+", 923], [",", 925], ["K(+)-ATPase", 927], ["activity", 939], ["but", 948], ["strongly", 952], ["dissipated", 961], ["the", 972], ["proton", 976], ["gradient", 983], ["formed", 992], ["in", 999], ["the", 1002], ["gastric", 1006], ["membrane", 1014], ["vesicles", 1023], ["and", 1032], ["reduced", 1036], ["the", 1044], ["volume", 1048], ["of", 1055], ["luminal", 1058], ["space", 1066], [".", 1071], ["Thus", 1073], ["KN-93", 1078], ["acts", 1084], ["at", 1089], ["pH", 1092], ["gradient", 1095], ["formation", 1104], ["whereas", 1114], ["KN-62", 1122], ["acts", 1128], ["only", 1133], ["at", 1138], ["CaM", 1141], ["Kinase", 1145], ["II", 1152], [".", 1154]]}
{"context": "Sedation is an important aspect of care for critically ill newborns. Proper sedation reduces stress during procedures such as mechanical ventilation. Midazolam, a short-acting benzodiazepine, is widely administered as a sedative in newborn intensive care units but is not without side effects. Three term newborns developed myoclonic-like abnormal movements after receiving midazolam. In one, flumazenil controlled the abnormal movements. Flumazenil is a potent benzodiazepine antagonist that competitively blocks the central effects of benzodiazepines. It can reverse the sedative effects of benzodiazepines occurring after diagnostic or therapeutic procedures or after benzodiazepine overdose. Flumazenil may be considered in cases of abnormal movements associated with midazolam. However, further studies are needed to provide guidelines for the administration of this drug in newborns.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "53789d187e204d27ba5d871adbcd3fd2", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[105, 105], [65, 65], [71, 71]], "char_spans": [[696, 705], [393, 402], [439, 448]]}]}], "context_tokens": [["Sedation", 0], ["is", 9], ["an", 12], ["important", 15], ["aspect", 25], ["of", 32], ["care", 35], ["for", 40], ["critically", 44], ["ill", 55], ["newborns", 59], [".", 67], ["Proper", 69], ["sedation", 76], ["reduces", 85], ["stress", 93], ["during", 100], ["procedures", 107], ["such", 118], ["as", 123], ["mechanical", 126], ["ventilation", 137], [".", 148], ["Midazolam", 150], [",", 159], ["a", 161], ["short", 163], ["-", 168], ["acting", 169], ["benzodiazepine", 176], [",", 190], ["is", 192], ["widely", 195], ["administered", 202], ["as", 215], ["a", 218], ["sedative", 220], ["in", 229], ["newborn", 232], ["intensive", 240], ["care", 250], ["units", 255], ["but", 261], ["is", 265], ["not", 268], ["without", 272], ["side", 280], ["effects", 285], [".", 292], ["Three", 294], ["term", 300], ["newborns", 305], ["developed", 314], ["myoclonic", 324], ["-", 333], ["like", 334], ["abnormal", 339], ["movements", 348], ["after", 358], ["receiving", 364], ["midazolam", 374], [".", 383], ["In", 385], ["one", 388], [",", 391], ["flumazenil", 393], ["controlled", 404], ["the", 415], ["abnormal", 419], ["movements", 428], [".", 437], ["Flumazenil", 439], ["is", 450], ["a", 453], ["potent", 455], ["benzodiazepine", 462], ["antagonist", 477], ["that", 488], ["competitively", 493], ["blocks", 507], ["the", 514], ["central", 518], ["effects", 526], ["of", 534], ["benzodiazepines", 537], [".", 552], ["It", 554], ["can", 557], ["reverse", 561], ["the", 569], ["sedative", 573], ["effects", 582], ["of", 590], ["benzodiazepines", 593], ["occurring", 609], ["after", 619], ["diagnostic", 625], ["or", 636], ["therapeutic", 639], ["procedures", 651], ["or", 662], ["after", 665], ["benzodiazepine", 671], ["overdose", 686], [".", 694], ["Flumazenil", 696], ["may", 707], ["be", 711], ["considered", 714], ["in", 725], ["cases", 728], ["of", 734], ["abnormal", 737], ["movements", 746], ["associated", 756], ["with", 767], ["midazolam", 772], [".", 781], ["However", 783], [",", 790], ["further", 792], ["studies", 800], ["are", 808], ["needed", 812], ["to", 819], ["provide", 822], ["guidelines", 830], ["for", 841], ["the", 845], ["administration", 849], ["of", 864], ["this", 867], ["drug", 872], ["in", 877], ["newborns", 880], [".", 888]]}
{"context": "Diamond-Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by a specific deficiency in erythroid progenitors. Forty percent of the patients are blood transfusion-dependent. Recent reports show that the ribosomal protein S19 (RPS19) gene is mutated in 25% of all patients with DBA. We constructed oncoretroviral vectors containing the RPS19 gene to develop gene therapy for RPS19-deficient DBA. These vectors were used to introduce the RPS19 gene into CD34(+) bone marrow (BM) cells from 4 patients with DBA with RPS19 gene mutations. Overexpression of the RPS19 transgene increased the number of erythroid colonies by almost 3-fold. High expression levels of the RPS19 transgene improved erythroid colony-forming ability substantially whereas low expression levels had no effect. Overexpression of RPS19 had no detrimental effect on granulocyte-macrophage colony formation. Therefore, these findings suggest that gene therapy for RPS19-deficient patients with DBA using viral vectors that express the RPS19 gene is feasible.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "0bede4582a9e40d4bb498c8ee7d6c64e", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[5, 5], [164, 164], [55, 55], [71, 71], [95, 95]], "char_spans": [[25, 27], [990, 992], [306, 308], [419, 421], [533, 535]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["congenital", 35], ["bone", 46], ["marrow", 51], ["failure", 58], ["syndrome", 66], ["characterized", 75], ["by", 89], ["a", 92], ["specific", 94], ["deficiency", 103], ["in", 114], ["erythroid", 117], ["progenitors", 127], [".", 138], ["Forty", 140], ["percent", 146], ["of", 154], ["the", 157], ["patients", 161], ["are", 170], ["blood", 174], ["transfusion", 180], ["-", 191], ["dependent", 192], [".", 201], ["Recent", 203], ["reports", 210], ["show", 218], ["that", 223], ["the", 228], ["ribosomal", 232], ["protein", 242], ["S19", 250], ["(", 254], ["RPS19", 255], [")", 260], ["gene", 262], ["is", 267], ["mutated", 270], ["in", 278], ["25", 281], ["%", 283], ["of", 285], ["all", 288], ["patients", 292], ["with", 301], ["DBA", 306], [".", 309], ["We", 311], ["constructed", 314], ["oncoretroviral", 326], ["vectors", 341], ["containing", 349], ["the", 360], ["RPS19", 364], ["gene", 370], ["to", 375], ["develop", 378], ["gene", 386], ["therapy", 391], ["for", 399], ["RPS19-deficient", 403], ["DBA", 419], [".", 422], ["These", 424], ["vectors", 430], ["were", 438], ["used", 443], ["to", 448], ["introduce", 451], ["the", 461], ["RPS19", 465], ["gene", 471], ["into", 476], ["CD34(+", 481], [")", 487], ["bone", 489], ["marrow", 494], ["(", 501], ["BM", 502], [")", 504], ["cells", 506], ["from", 512], ["4", 517], ["patients", 519], ["with", 528], ["DBA", 533], ["with", 537], ["RPS19", 542], ["gene", 548], ["mutations", 553], [".", 562], ["Overexpression", 564], ["of", 579], ["the", 582], ["RPS19", 586], ["transgene", 592], ["increased", 602], ["the", 612], ["number", 616], ["of", 623], ["erythroid", 626], ["colonies", 636], ["by", 645], ["almost", 648], ["3-fold", 655], [".", 661], ["High", 663], ["expression", 668], ["levels", 679], ["of", 686], ["the", 689], ["RPS19", 693], ["transgene", 699], ["improved", 709], ["erythroid", 718], ["colony", 728], ["-", 734], ["forming", 735], ["ability", 743], ["substantially", 751], ["whereas", 765], ["low", 773], ["expression", 777], ["levels", 788], ["had", 795], ["no", 799], ["effect", 802], [".", 808], ["Overexpression", 810], ["of", 825], ["RPS19", 828], ["had", 834], ["no", 838], ["detrimental", 841], ["effect", 853], ["on", 860], ["granulocyte", 863], ["-", 874], ["macrophage", 875], ["colony", 886], ["formation", 893], [".", 902], ["Therefore", 904], [",", 913], ["these", 915], ["findings", 921], ["suggest", 930], ["that", 938], ["gene", 943], ["therapy", 948], ["for", 956], ["RPS19-deficient", 960], ["patients", 976], ["with", 985], ["DBA", 990], ["using", 994], ["viral", 1000], ["vectors", 1006], ["that", 1014], ["express", 1019], ["the", 1027], ["RPS19", 1031], ["gene", 1037], ["is", 1042], ["feasible", 1045], [".", 1053]]}
{"context": "Transgenic mice over-expressing a mutated form of the human amyloid precursor protein (APP, 695 isoform) bearing a mutation associated with Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were studied at age periods (3 and 10 months) prior to the overt development of neuritic amyloid plaques. Both 3- and 10-month-old APPLd2 mice had reflex eyelid responses like those of controls, but only younger mice were able to acquire a classical conditioning of eyelid responses in a trace paradigm. In vitro studies on hippocampal slices showed that 10-month-old APPLd2 mice also presented deficits in paired-pulse facilitation and long-term potentiation, but presented a normal synaptic activation of CA1 pyramidal cells by the stimulation of Schaffer collaterals. It is proposed that definite functional changes may appear well in advance of noticeable structural alterations in this animal model of Alzheimer's disease, and that specific learning tasks could have a relevant diagnostic value.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "b8293e4bcc944de3949762790d040d05", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[25, 27], [167, 169]], "char_spans": [[140, 158], [943, 961]]}]}], "context_tokens": [["Transgenic", 0], ["mice", 11], ["over", 16], ["-", 20], ["expressing", 21], ["a", 32], ["mutated", 34], ["form", 42], ["of", 47], ["the", 50], ["human", 54], ["amyloid", 60], ["precursor", 68], ["protein", 78], ["(", 86], ["APP", 87], [",", 90], ["695", 92], ["isoform", 96], [")", 103], ["bearing", 105], ["a", 113], ["mutation", 115], ["associated", 124], ["with", 135], ["Alzheimer", 140], ["'s", 149], ["disease", 152], ["(", 160], ["V642I", 161], [",", 166], ["so", 168], ["-", 170], ["called", 171], ["London", 178], ["mutation", 185], [",", 193], ["hereafter", 195], ["APPLd2", 205], [")", 211], ["and", 213], ["wild", 217], ["-", 221], ["type", 222], ["controls", 227], ["were", 236], ["studied", 241], ["at", 249], ["age", 252], ["periods", 256], ["(", 264], ["3", 265], ["and", 267], ["10", 271], ["months", 274], [")", 280], ["prior", 282], ["to", 288], ["the", 291], ["overt", 295], ["development", 301], ["of", 313], ["neuritic", 316], ["amyloid", 325], ["plaques", 333], [".", 340], ["Both", 342], ["3-", 347], ["and", 350], ["10-month", 354], ["-", 362], ["old", 363], ["APPLd2", 367], ["mice", 374], ["had", 379], ["reflex", 383], ["eyelid", 390], ["responses", 397], ["like", 407], ["those", 412], ["of", 418], ["controls", 421], [",", 429], ["but", 431], ["only", 435], ["younger", 440], ["mice", 448], ["were", 453], ["able", 458], ["to", 463], ["acquire", 466], ["a", 474], ["classical", 476], ["conditioning", 486], ["of", 499], ["eyelid", 502], ["responses", 509], ["in", 519], ["a", 522], ["trace", 524], ["paradigm", 530], [".", 538], ["In", 540], ["vitro", 543], ["studies", 549], ["on", 557], ["hippocampal", 560], ["slices", 572], ["showed", 579], ["that", 586], ["10-month", 591], ["-", 599], ["old", 600], ["APPLd2", 604], ["mice", 611], ["also", 616], ["presented", 621], ["deficits", 631], ["in", 640], ["paired", 643], ["-", 649], ["pulse", 650], ["facilitation", 656], ["and", 669], ["long", 673], ["-", 677], ["term", 678], ["potentiation", 683], [",", 695], ["but", 697], ["presented", 701], ["a", 711], ["normal", 713], ["synaptic", 720], ["activation", 729], ["of", 740], ["CA1", 743], ["pyramidal", 747], ["cells", 757], ["by", 763], ["the", 766], ["stimulation", 770], ["of", 782], ["Schaffer", 785], ["collaterals", 794], [".", 805], ["It", 807], ["is", 810], ["proposed", 813], ["that", 822], ["definite", 827], ["functional", 836], ["changes", 847], ["may", 855], ["appear", 859], ["well", 866], ["in", 871], ["advance", 874], ["of", 882], ["noticeable", 885], ["structural", 896], ["alterations", 907], ["in", 919], ["this", 922], ["animal", 927], ["model", 934], ["of", 940], ["Alzheimer", 943], ["'s", 952], ["disease", 955], [",", 962], ["and", 964], ["that", 968], ["specific", 973], ["learning", 982], ["tasks", 991], ["could", 997], ["have", 1003], ["a", 1008], ["relevant", 1010], ["diagnostic", 1019], ["value", 1030], [".", 1035]]}
{"context": "To study the impact of genetic and lifestyle factors on protein biomarkers and develop personally normalized plasma protein profiles (PNPPP) controlling for non-disease-related variance. Proximity extension assays were used to measure 145 proteins in 632 controls and 344 cases with non-communicable diseases. Genetic and lifestyle factors explained 20-88% of the variation in healthy controls. Adjusting for these factors reduced the number of candidate biomarkers by 63%. PNPPP efficiently controls for non-disease-related variance, allowing both for efficient discovery of novel biomarkers and for covariate-independent linear cut-offs suitable for clinical use.", "qas": [{"question": "What is PNPPP?", "answers": ["personally normalized plasma protein profiles"], "qid": "fd51aa90ceb147e78cd27c4328ac7962", "question_tokens": [["What", 0], ["is", 5], ["PNPPP", 8], ["?", 13]], "detected_answers": [{"text": "personally normalized plasma protein profiles", "token_spans": [[14, 18]], "char_spans": [[87, 131]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["impact", 13], ["of", 20], ["genetic", 23], ["and", 31], ["lifestyle", 35], ["factors", 45], ["on", 53], ["protein", 56], ["biomarkers", 64], ["and", 75], ["develop", 79], ["personally", 87], ["normalized", 98], ["plasma", 109], ["protein", 116], ["profiles", 124], ["(", 133], ["PNPPP", 134], [")", 139], ["controlling", 141], ["for", 153], ["non", 157], ["-", 160], ["disease", 161], ["-", 168], ["related", 169], ["variance", 177], [".", 185], ["Proximity", 187], ["extension", 197], ["assays", 207], ["were", 214], ["used", 219], ["to", 224], ["measure", 227], ["145", 235], ["proteins", 239], ["in", 248], ["632", 251], ["controls", 255], ["and", 264], ["344", 268], ["cases", 272], ["with", 278], ["non", 283], ["-", 286], ["communicable", 287], ["diseases", 300], [".", 308], ["Genetic", 310], ["and", 318], ["lifestyle", 322], ["factors", 332], ["explained", 340], ["20", 350], ["-", 352], ["88", 353], ["%", 355], ["of", 357], ["the", 360], ["variation", 364], ["in", 374], ["healthy", 377], ["controls", 385], [".", 393], ["Adjusting", 395], ["for", 405], ["these", 409], ["factors", 415], ["reduced", 423], ["the", 431], ["number", 435], ["of", 442], ["candidate", 445], ["biomarkers", 455], ["by", 466], ["63", 469], ["%", 471], [".", 472], ["PNPPP", 474], ["efficiently", 480], ["controls", 492], ["for", 501], ["non", 505], ["-", 508], ["disease", 509], ["-", 516], ["related", 517], ["variance", 525], [",", 533], ["allowing", 535], ["both", 544], ["for", 549], ["efficient", 553], ["discovery", 563], ["of", 573], ["novel", 576], ["biomarkers", 582], ["and", 593], ["for", 597], ["covariate", 601], ["-", 610], ["independent", 611], ["linear", 623], ["cut", 630], ["-", 633], ["offs", 634], ["suitable", 639], ["for", 648], ["clinical", 652], ["use", 661], [".", 664]]}
{"context": "We conducted a review of patient medical records to assess treatment response patterns and prognostic indicators of response among chronic myeloid leukemia (CML) patients in the United States, the United Kingdom, Germany, and Japan. All 1,063 patients selected met the following inclusion criteria: aged 18 or older and in chronic phase at the time of diagnosis, Philadelphia chromosome and/or BCR-ABL positive, received first-line treatment with imatinib, and not enrolled in a randomized clinical trial during the period of retrospective review. Multivariable logistic regression models were used to evaluate prognostic indicators of complete hematological response (CHR), complete cytogenetic response (CCyR), and complete or major molecular response (C/MMR). Among patients treated with first-line imatinib, CHR at three months, CCyR at 12 months, and C/MMR at 18 months were observed in 53, 53.1, and 57.8 % of patients, respectively. Among patients treated with second-line dasatinib or nilotinib, CHR was achieved at three months in 49 and 42 %, CCyR at 12 months in 32 and 23 %, and MMR at 18 months in 30.5 and 26.1 % of patients, respectively. Prognostic indicators of first-line response included age, race, and Sokal score. For second-line treatment, duration of first-line hematological response and choice of drug used were also significant.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7f2a7d1273d0421f802f06a3bb2fdbbe", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[67, 69]], "char_spans": [[394, 400]]}]}], "context_tokens": [["We", 0], ["conducted", 3], ["a", 13], ["review", 15], ["of", 22], ["patient", 25], ["medical", 33], ["records", 41], ["to", 49], ["assess", 52], ["treatment", 59], ["response", 69], ["patterns", 78], ["and", 87], ["prognostic", 91], ["indicators", 102], ["of", 113], ["response", 116], ["among", 125], ["chronic", 131], ["myeloid", 139], ["leukemia", 147], ["(", 156], ["CML", 157], [")", 160], ["patients", 162], ["in", 171], ["the", 174], ["United", 178], ["States", 185], [",", 191], ["the", 193], ["United", 197], ["Kingdom", 204], [",", 211], ["Germany", 213], [",", 220], ["and", 222], ["Japan", 226], [".", 231], ["All", 233], ["1,063", 237], ["patients", 243], ["selected", 252], ["met", 261], ["the", 265], ["following", 269], ["inclusion", 279], ["criteria", 289], [":", 297], ["aged", 299], ["18", 304], ["or", 307], ["older", 310], ["and", 316], ["in", 320], ["chronic", 323], ["phase", 331], ["at", 337], ["the", 340], ["time", 344], ["of", 349], ["diagnosis", 352], [",", 361], ["Philadelphia", 363], ["chromosome", 376], ["and/or", 387], ["BCR", 394], ["-", 397], ["ABL", 398], ["positive", 402], [",", 410], ["received", 412], ["first", 421], ["-", 426], ["line", 427], ["treatment", 432], ["with", 442], ["imatinib", 447], [",", 455], ["and", 457], ["not", 461], ["enrolled", 465], ["in", 474], ["a", 477], ["randomized", 479], ["clinical", 490], ["trial", 499], ["during", 505], ["the", 512], ["period", 516], ["of", 523], ["retrospective", 526], ["review", 540], [".", 546], ["Multivariable", 548], ["logistic", 562], ["regression", 571], ["models", 582], ["were", 589], ["used", 594], ["to", 599], ["evaluate", 602], ["prognostic", 611], ["indicators", 622], ["of", 633], ["complete", 636], ["hematological", 645], ["response", 659], ["(", 668], ["CHR", 669], [")", 672], [",", 673], ["complete", 675], ["cytogenetic", 684], ["response", 696], ["(", 705], ["CCyR", 706], [")", 710], [",", 711], ["and", 713], ["complete", 717], ["or", 726], ["major", 729], ["molecular", 735], ["response", 745], ["(", 754], ["C", 755], ["/", 756], ["MMR", 757], [")", 760], [".", 761], ["Among", 763], ["patients", 769], ["treated", 778], ["with", 786], ["first", 791], ["-", 796], ["line", 797], ["imatinib", 802], [",", 810], ["CHR", 812], ["at", 816], ["three", 819], ["months", 825], [",", 831], ["CCyR", 833], ["at", 838], ["12", 841], ["months", 844], [",", 850], ["and", 852], ["C", 856], ["/", 857], ["MMR", 858], ["at", 862], ["18", 865], ["months", 868], ["were", 875], ["observed", 880], ["in", 889], ["53", 892], [",", 894], ["53.1", 896], [",", 900], ["and", 902], ["57.8", 906], ["%", 911], ["of", 913], ["patients", 916], [",", 924], ["respectively", 926], [".", 938], ["Among", 940], ["patients", 946], ["treated", 955], ["with", 963], ["second", 968], ["-", 974], ["line", 975], ["dasatinib", 980], ["or", 990], ["nilotinib", 993], [",", 1002], ["CHR", 1004], ["was", 1008], ["achieved", 1012], ["at", 1021], ["three", 1024], ["months", 1030], ["in", 1037], ["49", 1040], ["and", 1043], ["42", 1047], ["%", 1050], [",", 1051], ["CCyR", 1053], ["at", 1058], ["12", 1061], ["months", 1064], ["in", 1071], ["32", 1074], ["and", 1077], ["23", 1081], ["%", 1084], [",", 1085], ["and", 1087], ["MMR", 1091], ["at", 1095], ["18", 1098], ["months", 1101], ["in", 1108], ["30.5", 1111], ["and", 1116], ["26.1", 1120], ["%", 1125], ["of", 1127], ["patients", 1130], [",", 1138], ["respectively", 1140], [".", 1152], ["Prognostic", 1154], ["indicators", 1165], ["of", 1176], ["first", 1179], ["-", 1184], ["line", 1185], ["response", 1190], ["included", 1199], ["age", 1208], [",", 1211], ["race", 1213], [",", 1217], ["and", 1219], ["Sokal", 1223], ["score", 1229], [".", 1234], ["For", 1236], ["second", 1240], ["-", 1246], ["line", 1247], ["treatment", 1252], [",", 1261], ["duration", 1263], ["of", 1272], ["first", 1275], ["-", 1280], ["line", 1281], ["hematological", 1286], ["response", 1300], ["and", 1309], ["choice", 1313], ["of", 1320], ["drug", 1323], ["used", 1328], ["were", 1333], ["also", 1338], ["significant", 1343], [".", 1354]]}
{"context": "Emerging data suggest that second-generation antipsychotics such as aripiprazole may be effective in the treatment of post-traumatic stress disorder (PTSD). However, few clinical trials have used aripiprazole in PTSD, and data are limited on its use in Veterans with PTSD. The objective of this pilot trial was to investigate the safety and efficacy of aripiprazole in Veterans with PTSD. Ten individuals (five men and five women) meeting the Diagnostic and statistical manual of mental disorders, 4th ed., PTSD criteria participated in this 12-week, open-label, flexibly dosed monotherapy trial. The dose range of aripiprazole was 5-30 mg/day, titrated to tolerability and clinical response. The primary outcome measure was the Clinician-Administered PTSD Scale. Additional outcomes included the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale (Top-8), the Davidson Trauma Scale, the Positive and Negative Syndrome Scale, the Beck Depression Inventory-Fast Screen, and Clinical Global Impressions-Improvement. Eight participants completed the study, and aripiprazole was generally well tolerated and associated with a significant improvement in PTSD symptoms, as measured by the Clinician-Administered PTSD Scale (primary outcome measure) and by the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale, and the Davidson Trauma Scale. An improvement was also observed on all three Positive and Negative Syndrome Scale subscales and the Beck Depression Inventory-Fast Screen, and the average Clinical Global Impressions-Improvement ratings indicated that patients were 'much improved'. These promising initial results merit further investigation in a larger, randomized-controlled trial.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "0b4eb5fc8d864052918d6cffa3730c7d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[18, 22]], "char_spans": [[118, 147]]}, {"text": "PTSD", "token_spans": [[48, 48], [226, 226], [93, 93], [205, 205], [138, 138], [36, 36], [68, 68], [153, 153], [215, 215], [233, 233], [24, 24], [146, 146]], "char_spans": [[267, 270], [1271, 1274], [507, 510], [1160, 1163], [752, 755], [212, 215], [383, 386], [848, 851], [1217, 1220], [1316, 1319], [150, 153], [803, 806]]}]}], "context_tokens": [["Emerging", 0], ["data", 9], ["suggest", 14], ["that", 22], ["second", 27], ["-", 33], ["generation", 34], ["antipsychotics", 45], ["such", 60], ["as", 65], ["aripiprazole", 68], ["may", 81], ["be", 85], ["effective", 88], ["in", 98], ["the", 101], ["treatment", 105], ["of", 115], ["post", 118], ["-", 122], ["traumatic", 123], ["stress", 133], ["disorder", 140], ["(", 149], ["PTSD", 150], [")", 154], [".", 155], ["However", 157], [",", 164], ["few", 166], ["clinical", 170], ["trials", 179], ["have", 186], ["used", 191], ["aripiprazole", 196], ["in", 209], ["PTSD", 212], [",", 216], ["and", 218], ["data", 222], ["are", 227], ["limited", 231], ["on", 239], ["its", 242], ["use", 246], ["in", 250], ["Veterans", 253], ["with", 262], ["PTSD", 267], [".", 271], ["The", 273], ["objective", 277], ["of", 287], ["this", 290], ["pilot", 295], ["trial", 301], ["was", 307], ["to", 311], ["investigate", 314], ["the", 326], ["safety", 330], ["and", 337], ["efficacy", 341], ["of", 350], ["aripiprazole", 353], ["in", 366], ["Veterans", 369], ["with", 378], ["PTSD", 383], [".", 387], ["Ten", 389], ["individuals", 393], ["(", 405], ["five", 406], ["men", 411], ["and", 415], ["five", 419], ["women", 424], [")", 429], ["meeting", 431], ["the", 439], ["Diagnostic", 443], ["and", 454], ["statistical", 458], ["manual", 470], ["of", 477], ["mental", 480], ["disorders", 487], [",", 496], ["4th", 498], ["ed", 502], [".", 504], [",", 505], ["PTSD", 507], ["criteria", 512], ["participated", 521], ["in", 534], ["this", 537], ["12-week", 542], [",", 549], ["open", 551], ["-", 555], ["label", 556], [",", 561], ["flexibly", 563], ["dosed", 572], ["monotherapy", 578], ["trial", 590], [".", 595], ["The", 597], ["dose", 601], ["range", 606], ["of", 612], ["aripiprazole", 615], ["was", 628], ["5", 632], ["-", 633], ["30", 634], ["mg", 637], ["/", 639], ["day", 640], [",", 643], ["titrated", 645], ["to", 654], ["tolerability", 657], ["and", 670], ["clinical", 674], ["response", 683], [".", 691], ["The", 693], ["primary", 697], ["outcome", 705], ["measure", 713], ["was", 721], ["the", 725], ["Clinician", 729], ["-", 738], ["Administered", 739], ["PTSD", 752], ["Scale", 757], [".", 762], ["Additional", 764], ["outcomes", 775], ["included", 784], ["the", 793], ["Short", 797], ["PTSD", 803], ["Rating", 808], ["Interview", 815], [",", 824], ["the", 826], ["Treatment", 830], ["Outcome", 840], ["PTSD", 848], ["Scale", 853], ["(", 859], ["Top-8", 860], [")", 865], [",", 866], ["the", 868], ["Davidson", 872], ["Trauma", 881], ["Scale", 888], [",", 893], ["the", 895], ["Positive", 899], ["and", 908], ["Negative", 912], ["Syndrome", 921], ["Scale", 930], [",", 935], ["the", 937], ["Beck", 941], ["Depression", 946], ["Inventory", 957], ["-", 966], ["Fast", 967], ["Screen", 972], [",", 978], ["and", 980], ["Clinical", 984], ["Global", 993], ["Impressions", 1000], ["-", 1011], ["Improvement", 1012], [".", 1023], ["Eight", 1025], ["participants", 1031], ["completed", 1044], ["the", 1054], ["study", 1058], [",", 1063], ["and", 1065], ["aripiprazole", 1069], ["was", 1082], ["generally", 1086], ["well", 1096], ["tolerated", 1101], ["and", 1111], ["associated", 1115], ["with", 1126], ["a", 1131], ["significant", 1133], ["improvement", 1145], ["in", 1157], ["PTSD", 1160], ["symptoms", 1165], [",", 1173], ["as", 1175], ["measured", 1178], ["by", 1187], ["the", 1190], ["Clinician", 1194], ["-", 1203], ["Administered", 1204], ["PTSD", 1217], ["Scale", 1222], ["(", 1228], ["primary", 1229], ["outcome", 1237], ["measure", 1245], [")", 1252], ["and", 1254], ["by", 1258], ["the", 1261], ["Short", 1265], ["PTSD", 1271], ["Rating", 1276], ["Interview", 1283], [",", 1292], ["the", 1294], ["Treatment", 1298], ["Outcome", 1308], ["PTSD", 1316], ["Scale", 1321], [",", 1326], ["and", 1328], ["the", 1332], ["Davidson", 1336], ["Trauma", 1345], ["Scale", 1352], [".", 1357], ["An", 1359], ["improvement", 1362], ["was", 1374], ["also", 1378], ["observed", 1383], ["on", 1392], ["all", 1395], ["three", 1399], ["Positive", 1405], ["and", 1414], ["Negative", 1418], ["Syndrome", 1427], ["Scale", 1436], ["subscales", 1442], ["and", 1452], ["the", 1456], ["Beck", 1460], ["Depression", 1465], ["Inventory", 1476], ["-", 1485], ["Fast", 1486], ["Screen", 1491], [",", 1497], ["and", 1499], ["the", 1503], ["average", 1507], ["Clinical", 1515], ["Global", 1524], ["Impressions", 1531], ["-", 1542], ["Improvement", 1543], ["ratings", 1555], ["indicated", 1563], ["that", 1573], ["patients", 1578], ["were", 1587], ["'", 1592], ["much", 1593], ["improved", 1598], ["'", 1606], [".", 1607], ["These", 1609], ["promising", 1615], ["initial", 1625], ["results", 1633], ["merit", 1641], ["further", 1647], ["investigation", 1655], ["in", 1669], ["a", 1672], ["larger", 1674], [",", 1680], ["randomized", 1682], ["-", 1692], ["controlled", 1693], ["trial", 1704], [".", 1709]]}
{"context": "Restless legs syndrome, now called Willis-Ekbom Disease (RLS/WED), is a sensorimotor-related sleep disorder. Little is known of the effect of RLS/WED on motor function. The current study investigated upper limb function in RLS/WED patients. We hypothesised that RLS/WED patients exhibit subtle changes in tremor amplitude but normal dexterity and movement speed and rhythmicity compared to healthy controls. RLS/WED patients (n=17, 59 \u00b1 7 years) with moderate disease and healthy controls (n=17, 58 \u00b1 6 years) completed screening tests and five tasks including object manipulation, maximal pinch grip, flexion and extension of the index finger (tremor assessment), maximal finger tapping (movement speed and rhythmicity assessment), and the grooved pegboard test. Force, acceleration, and/or first dorsal interosseus EMG were recorded during four of the tasks. Task performance did not differ between groups. Learning was evident on tasks with repeated trials and the magnitude of learning did not differ between groups. Hand function, tremor, and task learning were unaffected in RLS/WED patients. Patients manipulated objects in a normal manner and exhibited normal movement speed, rhythmicity, and tremor. Further research is needed to assess other types of movement in RLS/WED patients to gain insight into the motor circuitry affected and the underlying pathophysiology.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "3e5986f118e1472abdf00781a69c02a0", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], [",", 22], ["now", 24], ["called", 28], ["Willis", 35], ["-", 41], ["Ekbom", 42], ["Disease", 48], ["(", 56], ["RLS", 57], ["/", 60], ["WED", 61], [")", 64], [",", 65], ["is", 67], ["a", 70], ["sensorimotor", 72], ["-", 84], ["related", 85], ["sleep", 93], ["disorder", 99], [".", 107], ["Little", 109], ["is", 116], ["known", 119], ["of", 125], ["the", 128], ["effect", 132], ["of", 139], ["RLS", 142], ["/", 145], ["WED", 146], ["on", 150], ["motor", 153], ["function", 159], [".", 167], ["The", 169], ["current", 173], ["study", 181], ["investigated", 187], ["upper", 200], ["limb", 206], ["function", 211], ["in", 220], ["RLS", 223], ["/", 226], ["WED", 227], ["patients", 231], [".", 239], ["We", 241], ["hypothesised", 244], ["that", 257], ["RLS", 262], ["/", 265], ["WED", 266], ["patients", 270], ["exhibit", 279], ["subtle", 287], ["changes", 294], ["in", 302], ["tremor", 305], ["amplitude", 312], ["but", 322], ["normal", 326], ["dexterity", 333], ["and", 343], ["movement", 347], ["speed", 356], ["and", 362], ["rhythmicity", 366], ["compared", 378], ["to", 387], ["healthy", 390], ["controls", 398], [".", 406], ["RLS", 408], ["/", 411], ["WED", 412], ["patients", 416], ["(", 425], ["n=17", 426], [",", 430], ["59", 432], ["\u00b1", 435], ["7", 437], ["years", 439], [")", 444], ["with", 446], ["moderate", 451], ["disease", 460], ["and", 468], ["healthy", 472], ["controls", 480], ["(", 489], ["n=17", 490], [",", 494], ["58", 496], ["\u00b1", 499], ["6", 501], ["years", 503], [")", 508], ["completed", 510], ["screening", 520], ["tests", 530], ["and", 536], ["five", 540], ["tasks", 545], ["including", 551], ["object", 561], ["manipulation", 568], [",", 580], ["maximal", 582], ["pinch", 590], ["grip", 596], [",", 600], ["flexion", 602], ["and", 610], ["extension", 614], ["of", 624], ["the", 627], ["index", 631], ["finger", 637], ["(", 644], ["tremor", 645], ["assessment", 652], [")", 662], [",", 663], ["maximal", 665], ["finger", 673], ["tapping", 680], ["(", 688], ["movement", 689], ["speed", 698], ["and", 704], ["rhythmicity", 708], ["assessment", 720], [")", 730], [",", 731], ["and", 733], ["the", 737], ["grooved", 741], ["pegboard", 749], ["test", 758], [".", 762], ["Force", 764], [",", 769], ["acceleration", 771], [",", 783], ["and/or", 785], ["first", 792], ["dorsal", 798], ["interosseus", 805], ["EMG", 817], ["were", 821], ["recorded", 826], ["during", 835], ["four", 842], ["of", 847], ["the", 850], ["tasks", 854], [".", 859], ["Task", 861], ["performance", 866], ["did", 878], ["not", 882], ["differ", 886], ["between", 893], ["groups", 901], [".", 907], ["Learning", 909], ["was", 918], ["evident", 922], ["on", 930], ["tasks", 933], ["with", 939], ["repeated", 944], ["trials", 953], ["and", 960], ["the", 964], ["magnitude", 968], ["of", 978], ["learning", 981], ["did", 990], ["not", 994], ["differ", 998], ["between", 1005], ["groups", 1013], [".", 1019], ["Hand", 1021], ["function", 1026], [",", 1034], ["tremor", 1036], [",", 1042], ["and", 1044], ["task", 1048], ["learning", 1053], ["were", 1062], ["unaffected", 1067], ["in", 1078], ["RLS", 1081], ["/", 1084], ["WED", 1085], ["patients", 1089], [".", 1097], ["Patients", 1099], ["manipulated", 1108], ["objects", 1120], ["in", 1128], ["a", 1131], ["normal", 1133], ["manner", 1140], ["and", 1147], ["exhibited", 1151], ["normal", 1161], ["movement", 1168], ["speed", 1177], [",", 1182], ["rhythmicity", 1184], [",", 1195], ["and", 1197], ["tremor", 1201], [".", 1207], ["Further", 1209], ["research", 1217], ["is", 1226], ["needed", 1229], ["to", 1236], ["assess", 1239], ["other", 1246], ["types", 1252], ["of", 1258], ["movement", 1261], ["in", 1270], ["RLS", 1273], ["/", 1276], ["WED", 1277], ["patients", 1281], ["to", 1290], ["gain", 1293], ["insight", 1298], ["into", 1306], ["the", 1311], ["motor", 1315], ["circuitry", 1321], ["affected", 1331], ["and", 1340], ["the", 1344], ["underlying", 1348], ["pathophysiology", 1359], [".", 1374]]}
{"context": "To determine the appropriate method to calculate the rate of methicillin-resistant Staphylococcus aureus (MRSA) infection and colonization (hereafter, MRSA rates) for interhospital comparisons, such that the large number of patients who are already MRSA positive on admission is taken into account. A prospective, multicenter, hospital-based surveillance of MRSA-positive case patients from January through December 2004. Data from 31 hospitals participating in the German national nosocomial infections surveillance system (KISS) were recorded during routine surveillance by the infection control team at each hospital. Data for 4,215 MRSA-positive case patients were evaluated. From this data, the following values were calculated. The median incidence density was 0.71 MRSA-positive case patients per 1,000 patient-days, and the median nosocomial incidence density was 0.27 patients with nosocomial MRSA infection or colonization per 1,000 patient-days (95% CI, 0.18-0.34). The median average daily MRSA burden was 1.13 MRSA patient-days per 100 patient-days (95% CI, 0.86-1.51), with the average daily MRSA burden defined as the total number of MRSA patient-days divided by the total number of patient-days times 100. The median MRSA-days-associated nosocomial MRSA infection and colonization rate, which describes the MRSA infection risk for other patients in hospitals housing large numbers of MRSA-positive patients and/or many patients who were MRSA positive on admission, was 23.1 cases of nosocomial MRSA infection and colonization per 1,000 MRSA patient-days (95% CI, 17.4-28.6). The values were also calculated for various MRSA screening levels. The MRSA-days-associated nosocomial MRSA rate allows investigators to assess the extent of MRSA colonization and infection at each hospital, taking into account cases that have been imported from other hospitals, as well as from the community. This information provides an appropriate incentive for hospitals to introduce further infection control measures.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "678ea6e0e70c41d294ee49eb162b3e9a", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[16, 16], [208, 208], [173, 173], [272, 272], [262, 262], [299, 299], [253, 253], [60, 60], [177, 177], [241, 241], [319, 319], [128, 128], [304, 304], [24, 24], [150, 150], [278, 278], [310, 310], [41, 41], [104, 104], [200, 200], [232, 232], [226, 226]], "char_spans": [[106, 109], [1149, 1152], [1002, 1005], [1510, 1513], [1453, 1456], [1635, 1638], [1400, 1403], [358, 361], [1023, 1026], [1323, 1326], [1749, 1752], [772, 775], [1662, 1665], [151, 154], [902, 905], [1552, 1555], [1694, 1697], [249, 252], [636, 639], [1106, 1109], [1265, 1268], [1233, 1236]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["appropriate", 17], ["method", 29], ["to", 36], ["calculate", 39], ["the", 49], ["rate", 53], ["of", 58], ["methicillin", 61], ["-", 72], ["resistant", 73], ["Staphylococcus", 83], ["aureus", 98], ["(", 105], ["MRSA", 106], [")", 110], ["infection", 112], ["and", 122], ["colonization", 126], ["(", 139], ["hereafter", 140], [",", 149], ["MRSA", 151], ["rates", 156], [")", 161], ["for", 163], ["interhospital", 167], ["comparisons", 181], [",", 192], ["such", 194], ["that", 199], ["the", 204], ["large", 208], ["number", 214], ["of", 221], ["patients", 224], ["who", 233], ["are", 237], ["already", 241], ["MRSA", 249], ["positive", 254], ["on", 263], ["admission", 266], ["is", 276], ["taken", 279], ["into", 285], ["account", 290], [".", 297], ["A", 299], ["prospective", 301], [",", 312], ["multicenter", 314], [",", 325], ["hospital", 327], ["-", 335], ["based", 336], ["surveillance", 342], ["of", 355], ["MRSA", 358], ["-", 362], ["positive", 363], ["case", 372], ["patients", 377], ["from", 386], ["January", 391], ["through", 399], ["December", 407], ["2004", 416], [".", 420], ["Data", 422], ["from", 427], ["31", 432], ["hospitals", 435], ["participating", 445], ["in", 459], ["the", 462], ["German", 466], ["national", 473], ["nosocomial", 482], ["infections", 493], ["surveillance", 504], ["system", 517], ["(", 524], ["KISS", 525], [")", 529], ["were", 531], ["recorded", 536], ["during", 545], ["routine", 552], ["surveillance", 560], ["by", 573], ["the", 576], ["infection", 580], ["control", 590], ["team", 598], ["at", 603], ["each", 606], ["hospital", 611], [".", 619], ["Data", 621], ["for", 626], ["4,215", 630], ["MRSA", 636], ["-", 640], ["positive", 641], ["case", 650], ["patients", 655], ["were", 664], ["evaluated", 669], [".", 678], ["From", 680], ["this", 685], ["data", 690], [",", 694], ["the", 696], ["following", 700], ["values", 710], ["were", 717], ["calculated", 722], [".", 732], ["The", 734], ["median", 738], ["incidence", 745], ["density", 755], ["was", 763], ["0.71", 767], ["MRSA", 772], ["-", 776], ["positive", 777], ["case", 786], ["patients", 791], ["per", 800], ["1,000", 804], ["patient", 810], ["-", 817], ["days", 818], [",", 822], ["and", 824], ["the", 828], ["median", 832], ["nosocomial", 839], ["incidence", 850], ["density", 860], ["was", 868], ["0.27", 872], ["patients", 877], ["with", 886], ["nosocomial", 891], ["MRSA", 902], ["infection", 907], ["or", 917], ["colonization", 920], ["per", 933], ["1,000", 937], ["patient", 943], ["-", 950], ["days", 951], ["(", 956], ["95", 957], ["%", 959], ["CI", 961], [",", 963], ["0.18", 965], ["-", 969], ["0.34", 970], [")", 974], [".", 975], ["The", 977], ["median", 981], ["average", 988], ["daily", 996], ["MRSA", 1002], ["burden", 1007], ["was", 1014], ["1.13", 1018], ["MRSA", 1023], ["patient", 1028], ["-", 1035], ["days", 1036], ["per", 1041], ["100", 1045], ["patient", 1049], ["-", 1056], ["days", 1057], ["(", 1062], ["95", 1063], ["%", 1065], ["CI", 1067], [",", 1069], ["0.86", 1071], ["-", 1075], ["1.51", 1076], [")", 1080], [",", 1081], ["with", 1083], ["the", 1088], ["average", 1092], ["daily", 1100], ["MRSA", 1106], ["burden", 1111], ["defined", 1118], ["as", 1126], ["the", 1129], ["total", 1133], ["number", 1139], ["of", 1146], ["MRSA", 1149], ["patient", 1154], ["-", 1161], ["days", 1162], ["divided", 1167], ["by", 1175], ["the", 1178], ["total", 1182], ["number", 1188], ["of", 1195], ["patient", 1198], ["-", 1205], ["days", 1206], ["times", 1211], ["100", 1217], [".", 1220], ["The", 1222], ["median", 1226], ["MRSA", 1233], ["-", 1237], ["days", 1238], ["-", 1242], ["associated", 1243], ["nosocomial", 1254], ["MRSA", 1265], ["infection", 1270], ["and", 1280], ["colonization", 1284], ["rate", 1297], [",", 1301], ["which", 1303], ["describes", 1309], ["the", 1319], ["MRSA", 1323], ["infection", 1328], ["risk", 1338], ["for", 1343], ["other", 1347], ["patients", 1353], ["in", 1362], ["hospitals", 1365], ["housing", 1375], ["large", 1383], ["numbers", 1389], ["of", 1397], ["MRSA", 1400], ["-", 1404], ["positive", 1405], ["patients", 1414], ["and/or", 1423], ["many", 1430], ["patients", 1435], ["who", 1444], ["were", 1448], ["MRSA", 1453], ["positive", 1458], ["on", 1467], ["admission", 1470], [",", 1479], ["was", 1481], ["23.1", 1485], ["cases", 1490], ["of", 1496], ["nosocomial", 1499], ["MRSA", 1510], ["infection", 1515], ["and", 1525], ["colonization", 1529], ["per", 1542], ["1,000", 1546], ["MRSA", 1552], ["patient", 1557], ["-", 1564], ["days", 1565], ["(", 1570], ["95", 1571], ["%", 1573], ["CI", 1575], [",", 1577], ["17.4", 1579], ["-", 1583], ["28.6", 1584], [")", 1588], [".", 1589], ["The", 1591], ["values", 1595], ["were", 1602], ["also", 1607], ["calculated", 1612], ["for", 1623], ["various", 1627], ["MRSA", 1635], ["screening", 1640], ["levels", 1650], [".", 1656], ["The", 1658], ["MRSA", 1662], ["-", 1666], ["days", 1667], ["-", 1671], ["associated", 1672], ["nosocomial", 1683], ["MRSA", 1694], ["rate", 1699], ["allows", 1704], ["investigators", 1711], ["to", 1725], ["assess", 1728], ["the", 1735], ["extent", 1739], ["of", 1746], ["MRSA", 1749], ["colonization", 1754], ["and", 1767], ["infection", 1771], ["at", 1781], ["each", 1784], ["hospital", 1789], [",", 1797], ["taking", 1799], ["into", 1806], ["account", 1811], ["cases", 1819], ["that", 1825], ["have", 1830], ["been", 1835], ["imported", 1840], ["from", 1849], ["other", 1854], ["hospitals", 1860], [",", 1869], ["as", 1871], ["well", 1874], ["as", 1879], ["from", 1882], ["the", 1887], ["community", 1891], [".", 1900], ["This", 1902], ["information", 1907], ["provides", 1919], ["an", 1928], ["appropriate", 1931], ["incentive", 1943], ["for", 1953], ["hospitals", 1957], ["to", 1967], ["introduce", 1970], ["further", 1980], ["infection", 1988], ["control", 1998], ["measures", 2006], [".", 2014]]}
{"context": "Neurofibromatosis type 1 (NF1) is characterized primarily by tumor formation in the nervous system, but patients report other neurological complications including pain and itch. Individuals with NF1 harbor 1 mutated NF1 allele causing heterozygous expression in all of their cells. In mice, Nf1 heterozygosity leads to hyperexcitability of sensory neurons and hyperproliferation of mast cells, both of which could lead to increased hypersensitivity and scratching in response to noxious and pruritic stimuli. To determine whether Nf1 heterozygosity may increase pain and itch behaviors independent of secondary effects of tumor formation, we used mice with a targeted, heterozygous Nf1 gene deletion (Nf1\u00b1) that lack tumors. Nf1\u00b1 mice exhibited normal baseline responses to thermal and mechanical stimuli. Moreover, similar to wild-type littermates, Nf1\u00b1 mice developed inflammation-induced heat\u00a0and mechanical hypersensitivity, capsaicin-induced nocifensive behavior, histamine-dependent or -independent scratching, and chronic constriction injury-induced cold allodynia. However, Nf1\u00b1\u00a0mice exhibited an attenuated first phase of formalin-induced spontaneous behavior and expedited resolution of formalin-induced heat hypersensitivity. These results are not consistent with the hypothesis that Nf1 heterozygosity alone is sufficient to increase pain and itch sensation in mice, and they suggest that additional mechanisms may underlie reports of increased pain and itch in NF1 patients. This study assessed whether Nf1 heterozygosity in mice increased hypersensitivity and scratching following noxious and pruritic stimuli. Using Nf1\u00b1 mice lacking tumors, this study finds no increases in pain or itch behavior, suggesting that there is no predisposition for either clinical symptom solely due to Nf1 heterozygosity.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "40227f76b00344a78411177630545e7b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[48, 48], [83, 83], [107, 107], [30, 30], [205, 205], [234, 234], [285, 285], [4, 4], [34, 34], [241, 241]], "char_spans": [[291, 293], [530, 532], [682, 684], [195, 197], [1295, 1297], [1474, 1476], [1798, 1800], [26, 28], [216, 218], [1516, 1518]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["characterized", 34], ["primarily", 48], ["by", 58], ["tumor", 61], ["formation", 67], ["in", 77], ["the", 80], ["nervous", 84], ["system", 92], [",", 98], ["but", 100], ["patients", 104], ["report", 113], ["other", 120], ["neurological", 126], ["complications", 139], ["including", 153], ["pain", 163], ["and", 168], ["itch", 172], [".", 176], ["Individuals", 178], ["with", 190], ["NF1", 195], ["harbor", 199], ["1", 206], ["mutated", 208], ["NF1", 216], ["allele", 220], ["causing", 227], ["heterozygous", 235], ["expression", 248], ["in", 259], ["all", 262], ["of", 266], ["their", 269], ["cells", 275], [".", 280], ["In", 282], ["mice", 285], [",", 289], ["Nf1", 291], ["heterozygosity", 295], ["leads", 310], ["to", 316], ["hyperexcitability", 319], ["of", 337], ["sensory", 340], ["neurons", 348], ["and", 356], ["hyperproliferation", 360], ["of", 379], ["mast", 382], ["cells", 387], [",", 392], ["both", 394], ["of", 399], ["which", 402], ["could", 408], ["lead", 414], ["to", 419], ["increased", 422], ["hypersensitivity", 432], ["and", 449], ["scratching", 453], ["in", 464], ["response", 467], ["to", 476], ["noxious", 479], ["and", 487], ["pruritic", 491], ["stimuli", 500], [".", 507], ["To", 509], ["determine", 512], ["whether", 522], ["Nf1", 530], ["heterozygosity", 534], ["may", 549], ["increase", 553], ["pain", 562], ["and", 567], ["itch", 571], ["behaviors", 576], ["independent", 586], ["of", 598], ["secondary", 601], ["effects", 611], ["of", 619], ["tumor", 622], ["formation", 628], [",", 637], ["we", 639], ["used", 642], ["mice", 647], ["with", 652], ["a", 657], ["targeted", 659], [",", 667], ["heterozygous", 669], ["Nf1", 682], ["gene", 686], ["deletion", 691], ["(", 700], ["Nf1\u00b1", 701], [")", 705], ["that", 707], ["lack", 712], ["tumors", 717], [".", 723], ["Nf1\u00b1", 725], ["mice", 730], ["exhibited", 735], ["normal", 745], ["baseline", 752], ["responses", 761], ["to", 771], ["thermal", 774], ["and", 782], ["mechanical", 786], ["stimuli", 797], [".", 804], ["Moreover", 806], [",", 814], ["similar", 816], ["to", 824], ["wild", 827], ["-", 831], ["type", 832], ["littermates", 837], [",", 848], ["Nf1\u00b1", 850], ["mice", 855], ["developed", 860], ["inflammation", 870], ["-", 882], ["induced", 883], ["heat", 891], ["and", 896], ["mechanical", 900], ["hypersensitivity", 911], [",", 927], ["capsaicin", 929], ["-", 938], ["induced", 939], ["nocifensive", 947], ["behavior", 959], [",", 967], ["histamine", 969], ["-", 978], ["dependent", 979], ["or", 989], ["-independent", 992], ["scratching", 1005], [",", 1015], ["and", 1017], ["chronic", 1021], ["constriction", 1029], ["injury", 1042], ["-", 1048], ["induced", 1049], ["cold", 1057], ["allodynia", 1062], [".", 1071], ["However", 1073], [",", 1080], ["Nf1\u00b1", 1082], ["mice", 1087], ["exhibited", 1092], ["an", 1102], ["attenuated", 1105], ["first", 1116], ["phase", 1122], ["of", 1128], ["formalin", 1131], ["-", 1139], ["induced", 1140], ["spontaneous", 1148], ["behavior", 1160], ["and", 1169], ["expedited", 1173], ["resolution", 1183], ["of", 1194], ["formalin", 1197], ["-", 1205], ["induced", 1206], ["heat", 1214], ["hypersensitivity", 1219], [".", 1235], ["These", 1237], ["results", 1243], ["are", 1251], ["not", 1255], ["consistent", 1259], ["with", 1270], ["the", 1275], ["hypothesis", 1279], ["that", 1290], ["Nf1", 1295], ["heterozygosity", 1299], ["alone", 1314], ["is", 1320], ["sufficient", 1323], ["to", 1334], ["increase", 1337], ["pain", 1346], ["and", 1351], ["itch", 1355], ["sensation", 1360], ["in", 1370], ["mice", 1373], [",", 1377], ["and", 1379], ["they", 1383], ["suggest", 1388], ["that", 1396], ["additional", 1401], ["mechanisms", 1412], ["may", 1423], ["underlie", 1427], ["reports", 1436], ["of", 1444], ["increased", 1447], ["pain", 1457], ["and", 1462], ["itch", 1466], ["in", 1471], ["NF1", 1474], ["patients", 1478], [".", 1486], ["This", 1488], ["study", 1493], ["assessed", 1499], ["whether", 1508], ["Nf1", 1516], ["heterozygosity", 1520], ["in", 1535], ["mice", 1538], ["increased", 1543], ["hypersensitivity", 1553], ["and", 1570], ["scratching", 1574], ["following", 1585], ["noxious", 1595], ["and", 1603], ["pruritic", 1607], ["stimuli", 1616], [".", 1623], ["Using", 1625], ["Nf1\u00b1", 1631], ["mice", 1636], ["lacking", 1641], ["tumors", 1649], [",", 1655], ["this", 1657], ["study", 1662], ["finds", 1668], ["no", 1674], ["increases", 1677], ["in", 1687], ["pain", 1690], ["or", 1695], ["itch", 1698], ["behavior", 1703], [",", 1711], ["suggesting", 1713], ["that", 1724], ["there", 1729], ["is", 1735], ["no", 1738], ["predisposition", 1741], ["for", 1756], ["either", 1760], ["clinical", 1767], ["symptom", 1776], ["solely", 1784], ["due", 1791], ["to", 1795], ["Nf1", 1798], ["heterozygosity", 1802], [".", 1816]]}
{"context": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic. In search for the pathophysiology and causative agent of VE, we performed a cross-sectional study on clinical, serological and neuroimaging data on chronic VE patients during two medical expeditions to three villages within the Viliuiski river basin in the Republic of Sakha in 2000 and to the capital Yakutsk in 2006. The severity of the core clinical picture with predominant sensory ataxia, gait apraxia, lower limb spasticity, cognitive impairment and bladder dysfunction correlated with the degree of MRI findings showing enlargement of inner ventricular spaces as in communicating hydrocephalus. Laboratory studies revealed transient eosinophilia during the preceding acute meningitis-like phase, but no ongoing inflammatory process in the CSF. We found immune reactions against Toxocara canis in the majority of chronic VE patients but rarely in controls (P = 0.025; Fisher's exact test). Histological analysis of subacute to subchronic VE brain samples showed eosinophilic infiltrations with no signs of persistent Toxocara canis infection. Our data showed that pressure by the communicating hydrocephalus as a mechanical factor is the major pathogenic mechanism in chronic VE, most likely triggered by eosinophilic meningitis. There are no signs for an ongoing inflammatory process in chronic VE. The past eosinophilic reaction in VE might be caused by Toxocara ssp. infection and might therefore represent the first hint for an initial cause leading to the development of chronic VE. Our data provide a framework for future studies and potential therapeutic interventions for this enigmatic epidemic neurological disease potentially spreading in Sakha Republic.", "qas": [{"question": "Viliuisk encephalomyelitis is diagnosed in which geographical area?", "answers": ["Northeast Siberia"], "qid": "15bd193287ec4c43b761c54699d4ca55", "question_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["is", 27], ["diagnosed", 30], ["in", 40], ["which", 43], ["geographical", 49], ["area", 62], ["?", 66]], "detected_answers": [{"text": "Northeast Siberia", "token_spans": [[11, 12]], "char_spans": [[70, 86]]}]}], "context_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["(", 27], ["VE", 28], [")", 30], ["is", 32], ["an", 35], ["endemic", 38], ["neurological", 46], ["disease", 59], ["in", 67], ["Northeast", 70], ["Siberia", 80], ["and", 88], ["generally", 92], ["considered", 102], ["to", 113], ["be", 116], ["a", 119], ["chronic", 121], ["encephalomyelitis", 129], ["of", 147], ["unknown", 150], ["origin", 158], ["actually", 165], ["spreading", 174], ["in", 184], ["the", 187], ["Sakha", 191], ["(", 197], ["Yakutian", 198], [")", 206], ["Republic", 208], [".", 216], ["In", 218], ["search", 221], ["for", 228], ["the", 232], ["pathophysiology", 236], ["and", 252], ["causative", 256], ["agent", 266], ["of", 272], ["VE", 275], [",", 277], ["we", 279], ["performed", 282], ["a", 292], ["cross", 294], ["-", 299], ["sectional", 300], ["study", 310], ["on", 316], ["clinical", 319], [",", 327], ["serological", 329], ["and", 341], ["neuroimaging", 345], ["data", 358], ["on", 363], ["chronic", 366], ["VE", 374], ["patients", 377], ["during", 386], ["two", 393], ["medical", 397], ["expeditions", 405], ["to", 417], ["three", 420], ["villages", 426], ["within", 435], ["the", 442], ["Viliuiski", 446], ["river", 456], ["basin", 462], ["in", 468], ["the", 471], ["Republic", 475], ["of", 484], ["Sakha", 487], ["in", 493], ["2000", 496], ["and", 501], ["to", 505], ["the", 508], ["capital", 512], ["Yakutsk", 520], ["in", 528], ["2006", 531], [".", 535], ["The", 537], ["severity", 541], ["of", 550], ["the", 553], ["core", 557], ["clinical", 562], ["picture", 571], ["with", 579], ["predominant", 584], ["sensory", 596], ["ataxia", 604], [",", 610], ["gait", 612], ["apraxia", 617], [",", 624], ["lower", 626], ["limb", 632], ["spasticity", 637], [",", 647], ["cognitive", 649], ["impairment", 659], ["and", 670], ["bladder", 674], ["dysfunction", 682], ["correlated", 694], ["with", 705], ["the", 710], ["degree", 714], ["of", 721], ["MRI", 724], ["findings", 728], ["showing", 737], ["enlargement", 745], ["of", 757], ["inner", 760], ["ventricular", 766], ["spaces", 778], ["as", 785], ["in", 788], ["communicating", 791], ["hydrocephalus", 805], [".", 818], ["Laboratory", 820], ["studies", 831], ["revealed", 839], ["transient", 848], ["eosinophilia", 858], ["during", 871], ["the", 878], ["preceding", 882], ["acute", 892], ["meningitis", 898], ["-", 908], ["like", 909], ["phase", 914], [",", 919], ["but", 921], ["no", 925], ["ongoing", 928], ["inflammatory", 936], ["process", 949], ["in", 957], ["the", 960], ["CSF", 964], [".", 967], ["We", 969], ["found", 972], ["immune", 978], ["reactions", 985], ["against", 995], ["Toxocara", 1003], ["canis", 1012], ["in", 1018], ["the", 1021], ["majority", 1025], ["of", 1034], ["chronic", 1037], ["VE", 1045], ["patients", 1048], ["but", 1057], ["rarely", 1061], ["in", 1068], ["controls", 1071], ["(", 1080], ["P", 1081], ["=", 1083], ["0.025", 1085], [";", 1090], ["Fisher", 1092], ["'s", 1098], ["exact", 1101], ["test", 1107], [")", 1111], [".", 1112], ["Histological", 1114], ["analysis", 1127], ["of", 1136], ["subacute", 1139], ["to", 1148], ["subchronic", 1151], ["VE", 1162], ["brain", 1165], ["samples", 1171], ["showed", 1179], ["eosinophilic", 1186], ["infiltrations", 1199], ["with", 1213], ["no", 1218], ["signs", 1221], ["of", 1227], ["persistent", 1230], ["Toxocara", 1241], ["canis", 1250], ["infection", 1256], [".", 1265], ["Our", 1267], ["data", 1271], ["showed", 1276], ["that", 1283], ["pressure", 1288], ["by", 1297], ["the", 1300], ["communicating", 1304], ["hydrocephalus", 1318], ["as", 1332], ["a", 1335], ["mechanical", 1337], ["factor", 1348], ["is", 1355], ["the", 1358], ["major", 1362], ["pathogenic", 1368], ["mechanism", 1379], ["in", 1389], ["chronic", 1392], ["VE", 1400], [",", 1402], ["most", 1404], ["likely", 1409], ["triggered", 1416], ["by", 1426], ["eosinophilic", 1429], ["meningitis", 1442], [".", 1452], ["There", 1454], ["are", 1460], ["no", 1464], ["signs", 1467], ["for", 1473], ["an", 1477], ["ongoing", 1480], ["inflammatory", 1488], ["process", 1501], ["in", 1509], ["chronic", 1512], ["VE", 1520], [".", 1522], ["The", 1524], ["past", 1528], ["eosinophilic", 1533], ["reaction", 1546], ["in", 1555], ["VE", 1558], ["might", 1561], ["be", 1567], ["caused", 1570], ["by", 1577], ["Toxocara", 1580], ["ssp", 1589], [".", 1592], ["infection", 1594], ["and", 1604], ["might", 1608], ["therefore", 1614], ["represent", 1624], ["the", 1634], ["first", 1638], ["hint", 1644], ["for", 1649], ["an", 1653], ["initial", 1656], ["cause", 1664], ["leading", 1670], ["to", 1678], ["the", 1681], ["development", 1685], ["of", 1697], ["chronic", 1700], ["VE", 1708], [".", 1710], ["Our", 1712], ["data", 1716], ["provide", 1721], ["a", 1729], ["framework", 1731], ["for", 1741], ["future", 1745], ["studies", 1752], ["and", 1760], ["potential", 1764], ["therapeutic", 1774], ["interventions", 1786], ["for", 1800], ["this", 1804], ["enigmatic", 1809], ["epidemic", 1819], ["neurological", 1828], ["disease", 1841], ["potentially", 1849], ["spreading", 1861], ["in", 1871], ["Sakha", 1874], ["Republic", 1880], [".", 1888]]}
{"context": "Diamond-Blackfan anemia (DBA) features hypoplastic anemia and congenital malformations, largely caused by mutations in various ribosomal proteins. The aim of this study was to characterize the spectrum of genetic lesions causing DBA and identify genotypes that correlate with phenotypes of clinical significance. Seventy-four patients with DBA from across Canada were included. Nucleotide-level mutations or large deletions were identified in 10 ribosomal genes in 45 cases. The RPS19 mutation group was associated with higher requirement for chronic treatment for anemia than other DBA groups. Patients with RPS19 mutations, however, were more likely to maintain long-term corticosteroid response without requirement for further chronic transfusions. Conversely, patients with RPL11 mutations were less likely to need chronic treatment. Birth defects, including cardiac, skeletal, hand, cleft lip or palate and genitourinary malformations, also varied among the various genetic groups. Patients with RPS19 mutations had the fewest number of defects, while patients with RPL5 had the greatest number of birth defects. This is the first study to show differences between DBA genetic groups with regards to treatment. Previously unreported differences in the rate and types of birth defects were also identified. These data allow better patient counseling, a more personalized monitoring plan, and may also suggest differential functions of DBA genes on ribosome and extra-ribosomal functions.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "64a4ffe678aa497da235a1cde7d5712e", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[37, 37], [5, 5], [54, 54], [236, 236], [94, 94], [193, 193]], "char_spans": [[229, 231], [25, 27], [340, 342], [1439, 1441], [583, 585], [1170, 1172]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["features", 30], ["hypoplastic", 39], ["anemia", 51], ["and", 58], ["congenital", 62], ["malformations", 73], [",", 86], ["largely", 88], ["caused", 96], ["by", 103], ["mutations", 106], ["in", 116], ["various", 119], ["ribosomal", 127], ["proteins", 137], [".", 145], ["The", 147], ["aim", 151], ["of", 155], ["this", 158], ["study", 163], ["was", 169], ["to", 173], ["characterize", 176], ["the", 189], ["spectrum", 193], ["of", 202], ["genetic", 205], ["lesions", 213], ["causing", 221], ["DBA", 229], ["and", 233], ["identify", 237], ["genotypes", 246], ["that", 256], ["correlate", 261], ["with", 271], ["phenotypes", 276], ["of", 287], ["clinical", 290], ["significance", 299], [".", 311], ["Seventy", 313], ["-", 320], ["four", 321], ["patients", 326], ["with", 335], ["DBA", 340], ["from", 344], ["across", 349], ["Canada", 356], ["were", 363], ["included", 368], [".", 376], ["Nucleotide", 378], ["-", 388], ["level", 389], ["mutations", 395], ["or", 405], ["large", 408], ["deletions", 414], ["were", 424], ["identified", 429], ["in", 440], ["10", 443], ["ribosomal", 446], ["genes", 456], ["in", 462], ["45", 465], ["cases", 468], [".", 473], ["The", 475], ["RPS19", 479], ["mutation", 485], ["group", 494], ["was", 500], ["associated", 504], ["with", 515], ["higher", 520], ["requirement", 527], ["for", 539], ["chronic", 543], ["treatment", 551], ["for", 561], ["anemia", 565], ["than", 572], ["other", 577], ["DBA", 583], ["groups", 587], [".", 593], ["Patients", 595], ["with", 604], ["RPS19", 609], ["mutations", 615], [",", 624], ["however", 626], [",", 633], ["were", 635], ["more", 640], ["likely", 645], ["to", 652], ["maintain", 655], ["long", 664], ["-", 668], ["term", 669], ["corticosteroid", 674], ["response", 689], ["without", 698], ["requirement", 706], ["for", 718], ["further", 722], ["chronic", 730], ["transfusions", 738], [".", 750], ["Conversely", 752], [",", 762], ["patients", 764], ["with", 773], ["RPL11", 778], ["mutations", 784], ["were", 794], ["less", 799], ["likely", 804], ["to", 811], ["need", 814], ["chronic", 819], ["treatment", 827], [".", 836], ["Birth", 838], ["defects", 844], [",", 851], ["including", 853], ["cardiac", 863], [",", 870], ["skeletal", 872], [",", 880], ["hand", 882], [",", 886], ["cleft", 888], ["lip", 894], ["or", 898], ["palate", 901], ["and", 908], ["genitourinary", 912], ["malformations", 926], [",", 939], ["also", 941], ["varied", 946], ["among", 953], ["the", 959], ["various", 963], ["genetic", 971], ["groups", 979], [".", 985], ["Patients", 987], ["with", 996], ["RPS19", 1001], ["mutations", 1007], ["had", 1017], ["the", 1021], ["fewest", 1025], ["number", 1032], ["of", 1039], ["defects", 1042], [",", 1049], ["while", 1051], ["patients", 1057], ["with", 1066], ["RPL5", 1071], ["had", 1076], ["the", 1080], ["greatest", 1084], ["number", 1093], ["of", 1100], ["birth", 1103], ["defects", 1109], [".", 1116], ["This", 1118], ["is", 1123], ["the", 1126], ["first", 1130], ["study", 1136], ["to", 1142], ["show", 1145], ["differences", 1150], ["between", 1162], ["DBA", 1170], ["genetic", 1174], ["groups", 1182], ["with", 1189], ["regards", 1194], ["to", 1202], ["treatment", 1205], [".", 1214], ["Previously", 1216], ["unreported", 1227], ["differences", 1238], ["in", 1250], ["the", 1253], ["rate", 1257], ["and", 1262], ["types", 1266], ["of", 1272], ["birth", 1275], ["defects", 1281], ["were", 1289], ["also", 1294], ["identified", 1299], [".", 1309], ["These", 1311], ["data", 1317], ["allow", 1322], ["better", 1328], ["patient", 1335], ["counseling", 1343], [",", 1353], ["a", 1355], ["more", 1357], ["personalized", 1362], ["monitoring", 1375], ["plan", 1386], [",", 1390], ["and", 1392], ["may", 1396], ["also", 1400], ["suggest", 1405], ["differential", 1413], ["functions", 1426], ["of", 1436], ["DBA", 1439], ["genes", 1443], ["on", 1449], ["ribosome", 1452], ["and", 1461], ["extra", 1465], ["-", 1470], ["ribosomal", 1471], ["functions", 1481], [".", 1490]]}
{"context": "To investigate the clinicopathologic features of focal cortical dysplasia (FCD) in patients with refractory epilepsy. The clinical, radiologic and pathologic features of 38 cases of FCD receiving surgical treatment in 2005 were reviewed retrospectively. The mean age of disease onset was 9.2 years. The disease lasted for 11.9 years on average and often presented as complex partial seizure. Radiologic examination revealed hippocampal sclerosis, or abnormal signals in the grey matter in 21 cases. According to Palmini's classification system, the following pathologic subgroups were identified: FCD type IA (3/38), FCD type IB (20/38), FCD type IIA (5/38) and FCD type IIB (5/38). The remaining 5 cases were classified as mild cortical dysplasia. Topographically, FCD type II was often seen in the extratemporal region (8/10), predominantly in the frontal lobe (5/8). Dual pathology was identified only in cases with FCD type IB. Immunohistochemical study showed that the giant neurons, immature neurons and dysmorphic neurons were strongly positive for NeuN. A small number of balloon cells expressed nestin. FCD is a common cause of refractory epilepsy. FCD type IB is the predominant pathologic subtype. Associated hippocampal sclerosis is sometimes seen. Clinicopathologic differences between FCD type I and FCD type II are observed.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "c273e4acf5d244feb5d5fca095c0254f", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[6, 8]], "char_spans": [[49, 72]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["clinicopathologic", 19], ["features", 37], ["of", 46], ["focal", 49], ["cortical", 55], ["dysplasia", 64], ["(", 74], ["FCD", 75], [")", 78], ["in", 80], ["patients", 83], ["with", 92], ["refractory", 97], ["epilepsy", 108], [".", 116], ["The", 118], ["clinical", 122], [",", 130], ["radiologic", 132], ["and", 143], ["pathologic", 147], ["features", 158], ["of", 167], ["38", 170], ["cases", 173], ["of", 179], ["FCD", 182], ["receiving", 186], ["surgical", 196], ["treatment", 205], ["in", 215], ["2005", 218], ["were", 223], ["reviewed", 228], ["retrospectively", 237], [".", 252], ["The", 254], ["mean", 258], ["age", 263], ["of", 267], ["disease", 270], ["onset", 278], ["was", 284], ["9.2", 288], ["years", 292], [".", 297], ["The", 299], ["disease", 303], ["lasted", 311], ["for", 318], ["11.9", 322], ["years", 327], ["on", 333], ["average", 336], ["and", 344], ["often", 348], ["presented", 354], ["as", 364], ["complex", 367], ["partial", 375], ["seizure", 383], [".", 390], ["Radiologic", 392], ["examination", 403], ["revealed", 415], ["hippocampal", 424], ["sclerosis", 436], [",", 445], ["or", 447], ["abnormal", 450], ["signals", 459], ["in", 467], ["the", 470], ["grey", 474], ["matter", 479], ["in", 486], ["21", 489], ["cases", 492], [".", 497], ["According", 499], ["to", 509], ["Palmini", 512], ["'s", 519], ["classification", 522], ["system", 537], [",", 543], ["the", 545], ["following", 549], ["pathologic", 559], ["subgroups", 570], ["were", 580], ["identified", 585], [":", 595], ["FCD", 597], ["type", 601], ["IA", 606], ["(", 609], ["3/38", 610], [")", 614], [",", 615], ["FCD", 617], ["type", 621], ["IB", 626], ["(", 629], ["20/38", 630], [")", 635], [",", 636], ["FCD", 638], ["type", 642], ["IIA", 647], ["(", 651], ["5/38", 652], [")", 656], ["and", 658], ["FCD", 662], ["type", 666], ["IIB", 671], ["(", 675], ["5/38", 676], [")", 680], [".", 681], ["The", 683], ["remaining", 687], ["5", 697], ["cases", 699], ["were", 705], ["classified", 710], ["as", 721], ["mild", 724], ["cortical", 729], ["dysplasia", 738], [".", 747], ["Topographically", 749], [",", 764], ["FCD", 766], ["type", 770], ["II", 775], ["was", 778], ["often", 782], ["seen", 788], ["in", 793], ["the", 796], ["extratemporal", 800], ["region", 814], ["(", 821], ["8/10", 822], [")", 826], [",", 827], ["predominantly", 829], ["in", 843], ["the", 846], ["frontal", 850], ["lobe", 858], ["(", 863], ["5/8", 864], [")", 867], [".", 868], ["Dual", 870], ["pathology", 875], ["was", 885], ["identified", 889], ["only", 900], ["in", 905], ["cases", 908], ["with", 914], ["FCD", 919], ["type", 923], ["IB", 928], [".", 930], ["Immunohistochemical", 932], ["study", 952], ["showed", 958], ["that", 965], ["the", 970], ["giant", 974], ["neurons", 980], [",", 987], ["immature", 989], ["neurons", 998], ["and", 1006], ["dysmorphic", 1010], ["neurons", 1021], ["were", 1029], ["strongly", 1034], ["positive", 1043], ["for", 1052], ["NeuN.", 1056], ["A", 1062], ["small", 1064], ["number", 1070], ["of", 1077], ["balloon", 1080], ["cells", 1088], ["expressed", 1094], ["nestin", 1104], [".", 1110], ["FCD", 1112], ["is", 1116], ["a", 1119], ["common", 1121], ["cause", 1128], ["of", 1134], ["refractory", 1137], ["epilepsy", 1148], [".", 1156], ["FCD", 1158], ["type", 1162], ["IB", 1167], ["is", 1170], ["the", 1173], ["predominant", 1177], ["pathologic", 1189], ["subtype", 1200], [".", 1207], ["Associated", 1209], ["hippocampal", 1220], ["sclerosis", 1232], ["is", 1242], ["sometimes", 1245], ["seen", 1255], [".", 1259], ["Clinicopathologic", 1261], ["differences", 1279], ["between", 1291], ["FCD", 1299], ["type", 1303], ["I", 1308], ["and", 1310], ["FCD", 1314], ["type", 1318], ["II", 1323], ["are", 1326], ["observed", 1330], [".", 1338]]}
{"context": "The two major virulence factors of Bacillus anthracis are the tripartite toxin and the polyglutamate capsule, which are encoded by genes on the large plasmids, pXO1 and pXO2, respectively. The genes atxA, located on pXO1, and acpA, located on pXO2, encode positive trans-acting proteins that are involved in bicarbonate-mediated regulation of toxin and capsule production, respectively. A derivative strain cured of pXO1 produced less capsular substance than the parent strain harbouring both pXO1 and pXO2, and electroporation of the strain cured of pXO1 with a plasmid containing the cloned atxA gene resulted in an increased level of capsule production. An acpA-null mutant was complemented by not only acpA but also the atxA gene. The cap region, which is essential for encapsulation, contains three genes capB, capC, and capA, arranged in that order. The atxA gene stimulated capsule synthesis from the cloned cap region. Transcriptional analysis of cap by RNA slot-blot hybridization and primer-extension analysis revealed that atxA activated expression of cap in trans at the transcriptional level. These results indicate that cross-talk occurs, in which the pXO1-located gene, atxA, activates transcription of the cap region genes located on pXO2. We identified two major apparent transcriptional start sites, designated P1 and P2, located at positions 731 bp and 625 bp, respectively, upstream of the translation-initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70 bp extending upstream of the P1 site. These results suggest that cross-talk by atxA to the genes encoding capsule synthesis is caused by the interaction of the atxA gene product with a regulatory sequence upstream of cap.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "cf65aa1d62524b4690d8d12f1565be18", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "bicarbonate", "token_spans": [[281, 281], [58, 58]], "char_spans": [[1568, 1578], [308, 318]]}]}], "context_tokens": [["The", 0], ["two", 4], ["major", 8], ["virulence", 14], ["factors", 24], ["of", 32], ["Bacillus", 35], ["anthracis", 44], ["are", 54], ["the", 58], ["tripartite", 62], ["toxin", 73], ["and", 79], ["the", 83], ["polyglutamate", 87], ["capsule", 101], [",", 108], ["which", 110], ["are", 116], ["encoded", 120], ["by", 128], ["genes", 131], ["on", 137], ["the", 140], ["large", 144], ["plasmids", 150], [",", 158], ["pXO1", 160], ["and", 165], ["pXO2", 169], [",", 173], ["respectively", 175], [".", 187], ["The", 189], ["genes", 193], ["atxA", 199], [",", 203], ["located", 205], ["on", 213], ["pXO1", 216], [",", 220], ["and", 222], ["acpA", 226], [",", 230], ["located", 232], ["on", 240], ["pXO2", 243], [",", 247], ["encode", 249], ["positive", 256], ["trans", 265], ["-", 270], ["acting", 271], ["proteins", 278], ["that", 287], ["are", 292], ["involved", 296], ["in", 305], ["bicarbonate", 308], ["-", 319], ["mediated", 320], ["regulation", 329], ["of", 340], ["toxin", 343], ["and", 349], ["capsule", 353], ["production", 361], [",", 371], ["respectively", 373], [".", 385], ["A", 387], ["derivative", 389], ["strain", 400], ["cured", 407], ["of", 413], ["pXO1", 416], ["produced", 421], ["less", 430], ["capsular", 435], ["substance", 444], ["than", 454], ["the", 459], ["parent", 463], ["strain", 470], ["harbouring", 477], ["both", 488], ["pXO1", 493], ["and", 498], ["pXO2", 502], [",", 506], ["and", 508], ["electroporation", 512], ["of", 528], ["the", 531], ["strain", 535], ["cured", 542], ["of", 548], ["pXO1", 551], ["with", 556], ["a", 561], ["plasmid", 563], ["containing", 571], ["the", 582], ["cloned", 586], ["atxA", 593], ["gene", 598], ["resulted", 603], ["in", 612], ["an", 615], ["increased", 618], ["level", 628], ["of", 634], ["capsule", 637], ["production", 645], [".", 655], ["An", 657], ["acpA", 660], ["-", 664], ["null", 665], ["mutant", 670], ["was", 677], ["complemented", 681], ["by", 694], ["not", 697], ["only", 701], ["acpA", 706], ["but", 711], ["also", 715], ["the", 720], ["atxA", 724], ["gene", 729], [".", 733], ["The", 735], ["cap", 739], ["region", 743], [",", 749], ["which", 751], ["is", 757], ["essential", 760], ["for", 770], ["encapsulation", 774], [",", 787], ["contains", 789], ["three", 798], ["genes", 804], ["capB", 810], [",", 814], ["capC", 816], [",", 820], ["and", 822], ["capA", 826], [",", 830], ["arranged", 832], ["in", 841], ["that", 844], ["order", 849], [".", 854], ["The", 856], ["atxA", 860], ["gene", 865], ["stimulated", 870], ["capsule", 881], ["synthesis", 889], ["from", 899], ["the", 904], ["cloned", 908], ["cap", 915], ["region", 919], [".", 925], ["Transcriptional", 927], ["analysis", 943], ["of", 952], ["cap", 955], ["by", 959], ["RNA", 962], ["slot", 966], ["-", 970], ["blot", 971], ["hybridization", 976], ["and", 990], ["primer", 994], ["-", 1000], ["extension", 1001], ["analysis", 1011], ["revealed", 1020], ["that", 1029], ["atxA", 1034], ["activated", 1039], ["expression", 1049], ["of", 1060], ["cap", 1063], ["in", 1067], ["trans", 1070], ["at", 1076], ["the", 1079], ["transcriptional", 1083], ["level", 1099], [".", 1104], ["These", 1106], ["results", 1112], ["indicate", 1120], ["that", 1129], ["cross", 1134], ["-", 1139], ["talk", 1140], ["occurs", 1145], [",", 1151], ["in", 1153], ["which", 1156], ["the", 1162], ["pXO1-located", 1166], ["gene", 1179], [",", 1183], ["atxA", 1185], [",", 1189], ["activates", 1191], ["transcription", 1201], ["of", 1215], ["the", 1218], ["cap", 1222], ["region", 1226], ["genes", 1233], ["located", 1239], ["on", 1247], ["pXO2", 1250], [".", 1254], ["We", 1256], ["identified", 1259], ["two", 1270], ["major", 1274], ["apparent", 1280], ["transcriptional", 1289], ["start", 1305], ["sites", 1311], [",", 1316], ["designated", 1318], ["P1", 1329], ["and", 1332], ["P2", 1336], [",", 1338], ["located", 1340], ["at", 1348], ["positions", 1351], ["731", 1361], ["bp", 1365], ["and", 1368], ["625", 1372], ["bp", 1376], [",", 1378], ["respectively", 1380], [",", 1392], ["upstream", 1394], ["of", 1403], ["the", 1406], ["translation", 1410], ["-", 1421], ["initiation", 1422], ["codon", 1433], ["of", 1439], ["capB.", 1442], ["Transcription", 1448], ["initiated", 1462], ["from", 1472], ["P1", 1477], ["and", 1480], ["P2", 1484], ["was", 1487], ["activated", 1491], ["by", 1501], ["both", 1504], ["atxA", 1509], ["and", 1514], ["acpA", 1518], [",", 1522], ["and", 1524], ["activation", 1528], ["appeared", 1539], ["to", 1548], ["be", 1551], ["stimulated", 1554], ["by", 1565], ["bicarbonate", 1568], [".", 1579], ["Deletion", 1581], ["analysis", 1590], ["of", 1599], ["the", 1602], ["upstream", 1606], ["region", 1615], ["of", 1622], ["the", 1625], ["cap", 1629], ["promoter", 1633], ["revealed", 1642], ["that", 1651], ["activation", 1656], ["by", 1667], ["both", 1670], ["atxA", 1675], ["and", 1680], ["acpA", 1684], ["required", 1689], ["a", 1698], ["DNA", 1700], ["segment", 1704], ["of", 1712], ["70", 1715], ["bp", 1718], ["extending", 1721], ["upstream", 1731], ["of", 1740], ["the", 1743], ["P1", 1747], ["site", 1750], [".", 1754], ["These", 1756], ["results", 1762], ["suggest", 1770], ["that", 1778], ["cross", 1783], ["-", 1788], ["talk", 1789], ["by", 1794], ["atxA", 1797], ["to", 1802], ["the", 1805], ["genes", 1809], ["encoding", 1815], ["capsule", 1824], ["synthesis", 1832], ["is", 1842], ["caused", 1845], ["by", 1852], ["the", 1855], ["interaction", 1859], ["of", 1871], ["the", 1874], ["atxA", 1878], ["gene", 1883], ["product", 1888], ["with", 1896], ["a", 1901], ["regulatory", 1903], ["sequence", 1914], ["upstream", 1923], ["of", 1932], ["cap", 1935], [".", 1938]]}
{"context": "The calcium-regulated protein phosphatase calcineurin (PP2B) functions as a regulator of gene expression in diverse tissues through the dephosphorylation and activation of a family of transcription factors known as nuclear factor of activated T cells (NFAT). Here we show that NFATc3, in addition to being calcium responsive, is regulated through an indirect recruitment of class II histone deacetylases (HDACs). Specifically, yeast two-hybrid screening with the rel homology domain of NFATc3 identified the chaperone mammalian relative of DnaJ (Mrj) as a specific interacting factor. Mrj and NFATc3 were shown to directly associate with one another in mammalian cells and in vitro. Mrj served as a potent inhibitor of NFAT transcriptional activity within the nucleus through a mechanism involving histone deacetylase recruitment in conjunction with heat shock stimulation. Indeed, Mrj was determined to interact with class II histone deacetylases, each of which translocated to the nucleus following heat shock stimulation. Mrj also decreased NFATc3 occupancy of the tumor necrosis factor-alpha promoter in cardiomyocytes in an HDAC-dependent manner, and Mrj blocked calcineurin-induced cardiomyocyte hypertrophic growth. Conversely, small-interfering-RNA-mediated reduction of Mrj augmented NFAT transcriptional activity and spontaneously induced cardiac myocyte growth. Collectively, our results define a novel response pathway whereby NFATc3 is negatively regulated by class II histone deacetylases through the DnaJ (heat shock protein-40) superfamily member Mrj.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "ed2c56657551418794065dae4cc3bb3c", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[196, 196], [6, 6]], "char_spans": [[1168, 1178], [42, 52]]}]}], "context_tokens": [["The", 0], ["calcium", 4], ["-", 11], ["regulated", 12], ["protein", 22], ["phosphatase", 30], ["calcineurin", 42], ["(", 54], ["PP2B", 55], [")", 59], ["functions", 61], ["as", 71], ["a", 74], ["regulator", 76], ["of", 86], ["gene", 89], ["expression", 94], ["in", 105], ["diverse", 108], ["tissues", 116], ["through", 124], ["the", 132], ["dephosphorylation", 136], ["and", 154], ["activation", 158], ["of", 169], ["a", 172], ["family", 174], ["of", 181], ["transcription", 184], ["factors", 198], ["known", 206], ["as", 212], ["nuclear", 215], ["factor", 223], ["of", 230], ["activated", 233], ["T", 243], ["cells", 245], ["(", 251], ["NFAT", 252], [")", 256], [".", 257], ["Here", 259], ["we", 264], ["show", 267], ["that", 272], ["NFATc3", 277], [",", 283], ["in", 285], ["addition", 288], ["to", 297], ["being", 300], ["calcium", 306], ["responsive", 314], [",", 324], ["is", 326], ["regulated", 329], ["through", 339], ["an", 347], ["indirect", 350], ["recruitment", 359], ["of", 371], ["class", 374], ["II", 380], ["histone", 383], ["deacetylases", 391], ["(", 404], ["HDACs", 405], [")", 410], [".", 411], ["Specifically", 413], [",", 425], ["yeast", 427], ["two", 433], ["-", 436], ["hybrid", 437], ["screening", 444], ["with", 454], ["the", 459], ["rel", 463], ["homology", 467], ["domain", 476], ["of", 483], ["NFATc3", 486], ["identified", 493], ["the", 504], ["chaperone", 508], ["mammalian", 518], ["relative", 528], ["of", 537], ["DnaJ", 540], ["(", 545], ["Mrj", 546], [")", 549], ["as", 551], ["a", 554], ["specific", 556], ["interacting", 565], ["factor", 577], [".", 583], ["Mrj", 585], ["and", 589], ["NFATc3", 593], ["were", 600], ["shown", 605], ["to", 611], ["directly", 614], ["associate", 623], ["with", 633], ["one", 638], ["another", 642], ["in", 650], ["mammalian", 653], ["cells", 663], ["and", 669], ["in", 673], ["vitro", 676], [".", 681], ["Mrj", 683], ["served", 687], ["as", 694], ["a", 697], ["potent", 699], ["inhibitor", 706], ["of", 716], ["NFAT", 719], ["transcriptional", 724], ["activity", 740], ["within", 749], ["the", 756], ["nucleus", 760], ["through", 768], ["a", 776], ["mechanism", 778], ["involving", 788], ["histone", 798], ["deacetylase", 806], ["recruitment", 818], ["in", 830], ["conjunction", 833], ["with", 845], ["heat", 850], ["shock", 855], ["stimulation", 861], [".", 872], ["Indeed", 874], [",", 880], ["Mrj", 882], ["was", 886], ["determined", 890], ["to", 901], ["interact", 904], ["with", 913], ["class", 918], ["II", 924], ["histone", 927], ["deacetylases", 935], [",", 947], ["each", 949], ["of", 954], ["which", 957], ["translocated", 963], ["to", 976], ["the", 979], ["nucleus", 983], ["following", 991], ["heat", 1001], ["shock", 1006], ["stimulation", 1012], [".", 1023], ["Mrj", 1025], ["also", 1029], ["decreased", 1034], ["NFATc3", 1044], ["occupancy", 1051], ["of", 1061], ["the", 1064], ["tumor", 1068], ["necrosis", 1074], ["factor", 1083], ["-", 1089], ["alpha", 1090], ["promoter", 1096], ["in", 1105], ["cardiomyocytes", 1108], ["in", 1123], ["an", 1126], ["HDAC", 1129], ["-", 1133], ["dependent", 1134], ["manner", 1144], [",", 1150], ["and", 1152], ["Mrj", 1156], ["blocked", 1160], ["calcineurin", 1168], ["-", 1179], ["induced", 1180], ["cardiomyocyte", 1188], ["hypertrophic", 1202], ["growth", 1215], [".", 1221], ["Conversely", 1223], [",", 1233], ["small", 1235], ["-", 1240], ["interfering", 1241], ["-", 1252], ["RNA", 1253], ["-", 1256], ["mediated", 1257], ["reduction", 1266], ["of", 1276], ["Mrj", 1279], ["augmented", 1283], ["NFAT", 1293], ["transcriptional", 1298], ["activity", 1314], ["and", 1323], ["spontaneously", 1327], ["induced", 1341], ["cardiac", 1349], ["myocyte", 1357], ["growth", 1365], [".", 1371], ["Collectively", 1373], [",", 1385], ["our", 1387], ["results", 1391], ["define", 1399], ["a", 1406], ["novel", 1408], ["response", 1414], ["pathway", 1423], ["whereby", 1431], ["NFATc3", 1439], ["is", 1446], ["negatively", 1449], ["regulated", 1460], ["by", 1470], ["class", 1473], ["II", 1479], ["histone", 1482], ["deacetylases", 1490], ["through", 1503], ["the", 1511], ["DnaJ", 1515], ["(", 1520], ["heat", 1521], ["shock", 1526], ["protein-40", 1532], [")", 1542], ["superfamily", 1544], ["member", 1556], ["Mrj", 1563], [".", 1566]]}
{"context": "Heme is critical for a variety of cellular processes, but excess intracellular heme may result in oxidative stress and membrane injury. Feline leukemia virus subgroup C receptor (FLVCR1), a member of the SLC49 family of four paralogous genes, is a cell surface heme exporter, essential for erythropoiesis and systemic iron homeostasis. Disruption of FLVCR1 function blocks development of erythroid progenitors, likely due to heme toxicity. Mutations of SLC49A1 encoding FLVCR1 are noted in patients with a rare neurodegenerative disorder: posterior column ataxia with retinitis pigmentosa. FLVCR2 is highly homologous to FLVCR1 and may function as a cellular heme importer. Mutations of SLC49A2 encoding FLVCR2 are observed in Fowler syndrome, a rare proliferative vascular disorder of the brain. The functions of the remaining members of the SLC49 family, MFSD7 and DIRC2 (encoded by the SLC49A3 and SLC49A4 genes), are unknown, although the latter is implicated in hereditary renal carcinomas. SLC48A1 (heme responsive gene-1, HRG-1), the sole member of the SLC48 family, is associated with the endosome and appears to transport heme from the endosome into the cytosol.", "qas": [{"question": "Which SLC family is FLVCR1 a member of?", "answers": ["SLC49"], "qid": "a338247c1f654179887259220bfbd8d6", "question_tokens": [["Which", 0], ["SLC", 6], ["family", 10], ["is", 17], ["FLVCR1", 20], ["a", 27], ["member", 29], ["of", 36], ["?", 38]], "detected_answers": [{"text": "SLC49", "token_spans": [[140, 140], [37, 37]], "char_spans": [[843, 847], [204, 208]]}]}], "context_tokens": [["Heme", 0], ["is", 5], ["critical", 8], ["for", 17], ["a", 21], ["variety", 23], ["of", 31], ["cellular", 34], ["processes", 43], [",", 52], ["but", 54], ["excess", 58], ["intracellular", 65], ["heme", 79], ["may", 84], ["result", 88], ["in", 95], ["oxidative", 98], ["stress", 108], ["and", 115], ["membrane", 119], ["injury", 128], [".", 134], ["Feline", 136], ["leukemia", 143], ["virus", 152], ["subgroup", 158], ["C", 167], ["receptor", 169], ["(", 178], ["FLVCR1", 179], [")", 185], [",", 186], ["a", 188], ["member", 190], ["of", 197], ["the", 200], ["SLC49", 204], ["family", 210], ["of", 217], ["four", 220], ["paralogous", 225], ["genes", 236], [",", 241], ["is", 243], ["a", 246], ["cell", 248], ["surface", 253], ["heme", 261], ["exporter", 266], [",", 274], ["essential", 276], ["for", 286], ["erythropoiesis", 290], ["and", 305], ["systemic", 309], ["iron", 318], ["homeostasis", 323], [".", 334], ["Disruption", 336], ["of", 347], ["FLVCR1", 350], ["function", 357], ["blocks", 366], ["development", 373], ["of", 385], ["erythroid", 388], ["progenitors", 398], [",", 409], ["likely", 411], ["due", 418], ["to", 422], ["heme", 425], ["toxicity", 430], [".", 438], ["Mutations", 440], ["of", 450], ["SLC49A1", 453], ["encoding", 461], ["FLVCR1", 470], ["are", 477], ["noted", 481], ["in", 487], ["patients", 490], ["with", 499], ["a", 504], ["rare", 506], ["neurodegenerative", 511], ["disorder", 529], [":", 537], ["posterior", 539], ["column", 549], ["ataxia", 556], ["with", 563], ["retinitis", 568], ["pigmentosa", 578], [".", 588], ["FLVCR2", 590], ["is", 597], ["highly", 600], ["homologous", 607], ["to", 618], ["FLVCR1", 621], ["and", 628], ["may", 632], ["function", 636], ["as", 645], ["a", 648], ["cellular", 650], ["heme", 659], ["importer", 664], [".", 672], ["Mutations", 674], ["of", 684], ["SLC49A2", 687], ["encoding", 695], ["FLVCR2", 704], ["are", 711], ["observed", 715], ["in", 724], ["Fowler", 727], ["syndrome", 734], [",", 742], ["a", 744], ["rare", 746], ["proliferative", 751], ["vascular", 765], ["disorder", 774], ["of", 783], ["the", 786], ["brain", 790], [".", 795], ["The", 797], ["functions", 801], ["of", 811], ["the", 814], ["remaining", 818], ["members", 828], ["of", 836], ["the", 839], ["SLC49", 843], ["family", 849], [",", 855], ["MFSD7", 857], ["and", 863], ["DIRC2", 867], ["(", 873], ["encoded", 874], ["by", 882], ["the", 885], ["SLC49A3", 889], ["and", 897], ["SLC49A4", 901], ["genes", 909], [")", 914], [",", 915], ["are", 917], ["unknown", 921], [",", 928], ["although", 930], ["the", 939], ["latter", 943], ["is", 950], ["implicated", 953], ["in", 964], ["hereditary", 967], ["renal", 978], ["carcinomas", 984], [".", 994], ["SLC48A1", 996], ["(", 1004], ["heme", 1005], ["responsive", 1010], ["gene-1", 1021], [",", 1027], ["HRG-1", 1029], [")", 1034], [",", 1035], ["the", 1037], ["sole", 1041], ["member", 1046], ["of", 1053], ["the", 1056], ["SLC48", 1060], ["family", 1066], [",", 1072], ["is", 1074], ["associated", 1077], ["with", 1088], ["the", 1093], ["endosome", 1097], ["and", 1106], ["appears", 1110], ["to", 1118], ["transport", 1121], ["heme", 1131], ["from", 1136], ["the", 1141], ["endosome", 1145], ["into", 1154], ["the", 1159], ["cytosol", 1163], [".", 1170]]}
{"context": "Imatinib mesylate (IM) binds to the BCR-ABL protein, inhibiting its kinase activity and effectively controlling diseases driven by this kinase. IM resistance has been associated with kinase mutations or increased BCR-ABL expression. However, disease progression may be mediated by other mechanisms that render tumor cells independent of BCR-ABL. To demonstrate this potential, IM-resistant cells were found in chronic myelogenous leukemia patients with continuous BCR-ABL gene expression but undetectable BCR-ABL protein expression. These cells were unresponsive to IM and acquired BCR-ABL-independent signaling characteristics. IM resistance in some patients may be mediated through loss of kinase target dependence.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7887f12a541643aebe9893f82a5f0c28", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[86, 88], [36, 38], [100, 102], [8, 10], [57, 59], [79, 81]], "char_spans": [[505, 511], [213, 219], [582, 588], [36, 42], [337, 343], [464, 470]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["IM", 19], [")", 21], ["binds", 23], ["to", 29], ["the", 32], ["BCR", 36], ["-", 39], ["ABL", 40], ["protein", 44], [",", 51], ["inhibiting", 53], ["its", 64], ["kinase", 68], ["activity", 75], ["and", 84], ["effectively", 88], ["controlling", 100], ["diseases", 112], ["driven", 121], ["by", 128], ["this", 131], ["kinase", 136], [".", 142], ["IM", 144], ["resistance", 147], ["has", 158], ["been", 162], ["associated", 167], ["with", 178], ["kinase", 183], ["mutations", 190], ["or", 200], ["increased", 203], ["BCR", 213], ["-", 216], ["ABL", 217], ["expression", 221], [".", 231], ["However", 233], [",", 240], ["disease", 242], ["progression", 250], ["may", 262], ["be", 266], ["mediated", 269], ["by", 278], ["other", 281], ["mechanisms", 287], ["that", 298], ["render", 303], ["tumor", 310], ["cells", 316], ["independent", 322], ["of", 334], ["BCR", 337], ["-", 340], ["ABL", 341], [".", 344], ["To", 346], ["demonstrate", 349], ["this", 361], ["potential", 366], [",", 375], ["IM", 377], ["-", 379], ["resistant", 380], ["cells", 390], ["were", 396], ["found", 401], ["in", 407], ["chronic", 410], ["myelogenous", 418], ["leukemia", 430], ["patients", 439], ["with", 448], ["continuous", 453], ["BCR", 464], ["-", 467], ["ABL", 468], ["gene", 472], ["expression", 477], ["but", 488], ["undetectable", 492], ["BCR", 505], ["-", 508], ["ABL", 509], ["protein", 513], ["expression", 521], [".", 531], ["These", 533], ["cells", 539], ["were", 545], ["unresponsive", 550], ["to", 563], ["IM", 566], ["and", 569], ["acquired", 573], ["BCR", 582], ["-", 585], ["ABL", 586], ["-", 589], ["independent", 590], ["signaling", 602], ["characteristics", 612], [".", 627], ["IM", 629], ["resistance", 632], ["in", 643], ["some", 646], ["patients", 651], ["may", 660], ["be", 664], ["mediated", 667], ["through", 676], ["loss", 684], ["of", 689], ["kinase", 692], ["target", 699], ["dependence", 706], [".", 716]]}
{"context": "Chediak-Higashi syndrome is a genetic disorder caused by mutations in a gene encoding a protein named LYST in humans (\"lysosomal trafficking regulator\") or Beige in mice. A prominent feature of this disease is the accumulation of enlarged lysosome-related granules in a variety of cells. The genome of Dictyostelium discoideum contains six genes encoding proteins that are related to LYST/Beige in amino acid sequence, and disruption of one of these genes, lvsA (large volume sphere), results in profound defects in cytokinesis. To better understand the function of this family of proteins in membrane trafficking, we have analyzed mutants disrupted in lvsA, lvsB, lvsC, lvsD, lvsE, and lvsF. Of all these, only lvsA and lvsB mutants displayed interesting phenotypes in our assays. lvsA-null cells exhibited defects in phagocytosis and contained abnormal looking contractile vacuole membranes. Loss of LvsB, the Dictyostelium protein most similar to LYST/Beige, resulted in the formation of enlarged vesicles that by multiple criteria appeared to be acidic lysosomes. The rates of endocytosis, phagocytosis, and fluid phase exocytosis were normal in lvsB-null cells. Also, the rates of processing and the efficiency of targeting of lysosomal alpha-mannosidase were normal, although lvsB mutants inefficiently retained alpha-mannosidase, as well as two other lysosomal cysteine proteinases. Finally, results of pulse-chase experiments indicated that an increase in fusion rates accounted for the enlarged lysosomes in lvsB-null cells, suggesting that LvsB acts as a negative regulator of fusion. Our results support the notion that LvsB/LYST/Beige function in a similar manner to regulate lysosome biogenesis.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "40cc928d16714c79baadc63e10e82c30", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["is", 25], ["a", 28], ["genetic", 30], ["disorder", 38], ["caused", 47], ["by", 54], ["mutations", 57], ["in", 67], ["a", 70], ["gene", 72], ["encoding", 77], ["a", 86], ["protein", 88], ["named", 96], ["LYST", 102], ["in", 107], ["humans", 110], ["(", 117], ["\"", 118], ["lysosomal", 119], ["trafficking", 129], ["regulator", 141], ["\"", 150], [")", 151], ["or", 153], ["Beige", 156], ["in", 162], ["mice", 165], [".", 169], ["A", 171], ["prominent", 173], ["feature", 183], ["of", 191], ["this", 194], ["disease", 199], ["is", 207], ["the", 210], ["accumulation", 214], ["of", 227], ["enlarged", 230], ["lysosome", 239], ["-", 247], ["related", 248], ["granules", 256], ["in", 265], ["a", 268], ["variety", 270], ["of", 278], ["cells", 281], [".", 286], ["The", 288], ["genome", 292], ["of", 299], ["Dictyostelium", 302], ["discoideum", 316], ["contains", 327], ["six", 336], ["genes", 340], ["encoding", 346], ["proteins", 355], ["that", 364], ["are", 369], ["related", 373], ["to", 381], ["LYST", 384], ["/", 388], ["Beige", 389], ["in", 395], ["amino", 398], ["acid", 404], ["sequence", 409], [",", 417], ["and", 419], ["disruption", 423], ["of", 434], ["one", 437], ["of", 441], ["these", 444], ["genes", 450], [",", 455], ["lvsA", 457], ["(", 462], ["large", 463], ["volume", 469], ["sphere", 476], [")", 482], [",", 483], ["results", 485], ["in", 493], ["profound", 496], ["defects", 505], ["in", 513], ["cytokinesis", 516], [".", 527], ["To", 529], ["better", 532], ["understand", 539], ["the", 550], ["function", 554], ["of", 563], ["this", 566], ["family", 571], ["of", 578], ["proteins", 581], ["in", 590], ["membrane", 593], ["trafficking", 602], [",", 613], ["we", 615], ["have", 618], ["analyzed", 623], ["mutants", 632], ["disrupted", 640], ["in", 650], ["lvsA", 653], [",", 657], ["lvsB", 659], [",", 663], ["lvsC", 665], [",", 669], ["lvsD", 671], [",", 675], ["lvsE", 677], [",", 681], ["and", 683], ["lvsF.", 687], ["Of", 693], ["all", 696], ["these", 700], [",", 705], ["only", 707], ["lvsA", 712], ["and", 717], ["lvsB", 721], ["mutants", 726], ["displayed", 734], ["interesting", 744], ["phenotypes", 756], ["in", 767], ["our", 770], ["assays", 774], [".", 780], ["lvsA", 782], ["-", 786], ["null", 787], ["cells", 792], ["exhibited", 798], ["defects", 808], ["in", 816], ["phagocytosis", 819], ["and", 832], ["contained", 836], ["abnormal", 846], ["looking", 855], ["contractile", 863], ["vacuole", 875], ["membranes", 883], [".", 892], ["Loss", 894], ["of", 899], ["LvsB", 902], [",", 906], ["the", 908], ["Dictyostelium", 912], ["protein", 926], ["most", 934], ["similar", 939], ["to", 947], ["LYST", 950], ["/", 954], ["Beige", 955], [",", 960], ["resulted", 962], ["in", 971], ["the", 974], ["formation", 978], ["of", 988], ["enlarged", 991], ["vesicles", 1000], ["that", 1009], ["by", 1014], ["multiple", 1017], ["criteria", 1026], ["appeared", 1035], ["to", 1044], ["be", 1047], ["acidic", 1050], ["lysosomes", 1057], [".", 1066], ["The", 1068], ["rates", 1072], ["of", 1078], ["endocytosis", 1081], [",", 1092], ["phagocytosis", 1094], [",", 1106], ["and", 1108], ["fluid", 1112], ["phase", 1118], ["exocytosis", 1124], ["were", 1135], ["normal", 1140], ["in", 1147], ["lvsB", 1150], ["-", 1154], ["null", 1155], ["cells", 1160], [".", 1165], ["Also", 1167], [",", 1171], ["the", 1173], ["rates", 1177], ["of", 1183], ["processing", 1186], ["and", 1197], ["the", 1201], ["efficiency", 1205], ["of", 1216], ["targeting", 1219], ["of", 1229], ["lysosomal", 1232], ["alpha", 1242], ["-", 1247], ["mannosidase", 1248], ["were", 1260], ["normal", 1265], [",", 1271], ["although", 1273], ["lvsB", 1282], ["mutants", 1287], ["inefficiently", 1295], ["retained", 1309], ["alpha", 1318], ["-", 1323], ["mannosidase", 1324], [",", 1335], ["as", 1337], ["well", 1340], ["as", 1345], ["two", 1348], ["other", 1352], ["lysosomal", 1358], ["cysteine", 1368], ["proteinases", 1377], [".", 1388], ["Finally", 1390], [",", 1397], ["results", 1399], ["of", 1407], ["pulse", 1410], ["-", 1415], ["chase", 1416], ["experiments", 1422], ["indicated", 1434], ["that", 1444], ["an", 1449], ["increase", 1452], ["in", 1461], ["fusion", 1464], ["rates", 1471], ["accounted", 1477], ["for", 1487], ["the", 1491], ["enlarged", 1495], ["lysosomes", 1504], ["in", 1514], ["lvsB", 1517], ["-", 1521], ["null", 1522], ["cells", 1527], [",", 1532], ["suggesting", 1534], ["that", 1545], ["LvsB", 1550], ["acts", 1555], ["as", 1560], ["a", 1563], ["negative", 1565], ["regulator", 1574], ["of", 1584], ["fusion", 1587], [".", 1593], ["Our", 1595], ["results", 1599], ["support", 1607], ["the", 1615], ["notion", 1619], ["that", 1626], ["LvsB", 1631], ["/", 1635], ["LYST", 1636], ["/", 1640], ["Beige", 1641], ["function", 1647], ["in", 1656], ["a", 1659], ["similar", 1661], ["manner", 1669], ["to", 1676], ["regulate", 1679], ["lysosome", 1688], ["biogenesis", 1697], [".", 1707]]}
{"context": "Until recently, the mechanism of adaptive thermogenesis was ascribed to the expression of uncoupling protein 1 (UCP1) in brown and beige adipocytes. UCP1 is known to catalyze a proton leak of the inner mitochondrial membrane, resulting in uncoupled oxidative metabolism with no production of adenosine triphosphate and increased energy expenditure. Thus increasing brown and beige adipose tissue with augmented UCP1 expression is a viable target for obesity-related disorders. Recent work demonstrates an UCP1-independent pathway to uncouple mitochondrial respiration. A secreted enzyme, PM20D1, enriched in UCP1+ adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids. N-acyl amino acids act as endogenous uncouplers of mitochondrial respiration at physiological concentrations. Administration of PM20D1 or its products, N-acyl amino acids, to diet-induced obese mice improves glucose tolerance by increasing energy expenditure. In short-term studies, treated animals exhibit no toxicity while experiencing 10% weight loss primarily of adipose tissue. Further study of this metabolic pathway may identify novel therapies for diabesity, the disease state associated with diabetes and obesity.", "qas": [{"question": "Where is the enzyme PM20D1 localized?", "answers": ["UCP1+ adipocytes"], "qid": "f4dbacd4b84947bea18cfff2673de042", "question_tokens": [["Where", 0], ["is", 6], ["the", 9], ["enzyme", 13], ["PM20D1", 20], ["localized", 27], ["?", 36]], "detected_answers": [{"text": "UCP1+ adipocytes", "token_spans": [[96, 98]], "char_spans": [[608, 623]]}]}], "context_tokens": [["Until", 0], ["recently", 6], [",", 14], ["the", 16], ["mechanism", 20], ["of", 30], ["adaptive", 33], ["thermogenesis", 42], ["was", 56], ["ascribed", 60], ["to", 69], ["the", 72], ["expression", 76], ["of", 87], ["uncoupling", 90], ["protein", 101], ["1", 109], ["(", 111], ["UCP1", 112], [")", 116], ["in", 118], ["brown", 121], ["and", 127], ["beige", 131], ["adipocytes", 137], [".", 147], ["UCP1", 149], ["is", 154], ["known", 157], ["to", 163], ["catalyze", 166], ["a", 175], ["proton", 177], ["leak", 184], ["of", 189], ["the", 192], ["inner", 196], ["mitochondrial", 202], ["membrane", 216], [",", 224], ["resulting", 226], ["in", 236], ["uncoupled", 239], ["oxidative", 249], ["metabolism", 259], ["with", 270], ["no", 275], ["production", 278], ["of", 289], ["adenosine", 292], ["triphosphate", 302], ["and", 315], ["increased", 319], ["energy", 329], ["expenditure", 336], [".", 347], ["Thus", 349], ["increasing", 354], ["brown", 365], ["and", 371], ["beige", 375], ["adipose", 381], ["tissue", 389], ["with", 396], ["augmented", 401], ["UCP1", 411], ["expression", 416], ["is", 427], ["a", 430], ["viable", 432], ["target", 439], ["for", 446], ["obesity", 450], ["-", 457], ["related", 458], ["disorders", 466], [".", 475], ["Recent", 477], ["work", 484], ["demonstrates", 489], ["an", 502], ["UCP1-independent", 505], ["pathway", 522], ["to", 530], ["uncouple", 533], ["mitochondrial", 542], ["respiration", 556], [".", 567], ["A", 569], ["secreted", 571], ["enzyme", 580], [",", 586], ["PM20D1", 588], [",", 594], ["enriched", 596], ["in", 605], ["UCP1", 608], ["+", 612], ["adipocytes", 614], [",", 624], ["exhibits", 626], ["catalytic", 635], ["and", 645], ["hydrolytic", 649], ["activity", 660], ["to", 669], ["reversibly", 672], ["form", 683], ["N", 688], ["-", 689], ["acyl", 690], ["amino", 695], ["acids", 701], [".", 706], ["N", 708], ["-", 709], ["acyl", 710], ["amino", 715], ["acids", 721], ["act", 727], ["as", 731], ["endogenous", 734], ["uncouplers", 745], ["of", 756], ["mitochondrial", 759], ["respiration", 773], ["at", 785], ["physiological", 788], ["concentrations", 802], [".", 816], ["Administration", 818], ["of", 833], ["PM20D1", 836], ["or", 843], ["its", 846], ["products", 850], [",", 858], ["N", 860], ["-", 861], ["acyl", 862], ["amino", 867], ["acids", 873], [",", 878], ["to", 880], ["diet", 883], ["-", 887], ["induced", 888], ["obese", 896], ["mice", 902], ["improves", 907], ["glucose", 916], ["tolerance", 924], ["by", 934], ["increasing", 937], ["energy", 948], ["expenditure", 955], [".", 966], ["In", 968], ["short", 971], ["-", 976], ["term", 977], ["studies", 982], [",", 989], ["treated", 991], ["animals", 999], ["exhibit", 1007], ["no", 1015], ["toxicity", 1018], ["while", 1027], ["experiencing", 1033], ["10", 1046], ["%", 1048], ["weight", 1050], ["loss", 1057], ["primarily", 1062], ["of", 1072], ["adipose", 1075], ["tissue", 1083], [".", 1089], ["Further", 1091], ["study", 1099], ["of", 1105], ["this", 1108], ["metabolic", 1113], ["pathway", 1123], ["may", 1131], ["identify", 1135], ["novel", 1144], ["therapies", 1150], ["for", 1160], ["diabesity", 1164], [",", 1173], ["the", 1175], ["disease", 1179], ["state", 1187], ["associated", 1193], ["with", 1204], ["diabetes", 1209], ["and", 1218], ["obesity", 1222], [".", 1229]]}
{"context": "The Ehlers-Danlos syndrome (EDS) comprises a group of hereditary connective tissue disorders. Periventricular nodular heterotopia (PNH) is a human neuronal migration disorder characterised by seizures and conglomerates of neural cells around the lateral ventricles of the brain, caused by FLNA mutations. FLNA encodes filamin A, an actin binding protein involved in cytoskeletal organisation. The amino-terminal actin binding domain (ABD) of filamins contains two tandem calponin homology domains, CHD1 and CHD2. To report clinical and genetic analyses in a Spanish family affected by a connective tissue disorder suggestive of EDS type III and PNH. A clinical and molecular study was undertaken in the three affected women. Clinical histories, physical and neurological examinations, brain magnetic resonance imaging studies, and skin biopsies were done. Genetic analysis of the FLNA gene was undertaken by direct sequencing and restriction fragment length polymorphism analysis. Mutation analysis of the FLNA gene resulted in the identification of a novel mutation in exon 3 (c.383C-->T) segregating with the combination of both syndromes. This mutation results in a substitution of an alanine residue (A128V) in CHD1. The findings suggest that the Ala128Val mutation causes the dual EDS-PNH phenotype. This association constitutes a new variant within the EDS spectrum. This is the first description of a familial EDS-PNH association with a mutation in FLNA.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "684689885e4249239d6a8040baf14481", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14], [100, 101]], "char_spans": [[65, 81], [587, 603]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["(", 27], ["EDS", 28], [")", 31], ["comprises", 33], ["a", 43], ["group", 45], ["of", 51], ["hereditary", 54], ["connective", 65], ["tissue", 76], ["disorders", 83], [".", 92], ["Periventricular", 94], ["nodular", 110], ["heterotopia", 118], ["(", 130], ["PNH", 131], [")", 134], ["is", 136], ["a", 139], ["human", 141], ["neuronal", 147], ["migration", 156], ["disorder", 166], ["characterised", 175], ["by", 189], ["seizures", 192], ["and", 201], ["conglomerates", 205], ["of", 219], ["neural", 222], ["cells", 229], ["around", 235], ["the", 242], ["lateral", 246], ["ventricles", 254], ["of", 265], ["the", 268], ["brain", 272], [",", 277], ["caused", 279], ["by", 286], ["FLNA", 289], ["mutations", 294], [".", 303], ["FLNA", 305], ["encodes", 310], ["filamin", 318], ["A", 326], [",", 327], ["an", 329], ["actin", 332], ["binding", 338], ["protein", 346], ["involved", 354], ["in", 363], ["cytoskeletal", 366], ["organisation", 379], [".", 391], ["The", 393], ["amino", 397], ["-", 402], ["terminal", 403], ["actin", 412], ["binding", 418], ["domain", 426], ["(", 433], ["ABD", 434], [")", 437], ["of", 439], ["filamins", 442], ["contains", 451], ["two", 460], ["tandem", 464], ["calponin", 471], ["homology", 480], ["domains", 489], [",", 496], ["CHD1", 498], ["and", 503], ["CHD2", 507], [".", 511], ["To", 513], ["report", 516], ["clinical", 523], ["and", 532], ["genetic", 536], ["analyses", 544], ["in", 553], ["a", 556], ["Spanish", 558], ["family", 566], ["affected", 573], ["by", 582], ["a", 585], ["connective", 587], ["tissue", 598], ["disorder", 605], ["suggestive", 614], ["of", 625], ["EDS", 628], ["type", 632], ["III", 637], ["and", 641], ["PNH", 645], [".", 648], ["A", 650], ["clinical", 652], ["and", 661], ["molecular", 665], ["study", 675], ["was", 681], ["undertaken", 685], ["in", 696], ["the", 699], ["three", 703], ["affected", 709], ["women", 718], [".", 723], ["Clinical", 725], ["histories", 734], [",", 743], ["physical", 745], ["and", 754], ["neurological", 758], ["examinations", 771], [",", 783], ["brain", 785], ["magnetic", 791], ["resonance", 800], ["imaging", 810], ["studies", 818], [",", 825], ["and", 827], ["skin", 831], ["biopsies", 836], ["were", 845], ["done", 850], [".", 854], ["Genetic", 856], ["analysis", 864], ["of", 873], ["the", 876], ["FLNA", 880], ["gene", 885], ["was", 890], ["undertaken", 894], ["by", 905], ["direct", 908], ["sequencing", 915], ["and", 926], ["restriction", 930], ["fragment", 942], ["length", 951], ["polymorphism", 958], ["analysis", 971], [".", 979], ["Mutation", 981], ["analysis", 990], ["of", 999], ["the", 1002], ["FLNA", 1006], ["gene", 1011], ["resulted", 1016], ["in", 1025], ["the", 1028], ["identification", 1032], ["of", 1047], ["a", 1050], ["novel", 1052], ["mutation", 1058], ["in", 1067], ["exon", 1070], ["3", 1075], ["(", 1077], ["c.383C-->T", 1078], [")", 1088], ["segregating", 1090], ["with", 1102], ["the", 1107], ["combination", 1111], ["of", 1123], ["both", 1126], ["syndromes", 1131], [".", 1140], ["This", 1142], ["mutation", 1147], ["results", 1156], ["in", 1164], ["a", 1167], ["substitution", 1169], ["of", 1182], ["an", 1185], ["alanine", 1188], ["residue", 1196], ["(", 1204], ["A128V", 1205], [")", 1210], ["in", 1212], ["CHD1", 1215], [".", 1219], ["The", 1221], ["findings", 1225], ["suggest", 1234], ["that", 1242], ["the", 1247], ["Ala128Val", 1251], ["mutation", 1261], ["causes", 1270], ["the", 1277], ["dual", 1281], ["EDS", 1286], ["-", 1289], ["PNH", 1290], ["phenotype", 1294], [".", 1303], ["This", 1305], ["association", 1310], ["constitutes", 1322], ["a", 1334], ["new", 1336], ["variant", 1340], ["within", 1348], ["the", 1355], ["EDS", 1359], ["spectrum", 1363], [".", 1371], ["This", 1373], ["is", 1378], ["the", 1381], ["first", 1385], ["description", 1391], ["of", 1403], ["a", 1406], ["familial", 1408], ["EDS", 1417], ["-", 1420], ["PNH", 1421], ["association", 1425], ["with", 1437], ["a", 1442], ["mutation", 1444], ["in", 1453], ["FLNA", 1456], [".", 1460]]}
{"context": "To investigate the accuracy of the sequential combination of the probe-to-bone test and plain X-rays for diagnosing osteomyelitis in the foot of patients with diabetes. We prospectively compiled data on a series of 338 patients with diabetes with 356 episodes of foot infection who were hospitalized in the Diabetic Foot Unit of La Paloma Hospital from 1 October 2002 to 31 April 2010. For each patient we did a probe-to-bone test at the time of the initial evaluation and then obtained plain X-rays of the involved foot. All patients with positive results on either the probe-to-bone test or plain X-ray underwent an appropriate surgical procedure, which included obtaining a bone specimen that was processed for histology and culture. We calculated the sensitivity, specificity, predictive values and likelihood ratios of the procedures, using the histopathological diagnosis of osteomyelitis as the criterion standard. Overall, 72.4% of patients had histologically proven osteomyelitis, 85.2% of whom had positive bone culture. The performance characteristics of both the probe-to-bone test and plain X-rays were excellent. The sequential diagnostic approach had a sensitivity of 0.97, specificity of 0.92, positive predictive value of 0.97, negative predictive value of 0.93, positive likelihood ratio of 12.8 and negative likelihood ratio of 0.02. Only 6.6% of patients with negative results on both diagnostic studies had osteomyelitis. Clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain X-ray, or especially both, are positive.", "qas": [{"question": "Which disease can be diagnosed with the \"probe to bone\" test?", "answers": ["diabetic foot osteomyelitis"], "qid": "a31831baf7b64813bd2cd193e35c0c77", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["diagnosed", 21], ["with", 31], ["the", 36], ["\"", 40], ["probe", 41], ["to", 47], ["bone", 50], ["\"", 54], ["test", 56], ["?", 60]], "detected_answers": [{"text": "diabetic foot osteomyelitis", "token_spans": [[285, 287]], "char_spans": [[1597, 1623]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["accuracy", 19], ["of", 28], ["the", 31], ["sequential", 35], ["combination", 46], ["of", 58], ["the", 61], ["probe", 65], ["-", 70], ["to", 71], ["-", 73], ["bone", 74], ["test", 79], ["and", 84], ["plain", 88], ["X", 94], ["-", 95], ["rays", 96], ["for", 101], ["diagnosing", 105], ["osteomyelitis", 116], ["in", 130], ["the", 133], ["foot", 137], ["of", 142], ["patients", 145], ["with", 154], ["diabetes", 159], [".", 167], ["We", 169], ["prospectively", 172], ["compiled", 186], ["data", 195], ["on", 200], ["a", 203], ["series", 205], ["of", 212], ["338", 215], ["patients", 219], ["with", 228], ["diabetes", 233], ["with", 242], ["356", 247], ["episodes", 251], ["of", 260], ["foot", 263], ["infection", 268], ["who", 278], ["were", 282], ["hospitalized", 287], ["in", 300], ["the", 303], ["Diabetic", 307], ["Foot", 316], ["Unit", 321], ["of", 326], ["La", 329], ["Paloma", 332], ["Hospital", 339], ["from", 348], ["1", 353], ["October", 355], ["2002", 363], ["to", 368], ["31", 371], ["April", 374], ["2010", 380], [".", 384], ["For", 386], ["each", 390], ["patient", 395], ["we", 403], ["did", 406], ["a", 410], ["probe", 412], ["-", 417], ["to", 418], ["-", 420], ["bone", 421], ["test", 426], ["at", 431], ["the", 434], ["time", 438], ["of", 443], ["the", 446], ["initial", 450], ["evaluation", 458], ["and", 469], ["then", 473], ["obtained", 478], ["plain", 487], ["X", 493], ["-", 494], ["rays", 495], ["of", 500], ["the", 503], ["involved", 507], ["foot", 516], [".", 520], ["All", 522], ["patients", 526], ["with", 535], ["positive", 540], ["results", 549], ["on", 557], ["either", 560], ["the", 567], ["probe", 571], ["-", 576], ["to", 577], ["-", 579], ["bone", 580], ["test", 585], ["or", 590], ["plain", 593], ["X", 599], ["-", 600], ["ray", 601], ["underwent", 605], ["an", 615], ["appropriate", 618], ["surgical", 630], ["procedure", 639], [",", 648], ["which", 650], ["included", 656], ["obtaining", 665], ["a", 675], ["bone", 677], ["specimen", 682], ["that", 691], ["was", 696], ["processed", 700], ["for", 710], ["histology", 714], ["and", 724], ["culture", 728], [".", 735], ["We", 737], ["calculated", 740], ["the", 751], ["sensitivity", 755], [",", 766], ["specificity", 768], [",", 779], ["predictive", 781], ["values", 792], ["and", 799], ["likelihood", 803], ["ratios", 814], ["of", 821], ["the", 824], ["procedures", 828], [",", 838], ["using", 840], ["the", 846], ["histopathological", 850], ["diagnosis", 868], ["of", 878], ["osteomyelitis", 881], ["as", 895], ["the", 898], ["criterion", 902], ["standard", 912], [".", 920], ["Overall", 922], [",", 929], ["72.4", 931], ["%", 935], ["of", 937], ["patients", 940], ["had", 949], ["histologically", 953], ["proven", 968], ["osteomyelitis", 975], [",", 988], ["85.2", 990], ["%", 994], ["of", 996], ["whom", 999], ["had", 1004], ["positive", 1008], ["bone", 1017], ["culture", 1022], [".", 1029], ["The", 1031], ["performance", 1035], ["characteristics", 1047], ["of", 1063], ["both", 1066], ["the", 1071], ["probe", 1075], ["-", 1080], ["to", 1081], ["-", 1083], ["bone", 1084], ["test", 1089], ["and", 1094], ["plain", 1098], ["X", 1104], ["-", 1105], ["rays", 1106], ["were", 1111], ["excellent", 1116], [".", 1125], ["The", 1127], ["sequential", 1131], ["diagnostic", 1142], ["approach", 1153], ["had", 1162], ["a", 1166], ["sensitivity", 1168], ["of", 1180], ["0.97", 1183], [",", 1187], ["specificity", 1189], ["of", 1201], ["0.92", 1204], [",", 1208], ["positive", 1210], ["predictive", 1219], ["value", 1230], ["of", 1236], ["0.97", 1239], [",", 1243], ["negative", 1245], ["predictive", 1254], ["value", 1265], ["of", 1271], ["0.93", 1274], [",", 1278], ["positive", 1280], ["likelihood", 1289], ["ratio", 1300], ["of", 1306], ["12.8", 1309], ["and", 1314], ["negative", 1318], ["likelihood", 1327], ["ratio", 1338], ["of", 1344], ["0.02", 1347], [".", 1351], ["Only", 1353], ["6.6", 1358], ["%", 1361], ["of", 1363], ["patients", 1366], ["with", 1375], ["negative", 1380], ["results", 1389], ["on", 1397], ["both", 1400], ["diagnostic", 1405], ["studies", 1416], ["had", 1424], ["osteomyelitis", 1428], [".", 1441], ["Clinicians", 1443], ["seeing", 1454], ["patients", 1461], ["in", 1470], ["a", 1473], ["setting", 1475], ["similar", 1483], ["to", 1491], ["ours", 1494], ["(", 1499], ["specialized", 1500], ["diabetic", 1512], ["foot", 1521], ["unit", 1526], ["with", 1531], ["a", 1536], ["high", 1538], ["prevalence", 1543], ["of", 1554], ["osteomyelitis", 1557], [")", 1570], ["can", 1572], ["confidently", 1576], ["diagnose", 1588], ["diabetic", 1597], ["foot", 1606], ["osteomyelitis", 1611], ["when", 1625], ["either", 1630], ["the", 1637], ["probe", 1641], ["-", 1646], ["to", 1647], ["-", 1649], ["bone", 1650], ["test", 1655], ["or", 1660], ["a", 1663], ["plain", 1665], ["X", 1671], ["-", 1672], ["ray", 1673], [",", 1676], ["or", 1678], ["especially", 1681], ["both", 1692], [",", 1696], ["are", 1698], ["positive", 1702], [".", 1710]]}
{"context": "Alpha-synuclein (\u03b1-Syn) is the principal protein component of Lewy bodies, a pathological hallmark of Parkinson's disease (PD). This protein may regulate protein phosphatase 2A (PP2A) activity, although the molecular mechanisms for \u03b1-Syn-mediated regulation of PP2A and the potential neuroprotective actions of PP2A against PD-associated pathology remain largely unexplored. We found that \u03b1-Syn gene overexpression in SK-N-SH cells and primary neurons led to PP2A/C phosphorylation at Y307, a known target of Src kinase, and consequent phosphatase inhibition. In addition, phospho-activated Src (p-Y416 Src, pSrc) was higher in SK-N-SH cells and primary neurons overexpressing \u03b1-Syn. Thus, \u03b1-Syn may promote Src activation and PP2A inactivation, leading to hyperphosphorylation of proteins. Immunoprecipitation revealed higher calmodulin/Src complex formation in \u03b1-Syn-overexpressing cells and \u03b1-Syn transgenic mice. A TUNEL apoptosis assay and an MTT cell viability assay demonstrated that the PP2A activator C2-ceramide protected neurons against \u03b1-Syn-induced cell injury. Buffering the Ca(2+) elevations induced by \u03b1-Syn overexpression ameliorated the cytotoxicity of \u03b1-Syn. Our findings define a potential molecular mechanism for \u03b1-Syn-mediated regulation of PP2A through formation of the calmodulin/Src complex, activation of Src, and Src-mediated phospho-inhibition of PP2A. Overexpression of \u03b1-Syn may lead to neurodegeneration in PD in part by suppressing the endogenous neuroprotective activity of PP2A.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "cf97c5fcf3d94305a47f705ecb7271f5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["(", 16], ["\u03b1", 17], ["-", 18], ["Syn", 19], [")", 22], ["is", 24], ["the", 27], ["principal", 31], ["protein", 41], ["component", 49], ["of", 59], ["Lewy", 62], ["bodies", 67], [",", 73], ["a", 75], ["pathological", 77], ["hallmark", 90], ["of", 99], ["Parkinson", 102], ["'s", 111], ["disease", 114], ["(", 122], ["PD", 123], [")", 125], [".", 126], ["This", 128], ["protein", 133], ["may", 141], ["regulate", 145], ["protein", 154], ["phosphatase", 162], ["2A", 174], ["(", 177], ["PP2A", 178], [")", 182], ["activity", 184], [",", 192], ["although", 194], ["the", 203], ["molecular", 207], ["mechanisms", 217], ["for", 228], ["\u03b1", 232], ["-", 233], ["Syn", 234], ["-", 237], ["mediated", 238], ["regulation", 247], ["of", 258], ["PP2A", 261], ["and", 266], ["the", 270], ["potential", 274], ["neuroprotective", 284], ["actions", 300], ["of", 308], ["PP2A", 311], ["against", 316], ["PD", 324], ["-", 326], ["associated", 327], ["pathology", 338], ["remain", 348], ["largely", 355], ["unexplored", 363], [".", 373], ["We", 375], ["found", 378], ["that", 384], ["\u03b1", 389], ["-", 390], ["Syn", 391], ["gene", 395], ["overexpression", 400], ["in", 415], ["SK", 418], ["-", 420], ["N", 421], ["-", 422], ["SH", 423], ["cells", 426], ["and", 432], ["primary", 436], ["neurons", 444], ["led", 452], ["to", 456], ["PP2A", 459], ["/", 463], ["C", 464], ["phosphorylation", 466], ["at", 482], ["Y307", 485], [",", 489], ["a", 491], ["known", 493], ["target", 499], ["of", 506], ["Src", 509], ["kinase", 513], [",", 519], ["and", 521], ["consequent", 525], ["phosphatase", 536], ["inhibition", 548], [".", 558], ["In", 560], ["addition", 563], [",", 571], ["phospho", 573], ["-", 580], ["activated", 581], ["Src", 591], ["(", 595], ["p", 596], ["-", 597], ["Y416", 598], ["Src", 603], [",", 606], ["pSrc", 608], [")", 612], ["was", 614], ["higher", 618], ["in", 625], ["SK", 628], ["-", 630], ["N", 631], ["-", 632], ["SH", 633], ["cells", 636], ["and", 642], ["primary", 646], ["neurons", 654], ["overexpressing", 662], ["\u03b1", 677], ["-", 678], ["Syn", 679], [".", 682], ["Thus", 684], [",", 688], ["\u03b1", 690], ["-", 691], ["Syn", 692], ["may", 696], ["promote", 700], ["Src", 708], ["activation", 712], ["and", 723], ["PP2A", 727], ["inactivation", 732], [",", 744], ["leading", 746], ["to", 754], ["hyperphosphorylation", 757], ["of", 778], ["proteins", 781], [".", 789], ["Immunoprecipitation", 791], ["revealed", 811], ["higher", 820], ["calmodulin", 827], ["/", 837], ["Src", 838], ["complex", 842], ["formation", 850], ["in", 860], ["\u03b1", 863], ["-", 864], ["Syn", 865], ["-", 868], ["overexpressing", 869], ["cells", 884], ["and", 890], ["\u03b1", 894], ["-", 895], ["Syn", 896], ["transgenic", 900], ["mice", 911], [".", 915], ["A", 917], ["TUNEL", 919], ["apoptosis", 925], ["assay", 935], ["and", 941], ["an", 945], ["MTT", 948], ["cell", 952], ["viability", 957], ["assay", 967], ["demonstrated", 973], ["that", 986], ["the", 991], ["PP2A", 995], ["activator", 1000], ["C2-ceramide", 1010], ["protected", 1022], ["neurons", 1032], ["against", 1040], ["\u03b1", 1048], ["-", 1049], ["Syn", 1050], ["-", 1053], ["induced", 1054], ["cell", 1062], ["injury", 1067], [".", 1073], ["Buffering", 1075], ["the", 1085], ["Ca(2", 1089], ["+", 1093], [")", 1094], ["elevations", 1096], ["induced", 1107], ["by", 1115], ["\u03b1", 1118], ["-", 1119], ["Syn", 1120], ["overexpression", 1124], ["ameliorated", 1139], ["the", 1151], ["cytotoxicity", 1155], ["of", 1168], ["\u03b1", 1171], ["-", 1172], ["Syn", 1173], [".", 1176], ["Our", 1178], ["findings", 1182], ["define", 1191], ["a", 1198], ["potential", 1200], ["molecular", 1210], ["mechanism", 1220], ["for", 1230], ["\u03b1", 1234], ["-", 1235], ["Syn", 1236], ["-", 1239], ["mediated", 1240], ["regulation", 1249], ["of", 1260], ["PP2A", 1263], ["through", 1268], ["formation", 1276], ["of", 1286], ["the", 1289], ["calmodulin", 1293], ["/", 1303], ["Src", 1304], ["complex", 1308], [",", 1315], ["activation", 1317], ["of", 1328], ["Src", 1331], [",", 1334], ["and", 1336], ["Src", 1340], ["-", 1343], ["mediated", 1344], ["phospho", 1353], ["-", 1360], ["inhibition", 1361], ["of", 1372], ["PP2A.", 1375], ["Overexpression", 1381], ["of", 1396], ["\u03b1", 1399], ["-", 1400], ["Syn", 1401], ["may", 1405], ["lead", 1409], ["to", 1414], ["neurodegeneration", 1417], ["in", 1435], ["PD", 1438], ["in", 1441], ["part", 1444], ["by", 1449], ["suppressing", 1452], ["the", 1464], ["endogenous", 1468], ["neuroprotective", 1479], ["activity", 1495], ["of", 1504], ["PP2A.", 1507]]}
{"context": "To investigate the migraine locus around the C19p13 region through analysis of the NOTCH3 gene (C19p13.2-p13.1), previously shown to be a gene involved in CADASIL and the TNFSF7 gene (C19p13), homologous to the ligands of TNF-alpha and TNF-beta, genes that have previously been associated with migraine. The NOTCH3 gene was analysed by sequencing all exons with known CADASIL mutations in a typical (non-familial hemiplegic) migraine family (MF1) that has previously been shown to be linked to C19p13. The TNFSF7 gene was investigated through SNP association analysis using a matched case-control migraine population. NOTCH3 gene sequencing results for affected members of MF1 proved to be negative for all known sequence variants giving rise to mutations for CADASIL. TNFSF7 gene chi-square results showed non-significant P values across all populations tested against controls, except for the MO subgroup which displayed a possible association with the TNFSF7 SNP (genotype, allele analysis P = 0.036, P = 0.017 respectively). Our results suggest that common migraine is not caused by any known CADASIL mutations in the NOTCH3 gene of interest. However, the TNFSF7 gene displayed signs of involvement in a MO affected population and indicates that further independent studies of this marker are warranted.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "fc24f2392a694a878abd703ed179be42", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[13, 14], [203, 204], [59, 60], [114, 115]], "char_spans": [[83, 93], [1122, 1132], [308, 318], [618, 628]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["migraine", 19], ["locus", 28], ["around", 34], ["the", 41], ["C19p13", 45], ["region", 52], ["through", 59], ["analysis", 67], ["of", 76], ["the", 79], ["NOTCH3", 83], ["gene", 90], ["(", 95], ["C19p13.2-p13.1", 96], [")", 110], [",", 111], ["previously", 113], ["shown", 124], ["to", 130], ["be", 133], ["a", 136], ["gene", 138], ["involved", 143], ["in", 152], ["CADASIL", 155], ["and", 163], ["the", 167], ["TNFSF7", 171], ["gene", 178], ["(", 183], ["C19p13", 184], [")", 190], [",", 191], ["homologous", 193], ["to", 204], ["the", 207], ["ligands", 211], ["of", 219], ["TNF", 222], ["-", 225], ["alpha", 226], ["and", 232], ["TNF", 236], ["-", 239], ["beta", 240], [",", 244], ["genes", 246], ["that", 252], ["have", 257], ["previously", 262], ["been", 273], ["associated", 278], ["with", 289], ["migraine", 294], [".", 302], ["The", 304], ["NOTCH3", 308], ["gene", 315], ["was", 320], ["analysed", 324], ["by", 333], ["sequencing", 336], ["all", 347], ["exons", 351], ["with", 357], ["known", 362], ["CADASIL", 368], ["mutations", 376], ["in", 386], ["a", 389], ["typical", 391], ["(", 399], ["non", 400], ["-", 403], ["familial", 404], ["hemiplegic", 413], [")", 423], ["migraine", 425], ["family", 434], ["(", 441], ["MF1", 442], [")", 445], ["that", 447], ["has", 452], ["previously", 456], ["been", 467], ["shown", 472], ["to", 478], ["be", 481], ["linked", 484], ["to", 491], ["C19p13", 494], [".", 500], ["The", 502], ["TNFSF7", 506], ["gene", 513], ["was", 518], ["investigated", 522], ["through", 535], ["SNP", 543], ["association", 547], ["analysis", 559], ["using", 568], ["a", 574], ["matched", 576], ["case", 584], ["-", 588], ["control", 589], ["migraine", 597], ["population", 606], [".", 616], ["NOTCH3", 618], ["gene", 625], ["sequencing", 630], ["results", 641], ["for", 649], ["affected", 653], ["members", 662], ["of", 670], ["MF1", 673], ["proved", 677], ["to", 684], ["be", 687], ["negative", 690], ["for", 699], ["all", 703], ["known", 707], ["sequence", 713], ["variants", 722], ["giving", 731], ["rise", 738], ["to", 743], ["mutations", 746], ["for", 756], ["CADASIL", 760], [".", 767], ["TNFSF7", 769], ["gene", 776], ["chi", 781], ["-", 784], ["square", 785], ["results", 792], ["showed", 800], ["non", 807], ["-", 810], ["significant", 811], ["P", 823], ["values", 825], ["across", 832], ["all", 839], ["populations", 843], ["tested", 855], ["against", 862], ["controls", 870], [",", 878], ["except", 880], ["for", 887], ["the", 891], ["MO", 895], ["subgroup", 898], ["which", 907], ["displayed", 913], ["a", 923], ["possible", 925], ["association", 934], ["with", 946], ["the", 951], ["TNFSF7", 955], ["SNP", 962], ["(", 966], ["genotype", 967], [",", 975], ["allele", 977], ["analysis", 984], ["P", 993], ["=", 995], ["0.036", 997], [",", 1002], ["P", 1004], ["=", 1006], ["0.017", 1008], ["respectively", 1014], [")", 1026], [".", 1027], ["Our", 1029], ["results", 1033], ["suggest", 1041], ["that", 1049], ["common", 1054], ["migraine", 1061], ["is", 1070], ["not", 1073], ["caused", 1077], ["by", 1084], ["any", 1087], ["known", 1091], ["CADASIL", 1097], ["mutations", 1105], ["in", 1115], ["the", 1118], ["NOTCH3", 1122], ["gene", 1129], ["of", 1134], ["interest", 1137], [".", 1145], ["However", 1147], [",", 1154], ["the", 1156], ["TNFSF7", 1160], ["gene", 1167], ["displayed", 1172], ["signs", 1182], ["of", 1188], ["involvement", 1191], ["in", 1203], ["a", 1206], ["MO", 1208], ["affected", 1211], ["population", 1220], ["and", 1231], ["indicates", 1235], ["that", 1245], ["further", 1250], ["independent", 1258], ["studies", 1270], ["of", 1278], ["this", 1281], ["marker", 1286], ["are", 1293], ["warranted", 1297], [".", 1306]]}
{"context": "Vaginal microbicides for the prevention of HIV transmission may be an important option for protecting women from infection. Incorporation of dapivirine, a lead candidate nonnucleoside reverse transcriptase inhibitor, into intravaginal rings (IVRs) for sustained mucosal delivery may increase microbicide product adherence and efficacy compared with conventional vaginal formulations. Twenty-four healthy HIV-negative women 18-35 years of age were randomly assigned (1:1:1) to dapivirine matrix IVR, dapivirine reservoir IVR, or placebo IVR. Dapivirine concentrations were measured in plasma and vaginal fluid samples collected at sequential time points over the 33-day study period (28 days of IVR use, 5 days of follow-up). Safety was assessed by pelvic/colposcopic examinations, clinical laboratory tests, and adverse events. Both IVR types were safe and well tolerated with similar adverse events observed in the placebo and dapivirine groups. Dapivirine from both IVR types was successfully distributed throughout the lower genital tract at concentrations over 4 logs greater than the EC50 against wild-type HIV-1 (LAI) in MT4 cells. Maximum concentration (Cmax) and area under the concentration-time curve (AUC) values were significantly higher with the matrix than reservoir IVR. Mean plasma concentrations of dapivirine were <2 ng/mL. These findings suggest that IVR delivery of microbicides is a viable option meriting further study.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "34061c30316348ec982b81f03c74200e", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[58, 58], [6, 6]], "char_spans": [[404, 406], [43, 45]]}]}], "context_tokens": [["Vaginal", 0], ["microbicides", 8], ["for", 21], ["the", 25], ["prevention", 29], ["of", 40], ["HIV", 43], ["transmission", 47], ["may", 60], ["be", 64], ["an", 67], ["important", 70], ["option", 80], ["for", 87], ["protecting", 91], ["women", 102], ["from", 108], ["infection", 113], [".", 122], ["Incorporation", 124], ["of", 138], ["dapivirine", 141], [",", 151], ["a", 153], ["lead", 155], ["candidate", 160], ["nonnucleoside", 170], ["reverse", 184], ["transcriptase", 192], ["inhibitor", 206], [",", 215], ["into", 217], ["intravaginal", 222], ["rings", 235], ["(", 241], ["IVRs", 242], [")", 246], ["for", 248], ["sustained", 252], ["mucosal", 262], ["delivery", 270], ["may", 279], ["increase", 283], ["microbicide", 292], ["product", 304], ["adherence", 312], ["and", 322], ["efficacy", 326], ["compared", 335], ["with", 344], ["conventional", 349], ["vaginal", 362], ["formulations", 370], [".", 382], ["Twenty", 384], ["-", 390], ["four", 391], ["healthy", 396], ["HIV", 404], ["-", 407], ["negative", 408], ["women", 417], ["18", 423], ["-", 425], ["35", 426], ["years", 429], ["of", 435], ["age", 438], ["were", 442], ["randomly", 447], ["assigned", 456], ["(", 465], ["1:1:1", 466], [")", 471], ["to", 473], ["dapivirine", 476], ["matrix", 487], ["IVR", 494], [",", 497], ["dapivirine", 499], ["reservoir", 510], ["IVR", 520], [",", 523], ["or", 525], ["placebo", 528], ["IVR", 536], [".", 539], ["Dapivirine", 541], ["concentrations", 552], ["were", 567], ["measured", 572], ["in", 581], ["plasma", 584], ["and", 591], ["vaginal", 595], ["fluid", 603], ["samples", 609], ["collected", 617], ["at", 627], ["sequential", 630], ["time", 641], ["points", 646], ["over", 653], ["the", 658], ["33-day", 662], ["study", 669], ["period", 675], ["(", 682], ["28", 683], ["days", 686], ["of", 691], ["IVR", 694], ["use", 698], [",", 701], ["5", 703], ["days", 705], ["of", 710], ["follow", 713], ["-", 719], ["up", 720], [")", 722], [".", 723], ["Safety", 725], ["was", 732], ["assessed", 736], ["by", 745], ["pelvic", 748], ["/", 754], ["colposcopic", 755], ["examinations", 767], [",", 779], ["clinical", 781], ["laboratory", 790], ["tests", 801], [",", 806], ["and", 808], ["adverse", 812], ["events", 820], [".", 826], ["Both", 828], ["IVR", 833], ["types", 837], ["were", 843], ["safe", 848], ["and", 853], ["well", 857], ["tolerated", 862], ["with", 872], ["similar", 877], ["adverse", 885], ["events", 893], ["observed", 900], ["in", 909], ["the", 912], ["placebo", 916], ["and", 924], ["dapivirine", 928], ["groups", 939], [".", 945], ["Dapivirine", 947], ["from", 958], ["both", 963], ["IVR", 968], ["types", 972], ["was", 978], ["successfully", 982], ["distributed", 995], ["throughout", 1007], ["the", 1018], ["lower", 1022], ["genital", 1028], ["tract", 1036], ["at", 1042], ["concentrations", 1045], ["over", 1060], ["4", 1065], ["logs", 1067], ["greater", 1072], ["than", 1080], ["the", 1085], ["EC50", 1089], ["against", 1094], ["wild", 1102], ["-", 1106], ["type", 1107], ["HIV-1", 1112], ["(", 1118], ["LAI", 1119], [")", 1122], ["in", 1124], ["MT4", 1127], ["cells", 1131], [".", 1136], ["Maximum", 1138], ["concentration", 1146], ["(", 1160], ["Cmax", 1161], [")", 1165], ["and", 1167], ["area", 1171], ["under", 1176], ["the", 1182], ["concentration", 1186], ["-", 1199], ["time", 1200], ["curve", 1205], ["(", 1211], ["AUC", 1212], [")", 1215], ["values", 1217], ["were", 1224], ["significantly", 1229], ["higher", 1243], ["with", 1250], ["the", 1255], ["matrix", 1259], ["than", 1266], ["reservoir", 1271], ["IVR", 1281], [".", 1284], ["Mean", 1286], ["plasma", 1291], ["concentrations", 1298], ["of", 1313], ["dapivirine", 1316], ["were", 1327], ["<", 1332], ["2", 1333], ["ng", 1335], ["/", 1337], ["mL.", 1338], ["These", 1342], ["findings", 1348], ["suggest", 1357], ["that", 1365], ["IVR", 1370], ["delivery", 1374], ["of", 1383], ["microbicides", 1386], ["is", 1399], ["a", 1402], ["viable", 1404], ["option", 1411], ["meriting", 1418], ["further", 1427], ["study", 1435], [".", 1440]]}
{"context": "alpha-Synuclein is a presynaptic protein recently identified as a specific component of Lewy bodies (LB) and Lewy neurites. The aim of this study was to assess the morphology and distribution of alpha-synuclein immunoreactivity in cases of dementia with LB (DLB), and to compare alpha-synuclein with ubiquitin immunostaining. We examined substantia nigra, paralimbic regions (entorhinal cortex, cingulate gyrus, insula and hippocampus), and neocortex (frontal and occipital association cortices) with double alpha-synuclein and ubiquitin immunostaining in 25 cases meeting neuropathological criteria for DLB. alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB from globose tangles. It was also slightly more sensitive, staining 4-5% more intracytoplasmic structures, especially diffuse alpha-synuclein deposits that were ubiquitin negative. In addition to LB, alpha-synuclein staining showed filiform and globose neurites in the substantia nigra, CA2-3 regions of the hippocampus, and entorhinal cortex. A spectrum of alpha-synuclein staining was seen in substantia nigra: from diffuse \"cloud-like\" inclusions to aggregated intracytoplasmic inclusions with variable ubiquitin staining to classic LB. We hypothesize that these represent different stages in LB formation.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "657d5d7eecf249cb96e36f5b3a818fcf", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[36, 38], [142, 144], [156, 158], [53, 55], [90, 92], [105, 107], [185, 187], [0, 2]], "char_spans": [[195, 209], [843, 857], [917, 931], [279, 293], [508, 522], [609, 623], [1075, 1089], [0, 14]]}]}], "context_tokens": [["alpha", 0], ["-", 5], ["Synuclein", 6], ["is", 16], ["a", 19], ["presynaptic", 21], ["protein", 33], ["recently", 41], ["identified", 50], ["as", 61], ["a", 64], ["specific", 66], ["component", 75], ["of", 85], ["Lewy", 88], ["bodies", 93], ["(", 100], ["LB", 101], [")", 103], ["and", 105], ["Lewy", 109], ["neurites", 114], [".", 122], ["The", 124], ["aim", 128], ["of", 132], ["this", 135], ["study", 140], ["was", 146], ["to", 150], ["assess", 153], ["the", 160], ["morphology", 164], ["and", 175], ["distribution", 179], ["of", 192], ["alpha", 195], ["-", 200], ["synuclein", 201], ["immunoreactivity", 211], ["in", 228], ["cases", 231], ["of", 237], ["dementia", 240], ["with", 249], ["LB", 254], ["(", 257], ["DLB", 258], [")", 261], [",", 262], ["and", 264], ["to", 268], ["compare", 271], ["alpha", 279], ["-", 284], ["synuclein", 285], ["with", 295], ["ubiquitin", 300], ["immunostaining", 310], [".", 324], ["We", 326], ["examined", 329], ["substantia", 338], ["nigra", 349], [",", 354], ["paralimbic", 356], ["regions", 367], ["(", 375], ["entorhinal", 376], ["cortex", 387], [",", 393], ["cingulate", 395], ["gyrus", 405], [",", 410], ["insula", 412], ["and", 419], ["hippocampus", 423], [")", 434], [",", 435], ["and", 437], ["neocortex", 441], ["(", 451], ["frontal", 452], ["and", 460], ["occipital", 464], ["association", 474], ["cortices", 486], [")", 494], ["with", 496], ["double", 501], ["alpha", 508], ["-", 513], ["synuclein", 514], ["and", 524], ["ubiquitin", 528], ["immunostaining", 538], ["in", 553], ["25", 556], ["cases", 559], ["meeting", 565], ["neuropathological", 573], ["criteria", 591], ["for", 600], ["DLB", 604], [".", 607], ["alpha", 609], ["-", 614], ["Synuclein", 615], ["immunostaining", 625], ["was", 640], ["more", 644], ["specific", 649], ["than", 658], ["ubiquitin", 663], ["immunostaining", 673], ["in", 688], ["that", 691], ["it", 696], ["differentiated", 699], ["LB", 714], ["from", 717], ["globose", 722], ["tangles", 730], [".", 737], ["It", 739], ["was", 742], ["also", 746], ["slightly", 751], ["more", 760], ["sensitive", 765], [",", 774], ["staining", 776], ["4", 785], ["-", 786], ["5", 787], ["%", 788], ["more", 790], ["intracytoplasmic", 795], ["structures", 812], [",", 822], ["especially", 824], ["diffuse", 835], ["alpha", 843], ["-", 848], ["synuclein", 849], ["deposits", 859], ["that", 868], ["were", 873], ["ubiquitin", 878], ["negative", 888], [".", 896], ["In", 898], ["addition", 901], ["to", 910], ["LB", 913], [",", 915], ["alpha", 917], ["-", 922], ["synuclein", 923], ["staining", 933], ["showed", 942], ["filiform", 949], ["and", 958], ["globose", 962], ["neurites", 970], ["in", 979], ["the", 982], ["substantia", 986], ["nigra", 997], [",", 1002], ["CA2", 1004], ["-", 1007], ["3", 1008], ["regions", 1010], ["of", 1018], ["the", 1021], ["hippocampus", 1025], [",", 1036], ["and", 1038], ["entorhinal", 1042], ["cortex", 1053], [".", 1059], ["A", 1061], ["spectrum", 1063], ["of", 1072], ["alpha", 1075], ["-", 1080], ["synuclein", 1081], ["staining", 1091], ["was", 1100], ["seen", 1104], ["in", 1109], ["substantia", 1112], ["nigra", 1123], [":", 1128], ["from", 1130], ["diffuse", 1135], ["\"", 1143], ["cloud", 1144], ["-", 1149], ["like", 1150], ["\"", 1154], ["inclusions", 1156], ["to", 1167], ["aggregated", 1170], ["intracytoplasmic", 1181], ["inclusions", 1198], ["with", 1209], ["variable", 1214], ["ubiquitin", 1223], ["staining", 1233], ["to", 1242], ["classic", 1245], ["LB", 1253], [".", 1255], ["We", 1257], ["hypothesize", 1260], ["that", 1272], ["these", 1277], ["represent", 1283], ["different", 1293], ["stages", 1303], ["in", 1310], ["LB", 1313], ["formation", 1316], [".", 1325]]}
{"context": "Dot1 is an evolutionarily conserved histone methyltransferase that methylates lysine-79 of histone H3 in the core domain. Unlike other histone methyltransferases, Dot1 does not contain a SET domain, and it specifically methylates nucleosomal histone H3. We have solved a 2.5 A resolution structure of the catalytic domain of human Dot1, hDOT1L, in complex with S-adenosyl-L-methionine (SAM). The structure reveals a unique organization of a mainly alpha-helical N-terminal domain and a central open alpha/beta structure, an active site consisting of a SAM binding pocket, and a potential lysine binding channel. We also show that a flexible, positively charged region at the C terminus of the catalytic domain is critical for nucleosome binding and enzymatic activity. These structural and biochemical analyses, combined with molecular modeling, provide mechanistic insights into the catalytic mechanism and nucleosomal specificity of Dot1 proteins.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "aa7139e1cfe6425786610c4bf1781099", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[28, 29]], "char_spans": [[187, 196]]}]}], "context_tokens": [["Dot1", 0], ["is", 5], ["an", 8], ["evolutionarily", 11], ["conserved", 26], ["histone", 36], ["methyltransferase", 44], ["that", 62], ["methylates", 67], ["lysine-79", 78], ["of", 88], ["histone", 91], ["H3", 99], ["in", 102], ["the", 105], ["core", 109], ["domain", 114], [".", 120], ["Unlike", 122], ["other", 129], ["histone", 135], ["methyltransferases", 143], [",", 161], ["Dot1", 163], ["does", 168], ["not", 173], ["contain", 177], ["a", 185], ["SET", 187], ["domain", 191], [",", 197], ["and", 199], ["it", 203], ["specifically", 206], ["methylates", 219], ["nucleosomal", 230], ["histone", 242], ["H3", 250], [".", 252], ["We", 254], ["have", 257], ["solved", 262], ["a", 269], ["2.5", 271], ["A", 275], ["resolution", 277], ["structure", 288], ["of", 298], ["the", 301], ["catalytic", 305], ["domain", 315], ["of", 322], ["human", 325], ["Dot1", 331], [",", 335], ["hDOT1L", 337], [",", 343], ["in", 345], ["complex", 348], ["with", 356], ["S", 361], ["-", 362], ["adenosyl", 363], ["-", 371], ["L", 372], ["-", 373], ["methionine", 374], ["(", 385], ["SAM", 386], [")", 389], [".", 390], ["The", 392], ["structure", 396], ["reveals", 406], ["a", 414], ["unique", 416], ["organization", 423], ["of", 436], ["a", 439], ["mainly", 441], ["alpha", 448], ["-", 453], ["helical", 454], ["N", 462], ["-", 463], ["terminal", 464], ["domain", 473], ["and", 480], ["a", 484], ["central", 486], ["open", 494], ["alpha", 499], ["/", 504], ["beta", 505], ["structure", 510], [",", 519], ["an", 521], ["active", 524], ["site", 531], ["consisting", 536], ["of", 547], ["a", 550], ["SAM", 552], ["binding", 556], ["pocket", 564], [",", 570], ["and", 572], ["a", 576], ["potential", 578], ["lysine", 588], ["binding", 595], ["channel", 603], [".", 610], ["We", 612], ["also", 615], ["show", 620], ["that", 625], ["a", 630], ["flexible", 632], [",", 640], ["positively", 642], ["charged", 653], ["region", 661], ["at", 668], ["the", 671], ["C", 675], ["terminus", 677], ["of", 686], ["the", 689], ["catalytic", 693], ["domain", 703], ["is", 710], ["critical", 713], ["for", 722], ["nucleosome", 726], ["binding", 737], ["and", 745], ["enzymatic", 749], ["activity", 759], [".", 767], ["These", 769], ["structural", 775], ["and", 786], ["biochemical", 790], ["analyses", 802], [",", 810], ["combined", 812], ["with", 821], ["molecular", 826], ["modeling", 836], [",", 844], ["provide", 846], ["mechanistic", 854], ["insights", 866], ["into", 875], ["the", 880], ["catalytic", 884], ["mechanism", 894], ["and", 904], ["nucleosomal", 908], ["specificity", 920], ["of", 932], ["Dot1", 935], ["proteins", 940], [".", 948]]}
{"context": "Diamond-Blackfan anemia (DBA) is a rare congenital pure red cell aplasia characterized by normochromic macrocytic anemia, reticulocytopenia, and normocellular bone marrow with a selective deficiency of erythroid precursors. Ribosomal protein S19 (RPS19), currently the only gene associated with DBA, is mutated in 25% of DBA patients, but its role in erythropoiesis is unknown. We attempted to elucidate the importance of RPS19 in translation in relation to the pathogenesis of DBA. We measured translation and proliferation rates in unstimulated and phytohemagglutinin (PHA)-stimulated lymphocytes isolated from DBA patients, as well as in K562 cells expressing several RPS19 mutants to directly test the effect of RPS19 mutations on translation. The effect of leucine on overall translation was also studied. We found that the level of translation was on average 48-73% of controls in both unstimulated and PHA-activated DBA lymphocytes irrespective of mutations in RPS19. The addition of leucine increased the translational level in RPS19-non-mutated DBA cells, but not in cells with an RPS19 mutation. In unstimulated DBA cells, proliferation was significantly impaired in both RPS19-mutated and non-mutated cells, but in both groups could be efficiently activated by PHA. Studies on K562 cells showed that RPS19 mutations affecting RPS19 conserved arginines R56Q and R62Q could significantly inhibit the rate of protein synthesis, indicating the importance of RPS19 in translation. Our results indicate that inefficient translation may be the main cause of DBA, and administration of leucine may be beneficial for at least some DBA patients.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "f06fc76bb7624c4ba8baf1c01fb0c0a8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[48, 48], [192, 192], [83, 83], [5, 5], [100, 100], [276, 276], [263, 263], [56, 56], [158, 158], [178, 178]], "char_spans": [[295, 297], [1122, 1124], [478, 480], [25, 27], [613, 615], [1633, 1635], [1562, 1564], [321, 323], [923, 925], [1054, 1056]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["rare", 35], ["congenital", 40], ["pure", 51], ["red", 56], ["cell", 60], ["aplasia", 65], ["characterized", 73], ["by", 87], ["normochromic", 90], ["macrocytic", 103], ["anemia", 114], [",", 120], ["reticulocytopenia", 122], [",", 139], ["and", 141], ["normocellular", 145], ["bone", 159], ["marrow", 164], ["with", 171], ["a", 176], ["selective", 178], ["deficiency", 188], ["of", 199], ["erythroid", 202], ["precursors", 212], [".", 222], ["Ribosomal", 224], ["protein", 234], ["S19", 242], ["(", 246], ["RPS19", 247], [")", 252], [",", 253], ["currently", 255], ["the", 265], ["only", 269], ["gene", 274], ["associated", 279], ["with", 290], ["DBA", 295], [",", 298], ["is", 300], ["mutated", 303], ["in", 311], ["25", 314], ["%", 316], ["of", 318], ["DBA", 321], ["patients", 325], [",", 333], ["but", 335], ["its", 339], ["role", 343], ["in", 348], ["erythropoiesis", 351], ["is", 366], ["unknown", 369], [".", 376], ["We", 378], ["attempted", 381], ["to", 391], ["elucidate", 394], ["the", 404], ["importance", 408], ["of", 419], ["RPS19", 422], ["in", 428], ["translation", 431], ["in", 443], ["relation", 446], ["to", 455], ["the", 458], ["pathogenesis", 462], ["of", 475], ["DBA", 478], [".", 481], ["We", 483], ["measured", 486], ["translation", 495], ["and", 507], ["proliferation", 511], ["rates", 525], ["in", 531], ["unstimulated", 534], ["and", 547], ["phytohemagglutinin", 551], ["(", 570], ["PHA)-stimulated", 571], ["lymphocytes", 587], ["isolated", 599], ["from", 608], ["DBA", 613], ["patients", 617], [",", 625], ["as", 627], ["well", 630], ["as", 635], ["in", 638], ["K562", 641], ["cells", 646], ["expressing", 652], ["several", 663], ["RPS19", 671], ["mutants", 677], ["to", 685], ["directly", 688], ["test", 697], ["the", 702], ["effect", 706], ["of", 713], ["RPS19", 716], ["mutations", 722], ["on", 732], ["translation", 735], [".", 746], ["The", 748], ["effect", 752], ["of", 759], ["leucine", 762], ["on", 770], ["overall", 773], ["translation", 781], ["was", 793], ["also", 797], ["studied", 802], [".", 809], ["We", 811], ["found", 814], ["that", 820], ["the", 825], ["level", 829], ["of", 835], ["translation", 838], ["was", 850], ["on", 854], ["average", 857], ["48", 865], ["-", 867], ["73", 868], ["%", 870], ["of", 872], ["controls", 875], ["in", 884], ["both", 887], ["unstimulated", 892], ["and", 905], ["PHA", 909], ["-", 912], ["activated", 913], ["DBA", 923], ["lymphocytes", 927], ["irrespective", 939], ["of", 952], ["mutations", 955], ["in", 965], ["RPS19", 968], [".", 973], ["The", 975], ["addition", 979], ["of", 988], ["leucine", 991], ["increased", 999], ["the", 1009], ["translational", 1013], ["level", 1027], ["in", 1033], ["RPS19-non", 1036], ["-", 1045], ["mutated", 1046], ["DBA", 1054], ["cells", 1058], [",", 1063], ["but", 1065], ["not", 1069], ["in", 1073], ["cells", 1076], ["with", 1082], ["an", 1087], ["RPS19", 1090], ["mutation", 1096], [".", 1104], ["In", 1106], ["unstimulated", 1109], ["DBA", 1122], ["cells", 1126], [",", 1131], ["proliferation", 1133], ["was", 1147], ["significantly", 1151], ["impaired", 1165], ["in", 1174], ["both", 1177], ["RPS19-mutated", 1182], ["and", 1196], ["non", 1200], ["-", 1203], ["mutated", 1204], ["cells", 1212], [",", 1217], ["but", 1219], ["in", 1223], ["both", 1226], ["groups", 1231], ["could", 1238], ["be", 1244], ["efficiently", 1247], ["activated", 1259], ["by", 1269], ["PHA", 1272], [".", 1275], ["Studies", 1277], ["on", 1285], ["K562", 1288], ["cells", 1293], ["showed", 1299], ["that", 1306], ["RPS19", 1311], ["mutations", 1317], ["affecting", 1327], ["RPS19", 1337], ["conserved", 1343], ["arginines", 1353], ["R56Q", 1363], ["and", 1368], ["R62Q", 1372], ["could", 1377], ["significantly", 1383], ["inhibit", 1397], ["the", 1405], ["rate", 1409], ["of", 1414], ["protein", 1417], ["synthesis", 1425], [",", 1434], ["indicating", 1436], ["the", 1447], ["importance", 1451], ["of", 1462], ["RPS19", 1465], ["in", 1471], ["translation", 1474], [".", 1485], ["Our", 1487], ["results", 1491], ["indicate", 1499], ["that", 1508], ["inefficient", 1513], ["translation", 1525], ["may", 1537], ["be", 1541], ["the", 1544], ["main", 1548], ["cause", 1553], ["of", 1559], ["DBA", 1562], [",", 1565], ["and", 1567], ["administration", 1571], ["of", 1586], ["leucine", 1589], ["may", 1597], ["be", 1601], ["beneficial", 1604], ["for", 1615], ["at", 1619], ["least", 1622], ["some", 1628], ["DBA", 1633], ["patients", 1637], [".", 1645]]}
{"context": "In yeast, the macromolecular complex Set1/COMPASS is capable of methylating H3K4, a posttranslational modification associated with actively transcribed genes. There is only one Set1 in yeast; yet in mammalian cells there are multiple H3K4 methylases, including Set1A/B, forming human COMPASS complexes, and MLL1-4, forming human COMPASS-like complexes. We have shown that Wdr82, which associates with chromatin in a histone H2B ubiquitination-dependent manner, is a specific component of Set1 complexes but not that of MLL1-4 complexes. RNA interference-mediated knockdown of Wdr82 results in a reduction in the H3K4 trimethylation levels, although these cells still possess active MLL complexes. Comprehensive in vitro enzymatic studies with Set1 and MLL complexes demonstrated that the Set1 complex is a more robust H3K4 trimethylase in vitro than the MLL complexes. Given our in vivo and in vitro observations, it appears that the human Set1 complex plays a more widespread role in H3K4 trimethylation than do the MLL complexes in mammalian cells.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "66e99ba7d17c47c9b3445238952287b4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[37, 37], [173, 173], [11, 11], [142, 142], [110, 110]], "char_spans": [[234, 237], [985, 988], [76, 79], [818, 821], [612, 615]]}]}], "context_tokens": [["In", 0], ["yeast", 3], [",", 8], ["the", 10], ["macromolecular", 14], ["complex", 29], ["Set1/COMPASS", 37], ["is", 50], ["capable", 53], ["of", 61], ["methylating", 64], ["H3K4", 76], [",", 80], ["a", 82], ["posttranslational", 84], ["modification", 102], ["associated", 115], ["with", 126], ["actively", 131], ["transcribed", 140], ["genes", 152], [".", 157], ["There", 159], ["is", 165], ["only", 168], ["one", 173], ["Set1", 177], ["in", 182], ["yeast", 185], [";", 190], ["yet", 192], ["in", 196], ["mammalian", 199], ["cells", 209], ["there", 215], ["are", 221], ["multiple", 225], ["H3K4", 234], ["methylases", 239], [",", 249], ["including", 251], ["Set1A", 261], ["/", 266], ["B", 267], [",", 268], ["forming", 270], ["human", 278], ["COMPASS", 284], ["complexes", 292], [",", 301], ["and", 303], ["MLL1", 307], ["-", 311], ["4", 312], [",", 313], ["forming", 315], ["human", 323], ["COMPASS", 329], ["-", 336], ["like", 337], ["complexes", 342], [".", 351], ["We", 353], ["have", 356], ["shown", 361], ["that", 367], ["Wdr82", 372], [",", 377], ["which", 379], ["associates", 385], ["with", 396], ["chromatin", 401], ["in", 411], ["a", 414], ["histone", 416], ["H2B", 424], ["ubiquitination", 428], ["-", 442], ["dependent", 443], ["manner", 453], [",", 459], ["is", 461], ["a", 464], ["specific", 466], ["component", 475], ["of", 485], ["Set1", 488], ["complexes", 493], ["but", 503], ["not", 507], ["that", 511], ["of", 516], ["MLL1", 519], ["-", 523], ["4", 524], ["complexes", 526], [".", 535], ["RNA", 537], ["interference", 541], ["-", 553], ["mediated", 554], ["knockdown", 563], ["of", 573], ["Wdr82", 576], ["results", 582], ["in", 590], ["a", 593], ["reduction", 595], ["in", 605], ["the", 608], ["H3K4", 612], ["trimethylation", 617], ["levels", 632], [",", 638], ["although", 640], ["these", 649], ["cells", 655], ["still", 661], ["possess", 667], ["active", 675], ["MLL", 682], ["complexes", 686], [".", 695], ["Comprehensive", 697], ["in", 711], ["vitro", 714], ["enzymatic", 720], ["studies", 730], ["with", 738], ["Set1", 743], ["and", 748], ["MLL", 752], ["complexes", 756], ["demonstrated", 766], ["that", 779], ["the", 784], ["Set1", 788], ["complex", 793], ["is", 801], ["a", 804], ["more", 806], ["robust", 811], ["H3K4", 818], ["trimethylase", 823], ["in", 836], ["vitro", 839], ["than", 845], ["the", 850], ["MLL", 854], ["complexes", 858], [".", 867], ["Given", 869], ["our", 875], ["in", 879], ["vivo", 882], ["and", 887], ["in", 891], ["vitro", 894], ["observations", 900], [",", 912], ["it", 914], ["appears", 917], ["that", 925], ["the", 930], ["human", 934], ["Set1", 940], ["complex", 945], ["plays", 953], ["a", 959], ["more", 961], ["widespread", 966], ["role", 977], ["in", 982], ["H3K4", 985], ["trimethylation", 990], ["than", 1005], ["do", 1010], ["the", 1013], ["MLL", 1017], ["complexes", 1021], ["in", 1031], ["mammalian", 1034], ["cells", 1044], [".", 1049]]}
{"context": "Erythrasma is a skin infection which is caused by Corynebacterium minutissimum. Interdigital erythrasma is the most common form. The aim of this study was to detect the frequency and risk factors of interdigital erythrasma in patients with clinically suspected tinea pedis. This study was conducted between June and December 2010 and included 122 patients who had interdigital foot lesions. All patients were examined using a Wood's lamp. The smears were stained using Gram's method. Direct examination was performed using 20% potassium hydroxide. Sabouraud dextrose agar and brain heart infusion agar were used for cultures. Moreover, the demographical characteristics of patients, concomitant diseases and clinical findings were also recorded. Cases that were found to be positive on Wood's lamp examination and/or Gram staining/culture were considered as erythrasma. The rate of erythrasma was found to be 46.7%. The mean age was 43.6 years, and the disease was more prevalent in men. The most common clinical finding was desquamation. Mycological examination was found as positive in 40.35% of the patients. No growth was observed in bacteriological cultures. It was found that using only Wood's lamp examination or Gram staining resulted in 11 (9%) and 19 positive patients (15.6%), respectively, whereas using both Wood's lamp examination and Gram staining concurrently resulted in 27 positive patients (22.1%). Interdigital erythrasma is a commonly seen condition and can clinically mimic tinea pedis. A Wood's lamp is a good diagnostic tool, but Gram staining, particularly in those with a negative Wood's lamp result, may be a useful method.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "f259dac2d37f4a20997aff4a16f394eb", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[9, 10]], "char_spans": [[50, 77]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["skin", 16], ["infection", 21], ["which", 31], ["is", 37], ["caused", 40], ["by", 47], ["Corynebacterium", 50], ["minutissimum", 66], [".", 78], ["Interdigital", 80], ["erythrasma", 93], ["is", 104], ["the", 107], ["most", 111], ["common", 116], ["form", 123], [".", 127], ["The", 129], ["aim", 133], ["of", 137], ["this", 140], ["study", 145], ["was", 151], ["to", 155], ["detect", 158], ["the", 165], ["frequency", 169], ["and", 179], ["risk", 183], ["factors", 188], ["of", 196], ["interdigital", 199], ["erythrasma", 212], ["in", 223], ["patients", 226], ["with", 235], ["clinically", 240], ["suspected", 251], ["tinea", 261], ["pedis", 267], [".", 272], ["This", 274], ["study", 279], ["was", 285], ["conducted", 289], ["between", 299], ["June", 307], ["and", 312], ["December", 316], ["2010", 325], ["and", 330], ["included", 334], ["122", 343], ["patients", 347], ["who", 356], ["had", 360], ["interdigital", 364], ["foot", 377], ["lesions", 382], [".", 389], ["All", 391], ["patients", 395], ["were", 404], ["examined", 409], ["using", 418], ["a", 424], ["Wood", 426], ["'s", 430], ["lamp", 433], [".", 437], ["The", 439], ["smears", 443], ["were", 450], ["stained", 455], ["using", 463], ["Gram", 469], ["'s", 473], ["method", 476], [".", 482], ["Direct", 484], ["examination", 491], ["was", 503], ["performed", 507], ["using", 517], ["20", 523], ["%", 525], ["potassium", 527], ["hydroxide", 537], [".", 546], ["Sabouraud", 548], ["dextrose", 558], ["agar", 567], ["and", 572], ["brain", 576], ["heart", 582], ["infusion", 588], ["agar", 597], ["were", 602], ["used", 607], ["for", 612], ["cultures", 616], [".", 624], ["Moreover", 626], [",", 634], ["the", 636], ["demographical", 640], ["characteristics", 654], ["of", 670], ["patients", 673], [",", 681], ["concomitant", 683], ["diseases", 695], ["and", 704], ["clinical", 708], ["findings", 717], ["were", 726], ["also", 731], ["recorded", 736], [".", 744], ["Cases", 746], ["that", 752], ["were", 757], ["found", 762], ["to", 768], ["be", 771], ["positive", 774], ["on", 783], ["Wood", 786], ["'s", 790], ["lamp", 793], ["examination", 798], ["and/or", 810], ["Gram", 817], ["staining", 822], ["/", 830], ["culture", 831], ["were", 839], ["considered", 844], ["as", 855], ["erythrasma", 858], [".", 868], ["The", 870], ["rate", 874], ["of", 879], ["erythrasma", 882], ["was", 893], ["found", 897], ["to", 903], ["be", 906], ["46.7", 909], ["%", 913], [".", 914], ["The", 916], ["mean", 920], ["age", 925], ["was", 929], ["43.6", 933], ["years", 938], [",", 943], ["and", 945], ["the", 949], ["disease", 953], ["was", 961], ["more", 965], ["prevalent", 970], ["in", 980], ["men", 983], [".", 986], ["The", 988], ["most", 992], ["common", 997], ["clinical", 1004], ["finding", 1013], ["was", 1021], ["desquamation", 1025], [".", 1037], ["Mycological", 1039], ["examination", 1051], ["was", 1063], ["found", 1067], ["as", 1073], ["positive", 1076], ["in", 1085], ["40.35", 1088], ["%", 1093], ["of", 1095], ["the", 1098], ["patients", 1102], [".", 1110], ["No", 1112], ["growth", 1115], ["was", 1122], ["observed", 1126], ["in", 1135], ["bacteriological", 1138], ["cultures", 1154], [".", 1162], ["It", 1164], ["was", 1167], ["found", 1171], ["that", 1177], ["using", 1182], ["only", 1188], ["Wood", 1193], ["'s", 1197], ["lamp", 1200], ["examination", 1205], ["or", 1217], ["Gram", 1220], ["staining", 1225], ["resulted", 1234], ["in", 1243], ["11", 1246], ["(", 1249], ["9", 1250], ["%", 1251], [")", 1252], ["and", 1254], ["19", 1258], ["positive", 1261], ["patients", 1270], ["(", 1279], ["15.6", 1280], ["%", 1284], [")", 1285], [",", 1286], ["respectively", 1288], [",", 1300], ["whereas", 1302], ["using", 1310], ["both", 1316], ["Wood", 1321], ["'s", 1325], ["lamp", 1328], ["examination", 1333], ["and", 1345], ["Gram", 1349], ["staining", 1354], ["concurrently", 1363], ["resulted", 1376], ["in", 1385], ["27", 1388], ["positive", 1391], ["patients", 1400], ["(", 1409], ["22.1", 1410], ["%", 1414], [")", 1415], [".", 1416], ["Interdigital", 1418], ["erythrasma", 1431], ["is", 1442], ["a", 1445], ["commonly", 1447], ["seen", 1456], ["condition", 1461], ["and", 1471], ["can", 1475], ["clinically", 1479], ["mimic", 1490], ["tinea", 1496], ["pedis", 1502], [".", 1507], ["A", 1509], ["Wood", 1511], ["'s", 1515], ["lamp", 1518], ["is", 1523], ["a", 1526], ["good", 1528], ["diagnostic", 1533], ["tool", 1544], [",", 1548], ["but", 1550], ["Gram", 1554], ["staining", 1559], [",", 1567], ["particularly", 1569], ["in", 1582], ["those", 1585], ["with", 1591], ["a", 1596], ["negative", 1598], ["Wood", 1607], ["'s", 1611], ["lamp", 1614], ["result", 1619], [",", 1625], ["may", 1627], ["be", 1631], ["a", 1634], ["useful", 1636], ["method", 1643], [".", 1649]]}
{"context": "It is well known that autonomic failure is severer in patients with dementia with Lewy bodies (DLB) compared with patients with Parkinson's disease (PD). According to the Braak's hypothesis, Lewy bodies first appear in the olfactory bulb or peripheral autonomic nervous system. Lewy bodies in the peripheral autonomic nervous system ascend to dorsal motor nuclei of vagus nerve, while those in the olfactory bulb expand to the limbic system. Lewy bodies later attain the substantia nigra. However, it seems that Braak staging can not explain difference in severity of autonomic failure between DLB and PD. As a possibility, in DLB patients with significant autonomic failure, Lewy bodies may have been localized to the peripheral autonomic nervous system in a long time before onset of dementia or parkinsonism, and propagation of Lewy bodies into the central nervous system may be initiated by apparition of certain promotion factor, such as ageing and amyloid-\u03b2.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "db39b179aff4498e87b78355b6034f5b", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[23, 27]], "char_spans": [[128, 150]]}]}], "context_tokens": [["It", 0], ["is", 3], ["well", 6], ["known", 11], ["that", 17], ["autonomic", 22], ["failure", 32], ["is", 40], ["severer", 43], ["in", 51], ["patients", 54], ["with", 63], ["dementia", 68], ["with", 77], ["Lewy", 82], ["bodies", 87], ["(", 94], ["DLB", 95], [")", 98], ["compared", 100], ["with", 109], ["patients", 114], ["with", 123], ["Parkinson", 128], ["'s", 137], ["disease", 140], ["(", 148], ["PD", 149], [")", 151], [".", 152], ["According", 154], ["to", 164], ["the", 167], ["Braak", 171], ["'s", 176], ["hypothesis", 179], [",", 189], ["Lewy", 191], ["bodies", 196], ["first", 203], ["appear", 209], ["in", 216], ["the", 219], ["olfactory", 223], ["bulb", 233], ["or", 238], ["peripheral", 241], ["autonomic", 252], ["nervous", 262], ["system", 270], [".", 276], ["Lewy", 278], ["bodies", 283], ["in", 290], ["the", 293], ["peripheral", 297], ["autonomic", 308], ["nervous", 318], ["system", 326], ["ascend", 333], ["to", 340], ["dorsal", 343], ["motor", 350], ["nuclei", 356], ["of", 363], ["vagus", 366], ["nerve", 372], [",", 377], ["while", 379], ["those", 385], ["in", 391], ["the", 394], ["olfactory", 398], ["bulb", 408], ["expand", 413], ["to", 420], ["the", 423], ["limbic", 427], ["system", 434], [".", 440], ["Lewy", 442], ["bodies", 447], ["later", 454], ["attain", 460], ["the", 467], ["substantia", 471], ["nigra", 482], [".", 487], ["However", 489], [",", 496], ["it", 498], ["seems", 501], ["that", 507], ["Braak", 512], ["staging", 518], ["can", 526], ["not", 530], ["explain", 534], ["difference", 542], ["in", 553], ["severity", 556], ["of", 565], ["autonomic", 568], ["failure", 578], ["between", 586], ["DLB", 594], ["and", 598], ["PD", 602], [".", 604], ["As", 606], ["a", 609], ["possibility", 611], [",", 622], ["in", 624], ["DLB", 627], ["patients", 631], ["with", 640], ["significant", 645], ["autonomic", 657], ["failure", 667], [",", 674], ["Lewy", 676], ["bodies", 681], ["may", 688], ["have", 692], ["been", 697], ["localized", 702], ["to", 712], ["the", 715], ["peripheral", 719], ["autonomic", 730], ["nervous", 740], ["system", 748], ["in", 755], ["a", 758], ["long", 760], ["time", 765], ["before", 770], ["onset", 777], ["of", 783], ["dementia", 786], ["or", 795], ["parkinsonism", 798], [",", 810], ["and", 812], ["propagation", 816], ["of", 828], ["Lewy", 831], ["bodies", 836], ["into", 843], ["the", 848], ["central", 852], ["nervous", 860], ["system", 868], ["may", 875], ["be", 879], ["initiated", 882], ["by", 892], ["apparition", 895], ["of", 906], ["certain", 909], ["promotion", 917], ["factor", 927], [",", 933], ["such", 935], ["as", 940], ["ageing", 943], ["and", 950], ["amyloid", 954], ["-", 961], ["\u03b2", 962], [".", 963]]}
{"context": "Objective. A study to determine if addition of palatal petechiae to Centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. Hypothesis. In children, Centor Criteria does not cover all the symptoms and signs of acute strep pharyngitis. We hypothesize that addition of palatal petechiae to Centor Criteria will increase the possibility of clinical diagnosis of group A streptococcal pharyngitis in children. Methods. One hundred patients with a complaint of sore throat were enrolled in the study. All the patients were examined clinically using the Centor Criteria. They were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. All the patients were given rapid strep tests, and throat cultures were sent. No antibiotics were given until culture results were obtained. Results. The sample size was 100 patients. All 100 had fever, sore throat, and erythema of tonsils. Twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. In total, 9 out of the 100 patients had positive throat cultures. We observed that petechiae over the palate, a very significant sign, is not included in the Centor Criteria. Palatal petechiae were present in 8 out of the 100 patients. Six out of these 8 with palatal petechiae had positive throat culture for strep (75%). Only 7 out of 20 with exudates had positive strep culture. Sixteen out of the 100 patients had rapid strep test positive. Those 84/100 who had negative rapid strep also had negative throat culture. Statistics. We used Fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant P value <.0001. Conclusion. Our study concludes that addition of petechiae over the palate to Centor Criteria will increase the possibility of diagnosing acute group A streptococcal pharyngitis in children.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "345cc6f39eb0472ebb37229e6f4e34b1", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[356, 357], [67, 68]], "char_spans": [[1984, 2008], [406, 430]]}]}], "context_tokens": [["Objective", 0], [".", 9], ["A", 11], ["study", 13], ["to", 19], ["determine", 22], ["if", 32], ["addition", 35], ["of", 44], ["palatal", 47], ["petechiae", 55], ["to", 65], ["Centor", 68], ["criteria", 75], ["adds", 84], ["more", 89], ["value", 94], ["for", 100], ["clinical", 104], ["diagnosis", 113], ["of", 123], ["acute", 126], ["strep", 132], ["pharyngitis", 138], ["in", 150], ["children", 153], [".", 161], ["Hypothesis", 163], [".", 173], ["In", 175], ["children", 178], [",", 186], ["Centor", 188], ["Criteria", 195], ["does", 204], ["not", 209], ["cover", 213], ["all", 219], ["the", 223], ["symptoms", 227], ["and", 236], ["signs", 240], ["of", 246], ["acute", 249], ["strep", 255], ["pharyngitis", 261], [".", 272], ["We", 274], ["hypothesize", 277], ["that", 289], ["addition", 294], ["of", 303], ["palatal", 306], ["petechiae", 314], ["to", 324], ["Centor", 327], ["Criteria", 334], ["will", 343], ["increase", 348], ["the", 357], ["possibility", 361], ["of", 373], ["clinical", 376], ["diagnosis", 385], ["of", 395], ["group", 398], ["A", 404], ["streptococcal", 406], ["pharyngitis", 420], ["in", 432], ["children", 435], [".", 443], ["Methods", 445], [".", 452], ["One", 454], ["hundred", 458], ["patients", 466], ["with", 475], ["a", 480], ["complaint", 482], ["of", 492], ["sore", 495], ["throat", 500], ["were", 507], ["enrolled", 512], ["in", 521], ["the", 524], ["study", 528], [".", 533], ["All", 535], ["the", 539], ["patients", 543], ["were", 552], ["examined", 557], ["clinically", 566], ["using", 577], ["the", 583], ["Centor", 587], ["Criteria", 594], [".", 602], ["They", 604], ["were", 609], ["also", 614], ["examined", 619], ["for", 628], ["other", 632], ["signs", 638], ["and", 644], ["symptoms", 648], ["like", 657], ["petechial", 662], ["lesions", 672], ["over", 680], ["the", 685], ["palate", 689], [",", 695], ["abdominal", 697], ["pain", 707], [",", 711], ["and", 713], ["skin", 717], ["rash", 722], [".", 726], ["All", 728], ["the", 732], ["patients", 736], ["were", 745], ["given", 750], ["rapid", 756], ["strep", 762], ["tests", 768], [",", 773], ["and", 775], ["throat", 779], ["cultures", 786], ["were", 795], ["sent", 800], [".", 804], ["No", 806], ["antibiotics", 809], ["were", 821], ["given", 826], ["until", 832], ["culture", 838], ["results", 846], ["were", 854], ["obtained", 859], [".", 867], ["Results", 869], [".", 876], ["The", 878], ["sample", 882], ["size", 889], ["was", 894], ["100", 898], ["patients", 902], [".", 910], ["All", 912], ["100", 916], ["had", 920], ["fever", 924], [",", 929], ["sore", 931], ["throat", 936], [",", 942], ["and", 944], ["erythema", 948], ["of", 957], ["tonsils", 960], [".", 967], ["Twenty", 969], ["of", 976], ["the", 979], ["100", 983], ["patients", 987], ["had", 996], ["tonsillar", 1000], ["exudates", 1010], [",", 1018], ["85/100", 1020], ["had", 1027], ["tender", 1031], ["anterior", 1038], ["cervical", 1047], ["lymph", 1056], ["nodes", 1062], [",", 1067], ["and", 1069], ["86/100", 1073], ["had", 1080], ["no", 1084], ["cough", 1087], [".", 1092], ["In", 1094], ["total", 1097], [",", 1102], ["9", 1104], ["out", 1106], ["of", 1110], ["the", 1113], ["100", 1117], ["patients", 1121], ["had", 1130], ["positive", 1134], ["throat", 1143], ["cultures", 1150], [".", 1158], ["We", 1160], ["observed", 1163], ["that", 1172], ["petechiae", 1177], ["over", 1187], ["the", 1192], ["palate", 1196], [",", 1202], ["a", 1204], ["very", 1206], ["significant", 1211], ["sign", 1223], [",", 1227], ["is", 1229], ["not", 1232], ["included", 1236], ["in", 1245], ["the", 1248], ["Centor", 1252], ["Criteria", 1259], [".", 1267], ["Palatal", 1269], ["petechiae", 1277], ["were", 1287], ["present", 1292], ["in", 1300], ["8", 1303], ["out", 1305], ["of", 1309], ["the", 1312], ["100", 1316], ["patients", 1320], [".", 1328], ["Six", 1330], ["out", 1334], ["of", 1338], ["these", 1341], ["8", 1347], ["with", 1349], ["palatal", 1354], ["petechiae", 1362], ["had", 1372], ["positive", 1376], ["throat", 1385], ["culture", 1392], ["for", 1400], ["strep", 1404], ["(", 1410], ["75", 1411], ["%", 1413], [")", 1414], [".", 1415], ["Only", 1417], ["7", 1422], ["out", 1424], ["of", 1428], ["20", 1431], ["with", 1434], ["exudates", 1439], ["had", 1448], ["positive", 1452], ["strep", 1461], ["culture", 1467], [".", 1474], ["Sixteen", 1476], ["out", 1484], ["of", 1488], ["the", 1491], ["100", 1495], ["patients", 1499], ["had", 1508], ["rapid", 1512], ["strep", 1518], ["test", 1524], ["positive", 1529], [".", 1537], ["Those", 1539], ["84/100", 1545], ["who", 1552], ["had", 1556], ["negative", 1560], ["rapid", 1569], ["strep", 1575], ["also", 1581], ["had", 1586], ["negative", 1590], ["throat", 1599], ["culture", 1606], [".", 1613], ["Statistics", 1615], [".", 1625], ["We", 1627], ["used", 1630], ["Fisher", 1635], ["'s", 1641], ["exact", 1644], ["test", 1650], [",", 1654], ["comparing", 1656], ["throat", 1666], ["culture", 1673], ["positive", 1681], ["and", 1690], ["negative", 1694], ["versus", 1703], ["presence", 1710], ["of", 1719], ["exudates", 1722], ["and", 1731], ["palatal", 1735], ["hemorrhages", 1743], ["with", 1755], ["positive", 1760], ["and", 1769], ["negative", 1773], ["throat", 1782], ["cultures", 1789], ["and", 1798], ["the", 1802], ["resultant", 1806], ["P", 1816], ["value", 1818], ["<", 1824], [".0001", 1825], [".", 1830], ["Conclusion", 1832], [".", 1842], ["Our", 1844], ["study", 1848], ["concludes", 1854], ["that", 1864], ["addition", 1869], ["of", 1878], ["petechiae", 1881], ["over", 1891], ["the", 1896], ["palate", 1900], ["to", 1907], ["Centor", 1910], ["Criteria", 1917], ["will", 1926], ["increase", 1931], ["the", 1940], ["possibility", 1944], ["of", 1956], ["diagnosing", 1959], ["acute", 1970], ["group", 1976], ["A", 1982], ["streptococcal", 1984], ["pharyngitis", 1998], ["in", 2010], ["children", 2013], [".", 2021]]}
{"context": "Defects in DNA mismatch repair have been associated with both hereditary and sporadic forms of cancer. Recently, it has been shown that human cell lines deficient in mismatch repair were also defective in the transcription-coupled repair (TCR) of UV-induced DNA damage. We examined whether TCR of ionizing radiation-induced DNA damage also requires the genes involved in DNA mismatch repair. Cells defective in the hMSH2 gene were deficient in the removal of oxidative damage, including thymine glycols, from the transcribed strand of an active gene. However, an hMLH1 mutant showed normal levels of TCR. By comparison, defects in either hMSH2 or hMLH1 resulted in reduced TCR of UV damage. Introducing chromosomes carrying either hMSH2 or hMLH1 into these cell lines restored their ability to carry out TCR. Deficiencies in either hMSH2 or hMLH1 did not result in decreased overall genomic levels of repair or lead to an increased sensitivity to either UV or ionizing radiation. Our results provide the first evidence for a protein that is absolutely required for the preferential removal of UV-induced DNA damage but not oxidative DNA damage from the transcribed strand of an active human gene.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "10f594ced5e64fcfaf6ab93cda76d0f5", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[92, 93], [205, 206]], "char_spans": [[513, 530], [1153, 1170]]}]}], "context_tokens": [["Defects", 0], ["in", 8], ["DNA", 11], ["mismatch", 15], ["repair", 24], ["have", 31], ["been", 36], ["associated", 41], ["with", 52], ["both", 57], ["hereditary", 62], ["and", 73], ["sporadic", 77], ["forms", 86], ["of", 92], ["cancer", 95], [".", 101], ["Recently", 103], [",", 111], ["it", 113], ["has", 116], ["been", 120], ["shown", 125], ["that", 131], ["human", 136], ["cell", 142], ["lines", 147], ["deficient", 153], ["in", 163], ["mismatch", 166], ["repair", 175], ["were", 182], ["also", 187], ["defective", 192], ["in", 202], ["the", 205], ["transcription", 209], ["-", 222], ["coupled", 223], ["repair", 231], ["(", 238], ["TCR", 239], [")", 242], ["of", 244], ["UV", 247], ["-", 249], ["induced", 250], ["DNA", 258], ["damage", 262], [".", 268], ["We", 270], ["examined", 273], ["whether", 282], ["TCR", 290], ["of", 294], ["ionizing", 297], ["radiation", 306], ["-", 315], ["induced", 316], ["DNA", 324], ["damage", 328], ["also", 335], ["requires", 340], ["the", 349], ["genes", 353], ["involved", 359], ["in", 368], ["DNA", 371], ["mismatch", 375], ["repair", 384], [".", 390], ["Cells", 392], ["defective", 398], ["in", 408], ["the", 411], ["hMSH2", 415], ["gene", 421], ["were", 426], ["deficient", 431], ["in", 441], ["the", 444], ["removal", 448], ["of", 456], ["oxidative", 459], ["damage", 469], [",", 475], ["including", 477], ["thymine", 487], ["glycols", 495], [",", 502], ["from", 504], ["the", 509], ["transcribed", 513], ["strand", 525], ["of", 532], ["an", 535], ["active", 538], ["gene", 545], [".", 549], ["However", 551], [",", 558], ["an", 560], ["hMLH1", 563], ["mutant", 569], ["showed", 576], ["normal", 583], ["levels", 590], ["of", 597], ["TCR", 600], [".", 603], ["By", 605], ["comparison", 608], [",", 618], ["defects", 620], ["in", 628], ["either", 631], ["hMSH2", 638], ["or", 644], ["hMLH1", 647], ["resulted", 653], ["in", 662], ["reduced", 665], ["TCR", 673], ["of", 677], ["UV", 680], ["damage", 683], [".", 689], ["Introducing", 691], ["chromosomes", 703], ["carrying", 715], ["either", 724], ["hMSH2", 731], ["or", 737], ["hMLH1", 740], ["into", 746], ["these", 751], ["cell", 757], ["lines", 762], ["restored", 768], ["their", 777], ["ability", 783], ["to", 791], ["carry", 794], ["out", 800], ["TCR", 804], [".", 807], ["Deficiencies", 809], ["in", 822], ["either", 825], ["hMSH2", 832], ["or", 838], ["hMLH1", 841], ["did", 847], ["not", 851], ["result", 855], ["in", 862], ["decreased", 865], ["overall", 875], ["genomic", 883], ["levels", 891], ["of", 898], ["repair", 901], ["or", 908], ["lead", 911], ["to", 916], ["an", 919], ["increased", 922], ["sensitivity", 932], ["to", 944], ["either", 947], ["UV", 954], ["or", 957], ["ionizing", 960], ["radiation", 969], [".", 978], ["Our", 980], ["results", 984], ["provide", 992], ["the", 1000], ["first", 1004], ["evidence", 1010], ["for", 1019], ["a", 1023], ["protein", 1025], ["that", 1033], ["is", 1038], ["absolutely", 1041], ["required", 1052], ["for", 1061], ["the", 1065], ["preferential", 1069], ["removal", 1082], ["of", 1090], ["UV", 1093], ["-", 1095], ["induced", 1096], ["DNA", 1104], ["damage", 1108], ["but", 1115], ["not", 1119], ["oxidative", 1123], ["DNA", 1133], ["damage", 1137], ["from", 1144], ["the", 1149], ["transcribed", 1153], ["strand", 1165], ["of", 1172], ["an", 1175], ["active", 1178], ["human", 1185], ["gene", 1191], [".", 1195]]}
{"context": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran. It has demonstrated prompt and durable reversal of the anticoagulant effects of dabigatran in animal studies and phase 1 studies of young, elderly, and renally impaired volunteers. Although elective invasive procedures and most bleeding complications in dabigatran-treated patients can be managed by temporarily stopping dabigatran therapy and using supportive measures, there are rare clinical situations that require urgent reversal of the anticoagulant effect of dabigatran. The effectiveness and safety of 5 g of intravenous idarucizumab is being investigated in a prospective, open-label, single-cohort study in patients with serious bleeding or in those requiring an urgent procedure. In an interim analysis of the first 90 participants, idarucizumab rapidly and completely reversed the anticoagulant activity of dabigatran in 88%-98% of participants, and there were no safety concerns, with no deaths or serious adverse events being attributable to idarucizumab. Supported by these interim results, idarucizumab has been approved in the United States and the European Union for use when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in patients with life-threatening or uncontrolled bleeding. Clinical use of idarucizumab should follow the same processes as patient enrollment in this study, which is projected to be completed in 2016. The outcomes achieved with this specific reversal agent are likely to be of continued interest to treating physicians.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "8031bea26fff4e0ca71ad6c3b3448396", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[60, 60], [140, 140], [23, 23], [9, 9], [50, 50], [193, 193], [81, 81]], "char_spans": [[405, 414], [903, 912], [164, 173], [72, 81], [338, 347], [1219, 1228], [550, 559]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["monoclonal", 18], ["antibody", 29], ["fragment", 38], ["specifically", 47], ["targeted", 60], ["to", 69], ["dabigatran", 72], [".", 82], ["It", 84], ["has", 87], ["demonstrated", 91], ["prompt", 104], ["and", 111], ["durable", 115], ["reversal", 123], ["of", 132], ["the", 135], ["anticoagulant", 139], ["effects", 153], ["of", 161], ["dabigatran", 164], ["in", 175], ["animal", 178], ["studies", 185], ["and", 193], ["phase", 197], ["1", 203], ["studies", 205], ["of", 213], ["young", 216], [",", 221], ["elderly", 223], [",", 230], ["and", 232], ["renally", 236], ["impaired", 244], ["volunteers", 253], [".", 263], ["Although", 265], ["elective", 274], ["invasive", 283], ["procedures", 292], ["and", 303], ["most", 307], ["bleeding", 312], ["complications", 321], ["in", 335], ["dabigatran", 338], ["-", 348], ["treated", 349], ["patients", 357], ["can", 366], ["be", 370], ["managed", 373], ["by", 381], ["temporarily", 384], ["stopping", 396], ["dabigatran", 405], ["therapy", 416], ["and", 424], ["using", 428], ["supportive", 434], ["measures", 445], [",", 453], ["there", 455], ["are", 461], ["rare", 465], ["clinical", 470], ["situations", 479], ["that", 490], ["require", 495], ["urgent", 503], ["reversal", 510], ["of", 519], ["the", 522], ["anticoagulant", 526], ["effect", 540], ["of", 547], ["dabigatran", 550], [".", 560], ["The", 562], ["effectiveness", 566], ["and", 580], ["safety", 584], ["of", 591], ["5", 594], ["g", 596], ["of", 598], ["intravenous", 601], ["idarucizumab", 613], ["is", 626], ["being", 629], ["investigated", 635], ["in", 648], ["a", 651], ["prospective", 653], [",", 664], ["open", 666], ["-", 670], ["label", 671], [",", 676], ["single", 678], ["-", 684], ["cohort", 685], ["study", 692], ["in", 698], ["patients", 701], ["with", 710], ["serious", 715], ["bleeding", 723], ["or", 732], ["in", 735], ["those", 738], ["requiring", 744], ["an", 754], ["urgent", 757], ["procedure", 764], [".", 773], ["In", 775], ["an", 778], ["interim", 781], ["analysis", 789], ["of", 798], ["the", 801], ["first", 805], ["90", 811], ["participants", 814], [",", 826], ["idarucizumab", 828], ["rapidly", 841], ["and", 849], ["completely", 853], ["reversed", 864], ["the", 873], ["anticoagulant", 877], ["activity", 891], ["of", 900], ["dabigatran", 903], ["in", 914], ["88%-98", 917], ["%", 923], ["of", 925], ["participants", 928], [",", 940], ["and", 942], ["there", 946], ["were", 952], ["no", 957], ["safety", 960], ["concerns", 967], [",", 975], ["with", 977], ["no", 982], ["deaths", 985], ["or", 992], ["serious", 995], ["adverse", 1003], ["events", 1011], ["being", 1018], ["attributable", 1024], ["to", 1037], ["idarucizumab", 1040], [".", 1052], ["Supported", 1054], ["by", 1064], ["these", 1067], ["interim", 1073], ["results", 1081], [",", 1088], ["idarucizumab", 1090], ["has", 1103], ["been", 1107], ["approved", 1112], ["in", 1121], ["the", 1124], ["United", 1128], ["States", 1135], ["and", 1142], ["the", 1146], ["European", 1150], ["Union", 1159], ["for", 1165], ["use", 1169], ["when", 1173], ["reversal", 1178], ["of", 1187], ["the", 1190], ["anticoagulant", 1194], ["effects", 1208], ["of", 1216], ["dabigatran", 1219], ["is", 1230], ["needed", 1233], ["for", 1240], ["emergency", 1244], ["surgery", 1254], ["/", 1261], ["urgent", 1262], ["procedures", 1269], ["or", 1280], ["in", 1283], ["patients", 1286], ["with", 1295], ["life", 1300], ["-", 1304], ["threatening", 1305], ["or", 1317], ["uncontrolled", 1320], ["bleeding", 1333], [".", 1341], ["Clinical", 1343], ["use", 1352], ["of", 1356], ["idarucizumab", 1359], ["should", 1372], ["follow", 1379], ["the", 1386], ["same", 1390], ["processes", 1395], ["as", 1405], ["patient", 1408], ["enrollment", 1416], ["in", 1427], ["this", 1430], ["study", 1435], [",", 1440], ["which", 1442], ["is", 1448], ["projected", 1451], ["to", 1461], ["be", 1464], ["completed", 1467], ["in", 1477], ["2016", 1480], [".", 1484], ["The", 1486], ["outcomes", 1490], ["achieved", 1499], ["with", 1508], ["this", 1513], ["specific", 1518], ["reversal", 1527], ["agent", 1536], ["are", 1542], ["likely", 1546], ["to", 1553], ["be", 1556], ["of", 1559], ["continued", 1562], ["interest", 1572], ["to", 1581], ["treating", 1584], ["physicians", 1593], [".", 1603]]}
{"context": "The pathogenesis of restless legs syndrome (RLS) is unknown. Although iron deficiency anemia (IDA) is related with RLS, the mechanism of this relationship is still unknown. Therefore, we decided to examine some neurophysiological parameters that reflect the function of brainstem, spinal cord and peripheral nervous system. 34 patients diagnosed with IDA at the hematology department were questioned with a structured battery for RLS and additional symptoms. Of those, 14 patients had symptoms of RLS, while remaining 20 had no signs of this disorder. In both groups, electrophysiological examination including motor and sensory nerve conduction, F-responses, H-reflex, blink-reflex, and mixed nerve silent periods was performed. Neurological examination of all patients was normal. The two groups were identical for age and sex, and the difference between both groups concerning motor and sensory nerve conduction, F-wave, H-reflex, blink-reflex, and mixed nerve silent periods was insignificant. Results suggest that IDA does not cause electrophysiological changes in the peripheral nerves, spinal cord and brainstem, and therefore, measurement of these parameters in IDA patients does not seem effective for the confirmation of RLS.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "c11e38b5379143f9895440d3ed5f0ff2", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[13, 13]], "char_spans": [[70, 73]]}]}], "context_tokens": [["The", 0], ["pathogenesis", 4], ["of", 17], ["restless", 20], ["legs", 29], ["syndrome", 34], ["(", 43], ["RLS", 44], [")", 47], ["is", 49], ["unknown", 52], [".", 59], ["Although", 61], ["iron", 70], ["deficiency", 75], ["anemia", 86], ["(", 93], ["IDA", 94], [")", 97], ["is", 99], ["related", 102], ["with", 110], ["RLS", 115], [",", 118], ["the", 120], ["mechanism", 124], ["of", 134], ["this", 137], ["relationship", 142], ["is", 155], ["still", 158], ["unknown", 164], [".", 171], ["Therefore", 173], [",", 182], ["we", 184], ["decided", 187], ["to", 195], ["examine", 198], ["some", 206], ["neurophysiological", 211], ["parameters", 230], ["that", 241], ["reflect", 246], ["the", 254], ["function", 258], ["of", 267], ["brainstem", 270], [",", 279], ["spinal", 281], ["cord", 288], ["and", 293], ["peripheral", 297], ["nervous", 308], ["system", 316], [".", 322], ["34", 324], ["patients", 327], ["diagnosed", 336], ["with", 346], ["IDA", 351], ["at", 355], ["the", 358], ["hematology", 362], ["department", 373], ["were", 384], ["questioned", 389], ["with", 400], ["a", 405], ["structured", 407], ["battery", 418], ["for", 426], ["RLS", 430], ["and", 434], ["additional", 438], ["symptoms", 449], [".", 457], ["Of", 459], ["those", 462], [",", 467], ["14", 469], ["patients", 472], ["had", 481], ["symptoms", 485], ["of", 494], ["RLS", 497], [",", 500], ["while", 502], ["remaining", 508], ["20", 518], ["had", 521], ["no", 525], ["signs", 528], ["of", 534], ["this", 537], ["disorder", 542], [".", 550], ["In", 552], ["both", 555], ["groups", 560], [",", 566], ["electrophysiological", 568], ["examination", 589], ["including", 601], ["motor", 611], ["and", 617], ["sensory", 621], ["nerve", 629], ["conduction", 635], [",", 645], ["F", 647], ["-", 648], ["responses", 649], [",", 658], ["H", 660], ["-", 661], ["reflex", 662], [",", 668], ["blink", 670], ["-", 675], ["reflex", 676], [",", 682], ["and", 684], ["mixed", 688], ["nerve", 694], ["silent", 700], ["periods", 707], ["was", 715], ["performed", 719], [".", 728], ["Neurological", 730], ["examination", 743], ["of", 755], ["all", 758], ["patients", 762], ["was", 771], ["normal", 775], [".", 781], ["The", 783], ["two", 787], ["groups", 791], ["were", 798], ["identical", 803], ["for", 813], ["age", 817], ["and", 821], ["sex", 825], [",", 828], ["and", 830], ["the", 834], ["difference", 838], ["between", 849], ["both", 857], ["groups", 862], ["concerning", 869], ["motor", 880], ["and", 886], ["sensory", 890], ["nerve", 898], ["conduction", 904], [",", 914], ["F", 916], ["-", 917], ["wave", 918], [",", 922], ["H", 924], ["-", 925], ["reflex", 926], [",", 932], ["blink", 934], ["-", 939], ["reflex", 940], [",", 946], ["and", 948], ["mixed", 952], ["nerve", 958], ["silent", 964], ["periods", 971], ["was", 979], ["insignificant", 983], [".", 996], ["Results", 998], ["suggest", 1006], ["that", 1014], ["IDA", 1019], ["does", 1023], ["not", 1028], ["cause", 1032], ["electrophysiological", 1038], ["changes", 1059], ["in", 1067], ["the", 1070], ["peripheral", 1074], ["nerves", 1085], [",", 1091], ["spinal", 1093], ["cord", 1100], ["and", 1105], ["brainstem", 1109], [",", 1118], ["and", 1120], ["therefore", 1124], [",", 1133], ["measurement", 1135], ["of", 1147], ["these", 1150], ["parameters", 1156], ["in", 1167], ["IDA", 1170], ["patients", 1174], ["does", 1183], ["not", 1188], ["seem", 1192], ["effective", 1197], ["for", 1207], ["the", 1211], ["confirmation", 1215], ["of", 1228], ["RLS", 1231], [".", 1234]]}
{"context": "The focus of this article is acrokeratosis paraneoplastica, one of two disorders that have acquired the eponym Bazex syndrome. To date, all of the patients reported in the literature have had an underlying neoplasm, most commonly squamous cell carcinoma of the upper aerodigestive tract. In this review of 113 cases of acrokeratosis paraneoplastica (mean age, 61 years; 105 males, 8 females), the psoriasiform lesions preceded the diagnosis of the associated malignancy in 73 (67%) of 109 patients, whereas the cutaneous manifestations followed the diagnosis of the neoplasm in only 16 (15%) of 109; in the remainder, the onset of the skin lesions and the diagnosis of the tumor occurred simultaneously. Therefore, awareness of the cutaneous signs of Bazex syndrome is of obvious importance to dermatologists. Evidence in favor of the paraneoplastic nature of this disease is as follows: in 81 (93%) of 87 patients with adequate clinical descriptions, the skin lesions either improved significantly (or resolved) when the underlying neoplasm was treated or they remained unchanged in the setting of persistent disease. Occasionally, the reappearance of skin lesions has signaled a recurrence of the tumor.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "d451ee65e0e14baaa98a29b68092c5fc", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[139, 140], [18, 19]], "char_spans": [[751, 764], [111, 124]]}]}], "context_tokens": [["The", 0], ["focus", 4], ["of", 10], ["this", 13], ["article", 18], ["is", 26], ["acrokeratosis", 29], ["paraneoplastica", 43], [",", 58], ["one", 60], ["of", 64], ["two", 67], ["disorders", 71], ["that", 81], ["have", 86], ["acquired", 91], ["the", 100], ["eponym", 104], ["Bazex", 111], ["syndrome", 117], [".", 125], ["To", 127], ["date", 130], [",", 134], ["all", 136], ["of", 140], ["the", 143], ["patients", 147], ["reported", 156], ["in", 165], ["the", 168], ["literature", 172], ["have", 183], ["had", 188], ["an", 192], ["underlying", 195], ["neoplasm", 206], [",", 214], ["most", 216], ["commonly", 221], ["squamous", 230], ["cell", 239], ["carcinoma", 244], ["of", 254], ["the", 257], ["upper", 261], ["aerodigestive", 267], ["tract", 281], [".", 286], ["In", 288], ["this", 291], ["review", 296], ["of", 303], ["113", 306], ["cases", 310], ["of", 316], ["acrokeratosis", 319], ["paraneoplastica", 333], ["(", 349], ["mean", 350], ["age", 355], [",", 358], ["61", 360], ["years", 363], [";", 368], ["105", 370], ["males", 374], [",", 379], ["8", 381], ["females", 383], [")", 390], [",", 391], ["the", 393], ["psoriasiform", 397], ["lesions", 410], ["preceded", 418], ["the", 427], ["diagnosis", 431], ["of", 441], ["the", 444], ["associated", 448], ["malignancy", 459], ["in", 470], ["73", 473], ["(", 476], ["67", 477], ["%", 479], [")", 480], ["of", 482], ["109", 485], ["patients", 489], [",", 497], ["whereas", 499], ["the", 507], ["cutaneous", 511], ["manifestations", 521], ["followed", 536], ["the", 545], ["diagnosis", 549], ["of", 559], ["the", 562], ["neoplasm", 566], ["in", 575], ["only", 578], ["16", 583], ["(", 586], ["15", 587], ["%", 589], [")", 590], ["of", 592], ["109", 595], [";", 598], ["in", 600], ["the", 603], ["remainder", 607], [",", 616], ["the", 618], ["onset", 622], ["of", 628], ["the", 631], ["skin", 635], ["lesions", 640], ["and", 648], ["the", 652], ["diagnosis", 656], ["of", 666], ["the", 669], ["tumor", 673], ["occurred", 679], ["simultaneously", 688], [".", 702], ["Therefore", 704], [",", 713], ["awareness", 715], ["of", 725], ["the", 728], ["cutaneous", 732], ["signs", 742], ["of", 748], ["Bazex", 751], ["syndrome", 757], ["is", 766], ["of", 769], ["obvious", 772], ["importance", 780], ["to", 791], ["dermatologists", 794], [".", 808], ["Evidence", 810], ["in", 819], ["favor", 822], ["of", 828], ["the", 831], ["paraneoplastic", 835], ["nature", 850], ["of", 857], ["this", 860], ["disease", 865], ["is", 873], ["as", 876], ["follows", 879], [":", 886], ["in", 888], ["81", 891], ["(", 894], ["93", 895], ["%", 897], [")", 898], ["of", 900], ["87", 903], ["patients", 906], ["with", 915], ["adequate", 920], ["clinical", 929], ["descriptions", 938], [",", 950], ["the", 952], ["skin", 956], ["lesions", 961], ["either", 969], ["improved", 976], ["significantly", 985], ["(", 999], ["or", 1000], ["resolved", 1003], [")", 1011], ["when", 1013], ["the", 1018], ["underlying", 1022], ["neoplasm", 1033], ["was", 1042], ["treated", 1046], ["or", 1054], ["they", 1057], ["remained", 1062], ["unchanged", 1071], ["in", 1081], ["the", 1084], ["setting", 1088], ["of", 1096], ["persistent", 1099], ["disease", 1110], [".", 1117], ["Occasionally", 1119], [",", 1131], ["the", 1133], ["reappearance", 1137], ["of", 1150], ["skin", 1153], ["lesions", 1158], ["has", 1166], ["signaled", 1170], ["a", 1179], ["recurrence", 1181], ["of", 1192], ["the", 1195], ["tumor", 1199], [".", 1204]]}
{"context": "During mitosis, Promyelocytic leukemia nuclear bodies (PML NBs) change dramatically in morphology and composition, but little is known about function of PML in mitosis. Here, we show that PML is phosphorylated at T409 (PML p409) in a mitosis-specific manner. More importantly, PML p409 contributes to maintain the duration of pro-metaphase and regulates spindle checkpoint. Deficient PML p409 caused a shortening of pro-metaphase and challenged the nocodazole-triggered mitotic arrest. T409A mutation led to a higher frequency of misaligned chromosomes on metaphase plate, and subsequently death in late mitosis. In addition, inhibition of PML p409 repressed growth of tumor cells, suggesting that PML p409 is a potential target for cancer therapy. Collectively, our study demonstrated an important phosphorylated site of PML, which contributed to explore the role of PML in mitosis.", "qas": [{"question": "What is the effect of nocodazole cell treatment?", "answers": ["Mitotic arrest"], "qid": "fb1932c2568743f8a7e02da6141a50f9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["nocodazole", 22], ["cell", 33], ["treatment", 38], ["?", 47]], "detected_answers": [{"text": "Mitotic arrest", "token_spans": [[85, 86]], "char_spans": [[470, 483]]}]}], "context_tokens": [["During", 0], ["mitosis", 7], [",", 14], ["Promyelocytic", 16], ["leukemia", 30], ["nuclear", 39], ["bodies", 47], ["(", 54], ["PML", 55], ["NBs", 59], [")", 62], ["change", 64], ["dramatically", 71], ["in", 84], ["morphology", 87], ["and", 98], ["composition", 102], [",", 113], ["but", 115], ["little", 119], ["is", 126], ["known", 129], ["about", 135], ["function", 141], ["of", 150], ["PML", 153], ["in", 157], ["mitosis", 160], [".", 167], ["Here", 169], [",", 173], ["we", 175], ["show", 178], ["that", 183], ["PML", 188], ["is", 192], ["phosphorylated", 195], ["at", 210], ["T409", 213], ["(", 218], ["PML", 219], ["p409", 223], [")", 227], ["in", 229], ["a", 232], ["mitosis", 234], ["-", 241], ["specific", 242], ["manner", 251], [".", 257], ["More", 259], ["importantly", 264], [",", 275], ["PML", 277], ["p409", 281], ["contributes", 286], ["to", 298], ["maintain", 301], ["the", 310], ["duration", 314], ["of", 323], ["pro", 326], ["-", 329], ["metaphase", 330], ["and", 340], ["regulates", 344], ["spindle", 354], ["checkpoint", 362], [".", 372], ["Deficient", 374], ["PML", 384], ["p409", 388], ["caused", 393], ["a", 400], ["shortening", 402], ["of", 413], ["pro", 416], ["-", 419], ["metaphase", 420], ["and", 430], ["challenged", 434], ["the", 445], ["nocodazole", 449], ["-", 459], ["triggered", 460], ["mitotic", 470], ["arrest", 478], [".", 484], ["T409A", 486], ["mutation", 492], ["led", 501], ["to", 505], ["a", 508], ["higher", 510], ["frequency", 517], ["of", 527], ["misaligned", 530], ["chromosomes", 541], ["on", 553], ["metaphase", 556], ["plate", 566], [",", 571], ["and", 573], ["subsequently", 577], ["death", 590], ["in", 596], ["late", 599], ["mitosis", 604], [".", 611], ["In", 613], ["addition", 616], [",", 624], ["inhibition", 626], ["of", 637], ["PML", 640], ["p409", 644], ["repressed", 649], ["growth", 659], ["of", 666], ["tumor", 669], ["cells", 675], [",", 680], ["suggesting", 682], ["that", 693], ["PML", 698], ["p409", 702], ["is", 707], ["a", 710], ["potential", 712], ["target", 722], ["for", 729], ["cancer", 733], ["therapy", 740], [".", 747], ["Collectively", 749], [",", 761], ["our", 763], ["study", 767], ["demonstrated", 773], ["an", 786], ["important", 789], ["phosphorylated", 799], ["site", 814], ["of", 819], ["PML", 822], [",", 825], ["which", 827], ["contributed", 833], ["to", 845], ["explore", 848], ["the", 856], ["role", 860], ["of", 865], ["PML", 868], ["in", 872], ["mitosis", 875], [".", 882]]}
